FN Thomson Reuters Web of Science™
VR 1.0
PT J
AU Glasser, JR
Mallampalli, RK
AF Glasser, Jennifer R.
Mallampalli, Rama K.
TI Surfactant and its role in the pathobiology of pulmonary infection
SO MICROBES AND INFECTION
LA English
DT Review
DE Surfactant; Collectin; Phospholipid; Infection
ID ACUTE LUNG INJURY; RESPIRATORY-DISTRESS-SYNDROME; INNATE HOST-DEFENSE;
PROTEIN-A; APOPTOTIC MIMICRY; II PNEUMOCYTES; VIRUS ENTRY; SP-C;
COLLECTINS; DISEASE
AB Pulmonary surfactant is a complex surface-active substance comprised of key phospholipids and proteins that has many essential functions. Surfactant's unique composition is integrally related to its surface-active properties, its critical role in host defense, and emerging immunomodulatory activities ascribed to surfactant lipids. Together these effector functions provide for lung stability and protection from a barrage of potentially virulent infectious pathogens. (C) 2011 Institut Pasteur. Published by Elsevier Masson SAS. All rights reserved.
C1 [Glasser, Jennifer R.; Mallampalli, Rama K.] Acute Lung Injury Ctr Excellence, Dept Med, Pittsburgh, PA 15213 USA.
[Mallampalli, Rama K.] Univ Pittsburgh, Dept Cell Biol & Physiol, Pittsburgh, PA 15213 USA.
[Mallampalli, Rama K.] Vet Affairs Pittsburgh Healthcare Syst, Med Specialty Serv Line, Pittsburgh, PA 15213 USA.
RP Mallampalli, RK (reprint author), PACCM, Dept Med, NW628 Montefiore,3459 5th Ave, Pittsburgh, PA 15213 USA.
EM mallampallirk@upmc.edu
FU US Department of Veterans Affairs, Veterans Health Administration,
Office of Research and Development, Biomedical Laboratory Research and
Development; US Department of Veterans Affairs; National Institutes of
Health [HL096376, HL097376, HL098174]
FX We thank Ms. Tiffany Coon for critical review of the manuscript and
helpful suggestions. This material is based upon work supported, in
part, by the US Department of Veterans Affairs, Veterans Health
Administration, Office of Research and Development, Biomedical
Laboratory Research and Development. This work was supported by a Merit
Review Award from the US Department of Veterans Affairs and National
Institutes of Health R01 grants HL096376, HL097376 and HL098174 (to
R.K.M.). The contents presented do not represent the views of the
Department of Veterans Affairs or the United States Government.
NR 67
TC 20
Z9 24
U1 1
U2 18
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1286-4579
J9 MICROBES INFECT
JI Microbes Infect.
PD JAN
PY 2012
VL 14
IS 1
BP 17
EP 25
DI 10.1016/j.micinf.2011.08.019
PG 9
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 888UO
UT WOS:000300030300003
PM 21945366
ER
PT J
AU Tanner, JM
Chang, TI
AF Tanner, Jeffrey M.
Chang, Tina I.
TI Syndrome Z: A comparison of prevalence between females and males
SO SLEEP MEDICINE
LA English
DT Letter
C1 [Tanner, Jeffrey M.; Chang, Tina I.] VA Greater Los Angeles Healthcare Syst, Oral & Maxillofacial Surg Sect, Dent Serv, Los Angeles, CA 90073 USA.
[Chang, Tina I.] Univ Calif Los Angeles, Sch Dent, Los Angeles, CA 90024 USA.
RP Chang, TI (reprint author), VA Greater Los Angeles Healthcare Syst, Oral & Maxillofacial Surg Sect, Dent Serv, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA.
EM tinachangdmdmd@gmail.com
NR 5
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1389-9457
J9 SLEEP MED
JI Sleep Med.
PD JAN
PY 2012
VL 13
IS 1
BP 119
EP 120
DI 10.1016/j.sleep.2011.06.005
PG 2
WC Clinical Neurology
SC Neurosciences & Neurology
GA 890GA
UT WOS:000300131900025
PM 21982339
ER
PT J
AU Anderson, AL
Li, SH
Biswas, K
McSherry, F
Holmes, T
Iturriaga, E
Kahn, R
Chiang, N
Beresford, T
Campbell, J
Haning, W
Mawhinney, J
McCann, M
Rawson, R
Stock, C
Weis, D
Yu, E
Elkashef, AM
AF Anderson, Ann L.
Li, Shou-Hua
Biswas, Kousick
McSherry, Frances
Holmes, Tyson
Iturriaga, Erin
Kahn, Roberta
Chiang, Nora
Beresford, Thomas
Campbell, Jan
Haning, William
Mawhinney, Joseph
McCann, Michael
Rawson, Richard
Stock, Christopher
Weis, Dennis
Yu, Elmer
Elkashef, Ahmed M.
TI Modafinil for the treatment of methamphetamine dependence
SO DRUG AND ALCOHOL DEPENDENCE
LA English
DT Article
DE Methamphetamine; Substance-related disorders; Drug therapy; Modafinil;
Medication adherence; Attention Deficit Hyperactivity Disorders
ID PLACEBO-CONTROLLED TRIAL; ATTENTION-DEFICIT/HYPERACTIVITY DISORDER;
DOUBLE-BLIND; INDUCED WAKEFULNESS; COCAINE DEPENDENCE
AB Aim: Modafinil was tested for efficacy in decreasing use in methamphetamine-dependent participants, compared to placebo.
Methods: This was a randomized, double-blind, placebo-controlled study, with 12 weeks of treatment and a 4-week follow-up. Eight outpatient substance abuse treatment clinics participated in the study. There were 210 treatment-seekers randomized, who all had a DSM-IV diagnosis of methamphetamine dependence; 68 participants to placebo, 72 to modafinil 200 mg, and 70 to modafinil 400 mg, taken once daily on awakening. Participants came to the clinic three times per week for assessments, urine drug screens, and group psychotherapy. The primary outcome measure was a methamphetamine non-use week, which required all the week's qualitative urine drug screens to be negative for methamphetamine.
Results: Regression analysis showed no significant difference between either modafinil group (200 or 400 mg) or placebo in change in weekly percentage having a methamphetamine non-use week over the 12-week treatment period (p=0.53). Similarly, a number of secondary outcomes did not show significant effects of modafinil. However, an ad-hoc analysis of medication compliance, by urinalysis for modafinil and its metabolite, did find a significant difference in maximum duration of abstinence (23 days vs. 10 days, p=0.003), between those having the top quartile of compliance (> 85% of urines were positive for modafinil, N=36), and the lower three quartiles of modafinil 200 and 400 mg groups (N=106).
Conclusions: Although these data suggest that modafinil, plus group behavioral therapy, was not effective for decreasing methamphetamine use, the study is probably inconclusive because of inadequate compliance with taking medication. Published by Elsevier Ireland Ltd.
C1 [Anderson, Ann L.] Natl Inst Drug Abuse, DPMC, Div Pharmacotherapies & Med Consequences Drug Abu, NIH, Bethesda, MD 20892 USA.
[Biswas, Kousick; McSherry, Frances] VA Maryland Healthcare Ctr, Coop Studies Program, Perry Point, MD USA.
[Holmes, Tyson] Stanford Univ, Sch Med, Dept Psychiat & Behav Sci, Stanford, CA 94305 USA.
[Beresford, Thomas] VA Med Ctr, Psychiat Serv, Denver, CO USA.
[Campbell, Jan] Univ Kansas, Med Ctr, Kansas City, KS 66103 USA.
[Haning, William] Univ Hawaii, John A Burns Sch Med, Honolulu, HI 96822 USA.
[Mawhinney, Joseph] S Bay Treatment Ctr, San Diego, CA USA.
[McCann, Michael] Matrix Inst Addict, Los Angeles, CA USA.
[Rawson, Richard] UCLA Integrated Subst Abuse Program, Los Angeles, CA USA.
[Stock, Christopher] VA Salt Lake City Healthcare Syst, Salt Lake City, UT USA.
[Weis, Dennis] Iowa Lutheran Hosp, Des Moines, IA USA.
[Yu, Elmer] Philadelphia VA Med Ctr, Philadelphia, PA USA.
RP Anderson, AL (reprint author), Natl Inst Drug Abuse, DPMC, Div Pharmacotherapies & Med Consequences Drug Abu, NIH, 6001 Execut Blvd,Rm 4149, Bethesda, MD 20892 USA.
EM aa135m@nih.gov
FU NIDA [Y1-DA-4006-01]
FX Funding for this study was provided by NIDA Contract # Y1-DA-4006-01.
The National Institute on Drug Abuse-NIH had a major role in study
design, in the analysis and interpretation of data, and in the writing
and submission of this manuscript for publication.
NR 28
TC 44
Z9 45
U1 1
U2 11
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
IRELAND
SN 0376-8716
J9 DRUG ALCOHOL DEPEN
JI Drug Alcohol Depend.
PD JAN 1
PY 2012
VL 120
IS 1-3
BP 135
EP 141
DI 10.1016/j.drugalcdep.2011.07.007
PG 7
WC Substance Abuse; Psychiatry
SC Substance Abuse; Psychiatry
GA 881PY
UT WOS:000299499800019
PM 21840138
ER
PT J
AU Baca, CB
Vickrey, BG
Vassar, SD
Berg, AT
AF Baca, Christine B.
Vickrey, Barbara G.
Vassar, Stefanie D.
Berg, Anne T.
TI Seizure recency and quality of life in adolescents with childhood-onset
epilepsy
SO EPILEPSY & BEHAVIOR
LA English
DT Article
DE Epilepsy; Children and adolescents; Health-related quality of life;
Seizure recency; Seizure remission; Parent-proxy reports
ID TEMPORAL-LOBE EPILEPSY; LONG-TERM PROGNOSIS; CHILDREN; HEALTH; SURGERY;
IMPACT; OUTCOMES; SYMPTOMS; ANXIETY; ADULTS
AB Health-related quality of life (HRQOL) is associated with seizure recency among adults with epilepsy. In a prospective, community-based study of long-term outcomes of childhood-onset epilepsy, we evaluated whether worse HRQOL is associated with more recent seizures among children and adolescents with epilepsy. We used the Child Health Questionnaire (CHQ), a generic measure with child and parent-proxy versions, to measure HRQOL Among 277 children with epilepsy (CWE) assessed 9 years after diagnosis, parent-proxy reported but not child self-reported HRQOL was significantly worse for those having seizures in the prior year than for those who were seizure free >= 1 year across the majority of scales. There were no differences between CWE in remission for 1-5 years and those seizure free >= 5 years for child and parent-proxy reported HRQOL with the exception of the parent Emotional Impact scale, suggesting that HRQOL differences related to seizure recency level off after the initial year of remission. Published by Elsevier Inc.
C1 [Baca, Christine B.; Vickrey, Barbara G.; Vassar, Stefanie D.] Univ Calif Los Angeles, Dept Neurol, Los Angeles, CA 90024 USA.
[Baca, Christine B.; Vickrey, Barbara G.; Vassar, Stefanie D.] VA Greater Los Angeles Hlth Care Syst, Dept Neurol, Los Angeles, CA USA.
[Berg, Anne T.] NW Childrens Mem Hosp, Epilepsy Ctr, Chicago, IL USA.
RP Baca, CB (reprint author), UCLA Neurol, RNRC, C-247, Los Angeles, CA 90095 USA.
EM cbower@mednet.ucla.edu
FU National Institutes of Health (PI) [NINDS R37-NS31146]
FX This work was supported by Grant NINDS R37-NS31146 from the National
Institutes of Health (PI-Berg).
NR 40
TC 10
Z9 10
U1 2
U2 6
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1525-5050
J9 EPILEPSY BEHAV
JI Epilepsy Behav.
PD JAN
PY 2012
VL 23
IS 1
BP 47
EP 51
DI 10.1016/j.yebeh.2011.10.010
PG 5
WC Behavioral Sciences; Clinical Neurology; Psychiatry
SC Behavioral Sciences; Neurosciences & Neurology; Psychiatry
GA 883XO
UT WOS:000299668400009
PM 22134098
ER
PT J
AU Strutt, AM
Simpson, R
Jankovic, J
York, MK
AF Strutt, A. M.
Simpson, R.
Jankovic, J.
York, M. K.
TI Changes in cognitive-emotional and physiological symptoms of depression
following STN-DBS for the treatment of Parkinson's disease
SO EUROPEAN JOURNAL OF NEUROLOGY
LA English
DT Article
DE cognition; depression; emotion; motor symptoms; Parkinson's disease;
subthalamic nucleus deep brain stimulation; treatment
ID DEEP-BRAIN-STIMULATION; SUBTHALAMIC NUCLEUS STIMULATION;
QUALITY-OF-LIFE; TRIAL; MOOD; METAANALYSIS; MULTICENTER; OUTCOMES;
ANXIETY; SCALES
AB Background and purpose: Subthalamic nucleus deep brain stimulation (STN-DBS) has been shown to have beneficial effects on the motor features of Parkinsons disease (PD), but its impact on non-motor symptoms, most notably mood, has not been fully explored. Methods: In the first study to independently compare the emotional-cognitive and somatic/ physiological symptoms of depression, we examined mood differences in 17 bilateral STN-DBS and 22 matched non-surgical PD patients at baseline and 6 months. Results: The STN-DBS group reported higher levels of depression at baseline with significant endorsement of physical symptomatology. Postoperatively, no significant between-group differences in physical symptoms of depression were found. In contrast, a significant group by time interaction for cognitive-emotional symptoms of depression was found, with the STN-DBS group reporting an increase in psychological symptoms of distress. The STN-DBS group also reported an increase in anxiety following surgery. The suicide rate of 5% found in our study is consistent with other postoperative studies in PD. The impact of changes in levodopa and psychotropic medication are also explored. Conclusions: Preliminary results suggest that the motor improvement often observed in patients with PD following bilateral STN-DBS may be partially offset by an increase in affective-cognitive symptoms of depression.
C1 [Strutt, A. M.; Jankovic, J.; York, M. K.] Baylor Coll Med, Dept Neurol, Houston, TX 77030 USA.
[Strutt, A. M.; Jankovic, J.; York, M. K.] Baylor Coll Med, Parkinsons Dis Movement Disorder Clin, Houston, TX 77030 USA.
[Simpson, R.] Methodist Neurol Inst, Dept Neurosurg, Houston, TX USA.
[York, M. K.] PADRECC, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX USA.
RP Strutt, AM (reprint author), 6550 Fannin,Smith 1801, Houston, TX 77030 USA.
EM adrianam@bcm.edu
FU NIH/NINDS [K23]
FX Work funded by a NIH/NINDS K23 grant (PI: York) and supported with
resources from the Michael E. DeBakey Veteran's Affairs Hospital,
Houston, TX, USA. The authors thank Kara M. Rherer for her assistance
with data management, the participants of this study and the National
Parkinson's Foundation.
NR 35
TC 20
Z9 20
U1 2
U2 10
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1351-5101
J9 EUR J NEUROL
JI Eur. J. Neurol.
PD JAN
PY 2012
VL 19
IS 1
BP 121
EP 127
DI 10.1111/j.1468-1331.2011.03447.x
PG 7
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 878JW
UT WOS:000299254100021
PM 21668586
ER
PT J
AU Armstrong, EJ
Yeo, KK
Javed, U
Mahmud, E
Patel, M
Shunk, KA
MacGregor, JS
Low, RI
Rogers, JH
AF Armstrong, Ehrin J.
Yeo, Khung Keong
Javed, Usman
Mahmud, Ehtisham
Patel, Mitul
Shunk, Kendrick A.
MacGregor, John S.
Low, Reginald I.
Rogers, Jason H.
TI Angiographic Stent Thrombosis at Coronary Bifurcations Short- and
Long-Term Prognosis
SO JACC-CARDIOVASCULAR INTERVENTIONS
LA English
DT Article
DE bifurcation; stent thrombosis; thrombus
ID DRUG-ELUTING STENTS; ELEVATION MYOCARDIAL-INFARCTION; IMPLANTATION;
REGISTRY; LESIONS; RISK; PREDICTORS; SIROLIMUS; TRIALS
AB Objectives This study sought to describe the presentation, management, and outcomes of patients presenting with angiographic definite stent thrombosis (ST) at coronary bifurcations.
Background The development of drug-eluting stents has made it increasingly feasible to treat bifurcation lesions percutaneously. However, ST at coronary bifurcations may be associated with greater mortality than ST elsewhere.
Methods We analyzed a multicenter California registry comprising all cases of angiographic definite ST at 5 academic hospitals from 2005 to 2010. Stenting was defined as occurring at a bifurcation if the main vessel stent crossed a side branch >= 2.0 mm in diameter (provisional single-stent approach), or if there was a prior 2-stent bifurcation approach.
Results Among 173 cases of angiographic definite ST, we identified 20 cases of ST at coronary bifurcations. Nine of 20 bifurcation ST (45%) occurred with a stent present in both the parent and branch vessel. Eight cases had thrombus present in both the parent and side branch vessels. In-hospital mortality was much higher for subjects with bifurcation ST than ST at a nonbifurcation site (20% vs. 2%, p < 0.0001). During a median follow-up of 2.3 years, ST at a coronary bifurcation was associated with increased long-term mortality (hazard ratio [HR]: 3.3, 95% confidence interval [Cl]: 1.4 to 7.7, p = 0.007) and a significantly higher risk for major adverse cardiovascular events (HR: 2.2, 95% Cl: 1.04 to 4.8, p = 0.04) relative to ST at a nonbifurcation site.
Conclusions ST at coronary bifurcations is associated with a higher in-hospital and long-term mortality than ST at nonbifurcation lesions. (Stent Thrombus in Acute Coronary Syndromes; NCT00931502) (J Am Coll Cardiol Intv 2012;5:57-63) (C) 2012 by the American College of Cardiology Foundation
C1 [Armstrong, Ehrin J.; Yeo, Khung Keong; Javed, Usman; Low, Reginald I.; Rogers, Jason H.] Univ Calif Davis, Davis Med Ctr, Div Cardiovasc Med, Sacramento, CA 95817 USA.
[Mahmud, Ehtisham; Patel, Mitul] Univ Calif San Diego, Med Ctr, Div Cardiol, San Diego, CA 92103 USA.
[Shunk, Kendrick A.; MacGregor, John S.] Univ Calif San Francisco, Div Cardiol, Med Ctr, San Francisco, CA USA.
[Shunk, Kendrick A.] San Francisco VA Med Ctr, Div Cardiol, San Francisco, CA USA.
[MacGregor, John S.] San Francisco Gen Hosp, Div Cardiol, San Francisco, CA 94110 USA.
RP Rogers, JH (reprint author), Univ Calif Davis, Davis Med Ctr, Div Cardiovasc Med, 4860 Y St,Suite 2820, Sacramento, CA 95817 USA.
EM jason.rogers@ucdmc.ucdavis.edu
FU Boston Scientific; Abbott Vascular; Accumetrics; sanofi-aventis
FX Dr. Mahmud serves on the Speaker's Bureau for Medtronic and Eli Lilly;
is a consultant for Eli Lilly; and receives research support from Boston
Scientific, Abbott Vascular, Accumetrics, and sanofi-aventis. Dr. Low is
on the advisory board of and is a consultant for Abbott Vascular and
Boston Scientific. Dr. Rogers is a consultant for Volcano, Medtronic,
and Boston Scientific. All other authors have reported that they have
relationships relevant to the contents of this paper to disclose.
NR 21
TC 7
Z9 7
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1936-8798
J9 JACC-CARDIOVASC INTE
JI JACC-Cardiovasc. Interv.
PD JAN
PY 2012
VL 5
IS 1
BP 57
EP 63
DI 10.1016/j.jcin.2011.09.015
PG 7
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 883XU
UT WOS:000299669000008
PM 22230151
ER
PT J
AU Wong, KK
Muller, MLTM
Kuwabara, H
Studenski, SA
Bohnen, NI
AF Wong, Ka Kit
Mueller, Martijn L. T. M.
Kuwabara, Hiroto
Studenski, Stephanie A.
Bohnen, Nicolaas I.
TI Gender differences in nigrostriatal dopaminergic innervation are present
at young-to-middle but not at older age in normal adults
SO JOURNAL OF CLINICAL NEUROSCIENCE
LA English
DT Article
DE Aging; Gender; Basal ganglia; Dopamine; Menopause; Parkinson's disease;
Positron emission tomography
ID SEX-DIFFERENCES; TRANSPORTER AVAILABILITY; SPECT
AB Gender differences in brain dopaminergic activity have been variably reported in the literature. We performed an evaluation for gender effects on striatal dopamine transporter (DAT) binding in a group of normal subjects. Community-dwelling adults (n = 85, 50F/35M, mean age 62.7 +/- 16.2 SD, range 20-85) underwent DAT[C-11]-beta-carbomethoxy-3 beta-(4-fluorophenyl) tropane (beta-CFT) positron emission tomography (PET) imaging. Gender effects for DAT binding were compared using ANCOVA for two subgroups; young-to-middle aged adults and older adults, using an age threshold of 60 years. There were 54 subjects (24M/30F; mean age 72.9 +/- 7.3) 60 years and older and 31 (11M/20F; mean age 45.0 +/- 11.4) subjects younger than 60. Age-adjusted striatal DAT gender effects were present in the young-to-middle (F = 10.4, P = 0.003) but not in the elderly age group (F = 0.5, ns). Gender differences in nigrostriatal dopaminergic innervation are present, with higher levels of DAT binding in young-to-middle age women compared to men, but not present in the elderly. Published by Elsevier Ltd.
C1 [Wong, Ka Kit; Bohnen, Nicolaas I.] VA Ann Arbor Healthcare Syst, GRECC, Ann Arbor, MI USA.
[Mueller, Martijn L. T. M.; Bohnen, Nicolaas I.] Univ Michigan, Funct Neuroimaging Cognit & Mobil Lab, Dept Radiol, Ann Arbor, MI 48105 USA.
[Mueller, Martijn L. T. M.; Bohnen, Nicolaas I.] Univ Michigan, Funct Neuroimaging Cognit & Mobil Lab, Dept Neurol, Ann Arbor, MI 48105 USA.
[Kuwabara, Hiroto] Johns Hopkins Univ, Dept Radiol, Baltimore, MD USA.
[Studenski, Stephanie A.] VA Pittsburgh Healthcare Syst, GRECC, Pittsburgh, PA USA.
[Studenski, Stephanie A.] Univ Pittsburgh, Sch Med, Dept Med, Div Geriatr Med, Pittsburgh, PA USA.
[Wong, Ka Kit] Univ Michigan, Dept Nucl Med Radiol, Ann Arbor, MI 48105 USA.
RP Bohnen, NI (reprint author), VA Ann Arbor Healthcare Syst, GRECC, Ann Arbor, MI USA.
EM nbohnen@umich.edu
RI Muller, Martijn/A-7205-2010
OI Muller, Martijn/0000-0002-1133-7202
FU Department of Veterans Affairs
FX This study was funded by the Department of Veterans Affairs.
NR 7
TC 13
Z9 13
U1 1
U2 5
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0967-5868
J9 J CLIN NEUROSCI
JI J. Clin. Neurosci.
PD JAN
PY 2012
VL 19
IS 1
BP 183
EP 184
DI 10.1016/j.jocn.2011.05.013
PG 2
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 882YP
UT WOS:000299600100042
PM 22030267
ER
PT J
AU Aspinall, SL
Good, CB
Cunningham, FE
AF Aspinall, Sherrie L.
Good, Chester B.
Cunningham, Francesca E.
TI Glycemic Control Was Unchanged in Veterans Health Administration
Patients Converted from Glyburide to Glipizide
SO JOURNAL OF MANAGED CARE PHARMACY
LA English
DT Letter
C1 [Aspinall, Sherrie L.; Good, Chester B.; Cunningham, Francesca E.] VA Ctr Medicat Safety, Hines, IL USA.
[Good, Chester B.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA.
[Aspinall, Sherrie L.; Good, Chester B.] Univ Pittsburgh, Sch Pharm, Pittsburgh, PA USA.
[Good, Chester B.] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA.
RP Aspinall, SL (reprint author), VA Ctr Medicat Safety, Hines, IL USA.
EM sherrie.aspinall@va.gov
NR 3
TC 0
Z9 0
U1 2
U2 2
PU ACAD MANAGED CARE PHARMACY
PI ALEXANDRIA
PA 100 N PITT ST, 400, ALEXANDRIA, VA 22314-3134 USA
SN 1083-4087
J9 J MANAGE CARE PHARM
JI J. Manag. Care Pharm.
PD JAN-FEB
PY 2012
VL 18
IS 1
BP 73
EP 73
PG 1
WC Health Care Sciences & Services; Pharmacology & Pharmacy
SC Health Care Sciences & Services; Pharmacology & Pharmacy
GA 885BI
UT WOS:000299753100007
PM 22235958
ER
PT J
AU Tanner, JM
Chang, TI
Harada, ND
Santiago, SM
Weinreb, JE
Friedlander, AH
AF Tanner, Jeffrey M.
Chang, Tina I.
Harada, Nancy D.
Santiago, Silverio M.
Weinreb, Jane E.
Friedlander, Arthur H.
TI Prevalence of Comorbid Obstructive Sleep Apnea and Metabolic Syndrome:
Syndrome Z and Maxillofacial Surgery Implications
SO JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY
LA English
DT Article
ID INSULIN-RESISTANCE; CARDIOVASCULAR-DISEASE; DIABETES-MELLITUS; ABDOMINAL
OBESITY; APNOEA/HYPOPNOEA SYNDROME; MORBID-OBESITY; BLOOD-PRESSURE;
FATTY-ACIDS; RISK-FACTOR; FOLLOW-UP
AB Purpose: To determine the prevalence of the recently identified syndrome Z (SZ), which is the co-occurrence of obstructive sleep apnea (OSA; hypoxia, systemic and pulmonary hypertension, nocturnal arrhythmias) and metabolic syndrome (MetS; increased abdominal girth, hypertriglyceridemia, decreased high-density lipoprotein, hypertension, increased fasting glucose), which places the surgical patient at heightened risk of perioperative complications (myocardial infarction, stroke, pneumonia, wound infection).
Materials and Methods: Electronic medical records of 296 male veterans were assessed for the presence of SZ using the American Academy of Sleep Medicine definition of OSA and a modified Adult Treatment Panel III definition of MetS, where obesity was defined by a body mass index of at least 30 kg/m2 rather than by waist circumference.
Results: SZ was diagnosed in 59% of patients. These individuals commonly exhibited severe OSA and least commonly mild OSA. The more severe the OSA, the more likely (60%) that patients manifested moderate (4 risk markers) or severe (5 risk markers) MetS. Furthermore, with increasing apnea-hypopnea index values, the more severe were the MetS elements.
Conclusions: The results of this study demonstrate the high prevalence rate of MetS in patients with OSA seeking treatment. Given the risk of perioperative complications, it is suggested that all patients scheduled for maxillofacial surgical procedures to treat OSA be evaluated for SZ. This is a US government work. There are no restrictions on its use. Published by Elsevier Inc on behalf of the American Association of Oral and Maxillofacial Surgeons. J Oral Maxillofac Surg 70:179-187, 2012
C1 [Tanner, Jeffrey M.] VA Greater Los Angeles Healthcare Syst, Oral & Maxillofacial Sect, Dent Serv, Los Angeles, CA USA.
[Chang, Tina I.] VA Greater Los Angeles Healthcare Syst, Staff Oral & Maxillofacial Surg, Los Angeles, CA USA.
[Chang, Tina I.; Friedlander, Arthur H.] Univ Calif Los Angeles, Sch Dent, Los Angeles, CA 90024 USA.
[Harada, Nancy D.; Santiago, Silverio M.; Weinreb, Jane E.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
[Weinreb, Jane E.] Cedar Sinai Med Ctr, Los Angeles, CA USA.
[Weinreb, Jane E.] VA Greater Los Angeles Healthcare Syst, Diabet Program, Los Angeles, CA USA.
[Friedlander, Arthur H.] Ronald Reagan UCLA Med Ctr, Hosp Dent Serv, Los Angeles, CA USA.
RP Friedlander, AH (reprint author), VA Med Ctr, 11301 Wilshire Blvd B218,Rm 210A, Los Angeles, CA 90073 USA.
EM arthur.friedlander@med.va.gov
NR 84
TC 1
Z9 2
U1 0
U2 1
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0278-2391
J9 J ORAL MAXIL SURG
JI J. Oral Maxillofac. Surg.
PD JAN
PY 2012
VL 70
IS 1
BP 179
EP 187
DI 10.1016/j.joms.2011.01.012
PG 9
WC Dentistry, Oral Surgery & Medicine
SC Dentistry, Oral Surgery & Medicine
GA 877WX
UT WOS:000299214500046
PM 21601341
ER
PT J
AU Loboprabhu, S
Molinari, V
AF Loboprabhu, Sheila
Molinari, Victor
TI Severe Loneliness in Community-Dwelling Aging Adults with Mental Illness
SO JOURNAL OF PSYCHIATRIC PRACTICE
LA English
DT Article
DE loneliness; attachment; aging; community; depression
ID SOCIAL-ISOLATION; OLDER-PEOPLE; LATER LIFE; SUICIDE; PERSPECTIVES
AB Successful aging involves adapting to changing needs. The 2009 U.S. Census noted that 43% of adult Americans are single and that the oldest-old population is the most rapidly growing aging segment. Geriatric, lonely, hopeless individuals are at high risk for depression and suicide. Lonely individuals fail to adapt to their circumstances; and physical and mental illness place them at risk for neglect, morbidity, and mortality. The authors discuss the role of attachment in the individual's subjective experience of loneliness and suggest how attachment theory can be used to guide interventions to improve the individual's self-esteem, coping, and problem-solving abilities. This article also discusses the use of multimodal therapy, including psychodynamic, interpersonal, and cognitive-behavior therapy and coping skills training, to improve the individual's ability to adapt to the surrounding environment and to reintegrate into the community. (Journal of Psychiatric Practice 2012;18:20-28)
C1 [Loboprabhu, Sheila] Michael E DeBakey Dept Vet Affairs Med Ctr, Houston, TX 77030 USA.
[Loboprabhu, Sheila] S Cent MIRECC, Houston, TX USA.
[Loboprabhu, Sheila] Baylor Coll Med, Houston, TX 77030 USA.
[Molinari, Victor] Univ S Florida, Tampa, FL USA.
RP Loboprabhu, S (reprint author), Michael E DeBakey Dept Vet Affairs Med Ctr, 2002 Holcombe Blvd, Houston, TX 77030 USA.
EM SheilaM.Loboprabhu@va.gov
NR 45
TC 1
Z9 1
U1 3
U2 17
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1527-4160
J9 J PSYCHIATR PRACT
JI J. Psychiatr. Pract.
PD JAN
PY 2012
VL 18
IS 1
BP 20
EP 28
DI 10.1097/01.pra.0000410984.15852.59
PG 9
WC Psychiatry
SC Psychiatry
GA 883XP
UT WOS:000299668500004
PM 22261980
ER
PT J
AU Cirnigliaro, CM
Lesser, M
Moyer, J
Kirshblum, SC
Bauman, WA
Spungen, AM
AF Cirnigliaro, Christopher M.
Lesser, Marvin
Moyer, Jeremy
Kirshblum, Steven C.
Bauman, William A.
Spungen, Ann M.
TI Reproducibility and effect of posture on impulse oscillation parameters
in persons with spinal cord injury
SO JOURNAL OF SPINAL CORD MEDICINE
LA English
DT Article
DE Spinal cord injuries; Paraplegia; Tetraplegia; Forced oscillation
technique; Airway dynamics; Respiratory resistance; Airway obstruction;
Spirometry; Plethysmography
ID RESPIRATORY IMPEDANCE; FORCED OSCILLATION; LUNG; RESISTANCE; MECHANICS;
PLETHYSMOGRAPHY; OSCILLOMETRY; QUADRIPLEGIA; SPIROMETRY; OBESITY
AB Background: The impulse oscillation system (IOS) offers significant value in the assessment of airway dynamics in persons with spinal cord injury (SCI) because of minimal patient effort but measurement reproducibility in SCI is unknown.
Objective: To evaluate between-day reproducibility and the effect of posture on airway resistance [respiratory resistances at 5 Hz (R5) and 20 Hz (R20)] in subjects with tetraplegia, paraplegia and able-bodied controls.
Methods: Ten subjects with tetraplegia, 10 subjects with paraplegia and 11 able-bodied individuals were evaluated using IOS. Three 30 second trials were obtained in each while in the seated and supine position on Day 1, and repeated on Day 2.
Results: The within-day coefficient of variation (CV%) for R5 and R20 were comparable in the 3 study groups in the seated and supine positions. Compared to controls, the between-day CV% for the combined data was higher in subjects with tetraplegia and paraplegia for R5 seated, and was higher in subjects with tetraplegia for R5 supine.
Conclusions: IOS has applicability to the study of within-day respiratory resistance in SCI. However, performing longer-term studies in subjects with tetraplegia and paraplegia may be problematic because of the greater variability for R5 when compared to able-bodied individuals.
C1 [Cirnigliaro, Christopher M.; Kirshblum, Steven C.] VA Ctr Excellence Med Consequences SCI, Kessler Inst Rehabil, W Orange, NJ 07052 USA.
[Cirnigliaro, Christopher M.; Lesser, Marvin; Moyer, Jeremy; Bauman, William A.; Spungen, Ann M.] James J Peters VA Med Ctr, Rehabil Res & Dev Ctr Excellence Med Consequences, Bronx, NY USA.
[Lesser, Marvin; Bauman, William A.; Spungen, Ann M.] James J Peters VA Med Ctr, Med & Spinal Cord Injury Serv, Bronx, NY USA.
[Lesser, Marvin; Bauman, William A.; Spungen, Ann M.] Mt Sinai Sch Med, Dept Med, New York, NY USA.
[Lesser, Marvin; Bauman, William A.; Spungen, Ann M.] Mt Sinai Sch Med, Dept Rehabil Med, New York, NY USA.
[Kirshblum, Steven C.] Univ Med & Dent New Jersey, Dept Phys Med & Rehabil, Newark, NJ 07103 USA.
RP Cirnigliaro, CM (reprint author), VA Ctr Excellence Med Consequences SCI, Kessler Inst Rehabil, Room L052m,1199 Pleasant Valley Way, W Orange, NJ 07052 USA.
EM christopher.cirnigliaro@va.gov
FU James J. Peters Medical Center, Bronx, NY; Department of Veterans
Affairs Rehabilitation Research and Development Service; Kessler
Institute for Rehabilitation; United Spinal Association [208]
FX The authors thank The James J. Peters Medical Center, Bronx, NY, The
Department of Veterans Affairs Rehabilitation Research and Development
Service, and Kessler Institute for Rehabilitation for their support.
This work was funded by a clinical SCI Grant (#208) from United Spinal
Association.
NR 25
TC 0
Z9 0
U1 0
U2 1
PU MANEY PUBLISHING
PI LEEDS
PA STE 1C, JOSEPHS WELL, HANOVER WALK, LEEDS LS3 1AB, W YORKS, ENGLAND
SN 1079-0268
J9 J SPINAL CORD MED
JI J. Spinal Cord. Med.
PD JAN
PY 2012
VL 35
IS 1
BP 28
EP 34
DI 10.1179/2045772311Y.0000000047
PG 7
WC Clinical Neurology
SC Neurosciences & Neurology
GA 879PX
UT WOS:000299345200005
PM 22330188
ER
PT J
AU Konrad-Martin, D
Dille, MF
McMillan, G
Griest, S
McDermott, D
Fausti, SA
Austin, DF
AF Konrad-Martin, Dawn
Dille, Marilyn F.
McMillan, Garnett
Griest, Susan
McDermott, Daniel
Fausti, Stephen A.
Austin, Donald F.
TI Age-Related Changes in the Auditory Brainstem Response
SO JOURNAL OF THE AMERICAN ACADEMY OF AUDIOLOGY
LA English
DT Article
DE Aging; auditory brainstem response; auditory nerve; hearing loss;
veterans
ID DIABETES-RELATED CHANGES; WAVE-V LATENCY; EVOKED-POTENTIALS;
HEARING-LOSS; NERVE ACTIVITY; SEX; CARBOPLATIN; MODEL; ABR; THRESHOLDS
AB Purpose: This cross-sectional study had two goals: (1) Identify and quantify the effects of aging on the auditory brainstem response (ABR); (2) Describe how click rate and hearing impairment modify effects of aging.
Research Design and Analysis: ABR measures were obtained from 131 predominately male Veteran participants aged 26 to 71 yr. Metrics analyzed include amplitude and latency for waves I, Ill, and V, and the I V interpeak latency interval (IPI) at three repetition rates (11, 51, and 71 clicks/sec) using both polarities. In order to avoid confounding from missing data due to hearing impairment, participants had hearing thresholds <40 dB HL at 2 kHz and 70 dB HL at 4 kHz in at least one ear. Additionally, the median 2, 3, and 4 kHz pure tone threshold average (PTA(2,3,4)) for the sample, similar to 17 dB HL, was used to delineate subgroups of better and worse hearing ears, and only the better hearing sample was modeled statistically. We modeled ABR responses using age, repetition rate, and PTA(2,3,4) as covariates. Random effects were used to model correlation between the two ears of a subject and across repetition rates. Inferences regarding effects of aging on ABR measures at each rate were derived from the fitted model. Results were compared to data from subjects with poorer hearing.
Results: Aging substantially diminished amplitudes of all of the principal ABR peaks, largely independent of any threshold differences within the group. For waves I and III, age-related amplitude decrements were greatest at a low (11/sec) click rate. At the 11/sec rate, the model-based mean wave III amplitude was significantly smaller in older compared with younger subjects even after adjusting for wave I amplitude. Aging also increased ABR peak latencies, with significant shifts limited to early waves. The I-V IPI did not change with age. For both younger and older subjects, increasing click presentation rate significantly decreased amplitudes of early peaks and prolonged latencies of later peaks, resulting in increased IPIs. Advanced age did not enhance effects of rate. Instead, the rate effect on wave I and III amplitudes was attenuated for the older subjects due to reduced peak amplitudes at lower click rates. Compared with model predictions from the sample of better hearing subjects, mean ABR amplitudes were diminished in the group with poorer hearing, and wave V latencies were prolonged.
Conclusions: In a sample of veterans, aging substantially reduced amplitudes of all principal ABR peaks, with significant latency shifts limited to waves 1 and III. Aging did not influence the I V IPI even at high click rates, suggesting that the observed absolute latency changes associated with aging can be attributed to changes in auditory nerve input. In contrast, ABR amplitude changes with age are not adequately explained by changes in wave I. Results suggest that aging reduces the numbers and/or synchrony of contributing auditory nerve units. Results also support the concept that aging reduces the numbers, though perhaps not the synchrony, of central ABR generators.
C1 [Konrad-Martin, Dawn; Dille, Marilyn F.; McMillan, Garnett; Griest, Susan; McDermott, Daniel; Fausti, Stephen A.; Austin, Donald F.] Portland VA Med Ctr, VA RR&D Natl Ctr Rehabilitat Auditory Res, Portland, OR USA.
[Konrad-Martin, Dawn; Griest, Susan] Oregon Hlth & Sci Univ, Sch Med, Dept Otolaryngol Head & Neck Surg, Portland, OR 97201 USA.
[Austin, Donald F.] Oregon Hlth & Sci Univ, Sch Med, Dept Publ Hlth & Prevent Med, Portland, OR 97201 USA.
RP Konrad-Martin, D (reprint author), NCRAR, 3710 SW US Vet Hosp Rd, Portland, OR 97239 USA.
EM dawn.martin@va.gov
FU National Institutes of Health (NIH), National Institute on Deafness and
Other Communication Disorders (NIDCD) [R03 DC008203]; Office of
Rehabilitation Research and Development Service (RR&D), Department of
Veterans Affairs [C4447K, C3446R]
FX This work was supported by grants from the National Institutes of Health
(NIH), National Institute on Deafness and Other Communication Disorders
(NIDCD) (Grant R03 DC008203 awarded to the first author), and the Office
of Rehabilitation Research and Development Service (RR&D), Department of
Veterans Affairs (grant C4447K awarded to the first author and C3446R
awarded to the last author for the parent study on diabetes mellitus).
NR 42
TC 30
Z9 35
U1 0
U2 21
PU AMER ACAD AUDIOLOGY
PI RESTON
PA 11730 PLAZA DR, STE 300, RESTON, VA 20190 USA
SN 1050-0545
J9 J AM ACAD AUDIOL
JI J. Am. Acad. Audiol.
PD JAN
PY 2012
VL 23
IS 1
BP 18
EP 35
DI 10.3766/jaaa.23.1.3
PG 18
WC Audiology & Speech-Language Pathology; Otorhinolaryngology
SC Audiology & Speech-Language Pathology; Otorhinolaryngology
GA 883QV
UT WOS:000299649700003
PM 22284838
ER
PT J
AU Jones, EG
El-Zawahry, AM
AF Jones, Elizabeth Geiger
El-Zawahry, Ahmed M.
TI Curative Treatment Without Surgical ReconstructionaAftr Perineal
Debridement of Fournier's Gangrene
SO JOURNAL OF WOUND OSTOMY AND CONTINENCE NURSING
LA English
DT Article
ID HYPERBARIC-OXYGEN; MANAGEMENT; THERAPY
AB BACKGROUND: Fournier's gangrene (necrotizing fasciitis) is an acute life-threatening disease of the perineal area that requires urgent medical intervention. Once the affected area is surgically debrided and the patient is stabilized, surgical management typically involves 1 or more additional procedures that may include split-thickness skin grafts, flaps, or an elective diverting urostomy and/or colostomy. The professional literature discussing nonsurgical approaches to healing for Fournier's gangrene after surgical debridement is sparse.
CASE: We present 3 cases of male patients with Fournier's gangrene from our facility who healed uneventfully with negative pressure wound therapy placed after extensive debridement without further surgical intervention. An added benefit was a satisfactory aesthetic effect.
CONCLUSION: Expert wound management including negative pressure wound therapy after surgical debridement of Fournier's gangrene eliminated the need for further operative procedures and prolonged hospitalizations in these cases. We believe that surgical teams should consider using negative pressure wound therapy as part of the initial curative plan of care after debridement, and that plans for restorative plastic surgery should be restricted to patients who do not exhibit adequate improvement with conservative wound management.
C1 [El-Zawahry, Ahmed M.] Med Univ S Carolina, Charleston, SC USA.
[El-Zawahry, Ahmed M.] Ralph H Johnson VA Med Ctr, Dept Urol, Charleston, SC 29401 USA.
EM Gwammyliz@heavi.tv
NR 15
TC 2
Z9 2
U1 2
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1071-5754
J9 J WOUND OSTOMY CONT
JI J. Wound Ostomy Cont. Nurs.
PD JAN-FEB
PY 2012
VL 39
IS 1
BP 98
EP 102
DI 10.1097/WON.0b013e31823fe212
PG 5
WC Nursing
SC Nursing
GA 881OY
UT WOS:000299497200012
PM 22237647
ER
PT J
AU Joyce, VR
Barnett, PG
Chow, A
Bayoumi, AM
Griffin, SC
Sun, HY
Holodniy, M
Brown, ST
Kyriakides, TC
Cameron, DW
Youle, M
Sculpher, M
Anis, AH
Owens, DK
AF Joyce, Vilija R.
Barnett, Paul G.
Chow, Adam
Bayoumi, Ahmed M.
Griffin, Susan C.
Sun, Huiying
Holodniy, Mark
Brown, Sheldon T.
Kyriakides, Tassos C.
Cameron, D. William
Youle, Mike
Sculpher, Mark
Anis, Aslam H.
Owens, Douglas K.
TI Effect of Treatment Interruption and Intensification of Antiretroviral
Therapy on Health-Related Quality of Life in Patients with Advanced HIV:
A Randomized, Controlled Trial
SO MEDICAL DECISION MAKING
LA English
DT Article
DE AIDS; HIV; highly active antiretroviral therapy; quality of life;
treatment interruption; treatment intensification; randomized trial
ID HUMAN-IMMUNODEFICIENCY-VIRUS; CD4 CELL COUNTS; STRUCTURED TREATMENT
INTERRUPTIONS; INFECTED PATIENTS; HIV-1-INFECTED PATIENTS;
DRUG-RESISTANCE; VIROLOGICAL FAILURE; CUBIC MILLIMETER; UTILITY SCORES;
CLINICAL-TRIAL
AB Background. The effect of antiretroviral therapy (ART) interruption or intensification on health-related quality of life (HRQoL) in advanced HIV patients is unknown. Objective. To assess the impact of temporary treatment interruption and intensification of ART on HRQoL. Design. A 2 x 2 factorial open label randomized controlled trial. Setting. Hospitals in the United States, Canada, and the United Kingdom. Patients. Multidrug resistant (MDR) HIV patients. Intervention. Patients were randomized to receive a 12-wk interruption or not, and ART intensification or standard ART. Measurements. The Health Utilities Index (HUI3), EQ-5D, standard gamble (SG), time tradeoff (TTO), visual analog scale (VAS), and the Medical Outcomes Study HIV Health Survey (MOS-HIV). Results. There were no significant differences in HRQoL among the four groups during follow-up; however, there was a temporary significant decline in HRQoL on some measures within the interruption group during interruption (HUI3 -0.05, P = 0.03; VAS -5.9, P = 0.002; physical health summary -2.9, P = 0.001; mental health summary -1.9, P = 0.02). Scores declined slightly overall during follow-up. Multivariate analysis showed significantly lower HRQoL associated with some clinical events. Limitations. The results may not apply to HIV patients who have not experienced multiple treatment failures or who have not developed MDR HIV. Conclusions. Temporary ART interruption and ART intensification provided neither superior nor inferior HRQoL compared with no interruption and standard ART. Among surviving patients, HRQoL scores declined only slightly over years of follow-up in this advanced HIV cohort; however, approximately one-third of patients died during the trial follow up. Lower HRQoL was associated with adverse clinical events.
C1 [Joyce, Vilija R.; Barnett, Paul G.; Chow, Adam] VA Palo Alto Hlth Care Syst, VA Cooperat Studies Program Coordinating Ctr, VA HSR&D Hlth Econ Resource Ctr, Menlo Pk, CA 94025 USA.
[Bayoumi, Ahmed M.] St Michaels Hosp, Li Ka Shing Knowledge Inst, Keenan Res Ctr, Ctr Res Inner City Hlth, Toronto, ON M5B 1W8, Canada.
[Bayoumi, Ahmed M.] St Michaels Hosp, Div Gen Internal Med, Toronto, ON M5B 1W8, Canada.
[Bayoumi, Ahmed M.] Univ Toronto, Dept Med, Toronto, ON M5S 1A1, Canada.
[Bayoumi, Ahmed M.] Univ Toronto, Dept Hlth Policy Management & Evaluat, Toronto, ON M5S 1A1, Canada.
[Griffin, Susan C.; Sculpher, Mark] Univ York, Ctr Hlth Econ, York YO10 5DD, N Yorkshire, England.
[Sun, Huiying] St Pauls Hosp, Ctr Hlth Evaluat & Outcome Sci, Vancouver, BC V6Z 1Y6, Canada.
[Sun, Huiying; Anis, Aslam H.] Canadian HIV Trials Network, Vancouver, BC, Canada.
[Holodniy, Mark; Owens, Douglas K.] VA Palo Alto Hlth Care Syst, Palo Alto, CA USA.
[Brown, Sheldon T.] James J Peters VA Med Ctr, Bronx, NY USA.
[Kyriakides, Tassos C.] VA Cooperat Studies Program Coordinating Ctr, West Haven, CT USA.
[Cameron, D. William] Univ Ottawa, Ottawa Hosp Res Inst, Div Infect Dis, Ottawa, ON, Canada.
[Youle, Mike] Royal Free Hosp, London NW3 2QG, England.
[Anis, Aslam H.] Univ British Columbia, Dept Hlth Care & Epidemiol, Vancouver, BC V6T 1W5, Canada.
[Owens, Douglas K.] Stanford Univ, Ctr Primary Care & Outcomes Res, Stanford, CA 94305 USA.
RP Joyce, VR (reprint author), VA Palo Alto Hlth Care Syst, Hlth Econ Resource Ctr, 795 Willow Rd,152 MPD, Menlo Pk, CA 94025 USA.
EM vilija.joyce@va.gov
RI Joyce, Vilija/A-2578-2013
OI Joyce, Vilija/0000-0002-2484-4625; Cameron, Bill/0000-0002-0090-3539
FU Ontario HIV Treatment Network, Ontario Ministry of Health; Department of
Veterans Affairs; Veterans Health Administration; Office of Research and
Development; UK Medical Research Council; Canadian Institutes for Health
Research; United Kingdom Medical Research Council
FX Dr. Cameron is supported by a Career Scientist Award of the Ontario HIV
Treatment Network, Ontario Ministry of Health. We thank the
investigators and staff at the participating sites. We also thank Dr.
Diane Fairclough for her expertise in missing data analysis techniques
and longitudinal modeling.; Received 14 July 2010 from the VA Palo Alto
Health Care System, VA Cooperative Studies Program Coordinating Center,
VA HSR&D Health Economics Resource Center, Menlo Park, California (VRJ,
PGB, AC); Centre for Research on Inner City Health, The Keenan Research
Centre in the Li Ka Shing Knowledge Institute and Division of General
Internal Medicine, St. Michael's Hospital, Toronto, Ontario, Canada and
Departments of Medicine and Health Policy, Management and Evaluation,
University of Toronto, Ontario, Canada (AMB); Centre for Health
Economics, University of York, York, United Kingdom (SCG, MS); Centre
for Health Evaluation and Outcome Sciences, St. Paul's Hospital,
Vancouver, British Columbia, Canada (HS); Canadian HIV Trials Network,
Vancouver, British Columbia, Canada (HS, AHA); VA Palo Alto Health Care
System, Palo Alto, California (MH, DKO); James J. Peters VA Medical
Center, Bronx, New York (STB); VA Cooperative Studies Program
Coordinating Center, West Haven, Connecticut (TCK); Division of
Infectious Diseases, University of Ottawa at the Ottawa Hospital
Research Institute, Ottawa, Ontario, Canada (DWC); Royal Free Hospital,
London, United Kingdom (MY); Department of Health Care and Epidemiology,
University of British Columbia, Vancouver, British Columbia, Canada
(AHA); and Center for Primary Care and Outcomes Research, Stanford
University, Stanford, California (DKO). Earlier versions of this work
were presented at the Canadian Association for HIV Research Conference,
Vancouver, Canada, April 2009 and at the Society for Medical Decision
Making Annual Meeting, Los Angeles, California, October 2009. This
material is based on work supported by the Department of Veterans
Affairs, Veterans Health Administration, Office of Research and
Development, Cooperative Studies Program; the UK Medical Research
Council; and the Canadian Institutes for Health Research. Options in
Management with Antiretrovirals is the initial trial of the newly
established trinational program involving the above 3 agencies. The
views expressed in this article are those of the authors and do not
necessarily reflect the position or policy of the Department of Veterans
Affairs or the United States government. Primary funding source:
Department of Veterans Affairs Cooperative Studies Program, the United
Kingdom Medical Research Council, and the Canadian Institutes for Health
Research. Trial registration: http://clinicaltrials.gov, No.
NCT00050089. Revision accepted for publication 8 December 2010.
NR 50
TC 4
Z9 4
U1 1
U2 3
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0272-989X
J9 MED DECIS MAKING
JI Med. Decis. Mak.
PD JAN-FEB
PY 2012
VL 32
IS 1
BP 70
EP 82
DI 10.1177/0272989X10397615
PG 13
WC Health Care Sciences & Services; Medical Informatics
SC Health Care Sciences & Services; Medical Informatics
GA 884JN
UT WOS:000299701100011
PM 21383086
ER
PT J
AU Singh, JA
Kundukulam, JA
Bhandari, M
AF Singh, Jasvinder A.
Kundukulam, Joseph A.
Bhandari, Mohit
TI A systematic review of validated methods for identifying orthopedic
implant removal and revision using administrative data
SO PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
LA English
DT Review
DE systematic review; orthopedic implant; implant removal; revision; total
hip arthroplasty; arthroplasty
ID TOTAL KNEE ARTHROPLASTY; TOTAL HIP-ARTHROPLASTY; STATES MEDICARE
POPULATION; TOTAL JOINT ARTHROPLASTY; TOTAL SHOULDER ARTHROPLASTY; TERM
COMPLICATION RATES; QUALITY-OF-LIFE; UNITED-STATES; PATIENT OUTCOMES;
HOSPITAL VOLUME
AB Purpose To identify studies that have validated administrative and claims database algorithms for identifying patients with orthopedic device revision or removal. Methods As a part of the Food and Drug Administration's Mini-Sentinel pilot program, we performed a systematic review to identify algorithms for orthopedic implant removal/ revision in administrative and claims databases in the USA or Canada. Results Five studies examined the validity of database algorithms against a gold standard of documentation in medical records (n = 3) or codes/ documentation in another database (n = 2). The positive predictive values (PPV) of the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) and/or the Current Procedural Terminology codes for revision total hip arthroplasty (THA) in the US Medicare population compared with medical record review were 92% and 91%, respectively. In another study of the US Medicare population, multiple ICD-9 codes for revision total knee arthroplasty were compared with newly available single ICD-9-CM codes for revision knee arthroplasty; sensitivity was 87% and specificity was 99% (PPV not provided). The fourth study validated the ICD-9-CM codes for revision total knee arthroplasty against Ontario health insurance physician fee service claims as the gold standard and found a PPV of 32%. In the last study in Medicare population, the accuracy of the attribution of revision THA to the same side as the earlier index primary THA was examined; PPV for same laterality of revision THA was 71% (using ICD-9-CM codes). Conclusions Validation data, with regard to the ICD-9-CM or the Current Procedural Terminology code algorithms for revision THA in the Medicare population, exist. More validation studies are needed to confirm these findings and examine other large databases. Copyright c (C) 2012 John Wiley & Sons, Ltd.
C1 [Singh, Jasvinder A.; Kundukulam, Joseph A.] Univ Alabama, Dept Med, Birmingham, AL 35294 USA.
[Singh, Jasvinder A.] Univ Alabama, Div Epidemiol, Sch Publ Hlth, Birmingham, AL 35294 USA.
[Singh, Jasvinder A.] Birmingham VA Med Ctr, Med Serv, Birmingham, AL USA.
[Singh, Jasvinder A.] Birmingham VA Med Ctr, Ctr Surg Med Acute Care Res & Transit C SMART, Birmingham, AL USA.
[Singh, Jasvinder A.] Mayo Clin, Sch Med, Dept Orthoped Surg, Rochester, MN USA.
[Bhandari, Mohit] McMaster Univ, Dept Surg, Hamilton, ON L8S 4L8, Canada.
RP Singh, JA (reprint author), Univ Alabama, Dept Med, Fac Off Tower 805B,510 20th St S, Birmingham, AL 35294 USA.
EM Jasvinder.md@gmail.com
OI singh, jasvinder/0000-0003-3485-0006
FU Allergan; Takeda; Savient; Wyeth; Amgen; URL pharmaceuticals; Novartis;
Stryker; Smith; Nephew; Zimmer; Pfizer; DePuy; FDA through the
Department of Health and Human Services (HHS) [HHSF223200910006I]
FX There are no financial conflicts related to this work. J.A.S. has
received speaker honoraria from Abbott; research and travel grants from
Allergan, Takeda, Savient, Wyeth, and Amgen; and consultant fees from
Savient, URL pharmaceuticals, and Novartis. M.B. has received research
funding from Stryker, Smith, and Nephew, Zimmer, Pfizer, Amgen, and
DePuy. J.A.K. has no financial relationships.; This work was supported
by the FDA through the Department of Health and Human Services (HHS)
contract number HHSF223200910006I. The study sponsors had no role in the
study design; in the collection, analysis, and interpretation of data;
in the writing of the manuscript; and in the decision to submit the
manuscript for publication. The views expressed in this document do not
necessarily reflect the official policies of the Department of Health
and Human Services, nor does the mention of trade names, commercial
practices, or organizations imply endorsement by the US government. The
views expressed in this article are those of the authors and do not
necessarily reflect the position or policy of the Department of Veterans
Affairs.
NR 61
TC 8
Z9 8
U1 1
U2 7
PU WILEY PERIODICALS, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN STREET, MALDEN, MA 02148-529 USA
SN 1053-8569
J9 PHARMACOEPIDEM DR S
JI Pharmacoepidemiol. Drug Saf.
PD JAN
PY 2012
VL 21
SU 1
BP 265
EP 273
DI 10.1002/pds.2309
PG 9
WC Public, Environmental & Occupational Health; Pharmacology & Pharmacy
SC Public, Environmental & Occupational Health; Pharmacology & Pharmacy
GA 878JU
UT WOS:000299253900031
PM 22262616
ER
PT J
AU Hoerster, KD
Butler, DA
Mayer, JA
Finlayson, T
Gallo, LC
AF Hoerster, Katherine D.
Butler, Dalila A.
Mayer, Joni A.
Finlayson, Tracy
Gallo, Linda C.
TI Use of conventional care and complementary/alternative medicine among US
adults with arthritis
SO PREVENTIVE MEDICINE
LA English
DT Article
DE Arthritis; Epidemiology; Disparities; Access to care
ID ALTERNATIVE MEDICINE; ACTIVITY LIMITATIONS; IMPACT
AB Objective: Managing arthritis and co-morbid conditions is of public health importance. It is therefore critical to have a comprehensive understanding of healthcare utilization among US adults with arthritis. Thus, the present study identified characteristics associated with using both complementary and alternative medicine (CAM) and conventional healthcare.
Method: Using 2007 National Health Interview Survey data, multinomial logistic regression was performed to compare four categories of past year healthcare use (both CAM and conventional care vs. conventional care only, CAM only, and no healthcare use) on their potential correlates.
Results: The sample (n = 3850) was 62.8% female and 80.4% non-Hispanic White. Nearly half were at least 65 years old, and had used both CAM and conventional services in the previous year. The following characteristics were associated with having used neither CAM nor conventional care in the previous year (vs. having used both CAM and conventional care): being from an ethnic and racial minority group (ORs = 2.44. 3.26, and 3.91) and being uninsured (OR = 4.06), identifying individuals potentially at risk for unmet need.
Conclusion: To ensure access to comprehensive care, potentially underserved populations should be targeted with outreach (e.g., providing low-cost, accessible care, and education about benefits of various treatments for arthritis and co-morbid conditions). Published by Elsevier Inc.
C1 [Hoerster, Katherine D.; Butler, Dalila A.; Mayer, Joni A.; Finlayson, Tracy] San Diego State Univ, Grad Sch Publ Hlth, San Diego, CA 92123 USA.
[Hoerster, Katherine D.; Gallo, Linda C.] Univ Calif San Diego, San Diego State Univ, San Diego Joint Doctoral Program Clin Psychol, San Diego, CA 92120 USA.
San Diego State Univ, Dept Psychol, San Diego, CA 92182 USA.
RP Hoerster, KD (reprint author), VA Puget Sound Healthcare Syst, Seattle Div, 1660 S Columbian Way S-116, Seattle, WA 98108 USA.
EM Katherine.Hoerster@va.gov
OI Gallo, Linda C./0000-0002-3678-5888
NR 14
TC 6
Z9 6
U1 0
U2 0
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0091-7435
J9 PREV MED
JI Prev. Med.
PD JAN 1
PY 2012
VL 54
IS 1
BP 13
EP 17
DI 10.1016/j.ypmed.2011.08.023
PG 5
WC Public, Environmental & Occupational Health; Medicine, General &
Internal
SC Public, Environmental & Occupational Health; General & Internal Medicine
GA 881BM
UT WOS:000299455500005
PM 21889528
ER
PT J
AU Khanna, D
Maranian, P
Rothrock, N
Cella, D
Gershon, R
Khanna, PP
Spiegel, B
Furst, DE
Clements, PJ
Bechtel, A
Hays, RD
AF Khanna, Dinesh
Maranian, Paul
Rothrock, Nan
Cella, David
Gershon, Richard
Khanna, Puja P.
Spiegel, Brennan
Furst, Daniel E.
Clements, Phil J.
Bechtel, Amber
Hays, Ron D.
TI Feasibility and Construct Validity of PROMIS and "Legacy" Instruments in
an Academic Scleroderma Clinic
SO VALUE IN HEALTH
LA English
DT Article
DE construct validity; health-related quality of life; systemic sclerosis;
PROMIS
ID INFORMATION-SYSTEM PROMIS; QUALITY-OF-LIFE; QUESTIONNAIRE-DISABILITY
INDEX; MEDICAL OUTCOMES; SCLEROSIS; HEALTH; POPULATION; PREVALENCE;
DEPRESSION; ARTHRITIS
AB Objective: The National Institutes of Health Patient-Reported Outcomes Measurement Information System (PROMIS) roadmap initiative is a cooperative group program of research designed to develop, evaluate, and standardize item banks to measure patient-reported outcomes relevant across medical conditions. The objective of the current study was to assess feasibility and evaluation of the construct validity of PROMIS item banks versus legacy measures in an observational study in systemic sclerosis (SSc). We hypothesized that the PROMIS item banks can be administered in a clinical setting if there is adequate staff support without disrupting the flow of clinic. Methods: Patients with SSc in a single academic center completed computerized adaptive test (CAT) administered PROMIS item banks during the clinic visit and legacy measures (using paper and pencil). The construct validity of PROMIS items was evaluated by examining correlations with corresponding legacy measures using multitrait-multimethod analysis. Results: Participants consisted of 143 SSc patients with an average age of 51.5 years; 71% were female and 68% were white. The average number of items completed for each CAT-administered item bank ranged from 5 to 8 (69 CAT items per patient), and the average time to complete each CAT-administered item bank ranged from 48 seconds to 1.9 minutes per patient (average time similar to 11.9 minutes/ per patient for 11 banks). All correlations between PROMIS domains and respective legacy measures were large and in the hypothesized direction (ranged from 0.61 to 0.82). Conclusion: Our study supports the construct validity of the CAT-administered PROMIS item banks and shows that they can be administered successfully in a clinic with support staff. Future studies should assess the feasibility of PROMIS item banks in a busy clinical practice.
C1 [Khanna, Dinesh] Univ Michigan, Scleroderma Program, Div Rheumatol, Dept Internal Med, Ann Arbor, MI 48106 USA.
[Maranian, Paul; Furst, Daniel E.; Clements, Phil J.; Bechtel, Amber] Univ Calif Los Angeles, David Geffen Sch Med, Div Rheumatol, Los Angeles, CA 90095 USA.
[Rothrock, Nan; Cella, David; Gershon, Richard] Northwestern Univ, Feinberg Sch Med, Dept Med Social Sci, Chicago, IL 60611 USA.
[Spiegel, Brennan] Univ Calif Los Angeles, David Geffen Sch Med, Div Digest Dis, Los Angeles, CA 90095 USA.
[Spiegel, Brennan] Univ Calif Los Angeles, David Geffen Sch Med, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90095 USA.
[Hays, Ron D.] Univ Calif Los Angeles, David Geffen Sch Med, Div Gen Internal Med & Hlth Serv Res, Los Angeles, CA 90095 USA.
[Hays, Ron D.] RAND, Los Angeles, CA USA.
RP Khanna, D (reprint author), Univ Michigan, Scleroderma Program, Div Rheumatol, Dept Internal Med, 24 Frank Lloyd Wright Dr,Lobby M,Suite 2500,SPC 5, Ann Arbor, MI 48106 USA.
EM khannad@med.umich.edu
RI Hays, Ronald/D-5629-2013
FU National Institutes of Health (NIH/ NIAMS) [U01 AR057936A]; National
Institutes of Health through NIH [AR052177]; NIAMS [K23 AR053858-05];
Scleroderma Foundation; National Institutes of Health [T32 AR 053463];
UCLA Resource Center for Minority Aging Research/Center for Health
Improvement in Minority Elderly (RCMAR/CHIME); NIH/NIA [P30AG021684];
UCLA/ Drew, EXPORT, NCMHD [2P20MD000182]
FX D. Khanna, Maranian, Rothrock, Cella, Gershon, Furst, PP Khanna,
Spiegel, Bechtel and Hays were supported by a National Institutes of
Health Award (NIH/ NIAMS U01 AR057936A), and the National Institutes of
Health through the NIH Roadmap for Medical Research Grant (AR052177). D.
Khanna is also supported by NIAMS K23 AR053858-05 and the Scleroderma
Foundation (New Investigator Award). Dr. PP Khanna was also supported by
National Institutes of Health Award (T32 AR 053463). Hays was also
supported by the UCLA Resource Center for Minority Aging Research/Center
for Health Improvement in Minority Elderly (RCMAR/CHIME), NIH/NIA Grant
Award Number P30AG021684, and the UCLA/ Drew Project EXPORT, NCMHD,
2P20MD000182.
NR 37
TC 20
Z9 20
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1098-3015
J9 VALUE HEALTH
JI Value Health
PD JAN-FEB
PY 2012
VL 15
IS 1
BP 128
EP 134
DI 10.1016/j.jval.2011.08.006
PG 7
WC Economics; Health Care Sciences & Services; Health Policy & Services
SC Business & Economics; Health Care Sciences & Services
GA 879GU
UT WOS:000299318500015
PM 22264980
ER
PT J
AU Xu, S
Shetterly, S
Powers, D
Raebel, MA
Tsai, TT
Ho, PM
Magid, D
AF Xu, Stanley
Shetterly, Susan
Powers, David
Raebel, Marsha A.
Tsai, Thomas T.
Ho, P. Michael
Magid, David
TI Extension of Kaplan-Meier Methods in Observational Studies with
Time-Varying Treatment
SO VALUE IN HEALTH
LA English
DT Article
DE Kaplan Meier estimates; Observational study; Stabilized weights; Stents;
Time-varying treatment
ID MARGINAL STRUCTURAL MODELS; PROPENSITY SCORE; INVERSE PROBABILITY;
ANTIRETROVIRAL THERAPY; SURVIVAL; EPIDEMIOLOGY; ZIDOVUDINE; MORTALITY;
WEIGHTS; SAMPLES
AB Objectives: Inverse probability of treatment weighted Kaplan-Meier estimates have been developed to compare two treatments in the presence of confounders in observational studies. Recently, stabilized weights were developed to reduce the influence of extreme inverse probability of treatment-weighted weights in estimating treatment effects. The objective of this research was to use adjusted Kaplan-Meier estimates and modified log-rank and Wilcoxon tests to examine the effect of a treatment that varies over time in an observational study. Methods: We proposed stabilized weight adjusted Kaplan-Meier estimates and modified log-rank and Wilcoxon tests when the treatment was time-varying over the follow-up period. We applied these new methods in examining the effect of an anti-platelet agent, clopidogrel, on subsequent events, including bleeding, myocardial infarction, and death after a drug-eluting stent was implanted into a coronary artery. In this population, clopidogrel use may change over time based on a patient's behavior (e. g., nonadherence) and physicians' recommendations (e. g., end of duration of therapy). Consequently, clopidogrel use was treated as a time-varying variable. Results: We demonstrate that 1) the sample sizes at three chosen time points are almost identical in the original and weighted datasets; and 2) the covariates between patients on and off clopidogrel were well balanced after stabilized weights were applied to the original samples. Conclusions: The stabilized weight-adjusted Kaplan-Meier estimates and modified log-rank and Wilcoxon tests are useful in presenting and comparing survival functions for time-varying treatments in observational studies while adjusting for known confounders.
C1 [Xu, Stanley; Shetterly, Susan; Powers, David; Raebel, Marsha A.; Tsai, Thomas T.; Ho, P. Michael; Magid, David] Kaiser Permanente Colorado, Inst Hlth Res, Denver, CO 80111 USA.
[Xu, Stanley; Raebel, Marsha A.; Tsai, Thomas T.; Ho, P. Michael; Magid, David] Univ Colorado, Denver, CO 80202 USA.
[Tsai, Thomas T.; Ho, P. Michael] Denver VA Med Ctr, Denver, CO USA.
RP Xu, S (reprint author), Kaiser Permanente Colorado, Inst Hlth Res, 10065 E Harvard Ave, Denver, CO 80111 USA.
EM stan.xu@kp.org
FU Strategic Initiatives Funds of Kaiser Permanente Colorado; NIH/NCRR
Colorado CTSI [TL1 RR025780]; Agency for Healthcare Research and Quality
[290-05-0033]; US Department of Health and Human Services
FX This project was supported by Strategic Initiatives Funds of Kaiser
Permanente Colorado, supported by NIH/NCRR Colorado CTSI grant No. TL1
RR025780, and funded under Contract No. 290-05-0033 from the Agency for
Healthcare Research and Quality, US Department of Health and Human
Services as part of the Developing Evidence to Inform Decisions about
Effectiveness 16 program.
NR 28
TC 8
Z9 9
U1 0
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1098-3015
J9 VALUE HEALTH
JI Value Health
PD JAN-FEB
PY 2012
VL 15
IS 1
BP 167
EP 174
DI 10.1016/j.jval.2011.07.010
PG 8
WC Economics; Health Care Sciences & Services; Health Policy & Services
SC Business & Economics; Health Care Sciences & Services
GA 879GU
UT WOS:000299318500020
PM 22264985
ER
PT J
AU Haisley, E
Volpp, KG
Pellathy, T
Loewenstein, G
AF Haisley, Emily
Volpp, Kevin G.
Pellathy, Thomas
Loewenstein, George
TI The Impact of Alternative Incentive Schemes on Completion of Health Risk
Assessments
SO AMERICAN JOURNAL OF HEALTH PROMOTION
LA English
DT Article
DE Behavioral Economics; Corporate Wellness Programs; Health Incentives;
Health Risk Assessments; Preventive Health Care; Prevention Research
ID RANDOMIZED-TRIAL; PROMOTION; LIFE
AB Purpose. The biggest challenge for corporate wellness initiatives is low rates of employee participation. We test whether a behavioral economic approach to incentive design (i.e., a lottery) is more effective than a direct economic payment of equivalent monetary value (i.e., a grocery gift certificate) in encouraging employees to complete health risk assessments (HRAs).
Design. Employees were assigned to one of three arms. Assignment to a treatment arm versus the nontreatment arm was determined by management. Assignment to an arm among those eligible for treatment was randomized by office.
Setting. A large health care management and information technology consulting company.
Patients. A total of 1299 employees across 14 offices participated.
Intervention. All employees were eligible to receive $25 for completing the HRA. Those in the lottery condition were assigned to teams of four to eight people and, conditional on HRA completion, were entered into a lottery with a prize of $100 (expected value, $25) and a bonus value of an additional $25 if 80% of team members participated. Those in the grocery gift certificate condition who completed an HRA received a $25 grocery gift certificate. Those in the comparison condition received no additional incentive.
Measures. HRA completion rates. Analysis. Logistic regression analysis.
Results. HRA completion rates were significantly higher among participations in the lottery incentive condition (64%) than in both the grocery gift certificate condition (44%) and the comparison condition (40%). Effects were larger for lower-income employees, as indicated by a significant interaction between income and the lottery incentive.
Conclusion. Lottery incentives that incorporate regret aversion and social pressure can provide higher impact for the same amount of money as simple economic incentives. (Am J Health Promot 2012;26131:184-188.)
C1 [Loewenstein, George] Carnegie Mellon Univ, Dept Social & Decis Sci, Pittsburgh, PA 15213 USA.
[Haisley, Emily] Barclays Wealth, Behav Finance Grp, London, England.
[Volpp, Kevin G.] Univ Penn, Ctr Hlth Equ Res & Promot, Philadelphia Vet Affairs Med Ctr,Wharton Sch, Dept Med,Sch Med,Dept Hlth Care Management, Philadelphia, PA 19104 USA.
[Pellathy, Thomas] McKinsey & Co Inc, Pittsburgh, PA USA.
RP Loewenstein, G (reprint author), Carnegie Mellon Univ, Dept Social & Decis Sci, 5000 Forbes Ave, Pittsburgh, PA 15213 USA.
EM g120@andrew.cmu.edu
NR 12
TC 24
Z9 24
U1 1
U2 19
PU AMER JOURNAL HEALTH PROMOTION INC
PI TROY
PA PO BOX 1254, TROY, MI 48099-1254 USA
SN 0890-1171
J9 AM J HEALTH PROMOT
JI Am. J. Health Promot.
PD JAN-FEB
PY 2012
VL 26
IS 3
BP 184
EP 188
DI 10.4278/ajhp.100729-ARB-257
PG 5
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 880ZE
UT WOS:000299448300010
PM 22208418
ER
PT J
AU DiMartini, A
Cruz, RJ
Dew, MA
Fitzgerald, MG
Chiappetta, L
Myaskovsky, L
DeVera, ME
AF DiMartini, A.
Cruz, R. J., Jr.
Dew, M. A.
Fitzgerald, M. G.
Chiappetta, L.
Myaskovsky, L.
DeVera, M. E.
TI Motives and Decision Making of Potential Living Liver Donors:
Comparisons Between Gender, Relationships and Ambivalence
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Article
DE Donor screening; living liver donors; psychological characteristics of
donors
ID BONE-MARROW DONORS; DONATION; OUTCOMES; TRANSPLANTATION
AB The motives and decision making of potential living liver donors are critical areas for transplant clinicians evaluating these candidates to understand, yet these topics remain relatively unstudied. Thus, we surveyed 77 prospective living liver donors at the point of donation evaluation using structured instruments to gather more information on their approach to and concerns about donation. We collected information on donation decision making, motives for donation and anticipated social and physical concerns about postdonation outcomes. We examined three additional characteristics of donors: gender, the relationship of the donor to the intended recipient and the presence of ambivalence about donation. Women had more concerns about their family/social responsibilities. Those donating to nonimmediate family were more likely to have been asked to donate but less likely to feel they had to donate. However, ambivalent donors were the most distinct having difficulties and concerns across most areas from their motivations for donating, to deciding to be tested and to donate, to concerns about the postdonation outcomes. We discuss the clinical relevance of these findings to donor evaluation and preparation.
C1 [DiMartini, A.; Dew, M. A.; Fitzgerald, M. G.; Chiappetta, L.; Myaskovsky, L.] Univ Pittsburgh, Med Ctr, Dept Psychiat, Pittsburgh, PA 15260 USA.
[DiMartini, A.; Cruz, R. J., Jr.; DeVera, M. E.] Univ Pittsburgh, Med Ctr, Dept Transplantat Surg, Pittsburgh, PA USA.
[DiMartini, A.; Cruz, R. J., Jr.; Fitzgerald, M. G.; DeVera, M. E.] Univ Pittsburgh, Thomas E Starzl Transplantat Inst, Pittsburgh, PA USA.
[Dew, M. A.] Univ Pittsburgh, Dept Psychol, Med Ctr, Pittsburgh, PA 15260 USA.
[Dew, M. A.] Univ Pittsburgh, Dept Epidemiol, Med Ctr, Pittsburgh, PA 15261 USA.
[Myaskovsky, L.] Univ Pittsburgh, Dept Med, Med Ctr, Pittsburgh, PA USA.
[Myaskovsky, L.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA.
RP DiMartini, A (reprint author), Univ Pittsburgh, Med Ctr, Dept Psychiat, Pittsburgh, PA 15260 USA.
EM dimartiniaf@upmc.edu
FU Starzl Transplant Institute; International Transplant Nurses Society
FX This research is funded by grants from the Starzl Transplant Institute
Junior Investigator Award (Cruz) and an International Transplant Nurses
Society research program grant.
NR 22
TC 14
Z9 14
U1 0
U2 3
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1600-6135
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD JAN
PY 2012
VL 12
IS 1
BP 136
EP 151
DI 10.1111/j.1600-6143.2011.03805.x
PG 16
WC Surgery; Transplantation
SC Surgery; Transplantation
GA 875XU
UT WOS:000299069300018
PM 22081865
ER
PT J
AU Arling, G
Reeves, M
Ross, J
Williams, LS
Keyhani, S
Chumbler, N
Phipps, MS
Roumie, C
Myers, LJ
Salanitro, AH
Ordin, DL
Myers, J
Bravata, DM
AF Arling, Greg
Reeves, Mathew
Ross, Joseph
Williams, Linda S.
Keyhani, Salomeh
Chumbler, Neale
Phipps, Michael S.
Roumie, Christianne
Myers, Laura J.
Salanitro, Amanda H.
Ordin, Diana L.
Myers, Jennifer
Bravata, Dawn M.
TI Estimating and Reporting on the Quality of Inpatient Stroke Care by
Veterans Health Administration Medical Centers
SO CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES
LA English
DT Article
DE acute stroke; performance measurement; quality indicators; stroke
management; statistics
ID ACUTE ISCHEMIC-STROKE; PLASMINOGEN-ACTIVATOR; PERFORMANCE-MEASURES;
OF-CARE; OUTCOMES; MORTALITY; MODELS; IMPACT; INTERVENTION; IMPROVEMENT
AB Background-Reporting of quality indicators (QIs) in Veterans Health Administration Medical Centers is complicated by estimation error caused by small numbers of eligible patients per facility. We applied multilevel modeling and empirical Bayes (EB) estimation in addressing this issue in performance reporting of stroke care quality in the Medical Centers.
Methods and Results-We studied a retrospective cohort of 3812 veterans admitted to 106 Medical Centers with ischemic stroke during fiscal year 2007. The median number of study patients per facility was 34 (range, 12-105). Inpatient stroke care quality was measured with 13 evidence-based QIs. Eligible patients could either pass or fail each indicator. Multilevel modeling of a patient's pass/fail on individual QIs was used to produce facility-level EB-estimated QI pass rates and confidence intervals. The EB estimation reduced interfacility variation in QI rates. Small facilities and those with exceptionally high or low rates were most affected. We recommended 8 of the 13 QIs for performance reporting: dysphagia screening, National Institutes of Health Stroke Scale documentation, early ambulation, fall risk assessment, pressure ulcer risk assessment, Functional Independence Measure documentation, lipid management, and deep vein thrombosis prophylaxis. These QIs displayed sufficient variation across facilities, had room for improvement, and identified sites with performance that was significantly above or below the population average. The remaining 5 QIs were not recommended because of too few eligible patients or high pass rates with little variation.
Conclusions-Considerations of statistical uncertainty should inform the choice of QIs and their application to performance reporting. (Circ Cardiovasc Qual Outcomes. 2012;5:44-51.)
C1 [Arling, Greg; Williams, Linda S.; Chumbler, Neale; Bravata, Dawn M.] Regenstrief Inst Hlth Care, Indianapolis, IN 46202 USA.
[Arling, Greg; Reeves, Mathew; Williams, Linda S.; Chumbler, Neale; Myers, Laura J.; Ordin, Diana L.; Myers, Jennifer; Bravata, Dawn M.] Stroke Qual Enhancement Res Initiat QUERI, VHA Hlth Serv Res & Dev HSR& D, Indianapolis, IN USA.
[Ordin, Diana L.] VHA, Off Informat & Analyt, Washington, DC USA.
[Arling, Greg; Myers, Laura J.; Bravata, Dawn M.] Indiana Univ Sch Med, Dept Med, Indianapolis, IN USA.
[Reeves, Mathew] Michigan State Univ, Dept Epidemiol, E Lansing, MI 48824 USA.
[Ross, Joseph] Yale Univ, Sch Med, Dept Med, Gen Internal Med Sect, New Haven, CT 06510 USA.
[Ross, Joseph] Yale New Haven Med Ctr, Ctr Outcomes Res & Evaluat, New Haven, CT 06504 USA.
[Williams, Linda S.; Chumbler, Neale; Myers, Laura J.; Myers, Jennifer; Bravata, Dawn M.] Richard L Roudebush VHA Med Ctr, VHA HSR&D Ctr Excellence Implementing Evidence Ba, Indianapolis, IN USA.
[Williams, Linda S.] Indiana Univ Sch Med, Dept Neurol, Indianapolis, IN USA.
[Keyhani, Salomeh] Univ Calif San Francisco, Div Gen Internal Med, San Francisco, CA 94143 USA.
[Keyhani, Salomeh] San Francisco VA Med Ctr, HSR&D Res Enhancement Award Program, San Francisco, CA USA.
[Chumbler, Neale] Indiana Univ Purdue Univ, Indiana Univ, Sch Liberal Arts, Dept Sociol, Indianapolis, IN 46202 USA.
[Phipps, Michael S.] Yale Univ, Sch Med, Robert Wood Johnson Fdn, Clin Scholars Program, New Haven, CT USA.
[Phipps, Michael S.] Yale Univ, Sch Med, Dept Neurol, New Haven, CT 06510 USA.
[Roumie, Christianne] Vet Affairs Tennessee Valley Healthcare Syst, HSR&D Targeted Res Enhancement Program Ctr, GRECC, Nashville, TN USA.
[Roumie, Christianne] Vet Affairs Tennessee Valley Healthcare Syst, Clin Res Training Ctr Excellence, Nashville, TN USA.
[Roumie, Christianne; Salanitro, Amanda H.] Vanderbilt Univ, Med Ctr, Inst Med & Publ Hlth, Nashville, TN USA.
[Salanitro, Amanda H.] Vanderbilt Univ, Med Ctr, Sect Hosp Med, Nashville, TN USA.
RP Arling, G (reprint author), Regenstrief Inst Hlth Care, 410 W 10th St,Suite 2000, Indianapolis, IN 46202 USA.
EM GArling@IUPUI.edu
OI Phipps, Michael/0000-0001-8398-5404
FU Department of Veterans Affairs, Veterans Health Administration (VHA),
Office of Quality and Performance and Health Services Research, and
Development Service Quality Enhancement Research Initiative [RRP
09-184]; National Institute on Aging; American Federation of Aging
Research [K08 AG032886]; VA HSRD
FX The Department of Veterans Affairs, Veterans Health Administration
(VHA), Office of Quality and Performance and Health Services Research,
and Development Service Quality Enhancement Research Initiative (RRP
09-184) supported this project. Dr Ross is supported by the National
Institute on Aging and by the American Federation of Aging Research
through the Paul B. Beason Career Development Award Program (K08
AG032886). Dr Keyhani is supported by a VA HSR&D Career Development
Award.
NR 42
TC 18
Z9 19
U1 1
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1941-7705
J9 CIRC-CARDIOVASC QUAL
JI Circ.-Cardiovasc. Qual. Outcomes
PD JAN
PY 2012
VL 5
IS 1
BP 44
EP U102
DI 10.1161/CIRCOUTCOMES.111.961474
PG 23
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 880ML
UT WOS:000299411100009
PM 22147888
ER
PT J
AU Brennan, JM
Peterson, ED
Messenger, JC
Rumsfeld, JS
Weintraub, WS
Anstrom, KJ
Eisenstein, EL
Milford-Beland, S
Grau-Sepulveda, MV
Booth, ME
Dokholyan, RS
Douglas, PS
AF Brennan, J. Matthew
Peterson, Eric D.
Messenger, John C.
Rumsfeld, John S.
Weintraub, William S.
Anstrom, Kevin J.
Eisenstein, Eric L.
Milford-Beland, Sarah
Grau-Sepulveda, Maria V.
Booth, Michael E.
Dokholyan, Rachel S.
Douglas, Pamela S.
CA Duke Clinical Res Inst DEcIDE Team
TI Linking the National Cardiovascular Data Registry CathPCI Registry With
Medicare Claims Data Validation of a Longitudinal Cohort of Elderly
Patients Undergoing Cardiac Catheterization
SO CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES
LA English
DT Article
DE catheterization; data linkage; outcomes
AB Background-The National Cardiovascular Data Registry CathPCI Registry was recently linked with longitudinal Centers for Medicare & Medicaid (CMS) claims data. The degree to which this linked cohort is representative of the overall CathPCI Registry and CMS PCI populations is unknown.
Methods and Results-CathPCI Registry records were linked to CMS inpatient claims using indirect identifiers. We examined the degree to which hospitals and patients in the linked cohort are representative of the elderly (>= 65 years) CathPCI Registry and CMS populations. From 2004 to 2006, 1492 hospitals filed CMS PCI claims and 663 contributed CathPCI Registry data. Of these hospitals, 643 (97%) were linked across data sources. Compared with all CMS PCI hospitals, the linked data set contained fewer governmental, northeastern, southern, and low-volume (<200 beds) sites. Among CMS beneficiaries, 993 351 PCI procedures were performed, including 398 508 (40.1%) at centers in the linked database. Of these, 341 916 (86%) were linked to CathPCI Registry records. Linked and unlinked CMS patients had similar demographic and clinical features. In the CathPCI Registry database, 477 456 elderly patients underwent PCI, with 359 077 (75%) linked to CMS claims. Linked and unlinked National Cardiovascular Data Registry patients were similar, except for less commercial or health maintenance organization insurance in the linked cohort.
Conclusions-By using deterministic matching strategies, a large and representative cohort with detailed clinical data from the CathPCI Registry and longitudinal follow-up from CMS claims has been created. (Circ Cardiovasc Qual Outcomes. 2012;5:134-140.)
C1 [Brennan, J. Matthew; Peterson, Eric D.; Eisenstein, Eric L.; Milford-Beland, Sarah; Grau-Sepulveda, Maria V.; Booth, Michael E.; Dokholyan, Rachel S.; Douglas, Pamela S.] Duke Univ, Duke Clin Res Inst, Med Ctr, Durham, NC 27705 USA.
[Messenger, John C.; Rumsfeld, John S.] Denver Vet Affairs Med Ctr, Denver, CO USA.
[Weintraub, William S.] Christiana Care Hlth Syst, Newark, DE USA.
RP Brennan, JM (reprint author), Duke Univ, Duke Clin Res Inst, Med Ctr, 2400 Pratt St, Durham, NC 27705 USA.
EM brenn009@mc.duke.edu
FU Agency for Healthcare Research and Quality, US Department of Health and
Human Services, Rockville, MD [24-EHC-1, HHSAA290-2005, 0032-TO4-WA2];
National Cardiovascular Data Registry, American College of Cardiology,
Washington, DC; BMS/Sanofi; Merck; Lilly; JJ; Society of Thoracic
Surgeons; ACC; Alexion; AstraZeneca; Bristol Myers Squibb; Innocoll
Pharmaceuticals; Medtronic; Pfizer; Proctor Gamble; Eli Lilly
FX This project was sponsored by the Agency for Healthcare Research and
Quality, US Department of Health and Human Services, Rockville, MD, as
part of the Cardiovascular Consortium and funded under Project ID:
24-EHC-1 and Work Assignment No. HHSAA290-2005 to 0032-TO4-WA2 as part
of the Developing Evidence to Inform Decisions about Effectiveness
(DEcIDE) program. Additional support was obtained from the National
Cardiovascular Data Registry, American College of Cardiology,
Washington, DC.; Dr Peterson reports receiving research funding from
BMS/Sanofi, Merck, Lilly, J&J, Society of Thoracic Surgeons, and ACC
(significant). Dr Messenger reports serving as the site principal
investigator for the Resolute Study and the EDUCATE study: Medtronic,
Inc (modest). Dr Rumsfeld is the Chief Science Officer for National
Cardiovascular Data Registry. Dr Anstrom reports receiving research and
salary support from Alexion, AstraZeneca, Bristol Myers Squibb, Lilly,
Innocoll Pharmaceuticals, Medtronic, Pfizer, and Proctor & Gamble
(modest); being on the data safety monitoring boards of Pfizer and
Vertex (modest); and providing consulting services to Pacific
Therapeutics, Bristol Myers Squibb, and AstraZeneca (modest). Dr
Eisenstein reports receiving research funding from Medtronic and Eli
Lilly (significant).
NR 6
TC 26
Z9 26
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1941-7705
J9 CIRC-CARDIOVASC QUAL
JI Circ.-Cardiovasc. Qual. Outcomes
PD JAN
PY 2012
VL 5
IS 1
BP 134
EP 140
DI 10.1161/CIRCOUTCOMES.111.963280
PG 7
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 880ML
UT WOS:000299411100020
PM 22253370
ER
PT J
AU DeFronzo, RA
Davidson, JA
Del Prato, S
AF DeFronzo, R. A.
Davidson, J. A.
Del Prato, S.
TI The role of the kidneys in glucose homeostasis: a new path towards
normalizing glycaemia
SO DIABETES OBESITY & METABOLISM
LA English
DT Review
DE clinical trials; diabetes; glucose homeostasis; glycosuria;
hyperglycaemia; kidneys; renal glucose transport; SGLT2; SGLT2
inhibitors; sodium-glucose cotransporters
ID TYPE-2 DIABETES-MELLITUS; SELECTIVE SGLT2 INHIBITOR; JAPANESE
HEALTHY-VOLUNTEERS; RENAL PROXIMAL TUBULES; BETA-CELL DYSFUNCTION; FREE
FATTY-ACIDS; INSULIN-RESISTANCE; BLOOD-GLUCOSE; DOUBLE-BLIND;
BODY-WEIGHT
AB The maintenance of normal glucose homeostasis requires a complex, highly integrated interaction among the liver, muscle, adipocytes, pancreas and neuroendocrine system. Recent studies have showed that the kidneys also play a central role in glucose homeostasis by reabsorbing all the filtered glucose, an adaptive mechanism that ensures sufficient energy is available during fasting periods. This mechanism becomes maladaptive in diabetes, however, as hyperglycaemia augments the expression and activity of the sodiumglucose cotransporter (SGLT) 2 in the proximal tubule of the kidney. As a result, glucose reabsorption may be increased by as much as 20% in individuals with poorly controlled diabetes. SGLT2 is a low-affinity, high-capacity glucose transport protein that reabsorbs 90% of filtered glucose, while the high-affinity, low-capacity SGLT1 transporter reabsorbs the remaining 10%. SGLT2 represents a novel target for the treatment of diabetes. In animal studies, SGLT2 inhibition reduces plasma glucose levels, resulting in improved beta-cell function and enhanced insulin sensitivity in liver and muscle. Human studies have confirmed the efficacy of SLGT2 inhibitors in improving glucose control and reducing the A1c. Because the mechanism of SGLT2 inhibition is independent of circulating insulin levels or insulin sensitivity, these agents can be combined with all other antidiabetic classes, including exogenous insulin. Although the long-term efficacy and safety of SGLT2 inhibitors remain under study, the class represents a novel therapeutic approach with potential for the treatment of both type 2 and 1 diabetes.
C1 [DeFronzo, R. A.] Univ Texas Hlth Sci Ctr San Antonio, Diabet Div, Dept Med, San Antonio, TX 78229 USA.
[DeFronzo, R. A.] Audie L Murphy Mem Vet Adm Med Ctr, San Antonio, TX 78284 USA.
[Davidson, J. A.] Univ Texas SW Med Sch, Diabet Div, Dallas, TX USA.
[Del Prato, S.] Univ Pisa, Diabet Div, Pisa, Italy.
RP DeFronzo, RA (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Diabet Div, Dept Med, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.
EM albarado@uthscsa.edu; davidsonmd@sbcglobal.net
RI Del Prato, Stefano/K-3405-2016
OI Del Prato, Stefano/0000-0002-5388-0270
FU AstraZeneca; Bayer Healthcare; Bristol-Myers Squibb; GlaxoSmithKline;
Johnson Johnson; Merck Sharp Dohme; Novartis; Novo Nordisk; Pfizer Inc;
Sanofi-Aventis
FX The authors have drafted this article on behalf of the Worldwide
Initiative for Diabetes Education (WorldWIDE). WorldWIDE had no input
into writing the initial version of the manuscript or into any revisions
of the manuscript. WorldWIDE is a charitable foundation that provides
training, education and information to healthcare providers. The mission
of WorldWIDE is to challenge and shape the future management of diabetes
in order to provide optimal treatment for all patients and to enhance
professional education for physicians and other diabetes professionals.
Publication of the article would help to achieve this goal. WorldWIDE
receives financial support from AstraZeneca, Bayer Healthcare,
Bristol-Myers Squibb, GlaxoSmithKline, Johnson & Johnson, Merck Sharp
&Dohme, Novartis, Novo Nordisk, Pfizer Inc and Sanofi-Aventis. The
authors acknowledge the editorial assistance of IntraMed Educational
Group in the styling of this manuscript.
NR 76
TC 152
Z9 164
U1 6
U2 35
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1462-8902
EI 1463-1326
J9 DIABETES OBES METAB
JI Diabetes Obes. Metab.
PD JAN
PY 2012
VL 14
IS 1
BP 5
EP 14
DI 10.1111/j.1463-1326.2011.01511.x
PG 10
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 862AW
UT WOS:000298063200002
PM 21955459
ER
PT J
AU Henry, RR
Aroda, VR
Mudaliar, S
Garvey, WT
Chou, HS
Jones, MR
AF Henry, R. R.
Aroda, V. R.
Mudaliar, S.
Garvey, W. T.
Chou, H. S.
Jones, M. R.
TI Effects of colesevelam on glucose absorption and hepatic/peripheral
insulin sensitivity in patients with type 2 diabetes mellitus
SO DIABETES OBESITY & METABOLISM
LA English
DT Article
DE bile acid sequestrant; colesevelam; glucose; insulin sensitivity; type 2
diabetes mellitus
ID GLYCEMIC CONTROL; SECRETION; THERAPY; HYDROCHLORIDE
AB Aim: Colesevelam lowers glucose and low-density lipoprotein cholesterol levels in patients with type 2 diabetes mellitus. This study examined the mechanisms by which colesevelam might affect glucose control.
Methods: In this 12-week, randomized, double-blind, placebo-controlled study, subjects with type 2 diabetes and haemoglobin A(1c)(HbA(1c)) >= 7.5% on either stable diet and exercise or sulphonylurea therapy were randomized to colesevelam 3.75 g/day (n = 16) or placebo (n = 14). Hepatic/peripheral insulin sensitivity was evaluated at baseline and at week 12 by infusion of (3)H-labelled glucose followed by a 2-step hyperinsulinemic-euglycemic clamp. Two 75-g oral glucose tolerance tests (OGTTs) were conducted at baseline, one with and one without co-administration of colesevelam. A final OGTT was conducted at week 12. HbA(1c) and fasting plasma glucose (FPG) levels were evaluated pre- and post-treatment.
Results: Treatment with colesevelam, compared to placebo, had no significant effects on basal endogenous glucose output, response to insulin or on maximal steady-state glucose disposal rate. At baseline, co-administration of colesevelam with oral glucose reduced total area under the glucose curve (AUCg) but not incremental AUCg. At week 12, neither total AUCg nor incremental AUCg were changed from pre-treatment values in either group. Post-load insulin levels increased with colesevelam at 30 and 120 min, but these changes in total area under the insulin curve (AUCi) and incremental AUCi did not differ between groups. Both HbA(1c) and FPG improved with colesevelam, but treatment differences were not significant.
Conclusions: Colesevelam does not affect hepatic or peripheral insulin sensitivity and does not directly affect glucose absorption.
C1 [Henry, R. R.; Mudaliar, S.] VA San Diego Healthcare Syst, Sect Diabet Endocrinol & Metab, San Diego, CA 92161 USA.
[Henry, R. R.; Mudaliar, S.] Univ Calif San Diego, San Diego, CA 92161 USA.
[Aroda, V. R.] MedStar Hlth Res Inst, Hyattsville, MD USA.
[Garvey, W. T.] Univ Alabama, Dept Nutr Sci, Birmingham, AL 35294 USA.
[Garvey, W. T.] Birmingham VA Med Ctr, Birmingham, AL USA.
[Chou, H. S.] Daiichi Sankyo Prod Dev, Edison, NJ USA.
[Jones, M. R.] Daiichi Sankyo Inc, Parsippany, NJ USA.
RP Henry, RR (reprint author), VA San Diego Healthcare Syst, Sect Diabet Endocrinol & Metab, 3350 La Jolla Village Dr,111G, San Diego, CA 92161 USA.
EM rrhenry@vapop.ucsd.edu
FU Daiichi Sankyo Inc.; VA San Diego Healthcare System; Department of
Veteran Affairs; Veterans Medical Research Foundation; Diabetes
Education and Research Center [DK 063491]; General Clinical Research
Center [MO1 RR-00827]; University of Alabama Birmingham from the Center
for Clinical and Translational Science [UL1 RR02577]; Diabetes Research
and Training Center [P60 DK079626]
FX This study was sponsored by Daiichi Sankyo Inc. Editorial assistance was
provided by Karen Stauffer, PhD, of inScience Communications, a Wolters
Kluwer business. This assistance was performed in compliance with Good
Publication Practices outlined by the International Committee of Medical
Journal Editors and was funded by Daiichi Sankyo Inc. Support is
acknowledged in San Diego from the VA San Diego Healthcare System,
Department of Veteran Affairs, Veterans Medical Research Foundation, the
Diabetes Education and Research Center DK 063491, and the General
Clinical Research Center MO1 RR-00827. Support is acknowledged from the
University of Alabama Birmingham from the Center for Clinical and
Translational Science (UL1 RR02577) and the Diabetes Research and
Training Center (P60 DK079626).
NR 13
TC 12
Z9 12
U1 0
U2 0
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1462-8902
J9 DIABETES OBES METAB
JI Diabetes Obes. Metab.
PD JAN
PY 2012
VL 14
IS 1
BP 40
EP 46
DI 10.1111/j.1463-1326.2011.01486.x
PG 7
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 862AW
UT WOS:000298063200006
PM 21831167
ER
PT J
AU Nicolau, DP
Carmeli, Y
Crank, CW
Goff, DA
Graber, CJ
Lima, ALL
Goldstein, EJC
AF Nicolau, David P.
Carmeli, Yehuda
Crank, Christopher W.
Goff, Debra A.
Graber, Christopher J.
Lima, Ana Lucia L.
Goldstein, Ellie J. C.
TI Carbapenem stewardship: does ertapenem affect Pseudomonas susceptibility
to other carbapenems? A review of the evidence
SO INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
LA English
DT Review
DE Carbapenem; Ecology; Ertapenem; Pseudomonas; Stewardship; Susceptibility
ID 25 HOSPITALS; AERUGINOSA; IMIPENEM; THERAPY; IMPACT
AB The group 2 carbapenems (imipenem, meropenem and, more recently, doripenem) have been a mainstay of treatment for patients with serious hospital infections caused by Pseudomonas aeruginosa, Enterobacteriaceae and other difficult-to-treat Gram-negative pathogens as well as mixed aerobic/anaerobic infections. When ertapenem, a group 1 carbapenem, was introduced, questions were raised about the potential for ertapenem to select for imipenem-and meropenem-resistant Pseudomonas. Results from ten clinical studies evaluating the effect of ertapenem use on the susceptibility of Pseudomonas to carbapenems have uniformly shown that ertapenem use does not result in decreased Pseudomonas susceptibility to these antipseudomonal carbapenems. Here we review these studies evaluating the evidence of how ertapenem use affects P. aeruginosa as well as provide considerations for ertapenem use in the context of institutional stewardship initiatives. (C) 2011 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.
C1 [Nicolau, David P.] Hartford Hosp, Ctr Anti Infect Res & Dev, Hartford, CT 06102 USA.
[Carmeli, Yehuda] Tel Aviv Univ, Tel Aviv Sourasky Med Ctr, Div Epidemiol, IL-69978 Tel Aviv, Israel.
[Crank, Christopher W.] Rush Univ, Med Ctr, Chicago, IL 60612 USA.
[Goff, Debra A.] Ohio State Univ, Med Ctr, Dept Pharm, Coll Pharm, Columbus, OH 43210 USA.
[Graber, Christopher J.; Goldstein, Ellie J. C.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
[Graber, Christopher J.] VA Greater Los Angeles Healthcare Syst, Infect Dis Sect, Los Angeles, CA USA.
[Lima, Ana Lucia L.] Univ Sao Paulo, Sch Med, Hosp Clin, Inst Orthopaed & Traumatol, Sao Paulo, Brazil.
[Goldstein, Ellie J. C.] St Johns Hlth Ctr, Dept Infect Dis, Santa Monica, CA USA.
RP Nicolau, DP (reprint author), Hartford Hosp, Ctr Anti Infect Res & Dev, 80 Seymour St, Hartford, CT 06102 USA.
EM dnicola@harthosp.org
OI Lima, Ana/0000-0002-1055-0554; Lima, Ana Lucia
Munhoz/0000-0002-2396-9880
FU Achaogen Inc.; Basilea Pharmaceutica; BioLine Therapeutics; Cempra
Pharmaceuticals Inc.; Intercell AG; Johnson and Johnson Pharmaceuticals;
Merck; Cubist; Ortho Pharmaceuticals; Schering-Plough Pharmaceuticals;
Optimer Pharmaceuticals; Theravance Inc.; Pfizer Inc.; Astellas Inc.;
Cerexa Inc.; Impex Pharmaceuticals; Novexel; Novartis; Clinical
Microbiology Institute; Genzyme; NanoPacific Holdings Inc.; Romark
Laboratories LC; ViroXis Corp.; Warner Chilcott; Avid-Biotics Corp.;
GLSynthesis Inc.; Immunome Inc.; Toltec Pharma LLC.;
Ortho-McNeil-Janssen; Sanofi-Aventis; Bayer-Schering Pharma;
AstraZeneca; Cerexa; Forest; Johnson Johnson; Pfizer
FX Competing interests: YC has served on speaker bureaus, scientific
advisory boards and/or received research grants from Achaogen Inc.,
Basilea Pharmaceutica, BioLine Therapeutics, Cempra Pharmaceuticals
Inc., Intercell AG, Johnson and Johnson Pharmaceuticals and Merck. DAG
has served on speaker bureaus and/or received research grants from
Cubist, Merck and Ortho Pharmaceuticals. EJCG has served on advisory
boards for Merck, Optimer Pharmaceuticals, Bayer Pharmaceuticals,
Theravance Inc., BioK+, ViroPharma and Kindred Healthcare Corp., on
speaker bureaus for Bayer Inc., Merck, Sanofi Pasteur and Forest Labs,
and has received research grants from Merck, Schering-Plough
Pharmaceuticals, Optimer Pharmaceuticals, Theravance Inc., Cubist,
Pfizer Inc., Astellas Inc., Cerexa Inc., Impex Pharmaceuticals, Novexel,
Novartis, Clinical Microbiology Institute, Genzyme, NanoPacific Holdings
Inc., Romark Laboratories LC, ViroXis Corp., Warner Chilcott,
Avid-Biotics Corp., GLSynthesis Inc., Immunome Inc. and Toltec Pharma
LLC. CJG has received a research grant from Merck and an unrestricted
educational grant from Ortho-McNeil-Janssen, and has served on an
advisory board for Pfizer. ALLL has served on speaker bureaus and/or
received research grants from Merck, Sanofi-Aventis and Bayer-Schering
Pharma. DPN has served on speaker bureaus and/or received research
grants from AstraZeneca, Cerexa, Cubist, Forest, Johnson & Johnson,
Merck and Pfizer. CWC declares no competing interests.
NR 19
TC 22
Z9 25
U1 0
U2 1
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0924-8579
J9 INT J ANTIMICROB AG
JI Int. J. Antimicrob. Agents
PD JAN
PY 2012
VL 39
IS 1
BP 11
EP 15
DI 10.1016/j.ijantimicag.2011.08.018
PG 5
WC Infectious Diseases; Microbiology; Pharmacology & Pharmacy
SC Infectious Diseases; Microbiology; Pharmacology & Pharmacy
GA 863DO
UT WOS:000298143200002
PM 22047702
ER
PT J
AU Farr, SA
Price, TO
Dominguez, LJ
Motisi, A
Saiano, F
Niehoff, ML
Morley, JE
Banks, WA
Ercal, N
Barbagallo, M
AF Farr, Susan A.
Price, Tulin O.
Dominguez, Ligia J.
Motisi, Antonio
Saiano, Filippo
Niehoff, Michael L.
Morley, John E.
Banks, William A.
Ercal, Nuran
Barbagallo, Mario
TI Extra Virgin Olive Oil Improves Learning and Memory in SAMP8 Mice
SO JOURNAL OF ALZHEIMERS DISEASE
LA English
DT Article
DE Extra virgin olive oil; learning; memory; object recognition; oxidative
stress; SAMP8; T-maze
ID SENESCENCE-ACCELERATED MICE; ALPHA-LIPOIC ACID; ALZHEIMERS-DISEASE;
MEDITERRANEAN DIET; AMYLOID-BETA; GLUTATHIONE DISULFIDE; SENSORY
PROPERTIES; OXIDATIVE STRESS; FATTY-ACIDS; MOUSE MODEL
AB Polyphenols are potent antioxidants found in extra virgin olive oil (EVOO); antioxidants have been shown to reverse age-and disease-related learning and memory deficits. We examined the effects of EVOO on learning and memory in SAMP8 mice, an age-related learning/memory impairment model associated with increased amyloid-beta protein and brain oxidative damage. We administered EVOO, coconut oil, or butter to 11 month old SAMP8 mice for 6 weeks. Mice were tested in T-maze foot shock avoidance and one-trial novel object recognition with a 24 h delay. Mice which received EVOO had improved acquisition in the T-maze and spent more time with the novel object in one-trial novel object recognition versus mice which received coconut oil or butter. Mice that received EVOO had improve T-maze retention compared to the mice that received butter. EVOO increased brain glutathione levels suggesting reduced oxidative stress as a possible mechanism. These effects plus increased glutathione reductase activity, superoxide dismutase activity, and decreased tissue levels of 4-hydroxynoneal and 3-nitrotyrosine were enhanced with enriched EVOO (3x and 5x polyphenols concentration). Our findings suggest that EVOO has beneficial effects on learning and memory deficits found in aging and diseases, such as those related to the overproduction of amyloid-beta protein, by reversing oxidative damage in the brain, effects that are augmented with increasing concentrations of polyphenols in EVOO.
C1 [Farr, Susan A.] St Louis Univ, Sch Med, VA Med Ctr, Dept Internal Med,Div Geriatr Med, St Louis, MO 63106 USA.
[Farr, Susan A.; Morley, John E.] VA Med Ctr, GRECC, St Louis, MO USA.
[Price, Tulin O.] St Louis Univ, Sch Med, Div Endocrinol, Dept Internal Med, St Louis, MO 63106 USA.
[Dominguez, Ligia J.; Motisi, Antonio; Barbagallo, Mario] Univ Palermo, Div Geriatr Med, Palermo, Italy.
[Saiano, Filippo] Univ Palermo, Fac Agron, Dept DEMETRA, Palermo, Italy.
Univ Palermo, Dept Agroenvironm Syst, Palermo, Italy.
[Banks, William A.] Vet Affairs Puget Sound Hlth Care Syst, GRECC, Seattle, WA USA.
[Banks, William A.] Univ Washington, Sch Med, Div Gerontol & Geriatr Med, Dept Internal Med, Seattle, WA USA.
[Ercal, Nuran] Missouri Univ Sci & Technol, Dept Chem, Rolla, MO USA.
RP Farr, SA (reprint author), St Louis Univ, Sch Med, VA Med Ctr, Dept Internal Med,Div Geriatr Med, 915 N Grand Blvd,151-JC, St Louis, MO 63106 USA.
EM farrsa@slu.edu
OI BARBAGALLO, MARIO/0000-0002-1349-6530; dominguez, ligia
j/0000-0003-1466-8610
FU VA Medical Center, St. Louis, MO
FX This work was supported by VA Medical Center, St. Louis, MO.
NR 54
TC 52
Z9 53
U1 2
U2 14
PU IOS PRESS
PI AMSTERDAM
PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS
SN 1387-2877
J9 J ALZHEIMERS DIS
JI J. Alzheimers Dis.
PY 2012
VL 28
IS 1
BP 81
EP 92
DI 10.3233/JAD-2011-110662
PG 12
WC Neurosciences
SC Neurosciences & Neurology
GA 879EG
UT WOS:000299311900007
PM 21955812
ER
PT J
AU Baker, LD
Bayer-Carter, JL
Skinner, J
Montine, TJ
Cholerton, BA
Callaghan, M
Leverenz, JB
Walter, BK
Tsai, E
Postupna, N
Lampe, J
Craft, S
AF Baker, Laura D.
Bayer-Carter, Jennifer L.
Skinner, Jeannine
Montine, Thomas J.
Cholerton, Brenna A.
Callaghan, Maureen
Leverenz, James B.
Walter, Brooke K.
Tsai, Elaine
Postupna, Nadia
Lampe, Johanna
Craft, Suzanne
TI High-Intensity Physical Activity Modulates Diet Effects on Cerebrospinal
Amyloid-beta Levels in Normal Aging and Mild Cognitive Impairment
SO JOURNAL OF ALZHEIMERS DISEASE
LA English
DT Article
DE Aging; Alzheimer's disease; amyloid; biomarker; brain; diet; exercise;
interleukin; mild cognitive impairment; tau
ID TRANSGENIC MOUSE MODEL; ALZHEIMERS-DISEASE; OLDER-ADULTS; CALORIC
RESTRICTION; VOLUNTARY EXERCISE; MEDITERRANEAN DIET; RISK; BRAIN; MICE;
AGE
AB We previously showed that amyloid-beta 1-42 (A beta(42)) levels in cerebrospinal fluid (CSF) were markedly altered in response to a 4-week dietary intervention in normal aging and mild cognitive impairment (MCI). Here, we re-examined the data to assess whether diet-induced effects on CSF A beta(42) were modulated by high intensity physical activity (hi-PA). Normal older adults (n = 18, mean age = 68.6 +/- 7.4 y) and adults with amnestic MCI (n = 23, mean age = 68.0 +/- 6.5 y) received a low saturated fat/low glycemic index (LOW) diet or a high saturated fat/high glycemic index (HIGH) diet, and CSF levels of A beta(42), tau, and IL-8 were measured at baseline and week 4. Pre-study activity levels were assessed using a 7-d questionnaire, and weekly duration of hi-PA was quantified. At baseline, increased hi-PA in normals predicted lower CSF levels of tau (r = -0.54, p = 0.020) and IL-8 (r = -0.70, p = 0.025). Diet-induced effects on CSF A beta(42) during the intervention study were modulated by hi-PA, and the nature of this effect differed for normals and MCI (ANOVA, p = 0.039). That is, for normal adults, increased hi-PA attenuated the effects of the HIGH diet on CSF A beta(42) whereas in MCI, increased hi-PA potentiated the effects of the LOW diet. Our results suggest that normal adults who engage in hi-PA are less vulnerable to the pathological effects of an unhealthy diet, while in MCI, the benefit of a healthy diet on A beta modulation is greatest when paired with hi-PA. Exercise may thus interact with diet to alter pathological processes that ultimately modify risk of Alzheimer's disease.
C1 [Baker, Laura D.; Bayer-Carter, Jennifer L.; Skinner, Jeannine; Cholerton, Brenna A.; Callaghan, Maureen; Craft, Suzanne] Vet Affairs Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA USA.
[Leverenz, James B.] Vet Affairs Puget Sound Hlth Care Syst, Mental Illness & Parkinson Dis Res Ctr, Seattle, WA USA.
[Baker, Laura D.; Skinner, Jeannine; Cholerton, Brenna A.; Walter, Brooke K.; Tsai, Elaine; Craft, Suzanne] Vet Affairs Puget Sound Hlth Care Syst, Dept Med, Seattle, WA USA.
Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA.
[Montine, Thomas J.; Postupna, Nadia] Univ Washington, Sch Med, Dept Pathol, Seattle, WA 98195 USA.
[Leverenz, James B.; Walter, Brooke K.] Univ Washington, Sch Med, Dept Neurol, Seattle, WA 98195 USA.
[Lampe, Johanna] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA.
[Leverenz, James B.] Vet Affairs Puget Sound Hlth Care Syst, Mental Illness & Parkinson Educ Ctr, Seattle, WA USA.
[Leverenz, James B.] Vet Affairs Puget Sound Hlth Care Syst, Mental Illness & Parkinson Clin Ctr, Seattle, WA USA.
RP Baker, LD (reprint author), S-182-GRECC,VAPSHCS 1660 S Columbian Way, Seattle, WA 98108 USA.
EM ldbaker@uw.edu
FU NIA [R37 AG-10880, P50 AG05136, 5T32 AG000258]; Nancy and Buster Alvord
Endowment; Office of Research and Development Medical Research Service;
Geriatric Research, Education and Clinical Center of the Department of
Veterans Affairs
FX This research was supported by NIA R37 AG-10880 (Craft), NIA P50 AG05136
Project 1 (Montine), NIA 5T32 AG000258 (Postupna), the Nancy and Buster
Alvord Endowment, and the Office of Research and Development Medical
Research Service and the Geriatric Research, Education and Clinical
Center of the Department of Veterans Affairs. Dr. Baker had full access
to all data and takes responsibility for its integrity and the accuracy
of the data analysis which was conducted without input from the funding
agencies.
NR 60
TC 13
Z9 13
U1 3
U2 24
PU IOS PRESS
PI AMSTERDAM
PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS
SN 1387-2877
J9 J ALZHEIMERS DIS
JI J. Alzheimers Dis.
PY 2012
VL 28
IS 1
BP 137
EP 146
DI 10.3233/JAD-2011-111076
PG 10
WC Neurosciences
SC Neurosciences & Neurology
GA 879EG
UT WOS:000299311900012
PM 21971406
ER
PT J
AU Nielson, CM
Zmuda, JM
Carlos, AS
Wagoner, WJ
Larson, EA
Orwoll, ES
Klein, RF
AF Nielson, Carrie M.
Zmuda, Joseph M.
Carlos, Amy S.
Wagoner, Wendy J.
Larson, Emily A.
Orwoll, Eric S.
Klein, Robert F.
TI Rare coding variants in ALPL are associated with low serum alkaline
phosphatase and low bone mineral density
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE OSTEOPOROSIS; HEREDITY; GENETICS; ALKALINE PHOSPHATASE
ID QUANTITATIVE TRAIT LOCI; GENOME-WIDE ASSOCIATION; INFANTILE
HYPOPHOSPHATASIA; OSTEOPOROTIC FRACTURES; LINKAGE ANALYSIS; INBRED
STRAINS; PLASMA-LEVELS; MICE; C57BL/6J; GENES
AB Alkaline phosphatase (ALP) plays an essential role in the regulation of tissue mineralization, and its activity is highly heritable. Guided by genetic associations discovered in a murine model, we hypothesized a role for rare coding variants in determining serum ALP level and bone mineral density (BMD) in humans. We sequenced the coding regions of the ALP gene (ALPL) in men with low and normal serum ALP activity levels. Single-nucleotide ALPL variants, including 19 rare nonsynonymous variants (minor allele frequency <1%), were much more frequent among the low ALP group (33.8%) than the normal group (1.4%, p=1 x 10(-11)). Within the low ALP group, men with a rare, nonsynonymous variant had 11.2% lower mean serum ALP (p=3.9x 10(-4)), 6.7% lower BMD (p=0.03), and 11.1% higher serum phosphate (p=0.002) than those without. In contrast, common nonsynonymous variants had no association with serum ALP, phosphate, or BMD. Multiple rare ALPL coding variants are present in the general population, and nonsynonymous coding variants may be responsible for heritable differences in mineralization and thus BMD. (C) 2012 American Society for Bone and Mineral Research
C1 [Nielson, Carrie M.; Carlos, Amy S.; Wagoner, Wendy J.; Larson, Emily A.; Orwoll, Eric S.; Klein, Robert F.] Oregon Hlth & Sci Univ, Bone & Mineral Res Unit, Dept Med, Portland, OR 97239 USA.
[Zmuda, Joseph M.] Univ Pittsburgh, Dept Epidemiol, Pittsburgh, PA 15261 USA.
[Zmuda, Joseph M.] Univ Pittsburgh, Dept Human Genet, Pittsburgh, PA USA.
[Klein, Robert F.] Portland VA Med Ctr, Portland, OR USA.
RP Klein, RF (reprint author), Oregon Hlth & Sci Univ, Bone & Mineral Unit CR113, 3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA.
EM Kleinro@ohsu.edu
OI Orwoll, Eric/0000-0002-8520-7355
FU National Institutes of Health; National Institute of Arthritis and
Musculoskeletal and Skin Diseases (NIAMS) [AR44659, R01-AR051124];
National Institute on Aging (NIA) [R01-AG033618]; National Center for
Research Resources (NCRR); NIH Roadmap for Medical Research [U01
AR45580, U01 AR45614, U01 AR45632, U01 AR45647, U01 AR45654, U01
AR45583, U01 AG18197, U01-AG027810, UL1 RR024140]; Office of Research on
Women's Health; National Institute of Child Health and Human
Development, Building Interdisciplinary Research Careers in Women's
Health (BIRCWH) [HD043488-08]; VA Medical Research Service
FX The Osteoporotic Fractures in Men (MrOS) Study is supported by National
Institutes of Health funding; the following institutes provide support:
the National Institute of Arthritis and Musculoskeletal and Skin
Diseases (NIAMS), the National Institute on Aging (NIA), the National
Center for Research Resources (NCRR), and NIH Roadmap for Medical
Research under the following grant numbers: U01 AR45580, U01 AR45614,
U01 AR45632, U01 AR45647, U01 AR45654, U01 AR45583, U01 AG18197,
U01-AG027810, and UL1 RR024140. Dr. Nielson is also supported by the
Office of Research on Women's Health and the National Institute of Child
Health and Human Development, Building Interdisciplinary Research
Careers in Women's Health (BIRCWH) grant number HD043488-08. Dr. Klein's
research effort is supported by the National Institute of Arthritis,
Musculoskeletal and Skin Diseases (AR44659) and the VA Medical Research
Service. Dr. Zmuda's research effort is supported by the National
Institute of Arthritis and Musculoskeletal and Skin Diseases
(R01-AR051124) and by the National Institute on Aging (R01-AG033618).
NR 61
TC 10
Z9 10
U1 1
U2 3
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0884-0431
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD JAN
PY 2012
VL 27
IS 1
BP 93
EP 103
DI 10.1002/jbmr.527
PG 11
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 867UA
UT WOS:000298479000009
PM 21956185
ER
PT J
AU Barber, JP
Barrett, MS
Gallop, R
Rynn, MA
Rickels, K
AF Barber, Jacques P.
Barrett, Marna S.
Gallop, Robert
Rynn, Moira A.
Rickels, Karl
TI Short-Term Dynamic Psychotherapy Versus Pharmacotherapy for Major
Depressive Disorder: A Randomized, Placebo-Controlled Trial
SO JOURNAL OF CLINICAL PSYCHIATRY
LA English
DT Article
ID COLLABORATIVE RESEARCH-PROGRAM; MENTAL-HEALTH TREATMENT;
STAR-ASTERISK-D; CLINICAL-TRIALS; COGNITIVE THERAPY; PSYCHODYNAMIC
PSYCHOTHERAPY; NATIONAL-INSTITUTE; RATING-SCALE; CARE; CITALOPRAM
AB Objective: To determine whether supportive-expressive psychotherapy (SET), a form of dynamic psychotherapy, and pharmacotherapy + clinical management (MED) for major depressive disorder (MDD) are more effective than pill-placebo + clinical management (PBO).
Method:This National Institute of Mental Health (NIMH)-sponsored randomized controlled trial was conducted (from November 2001 through June 2007) at the University of Pennsylvania Medical School. The sample included 156 patients diagnosed with MDD (DSM-IV) and having a 17-item Hamilton Rating Scale for Depression (HRSD17) score >= 14 for at least 2 consecutive weeks. This was an underserved sample in which 41% were male, 52% were self-designated minorities, and 76% had an annual income under $30,000. Treatment lasted 16 weeks. Medication patients not responsive by week 8 (maximum dose 200 mg/d of sertraline) were switched to venlafaxine (maximum dose 375 mg/d). Nonresponsive placebo patients at week 8 were switched to a different placebo.
Results: Patients' depression improved over the 16 weeks (P<.0001), with no between-group differences (P=.95), even among severely (HRSD17 score >= 20) depressed patients (P=.45). Response rates did not differ between groups (P=.73). Gender and minority status moderated outcome (P=.014), with psychotherapy more efficacious for minority men than MED (P=.027, Cohen d=1.02) and PBO (P=.019, d=1.09). PBO was more efficacious for white men than MED (P=.03, d=0.62) and SET (P=.003, d=1.07). For white women, MED (P=.005, d=0.77) and SET (P=.033, d=0.71) were more efficacious than placebo. No differences among treatments were found for minority women.
Conclusions:This trial of urban MDD patients failed to confirm that either active treatment was better than placebo. Minority status and gender had significant and differential effects on outcome that warrant replication in future studies.
C1 [Barber, Jacques P.; Barrett, Marna S.; Gallop, Robert] Univ Penn, Sch Med, Dept Psychiat, Ctr Psychotherapy Res, Philadelphia, PA 19104 USA.
[Barber, Jacques P.] Philadelphia VA Med Ctr, CESATE, Philadelphia, PA USA.
[Barber, Jacques P.] Philadelphia VA Med Ctr, MIRECC, Philadelphia, PA USA.
[Barrett, Marna S.; Rynn, Moira A.; Rickels, Karl] Univ Penn, Sch Med, Dept Psychiat, Mood & Anxiety Disorders Sect, Philadelphia, PA 19104 USA.
[Rynn, Moira A.] Columbia Univ, Div Child & Adolescent Psychiat, New York, NY USA.
[Rynn, Moira A.] New York State Psychiat Inst & Hosp, New York, NY 10032 USA.
RP Barber, JP (reprint author), Adelphi Univ, Hy Weinberg Ctr, Derner Inst Adv Psychol Studies, Rm 301,1 South Ave,POB 701, Garden City, NY 11530 USA.
EM jbarber@adelphi.edu
FU National Institute of Mental Health (NIMH) [R01 MH 061410]; National
Institute on Drug Abuse (NIDA); Guilford Press; Basic Books; Cambridge
University Press; Boehringer Ingelheim Pharmaceuticals; Wyeth
Pharmaceuticals; Neuropharm; Astra Zeneca; Pfizer Pharmaceuticals; Eli
Lilly and Company; Forest Laboratories; Bristol-Myers Squibb; Organon;
Cephalon; Johnson & Johnson Pharmaceutical Research Development;
AstraZeneca; Bristol-Meyers Squibb; Epix Pharmaceuticals; Genaissance
Pharmaceuticals (PGxHealth); GlaxoSmithkline; Merck Co; Pamlab; Pfizer;
Somerset Pharmaceuticals; Wyeth Laboratory; Pfizer Corp.
FX Dr Barber has received funding from the National Institute of Mental
Health (NIMH) and the National Institute on Drug Abuse (NIDA); authors'
fees from Guilford Press, Basic Books, and Cambridge University Press;
and honoraria from Lundbeck. Dr Rynn has received research support from
NIMH, Boehringer Ingelheim Pharmaceuticals, Wyeth Pharmaceuticals,
Neuropharm, Astra Zeneca, Pfizer Pharmaceuticals, Eli Lilly and Company,
Forest Laboratories, Bristol-Myers Squibb, Organon, Cephalon, and
Johnson & Johnson Pharmaceutical Research & Development; has served as a
consultant for Wyeth Pharmaceuticals, Pfizer Pharmaceuticals, Astra
Zeneca, Pharmastar, Eli Lilly and Company, and Pepper Hamilton; has been
on speakers' bureaus for Pfizer Pharmaceuticals and Wyeth
Pharmaceuticals; has received royalties from APPI Press; and has
received honoraria from Post Graduate Institute for Medicine, American
Psychiatric Association, American Education Services, Oxford University
Press, Case Western Reserve University, and Pennsylvania Medical
Society. Please note that during this time period there are Grand Rounds
for which she does not have the documentation of the funding source. Dr
Rickels (from 2002 to 2009) has received honoraria and served as a
consultant or on advisory boards to Cephalon, DOV Pharmaceuticals, Eli
Lilly & Co, Hoffman-La Roche, Jazz Pharmaceuticals, Johnson & Johnson,
Novartis Pharmaceuticals, Pfizer Inc, Epix (PreDix) Pharmaceuticals,
PGxHealth, and Sanofi-Synthelabo Research; and has received research
grants (issued to the University of Pennsylvania) from AstraZeneca,
Bristol-Meyers Squibb, Cephalon, Epix Pharmaceuticals, Genaissance
Pharmaceuticals (PGxHealth), GlaxoSmithkline, Merck & Co, NIMH, Pamlab,
Pfizer, Somerset Pharmaceuticals, and Wyeth Laboratory. Drs Barrett and
Gallops have no potential conflict of interest to disclose.; Written
with support from NIMH grant R01 MH 061410 (Jacques P. Barber, PI). The
sertraline and placebo pills were provided by a grant from Pfizer Corp.
Neither sponsor had any role in the study besides funding the study
(NIMH) or supplying the sertraline and placebo pills (Pfizer).
NR 47
TC 57
Z9 57
U1 1
U2 19
PU PHYSICIANS POSTGRADUATE PRESS
PI MEMPHIS
PA P O BOX 752870, MEMPHIS, TN 38175-2870 USA
SN 0160-6689
J9 J CLIN PSYCHIAT
JI J. Clin. Psychiatry
PD JAN
PY 2012
VL 73
IS 1
BP 66
EP 73
DI 10.4088/JCP.11m06831
PG 8
WC Psychology, Clinical; Psychiatry
SC Psychology; Psychiatry
GA 880LK
UT WOS:000299408400010
PM 22152401
ER
PT J
AU Mohamed, S
Rosenheck, R
Lyketsos, CG
Kaczynski, R
Sultzer, DL
Schneider, LS
AF Mohamed, Somaia
Rosenheck, Robert
Lyketsos, Constantine G.
Kaczynski, Richard
Sultzer, David L.
Schneider, Lon S.
TI Effect of Second-Generation Antipsychotics on Caregiver Burden in
Alzheimer's Disease
SO JOURNAL OF CLINICAL PSYCHIATRY
LA English
DT Article
ID RATING-SCALE BPRS; FAMILY CAREGIVERS; BEHAVIORAL DISTURBANCES; DEMENTIA
VICTIMS; OLDER-ADULTS; CATIE-AD; HEALTH; PREDICTORS; TRIAL; DEPRESSION
AB Background: Alzheimer's disease (AD) imposes a severe burden upon patients and their caregivers. Severity of psychiatric symptoms and behavioral disturbances is an important determinant of caregivers' experience of burden. These symptoms may be improved with atypical antipsychotic treatment.
Objective: Data from the Clinical Antipsychotic Trials of Intervention Effectiveness-Alzheimer's Disease (CATIE-AD) trial were used to evaluate the effect of atypical antipsychotics versus placebo on the experiences of caregivers of outpatients with AD.
Method: We compared the effect of atypical antipsychotic drugs (olanzapine, risperidone, or quetiapine considered together as a group) versus placebo on the experiences of caregivers of AD outpatients (diagnosed according to DSM-IV-TR). We also evaluated whether improvement in patients' psychiatric and behavioral symptoms mediated the relationship between drug treatment and caregiver burden. The CATIE-AD trial, conducted from April 2001 through November 2004, included outpatients (mean age = 77.9 years [SD = 7.5 years]) in usual care settings and assessed treatment effectiveness over a 9-month period at 42 US sites. In a set of secondary analyses, data from CATIE-AD participants who had at least 1 postbaseline outcome assessment and data from their caregivers were examined in an intention-to-treat (ITT) analysis (N = 361). A phase 1-only analysis was conducted including only observations while patients were receiving the initially randomized drug (N = 153). The Burden Interview, the Beck Depression Inventory, and the Neuropsychiatric Inventory (NPI) Caregiver Distress Scale were used to evaluate caregiver burden.
Results: In both ITT and phase 1-only analyses, caregivers of patients treated with second-generation antipsychotics scored significantly lower than caregivers of patients receiving placebo on both the Burden Interview (P = .0090) and the NPI Caregiver Distress Scale (P = .0209). These differences appeared to have been mediated by lower levels of agitation, hostility, and psychotic distortions.
Conclusion: In AD patients with symptoms of psychosis, agitation, or aggressive behavior, medications can have a small but significant impact on caregiver burden. J Clin Psychiatry 2012;73(1):121-128 (C) Copyright 2011 Physicians Postgraduate Press, Inc.
C1 [Mohamed, Somaia; Rosenheck, Robert; Kaczynski, Richard] Vet Affairs New England Mental Illness Res Educ &, West Haven, CT USA.
[Mohamed, Somaia; Rosenheck, Robert; Kaczynski, Richard] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT USA.
[Lyketsos, Constantine G.] Johns Hopkins Univ, Dept Psychiat & Behav Sci, Baltimore, MD USA.
[Lyketsos, Constantine G.] Johns Hopkins Bayview Med Ctr, Baltimore, MD USA.
[Sultzer, David L.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA.
[Sultzer, David L.] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
[Schneider, Lon S.] Univ So Calif, Keck Sch Med, Dept Psychiat & Behav Sci, Los Angeles, CA 90033 USA.
RP Mohamed, S (reprint author), Vet Affairs Connecticut Hlth Care Syst, 950 Campbell Ave,182, West Haven, CT 06516 USA.
EM Somaia.Mohamed@yale.edu
FU Eli Lilly; Janssen; AstraZeneca; Pfizer; National Institute of Mental
Health (NIMH) [N01 MH9001]; National Institute on Aging; Associated
Jewish Federation of Baltimore; Harry and Jeanette Weinberg Foundation;
Forest; GlaxoSmithKline; Eisai; Ortho-McNeil; Bristol-Myers Squibb;
Novartis; National Football League (NFL); Elan; Supernus; Adlyfe;
Takeda; Lundbeck; Merz; Genentech; NFL Players Association; Forest
Research Institute; Johnson Johnson; National Institutes of Health (NIH)
[P50 AG05142, P01 AG05146]; Pfizer, Madison, New Jersey; Department of
Veterans Affairs
FX Dr Rosenheck has received research support from Eli Lilly, Janssen,
AstraZeneca, and Wyeth (currently Pfizer); has been a consultant to
GlaxoSmithKline, Bristol-Myers Squibb, Organon, and Janssen; and has
provided expert testimony in matters pertaining to Eli Lilly, Eli Lilly
Canada, Novapharm, Janssen-Ortho, and Janssen. Dr Lyketsos has received
grant support (for research or CME) from the National Institute of
Mental Health (NIMH), the National Institute on Aging, The Associated
Jewish Federation of Baltimore, The Harry and Jeanette Weinberg
Foundation, Forest, GlaxoSmithKline, Eisai, Pfizer, AstraZeneca, Eli
Lilly, Ortho-McNeil, Bristol-Myers Squibb, Novartis, National Football
League (NFL), and Elan; has received consulting fees from AstraZeneca,
GlaxoSmithKline, Eisai, Elan, Novartis, Forest, Supernus, Adlyfe,
Takeda, Wyeth (currently Pfizer), Lundbeck, Merz, Eli Lilly, Genentech,
Pfizer, NFL Players Association, and the NFL; and has received speaking
honoraria or travel support from Pfizer, Forest, GlaxoSmithKline, and
Health Monitor. Dr Sultzer has received research support from Eli Lilly
and Forest Research Institute. Dr Schneider has received consulting fees
from AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Forest,
GlaxoSmithKline, Novartis, Johnson & Johnson, and Pfizer and has
received research grant support from Novartis, Eli Lilly, and Pfizer.
Drs Mohamed and Kaczynski have no potential conflicts of interest with
regard to the subject of this article.; Conduct of the study was
supported by grant N01 MH9001 from NIMH, the National Institutes of
Health (NIH) (to Dr Schneider). Dr Schneider's efforts in writing the
manuscript were partially supported by grant P50 AG05142 from NIH to the
University of Southern California Alzheimer Disease Research Center, Los
Angeles, California. Dr Mohamed's efforts in writing the manuscript were
partially supported by a contract with Wyeth Pharmaceuticals (currently
Pfizer), Madison, New Jersey. Dr Lyketsos' efforts in writing the
manuscript were supported by grant P01 AG05146 from NIH to the Johns
Hopkins University Alzheimer's Disease Research Center, Baltimore,
Maryland. Dr Sultzer's efforts in writing the manuscript were partially
supported by the Department of Veterans Affairs (Merit Review Program).
NR 47
TC 7
Z9 7
U1 3
U2 8
PU PHYSICIANS POSTGRADUATE PRESS
PI MEMPHIS
PA P O BOX 240008, MEMPHIS, TN 38124 USA
SN 0160-6689
J9 J CLIN PSYCHIAT
JI J. Clin. Psychiatry
PD JAN
PY 2012
VL 73
IS 1
BP 121
EP 128
DI 10.4088/JCP.10m06574
PG 8
WC Psychology, Clinical; Psychiatry
SC Psychology; Psychiatry
GA 880LK
UT WOS:000299408400018
PM 21939611
ER
PT J
AU Carlson, KF
Meis, LA
Jensen, AC
Simon, AB
Gravely, AA
Taylor, BC
Bangerter, A
Schaaf, KW
Griffin, JM
AF Carlson, Kathleen F.
Meis, Laura A.
Jensen, Agnes C.
Simon, Alisha Baines
Gravely, Amy A.
Taylor, Brent C.
Bangerter, Ann
Schaaf, Katy Wilder
Griffin, Joan M.
TI Caregiver Reports of Subsequent Injuries Among Veterans With Traumatic
Brain Injury After Discharge From Inpatient Polytrauma Rehabilitation
Programs
SO JOURNAL OF HEAD TRAUMA REHABILITATION
LA English
DT Article
DE caregivers; health services; rehabilitation; traumatic brain injury;
trauma; injury
ID SPINAL-CORD-INJURY; RISK; MORTALITY; POPULATION; BEHAVIOR; DEATH; CARE;
INDIVIDUALS; POSTINJURY; CHILDREN
AB Objective: We examined prevalence of, and potential risk factors for, nonfatal injuries among Veterans with traumatic brain injury (TBI) postdischarge from Veterans Affairs inpatient polytrauma rehabilitation programs. Methods: We surveyed caregivers of patients who had military service anytime from 2001 to 2009, sustained polytrauma including TBI, received Veterans Affairs inpatient care from 2001 to 2009, were discharged at least 3 months before the study, and were alive when the study was fielded about caregiver and patient health, including patients' medically treated "accidents/new injuries" since discharge. We examined prevalence and source(s) of subsequent injuries and estimated patients' injury risk in reference to hypothesized risk factors. Odds ratios and 95% confidence intervals were calculated using multivariate logistic regression. Results: Caregivers reported that nearly one-third (32%) of patients incurred medically treated injuries after discharge; most were associated with falls (49%) and motor vehicles (37%). Odds of subsequent injury were associated with select demographics, initial injury characteristics, and postdischarge health and functioning. Characteristics of caregivers, including physical and mental health, were also associated with patients' odds of subsequent injury. Conclusions: A significant number of caregivers reported subsequent nonfatal injuries among patients treated for TBI/polytrauma in inpatient rehabilitation settings. Enhanced injury prevention efforts may be beneficial for this population.
C1 [Carlson, Kathleen F.] Portland VA Med Ctr, Portland Ctr Study Chron Comorbid Mental & Phys D, Portland, OR USA.
[Carlson, Kathleen F.] Oregon Hlth & Sci Univ, Dept Publ Hlth & Prevent Med, Portland, OR 97201 USA.
[Meis, Laura A.; Jensen, Agnes C.; Simon, Alisha Baines; Gravely, Amy A.; Taylor, Brent C.; Bangerter, Ann; Griffin, Joan M.] Minneapolis VA Hlth Care Syst, Ctr Chron Dis Outcomes Res, Minneapolis, MN USA.
[Taylor, Brent C.] Univ Minnesota, Sch Publ Hlth, Div Epidemiol & Community Hlth, Minneapolis, MN USA.
[Meis, Laura A.; Taylor, Brent C.; Griffin, Joan M.] Univ Minnesota, Sch Med, Dept Med, Minneapolis, MN 55455 USA.
[Schaaf, Katy Wilder] Virginia Commonwealth Univ, Dept Phys Med & Rehabil, Sch Med, Neuropsychol & Rehabil Psychol Serv, Richmond, VA USA.
[Schaaf, Katy Wilder] Hunter Holmes McGuire VA Med Ctr, Richmond, VA USA.
RP Carlson, KF (reprint author), Portland VA Med Ctr R&D 66, Portland Ctr Study Chron Comorbid Mental & Phys D, 3715 SW US Vet Hosp Rd, Portland, OR 97239 USA.
EM kathleen.carlson@va.gov
RI Taylor, Brent/A-8069-2009
OI Taylor, Brent/0000-0002-2140-8377
FU Veterans Health Administration Health Services Research and Development
Service [SDR 07-044, CDA 08-025]
FX This work was supported by grants from the Veterans Health
Administration Health Services Research and Development Service (SDR
07-044; CDA 08-025). The opinions expressed in this article are those of
the authors and do not necessarily reflect the position or policy of the
Department of Veterans Affairs or the United States government.
NR 50
TC 10
Z9 10
U1 3
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0885-9701
J9 J HEAD TRAUMA REHAB
JI J. Head Trauma Rehabil.
PD JAN-FEB
PY 2012
VL 27
IS 1
BP 14
EP 25
DI 10.1097/HTR.0b013e318236bd86
PG 12
WC Clinical Neurology; Rehabilitation
SC Neurosciences & Neurology; Rehabilitation
GA 879JV
UT WOS:000299326400002
PM 22218200
ER
PT J
AU Afzali, A
Berry, K
Ioannou, GN
AF Afzali, Anita
Berry, Kristin
Ioannou, George N.
TI Excellent posttransplant survival for patients with nonalcoholic
steatohepatitis in the United States
SO LIVER TRANSPLANTATION
LA English
DT Article
ID FATTY LIVER-DISEASE; CRYPTOGENIC CIRRHOSIS; NATURAL-HISTORY;
TRANSPLANTATION; POPULATION; PREVALENCE
AB Because of the ongoing epidemics of obesity and diabetes, nonalcoholic steatohepatitis (NASH) may become a leading indication for liver transplantation. There are concerns about the posttransplant survival of patients with NASH because of associated cardiovascular and metabolic risk factors. We aimed to determine recent trends in the proportion of patients undergoing transplantation for NASH-related cirrhosis in the United States and to estimate their posttransplant survival. We used data provided by the United Network for Organ Sharing for first-time adult cadaveric liver transplants performed in the United States between January 1, 1997 and October 31, 2010 (n = 53,738). The proportion of liver transplants performed for NASH-related cirrhosis increased dramatically from 1.2% in 1997-2003 to 7.4% in 2010 when NASH was the fourth most common indication for transplantation. The posttransplant survival of patients with NASH (n = 1810) at 1 (87.6%), 3 (82.2%), and 5 years (76.7%) was superior to the survival of patients with hepatocellular carcinoma, hepatitis C virus, alcoholic liver disease, acute hepatic necrosis, hemochromatosis, or cryptogenic liver disease and was inferior to the survival of only 4 groups of patients (those with primary biliary cirrhosis, primary sclerosing cholangitis, autoimmune hepatitis, or hepatitis B virus). In conclusion, NASH-related cirrhosis is increasing rapidly as an indication for liver transplantation in the United States and is associated with excellent posttransplant survival. Liver Transpl 18:2937, 2012. (C) 2011 AASLD.
C1 [Afzali, Anita; Ioannou, George N.] Univ Washington, Div Gastroenterol, Dept Med, Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA 98195 USA.
[Berry, Kristin] Univ Washington, Dept Biostat, Seattle, WA 98195 USA.
[Afzali, Anita; Ioannou, George N.] Vet Affairs Puget Sound Hlth Care Syst, Res Enhancement Award Program, Seattle, WA USA.
RP Afzali, A (reprint author), Univ Washington, Div Gastroenterol, Dept Med, Vet Affairs Puget Sound Hlth Care Syst, 1959 NE Pacific St,Suite AA103,Box 356424, Seattle, WA 98195 USA.
EM anitaa@medicine.washington.edu
FU Health Resources and Services Administration [234-2005-370011C]
FX This work was supported in part by the Health Resources and Services
Administration (contract 234-2005-370011C). The content is the
responsibility of the authors alone and does not necessarily reflect the
views or policies of the Department of Health and Human Services, nor
does mention of trade names, commercial products, or organizations imply
endorsement by the US Government.
NR 21
TC 50
Z9 51
U1 0
U2 1
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1527-6465
J9 LIVER TRANSPLANT
JI Liver Transplant.
PD JAN
PY 2012
VL 18
IS 1
BP 29
EP 37
DI 10.1002/lt.22435
PG 9
WC Gastroenterology & Hepatology; Surgery; Transplantation
SC Gastroenterology & Hepatology; Surgery; Transplantation
GA 867VO
UT WOS:000298483100005
PM 21932374
ER
PT J
AU Ueno, K
Hirata, H
Majid, S
Yamamura, S
Shahryari, V
Tabatabai, ZL
Hinoda, Y
Dahiya, R
AF Ueno, Koji
Hirata, Hiroshi
Majid, Shahana
Yamamura, Soichiro
Shahryari, Varahram
Tabatabai, Z. Laura
Hinoda, Yuji
Dahiya, Rajvir
TI Tumor Suppressor MicroRNA-493 Decreases Cell Motility and Migration
Ability in Human Bladder Cancer Cells by Downregulating RhoC and FZD4
SO MOLECULAR CANCER THERAPEUTICS
LA English
DT Article
ID IN-VITRO; HEPATOCELLULAR-CARCINOMA; GENOMIC ANALYSIS; METASTASIS;
INVASION; PATHWAY; PROGRESSION; INHIBITION; BIOMARKERS; ACTIVATION
AB The purpose of this study was to identify new tumor suppressor microRNAs (miRNA; miR) in bladder cancer, conduct functional analysis of their suppressive role, and identify their specific target genes. To explore tumor suppressor miRs in bladder cancer, miR microarray was conducted using SV-HUC-1, T24, J82, and TCCSUP cells. Expression of miR-493 in bladder cancer (T24, J82, and TCCSUP) cells was downregulated compared with normal SV-HUC-1 cells. Also, the expression of miR-493 was significantly lower in bladder cancer tissues than in their corresponding noncancerous tissues. Transfection of miR-493 into T24 or J82 cells decreased their cell growth andmigration abilities. On the basis of this result, to identify potential miR-493 target genes, we used target scan algorithms to identify target oncogenes related to invasion and migration. miR-493 decreased 30-untranslated region luciferase activity and protein expression of FZD4 and RhoC. miR-493 also decreased binding of RhoC and Rock-1. miR-493 is a new tumor suppressor miRNA in bladder cancer and inhibits cell motility through downregulation of RhoC and FZD4. Mol Cancer Ther; 11(1); 244-53. (C) 2011 AACR.
C1 [Ueno, Koji; Hirata, Hiroshi; Majid, Shahana; Yamamura, Soichiro; Shahryari, Varahram; Dahiya, Rajvir] San Francisco VA Med Ctr, Dept Urol, San Francisco, CA USA.
[Tabatabai, Z. Laura] San Francisco VA Med Ctr, Dept Pathol, San Francisco, CA USA.
[Dahiya, Rajvir] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Hinoda, Yuji] Yamaguchi Univ, Grad Sch Med, Dept Oncol & Lab Med, Ube, Yamaguchi 755, Japan.
RP Dahiya, R (reprint author), Vet Affairs Med Ctr, Urol Res Ctr 112F, 4150 Clement St, San Francisco, CA 94121 USA.
EM rdahiya@urology.ucsf.edu
FU NIH [R01CA130860, R01CA138642, R01CA111470, T32DK007790]; VA
FX This study was supported by grants R01CA130860, R01CA138642,
R01CA111470, T32DK007790 from the NIH, VA Research Enhancement Award
Program (REAP), and Merit Review grants.
NR 30
TC 40
Z9 43
U1 2
U2 5
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1535-7163
J9 MOL CANCER THER
JI Mol. Cancer Ther.
PD JAN
PY 2012
VL 11
IS 1
BP 244
EP 253
DI 10.1158/1535-7163.MCT-11-0592
PG 10
WC Oncology
SC Oncology
GA 879CV
UT WOS:000299308200024
PM 22057916
ER
PT J
AU Li, YX
Berenji, GR
Shaba, WF
Tafti, B
Yevdayev, E
Dadparvar, S
AF Li, Yuxin
Berenji, Gholam R.
Shaba, Wisam F.
Tafti, Bashir
Yevdayev, Ella
Dadparvar, Simin
TI Association of vascular fluoride uptake with vascular calcification and
coronary artery disease
SO NUCLEAR MEDICINE COMMUNICATIONS
LA English
DT Article
DE atherosclerosis; bone scan; sodium [(18)F] fluoride; positron emission
tomography; vascular calcification
ID BEAM COMPUTED-TOMOGRAPHY; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR EVENTS;
PET; CALCIUM; FEASIBILITY; RISK; FLUORODEOXYGLUCOSE; F-18-FLUORIDE;
INFLAMMATION
AB Objective The feasibility of a fluoride positron emission tomography/computed tomography (PET/CT) scan for imaging atherosclerosis has not been well documented. The purpose of this study was to assess fluoride uptake of vascular calcification in various major arteries, including coronary arteries.
Methods We retrospectively reviewed the imaging data and cardiovascular history of 61 patients who received whole-body sodium [(18)F] fluoride PET/CT studies at our institution from 2009 to 2010. Fluoride uptake and calcification in major arteries, including coronary arteries, were analyzed by both visual assessment and standardized uptake value measurement.
Results Fluoride uptake in vascular walls was demonstrated in 361 sites of 54 (96%) patients, whereas calcification was observed in 317 sites of 49 (88%) patients. Significant correlation between fluoride uptake and calcification was observed in most of the arterial walls, except in those of the abdominal aorta. Fluoride uptake in coronary arteries was demonstrated in 28 (46%) patients and coronary calcifications were observed in 34 (56%) patients. There was significant correlation between history of cardiovascular events and presence of fluoride uptake in coronary arteries. The coronary fluoride uptake value in patients with cardiovascular events was significantly higher than in patients without cardiovascular events.
Conclusion sodium [(18)F] fluoride PET/CT might be useful in the evaluation of the atherosclerotic process in major arteries, including coronary arteries. An increased fluoride uptake in coronary arteries may be associated with an increased cardiovascular risk. Nucl Med Commun 33:14-20 (C) 2011 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins.
C1 [Berenji, Gholam R.] VA Greater Los Angeles Healthcare Syst, Nucl Med Serv 115, Los Angeles, CA 90073 USA.
[Dadparvar, Simin] Univ PA Hlth Syst, Philadelphia, PA USA.
RP Berenji, GR (reprint author), VA Greater Los Angeles Healthcare Syst, Nucl Med Serv 115, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA.
EM Gholam.Berenji@va.gov
NR 33
TC 29
Z9 29
U1 0
U2 6
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0143-3636
J9 NUCL MED COMMUN
JI Nucl. Med. Commun.
PD JAN
PY 2012
VL 33
IS 1
BP 14
EP 20
DI 10.1097/MNM.0b013e32834c187e
PG 7
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA 872ZL
UT WOS:000298850000003
PM 21946616
ER
PT J
AU Robertson, SM
Stanley, MA
Cully, JA
Naik, AD
AF Robertson, Suzanne M.
Stanley, Melinda A.
Cully, Jeffrey A.
Naik, Aanand D.
TI Positive Emotional Health and Diabetes Care: Concepts, Measurement, and
Clinical Implications
SO PSYCHOSOMATICS
LA English
DT Review
ID QUALITY-OF-LIFE; TREATMENT SATISFACTION; GLYCEMIC CONTROL; PSYCHOLOGICAL
ADJUSTMENT; CONTROLLED TRIAL; SELF-MANAGEMENT; NEGATIVE AFFECT; MOOD;
RESILIENCE; PEOPLE
AB Background: Numerous studies describe the effect of emotional problems, including diabetes-related distress and depression, on diabetes outcomes. Little attention has been devoted to positive emotional health and its potential role in facilitating patients' self-management and improved outcomes. Objective: This review describes the conceptualization and measurement of three empirically-tested aspects of positive emotional health (well-being, positive affect, resilience) in the diabetes literature and their relationship to diabetes outcomes. Method: A literature review was conducted using PubMed and the Cochrane Library databases from 1970 to January 2011 to identify studies focused on well-being, positive affect, and resilience in diabetes patients. Results: Twenty-two studies were identified based on our inclusion criteria. Well-being studies were least. likely to include conceptualizations and relied on two primary measurement instruments compared to more heterogeneous presentations found in positive affect and resilience studies. All three aspects of positive emotional health were linked to health-related outcomes and self-management. Conclusion: Positive emotional health may facilitate chronic care self-management and improved health outcomes. We present a model to guide future research and intervention development efforts designed to enhance positive emotional health. (Psychosomatics 2012; 53:1-12)
C1 [Robertson, Suzanne M.; Stanley, Melinda A.; Cully, Jeffrey A.; Naik, Aanand D.] Houston Hlth Serv Res & Dev Ctr Excellence, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX USA.
[Stanley, Melinda A.; Cully, Jeffrey A.; Naik, Aanand D.] Baylor Coll Med, Menninger Dept Psychiat & Behav Sci, Houston, TX 77030 USA.
[Stanley, Melinda A.; Cully, Jeffrey A.; Naik, Aanand D.] VA S Cent Mental Illness Res Educ & Clin Ctr, Houston, TX USA.
RP Robertson, SM (reprint author), Houston VA Hlth Serv Res & Dev Ctr Excellence, Michael E DeBakey VA Med Ctr, 2002 Holcombe Blvd,MEDVAMC 152, Houston, TX 77030 USA.
EM smr1@bcm.tmc.edu
FU Houston VA Health Services Research and Development Center of Excellence
[HFP90-020]; VA Office of Academic Affiliations; National Institute of
Aging [5K23AG027144]; Doris Duke Charitable Foundation
FX This review is supported with resources and the use of facilities at the
Houston VA Health Services Research and Development Center of Excellence
(HFP90-020) at the Michael E. DeBakey VA Medical Center, Houston, TX
Suzanne M. Robertson is a VA HSR post-doctoral fellow supported by VA
Office of Academic Affiliations. Aanand D. Naik receives support from a
National Institute of Aging Career Development Award (5K23AG027144) and
a Doris Duke Charitable Foundation Clinical Scientist Development Award.
The views expressed reflect those of the authors and not necessarily
those of the Department of Veterans Affairs or Baylor College of
Medicine.
NR 47
TC 9
Z9 9
U1 1
U2 11
PU AMER PSYCHIATRIC PUBLISHING, INC
PI ARLINGTON
PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA
SN 0033-3182
J9 PSYCHOSOMATICS
JI Psychosomatics
PD JAN-FEB
PY 2012
VL 53
IS 1
BP 1
EP 12
PG 12
WC Psychiatry; Psychology
SC Psychiatry; Psychology
GA 882TB
UT WOS:000299585700001
PM 22221716
ER
PT J
AU Saperstein, AM
Thysen, J
Medalia, A
AF Saperstein, Alice M.
Thysen, Julie
Medalia, Alice
TI The Measure of Insight into Cognition: Reliability and validity of
clinician-rated and self-report scales of neurocognitive insight for
schizophrenia
SO SCHIZOPHRENIA RESEARCH
LA English
DT Article
DE Neurocognition; Insight
ID PSYCHOSIS; ILLNESS; CONSEQUENCES; PERFORMANCE; DEPRESSION; AWARENESS;
SYMPTOMS; DEFICITS
AB Poor insight into the neurocognitive deficits in schizophrenia-spectrum disorders may have significant clinical implications for treatment. The purpose of this study was to replicate and extend the psychometric findings initially reported on the Measure of Insight into Cognition Clinician-Rated (MIC-CR) and Self-Report (MIC-SR) which assess awareness, attribution, and frequency of neurocognitive deficits. Assessments conducted one week apart allowed for internal consistency, test-retest reliability, concurrent validity, and administration order effects to be determined. In this study sample (N = 80), 73 demonstrated significant neurocognitive impairment, yet on the MIC-CR, the average awareness and attribution scores indicated only partial awareness and attribution of neurocognitive deficits. The average MIC-SR score indicated rare frequency of cognitive difficulty in everyday life. Cronbach's alphas for the MIC-CR (0.83) and MIC-SR (0.93) were consistent with the initial validation study; test-retest reliability for both MIC assessments was significant (p < 0.001). In new analyses, concurrent validity was demonstrated by significant correlations between the MIC-CR and MIC-SR in the first validation sample: r=-0.75 (p < 0.001) and the current replication sample: r=-0.70 (p < 0.001). Effect sizes were large when frequencies of neurocognitive complaints (MIC-SR) were compared between subjects with good versus poor awareness on the MIC-CR. Reliability and concurrent validity results were similar and significant regardless of order of MIC-CR and MIC-SR administration. The MIC-CR and MIC-SR are thus reliable and valid complementary instruments to assess neurocognitive insight in people with schizophrenia spectrum disorders. (C) 2011 Elsevier B.V. All rights reserved.
C1 [Saperstein, Alice M.; Medalia, Alice] Columbia Univ Coll Phys & Surg, Dept Psychiat, New York, NY 10032 USA.
[Thysen, Julie] James J Peters VA Med Ctr, Mt Sinai Sch Med, Bronx, NY 10468 USA.
RP Saperstein, AM (reprint author), Columbia Univ Coll Phys & Surg, Dept Psychiat, 1051 Riverside Dr, New York, NY 10032 USA.
EM saperst@nyspi.columbia.edu; am2938@columbia.edu
FU Eli Lilly [F1D-US-X310]
FX This research was supported by an Eli Lilly Investigator Initiated
Trial, Grant # F1D-US-X310, PI: Alice Medalia, PhD. This institution had
no further role in the study design, in the collection, analysis or
interpretation of data, in writing the report, or in the decision to
submit the paper for publication.
NR 24
TC 5
Z9 5
U1 0
U2 4
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0920-9964
J9 SCHIZOPHR RES
JI Schizophr. Res.
PD JAN
PY 2012
VL 134
IS 1
BP 54
EP 58
DI 10.1016/j.schres.2011.10.002
PG 5
WC Psychiatry
SC Psychiatry
GA 881NH
UT WOS:000299492900009
PM 22036020
ER
PT J
AU Smith, GE
Camp, C
Cooley, S
Gonzalez, HM
Hartman-Stein, P
LaRue, A
Pachana, NA
Zeiss, A
AF Smith, Glenn E.
Camp, Cameron
Cooley, Susan
Gonzalez, Hector M.
Hartman-Stein, Paula
LaRue, Asenath
Pachana, Nancy A.
Zeiss, Antonette
CA Amer Psychological Assoc
TI Guidelines for the Evaluation of Dementia and Age-Related Cognitive
Change
SO AMERICAN PSYCHOLOGIST
LA English
DT Article
ID DIAGNOSTIC-CRITERIA; ALZHEIMERS-DISEASE; INFORMANT INTERVIEW;
IMPAIRMENT; PREVALENCE; MANAGEMENT; AGITATION; CONSENSUS
C1 [Smith, Glenn E.] Mayo Clin, Coll Med, Dept Psychiat & Psychol, Rochester, MN USA.
[Camp, Cameron] Hearthstone Alzheimer Care, Res & Prod Dev, Woburn, MA USA.
[Cooley, Susan] US Dept Vet Affairs, Off Geriatr & Extended Care, Geriatr Res & Dev & Dementia Initiat, Washington, DC USA.
[Gonzalez, Hector M.] Wayne State Univ, Inst Gerontol, Detroit, MI 48202 USA.
[Gonzalez, Hector M.] Wayne State Univ, Dept Family Med & Publ Hlth Sci, Detroit, MI 48202 USA.
[Hartman-Stein, Paula] Ctr Hlth Aging, Kent, OH USA.
[Hartman-Stein, Paula] Kent State Univ, E Liverpool, OH USA.
[LaRue, Asenath] Univ Wisconsin, Wisconsin Alzheimers Inst, Madison, WI 53706 USA.
[Pachana, Nancy A.] Univ Queensland, Sch Psychol, Brisbane, Qld 4072, Australia.
[Pachana, Nancy A.] Univ Queensland, Ageing Mind Initiat, Brisbane, Qld 4072, Australia.
[Zeiss, Antonette] US Dept Vet Affairs, Off Patient Care Serv, Off Mental Hlth Serv, Washington, DC USA.
RP Smith, GE (reprint author), Amer Psychol Assoc, Publ Interest Directorate, Off Aging, 750 1st St,NE, Washington, DC 20002 USA.
NR 41
TC 14
Z9 14
U1 2
U2 7
PU AMER PSYCHOLOGICAL ASSOC
PI WASHINGTON
PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA
SN 0003-066X
J9 AM PSYCHOL
JI Am. Psychol.
PD JAN
PY 2012
VL 67
IS 1
BP 1
EP 9
DI 10.1037/a0024643
PG 9
WC Psychology, Multidisciplinary
SC Psychology
GA 878BP
UT WOS:000299226800001
ER
PT J
AU Hook, V
Funkelstein, L
Wegrzyn, J
Bark, S
Kindy, M
Hook, G
AF Hook, Vivian
Funkelstein, Lydiane
Wegrzyn, Jill
Bark, Steven
Kindy, Mark
Hook, Gregory
TI Cysteine Cathepsins in the secretory vesicle produce active peptides:
Cathepsin L generates peptide neurotransmitters and cathepsin B produces
beta-amyloid of Alzheimer's disease
SO BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS
LA English
DT Review
DE Cathepsin L; Cathepsin B; Secretory vesicle; Peptide neurotransmitters;
beta-amyloid; Alzheimer's disease
ID PRECURSOR PROTEIN; TRANSGENIC MICE; IN-VIVO; CHROMOGRANIN-A; WILD-TYPE;
SELECTIVE INHIBITOR; CHROMAFFIN GRANULES; NEUROPEPTIDE-Y; FULL-LENGTH;
MOUSE-BRAIN
AB Recent new findings indicate significant biological roles of cysteine cathepsin proteases in secretory vesicles for production of biologically active peptides. Notably, cathepsin L in secretory vesicles functions as a key protease for proteolytic processing of proneuropeptides (and prohormones) into active neuropeptides that are released to mediate cell-cell communication in the nervous system for neurotransmission. Moreover, cathepsin B in secretory vesicles has been recently identified as a beta-secretase for production of neurotoxic beta-amyloid (A beta) peptides that accumulate in Alzheimer's disease (AD), participating as a notable factor in the severe memory loss in AD. These secretory vesicle functions of cathepsins L and B for production of biologically active peptides contrast with the well-known role of cathepsin proteases in lysosomes for the degradation of proteins to result in their inactivation. The unique secretory vesicle proteome indicates proteins of distinct functional categories that provide the intravesicular environment for support of cysteine cathepsin functions. Features of the secretory vesicle protein systems insure optimized intravesicular conditions that support the proteolytic activity of cathepsins. These new findings of recently discovered biological roles of cathepsins L and B indicate their significance in human health and disease. This article is part of a Special Issue entitled: Proteolysis 50 years after the discovery of lysosome. (C) 2011 Elsevier B.V. All rights reserved.
C1 [Hook, Vivian; Funkelstein, Lydiane; Wegrzyn, Jill; Bark, Steven] Univ Calif San Diego, Skaggs Sch Pharm & Pharmaceut Sci, Dept Neurosci, La Jolla, CA 92093 USA.
[Hook, Vivian; Funkelstein, Lydiane; Wegrzyn, Jill; Bark, Steven] Univ Calif San Diego, Skaggs Sch Pharm & Pharmaceut Sci, Dept Pharmacol, La Jolla, CA 92093 USA.
[Hook, Vivian; Funkelstein, Lydiane; Wegrzyn, Jill; Bark, Steven] Univ Calif San Diego, Skaggs Sch Pharm & Pharmaceut Sci, Dept Med, La Jolla, CA 92093 USA.
[Kindy, Mark] Med Univ S Carolina, Dept Neurosci, Charleston, SC 29425 USA.
[Kindy, Mark] Ralph H Johnson VA Med Ctr, Charleston, SC 29425 USA.
[Hook, Gregory] Amer Life Sci Pharmaceut Inc, San Diego, CA 92109 USA.
RP Hook, V (reprint author), Univ Calif San Diego, Skaggs Sch Pharm & Pharmaceut Sci, Dept Neurosci, 9500 Gilman Dr,MC 0744, La Jolla, CA 92093 USA.
EM vhook@ucsd.edu
OI Wegrzyn, Jill/0000-0001-5923-0888
FU National Institutes of Health [R01DA04271, R01NS24553, R01MH077305,
P01HL58120, K01DA023065]; Alzheimer's Association; NIA/NIH [AG027446,
1R44AG032784]; [P30NS047101]
FX The cathepsin L and proteomics research was supported by grants from the
National Institutes of Health to V. Hook consisting of R01DA04271,
R01NS24553, R01MH077305, P01HL58120 from the NIH, a grant from the
Alzheimer's Association, and a grant to J. Gleeson, P30NS047101, for the
microscopy core. S. Bark was supported by a NIH Mentored Scientist Award
(K01DA023065). The authors also appreciate scientific advice by Dr.
Shin-Rong Hwang, and technical assistance by Mr. Thomas Toneff, at the
Skaggs School of Pharmacy and Pharmaceutical Sciences, Univ. of Calif.,
San Diego, La Jolla, CA. The authors appreciate collaboration of these
studies with Dr. Thomas Reinheckel and Dr. Christoph Peters at the
Albert-Ludwigs University, Freiburg, Germany.; The cathepsin B and
Alzheimer's research was supported by the NIA/NIH R21 Grant AG027446 and
1R44AG032784 (to American Life Science Pharmaceuticals (ALSP)), and by
an award from the Alzheimer's Association to V. Hook. V.H. holds equity
in ALSP and serves on the Scientific Advisory Board of ALSP. The terms
of this agreement have been reviewed by the University of California,
San Diego, in accordance with its conflict of interest policies. G.H.
holds equity in and is employed by ALSP.
NR 121
TC 22
Z9 23
U1 1
U2 24
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1570-9639
J9 BBA-PROTEINS PROTEOM
JI BBA-Proteins Proteomics
PD JAN
PY 2012
VL 1824
IS 1
SI SI
BP 89
EP 104
DI 10.1016/j.bbapap.2011.08.015
PG 16
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA 871CS
UT WOS:000298715900010
PM 21925292
ER
PT J
AU Li, Y
Schiepers, C
Lake, R
Dadparvar, S
Berenji, GR
AF Li, Yuxin
Schiepers, Christiaan
Lake, Ralph
Dadparvar, Simin
Berenji, Gholam R.
TI Clinical utility of F-18-fluoride PET/CT in benign and malignant bone
diseases
SO BONE
LA English
DT Review
DE F-18-sodium fluoride; Positron emission tomography, computed tomography,
PET-CT; Bone scan
ID POSITRON-EMISSION-TOMOGRAPHY; F-18 FLUORIDE-ION; BRAIN TRANSFER
CONSTANTS; CELL LUNG-CANCER; TIME UPTAKE DATA; WHOLE-BODY PET;
BREAST-CANCER; PROSTATE-CANCER; METABOLIC-ACTIVITY; SODIUM-FLUORIDE
AB F-18 labeled sodium fluoride is a positron-emitting, bone seeking agent with more favorable skeletal kinetics than conventional phosphate and diphosphonate compounds. With the expanding clinical usage of PET/CT', there is renewed interest in using F-18-fluoride PET/CT for imaging bone diseases. Growing evidence indicates that F-18 fluoride PET/CT offers increased sensitivity, specificity, and diagnostic accuracy in evaluating metastatic bone disease compared to Tc-99m based bone scintigraphy. National Oncologic PET Registry (NOPR) has expanded coverage for F-18 sodium fluoride PET scans since February 2011 for the evaluation of osseous metastatic disease. In this article, we reviewed the pharmacological characteristics of sodium fluoride, as well as the clinical utility of PET/CT' using F-18-fluoride in both benign and malignant bone disorders. Published by Elsevier Inc.
C1 [Berenji, Gholam R.] VA Greater Los Angeles Healthcare Syst, Nucl Med Serv 115, Los Angeles, CA 90073 USA.
[Schiepers, Christiaan] Univ Calif Los Angeles, Dept Mol & Med Pharmacol, David Geffen Sch Med, Los Angeles, CA 90095 USA.
[Dadparvar, Simin] Univ PA Hlth Syst, Philadelphia, PA USA.
RP Berenji, GR (reprint author), VA Greater Los Angeles Healthcare Syst, Nucl Med Serv 115, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA.
EM Gholam.Berenji@va.gov
NR 75
TC 34
Z9 34
U1 1
U2 13
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 8756-3282
J9 BONE
JI Bone
PD JAN
PY 2012
VL 50
IS 1
BP 128
EP 139
DI 10.1016/j.bone.2011.09.053
PG 12
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 875VV
UT WOS:000299064200017
PM 22001678
ER
PT J
AU Hendrickson, RG
McKeown, NJ
AF Hendrickson, Robert G.
McKeown, Nathanael J.
TI Is maternal opioid use hazardous to breast-fed infants?
SO CLINICAL TOXICOLOGY
LA English
DT Editorial Material
DE Opioids; Breast milk; Human milk; Breastfeeding; Analgesics
ID PATIENT-CONTROLLED ANALGESIA; HUMAN-MILK; HUMAN LIVER; CODEINE USE;
METHADONE-MAINTENANCE; NEONATAL-PERIOD; PREGNANT-WOMEN; DRUG-THERAPY;
IN-VITRO; MORPHINE
AB Over the last few decades, the rate of breastfeeding has increased steadily in the developed countries of the world. During this time, opioid use in the general population has steadily increased as well. Despite this, clinicians remain unclear whether opioid use is safe during breastfeeding. While the vast majority of medications used during breastfeeding occur without incident, case reports and studies have reported possible opioid toxicity in breast-fed infants. Multiple enzymes are involved in the metabolism of opioids. CYP2D6 catabolizes O-demethylation of codeine, tramadol, oxycodone, and hydrocodone to more potent metabolites. CYP3A4 inactivates methadone, meperidine, and buprenorphine. Glucoronide conjugation by the UGT enzyme family inactivates morphine and hydromorphone. Genetic polymorphisms and interfering medications affect the maternal metabolism, which in turn determines the exposure and risk to the breast-fed neonate. We review the production of breast milk, the transfer of xenobiotics from blood to milk, the characteristics that alter xenobiotic breast-milk concentrations, and we review the evidence of specific common opioids and infant toxicity. The short-term maternal use of prescription opioids is usually safe and infrequently presents a hazard to the newborn.
C1 [Hendrickson, Robert G.; McKeown, Nathanael J.] Oregon Hlth & Sci Univ, Portland, OR 97219 USA.
[Hendrickson, Robert G.; McKeown, Nathanael J.] Oregon Poison Ctr, Portland, OR USA.
[McKeown, Nathanael J.] Portland VA Med Ctr, Portland, OR USA.
RP Hendrickson, RG (reprint author), Oregon Hlth & Sci Univ, 3181 SW Sam Jackson Pk Rd,Mail Code CB550, Portland, OR 97219 USA.
EM hendriro@ohsu.edu
NR 110
TC 17
Z9 18
U1 3
U2 14
PU INFORMA HEALTHCARE
PI NEW YORK
PA 52 VANDERBILT AVE, NEW YORK, NY 10017 USA
SN 1556-3650
J9 CLIN TOXICOL
JI Clin. Toxicol.
PD JAN
PY 2012
VL 50
IS 1
BP 1
EP 14
DI 10.3109/15563650.2011.635147
PG 14
WC Toxicology
SC Toxicology
GA 876RZ
UT WOS:000299126700001
PM 22148986
ER
PT J
AU Fiedler, SE
Sisson, JH
Wyatt, TA
Pavlik, JA
Gambling, TM
Carson, JL
Carr, DW
AF Fiedler, Sarah E.
Sisson, Joseph H.
Wyatt, Todd A.
Pavlik, Jacqueline A.
Gambling, Todd M.
Carson, Johnny L.
Carr, Daniel W.
TI Loss of ASP but not ROPN1 reduces mammalian ciliary motility
SO CYTOSKELETON
LA English
DT Article
DE ROPN1L; ropporin; A-kinase anchoring protein; OmniBank (R)
ID KINASE ANCHORING PROTEIN; RADIAL SPOKE PROTEIN-3; AIRWAY
EPITHELIAL-CELLS; BEAT FREQUENCY; DEPENDENT PHOSPHORYLATION; FLAGELLAR
MOTILITY; REGULATORY SUBUNIT; BINDING-PROTEIN; FIBROUS SHEATH; CAMP
AB Protein kinase A (PKA) signaling is targeted by interactions with A-kinase anchoring proteins (AKAPs) via a dimerization/docking domain on the regulatory (R) subunit of PKA. Four other mammalian proteins [AKAP-associated sperm protein (ASP), ropporin (ROPN1), sperm protein 17 (SP17) and calcium binding tyrosine-(Y)-phosphorylation regulated protein (CABYR)] share this highly conserved RII dimerization/docking (R2D2) domain. ASP and ROPN1 are 41% identical in sequence, interact with a variety of AKAPs in a manner similar to PKA, and are expressed in ciliated and flagellated human cells. To test the hypothesis that these proteins regulate motility, we developed mutant mouse lines lacking ASP or ROPN1. Both mutant lines produced normal numbers of cilia with intact ciliary ultrastructure. Lack of ROPN1 had no effect on ciliary motility. However, the beat frequency of cilia from mice lacking ASP is significantly slower than wild type, indicating that ASP signaling may regulate ciliary motility. This is the first demonstration of in vivo function for ASP. Similar localization of ASP in mice and humans indicates that these findings may translate to human physiology, and that these mice will be an excellent model for future studies related to the pathogenesis of human disease. (C) 2011 Wiley Periodicals, Inc.
C1 [Fiedler, Sarah E.; Carr, Daniel W.] VA Med Ctr, Portland, OR USA.
[Fiedler, Sarah E.; Carr, Daniel W.] Oregon Hlth & Sci Univ, Dept Med, Portland, OR 97201 USA.
[Sisson, Joseph H.; Wyatt, Todd A.; Pavlik, Jacqueline A.] Univ Nebraska Med Ctr, Dept Internal Med, Pulm Crit Care Sleep & Allergy Div, Durham Res Ctr 2 1046, Omaha, NE USA.
[Gambling, Todd M.; Carson, Johnny L.] Univ N Carolina, Ctr Environm Med Asthma & Lung Biol, Chapel Hill, NC USA.
[Carson, Johnny L.] Univ N Carolina, Dept Pediat, Chapel Hill, NC USA.
RP Carr, DW (reprint author), Portland VA Med Ctr, Mail Code R&D8,3710 SW US Vet Hosp Rd, Portland, OR 97239 USA.
EM carrd@ohsu.edu
FU NIH [HD 36408, 5 R37AA008769-18]; VA Merit Award; Flight Attendant
Medical Research Institute; US Environmental Protection Agency
[CR833463-01]; Center for Environmental Medicine, Asthma, and Lung
Biology at the University of North Carolina at Chapel Hill
FX Funding for this project is provided by NIH Grant HD 36408 (DWC), VA
Merit Award (DWC), NIH Grant 5 R37AA008769-18 (JHS), a Clinical
Innovator Award (JLC) from the Flight Attendant Medical Research
Institute, and the US Environmental Protection Agency (JLC). Although
the research described in this article has been funded wholly or in part
by the US Environmental Protection Agency through cooperative agreement
CR833463-01 with the Center for Environmental Medicine, Asthma, and Lung
Biology at the University of North Carolina at Chapel Hill, it has not
been subjected to the agency's required peer and policy review, and
therefore does not necessarily reflect the views of the agency and no
official endorsement should be inferred. Mention of trade names or
commercial products does not constitute endorsement or recommendation
for use.
NR 39
TC 8
Z9 8
U1 0
U2 1
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1949-3584
J9 CYTOSKELETON
JI Cytoskeleton
PD JAN
PY 2012
VL 69
IS 1
BP 22
EP 32
DI 10.1002/cm.20539
PG 11
WC Cell Biology
SC Cell Biology
GA 877DG
UT WOS:000299156500002
PM 22021175
ER
PT J
AU Lampiris, HW
AF Lampiris, Harry W.
TI Elvitegravir: a once-daily, boosted, HIV-1 integrase inhibitor
SO EXPERT REVIEW OF ANTI-INFECTIVE THERAPY
LA English
DT Article
DE cobicistat; elvitegravir; HIV-1 integrase; integrase drug interactions;
integrase inhibitor; integrase pharmacokinetics; integrase resistance
ID ANTIRETROVIRAL THERAPY; EXPERIENCED PATIENTS; STRAND TRANSFER; IN-VITRO;
RESISTANCE; RALTEGRAVIR; PHARMACOKINETICS; INFECTION; FAILURE; EVOLUTION
AB The development of HIV-1 integrase strand transfer inhibitors (INSTIs) has been a major therapeutic breakthrough in the management of HIV-1 infection. The first HIV-1 integrase inhibitor, raltegravir, was licensed in 2007 and was subsequently approved for use in treatment-naive patients. Since then, newer members of the INSTI class have been developed, including elvitegravir (EVG), which is in advanced clinical development and is being developed for use in both treatment-naive and treatment-experienced patients. EVG utilizes pharmacokinetic boosting to achieve adequate serum levels with once-daily dosing. Boosting agents with which it is being studied include ritonavir and cobicistat. In addition, EVG is being studied as a once-daily INSTI in a coformulated fixed-dose combination pill with the agents tenofovir disoproxil fumarate, emtricitabine and cobicistat (QUAD pill), which has the additional potential benefit of convenient once-daily dosing. The in vitro activity, pharmacokinetic and pharmacodynamic properties, results of Phase I-III clinical trials, resistance profile and drug-drug interactions of EVG will be reviewed in this article.
C1 [Lampiris, Harry W.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Lampiris, Harry W.] San Francisco VA Med Ctr, San Francisco, CA USA.
RP Lampiris, HW (reprint author), Univ Calif San Francisco, San Francisco, CA 94143 USA.
EM harry.lampiris@va.gov
NR 40
TC 11
Z9 12
U1 1
U2 2
PU EXPERT REVIEWS
PI LONDON
PA UNITEC HOUSE, 3RD FL, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON N3 1QB,
ENGLAND
SN 1478-7210
J9 EXPERT REV ANTI-INFE
JI Expert Rev. Anti-Infect. Ther.
PD JAN
PY 2012
VL 10
IS 1
BP 13
EP 20
DI 10.1586/ERI.11.157
PG 8
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 875ES
UT WOS:000299013800007
PM 22149610
ER
PT J
AU Chattergoon, NN
Giraud, GD
Louey, S
Stork, P
Fowden, AL
Thornburg, KL
AF Chattergoon, Natasha N.
Giraud, George D.
Louey, Samantha
Stork, Philip
Fowden, Abigail L.
Thornburg, Kent L.
TI Thyroid hormone drives fetal cardiomyocyte maturation
SO FASEB JOURNAL
LA English
DT Article
DE proliferation; sheep fetus; p21
ID SIGNAL-REGULATED KINASE; CELL-CYCLE ACTIVITY; INTRAUTERINE GROWTH
RESTRICTION; ATRIAL-NATRIURETIC-FACTOR; ACTIVATED PROTEIN-KINASE;
CARDIAC-MUSCLE-CELLS; MEK-ERK PATHWAY; SARCOPLASMIC-RETICULUM;
POSTNATAL-DEVELOPMENT; SHEEP CARDIOMYOCYTES
AB Tri-iodo-L-thyronine (T-3) suppresses the proliferation of near-term serum-stimulated fetal ovine cardiomyocytes in vitro. Thus, we hypothesized that T-3 is a major stimulant of cardiomyocyte maturation in vivo. We studied 3 groups of sheep fetuses on gestational days 125-130 (term similar to 145 d): a T-3-infusion group, to mimic fetal term levels (plasma T-3 levels increased from similar to 0.1 to similar to 1.0 ng/ml; t(1/2) similar to 24 h); a thyroidectomized group, to produce low thyroid hormone levels; and a vehicle-infusion group, to serve as intact controls. At 130 d of gestation, sections of left ventricular freewall were harvested, and the remaining myocardium was enzymatically dissociated. Proteins involved in cell cycle regulation (p21, cyclin D1), proliferation (ERK), and hypertrophy (mTOR) were measured in left ventricular tissue. Evidence that elevated T-3 augmented the maturation rate of cardiomyocytes included 14% increased width, 31% increase in binucleation, 39% reduction in proliferation, 150% reduction in cyclin D1 protein, and 500% increase in p21 protein. Increased expression of phospho-mTOR, ANP, and SERCA2a also suggests that T-3 promotes maturation and hypertrophy of fetal cardiomyocytes. Thyroidectomized fetuses had reduced cell cycle activity and binucleation. These findings support the hypothesis that T-3 is a prime driver of prenatal cardiomyocyte maturation.-Chattergoon, N. N., Giraud, G. D., Louey, S., Stork, P., Fowden, A. L., Thornburg, K. L. Thyroid hormone drives fetal cardiomyocyte maturation FASEB J. 26, 397-408 (2012). www.fasebj.org
C1 [Chattergoon, Natasha N.; Giraud, George D.; Louey, Samantha; Thornburg, Kent L.] Oregon Hlth & Sci Univ, Heart Res Ctr, Portland, OR 97239 USA.
[Giraud, George D.; Thornburg, Kent L.] Oregon Hlth & Sci Univ, Dept Physiol & Pharmacol, Portland, OR 97239 USA.
[Giraud, George D.; Louey, Samantha; Thornburg, Kent L.] Oregon Hlth & Sci Univ, Dept Med, Portland, OR 97239 USA.
[Stork, Philip] Oregon Hlth & Sci Univ, Vollum Inst, Portland, OR 97239 USA.
[Giraud, George D.] Portland VA Med Ctr, Portland, OR USA.
[Fowden, Abigail L.] Univ Cambridge, Physiol Lab, Dept Physiol Dev & Neurosci, Cambridge CB2 3EG, England.
RP Thornburg, KL (reprint author), Oregon Hlth & Sci Univ, Heart Res Ctr, 3303 SW Bond Ave,CH15H, Portland, OR 97239 USA.
EM thornbur@ohsu.edu
FU U.S. National Institute of Child Health and Human Development [P01 HD
34430]; National Heart, Lung, and Blood Institute (NHLBI) [R21 HL093617,
T32HL094294]; National Institutes of Health [R01 HL102763]
FX The authors thank Mr. Robert Webber and Ms. Loni Socha for excellent
technical assistance. The authors appreciate support from the M. Lowell
Edwards Endowment. This study was supported by funds from U.S. National
Institute of Child Health and Human Development grant P01 HD 34430,
National Heart, Lung, and Blood Institute (NHLBI) grant R21 HL093617,
and National Institutes of Health grant R01 HL102763. N.N.C. was
supported by NHLBI training grant T32HL094294.
NR 91
TC 38
Z9 39
U1 2
U2 11
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
J9 FASEB J
JI Faseb J.
PD JAN
PY 2012
VL 26
IS 1
BP 397
EP 408
DI 10.1096/fj.10-179895
PG 12
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
Topics; Cell Biology
GA 877SF
UT WOS:000299202200039
PM 21974928
ER
PT J
AU Johnson, KA
Hartwell, K
LeMatty, T
Borckardt, J
Morgan, PS
Govindarajan, K
Brady, K
George, MS
AF Johnson, Kevin A.
Hartwell, Karen
LeMatty, Todd
Borckardt, Jeffrey
Morgan, Paul S.
Govindarajan, Koushik
Brady, Kathleen
George, Mark S.
TI Intermittent "Real-time" fMRI Feedback Is Superior to Continuous
Presentation for a Motor Imagery Task: A Pilot Study
SO JOURNAL OF NEUROIMAGING
LA English
DT Article
DE fMRI; neurofeedback; real-time fMRI; motor imagery
ID RESONANCE-IMAGING FMRI; CORTICAL ACTIVITY; BRAIN ACTIVATION;
SELF-REGULATION; FUNCTIONAL MRI; NEUROFEEDBACK
AB BACKGROUND
Real-time functional MRI feedback (RTfMRIf) is a developing technique, with unanswered methodological questions. Given a delay of seconds between neural activity and the measurable hemodynamic response, one issue is the optimal method for presentation of neurofeedback to subjects. The primary objective of this preliminary study was to compare the methods of continuous and intermittent presentation of neural feedback on targeted brain activity.
METHODS
Thirteen participants performed a motor imagery task and were instructed to increase activation in an individually defined region of left premotor cortex using RTfMRIf. The fMRI signal change was compared between real and false feedback for scans with either continuous or intermittent feedback presentation.
RESULTS
More individuals were able to increase their fMRI signal with intermittent feedback, while some individuals had decreased signal with continuous feedback. The evaluation of feedback itself activated an extensive amount of brain regions, and false feedback resulted in brain activation outside of the individually defined region of interest.
CONCLUSIONS
As implemented in this study, intermittent presentation of feedback is more effective than continuous presentation in promoting self-modulation of brain activity. Furthermore, it appears that the process of evaluating feedback involves many brain regions that can be isolated using intermittent presentation.
C1 [Johnson, Kevin A.] Stanford Univ, Dept Anesthesiol, Syst Neurosci & Pain Lab, Palo Alto, CA 94304 USA.
[Hartwell, Karen; LeMatty, Todd; Brady, Kathleen] Med Univ S Carolina, Dept Psychiat, CNS Div, Charleston, SC 29425 USA.
[Johnson, Kevin A.; Borckardt, Jeffrey; George, Mark S.] Med Univ S Carolina, Dept Psychiat, Brain Stimulat Lab, Charleston, SC 29425 USA.
[Johnson, Kevin A.; Morgan, Paul S.; Govindarajan, Koushik; George, Mark S.] Med Univ S Carolina, Ctr Adv Imaging Res, Charleston, SC 29425 USA.
[Morgan, Paul S.] Med Univ S Carolina, Dept Radiol, Charleston, SC 29425 USA.
[Hartwell, Karen; Brady, Kathleen; George, Mark S.] Ralph H Johnson VA Med Ctr, Charleston, SC USA.
RP Johnson, KA (reprint author), Stanford Univ, Dept Anesthesiol, Syst Neurosci & Pain Lab, 780 Welch Rd 208, Palo Alto, CA 94304 USA.
EM johnsk@stanford.edu
OI Morgan, Paul/0000-0002-5870-1446
FU NIH/NIDA (Brady, George) [1R21DA026085-01]
FX The authors have no conflicts of interest to disclose. This study is
supported in part by NIH/NIDA 1R21DA026085-01 (Brady, George).
NR 17
TC 37
Z9 39
U1 0
U2 5
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1051-2284
J9 J NEUROIMAGING
JI J. Neuroimaging
PD JAN
PY 2012
VL 22
IS 1
BP 58
EP 66
DI 10.1111/j.1552-6569.2010.00529.x
PG 9
WC Clinical Neurology; Neuroimaging; Radiology, Nuclear Medicine & Medical
Imaging
SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging
GA 877DZ
UT WOS:000299158500011
PM 20977537
ER
PT J
AU Marcum, ZA
Amuan, ME
Hanlon, JT
Aspinall, SL
Handler, SM
Ruby, CM
Pugh, MJV
AF Marcum, Zachary A.
Amuan, Megan E.
Hanlon, Joseph T.
Aspinall, Sherrie L.
Handler, Steven M.
Ruby, Christine M.
Pugh, Mary Jo V.
TI Prevalence of Unplanned Hospitalizations Caused by Adverse Drug
Reactions in Older Veterans
SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
LA English
DT Article
DE adverse drug reactions; veterans; aged; pharmacoepidemiology
ID MEDICATION-USE; ELDERLY-PATIENTS; AMBULATORY-CARE; ADULTS; EVENTS;
ADMISSION; GUIDELINES; POLYPHARMACY; PATIENT; RATES
AB OBJECTIVES: To describe the prevalence of unplanned hospitalizations caused by adverse drug reactions (ADRs) in older veterans and to examine the association between this outcome and polypharmacy after controlling for comorbidities and other patient characteristics.
DESIGN: Retrospective cohort.
SETTING: Veterans Affairs Medical Centers.
PARTICIPANTS: Six hundred seventy-eight randomly selected unplanned hospitalizations of older (aged >= 65) veterans between October 1, 2003, and September 30, 2006.
MEASUREMENTS: Naranjo ADR algorithm, ADR preventability, and polypharmacy (0-4, 5-8, and >= 9 scheduled medications).
RESULTS: Seventy ADRs involving 113 drugs were found in 68 (10%) hospitalizations of older veterans, of which 25 (36.8%) were preventable. Extrapolating to the population of more than 2.4 million older veterans receiving care during the study period, 8,000 hospitalizations may have been unnecessary. The most common ADRs that occurred were bradycardia (n = 6; beta-blockers, digoxin), hypoglycemia (n = 6; sulfonylureas, insulin), falls (n = 6; antidepressants, angiotensin-converting enzyme inhibitors), and mental status changes (n = 6; anticonvulsants, benzodiazepines). Overall, 44.8% of veterans took nine or more outpatient medications and 35.4% took five to eight. Using multivariable logistic regression and controlling for demographic, health-status, and access-to-care variables, polypharmacy (>= 9 and 5-8) was associated with greater risk of ADR-related hospitalization (adjusted odds ratio (AOR) = 3.90, 95% confidence interval (CI) = 1.43-10.61 and AOR = 2.85, 95% CI = 1.03-7.85, respectively).
CONCLUSION: ADRs, determined using a validated causality algorithm, are a common cause of unplanned hospitalization in older veterans, are frequently preventable, and are associated with polypharmacy. J Am Geriatr Soc 60:34-41, 2012.
C1 [Marcum, Zachary A.; Hanlon, Joseph T.; Handler, Steven M.; Ruby, Christine M.] Univ Pittsburgh, Sch Med, Dept Geriatr, Pittsburgh, PA 15213 USA.
[Handler, Steven M.] Univ Pittsburgh, Sch Med, Dept Biomed Informat, Pittsburgh, PA 15213 USA.
[Hanlon, Joseph T.; Aspinall, Sherrie L.; Ruby, Christine M.] Univ Pittsburgh, Sch Pharm, Dept Pharm & Therapeut, Pittsburgh, PA 15213 USA.
[Amuan, Megan E.] Bedford Vet Affairs Med Ctr, Bedford, MA USA.
[Hanlon, Joseph T.; Handler, Steven M.] Vet Affairs Pittsburgh Healthcare Syst, Ctr Geriatr Res Educ & Clin, Pittsburgh, PA USA.
[Hanlon, Joseph T.; Aspinall, Sherrie L.] Vet Affairs Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA.
[Aspinall, Sherrie L.] Vet Affairs Ctr Medicat Safety, Hines, IL USA.
[Pugh, Mary Jo V.] S Texas Vet Hlth Care Syst, Vet Evidence Based Res Disseminat & Implementat C, San Antonio, TX USA.
[Pugh, Mary Jo V.] Univ Texas Hlth Sci Ctr San Antonio, Dept Epidemiol & Biostat, San Antonio, TX 78229 USA.
[Pugh, Mary Jo V.] Univ Texas Hlth Sci Ctr San Antonio, Div Geriatr & Gerontol, Dept Med, San Antonio, TX 78229 USA.
RP Marcum, ZA (reprint author), Univ Pittsburgh, Dept Geriatr Med, Kaufmann Med Bldg,Suite 500,3471 5th Ave, Pittsburgh, PA 15213 USA.
EM zam12@pitt.edu
OI Handler, Steven/0000-0002-3940-3224; Pugh, Mary Jo/0000-0003-4196-7763
FU National Institute on Aging (NIA) [R01AG027017, P30AG024827,
T32AG021885, K07AG033174, R01AG034056]; National Institute of Mental
Health [R34 MH082682]; National Institute of Nursing Research
[R01NR010135]; Agency for Healthcare Research and Quality [R01HS017695,
R01HS018721, R18HS018151, K12HS019461]; VA Health Services Research and
Development Service (HSR D) [IIR-06-062, DHI 09-237, IIR 02274, IIR
08-274, SDR-07-042, IIR-05-121, IAF-06-080, IIR-09335]; NIA
[K07AG033174, U01 AG012553]; Pennsylvania Department of Aging; Epilepsy
Foundation; SHP [08-140]
FX Dr. Hanlon has received research funding from National Institute on
Aging (NIA) Grants R01AG027017, P30AG024827, T32AG021885, K07AG033174,
and R01AG034056; National Institute of Mental Health Grant R34 MH082682,
National Institute of Nursing Research Grant R01NR010135, Agency for
Healthcare Research and Quality Grant R01HS017695, and VA Health
Services Research and Development Service (HSR& D) IIR-06-062. Dr.
Handler has received research funding from Agency for Healthcare
Research and Quality Grants R01HS018721 and R18HS018151; NIA Grant
K07AG033174, a Pennsylvania Department of Aging grant, and from VA HSR&
D IIR-06-062. Dr. Pugh has received research funding from VA HSR& D DHI
09-237 (PI); VA HSR& D IIR-06-062 (PI), Epilepsy Foundation (PI), VA
HSR& D PPO 09-295 PI, VA HSR& D IIR 02274 PI. Pugh as co-I: VA HSR& D
IIR 08-274, VA HSR& D SDR-07-042, IIR-05-121, IAF-06-080, IIR-09335, SHP
08-140, TRX 01-091 Department of Defense CDMRP 09090014, NIH
R01-NR010828, Pugh Speaker Honoraria: 2009 Kelsey Seybold Research
Foundation. The investigators received support from NIA Grant U01
AG012553 and Agency for Healthcare Research and Quality Grant
K12HS019461. The views expressed in this article are those of the
authors and do not necessarily represent the views of the Department of
Veterans Affairs.
NR 50
TC 47
Z9 48
U1 1
U2 7
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0002-8614
J9 J AM GERIATR SOC
JI J. Am. Geriatr. Soc.
PD JAN
PY 2012
VL 60
IS 1
BP 34
EP 41
DI 10.1111/j.1532-5415.2011.03772.x
PG 8
WC Geriatrics & Gerontology; Gerontology
SC Geriatrics & Gerontology
GA 875PN
UT WOS:000299044100005
PM 22150441
ER
PT J
AU Shega, JW
Dale, W
Andrew, M
Paice, J
Rockwood, K
Weiner, DK
AF Shega, Joseph W.
Dale, William
Andrew, Melissa
Paice, Judith
Rockwood, Kenneth
Weiner, Debra K.
TI Persistent Pain and Frailty: A Case for Homeostenosis
SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
LA English
DT Article
DE pain; frailty; older adults; homeostenosis
ID LOW-BACK-PAIN; OLDER-ADULTS; MORTALITY; PEOPLE; PREVALENCE; MANAGEMENT;
DEMENTIA; IMPACT; CARE; 3MS
AB OBJECTIVES: To compare the association between self-reported moderate to severe pain and frailty.
DESIGN: Cross-sectional analysis of the Canadian Study of Health and Aging Wave 2.
SETTING: Community.
PARTICIPANTS: Representative sample of persons aged 65 and older in Canada.
MEASUREMENTS: Pain (exposure) was categorized as no or very mild pain versus moderate or greater pain. Frailty (outcome) was operationalized as the accumulation of 33 possible self-reported health attitudes, illnesses, and functional abilities, subsequently divided into tertiles (not frail, prefrail, and frail). Multivariable logistic regression assessed for the association between pain and frailty.
RESULTS: Of participants who reported moderate or greater pain (35.5%, 1,765/4,968), 16.2% were not frail, 34.1% were prefrail, and 49.8% were frail. For persons with moderate or greater pain, the odds of being prefrail rather than not frail were higher by a factor of 2.52 (95% confidence interval (CI) = 2.13-2.99; P < .001). For persons with moderate or greater pain, the odds of being frail rather than not frail were higher by a factor of 5.52 (95% CI = 4.49-6.64 P < .001).
CONCLUSION: Moderate or higher pain was independently associated with frailty. Although causality cannot be ascertained in a cross-sectional analysis, interventions to improve pain management may help prevent or ameliorate frailty. J Am Geriatr Soc 60:113-117, 2012.
C1 [Shega, Joseph W.; Dale, William] Univ Chicago, Sect Geriatr & Palliat Med, Chicago, IL 60637 USA.
[Shega, Joseph W.] Univ Chicago, Sect Hematol & Oncol, Chicago, IL 60637 USA.
[Andrew, Melissa; Rockwood, Kenneth] Dalhousie Univ, Div Geriatr Med, Halifax, NS, Canada.
[Paice, Judith] Northwestern Univ, Feinberg Sch Med, Div Hematol Oncol, Chicago, IL 60611 USA.
[Weiner, Debra K.] Vet Affairs Pittsburgh Healthcare Syst, Ctr Geriatr Res Educ & Clin, Pittsburgh, PA USA.
[Weiner, Debra K.] Univ Pittsburgh, Dept Med, Pittsburgh, PA USA.
[Weiner, Debra K.] Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA USA.
[Weiner, Debra K.] Univ Pittsburgh, Dept Anesthesiol, Pittsburgh, PA USA.
RP Shega, JW (reprint author), Univ Chicago, Sect Geriatr & Palliat Med, MC 6098,5841 S Maryland Ave, Chicago, IL 60637 USA.
EM jshega@gmail.com
FU National Health Research Development Program; Seniors' Independence
Research program [6606-3954-MC(S)]; National Institute on Aging
[K23AG029815]; Canadian Institutes of Health Research [MOP-62823];
Dalhousie Medical Research Foundation; QEII Research Foundation
FX All the data reported here were gathered using public funding from the
National Health Research Development Program, which administrated a
grant from the Seniors' Independence Research program (6606-3954-MC(S)).
Funding for these analyses came from a career development award
K23AG029815 from the National Institute on Aging and from the Canadian
Institutes of Health Research through operating grant MOP-62823.
Additional support came from the Dalhousie Medical Research Foundation
(career support to KR as Kathryn Allen Weldon Professor of Alzheimer
Research) and the Fountain Innovation Fund of the QEII Research
Foundation.
NR 29
TC 22
Z9 22
U1 2
U2 9
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0002-8614
J9 J AM GERIATR SOC
JI J. Am. Geriatr. Soc.
PD JAN
PY 2012
VL 60
IS 1
BP 113
EP 117
DI 10.1111/j.1532-5415.2011.03769.x
PG 5
WC Geriatrics & Gerontology; Gerontology
SC Geriatrics & Gerontology
GA 875PN
UT WOS:000299044100015
PM 22150394
ER
PT J
AU O'Hare, AM
AF O'Hare, Ann M.
TI Age and Access to Kidney Transplantation
SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
LA English
DT Editorial Material
ID OLDER-ADULTS; PROGNOSTIC INDEX; MORTALITY; VALIDATION
C1 [O'Hare, Ann M.] Univ Washington, Dept Med, Seattle, WA 98195 USA.
[O'Hare, Ann M.] Vet Affairs Puget Sound Healthcare Syst, Dept Med, Seattle, WA USA.
[O'Hare, Ann M.] Grp Hlth Res Inst Seattle, Seattle, WA USA.
RP O'Hare, AM (reprint author), Univ Washington, Dept Med, Seattle, WA 98195 USA.
NR 15
TC 1
Z9 1
U1 1
U2 1
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0002-8614
J9 J AM GERIATR SOC
JI J. Am. Geriatr. Soc.
PD JAN
PY 2012
VL 60
IS 1
BP 151
EP 153
DI 10.1111/j.1532-5415.2011.03790.x
PG 3
WC Geriatrics & Gerontology; Gerontology
SC Geriatrics & Gerontology
GA 875PN
UT WOS:000299044100022
PM 22239294
ER
PT J
AU Zhan, W
Kang, GA
Glass, GA
Zhang, Y
Shirley, C
Millin, R
Possin, KL
Nezamzadeh, M
Weiner, MW
Marks, WJ
Schuff, N
AF Zhan, Wang
Kang, Gail A.
Glass, Graham A.
Zhang, Yu
Shirley, Cheryl
Millin, Rachel
Possin, Katherine L.
Nezamzadeh, Marzieh
Weiner, Michael W.
Marks, William J., Jr.
Schuff, Norbert
TI Regional Alterations of Brain Microstructure in Parkinson's Disease
Using Diffusion Tensor Imaging
SO MOVEMENT DISORDERS
LA English
DT Article
DE diffusion tensor imaging; magnetic resonance imaging; Parkinson's
disease; subtypes
ID SUBSTANTIA-NIGRA; BASAL GANGLIA; RAT MODEL; TRACT; SENSORIMOTOR;
DISORDERS; DEMENTIA; MRI
AB This study tested the hypothesis that diffusion tensor imaging can detect alteration in microscopic integrity of white matter and basal ganglia regions known to be involved in Parkinson's disease (PD) pathology. It was also hypothesized that there is an association between diffusion abnormality and PD severity and subtype. Diffusion tensor imaging at 4 Tesla was obtained in 12 PD and 20 control subjects, and measures of fractional anisotropy and mean diffusivity were evaluated using both region-of-interest and voxel-based methods. Movement deficits and subtypes in PD subjects were assessed using the Motor Subscale (Part III) of the Unified Parkinson's Disease Rating Scale. Reduced fractional anisotropy (P < .05, corrected) was found in PD subjects in regions related to the precentral gyrus, substantia nigra, putamen, posterior striatum, frontal lobe, and the supplementary motor areas. Reduced fractional anisotropy in the substantia nigra correlated (P < .05, corrected) with the increased rating scale motor scores. Significant spatial correlations between fractional anisotropy alterations in the putamen and other PD-affected regions were also found in the context of PD subtypes index analysis. Our data suggest that microstructural alterations detected with diffusion tensor might serve as a potential biomarker for PD. (C) 2011 Movement Disorder Society
C1 [Zhan, Wang; Zhang, Yu; Shirley, Cheryl; Millin, Rachel; Nezamzadeh, Marzieh; Weiner, Michael W.; Schuff, Norbert] Univ Calif San Francisco, Dept Radiol & Med Imaging, Ctr Imaging Neurodegenerat Dis, San Francisco, CA 94121 USA.
[Kang, Gail A.; Glass, Graham A.; Marks, William J., Jr.] San Francisco VA Med Ctr, Parkinsons Dis Res Educ & Clin Ctr, San Francisco, CA USA.
[Kang, Gail A.; Glass, Graham A.; Possin, Katherine L.; Marks, William J., Jr.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94121 USA.
RP Zhan, W (reprint author), Univ Calif San Francisco, Dept Radiol, VA Med Ctr 114M, 4150 Clement St, San Francisco, CA 94121 USA.
EM Wang.Zhan@gmail.com
FU Michael J. Fox Foundation [MJJF-BM2007]; NIH/NIRR "Research Resource for
MRI of Neurodegenerative Disorders" [1 P41RR023953]; Larry L. Hillblom
Foundation [2008-A-020-FEL]
FX This work was supported in part by the Michael J. Fox Foundation for
Parkinson's Research, "Multimodal MRI Markers for Parkinson's Disease"
(MJJF-BM2007); NIH/NIRR "Research Resource for MRI of Neurodegenerative
Disorders" (1 P41RR023953); and the Larry L. Hillblom Foundation, "Early
markers and brain bases of spatial impairment in alpha-synuclein
disorders" (2008-A-020-FEL).
NR 47
TC 59
Z9 61
U1 1
U2 13
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0885-3185
J9 MOVEMENT DISORD
JI Mov. Disord.
PD JAN
PY 2012
VL 27
IS 1
BP 90
EP 97
DI 10.1002/mds.23917
PG 8
WC Clinical Neurology
SC Neurosciences & Neurology
GA 877DA
UT WOS:000299155900015
PM 21850668
ER
PT J
AU Flaherty, P
Natsoulis, G
Muralidharan, O
Winters, M
Buenrostro, J
Bell, J
Brown, S
Holodniy, M
Zhang, N
Ji, HP
AF Flaherty, Patrick
Natsoulis, Georges
Muralidharan, Omkar
Winters, Mark
Buenrostro, Jason
Bell, John
Brown, Sheldon
Holodniy, Mark
Zhang, Nancy
Ji, Hanlee P.
TI Ultrasensitive detection of rare mutations using next-generation
targeted resequencing
SO NUCLEIC ACIDS RESEARCH
LA English
DT Article
ID DNA; VARIANTS; PERFORMANCE; CANCER
AB With next-generation DNA sequencing technologies, one can interrogate a specific genomic region of interest at very high depth of coverage and identify less prevalent, rare mutations in heterogeneous clinical samples. However, the mutation detection levels are limited by the error rate of the sequencing technology as well as by the availability of variant-calling algorithms with high statistical power and low false positive rates. We demonstrate that we can robustly detect mutations at 0.1% fractional representation. This represents accurate detection of one mutant per every 1000 wild-type alleles. To achieve this sensitive level of mutation detection, we integrate a high accuracy indexing strategy and reference replication for estimating sequencing error variance. We employ a statistical model to estimate the error rate at each position of the reference and to quantify the fraction of variant base in the sample. Our method is highly specific (99%) and sensitive (100%) when applied to a known 0.1% sample fraction admixture of two synthetic DNA samples to validate our method. As a clinical application of this method, we analyzed nine clinical samples of H1N1 influenza A and detected an oseltamivir (antiviral therapy) resistance mutation in the H1N1 neuraminidase gene at a sample fraction of 0.18%.
C1 [Flaherty, Patrick; Natsoulis, Georges; Buenrostro, Jason; Bell, John; Ji, Hanlee P.] Stanford Univ, Stanford Genome Technol Ctr, Palo Alto, CA 94304 USA.
[Flaherty, Patrick] Stanford Univ, Dept Biochem, Stanford, CA 94305 USA.
[Muralidharan, Omkar; Zhang, Nancy] Stanford Univ, Dept Stat, Stanford, CA 94305 USA.
[Winters, Mark; Holodniy, Mark] Stanford Univ, Div Infect Dis, Dept Med, Stanford, CA 94305 USA.
[Brown, Sheldon] James J Peters VA Med Ctr, Bronx, NY 10468 USA.
[Holodniy, Mark] VA Palo Alto Hlth Care Syst, Palo Alto, CA 94304 USA.
[Ji, Hanlee P.] Stanford Univ, Div Oncol, Dept Med, Sch Med, Stanford, CA 94305 USA.
RP Ji, HP (reprint author), Stanford Univ, Stanford Genome Technol Ctr, Palo Alto, CA 94304 USA.
EM genomics_ji@stanford.edu
FU National Science Foundation, Division of Mathematical Sciences (NSF DMS)
DMS [1043204]; Department of Veterans Affairs; National Institutes of
Health (NIH) [5K08CA96879-6, DK56339, 2P01HG000205, R21CA140089]; Doris
Duke Clinical Foundation; Reddere Foundation; Liu Bie Ju Cha and Family
Fellowship in Cancer; Wang Family Foundation; Howard Hughes Medical
Foundation
FX National Science Foundation, Division of Mathematical Sciences (NSF DMS)
DMS (Grant #1043204 to N.Z. and H.P.J.); Department of Veterans Affairs
(in part, to M. H.); National Institutes of Health (NIH) (grants
5K08CA96879-6 to H.P.J., DK56339 to H.P.J, 2P01HG000205 to J.B., J.M.B.,
H.P.J. and P. F. and R21CA140089 to G.N. and H.P.J.); Doris Duke
Clinical Foundation (to H.P.J.); Reddere Foundation (to H.P.J.); Liu Bie
Ju Cha and Family Fellowship in Cancer (to H.P.J.); Wang Family
Foundation (to H.P.J.); Howard Hughes Medical Foundation (to H.P.J.).
Funding for open access charge: NIH (grant 2P01HG000205) and NSF DMS
(grant 1043204).
NR 21
TC 54
Z9 54
U1 1
U2 10
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0305-1048
J9 NUCLEIC ACIDS RES
JI Nucleic Acids Res.
PD JAN
PY 2012
VL 40
IS 1
AR e2
DI 10.1093/nar/gkr861
PG 12
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 871JG
UT WOS:000298733500002
PM 22013163
ER
PT J
AU Livhits, M
Mercado, C
Yermilov, I
Parikh, JA
Dutson, E
Mehran, A
Ko, CY
Gibbons, MM
AF Livhits, Masha
Mercado, Cheryl
Yermilov, Irina
Parikh, Janak A.
Dutson, Erik
Mehran, Amir
Ko, Clifford Y.
Gibbons, Melinda Maggard
TI Preoperative Predictors of Weight Loss Following Bariatric Surgery:
Systematic Review
SO OBESITY SURGERY
LA English
DT Review
DE Bariatric surgery; Predictors; Weight loss; Preoperative; Outcomes
ID Y GASTRIC BYPASS; VERTICAL BANDED GASTROPLASTY; QUALITY-OF-LIFE;
MORBIDLY OBESE-PATIENTS; BODY-MASS INDEX; 12-MONTH POSTOPERATIVE
OUTCOMES; DUODENAL SWITCH OPERATION; CHILDHOOD SEXUAL-ABUSE;
BINGE-EATING DISORDER; RISKS VS. BENEFITS
AB Obesity affects 32% of adults in the USA. Surgery generates substantial weight loss, but 20-30% fails to achieve successful weight loss. Our objective was to identify preoperative psychosocial factors associated with weight loss following bariatric surgery.
We performed a literature search of PubMedA (R) and the Cochrane Database of Reviews of Effectiveness between 1988 and April 2010. Articles were screened for bariatric surgery and weight loss if they included a preoperative predictor of weight loss: body mass index (BMI), preoperative weight loss, eating disorders, or psychiatric disorder/substance abuse. One thousand seven titles were reviewed, 534 articles screened, and 115 included in the review.
Factors that may be positively associated with weight loss after surgery include mandatory preoperative weight loss (7 of 14 studies with positive association). Factors that may be negatively associated with weight loss include preoperative BMI (37 out of 62 studies with negative association), super-obesity (24 out of 33 studies), and personality disorders (7 out of 14 studies). Meta-analysis revealed a decrease of 10.1% excess weight loss (EWL) for super-obese patients (95% confidence interval (CI) [3.7-16.5%]), though there was significant heterogeneity in the meta-analysis, and an increase of 5.9% EWL for patients with binge eating at 12 months after surgery (95% CI [1.9-9.8%]).
Further studies are necessary to investigate whether preoperative factors can predict a clinically meaningful difference in weight loss after bariatric surgery. The identification of predictive factors may improve patient selection and help develop interventions targeting specific needs of patients.
C1 [Livhits, Masha; Yermilov, Irina; Parikh, Janak A.; Ko, Clifford Y.; Gibbons, Melinda Maggard] VA Greater Los Angeles Healthcare Syst, Dept Surg, Los Angeles, CA 90073 USA.
[Livhits, Masha; Mercado, Cheryl; Yermilov, Irina; Parikh, Janak A.; Dutson, Erik; Mehran, Amir; Ko, Clifford Y.; Gibbons, Melinda Maggard] Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, Los Angeles, CA 90095 USA.
[Gibbons, Melinda Maggard] Olive View UCLA, Dept Surg, Los Angeles, CA 91342 USA.
RP Livhits, M (reprint author), VA Greater Los Angeles Healthcare Syst, Dept Surg, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA.
EM mlivhits@mednet.ucla.edu
FU VA Department of Surgery; Robert Wood Johnson Physician Faculty
FX We would like to acknowledge the generous contribution of Paul G.
Shekelle to the design of our project and critical review of the
analysis. The VA Department of Surgery provided support for Dr. Livhits
and Dr. Gibbons. Dr. Gibbons's time was supported in part by a grant
from the Robert Wood Johnson Physician Faculty Scholars program.
NR 145
TC 154
Z9 155
U1 5
U2 42
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0960-8923
EI 1708-0428
J9 OBES SURG
JI Obes. Surg.
PD JAN
PY 2012
VL 22
IS 1
BP 70
EP 89
DI 10.1007/s11695-011-0472-4
PG 20
WC Surgery
SC Surgery
GA 876PU
UT WOS:000299120700013
PM 21833817
ER
PT J
AU Bourguignon, LYW
Earle, C
Wong, G
Spevak, CC
Krueger, K
AF Bourguignon, L. Y. W.
Earle, C.
Wong, G.
Spevak, C. C.
Krueger, K.
TI Stem cell marker (Nanog) and Stat-3 signaling promote MicroRNA-21
expression and chemoresistance in hyaluronan/CD44-activated head and
neck squamous cell carcinoma cells
SO ONCOGENE
LA English
DT Article
DE nanog; Stat-3; miR-21; hyaluronan; CD44; head & neck cancer
ID NF-KAPPA-B; CANCER STATISTICS; GENE-EXPRESSION; TUMOR-CELLS; RHO-KINASE;
HYALURONAN; BREAST; PROGRESSION; ACTIVATION; TRANSCRIPTION
AB MicroRNAs are often associated with the pathogenesis of many cancers, including head and neck squamous cell carcinoma (HNSCC). In particular, microRNA-21 (miR-21) appears to have a critical role in tumor cell survival, chemoresistance and HNSCC progression. In this study, we investigated matrix hyaluronan (HA)-induced CD44 (a primary HA receptor) interaction with the stem cell markers, Nanog and Stat-3, in HNSCC cells (HSC-3 cells). Our results indicate that HA binding to CD44 promotes Nanog-Stat-3 (also tyrosine phosphorylated Stat-3) complex formation, nuclear translocation and transcriptional activation. Further analyses reveal that miR-21 is controlled by an upstream promoter containing Stat-3 binding site(s), while chromatin immunoprecipitation assays demonstrate that stimulation of miR-21 expression by HA/CD44 signaling is Nanog/Stat-3-dependent in HNSCC cells. This process results in a decrease of a tumor suppressor protein (PDCD4), and an upregulation of i nhibitors of the apoptosis family of proteins (IAPs) as well as chemoresistance in HSC-3 cells. Treatment of HSC-3 cells with Nanog- and/or Stat-3-specific small interfering RNAs effectively blocks HA-mediated Nanog-Stat-3 signaling events, abrogates miR-21 production and increases PDCD4 expression. Subsequently, this Nanog-Stat-3 signaling inhibition causes downregulation of survival protein (IAP) expression and enhancement of chemosensitivity. To further evaluate the role of miR-21 in tumor cell-specific functions, HSC-3 cells were also transfected with a specific anti-miR-21 inhibitor in order to silence miR-21 expression and block its target functions. Our results demonstrate that anti-miR-21 inhibitor not only upregulates PDCD4 expression but also decreases IAP expression and enhances chemosensitivity in HA-treated HNSCC cells. Together, these findings indicate that the HA-induced CD44 interaction with Nanog and Stat-3 has a pivotal role in miR-21 production leading to PDCD4 reduction, IAP upregulation and chemoresistance in HNSCC cells. This novel Nanog/Stat-3 signaling pathway-specific mechanism involved in miR-21 production is significant for the formation of future intervention strategies in the treatment of HA/CD44-activated HNSCC. Oncogene (2012) 31, 149-160; doi:10.1038/onc.2011.222; published online 20 June 2011
C1 [Bourguignon, L. Y. W.] Univ Calif San Francisco, Dept Med, Endocrine Unit 111N, San Francisco, CA 94121 USA.
San Francisco VA Med Ctr, San Francisco, CA USA.
RP Bourguignon, LYW (reprint author), Univ Calif San Francisco, Dept Med, Endocrine Unit 111N, 4150 Clement St, San Francisco, CA 94121 USA.
EM lilly.bourguignon@ucsf.edu
FU Veterans Affairs (VA) Merit Review grant; United States Public Health
grants [R01 CA66163, R01 CA78633, P01 AR39448]
FX We gratefully acknowledge the assistance of Drs Gerard J Bourguignon and
Walter M Holleran in the preparation and review of this manuscript. We
are grateful for Ms Christina Camacho for her assistance in preparing
graphs and illustrations. We would also like to thank for Dr Shaomeng
Wang from the University of Michigan for providing us an IAP inhibitor,
SM164. This work was supported by Veterans Affairs (VA) Merit Review
grant and United States Public Health grants (R01 CA66163, R01 CA78633
and P01 AR39448). LYWB is a VA Senior Research Career Scientist.
NR 30
TC 90
Z9 94
U1 2
U2 12
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-9232
J9 ONCOGENE
JI Oncogene
PD JAN
PY 2012
VL 31
IS 2
BP 149
EP 160
DI 10.1038/onc.2011.222
PG 12
WC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
Heredity
SC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
Heredity
GA 879CN
UT WOS:000299307400002
PM 21685938
ER
PT J
AU Meghani, SH
Polomano, RC
Tait, RC
Vallerand, AH
Anderson, KO
Gallagher, RM
AF Meghani, Salimah H.
Polomano, Rosemary C.
Tait, Raymond C.
Vallerand, April H.
Anderson, Karen O.
Gallagher, Rollin M.
TI Advancing a National Agenda to Eliminate Disparities in Pain Care:
Directions for Health Policy, Education, Practice, and Research
SO PAIN MEDICINE
LA English
DT Article
DE Pain; Disparities-Ethnic; Disparities-Racial; Pain Management; Pain
Treatment; Policy; Advocacy; Legislation; Ethnic Disparities; Opioids;
Analgesics; United States
ID LIMITED ENGLISH PROFICIENCY; PATIENT-PHYSICIAN RELATIONSHIP; RANDOMIZED
CONTROLLED-TRIAL; EMERGENCY-DEPARTMENT; UNITED-STATES; CULTURAL
COMPETENCE; ETHNIC DISPARITIES; WHITE AMERICANS; CANCER-PATIENTS;
MUSCULOSKELETAL PAIN
AB Background. Pain is strongly associated with significant personal and societal costs. A crucial element of any initiative on pain must focus on eliminating pain care disparities that are pervasive throughout the United States health care settings.
Objectives. This report focuses on macro-level factors related to pain care disparities in the United States that may be amenable to policy interventions.
Methods. We identify concrete opportunities for achieving equity in pain care, especially those occasioned by recent legislative changes in the United States health care system. An aggressive policy, advocacy, and research agenda is synthesized in five domains: 1) structural/system; 2) policy and advocacy; 3) workforce; 4) provider; and 5) research.
Results. Inequities in pain care remain an important and neglected health policy concern. Many direct and indirect provisions within the Affordable Care Act (ACA) and other national initiatives that leverage on ACA offer opportunities to achieve equity in pain care. These include changes in insurance, in public, provider, and legislative education, in primary care and pain specialist training, improving workforce diversity, achieving uniformity in race/ethnicity data collection, emphasizing patient-centered outcomes research, and encouraging focus on pain care disparities within the comparative effectiveness research paradigm.
Conclusions. Recent national legislative initiatives within ACA are expected to generate multilevel efforts that will impact the flow of funding to address the pervasive issue of disparities. It is an opportune time for the pain community to take a lead in implementing a concerted agenda on pain care disparities in order to leverage these national initiatives.
C1 [Meghani, Salimah H.] Univ Penn, Ctr Bioeth, NewCourtland Ctr Transit & Hlth, Dept Biobehav Hlth Sci,Sch Nursing, Philadelphia, PA 19104 USA.
[Tait, Raymond C.] St Louis Univ, St Louis, MO 63103 USA.
[Vallerand, April H.] Wayne State Univ, Detroit, MI USA.
[Anderson, Karen O.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
[Gallagher, Rollin M.] Univ Penn, Philadelphia VA Med Ctr, Philadelphia, PA 19104 USA.
RP Meghani, SH (reprint author), Univ Penn, Ctr Bioeth, NewCourtland Ctr Transit & Hlth, Dept Biobehav Hlth Sci,Sch Nursing, Claire M Fagin Hall,418 Curie Blvd,Room 337, Philadelphia, PA 19104 USA.
EM meghanis@nursing.upenn.edu
RI Vallerand, April/I-8150-2012
FU Pricara, Unit of Ortho-McNeil, Inc.
FX This work was supported by an unrestricted educational grant to the
Philadelphia Research and Education Foundation, Philadelphia VA Medical
Center, from Pricara, Unit of Ortho-McNeil, Inc., administered by
Ortho-McNeil Janssen Scientific Affairs.
NR 152
TC 34
Z9 34
U1 4
U2 22
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1526-2375
J9 PAIN MED
JI Pain Med.
PD JAN
PY 2012
VL 13
IS 1
BP 5
EP 28
DI 10.1111/j.1526-4637.2011.01289.x
PG 24
WC Medicine, General & Internal
SC General & Internal Medicine
GA 874KB
UT WOS:000298954200002
PM 22142450
ER
PT J
AU Wu, Y
Collier, L
Pan, J
Qin, W
Bauman, WA
Cardozo, CP
AF Wu, Y.
Collier, L.
Pan, J.
Qin, W.
Bauman, W. A.
Cardozo, C. P.
TI Testosterone reduced methylprednisolone-induced muscle atrophy in spinal
cord-injured rats
SO SPINAL CORD
LA English
DT Article
DE Spinal cord injury; methylprednisolone; muscle atrophy; atrogenes;
testosterone
ID HIGH-DOSE METHYLPREDNISOLONE; GROWTH-FACTOR-I; SKELETAL-MUSCLE; SERUM
TESTOSTERONE; CONTROLLED-TRIAL; GENE-EXPRESSION; UP-REGULATION;
MYOSTATIN; DIAPHRAGM; PROTEIN
AB Study design: Male rats with complete transections of the spinal cord were administered vehicle or methylprednisolone (MP) for 24 h, with or without infusion, for 7 days, of testosterone at either a replacement or low pharmacological doses. Muscles were collected at 7 days after SCI.
Objective: The objective of this study is to determine, in a rat model of complete spinal cord transection, whether testosterone reduces muscle atrophy or upregulates muscle atrophy-linked genes, induced by 24 h of MP administration at doses comparable to those prescribed in man during the period immediately following acute spinal cord injury (SCI) in an attempt to preserve neurological function.
Results: MP significantly reduced the mass of triceps, soleus and plantaris, and significantly increased expression of genes that promote atrophy. Testosterone significantly reduced muscle atrophy induced by MP, but did not prevent it; there was no difference between low-or high-dose testosterone in reducing MP-induced muscle loss. High-dose testosterone reduced expression of muscle atrophy genes more than did low dose. Testosterone-induced declines in mRNA levels for these atrophy-associated genes did not correlate well with protection against MP-induced muscle atrophy.
Conclusions: MP induces marked and lasting changes in the biology of muscle that persisted for at least 7 days, or 6 days after MP has been eliminated from the body. Testosterone partially protected against muscle atrophy and gene expression changes caused by 1 day of MP. Spinal Cord (2012) 50, 57-62; doi:10.1038/sc.2011.91; published online 20 September 2011
C1 [Wu, Y.; Collier, L.; Pan, J.; Qin, W.; Bauman, W. A.; Cardozo, C. P.] James J Peters VA Med Ctr, Ctr Excellence Med Consequences Spinal Cord Injur, Dept Vet Affairs, Bronx, NY 10468 USA.
[Qin, W.; Bauman, W. A.; Cardozo, C. P.] Mt Sinai Sch Med, Dept Med, New York, NY USA.
[Bauman, W. A.; Cardozo, C. P.] Mt Sinai Sch Med, Dept Rehabil Med, New York, NY USA.
RP Cardozo, CP (reprint author), James J Peters VA Med Ctr, Ctr Excellence Med Consequences Spinal Cord Injur, Dept Vet Affairs, Room 7A-13,130 W Kingsbridge Rd, Bronx, NY 10468 USA.
EM Chris.Cardozo@mssm.edu
FU Veterans Health Administration, Rehabilitation Research and Development
Service [B4162C, B3347 K]
FX This research was supported by the Veterans Health Administration,
Rehabilitation Research and Development Service (B4162C and B3347 K).
NR 33
TC 1
Z9 1
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1362-4393
EI 1476-5624
J9 SPINAL CORD
JI Spinal Cord
PD JAN
PY 2012
VL 50
IS 1
BP 57
EP 62
DI 10.1038/sc.2011.91
PG 6
WC Clinical Neurology; Rehabilitation
SC Neurosciences & Neurology; Rehabilitation
GA 879FB
UT WOS:000299314000011
PM 21931329
ER
PT J
AU Williams, RE
Bauman, WA
Spungen, AM
Vinnakota, RR
Farid, RZ
Galea, M
Korsten, MA
AF Williams, R. E., III
Bauman, W. A.
Spungen, A. M.
Vinnakota, R. R.
Farid, R. Z.
Galea, M.
Korsten, M. A.
TI SmartPill technology provides safe and effective assessment of
gastrointestinal function in persons with spinal cord injury
SO SPINAL CORD
LA English
DT Article
DE spinal cord injury; gastric emptying time; colonic transit time; whole
gut transit time; gastroesophageal reflux disease
ID CAPSULE
AB Study design: Spinal cord injury (SCI) results in gastrointestinal (GI) complications, including gastroesophageal reflux disease and constipation, but much of the data is based on older technology.
Objective: GI transit times were determined in subjects with SCI using a new device called a SmartPill. Our principal goal was to assess whether this new technology can be applied in persons with SCI.
Methods: SCI and age-and gender-matched able-bodied (AB) control subjects not taking proton pump inhibitors were studied. Following an 8-h overnight fast, subjects consumed 120 g EggBeaters (60 kcal), two slices of white bread (120 kcal) and 30g strawberry jam (74 kcal). A pH calibrated SmartPill capsule was swallowed with 8 ounces of water, after which subjects fasted for an additional 6 h prior to consuming an Ensure Plus nutrition shake (350kcal). Subjects remained fasted for an additional 2 h, after which time they resumed their regular diets.
Results: Twenty subjects with SCI and 10 AB control subjects were studied. Data are expressed as mean +/- s.d. Comparing the group with SCI to the AB control group, gastric emptying time (GET), colonic transit time (CTT) and whole gut transit time (WGTT) were prolonged (GET: 10.6 +/- 7.2 vs 3.5 +/- 1.0h, P < 0.01; CTT: 52.3 +/- 42.9 vs 14.2 +/- 7.6 h, P = 0.01; WGTT: 3.3 +/- 2.5 vs 1.0 +/- 0.7 days, P < 0.01). No complications or side effects were reported.
Conclusion: Our results indicate that the SmartPill technology is a safe, non-invasive assessment technique that provides valid diagnostic information in persons with SCI. Spinal Cord (2012) 50, 81-84; doi:10.1038/sc.2011.92; published online 30 August 2011
C1 [Korsten, M. A.] James J Peters Vet Affairs Med Ctr, Gastroenterol Serv, VA RR&D Ctr Excellence Med Consequences Spinal Co, Bronx, NY 10468 USA.
[Bauman, W. A.; Spungen, A. M.; Korsten, M. A.] James J Peters Vet Affairs Med Ctr, Med Serv, Bronx, NY 10468 USA.
[Bauman, W. A.; Spungen, A. M.; Korsten, M. A.] Mt Sinai Med Ctr, Dept Med, New York, NY 10029 USA.
[Bauman, W. A.; Spungen, A. M.; Korsten, M. A.] Mt Sinai Med Ctr, Dept Rehabil Med, New York, NY 10029 USA.
[Galea, M.] James J Peters Vet Affairs Med Ctr, Spinal Cord Injury Serv, Bronx, NY 10468 USA.
RP Korsten, MA (reprint author), James J Peters Vet Affairs Med Ctr, Gastroenterol Serv, VA RR&D Ctr Excellence Med Consequences Spinal Co, 130 W Kingsbridge Rd, Bronx, NY 10468 USA.
EM mark.korsten@va.gov
FU Department of Veteran Affairs Rehabilitation Research and Development
Service Center of Excellence for the Medical Consequences of Spinal Cord
Injury [B4162-C]; James J Peters VA Medical Center
FX The Department of Veteran Affairs Rehabilitation Research and
Development Service Center of Excellence for the Medical Consequences of
Spinal Cord Injury (#B4162-C) and the James J Peters VA Medical Center
have provided the support that made this work possible.
NR 11
TC 8
Z9 8
U1 3
U2 8
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1362-4393
J9 SPINAL CORD
JI Spinal Cord
PD JAN
PY 2012
VL 50
IS 1
BP 81
EP 84
DI 10.1038/sc.2011.92
PG 4
WC Clinical Neurology; Rehabilitation
SC Neurosciences & Neurology; Rehabilitation
GA 879FB
UT WOS:000299314000016
PM 21876549
ER
PT J
AU Tomedi, LE
Bogen, DL
Hanusa, BH
Wisner, KL
Bodnar, LM
AF Tomedi, Laura Elizabeth
Bogen, Debra L.
Hanusa, Barbara H.
Wisner, Katherine L.
Bodnar, Lisa M.
TI A Pilot Study of the Nutritional Status of Opiate-Using Pregnant Women
on Methadone Maintenance Therapy
SO SUBSTANCE USE & MISUSE
LA English
DT Article
DE methadone; pregnancy; nutrition; obesity; dietary intake; nutritional
biomarkers
ID POSTNATAL DEPRESSION SCALE; NEURAL-TUBE DEFECTS; ILLICIT DRUG-USE;
HISTORY QUESTIONNAIRE; SUBSTANCE USE; BIRTH-WEIGHT; LIFE-STYLE; VITAMIN;
PREVALENCE; VALIDATION
AB Pregnant women in methadone maintenance therapy may have poor nutrition during pregnancy. In 2006-2008, methadone-treated pregnant women (n = 22) were recruited at an urban academic medical center and compared with nondrug-using pregnant women (n = 119) at 20-35 weeks' gestation. We measured adiposity using prepregnancy body mass index (BMI), dietary intake using a food frequency questionnaire, and micronutrient and essential fatty acid status using biomarkers. Methadone-treated women had lower BMI, consumed more calories, had lower serum carotenoid concentrations, and higher plasma homocysteine concentrations than controls. The study's limitations and implications for future research are discussed.
C1 [Tomedi, Laura Elizabeth; Wisner, Katherine L.; Bodnar, Lisa M.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA 15213 USA.
[Bogen, Debra L.] Univ Pittsburgh, Childrens Hosp Pittsburgh, Sch Med, Div Gen Acad Pediat, Pittsburgh, PA USA.
[Hanusa, Barbara H.] Vet Affairs Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA.
[Wisner, Katherine L.] Univ Pittsburgh, Sch Med, Western Psychiat Inst & Clin, Pittsburgh, PA USA.
[Wisner, Katherine L.] Univ Pittsburgh, Dept Obstet Gynecol & Reprod Sci, Sch Med, Pittsburgh, PA USA.
RP Tomedi, LE (reprint author), Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA 15213 USA.
EM let20@pitt.edu
FU Children's Hospital of Pittsburgh Research Advisory Committee; Gerber
Foundation; National Institutes of Health (NIH) [MO1RR00056]; Building
Interdisciplinary Research Careers in Women's Health (BIRCWH) Award [K12
HD043441]; NIH/NIMH (National Institute of Mental Health) [R01 MH060335,
K01 MH074092]; National Institute of Child Health and Human Development
(NICHD) [HD 055 162-03 NIH NRSA T32]
FX This study was funded by the Children's Hospital of Pittsburgh Research
Advisory Committee and the Gerber Foundation. Study visits were
conducted in the Magee-Womens Hospital Clinical and Translational
Research Center, which is funded by National Institutes of Health (NIH;
grant MO1RR00056). The authors' contributions to this work were
supported by K12 HD043441 [Building Interdisciplinary Research Careers
in Women's Health (BIRCWH) Award], NIH/NIMH (National Institute of
Mental Health) grants R01 MH060335 and K01 MH074092, and the
Reproductive, Perinatal and Pediatric Epidemiology grant HD 055 162-03
NIH NRSA T32 [National Institute of Child Health and Human Development
(NICHD)].
NR 52
TC 2
Z9 2
U1 3
U2 5
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1082-6084
EI 1532-2491
J9 SUBST USE MISUSE
JI Subst. Use Misuse
PY 2012
VL 47
IS 3
BP 286
EP 295
DI 10.3109/10826084.2011.635324
PG 10
WC Substance Abuse; Psychiatry; Psychology
SC Substance Abuse; Psychiatry; Psychology
GA 873BT
UT WOS:000298856500008
PM 22217127
ER
PT J
AU Mufson, EJ
Binder, L
Counts, SE
DeKosky, ST
deToledo-Morrell, L
Ginsberg, SD
Ikonomovic, MD
Perez, SE
Scheff, SW
AF Mufson, Elliott J.
Binder, Lester
Counts, Scott E.
DeKosky, Steven T.
deToledo-Morrell, Leyla
Ginsberg, Stephen D.
Ikonomovic, Milos D.
Perez, Sylvia E.
Scheff, Stephen W.
TI Mild cognitive impairment: pathology and mechanisms
SO ACTA NEUROPATHOLOGICA
LA English
DT Review
DE Alzheimer's disease; Amyloid; Cholinergic; Dementia; MCI;
Neurofibrillary tangles; Neuropathology; Molecular; Neurotrophins;
Synapses
ID EARLY ALZHEIMERS-DISEASE; CHOLINERGIC BASAL FOREBRAIN; AMYLOID PRECURSOR
PROTEIN; NICOTINIC ACETYLCHOLINE-RECEPTOR; ENTORHINAL CORTEX NEURONS;
CENTRAL-NERVOUS-SYSTEM; PRIMARY VISUAL-CORTEX; E TYPE-4 ALLELE;
SUBSTANTIA INNOMINATA; NUCLEUS BASALIS
AB Mild cognitive impairment (MCI) is rapidly becoming one of the most common clinical manifestations affecting the elderly. The pathologic and molecular substrate of people diagnosed with MCI is not well established. Since MCI is a human specific disorder and neither the clinical nor the neuropathological course appears to follow a direct linear path, it is imperative to characterize neuropathology changes in the brains of people who came to autopsy with a well-characterized clinical diagnosis of MCI. Herein, we discuss findings derived from clinical pathologic studies of autopsy cases who died with a clinical diagnosis of MCI. The heterogeneity of clinical MCI imparts significant challenges to any review of this subject. The pathologic substrate of MCI is equally complex and must take into account not only conventional plaque and tangle pathology but also a wide range of cellular, biochemical and molecular deficits, many of which relate to cognitive decline as well as compensatory responses to the progressive disease process. The multifaceted nature of the neuronal disconnection syndrome associated with MCI suggests that there is no single event which precipitates this prodromal stage of AD. In fact, it can be argued that neuronal degeneration initiated at different levels of the central nervous system drives cognitive decline as a final common pathway at this stage of the dementing disease process.
C1 [Mufson, Elliott J.; Counts, Scott E.; deToledo-Morrell, Leyla; Perez, Sylvia E.] Rush Univ, Med Ctr, Dept Neurol Sci, Chicago, IL 60612 USA.
[Binder, Lester] Northwestern Univ, Dept Cell & Mol Biol, Feinberg Sch Med, Chicago, IL 60611 USA.
[DeKosky, Steven T.] Univ Virginia, Sch Med, Charlottesville, VA 22908 USA.
[Ginsberg, Stephen D.] NYU, Langone Med Ctr, Ctr Dementia Res, Nathan Kline Inst,Dept Psychiat, Orangeburg, NY 10962 USA.
[Ginsberg, Stephen D.] NYU, Langone Med Ctr, Ctr Dementia Res, Nathan Kline Inst,Dept Physiol, Orangeburg, NY 10962 USA.
[Ginsberg, Stephen D.] NYU, Langone Med Ctr, Ctr Dementia Res, Nathan Kline Inst,Dept Neurosci, Orangeburg, NY 10962 USA.
[Ikonomovic, Milos D.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
[Ikonomovic, Milos D.] Univ Pittsburgh, Dept Neurol, Educ & Clin Ctr, Pittsburgh, PA 15260 USA.
[Ikonomovic, Milos D.] Univ Pittsburgh, Dept Psychiat, Educ & Clin Ctr, Pittsburgh, PA USA.
[Ikonomovic, Milos D.] Univ Pittsburgh, Dept Geriatr Res, Educ & Clin Ctr, Pittsburgh, PA USA.
[Scheff, Stephen W.] Univ Kentucky, Sanders Brown Ctr Aging, Lexington, KY 40536 USA.
RP Mufson, EJ (reprint author), Rush Univ, Med Ctr, Dept Neurol Sci, 1735 W Harrison St,Suite 300, Chicago, IL 60612 USA.
EM emufson@rush.edu
OI Ginsberg, Stephen /0000-0002-1797-4288
FU NIA [PO1 AG14999, PO1 AG09466, AG10688, AG025204]
FX This study was supported by NIA grants PO1 AG14999, PO1 AG09466, AG10688
and AG025204. We thank all our collaborators and the participants in
each Alzheimer's Disease Center, institute and organization without whom
the information reviewed would not have been possible.
NR 188
TC 62
Z9 62
U1 5
U2 17
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0001-6322
J9 ACTA NEUROPATHOL
JI Acta Neuropathol.
PD JAN
PY 2012
VL 123
IS 1
BP 13
EP 30
DI 10.1007/s00401-011-0884-1
PG 18
WC Clinical Neurology; Neurosciences; Pathology
SC Neurosciences & Neurology; Pathology
GA 870BF
UT WOS:000298643400002
PM 22101321
ER
PT J
AU White, WB
Grady, D
Giudice, LC
Berry, SM
Zborowski, J
Snabes, MC
AF White, William B.
Grady, Deborah
Giudice, Linda C.
Berry, Scott M.
Zborowski, Joanne
Snabes, Michael C.
TI A cardiovascular safety study of LibiGel (testosterone gel) in
postmenopausal women with elevated cardiovascular risk and hypoactive
sexual desire disordera
SO AMERICAN HEART JOURNAL
LA English
DT Article
ID SURGICALLY MENOPAUSAL WOMEN; METABOLIC SYNDROME; BREAST-CANCER;
UNITED-STATES; HEALTH; DYSFUNCTION; PREVALENCE; EVENTS; MEN; ESTROGEN
AB Evaluation of the safety of hormonal preparations for the treatment of female sexual dysfunction is important to assess the benefit-to-risk profile of these drugs and has been strongly encouraged by the Food and Drug Administration. LibiGel (Biosante Pharmaceuticals, Inc., Lincolnshire, IL), a low-dose testosterone gel, is under development for the treatment of hypoactive sexual desire disorder (HSDD) in oophorectomized women. To evaluate the long-term effects of LibiGel on risk for cardiovascular (CV) events, breast cancer, and general safety, a randomized, placebo-controlled clinical study using a novel adaptive design to optimize sample size and power is being conducted. The primary end point of the BioSante LibiGel Safety Study (BLISS) is a composite of CV events including death, nonfatal myocardial infarction, nonfatal stroke, coronary revascularization, hospitalized unstable angina, and venous thromboembolic events. Breast cancer is a coprimary end point. Postmenopausal women (both surgically and naturally) with HSDD and increased risk for CV events will be followed up for up to 5 years postrandomization with an interim data analysis for regulatory approval after the last woman enrolled has been on therapy for at least 12 months. Determination of the number of subjects to enroll is based on an adaptive design that uses interim data to estimate the predictive probability of study success. In agreement with the Food and Drug Administration, LibiGel will be declared safe if the upper limit of the 97.2% CI of the hazard ratio is <= 2.0 or the upper bound of the 97.2% CI for the absolute difference between CV event rates per 100 person-years is <= 1% and the observed hazard ratio is <= 2.0. The BLISS study will define the CV safety profile of low-dose testosterone therapy in the formulation of LibiGel for postmenopausal women with HSDD, and the trial design may provide a paradigm for studies that aim to document long-term safety when the proposed outcome under study is an uncommon adverse event. (Am Heart J 2012;163:27-32.)
C1 [White, William B.] Univ Connecticut, Sch Med, Calhoun Cardiol Ctr, Div Hypertens & Clin Pharmacol, Farmington, CT 06030 USA.
[Grady, Deborah] Univ Calif San Francisco, Dept Med, San Francisco, CA USA.
[Grady, Deborah] Univ Calif San Francisco, San Francisco Vet Adm Med Ctr, San Francisco, CA 94143 USA.
[Giudice, Linda C.] Univ Calif San Francisco, Dept Obstet & Gynecol & Reprod Sci, San Francisco, CA 94143 USA.
[Berry, Scott M.] Berry Consultants, Austin, TX USA.
[Zborowski, Joanne; Snabes, Michael C.] Biosante Pharmaceut Inc, Lincolnshire, IL USA.
RP White, WB (reprint author), Univ Connecticut, Sch Med, Calhoun Cardiol Ctr, Div Hypertens & Clin Pharmacol, 263 Farmington Ave, Farmington, CT 06030 USA.
EM wwhite@nso1.uchc.edu
FU BioSante Pharmaceuticals, Inc, Lincolnshire, IL
FX The sponsor of this study is BioSante Pharmaceuticals, Inc,
Lincolnshire, IL.
NR 26
TC 24
Z9 26
U1 0
U2 3
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-8703
J9 AM HEART J
JI Am. Heart J.
PD JAN
PY 2012
VL 163
IS 1
BP 27
EP 32
DI 10.1016/j.ahj.2011.09.021
PG 6
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 863HI
UT WOS:000298153000007
PM 22172433
ER
PT J
AU Goodfriend, T
AF Goodfriend, Theodore
TI Molecular Trafficking of Angiotensin Receptors
SO AMERICAN JOURNAL OF HYPERTENSION
LA English
DT Editorial Material
C1 William S Middleton Mem Vet Adm Med Ctr, Madison, WI 53705 USA.
RP Goodfriend, T (reprint author), William S Middleton Mem Vet Adm Med Ctr, Madison, WI 53705 USA.
EM tgoodfri@facstaff.wisc.edu
NR 2
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0895-7061
J9 AM J HYPERTENS
JI Am. J. Hypertens.
PD JAN
PY 2012
VL 25
IS 1
BP 23
EP 23
DI 10.1038/ajh.2011.222
PG 1
WC Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA 864UE
UT WOS:000298264800008
PM 22170076
ER
PT J
AU Peralta, CA
Jacobs, DR
Katz, R
Ix, JH
Madero, M
Duprez, DA
Sarnak, MJ
Criqui, MH
Kramer, HJ
Palmas, W
Herrington, D
Shlipak, MG
AF Peralta, Carmen A.
Jacobs, David R., Jr.
Katz, Ronit
Ix, Joachim H.
Madero, Magdalena
Duprez, Daniel A.
Sarnak, Mark J.
Criqui, Michael H.
Kramer, Holly J.
Palmas, Walter
Herrington, David
Shlipak, Michael G.
TI Association of Pulse Pressure, Arterial Elasticity, and Endothelial
Function With Kidney Function Decline Among Adults With Estimated GFR >
60 mL/min/1.73 m(2): The Multi-Ethnic Study of Atherosclerosis (MESA)
SO AMERICAN JOURNAL OF KIDNEY DISEASES
LA English
DT Article
DE Kidney function; arterial elasticity; chronic kidney disease;
atherosclerosis
ID GLOMERULAR-FILTRATION-RATE; BLOOD-PRESSURE; HYPERTENSIVE PATIENTS;
CARDIOVASCULAR-DISEASE; RENAL-FUNCTION; WAVE VELOCITY; STIFFNESS; RISK;
DYSFUNCTION; POPULATION
AB Background: The association of subclinical vascular disease and early declines in kidney function has not been well studied.
Study Design: Prospective cohort study.
Setting & Participants: Multi-Ethnic Study of Atherosclerosis (MESA) participants with estimated glomerular filtration rate (eGFR) >= 60 mL/min/1.73 m(2) with follow-up of 5 years.
Predictors: Pulse pressure, small (SAE) and large arterial elasticity (LAE), and flow-mediated dilation.
Outcomes: Kidney function decline.
Measurements: SAE and LAE were measured by pulse contour analysis of the radial artery. Kidney function was assessed by eGFR based on serum creatinine (eGFR(SCr)) and cystatin C (eGFR(SCysC)).
Results: For 4,853 adults, higher pulse pressure and lower SAE and LAE had independent and linear associations with faster rates of kidney function decline. Compared with persons with pulse pressure of 40-50 mm Hg, eGFR(SCysC) declines were 0.29 (P = 0.006), 0.56 (P < 0.001), and 0.91 (P < 0.001) mL/min/1.73 m(2)/y faster in persons with pulse pressure of 50-60, 60-70, and >70 mm Hg, respectively. Compared with the highest quartile of SAE (most elastic), eGFR(SCysC) declines were 0.26 (P = 0.009), 0.35 (P = 0.001), and 0.70 (P < 0.001) mL/min/1.73 m(2)/y faster for the second, third, and fourth quartiles, respectively. For LAE, compared with the highest quartile, eGFR(SCysC) declines were 0.28 (P = 0.004), 0.58 (P < 0.001), and 0.83 (P < 0.001) mL/min/1.73 m(2)/y faster for each decreasing quartile of LAE. Findings were similar for eGFR(SCr). In contrast, for 2,997 adults with flow-mediated dilation and kidney function measures, flow-mediated dilation was not associated significantly with kidney function decline. For every 1-standard deviation greater flow-mediated dilation, eGFR(SCysC) and eGFR(SCr) changed by 0.05 (P = 0.3) and 0.06 mL/min/1.73 m(2)/y (P = 0.04), respectively.
Limitations: We had no direct measure of GFR, in common with nearly all large population-based studies.
Conclusions: Higher pulse pressure and lower arterial elasticity, but not flow-mediated dilation, were associated linearly and independently with faster kidney function decline in persons with eGFR >= 60 mL/min/1.73 m(2). Future studies should investigate whether treatments to decrease the stiffness of large and small arteries may slow the rate of kidney function loss. Am J Kidney Dis. 59(1):41-49. (C) 2011 by the National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.
C1 [Peralta, Carmen A.; Shlipak, Michael G.] San Francisco VA Med Ctr, San Francisco, CA USA.
[Peralta, Carmen A.; Shlipak, Michael G.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Jacobs, David R., Jr.] Univ Minnesota, Sch Publ Hlth, Minneapolis, MN USA.
[Katz, Ronit] Univ Washington, Dept Biostat, Seattle, WA 98195 USA.
[Ix, Joachim H.] Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA.
[Madero, Magdalena] Inst Nacl Cardiol Ignacio Chavez, Div Nephrol, Mexico City, DF, Mexico.
[Duprez, Daniel A.] Univ Minnesota, Div Cardiovasc, Sch Med, Minneapolis, MN 55455 USA.
[Sarnak, Mark J.] Tufts Med Ctr, Div Nephrol, Boston, MA USA.
[Criqui, Michael H.] Univ Calif San Diego, Dept Family & Prevent Med, La Jolla, CA 92093 USA.
[Kramer, Holly J.] Loyola Univ, Med Ctr, Div Nephrol, Maywood, IL 60153 USA.
[Palmas, Walter] Columbia Univ Coll Phys & Surg, Dept Med, New York, NY 10032 USA.
[Herrington, David] Wake Forest Univ, Sch Med, Internal Med Sect Cardiol, Winston Salem, NC 27109 USA.
RP Peralta, CA (reprint author), 4150 Clement St,111A1, San Francisco, CA 94121 USA.
EM carmenalicia.peralta@ucsf.edu
OI Kramer, Holly/0000-0002-6374-837X
FU National Heart, Lung, and Blood Institute [N01-HC-95159, N01-HC-95169];
National Institute of Diabetes and Digestive and Kidney Disease
[1K23DK082793-01]
FX This research was supported by contracts N01-HC-95159 through
N01-HC-95169 from the National Heart, Lung, and Blood Institute and by
the National Institute of Diabetes and Digestive and Kidney Disease
(grant 1K23DK082793-01, Dr Peralta). These funding sources had no
involvement in the design or execution of this study.
NR 44
TC 41
Z9 42
U1 1
U2 4
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0272-6386
J9 AM J KIDNEY DIS
JI Am. J. Kidney Dis.
PD JAN
PY 2012
VL 59
IS 1
BP 41
EP 49
DI 10.1053/j.ajkd.2011.08.015
PG 9
WC Urology & Nephrology
SC Urology & Nephrology
GA 863HO
UT WOS:000298153600011
PM 22000727
ER
PT J
AU Johansen, KL
Painter, P
AF Johansen, Kirsten L.
Painter, Patricia
TI Exercise in Individuals With CKD
SO AMERICAN JOURNAL OF KIDNEY DISEASES
LA English
DT Review
DE Exercise; physical activity; chronic kidney disease
ID CHRONIC KIDNEY-DISEASE; CHRONIC-RENAL-FAILURE;
AMERICAN-HEART-ASSOCIATION; QUALITY-OF-LIFE; PHYSICAL-ACTIVITY;
CARDIOVASCULAR OUTCOMES; PREDIALYSIS PATIENTS; SPORTS-MEDICINE;
RISK-FACTOR; CAPACITY
AB There are few studies evaluating exercise in the nondialysis chronic kidney disease (CKD) population. This review covers the rationale for exercise in patients with CKD not requiring dialysis and the effects of exercise training on physical functioning, progression of kidney disease, and cardiovascular risk factors. In addition, we address the issue of the risk of exercise and make recommendations for implementation of exercise in this population. Evidence from uncontrolled studies and small randomized controlled trials shows that exercise training results in improved physical performance and functioning in patients with CKD. In addition, although there are no studies examining cardiovascular outcomes, several studies suggest that cardiovascular risk factors such as hypertension, inflammation, and oxidative stress may be improved with exercise training in this population. Although the current literature does not allow for definitive conclusions about whether exercise training slows the progression of kidney disease, no study has reported worsening of kidney function as a result of exercise training. In the absence of guidelines specific to the CKD population, recent guidelines developed for older individuals and patients with chronic disease should be applied to the CKD population. In sum, exercise appears to be safe in this patient population if begun at moderate intensity and increased gradually. The evidence suggests that the risk of remaining inactive is higher. Patients should be advised to increase their physical activity when possible and be referred to physical therapy or cardiac rehabilitation programs when appropriate. Am J Kidney Dis. 59(1):126-134. (C) 2011 by the National Kidney Foundation, Inc.
C1 [Johansen, Kirsten L.] San Francisco VA Med Ctr, Nephrol Sect, San Francisco, CA 94121 USA.
[Johansen, Kirsten L.] Univ Calif San Francisco, Div Nephrol, San Francisco, CA 94143 USA.
[Painter, Patricia] Univ Minnesota, Sch Nursing, Div Hypertens & Renal Dis, Minneapolis, MN 55455 USA.
RP Johansen, KL (reprint author), San Francisco VA Med Ctr, Nephrol Sect, 4150 Clement St,111J, San Francisco, CA 94121 USA.
EM kirsten.johansen@ucsf.edu
FU NIDDK NIH HHS [K24 DK085153, K24 DK085153-01A1, K24 DK085153-02, K24
DK085153-03]
NR 52
TC 65
Z9 69
U1 1
U2 24
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0272-6386
J9 AM J KIDNEY DIS
JI Am. J. Kidney Dis.
PD JAN
PY 2012
VL 59
IS 1
BP 126
EP 134
DI 10.1053/j.ajkd.2011.10.008
PG 9
WC Urology & Nephrology
SC Urology & Nephrology
GA 863HO
UT WOS:000298153600022
PM 22113127
ER
PT J
AU New, DD
Block, K
Bhandhari, B
Gorin, Y
Abboud, HE
AF New, David D.
Block, Karen
Bhandhari, Basant
Gorin, Yves
Abboud, Hanna E.
TI IGF-I increases the expression of fibronectin by Nox4-dependent Akt
phosphorylation in renal tubular epithelial cells
SO AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY
LA English
DT Article
DE extracellular matrix; growth factor signaling; kidney; reactive oxygen
species; redox signaling; NADPH oxidase 4; insulin-like growth factor
ID GROWTH-FACTOR-I; MESSENGER-RNA TRANSLATION; SMOOTH-MUSCLE-CELLS; NAD(P)H
OXIDASE; DIABETIC-NEPHROPATHY; NADPH OXIDASES; HIGH GLUCOSE;
PROTEIN-SYNTHESIS; MESANGIAL CELLS; ANGIOTENSIN-II
AB New DD, Block K, Bhandhari B, Gorin Y, Abboud HE. IGF-I increases the expression of fibronectin by Nox4-dependent Akt phosphorylation in renal tubular epithelial cells. Am J Physiol Cell Physiol 302: C122-C130, 2012. First published September 21, 2011; doi:10.1152/ajpcell.00141.2011.-Extracellular matrix accumulation contributes to the progression of chronic kidney disease. Many growth factors including insulin-like growth factor-I (IGF-I) enhance matrix protein accumulation. Proximal tubular epithelial cells (PTCs) synthesize matrix proteins. NADPH oxidases are major sources of reactive oxygen species (ROS), important signaling molecules that mediate biological responses in a variety of cells and tissue. We investigated the mechanism by which IGF-I regulates fibronectin accumulation in PTCs and the role of a potential redox-dependent signaling pathway. IGF-I induces an increase in NADPH-dependent superoxide generation, enhances the release of hydrogen peroxide, and increases the expression of NADPH oxidase 4 (Nox4) in PTCs. IGF-I also stimulates phosphorylation of Akt, and inhibition of Akt or its upstream activator phosphatidylinositol 3-kinase attenuates IGF-I-induced fibronectin accumulation. Expression of dominant negative Akt also inhibits IGF-I-induced expression of fibronectin, indicating a role for this kinase in fibronectin accumulation. Expression of dominant negative adenovirus Nox4 inhibits IGF-I-induced NADPH oxidase activity, Akt phosphorylation, and fibronectin protein expression. Moreover, transfection of small interfering RNA targeting Nox4 decreases Nox4 protein expression and blocks IGF-I-induced Akt phosphorylation and the increase in fibronectin, placing Nox4 and ROS upstream of Akt signaling pathway. To confirm the role of Nox4, PTCs were infected with adenovirus construct expressing wild-type Nox4. Ad-Nox4, but not control Ad-green fluorescent protein, upregulated Nox4 expression and increased NADPH oxidase activity as well as fibronectin expression. Taken together, these results provide the first evidence for a role of Nox4 in IGF-I-induced Akt phosphorylation and fibronectin expression in tubular epithelial cells.
C1 [Abboud, Hanna E.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Div Nephrol, San Antonio, TX 78229 USA.
[Block, Karen] Audie L Murphy Mem Hosp, S Texas Vet Healthcare Syst, San Antonio, TX USA.
RP Abboud, HE (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Div Nephrol, MC 7882,7703 Floyd Curl Dr, San Antonio, TX 78229 USA.
EM abboud@uthscsa.edu
OI Gorin, Yves/0000-0003-4048-6925
FU Veterans Administration; National Institutes of Health [DK-R01-078971,
CA131272, DK-079996]; Juvenile Diabetes Research Foundation; Career
Development Award
FX Support for these studies was provided by the following sources:
Veterans Administration Merit Review grant and National Institutes of
Health Grant DK-R01-078971 (H. E. Abboud) and Career Development Award
and National Institutes of Health Grant CA131272 (K. Block), Juvenile
Diabetes Research Foundation regular research grant, and National
Institutes of Health Grant DK-079996 (Y. Gorin).
NR 51
TC 28
Z9 28
U1 1
U2 3
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0363-6143
J9 AM J PHYSIOL-CELL PH
JI Am. J. Physiol.-Cell Physiol.
PD JAN
PY 2012
VL 302
IS 1
BP C122
EP C130
DI 10.1152/ajpcell.00141.2011
PG 9
WC Cell Biology; Physiology
SC Cell Biology; Physiology
GA 866IN
UT WOS:000298374100015
PM 21940672
ER
PT J
AU Morton, GJ
Thatcher, BS
Reidelberger, RD
Ogimoto, K
Wolden-Hanson, T
Baskin, DG
Schwartz, MW
Blevins, JE
AF Morton, Gregory J.
Thatcher, Brendan S.
Reidelberger, Roger D.
Ogimoto, Kayoko
Wolden-Hanson, Tami
Baskin, Denis G.
Schwartz, Michael W.
Blevins, James E.
TI Peripheral oxytocin suppresses food intake and causes weight loss in
diet-induced obese rats
SO AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM
LA English
DT Article
DE leptin; food intake
ID BRAIN-STEM NUCLEI; CENTRALLY ADMINISTERED OXYTOCIN; DEFICIENT MICE;
PARAVENTRICULAR NUCLEUS; ENERGY-EXPENDITURE; LEPTIN RESISTANCE;
SPINAL-CORD; SIM1 GENE; HYPERPHAGIC OBESITY; SOLITARY TRACT
AB Morton GJ, Thatcher BS, Reidelberger RD, Ogimoto K, Wolden-Hanson T, Baskin DG, Schwartz MW, Blevins JE. Peripheral oxytocin suppresses food intake and causes weight loss in diet-induced obese rats. Am J Physiol Endocrinol Metab 302: E134-E144, 2012. First published October 18, 2011; doi:10.1152/ajpendo.00296.2011.-Growing evidence suggests that oxytocin plays an important role in the regulation of energy balance and that central oxytocin administration induces weight loss in diet-induced obese (DIO) animals. To gain a better understanding of how oxytocin mediates these effects, we examined feeding and neuronal responses to oxytocin in animals rendered obese following exposure to either a high-fat (HFD) or low-fat diet (LFD). Our findings demonstrate that peripheral administration of oxytocin dose-dependently reduces food intake and body weight to a similar extent in rats maintained on either diet. Moreover, the effect of oxytocin to induce weight loss remained intact in leptin receptor-deficient Koletsky (fak/fak) rats relative to their lean littermates. To determine whether systemically administered oxytocin activates hindbrain areas that regulate meal size, we measured neuronal c-Fos induction in the nucleus of the solitary tract (NTS) and area postrema (AP). We observed a robust neuronal response to oxytocin in these hindbrain areas that was unexpectedly increased in rats rendered obese on a HFD relative to lean, LFD-fed controls. Finally, we report that repeated daily peripheral administration of oxytocin in DIO animals elicited a sustained reduction of food intake and body weight while preventing the reduction of energy expenditure characteristic of weight-reduced animals. These findings extend recent evidence suggesting that oxytocin circumvents leptin resistance and induces weight-loss in DIO animals through a mechanism involving activation of neurons in the NTS and AP, key hindbrain areas for processing satiety-related inputs.
C1 [Morton, Gregory J.; Ogimoto, Kayoko; Schwartz, Michael W.] Univ Washington, Dept Med, Diabet & Obes Ctr Excellence, Seattle, WA USA.
[Morton, Gregory J.; Baskin, Denis G.; Schwartz, Michael W.; Blevins, James E.] Univ Washington, Sch Med, Dept Med, Div Metab Endocrinol & Nutr, Seattle, WA 98195 USA.
[Thatcher, Brendan S.; Wolden-Hanson, Tami; Baskin, Denis G.; Blevins, James E.] Vet Affairs Puget Sound Hlth Care Syst, Dept Vet Affairs Med Ctr, Off Res & Dev, Med Res Serv, Seattle, WA USA.
[Reidelberger, Roger D.] Nebraska Western Iowa Hlth Care Syst, Dept Vet Affairs, Omaha, NE USA.
[Reidelberger, Roger D.] Creighton Univ, Dept Biomed Sci, Omaha, NE 68178 USA.
RP Morton, GJ (reprint author), Univ Washington S Lake Union, Dept Med, 815 Mercer St,N334,Box 358055, Seattle, WA 98109 USA.
EM gjmorton@u.washington.edu
RI Schwartz, Michael/H-9950-2012
FU Office of Research and Development, Medical Research Service, Department
of Veterans Affairs; Veterans Affairs Puget Sound Health Care System;
Department of Veterans Affairs; Department of Veterans Affairs Nebraska
Western Iowa Health Care System; NIH [DK-068304, DK-083042, DK-052989,
DK-089056]; American Heart Association; Cellular and Molecular Imaging
Core of the National Institutes of Health (NIH) Diabetes Endocrinology
Research Center (DERC) [P30 DK-17047]; NIH Nutrition Obesity Research
Unit Animal Studies Physiology Core at the University of Washington
(NORC) [P30 DK-035816]; NIH Mouse Metabolic Phenotyping Center Diabetes
and Energy Balance Core (MMPC) [U24 DK-076126]
FX This work was supported by resources from the Office of Research and
Development, Medical Research Service, Department of Veterans Affairs,
including the Department of Veterans Affairs Career Development Program,
Merit Review Research Program, and the Career Scientist Program. D. G.
Baskin is the recipient of a Department of Veterans Affairs Senior
Research Career Scientist Award at the Veterans Affairs Puget Sound
Health Care System. R. D. Reidelberger is the recipient of a Department
of Veterans Affairs Research Career Scientist Award at the Department of
Veterans Affairs Nebraska Western Iowa Health Care System. M. W.
Schwartz is supported by NIH grants (DK-068304, DK-083042, DK-052989).
G. J. Morton is supported by an NIH grant (DK-089056) and a Scientist
Development Grant from the American Heart Association. This research was
also supported by the Cellular and Molecular Imaging Core of the
National Institutes of Health (NIH) Diabetes Endocrinology Research
Center (DERC, P30 DK-17047), the NIH Nutrition Obesity Research Unit
Animal Studies Physiology Core at the University of Washington (NORC,
P30 DK-035816), and the NIH Mouse Metabolic Phenotyping Center Diabetes
and Energy Balance Core (MMPC, U24 DK-076126).
NR 64
TC 63
Z9 64
U1 1
U2 16
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0193-1849
J9 AM J PHYSIOL-ENDOC M
JI Am. J. Physiol.-Endocrinol. Metab.
PD JAN
PY 2012
VL 302
IS 1
BP E134
EP E144
DI 10.1152/ajpendo.00296.2011
PG 11
WC Endocrinology & Metabolism; Physiology
SC Endocrinology & Metabolism; Physiology
GA 866JU
UT WOS:000298377600015
PM 22008455
ER
PT J
AU Zhao, KQ
Xiong, GX
Wilber, M
Cohen, NA
Kreindler, JL
AF Zhao, Ke-Qing
Xiong, Guoxiang
Wilber, Morgan
Cohen, Noam A.
Kreindler, James L.
TI A role for two-pore K+ channels in modulating Na+ absorption and Cl-
secretion in normal human bronchial epithelial cells
SO AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY
LA English
DT Article
DE chloride secretion; cystic fibrosis; ion transport
ID CHLORIDE SECRETION; ANION SECRETION; POTASSIUM CHANNELS; AIRWAY
EPITHELIA; ION-TRANSPORT; LUNG-DISEASE; LINE CALU-3; CONDUCTANCE;
MEMBRANE; LIQUID
AB Zhao KQ, Xiong G, Wilber M, Cohen NA, Kreindler JL. A role for two-pore K+ channels in modulating Na+ absorption and Cl- secretion in normal human bronchial epithelial cells. Am J Physiol Lung Cell Mol Physiol 302: L4-L12, 2012. First published September 30, 2011; doi: 10.1152/ajplung.00102.2011.-Mucociliary clearance is the primary innate physical defense mechanism against inhaled pathogens and toxins. Vectorial ion transport, primarily sodium absorption and anion secretion, by airway epithelial cells supports mucociliary clearance. This is evidenced by diseases of abnormal ion transport such as cystic fibrosis and pseudohypoaldosteronism that are characterized by changes in mucociliary clearance. Sodium absorption and chloride secretion in human bronchial epithelial cells depend on potassium channel activity, which creates a favorable electrochemical gradient for both by hyperpolarizing the apical plasma membrane. Although the role of basolateral membrane potassium channels is firmly established and extensively studied, a role for apical membrane potassium channels has also been described. Here, we demonstrate that bupivacaine and quinidine, blockers of four-transmembrane domain, two-pore potassium (K2P) channels, inhibit both amiloride-sensitive sodium absorption and forskolin-stimulated anion secretion in polarized, normal human bronchial epithelial cells at lower concentrations when applied to the mucosal surface than when applied to the serosal surface. Transcripts from four genes, KCNK1 (TWIK-1), KCNK2 (TREK-1), KCNK5 (TASK-2), and KCNK6 (TWIK-2), encoding K2P channels were identified by RT-PCR. Protein expression at the apical membrane was confirmed by immunofluorescence. Our data provide further evidence that potassium channels, in particular K2P channels, are expressed and functional in the apical membrane of airway epithelial cells where they may be targets for therapeutic manipulation.
C1 [Zhao, Ke-Qing] Fudan Univ, Sch Shanghai Med, Dept Otorhinolaryngol Head & Neck Surg, Eye & Ear Nose & Throat Hosp, Shanghai 200433, Peoples R China.
[Zhao, Ke-Qing; Cohen, Noam A.] Univ Penn, Dept Otorhinolaryngol Head & Neck Surg, Philadelphia, PA 19104 USA.
[Xiong, Guoxiang] Childrens Hosp Philadelphia, Div Neurol, Philadelphia, PA 19104 USA.
[Cohen, Noam A.] Philadelphia Vet Affairs Med Ctr, Surg Serv, Philadelphia, PA USA.
[Kreindler, James L.] Univ Penn, Sch Med, Dept Pediat, Philadelphia, PA 19104 USA.
RP Kreindler, JL (reprint author), Abramson Res Ctr, 3615 Civ Ctr Blvd,Rm 1016-D, Philadelphia, PA 19104 USA.
EM kreindler@email.chop.edu
OI Cohen, Noam/0000-0002-9462-3932
FU National Heart, Lung, and Blood Institute [K08-HL-081080]; Children's
Hospital of Philadelphia
FX This work was funded by National Heart, Lung, and Blood Institute Grant
K08-HL-081080 (to J. L. Kreindler) and by institutional funds from the
Children's Hospital of Philadelphia.
NR 33
TC 19
Z9 21
U1 0
U2 3
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 1040-0605
J9 AM J PHYSIOL-LUNG C
JI Am. J. Physiol.-Lung Cell. Mol. Physiol.
PD JAN
PY 2012
VL 302
IS 1
BP L4
EP L12
DI 10.1152/ajplung.00102.2011
PG 9
WC Physiology; Respiratory System
SC Physiology; Respiratory System
GA 866VC
UT WOS:000298413000002
PM 21964404
ER
PT J
AU Cannuscio, C
Bugos, E
Hersh, S
Asch, DA
Weiss, EE
AF Cannuscio, Carolyn
Bugos, Eva
Hersh, Shari
Asch, David A.
Weiss, Eve E.
TI Using ART to AMPLIFY Youth Voices on Housing Insecurity
SO AMERICAN JOURNAL OF PUBLIC HEALTH
LA English
DT Editorial Material
C1 [Cannuscio, Carolyn; Asch, David A.] Univ Penn, Ctr Hlth Equi Res & Promot, Philadelphia VA Med Ctr, Philadelphia, PA 19104 USA.
[Cannuscio, Carolyn; Asch, David A.] Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA.
[Cannuscio, Carolyn] Univ Penn, Perelman Sch Med, Dept Family Med & Community Hlth, Philadelphia, PA 19104 USA.
[Cannuscio, Carolyn; Bugos, Eva; Weiss, Eve E.] Univ Penn, Mixed Methods Res Lab, Philadelphia, PA 19104 USA.
[Cannuscio, Carolyn; Bugos, Eva; Weiss, Eve E.] Univ Penn, Ctr Publ Hlth Initiat, Philadelphia, PA 19104 USA.
[Hersh, Shari] Mural Arts Program, Philadelphia, PA USA.
RP Cannuscio, C (reprint author), Univ Penn, Ctr Hlth Equi Res & Promot, Philadelphia VA Med Ctr, 3620 Hamilton Walk,Anat & Chem Bldg,Room 145, Philadelphia, PA 19104 USA.
EM carolyncannu@gmail.com
OI Asch, David/0000-0002-7970-286X
NR 4
TC 2
Z9 2
U1 2
U2 14
PU AMER PUBLIC HEALTH ASSOC INC
PI WASHINGTON
PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA
SN 0090-0036
J9 AM J PUBLIC HEALTH
JI Am. J. Public Health
PD JAN
PY 2012
VL 102
IS 1
BP 10
EP 12
DI 10.2105/AJPH.2011.300494
PG 3
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 867IZ
UT WOS:000298449400005
PM 22095365
ER
PT J
AU Dick, AA
Mercer, LD
Smith, JM
McDonald, RA
Young, B
Healey, PJ
AF Dick, Andre A.
Mercer, Laina D.
Smith, Jodi M.
McDonald, Ruth A.
Young, Bessie
Healey, Patrick J.
TI Living Donor Kidney Transplantation in Adolescents: Does Size Matter?
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Meeting Abstract
CT American-Society-of-Transplant-Surgeons (ASTS) 12th Annual State of the
Art Winter Symposium/North-American-Transplant-Coordinators-Organization
(NATCO) Symposium for Advanced Transplant Professionals
CY JAN 12-15, 2012
CL Miami, FL
SP Amer Soc Transplant Surg (ASTS), N Amer Transplant Coordinators Org (NATCO)
C1 [Dick, Andre A.; Healey, Patrick J.] Seattle Childrens Hosp, Div Pediat Transplantat, Seattle, WA USA.
[Mercer, Laina D.] Seattle Childrens Hosp, Seattle Childrens Res Inst, Seattle, WA USA.
[Smith, Jodi M.; McDonald, Ruth A.] Seattle Childrens Hosp, Div Nephrol, Dept Pediat, Seattle, WA USA.
[Young, Bessie] VA Puget Sound Hlth Care Syst, Div Nephrol, Seattle, WA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1600-6135
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD JAN
PY 2012
VL 12
SU 2
SI SI
BP 70
EP 70
PG 1
WC Surgery; Transplantation
SC Surgery; Transplantation
GA 867UW
UT WOS:000298481300050
ER
PT J
AU Azadani, AN
Chitsaz, S
Matthews, PB
Jaussaud, N
Leung, J
Tsinman, T
Ge, L
Tseng, EE
AF Azadani, Ali N.
Chitsaz, Sam
Matthews, Peter B.
Jaussaud, Nicolas
Leung, James
Tsinman, Tonia
Ge, Liang
Tseng, Elaine E.
TI Comparison of Mechanical Properties of Human Ascending Aorta and Aortic
Sinuses
SO ANNALS OF THORACIC SURGERY
LA English
DT Article
ID FINITE-ELEMENT; VALVE INCOMPETENCE; ROOT; ANEURYSM; ARTERIES; MODEL; AGE
AB Background. Computational finite element models of the aortic root have previously used material properties of the ascending aorta to describe both aortic sinuses and ascending aorta. We have previously demonstrated significant material property differences between ascending aorta and sinuses in pigs. However, it is unknown whether these regional material property differences exist in humans. The main objective of this study was to investigate biomechanics of fresh human ascending aorta and aortic sinuses and compare nonlinear material properties of these regions.
Methods. Fresh human aortic root specimens obtained from the California Transplant Donor Network (Oakland, CA) were subjected to displacement-controlled equibiaxial stretch testing within 24 hours of harvest. Stress-strain data recorded were used to derive strain energy functions for each region. Tissue behavior was quantified by tissue stiffness and a direct comparison was made between different regions of aortic root at physiologic stress levels.
Results. All regions demonstrated a nonlinear response to strain during stretch testing in both circumferential and longitudinal directions. No significant difference in tissue stiffness was found between anterior and posterior regions of the ascending aorta or among the three sinuses in both directions. However, our results demonstrated that human ascending aorta is significantly more compliant than aortic sinuses in both circumferential and longitudinal directions within the physiologic stress range.
Conclusions. Significant material and structural differences were observed between human ascending aorta and aortic sinuses. Regionally specific material properties should be employed in computational models used to assess treatments of structural aortic root disease. (Ann Thorac Surg 2012;93:87-94) (C) 2012 by The Society of Thoracic Surgeons
C1 [Tseng, Elaine E.] Univ Calif San Francisco, Med Ctr, Div Cardiothorac Surg, Dept Surg, San Francisco, CA 94143 USA.
San Francisco VA Med Ctr, San Francisco, CA USA.
RP Tseng, EE (reprint author), Univ Calif San Francisco, Med Ctr, Div Cardiothorac Surg, Dept Surg, 500 Parnassus Ave,Ste 405W,Box 0118, San Francisco, CA 94143 USA.
EM elaine.tseng@ucsfmedctr.org
RI Chitsaz, Sam/C-4586-2008
FU American Heart Association
FX We thank Dr Philip Ursell for his histologic characterization and the
California Transplant Donor Network for the hearts. This work was
supported by an American Heart Association Grant-in-Aid, which was
administered by the Northern California Institute for Research and
Education with resources of the Veterans Affairs Medical Center, San
Francisco, California.
NR 18
TC 20
Z9 20
U1 1
U2 13
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0003-4975
J9 ANN THORAC SURG
JI Ann. Thorac. Surg.
PD JAN
PY 2012
VL 93
IS 1
BP 87
EP 94
DI 10.1016/j.athoracsur.2011.08.002
PG 8
WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery
SC Cardiovascular System & Cardiology; Respiratory System; Surgery
GA 864QR
UT WOS:000298255400019
PM 22075218
ER
PT J
AU Roussos, P
Katsel, P
Davis, KL
Bitsios, P
Giakoumaki, SG
Jogia, J
Rozsnyai, K
Collier, D
Frangou, S
Siever, LJ
Haroutunian, V
AF Roussos, Panos
Katsel, Pavel
Davis, Kenneth L.
Bitsios, Panos
Giakoumaki, Stella G.
Jogia, Jigar
Rozsnyai, Kinga
Collier, David
Frangou, Sophia
Siever, Larry J.
Haroutunian, Vahram
TI Molecular and Genetic Evidence for Abnormalities in the Nodes of Ranvier
in Schizophrenia
SO ARCHIVES OF GENERAL PSYCHIATRY
LA English
DT Article
ID MULTIPLE BRAIN-REGIONS; ANTERIOR CINGULATE CORTEX; GENOME-WIDE
ASSOCIATION; MILD ALZHEIMER-DISEASE; BIPOLAR DISORDER; EXPRESSION;
MYELIN; HIPPOCAMPUS; DYSFUNCTION; PHENOTYPE
AB Context: Genetic, neuroimaging, and molecular neurobiological evidence support the hypothesis that the disconnectivity syndrome in schizophrenia (SZ) could arise from failures of saltatory conduction and abnormalities at the nodes of Ranvier (NOR) interface where myelin and axons interact.
Objective: To identify abnormalities in the expression of oligodendroglial genes and proteins that participate in the formation, maintenance, and integrity of the NOR in SZ.
Design: The messenger RNA (mRNA) expression levels of multiple NOR genes were quantified in 2 independent postmortem brain cohorts of individuals with SZ, and generalizability to protein expression was confirmed. The effect of the ANK3 genotype on the mRNA expression level was tested in postmortem human brain. Case-control analysis tested the association of the ANK3 genotype with SZ. The ANK3 genotype's influence on cognitive task performance and functional magnetic resonance imaging activation was tested in 2 independent cohorts of healthy individuals.
Setting: Research hospital.
Patients: Postmortem samples from patients with SZ and healthy controls were used for the brain expression study (n=46) and the case-control analysis (n=272). Healthy white men and women participated in the cognitive (n=513) and neuroimaging (n=52) studies.
Main Outcome Measures: The mRNA and protein levels in postmortem brain samples, genetic association with schizophrenia, cognitive performance, and blood oxygenation level-dependent functional magnetic resonance imaging.
Results: The mRNA expression of multiple NOR genes was decreased in schizophrenia. The ANK3 rs9804190 C allele was associated with lower ANK3 mRNA expression levels, higher risk for SZ in the case-control cohort, and poorer working memory and executive function performance and increased prefrontal activation during a working memory task in healthy individuals.
Conclusions: These results point to abnormalities in the expression of genes and protein associated with the integrity of the NOR and suggest them as substrates for the disconnectivity syndrome in SZ. The association of ANK3 with lower brain mRNA expression levels implicates a molecular mechanism for its genetic, clinical, and cognitive associations with SZ.
C1 [Roussos, Panos; Katsel, Pavel; Davis, Kenneth L.; Siever, Larry J.; Haroutunian, Vahram] Mt Sinai Sch Med, Dept Psychiat, New York, NY USA.
[Roussos, Panos; Siever, Larry J.; Haroutunian, Vahram] James J Peters Vet Affairs Med Ctr, Bronx, NY USA.
[Roussos, Panos; Bitsios, Panos; Giakoumaki, Stella G.] Univ Crete, Dept Psychiat & Behav Sci, Fac Med, Iraklion, Crete, Greece.
[Jogia, Jigar; Frangou, Sophia] Kings Coll London, Sect Neurobiol Psychosis, Inst Psychiat, London, England.
[Rozsnyai, Kinga; Collier, David] Kings Coll London, Social Genet & Dev Psychiat Res Ctr, Inst Psychiat, London, England.
RP Haroutunian, V (reprint author), Mt Sinai Sch Med, Dept Psychiat, Room 4F-33,130 Kingsbridge Rd, Bronx, NY 10468 USA.
EM vahram.haroutunian@mssm.edu
RI Frangou, Sophia/A-2672-2013; Collier, David/D-1649-2011; Roussos,
Panos/J-7090-2013
OI Collier, David/0000-0003-4087-1559; Roussos, Panos/0000-0002-4640-6239;
Jogia, Jigar/0000-0003-1799-1245
FU National Institutes of Health [MH066392, MH064673]; Veterans Affairs
Mental Illness Research Education and Clinical Center; Veterans Affairs
FX This work was supported by grants MH066392 and MH064673 from the
National Institutes of Health (Dr Haroutunian), a Veterans Affairs
Mental Illness Research Education and Clinical Center award (Dr Siever),
and a Veterans Affairs merit award (Dr Haroutunian).
NR 39
TC 45
Z9 48
U1 0
U2 12
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA
SN 0003-990X
J9 ARCH GEN PSYCHIAT
JI Arch. Gen. Psychiatry
PD JAN
PY 2012
VL 69
IS 1
BP 7
EP 15
DI 10.1001/archgenpsychiatry.2011.110
PG 9
WC Psychiatry
SC Psychiatry
GA 870NH
UT WOS:000298675700002
PM 21893642
ER
PT J
AU Olfson, M
Marcus, SC
Bridge, JA
AF Olfson, Mark
Marcus, Steven C.
Bridge, Jeffrey A.
TI Emergency Treatment of Deliberate Self-harm
SO ARCHIVES OF GENERAL PSYCHIATRY
LA English
DT Article
ID BORDERLINE PERSONALITY-DISORDER; ATTEMPTED-SUICIDE; FOLLOW-UP; COMPLETED
SUICIDE; DEPARTMENT VISITS; HEALTH-CARE; COHORT; ADULTS; RISK;
DEPRESSION
AB Context: Although concern exists over the quality of emergency mental health services, little is known about the mental health care of adults who are admitted to emergency departments for deliberately harming themselves and then discharged to the community.
Objective: To describe the predictors of emergency department discharge, the emergency mental health assessments, and the follow-up outpatient mental health care of adult Medicaid beneficiaries treated for deliberate self-harm.
Design: A retrospective longitudinal cohort analysis.
Setting: National Medicaid claims data supplemented with county-level sociodemographic variables and Medicaid state policy survey data.
Participants: Adults aged 21 to 64 years who were treated in emergency departments for 7355 episodes of deliberate self-harm, focusing on those who were discharged to the community (4595 episodes).
Main Outcome Measures: Rates and adjusted risk ratios (ARRs) of discharge to the community, mental health assessments in the emergency department, and outpatient mental health visits during the 30 days following the emergency department visit.
Results: Most patients (62.5%) were discharged to the community. Emergency department discharge was directly related to younger patient age (21-31 years vs 45-64 years) (ARR, 1.18 [99% confidence interval {CI}, 1.10-1.25]) and self-harm by cutting (ARR, 1.18 [99% CI, 1.12-1.24]) and inversely related to poisoning (ARR, 0.84 [99% CI, 0.80-0.89]) and recent psychiatric hospitalization (ARR, 0.74 [99% CI, 0.67-0.81]). Approximately one-half of discharged patients (47.5%) received a mental health assessment in the emergency department, and a similar percentage of discharged patients (52.4%) received a follow-up outpatient mental health visit within 30 days. Follow-up mental health care was directly related to recent outpatient mental health care (ARR, 2.30 [99% CI, 2.11-2.50]) and treatment in a state with Medicaid coverage of mental health clinic services (ARR, 1.13 [99% CI, 1.05-1.22]) and inversely related to African American (ARR, 0.86 [99% CI, 0.75-0.96]) and Hispanic (ARR, 0.86 [99% CI, 0.75-0.99]) race/ethnicity.
Conclusion: Most adult Medicaid beneficiaries who present for emergency care for deliberate self-harm are discharged to the community, and many do not receive emergency mental health assessments or follow-up outpatient mental health care.
C1 [Olfson, Mark] Columbia Univ, New York State Psychiat Inst, Dept Psychiat, Coll Phys & Surg, New York, NY 10032 USA.
[Marcus, Steven C.] Univ Penn, Ctr Hlth Equ Res & Promot, Philadelphia Vet Affairs Med Ctr, Philadelphia, PA 19104 USA.
[Marcus, Steven C.] Univ Penn, Sch Social Policy & Practice, Philadelphia, PA 19104 USA.
[Bridge, Jeffrey A.] Ohio State Univ, Res Inst, Nationwide Childrens Hosp, Ctr Innovat Pediat Practice, Columbus, OH USA.
[Bridge, Jeffrey A.] Ohio State Univ, Dept Pediat, Columbus, OH USA.
RP Olfson, M (reprint author), Columbia Univ, New York State Psychiat Inst, Dept Psychiat, Coll Phys & Surg, 1051 Riverside Dr, New York, NY 10032 USA.
EM mo49@columbia.edu
FU Eli Lilly; Bristol-Myers Squibb; AstraZeneca; Dainippon Sumitomo; Forest
Research Institute; Ortho-McNeil-Janssen; Pfizer Inc; Roche
Pharmaceuticals; sanofi-aventis; Schering-Plough; Sepracor; United
BioSource; Lundbeck; American Foundation for Suicide Prevention
FX Dr Olfson has received a research grant to Columbia University from Eli
Lilly and Bristol-Myers Squibb. Dr Bridge has received honoraria for
participation in a suicidality consensus conference supported by
independent educational or other unrestricted grant support from
AstraZeneca, Dainippon Sumitomo, Eli Lilly, Forest Research Institute,
Ortho-McNeil-Janssen, Pfizer Inc, Roche Pharmaceuticals, sanofi-aventis,
Schering-Plough, Sepracor, and United BioSource; and he has presented on
suicide prevention in children and adolescents at a conference supported
in part by Eli Lilly and Lundbeck.; This research was funded by a grant
to Columbia University from the American Foundation for Suicide
Prevention.
NR 60
TC 24
Z9 24
U1 5
U2 10
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA
SN 0003-990X
J9 ARCH GEN PSYCHIAT
JI Arch. Gen. Psychiatry
PD JAN
PY 2012
VL 69
IS 1
BP 80
EP 88
DI 10.1001/archgenpsychiatry.2011.108
PG 9
WC Psychiatry
SC Psychiatry
GA 870NH
UT WOS:000298675700010
PM 21893643
ER
PT J
AU Craft, S
Baker, LD
Montine, TJ
Minoshima, S
Watson, GS
Claxton, A
Arbuckle, M
Callaghan, M
Tsai, E
Plymate, SR
Green, PS
Leverenz, J
Cross, D
Gerton, B
AF Craft, Suzanne
Baker, Laura D.
Montine, Thomas J.
Minoshima, Satoshi
Watson, G. Stennis
Claxton, Amy
Arbuckle, Matthew
Callaghan, Maureen
Tsai, Elaine
Plymate, Stephen R.
Green, Pattie S.
Leverenz, James
Cross, Donna
Gerton, Brooke
TI Intranasal Insulin Therapy for Alzheimer Disease and Amnestic Mild
Cognitive Impairment A Pilot Clinical Trial
SO ARCHIVES OF NEUROLOGY
LA English
DT Article
ID AMYLOID-BETA; RATING-SCALE; OLDER-ADULTS; HUMAN BRAIN; IN-VIVO;
MECHANISMS; PLASTICITY; INCREASES; OLIGOMERS; SEVERITY
AB Objective: To examine the effects of intranasal insulin administration on cognition, function, cerebral glucose metabolism, and cerebrospinal fluid biomarkers in adults with amnestic mild cognitive impairment or Alzheimer disease (AD).
Design: Randomized, double-blind, placebo-controlled trial.
Setting: Clinical research unit of a Veterans Affairs medical center.
Participants: The intent-to-treat sample consisted of 104 adults with amnestic mild cognitive impairment (n=64) or mild to moderate AD (n=40).
Intervention: Participants received placebo (n=30), 20 IU of insulin (n=36), or 40 IU of insulin (n=38) for 4 months, administered with a nasal drug delivery device (Kurve Technology, Bothell, Washington).
Main Outcome Measures: Primary measures consisted of delayed story recall score and the Dementia Severity Rating Scale score, and secondary measures included the Alzheimer Disease's Assessment Scale-cognitive subscale (ADAS-cog) score and the Alzheimer's Disease Cooperative Study-activities of daily living (ADCS-ADL) scale. A subset of participants underwent lumbar puncture (n=23) and positron emission tomography with fludeoxyglucose F 18 (n=40) before and after treatment.
Results: Outcome measures were analyzed using repeated-measures analysis of covariance. Treatment with 20 IU of insulin improved delayedmemory(P <.05), and both doses of insulin (20 and 40 IU) preserved caregiver-rated functional ability (P <.01). Both insulin doses also preserved general cognition as assessed by the ADAS-cog score for younger participants and functional abilities as assessed by the ADCS-ADL scale for adults with AD (P <.05). Cerebrospinal fluid biomarkers did not change for insulin-treated participants as a group, but, in exploratory analyses, changes in memory and function were associated with changes in the A beta 42 level and in the tau protein-to-A beta 42 ratio in cerebrospinal fluid. Placebo-assigned participants showed decreased fludeoxyglucose F 18 uptake in the parietotemporal, frontal, precuneus, and cuneus regions and insulin-minimized progression. No treatment-related severe adverse events occurred.
Conclusions: These results support longer trials of intranasal insulin therapy for patients with amnestic mild cognitive impairment and patients with AD.
C1 [Craft, Suzanne; Baker, Laura D.; Watson, G. Stennis; Claxton, Amy; Arbuckle, Matthew; Callaghan, Maureen; Plymate, Stephen R.] Vet Affairs Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA 98108 USA.
[Leverenz, James; Gerton, Brooke] Vet Affairs Puget Sound Hlth Care Syst, Mental Illness Res Educ & Clin Ctr, Seattle, WA 98108 USA.
[Craft, Suzanne; Baker, Laura D.; Watson, G. Stennis; Claxton, Amy; Leverenz, James] Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA.
[Montine, Thomas J.] Univ Washington, Sch Med, Dept Pathol, Seattle, WA 98195 USA.
[Minoshima, Satoshi; Cross, Donna] Univ Washington, Sch Med, Dept Radiol, Seattle, WA 98195 USA.
[Tsai, Elaine; Plymate, Stephen R.; Green, Pattie S.] Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA.
[Leverenz, James; Gerton, Brooke] Univ Washington, Sch Med, Dept Neurol, Seattle, WA USA.
RP Craft, S (reprint author), Vet Affairs Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, S-182,1660 S Columbian Way, Seattle, WA 98108 USA.
EM scraft@uw.edu
FU National Institute of Aging [AG027415, P50 AG05136, T32 AG000258]; Nancy
and Buster Alvord Endowment; Department of Veterans Affairs
FX This research was supported by National Institute of Aging grants
AG027415 (to Dr Craft), P50 AG05136 (to Dr Montine), and T32 AG000258
(to Dr Claxton), the Nancy and Buster Alvord Endowment, and the
Department of Veterans Affairs. This material is the result of work
supported in part by resources from the Veterans Affairs Puget Sound
Health Care System, Seattle, Washington.
NR 31
TC 394
Z9 401
U1 17
U2 83
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA
SN 0003-9942
J9 ARCH NEUROL-CHICAGO
JI Arch. Neurol.
PD JAN
PY 2012
VL 69
IS 1
BP 29
EP 38
DI 10.1001/archneurol.2011.233
PG 10
WC Clinical Neurology
SC Neurosciences & Neurology
GA 874GX
UT WOS:000298944500004
PM 21911655
ER
PT J
AU Grossman, JM
Ranganath, VK
Chen, WL
Furst, DE
McMahon, M
Volkmann, E
Gordon, R
Deal, C
Caplan, L
Curtis, JR
Patkar, NM
Saag, KG
AF Grossman, Jennifer M.
Ranganath, Veena K.
Chen, Weiling
Furst, Daniel E.
McMahon, Maureen
Volkmann, Elizabeth
Gordon, Rebecca
Deal, Chad
Caplan, Liron
Curtis, Jeffrey R.
Patkar, Nivedita M.
Saag, Kenneth G.
TI Fracture risk in glucocorticoid-induced osteoporosis: comment on the
article by Grossman et al
SO ARTHRITIS CARE & RESEARCH
LA English
DT Letter
C1 [Grossman, Jennifer M.; Ranganath, Veena K.; Chen, Weiling; Furst, Daniel E.; McMahon, Maureen; Volkmann, Elizabeth; Gordon, Rebecca] Univ Calif Los Angeles, Los Angeles, CA 90024 USA.
[Gordon, Rebecca] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
[Deal, Chad] Cleveland Clin, Cleveland, OH 44106 USA.
[Caplan, Liron] Univ Colorado, Denver, CO 80202 USA.
[Curtis, Jeffrey R.; Patkar, Nivedita M.; Saag, Kenneth G.] Univ Alabama, Birmingham, AL USA.
RP Grossman, JM (reprint author), Univ Calif Los Angeles, Los Angeles, CA 90024 USA.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 2151-464X
J9 ARTHRIT CARE RES
JI Arthritis Care Res.
PD JAN
PY 2012
VL 64
IS 1
BP 157
EP 158
DI 10.1002/acr.20650
PG 2
WC Rheumatology
SC Rheumatology
GA 868QB
UT WOS:000298536700025
ER
PT J
AU Smolderen, KG
Spertus, JA
Reid, KJ
Buchanan, DM
Vaccarino, V
Lichtman, JH
Bekelman, DB
Chan, PS
AF Smolderen, Kim G.
Spertus, John A.
Reid, Kimberly J.
Buchanan, Donna M.
Vaccarino, Viola
Lichtman, Judith H.
Bekelman, David B.
Chan, Paul S.
TI Association of Somatic and Cognitive Depressive Symptoms and Biomarkers
in Acute Myocardial Infarction: Insights from the Translational Research
Investigating Underlying Disparities in Acute Myocardial Infarction
Patients' Health Status Registry
SO BIOLOGICAL PSYCHIATRY
LA English
DT Article
DE Coagulation; depressive symptoms; inflammation; mechanisms; myocardial
infarction; neurohormones
ID C-REACTIVE PROTEIN; ACUTE CORONARY SYNDROMES; BRAIN NATRIURETIC PEPTIDE;
HEART-RATE-VARIABILITY; N-TERMINAL PROATRIAL; CARDIOVASCULAR-DISEASE;
INFLAMMATORY BIOMARKERS; SICKNESS BEHAVIOR; NATIONAL-HEART; PROGNOSIS
AB Background: Somatic depressive symptoms and certain biomarkers are each associated with worse acute myocardial infarction (AMI) prognosis, but the relationship between depressive symptom domains and inflammatory, neurohormonal, and coagulation markers is unknown.
Methods: We examined the relationship between depressive symptoms and 1-month biomarker levels (high-sensitivity C-reactive protein [hs-CRP], N-terminal pro-brain natriuretic peptide [NT-proBNP], white blood cell [WBC], platelet counts) in 1265 AMI patients. Depressive symptoms (9-item Patient Health Questionnaire) were assessed during index hospitalization and categorized as somatic or cognitive. Using median regression models, the upper quartile of somatic and cognitive depression scores and each biomarker were compared with the lower three quartiles, adjusting for site, demographics, and clinical characteristics.
Results: Although hs-CRP values were higher in patients with somatic symptoms, this association was attenuated after adjustment (B(per SD increase) = .02, 95% confidence interval: .00; .05, p = .07). WBC count was independently associated with somatic depressive symptoms (B(per SD increase) = .28, 95% confidence interval: .12; .44, p = .001). Cognitive depressive symptoms were not associated with hs-CRP or WBC count. Neither dimension was associated with NT-proBNP or platelet levels. For each biomarker, the depression dimensions explained <1% of their variation.
Conclusions: Neither somatic nor cognitive depressive symptoms were meaningfully associated with hs-CRP, NT-proBNP, WBC, or platelet counts 1 month after AMI, suggesting that the association between depression and long-term outcomes may be unrelated to these biomarkers. Future research should explore other biomarkers to better illuminate pathways by which depression adversely impacts AMI prognosis.
C1 [Smolderen, Kim G.; Spertus, John A.; Reid, Kimberly J.; Buchanan, Donna M.; Chan, Paul S.] St Lukes Mid Amer Heart & Vasc Inst, Kansas City, MO 64111 USA.
[Smolderen, Kim G.] Tilburg Univ, Dept Med Psychol, Ctr Res Psychol Somat Dis, NL-5000 LE Tilburg, Netherlands.
[Spertus, John A.; Chan, Paul S.] Univ Missouri, Dept Med, Kansas City, MO 64110 USA.
[Spertus, John A.; Chan, Paul S.] Univ Missouri, Dept Biomed & Hlth Informat, Kansas City, MO 64110 USA.
[Vaccarino, Viola] Emory Univ, Rollins Sch Publ Hlth, Dept Epidemiol, Atlanta, GA 30322 USA.
[Lichtman, Judith H.] Yale Univ, Sch Publ Hlth, Div Chron Dis Epidemiol, New Haven, CT USA.
[Bekelman, David B.] Denver Vet Affairs Med Ctr, Res Sect, Denver, CO USA.
[Bekelman, David B.] Denver Vet Affairs Med Ctr, Geriatr Sect, Denver, CO USA.
[Vaccarino, Viola] Emory Univ, Sch Med, Div Cardiol, Atlanta, GA 30322 USA.
RP Smolderen, KG (reprint author), St Lukes Mid Amer Heart & Vasc Inst, 4401 Wornall Rd, Kansas City, MO 64111 USA.
EM k.g.e.smolderen@gmail.com
RI Smolderen, Kim/B-8078-2015
FU National Heart, Lung, and Blood Institute Specialized Center of
Clinically Oriented Research in Cardiac Dysfunction and Disease [P50
HL077113]; CV Therapeutics, Palo Alto, California; American Heart
Association [AHA: 0875149N]; Netherlands Organization for Scientific
Research [916.11.179]
FX Grant support was received from the National Heart, Lung, and Blood
Institute Specialized Center of Clinically Oriented Research in Cardiac
Dysfunction and Disease (Grant number P50 HL077113) and CV Therapeutics,
Palo Alto, California. Dr. Smolderen was supported by the Outcomes
Research postdoctoral fellowship awarded by the American Heart
Association Pharmaceutical Roundtable and David and Stevie Spina (Grant
number AHA: 0875149N) and by The Netherlands Organization for Scientific
Research (Veni Grant number: 916.11.179).
NR 50
TC 8
Z9 9
U1 1
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0006-3223
J9 BIOL PSYCHIAT
JI Biol. Psychiatry
PD JAN 1
PY 2012
VL 71
IS 1
BP 22
EP 29
DI 10.1016/j.biopsych.2011.07.029
PG 8
WC Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA 863BI
UT WOS:000298137400007
PM 21903199
ER
PT J
AU Singh, H
Giardina, TD
Petersen, LA
Smith, MW
Paul, LW
Dismukes, K
Bhagwath, G
Thomas, EJ
AF Singh, Hardeep
Giardina, Traber Davis
Petersen, Laura A.
Smith, Michael W.
Paul, Lindsey Wilson
Dismukes, Key
Bhagwath, Gayathri
Thomas, Eric J.
TI Exploring situational awareness in diagnostic errors in primary care
SO BMJ QUALITY & SAFETY
LA English
DT Article
ID PATIENT SAFETY; MALPRACTICE CLAIMS; DECISION-MAKING; MISSED
OPPORTUNITIES; CANCER DIAGNOSIS; DYNAMIC-SYSTEMS; ADVERSE EVENTS;
MEDICINE; STRATEGIES; COGNITION
AB Objective: Diagnostic errors in primary care are harmful but poorly studied. To facilitate the understanding of diagnostic errors in real-world primary care settings that use electronic health records (EHRs), this study explored the use of the situational awareness (SA) framework from aviation human factors research.
Methods: A mixed-methods study was conducted involving reviews of EHR data followed by semi-structured interviews of selected providers from two institutions in the USA. The study population included 380 consecutive patients with colorectal and lung cancers diagnosed between February 2008 and January 2009. Using a pre-tested data collection instrument, trained physicians identified diagnostic errors, defined as lack of timely action on one or more established indications for diagnostic work-up for lung and colorectal cancers. Twenty-six providers involved in cases with and without errors were interviewed. Interviews probed for providers' lack of SA and how this may have influenced the diagnostic process.
Results: Of 254 cases meeting inclusion criteria, errors were found in 30 of 92 (32.6%) lung cancer cases and 56 of 167 (33.5%) colorectal cancer cases. Analysis of interviews related to error cases revealed evidence of lack of one of four levels of SA applicable to primary care practice: information perception, information comprehension, forecasting future events, and choosing appropriate action based on the first three levels. In cases without error, application of the SA framework provided insight into processes involved in attention management.
Conclusions: A framework of SA can help analyse and understand diagnostic errors in primary care settings that use EHRs.
C1 [Singh, Hardeep; Giardina, Traber Davis; Petersen, Laura A.; Smith, Michael W.] Baylor Coll Med, Houston VA HSR&D Ctr Excellence, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA.
[Singh, Hardeep; Giardina, Traber Davis; Petersen, Laura A.; Smith, Michael W.] Baylor Coll Med, Dept Med, Sect Hlth Serv Res, Houston, TX 77030 USA.
[Paul, Lindsey Wilson] Univ Texas Austin, Sch Social Work, Austin, TX 78712 USA.
[Dismukes, Key] NASA, Ames Res Ctr, Moffett Field, CA 94035 USA.
[Bhagwath, Gayathri] Univ Texas Galveston, Med Branch, Dept Internal Med, Div Hematol Oncol, Galveston, TX 77550 USA.
[Thomas, Eric J.] Univ Texas Houston, Sch Med, Dept Med, Div Gen Med, Houston, TX 77030 USA.
[Thomas, Eric J.] Univ Texas Houston, Sch Med, Mem Hermann Ctr Healthcare Qual, Houston, TX USA.
RP Singh, H (reprint author), Med Ctr 152, 2002 Holcombe Blvd, Houston, TX 77030 USA.
EM hardeeps@bcm.edu
OI Davis Giardina, Traber/0000-0002-9184-6524
FU NIH [K23CA125585]; Houston VA HSR&D Center of Excellence [HFP90-020]
FX This study was supported by an NIH K23 career development award
(K23CA125585) to Dr Singh, and in part by the Houston VA HSR&D Center of
Excellence (HFP90-020). These sources had no role in the design and
conduct of the study; collection, management, analysis, and
interpretation of the data; and preparation, review, or approval of the
manuscript.
NR 77
TC 19
Z9 20
U1 4
U2 14
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 2044-5415
J9 BMJ QUAL SAF
JI BMJ Qual. Saf.
PD JAN
PY 2012
VL 21
IS 1
BP 30
EP 38
DI 10.1136/bmjqs-2011-000310
PG 9
WC Health Care Sciences & Services; Health Policy & Services
SC Health Care Sciences & Services
GA 862ZZ
UT WOS:000298133900005
PM 21890757
ER
PT J
AU Rahbar, H
Tavakkol, Z
Bhargava, P
AF Rahbar, H.
Tavakkol, Z.
Bhargava, P.
TI Characteristic CT appearance of lung cysts prompting the diagnosis of a
rare genodermatosis
SO BRITISH JOURNAL OF RADIOLOGY
LA English
DT Editorial Material
ID HOGG-DUBE-SYNDROME; HEREDITARY
C1 [Rahbar, H.; Bhargava, P.] Univ Washington, Sch Med, Dept Radiol, Seattle, WA 98195 USA.
[Rahbar, H.; Bhargava, P.] VA Puget Sound Hlth Care Syst, Seattle, WA USA.
[Tavakkol, Z.] Univ Washington, Div Dermatol, Sch Med, Dept Med, Seattle, WA 98195 USA.
RP Bhargava, P (reprint author), VA Puget Sound Hlth Care Ctr, Mail Box 358280,1660 S Columbian Way, Seattle, WA 98108 USA.
EM bhargp@u.washington.edu
OI Bhargava, Puneet/0000-0002-3849-9666
NR 6
TC 0
Z9 0
U1 0
U2 0
PU BRITISH INST RADIOLOGY
PI LONDON
PA 36 PORTLAND PLACE, LONDON W1N 4AT, ENGLAND
SN 0007-1285
J9 BRIT J RADIOL
JI Br. J. Radiol.
PD JAN
PY 2012
VL 85
IS 1009
BP 93
EP 95
DI 10.1259/bjr/13687494
PG 3
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA 866RH
UT WOS:000298398900018
PM 22190751
ER
PT J
AU Dunn, JH
Ellis, LZ
Fujita, M
AF Dunn, Jeffrey H.
Ellis, Lixia Z.
Fujita, Mayumi
TI Inflammasomes as molecular mediators of inflammation and cancer:
Potential role in melanoma
SO CANCER LETTERS
LA English
DT Review
DE Inflammasome; Inflammation; Cancer; Melanoma; IL-1 beta; ASC
ID INTERLEUKIN-1 INDUCES INTERLEUKIN-1; CASPASE RECRUITMENT DOMAIN; INNATE
IMMUNE-RESPONSE; FAMILIAL MEDITERRANEAN FEVER; TUMOR-HOST INTERACTIONS;
TOLL-LIKE RECEPTORS; SPECK-LIKE PROTEIN; NF-KAPPA-B; NALP3 INFLAMMASOME;
IN-VITRO
AB The inflammasome is a multi-protein complex that mediates immune responses to microbial, host, and environmental signals. When active, inflammasomes regulate caspase-1 activation and IL-1 beta secretion. There is a strong link between inflammation and cancer, and IL-1 beta is one of the major molecules involved in both of these disease processes. Here we review the role of inflammasomes in regulating IL-1 beta secretion, and the impact of this pathway on cancer pathogenesis, with a focus on melanoma. This represents an exciting new area of research, and could potentially result in new targets for melanoma therapeutics in the future. Published by Elsevier Ireland Ltd.
C1 [Dunn, Jeffrey H.; Ellis, Lixia Z.; Fujita, Mayumi] Univ Colorado Denver, Dept Dermatol, Sch Med, Aurora, CO 80045 USA.
[Fujita, Mayumi] Denver Vet Affairs Med Ctr, Denver, CO 80220 USA.
RP Fujita, M (reprint author), Univ Colorado Denver, Dept Dermatol, Sch Med, Mail Stop 8127,12801 E 17th Ave,RC-1 S,Rm 4124, Aurora, CO 80045 USA.
EM mayumi.fujita@ucdenver.edu
FU Dermatology Foundation; Wendy Will Case Cancer Fund grant; Cancer League
of Colorado; Tadamitsu Cancer Research Fund
FX The authors thank Charles A Dinarello, MD, Miyako Okamoto, MD, PhD and
Weimin Liu, MD (University of Colorado Denver) for helpful discussions.
This work was supported, in whole or in part, by Dermatology Foundation
(to M.F.), Wendy Will Case Cancer Fund grant (to M.F.), Cancer League of
Colorado (to M.F.) and Tadamitsu Cancer Research Fund (to M.F.). The
funders had no role in study design, data collection, analysis and
interpretation, manuscript preparation and decision to submit the
manuscript.
NR 163
TC 29
Z9 29
U1 1
U2 9
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
IRELAND
SN 0304-3835
J9 CANCER LETT
JI Cancer Lett.
PD JAN 1
PY 2012
VL 314
IS 1
BP 24
EP 33
DI 10.1016/j.canlet.2011.10.001
PG 10
WC Oncology
SC Oncology
GA 868OF
UT WOS:000298531900003
PM 22050907
ER
PT J
AU Hirata, H
Hinoda, Y
Ueno, K
Shahryari, V
Tabatabai, ZL
Dahiya, R
AF Hirata, Hiroshi
Hinoda, Yuji
Ueno, Koji
Shahryari, Varahram
Tabatabai, Z. Laura
Dahiya, Rajvir
TI MicroRNA-1826 targets VEGFC, beta-catenin (CTNNB1) and MEK1 (MAP2K1) in
human bladder cancer
SO CARCINOGENESIS
LA English
DT Article
ID LYMPH-NODE METASTASIS; FACTOR-C EXPRESSION; SIGNAL-TRANSDUCTION; KINASE
CASCADE; CELL-LINES; TUMORS; LYMPHANGIOGENESIS; ACTIVATION; BIOMARKERS;
CARCINOMA
AB The Wnt/beta-catenin (CTNNB1) and Ras-Raf-MEK-ERK signaling pathway play an important role in bladder cancer (BC) progression. Tumor-suppressive microRNAs (miRNAs) targeting these cancer pathways may provide a new therapeutic approach for BC. We initially identified miRNA-1826 potentially targeting CTNNB1, VEGFC and MEK1 using several target scan algorithms. Also 3' untranslated region luciferase activity and protein expression of these target genes were significantly downregulated in miR-1826-transfected BC cells (J82 and T24). The expression of miR-1826 was lower in BC tissues and inverse correlation of miR-1826 with several clinical parameters (pT, grade) was observed. Also the expression of miR-1826 was much lower in three BC cell lines (J82, T24 and TCCSUP) compared with a normal bladder cell line (SV-HUC-1). We then performed analyses to look at miR-1826 function and found that miR-1826 inhibited BC cell viability, invasion and migration. We also found increased apoptosis and G(1) cell cycle arrest in miR-1826-transfected BC cells. To examine whether the effect of miR-1826 was through CTNNB1 (beta-catenin) or MEK1 knockdown, we knocked down CTNNB1/MEK1 messenger RNA using a small interfering RNA (siRNA) technique. We observed that CTNNB1 or MEK1 siRNA knockdown resulted in effects similar to those with miR-1826 in BC cells. In conclusion, our data suggest that the miR-1826 plays an important role as tumor suppressor via CTNNB1/MEK1/VEGFC downregulation in BC.
C1 [Hirata, Hiroshi; Ueno, Koji; Shahryari, Varahram; Dahiya, Rajvir] San Francisco VA Med Ctr, Dept Urol, San Francisco, CA 94121 USA.
[Hinoda, Yuji; Tabatabai, Z. Laura] Univ Calif San Francisco, San Francisco, CA 94121 USA.
[Hinoda, Yuji; Tabatabai, Z. Laura] Yamaguchi Univ, Grad Sch Med, Dept Oncol AnLab Med, Yamaguchi 7558505, Japan.
[Tabatabai, Z. Laura] San Francisco VA Med Ctr, Dept Pathol, San Francisco, CA 94121 USA.
RP Dahiya, R (reprint author), Vet Affairs Med Ctr, Urol Res Ctr 112F, San Francisco, CA 94121 USA.
EM rdahiya@urology.ucsf.edu
FU National Institutes of Health [RO1CA130860, RO1CA111470, RO1CA138642,
T32-DK07790]; VA Research Enhancement Award Program; Merit Review
grants; Yamada Science Foundation
FX RO1CA130860, RO1CA111470, RO1CA138642, T32-DK07790 from the National
Institutes of Health, VA Research Enhancement Award Program, Merit
Review grants and Yamada Science Foundation.
NR 36
TC 40
Z9 43
U1 2
U2 7
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0143-3334
J9 CARCINOGENESIS
JI Carcinogenesis
PD JAN
PY 2012
VL 33
IS 1
BP 41
EP 48
DI 10.1093/carcin/bgr239
PG 8
WC Oncology
SC Oncology
GA 870HF
UT WOS:000298659200006
PM 22049531
ER
PT J
AU Zemans, RL
Stream, AR
Musani, AI
Dhaliwal, G
AF Zemans, Rachel L.
Stream, Amanda R.
Musani, Ali I.
Dhaliwal, Gurpreet
TI A 46-Year-Old Man With Seizures, Brain Lesions, and Pulmonary
Infiltrates
SO CHEST
LA English
DT Editorial Material
ID ALVEOLAR PROTEINOSIS; THERAPY
C1 [Zemans, Rachel L.; Musani, Ali I.] Natl Jewish Hlth, Dept Med, Denver, CO 80206 USA.
[Zemans, Rachel L.; Stream, Amanda R.; Musani, Ali I.] Univ Colorado Denver, Dept Med, Aurora, CO USA.
[Dhaliwal, Gurpreet] San Francisco VA Med Ctr, Dept Med, San Francisco, CA USA.
[Dhaliwal, Gurpreet] Univ Calif San Francisco, Dept Med, San Francisco, CA USA.
RP Zemans, RL (reprint author), Natl Jewish Hlth, Dept Med, 1400 Jackson St,A555, Denver, CO 80206 USA.
EM ZemansR@NJHealth.org
FU NHLBI NIH HHS [HL103772, K08 HL103772]
NR 10
TC 0
Z9 0
U1 1
U2 2
PU AMER COLL CHEST PHYSICIANS
PI NORTHBROOK
PA 3300 DUNDEE ROAD, NORTHBROOK, IL 60062-2348 USA
SN 0012-3692
J9 CHEST
JI Chest
PD JAN
PY 2012
VL 141
IS 1
BP 265
EP 269
DI 10.1378/chest.11-1397
PG 5
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA 874FW
UT WOS:000298941800041
PM 22215837
ER
PT J
AU Butt, AA
Kanwal, F
AF Butt, Adeel A.
Kanwal, Fasiha
TI Boceprevir and Telaprevir in the Management of Hepatitis C
Virus-Infected Patients
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Review
ID GENOTYPE 1 INFECTION; PROTEASE INHIBITOR; ANTIVIRAL THERAPY; PLUS
RIBAVIRIN; INTERFERON; RESISTANCE
AB Recent approval of direct-acting antiviral agents (DAAs) against hepatitis C virus (HCV) offers a major advance in the management of HCV infection. These DAAs, boceprevir and telaprevir, when given with pegylated interferon alfa (Peg-IFN) and ribavirin (RBV), result in a much higher sustained virologic response rate compared with Peg-IFN and RBV. The DAA-containing regimens are approved for HCV genotype 1 infection in HCV treatment-naive and HCV treatment-experienced patients. In this review, we present an overview of pharmacology, efficacy, adverse events, and emergence of resistance-associated variants with the use of these agents. As with all drugs, especially newly approved drugs, clinicians must consult the package insert for detailed prescribing information, list of all reported adverse events, contraindications, and drug interactions.
C1 [Butt, Adeel A.] Univ Pittsburgh, Sch Med, Div Infect Dis, Dept Med, Pittsburgh, PA 15213 USA.
[Butt, Adeel A.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
[Butt, Adeel A.] Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA.
[Kanwal, Fasiha] St Louis Univ, Sch Med, St Louis Vet Affairs Med Ctr, St Louis, MO 63103 USA.
[Kanwal, Fasiha] St Louis Univ, Sch Med, Dept Med, Div Gastroenterol & Hepatol, St Louis, MO 63103 USA.
RP Butt, AA (reprint author), Univ Pittsburgh, Sch Med, Dept Med & Infect Dis, 3601 5th Ave,Ste 3A, Pittsburgh, PA 15213 USA.
EM aabutt@pitt.edu
FU Merck Sharp Dohme Corp.
FX A. A. B. has received investigator-initiated grant support (to
University of Pittsburgh) from Merck Sharp & Dohme Corp.
NR 21
TC 45
Z9 48
U1 1
U2 9
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1058-4838
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD JAN 1
PY 2012
VL 54
IS 1
BP 96
EP 104
DI 10.1093/cid/cir774
PG 9
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 866LX
UT WOS:000298383500020
PM 22156853
ER
PT J
AU Daniel, BS
Hertl, M
Werth, VP
Eming, R
Murrell, DF
AF Daniel, Benjamin S.
Hertl, Michael
Werth, Victoria P.
Eming, Ruediger
Murrell, Dedee F.
TI Severity score indexes for blistering diseases
SO CLINICS IN DERMATOLOGY
LA English
DT Article
ID PEMPHIGUS-VULGARIS; ORAL PEMPHIGUS; IMMUNOADSORPTION; AUTOANTIBODIES;
PROGRESSION; ANTIBODIES; RITUXIMAB
AB Scoring systems are used to assess the severity of a disease and the response to treatment. The main severity scoring indexes are the Autoimmune Bullous Skin Disorder Intensity Score (ABSIS) and the Pemphigus Disease Area Index (PDAI). They have been validated and are already used in the evaluation of pemphigus and in clinical trials. They quantify disease severity by performing a global assessment of all lesions. In recent years, other severity scoring systems have been developed for pemphigus and other autoimmune blistering diseases. (C) 2012 Elsevier Inc. All rights reserved.
C1 [Daniel, Benjamin S.; Murrell, Dedee F.] St George Hosp, Dept Dermatol, Sydney, NSW, Australia.
[Daniel, Benjamin S.; Murrell, Dedee F.] Univ New S Wales, Dept Dermatol, Sydney, NSW, Australia.
[Hertl, Michael; Eming, Ruediger] Univ Marburg, Dept Dermatol, Marburg, Germany.
[Werth, Victoria P.] Philadelphia VA Med Ctr, Dept Dermatol, Philadelphia, PA USA.
[Werth, Victoria P.] Univ Penn, Sch Med, Philadelphia, PA 19104 USA.
RP Murrell, DF (reprint author), St George Hosp, Dept Dermatol, Sydney, NSW, Australia.
EM d.murrell@unsw.edu.au
FU National Institutes of Health [NIH K24-AR 02207]
FX This work was supported in part by the National Institutes of Health
(grant number NIH K24-AR 02207) to VPW.
NR 28
TC 26
Z9 28
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0738-081X
J9 CLIN DERMATOL
JI Clin. Dermatol.
PD JAN-FEB
PY 2012
VL 30
IS 1
BP 108
EP 113
DI 10.1016/j.clindermatol.2011.03.017
PG 6
WC Dermatology
SC Dermatology
GA 864BS
UT WOS:000298212600014
PM 22137234
ER
PT J
AU Ripoll, LH
AF Ripoll, Luis H.
TI Clinical psychopharmacology of borderline personality disorder: an
update on the available evidence in light of the Diagnostic and
Statistical Manual of Mental Disorders-5
SO CURRENT OPINION IN PSYCHIATRY
LA English
DT Review
DE Borderline personality disorder; Diagnostic and Statistical Manual of
Mental Disorders-5; psychopharmacology
ID 18-MONTH FOLLOW-UP; POSITRON-EMISSION-TOMOGRAPHY; DIALECTICAL
BEHAVIOR-THERAPY; SELF-INJURIOUS-BEHAVIOR; DOUBLE-BLIND; TOPIRAMATE
TREATMENT; 10-YEAR COURSE; PART II; PHARMACOLOGICAL-TREATMENT; AFFECTIVE
INSTABILITY
AB Purpose of review
Clinical considerations for evidence-based treatment of borderline personality disorder (BPD) are outlined in the context of the best available evidence, discussed with reference to BPD traits currently identified in the upcoming Diagnostic and Statistical Manual of Mental Disorders - 5 (DSM-5) revision. The DSM-5 will highlight refractory affective, interpersonal, and identity symptoms in BPD as potential treatment targets. In addition to providing a framework for clinical decision-making, future research strategies will also focus on neurotransmitter systems of greater relevance to understanding overall personality functioning.
Recent findings
Although only a few randomized controlled trials of psychopharmacological treatments for BPD have been published recently, several meta-analyses and systematic reviews converge on the consensus effectiveness of lamotrigine, topiramate, valproate, aripiprazole, olanzapine, and omega-3 fatty acid supplementation. Stronger evidence exists for treating disinhibition and antagonism than negative affectivity, particularly interpersonal facets of such traits. In addition, basic research suggests a future role for modifying glutamatergic, opioid, and oxytocinergic neurotransmitter systems to treat BPD.
Summary
Clinicians should utilize omega-3, anticonvulsants, and atypical antipsychotic agents in treating specific DSM-5 BPD traits, notably disinhibition, antagonism, and some aspects of negative affectivity. Future research will focus on normalizing opioid and oxytocin dysregulation, as an adjunct to evidence-based psychotherapy, in an effort to improve interpersonal functioning.
C1 [Ripoll, Luis H.] MIRECC, James J Peters VA Med Ctr, Bronx, NY 10468 USA.
[Ripoll, Luis H.] Mt Sinai Sch Med, Mood & Personal Res Program, New York, NY USA.
RP Ripoll, LH (reprint author), MIRECC, James J Peters VA Med Ctr, 130 W Kingsbridge Rd, Bronx, NY 10468 USA.
EM luis.ripoll@mssm.edu
FU US Department of Veteran Affairs via a MIRECC
FX The author has nothing to disclose, in terms of private funding relevant
to this research. At present, he is funded entirely through US
Department of Veteran Affairs via a MIRECC Fellowship.
NR 91
TC 7
Z9 7
U1 1
U2 25
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0951-7367
J9 CURR OPIN PSYCHIATR
JI Curr. Opin. Psychiatr.
PD JAN
PY 2012
VL 25
IS 1
BP 52
EP 58
DI 10.1097/YCO.0b013e32834c3f19
PG 7
WC Psychiatry
SC Psychiatry
GA 863CS
UT WOS:000298141000009
PM 22037092
ER
PT J
AU Sikanderkhel, S
Luthra, M
Chavalitdhamrong, D
AF Sikanderkhel, Saad
Luthra, Munish
Chavalitdhamrong, Disaya
TI SNAKESKIN-LIKE PATTERN MIMICKING PORTAL HYPERTENSIVE GASTROPATHY IN
PATIENT WITH EOSINOPHILIC GASTRITIS
SO DIGESTIVE ENDOSCOPY
LA English
DT Editorial Material
C1 [Sikanderkhel, Saad; Luthra, Munish; Chavalitdhamrong, Disaya] Mt Sinai Sch Med, James J Peters Vet Affairs Med Ctr, Bronx, NY USA.
RP Sikanderkhel, S (reprint author), Mt Sinai Sch Med, James J Peters Vet Affairs Med Ctr, Bronx, NY USA.
NR 4
TC 0
Z9 0
U1 1
U2 1
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0915-5635
J9 DIGEST ENDOSC
JI Dig. Endosc.
PD JAN
PY 2012
VL 24
IS 1
BP 53
EP 53
DI 10.1111/j.1443-1661.2011.01155.x
PG 1
WC Gastroenterology & Hepatology; Surgery
SC Gastroenterology & Hepatology; Surgery
GA 869KT
UT WOS:000298597500013
PM 22211417
ER
PT J
AU Sonnenberg, A
AF Sonnenberg, A.
TI Test sequence in the management of gastrointestinal bleeding
SO ENDOSCOPY
LA English
DT Article
ID EPIDEMIOLOGY; DIAGNOSIS
AB Background and study aim: A large variety of test procedures is available to diagnose and treat patients with suspected gastrointestinal bleeding. The aim of the study was to investigate which test sequence should be utilized in managing gastrointestinal bleeding.
Methods: For each endoscopic, radiologic, or laboratory test procedure, professional fees and facility costs were estimated based on payments allowed by the US Centers for Medicare and Medicaid Services during the fiscal year 2010. A threshold analysis was used to compare the costs associated with different test sequences of varying clinical scenarios.
Results: A threshold represents the lowest expected probability of success, for which a test would still be indicated. In a work-up including all possible management options, the threshold associated with laboratory tests and gastric lavage was 1%, esophagogastroduodenoscopy (EGD) 8%, colonoscopy 9%, nuclear scan 9%, enteroscopy 11%, computed tomography (CT) angiography 14%, capsule endoscopy 23%, and angiography with transcatheter embolization 25%. Varying sets of thresholds were calculated for different clinical scenarios. The thresholds of EGD and colonoscopy remained low in most scenarios. In sensitivity analysis, rising risk of complications or costs of a procedure also lead to rising threshold values for it, potentially rendering the particular procedure untenable.
Conclusions: A low threshold indicated a preferred management option that should be used early rather than late in a sequence of multiple possible test procedures to work up instances of gastrointestinal bleeding.
C1 [Sonnenberg, A.] Portland VA Med Ctr, Portland, OR 97239 USA.
[Sonnenberg, A.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
RP Sonnenberg, A (reprint author), Portland VA Med Ctr, P3-GI 3710 SW US Vet Hosp Rd, Portland, OR 97239 USA.
EM sonnenbe@ohsu.edu
NR 8
TC 5
Z9 5
U1 2
U2 2
PU GEORG THIEME VERLAG KG
PI STUTTGART
PA RUDIGERSTR 14, D-70469 STUTTGART, GERMANY
SN 0013-726X
J9 ENDOSCOPY
JI Endoscopy
PD JAN
PY 2012
VL 44
IS 1
BP 43
EP 47
DI 10.1055/s-0031-1291536
PG 5
WC Gastroenterology & Hepatology; Surgery
SC Gastroenterology & Hepatology; Surgery
GA 866TF
UT WOS:000298405400008
PM 22198774
ER
PT J
AU Graber, CJ
Hutchings, C
Dong, F
Lee, W
Chung, JK
Tran, T
AF Graber, C. J.
Hutchings, C.
Dong, F.
Lee, W.
Chung, J. K.
Tran, T.
TI Changes in antibiotic usage and susceptibility in nosocomial
Enterobacteriaceae and Pseudomonas isolates following the introduction
of ertapenem to hospital formulary
SO EPIDEMIOLOGY AND INFECTION
LA English
DT Article
DE Antibiotic resistance; antibiotics; hospital-acquired (nosocomial)
infections; hospital microbiology; Pseudomonas
ID TIME-SERIES ANALYSIS; RESISTANT; AERUGINOSA; IMIPENEM; THERAPY; RATES
AB There is concern that widespread usage of ertapenem may promote cross-resistance to other carbapenems. To analyse the impact that adding ertapenem to our hospital formulary had on usage of other broad-spectrum agents and on susceptibilities of nosocomial Enterobacteriaceae and Pseudomonas isolates, we performed interrupted time-series analyses to determine the change in linear trend in antibiotic usage and change in mean proportion and linear trend of susceptibility pre-(March 2004-June 2005) and post-(July 2005-December 2008) ertapenem introduction. Usage of piperacillin-tazobactam (P = 0.0013) and ampicillin-sulbactam (P = 0.035) declined post-ertapenem introduction. For Enterobacteriaceae, the mean proportion susceptible to ciprofloxacin (P = 0.016) and piperacillin-tazobactam (P = 0.038) increased, while the linear trend in susceptibility significantly increased for cefepime (P = 0.012) but declined for ceftriaxone (P = 0.0032). For Pseudomonas, the mean proportion susceptible to cefepime (P = 0.011) and piperacillin-tazobactam (P = 0.028) increased, as did the linear trend in susceptibility to ciprofloxacin (P = 0.028). Notably, no significant changes in carbapenem susceptibility were observed.
C1 [Graber, C. J.] Univ Calif Los Angeles, David Geffen Sch Med, UCLA Infect Dis Sect, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA.
[Graber, C. J.; Tran, T.] VA Greater Los Angeles Healthcare Syst, Infect Dis Sect, Los Angeles, CA USA.
[Hutchings, C.; Dong, F.; Tran, T.] VA Greater Los Angeles Healthcare Syst, Serv Pharm, Los Angeles, CA USA.
[Lee, W.] Univ So Calif, Keck Sch Med, Dept Biostat, Los Angeles, CA 90033 USA.
[Chung, J. K.] Univ So Calif, Sch Pharm, Los Angeles, CA USA.
RP Graber, CJ (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, UCLA Infect Dis Sect, VA Greater Los Angeles Healthcare Syst, 11301 Wilshire Blvd,111-F, Los Angeles, CA 90073 USA.
EM cgraber@ucla.edu
FU Merck Pharmaceuticals; Ortho-McNeil-Janssen
FX This project was supported by a grant from Merck Pharmaceuticals.;
C.J.G. has received an unrestricted educational grant from
Ortho-McNeil-Janssen and has served on an advisory board for Pfizer.
NR 13
TC 3
Z9 3
U1 0
U2 2
PU CAMBRIDGE UNIV PRESS
PI NEW YORK
PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA
SN 0950-2688
J9 EPIDEMIOL INFECT
JI Epidemiol. Infect.
PD JAN
PY 2012
VL 140
IS 1
BP 115
EP 125
DI 10.1017/S0950268811000082
PG 11
WC Public, Environmental & Occupational Health; Infectious Diseases
SC Public, Environmental & Occupational Health; Infectious Diseases
GA 868TC
UT WOS:000298547400015
PM 21303590
ER
PT J
AU Styskal, J
Van Remmen, H
Richardson, A
Salmon, AB
AF Styskal, JennaLynn
Van Remmen, Holly
Richardson, Arlan
Salmon, Adam B.
TI Oxidative stress and diabetes: What can we learn about insulin
resistance from antioxidant mutant mouse models?
SO FREE RADICAL BIOLOGY AND MEDICINE
LA English
DT Review
DE Oxidative stress; Diabetes; Obesity; Adipose; Insulin resistance
ID EXTRACELLULAR-SUPEROXIDE-DISMUTASE; CELLULAR GLUTATHIONE-PEROXIDASE;
METHIONINE SULFOXIDE REDUCTASE; MEMBRANE LIPID-PEROXIDATION; OXIDANT
TISSUE-INJURY; RAT SKELETAL-MUSCLE; GENE-TARGETED MICE; ALPHA-LIPOIC
ACID; RED-BLOOD-CELLS; NF-KAPPA-B
AB The development of metabolic dysfunctions like diabetes and insulin resistance in mammals is regulated by a myriad of factors. Oxidative stress seems to play a central role in this process as recent evidence shows a general increase in oxidative damage and a decrease in oxidative defense associated with several metabolic diseases. These changes in oxidative stress can be directly correlated with increased fat accumulation, obesity, and consumption of high-calorie/high-fat diets. Modulation of oxidant protection through either genetic mutation or treatment with antioxidants can significantly alter oxidative stress resistance and accumulation of oxidative damage in laboratory rodents. Antioxidant mutant mice have previously been utilized to examine the role of oxidative stress in other disease models, but have been relatively unexplored as models to study the regulation of glucose metabolism. In this review, we will discuss the evidence for oxidative stress as a primary mechanism linking obesity and metabolic disorders and whether alteration of antioxidant status in laboratory rodents can significantly alter the development of insulin resistance or diabetes. (C) 2011 Elsevier Inc. All rights reserved.
C1 [Styskal, JennaLynn; Van Remmen, Holly; Richardson, Arlan; Salmon, Adam B.] Univ Texas Hlth Sci Ctr San Antonio, Sam & Ann Barshop Inst Longev & Aging Studies, San Antonio, TX 78245 USA.
[Styskal, JennaLynn; Van Remmen, Holly; Richardson, Arlan] Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA.
[Van Remmen, Holly; Richardson, Arlan; Salmon, Adam B.] S Texas Vet Hlth Care Syst, Geriatr Res Educ & Clin Ctr, San Antonio, TX 78229 USA.
[Salmon, Adam B.] Univ Texas Hlth Sci Ctr San Antonio, Dept Mol Med, San Antonio, TX 78245 USA.
RP Salmon, AB (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Sam & Ann Barshop Inst Longev & Aging Studies, 15355 Lambda Dr,MSC 7755, San Antonio, TX 78245 USA.
EM salmona@uthscsa.edu
FU NIH [T32 AG021890-05, R01AG015908, R01AG023843, P01AG19316, P01AG020591,
R37AG026557]; Department of Veterans Affairs; San Antonio Nathan Shock
Center of Excellence in the Basic Biology of Aging
FX This work was supported by NIH Training Grant T32 AG021890-05, NIH
Grants R01AG015908, R01AG023843, P01AG19316, P01AG020591, and
R37AG026557, the Department of Veterans Affairs (Merit Grants and a
Research Enhancement Award Program), and the Mitocondrial Function and
Oxidative Damage Core Facility of the San Antonio Nathan Shock Center of
Excellence in the Basic Biology of Aging.
NR 184
TC 90
Z9 91
U1 1
U2 25
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0891-5849
J9 FREE RADICAL BIO MED
JI Free Radic. Biol. Med.
PD JAN 1
PY 2012
VL 52
IS 1
BP 46
EP 58
DI 10.1016/j.freeradbiomed.2011.10.441
PG 13
WC Biochemistry & Molecular Biology; Endocrinology & Metabolism
SC Biochemistry & Molecular Biology; Endocrinology & Metabolism
GA 874RJ
UT WOS:000298975500005
PM 22056908
ER
PT J
AU Parshall, MB
Carle, AC
Ice, U
Taylor, R
Powers, J
AF Parshall, Mark B.
Carle, Adam C.
Ice, Unchalee
Taylor, Robert
Powers, Joyce
TI Validation of a three-factor measurement model of dyspnea in
hospitalized adults with heart failure
SO HEART & LUNG
LA English
DT Article
DE Chronic obstructive pulmonary disease; Confirmatory factor analysis;
Dyspnea; Respiratory sensation
ID OBSTRUCTIVE PULMONARY-DISEASE; CO2-INDUCED AIR HUNGER; RESPIRATORY
SENSATIONS; CARDIORESPIRATORY DISEASES; VENTILATED QUADRIPLEGICS;
RESPONSE CHARACTERISTICS; QUALITATIVE ASPECTS; CLINICAL-TRIALS; FIT
INDEXES; BREATHLESSNESS
AB OBJECTIVE: The purpose of this study was to validate a 3-factor measurement model of dyspnea sensory quality (WORK-EFFORT, TIGHTNESS, SMOTHERING-AIR HUNGER) originally derived in patients with exacerbated chronic obstructive pulmonary disease.
METHODS: In this validation study, adult patients with heart failure were enrolled after hospital admission (median hospital day 1) and asked to rate the intensity of dyspnea sensory quality descriptors on the day of enrollment (study day 1; N = 119) and in a recall version for the day of admission (study day 0; n = 97).
RESULTS: Confirmatory factor analysis demonstrated good model fit for both days. Cronbach's alpha for each factor was greater than .87 for both study days.
CONCLUSION: This is the first study to validate a previously specified measurement model of dyspnea sensory quality in an independent sample. Results indicate that measurement of dyspnea sensory quality in exacerbated cardiopulmonary disease does not necessarily require disease-specific questionnaires.
Cite this article: Parshall, M. B., Carle, A. C., Ice, U., Taylor, R., & Powers, J. (2012, JANUARY/FEBRUARY). Validation of a three-factor measurement model of dyspnea in hospitalized adults with heart failure. Heart & Lung, 41(1), 44-56. doi:10.1016/j.hrtlng.2011.05.003.
C1 [Parshall, Mark B.; Ice, Unchalee] Univ New Mexico, Coll Nursing, Hlth Sci Ctr, Albuquerque, NM 87131 USA.
[Carle, Adam C.] Univ Cincinnati, Coll Med, James M Anderson Ctr Hlth Syst Excellence, Cincinnati, OH USA.
[Taylor, Robert] Univ New Mexico, Sch Med, Dept Internal Med, Div Cardiol,Hlth Sci Ctr, Albuquerque, NM 87131 USA.
[Powers, Joyce] US Dept Vet Affairs, Raymond G Murphy VA Med Ctr, Albuquerque, NM USA.
RP Parshall, MB (reprint author), Univ New Mexico, Coll Nursing, Hlth Sci Ctr, MSC 09 5350,1 Univ New Mexico, Albuquerque, NM 87131 USA.
EM mparshall@salud.unm.edu
FU National Institute of Nursing Research [1 R15 NR008883]
FX Funded by a grant from the National Institute of Nursing Research (1 R15
NR008883). The opinions expressed in this article are solely those, of
the authors.
NR 78
TC 6
Z9 6
U1 1
U2 2
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0147-9563
J9 HEART LUNG
JI Heart Lung
PD JAN-FEB
PY 2012
VL 41
IS 1
BP 44
EP 56
DI 10.1016/j.hrtlng.2011.05.003
PG 13
WC Cardiac & Cardiovascular Systems; Nursing; Respiratory System
SC Cardiovascular System & Cardiology; Nursing; Respiratory System
GA 875KE
UT WOS:000299028000008
PM 21794918
ER
PT J
AU Anderson, J
Wagner, J
Bessesen, M
Williams, LC
AF Anderson, Judith
Wagner, Julia
Bessesen, Mary
Williams, Linda C.
TI Usability testing in the hospital
SO HUMAN FACTORS AND ERGONOMICS IN MANUFACTURING & SERVICE INDUSTRIES
LA English
DT Article
DE Patient safety; Usability; Hospital; Healthcare; Human factors
engineering
ID CONSULTATION; IMPROVE
AB It is not unusual for hospitals to purchase equipment, devices, and materials based on preferences expressed by staff, based on economics and the best offer, or based on the promise of improvement by a new version. However, routinely subjecting potential purchases to basic usability testing provides valuable information upon which to base the decisions. Responsible manufacturers are interested in knowing of needed improvements to their products. Usability testing will also guide training for implementation. Usability testing is included in an introductory human factors engineering (HFE) session as part of a patient safety training course for physicians. Clinicians equipped with this skill are able to build evidence to support purchase decisions, make demands for improved design, and encourage a more thorough HFE evaluation by experts. (c) 2011 Wiley Periodicals, Inc.
C1 [Anderson, Judith] VA Natl Ctr Patient Safety, Denver, CO USA.
[Wagner, Julia; Bessesen, Mary] Denver VAMC, Denver, CO USA.
[Williams, Linda C.] VA Natl Ctr Patient Safety, Ann Arbor, MI USA.
RP Williams, LC (reprint author), 24 Frank Lloyd Wright Dr,M2100, Ann Arbor, MI 48106 USA.
EM linbywilliams@gmail.com
OI Bessesen, Mary/0000-0001-9305-1293
NR 16
TC 1
Z9 1
U1 1
U2 8
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1090-8471
J9 HUM FACTOR ERGON MAN
JI Hum. Factors Ergonom. Manuf. Serv. Ind.
PD JAN-FEB
PY 2012
VL 22
IS 1
SI SI
BP 52
EP 63
DI 10.1002/hfm.20277
PG 12
WC Engineering, Manufacturing; Ergonomics
SC Engineering
GA 869JG
UT WOS:000298593600006
ER
PT J
AU Lesselroth, BJ
Dorr, DA
Adams, K
Church, V
Adams, S
Mazur, D
Russ, Y
Felder, R
Douglas, DM
AF Lesselroth, Blake J.
Dorr, David A.
Adams, Kathleen
Church, Victoria
Adams, Shawn
Mazur, Dennis
Russ, Yelizaveta
Felder, Robert
Douglas, David M.
TI Medication review software to improve the accuracy of outpatient
medication histories: protocol for a randomized controlled trial
SO HUMAN FACTORS AND ERGONOMICS IN MANUFACTURING & SERVICE INDUSTRIES
LA English
DT Review
DE Medication reconciliation; Medication errors; Technology assessment;
Biomedical; Adverse drug events; Medical records systems; Computerized;
Consumer health information
ID ADVERSE DRUG EVENTS; HOSPITAL DISCHARGE; CLINICAL IMPORTANCE;
RECONCILIATION; DISCREPANCIES; ERRORS; CARE; IMPLEMENTATION; ADMISSION;
DESIGN
AB Medication-prescribing errors generated at interfaces-in-care are the most common cause of preventable health care errors and contribute substantially to adverse patient outcomes. For this reason, standardized medication reconciliation (MR) processes need to be inserted at these interfaces. However, MR is an inherently complex task, and little data exist to inform system-based operationalization. The Portland Informatics Center addressed this challenge by creating an electronic patient-directed multimedia survey to automate the medication history collection. This article describes a research protocol designed to compare the software's medication discrepancy detection rate with traditional history collection strategies. For this randomized, controlled, single-blind trial, participants are randomly allocated into one of two groups: the control group reviews a paper list printed from the electronic record, whereas the intervention group uses a computer-assisted reconciliation survey that includes display of visual data (i.e., medication pictures). (c) 2011 Wiley Periodicals, Inc.
C1 [Lesselroth, Blake J.; Adams, Kathleen; Church, Victoria; Adams, Shawn; Mazur, Dennis; Russ, Yelizaveta; Felder, Robert; Douglas, David M.] Portland Oregon Vet Affairs Med Ctr, Portland, OR USA.
[Lesselroth, Blake J.; Dorr, David A.; Mazur, Dennis] Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
RP Lesselroth, BJ (reprint author), Portland VA Med Ctr, P3 MED,3710 SW US Vet Hosp Dr, Portland, OR 97239 USA.
EM blake.lesselroth@va.gov
FU VA National Center for Patient Safety
FX The authors thank the VA National Center for Patient Safety for support
of this project. The authors also thank Ms. Kelly Finley for assistance
preparing this manuscript for publication.
NR 56
TC 4
Z9 4
U1 1
U2 12
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1090-8471
J9 HUM FACTOR ERGON MAN
JI Hum. Factors Ergonom. Manuf. Serv. Ind.
PD JAN-FEB
PY 2012
VL 22
IS 1
SI SI
BP 72
EP 86
DI 10.1002/hfm.20287
PG 15
WC Engineering, Manufacturing; Ergonomics
SC Engineering
GA 869JG
UT WOS:000298593600008
ER
PT J
AU Izadi, N
Goetz, MB
Graber, CJ
AF Izadi, Neema
Goetz, Matthew Bidwell
Graber, Christopher J.
TI Inverse Correlation of Initial CD8 Lymphocyte Count and CD4 Lymphocyte
Response to Combination Antiretroviral Therapy in Treatment-Naive
HIV-Infected Patients
SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
LA English
DT Letter
ID T-CELL-ACTIVATION; HIV-1-INFECTED PATIENTS; COLLABORATIVE ANALYSIS;
IMMUNE ACTIVATION; PREDICT; COHORT; SUPPRESSION; RECOVERY; MARKER; DEATH
C1 [Izadi, Neema; Goetz, Matthew Bidwell; Graber, Christopher J.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
[Goetz, Matthew Bidwell; Graber, Christopher J.] VA Greater Los Angeles Healthcare Syst, Dept Med, Infect Dis Sect, Los Angeles, CA USA.
RP Izadi, N (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
OI Goetz, Matthew/0000-0003-4542-992X
NR 19
TC 1
Z9 1
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1525-4135
J9 JAIDS-J ACQ IMM DEF
JI JAIDS
PD JAN 1
PY 2012
VL 59
IS 1
BP E1
EP E3
DI 10.1097/QAI.0b013e31823d3277
PG 3
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA 865DW
UT WOS:000298292000001
PM 22156822
ER
PT J
AU Watson, KE
Dovi, WF
Conhaim, RL
AF Watson, Kal E.
Dovi, William F.
Conhaim, Robert L.
TI Evidence for active control of perfusion within lung microvessels
SO JOURNAL OF APPLIED PHYSIOLOGY
LA English
DT Article
DE pulmonary circulation; microcirculation; vasoconstriction; circulatory
control; vasoreactivity
ID ESTIMATED FUNCTIONAL DIAMETER; ALVEOLAR SEPTAL MICROVESSELS; ISOLATED
RAT LUNGS; PULMONARY-HYPERTENSION; VASCULAR-RESISTANCE; THROMBOXANE;
CONTRACTILE; CIRCULATION; HYPOXIA; MUSCLE
AB Watson KE, Dovi WF, Conhaim RL. Evidence for active control of perfusion within lung microvessels. J Appl Physiol 112: 48-53, 2012. First published October 13, 2011; doi:10.1152/japplphysiol.00820.2011.-Vasoconstrictors cause contraction of pulmonary microvascular endothelial cells in culture. We wondered if this meant that contraction of these cells in situ caused active control of microvascular perfusion. If true, it would mean that pulmonary microvessels were not simply passive tubes and that control of pulmonary microvascular perfusion was not mainly due to the contraction and dilation of arterioles. To test this idea, we vasoconstricted isolated perfused rat lungs with angiotensin II, bradykinin, serotonin, or U46619 (a thromboxane analog) at concentrations that produced equal flows. We also perfused matched-flow controls. We then infused a bolus of 3 mu m diameter particles into each lung and measured the rate of appearance of the particles in the venous effluent. We also measured microscopic trapping patterns of particles retained within each lung. Thirty seconds after particle infusion, venous particle concentrations were significantly lower (P <= 0.05) for lungs perfused with angiotensin II or bradykinin than for those perfused with U46619, but not significantly different from serotonin perfused lungs or matched flow controls. Microscopic clustering of particles retained within the lungs was significantly greater (P <= 0.05) for lungs perfused with angiotensin II, bradykinin, or serotonin, than for lungs perfused with U46619 or for matched flow controls. Our results suggest that these agents did not produce vasoconstriction by a common mechanism and support the idea that pulmonary microvessels possess a level of active control and are not simply passive exchange vessels.
C1 [Dovi, William F.; Conhaim, Robert L.] Univ Wisconsin, Sch Med & Publ Hlth, William S Middleton Mem Vet Hosp, Madison, WI USA.
[Watson, Kal E.; Conhaim, Robert L.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Surg, Madison, WI USA.
RP Conhaim, RL (reprint author), H5-301 BX3236,600 Highland Ave, Madison, WI 53792 USA.
EM conhaim@surgery.wisc.edu
FU Veterans Health Administration, Office of Research and Development,
Department of Veterans Affairs, Biomedical Laboratory Research and
Development Service
FX This work was supported by the Veterans Health Administration, Office of
Research and Development, Department of Veterans Affairs, Biomedical
Laboratory Research and Development Service.
NR 23
TC 3
Z9 3
U1 1
U2 1
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 8750-7587
J9 J APPL PHYSIOL
JI J. Appl. Physiol.
PD JAN
PY 2012
VL 112
IS 1
BP 48
EP 53
DI 10.1152/japplphysiol.00820.2011
PG 6
WC Physiology; Sport Sciences
SC Physiology; Sport Sciences
GA 866SR
UT WOS:000298403700007
PM 21998262
ER
PT J
AU Trivedi, RB
Piette, J
Fihn, SD
Edelman, D
AF Trivedi, Ranak B.
Piette, John
Fihn, Stephan D.
Edelman, David
TI Examining the Interrelatedness of Patient and Spousal Stress in Heart
Failure Conceptual Model and Pilot Data
SO JOURNAL OF CARDIOVASCULAR NURSING
LA English
DT Article
DE caregivers; heart failure; patient compliance; social support; spouse
ID SELF-CARE; PSYCHOSOCIAL INTERVENTIONS; PROGNOSTIC IMPORTANCE; HOSPITAL
READMISSION; MARITAL QUALITY; CHRONIC ILLNESS; SOCIAL SUPPORT;
RISK-FACTOR; DEPRESSION; FAMILY
AB Background and Research Objective: Recent research has highlighted the positive influence that spouses can have on patient outcomes. It is not clear whether patients and spouses influence each other's well-being reciprocally or whether spousal well-being affects the success of patients' disease management. Our goals were 2-fold: (a) to propose a conceptual framework to examine the reciprocity between patient and spouses' well-being, especially as it relates to disease management, and (b) to begin to assess the validity of this model using pilot data. Subjects and Methods: Twenty-three veterans with heart failure (HF) and their spouses were recruited into a pilot cross-sectional observational study. Participants completed psychosocial surveys to assess depressive symptoms, caregiver burden, relationship satisfaction, and disease management. Descriptive analyses and bivariate correlations between these measures were calculated. Results: Using standard cutoffs, analyses suggested clinically significant depressive symptoms in patients (Center for Epidemiological Studies-Depression score >16; mean, 21.8 [SD, 13]) and a high level of caregiver burden among spouses (Zarit Burden Interview score >15; mean, 22.4 [SD, 15.4]). Both patients and spouses reported high relationship satisfaction levels (Dyadic Adjustment Scale score >100; mean, 112.6 [SD, 26.5] and 115.9 [SD, 14.4], respectively). On average, patients reported poor disease management (Self-care of Heart Failure Index subscale <70 across all subscales: confidence = 53.3 [SD, 28.2]; maintenance = 59.7 [SD, 17.3]; management = 54.0 [SD, 19.4]). Patient depressive symptoms were positively correlated with spouse depressive symptoms (r = 0.53) and caregiver burden (r = 0.64; all P's < .05). Spouses' depressive symptoms were additionally correlated with lower levels of perceived social support among patients (r = -0.47), poor patient relationship satisfaction (r = -0.51), and worse patient confidence in HF management (r = -0.48). Greater caregiver burden was associated with more patient disease complaints (r = 0.49), poorer patients' relationship satisfaction (r = -0.72), and poorer patients' perceived social support (r = -0.73). Conclusions: These results provide preliminary support to the proposed conceptual model. Further research is necessary to determine which spousal factors appear to be most relevant to disease management. Disease management interventions may benefit from engaging spouses in a way that enhances their role without adding to their burden.
C1 [Trivedi, Ranak B.] VA Puget Sound Hlth Care Syst, NW HSR&D Ctr Excellence, Seattle, WA USA.
[Fihn, Stephan D.] Univ Washington, Dept Med, Seattle, WA 98195 USA.
[Piette, John] Ann Arbor HSR&D Ctr Excellence, Ann Arbor, MI USA.
[Fihn, Stephan D.] Vet Affairs Puget Sound, NW HSR&D Ctr Excellence, Seattle, WA USA.
[Edelman, David] Duke Univ, Med Ctr, Durham, NC USA.
RP Trivedi, RB (reprint author), 1100 Olive Way,Suite 1400, Seattle, WA 98101 USA.
EM ranak.trivedi@va.gov
OI Edelman, David/0000-0001-7112-6151
FU VA Puget Sound Health Care System; Durham VA Medical Center
FX This work was supported in part by the resources provided by the VA
Puget Sound Health Care System and the
NR 46
TC 10
Z9 10
U1 5
U2 14
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0889-4655
J9 J CARDIOVASC NURS
JI J. Cardiovasc. Nurs.
PD JAN-FEB
PY 2012
VL 27
IS 1
BP 24
EP 32
DI 10.1097/JCN.0b013e3182129ce7
PG 9
WC Cardiac & Cardiovascular Systems; Nursing
SC Cardiovascular System & Cardiology; Nursing
GA 866JO
UT WOS:000298376900004
PM 21743348
ER
PT J
AU Davila, JA
Duan, ZG
McGlynn, KA
El-Serag, HB
AF Davila, Jessica A.
Duan, Zhigang
McGlynn, Katherine A.
El-Serag, Hashem B.
TI Utilization and Outcomes of Palliative Therapy for Hepatocellular
Carcinoma A Population-based Study in the United States
SO JOURNAL OF CLINICAL GASTROENTEROLOGY
LA English
DT Article
DE hepatocellular carcinoma; palliative treatment; chemotherapy
ID RANDOMIZED CONTROLLED TRIAL; CHEMOEMBOLIZATION; DOXORUBICIN
AB Goals: To evaluate the utilization and determinants of receiving palliative treatment for hepatocellular carcinoma (HCC), and its effect on survival.
Background: Palliative treatment for HCC, including transarterial chemoembolization (TACE) and systemic chemotherapy, is available for patients who do not receive potentially curative therapy. The utilization and outcomes of these therapies in clinical practice are unknown.
Study: We conducted a population-based cohort study using the Surveillance, Epidemiology, and End-Results Registry data linked to Medicare claims of HCC patients aged above 65 years diagnosed during 2000 to 2005 who did not receive liver transplant, resection, or ablation. The proportions of patients who received TACE or systemic chemotherapy were calculated by tumor stage, liver disease status, and non-HCC comorbidity. Determinants of receiving palliative therapy were examined in logistic regression models and propensity scores were calculated. Cox proportional hazards models were used to evaluate mortality risk.
Results: We identified 3163 HCC patients (median age, 75 y; 67% men) who did not receive potentially curative treatment. Approximately 12.5% of patients received TACE and 11.0% received chemotherapy. In patients with early or intermediate stage HCC, no liver decompensation, and little or no comorbidity, only 22.8% received TACE and 13.8% received chemotherapy. Median survival was significantly higher among patients who received TACE (14.0 mo) compared with who received chemotherapy (5.0 mo) or no therapy (2.0 mo). A significant reduction in overall mortality was observed for TACE (54%) and chemotherapy (33%).
Conclusions: Utilization of palliative treatment for HCC is low, which could not be explained by clinical features. However, misclassification could have occurred due to the data source. Receipt of TACE or systemic chemotherapy was associated with a reduction in mortality.
C1 [Davila, Jessica A.; Duan, Zhigang] Houston Vet Affairs Med Ctr, Sect Hlth Serv Res, Houston, TX USA.
[El-Serag, Hashem B.] Houston Vet Affairs Med Ctr, Gastroenterol Sect, Houston, TX USA.
Baylor Coll Med, Houston, TX 77030 USA.
RP Davila, JA (reprint author), Michael E DeBakey VA Med Ctr, 2002 Holcombe Blvd,152, Houston, TX 77030 USA.
EM jdavila@bcm.tmc.edu
FU Onyx Pharmaceuticals; Houston VA HSR&D Center of Excellence [HFP90-020]
FX Supported in part by Onyx Pharmaceuticals and the Houston VA HSR&D
Center of Excellence (HFP90-020).
NR 19
TC 29
Z9 30
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0192-0790
J9 J CLIN GASTROENTEROL
JI J. Clin. Gastroenterol.
PD JAN
PY 2012
VL 46
IS 1
BP 71
EP 77
DI 10.1097/MCG.0b013e318224d669
PG 7
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 863FA
UT WOS:000298147000016
PM 22157221
ER
PT J
AU Cushman, WC
Davis, BR
Pressel, SL
Cutler, JA
Einhorn, PT
Ford, CE
Oparil, S
Probstfield, JL
Whelton, PK
Wright, JT
Alderman, MH
Basile, JN
Black, HR
Grimm, RH
Hamilton, BP
Haywood, LJ
Ong, ST
Piller, LB
Simpson, LM
Stanford, C
Weiss, RJ
AF Cushman, William C.
Davis, Barry R.
Pressel, Sara L.
Cutler, Jeffrey A.
Einhorn, Paula T.
Ford, Charles E.
Oparil, Suzanne
Probstfield, Jeffrey L.
Whelton, Paul K.
Wright, Jackson T., Jr.
Alderman, Michael H.
Basile, Jan N.
Black, Henry R.
Grimm, Richard H., Jr.
Hamilton, Bruce P.
Haywood, L. Julian
Ong, Stephen T.
Piller, Linda B.
Simpson, Lara M.
Stanford, Carol
Weiss, Robert J.
CA ALLHAT Collaborative Res Grp
TI Mortality and Morbidity During and After the Antihypertensive and
Lipid-Lowering Treatment to Prevent Heart Attack Trial
SO JOURNAL OF CLINICAL HYPERTENSION
LA English
DT Article
ID CONVERTING-ENZYME-INHIBITOR; BLOOD-PRESSURE; CARDIOVASCULAR EVENTS;
FOLLOW-UP; ALLHAT; OUTCOMES; THERAPY; RISK; PARTICIPANTS; HYPERTENSION
AB A randomized, double-blind, active-controlled, multicenter trial assigned 32,804 participants aged 55 years and older with hypertension and =1 other coronary heart disease risk factors to receive chlorthalidone (n=15,002), amlodipine (n=8898), or lisinopril (n=8904) for 4 to 8 years, when double-blinded therapy was discontinued. Passive surveillance continued for a total follow-up of 8 to 13 years using national administrative databases to ascertain deaths and hospitalizations. During the post-trial period, fatal outcomes and nonfatal outcomes were available for 98% and 65% of participants, respectively, due to lack of access to administrative databases for the remainder. This paper assesses whether mortality and morbidity differences persisted or new differences developed during the extended follow-up. Primary outcome was cardiovascular mortality and secondary outcomes were mortality, stroke, coronary heart disease, heart failure, cardiovascular disease, and end-stage renal disease. For the post-trial period, data are not available on medications or blood pressure levels. No significant differences (P<.05) appeared in cardiovascular mortality for amlodipine (hazard ratio [HR], 1.00; 95% confidence interval [CI], 0.931.06) or lisinopril (HR, 0.97; CI, 0.901.03), each compared with chlorthalidone. The only significant differences in secondary outcomes were for heart failure, which was higher with amlodipine (HR, 1.12; CI, 1.021.22), and stroke mortality, which was higher with lisinopril (HR, 1.20; CI, 1.011.41), each compared with chlorthalidone. Similar to the previously reported in-trial result, there was a significant treatment-by-race interaction for cardiovascular disease for lisinopril vs chlorthalidone. Black participants had higher risk than non-black participants taking lisinopril compared with chlorthalidone. After accounting for multiple comparisons, none of these results were significant. These findings suggest that neither calcium channel blockers nor angiotensin-converting enzyme inhibitors are superior to diuretics for the long-term prevention of major cardiovascular complications of hypertension. J Clin Hypertens (Greenwich). 2012; 14: 20-31. (C) 2011 Wiley Periodicals, Inc.
C1 [Pressel, Sara L.] Univ Texas Hlth Sci Ctr Houston, Univ Texas Houston, ALLHAT Clin Trials Ctr, Sch Publ Hlth, Houston, TX 77030 USA.
[Cushman, William C.] Memphis Vet Affairs Med Ctr, Memphis, TN USA.
[Cutler, Jeffrey A.; Einhorn, Paula T.] Natl Heart Lung & Blood Inst, Bethesda, MD USA.
[Oparil, Suzanne] Univ Alabama Birmingham, Sch Med, Birmingham, AL USA.
[Probstfield, Jeffrey L.] Univ Washington, Med Ctr, Seattle, WA 98195 USA.
[Whelton, Paul K.] Loyola Univ, Med Ctr, Maywood, IL 60153 USA.
[Wright, Jackson T., Jr.] Case Western Reserve Univ, Med Ctr, Cleveland, OH 44106 USA.
[Alderman, Michael H.] Albert Einstein Coll Med, Bronx, NY 10467 USA.
[Basile, Jan N.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA.
[Black, Henry R.] NYU, Langone Med Ctr, New York, NY USA.
[Grimm, Richard H., Jr.] Berman Ctr Outcomes & Clin Res, Minneapolis, MN USA.
[Hamilton, Bruce P.] Baltimore Vet Adm, Med Ctr, Baltimore, MD USA.
[Haywood, L. Julian] Univ So Calif, Keck Sch Med, Los Angeles, CA 90033 USA.
[Ong, Stephen T.] Healthcare Greater Washington, Oxon Hill, MD USA.
[Stanford, Carol] Univ Missouri, Kansas City Sch Med, Kansas City, MO 64110 USA.
[Weiss, Robert J.] Androscoggin Cardiol Associates, Auburn, AL USA.
RP Pressel, SL (reprint author), Univ Texas Hlth Sci Ctr Houston, Univ Texas Houston, ALLHAT Clin Trials Ctr, Sch Publ Hlth, RAS W908,,1200 Herman Pressler Dr, Houston, TX 77030 USA.
EM sara.l.pressel@uth.tmc.edu
FU National Heart, Lung, and Blood Institute (NHLBI) [NO1-HC-35130];
Pfizer; AstraZeneca; Bristol-Myers Squibb; Pfizer Inc.; Merck;
GlaxoSmithKline; Forest; Novartis; Takeda
FX This study was supported by contract NO1-HC-35130 with the National
Heart, Lung, and Blood Institute (NHLBI). ALLHAT investigators received
contributions of study medications supplied by Pfizer (amlodipine
besylate and doxazosin mesylate), AstraZeneca (atenolol and lisinopril),
and Bristol-Myers Squibb (pravastatin), and financial support provided
by Pfizer Inc. The authors report no conflicts of interest with regard
to this paper. Michael H. Alderman has consulted for AstraZeneca, Merck,
and Sankyo; has received honoraria from Bristol-Myers Squibb and Merck;
has had grants/contracts with Sankyo; and has held a financial interest
in Merck. Jan N. Basile has consulted for Abbott Laboratories,
Boehringer Ingelheim, Daiichi Sankyo, Forest Laboratories, Forest
Pharmaceuticals, Merck, Novartis, Reddy Pharmaceuticals, Sankyo, and
SmithKline Beecham/Glaxo Wellcome; and has received honoraria from
Abbott Laboratories, AstraZeneca, Boehringer Ingelheim, Daiichi Sankyo,
Forest Laboratories, Merck, Novartis, and Pfizer; Henry R. Black has
consulted for Abbott Laboratories, AstraZeneca, Aventis, Bayer
Corporation, Biovail, Boehringer Ingelheim, Bristol-Meyers Squibb, CVRx,
Daiichi Sankyo, Forest Pharmaceuticals, Gilead, GlaxoSmithKline,
Horizons Pharmaceuticals, Inter-cure, Merck, Novartis, Pfizer, Sankyo,
Sanofi Aventis, Sanofi-Synthelabo, Servier, and Takeda; has received
honoraria from Biovail, Boehringer Ingelheim, Bristol-Myers Squibb, CV
Therapeutics, Forest Laboratories, Merck, Novartis, Pfizer,
Sanofi-Synthelabo, and Servier; and has had grants/contracts with
Pfizer. William C. Cushman has consulted for Abbott Laboratories,
Bristol-Myers Squibb, Calpis, Daiichi Sankyo, Forest Pharmaceuticals,
Gilead Colorado, Johnson and Johnson, King, Myogen, Novartis, Pfizer,
Pharmacopeia, Reddy Pharmaceuticals, Roche, Sankyo, Sanofi Aventis,
Sanofi-Synthelabo, Sciele, Takeda, and Theravance; has received
honoraria from Abbott Laboratories, AstraZeneca, Boehringer Ingelheim,
Bristol-Myers Squibb, Forest Pharmaceuticals, King, and Novartis and has
had grants/contracts with Abbott Laboratories, Biovail, King, and
Novartis. Barry R. Davis has consulted for BioMarin, Forest
Pharmaceuticals, GlaxoSmithKline, Merck, Proctor and Gamble, and Takeda;
and has held a financial interest in Amgen. Charles E. Ford has
consulted for BioMarin. Richard H. Grimm, Jr has consulted for Calpis,
Merck, Merck/SP, Novartis, Pfizer, and Takeda; has received honoraria
from AstraZeneca, Merck, Novartis, and Takeda; and has had
grants/contracts with Merck, Novartis, and Pfizer. Bruce P. Hamilton has
had grants/contracts with GlaxoSmithKline. L. Julian Haywood has held a
financial interest in Pfizer. Stephen T. Ong has received honoraria from
Novartis; and has had grants/contracts with Abbott Laboratories, Arena,
Daiichi Sankyo, Ferring, Forest Pharmaceutical, Gilead Colorado,
GlaxoSmithKline, Mylan Bertek, Novartis, Pharmacopeia, Roche, Sankyo,
and Sanofi Aventis. Suzanne Oparil has consulted for Boehringer
Ingelheim, Daiichi Sankyo, Eli Lilly, Encysive Pharm, Forest
Pharmaceuticals, GlaxoSmithKline, Merck, NicOx, Novartis, Pfizer, Salt
Institute, Sankyo, Sanofi Aventis, Schering Plough, and SmithKline
Beecham/Glaxo Wellcome; has received honoraria from Boehringer
Ingelheim, Bristol-Myers Squibb, and Encysive Pharm; has had
grants/contracts with Daiichi Sankyo, Eisai Medical Research, Encysive
Pharm, Gilead, Novartis, Pfizer, Sankyo, and Takeda; and has held a
financial interest in Encysive Pharm. Jeffrey L.; Prob-stfield has
consulted for Boehringer Ingelheim, King, and King
Pharmceuticals/Monarch; has received honoraria from Boehringer
Ingelheim; and has had grants/contracts with Boehringer Ingelheim, King,
King Pharmaceuticals/Monarch, KOS, and Sanofi Aventis. Carol Stanford
has held a financial interest in Pfizer. Robert J. Weiss has had
grants/contracts with Forest, Novartis, and Takeda. Jackson T. Wright,
Jr has consulted for Abbott Laboratories, AstraZeneca, Bayer
Corporation, Biovail, CV Therapeutics, CVRx, Daiichi Sankyo, Forest
Pharmaceuticals, GlaxoSmithKline, Merck, NitroMed, Novartis, Pfizer,
Reliant Pharm, Sankyo, Sanofi Aventis, Sanofi-Synthelabo, and SmithKline
Beecham/Glaxo Wellcome; and has had grants/contracts with
GlaxoSmithKline and Novartis. Jeffrey A. Cutler, Paula T. Einhorn, Linda
B. Piller, Sara L. Pressel, Lara M. Simpson, and Paul K. Whelton have no
financial conflicts of interest to report. The NHLBI sponsored the study
and was involved in all aspects other than direct operations of the
study centers. This included collection, analysis, and interpretation of
the data plus the decision to submit the manuscript for publication.
Pfizer Inc, AstraZeneca, and Bristol-Myers Squibb had no role in the
design and conduct of the study, the collection, analysis, and
interpretation of the data or the preparation or approval of the
manuscript. Editorial assistance was provided by Ellen Breckenridge, an
employee of the ALLHAT Collaborative Research Group. The position was
paid for by grant funds provided by the NHLBI for the ALLHAT project.
NR 27
TC 21
Z9 24
U1 2
U2 8
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1524-6175
EI 1751-7176
J9 J CLIN HYPERTENS
JI J. Clin. Hypertens.
PD JAN
PY 2012
VL 14
IS 1
BP 20
EP 31
DI 10.1111/j.1751-7176.2011.00568.x
PG 12
WC Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA 871IV
UT WOS:000298732400006
PM 22235820
ER
PT J
AU Kearney, DJ
McDermott, K
Malte, C
Martinez, M
Simpson, TL
AF Kearney, David J.
McDermott, Kelly
Malte, Carol
Martinez, Michelle
Simpson, Tracy L.
TI Association of participation in a mindfulness program with measures of
PTSD, depression and quality of life in a veteran sample
SO JOURNAL OF CLINICAL PSYCHOLOGY
LA English
DT Article
DE mindfulness; posttraumatic stress disorder; acceptance; depression;
meditation
ID POSTTRAUMATIC-STRESS-DISORDER; PROSTATE-CANCER OUTPATIENTS; NATIONAL
COMORBIDITY SURVEY; BEHAVIORAL ACTIVATION; REDUCTION PROGRAM; COGNITIVE
THERAPY; SEXUAL TRAUMA; SCALE BADS; SYMPTOMS; MEDITATION
AB Objectives: To assess outcomes of veterans who participated in mindfulness-based stress reduction (MBSR). Design: Posttraumatic stress disorder (PTSD) symptoms, depression, functional status, behavioral activation, experiential avoidance, and mindfulness were assessed at baseline, and 2 and 6 months after enrollment. Results: At 6 months, there were significant improvements in PTSD symptoms (standardized effect size, d = -0.64, p< 0.001); depression (d = -0.70, p<0.001); behavioral activation (d = 0.62, p<0.001); mental component summary score of the Short Form-8 (d = 0.72, p<0.001); acceptance (d = 0.67, p<0.001); and mindfulness (d = 0.78, p<0.001), and 47.7% of veterans had clinically significant improvements in PTSD symptoms. Conclusions: MBSR shows promise as an intervention for PTSD and warrants further study in randomized controlled trials. (c) 2011 Wiley Periodicals, Inc. J Clin Psychol 68:116, 2012.
C1 [Kearney, David J.; McDermott, Kelly; Malte, Carol; Martinez, Michelle; Simpson, Tracy L.] VA Puget Sound Hlth Care Syst, Seattle, WA USA.
RP Kearney, DJ (reprint author), Seattle VAMC 111GI,1660 S Columbian Way, Seattle, WA 98108 USA.
EM david.kearney@va.gov
RI Schueter, nicos/A-3625-2014
NR 59
TC 72
Z9 72
U1 3
U2 55
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0021-9762
J9 J CLIN PSYCHOL
JI J. Clin. Psychol.
PD JAN
PY 2012
VL 68
IS 1
BP 101
EP 116
DI 10.1002/jclp.20853
PG 16
WC Psychology, Clinical
SC Psychology
GA 865HE
UT WOS:000298301000009
PM 22125187
ER
PT J
AU Li, Y
Rimbara, E
Thirumurthi, S
Trespalacios, A
Reddy, R
Sabounchi, S
Attumi, TA
Graham, DY
AF Li, Yuan
Rimbara, Emiko
Thirumurthi, Selvi
Trespalacios, Alba
Reddy, Rita
Sabounchi, Saman
Attumi, Taraq Assed
Graham, David Yates
TI Detection of clarithromycin resistance in Helicobacter pylori following
noncryogenic storage of rapid urease tests for 30 days
SO JOURNAL OF DIGESTIVE DISEASES
LA English
DT Article
DE clarithromycin resistance; Helicobacter pylori; noncryogenic storage;
polymerase chain reaction; rapid urease test; susceptibility test
ID POLYMERASE-CHAIN-REACTION; 23S RIBOSOMAL-RNA; ANTIBIOTIC-RESISTANCE;
BIOPSY SPECIMENS; GASTRIC TISSUE; INFECTION; SUSCEPTIBILITY;
POLYMORPHISM; PREVALENCE; MUTATIONS
AB OBJECTIVE: Traditional Helicobacter pylori (H. pylori) eradication therapy has been undermined by increasing antimicrobial, especially clarithromycin, resistance. Susceptibility testing in some areas is difficult to achieve or unavailable. We aimed to determine whether gastric biopsy specimens stored at room temperature for rapid urease test (RUT) were suitable for clarithromycin susceptibility testing of H. pylori.
METHODS: After 30 days of storage at room temperature, DNA was extracted from gastric biopsies present in RUTs (Hpfast). H. pylori status and clarithromycin susceptibility were evaluated using H. pylori- specific polymerase chain reaction (PCR) for ureA, vacA, and allele- specific primer- PCR of the 23S rRNA genes. The PCR results were compared with histology, RUT, and culture results. H. pylori positive was defined as RUT and either culture or histology positive; H. pylori negative as RUT, culture and histology negative.
RESULTS: Samples from 31 patients were evaluated; 11 were H. pylori positive including 9 by culture; seven of which had allele- specific primer- PCR results from the RUT specimen for the detection of mutations of the 23S rRNA gene. When both tests were available, culture and PCR results were concordant in 7 cases. In 15 of the 20 histology, RUT and culture negative patients, three PCR were negative. In one patient, all of the three tests were positive; and in three only the 23S rRNA was positive and in one only ureA was positive.
CONCLUSION: Gastric biopsy specimens stored in the gel of RUT for 30 days can be used for molecular testing to confirm the diagnosis of H. pylori infection and test for clarithromycin susceptibility.
C1 [Li, Yuan; Rimbara, Emiko; Thirumurthi, Selvi; Trespalacios, Alba; Reddy, Rita; Sabounchi, Saman; Attumi, Taraq Assed; Graham, David Yates] Baylor Coll Med, Ben Taub Gen Hosp, Dept Med, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA.
RP Graham, DY (reprint author), Baylor Coll Med, Dept Med, Michael E DeBakey Vet Affairs, Affairs Med Ctr, 2002 Holcombe Blvd, Houston, TX 77030 USA.
EM dgraham@bcm.edu
RI Rimbara, Emiko/F-4113-2017
OI Rimbara, Emiko/0000-0001-8847-1840
FU Office of Research and Development Medical Research Service, Department
of Veterans Affairs, Public Health Service [DK56338]; Texas Medical
Center Digestive Diseases Center [DK067366, CA116845]
FX Dr GRAHAM is supported in part by the Office of Research and Development
Medical Research Service, Department of Veterans Affairs, Public Health
Service grant DK56338 which funds the Texas Medical Center Digestive
Diseases Center, DK067366 and CA116845. The contents are solely the
responsibility of the authors and do not necessarily represent the
official views of the Veterans Affairs or National Institutes of Health.
Dr GRAHAM is an unpaid consultant for Novartis in relation to vaccine
development for the treatment or prevention of H. pylori infection. Dr
GRAHAM is also a paid consultant for Otsuka Pharmaceuticals regarding
diagnostic testing and has received royalties on the Baylor College of
Medicine patent covering materials related to the 13C-urea
breath test. The other authors have nothing to declare.
NR 21
TC 8
Z9 9
U1 1
U2 2
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1751-2972
J9 J DIGEST DIS
JI J. Dig. Dis.
PD JAN
PY 2012
VL 13
IS 1
BP 54
EP 59
DI 10.1111/j.1751-2980.2011.00549.x
PG 6
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 867UK
UT WOS:000298480100009
PM 22188917
ER
PT J
AU Burks, DJ
Robbins, R
AF Burks, Derek J.
Robbins, Rockey
TI Psychologists' Authenticity: Implications for Work in Professional and
Therapeutic Settings
SO JOURNAL OF HUMANISTIC PSYCHOLOGY
LA English
DT Article
DE authenticity; genuineness; humanistic psychotherapy; therapeutic
relationship
ID QUALITATIVE RESEARCH; CONCEPTUALIZATION
AB Psychologists engage in a multitude of social roles of varying degrees of emotionality, subjectivity, and objectivity because of the nature of their profession as well as their unique backgrounds that have drawn them to that profession. This study sought to understand how psychologists recognize and experience the concept of authenticity in the context of their professional lives. A purposeful sample of 17 clinical psychologists from metropolitan areas in the Southwest and the Pacific Northwest were interviewed. Using a phenomenological, qualitative research design, 262 significant statements were extracted and grouped together, resulting in 11 emergent themes specifically relating to a therapeutic, health care context. Rigor and thoroughness were achieved via multiple validation procedures. Psychologists defined authenticity as the matching of one's inner thoughts, beliefs, and feelings with one's outer presentation and behaviors. They believed that authenticity involves sensory and emotional qualities rather than purely cognitive or verbal qualities. Concepts of self-disclosure and mindful awareness were discussed as related to authenticity. It is of note that both humanistic and nonhumanistically inclined psychologists equally valued authenticity in the professional and therapeutic setting. Participants also discussed how authenticity and inauthenticity are experienced and modified in the therapeutic relationship, as well as the negative effects of inauthenticity in professional contexts.
C1 [Robbins, Rockey] Univ Oklahoma, Coll Educ, Norman, OK 73019 USA.
RP Burks, DJ (reprint author), Portland VA Med Ctr, P3MIRECC,POB 1034, Portland, OR 97207 USA.
EM derek.burks@va.gov
NR 41
TC 2
Z9 4
U1 1
U2 10
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0022-1678
J9 J HUMANIST PSYCHOL
JI J. Humanist. Psychol.
PD JAN
PY 2012
VL 52
IS 1
BP 75
EP 104
DI 10.1177/0022167810381472
PG 30
WC Psychology, Multidisciplinary
SC Psychology
GA 868YR
UT WOS:000298563000005
ER
PT J
AU Grobman, LE
Wu, DY
Dong, DZ
Wu, PC
AF Grobman, L. E.
Wu, D. Y.
Dong, D. Z.
Wu, P. C.
TI THE ROLE OF COXSACKIE-ADENOVIRUS RECEPTOR AS A SENESCENCE BIOMARKER
DURING RECTAL CANCER TREATMENT
SO JOURNAL OF INVESTIGATIVE MEDICINE
LA English
DT Meeting Abstract
CT Western Regional Meeting
CY JAN 25-28, 2012
CL Carmel, CA
C1 [Grobman, L. E.; Wu, D. Y.; Wu, P. C.] Univ Washington, Seattle, WA 98195 USA.
[Wu, D. Y.; Dong, D. Z.; Wu, P. C.] VA Puget Sound, Seattle, WA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1081-5589
J9 J INVEST MED
JI J. Invest. Med.
PD JAN
PY 2012
VL 60
IS 1
BP 148
EP 148
PG 1
WC Medicine, General & Internal; Medicine, Research & Experimental
SC General & Internal Medicine; Research & Experimental Medicine
GA 869XV
UT WOS:000298634401081
ER
PT J
AU MIller, M
Knaub, L
Reusch, JE
AF MIller, M.
Knaub, L.
Reusch, J. E.
TI ATTENUATION OF ACUTE EXERCISE-INDUCED MITOCHONDRIAL BIOGENESIS AND
OXIDANT DEFENSE IN A MODEL OF INSULIN RESISTANT DIABETES
SO JOURNAL OF INVESTIGATIVE MEDICINE
LA English
DT Meeting Abstract
CT Western Regional Meeting
CY JAN 25-28, 2012
CL Carmel, CA
C1 [MIller, M.; Knaub, L.; Reusch, J. E.] Univ Colorado, Sch Med, Aurora, CO USA.
[Reusch, J. E.] Denver VA Med Ctr, Denver, CO USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1081-5589
J9 J INVEST MED
JI J. Invest. Med.
PD JAN
PY 2012
VL 60
IS 1
BP 176
EP 176
PG 1
WC Medicine, General & Internal; Medicine, Research & Experimental
SC General & Internal Medicine; Research & Experimental Medicine
GA 869XV
UT WOS:000298634401178
ER
PT J
AU Hartvigson, PE
Erikson, MA
Banks, WA
AF Hartvigson, P. E.
Erikson, M. A.
Banks, W. A.
TI SYSTEMIC INFLAMMATION INHIBITS LOW-DENSITY LIPOPROTEIN RECEPTOR-RELATED
PROTEIN-1 MEDIATED CLEARANCE OF AMYLOID-beta FROM BLOOD: IMPLICATIONS
FOR ALZHEIMER'S DISEASE
SO JOURNAL OF INVESTIGATIVE MEDICINE
LA English
DT Meeting Abstract
CT Western Regional Meeting
CY JAN 25-28, 2012
CL Carmel, CA
C1 [Hartvigson, P. E.; Erikson, M. A.; Banks, W. A.] VA Puget Sound Hlth Care Syst, Seattle, WA USA.
[Hartvigson, P. E.; Banks, W. A.] Univ Washington, Sch Med, Seattle, WA USA.
[Erikson, M. A.] St Louis Univ, St Louis, MO 63103 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1081-5589
J9 J INVEST MED
JI J. Invest. Med.
PD JAN
PY 2012
VL 60
IS 1
BP 240
EP 240
PG 1
WC Medicine, General & Internal; Medicine, Research & Experimental
SC General & Internal Medicine; Research & Experimental Medicine
GA 869XV
UT WOS:000298634401409
ER
PT J
AU Obioha, O
Bassett, J
Saigal, C
Bennett, C
AF Obioha, O.
Bassett, J.
Saigal, C.
Bennett, C.
TI DISSEMINATION OF TOBACCO CONTROL GUIDELINES TO A SPECIALTY CARE SETTING:
A UROLOGIC PERSPECTIVE
SO JOURNAL OF INVESTIGATIVE MEDICINE
LA English
DT Meeting Abstract
CT Western Regional Meeting
CY JAN 25-28, 2012
CL Carmel, CA
C1 [Obioha, O.; Bassett, J.; Saigal, C.; Bennett, C.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
[Bassett, J.; Saigal, C.; Bennett, C.] W Los Angeles VA Hosp, Los Angeles, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1081-5589
J9 J INVEST MED
JI J. Invest. Med.
PD JAN
PY 2012
VL 60
IS 1
BP 244
EP 245
PG 2
WC Medicine, General & Internal; Medicine, Research & Experimental
SC General & Internal Medicine; Research & Experimental Medicine
GA 869XV
UT WOS:000298634401424
ER
PT J
AU Bains, S
Egede, LE
AF Bains, S.
Egede, L. E.
TI ASSOCIATIONS BETWEEN HEALTH LITERACY AND PREVENTATIVE CARE BEHAVIOR:
ANALYSIS OF A NATIONAL SAMPLE
SO JOURNAL OF INVESTIGATIVE MEDICINE
LA English
DT Meeting Abstract
CT Western Regional Meeting
CY JAN 25-28, 2012
CL Carmel, CA
C1 [Bains, S.; Egede, L. E.] Med Univ S Carolina, Charleston, SC 29425 USA.
[Egede, L. E.] Ralph H Johnson VAMC, Charleston, SC USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1081-5589
J9 J INVEST MED
JI J. Invest. Med.
PD JAN
PY 2012
VL 60
IS 1
BP 353
EP 353
PG 1
WC Medicine, General & Internal; Medicine, Research & Experimental
SC General & Internal Medicine; Research & Experimental Medicine
GA 869XV
UT WOS:000298634402152
ER
PT J
AU Vasquez, K
Wagner, BT
AF Vasquez, K.
Wagner, B. T.
TI NEPHROGENIC SYSTEMIC FIBROSIS: THE CONTRIBUTION OF BONE MARROW-DERIVED
FIBROCYTES TO SKIN LESIONS AND ASSOCIATION WITH L-CATHEPSIN
SO JOURNAL OF INVESTIGATIVE MEDICINE
LA English
DT Meeting Abstract
CT Western Regional Meeting
CY JAN 25-28, 2012
CL Carmel, CA
C1 [Vasquez, K.; Wagner, B. T.] S Texas Vet Hlth Care Syst, San Antonio, TX USA.
[Vasquez, K.; Wagner, B. T.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1081-5589
J9 J INVEST MED
JI J. Invest. Med.
PD JAN
PY 2012
VL 60
IS 1
BP 425
EP 425
PG 1
WC Medicine, General & Internal; Medicine, Research & Experimental
SC General & Internal Medicine; Research & Experimental Medicine
GA 869XV
UT WOS:000298634402416
ER
PT J
AU Billue, K
Safford, M
Salanitro, A
Houston, T
Curry, W
Kim, Y
Allison, J
Estrada, C
AF Billue, K.
Safford, M.
Salanitro, A.
Houston, T.
Curry, W.
Kim, Y.
Allison, J.
Estrada, C.
TI DIABETES MEDICATION INTENSIFICATION IN RURAL PRIMARY CARE PRACTICES: A
CLUSTER-RANDOMIZED EFFECTIVENESS TRIAL
SO JOURNAL OF INVESTIGATIVE MEDICINE
LA English
DT Meeting Abstract
CT Western Regional Meeting
CY JAN 25-28, 2012
CL Carmel, CA
C1 [Billue, K.; Safford, M.; Salanitro, A.; Curry, W.; Kim, Y.; Estrada, C.] Univ Alabama, Birmingham, AL USA.
[Estrada, C.] Birmingham VAMC, Birmingham, AL USA.
[Houston, T.; Allison, J.] Univ Massachusetts, Sch Med, Worcester, MA USA.
RI Houston, Thomas/F-2469-2013
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1081-5589
J9 J INVEST MED
JI J. Invest. Med.
PD JAN
PY 2012
VL 60
IS 1
BP 460
EP 461
PG 2
WC Medicine, General & Internal; Medicine, Research & Experimental
SC General & Internal Medicine; Research & Experimental Medicine
GA 869XV
UT WOS:000298634402541
ER
PT J
AU Bains, S
Egede, LE
AF Bains, S.
Egede, L. E.
TI DEMOGRAPHIC, GEOGRAPHIC AND LANGUAGE PREDICTORS OF HEALTH LITERACY:
ANALYSIS OF THE 2003 NATIONAL ASSESSMENT OF ADULT LITERACY SURVEY
SO JOURNAL OF INVESTIGATIVE MEDICINE
LA English
DT Meeting Abstract
CT Western Regional Meeting
CY JAN 25-28, 2012
CL Carmel, CA
C1 [Bains, S.; Egede, L. E.] Med Univ S Carolina, Charleston, SC 29425 USA.
[Egede, L. E.] Ralph H Johnson VAMC, Charleston, SC USA.
NR 0
TC 0
Z9 0
U1 1
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1081-5589
J9 J INVEST MED
JI J. Invest. Med.
PD JAN
PY 2012
VL 60
IS 1
BP 463
EP 463
PG 1
WC Medicine, General & Internal; Medicine, Research & Experimental
SC General & Internal Medicine; Research & Experimental Medicine
GA 869XV
UT WOS:000298634402551
ER
PT J
AU Newsom, J
Taylor, B
AF Newsom, J.
Taylor, B.
TI CAN MEDICAL TEAM MEMBERS PREDICT 30-DAY READMISSION RISK ON ADMISSION?
SO JOURNAL OF INVESTIGATIVE MEDICINE
LA English
DT Meeting Abstract
CT Western Regional Meeting
CY JAN 25-28, 2012
CL Carmel, CA
C1 [Newsom, J.; Taylor, B.] Univ Alabama, Birmingham, AL USA.
[Newsom, J.; Taylor, B.] Birmingham VA Med Ctr, Birmingham, AL USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1081-5589
J9 J INVEST MED
JI J. Invest. Med.
PD JAN
PY 2012
VL 60
IS 1
BP 463
EP 464
PG 2
WC Medicine, General & Internal; Medicine, Research & Experimental
SC General & Internal Medicine; Research & Experimental Medicine
GA 869XV
UT WOS:000298634402552
ER
PT J
AU Newsom, J
Kraemer, R
Estrada, C
Morris, J
Willett, L
AF Newsom, J.
Kraemer, R.
Estrada, C.
Morris, J.
Willett, L.
TI EXTERNAL VALIDATION OF A CLINICAL VIGNETTE SCORING TOOL
SO JOURNAL OF INVESTIGATIVE MEDICINE
LA English
DT Meeting Abstract
CT Western Regional Meeting
CY JAN 25-28, 2012
CL Carmel, CA
C1 [Newsom, J.; Kraemer, R.; Estrada, C.; Morris, J.; Willett, L.] Univ Alabama, Birmingham, AL USA.
[Newsom, J.; Estrada, C.] Birmingham VA Med Ctr, Birmingham, AL USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1081-5589
J9 J INVEST MED
JI J. Invest. Med.
PD JAN
PY 2012
VL 60
IS 1
BP 464
EP 464
PG 1
WC Medicine, General & Internal; Medicine, Research & Experimental
SC General & Internal Medicine; Research & Experimental Medicine
GA 869XV
UT WOS:000298634402553
ER
PT J
AU Kertesz, S
Steward, J
Johnson, N
Pollio, D
Holt, C
Austin, E
Gordon, A
Stringfellow, E
Granstaff, U
AF Kertesz, S.
Steward, J.
Johnson, N.
Pollio, D.
Holt, C.
Austin, E.
Gordon, A.
Stringfellow, E.
Granstaff, U.
TI COMPARISON OF CUSTOMIZED VERSUS MAINSTREAM PRIMARY CARE FOR HOMELESS
INDIVIDUALS: THE PRIMARY CARE QUALITY-HOMELESS SURVEY
SO JOURNAL OF INVESTIGATIVE MEDICINE
LA English
DT Meeting Abstract
CT Western Regional Meeting
CY JAN 25-28, 2012
CL Carmel, CA
C1 [Kertesz, S.; Johnson, N.; Austin, E.; Granstaff, U.] Birmingham VAMC, Birmingham, AL USA.
[Kertesz, S.; Steward, J.] Univ Alabama, Birmingham, AL USA.
[Pollio, D.] Univ Alabama, Tuscaloosa, AL USA.
[Holt, C.] Univ Maryland, Baltimore, MD 21201 USA.
[Gordon, A.] Pittsburgh VAMC, Pittsburgh, PA USA.
[Stringfellow, E.] Boston HCH, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1081-5589
J9 J INVEST MED
JI J. Invest. Med.
PD JAN
PY 2012
VL 60
IS 1
BP 465
EP 465
PG 1
WC Medicine, General & Internal; Medicine, Research & Experimental
SC General & Internal Medicine; Research & Experimental Medicine
GA 869XV
UT WOS:000298634402556
ER
PT J
AU Potter, RM
Harikumar, KG
Wu, SV
Miller, LJ
AF Potter, Ross M.
Harikumar, Kaleeckal G.
Wu, S. Vincent
Miller, Laurence J.
TI Differential sensitivity of types 1 and 2 cholecystokinin receptors to
membrane cholesterol
SO JOURNAL OF LIPID RESEARCH
LA English
DT Article
DE receptor binding; biological activity; chimeric receptors; G
protein-coupled receptors; perfringolysin
ID PROTEIN-COUPLED RECEPTOR; PERFRINGOLYSIN-O; BETA(2)-ADRENERGIC RECEPTOR;
CANNABINOID RECEPTORS; INTRACELLULAR LOOP; HUMAN GALLBLADDERS;
PLASMA-MEMBRANE; LIGAND-BINDING; CCK RECEPTOR; II-RECEPTOR
AB Recent studies indicate that membrane cholesterol can associate with G protein-coupled receptors (GPCRs) and affect their function. Previously, we reported that manipulation of membrane cholesterol affects ligand binding and signal transduction of the type 1 cholecystokinin receptor (CCK1R), a Class A GPCR. We now demonstrate that the closely related type 2 cholecystokinin receptor (CCK2R) does not share this cholesterol sensitivity. The sequences of both receptors reveal almost identical cholesterol interaction motifs in analogous locations in transmembrane segments two, three, four, and five. The disparity in cholesterol sensitivity between these receptors, despite their close structural relationship, provides a unique opportunity to define the possible structural basis of cholesterol sensitivity of CCK1R. To evaluate the relative contributions of different regions of CCK1R to cholesterol sensitivity, we performed ligand binding studies and biological activity assays of wildtype and CCK2R/CCK1R chimeric receptor-bearing Chinese hamster ovary cells after manipulation of membrane cholesterol. We also extended these studies to site-directed mutations within the cholesterol interaction motifs. The results contribute to a better understanding of the structural requirements for cholesterol sensitivity in CCK1R and provides insight into the function of other cholesterol-sensitive Class A GPCRs.-Potter, R.M., K.G. Harikumar, S.V. Wu, and L.J. Miller. Differential sensitivity of types 1 and 2 cholecystokinin receptors to membrane cholesterol. J. Lipid Res. 2012. 53: 137-148.
C1 [Potter, Ross M.; Harikumar, Kaleeckal G.; Miller, Laurence J.] Mayo Clin, Dept Mol Pharmacol & Expt Therapeut, Scottsdale, AZ 85259 USA.
[Wu, S. Vincent] Vet Adm Greater Los Angeles Healthcare Syst, Dept Med, Los Angeles, CA 90073 USA.
RP Miller, LJ (reprint author), Mayo Clin, Dept Mol Pharmacol & Expt Therapeut, Scottsdale, AZ 85259 USA.
EM miller@mayo.edu
FU National Institutes of Health [DK-32878]; Mayo Clinic
FX This work was supported by Grant DK-32878 from the National Institutes
of Health and by the Mayo Clinic-Kinney Career Development Award. Its
contents are solely the responsibility of the authors and do not
necessarily represent the official views of the National Institutes of
Health or other granting agencies.
NR 62
TC 17
Z9 17
U1 0
U2 8
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0022-2275
J9 J LIPID RES
JI J. Lipid Res.
PD JAN
PY 2012
VL 53
IS 1
BP 137
EP 148
DI 10.1194/jlr.M020065
PG 12
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 866TI
UT WOS:000298405900014
PM 22021636
ER
PT J
AU Eatesam, M
Noworolski, SM
Tien, PC
Nystrom, M
Dodge, JL
Merriman, RB
Qayyum, A
AF Eatesam, Mamak
Noworolski, Susan M.
Tien, Phyllis C.
Nystrom, Michelle
Dodge, Jennifer L.
Merriman, Raphael B.
Qayyum, Aliya
TI Liver diffusivity in healthy volunteers and patients with chronic liver
disease: Comparison of breathhold and free-breathing techniques
SO JOURNAL OF MAGNETIC RESONANCE IMAGING
LA English
DT Article
DE diffusion-weighted imaging (DWI); breathhold (BH); free-breathing (FB);
nonalcoholic fatty liver disease (NAFLD); hepatitis C (HCV)
ID WOMENS INTERAGENCY HIV; WEIGHTED MRI; FIBROSIS; COEFFICIENT; EXPERIENCE;
DIAGNOSIS; CIRRHOSIS; REPRODUCIBILITY; PARAMETERS; HEPATITIS
AB Purpose: To compare liver ADC obtained with breathhold and free-breathing diffusion weighted imaging (DWI) in healthy volunteers and patients with liver disease.
Materials and Methods: Twenty-eight subjects, 12 healthy volunteers and 16 patients (9 NAFLD, 7 chronic active HCV), underwent breathhold (BH) and free-breathing (FB) DWI MRI at 1.5 Tesla. Pearson's correlation coefficient was used to determine correlation while paired t-tests assessed differences between BH and FB ADC. Estimated bias was calculated using the Bland-Altman method.
Results: Liver ADC (x10(-3) mm(2)/s) was lower on BH for all groups (mean difference 0.36 +/- 0.20; P < 0.01). ADC was higher in healthy volunteers (BH 1.80 +/- 0.18; FB 2.24 +/- 0.20) compared with NAFLD patients (BH 1.43 +/- 0.27; FB 1.78 +/- 0.28) (P < 0.001) and HCV patients (BH 1.63 +/- 0.191; FB 1.88 +/- 0.12). Overall correlation between BH and FB ADC was (r = 0.75), greatest in NAFLD (r = 0.90) compared with the correlation in HCV (r = 0.24) and healthy subjects (r = 0.34). Bland-Altman plots did not show agreement in mean absolute difference and estimated bias between subjects.
Conclusion: Correlation between BH and FB liver ADC is moderate indicating that BH and FB should not be used interchangeably. Additionally, the lower ADC values in BH versus FB should be accounted for when comparing different liver DWI studies.
C1 [Eatesam, Mamak; Noworolski, Susan M.; Nystrom, Michelle; Qayyum, Aliya] Univ Calif San Francisco, Dept Radiol & Biomed Imaging, San Francisco, CA 94143 USA.
[Noworolski, Susan M.] Univ Calif San Francisco & Berkeley, Grad Grp Bioengn, Berkeley, CA USA.
[Tien, Phyllis C.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA.
[Tien, Phyllis C.] San Francisco VA Med Ctr, Med Serv, San Francisco, CA USA.
[Dodge, Jennifer L.] Univ Calif San Francisco, Dept Internal Med, Fresno Med Educ Program, San Francisco, CA 94143 USA.
[Merriman, Raphael B.] Calif Pacific Med Ctr, Dept Med, San Francisco, CA USA.
RP Qayyum, A (reprint author), Univ Calif San Francisco, Dept Radiol & Biomed Imaging, Box 0628,M-372,505 Parnassus Ave, San Francisco, CA 94143 USA.
EM aliya.qayyum@radiology.ucsf.edu
FU NIH [K23 AI-66943, UO1 AI-34989, MO1-RR-00083, R01 DK061738-SI, R01
DK074718-01]; National Institute of Allergy and Infectious Diseases
[UO1-AI-35004, UO1-AI-31834, UO1-AI-34994, UO1-AI-34989, UO1-AI-34993,
UO1-AI-42590]; National Institute of Child Health and Human Development
[UO1-HD-32632]; National Cancer Institute; National Institute on Drug
Abuse; National Institute on Deafness and Other Communication Disorders;
National Center for Research Resources (UCSF-CTSI) [UL1 RR024131]; UCSF
FX Contract grant sponsor: NIH; Contract grant number: K23 AI-66943, UO1
AI-34989, MO1-RR-00083, R01 DK061738-SI, R01 DK074718-01; Contract grant
sponsor: National Institute of Allergy and Infectious Diseases; Contract
grant number: UO1-AI-35004, UO1-AI-31834, UO1-AI-34994, UO1-AI-34989,
UO1-AI-34993, UO1-AI-42590; Contract grant sponsor: National Institute
of Child Health and Human Development; Contract grant number:
UO1-HD-32632; Contract grant sponsor: National Cancer Institute;
Contract grant sponsor: National Institute on Drug Abuse; Contract grant
sponsor: National Institute on Deafness and Other Communication
Disorders; Contract grant sponsor: National Center for Research
Resources (UCSF-CTSI); Contract grant number: UL1 RR024131; Contract
grant sponsor: UCSF Hellman Family Award.
NR 30
TC 3
Z9 4
U1 0
U2 3
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1053-1807
J9 J MAGN RESON IMAGING
JI J. Magn. Reson. Imaging
PD JAN
PY 2012
VL 35
IS 1
BP 103
EP 109
DI 10.1002/jmri.22748
PG 7
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA 862LT
UT WOS:000298093200011
PM 22034200
ER
PT J
AU Baer, JS
Carpenter, KM
Beadnell, B
Stoner, SA
Ingalsbe, MH
Hartzler, B
Rosengren, DB
Drager, Z
AF Baer, John S.
Carpenter, Kelly M.
Beadnell, Blair
Stoner, Susan A.
Ingalsbe, Michelle Hansten
Hartzler, Bryan
Rosengren, David B.
Drager, Zach
TI Computer Assessment of Simulated Patient Interviews (CASPI):
Psychometric Properties of a Web-Based System for the Assessment of
Motivational Interviewing Skills
SO JOURNAL OF STUDIES ON ALCOHOL AND DRUGS
LA English
DT Article
ID VIDEO ASSESSMENT; CLINICIAN; COMPETENCE; VALIDITY; RELIABILITY;
VALIDATION; ADDICTION; BEHAVIOR; SCALE; VASE
AB Objective: Benefits of empirically supported interventions hinge on clinician skill, particularly for motivational interviewing (MI). Existing MI skill assessments are limited with respect to validity (e.g., self-report) and practicality (e.g., coding session tapes). To address these limitations, we developed and evaluated two versions of a web-based assessment of MI skills, the Computer Assessment of Simulated Patient Interviews (CASPI). Method: Ninety-six counselors from the community and 24 members of the Motivational Interviewing Network of Trainers (MINT) completed the CASPI (N = 120), in which they verbally responded via microphones to video clips comprising three 9-item vignettes. Three coders used an emergent coding scheme, which was compared with alternative MI skills measures. Results: CASPI demonstrated excellent internal consistency when averaging across two or three vignettes (alpha's = .86.89). Intraclass correlations were above 40 for most items. Confirmatory factor analyses supported a correlated three-factor model: MI-consistent, resistance-engendering, and global change talk orientation rating. Means and factor loadings were invariant across forms (i.e., the two alternative versions of CASPI), and factor loadings were invariant across subgroup (i.e., community counselor or MINT member). Test retest reliability was good for MI-consistent and resistance-engendering scores (r = .74 and .80, respectively) but low for change talk orientation (r = .29) unless coder was taken into account (r = .69). CASPI showed excellent construct and criterion-related validity. Conclusions: CASPI represents a promising method of assessing MI skills. Future studies are needed to establish its performance in real-world contexts. (J. Stud. Alcohol Drugs, 73, 154-164, 2012)
C1 [Baer, John S.] Univ Washington, Dept Psychol, Seattle, WA 98195 USA.
[Baer, John S.; Ingalsbe, Michelle Hansten; Hartzler, Bryan; Rosengren, David B.] Univ Washington, Inst Alcohol & Drug Abuse, Seattle, WA 98195 USA.
[Carpenter, Kelly M.; Stoner, Susan A.; Drager, Zach] Talaria Inc, Seattle, WA USA.
[Beadnell, Blair] Univ Washington, Sch Social Work, Seattle, WA 98195 USA.
[Beadnell, Blair; Rosengren, David B.] Prevent Res Inst, Lexington, KY USA.
RP Baer, JS (reprint author), VA Puget Sound HCS, S-116-ATC,1660 S Columbian Way, Seattle, WA 98108 USA.
EM jsbaer@uw.edu
FU National Institute on Drug Abuse [R42 DA020284]
FX This research was supported by a Small Business Technology Transfer
grant from the National Institute on Drug Abuse (R42 DA020284).
NR 24
TC 4
Z9 4
U1 0
U2 2
PU ALCOHOL RES DOCUMENTATION INC CENT ALCOHOL STUD RUTGERS UNIV
PI PISCATAWAY
PA C/O DEIRDRE ENGLISH, 607 ALLISON RD, PISCATAWAY, NJ 08854-8001 USA
SN 1937-1888
J9 J STUD ALCOHOL DRUGS
JI J. Stud. Alcohol Drugs
PD JAN
PY 2012
VL 73
IS 1
BP 154
EP 164
PG 11
WC Substance Abuse; Psychology
SC Substance Abuse; Psychology
GA 873QP
UT WOS:000298898400020
PM 22152673
ER
PT J
AU Klein, AA
Slaymaker, VJ
Dugosh, KL
Mckay, JR
AF Klein, Audrey A.
Slaymaker, Valerie J.
Dugosh, Karen L.
Mckay, James R.
TI Computerized continuing care support for alcohol and drug dependence: A
preliminary analysis of usage and outcomes
SO JOURNAL OF SUBSTANCE ABUSE TREATMENT
LA English
DT Article
DE Alcohol dependence; Drug dependence; Continuing care; Computer based;
Residential treatment
ID RANDOMIZED CONTROLLED-TRIAL; COGNITIVE-BEHAVIORAL THERAPY; ASSISTED
INTERVENTION; PROBLEM DRINKERS; CLINICAL-TRIAL; DIABETES CARE;
FOLLOW-UP; RELIABILITY; PROGRAM; INSTRUMENT
AB The central aim of this administrative data analysis was to examine usage of a Web-based disease management program designed to provide continuing recovery support to patients discharged from residential drug and alcohol treatment. Tailored clinical content was delivered in a multimedia format over the course of 18 months posttreatment. The program also included access to a recovery coach across the 18 months. Consistent with other disease management programs, program usage decreased over time. A small subsample of patients accessed a large number of program modules in the year following treatment; these patients had significantly higher abstinence rates and consumed less alcohol than patients accessing few or no modules. Regression analyses revealed a significant relationship between the number of modules accessed and substance use outcomes in the year following treatment when controlling for motivation, self-efficacy, and pretreatment substance use. Limiting the analyses to only the more compliant patients did not reduce the magnitude of these effects. These preliminary results suggest that computerized support programs may be beneficial to patients recently treated for drug and alcohol issues. Methods to increase program engagement need additional study. (C) 2012 Elsevier Inc. All rights reserved.
C1 [Klein, Audrey A.; Slaymaker, Valerie J.] Hazelden Fdn, Butler Ctr Res, Ctr City, MN 55012 USA.
[Dugosh, Karen L.] Treatment Res Inst, Philadelphia, PA USA.
[Mckay, James R.] Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA.
[Mckay, James R.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA.
RP Klein, AA (reprint author), Hazelden Fdn, Butler Ctr Res, POB 11,BC-4, Ctr City, MN 55012 USA.
EM aklein@hazelden.org
NR 27
TC 14
Z9 15
U1 0
U2 9
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0740-5472
J9 J SUBST ABUSE TREAT
JI J. Subst. Abus. Treat.
PD JAN
PY 2012
VL 42
IS 1
BP 25
EP 34
DI 10.1016/j.jsat.2011.07.002
PG 10
WC Psychology, Clinical; Substance Abuse
SC Psychology; Substance Abuse
GA 860OF
UT WOS:000297956900004
PM 21862275
ER
PT J
AU Brewster, LP
Palmatier, J
Manley, CJ
Hall, DE
Brems, JJ
AF Brewster, Luke P.
Palmatier, Jason
Manley, C. J.
Hall, Daniel E.
Brems, J. J.
TI Limitations on Surrogate Decision-Making for Emergent Liver
Transplantation
SO JOURNAL OF SURGICAL RESEARCH
LA English
DT Article
DE surrogate consent; ethics; fulminant hepatic failure; liver
transplantation
ID RISK-RELATED STANDARDS; INFORMED-CONSENT; OF-LIFE; COMPETENCE; ACCURACY;
PERSPECTIVE; DEBATE; ETHICS; CARE
AB Background. Surrogate consent is an accepted form of promoting patient autonomy when patients cannot consent, but it can lead to surrogate duress and may be unreliable. Since consent for liver transplantation in patients with fulminant hepatic failure (FHF) is typically performed by surrogates and these patients typically regain decisional capacity, we chose this population to query patients' opinion on the surrogate consent process.
Materials and Methods. We developed a questionnaire that queried transplanted patients' experience and opinion on surrogate consent, suitability of surrogates, and return of decisional capacity. This survey was then sent to consecutive survivors of liver transplantation for FHF at our institution.
Results. Eleven of 14 patients eligible to participate completed the questionnaire. The mean follow-up for all survivors was 41 mo, with a range of survival since transplant of 5 mo to 10 y. Although 10/11 respondents agreed with their surrogates to consent to liver transplantation, all 11 patients thought that surrogates should not be able to decline liver transplantation for this condition. In distinction, 3/11 patients believed patients could decline liver transplantation.
Conclusions. This is the first study to demonstrate that liver transplant patients do not think surrogate decision-makers should be permitted to contravene physician recommendations regarding transplant. In clinical settings when patients cannot speak for themselves, it may be appropriate for surrogates and clinicians to act together according to the patients' best interest rather than attempt to determine what the patient would want. This approach might reduce surrogate distress, better represent patient preferences, and improve the decision-making process for affected patients. (C) 2012 Elsevier Inc. All rights reserved.
C1 [Brewster, Luke P.] Emory Univ Hosp, Dept Surg, Atlanta, GA 30322 USA.
[Palmatier, Jason; Manley, C. J.] Loyola Univ, Stritch Sch Med, Maywood, IL 60153 USA.
[Hall, Daniel E.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA.
[Hall, Daniel E.] Univ Pittsburgh, Dept Surg, Med Ctr, Pittsburgh, PA USA.
[Brems, J. J.] Sherman Hosp, Dept Surg, Elgin, IL USA.
RP Brewster, LP (reprint author), Emory Univ Hosp, Dept Surg, 676 N Parkwood Rd, Decatur, GA 30030 USA.
EM lukebrewst@aol.com
RI Hall, Daniel/H-4843-2013
OI Hall, Daniel/0000-0001-6382-0522
NR 31
TC 1
Z9 1
U1 0
U2 1
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0022-4804
J9 J SURG RES
JI J. Surg. Res.
PD JAN
PY 2012
VL 172
IS 1
BP 48
EP 52
DI 10.1016/j.jss.2011.04.042
PG 5
WC Surgery
SC Surgery
GA 864DK
UT WOS:000298217000007
PM 21696773
ER
PT J
AU Mukherjee, R
Snipes, JM
Saunders, SM
Zavadzkas, JA
Spinale, FG
AF Mukherjee, Rupak
Snipes, Jonathan M.
Saunders, Stuart M.
Zavadzkas, Juozas A.
Spinale, Francis G.
TI Discordant Activation of Gene Promoters for Matrix Metalloproteinases
and Tissue Inhibitors of the Metalloproteinases Following Myocardial
Infarction
SO JOURNAL OF SURGICAL RESEARCH
LA English
DT Article
DE matrix metalloproteinase; tissue inhibitor of metalloproteinase;
myocardial infarction; remodeling
ID LEFT-VENTRICULAR ENLARGEMENT; EXTRACELLULAR-MATRIX; HEART-FAILURE;
TRANSCRIPTIONAL REGULATION; TARGETED DELETION; TRANSGENIC MICE; CARDIAC
RUPTURE; EXPRESSION; RAT; INDUCTION
AB Background. Left ventricular (LV) remodeling following myocardial infarction (MI) is associated with increased levels of specific matrix metalloproteinases (MMPs) and relative reduction of endogenous tissue inhibitors of the MMPs (TIMPs). However, transcriptional mechanisms for the disparate post-MI MMP/TIMP expression remain unknown. Using murine constructs designed to report gene promoter activation, this study tested the hypothesis that distinctly different temporal profiles of MMP-2, MMP-9, and TIMP-1 transcription occurs post-MI.
Methods/Results. Transcriptional activity (beta-galactosidase (beta-gal) reporter constructs) of MMP-2 (n = 49), MMP-9 (n = 62), or TIMP-1 (n = 40) was assayed at 1 h (acute), and 1-28 d after MI (coronary ligation) in transgenic reporter mice. At 7 d post-MI, the area of promoter activation normalized to LV area was increased from acute values for MMP-2 (63.4 +/- 5.8 versus 1.1% +/- 1.0%, P < 0.05) and MMP-9 (53.1 +/- 6.1 versus 1.3% +/- 0.9%, P < 0.05). While TIMP-1 promoter activation at 7 d post-MI increased from acute values (3.6 +/- 1.3 versus 0.3% +/- 0.5%, P < 0.05), this increase was smaller than that for MMP-2 or MMP-9 (both P < 0.05). MMP-2 promoter activation peaked in the MI region at 7 d post-MI and MMP-9 promoter activation was highest in the border region at 7 and 14 d post-MI. TIMP-1 promoter activation peaked within the MI region at 7 d post-MI and within the remote region at 14 d post-MI.
Conclusions. These findings provided direct in vivo evidence that discordant changes in temporal and spatial patterns of MMP/TIMP transcription occurs with MI. Restoration of TIMP-1 promoter activation may represent a molecular therapeutic target to attenuate/prevent adverse post-MI LV remodeling. (C) 2012 Elsevier Inc. All rights reserved.
C1 [Mukherjee, Rupak; Snipes, Jonathan M.; Saunders, Stuart M.; Zavadzkas, Juozas A.; Spinale, Francis G.] Med Univ S Carolina, Div Cardiothorac Surg, Charleston, SC 29425 USA.
[Spinale, Francis G.] Ralph H Johnson Vet Adm Med Ctr, Charleston, SC USA.
RP Mukherjee, R (reprint author), Med Univ S Carolina, Div Cardiothorac Surg, Strom Thurmond Res Bldg,770 MUSC Complex,Suite 62, Charleston, SC 29425 USA.
EM mukherr@musc.edu
FU National Institutes of Health [HL-66029, HL-45024, HL-97012,
PO1-HL48788]
FX This study was supported by National Institutes of Health grants
HL-66029 (RM), HL-45024, HL-97012, and PO1-HL48788 (FGS).
NR 36
TC 2
Z9 4
U1 0
U2 3
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0022-4804
J9 J SURG RES
JI J. Surg. Res.
PD JAN
PY 2012
VL 172
IS 1
BP 59
EP 67
DI 10.1016/j.jss.2010.06.015
PG 9
WC Surgery
SC Surgery
GA 864DK
UT WOS:000298217000009
PM 20863528
ER
PT J
AU Yarbrough, WM
Mukherjee, R
Stroud, RE
Rivers, WT
Oelsen, JM
Dixon, JA
Eckhouse, SR
Ikonomidis, JS
Zile, MR
Spinale, FG
AF Yarbrough, William M.
Mukherjee, Rupak
Stroud, Robert E.
Rivers, William T.
Oelsen, J. Marshall
Dixon, Jennifer A.
Eckhouse, Shaina R.
Ikonomidis, John S.
Zile, Michael R.
Spinale, Francis G.
TI Progressive induction of left ventricular pressure overload in a large
animal model elicits myocardial remodeling and a unique matrix signature
SO JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY
LA English
DT Article; Proceedings Paper
CT 91st Annual Meeting of the American-Association-for-Thoracic-Surgery
CY MAY 07-11, 2011
CL Philadelphia, PA
SP Amer Assoc Thorac Surg
ID AORTIC-VALVE-REPLACEMENT; HEART-FAILURE; TISSUE INHIBITOR;
GENE-EXPRESSION; DIASTOLIC DYSFUNCTION; CARDIAC FIBROBLASTS; DEPENDENT
CHANGES; FIBROSIS; HYPERTROPHY; DISEASE
AB Objective: Patients with severe left ventricular pressure overload secondary to aortic stenosis can present with signs and symptoms of heart failure despite normal left ventricular ejection fraction. This process occurs, at least in part, as a result of left ventricular pressure overload-induced extracellular matrix remodeling that promulgates increased left ventricular stiffness and impaired diastolic function. However, the determinants that drive extracellular matrix remodeling in this form of left ventricular pressure overload remain to be fully defined.
Methods: Left ventricular pressure overload was induced in mature pigs (n = 15) by progressive ascending aortic cuff inflation (once per week for 4 weeks), whereby left ventricular mass, left ventricular ejection fraction, and regional myocardial stiffness (rK(m)) were compared with referent controls (n = 12). Determinants of extracellular matrix remodeling were assessed by measuring levels of mRNA expression for fibrillar collagens, matrix metalloproteinases, and tissue inhibitors of matrix metalloproteinase 1 and 4.
Results: With left ventricular pressure overload, left ventricular mass and rK(m) increased by 2- and 3-fold, respectively, compared with control, with no change in left ventricular ejection fraction. Left ventricular myocardial collagen increased approximately 2-fold, which was accompanied by reduced solubility (ie, increased cross-linking) with left ventricular pressure overload, but mRNA expression for fibrillar collagen and matrix metalloproteinases remained relatively unchanged. In contrast, a robust increase in mRNA expression for tissue inhibitors of matrix metalloproteinase-1 and 4 occurred with left ventricular pressure overload.
Conclusions: In a progressive model of left ventricular pressure overload, which recapitulates the phenotype of aortic stenosis, increased extracellular matrix accumulation and subsequently increased myocardial stiffness were not due to increased fibrillar collagen expression but rather to determinants of post-translational control that included increased collagen stability (thereby resistant to matrix metalloproteinase degradation) and increased endogenous matrix metalloproteinase inhibition. Targeting these extracellular matrix post-translational events with left ventricular pressure overload may hold both diagnostic and therapeutic relevance. (J Thorac Cardiovasc Surg 2012;143:215-23)
C1 [Spinale, Francis G.] Univ S Carolina, Sch Med, CBA, Cardiovasc Translat Res Ctr, Columbia, SC 29208 USA.
[Yarbrough, William M.] Sisters Char Providence Hosp, Columbia, SC USA.
[Zile, Michael R.] Med Univ S Carolina, Charleston, SC 29425 USA.
[Mukherjee, Rupak; Stroud, Robert E.; Rivers, William T.; Oelsen, J. Marshall; Dixon, Jennifer A.; Eckhouse, Shaina R.; Ikonomidis, John S.; Spinale, Francis G.] Div Cardiothorac Surg & Adult Cardiol, Charleston, SC USA.
[Zile, Michael R.; Spinale, Francis G.] Ralph H Johnson Vet Adm Med Ctr, Charleston, SC USA.
RP Spinale, FG (reprint author), Univ S Carolina, Sch Med, CBA, Cardiovasc Translat Res Ctr, 6439 Garners Ferry Rd, Columbia, SC 29208 USA.
EM cvctrc@uscmed.sc.edu
FU NHLBI NIH HHS [R01 HL057952-12, HL 57952, HL059165, HL057952, R01
HL095608-03, HL095608, R01 HL057952, R01 HL095608, T32 HL007260, R01
HL059165, R01 HL111090, R01 HL059165-08]
NR 32
TC 20
Z9 21
U1 0
U2 3
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0022-5223
J9 J THORAC CARDIOV SUR
JI J. Thorac. Cardiovasc. Surg.
PD JAN
PY 2012
VL 143
IS 1
BP 215
EP 223
DI 10.1016/j.jtcvs.2011.09.032
PG 9
WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery
SC Cardiovascular System & Cardiology; Respiratory System; Surgery
GA 863GW
UT WOS:000298151800031
PM 22056365
ER
PT J
AU He, JC
Chuang, PY
Ma'ayan, A
Iyengar, R
AF He, John Cijiang
Chuang, Peter Y.
Ma'ayan, Avi
Iyengar, Ravi
TI Systems biology of kidney diseases
SO KIDNEY INTERNATIONAL
LA English
DT Review
DE cell signaling; gene transcription; kidney disease; microarray analysis;
protein interaction
ID HUMAN DIABETIC-NEPHROPATHY; FOCAL SEGMENTAL GLOMERULOSCLEROSIS;
GENOME-WIDE ASSOCIATION; BLOOD-PRESSURE REGULATION; VEGF-A EXPRESSION;
GENE-EXPRESSION; PROTEOMIC ANALYSIS; AFRICAN-AMERICANS; HUMAN URINE;
3-DIMENSIONAL RECONSTRUCTION
AB Kidney diseases manifest in progressive loss of renal function, which ultimately leads to complete kidney failure. The mechanisms underlying the origins and progression of kidney diseases are not fully understood. Multiple factors involved in the pathogenesis of kidney diseases have made the traditional candidate gene approach of limited value toward full understanding of the molecular mechanisms of these diseases. A systems biology approach that integrates computational modeling with large-scale data gathering of the molecular changes could be useful in identifying the multiple interacting genes and their products that drive kidney diseases. Advances in biotechnology now make it possible to gather large data sets to characterize the role of the genome, epigenome, transcriptome, proteome, and metabolome in kidney diseases. When combined with computational analyses, these experimental approaches will provide a comprehensive understanding of the underlying biological processes. Multiscale analysis that connects the molecular interactions and cell biology of different kidney cells to renal physiology and pathology can be utilized to identify modules of biological and clinical importance that are perturbed in disease processes. This integration of experimental approaches and computational modeling is expected to generate new knowledge that can help to identify marker sets to guide the diagnosis, monitor disease progression, and identify new therapeutic targets. Kidney International (2012) 81, 22-39; doi:10.1038/ki.2011.314; published online 31 August 2011
C1 [He, John Cijiang] Mt Sinai Sch Med, Dept Med, Div Nephrol, New York, NY 10029 USA.
[He, John Cijiang; Ma'ayan, Avi; Iyengar, Ravi] Mt Sinai Sch Med, Dept Pharmacol & Syst Therapeut, New York, NY 10029 USA.
[He, John Cijiang] James J Peters VAMC, Dept Med, New York, NY USA.
[Ma'ayan, Avi; Iyengar, Ravi] Mt Sinai Sch Med, Syst Biol Ctr New York, New York, NY 10029 USA.
RP He, JC (reprint author), Mt Sinai Sch Med, Dept Med, Div Nephrol, 1 Gustave L Levy Pl, New York, NY 10029 USA.
EM cijiang.he@mssm.edu
FU NIH [1R01DK078897, 1R01DK088541, 1RC4DK090860, RC2LM010994-01,
5R01DK087650, 5K08DK082760]; Systems Biology Center [5P50GM071558]
FX JCH is supported by NIH 1R01DK078897 and VA Merit Award; JCH and AM are
supported by NIH 1R01DK088541 and 1RC4DK090860; AM is supported by NIH
RC2LM010994-01. RI and AM are supported by the Systems Biology Center
grant 5P50GM071558; RI and JCH are supported by NIH 5R01DK087650. PYC is
supported by NIH 5K08DK082760.
NR 127
TC 39
Z9 39
U1 1
U2 22
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0085-2538
J9 KIDNEY INT
JI Kidney Int.
PD JAN
PY 2012
VL 81
IS 1
BP 22
EP 39
DI 10.1038/ki.2011.314
PG 18
WC Urology & Nephrology
SC Urology & Nephrology
GA 869XP
UT WOS:000298633600006
PM 21881558
ER
PT J
AU Barchue, SM
AF Barchue, Sylvia M.
TI Should Children Visit Patients in an Intensive Care Unit (ICU)?
SO MCN-THE AMERICAN JOURNAL OF MATERNAL-CHILD NURSING
LA English
DT Editorial Material
C1 James J Peters VA Med Ctr, Patient Care Ctr, Med Surg Units, ICU,ED & Pulm Care, Bronx, NY USA.
RP Barchue, SM (reprint author), James J Peters VA Med Ctr, Patient Care Ctr, Med Surg Units, ICU,ED & Pulm Care, Bronx, NY USA.
NR 3
TC 0
Z9 0
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0361-929X
J9 MCN-AM J MATERN-CHIL
JI MCN-Am. J. Matern.-Child Nurs.
PD JAN-FEB
PY 2012
VL 37
IS 1
BP 8
EP 8
PG 1
WC Nursing
SC Nursing
GA 864OR
UT WOS:000298250000002
ER
PT J
AU Morgan, A
AF Morgan, Aneita
TI Coordinated by Kathleen Leask Capitulo, DNSc, RN, FAAN
SO MCN-THE AMERICAN JOURNAL OF MATERNAL-CHILD NURSING
LA English
DT Editorial Material
C1 James J Peters VA Med Ctr, Clin Care Team, Intens Care Unit, Bronx, NY USA.
RP Morgan, A (reprint author), James J Peters VA Med Ctr, Clin Care Team, Intens Care Unit, Bronx, NY USA.
NR 3
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0361-929X
J9 MCN-AM J MATERN-CHIL
JI MCN-Am. J. Matern.-Child Nurs.
PD JAN-FEB
PY 2012
VL 37
IS 1
BP 9
EP 9
PG 1
WC Nursing
SC Nursing
GA 864OR
UT WOS:000298250000003
ER
PT J
AU Epstein, AJ
Ketcham, JD
Rathore, SS
Groeneveld, PW
AF Epstein, Andrew J.
Ketcham, Jonathan D.
Rathore, Saif S.
Groeneveld, Peter W.
TI Variations in the Use of an Innovative Technology by Payer The Case of
Drug-Eluting Stents
SO MEDICAL CARE
LA English
DT Article
DE variations in care; technology; access
ID ACUTE CORONARY SYNDROMES; HEALTH-CARE COSTS; INSURANCE TYPE; OUTCOMES;
CLOPIDOGREL; PREDICTORS; REGISTRY; THERAPY; ARTERY
AB Background: Despite receiving identical reimbursement for treating heart disease patients with bare metal stents (BMS) or drug-eluting coronary stents (DES), cardiologists' use of the new technology (DES) may have varied by patient payer type as DES diffused. Payer-related factors that differ between hospitals and/or differential treatment inside hospitals might explain any overall differences by payer type.
Objectives: To assess the association between payer and DES use and to examine between-hospital and within-hospital variation in DES use over time.
Methods: We conducted a retrospective analysis of 4.1 million hospitalizations involving DES or BMS from 2003 to 2008 Nationwide Inpatient Sample. We estimated hybrid-fixed effects logit models and calculated the adjusted within-quarter, cross-payer differences in DES use.
Results: Coronary stent patients with Medicaid or without insurance were significantly less likely to receive DES than were patients with private insurance throughout the study period. The differences fluctuated over time as the popularity of DES relative to BMS increased and decreased. The within-hospital gaps paralleled the overall differences, and were largest in Q3 2003 (Medicaid: 11.9, uninsured: 10.9% points) and Q4 2008 (Medicaid: 12.8, uninsured: 20.7% points), and smallest in Q4 2004 (Medicaid: 1.4, uninsured: 1.1% points). The between-hospital adjusted differences in DES use by payer were small and rarely significant.
Conclusions: We found substantial differences in DES use by payer within hospitals, suggesting physicians selected the new technology for patients in a manner associated with patients' payer type.
C1 [Epstein, Andrew J.; Groeneveld, Peter W.] Univ Penn, Sch Med, Dept Med, Div Gen Internal Med, Philadelphia, PA 19104 USA.
[Epstein, Andrew J.] Philadelphia Vet Affairs Med Ctr, Dept Vet Affairs, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA.
[Epstein, Andrew J.; Groeneveld, Peter W.] Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA.
[Ketcham, Jonathan D.] Arizona State Univ, WP Carey Sch Business, Dept Mkt, Tempe, AZ USA.
[Rathore, Saif S.] Yale Univ, Sch Med, MD PhD Program, New Haven, CT USA.
RP Epstein, AJ (reprint author), Univ Penn, Sch Med, Dept Med, Div Gen Internal Med, 423 Guardian Dr,11th Floor, Philadelphia, PA 19104 USA.
EM eandrew@mail.med.upenn.edu
FU National Heart, Lung, and Blood Institute [1R01HL086919]; Agency for
Healthcare Research and Quality [1R01HS018403]
FX This research was supported by the National Heart, Lung, and Blood
Institute (1R01HL086919) and by the Agency for Healthcare Research and
Quality (1R01HS018403). The content of this study does not reflect the
views of the VA or the United States government.
NR 38
TC 8
Z9 8
U1 1
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0025-7079
J9 MED CARE
JI Med. Care
PD JAN
PY 2012
VL 50
IS 1
BP 1
EP 9
DI 10.1097/MLR.0b013e31822d5de9
PG 9
WC Health Care Sciences & Services; Health Policy & Services; Public,
Environmental & Occupational Health
SC Health Care Sciences & Services; Public, Environmental & Occupational
Health
GA 863IY
UT WOS:000298157200001
PM 22167062
ER
PT J
AU Epstein, AJ
Polsky, D
Yang, FF
Yang, L
Groeneveld, PW
AF Epstein, Andrew J.
Polsky, Daniel
Yang, Feifei
Yang, Lin
Groeneveld, Peter W.
TI Geographic Variation in Implantable Cardioverter-Defibrillator Use and
Heart Failure Survival
SO MEDICAL CARE
LA English
DT Article
DE cardiovascular disease; congestive heart failure; health care
technology; mortality; utilization
ID CARDIAC RESYNCHRONIZATION THERAPY; PROPHYLACTIC IMPLANTATION; PRIMARY
PREVENTION; PROPENSITY SCORE; COMORBIDITY; DYSFUNCTION; COMMUNITY
AB Background: Implantable cardioverter-defibrillators and cardiac resynchronization therapy-defibrillators (ICD/CRT-Ds) are evidence-based preventative treatments for many patients with heart failure (HF), yet large numbers of eligible patients remain untreated. It is uncertain if localities with more frequent ICD/CRT-D use have had better rates of HF survival.
Objectives: To determine if US Hospital Referral Regions (HRRs) with larger increases in the rate of ICD/CRT-D utilization during 2002 to 2007 also had commensurate increases in HF survival.
Research Design: Retrospective cohort.
Participants: Medicare beneficiaries age 66 to 80 nonelectively hospitalized for HF from 2002 to 2007.
Measures: Each HRR's annual ICD/CRT-D rate was estimated from the cohort's Medicare procedure claims. Survival duration was determined from Medicare mortality records. HRR-year-level panel regression models were estimated to assess whether an HRR's ICD/CRT-D rate predicted HF survival, adjusting for baseline differences in survival across HRRs and secular trends.
Results: A total of 883,002 HF patients were propensity-score matched within HRR across 2002 to 2007. Across HRRs, growth in ICD/CRT-D use among such patients varied from 1 to 12 percentage points. Regression models indicated that a 1 percentage point increase in an HRR's ICD/CRT-D utilization among hospitalized HF patients was associated with an increase in 1-year survival of 0.12% [95% confidence interval (CI), 0.03%-0.21%, P = 0.009] and with a 0.26% increase in HF survival at 2 years (95% CI, 0.14%-0.37%, P < 0.001).
Conclusions: Localities with greater increases in ICD/CRT-D utilization from 2002 to 2007 also had greater improvements in HF survival. Areas with persistently low ICD/CRT-D use may be good targets for programs designed to increase the evidence-based use of defibrillators.
C1 [Epstein, Andrew J.; Groeneveld, Peter W.] Philadelphia Vet Affairs Med Ctr, Ctr Hlth Equ Res & Promot, Dept Vet Affairs, Philadelphia, PA USA.
[Epstein, Andrew J.; Polsky, Daniel; Yang, Feifei; Yang, Lin; Groeneveld, Peter W.] Univ Penn, Sch Med, Dept Med, Div Gen Internal Med, Philadelphia, PA 19104 USA.
[Epstein, Andrew J.; Polsky, Daniel; Groeneveld, Peter W.] Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA.
RP Groeneveld, PW (reprint author), 1229 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA.
EM petergro@mail.med.upenn.edu
FU National Heart, Lung, and Blood Institute [1R01HL086919]; Agency for
Healthcare Research and Quality [1R01HS018403]; Department of Veterans
Affairs' Health Services Research and Development Service, Washington,
DC; Pennsylvania Department of Health
FX Supported by the National Heart, Lung, and Blood Institute
(1R01HL086919) and by the Agency for Healthcare Research and Quality
(1R01HS018403). Dr Groeneveld was additionally supported by a Career
Development Transition Award from the Department of Veterans Affairs'
Health Services Research and Development Service, Washington, DC. This
project was also funded, in part, under a grant from the Pennsylvania
Department of Health, which specifically disclaims responsibility for
any analyses, interpretations, or conclusions.
NR 27
TC 8
Z9 8
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0025-7079
J9 MED CARE
JI Med. Care
PD JAN
PY 2012
VL 50
IS 1
BP 10
EP 17
DI 10.1097/MLR.0b013e3182293510
PG 8
WC Health Care Sciences & Services; Health Policy & Services; Public,
Environmental & Occupational Health
SC Health Care Sciences & Services; Public, Environmental & Occupational
Health
GA 863IY
UT WOS:000298157200002
PM 22167063
ER
PT J
AU Keyhani, S
Arling, G
Williams, LS
Ross, JS
Ordin, DL
Myers, J
Tyndall, G
Vogel, B
Bravata, DM
AF Keyhani, Salomeh
Arling, Greg
Williams, Linda S.
Ross, Joseph S.
Ordin, Diana L.
Myers, Jennifer
Tyndall, Gary
Vogel, Bruce
Bravata, Dawn M.
TI The Use and Misuse of Thrombolytic Therapy Within the Veterans Health
Administration
SO MEDICAL CARE
LA English
DT Article
DE stroke; thrombolytic therapy; health services research
ID ACUTE ISCHEMIC-STROKE; TISSUE-PLASMINOGEN ACTIVATOR; QUALITY-OF-CARE;
ASSOCIATION; IMPROVEMENT; GUIDELINES; CENTERS; SYSTEM; ATTACK
AB Background: Within the Veterans Health Administration (VHA), approximately 6000 veterans are hospitalized with acute ischemic stroke annually. We examined the use and misuse of thrombolytic therapy with tissue plasminogen activator (tPA) in a national sample of veterans who were admitted to a VHA Medical Center (VAMC) with acute ischemic stroke.
Methods: Medical record reviews were conducted on 5000 acute stroke patients who were admitted to a VAMC in 2007. Patients were defined as eligible to receive tPA if they arrived at the hospital within 3 hours of stroke symptom onset and had no contra-indications to tPA. We compared eligible patients who received tPA to those who did not and examined the distribution of eligible patients across the 129 VAMCs included in this study.
Results: Among the 3931 ischemic stroke patients, 174 (4.4%) were eligible for tPA. Among the 135 patients who arrived within 2 hours of symptom onset which allowed adequate time for testing and evaluation, 19 (14.1%) received tPA. An additional 11 patients received tPA but did not meet eligibility criteria. Eligible patients receiving tPA were similar to eligible patients not receiving tPA in terms of clinical conditions and time to brain imaging. Among the 30 patients that received tPA, 5 (16.6%) received the wrong dose. Among the 85 VAMCs that received Z1 eligible patient, on average 2.3 patients were eligible for tPA annually.
Conclusions: Relatively few eligible veterans receive thrombolysis across the VHA system. Strategies to improve thrombolysis delivery will have to account for the low annual volume of eligible stroke patients cared for at individual VAMCs.
C1 [Keyhani, Salomeh] Univ Calif San Francisco, Dept Vet Affairs VHA, Hlth Serv Res & Dev Serv HSR&D, REAP, San Francisco, CA 94143 USA.
[Keyhani, Salomeh] Univ Calif San Francisco, Div Gen Internal Med, San Francisco, CA 94143 USA.
[Keyhani, Salomeh; Williams, Linda S.; Ordin, Diana L.; Myers, Jennifer; Vogel, Bruce; Bravata, Dawn M.] VHA HSR&D Stroke Qual Enhancement Res Initiat QUE, Indianapolis, IN USA.
[Arling, Greg] Indiana Univ Sch Med, Indiana Univ Ctr Aging Res, Indianapolis, IN USA.
[Arling, Greg; Williams, Linda S.; Bravata, Dawn M.] Regenstrief Inst Hlth Care, Indianapolis, IN USA.
[Williams, Linda S.; Myers, Jennifer; Bravata, Dawn M.] Richard L Roudebush VA Med Ctr, VHA HSR&D Ctr Excellence Implementing Evidence Ba, Indianapolis, IN USA.
[Williams, Linda S.] Indiana Univ Sch Med, Dept Neurol, Indianapolis, IN USA.
[Ross, Joseph S.] Yale Univ, Sch Med, Washington, DC USA.
[Ordin, Diana L.] VHA Off Qual & Performance OQP, Washington, DC USA.
[Tyndall, Gary] Syracuse VA Med Ctr, Emergency Dept, Syracuse, NY USA.
[Vogel, Bruce] N Florida S Georgia Vet Hlth Syst, VHA Rehabil Outcomes Res Ctr RORC, Gainesville, FL USA.
[Bravata, Dawn M.] Indiana Univ Sch Med, Dept Internal Med, Indianapolis, IN USA.
RP Keyhani, S (reprint author), San Francisco VA Med Ctr, 4150 Clement,111A1, San Francisco, CA 94121 USA.
EM salomeh.keyhani@va.gov
OI Tyndall, Gary/0000-0001-9984-4809
FU Department of Veterans Affairs; Veterans Health Administration (VHA);
Office of Quality and Performance and Health Services Research and
Development Service Quality Enhancement Research Initiative [RRP
09-184]; VA HSRD
FX The project reported here was supported by the Department of Veterans
Affairs, Veterans Health Administration (VHA), Office of Quality and
Performance and Health Services Research and Development Service Quality
Enhancement Research Initiative (RRP 09-184). Dr. Keyhani is also
supported by a VA HSR&D Career Development Award.
NR 25
TC 9
Z9 9
U1 2
U2 6
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0025-7079
J9 MED CARE
JI Med. Care
PD JAN
PY 2012
VL 50
IS 1
BP 66
EP 73
DI 10.1097/MLR.0b013e3182294092
PG 8
WC Health Care Sciences & Services; Health Policy & Services; Public,
Environmental & Occupational Health
SC Health Care Sciences & Services; Public, Environmental & Occupational
Health
GA 863IY
UT WOS:000298157200009
PM 22182924
ER
PT J
AU Afrin, LB
AF Afrin, Lawrence B.
TI Mast Cell Activation Syndrome Masquerading as Agranulocytosis
SO MILITARY MEDICINE
LA English
DT Article
ID SYSTEMIC MASTOCYTOSIS; DISEASE; KIT
AB Acquired agranulocytosis is a Tare, life-threatening disorder. The few known causes/associations usually are readily identifiable (e.g., drug reaction. Felty syndrome, megaloblastosis, large granular lymphocytic leukemia, etc.). We report a novel association with mast cell disease. A 61-year-old morbidly obese man developed rheumatoid arthritis unresponsive to several medications. Agranulocytosis developed shortly alter sulfasalazine was started but did not improve when the drug was soon stopped. Other symptoms across many systems developed including hives and presyncope. Marrow aspiration and biopsy showed only neutropenia. Serum tryptase was mildly elevated; urinary prostaglandin D, was markedly elevated. Other causes were not found. Mast cell activation syndrome (MCAS) was diagnosed. Oral antihistamines, montelukast, and cromolyn were unhelpful; aspirin was initially felt contraindicated. Imatinib immediately increased neutrophils from 0% to 25% but did not help symptoms; subsequent addition of aspirin increased neutrophils further and abated symptoms. Different presentations of different MCAS patients reflect elaboration of different mediators likely consequent to different Kit mutations. Mast cells (MCs) help regulate adipocytes, and adipocytes can inhibit granulopoiesis; thus, a Kit-mutated MC clone may have directly and/or indirectly driven agranulocytosis. MCAS should be considered in otherwise idiopathic agranulocytosis presenting with comorbidities best explained by MC mediator release.
C1 [Afrin, Lawrence B.] Ralph H Johnson Vet Affairs Med Ctr, Hematol Oncol Sect, Med Serv, Charleston, SC 29401 USA.
[Afrin, Lawrence B.] Med Univ S Carolina, Div Hematol Oncol, Charleston, SC 29425 USA.
RP Afrin, LB (reprint author), Ralph H Johnson Vet Affairs Med Ctr, Hematol Oncol Sect, Med Serv, 103 Bee St, Charleston, SC 29401 USA.
NR 16
TC 6
Z9 6
U1 0
U2 1
PU ASSOC MILITARY SURG US
PI BETHESDA
PA 9320 OLD GEORGETOWN RD, BETHESDA, MD 20814 USA
SN 0026-4075
J9 MIL MED
JI Milit. Med.
PD JAN
PY 2012
VL 177
IS 1
BP 113
EP 117
PG 5
WC Medicine, General & Internal
SC General & Internal Medicine
GA 874RP
UT WOS:000298976100025
PM 22338992
ER
PT J
AU Jensen, DM
AF Jensen, Dennis M.
TI ULCER Prediction and prevention of peptic ulcer rebleeding
SO NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY
LA English
DT Editorial Material
ID UPPER-GASTROINTESTINAL HEMORRHAGE
C1 VA Greater Los Angeles Healthcare Syst, CURE DDRC, Los Angeles, CA 90073 USA.
RP Jensen, DM (reprint author), VA Greater Los Angeles Healthcare Syst, CURE DDRC, Room 318,Bldg 115,11301 Wilshire Blvd, Los Angeles, CA 90073 USA.
EM djensen@mednet.ucla.edu
NR 9
TC 0
Z9 0
U1 0
U2 1
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1759-5045
J9 NAT REV GASTRO HEPAT
JI Nat. Rev. Gastroenterol. Hepatol.
PD JAN
PY 2012
VL 9
IS 1
BP 7
EP 8
DI 10.1038/nrgastro.2011.243
PG 2
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 866FY
UT WOS:000298367100001
PM 22143269
ER
PT J
AU Barkhof, F
Simon, JH
Fazekas, F
Rovaris, M
Kappos, L
de Stefano, N
Polman, CH
Petkau, J
Radue, EW
Sormani, MP
Li, DK
O'Connor, P
Montalban, X
Miller, DH
Filippi, M
AF Barkhof, Frederik
Simon, Jack H.
Fazekas, Franz
Rovaris, Marco
Kappos, Ludwig
de Stefano, Nicola
Polman, Chris H.
Petkau, John
Radue, Ernst W.
Sormani, Maria P.
Li, David K.
O'Connor, Paul
Montalban, Xavier
Miller, David H.
Filippi, Massimo
TI MRI monitoring of immunomodulation in relapse-onset multiple sclerosis
trials
SO NATURE REVIEWS NEUROLOGY
LA English
DT Review
ID PLACEBO-CONTROLLED TRIAL; GADOLINIUM-ENHANCED MRI; SURROGATE END-POINTS;
CONTROLLED PHASE IIB; DOUBLE-BLIND; CLINICAL-TRIALS; SPINAL-CORD; ORAL
FINGOLIMOD; INTRAMUSCULAR INTERFERON; CONTROLLED MULTICENTER
AB Over the past 15 years, MRI lesion activity has become the accepted surrogate primary outcome measure in proof-of-concept placebo-controlled clinical trials of new immunomodulating therapies in relapse-onset multiple sclerosis (MS). In parallel, the number of patients that are available for the placebo arm of trials has declined, and more-aggressive drugs are being developed. A critical review is warranted to ensure efficient MRI-and patient-resource utilization. Recently, an international panel reviewed the methodology for efficient use of MRI-monitored trials in relapse-onset MS. In this article, we provide up-to-date recommendations for scan acquisition, image analysis, outcome-measure definition and standards of reporting. Factors to consider for optimizing trial design, such as outcome measure selection and the unique requirements of phase II and phase III trials, including active-comparator studies, are outlined. Finally, we address safety considerations in the use of MRI in MS trials, and the safety-related responsibilities of the various parties involved in conducting such trials.
C1 [Barkhof, Frederik; Polman, Chris H.] Vrije Univ Amsterdam Med Ctr, Amsterdam, Netherlands.
[Simon, Jack H.] Portland VA Med Ctr, Portland, OR USA.
[Fazekas, Franz] Med Univ Graz, Graz, Austria.
[Rovaris, Marco] Sci Inst Fdn Don Gnocchi, Milan, Italy.
[Kappos, Ludwig; Radue, Ernst W.] Univ Basel Hosp, Basel, Switzerland.
[de Stefano, Nicola] Univ Siena, I-53100 Siena, Italy.
[Petkau, John; Li, David K.] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada.
[Sormani, Maria P.] Univ Genoa, I-16126 Genoa, Italy.
[O'Connor, Paul] St Michaels Hosp, Toronto, ON M5B 1W8, Canada.
[Montalban, Xavier] Hosp Valle De Hebron, Barcelona, Spain.
[Miller, David H.] UCL, London WC1E 6BT, England.
[Filippi, Massimo] Inst Sci, Milan, Italy.
[Filippi, Massimo] Univ Hosp San Raffaele, Milan, Italy.
RP Barkhof, F (reprint author), Vrije Univ Amsterdam Med Ctr, Amsterdam, Netherlands.
EM f.barkhof@vumc.nl
FU MAGNIMS; US National Multiple Sclerosis Society; Multiple Sclerosis
Society of Canada; Bayer-Schering Pharma
FX This work is based on a workshop of the Magnetic Resonance Imaging
Network in Multiple Sclerosis (MAGNIMS) working group, co-sponsored by
MAGNIMS, the US National Multiple Sclerosis Society and the Multiple
Sclerosis Society of Canada, and supported by an unrestricted
educational grant by Bayer-Schering Pharma. We thank A. Thompson and J.
Palace for their helpful input.
NR 80
TC 22
Z9 22
U1 1
U2 8
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1759-4758
EI 1759-4766
J9 NAT REV NEUROL
JI Nat. Rev. Neurol.
PD JAN
PY 2012
VL 8
IS 1
BP 13
EP 21
DI 10.1038/nrneurol.2011.190
PG 9
WC Clinical Neurology
SC Neurosciences & Neurology
GA 866VT
UT WOS:000298415000006
PM 22143362
ER
PT J
AU Aasly, JO
Shi, M
Sossi, V
Stewart, T
Johansen, KK
Wszolek, ZK
Uitti, RJ
Hasegawa, K
Yokoyama, T
Zabetian, CP
Kim, HM
Leverenz, JB
Ginghina, C
Armaly, J
Edwards, KL
Snapinn, KW
Stoessl, AJ
Zhang, J
AF Aasly, J. O.
Shi, M.
Sossi, V.
Stewart, T.
Johansen, K. K.
Wszolek, Z. K.
Uitti, R. J.
Hasegawa, K.
Yokoyama, T.
Zabetian, C. P.
Kim, H. M.
Leverenz, J. B.
Ginghina, C.
Armaly, J.
Edwards, K. L.
Snapinn, K. W.
Stoessl, A. J.
Zhang, J.
TI Cerebrospinal fluid amyloid beta and tau in LRRK2 mutation carriers
SO NEUROLOGY
LA English
DT Article
ID PARKINSONS-DISEASE; ALPHA-SYNUCLEIN; COGNITIVE DECLINE; ALZHEIMERS; PET
AB Objective: The goal of the current investigation was to examine a cohort of symptomatic and asymptomatic LRRK2 mutation carriers, in order to address whether the reported alterations in amyloid beta (A beta) and tau species in the CSF of patients with sporadic Parkinson disease (PD) are a part of PD pathogenesis, the aging process, or a comorbid disease in patients with PD, and to explore the possibility of A beta and tau as markers of early or presymptomatic PD.
Methods: CSF A beta 42, total tau, and phosphorylated tau were measured with Luminex assays in 26 LRRK2 mutation carriers, who were either asymptomatic (n = 18) or had a phenotype resembling sporadic PD (n = 8). All patients also underwent PET scans with (18)F-6-fluoro-L-dopa (FD), (11)C-(+/-)-alpha-dihydrotetrabenazine (DTBZ), and (11)C-d-threo-methylphenidate (MP) to measure dopaminergic function in the striatum. The levels of CSF markers were then compared to each PET measurement.
Results: Reduced CSF A beta 42 and tau levels correlated with lower striatal dopaminergic function as determined by all 3 PET tracers, with a significant association between A beta 42 and FD uptake. When cases were restricted to carriers of the G2019S mutation, the most common LRRK2 variant in our cohort, significant correlations were also observed for tau.
Conclusions: The disposition of A beta and tau is likely important in both LRRK2-related and sporadic PD, even during early phases of the disease. A better understanding of their production, aggregation, and degradation, including changes in their CSF levels, may provide insights into the pathogenesis of PD and the potential utility of these proteins as biomarkers. Neurology (R) 2012;78:55-61
C1 [Shi, M.; Stewart, T.; Ginghina, C.; Armaly, J.; Zhang, J.] Univ Washington, Sch Med, Dept Pathol, Seattle, WA 98195 USA.
[Aasly, J. O.; Johansen, K. K.] Norwegian Univ Sci & Technol, Dept Neurosci, N-7034 Trondheim, Norway.
[Aasly, J. O.; Johansen, K. K.] St Olavs Univ Hosp, Dept Neurol, Trondheim, Norway.
[Zabetian, C. P.; Kim, H. M.; Leverenz, J. B.] Univ Washington, Sch Med, Dept Neurol, Seattle, WA USA.
[Leverenz, J. B.] Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA.
[Sossi, V.] Univ British Columbia, Dept Phys & Astron, Vancouver Hosp & Hlth Sci Ctr, Vancouver, BC V5Z 1M9, Canada.
[Wszolek, Z. K.; Uitti, R. J.] Mayo Clin Florida, Dept Neurol, Jacksonville, FL USA.
[Hasegawa, K.; Yokoyama, T.] Sagamihara Natl Hosp, Natl Hosp Org, Dept Neurol, Sagamihara, Kanagawa, Japan.
[Zabetian, C. P.] Vet Affairs Puget Sound Hlth Care Syst, Ctr Geriatr Res Educ & Clin, Seattle, WA USA.
[Zabetian, C. P.; Kim, H. M.; Leverenz, J. B.] Vet Affairs Puget Sound Hlth Care Syst, Parkinsons Dis Res Educ & Clin Ctr, Seattle, WA USA.
[Leverenz, J. B.] Vet Affairs Puget Sound Hlth Care Syst, Mental Illness Res Educ & Clin Ctr, Seattle, WA USA.
[Edwards, K. L.; Snapinn, K. W.] Univ Washington, Sch Publ Hlth, Dept Epidemiol, Seattle, WA 98195 USA.
[Stoessl, A. J.] Univ British Columbia, Pacific Parkinsons Res Ctr, Vancouver, BC V5Z 1M9, Canada.
[Stoessl, A. J.] Vancouver Coastal Hlth, Vancouver, BC, Canada.
RP Zhang, J (reprint author), Univ Washington, Sch Med, Dept Pathol, Seattle, WA 98195 USA.
EM zhangj@uw.edu
RI Shi, Min/G-6165-2012
OI Shi, Min/0000-0002-6901-2558
FU NIH [AG025327, AG033398, P30ES007033-6364, ES004696-5897, ES012703,
ES016873, NS057567, NS060252, P50NS062684, NS065070, P50NS072187];
Department of Veterans Affairs [1I01BX000531]; Canadian Institutes of
Health Research; Michael Smith Foundation for Health Research; Pacific
Alzheimer Research Foundation; Canada Research Chairs program; Mayo
Clinic Florida Research Committee; Research Committee of CNS
Degenerative Diseases; Ministry of Health, Labour and Welfare of Japan;
Lundbeck Inc.; Allergan, Inc.; NIH/NINDS; Pacific Alzheimer Research
Foundation (Canada); CIHR; NIH; NIH (NINDS/NIA); US Department of
Veterans Affairs; Parkinson's Disease Foundation; American Parkinson
Disease Association; NIH/NIND; Michael J. Fox Foundation; Washington
Chapter American Parkinson's Disease Association/Northwest Collaborative
Care; Centers for Disease Control
FX Supported by NIH (AG025327, AG033398, P30ES007033-6364, ES004696-5897,
ES012703, ES016873, NS057567, NS060252 to J.Z., P50NS062684 to C.P.Z.,
J.B.L., and J.Z., NS065070 to C.P.Z., NS057567 and P50NS072187 to Z.K.W.
and R.J.U.), Department of Veterans Affairs (to J.B.L. and H. M. K., and
1I01BX000531 to C.P.Z.), Canadian Institutes of Health Research (to
A.J.S.), Michael Smith Foundation for Health Research (to A.J.S.),
Pacific Alzheimer Research Foundation (to A.J.S.), Canada Research
Chairs program (to A.J.S.), TRIUMF (to A.J.S.), Mayo Clinic Florida
Research Committee CR program (to Z.K.W. and R.J.U.), the gift from Carl
Edward Bolch, Jr. and Susan Bass Bolch (to Z.K.W. and R.J.U.), and
Grants-in-Aid from the Research Committee of CNS Degenerative Diseases,
the Ministry of Health, Labour and Welfare of Japan (to K.H. and T.Y.).;
Dr. Aasly serves on the editorial boards of Parkinsonism and Related
Disorders, Parkinson's Disease, and the Journal of the Norwegian Medical
Association; and his institution receives annual royalties from Lundbeck
Inc. from the licensing of the technology related to PARK8/LRRK2. Dr.
Shi reports no disclosures. Dr. Sossi has received research support from
Pacific Alzheimer Research Foundation. Dr. Stewart and Dr. Johansen
report no disclosures. Dr. Wszolek serves as Co-Editor-in-Chief of
Parkinsonism and Related Disorders, Regional Editor of the European
Journal of Neurology, and on the editorial boards of Neurologia i
Neurochirurgia Polska, Advances in Rehabilitation, the Medical Journal
of the Rzeszow University, and Clinical and Experimental Medical
Letters; holds and has contractual rights for receipt of future royalty
payments from patents re: A novel polynucleotide involved in heritable
Parkinson's disease; receives royalties from publishing Parkinsonism and
Related Disorders (Elsevier, 2007, 2008, 2009) and the European Journal
of Neurology (Wiley-Blackwell, 2007, 2008, 2009); and receives research
support from Allergan, Inc., the NIH/NINDS, Mayo Clinic Florida Research
Committee CR program, the Pacific Alzheimer Research Foundation
(Canada), the CIHR, the Mayo Clinic Florida Research Committee CR
program, and a gift from Carl Edward Bolch, Jr., and Susan Bass Bolch.
Dr. Uitti serves as an Associate Editor of Neurology (R); has received
research support from Advanced Neuromodulations Systems and from the
NIH; and his institution receives annual royalties from Lundbeck Inc.
from the licensing of the technology related to PARK8/LRRK2. Dr.
Hasegawa and Dr. Yokoyama report no disclosures. Dr. Zabetian has
received research support from NIH (NINDS/NIA), the US Department of
Veterans Affairs, the Parkinson's Disease Foundation, and the American
Parkinson Disease Association. Dr. Kim reports no disclosures. Dr.
Leverenz has served as a consultant for Bayer Schering Pharma, Novartis,
and Teva Pharmaceutical Industries Ltd.; has received speaker honoraria
from Novartis; and receives research support from the NIH/NIND, the
Michael J. Fox Foundation, the Washington Chapter American Parkinson's
Disease Association/Northwest Collaborative Care, and the US Department
of Veterans Affairs. Dr. Ginghina and J. Armaly report no disclosures.
Dr. Edwards has received research support from the NIH and the Centers
for Disease Control. K. W. Snapinn has received research support from
the NIH, the US Department of Veterans Affairs, and the Centers for
Disease Control. Dr. Stoessl serves on a scientific advisory board for
Biovail Corporation/Medgenesis; has received funding for travel and
speaker honoraria from Novartis, Teva Pharmaceutical Industries Ltd.,
Allergan, Inc., and Abbott; serves on the editorial boards of Annals of
Neurology, Lancet Neurology, and Parkinsonism & Related Disorders; and
receives research support from CIHR, the Michael Smith Foundation for
Health Research, the Michael J. Fox Foundation, and the Pacific
Alzheimer Research Foundation. Dr. Zhang serves on the editorial boards
of Neurological Disease, Neurochemical Research, the Journal of
Alzheimer's Disease, and Proteomics; and has received research support
from the NIH.
NR 20
TC 22
Z9 22
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0028-3878
J9 NEUROLOGY
JI Neurology
PD JAN
PY 2012
VL 78
IS 1
BP 55
EP 61
DI 10.1212/WNL.0b013e31823ed101
PG 7
WC Clinical Neurology
SC Neurosciences & Neurology
GA 869YG
UT WOS:000298635700011
PM 22170881
ER
PT J
AU Yoon, N
Kwon, JW
Seo, SW
Ahn, G
Choi, YL
AF Yoon, Nara
Kwon, Jong Won
Seo, Sung Wook
Ahn, Geunghwan
Choi, Yoon-La
TI Sclerosing epithelioid fibrosarcoma: Cytogenetic analysis of FUS
rearrangement
SO PATHOLOGY INTERNATIONAL
LA English
DT Article
DE beta-catenin; FUS; sclerosing epithelioid fibrosarcoma
ID GRADE FIBROMYXOID SARCOMA; DESMOID TUMORS; BETA-CATENIN; GENE
AB Sclerosing epithelioid fibrosarcoma (SEF) is a rare but distinct variant of fibrosarcoma. A 43-year-old man presented with a lesion in his back that had been present for three years but had recently increased in size. Magnetic resonance imaging (MRI) revealed a 6-cm sized ovoid mass showing low intensities on T1 and T2 weighted images. Histologically, the tumor was of moderate cellularity, and the cells were relatively uniform in size and shape. The cells were epithelioid, round, oval and polygonal with clear and slightly eosinophilic cytoplasm, forming nests, cords, or sheet-like patterns with a dense collagenous and hyalinized matrix. The tumor was positive for vimentin, but negative for smooth muscle actin, desmin, HMB45, and CD34. Although the tumor showed nuclear overexpression of beta-catenin protein, the CTNNB1 exon3 mutation was not detected. Fluorescent in situ hybridization for FUS using dual color break-apart probes showed rearrangement of the FUS. In accordance with previous studies, our case showed positive findings of FUS rearrangement, reinforcing the notion of a close relationship between low grade fibromyxoid sarcoma and SEF.
C1 [Choi, Yoon-La] Sungkyunkwan Univ, Dept Pathol, Samsung Med Ctr, Sch Med,Coll Med, Seoul 135710, South Korea.
[Kwon, Jong Won] Sungkyunkwan Univ, Dept Radiol, Samsung Med Ctr, Coll Med, Seoul 135710, South Korea.
[Seo, Sung Wook] Sungkyunkwan Univ, Dept Orthoped Surg, Samsung Med Ctr, Coll Med, Seoul 135710, South Korea.
[Ahn, Geunghwan] Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, Dept Pathol, San Francisco, CA 94143 USA.
RP Choi, YL (reprint author), Sungkyunkwan Univ, Dept Pathol, Samsung Med Ctr, Sch Med,Coll Med, 50 Ilwondong, Seoul 135710, South Korea.
EM ylachoi@skku.edu
NR 15
TC 6
Z9 6
U1 0
U2 5
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1320-5463
J9 PATHOL INT
JI Pathol. Int.
PD JAN
PY 2012
VL 62
IS 1
BP 65
EP 68
DI 10.1111/j.1440-1827.2011.02752.x
PG 4
WC Pathology
SC Pathology
GA 867US
UT WOS:000298480900010
PM 22192807
ER
PT J
AU Jahshan, C
Cadenhead, KS
Rissling, AJ
Kirihara, K
Braff, DL
Light, GA
AF Jahshan, C.
Cadenhead, K. S.
Rissling, A. J.
Kirihara, K.
Braff, D. L.
Light, G. A.
TI Automatic sensory information processing abnormalities across the
illness course of schizophrenia
SO PSYCHOLOGICAL MEDICINE
LA English
DT Article
DE MMN; prodromal; P300; RON; schizophrenia
ID MISMATCH NEGATIVITY GENERATION; EVENT-RELATED POTENTIALS; NEUROCOGNITIVE
DEFICITS; 1ST-EPISODE SCHIZOPHRENIA; 1ST EPISODE; PRODROMAL
SCHIZOPHRENIA; INVOLUNTARY ATTENTION; AUDITORY DISTRACTION;
SELECTIVE-ATTENTION; SPECTRUM DISORDERS
AB Background. Deficits in automatic sensory discrimination, as indexed by a reduction in the mismatch negativity (MMN) and P3a event-related potential amplitudes, are well documented in chronic schizophrenia. However, MMN and P3a have not been sufficiently studied early in the course of psychotic illness. The present study aimed to investigate MMN, P3a and reorienting negativity (RON) across the course of schizophrenia.
Method. MMN, P3a, and RON were assessed in 118 subjects across four groups: (1) individuals at risk for psychosis (n=26); (2) recent-onset patients (n=31); (3) chronic patients (n=33); and (4) normal controls (n=28) using a duration-deviant auditory oddball paradigm.
Results. Frontocentral deficits in MMN and P3a were present in all patient groups. The at-risk group's MMN and P3a amplitudes were intermediate to those of the control and recent-onset groups. The recent-onset and chronic patients, but not the at-risk subjects, showed significant RON amplitude reductions, relative to the control group. Associations between MMN, P3a, RON and psychosocial functioning were present in the chronic patients. In the at-risk subjects, P3a and RON deficits were significantly associated with higher levels of negative symptoms.
Conclusions. Abnormalities in the automatic processes of sensory discrimination, orienting and reorienting of attention are evident in the early phases of schizophrenia and raise the possibility of progressive worsening across stages of the illness. The finding that MMN and P3a, but not RON, were reduced before psychosis onset supports the continued examination of these components as potential early biomarkers of schizophrenia.
C1 [Cadenhead, K. S.; Rissling, A. J.; Kirihara, K.; Braff, D. L.; Light, G. A.] Univ Calif San Diego, Dept Psychiat, La Jolla, CA 92093 USA.
[Jahshan, C.] Vet Affairs Greater Los Angeles Healthcare Syst, Mental Illness Res Educ & Clin Ctr, Los Angeles, CA USA.
RP Light, GA (reprint author), Univ Calif San Diego, Dept Psychiat, 9500 Gilman Dr, La Jolla, CA 92093 USA.
EM glight@ucsd.edu
FU Department of Veteran Affairs (VISN 22 Mental Illness Research,
Education, and Clinical Center); National Institute of Mental Health
[MH079777, MH042228, MH065571]
FX This work was supported by grants from the Department of Veteran Affairs
(VISN 22 Mental Illness Research, Education, and Clinical Center) and
National Institute of Mental Health (MH079777; MH042228, and MH065571).
The authors wish to thank Jason Nunag, Steven Reding, Kathleen Shafer,
Marlena Pela, Joyce Sprock, and Richard Sharp for their assistance.
NR 86
TC 52
Z9 52
U1 1
U2 5
PU CAMBRIDGE UNIV PRESS
PI NEW YORK
PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA
SN 0033-2917
EI 1469-8978
J9 PSYCHOL MED
JI Psychol. Med.
PD JAN
PY 2012
VL 42
IS 1
BP 85
EP 97
DI 10.1017/S0033291711001061
PG 13
WC Psychology, Clinical; Psychiatry; Psychology
SC Psychology; Psychiatry
GA 874MG
UT WOS:000298961600008
PM 21740622
ER
PT J
AU Butler, PD
Chen, Y
Ford, JM
Geyer, MA
Silverstein, SM
Green, MF
AF Butler, Pamela D.
Chen, Yue
Ford, Judith M.
Geyer, Mark A.
Silverstein, Steven M.
Green, Michael F.
TI Perceptual Measurement in Schizophrenia: Promising Electrophysiology and
Neuroimaging Paradigms From CNTRICS
SO SCHIZOPHRENIA BULLETIN
LA English
DT Article
DE perception; CNTRICS; sensory processes; gain control; integration
ID PREPULSE INHIBITION; COROLLARY DISCHARGE; MISMATCH NEGATIVITY; AUDITORY
HALLUCINATIONS; EVOKED-POTENTIALS; MOTION PERCEPTION; ACOUSTIC STARTLE;
GATING DEFICITS; VISUAL-CORTEX; HUMANS
AB The sixth meeting of the Cognitive Neuroscience Treatment Research to Improve Cognition in Schizophrenia (CNTRICS) focused on selecting promising imaging paradigms for each of the cognitive constructs selected in the first CNTRICS meeting. In the domain of perception, the 2 constructs of interest were "gain control" and "visual integration." CNTRICS received 6 task nominations for imaging paradigms for gain control and 3 task nominations for integration. The breakout group for perception evaluated the degree to which each of these tasks met prespecified criteria. For gain control, the breakout group believed that one task (mismatch negativity) was already mature and was being incorporated into multisite clinical trials. The breakout group recommended that I visual task (steady-state visual evoked potentials to magnocellular- vs parvocellular-biased stimuli) and 2 auditory measures (an event-related potential (ERP) measure of corollary discharge and a functional magnetic resonance imaging (fMRI) version of prepulse inhibition of startle) be adapted for use in clinical trials in schizophrenia research. For visual integration, the breakout group recommended that fMRI and ERP versions of a contour integration test and an fMRI version of a coherent motion test be adapted for use in clinical trials. This manuscript describes the ways in which each of these tasks met the criteria used in the breakout group to evaluate and recommend tasks for further development.
C1 [Butler, Pamela D.] Schizophrenia Res Ctr, Nathan Kline Inst Psychiat Res, Orangeburg, NY USA.
[Butler, Pamela D.] NYU, Sch Med, Dept Psychiat, New York, NY USA.
[Chen, Yue] Harvard Univ, McLean Hosp, Sch Med, Dept Psychiat, Belmont, MA USA.
[Ford, Judith M.] Univ Calif San Francisco, VA Med Ctr, Dept Psychiat, San Francisco, CA 94143 USA.
[Geyer, Mark A.] Univ Calif San Diego, Dept Psychiat, La Jolla, CA 92093 USA.
[Silverstein, Steven M.] Univ Behav HealthCare, Univ Med & Dent New Jersey, Div Schizophrenia Res, Piscataway, NJ USA.
[Silverstein, Steven M.] Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Psychiat, Piscataway, NJ 08854 USA.
[Green, Michael F.] Univ Calif Los Angeles, Semel Inst Neurosci & Human Behav, Los Angeles, CA USA.
[Green, Michael F.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
RP Butler, PD (reprint author), 140 Old Orangeburg Rd, Orangeburg, NY 10962 USA.
EM butler@nki.rfmh.org
FU National Institutes of Health [MH84848, MH61824, MH58262, MH067967,
MH052885, MH084828, MH043292]; Veteran's Administration VISN 22 Mental
Illness Research, Education, and Clinical Center; VA Merit
FX National Institutes of Health (MH84848 to P.D.B., MH61824 to Y.C.,
MH58262 and MH067967 to J.M.F., MH052885 to M.A.G., MH084828 to S.M.S.,
MH043292 to M.F.G.); Veteran's Administration VISN 22 Mental Illness
Research, Education, and Clinical Center to M.F.G. and M.A.G.; VA Merit
to J.M.F.
NR 50
TC 37
Z9 38
U1 1
U2 10
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0586-7614
J9 SCHIZOPHRENIA BULL
JI Schizophr. Bull.
PD JAN
PY 2012
VL 38
IS 1
BP 81
EP 91
DI 10.1093/schbul/sbr106
PG 11
WC Psychiatry
SC Psychiatry
GA 875DZ
UT WOS:000299011900012
PM 21890745
ER
PT J
AU Huang, JN
Schmeidler, J
Beeri, MS
Rosendorff, C
Bhatia, S
West, RK
Bespalova, IN
Mavris, R
Silverman, JM
AF Huang, Jennifer
Schmeidler, James
Beeri, Michal S.
Rosendorff, Clive
Bhatia, Simmi
West, Rebecca K.
Bespalova, Irina N.
Mavris, Rizalina
Silverman, Jeremy M.
TI Haemoglobin A(1c) and cognitive function in very old, cognitively intact
men
SO AGE AND AGEING
LA English
DT Article
ID DIABETES-MELLITUS; ALZHEIMER-DISEASE; ANTAGONISTIC PLEIOTROPY; ELDERLY
SUBJECTS; RISK-FACTORS; DECLINE; DEMENTIA; MEMORY; AGE; IMPAIRMENT
C1 [Schmeidler, James; Beeri, Michal S.; West, Rebecca K.; Bespalova, Irina N.; Silverman, Jeremy M.] Mt Sinai Sch Med, Dept Psychiat, New York, NY 10029 USA.
[Beeri, Michal S.; Silverman, Jeremy M.] James J Peters Vet Affairs Med Ctr, Geriatr Res Educ & Clin Ctr, Bronx, NY USA.
RP Silverman, JM (reprint author), Mt Sinai Sch Med, Dept Psychiat, Box 1230,1 Gustave L Levy Pl, New York, NY 10029 USA.
EM jeremy.silverman@mssm.edu
FU National Institute of Aging [P01-AG02219, K01 AG023515, P50-AG05138];
United States Department of Veterans Affairs; Berkman Charitable Trust
FX This work was supported by National Institute of Aging (grant numbers:
P01-AG02219, K01 AG023515, P50-AG05138); United States Department of
Veterans Affairs; Berkman Charitable Trust
NR 30
TC 5
Z9 5
U1 1
U2 1
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0002-0729
J9 AGE AGEING
JI Age Ageing
PD JAN
PY 2012
VL 41
IS 1
BP 125
EP 128
DI 10.1093/ageing/afr124
PG 4
WC Geriatrics & Gerontology
SC Geriatrics & Gerontology
GA 859EL
UT WOS:000297858700025
PM 21930529
ER
PT J
AU Schally, AV
Halmos, G
AF Schally, Andrew V.
Halmos, Gabor
BE Kratz, F
Senter, P
Steinhagen, H
TI Targeting to Peptide Receptors
SO DRUG DELIVERY IN ONCOLOGY: FROM BASIC RESEARCH TO CANCER THERAPY, VOLS
1-3
LA English
DT Article; Book Chapter
ID HORMONE-RELEASING-HORMONE; CYTOTOXIC SOMATOSTATIN ANALOG; HUMAN BREAST
CANCERS; MULTIDRUG-RESISTANCE PROTEINS; EPIDERMAL-GROWTH-FACTOR;
BOMBESIN-LIKE PEPTIDES; RENAL-CELL CARCINOMAS; HUMAN PROSTATE-CANCER;
HUMAN OVARIAN CANCERS; HUMAN ENDOMETRIAL CANCERS
C1 [Schally, Andrew V.] Univ Miami, Miller Sch Med, Coral Gables, FL 33124 USA.
[Schally, Andrew V.] Univ Miami, Miller Sch Med, Div Hematol Oncol, Dept Med, Coral Gables, FL 33124 USA.
[Schally, Andrew V.] Vet Affairs Med Ctr, Polypeptide Canc Inst, Miami, FL 33125 USA.
[Schally, Andrew V.] US Dept Vet Affairs, Ford City, PA USA.
[Halmos, Gabor] Univ Debrecen, Med & Hlth Sci Ctr, Dept Biopharm, Debrecen, Hungary.
RP Schally, AV (reprint author), Univ Miami, Miller Sch Med, Coral Gables, FL 33124 USA.
NR 140
TC 5
Z9 5
U1 0
U2 1
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA PAPPELALLEE 3, W-69469 WEINHEIM, GERMANY
BN 978-3-527-32823-9
PY 2012
BP 1219
EP 1261
PG 43
WC Biochemistry & Molecular Biology; Oncology; Pharmacology & Pharmacy
SC Biochemistry & Molecular Biology; Oncology; Pharmacology & Pharmacy
GA BA8DL
UT WOS:000338009100041
ER
PT J
AU Linville, D
Brown, T
O'Neil, M
AF Linville, Deanna
Brown, Tiffany
O'Neil, Maya
TI Medical Providers' Self Perceived Knowledge and Skills for Working With
Eating Disorders: A National Survey
SO EATING DISORDERS
LA English
DT Article
AB Research indicates that individuals suffering from an eating disorder (ED) consult their general practitioners more frequently than those without an eating disorder (Mond, Myers, Crosby, Hay, & Mitchell, 2010). However, little is known about medical providers' existing knowledge of and training in ED detection, intervention, and treatment. This study aimed to examine national medical providers' self-perceived knowledge, skills, and needs around eating disorder screening and intervention strategies. Utilizing survey design, a randomized sample of national medical providers responded to a 23-question survey. Sixty-eight percent of respondents indicated that they did not think to screen for an eating disorder because it was not the presenting concern and nearly 59% of providers did not feel like they had the skills necessary to intervene with eating disorders. Training implications and future research directions are discussed.
C1 [Linville, Deanna] Univ Oregon, Coll Educ, Dept Counseling Psychol & Human Serv, Eugene, OR 97403 USA.
[Brown, Tiffany] Pacific Lutheran Univ, Dept Marriage & Family Therapy, Div Social Sci, Tacoma, WA 98447 USA.
[O'Neil, Maya] Portland VA Med Ctr, Hlth Serv Res & Dev, Portland, OR USA.
[O'Neil, Maya] Portland VA Med Ctr, Dept Psychiat, Portland, OR USA.
[O'Neil, Maya] Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
RP Linville, D (reprint author), 5251 Univ Oregon, Coll Educ, Dept Counseling Psychol & Human Serv, Eugene, OR 97403 USA.
EM Linville@uoregon.edu
NR 26
TC 6
Z9 7
U1 0
U2 1
PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD
PI ABINGDON
PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND
SN 1064-0266
EI 1532-530X
J9 EAT DISORD
JI Eat. Disord
PY 2012
VL 20
IS 1
BP 1
EP 13
DI 10.1080/10640266.2012.635557
PG 13
WC Psychology, Clinical; Psychiatry; Psychology
SC Psychology; Psychiatry
GA V32PE
UT WOS:000208962300001
PM 22188056
ER
PT B
AU Ripoll, LH
Triebwasser, J
Siever, LJ
AF Ripoll, Luis H.
Triebwasser, Joseph
Siever, Larry J.
BE Stein, DJ
Lerer, B
Stahl, SM
TI Evidence-based pharmacotherapy of personality disorders
SO ESSENTIAL EVIDENCE-BASED PSYCHOPHARMACOLOGY, 2ND EDITION
LA English
DT Article; Book Chapter
ID SOCIAL ANXIETY DISORDER; PLACEBO-CONTROLLED-TRIAL;
SELF-INJURIOUS-BEHAVIOR; POSITRON-EMISSION-TOMOGRAPHY; 18-MONTH
FOLLOW-UP; POSTTRAUMATIC-STRESS-DISORDER; IMPULSIVE AGGRESSIVE-BEHAVIOR;
RANDOMIZED CONTROLLED-TRIAL; VENLAFAXINE EXTENDED-RELEASE; FEMALE
BORDERLINE-PATIENTS
C1 [Ripoll, Luis H.; Triebwasser, Joseph; Siever, Larry J.] James J Peters VA Med Ctr, Mental Illness Res Educ & Clin Ctr, Bronx, NY USA.
RP Ripoll, LH (reprint author), James J Peters VA Med Ctr, Mental Illness Res Educ & Clin Ctr, Bronx, NY USA.
NR 185
TC 0
Z9 0
U1 0
U2 0
PU CAMBRIDGE UNIV PRESS
PI CAMBRIDGE
PA THE PITT BUILDING, TRUMPINGTON ST, CAMBRIDGE CB2 1RP, CAMBS, ENGLAND
BN 978-1-107-40010-8; 978-1-107-00795-6
PY 2012
BP 278
EP 315
D2 10.1017/CBO9780511910395
PG 38
WC Pharmacology & Pharmacy; Psychiatry
SC Pharmacology & Pharmacy; Psychiatry
GA BJM92
UT WOS:000329193200015
ER
PT J
AU Chao, LL
Weiner, MW
Neylan, TC
AF Chao, Linda L.
Weiner, Michael W.
Neylan, Thomas C.
TI Regional cerebral volumes in veterans with current versus remitted
posttraumatic stress disorder: a study at 4 Tesla
SO EUROPEAN JOURNAL OF PSYCHOTRAUMATOLOGY
LA English
DT Meeting Abstract
DE veterans; PTSD; brain volume
C1 [Chao, Linda L.; Weiner, Michael W.; Neylan, Thomas C.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA.
[Chao, Linda L.; Weiner, Michael W.] Univ Calif San Francisco, Dept Radiol & Biomed Imaging, San Francisco, CA 94143 USA.
[Chao, Linda L.; Weiner, Michael W.] San Francisco VA Med Ctr, Ctr Imaging Neurodegenerat Dis, San Francisco, CA USA.
[Chao, Linda L.; Neylan, Thomas C.] San Francisco VA Med Ctr, Mental Hlth Serv, San Francisco, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU CO-ACTION PUBLISHING
PI JARFALLA
PA RIPVAGEN 7, JARFALLA, SE-175 64, SWEDEN
SN 2000-8066
J9 EUR J PSYCHOTRAUMATO
JI Eur. J. Psychotraumatol.
PY 2012
VL 3
SU 1
DI 10.3402/ejpt.v3i0.19425
PG 2
WC Psychology, Clinical; Psychiatry
SC Psychology; Psychiatry
GA V31FC
UT WOS:000208868500186
ER
PT J
AU Hazlett, EA
Fernandez, N
Sasso, S
New, AS
Goodman, M
AF Hazlett, Erin A.
Fernandez, Nicholas
Sasso, Scott
New, Antonia S.
Goodman, Marianne
TI A non-verbal, quantitative measure of emotion dysregulation in veterans:
is affective startle a potential biomarker for suicide?
SO EUROPEAN JOURNAL OF PSYCHOTRAUMATOLOGY
LA English
DT Meeting Abstract
DE emotion; emotion dysregulation; fear/defensive brain circuitry;
affective startle eyeblink modulation; suicide ideation; suicidal
behavior
C1 [Hazlett, Erin A.; Fernandez, Nicholas; Sasso, Scott; New, Antonia S.; Goodman, Marianne] James J Peters VA Med Ctr, Mental Illness Res Educ & Clin Ctr MIRECC VISN, New York, NY USA.
[Hazlett, Erin A.; New, Antonia S.; Goodman, Marianne] Mt Sinai Sch Med, Dept Psychiat, New York, NY USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU CO-ACTION PUBLISHING
PI JARFALLA
PA RIPVAGEN 7, JARFALLA, SE-175 64, SWEDEN
SN 2000-8066
J9 EUR J PSYCHOTRAUMATO
JI Eur. J. Psychotraumatol.
PY 2012
VL 3
SU 1
DI 10.3402/ejpt.v3i0.19368
PG 2
WC Psychology, Clinical; Psychiatry
SC Psychology; Psychiatry
GA V31FC
UT WOS:000208868500183
ER
PT J
AU Luxenberg, A
O'Donovan, A
Inslicht, SS
Metzler, TJ
Hlavin, J
Weiner, MW
Neylan, TC
AF Luxenberg, Adam
O'Donovan, Aoife
Inslicht, Sabra S.
Metzler, Thomas J.
Hlavin, Jennifer
Weiner, Michael W.
Neylan, Thomas C.
TI Exaggerated autonomic responding to acoustic stimuli in Gulf War
Veterans with current versus remitted post-traumatic stress disorder
SO EUROPEAN JOURNAL OF PSYCHOTRAUMATOLOGY
LA English
DT Meeting Abstract
DE veterans; Gulf War; PTSD; autonomic response
C1 Univ Calif San Francisco, San Francisco, CA 94143 USA.
San Francisco VA Med Ctr, San Francisco, CA USA.
Northern Calif Inst Res & Educ, San Francisco, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU CO-ACTION PUBLISHING
PI JARFALLA
PA RIPVAGEN 7, JARFALLA, SE-175 64, SWEDEN
SN 2000-8066
J9 EUR J PSYCHOTRAUMATO
JI Eur. J. Psychotraumatol.
PY 2012
VL 3
SU 1
DI 10.3402/ejpt.v3i0.19369
PG 2
WC Psychology, Clinical; Psychiatry
SC Psychology; Psychiatry
GA V31FC
UT WOS:000208868500184
ER
PT J
AU O'Donovan, A
Cohen, BE
Bertenthal, D
Margaretten, M
Seal, K
Neylan, TC
AF O'Donovan, Aoife
Cohen, Beth E.
Bertenthal, Dan
Margaretten, Mary
Seal, Karen
Neylan, Thomas C.
TI Association of posttraumatic stress disorder with increased prevalence
of autoimmune disorders in Iraq and Afghanistan veterans
SO EUROPEAN JOURNAL OF PSYCHOTRAUMATOLOGY
LA English
DT Meeting Abstract
DE autoimmune disorders; inflammation; post-traumatic stress disorder;
psychiatric disorders; traumatic stress; veterans
C1 [O'Donovan, Aoife; Margaretten, Mary; Seal, Karen] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Cohen, Beth E.; Bertenthal, Dan] San Francisco VA Med Ctr, San Francisco, CA USA.
[Neylan, Thomas C.] Northern Calif Inst Res & Educ, San Francisco, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU CO-ACTION PUBLISHING
PI JARFALLA
PA RIPVAGEN 7, JARFALLA, SE-175 64, SWEDEN
SN 2000-8066
J9 EUR J PSYCHOTRAUMATO
JI Eur. J. Psychotraumatol.
PY 2012
VL 3
SU 1
DI 10.3402/ejpt.v3i0.19511
PG 1
WC Psychology, Clinical; Psychiatry
SC Psychology; Psychiatry
GA V31FC
UT WOS:000208868500053
ER
PT J
AU Peskind, ER
Cross, DJ
Yarnykh, V
Pagulayan, K
Hoff, D
Hart, K
Martin, N
Richards, T
Raskind, MA
Minoshima, S
Petrie, EC
AF Peskind, Elaine R.
Cross, Donna J.
Yarnykh, Vasily
Pagulayan, Kathleen
Hoff, David
Hart, Kim
Martin, Nathalie
Richards, Todd
Raskind, Murray A.
Minoshima, Satoshi
Petrie, Eric C.
TI Neuroimaging biomarkers in veterans with blast-mild traumatic brain
injury with or without comorbid PTSD
SO EUROPEAN JOURNAL OF PSYCHOTRAUMATOLOGY
LA English
DT Meeting Abstract
DE mild traumatic brain injury; neuroimaging; biomarkers; PTSD; magnetic
resonance imaging; FDG-PET
C1 VA Puget Sound Hlth Care Syst, Seattle, WA USA.
Univ Washington, Seattle, WA 98195 USA.
RI Yarnykh, Vasily/G-8757-2016; Yarnykh, Vasiliy/N-7635-2014
OI Yarnykh, Vasily/0000-0002-1583-8979;
NR 0
TC 0
Z9 0
U1 0
U2 4
PU CO-ACTION PUBLISHING
PI JARFALLA
PA RIPVAGEN 7, JARFALLA, SE-175 64, SWEDEN
SN 2000-8066
J9 EUR J PSYCHOTRAUMATO
JI Eur. J. Psychotraumatol.
PY 2012
VL 3
SU 1
DI 10.3402/ejpt.v3i0.19376
PG 1
WC Psychology, Clinical; Psychiatry
SC Psychology; Psychiatry
GA V31FC
UT WOS:000208868500185
ER
PT J
AU Sher, L
Holmes, K
Flory, JD
Bierer, LM
Yehuda, R
AF Sher, Leo
Holmes, Kristin
Flory, Janine D.
Bierer, Linda M.
Yehuda, Rachel
TI Clinical features of military veterans with or without a history of
suicide attempt
SO EUROPEAN JOURNAL OF PSYCHOTRAUMATOLOGY
LA English
DT Meeting Abstract
DE suicide; veterans; substance dependence; psychosis; bipolar disorder
C1 James J Peters Vet Adm Med Ctr, New York, NY USA.
Mt Sinai Sch Med, New York, NY USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU CO-ACTION PUBLISHING
PI JARFALLA
PA RIPVAGEN 7, JARFALLA, SE-175 64, SWEDEN
SN 2000-8066
J9 EUR J PSYCHOTRAUMATO
JI Eur. J. Psychotraumatol.
PY 2012
VL 3
SU 1
DI 10.3402/ejpt.v3i0.19476
PG 1
WC Psychology, Clinical; Psychiatry
SC Psychology; Psychiatry
GA V31FC
UT WOS:000208868500188
ER
PT J
AU Talbot, L
Richards, A
Inslicht, SS
O'Donovan, A
Neylan, TC
AF Talbot, Lisa
Richards, Anne
Inslicht, Sabra S.
O'Donovan, Aoife
Neylan, Thomas C.
TI Sleep and lipids in posttraumatic stress disorder
SO EUROPEAN JOURNAL OF PSYCHOTRAUMATOLOGY
LA English
DT Meeting Abstract
DE sleep; PTSD; lipids; cardiovascular risk; metabolism
C1 [Talbot, Lisa; Richards, Anne; Inslicht, Sabra S.; O'Donovan, Aoife; Neylan, Thomas C.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Talbot, Lisa; Richards, Anne; Inslicht, Sabra S.; O'Donovan, Aoife; Neylan, Thomas C.] San Francisco VA Med Ctr, San Francisco, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU CO-ACTION PUBLISHING
PI JARFALLA
PA RIPVAGEN 7, JARFALLA, SE-175 64, SWEDEN
SN 2000-8066
J9 EUR J PSYCHOTRAUMATO
JI Eur. J. Psychotraumatol.
PY 2012
VL 3
SU 1
DI 10.3402/ejpt.v3i0.19496
PG 2
WC Psychology, Clinical; Psychiatry
SC Psychology; Psychiatry
GA V31FC
UT WOS:000208868500012
ER
PT J
AU Edwards, CK
Green, JS
Volk, HD
Schiff, M
Kotzin, BL
Mitsuya, H
Kawaguchi, T
Sakata, KM
Cheronis, J
Trollinger, D
Bankaitis-Davis, D
Dinarello, CA
Norris, DA
Bevilacqua, MP
Fujita, M
Burmester, GR
AF Edwards, Carl K., III
Green, Julie S.
Volk, Hans-Dieter
Schiff, Michael
Kotzin, Brian L.
Mitsuya, Hiroaki
Kawaguchi, Tatsuya
Sakata, Ken-Mei
Cheronis, John
Trollinger, David
Bankaitis-Davis, Danute
Dinarello, Charles A.
Norris, David A.
Bevilacqua, Michael P.
Fujita, Mayumi
Burmester, Gerd-Rudiger
TI Combined anti-tumor necrosis factor-alpha therapy and DMARD therapy in
rheumatoid arthritis patients reduces inflammatory gene expression in
whole blood compared to DMARD therapy alone
SO FRONTIERS IN IMMUNOLOGY
LA English
DT Article
DE gene expression; rheumatoid arthritis; anti-TNF-alpha; whole blood;
biomarker
AB Periodic assessment of gene expression for diagnosis and monitoring in rheumatoid arthritis (RA) may provide a readily available and useful method to detect subclinical disease progression and follow responses to therapy with disease modifying anti-rheumatic agents (DMARDs) or anti-INF-a therapy. We used quantitative real-time PCR to compare peripheral blood gene expression profiles in active ("unstable") RA patients on DMARDs, stable RA patients on DMARDs, and stable RA patients treated with a combination of a disease-modifying anti-rheumatoid drug (DMARD) and an anti-TNF-e agent (infliximab or etanercept) to healthy human controls. The expression of 48 inflammatory genes were compared between healthy controls (N = 122), unstable DMARD patients (N = 18), stable DMARD patients (N = 26), and stable patients on combination therapy (N = 20). Expression of 13 genes was very low or undetectable in all study groups. Compared to healthy controls, patients with unstable RA on DMARDs exhibited increased expression of 25 genes, stable DMARD patients exhibited increased expression of 14 genes and decreased expression of five genes, and combined therapy patients exhibited increased expression of six genes and decreased expression of 10 genes. These findings demonstrate that active RA is associated with increased expression of circulating inflammatory markers whereas increases in inflammatory gene expression are diminished in patients with stable disease on either DMARD or anti-INF-a therapy. Furthermore, combination DMARD and anti-INF-a therapy is associated with greater reductions in circulating inflammatory gene expression compared to DMARD therapy alone. These results suggest that assessment of peripheral blood gene expression may prove useful to monitor disease progression and response to therapy.
C1 [Edwards, Carl K., III; Green, Julie S.; Norris, David A.; Bevilacqua, Michael P.; Fujita, Mayumi] Univ Colorado Denver, Dept Dermatol, Aurora, CO 80045 USA.
[Edwards, Carl K., III; Schiff, Michael; Kotzin, Brian L.] Univ Colorado Denver, Dept Rheumatol, Aurora, CO 80045 USA.
[Volk, Hans-Dieter; Burmester, Gerd-Rudiger] Campus Charite Mitte Inst Med Immunol, Berlin, Germany.
[Mitsuya, Hiroaki; Kawaguchi, Tatsuya; Sakata, Ken-Mei] Kumamoto Univ, Sch Med, Kumamoto 860, Japan.
[Cheronis, John; Trollinger, David; Bankaitis-Davis, Danute; Bevilacqua, Michael P.] Source Precis Med, Boulder, CO USA.
[Dinarello, Charles A.] Univ Colorado Denver, Dept Infect Dis, Aurora, CO 80045 USA.
[Norris, David A.; Fujita, Mayumi] Denver Vet Affairs Med Ctr, Denver, CO USA.
RP Fujita, M (reprint author), Univ Colorado Denver, Anschutz Med Campus,12801 East17thAvenue RC-1, Aurora, CO 80045 USA.
EM carl.edwards@ucdenver.edu; mayumi.fujita@ucdenver.edu
NR 53
TC 4
Z9 4
U1 1
U2 1
PU FRONTIERS RESEARCH FOUNDATION
PI LAUSANNE
PA PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015,
SWITZERLAND
SN 1664-3224
J9 FRONT IMMUNOL
JI Front. Immunol.
PY 2012
VL 3
AR 366
DI 10.3389/fimmu.2012.00366
PG 10
WC Immunology
SC Immunology
GA V40TQ
UT WOS:000209501300361
PM 23264777
ER
PT J
AU Harriff, MJ
Purdy, GE
Lewinsohn, DM
AF Harriff, Melanie J.
Purdy, Georgiana E.
Lewinsohn, David M.
TI Escape from the phagosome: the explanation for MHC-I processing of
mycobacterial antigens?
SO FRONTIERS IN IMMUNOLOGY
LA English
DT Review
DE Mycobacterium tuberculosis; phagosome; MHC-I antigen processing; CD8(+)
T cells
AB Mycobacterium tuberculosis (Mtb) is thought to live in an altered phagosomal environment. In this setting, the mechanisms by which mycobacterial antigens access the major histocompatibility class I (MHC-I) processing machinery remain incompletely understood. There is evidence that Mtb antigens can be processed in both endocytic and cytosolic environments, with different mechanisms being proposed for how Mtb antigens can access the cytosol. Recently, electron microscopy was used to demonstrate that Mtb has the potential to escape the phagosome and reside in the cytosol. This was postulated as the primary mechanism by which Mtb antigens enter the MHC-I processing and presentation pathway. In this commentary, we will review data on the escape of Mtb from the cytosol and whether this escape is required for antigen presentation to CD8(+) T cells.
C1 [Harriff, Melanie J.; Lewinsohn, David M.] Portland VA Med Ctr, Portland, OR USA.
[Harriff, Melanie J.; Lewinsohn, David M.] Oregon Hlth & Sci Univ, Pulm & Crit Care Med, Portland, OR 97239 USA.
[Purdy, Georgiana E.; Lewinsohn, David M.] Oregon Hlth & Sci Univ, Dept Mol Microbiol & Immunol, Portland, OR 97239 USA.
RP Lewinsohn, DM (reprint author), Oregon Hlth & Sci Univ, Pulm & Crit Care Med, 3181 SW Sam Jackson Pk Rd,Mail Code VA R&D11, Portland, OR 97239 USA.
EM lewinsod@ohsu.edu
RI Lewinsohn, David/I-4936-2013
OI Lewinsohn, David/0000-0001-9906-9494
NR 94
TC 16
Z9 16
U1 0
U2 1
PU FRONTIERS RESEARCH FOUNDATION
PI LAUSANNE
PA PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015,
SWITZERLAND
SN 1664-3224
J9 FRONT IMMUNOL
JI Front. Immunol.
PY 2012
VL 3
AR 40
DI 10.3389/fimmu.2012.00040
PG 11
WC Immunology
SC Immunology
GA V40TQ
UT WOS:000209501300039
PM 22566923
ER
PT J
AU Stengel, A
Tache, Y
AF Stengel, Andreas
Tache, Yvette
TI Ghrelin a pleiotropic hormone secreted from endocrine X/A-like cells of
the stomach
SO FRONTIERS IN NEUROSCIENCE
LA English
DT Review
DE acyl and desacyl; GOAT; ghrelin; nesfatin-1; NUCB2; endocrine cells;
stress
AB The gastric X/A-like endocrine cell receives growing attention due to its peptide products with ghrelin being the best characterized. This peptide hormone was identified a decade ago as a stimulator of food intake and to date remains the only known peripherally produced and centrally acting orexigenic hormone. In addition, subsequent studies identified numerous other functions of this peptide including the stimulation of gastrointestinal motility, the maintenance of energy homeostasis and an impact on reproduction. Moreover, ghrelin is also involved in the response to stress and assumed to play a role in coping functions and exert a modulatory action on immune pathways. Our knowledge on the regulation of ghrelin has markedly advanced during the past years by the identification of the ghrelin acylating enzyme, ghrelin-O-acyltransferase, and by the description of changes in expression, activation, and release under different metabolic as well as physically and psychically challenging conditions. However, our insight on regulatory processes of ghrelin at the cellular and subcellular levels is still very limited and warrants further investigation.
C1 [Stengel, Andreas] Charite, Dept Med, Div Psychosomat Med & Psychotherapy, D-13353 Berlin, Germany.
[Tache, Yvette] Univ Calif Los Angeles, Dept Med, Digest Dis Res Ctr, Los Angeles, CA 90024 USA.
[Tache, Yvette] Univ Calif Los Angeles, Dept Med, Ctr Neurobiol Stress, Div Digest Dis, Los Angeles, CA 90024 USA.
[Tache, Yvette] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
RP Tache, Y (reprint author), VA Greater Los Angeles Healthcare Syst, Ctr Neurobiol Stress, CURE Bldg 115,Room 117,11301 Wilshire Blvd, Los Angeles, CA 90073 USA.
EM ytache@mednet.ucla.edu
FU NIH [R01 DK-33061]; NUT [DK-41301]; VA Research Career Scientist;
Charite University funding
FX This work was supported by NIH R01 DK-33061, NUT (enter Grant DK-41301
(Animal Core), VA Research Career Scientist (Yvette Tache), and Charite
University funding (Andreas Stengel). We thank Ms. Eugenia Hu for
careful reading of the manuscript.
NR 231
TC 22
Z9 25
U1 1
U2 7
PU FRONTIERS RESEARCH FOUNDATION
PI LAUSANNE
PA PO BOX 110, LAUSANNE, 1015, SWITZERLAND
SN 1662-453X
J9 FRONT NEUROSCI-SWITZ
JI Front. Neurosci.
PY 2012
VL 6
AR UNSP 24
DI 10.3389/fnins.2012.00024
PG 16
WC Neurosciences
SC Neurosciences & Neurology
GA V35RF
UT WOS:000209165300040
PM 22355282
ER
PT J
AU Viveros, MP
Mendrek, A
Paus, T
Lopez-Rodriguez, AB
Marco, EM
Yehuda, R
Cohen, H
Lehrner, A
Wagner, EJ
AF Viveros, Maria-Paz
Mendrek, Adriana
Paus, Tomas
Belen Lopez-Rodriguez, Ana
Maria Marco, Eva
Yehuda, Rachel
Cohen, Hagit
Lehrner, Amy
Wagner, Edward J.
TI A comparative, developmental, and clinical perspective of
neurobehavioral sexual dimorphisms
SO FRONTIERS IN NEUROSCIENCE
LA English
DT Review
DE sexual differentiation; adolescence; schizophrenia; depression; bipolar
disorders; posttraumatic disorders; addiction; animal models
AB Women and men differ in a wide variety of behavioral traits and in their vulnerability to developing certain mental disorders. This review endeavors to explore how recent preclinical and clinical research findings have enhanced our understanding of the factors that underlie these disparities. We start with a brief overview of some of the important genetic, molecular, and hormonal determinants that contribute to the process of sexual differentiation. We then discuss the importance of animal models in studying the mechanisms responsible for sex differences in neuropsychiatric disorders (e.g., drug dependence) with a special emphasis on experimental models based on the neurodevelopmental and "three hits" hypotheses. Next, we describe the most common brain phenotypes observed in vivo with magnetic resonance imaging. We discuss the challenges in interpreting these phenotypes vis-a-vis the underlying neurobiology and revisit the known sex differences in brain structure from birth, through adolescence, and into adulthood. This is followed by a presentation of pertinent clinical and epidemiological data that point to important sex differences in the prevalence, course, and expression of psychopathologies such as schizophrenia, and mood disorders including major depression and posttraumatic stress disorder. Recent evidence implies that mood disorders and psychosis share some common genetic predispositions and neurobiological bases. Therefore, modern research is emphasizing dimensional representation of mental disorders and conceptualization of schizophrenia and major depression as a continuum of cognitive deficits and neurobiological abnormalities. Herein, we examine available evidence on cerebral sexual dimorphism to verify if sex differences vary quantitatively and/or qualitatively along the psychoses-depression continuum. Finally, sex differences in the prevalence of posttraumatic disorder and drug abuse have been described, and we consider the genomic and molecular data supporting these differences.
C1 [Viveros, Maria-Paz; Belen Lopez-Rodriguez, Ana; Maria Marco, Eva] Univ Complutense, Fac Biol, Physiol Dept Anim Physiol 2, Hlth Res Inst,Hosp Clin San Carlos, E-28040 Madrid, Spain.
[Mendrek, Adriana] Bishops Univ, Dept Psychol, Sherbrooke, PQ, Canada.
[Paus, Tomas] Univ Toronto, Rotman Res Inst, Toronto, ON, Canada.
[Paus, Tomas] McGill Univ, Montreal Neurol Inst, Montreal, PQ, Canada.
[Yehuda, Rachel] Mt Sinai Sch Med, New York, NY USA.
[Yehuda, Rachel; Cohen, Hagit] Ben Gurion Univ Negev, Fac Hlth Sci, Minist Hlth, Anxiety & Stress Res Unit,Mental Hlth Ctr, IL-84105 Beer Sheva, Israel.
[Lehrner, Amy] James J Peters Vet Affairs Med Ctr, Traumat Stress Studies Div, Bronx, NY USA.
[Wagner, Edward J.] Western Univ Hlth Sci, Coll Osteopath Med Pacific, Dept Basic Med Sci, Pomona, CA USA.
RP Viveros, MP (reprint author), Univ Complutense, Fac Biol, Dept Fisiol Fisiol Anim 2, C Jose Antonio Novais 2, E-28040 Madrid, Spain.
EM pazviver@bio.ucm.es
RI Lopez-Rodriguez, Ana Belen/A-8384-2015; Marco, Eva/K-8224-2015; Viveros,
Maria-Paz/S-6855-2016
OI Marco, Eva/0000-0002-2457-475X;
FU Instituto de Salud Carlos III, Redes tematicas de Investigacion
Cooperativa en salud (ISCIII y FEDER): Red de trastornos adictivos
[RD06/0001/1013]; GRUPOS UCM-BSCH [951579]; Ministerio de Ciencia e
Innovacion [BFU2009-10109]; Plan Nacional sobre Drogas [SAS/1250/2009]
FX This work was supported by Instituto de Salud Carlos III, Redes
tematicas de Investigacion Cooperativa en salud (ISCIII y FEDER): Red de
trastornos adictivos RD06/0001/1013; GRUPOS UCM-BSCH - 951579;
Ministerio de Ciencia e Innovacion BFU2009-10109, and Plan Nacional
sobre Drogas at SAS/1250/2009 official notification.
NR 257
TC 13
Z9 14
U1 3
U2 9
PU FRONTIERS RESEARCH FOUNDATION
PI LAUSANNE
PA PO BOX 110, LAUSANNE, 1015, SWITZERLAND
SN 1662-453X
J9 FRONT NEUROSCI-SWITZ
JI Front. Neurosci.
PY 2012
VL 6
AR UNSP 84
DI 10.3389/fnins.2012.00084
PG 21
WC Neurosciences
SC Neurosciences & Neurology
GA V35RF
UT WOS:000209165300093
PM 22701400
ER
PT J
AU Durazzo, TC
Hutchison, KE
Fryer, SL
Mon, A
Meyerhoff, DJ
AF Durazzo, Timothy C.
Hutchison, Kent E.
Fryer, Susanna L.
Mon, Anderson
Meyerhoff, Dieter J.
TI Associations of cigarette smoking and polymorphisms in brain-derived
neurotrophic factor and catechol-O-methyltransferase with neurocognition
in alcohol dependent individuals during early abstinence
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Article
DE cigarette smoking; brain-derived neurotrophic factor;
catechol-O-methyltransferase; neurocognition; alcohol dependence
AB Chronic cigarette smoking and polymorphisms in brain-derived neurotrophic factor (BDNF) and catechol-O-methyltransferase (COMT) are associated with neurocognition in normal controls and those with various neuropsychiatric conditions. The influence of BDNF and COMT on neurocognition in alcohol dependence is unclear. The primary goal of this report was to investigate the associations of single nucleotide polymorphisms (SNPs) in BDNF Val66Met (rs6265) and COMT Val158Met (rs4680) with neurocognition in a treatment-seeking alcohol dependent cohort and determine if neurocognitive differences between non-smokers and smokers previously observed in this cohort persist when controlled for these functional SNPs. Genotyping was conducted on 70 primarily male treatment-seeking alcohol dependent participants (ALC) who completed a comprehensive neuropsychological battery after 33 +/- 9 days of monitored abstinence. After controlling for COMT and BDNF genotypes, smoking ALC performed significantly worse than non-smoking ALC on the domains of auditory-verbal and visuospatial learning and memory, cognitive efficiency, general intelligence, processing speed, and global neurocognition. In smoking ALC, greater number of years of smoking over lifetime was related to poorer performance on multiple domains after controlling for genotypes and alcohol consumption. In addition, COMT Met homozygotes were superior to Val homozygotes on measures of executive skills and showed trends for higher general intelligence and visuospatial skills, while COMT Val/Met heterozygotes showed significantly better general intelligence than Val homozygotes. COMT Val homozygotes performed better than heterozygotes on auditory-verbal memory. BDNF genotype was not related to any neurocognitive domain. The findings are consistent with studies in normal controls and neuropsychiatric cohorts that reported COMT Met carriers demonstrated better performance on measures of executive skills and general intelligence. Results also indicated that the poorer performance of smoking compared to non-smoking ALC across multiple neurocognitive domains was not mediated by COMT or BDNF genotype. Overall, the findings lend support to the expanding clinical movement to make smoking cessation programs available to smokers at the inception of treatment for alcohol/substance use disorders.
C1 [Durazzo, Timothy C.; Fryer, Susanna L.; Mon, Anderson; Meyerhoff, Dieter J.] San Francisco VA Med Ctr, Ctr Imaging Neurodegenerat Dis, San Francisco, CA 94121 USA.
[Durazzo, Timothy C.; Fryer, Susanna L.; Mon, Anderson; Meyerhoff, Dieter J.] Univ Calif San Francisco, Dept Radiol & Biomed Imaging, San Francisco, CA 94143 USA.
[Hutchison, Kent E.] Univ Colorado, Boulder, CO 80309 USA.
RP Durazzo, TC (reprint author), San Francisco VA Med Ctr, Ctr Imaging Neurodegenerat Dis 114M, 4150 Clement St, San Francisco, CA 94121 USA.
EM timothy.durazzo@ucsf.edu
FU National Institute on Alcohol Abuse and Alcoholism [AA10788, AA012238];
National Institute on Drug Abuse [DA24136]
FX This material is the result of work supported by the National Institute
on Alcohol Abuse and Alcoholism (AA10788 to Dieter J. Meyerhoff;
AA012238 to Kent E. Hutchison) and the National Institute on Drug Abuse
(DA24136 to Timothy C. Durazzo) with resources and the use of facilities
at the San Francisco Veterans Administration Medical Center, San
Francisco, CA, USA. We thank Mary Rebecca Young, Kathleen Altieri, Ricky
Chen, and Drs. Peter Banys and Ellen Herbst of the Veterans
Administration Substance Abuse Day Hospital (which routinely offers
smoking cessation with substance abuse treatment), and Dr. David Pating,
Karen Moise, and their colleagues at the Kaiser Permanente Chemical
Dependency Recovery Program in San Francisco for their valuable
assistance in recruiting participants. We thank Dr. Wendy Ooteman for
assistance in collecting blood samples for DNA extraction. We also wish
to extend our gratitude to the study participants, who made this
research possible.
NR 86
TC 3
Z9 3
U1 1
U2 2
PU FRONTIERS RESEARCH FOUNDATION
PI LAUSANNE
PA PO BOX 110, LAUSANNE, 1015, SWITZERLAND
SN 1663-9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PY 2012
VL 3
AR UNSP 178
DI 10.3389/fphar.2012.00178
PG 9
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA V35XE
UT WOS:000209177700172
PM 23087644
ER
PT J
AU Yuan, JZ
Liu, YN
Tan, T
Guha, S
Gukovsky, I
Gukovskaya, A
Pandol, SJ
AF Yuan, Jingzhen
Liu, Yannan
Tan, Tanya
Guha, Sushovan
Gukovsky, Ilya
Gukovskaya, Anna
Pandol, Stephen J.
TI Protein kinase D regulates cell death pathways in experimental
pancreatitis
SO FRONTIERS IN PHYSIOLOGY
LA English
DT Article
DE pancreatic acinar cells; CCK; CID755673; CRT0066101; apoptosis; necrosis
AB Inflammation and acinar cell necrosis are two major pathological responses of acute pancreatitis, a serious disorder with no current therapies directed to its molecular pathogenesis. Serine/threonine protein kinase D family, which includes PKD/PKD1, PKD2, and PKD3, has been increasingly implicated in the regulation of multiple physiological and pathophysiological effects. We recently reported that PKD/PKD1, the predominant PKD isoform expressed in rat pancreatic acinar cells, mediates early events of pancreatitis including NE-kappa B activation and inappropriate intracellular digestive enzyme activation. In current studies, we investigated the role and mechanisms of PKD/PKD1 in the regulation of necrosis in pancreatic acinar cells by using two novel small molecule PKD inhibitors CID755673 and CR10066101 and molecular approaches in in vitro and in vivo experimental models of acute pancreatitis. Our results demonstrated that both CID755673 and CR10066101 are PKD-specific inhibitors and that PKD/PKD1 inhibition by either the chemical inhibitors or specific PKD/PKD1 siRNAs attenuated necrosis while promoting apoptosis induced by pathological doses of cholecystokinin-octapeptide (CCK) in pancreatic acinar cells. Conversely, up-regulation of PKD expression in pancreatic acinar cells increased necrosis and decreased apoptosis. We further showed that PKD/PKD1 regulated several key cell death signals including inhibitors of apoptotic proteins, caspases, receptor-interacting protein kinase 1 to promote necrosis. PKD/PKD1 inhibition by CID755673 significantly ameliorated necrosis and severity of pancreatitis in an in vivo experimental model of acute pancreatitis. Thus, our studies indicate that PKD/PKD1 is a key mediator of necrosis in acute pancreatitis and that PKD/PKD1 may represent a potential therapeutic target in acute pancreatitis.
C1 [Yuan, Jingzhen; Liu, Yannan; Tan, Tanya; Gukovsky, Ilya; Gukovskaya, Anna; Pandol, Stephen J.] Univ Calif Los Angeles, South California Res Ctr Alcohol Liver & Pancreat, Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA.
[Liu, Yannan] Beijing Hosp, Beijing, Peoples R China.
[Guha, Sushovan] Univ Texas MD Anderson Canc Ctr, Dept Gastroenterol Hepatol & Nutr, Houston, TX 77030 USA.
RP Yuan, JZ (reprint author), Univ Calif Los Angeles, South California Res Ctr Alcohol Liver & Pancreat, Vet Affairs Greater Los Angeles Healthcare Syst, West Los Angeles VA Healthcare Ctr, 11301 Wilshire Blvd,Bldg 258,Room 340, Los Angeles, CA 90073 USA.
EM jzyuan@ucla.edu
FU Department of Veterans Affairs Merits Grant; Southern California
Research Center for Alcoholic Liver and Pancreatic Diseases (NIH)
[P50-A11999]; UCLA Center of Excellence in Pancreatic Diseases (NIH)
[1P01AT0003960-01]; Lee Summer Student Research Award from Southern
California Research Center for Liver and Pancreatic Diseases
FX The authors would like to thank Dr. Aurelia Lugea for discussion and
help in animal experiment design and TUNEL staining, Dr. Olga Mareninova
for discussion of acinar cell staining. The authors also thank Dr. Edwin
Thrower (Yale University School of Medicine) and Dr. Christopher R.
Ireson and his group at the Cancer Research Technology Discovery
Laboratories, London, UK for providing us with CR10066101. This study
was supported by the Department of Veterans Affairs Merits Grant and the
Southern California Research Center for Alcoholic Liver and Pancreatic
Diseases (NIH Grant P50-A11999); UCLA Center of Excellence in Pancreatic
Diseases (NIH Grant 1P01AT0003960-01); and Lee Summer Student Research
Award from Southern California Research Center for Liver and Pancreatic
Diseases (to Tanya Tan).
NR 51
TC 17
Z9 18
U1 1
U2 4
PU FRONTIERS RESEARCH FOUNDATION
PI LAUSANNE
PA PO BOX 110, LAUSANNE, 1015, SWITZERLAND
SN 1664-042X
J9 FRONT PHYSIOL
JI Front. Physiol.
PY 2012
VL 3
AR UNSP 60
DI 10.3389/fphys.2012.00060
PG 17
WC Physiology
SC Physiology
GA V35UH
UT WOS:000209173000059
PM 22470346
ER
PT J
AU Zhang, Z
Sun, K
Saloner, DA
Wallace, AW
Ge, L
Baker, AJ
Guccione, JM
Ratcliffe, MB
AF Zhang, Zhihong
Sun, Kay
Saloner, David A.
Wallace, Arthur W.
Ge, Liang
Baker, Anthony J.
Guccione, Julius M.
Ratcliffe, Mark B.
TI The benefit of enhanced contractility in the infarct borderzone: a
virtual experiment
SO FRONTIERS IN PHYSIOLOGY
LA English
DT Article
DE myocardial Infarction; borderzone; finite element
AB Objectives: Contractile function in the normally perfused infarct borderzone (BZ) is depressed. However, the impact of reduced BZ contractility on left ventricular (LV) pump function is unknown. As a consequence, there have been no therapies specifically designed to improve BZ contractility. We tested the hypothesis that an improvement in borderzone contractility will improve LV pump function. Methods: From a previously reported study, magnetic resonance imaging (MRI) images with non-invasive tags were used to calculate 3D myocardial strain in five sheep 16 weeks after anteroapical myocardial infarction. Animal-specific finite element (FE) models were created using MRI data and LV pressure obtained at early diastolic filling. Analysis of borderzone function using those FE models has been previously reported. Chamber stiffness, pump function (Starling's law) and stress in the fiber, cross fiber, and circumferential directions were calculated. Animal-specific FE models were performed for three cases: (a) impaired BZ contractility (INJURED); (b) BZ-contractility fully restored (100% BZ IMPROVEMENT); or (c) BZ-contractility partially restored (50% BZ IMPROVEMENT). Results: 100% BZ IMPROVEMENT and 50% BZ IMPROVEMENT both caused an upward shift in the Starling relationship, resulting in a large (36 and 26%) increase in stroke volume at LVPED = 20 mmHg (8.0 ml, p < 0.001). Moreover, there were a leftward shift in the end-systolic pressure volume relationship, resulting in a 7 and 5% increase in LVPES at 110 mmHg (7.7 ml, p < 0.005). It showed that even 50% BZ IMPROVEMENT was sufficient to drive much of the calculated increase in function. Conclusion: Improved borderzone contractility has a beneficial effect on LV pump function. Partial improvement of borderzone contractility was sufficient to drive much of the calculated increase in function. Therapies specifically designed to improve borderzone contractility should be developed.
C1 [Zhang, Zhihong; Sun, Kay; Ge, Liang; Guccione, Julius M.; Ratcliffe, Mark B.] Univ Calif San Francisco, Dept Surg, San Francisco, CA USA.
[Zhang, Zhihong; Sun, Kay; Saloner, David A.; Wallace, Arthur W.; Ge, Liang; Baker, Anthony J.; Guccione, Julius M.; Ratcliffe, Mark B.] San Francisco VA Med Ctr, San Francisco, CA 94121 USA.
[Saloner, David A.] Univ Calif San Francisco, Dept Radiol, San Francisco, CA USA.
[Wallace, Arthur W.] Univ Calif San Francisco, Dept Anesthesia, San Francisco, CA 94143 USA.
[Ge, Liang; Guccione, Julius M.; Ratcliffe, Mark B.] Univ Calif San Francisco, Dept Bioengn, San Francisco, CA 94143 USA.
[Baker, Anthony J.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA.
RP Ratcliffe, MB (reprint author), San Francisco VA Med Ctr, Surg Serv 112, 4150 Clement St, San Francisco, CA 94121 USA.
EM mark.ratcliffe@va.gov
FU NIH [R01-HL-77921, R01-HL-63348]
FX This study was supported by NIH grant R01-HL-77921 (Dr. Guccione), and
R01-HL-63348 (Dr. Ratcliffe). This support is gratefully acknowledged.
NR 19
TC 3
Z9 3
U1 0
U2 0
PU FRONTIERS RESEARCH FOUNDATION
PI LAUSANNE
PA PO BOX 110, LAUSANNE, 1015, SWITZERLAND
SN 1664-042X
J9 FRONT PHYSIOL
JI Front. Physiol.
PY 2012
VL 3
AR UNSP 86
DI 10.3389/fphys.2012.00086
PG 6
WC Physiology
SC Physiology
GA V35UH
UT WOS:000209173000084
PM 22509168
ER
PT J
AU Clark, DG
AF Clark, David Glenn
TI Storage costs and heuristics interact to produce patterns of aphasic
sentence comprehension performance
SO FRONTIERS IN PSYCHOLOGY
LA English
DT Article
DE aphasia; syntax; semantics; sentence comprehension
AB Background: Despite general agreement that aphasic individuals exhibit difficulty understanding complex sentences, the nature of sentence complexity itself is unresolved. In addition, aphasic individuals appear to make use of heuristic strategies for understanding sentences. This research is a comparison of predictions derived from two approaches to the quantification of sentence complexity, one based on the hierarchical structure of sentences, and the other based on dependency locality theory (DLT). Complexity metrics derived from these theories are evaluated under various assumptions of heuristic use.
Method: A set of complexity metrics was derived from each general theory of sentence complexity and paired with assumptions of heuristic use. Probability spaces were generated that summarized the possible patterns of performance across 16 different sentence structures. The maximum likelihood of comprehension scores of 42 aphasic individuals was then computed for each probability space and the expected scores from the best-fitting points in the space were recorded for comparison to the actual scores. Predictions were then compared using measures of fit quality derived from linear mixed effects models.
Results: All three of the metrics that provide the most consistently accurate predictions of patient scores rely on storage costs based on the DLT. Patients appear to employ an Agent Theme heuristic, but vary in their tendency to accept heuristically generated interpretations. Furthermore, the ability to apply the heuristic may be degraded in proportion to aphasia severity.
Conclusion: DLT-derived storage costs provide the best prediction of sentence comprehension patterns in aphasia. Because these costs are estimated by counting incomplete syntactic dependencies at each point in a sentence, this finding suggests that aphasia is associated with reduced availability of cognitive resources for maintaining these dependencies.
C1 [Clark, David Glenn] Birmingham VA Med Ctr, Birmingham, AL USA.
[Clark, David Glenn] Univ Alabama Birmingham, Dept Neurol, Birmingham, AL 35294 USA.
RP Clark, DG (reprint author), Univ Alabama Birmingham, Dept Neurol, 1720 7th Ave South SC 620C, Birmingham, AL 35294 USA.
EM dgclark@uab.edu
NR 64
TC 0
Z9 0
U1 3
U2 5
PU FRONTIERS RESEARCH FOUNDATION
PI LAUSANNE
PA PO BOX 110, LAUSANNE, 1015, SWITZERLAND
SN 1664-1078
J9 FRONT PSYCHOL
JI Front. Psychol.
PY 2012
VL 3
AR 135
DI 10.3389/fpsyg.2012.00135
PG 19
WC Psychology, Multidisciplinary
SC Psychology
GA V31DI
UT WOS:000208863900147
PM 22590462
ER
PT S
AU Mahanian, M
Fiala, M
Mizwicki, MT
La Cava, A
AF Mahanian, Michelle
Fiala, Milan
Mizwicki, Mathew T.
La Cava, Antonio
BE Aggarwal, BB
Krishnan, S
Guha, S
TI Immune Modulation of Inflammation in Neurodegenerative Diseases
Alzheimer's Disease and Amyotrophic Lateral Sclerosis
SO INFLAMMATION, LIFESTYLE AND CHRONIC DISEASES: THE SILENT LINK
SE Oxidative Stress and Disease
LA English
DT Article; Book Chapter
ID CEREBRAL AMYLOID ANGIOPATHY; INNATE IMMUNITY; BETA-PROTEIN; MOUSE MODEL;
MACROPHAGES; ACTIVATION; MICROGLIA; CELLS; MICE; ALS
C1 [Mahanian, Michelle; Fiala, Milan; La Cava, Antonio] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA.
[Fiala, Milan] Univ Calif Los Angeles, David Geffen Sch Med, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90095 USA.
[Mizwicki, Mathew T.] Univ Calif Riverside, Dept Biochem, Riverside, CA 92521 USA.
RP Mahanian, M (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA.
NR 50
TC 0
Z9 0
U1 0
U2 0
PU CRC PRESS-TAYLOR & FRANCIS GROUP
PI BOCA RATON
PA 6000 BROKEN SOUND PARKWAY NW, STE 300, BOCA RATON, FL 33487-2742 USA
SN 2155-0255
BN 978-1-4398-3990-4; 978-1-4398-3989-8
J9 OXIDAT STRESS DIS
PY 2012
BP 41
EP 55
PG 15
WC Primary Health Care; Immunology
SC General & Internal Medicine; Immunology
GA BC8CS
UT WOS:000355550900003
ER
PT B
AU Pekow, CA
AF Pekow, Cynthia A.
BE Suckow, MA
Stevens, KA
Wilson, RP
TI Basic Experimental Methods in the Rabbit
SO LABORATORY RABBIT, GUINEA PIG, HAMSTER, AND OTHER RODENTS
SE American College of Laboratory Animal Medicine Series
LA English
DT Article; Book Chapter
ID ARTIFICIAL-INSEMINATION; ACCESS; CATHETERIZATION; COLLECTION; DEVICE;
BLOOD; SUBSTANCES; INTUBATION; ANIMALS; MODEL
C1 Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA 98108 USA.
RP Pekow, CA (reprint author), Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA 98108 USA.
NR 63
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER ACADEMIC PRESS INC
PI SAN DIEGO
PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA
BN 978-0-12-380921-6; 978-0-12-380920-9
J9 AM COLL LAB
PY 2012
BP 243
EP 258
DI 10.1016/B978-0-12-380920-9.00010-9
PG 16
WC Veterinary Sciences
SC Veterinary Sciences
GA BA2YY
UT WOS:000333993900011
ER
PT J
AU Kim, S
Beyer, BA
Lewis, C
Nadel, JA
AF Kim, S.
Beyer, B. A.
Lewis, C.
Nadel, J. A.
TI Normal CFTR inhibits a pro-inflammatory IL-1R-TACE-EGFR pathway in
airway epithelial cells.
SO MOLECULAR BIOLOGY OF THE CELL
LA English
DT Meeting Abstract
C1 [Kim, S.; Beyer, B. A.] Oregon Hlth & Sci Univ, Portland VA Med Ctr, Portland, OR 97201 USA.
[Lewis, C.; Nadel, J. A.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CELL BIOLOGY
PI BETHESDA
PA 8120 WOODMONT AVE, STE 750, BETHESDA, MD 20814-2755 USA
SN 1059-1524
EI 1939-4586
J9 MOL BIOL CELL
JI Mol. Biol. Cell
PY 2012
VL 23
MA 685
PG 1
WC Cell Biology
SC Cell Biology
GA V38MX
UT WOS:000209348602318
ER
PT J
AU Minchew, CL
Didenko, VV
AF Minchew, C. L.
Didenko, V. V.
TI Color-shifting FRET sensor for detection of phagocytic phase of
apoptosis.
SO MOLECULAR BIOLOGY OF THE CELL
LA English
DT Meeting Abstract
C1 [Minchew, C. L.; Didenko, V. V.] Baylor Coll Med, Neurosurg & Mol & Cellular Biol, Houston, TX 77030 USA.
[Minchew, C. L.; Didenko, V. V.] Michael E DeBakey Vet Adm Med Ctr, Houston, TX USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CELL BIOLOGY
PI BETHESDA
PA 8120 WOODMONT AVE, STE 750, BETHESDA, MD 20814-2755 USA
SN 1059-1524
EI 1939-4586
J9 MOL BIOL CELL
JI Mol. Biol. Cell
PY 2012
VL 23
MA 1708
PG 1
WC Cell Biology
SC Cell Biology
GA V38MX
UT WOS:000209348605076
ER
PT B
AU Sepulveda, JL
AF Sepulveda, Jorge L.
BE Dasgupta, A
Langman, LJ
TI Genetic Aspect of Opiate Metabolism and Addiction
SO PHARMACOGENOMICS OF ALCOHOL AND DRUGS OF ABUSE
LA English
DT Article; Book Chapter
ID OPIOID RECEPTOR GENE; METHADONE-MAINTENANCE TREATMENT; HUMAN
LIVER-MICROSOMES; SINGLE-NUCLEOTIDE POLYMORPHISM; P-GLYCOPROTEIN;
ALCOHOL DEPENDENCE; GLUCURONOSYLTRANSFERASE 2B7; HEROIN-ADDICTION;
N-DEMETHYLATION; CANCER-PATIENTS
C1 [Sepulveda, Jorge L.] Philadelphia VA Med Ctr, Pathol & Lab Med Serv, Philadelphia, PA 19104 USA.
[Sepulveda, Jorge L.] Univ Penn, Philadelphia, PA 19104 USA.
RP Sepulveda, JL (reprint author), Philadelphia VA Med Ctr, Pathol & Lab Med Serv, Philadelphia, PA 19104 USA.
NR 139
TC 0
Z9 0
U1 1
U2 3
PU CRC PRESS-TAYLOR & FRANCIS GROUP
PI BOCA RATON
PA 6000 BROKEN SOUND PARKWAY NW, STE 300, BOCA RATON, FL 33487-2742 USA
BN 978-1-4398-5612-3; 978-1-4398-5611-6
PY 2012
BP 165
EP 194
D2 10.1201/b11879
PG 30
WC Substance Abuse; Pharmacology & Pharmacy
SC Substance Abuse; Pharmacology & Pharmacy
GA BC9LX
UT WOS:000356613400009
ER
PT B
AU Sepulveda, JL
AF Sepulveda, Jorge L.
BE Dasgupta, A
Langman, LJ
TI Methodologies in Pharmacogenetics Testing
SO PHARMACOGENOMICS OF ALCOHOL AND DRUGS OF ABUSE
LA English
DT Article; Book Chapter
ID DNA; DIAGNOSTICS; ASSAY; NANOPORE; INVADER
C1 [Sepulveda, Jorge L.] Philadelphia VA Med Ctr, Pathol & Lab Med Serv, Philadelphia, PA 19104 USA.
[Sepulveda, Jorge L.] Univ Penn, Philadelphia, PA 19104 USA.
RP Sepulveda, JL (reprint author), Philadelphia VA Med Ctr, Pathol & Lab Med Serv, Philadelphia, PA 19104 USA.
NR 27
TC 0
Z9 0
U1 0
U2 0
PU CRC PRESS-TAYLOR & FRANCIS GROUP
PI BOCA RATON
PA 6000 BROKEN SOUND PARKWAY NW, STE 300, BOCA RATON, FL 33487-2742 USA
BN 978-1-4398-5612-3; 978-1-4398-5611-6
PY 2012
BP 211
EP 228
D2 10.1201/b11879
PG 18
WC Substance Abuse; Pharmacology & Pharmacy
SC Substance Abuse; Pharmacology & Pharmacy
GA BC9LX
UT WOS:000356613400011
ER
PT B
AU Farid, M
Spiegel, B
AF Farid, Mary
Spiegel, Brennan
BE Plevris, JN
Howden, CW
TI The Clinical Approach to Dyspepsia
SO PROBLEM-BASED APPROACH TO GASTROENTEROLOGY AND HEPATOLOGY
LA English
DT Article; Book Chapter
ID RANDOMIZED CONTROLLED-TRIAL; PRIMARY-CARE PATIENTS; PEPTIC-ULCER
DISEASE; HELICOBACTER-PYLORI; MANAGEMENT
C1 [Farid, Mary] Univ Calif Los Angeles, Affiliated Training Program Digest Dis, Los Angeles, CA 90095 USA.
[Spiegel, Brennan] Univ Calif Los Angeles, David Geffen Sch Med, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90095 USA.
[Spiegel, Brennan] UCLA VA Ctr Outcomes Res & Educ, Los Angeles, CA USA.
RP Farid, M (reprint author), Univ Calif Los Angeles, Affiliated Training Program Digest Dis, Los Angeles, CA 90095 USA.
RI Plevris, John/O-3517-2014
NR 10
TC 0
Z9 0
U1 0
U2 0
PU BLACKWELL SCIENCE PUBL
PI OXFORD
PA OSNEY MEAD, OXFORD OX2 0EL, ENGLAND
BN 978-1-4051-8227-0; 978-1-4443-4635-0
PY 2012
BP 39
EP 43
D2 10.1002/9781444346381
PG 5
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA BA6GX
UT WOS:000337140200004
ER
PT J
AU Maguen, S
Cohen, B
Ren, L
Bosch, J
Kimerling, R
Seal, K
AF Maguen, Shira
Cohen, Beth
Ren, Li
Bosch, Jeane
Kimerling, Rachel
Seal, Karen
TI Gender Differences in Military Sexual Trauma and Mental Health Diagnoses
among Iraq and Afghanistan Veterans with Posttraumatic Stress Disorder
SO WOMENS HEALTH ISSUES
LA English
DT Article
AB Objective: We examined correlates of posttraumatic stress disorder (PTSD), including military sexual trauma (MST), in Iraq and Afghanistan veterans. We also compared mental health comorbidities by gender among veterans with PTSD, with and without MST.
Methods: Retrospective data analyses were conducted using Department of Veterans Affairs (VA) administrative data from 213,803 Iraq and Afghanistan veterans and the subset diagnosed with PTSD from April 1, 2002, to October 1, 2008. We used descriptive statistics and multivariate logistic regression compared by gender to investigate independent correlates and mental health comorbidities associated with PTSD, with and without MST.
Results: Among women with PTSD, 31% screened positive for MST; 1% of men with PTSD screened positive for MST. Among those with PTSD, veterans with MST had more comorbid mental health diagnoses than those without MST. Women with PTSD and MST were more likely to receive comorbid depression, anxiety, and eating disorder diagnoses, and men were more likely to receive comorbid substance use disorder diagnoses.
Conclusions: MST is associated with an increased prevalence of mental health disorders comorbid with PTSD. Better understanding comorbidity patterns will allow for targeted evaluation and treatment of returning veterans with MST. Published by Elsevier Inc.
C1 [Maguen, Shira; Cohen, Beth; Ren, Li; Bosch, Jeane; Seal, Karen] San Francisco VA Med Ctr, San Francisco, CA 94121 USA.
[Maguen, Shira; Cohen, Beth; Seal, Karen] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA.
[Kimerling, Rachel] VA Palo Alto Hlth Care Syst, Ctr Hlth Care Evaluat, Menlo Pk, CA USA.
RP Maguen, S (reprint author), San Francisco VA Med Ctr, 4150 Clement St,116-P, San Francisco, CA 94121 USA.
EM Shira.Maguen@va.gov
RI Schueter, nicos/A-3625-2014
OI Kimerling, Rachel/0000-0003-0996-4212
FU NHLBI NIH HHS [K23 HL 094765-01]
NR 26
TC 54
Z9 54
U1 2
U2 7
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1049-3867
EI 1878-4321
J9 WOMEN HEALTH ISS
JI Womens Health Iss.
PD JAN-FEB
PY 2012
VL 22
IS 1
BP E61
EP E66
DI 10.1016/j.whi.2011.07.010
PG 6
WC Public, Environmental & Occupational Health; Women's Studies
SC Public, Environmental & Occupational Health; Women's Studies
GA V33SP
UT WOS:000209038800008
PM 21907590
ER
PT J
AU Subramanian, SL
Hull, RL
Zraika, S
Aston-Mourney, K
Udayasankar, J
Kahn, SE
AF Subramanian, S. L.
Hull, R. L.
Zraika, S.
Aston-Mourney, K.
Udayasankar, J.
Kahn, S. E.
TI cJUN N-terminal kinase (JNK) activation mediates islet amyloid-induced
beta cell apoptosis in cultured human islet amyloid polypeptide
transgenic mouse islets
SO DIABETOLOGIA
LA English
DT Article
DE Beta cell apoptosis; hIAPP; Islet amyloid; JNK activation
ID ENDOPLASMIC-RETICULUM STRESS; OXIDATIVE STRESS; HUMAN AMYLIN;
DIABETES-MELLITUS; ER STRESS; TYPE-2; EXPRESSION; INSULIN; GLUCOSE;
PROTEIN
AB Aggregation of human islet amyloid polypeptide (hIAPP) as islet amyloid is associated with increased beta cell apoptosis and reduced beta cell mass in type 2 diabetes. Islet amyloid formation induces oxidative stress, which contributes to beta cell apoptosis. The cJUN N-terminal kinase (JNK) pathway is a critical mediator of beta cell apoptosis in response to stress stimuli including oxidative stress and exogenous application of hIAPP. We determined whether amyloid formation by endogenous hIAPP mediates beta cell apoptosis through JNK activation and downstream signalling pathways.
hIAPP transgenic and non-transgenic mouse islets were cultured for up to 144 h in 16.7 mmol/l glucose to induce islet amyloid in the presence or absence of the amyloid inhibitor Congo Red or a cell-permeable JNK inhibitor. Amyloid, beta cell apoptosis, JNK signalling and activation of downstream targets in the intrinsic and extrinsic apoptotic pathways were measured.
JNK activation occurred with islet amyloid formation in hIAPP transgenic islets after 48 and 144 h in culture. Neither high glucose nor the hIAPP transgene alone was sufficient to activate JNK independent of islet amyloid. Inhibition of islet amyloid formation with Congo Red reduced beta cell apoptosis and partially decreased JNK activation. JNK inhibitor treatment reduced beta cell apoptosis without affecting islet amyloid. Islet amyloid increased mRNA levels of markers of the extrinsic (Fas, Fadd) and intrinsic (Bim [also known as Bcl2l11]) apoptotic pathways, caspase 3 and the anti-apoptotic molecule Bclxl (also known as Bcl2l1) in a JNK-dependent manner.
Islet amyloid formation induces JNK activation, which upregulates predominantly pro-apoptotic signals in both extrinsic and intrinsic pathways, resulting in beta cell apoptosis.
C1 [Subramanian, S. L.; Hull, R. L.; Zraika, S.; Aston-Mourney, K.; Udayasankar, J.; Kahn, S. E.] VA Puget Sound Hlth Care Syst, Dept Med, Div Metab Endocrinol & Nutr, Seattle, WA 98108 USA.
[Subramanian, S. L.; Hull, R. L.; Zraika, S.; Aston-Mourney, K.; Udayasankar, J.; Kahn, S. E.] Univ Washington, Seattle, WA 98108 USA.
RP Kahn, SE (reprint author), VA Puget Sound Hlth Care Syst, Dept Med, Div Metab Endocrinol & Nutr, 1660 S Columbian Way, Seattle, WA 98108 USA.
EM skahn@u.washington.edu
OI Aston-Mourney, Kathryn/0000-0003-1412-6715; Kahn,
Steven/0000-0001-7307-9002; Hull, Rebecca/0000-0001-9690-4087
FU Department of Veterans Affairs; National Institutes of Health
[DK-075998, DK-074404, DK-080945, DK-007247, DK-017047]; American
Diabetes Association; University of Washington; Juvenile Diabetes
Research Foundation
FX We thank B. Barrow, C. Braddock, M. Cone, C. Forsyth, M. Peters, M.
Watts and J. Willard for their excellent technical support. This work
was supported by the Department of Veterans Affairs and National
Institutes of Health grants DK-075998 (S. E. Kahn), DK-074404 (R. L.
Hull), DK-080945 (S. Zraika), DK-007247 and DK-017047. S. Subramanian
and K. Aston-Mourney were supported by an American Diabetes Association
Mentor-Based Fellowship. K. Aston-Mourney was also supported by a
University of Washington McAbee Fellowship. J. Udayasankar was supported
by a Juvenile Diabetes Research Foundation Postdoctoral Fellowship.
NR 47
TC 30
Z9 31
U1 0
U2 7
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0012-186X
J9 DIABETOLOGIA
JI Diabetologia
PD JAN
PY 2012
VL 55
IS 1
BP 166
EP 174
DI 10.1007/s00125-011-2338-7
PG 9
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 857SI
UT WOS:000297739000023
PM 22038516
ER
PT J
AU Wenger, A
Englund, M
Wirth, W
Hudelmaier, M
Kwoh, K
Eckstein, F
AF Wenger, Andrea
Englund, Martin
Wirth, Wolfgang
Hudelmaier, Martin
Kwoh, Kent
Eckstein, Felix
CA OAI Investigators
TI Relationship of 3D meniscal morphology and position with knee pain in
subjects with knee osteoarthritis: a pilot study
SO EUROPEAN RADIOLOGY
LA English
DT Article
DE Meniscus; Extrusion; Pain; Knee osteoarthritis; Magnetic resonance
imaging
ID BONE-MARROW LESIONS; CARTILAGE LOSS; MULTICENTER OSTEOARTHRITIS;
ARTICULAR-CARTILAGE; ELDERLY PERSONS; INITIATIVE OAI; RISK-FACTORS;
JOINT; ASSOCIATION; TEARS
AB To explore whether quantitative, three-dimensional measurements of meniscal position and size are associated with knee pain using a within-person, between-knee study design.
We studied 53 subjects (19 men, 34 women) from the Osteoarthritis Initiative, with identical radiographic OA grades in both knees, but frequent pain in one and no pain in the other knee. The tibial plateau and menisci were analyzed using coronally reconstructed double echo steady-state sequence with water excitation (DESSwe) MRI.
The medial meniscus covered a smaller proportion of the tibial plateau (-5%) and displayed greater extrusion of the body (+15%) in painful than in painless knees (paired t-test; p < 0.05). The external margin of the lateral meniscus showed greater extrusion of the body in painful knees (+22%; p = 0.03), but no significant difference in the position of its internal margin or tibial coverage. Medial or lateral extrusion a parts per thousand yen3 mm was more frequent in painful (n = 23) than in painless knees (n = 12; McNemar's test; p = 0.02). No significant association was observed between meniscal size and knee pain.
These data suggest a relationship between extrusion of the meniscal body, as measured with quantitative MRI, and knee pain in subjects with knee OA. Further studies need to confirm these findings and their clinical relevance.
Meniscal segmentation provides quantitative measures of meniscal size/position
Between-knee, within-person approaches can explore potential sources of knee pain
Meniscal extrusion may be a potential source of knee pain.
C1 [Wenger, Andrea; Wirth, Wolfgang; Hudelmaier, Martin; Eckstein, Felix] Paracelsus Med Univ, Inst Anat & Musculoskeletal Res, A-5020 Salzburg, Austria.
[Englund, Martin] Lund Univ, Dept Orthoped, Lund, Sweden.
[Englund, Martin] Boston Univ, Sch Med, Clin Epidemiol Res & Training Unit, Boston, MA 02118 USA.
[Wirth, Wolfgang; Hudelmaier, Martin; Eckstein, Felix] Chondrometrics GmbH, Ainring, Germany.
[Kwoh, Kent] Univ Pittsburgh, Div Rheumatol & Clin Immunol, Pittsburgh, PA USA.
[Kwoh, Kent] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
RP Wenger, A (reprint author), Paracelsus Med Univ, Inst Anat & Musculoskeletal Res, Strubergasse 21, A-5020 Salzburg, Austria.
EM andrea.wenger@pmu.ac.at
RI Wirth, Wolfgang/C-8724-2011; Englund, Martin/J-7245-2012
OI Wirth, Wolfgang/0000-0002-2297-8283; Englund, Martin/0000-0003-3320-2437
FU OAI [N01-AR-2-2258, N01-AR-2-2259, N01-AR-2-2260, N01-AR-2-2261,
N01-AR-2-2262]; National Institutes of Health; Pfizer, Inc.; Novartis
Pharmaceuticals Corporation; Merck Research Laboratories;
GlaxoSmithKline; Paracelsus Medical University; Swedish Research
Council; Faculty of Medicine, Lund University; Royal Physiographic
Society in Lund; [AR054731]
FX The study and image acquisition was supported by the OAI (contract nos.
N01-AR-2-2258; N01-AR-2-2259; N01-AR-2-2260; N01-AR-2-2261;
N01-AR-2-2262) funded by the National Institutes of Health and conducted
by the OAI Study Investigators. Private funding partners include Pfizer,
Inc.; Novartis Pharmaceuticals Corporation; Merck Research Laboratories;
and GlaxoSmithKline. Private sector funding for the OAI is managed by
the Foundation for the National Institutes of Health. This manuscript
has received the approval of the OAI Publications Committee based on a
review of its scientific content and data interpretation.; The image
analysis was supported by funds from Paracelsus Medical University (PMU
Forschungsfond). Dr. Englund is supported by the Swedish Research
Council, the Faculty of Medicine, Lund University, and the Royal
Physiographic Society in Lund and Dr. Kwoh by grant AR054731. Felix
Eckstein is CEO and co- owner of Chondrometrics GmbH; he also provides
consulting services to MerckSerono, Novartis and Sanofi Aventis.
Wolfgang Wirth is co-owner of Chondrometrics GmbH.
NR 53
TC 28
Z9 28
U1 0
U2 4
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0938-7994
J9 EUR RADIOL
JI Eur. Radiol.
PD JAN
PY 2012
VL 22
IS 1
BP 211
EP 220
DI 10.1007/s00330-011-2234-z
PG 10
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA 857UX
UT WOS:000297749100022
PM 21842432
ER
PT J
AU Holmes, B
Artinian, N
Anderson, L
Martin, J
Masri, J
Cloninger, C
Bernath, A
Bashir, T
Benavides-Serrato, A
Gera, J
AF Holmes, Brent
Artinian, Nicholas
Anderson, Lauren
Martin, Jheralyn
Masri, Janine
Cloninger, Cheri
Bernath, Andrew
Bashir, Tariq
Benavides-Serrato, Angelica
Gera, Joseph
TI Protor-2 interacts with tristetraprolin to regulate mRNA stability
during stress
SO CELLULAR SIGNALLING
LA English
DT Article
DE Protor-2; Tristetraprolin; mTORC2; mRNA stability; Stress
ID AU-RICH ELEMENTS; PROTEIN-KINASE; MTOR; BINDING; CANCER; RICTOR;
TURNOVER; GRANULES; ALPHA; DEADENYLATION
AB The A/U-rich RNA-binding protein tristetraprolin (TIP) is an mRNA destabilizing factor which plays a role in the regulated turnover of many transcripts encoding proteins involved in immune function and cell growth control. TTP also plays a role in stress-induced destabilization of mRNAs. Here we report the interaction of TTP with a component of the mTORC2 kinase, Protor-2 (PRR5-L, protein Q6MZQ0/FLJ14213/CAE45978). Protor-2 is structurally similar to human PRR5 and has been demonstrated to bind mTORC2 via Rictor and/or Sin1 and may signal downstream events promoting apoptosis. Protor-2 dissociates from mTORC2 upon hyperactivation of the kinase and is not required for mTORC2 integrity or activity. We identified Protor-2 in a yeast two-hybrid screen as a TTP interactor using the C-terminal mRNA decay domain of TTP as bait. The interaction of Protor-2 with TTP was also confirmed in vivo in co-immunoprecipitation experiments and Protor-2 was also detected in immunoprecipitates of Rictor. Protor-2 was shown to stimulate UP-mediated mRNA turnover of several TIP-associated mRNAs (TNF-alpha, GM-CSF, IL-3 and COX-2) in Jurkat cells when overexpressed while the half-lives of transcripts which do not decay via a TTP-mediated mechanism were unaffected. Knockdown of Protor-2 via RNAi inhibited TIP-mediated mRNA turnover of these TTP-associated mRNAs and inhibited association of TTP with cytoplasmic stress granules (SG) or mRNA processing bodies (P-bodies) following induction of the integrated stress response. These results suggest that Protor-2 associates with TTP to accelerate TTP-mediated mRNA turnover and functionally links the control of TIP-regulated mRNA stability to mTORC2 activity. (C) 2011 Elsevier Inc. All rights reserved.
C1 [Holmes, Brent; Artinian, Nicholas; Anderson, Lauren; Martin, Jheralyn; Masri, Janine; Cloninger, Cheri; Bernath, Andrew; Bashir, Tariq; Benavides-Serrato, Angelica; Gera, Joseph] Greater Los Angeles Vet Affairs Healthcare Syst, Dept Res & Dev, Los Angeles, CA 91343 USA.
[Gera, Joseph] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90048 USA.
[Gera, Joseph] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90048 USA.
[Gera, Joseph] Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90048 USA.
RP Gera, J (reprint author), VA UCLA Med Ctr, Dept Res & Dev, 16111 Plummer St 151,Bldg 1,Rm C111A, North Hills, CA 91343 USA.
EM jgera@mednet.ucla.edu
FU NIH [RO1CA109312]; US Department of Veterans Affairs
FX We thank Drs. Michael Hall and William Rigby for providing cell lines
and antibodies, Dr. Robert Nishimura for critical reading of the
manuscript and Ardella Sherwood for excellent administrative assistance.
This work was supported, in part, by grants from the NIH (RO1CA109312)
and the US Department of Veterans Affairs.
NR 45
TC 7
Z9 7
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0898-6568
J9 CELL SIGNAL
JI Cell. Signal.
PD JAN
PY 2012
VL 24
IS 1
BP 309
EP 315
DI 10.1016/j.cellsig.2011.09.015
PG 7
WC Cell Biology
SC Cell Biology
GA 852YH
UT WOS:000297392900034
PM 21964062
ER
PT B
AU Ghassemi, KA
Jensen, DM
AF Ghassemi, Kevin A.
Jensen, Dennis M.
BE Esrailian, E
TI NONVARICEAL UPPER GASTROINTESTINAL BLEEDING
SO GUT INSTINCTS: A CLINICIAN'S HANDBOOK OF DIGESTIVE AND LIVER DISEASES
LA English
DT Article; Book Chapter
ID MANAGEMENT
C1 [Ghassemi, Kevin A.; Jensen, Dennis M.] Univ Calif Los Angeles, David Geffen Sch Med, Div Digest Dis, Los Angeles, CA 90095 USA.
[Jensen, Dennis M.] UCLA Med Centet, W Los Angeles VA Med Ctr, CURE Digest Dis Res Ctr, Los Angeles, CA USA.
RP Ghassemi, KA (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Div Digest Dis, Los Angeles, CA 90095 USA.
NR 2
TC 0
Z9 0
U1 0
U2 0
PU SLACK INC
PI THOROFARE
PA 6900 GROVE ROAD, THOROFARE, NJ 08086-9447 USA
BN 978-1-55642-977-4
PY 2012
BP 59
EP 63
PG 5
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA BWY89
UT WOS:000295343100009
ER
PT B
AU Kovacs, TOG
AF Kovacs, Thomas O. G.
BE Esrailian, E
TI ACID-PEPTIC DISORDERS
SO GUT INSTINCTS: A CLINICIAN'S HANDBOOK OF DIGESTIVE AND LIVER DISEASES
LA English
DT Article; Book Chapter
C1 Univ Calif Los Angeles, David Geffen Sch Med, Div Digest Dis, VA Greater Los Angeles Hlth Care Syst, Los Angeles, CA 90095 USA.
RP Kovacs, TOG (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Div Digest Dis, VA Greater Los Angeles Hlth Care Syst, Los Angeles, CA 90095 USA.
NR 2
TC 0
Z9 0
U1 0
U2 0
PU SLACK INC
PI THOROFARE
PA 6900 GROVE ROAD, THOROFARE, NJ 08086-9447 USA
BN 978-1-55642-977-4
PY 2012
BP 65
EP 69
PG 5
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA BWY89
UT WOS:000295343100010
ER
PT B
AU Bhat, YM
Singh, IM
AF Bhat, Yasser M.
Singh, Inder M.
BE Esrailian, E
TI BILIARY DISEASES
SO GUT INSTINCTS: A CLINICIAN'S HANDBOOK OF DIGESTIVE AND LIVER DISEASES
LA English
DT Article; Book Chapter
C1 [Bhat, Yasser M.] San Francisco VA Med Ctr, San Francisco, CA USA.
[Bhat, Yasser M.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Singh, Inder M.] Univ Calif Los Angeles, David Geffen Sch Med, Div Digest Dis, Los Angeles, CA 90095 USA.
NR 3
TC 0
Z9 0
U1 0
U2 0
PU SLACK INC
PI THOROFARE
PA 6900 GROVE ROAD, THOROFARE, NJ 08086-9447 USA
BN 978-1-55642-977-4
PY 2012
BP 85
EP 93
PG 9
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA BWY89
UT WOS:000295343100013
ER
PT J
AU Wilhelm, CJ
Murphy-Crews, A
Menasco, DJ
Huckans, MS
Loftis, JM
AF Wilhelm, Clare J.
Murphy-Crews, Aaron
Menasco, Daniel J.
Huckans, Marilyn S.
Loftis, Jennifer M.
TI Corticotropin releasing factor-1 receptor antagonism alters the
biochemical, but not behavioral effects of repeated interleukin-1 beta
administration
SO NEUROPHARMACOLOGY
LA English
DT Article
DE Sickness behavior; Interleukin-1beta; Corticotropin releasing factor;
Forced swim test; p38 MAPK; Weight regulation; Cytokines
ID MAJOR DEPRESSIVE DISORDER; ACTIVATED PROTEIN-KINASE;
CHEMOTHERAPY-RELATED SYMPTOMS; INTERFERON-ALPHA; FORCED SWIM; SICKNESS
BEHAVIOR; CANCER; HORMONE; LIPOPOLYSACCHARIDE; RATS
AB Activation of the immune system via administration of cytokines is used for the treatment of chronic viral infections such as hepatitis C and for cancers resistant to radiotherapy. Cytokine-based treatments induce a range of "sickness" behaviors (e.g. depression, anxiety, pain, anorexia, and fatigue). Activation of the hypothalamic pituitary-adrenal axis via the induction of corticotropin releasing factor (CRF) may underlie these unwanted side effects. This study used repeated systemic injections of the pro-inflammatory cytokine interleukin-1 beta (IL-1 beta) to model the sickness behaviors and biochemical effects of immune system activation. We assessed the ability of CRF type I receptor (CRF1) antagonism to reduce biochemical and behavioral signs of sickness induced by IL-1 beta treatment. Forty Wistar rats were assigned to one of four groups: 1) saline + vehicle; 2) saline + DMP904 (CRF1 antagonist); 3) IL-1 beta + vehicle; 4) IL-1 beta + DMP904. Rats received intraperitoneal injections of either DMP904 or vehicle and of IL-1 beta or saline for six days. Sickness behavior was evaluated using body weight assessments and forced swim testing (FST). Blood and brain samples were collected to measure cytokine, p38 mitogen-activated protein kinase (MAPK), and phospho-p38 MAPK levels using multiplex techniques. There were significant reductions in body weights and FST immobility times associated with IL-1 beta administration. Rats administered IL-1 beta had significantly higher serum levels of IL-1 beta, but not interferon-gamma. Within the hippocampus, IL-1 beta reduced levels of p38 MAPK, but had no impact on levels of phospho-p38 MAPK except in the presence of DMP904. When administered alone, DMP904 had no significant effect on p38 MAPK or phospho-p38 MAPK in the hippocampus, but when given with IL-1 beta led to increased phosphorylation of p38 MAPIC IL-1 beta and DMP904 reduced levels of p38 MAPK within the hypothalamus, while co-administration of IL-1 beta and DMP904 abolished the effects of either drug alone. IL-1 beta decreased immobility time in the FST, and led to reductions in body weight, changes in serum cytokine levels and p38 MAPK regulation within the hippocampus and hypothalamus. DMP904 blocked some of the neurochemical effects of IL-1 beta, but did not impact the behavioral measures, or serum cytokines. Thus, additional studies will be needed to determine whether CRF1 antagonism is an effective treatment for cytokine-induced sickness.
This article is part of a Special Issue entitled 'Anxiety and Depression'. (C) 2011 Elsevier Ltd. All rights reserved.
C1 [Wilhelm, Clare J.; Menasco, Daniel J.; Huckans, Marilyn S.; Loftis, Jennifer M.] Portland VA Med Ctr, Res & Dev Serv, Portland, OR 97239 USA.
[Wilhelm, Clare J.; Huckans, Marilyn S.; Loftis, Jennifer M.] Oregon Hlth & Sci Univ, Dept Psychiat, Portland, OR 97239 USA.
[Murphy-Crews, Aaron; Loftis, Jennifer M.] Reed Coll, Portland, OR 97202 USA.
[Huckans, Marilyn S.] Portland VA Med Ctr, Div Mental Hlth, Portland, OR 97239 USA.
RP Loftis, JM (reprint author), Portland VA Med Ctr, Res & Dev Serv R&D 16, 3710 SW US Vet Hosp Rd, Portland, OR 97239 USA.
EM wilhelmc@ohsu.edu; aaron.murphycrews@gmail.com; dmenasco@mac.com;
Marilyn.huckans@va.gov; loftisj@ohsu.edu
FU Department of Veterans Affairs, Veterans Health Administration, Office
of Research and Development and Clinical Sciences Research and
Development; Department of Veterans Affairs, Veterans Health
Administration; Reed College (Portland, Oregon, USA); National Institute
of Mental Health [1-F32-MH071137-01]
FX This material is based upon work supported in part by the Department of
Veterans Affairs, Veterans Health Administration, Office of Research and
Development and Clinical Sciences Research and Development. JML and MSH
are supported by career development awards from the Department of
Veterans Affairs, Veterans Health Administration. This work was also
supported by Reed College (Portland, Oregon, USA) and the National
Institute of Mental Health (# 1-F32-MH071137-01). The authors would also
like to thank Bristol-Myers Squibb for generously providing the DMP904.
NR 76
TC 5
Z9 6
U1 0
U2 4
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0028-3908
EI 1873-7064
J9 NEUROPHARMACOLOGY
JI Neuropharmacology
PD JAN
PY 2012
VL 62
IS 1
SI SI
BP 313
EP 321
DI 10.1016/j.neuropharm.2011.07.040
PG 9
WC Neurosciences; Pharmacology & Pharmacy
SC Neurosciences & Neurology; Pharmacology & Pharmacy
GA 845MM
UT WOS:000296826800035
PM 21839099
ER
PT J
AU Anaya, DA
Cormier, JN
Xing, Y
Koller, P
Gaido, L
Hadfield, D
Chemaly, RF
Feig, BW
AF Anaya, Daniel A.
Cormier, Janice N.
Xing, Yan
Koller, Paul
Gaido, Lindsay
Hadfield, Donna
Chemaly, Roy F.
Feig, Barry W.
TI Development and Validation of a Novel Stratification Tool for
Identifying Cancer Patients at Increased Risk of Surgical Site Infection
SO ANNALS OF SURGERY
LA English
DT Article
ID LYMPH-NODE BIOPSY; WOUND-INFECTION; SURVEILLANCE NETWORK; POSTOPERATIVE
COMPLICATIONS; POSTDISCHARGE SURVEILLANCE; ANTIBIOTIC-PROPHYLAXIS;
MALIGNANT-MELANOMA; ABDOMINAL-SURGERY; CARDIAC-SURGERY; SYSTEM
AB Objective: To identify cancer-specific predictors of postoperative surgical site infection (SSI), and to develop a risk-stratification prognostic tool and compare its performance with traditional measures.
Background: The incidence and risk factors for SSI in cancer patients are unknown; current risk-stratification tools are not cancer-specific.
Methods: A prospective cohort study of patients undergoing elective operations (n = 503) at a tertiary cancer center was conducted. SSI was assessed using postdischarge active surveillance. Multivariate logistic regression analyses were performed to identify predictors of SSI, and beta-coefficients were used to create a scoring system. The sum of these was used to create a Risk of Surgical Site Infection in Cancer (RSSIC) score. The RSSIC was validated using bootstrapping techniques, and its discrimination was compared with the National Nosocomial Infection Surveillance (NNIS) risk index.
Results: The 30-day SSI incidence was 24%. Significant predictors of SSI included preoperative chemotherapy (OR = 1.94 [95% CI, 1.16-3.25]), clean-contaminated wounds (OR = 2.1 [95% CI, 1.24-3.55]), operative time = 2 hours (OR = 1.75 [95% CI, 1.01-3.04]) and = 4 hours (OR = 2.24 [95% CI, 1.22-4.1]), and surgical site: groin (OR = 4.65 [95% CI, 1.69-12.83]), and head/neck (OR = 0.12 [95% CI, 0.02-0.89]). The RSSIC score stratified patients into 4 risk strata for SSI. The performance of this score exceeded that of the NNIS score (AUC = 0.70 vs. 0.63, respectively; P = 0.01).
Conclusion: SSIs are common following cancer surgery. Preoperative chemotherapy, in addition to other common risk factors, was identified as a significant predictor for SSI in cancer patients. The RSSIC improves risk-stratification of cancer patients and identifies those that may benefit from more aggressive or novel preventive strategies.
C1 [Anaya, Daniel A.] Michael E DeBakey Dept Surg Surg Oncol, Houston, TX USA.
[Anaya, Daniel A.] Baylor Coll Med, Houston Hlth Serv, Houston, TX 77030 USA.
[Anaya, Daniel A.] Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Res Ctr Excellence, Houston, TX 77030 USA.
[Cormier, Janice N.; Xing, Yan; Koller, Paul; Feig, Barry W.] Univ Texas MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA.
[Gaido, Lindsay; Hadfield, Donna] Univ Texas MD Anderson Canc Ctr, Dept Nursing, Houston, TX 77030 USA.
[Chemaly, Roy F.] Univ Texas MD Anderson Canc Ctr, Dept Infect Dis Infect Control & Employee Hlth, Houston, TX 77030 USA.
RP Anaya, DA (reprint author), Michael E DeBakey VA Med Ctr, 2002 Holcombe Blvd,OCL 112, Houston, TX 77030 USA.
EM danaya@bcm.edu
FU Houston VA HSR&D Center of Excellence [HFP90-020]
FX This work was supported in part by the Houston VA HSR&D Center of
Excellence (HFP90-020). The views expressed in this article are those of
the author(s) and do not necessarily represent the views of the
Department of Veterans Affairs.
NR 43
TC 6
Z9 10
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0003-4932
J9 ANN SURG
JI Ann. Surg.
PD JAN
PY 2012
VL 255
IS 1
BP 134
EP 139
DI 10.1097/SLA.0b013e31823dc107
PG 6
WC Surgery
SC Surgery
GA 869ZM
UT WOS:000298638900021
PM 22143206
ER
PT J
AU Bains, SS
Egede, LE
AF Bains, Sujeev S.
Egede, Leonard E.
TI Association of Health Literacy with Complementary and Alternative
Medicine Use: A Cross-Sectional Study in Adult Primary Care Patients
SO BMC COMPLEMENTARY AND ALTERNATIVE MEDICINE
LA English
DT Article
ID QUALITY-OF-LIFE; BREAST-CANCER; SELF-CARE; CAM USE; ADHERENCE;
MEDICATION; THERAPIES; KNOWLEDGE; OUTCOMES; HYPERTENSION
AB Background: In the United States, it is estimated that 40% of adults utilize complementary and alternative medicine (CAM) therapies. Recently, national surveys report that over 90 million adults have inadequate health literacy. To date, no study has assessed health literacy and its effect on CAM use. The primary objective of this study was to assess the relationship between health literacy and CAM use independent of educational attainment. Second objective was to evaluate the differential effect of health literacy on CAM use by race.
Methods: 351 patients were recruited from an outpatient primary care clinic. Validated surveys assessed CAM use (I-CAM-Q), health literacy (REALM-R), and demographic information. We compared demographics by health literacy (adequate vs. inadequate) and overall and individual CAM categories by health literacy using chi square statistics. We found a race by health literacy interaction and ran sequential logistic regression models stratified by race to test the association between health literacy and overall CAM use (Model 1), Model 1 + education (Model 2), and Model 2 + other demographic characteristics (Model 3). We reported the adjusted effect of health literacy on CAM use for both whites and African Americans separately.
Results: 75% of the participants had adequate literacy and 80% used CAM. CAM use differed by CAM category. Among whites, adequate health literacy was significantly associated with increased CAM use in both unadjusted (Model 1, OR 7.68; p = 0.001) and models adjusted for education (Model 2, OR 7.70; p = 0.002) and other sociodemographics (Model 3, OR 9.42; p = 0.01). Among African Americans, adequate health literacy was not associated with CAM use in any of the models.
Conclusions: We found a race by literacy interaction suggesting that the relationship between health literacy and CAM use differed significantly by race. Adequate health literacy among whites is associated with increased CAM use, but not associated with CAM use in African Americans.
C1 [Bains, Sujeev S.; Egede, Leonard E.] Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA.
[Egede, Leonard E.] Ralph H Johnson VA Med Ctr, Ctr Dis Prevent & Hlth Intervent Diverse Populat, Charleston, SC 29401 USA.
[Bains, Sujeev S.; Egede, Leonard E.] Med Univ S Carolina, Ctr Hlth Dispar Res, Charleston, SC 29425 USA.
RP Egede, LE (reprint author), Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA.
EM egedel@musc.edu
FU NIDDK NIH HHS [K24 DK093699, T35 DK007431]
NR 41
TC 11
Z9 11
U1 2
U2 8
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1472-6882
J9 BMC COMPLEM ALTERN M
JI BMC Complement. Altern. Med.
PD DEC 30
PY 2011
VL 11
AR 138
DI 10.1186/1472-6882-11-138
PG 7
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA 890LF
UT WOS:000300145400001
PM 22208873
ER
PT J
AU Newman, JC
Feldman, R
AF Newman, John C.
Feldman, Robin
TI Copyright and Open Access at the Bedside
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Editorial Material
C1 [Newman, John C.] San Francisco VA Med Ctr, Div Geriatr, San Francisco, CA 94121 USA.
[Newman, John C.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Feldman, Robin] Univ Calif Hastings Coll Law, Law & Biosci Project, San Francisco, CA USA.
RP Newman, JC (reprint author), San Francisco VA Med Ctr, Div Geriatr, San Francisco, CA 94121 USA.
RI Newman, John/L-8112-2013
NR 4
TC 23
Z9 23
U1 0
U2 12
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD DEC 29
PY 2011
VL 365
IS 26
BP 2447
EP 2449
PG 3
WC Medicine, General & Internal
SC General & Internal Medicine
GA 868SD
UT WOS:000298544600002
PM 22204721
ER
PT J
AU Wong, ES
Wang, BCM
Garrison, LP
Alfonso-Cristancho, R
Flum, DR
Arterburn, DE
Sullivan, SD
AF Wong, Edwin S.
Wang, Bruce C. M.
Garrison, Louis P.
Alfonso-Cristancho, Rafael
Flum, David R.
Arterburn, David E.
Sullivan, Sean D.
TI Examining the BMI-mortality relationship using fractional polynomials
SO BMC MEDICAL RESEARCH METHODOLOGY
LA English
DT Article
ID BODY-MASS INDEX; ALL-CAUSE MORTALITY; FOLLOW-UP; EXCESS MORTALITY; LIFE
EXPECTANCY; UNITED-STATES; OLDER-ADULTS; OBESITY; WEIGHT; WOMEN
AB Background: Many previous studies estimating the relationship between body mass index (BMI) and mortality impose assumptions regarding the functional form for BMI and result in conflicting findings. This study investigated a flexible data driven modelling approach to determine the nonlinear and asymmetric functional form for BMI used to examine the relationship between mortality and obesity. This approach was then compared against other commonly used regression models.
Methods: This study used data from the National Health Interview Survey, between 1997 and 2000. Respondents were linked to the National Death Index with mortality follow-up through 2005. We estimated 5-year all-cause mortality for adults over age 18 using the logistic regression model adjusting for BMI, age and smoking status. All analyses were stratified by sex. The multivariable fractional polynomials (MFP) procedure was employed to determine the best fitting functional form for BMI and evaluated against the model that includes linear and quadratic terms for BMI and the model that groups BMI into standard weight status categories using a deviance difference test. Estimated BMI-mortality curves across models were then compared graphically.
Results: The best fitting adjustment model contained the powers -1 and -2 for BMI. The relationship between 5-year mortality and BMI when estimated using the MFP approach exhibited a J-shaped pattern for women and a U-shaped pattern for men. A deviance difference test showed a statistically significant improvement in model fit compared to other BMI functions. We found important differences between the MFP model and other commonly used models with regard to the shape and nadir of the BMI-mortality curve and mortality estimates.
Conclusions: The MFP approach provides a robust alternative to categorization or conventional linear-quadratic models for BMI, which limit the number of curve shapes. The approach is potentially useful in estimating the relationship between the full spectrum of BMI values and other health outcomes, or costs.
C1 [Wong, Edwin S.; Wang, Bruce C. M.; Garrison, Louis P.; Alfonso-Cristancho, Rafael; Sullivan, Sean D.] Univ Washington, Pharmaceut Outcomes Res & Policy Program, Seattle, WA 98195 USA.
[Wong, Edwin S.] VA Puget Sound Hlth Care Syst, NW Ctr Outcomes Res Older Adults, Seattle, WA USA.
[Flum, David R.] Univ Washington, Surg Outcomes Res Ctr, Seattle, WA 98195 USA.
[Arterburn, David E.] Grp Hlth Res Inst, Seattle, WA USA.
RP Wong, ES (reprint author), Univ Washington, Pharmaceut Outcomes Res & Policy Program, Seattle, WA 98195 USA.
EM eswong@uw.edu
FU HQ Air Force Surgeon General [FA7014-08-2-0002]; U.S. Air Force;
Department of Veterans Affairs [TPP 61-024]
FX This paper was written for the Bariatric Obesity Outcome Modeling
Collaborative. Members are listed at the end of the manuscript. This
work was supported by the HQ Air Force Surgeon General under Award No.
FA7014-08-2-0002. Opinions, interpretations, conclusions and
recommendations are those of the author and are not necessarily endorsed
by the U.S. Air Force. Dr. Wong was supported by the Department of
Veterans Affairs, Health Services Research and Development Post-Doctoral
Fellowship TPP 61-024.
NR 41
TC 15
Z9 15
U1 1
U2 7
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2288
J9 BMC MED RES METHODOL
JI BMC Med. Res. Methodol.
PD DEC 28
PY 2011
VL 11
AR 175
DI 10.1186/1471-2288-11-175
PG 11
WC Health Care Sciences & Services
SC Health Care Sciences & Services
GA 890SQ
UT WOS:000300165600001
PM 22204699
ER
PT J
AU Mathes, DW
Hwang, B
Graves, SS
Edwards, J
Chang, J
Storer, BE
Butts-Miwongtum, T
Sale, GE
Nash, RA
Storb, R
AF Mathes, David W.
Hwang, Billanna
Graves, Scott S.
Edwards, James
Chang, Jeff
Storer, Barry E.
Butts-Miwongtum, Tiffany
Sale, George E.
Nash, Richard A.
Storb, Rainer
TI Tolerance to Vascularized Composite Allografts in Canine Mixed
Hematopoietic Chimeras
SO TRANSPLANTATION
LA English
DT Article
DE Dog; Nonmyeloablative conditioning regimen; Mixed hematopoietic
chimerism; Skin grafting; Hematopoietic cell transplantation; CTA
transplantation; FoxP3; Tolerance; Vascularized Composite Allograft
ID TISSUE ALLOTRANSPLANT SURVIVAL; MESENCHYMAL STEM-CELLS; TOTAL-BODY
IRRADIATION; REGULATORY T-CELLS; LARGE-ANIMAL-MODEL; PHARMACOLOGICAL
IMMUNOSUPPRESSION; TRANSPLANTATION TOLERANCE; MARROW TRANSPLANTATION;
ADOPTIVE IMMUNOTHERAPY; MOLECULAR ANALYSIS
AB Background. Mixed donor-host chimerism, established through hematopoietic cell transplantation (HCT), is a reproducible strategy for the induction of tolerance toward solid organs. Here, we ask whether a nonmyeloablative conditioning regimen establishing mixed donor-host chimerism leads to tolerance of antigenic vascularized composite allografts.
Methods. Stable mixed chimerism was established in dogs given a sublethal dose (1-2 Gy) total body irradiation before and a short course of immunosuppression after dog leukocyte antigen-identical marrow transplantation. Vascularized composite allografts from marrow donors were performed after a median of 36 months (range, 4-54 months) after HCT.
Results. All marrow recipients maintained mixed donor-host hematopoietic chimerism and accepted vascularized composite allografts for periods ranging between 52 and 90 weeks; in turn, marrow donors rejected vascularized composite allografts from their respective marrow recipients within 18 to 29 days. Biopsies of muscle and skin of vascularized composite allografts from mixed chimeras showed few infiltrating cells compared with extensive infiltrates in biopsies of vascularized composite allografts from marrow donors. Elevated levels of CD3+ FoxP3+ T-regulatory cells were found in skin and muscle of vascularized composite allografts of mixed chimeras compared with normal tissues. In mixed chimeras, increased numbers of T-regulatory cells were found in draining compared with nondraining lymph nodes of vascularized composite allografts.
Conclusions. These data suggest that nonmyeloablative HCT may form the basis for future clinical applications of solid organ transplantation and that T-regulatory cells may function toward maintenance of the vascularized composite allograft.
C1 [Mathes, David W.; Hwang, Billanna; Graves, Scott S.; Chang, Jeff; Storer, Barry E.; Butts-Miwongtum, Tiffany; Sale, George E.; Nash, Richard A.; Storb, Rainer] Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98109 USA.
[Mathes, David W.; Edwards, James; Chang, Jeff] Univ Washington, Dept Surg, Seattle, WA 98195 USA.
[Graves, Scott S.; Nash, Richard A.; Storb, Rainer] Univ Washington, Dept Med, Seattle, WA USA.
[Storer, Barry E.] Univ Washington, Sch Publ Hlth, Seattle, WA 98195 USA.
[Sale, George E.] Univ Washington, Dept Pathol, Seattle, WA 98195 USA.
[Mathes, David W.] VA Puget Sound Hlth Care Syst, Plast Surg Serv, Seattle, WA USA.
RP Mathes, DW (reprint author), Fred Hutchinson Canc Res Ctr, Div Clin Res, POB 19024,D1-100,1100 Fairview Ave N, Seattle, WA 98109 USA.
EM dmathes@fhcrc.org
FU National Institutes of Health, Bethesda, MD [P01CA078902, P30CA015704];
National Endowment for Plastic Surgery; Plastic Surgery Educational
Foundation
FX This work was supported by the National Institutes of Health, Bethesda,
MD, grants P01CA078902 and P30CA015704.; David Mathes received support
from the National Endowment for Plastic Surgery Grant from the Plastic
Surgery Educational Foundation. Other authors declare no conflicts of
interest.
NR 50
TC 27
Z9 27
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0041-1337
J9 TRANSPLANTATION
JI Transplantation
PD DEC 27
PY 2011
VL 92
IS 12
BP 1301
EP 1308
DI 10.1097/TP.0b013e318237d6d4
PG 8
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA 863FW
UT WOS:000298149200007
PM 22082819
ER
PT J
AU Khodyakov, D
Hempel, S
Rubenstein, L
Shekelle, P
Foy, R
Salem-Schatz, S
O'Neill, S
Danz, M
Dalal, S
AF Khodyakov, Dmitry
Hempel, Susanne
Rubenstein, Lisa
Shekelle, Paul
Foy, Robbie
Salem-Schatz, Susanne
O'Neill, Sean
Danz, Margie
Dalal, Siddhartha
TI Conducting Online Expert panels: a feasibility and experimental
replicability study
SO BMC MEDICAL RESEARCH METHODOLOGY
LA English
DT Article
ID DELPHI TECHNIQUE; GUIDELINE DEVELOPMENT; CONSENSUS METHODS
AB Background: This paper has two goals. First, we explore the feasibility of conducting online expert panels to facilitate consensus finding among a large number of geographically distributed stakeholders. Second, we test the replicability of panel findings across four panels of different size.
Method: We engaged 119 panelists in an iterative process to identify definitional features of Continuous Quality Improvement (CQI). We conducted four parallel online panels of different size through three one-week phases by using the RAND's ExpertLens process. In Phase I, participants rated potentially definitional CQI features. In Phase II, they discussed rating results online, using asynchronous, anonymous discussion boards. In Phase III, panelists re-rated Phase I features and reported on their experiences as participants.
Results: 66% of invited experts participated in all three phases. 62% of Phase I participants contributed to Phase II discussions and 87% of them completed Phase III. Panel disagreement, measured by the mean absolute deviation from the median (MAD-M), decreased after group feedback and discussion in 36 out of 43 judgments about CQI features. Agreement between the four panels after Phase III was fair (four-way kappa = 0.36); they agreed on the status of five out of eleven CQI features. Results of the post-completion survey suggest that participants were generally satisfied with the online process. Compared to participants in smaller panels, those in larger panels were more likely to agree that they had debated each others' view points.
Conclusion: It is feasible to conduct online expert panels intended to facilitate consensus finding among geographically distributed participants. The online approach may be practical for engaging large and diverse groups of stakeholders around a range of health services research topics and can help conduct multiple parallel panels to test for the reproducibility of panel conclusions.
C1 [Khodyakov, Dmitry; Hempel, Susanne; Rubenstein, Lisa; Shekelle, Paul; O'Neill, Sean; Danz, Margie; Dalal, Siddhartha] RAND Corp, Santa Monica, CA 90401 USA.
[Rubenstein, Lisa; Danz, Margie] Vet Affairs Greater Los Angeles Sepulveda, North Hills, CA 91343 USA.
[Shekelle, Paul] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA.
[Foy, Robbie] Univ Leeds, Leeds Inst Hlth Sci, Leeds LS2 9JT, W Yorkshire, England.
[Salem-Schatz, Susanne] HealthCare Qual Initiat, Newton, MA 02459 USA.
[O'Neill, Sean] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA.
RP Khodyakov, D (reprint author), RAND Corp, 1776 Main St,POB 2138, Santa Monica, CA 90401 USA.
EM Dmitry_Khodyakov@rand.org
OI O'Neill, Sean/0000-0001-7759-8942
FU Robert Wood Johnson Foundation [65113, 67890]; RAND Corporation;
Veterans Health Administration
FX This study was supported by the Robert Wood Johnson Foundation (Grant ID
65113: Advancing the science of continuous quality improvement: A
framework for identifying, classifying and evaluating continuous quality
improvement studies and Grant ID 67890: Providing a framework for the
identification, classification, and evaluation of quality improvement
initiatives) and the RAND Corporation, with additional funding provided
by the Veterans Health Administration.
NR 30
TC 15
Z9 15
U1 4
U2 12
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2288
J9 BMC MED RES METHODOL
JI BMC Med. Res. Methodol.
PD DEC 23
PY 2011
VL 11
AR 174
DI 10.1186/1471-2288-11-174
PG 8
WC Health Care Sciences & Services
SC Health Care Sciences & Services
GA 921FJ
UT WOS:000302463200001
PM 22196011
ER
PT J
AU Needham, PG
Mikoluk, K
Dhakarwal, P
Khadem, S
Snyder, AC
Subramanya, AR
Brodsky, JL
AF Needham, Patrick G.
Mikoluk, Kasia
Dhakarwal, Pradeep
Khadem, Shaheen
Snyder, Avin C.
Subramanya, Arohan R.
Brodsky, Jeffrey L.
TI The Thiazide-sensitive NaCl Cotransporter Is Targeted for
Chaperone-dependent Endoplasmic Reticulum-associated Degradation
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID TRANSMEMBRANE CONDUCTANCE REGULATOR; INTEGRAL MEMBRANE-PROTEINS;
EPITHELIAL SODIUM-CHANNELS; ER-ASSOCIATED DEGRADATION;
NA+-CL-COTRANSPORTER; UBIQUITIN-LIGASE; CYSTIC-FIBROSIS;
SACCHAROMYCES-CEREVISIAE; FUNCTIONAL EXPRESSION; INTRACELLULAR
TRAFFICKING
AB The thiazide-sensitive NaCl cotransporter (NCC, SLC12A3) mediates salt reabsorption in the distal nephron of the kidney and is the target of thiazide diuretics, which are commonly prescribed to treat hypertension. Mutations in NCC also give rise to Gitelman syndrome, a hereditary salt-wasting disorder thought in most cases to arise from impaired NCC biogenesis through enhanced endoplasmic reticulum-associated degradation (ERAD). Because the machinery that mediates NCC quality control is completely undefined, we employed yeast as a model heterologous expression system to identify factors involved in NCC degradation. We confirmed that NCC was a bona fide ERAD substrate in yeast, as the majority of NCC polypeptide was integrated into ER membranes, and its turnover rate was sensitive to proteasome inhibition. NCC degradation was primarily dependent on the ER membrane-associated E3 ubiquitin ligase Hrd1. Whereas several ER luminal chaperones were dispensable for NCC ERAD, NCC ubiquitination and degradation required the activity of Ssa1, a cytoplasmic Hsp70 chaperone. Compatible findings were observed when NCC was expressed in mammalian kidney cells, as the cotransporter was polyubiquitinated and degraded by the proteasome, and mammalian cytoplasmic Hsp70 (Hsp72) coexpression stimulated the degradation of newly synthesized NCC. Hsp70 also preferentially associated with the ER-localized NCC glycosylated species, indicating that cytoplasmic Hsp70 plays a critical role in selecting immature forms of NCC for ERAD. Together, these results provide the first survey of components involved in the ERAD of a mammalian SLC12 cation chloride cotransporter and provide a framework for future studies on NCC ER quality control.
C1 [Needham, Patrick G.; Mikoluk, Kasia; Brodsky, Jeffrey L.] Univ Pittsburgh, Dept Biol Sci, Pittsburgh, PA 15261 USA.
[Dhakarwal, Pradeep; Khadem, Shaheen; Snyder, Avin C.; Subramanya, Arohan R.] Univ Pittsburgh, Sch Med, Renal Electrolyte Div, Dept Med, Pittsburgh, PA 15261 USA.
[Khadem, Shaheen; Subramanya, Arohan R.] Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA 15261 USA.
RP Needham, PG (reprint author), 3550 Terrace St,S832 Scaife Hall, Pittsburgh, PA 15261 USA.
EM ars129@pitt.edu
FU National Institutes of Health [DK79307, GM75061, DK84566]; United States
Department of Veterans Affairs; American Heart Association
[10BGIA3890010]
FX This work was supported, in whole or in part, by National Institutes of
Health Grants DK79307 (to the Pittsburgh Center for Kidney
Research-Model Organisms Core), GM75061 (to J. L. B.), and DK84566 (to
A. R. S.). This work was also supported by a Mid-Level Career
Development Award from the United States Department of Veterans Affairs
(to A. R. S.) and James A. Shaver Fund of the American Heart Association
Grant 10BGIA3890010 (to A. R. S.).
NR 64
TC 23
Z9 23
U1 1
U2 1
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
J9 J BIOL CHEM
JI J. Biol. Chem.
PD DEC 23
PY 2011
VL 286
IS 51
BP 43611
EP 43621
DI 10.1074/jbc.M111.288928
PG 11
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 866SH
UT WOS:000298402300004
PM 22027832
ER
PT J
AU Sun, Q
Prasad, R
Rosenthal, E
Katiyar, SK
AF Sun, Qian
Prasad, Ram
Rosenthal, Eben
Katiyar, Santosh K.
TI Grape seed proanthocyanidins inhibit the invasive potential of head and
neck cutaneous squamous cell carcinoma cells by targeting EGFR
expression and epithelial-to-mesenchymal transition
SO BMC COMPLEMENTARY AND ALTERNATIVE MEDICINE
LA English
DT Article
ID NF-KAPPA-B; GROWTH-FACTOR RECEPTOR; A431 CELLS; E-CADHERIN; CANCER;
FLUOROURACIL; PROGRESSION; ACTIVATION; BERBERINE; DOCETAXEL
AB Background: Head and neck squamous cell carcinoma (HNSCC) is responsible for over 20,000 deaths every year in United States. Most of the deaths are due, in large part, to its propensity to metastasize. We have examined the effect of bioactive component grape seed proanthocyanidins (GSPs) on human cutaneous HNSCC cell invasion and the molecular mechanisms underlying these effects using SCC13 cell line as an in vitro model.
Methods: The therapeutic effects of GSPs on cancer cell invasion were studied using Boyden chamber and wound healing assays. The effects of GSPs on the levels of various proteins related with cancer cell invasion were determined using western blot analysis.
Results: Using in vitro cell invasion assays, we observed that treatment of SCC13 cells with GSPs resulted in a concentration-dependent inhibition of cell invasion of these cells, which was associated with a reduction in the levels of epidermal growth factor receptor (EGFR). Treatment of cells with gefitinib and erlotinib, inhibitors of EGFR, or transient transfection of SCC13 cells with EGFR small interfering RNA, also inhibited invasion of these cells. The inhibition of cell invasion by GSPs was associated with the inhibition of the phosphorylation of ERK1/2, a member of mitogen-activated protein kinase family. Treatment of cells with UO126, an inhibitor of MEK, also inhibited the invasion potential of SCC13 cells. Additionally, inhibition of human cutaneous HNSCC cell invasion by GSPs was associated with reversal of epithelial-to-mesenchymal transition (EMT) process, which resulted in an increase in the levels of epithelial biomarker (E-cadherin) while loss of mesenchymal biomarkers (vimentin, fibronectin and N-cadherin) in cells. Similar effect on EMT biomarkers was also observed when cells were treated with erlotinib.
Conclusion: The results obtained from this study indicate that grape seed proanthocyanidins have the ability to inhibit the invasion of human cutaneous HNSCC cells by targeting the EGFR expression and reversing the process of epithelial-to-mesenchymal transition. These data suggest that GSPs can be developed as a complementary and alternative medicine for the prevention of invasion/metastasis of HNSCC cells.
C1 [Sun, Qian; Prasad, Ram; Katiyar, Santosh K.] Univ Alabama, Dept Dermatol, Birmingham, AL 35294 USA.
[Rosenthal, Eben] Univ Alabama, Dept Surg Otolaryngol, Birmingham, AL USA.
[Rosenthal, Eben; Katiyar, Santosh K.] Univ Alabama, Ctr Comprehens Canc, Birmingham, AL 35294 USA.
[Katiyar, Santosh K.] Univ Alabama, Nutr Obes Res Ctr, Birmingham, AL USA.
[Katiyar, Santosh K.] Birmingham Vet Affairs Med Ctr, Birmingham, AL 35294 USA.
RP Katiyar, SK (reprint author), Univ Alabama, Dept Dermatol, Birmingham, AL 35294 USA.
EM skatiyar@uab.edu
FU Veterans Administration; National Cancer Institute/NCCAM/NIH [CA140197,
CA140832]; UAB Skin Diseases Research Center [AR050948-01]
FX work was supported by the funds from Veterans Administration Merit
Review Award (S.K.K.) and National Cancer Institute/NCCAM/NIH (CA140197,
CA140832). NHEK were obtained from the UAB Skin Diseases Research Center
(AR050948-01). The content of this article does not necessarily reflect
the views or policies of the funding sources.
NR 25
TC 18
Z9 19
U1 2
U2 8
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1472-6882
J9 BMC COMPLEM ALTERN M
JI BMC Complement. Altern. Med.
PD DEC 21
PY 2011
VL 11
AR 134
DI 10.1186/1472-6882-11-134
PG 12
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA 876AS
UT WOS:000299079800001
PM 22188922
ER
PT J
AU Chen, JC
Brunzell, DH
Jackson, K
van der Vaart, A
Ma, JZ
Payne, TJ
Sherva, R
Farrer, LA
Gejman, P
Levinson, DF
Holmans, P
Aggen, SH
Damaj, I
Kuo, PH
Webb, BT
Anton, R
Kranzler, HR
Gelernter, J
Li, MD
Kendler, KS
Chen, XN
AF Chen, Jingchun
Brunzell, Darlene H.
Jackson, Kia
van der Vaart, Andrew
Ma, Jennie Z.
Payne, Thomas J.
Sherva, Richard
Farrer, Lindsay A.
Gejman, Pablo
Levinson, Douglas F.
Holmans, Peter
Aggen, Steven H.
Damaj, Imad
Kuo, Po-Hsiu
Webb, Bradley T.
Anton, Raymond
Kranzler, Henry R.
Gelernter, Joel
Li, Ming D.
Kendler, Kenneth S.
Chen, Xiangning
TI ACSL6 Is Associated with the Number of Cigarettes Smoked and Its
Expression Is Altered by Chronic Nicotine Exposure
SO PLOS ONE
LA English
DT Article
ID CANNABINOID RECEPTOR GENE; FAGERSTROM TOLERANCE QUESTIONNAIRE;
GENOME-WIDE ASSOCIATION; NEUROTROPHIC FACTOR; ALCOHOL DEPENDENCE;
AFRICAN-AMERICAN; ENDOCANNABINOID SYSTEM; CNR1 POLYMORPHISM;
WORKING-MEMORY; HEAVY SMOKING
AB Individuals with schizophrenia tend to be heavy smokers and are at high risk for tobacco dependence. However, the nature of the comorbidity is not entirely clear. We previously reported evidence for association of schizophrenia with SNPs and SNP haplotypes in a region of chromosome 5q containing the SPEC2, PDZ-GEF2 and ACSL6 genes. In this current study, analysis of the control subjects of the Molecular Genetics of Schizophrenia (MGS) sample showed similar pattern of association with number of cigarettes smoked per day (numCIG) for the same region. To further test if this locus is associated with tobacco smoking as measured by numCIG and FTND, we conducted replication and meta-analysis in 12 independent samples (n>16,000) for two markers in ACSL6 reported in our previous schizophrenia study. In the meta-analysis of the replication samples, we found that rs667437 and rs477084 were significantly associated with numCIG (p = 0.00038 and 0.00136 respectively) but not with FTND scores. We then used in vitro and in vivo techniques to test if nicotine exposure influences the expression of ACSL6 in brain. Primary cortical culture studies showed that chronic (5-day) exposure to nicotine stimulated ACSL6 mRNA expression. Fourteen days of nicotine administration via osmotic mini pump also increased ACSL6 protein levels in the prefrontal cortex and hippocampus of mice. These increases were suppressed by injection of the nicotinic receptor antagonist mecamylamine, suggesting that elevated expression of ACSL6 requires nicotinic receptor activation. These findings suggest that variations in the ACSL6 gene may contribute to the quantity of cigarettes smoked. The independent associations of this locus with schizophrenia and with numCIG in non-schizophrenic subjects suggest that this locus may be a common liability to both conditions.
C1 [Chen, Jingchun; Jackson, Kia; Aggen, Steven H.; Webb, Bradley T.; Kendler, Kenneth S.; Chen, Xiangning] Virginia Commonwealth Univ, Dept Psychiat, Richmond, VA 23284 USA.
[Chen, Jingchun; Jackson, Kia; Aggen, Steven H.; Webb, Bradley T.; Kendler, Kenneth S.; Chen, Xiangning] Virginia Commonwealth Univ, Virginia Inst Psychiat & Behav Genet, Richmond, VA USA.
[Brunzell, Darlene H.; Damaj, Imad] Virginia Commonwealth Univ, Dept Pharmacol & Toxicol, Richmond, VA USA.
[Brunzell, Darlene H.; Kendler, Kenneth S.] Virginia Commonwealth Univ, Inst Drug & Alcohol Studies, Richmond, VA USA.
[Brunzell, Darlene H.] Virginia Commonwealth Univ, Interdisciplinary Neurosci Program, Richmond, VA USA.
[van der Vaart, Andrew; Li, Ming D.] Univ Virginia, Dept Psychiat & Neurobehav Sci, Charlottesville, VA USA.
[Ma, Jennie Z.] Univ Virginia, Dept Publ Hlth Sci, Charlottesville, VA USA.
[Payne, Thomas J.] Univ Mississippi, Med Ctr, Dept Otolaryngol & Communicat Sci, Jackson, MS 39216 USA.
[Sherva, Richard; Farrer, Lindsay A.] Boston Univ, Sch Med, Dept Med Biomed Genet, Boston, MA 02118 USA.
[Gejman, Pablo] NorthShore Univ HealthSyst Res Inst, Ctr Psychiat Genet, Evanston, IL USA.
[Levinson, Douglas F.] Stanford Univ, Dept Psychiat & Behav Sci, Stanford, CA 94305 USA.
[Holmans, Peter] Cardiff Univ, Sch Med, Med Resource Council,& Neurol,Biostat & Bioinform, Ctr Neuropsychiat Genet & Genom,Dept Psychol Med, Cardiff, S Glam, Wales.
[Kuo, Po-Hsiu] Natl Taiwan Univ, Inst Epidemiol & Prevent Med, Taipei 10764, Taiwan.
[Anton, Raymond] Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA.
[Kranzler, Henry R.] Univ Penn, Dept Psychiat, Treatment Res Ctr, Sch Med 3900, Philadelphia, PA 19104 USA.
[Kranzler, Henry R.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA.
[Gelernter, Joel] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT USA.
[Gelernter, Joel] Yale Univ, Sch Med, Dept Genet, New Haven, CT 06510 USA.
[Gelernter, Joel] Yale Univ, Sch Med, Dept Neurobiol, New Haven, CT 06510 USA.
[Gelernter, Joel] Vet Affairs Connecticut Healthcare Ctr, West Haven, CT USA.
[Kendler, Kenneth S.; Chen, Xiangning] Virginia Commonwealth Univ, Dept Human & Mol Genet, Richmond, VA USA.
RP Chen, JC (reprint author), Virginia Commonwealth Univ, Dept Psychiat, Richmond, VA 23284 USA.
EM xchen@vcu.edu
RI Webb, Bradley/B-1459-2009; Holmans, Peter/F-4518-2015
OI Webb, Bradley/0000-0002-0576-5366; Holmans, Peter/0000-0003-0870-9412;
Farrer, Lindsay/0000-0001-5533-4225; Kuo, Po-Hsiu/0000-0003-0365-3587
FU National Institutes of Health [DA019498, DA011287]; Virginia Tobacco
Settlement Foundation [5100004ST]; Virginia Foundation for Healthy Youth
[8520667]
FX This study was supported by grants DA019498 to XC and DA011287 to KSK
from the National Institutes of Health, by funds from the Virginia
Tobacco Settlement Foundation through the Virginia Youth Tobacco Project
to Virginia Commonwealth University (subcontracted to KSK, #5100004ST)
and by a grant from Virginia Foundation for Healthy Youth 8520667 to
DHB. The funders had no role in study design, data collection and
analysis, decision to publish, or preparation of the manuscript.
NR 86
TC 5
Z9 5
U1 4
U2 7
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 20
PY 2011
VL 6
IS 12
AR e28790
DI 10.1371/journal.pone.0028790
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 870JU
UT WOS:000298666200011
ER
PT J
AU Zulman, DM
Nazi, KM
Turvey, CL
Wagner, TH
Woods, SS
An, LC
AF Zulman, Donna M.
Nazi, Kim M.
Turvey, Carolyn L.
Wagner, Todd H.
Woods, Susan S.
An, Larry C.
TI Patient Interest in Sharing Personal Health Record Information A
Web-Based Survey
SO ANNALS OF INTERNAL MEDICINE
LA English
DT Article
ID SHARED MEDICAL-RECORD; SATISFACTION; EXCHANGE
AB Background: Electronic personal health record (PHR) systems are proliferating but largely have not realized their potential for enhancing communication among patients and their network of care providers.
Objective: To explore preferences about sharing electronic health information among users of the U.S. Department of Veterans Affairs (VA) PHR system, My HealtheVet.
Design: Web-based survey of a convenience sample.
Setting: My HealtheVet Web site from 7 July through 4 October 2010.
Participants: 18 471 users of My HealtheVet.
Measurements: Interest in shared PHR access and preferences about who would receive access, the information that would be shared, and the activities that users would delegate.
Results: Survey respondents were predominantly men (92%) and aged 50 to 64 years (51%) or 65 years or older (39%); approximately 39% reported poor or fair health status. Almost 4 of 5 respondents (79%) were interested in sharing access to their PHR with someone outside of their health system (62% with a spouse or partner, 23% with a child, 15% with another family member, and 25% with a non-VA health care provider). Among those who selected a family member other than a spouse or partner, 47% lived apart from the specified person. Preferences about degree of access varied on the basis of the type of information being shared, the type of activity being performed, and the respondent's relationship with the selected person.
Limitations: The survey completion rate was 40.8%. Results might not be generalizable to all My HealtheVet users.
Conclusion: In a large survey of PHR users in the VA system, most respondents were interested in sharing access to their electronic health information with caregivers and non-VA providers. Existing and evolving PHR systems should explore secure mechanisms for shared PHR access to improve information exchange among patients and the multiple persons involved in their health care.
C1 [Zulman, Donna M.] Stanford Univ, Ctr Hlth Care Evaluat, VA Palo Alto Hlth Care Syst, Menlo Pk, CA 94025 USA.
Vet Rural Hlth Resource Ctr Cent Reg, Iowa City, IA USA.
Vet Affairs Hlth Care Syst, Ctr Comprehens Access & Delivery Res & Evaluat, Iowa City, IA USA.
US Dept Vet Affairs, Washington, DC USA.
Vet Affairs Hlth Serv Res & Dev Serv, Portland, OR USA.
Univ Michigan, Ctr Hlth Commun Res, Ann Arbor, MI 48109 USA.
RP Zulman, DM (reprint author), Stanford Univ, Ctr Hlth Care Evaluat, VA Palo Alto Hlth Care Syst, 795 Willow Rd,152-MPD, Menlo Pk, CA 94025 USA.
EM dzulman@stanford.edu
FU Veterans Health Administration; Robert Wood Johnson Foundation
FX Grant Support: By the Veterans Health Administration and The Robert Wood
Johnson Foundation Clinical Scholars Program.
NR 31
TC 51
Z9 51
U1 6
U2 18
PU AMER COLL PHYSICIANS
PI PHILADELPHIA
PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA
SN 0003-4819
EI 1539-3704
J9 ANN INTERN MED
JI Ann. Intern. Med.
PD DEC 20
PY 2011
VL 155
IS 12
BP 805
EP U46
DI 10.7326/0003-4819-155-12-201112200-00002
PG 7
WC Medicine, General & Internal
SC General & Internal Medicine
GA 864ZU
UT WOS:000298280500014
PM 22184687
ER
PT J
AU Frazier-Wood, AC
Glasser, S
Garvey, WT
Kabagambe, EK
Borecki, IB
Tiwari, HK
Tsai, MY
Hopkins, PN
Ordovas, JM
Arnett, DK
AF Frazier-Wood, Alexis C.
Glasser, Stephen
Garvey, W. Timothy
Kabagambe, Edmond K.
Borecki, Ingrid B.
Tiwari, Hemant K.
Tsai, Michael Y.
Hopkins, Paul N.
Ordovas, Jose M.
Arnett, Donna K.
TI A clustering analysis of lipoprotein diameters in the metabolic syndrome
SO LIPIDS IN HEALTH AND DISEASE
LA English
DT Article
DE lipoprotein particle diameter; insulin resistance; nuclear resonance
spectroscopy; Metabolic Syndrome; latent class analysis; GOLDN; waist
circumference; hypertension; hypertriglyceridemia; fasting glucose
ID NUCLEAR-MAGNETIC-RESONANCE; INSULIN-RESISTANCE ATHEROSCLEROSIS; LDL
SIZE; PARTICLE-SIZE; MEN; HYPERINSULINEMIA; DISEASE
AB Background: The presence of smaller low-density lipoproteins (LDL) has been associated with atherosclerosis risk, and the insulin resistance (IR) underlying the metabolic syndrome (MetS). In addition, some research has supported the association of very low-, low-and high-density lipoprotein (VLDL HDL) particle diameters with components of the metabolic syndrome (MetS), although this has been the focus of less research. We aimed to explore the relationship of VLDL, LDL and HDL diameters to MetS and its features, and by clustering individuals by their diameters of VLDL, LDL and HDL particles, to capture information across all three fractions of lipoprotein into a unified phenotype.
Methods: We used nuclear magnetic resonance spectroscopy measurements on fasting plasma samples from a general population sample of 1,036 adults (mean +/- SD, 48.8 +/- 16.2 y of age). Using latent class analysis, the sample was grouped by the diameter of their fasting lipoproteins, and mixed effects models tested whether the distribution of MetS components varied across the groups.
Results: Eight discrete groups were identified. Two groups (N = 251) were enriched with individuals meeting criteria for the MetS, and were characterized by the smallest LDL/HDL diameters. One of those two groups, one was additionally distinguished by large VLDL, and had significantly higher blood pressure, fasting glucose, triglycerides, and waist circumference (WC; P < .001). However, large VLDL, in the absence of small LDL and HDL particles, did not associate with MetS features. These associations held after additionally controlling for VLDL, LDL and HDL particle concentrations.
Conclusions: While small LDL diameters remain associated with IR and the MetS, the occurrence of these in conjunction with a shift to overall larger VLDL diameter may identify those with the highest fasting glucose, TG and WC within the MetS. If replicated, the association of this phenotype with more severe IR-features indicated that it may contribute to identifying of those most at risk for incident type II diabetes and cardiometabolic disease.
C1 [Frazier-Wood, Alexis C.; Kabagambe, Edmond K.; Arnett, Donna K.] Univ Alabama, Sch Publ Hlth, Dept Epidemiol, Birmingham, AL 35294 USA.
[Frazier-Wood, Alexis C.; Tiwari, Hemant K.] Univ Alabama, Dept Biostat, Sect Stat Genet, Sch Publ Hlth, Birmingham, AL 35294 USA.
[Glasser, Stephen] Univ Alabama, Dept Med, Div Prevent Med, Birmingham, AL 35294 USA.
[Garvey, W. Timothy] Birmingham VA Med Ctr, Birmingham, AL USA.
[Kabagambe, Edmond K.; Arnett, Donna K.] Univ Alabama, Sch Publ Hlth, Nutr Obes Res Ctr, Birmingham, AL 35294 USA.
[Borecki, Ingrid B.] Washington Univ, Sch Med, Dept Genet, Div Stat Genom, St Louis, MO 63110 USA.
[Tsai, Michael Y.] Univ Minnesota, Dept Lab Med & Pathol, Minneapolis, MN 55455 USA.
[Hopkins, Paul N.] Univ Utah, Dept Internal Med, Salt Lake City, UT 84112 USA.
[Ordovas, Jose M.] Tufts Univ, JM USDA HNRCA, Boston, MA 02111 USA.
[Ordovas, Jose M.] CNIC, Dept Epidemiol & Populat Genet, Madrid, Spain.
[Ordovas, Jose M.] IMDEA Food, Madrid, Spain.
RP Frazier-Wood, AC (reprint author), Univ Alabama, Sch Publ Hlth, Dept Epidemiol, Birmingham, AL 35294 USA.
EM LekkiWood@Gmail.com
RI Frazier-Wood, Alexis (Lekki)/B-8053-2010
OI Frazier-Wood, Alexis (Lekki)/0000-0001-7616-2119
FU NHLBI [U01HL072524]
FX This study was funded by NHLBI grant number U01HL072524. Financial
disclosures: None to declare. Disclosure: All authors declare that they
have no conflicts of interests.
NR 19
TC 3
Z9 4
U1 0
U2 1
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1476-511X
J9 LIPIDS HEALTH DIS
JI Lipids Health Dis.
PD DEC 19
PY 2011
VL 10
AR 237
DI 10.1186/1476-511X-10-237
PG 8
WC Biochemistry & Molecular Biology; Nutrition & Dietetics
SC Biochemistry & Molecular Biology; Nutrition & Dietetics
GA 878SQ
UT WOS:000299277300001
PM 22182248
ER
PT J
AU Hooker, CI
Bruce, L
Lincoln, SH
Fisher, M
Vinogradov, S
AF Hooker, Christine I.
Bruce, Lori
Lincoln, Sarah Hope
Fisher, Melissa
Vinogradov, Sophia
TI Theory of Mind Skills Are Related to Gray Matter Volume in the
Ventromedial Prefrontal Cortex in Schizophrenia
SO BIOLOGICAL PSYCHIATRY
LA English
DT Article
DE Empathy; mentalizing; MRI; schizophrenia; social functioning; theory of
mind
ID VOXEL-BASED MORPHOMETRY; FRONTAL-LOBE PATHOLOGY; SOCIAL COGNITION;
1ST-EPISODE SCHIZOPHRENIA; PROGRESSIVE DECREASE; EMPATHIC ABILITIES;
NEURAL BASIS; BRAIN; METAANALYSIS; RECOGNITION
AB Background: Among individuals with schizophrenia, deficits in theory of mind (ToM) skills predict poor social functioning. Therefore, identifying the neural basis of ToM may assist the development of treatments that improve social outcomes. Despite growing evidence that the ventromedial prefrontal cortex (VMPFC) facilitates ToM skills among healthy individuals, methodological challenges, such as the influence of general cognitive deficits, have made it difficult to identify the relationship between ToM processing and VMPFC function in schizophrenia.
Methods: We used voxel-based morphometry and a multi-method behavioral assessment of ToM processing, including performance-based (Recognition of Faux Pas Test), self-report (Interpersonal Reactivity Index, Perspective-Taking), and interview-rated (Quality of Life Scale-Empathy score) ToM assessments, to investigate whether ToM skills were related to VMPFC gray matter volume (GMV). Standardized neuropsychological measures were used to assess global cognition. Twenty-one schizophrenia and 17 healthy control subjects participated.
Results: Between-group behavioral analyses showed that, as compared with healthy participants, schizophrenia participants had worse ToM performance and lower self-reported ToM processing in daily life. The between-group analysis of GMV showed that schizophrenia participants had less VMPFC GMV than healthy participants. Moreover, among schizophrenia participants, all three measures of ToM processing were associated with VMPFC GMV, such that worse ToM skills were related to less VMPFC GMV. This association remained strong for self-reported and interview-rated ToM skills, even when controlling for the influence of global cognition.
Conclusions: The findings suggest that among individuals with schizophrenia, reduced VMPFC GMV is associated with deficits using ToM skills to enhance social relationships.
C1 [Hooker, Christine I.; Bruce, Lori; Lincoln, Sarah Hope] Harvard Univ, Dept Psychol, Cambridge, MA 02138 USA.
[Fisher, Melissa; Vinogradov, Sophia] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA.
[Fisher, Melissa; Vinogradov, Sophia] San Francisco VA Med Ctr, Dept Psychiat, San Francisco, CA USA.
RP Hooker, CI (reprint author), Harvard Univ, Dept Psychol, 820 William James Hall,33 Kirkland St, Cambridge, MA 02138 USA.
EM chooker@wjh.harvard.edu
FU National Alliance for Research on Schizophrenia and Depression Young
Investigator Award; National Institute of Mental Health [MH71746,
MH68725-02]; Growth to Spur the Acceleration of New Technologies
(BRDG-SPAN) Grant
FX This work was supported by a National Alliance for Research on
Schizophrenia and Depression Young Investigator Award (CIH) and National
Institute of Mental Health Grants MH71746 (CIH) and MH68725-02 (SV).;
Sophia Vinogradov is a paid consultant on an National Institute of
Mental Health Biomedical Research, Development, and Growth to Spur the
Acceleration of New Technologies (BRDG-SPAN) Grant to Brain Plasticity
Inc. Christine Hooker, Melissa Fisher, Lori Bruce, and Sarah Hope
Lincoln report no biomedical financial interests or potential conflicts
of interest.
NR 87
TC 42
Z9 44
U1 4
U2 17
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0006-3223
J9 BIOL PSYCHIAT
JI Biol. Psychiatry
PD DEC 15
PY 2011
VL 70
IS 12
BP 1169
EP 1178
DI 10.1016/j.biopsych.2011.07.027
PG 10
WC Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA 860WW
UT WOS:000297980000012
PM 21917239
ER
PT J
AU Lipsky, BA
Hoey, CT
Byren, I
AF Lipsky, Benjamin A.
Hoey, Christopher T.
Byren, Ivor
TI Chronic Bacterial Prostatitis: Enterococcal Disease? Reply
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Letter
ID URINARY-TRACT-INFECTIONS; MOXIFLOXACIN; DAPTOMYCIN; RESISTANCE
C1 [Lipsky, Benjamin A.] Univ Washington, Gen Med Serv, Dept Med, VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA.
[Hoey, Christopher T.] VA Puget Sound Hlth Care Syst, Serv Pharm, Seattle, WA USA.
[Byren, Ivor] Univ Oxford, Dept Med, Oxford Radcliffe Hosp, Oxford OX1 2JD, England.
RP Lipsky, BA (reprint author), Univ Washington, Gen Med Serv, Dept Med, VA Puget Sound Hlth Care Syst, 1660 S Columbian Way,S GMS 123, Seattle, WA 98108 USA.
EM balipsky@uw.edu
OI Lipsky, Benjamin A./0000-0001-9886-5114
NR 13
TC 1
Z9 1
U1 0
U2 2
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1058-4838
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD DEC 15
PY 2011
VL 53
IS 12
BP 1307
EP U170
DI 10.1093/cid/cir715
PG 2
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 851OF
UT WOS:000297279700031
ER
PT J
AU Jani, A
Epperson, E
Martin, J
Pacic, A
Ljubanovic, D
Martin, SL
Edelstein, CL
AF Jani, Alkesh
Epperson, Elaine
Martin, Jessica
Pacic, Arijana
Ljubanovic, Danica
Martin, Sandra L.
Edelstein, Charles L.
TI Renal Protection From Prolonged Cold Ischemia and Warm Reperfusion in
Hibernating Squirrels
SO TRANSPLANTATION
LA English
DT Article
DE Cold ischemia; Warm reperfusion; Hibernation
ID ARCTIC GROUND-SQUIRRELS; ISCHEMIA/REPERFUSION INJURY; ACCIDENTAL
HYPOTHERMIA; SUSPENDED ANIMATION; HYDROGEN-SULFIDE; LOW-TEMPERATURE;
APOPTOSIS; KIDNEY; PRESERVATION; SURVIVAL
AB Background. We have previously shown that cold ischemia (CI) results in massive increases in caspase-3 activity, tubular apoptosis, and brush border injury (BBI) in mouse kidneys. During hibernation, the 13-lined ground squirrel (GS) cycles through repeated CI during torpor, followed by warm ischemia/reperfusion (WI) during interbout arousal (IBA). We sought to determine whether CI and WI during hibernation caused caspase-3 activation, tubular apoptosis, acute tubular necrosis, or BBI, and reduced renal function. We also determined whether protection was dependent on the stage of hibernation.
Methods. Radiotelemeters were implanted in 1-year-old GS, and core body temperature was remotely monitored. GS kidneys at various stages of hibernation were subjected to ex vivo CI.
Results. Tubular apoptosis was not detected and caspase-3-like activity was not different between hibernating and summer kidneys. Despite prolonged CI followed by WI and reperfusion, acute tubular necrosis and apoptosis did not occur in hibernating kidneys. BBI was absent in torpid kidneys but significantly increased in IBA kidneys and associated with an increase in caspase-3-like activity, suggesting that IBA kidneys are more susceptible to injury than summer or torpid kidneys. Renal function and urine concentrating ability diminished during torpor but returned during IBA.
Conclusions. Despite BBI, IBA kidneys clear serum creatinine and concentrate urine. Kidneys from both summer and hibernating animals tolerated ex vivo CI, confirming that protection from apoptotic and necrotic cell death is independent of the stage of hibernation. An understanding of how renal protection occurs during hibernation may help in understanding the pathophysiology of delayed graft function.
C1 [Jani, Alkesh; Martin, Jessica; Edelstein, Charles L.] Univ Colorado, Div Renal Dis & Hypertens, Aurora, CO 80262 USA.
[Jani, Alkesh; Martin, Jessica; Edelstein, Charles L.] Univ Colorado, Denver Vet Affairs Med Ctr, Aurora, CO 80262 USA.
[Epperson, Elaine; Martin, Sandra L.] Univ Colorado, Dept Cell & Dev Biol, Aurora, CO 80262 USA.
[Pacic, Arijana; Ljubanovic, Danica] Univ Zagreb, Sch Med, Dept Pathol, Zagreb Univ Hosp Dubrava, Zagreb 41001, Croatia.
RP Jani, A (reprint author), Univ Colorado, Div Renal Dis & Hypertens, Anschutz Med Campus,Box C281,12700 East,19th Ave, Aurora, CO 80262 USA.
EM alkesh.jani@ucdenver.edu
FU NIH [K08DK69512, R01-HL-089049, RO1-DK-056851, RO1-DK-074835]
FX This study was supported by NIH grants K08DK69512 (A.J.), R01-HL-089049
(S. L. M.), and RO1-DK-056851 and RO1-DK-074835 (C. L. E.).
NR 44
TC 16
Z9 18
U1 2
U2 13
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0041-1337
J9 TRANSPLANTATION
JI Transplantation
PD DEC 15
PY 2011
VL 92
IS 11
BP 1215
EP 1221
DI 10.1097/TP.0b013e3182366401
PG 7
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA 853DP
UT WOS:000297406700010
PM 22082817
ER
PT J
AU Hershman, DL
Wilde, ET
Wright, JD
Buono, DL
Kalinsky, K
Malin, J
Tsai, WY
Neugut, AL
AF Hershman, D. L.
Wilde, E. T.
Wright, J. D.
Buono, D. L.
Kalinsky, K.
Malin, J.
Tsai, W. Y.
Neugut, A. L.
TI Uptake and Economic Impact of First-Cycle Colony Stimulating Factor Use
during the Adjuvant Treatment of Breast Cancer.
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Hershman, D. L.; Wilde, E. T.; Wright, J. D.; Buono, D. L.; Kalinsky, K.; Malin, J.; Tsai, W. Y.; Neugut, A. L.] Columbia Univ, New York, NY USA.
Mailman Sch Publ Hlth, New York, NY USA.
Greater Los Angeles VA Healthcare Syst, Los Angeles, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD DEC 15
PY 2011
VL 71
SU 24
MA PID06-04
DI 10.1158/0008-5472.SABCS11-P006-04
PG 1
WC Oncology
SC Oncology
GA V43RZ
UT WOS:000209699800108
ER
PT J
AU Luoh, SW
Ramsey, B
Park, B
Keenan, E
AF Luoh, S-W
Ramsey, B.
Park, B.
Keenan, E.
TI Borderline Estrogen and Progesterone Receptor Expression and Efficacy of
Anti-Estrogen Therapy Analyzed by Subpopulation Treatment Effect Pattern
Plot Analysis
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Luoh, S-W; Ramsey, B.; Park, B.; Keenan, E.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
Portland VA Med Ctr, Portland, OR USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD DEC 15
PY 2011
VL 71
SU 24
MA P5-13-19
DI 10.1158/0008-5472.SABCS11-P5-13-19
PG 1
WC Oncology
SC Oncology
GA V43RZ
UT WOS:000209699802089
ER
PT J
AU Bachmann, LH
Hobbs, MM
Sena, AC
Sobel, JD
Schwebke, JR
Krieger, JN
McClelland, RS
Workowski, KA
AF Bachmann, Laura H.
Hobbs, Marcia M.
Sena, Arlene C.
Sobel, Jack D.
Schwebke, Jane R.
Krieger, John N.
McClelland, R. Scott
Workowski, Kimberly A.
TI Trichomonas vaginalis Genital Infections: Progress and Challenges
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Article
ID HUMAN-IMMUNODEFICIENCY-VIRUS; SEXUALLY-TRANSMITTED INFECTIONS;
RANDOMIZED CLINICAL-TRIAL; SINGLE-DOSE TREATMENT; HIV-NEGATIVE WOMEN;
RISK-FACTORS; METRONIDAZOLE; TINIDAZOLE; PREVALENCE; URETHRITIS
AB Trichomonas vaginalis (TV) infection is the most prevalent curable sexually transmitted infection in the United States and worldwide. Most TV infections are asymptomatic, and the accurate diagnosis of this infection has been limited by lack of sufficiently sensitive and specific diagnostic tests, particularly for men. To provide updates for the 2010 Centers for Disease Control and Prevention's Sexually Transmitted Diseases Treatment Guidelines, a PubMed search was conducted of all TV literature published from 9 January 2004 through 24 September 2008. Approximately 175 pertinent abstracts and articles were reviewed and discussed with national experts. This article describes advances in TV diagnostics which have led to an improved understanding of the epidemiology of this pathogen, as well as potential biologic and epidemiological interactions between TV and human immunodeficiency virus (HIV). New data on treatment outcomes, metronidazole-resistant TV, management of nitroimidazole-allergic patients, frequency of recurrent TV infection following treatment, and screening considerations for TV in certain populations are also presented.
C1 [Bachmann, Laura H.] Wake Forest Univ Hlth Sci, Infect Dis Sect, Winston Salem, NC 27157 USA.
[Bachmann, Laura H.] WG Bill Hefner Med Ctr, Infect Dis Sect, Salisbury, CT USA.
[Sena, Arlene C.] Univ N Carolina, Dept Med, Div Infect Dis, Chapel Hill, NC USA.
[Hobbs, Marcia M.] Univ N Carolina, Dept Microbiol, Chapel Hill, NC USA.
[Hobbs, Marcia M.] Univ N Carolina, Dept Immunol, Chapel Hill, NC USA.
[Sobel, Jack D.] Wayne State Univ, Dept Med, Div Infect Dis, Detroit, MI 48202 USA.
[Schwebke, Jane R.] Univ Alabama, Dept Med, Div Infect Dis, Birmingham, AL 35294 USA.
[Krieger, John N.] Univ Washington, Dept Urol, Seattle, WA 98195 USA.
[Krieger, John N.] VA Puget Sound Hlth Care Syst, Dept Urol, Seattle, WA USA.
[McClelland, R. Scott] Univ Washington, Dept Med, Seattle, WA USA.
[McClelland, R. Scott] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA.
[McClelland, R. Scott] Univ Washington, Dept Global Hlth, Seattle, WA 98195 USA.
[Workowski, Kimberly A.] Ctr Dis Control & Prevent, Atlanta, GA USA.
[Workowski, Kimberly A.] Emory Univ, Dept Med, Div Infect Dis, Atlanta, GA 30322 USA.
RP Bachmann, LH (reprint author), Wake Forest Univ Hlth Sci, Infect Dis Sect, Med Ctr Blvd, Winston Salem, NC 27157 USA.
EM lbachman@wfubmc.edu
FU Centers for Disease Control and Prevention
FX This article was published as part of a supplement entitled "Sexually
Transmitted Disease Treatment Guidelines" sponsored by the Centers for
Disease Control and Prevention.
NR 73
TC 36
Z9 39
U1 1
U2 13
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1058-4838
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD DEC 15
PY 2011
VL 53
SU 3
BP S160
EP S172
DI 10.1093/cid/cir705
PG 13
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 847MY
UT WOS:000296978200012
PM 22080269
ER
PT J
AU Giardina, TD
Singh, H
AF Giardina, Traber Davis
Singh, Hardeep
TI Should Patients Get Direct Access to Their Laboratory Test Results? An
Answer With Many Questions
SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LA English
DT Editorial Material
ID FOLLOW-UP; RECORDS; MAIL
C1 Houston Vet Affairs Hlth Serv Res & Dev, Ctr Excellence, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX USA.
Baylor Coll Med, Sect Hlth Serv Res, Dept Med, Houston, TX 77030 USA.
RP Singh, H (reprint author), VA Med Ctr 152, 2002 Holcombe Blvd, Houston, TX 77030 USA.
EM hardeeps@bcm.edu
OI Davis Giardina, Traber/0000-0002-9184-6524
NR 10
TC 8
Z9 8
U1 2
U2 7
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0098-7484
EI 1538-3598
J9 JAMA-J AM MED ASSOC
JI JAMA-J. Am. Med. Assoc.
PD DEC 14
PY 2011
VL 306
IS 22
BP 2502
EP 2503
DI 10.1001/jama.2011.1797
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA 860YB
UT WOS:000297983300025
ER
PT J
AU Walter, LC
AF Walter, Louise C.
TI What Is the Right Cancer Screening Rate for Older Adults?
SO ARCHIVES OF INTERNAL MEDICINE
LA English
DT Editorial Material
ID AGE 80 YEARS; WOMEN; MAMMOGRAPHY; BURDENS
C1 [Walter, Louise C.] San Francisco VA Med Ctr, Div Geriatr, San Francisco, CA 94121 USA.
[Walter, Louise C.] Univ Calif San Francisco, Div Geriatr, San Francisco, CA 94143 USA.
RP Walter, LC (reprint author), San Francisco VA Med Ctr, Div Geriatr, 4150 Clement St,181G, San Francisco, CA 94121 USA.
EM louise.walter@ucsf.edu
FU NCI NIH HHS [R01 CA134425, CA134425]
NR 10
TC 7
Z9 7
U1 0
U2 0
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA
SN 0003-9926
J9 ARCH INTERN MED
JI Arch. Intern. Med.
PD DEC 12
PY 2011
VL 171
IS 22
BP 2037
EP 2039
PG 4
WC Medicine, General & Internal
SC General & Internal Medicine
GA 860VD
UT WOS:000297975100012
PM 22158574
ER
PT J
AU Finlay-Schultz, J
Canastar, A
Short, M
El Gazzar, M
Coughlan, C
Leonard, S
AF Finlay-Schultz, Jessica
Canastar, Andrew
Short, Margaret
El Gazzar, Mohamed
Coughlan, Christina
Leonard, Sherry
TI Transcriptional Repression of the alpha 7 Nicotinic Acetylcholine
Receptor Subunit Gene (CHRNA7) by Activating Protein-2 alpha (AP-2
alpha)
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID RNA-POLYMERASE-II; FACTOR AP-2; DNA-BINDING;
FUNCTIONAL-CHARACTERIZATION; LINKAGE ANALYSIS; CARCINOMA-CELLS;
FRONTAL-CORTEX; RETINOIC ACID; FACTOR EGR-1; SCHIZOPHRENIA
AB The CHRNA7 gene, which encodes the alpha 7 nicotinic acetylcholine receptor (alpha 7*nAChR), has been implicated as a candidate gene in schizophrenia. Expression of the alpha 7*nAChR mRNA and protein are reduced in multiple regions of post-mortem brain from patients diagnosed with schizophrenia. Transcriptional regulation may therefore be an important mechanism for the regulation of this gene. A 230-bp proximal promoter fragment, necessary for transcription in cultured neuroblastoma cells, was used to study a putative AP-2 alpha binding site. Mutation of the site indicates that AP-2 alpha plays a negative role in regulating CHRNA7 transcription. This was confirmed through knockdown and overexpression of AP-2 alpha. Electrophoretic mobility shift assays (EMSAs) identified positive DNA-protein interaction at this same site, and supershift assays indicate that the complex includes AP-2 alpha. The interaction was confirmed in cells using chromatin immunoprecipitation (ChIP). DNA methylation was discovered as an anomalous mechanism for CHRNA7 regulation in one cell line. These studies suggest a role for AP-2 alpha regulation of CHRNA7 mRNA expression in multiple tissues during development.
C1 [Finlay-Schultz, Jessica; Canastar, Andrew; El Gazzar, Mohamed; Leonard, Sherry] Univ Colorado Denver, Dept Psychiat, Aurora, CO 80045 USA.
[Finlay-Schultz, Jessica] Univ Colorado Denver, Dept Biochem & Mol Genet, Aurora, CO 80045 USA.
[Leonard, Sherry] Univ Colorado Denver, Dept Pharmacol, Aurora, CO 80045 USA.
[Coughlan, Christina] Univ Denver, Dept Biol Sci, Denver, CO 80208 USA.
[Short, Margaret; Leonard, Sherry] Denver Vet Affairs Med Ctr, Denver, CO 80220 USA.
RP Leonard, S (reprint author), Univ Colorado Denver, Dept Psychiat, Mail Stop 8344,POB 6511,Anschutz Med Campus, Aurora, CO 80045 USA.
EM Sherry.Leonard@ucdenver.edu
FU National Institutes of Health [DA009457, MH081177]; Veterans Affairs
Medical Research Service Merit Review
FX This work was supported, in whole or in part, by National Institutes of
Health Grants DA009457 and MH081177 and a Veterans Affairs Medical
Research Service Merit Review (to S. L.).
NR 75
TC 6
Z9 6
U1 0
U2 5
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
J9 J BIOL CHEM
JI J. Biol. Chem.
PD DEC 9
PY 2011
VL 286
IS 49
BP 42123
EP 42132
DI 10.1074/jbc.M111.276014
PG 10
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 863QI
UT WOS:000298180900023
PM 21979958
ER
PT J
AU Jayaraman, T
Tejero, J
Chen, BB
Blood, AB
Frizzell, S
Shapiro, C
Tiso, M
Hood, BL
Wang, XD
Zhao, XJ
Conrads, TP
Mallampalli, RK
Gladwin, MT
AF Jayaraman, Thottala
Tejero, Jesus
Chen, Bill B.
Blood, Arlin B.
Frizzell, Sheila
Shapiro, Calli
Tiso, Mauro
Hood, Brian L.
Wang, Xunde
Zhao, Xuejun
Conrads, Thomas P.
Mallampalli, Rama K.
Gladwin, Mark T.
TI 14-3-3 Binding and Phosphorylation of Neuroglobin during Hypoxia
Modulate Six-to-Five Heme Pocket Coordination and Rate of Nitrite
Reduction to Nitric Oxide
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID INOSITOL 1,4,5-TRISPHOSPHATE RECEPTOR; INDUCIBLE FACTOR-1-ALPHA;
OXIDATIVE STRESS; GLOBIN FAMILY; PROTEIN; BRAIN; CYTOGLOBIN; ACTIVATION;
CELLS; MECHANISMS
AB Neuroglobin protects neurons from hypoxia in vitro and in vivo; however, the underlying mechanisms for this effect remain poorly understood. Most of the neuroglobin is present in a hexacoordinate state with proximal and distal histidines in the heme pocket directly bound to the heme iron. At equilibrium, the concentration of the five-coordinate neuroglobin remains very low (0.1-5%). Recent studies have shown that post-translational redox regulation of neuroglobin surface thiol disulfide formation increases the open probability of the heme pocket and allows nitrite binding and reaction to form NO. We hypothesized that the equilibrium between the six-and five-coordinate states and secondary reactions with nitrite to form NO could be regulated by other hypoxia-dependent post-translational modification(s). Protein sequence models identified candidate sites for both 14-3-3 binding and phosphorylation. In both in vitro experiments and human SH-SY5Y neuronal cells exposed to hypoxia and glucose deprivation, we observed that 1) neuroglobin phosphorylation and protein-protein interactions with 14-3-3 increase during hypoxic and metabolic stress; 2) neuroglobin binding to 14-3-3 stabilizes and increases the half-life of phosphorylation; and 3) phosphorylation increases the open probability of the heme pocket, which increases ligand binding (CO and nitrite) and accelerates the rate of anaerobic nitrite reduction to form NO. These data reveal a series of hypoxia-dependent post-translational modifications to neuroglobin that regulate the six-to-five heme pocket equilibrium and heme access to ligands. Hypoxia-regulated reactions of nitrite and neuroglobin may contribute to the cellular adaptation to hypoxia.
C1 [Hood, Brian L.; Conrads, Thomas P.; Gladwin, Mark T.] Univ Pittsburgh, Div Pulm Allergy & Crit Care Med, Dept Pharmacol & Chem Biol, Sch Med, Pittsburgh, PA 15261 USA.
[Jayaraman, Thottala; Tejero, Jesus; Frizzell, Sheila; Shapiro, Calli; Tiso, Mauro; Zhao, Xuejun; Gladwin, Mark T.] Univ Pittsburgh, Vasc Med Inst, Pittsburgh, PA 15213 USA.
[Jayaraman, Thottala; Chen, Bill B.; Mallampalli, Rama K.; Gladwin, Mark T.] Univ Pittsburgh, Div Pulm Allergy & Crit Care Med, Dept Med, Pittsburgh, PA 15213 USA.
[Mallampalli, Rama K.] Vet Affairs Pittsburgh Healthcare Syst, Med Specialty Serv Line, Pittsburgh, PA 15240 USA.
[Wang, Xunde] NHLBI, NIH, Bethesda, MD 20892 USA.
[Blood, Arlin B.] Loma Linda Univ, Sch Med, Dept Pediat, Div Neonatol, Loma Linda, CA 92354 USA.
RP Gladwin, MT (reprint author), Univ Pittsburgh, Div Pulm Allergy & Crit Care Med, Dept Pharmacol & Chem Biol, Sch Med, Pittsburgh, PA 15261 USA.
EM gladwinmt@upmc.edu
RI Tejero, Jesus/G-3953-2017
OI Tejero, Jesus/0000-0003-3245-9978
FU National Institutes of Health [R01 HL098032, R01 HL096973, P01 HL103455,
R01 HL096376, R01 HL097376, R01 HL098174]; Institute for Transfusion
Medicine; Hemophilia Center of Western Pennsylvania
FX This work was supported, in whole or in part, by National Institutes of
Health Grants R01 HL098032, R01 HL096973, and P01 HL103455 (to M. T. G.)
and R01 HL096376, R01 HL097376, and R01 HL098174 (to R. K. M.). This
work was also supported by the Institute for Transfusion Medicine and
the Hemophilia Center of Western Pennsylvania (to M. T. G.). M. Tiso and
M. T. Gladwin are listed as co-inventors on a patent application
entitled "Neuroglobin as a Six-to-Five Coordinate-regulated Nitrite
Reductase."
NR 48
TC 29
Z9 31
U1 3
U2 12
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
J9 J BIOL CHEM
JI J. Biol. Chem.
PD DEC 9
PY 2011
VL 286
IS 49
BP 42679
EP 42689
DI 10.1074/jbc.M111.271973
PG 11
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 863QI
UT WOS:000298180900075
PM 21965683
ER
PT J
AU Smith, AK
Williams, BA
Lo, B
AF Smith, Alexander K.
Williams, Brie A.
Lo, Bernard
TI Discussing Overall Prognosis with the Very Elderly
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Editorial Material
C1 [Smith, Alexander K.; Williams, Brie A.] Univ Calif San Francisco, Div Geriatr, San Francisco, CA 94143 USA.
[Lo, Bernard] Univ Calif San Francisco, Div Gen Internal Med, San Francisco, CA 94143 USA.
[Smith, Alexander K.; Williams, Brie A.] San Francisco VA Med Ctr, San Francisco, CA USA.
RP Smith, AK (reprint author), Univ Calif San Francisco, Div Geriatr, San Francisco, CA 94143 USA.
FU NCRR NIH HHS [KL2 RR024130]
NR 5
TC 31
Z9 31
U1 0
U2 0
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD DEC 8
PY 2011
VL 365
IS 23
BP 2149
EP 2151
PG 4
WC Medicine, General & Internal
SC General & Internal Medicine
GA 857PQ
UT WOS:000297731400014
PM 22150033
ER
PT J
AU Sterling, TR
Villarino, ME
Borisov, AS
Shang, N
Gordin, F
Bliven-Sizemore, E
Hackman, J
Hamilton, CD
Menzies, D
Kerrigan, A
Weis, SE
Weiner, M
Wing, D
Conde, MB
Bozeman, L
Horsburgh, CR
Chaisson, RE
AF Sterling, Timothy R.
Villarino, M. Elsa
Borisov, Andrey S.
Shang, Nong
Gordin, Fred
Bliven-Sizemore, Erin
Hackman, Judith
Hamilton, Carol Dukes
Menzies, Dick
Kerrigan, Amy
Weis, Stephen E.
Weiner, Marc
Wing, Diane
Conde, Marcus B.
Bozeman, Lorna
Horsburgh, C. Robert, Jr.
Chaisson, Richard E.
CA TB Trials Consortium PREVENT TB
TI Three Months of Rifapentine and Isoniazid for Latent Tuberculosis
Infection
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Article
ID PREVENTIVE THERAPY; UNITED-STATES; RANDOMIZED-TRIAL; CLINICAL-TRIAL;
HIV-INFECTION; RIFAMPIN; PYRAZINAMIDE; PHARMACOKINETICS;
IMMUNOCOMPETENT; RIFABUTIN
AB BACKGROUND
Treatment of latent Mycobacterium tuberculosis infection is an essential component of tuberculosis control and elimination. The current standard regimen of isoniazid for 9 months is efficacious but is limited by toxicity and low rates of treatment completion.
METHODS
We conducted an open-label, randomized noninferiority trial comparing 3 months of directly observed once-weekly therapy with rifapentine (900 mg) plus isoniazid (900 mg) (combination-therapy group) with 9 months of self-administered daily isoniazid (300 mg) (isoniazid-only group) in subjects at high risk for tuberculosis. Subjects were enrolled from the United States, Canada, Brazil, and Spain and followed for 33 months. The primary end point was confirmed tuberculosis, and the noninferiority margin was 0.75%.
RESULTS
In the modified intention-to-treat analysis, tuberculosis developed in 7 of 3986 subjects in the combination-therapy group (cumulative rate, 0.19%) and in 15 of 3745 subjects in the isoniazid-only group (cumulative rate, 0.43%), for a difference of 0.24 percentage points. Rates of treatment completion were 82.1% in the combination-therapy group and 69.0% in the isoniazid-only group (P<0.001). Rates of permanent drug discontinuation owing to an adverse event were 4.9% in the combination-therapy group and 3.7% in the isoniazid-only group (P = 0.009). Rates of investigator-assessed drug-related hepatotoxicity were 0.4% and 2.7%, respectively (P<0.001).
CONCLUSIONS
The use of rifapentine plus isoniazid for 3 months was as effective as 9 months of isoniazid alone in preventing tuberculosis and had a higher treatment-completion rate. Long-term safety monitoring will be important. (Funded by the Centers for Disease Control and Prevention; PREVENT TB ClinicalTrials.gov number, NCT00023452.)
C1 [Villarino, M. Elsa; Borisov, Andrey S.; Shang, Nong; Bliven-Sizemore, Erin; Bozeman, Lorna] Ctr Dis Control & Prevent, Atlanta, GA USA.
[Gordin, Fred] George Washington Univ, Washington, DC USA.
[Gordin, Fred] Washington DC Vet Affairs Med Ctr, Washington, DC USA.
[Hackman, Judith; Chaisson, Richard E.] Johns Hopkins Univ, Sch Med, Baltimore, MD USA.
[Hamilton, Carol Dukes] Family Hlth Int, Durham, NC USA.
[Hamilton, Carol Dukes] Duke Univ, Durham, NC USA.
[Menzies, Dick] McGill Univ, Montreal Chest Inst, Montreal, PQ, Canada.
[Weis, Stephen E.] Univ N Texas Hlth Sci Ctr Ft Worth, Ft Worth, TX USA.
[Weiner, Marc] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA.
[Weiner, Marc] S Texas Vet Hlth Care Syst, San Antonio, TX USA.
[Wing, Diane] S Texas Consortium, Harlingen, TX USA.
[Conde, Marcus B.] Univ Fed Rio de Janeiro, Rio De Janeiro, Brazil.
[Horsburgh, C. Robert, Jr.] Boston Univ, Sch Med, Boston, MA 02118 USA.
[Sterling, Timothy R.] Vanderbilt Univ, Sch Med, Nashville, TN 37212 USA.
RP Sterling, TR (reprint author), A2209 Med Ctr N, 1161 21st Ave S, Nashville, TN 37232 USA.
EM timothy.sterling@vanderbilt.edu
RI Conde, Marcus/A-2501-2013
FU CDC; Bristol-Myers Squibb; Pfizer; Sanofi-Aventis; Otsuka America
Pharmaceutical
FX Supported by the CDC.; Dr. Sterling reports receiving research grant
funding from Bristol-Myers Squibb and Pfizer for HIV observational
studies; Dr. Hamilton, being employed by Family Health International;
Dr. Weiner, receiving research grant funding from Sanofi-Aventis; and
Dr. Horsburgh, receiving payments from Otsuka America Pharmaceutical for
scientific reviews of study protocols. No other potential conflict of
interest relevant to this article was reported.
NR 39
TC 241
Z9 252
U1 4
U2 27
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD DEC 8
PY 2011
VL 365
IS 23
BP 2155
EP 2166
PG 12
WC Medicine, General & Internal
SC General & Internal Medicine
GA 857PQ
UT WOS:000297731400001
PM 22150035
ER
PT J
AU Warne, JP
Alemi, F
Reed, AS
Varonin, JM
Chan, H
Piper, ML
Mullin, ME
Myers, MG
Corvera, CU
Xu, AW
AF Warne, James P.
Alemi, Farzad
Reed, Alison S.
Varonin, Jillian M.
Chan, Helen
Piper, Merisa L.
Mullin, Mark E.
Myers, Martin G., Jr.
Corvera, Carlos U.
Xu, Allison W.
TI Impairment of Central Leptin-Mediated PI3K Signaling Manifested as
Hepatic Steatosis Independent of Hyperphagia and Obesity (Retracted
article. See vol. 21, pg. 648, 2015)
SO CELL METABOLISM
LA English
DT Article; Retracted Publication
ID INSULIN-RESISTANCE; ADIPOSE-TISSUE; LIPID-METABOLISM; NERVOUS-SYSTEM;
FOOD-INTAKE; MICE; LIVER; RECEPTOR; NEURONS; HYPOTHALAMUS
AB Hepatic steatosis is generally thought to develop via peripheral mechanisms associated with obesity. We show that chronic central infusion of leptin suppresses hepatic lipogenic gene expression and reduces triglyceride content via stimulation of hepatic sympathetic activity. This leptin function is independent of feeding and body weight but requires phosphatidylinositol 3-kinase (PI3K) signaling. Attenuation of leptin-induced PI3K signaling, brought about by transgenic expression of phosphatase and tensin homolog (PTEN) in leptin receptor neurons, leads to decreased hepatic sympathetic tone and increased triglyceride levels without affecting adiposity or hepatic insulin signaling. Central leptin's effects on hepatic norepinephrine levels and triglyceride content are blunted in these mutant mice. Simultaneous downregulation of PI3K and signal transducer and activator of transcription-3 (Stat3) in leptin receptor neurons does not exacerbate obesity but causes more severe hepatic steatosis. Together, our results indicate that central cellular leptin resistance in PI3K signaling manifests as hepatic steatosis without causing obesity.
C1 [Warne, James P.; Reed, Alison S.; Varonin, Jillian M.; Chan, Helen; Piper, Merisa L.; Mullin, Mark E.; Xu, Allison W.] Univ Calif San Francisco, Ctr Diabet, San Francisco, CA 94143 USA.
[Alemi, Farzad; Corvera, Carlos U.] Univ Calif San Francisco, San Francisco VA Med Ctr, Dept Surg, San Francisco, CA 94143 USA.
[Myers, Martin G., Jr.] Univ Michigan, Sch Med, Dept Internal Med, Ann Arbor, MI 48109 USA.
[Myers, Martin G., Jr.] Univ Michigan, Sch Med, Dept Mol & Integrat Physiol, Ann Arbor, MI 48109 USA.
RP Xu, AW (reprint author), Univ Calif San Francisco, Ctr Diabet, San Francisco, CA 94143 USA.
EM axu@diabetes.ucsf.edu
FU NIH [R01DK080427, T32DK07161, DERC P30 DK063720]
FX We thank Drs. Michael Schwartz, Robert Farese, Jr., Jacquelyn Maher, and
Jamila Newton for their evaluation of the manuscript. This work was
supported by research grant from the NIH (R01DK080427 to A.W.X.) and, in
part, by a NIH Pediatric Endocrine Training grant (T32DK07161) to A.S.R.
This work was also supported, in part, by core facilities funded by NIH
DERC P30 DK063720.
NR 44
TC 27
Z9 28
U1 3
U2 11
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 1550-4131
EI 1932-7420
J9 CELL METAB
JI Cell Metab.
PD DEC 7
PY 2011
VL 14
IS 6
BP 791
EP 803
DI 10.1016/j.cmet.2011.11.001
PG 13
WC Cell Biology; Endocrinology & Metabolism
SC Cell Biology; Endocrinology & Metabolism
GA 862VO
UT WOS:000298122400012
PM 22152304
ER
PT J
AU Grijalva, CG
Chen, L
Delzell, E
Baddley, JW
Beukelman, T
Winthrop, KL
Griffin, MR
Herrinton, LJ
Liu, LY
Ouellet-Hellstrom, R
Patkar, NM
Solomon, DH
Lewis, JD
Xie, FL
Saag, KG
Curtis, JR
AF Grijalva, Carlos G.
Chen, Lang
Delzell, Elizabeth
Baddley, John W.
Beukelman, Timothy
Winthrop, Kevin L.
Griffin, Marie R.
Herrinton, Lisa J.
Liu, Liyan
Ouellet-Hellstrom, Rita
Patkar, Nivedita M.
Solomon, Daniel H.
Lewis, James D.
Xie, Fenglong
Saag, Kenneth G.
Curtis, Jeffrey R.
TI Initiation of Tumor Necrosis Factor-alpha Antagonists and the Risk of
Hospitalization for Infection in Patients With Autoimmune Diseases
SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LA English
DT Article
ID MODIFYING ANTIRHEUMATIC DRUGS; RHEUMATOID-ARTHRITIS PATIENTS; SERIOUS
BACTERIAL-INFECTIONS; PLACEBO-CONTROLLED TRIALS; HAZARDS
REGRESSION-MODEL; OPPORTUNISTIC INFECTIONS; BIOLOGICS-REGISTER;
BRITISH-SOCIETY; FACTOR THERAPY; METAANALYSIS
AB Context Although tumor necrosis factor (TNF)-alpha antagonists are increasingly used in place of nonbiologic comparator medications, their safety profile remains incomplete.
Objectives To determine whether initiation of TNF-alpha antagonists compared with nonbiologic comparators is associated with an increased risk of serious infections requiring hospitalization.
Design, Setting, and Patients Within a US multi-institutional collaboration, we assembled retrospective cohorts (1998-2007) of patients with rheumatoid arthritis (RA), inflammatory bowel disease (IBD), and psoriasis, psoriatic arthritis, or ankylosing spondylitis (psoriasis and spondyloarthropathies) combining data from Kaiser Permanente Northern California, New Jersey and Pennsylvania Pharmaceutical Assistance programs, Tennessee Medicaid, and national Medicaid/Medicare. TNF-alpha antagonists and nonbiologic regimens were compared in disease-specific propensity score (PS)-matched cohorts using Cox regression models with nonbiologics as the reference. Baseline glucocorticoid use was evaluated as a separate covariate.
Main Outcome Measure Infections requiring hospitalization (serious infections) during the first 12 months after initiation of TNF-alpha antagonists or nonbiologic regimens.
Results Study cohorts included 10 484 RA, 2323 IBD, and 3215 psoriasis and spondyloarthropathies matched pairs using TNF-alpha antagonists and comparator medications. Overall, we identified 1172 serious infections, most of which (53%) were pneumonia and skin and soft tissue infections. Among patients with RA, serious infection hospitalization rates were 8.16 (TNF-alpha antagonists) and 7.78 (comparator regimens) per 100 person-years (adjusted hazard ratio [aHR], 1.05 [95% CI, 0.91-1.21]). Among patients with IBD, rates were 10.91 (TNF-alpha antagonists) and 9.60 (comparator) per 100 person-years (aHR, 1.10 [95% CI, 0.83-1.46]). Among patients with psoriasis and spondyloarthropathies, rates were 5.41 (TNF-alpha antagonists) and 5.37 (comparator) per 100 person-years (aHR, 1.05 [95% CI, 0.76-1.45]). Among patients with RA, infliximab was associated with a significant increase in serious infections compared with etanercept (aHR, 1.26 [95% CI, 1.07-1.47]) and adalimumab (aHR, 1.23 [95% CI, 1.02-1.48]). Baseline glucocorticoid use was associated with a dose-dependent increase in infections.
Conclusion Among patients with autoimmune diseases, compared with treatment with nonbiologic regimens, initiation of TNF-alpha antagonists was not associated with an increased risk of hospitalizations for serious infections. JAMA. 2011;306(21):2331-2339 Published online November 6, 2011. doi:10.1001/jama.2011.1692
C1 [Grijalva, Carlos G.] Vanderbilt Univ, Sch Med, Div Pharmacoepidemiol, Dept Prevent Med, Nashville, TN 37212 USA.
[Chen, Lang; Delzell, Elizabeth; Baddley, John W.; Beukelman, Timothy; Patkar, Nivedita M.; Xie, Fenglong; Saag, Kenneth G.; Curtis, Jeffrey R.] Univ Alabama Birmingham, Birmingham, AL USA.
[Baddley, John W.] Birmingham VA Med Ctr, Birmingham, AL USA.
[Winthrop, Kevin L.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
[Herrinton, Lisa J.; Liu, Liyan] Kaiser Permanente No Calif, Oakland, CA USA.
[Ouellet-Hellstrom, Rita] US FDA, Silver Spring, MD USA.
[Solomon, Daniel H.] Brigham & Womens Hosp, Boston, MA 02115 USA.
[Solomon, Daniel H.] Harvard Univ, Boston, MA 02115 USA.
[Lewis, James D.] Univ Penn, Dept Med, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA.
[Lewis, James D.] Univ Penn, Dept Biostat & Epidemiol, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA.
RP Grijalva, CG (reprint author), Vanderbilt Univ, Sch Med, Div Pharmacoepidemiol, Dept Prevent Med, 1500 21st Ave S,Ste 2600, Nashville, TN 37212 USA.
EM carlos.grijalva@vanderbilt.edu
FU Amgen; Genentech; Centocor; Procter Gamble; Abbott; Eli Lilly;
Bristol-Myers Squibb; Takeda; Shire; Pfizer; Roche/Genentech; UCB
biopharma; CORRONA; Crescendo; Food and Drug Administration (FDA); US
Department of Health and Human Services (DHHS); Agency for Healthcare
Research and Quality (AHRQ) [U18 HS17919, R01HS018517]; National
Institutes of Health (NIH) [AR053351]; NIH via the University of Alabama
at Birmingham Center for Clinical and Translational Science [5KL2
RR025776-03]; National Institute of Arthritis and Musculoskeletal and
Skin Diseases [5P60AR56116]
FX All authors have completed and submitted the ICMJE Form for Disclosure
of Potential Conflicts of Interest. Dr Delzell reported receiving
research support from Amgen. Dr Baddley reported consulting for Abbott
and Merck. Dr Herrinton reported receiving research support from
Genentech, Centocor, and Procter & Gamble. Dr Solomon reported receiving
research support from Amgen, Abbott, Eli Lilly, and Bristol-Myers
Squibb. Dr Lewis reported consulting for Genentech, Abbott, CORRONA
(Consortium of Rheumatology Researchers of North America Inc),
Millennium Pharmaceuticals, Elan, AstraZeneca, Procter & Gamble,
GlaxoSmithKline, Alios Therapeutics, Roche, and Amgen; he also reported
receiving research support from Centocor, Takeda, and Shire, and
consultant honoraria from Amgen and Pfizer. Dr Winthrop reported
receiving consultant fees from Genentech and Abbott, research support
from Pfizer, and speakers honoraria from Amgen and Pfizer. Dr Saag
reported receiving research support from Amgen, Genentech, and Pfizer.
Dr Curtis reported receiving consultant fees and research grants from
Roche/Genentech, UCB biopharma, Centocor, CORRONA, Amgen, Pfizer,
Bristol-Myers Squibb, Crescendo, and Abbott. Other authors reported no
conflicts.; This work was supported by the Food and Drug Administration
(FDA), US Department of Health and Human Services (DHHS), and the Agency
for Healthcare Research and Quality (AHRQ) grant U18 HS17919. Dr Curtis
receives support from the National Institutes of Health (NIH; AR053351)
and AHRQ (R01HS018517). Dr Beukelman was supported by NIH grant 5KL2
RR025776-03 via the University of Alabama at Birmingham Center for
Clinical and Translational Science. Drs Grijalva and Griffin receive
support from the National Institute of Arthritis and Musculoskeletal and
Skin Diseases, grant 5P60AR56116.
NR 51
TC 141
Z9 146
U1 1
U2 7
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA
SN 0098-7484
J9 JAMA-J AM MED ASSOC
JI JAMA-J. Am. Med. Assoc.
PD DEC 7
PY 2011
VL 306
IS 21
BP 2331
EP 2339
DI 10.1001/jama.2011.1692
PG 9
WC Medicine, General & Internal
SC General & Internal Medicine
GA 856YH
UT WOS:000297680300018
PM 22056398
ER
PT J
AU Zile, MR
Gottdiener, JS
Hetzel, SJ
McMurray, JJ
Komajda, M
McKelvie, R
Baicu, CF
Massie, BM
Carson, PE
AF Zile, Michael R.
Gottdiener, John S.
Hetzel, Scott J.
McMurray, John J.
Komajda, Michel
McKelvie, Robert
Baicu, Catalin F.
Massie, Barry M.
Carson, Peter E.
CA I-PRESERVE Investigators
TI Prevalence and Significance of Alterations in Cardiac Structure and
Function in Patients With Heart Failure and a Preserved Ejection
Fraction
SO CIRCULATION
LA English
DT Article
DE heart failure; echocardiography; ventricular ejection fraction
ID VENTRICULAR DIASTOLIC DYSFUNCTION; SOCIETY-OF-CARDIOLOGY; HYPERTENSIVE
PATIENTS; SYSTOLIC FUNCTION; RANDOMIZED-TRIAL; COMMUNITY;
ECHOCARDIOGRAPHY; POPULATION; IRBESARTAN; OUTCOMES
AB Background-The purpose of this study was to examine the prevalence of abnormalities in cardiac structure and function present in patients with heart failure and a preserved ejection fraction (HFPEF) and to determine whether these alterations in structure and function were associated with cardiovascular morbidity and mortality.
Methods and Results-The Irbesartan in HFPEF trial (I-PRESERVE) enrolled 4128 patients; echocardiographic determination of left ventricular (LV) volume, mass, left atrial (LA) size, systolic function, and diastolic function were made at baseline in 745 patients. The primary end point was death or protocol-specific cardiovascular hospitalization. A secondary end point was the composite of heart failure death or heart failure hospitalization. Associations between baseline structure and function and patient outcomes were examined using univariate and multivariable Cox proportional hazard analyses. In this substudy, LV hypertrophy or concentric remodeling was present in 59%, LA enlargement was present in 66%, and diastolic dysfunction was present in 69% of the patients. Multivariable analyses controlling for 7 clinical variables (including log N-terminal pro-B-type natriuretic peptide) indicated that increased LV mass, mass/volume ratio, and LA size were independently associated with an increased risk of both primary and heart failure events (all P < 0.05).
Conclusions-Left ventricular hypertrophy or concentric remodeling, LA enlargement, and diastolic dysfunction were present in the majority of patients with HFPEF. Left ventricular mass and LA size were independently associated with an increased risk of morbidity and mortality. The presence of structural remodeling and diastolic dysfunction may be useful additions to diagnostic criteria and provide important prognostic insights in patients with HFPEF. Clinical Trial Registration-http://www.clinicaltrials.gov. Unique identifier: NCT00095238. (Circulation. 2011; 124: 2491-2501.)
C1 [Zile, Michael R.] Med Univ S Carolina, Dept Med, Div Cardiol, Charleston, SC 29425 USA.
[Zile, Michael R.; Baicu, Catalin F.] Vet Affairs Med Ctr, RHJ Dept, Charleston, SC 29403 USA.
[Gottdiener, John S.] Univ Maryland, Med Ctr, Baltimore, MD 21201 USA.
[Hetzel, Scott J.] Univ Wisconsin, Sch Med & Publ Hlth, Madison, WI USA.
[McMurray, John J.] Univ Glasgow, British Heart Fdn Glasgow Cardiovasc Res Ctr, Glasgow, Lanark, Scotland.
[Komajda, Michel] Univ Paris 06, Paris, France.
[Komajda, Michel] Hop La Pitie Salpetriere, Paris, France.
[McKelvie, Robert] McMaster Univ, Hamilton, ON, Canada.
[Massie, Barry M.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Massie, Barry M.] San Francisco VA Med Ctr, San Francisco, CA USA.
[Carson, Peter E.] Georgetown Univ, Washington, DC USA.
[Carson, Peter E.] Washington DC VAMC, Washington, DC USA.
RP Zile, MR (reprint author), Med Univ S Carolina, Dept Med, Div Cardiol, Ashley River Towers,25 Courtenay Dr,Room 7067, Charleston, SC 29425 USA.
EM zilem@musc.edu
OI mcmurray, john/0000-0002-6317-3975
FU Bristol-Myers Squibb; Sanofi-aventis; Servier
FX Drs Zile, Gottdiener, and Carson report receiving consulting fees from
Bristol-Myers Squibb and Sanofi-aventis. Dr McMurray reports receiving
support from Bristol-Myers Squibb (to Glasgow University) for his work
on this trial. Dr Komajda reports receiving consulting fees from
Bristol-Myers Squibb and Servier and lecture fees from Sanofi-aventis.
Dr McKelvie reports receiving consulting fees and lecture fees from
Bristol-Myers Squibb and Sanofi-aventis. S.J. Hetzel reports being
employed by the Statistical Data Analysis Center at the University of
Wisconsin Madison, which conducted the statistical analysis for this
trial that was supported by Bristol-Myers Squibb and Sanofi-Aventis. Dr
Massie reports receiving grant support and consulting fees from
Bristol-Myers Squibb and Sanofi-aventis.
NR 38
TC 154
Z9 162
U1 2
U2 10
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0009-7322
J9 CIRCULATION
JI Circulation
PD DEC 6
PY 2011
VL 124
IS 23
BP 2491
EP 2501
DI 10.1161/CIRCULATIONAHA.110.011031
PG 11
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA 863QW
UT WOS:000298183300013
PM 22064591
ER
PT J
AU Cope, EK
Goldstein-Daruech, N
Kofonow, JM
Christensen, L
McDermott, B
Monroy, F
Palmer, JN
Chiu, AG
Shirtliff, ME
Cohen, NA
Leid, JG
AF Cope, Emily K.
Goldstein-Daruech, Natalia
Kofonow, Jennifer M.
Christensen, Lanette
McDermott, Bridget
Monroy, Fernando
Palmer, James N.
Chiu, Alexander G.
Shirtliff, Mark E.
Cohen, Noam A.
Leid, Jeff G.
TI Regulation of Virulence Gene Expression Resulting from Streptococcus
pneumoniae and Nontypeable Haemophilus influenzae Interactions in
Chronic Disease
SO PLOS ONE
LA English
DT Article
ID UPPER RESPIRATORY-TRACT; ORAL MICROBIAL COMMUNITIES; CHRONIC
RHINOSINUSITIS; OTITIS-MEDIA; IN-VIVO; BIOFILM FORMATION;
PSEUDOMONAS-AERUGINOSA; CHINCHILLA MODEL; HUMAN HOST; BACTERIAL
AB Chronic rhinosinusitis (CRS) is a common inflammatory disease of the sinonasal cavity mediated, in part, by polymicrobial communities of bacteria. Recent molecular studies have confirmed the importance of Streptococcus pneumoniae and nontypeable Haemophilus influenzae (NTHi) in CRS. Here, we hypothesize that interaction between S. pneumoniae and NTHi mixed-species communities cause a change in bacterial virulence gene expression. We examined CRS as a model human disease to validate these polymicrobial interactions. Clinical strains of S. pneumoniae and NTHi were grown in mono-and co-culture in a standard biofilm assay. Reverse transcriptase real-time PCR (RTqPCR) was used to measure gene expression of key virulence factors. To validate these results, we investigated the presence of the bacterial RNA transcripts in excised human tissue from patients with CRS. Consequences of physical or chemical interactions between microbes were also investigated. Transcription of NTHi type IV pili was only expressed in co-culture in vitro, and expression could be detected ex vivo in diseased tissue. S. pneumoniae pyruvate oxidase was up-regulated in co-culture, while pneumolysin and pneumococcal adherence factor A were down-regulated. These results were confirmed in excised human CRS tissue. Gene expression was differentially regulated by physical contact and secreted factors. Overall, these data suggest that interactions between H. influenzae and S. pneumoniae involve physical and chemical mechanisms that influence virulence gene expression of mixed-species biofilm communities present in chronically diseased human tissue. These results extend previous studies of population-level virulence and provide novel insight into the importance of S. pneumoniae and NTHi in CRS.
C1 [Cope, Emily K.; Christensen, Lanette; McDermott, Bridget; Monroy, Fernando; Leid, Jeff G.] No Arizona Univ, Dept Biol Sci, Flagstaff, AZ 86011 USA.
[Goldstein-Daruech, Natalia; Kofonow, Jennifer M.; Palmer, James N.; Chiu, Alexander G.; Cohen, Noam A.] Univ Penn, Dept Otorhinolaryngol Head & Neck Surg, Philadelphia, PA 19104 USA.
[Cohen, Noam A.] Univ Penn, Philadelphia Vet Affairs Med Ctr, Surg Serv, Philadelphia, PA 19104 USA.
[Shirtliff, Mark E.] Univ Maryland, Sch Dent, Dept Microbial Pathogenesis, Baltimore, MD 21201 USA.
RP Cope, EK (reprint author), No Arizona Univ, Dept Biol Sci, Box 5640, Flagstaff, AZ 86011 USA.
EM Emily.Cope@nau.edu
RI Chiu, Alexander/J-1230-2014; Monroy, Francisco/N-2763-2013
OI Chiu, Alexander/0000-0002-7592-6575; Monroy,
Francisco/0000-0001-6455-3083; Cohen, Noam/0000-0002-9462-3932
FU Science Foundation Arizona [GRF 0204-08]; Flight Attendants Medical
Research Institute [103019]
FX This work was supported by Science Foundation Arizona GRF 0204-08
(http://www.sfaz.org) and the Flight Attendants Medical Research
Institute, Clinical Innovator Award #103019. The funders had no role in
study design, data collection and analysis, decision to publish, or
preparation of the manuscript.
NR 62
TC 17
Z9 17
U1 0
U2 11
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 5
PY 2011
VL 6
IS 12
AR e28523
DI 10.1371/journal.pone.0028523
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 863NX
UT WOS:000298172800045
PM 22162775
ER
PT J
AU Chu, VC
Bhattacharya, S
Nomoto, A
Lin, JH
Zaidi, SK
Oberley, TD
Weinman, SA
Azhar, S
Huang, TT
AF Chu, Victor C.
Bhattacharya, Sayanti
Nomoto, Ann
Lin, Jiahui
Zaidi, Syed Kashif
Oberley, Terry D.
Weinman, Steven A.
Azhar, Salman
Huang, Ting-Ting
TI Persistent Expression of Hepatitis C Virus Non-Structural Proteins Leads
to Increased Autophagy and Mitochondrial Injury in Human Hepatoma Cells
SO PLOS ONE
LA English
DT Article
ID CORE PROTEIN; OXIDATIVE STRESS; MICROVILLAR LOCALIZATION;
SUPEROXIDE-DISMUTASE; SCAVENGER RECEPTOR; ROS PRODUCTION; NS5A PROTEIN;
ER STRESS; CLASS-B; REPLICATION
AB HCV infection is a major cause of chronic liver disease and liver cancer in the United States. To address the pathogenesis caused by HCV infection, recent studies have focused on the direct cytopathic effects of individual HCV proteins, with the objective of identifying their specific roles in the overall pathogenesis. However, this approach precludes examination of the possible interactions between different HCV proteins and organelles. To obtain a better understanding of the various cytopathic effects of and cellular responses to HCV proteins, we used human hepatoma cells constitutively replicating HCV RNA encoding either the full-length polyprotein or the non-structural proteins, or cells constitutively expressing the structural protein core, to model the state of persistent HCV infection and examined the combination of various HCV proteins in cellular pathogenesis. Increased reactive oxygen species (ROS) generation in the mitochondria, mitochondrial injury and degeneration, and increased lipid accumulation were common among all HCV protein-expressing cells regardless of whether they expressed the structural or non-structural proteins. Expression of the non-structural proteins also led to increased oxidative stress in the cytosol, membrane blebbing in the endoplasmic reticulum, and accumulation of autophagocytic vacuoles. Alterations of cellular redox state, on the other hand, significantly changed the level of autophagy, suggesting a direct link between oxidative stress and HCV-mediated activation of autophagy. With the widespread cytopathic effects, cells with the full-length HCV polyprotein showed a modest antioxidant response and exhibited a significant increase in population doubling time and a concomitant decrease in cyclin D1. In contrast, cells expressing the non-structural proteins were able to launch a vigorous antioxidant response with up-regulation of antioxidant enzymes. The population doubling time and cyclin D1 level were also comparable to that of control cells. Finally, the cytopathic effects of core protein appeared to focus on the mitochondria without remarkable disturbances in the cytosol.
C1 Stanford Univ, Dept Neurol & Neurol Sci, Stanford, CA 94305 USA.
[Nomoto, Ann; Zaidi, Syed Kashif; Azhar, Salman; Huang, Ting-Ting] VA Palo Alto Hlth Care Syst, Ctr Geriatr Res Educ & Clin, Palo Alto, CA USA.
[Oberley, Terry D.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Pathol & Lab Med, Madison, WI USA.
[Oberley, Terry D.] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA.
[Weinman, Steven A.] Univ Kansas, Med Ctr, Dept Internal Med, Kansas City, KS 66103 USA.
RP Chu, VC (reprint author), Stanford Univ, Dept Neurol & Neurol Sci, Stanford, CA 94305 USA.
EM tthuang@stanford.edu
RI Zaidi, Syed Kashif /A-6160-2013
OI Zaidi, Syed Kashif /0000-0003-2391-414X
FU National Institutes of Health [AA012863, HL33881, CA122499]; Stanford
Digestive Disease Center
FX This work is supported by funding from National Institutes of Health
grant AA012863 to SW, HL33881 to SA, and CA122499 to T-TH, and from
Stanford Digestive Disease Center to T-TH. The funders had no role in
study design, data collection and analysis, decision to publish, or
preparation of the manuscript.
NR 58
TC 20
Z9 21
U1 0
U2 8
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 2
PY 2011
VL 6
IS 12
AR e28551
DI 10.1371/journal.pone.0028551
PG 14
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 863NO
UT WOS:000298171400106
PM 22164304
ER
PT J
AU Wang, Z
Chen, J
Boyd, JE
Zhang, HY
Jia, XZ
Qiu, JY
Xiao, ZP
AF Wang, Zhen
Chen, Jue
Boyd, Jennifer E.
Zhang, Haiyin
Jia, Xiuzhen
Qiu, Jianyin
Xiao, Zeping
TI Psychometric Properties of the Chinese Version of the Perceived Stress
Scale in Policewomen
SO PLOS ONE
LA English
DT Article
ID PSYCHOLOGICAL STRESS; DEPRESSION; VALIDATION; ANXIETY; DISEASE; WOMEN
AB Background: The 10-item Perceived Stress Scale (PSS-10) is one of most widely used instruments to measure a global level of perceived stress in a range of clinical and research settings. This study was conducted to examine the psychometric properties of the Simplified Chinese version of the PSS-10 in policewomen.
Methodology: A total of 240 policewomen were recruited in this study. The Simplified Chinese versions of the PSS-10, the Beck Depression Inventory Revised (BDI-II), and the Beck Anxiety Inventory (BAI) were administered to all participants, and 36 of the participants were re-tested two weeks after the initial testing.
Principal Findings: The overall Cronbach's alpha was 0.86, and the test-retest reliability coefficient was 0.68. Exploratory Factor Analysis (EFA) yielded 2 factors with eigenvalues of 4.76 and 1.48, accounting for 62.41% of variance. Factor 1 consisted of 6 items representing "negative feelings''; whereas Factor 2 consisted of 4 items representing "positive feelings''. The item loadings ranged from 0.72 to 0.83. The Confirmatory factor analysis (CFA) indicated a very good fit of this two-factor model to this sample. The PSS-10 significantly correlated with both BDI-II and BAI, indicating an acceptable concurrent validity.
Conclusions: The Simplified Chinese version of the PSS-10 demonstrated adequate psychometric properties for evaluating stress levels. The results support its use among the Chinese population.
C1 [Wang, Zhen; Chen, Jue; Zhang, Haiyin; Jia, Xiuzhen; Qiu, Jianyin; Xiao, Zeping] Shanghai Jiao Tong Univ, Sch Med, Shanghai Mental Hlth Ctr, Shanghai 200030, Peoples R China.
[Boyd, Jennifer E.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA.
[Boyd, Jennifer E.] San Francisco VA Med Ctr, San Francisco, CA USA.
RP Wang, Z (reprint author), Shanghai Jiao Tong Univ, Sch Med, Shanghai Mental Hlth Ctr, Shanghai 200030, Peoples R China.
EM xiaozeping@gmail.com
FU National Natural Science Fundation [30800370]; Shanghai Pujiang Program
[09PJ1408900]
FX This study was supported by grants from the National Natural Science
Fundation (30800370) and the Shanghai Pujiang Program (09PJ1408900). The
funders had no role in study design, data collection and analysis,
decision to publish, or preparation of the manuscript.
NR 28
TC 29
Z9 34
U1 3
U2 21
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 2
PY 2011
VL 6
IS 12
AR e28610
DI 10.1371/journal.pone.0028610
PG 4
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 863NO
UT WOS:000298171400113
PM 22164311
ER
PT J
AU Mason, ZD
Pearlman, J
Cooper, RA
Laferrier, JZ
AF Mason, Zachary D.
Pearlman, Jon
Cooper, Rory A.
Laferrier, Justin Z.
TI Comparison of prosthetic feet prescribed to active individuals using ISO
standards
SO PROSTHETICS AND ORTHOTICS INTERNATIONAL
LA English
DT Article
DE Prosthetic feet; testing of prosthetic and orthotic components
ID WHEELCHAIR-RELATED ACCIDENTS; UNITED-STATES; AMPUTEES; INJURY; SAFETY;
LIFE
AB Background: Little research has been done on the robustness of prosthetic feet prescribed to military personnel, and manufacturers are not required to test their products prior to sale. This is problematic because the prosthetic feet used by active individuals are subjected to loading conditions not seen in normal gait.
Objectives: To evaluate whether commercially available heavy-duty prosthetic feet intended for use by military personnel meet ISO 10328 standards.
Study Design: Bench testing of heavy-duty prosthetic feet using ISO 10328 standards.
Methods: Prosthetic feet from three different manufacturers were tested according to ISO 10328 standards, using a testing frame fitted with axial load and displacement transducers. Pass/fail information was recorded as well as the stiffness and creep of each foot before and after cyclic testing.
Results: All feet passed the ISO 10328 standards at the highest loading level, and some significant differences were found within a given model of prosthesis when comparing stiffness and creep before and after cyclic testing.
Conclusions: This study demonstrated that manufacturers of heavy-duty prosthetic feet adhere to the voluntary ISO 10328 standards. However, these standards may be insufficient because the tests simulate only idealized gait. Further development of the standards may be necessary to reproduce the circumstances that occur during extreme usage to ensure that prosthetic feet do not fail.
C1 [Mason, Zachary D.; Pearlman, Jon; Cooper, Rory A.; Laferrier, Justin Z.] Human Engn Res Labs, Pittsburgh, PA 15206 USA.
[Mason, Zachary D.] Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA 15260 USA.
[Pearlman, Jon; Cooper, Rory A.; Laferrier, Justin Z.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
[Pearlman, Jon; Cooper, Rory A.; Laferrier, Justin Z.] Univ Pittsburgh, Dept Rehabil Sci & Technol, Pittsburgh, PA 15260 USA.
RP Pearlman, J (reprint author), Human Engn Res Labs, 7180 Highland Dr 151R-1H, Pittsburgh, PA 15206 USA.
EM jlp46@pitt.edu
OI Pearlman, Jon/0000-0003-0830-9136
FU Telemedicine and Advanced Technology Research Center [W81XWH-07-1-0716]
FX This study was funded by the Telemedicine and Advanced Technology
Research Center under contract number W81XWH-07-1-0716.
NR 28
TC 0
Z9 0
U1 1
U2 8
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 0309-3646
J9 PROSTHET ORTHOT INT
JI Prosthet. Orthot. Int.
PD DEC
PY 2011
VL 35
IS 4
BP 418
EP 424
DI 10.1177/0309364611421692
PG 7
WC Orthopedics; Rehabilitation
SC Orthopedics; Rehabilitation
GA 962TM
UT WOS:000305568000013
PM 22031596
ER
PT J
AU George, M
Fletcher, M
AF George, Maureen
Fletcher, Monica
TI Pulmonary rehabilitation in the management of COPD: more than one way to
skin a cat
SO PRIMARY CARE RESPIRATORY JOURNAL
LA English
DT Editorial Material
ID RESPIRATORY SOCIETY; PROGRAMS; DISEASE; IMPACT
C1 [Fletcher, Monica] Educ Hlth, Warwick CV34 4AB, England.
[George, Maureen] Univ Penn, Sch Nursing, Dept Family & Community Hlth, Ctr Hlth Equ Res, Philadelphia, PA 19104 USA.
[George, Maureen] Ctr Global Womens Hlth, Philadelphia, PA USA.
RP Fletcher, M (reprint author), Educ Hlth, 10 Church St, Warwick CV34 4AB, England.
EM m.fletcher@educationforhealth.org
NR 16
TC 0
Z9 0
U1 0
U2 3
PU PRIMARY CARE RESPIRATORY SOC-PCRS UK
PI WATERBECK
PA EDITORIAL OFFICE, SMITHY HOUSE, WATERBECK, LOCKERBIE DG11 3EY, SCOTLAND
SN 1471-4418
J9 PRIM CARE RESP J
JI Prim. Care Respir. J.
PD DEC
PY 2011
VL 20
IS 4
BP 355
EP 356
DI 10.4104/pcrj.2011.00100
PG 2
WC Primary Health Care; Respiratory System
SC General & Internal Medicine; Respiratory System
GA 945MT
UT WOS:000304279300005
PM 22089280
ER
PT J
AU Salerno, A
Dixon, LB
Myers, RW
Smith, AM
Lamberti, JS
Jewell, TC
Essock, SM
AF Salerno, Anthony
Dixon, Lisa B.
Myers, Robert W.
Smith, Anne M.
Lamberti, J. Steven
Jewell, Thomas C.
Essock, Susan M.
TI A Public-Academic Partnership to Support a State Mental Health
Authority's Strategic Planning and Policy Decisions
SO PSYCHIATRIC SERVICES
LA English
DT Article
AB Mental health authorities across the country face numerous challenges in developing effective and practical strategies to adopt and sustain research-supported and stakeholder-endorsed mental health practices. This column describes how an academic center assists a mental health authority in making policy decisions by the use of advisory panels of multiple stakeholders, including members of the research community, advocacy organizations, service providers, and consumers. An advisory panel that focused on services involving family members for adults with serious mental health problems serves as a case example. (Psychiatric Services 62:1413-1415, 2011)
C1 [Salerno, Anthony; Essock, Susan M.] Columbia Univ, Dept Psychiat, Coll Phys & Surg, New York, NY USA.
[Salerno, Anthony] NYU, Silver Sch Social Work, McSilver Inst Poverty Policy & Res, New York, NY USA.
[Dixon, Lisa B.] Univ Maryland, Sch Med, Div Hlth Serv Res, Baltimore, MD 21201 USA.
[Dixon, Lisa B.] US Dept Vet Affairs, Capitol Hlth Care Network Mental Illness Res Educ, Baltimore, MD USA.
[Myers, Robert W.] New York State Off Mental Hlth, Div Adult Serv, Albany, NY USA.
[Smith, Anne M.; Jewell, Thomas C.] Univ Rochester, Dept Psychiat, Family Inst Educ Practice & Res, Rochester, NY USA.
[Jewell, Thomas C.] Columbia Univ, Ctr Practice Innovat, New York, NY USA.
[Lamberti, J. Steven] Univ Rochester, Med Ctr, Severe Mental Disorders Program, Dept Psychiat, Rochester, NY 14642 USA.
[Essock, Susan M.] Columbia Univ, Div Mental Hlth Serv & Policy Res, New York, NY USA.
RP Salerno, A (reprint author), 92 Winchester Dr, Monroe, NY 10950 USA.
EM anthony.salerno@nyu.edu
FU New York State Office of Mental Health (NYSOMH); Center for Practice
Innovations
FX The authors acknowledge the financial support provided by the New York
State Office of Mental Health (NYSOMH) to the Family Institute for
Education, Practice, and Research at the University of Rochester to
develop, field test, and improve the CCFC model. Furthermore, the NYSOMH
supported the Center for Practice Innovations, which organized the
advisory panel.
NR 5
TC 4
Z9 4
U1 0
U2 1
PU AMER PSYCHIATRIC PUBLISHING, INC
PI ARLINGTON
PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA
SN 1075-2730
J9 PSYCHIAT SERV
JI Psychiatr. Serv.
PD DEC
PY 2011
VL 62
IS 12
BP 1413
EP 1415
PG 3
WC Health Policy & Services; Public, Environmental & Occupational Health;
Psychiatry
SC Health Care Sciences & Services; Public, Environmental & Occupational
Health; Psychiatry
GA 912OI
UT WOS:000301809100002
PM 22193785
ER
PT J
AU Mancini, GBJ
Hartigan, PM
Bates, ER
Sedlis, SP
Maron, DJ
Spertus, JA
Berman, DS
Kostuk, WJ
Shaw, LJ
Weintraub, WS
Teo, KK
Dada, M
Chaitman, BR
O'Rourke, RA
Boden, WE
AF Mancini, G. B. John
Hartigan, Pamela M.
Bates, Eric R.
Sedlis, Steven P.
Maron, David J.
Spertus, John A.
Berman, Daniel S.
Kostuk, William J.
Shaw, Leslee J.
Weintraub, William S.
Teo, Koon K.
Dada, Marcin
Chaitman, Bernard R.
O'Rourke, Robert A.
Boden, William E.
CA Coordinators, CI
TI Angiographic Disease Progression and Residual Risk of Cardiovascular
Events While on Optimal Medical Therapy Observations From the COURAGE
Trial
SO CIRCULATION-CARDIOVASCULAR INTERVENTIONS
LA English
DT Article
DE coronary artery disease; angiography; angioplasty; atherosclerotic
plaque; rupture; revascularization
ID CORONARY-ARTERY-DISEASE; FRACTIONAL FLOW RESERVE; ATHEROSCLEROTIC
PLAQUES; INTERVENTION; TOMOGRAPHY; CULPRIT; LESIONS
AB Background-The extent to which recurrent events in patients with stable coronary artery disease is attributable to progression of an index lesion originally >= 50% diameter stenosis (DS) but not revascularized or originally <50% DS is unknown during optimal medical therapy (OMT).
Methods and Results-In the COURAGE (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation) trial, 205 patients assigned to OMT plus percutaneous coronary intervention (PCI) and 284 patients assigned to OMT only had symptom-driven angiograms suitable for analysis. Percentages of patients in the OMT + PCI and OMT-only cohorts with index lesions originally <50% DS were 30% and 32%, respectively; 20% and 68% had index lesions originally >= 50% DS. In both groups, index lesions originally <50% or >= 50% DS represented <4% and <25% of all such lesions, respectively. The only angiographic predictor of myocardial infarction or acute coronary syndrome was the number of lesions originally >= 50% DS that had not been revascularized (odds ratio, 1.15; confidence limits, 1.01-1.31; P<0.04).
Conclusions-Lesions originally <50% DS were index lesions in one third of patients referred for symptom-driven repeat angiography, but represented <4% of all such lesions. Nonrevascularized lesions originally >= 50% DS were more often index lesions in OMT-only patients, but still represented a minority (<25%) of all such lesions. These findings underscore the need for improved therapies to arrest plaque progression and reliable strategies for selecting stenoses warranting PCI.
C1 [Mancini, G. B. John] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada.
[Hartigan, Pamela M.] Connecticut VA Healthcare Syst, Vet Affairs Cooperat Studies Program, Coordinating Ctr, West Haven, CT USA.
[Bates, Eric R.] Univ Michigan, Med Ctr, Ann Arbor, MI USA.
[Sedlis, Steven P.] Univ Sch Med, VA New York Harbor Hlth Care Syst, New York, NY USA.
[Maron, David J.] Vanderbilt Univ, Med Ctr, Nashville, TN USA.
[Spertus, John A.] Univ Missouri, Mid Amer Heart Inst, Kansas City, MO 64110 USA.
[Berman, Daniel S.] Univ Calif Los Angeles, Cedars Sinai Heart Inst, Los Angeles, CA USA.
[Kostuk, William J.] Univ Western Ontario, London Hlth Sci Ctr, London, ON, Canada.
[Shaw, Leslee J.] Emory Univ, Sch Med, Atlanta, GA USA.
[Weintraub, William S.] Christiana Care Hlth Syst, Newark, DE USA.
[Teo, Koon K.] McMaster Univ, Med Ctr, Hamilton, ON, Canada.
[Dada, Marcin] Hartford Hosp, Hartford, CT 06115 USA.
[Chaitman, Bernard R.] St Louis Univ Hosp, St Louis, MO USA.
[O'Rourke, Robert A.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA.
[O'Rourke, Robert A.] S Texas Vet Hlth Care Syst, San Antonio, TX USA.
[Boden, William E.] Buffalo Gen Hosp, Buffalo, NY 14203 USA.
[Boden, William E.] SUNY Buffalo, Buffalo, NY 14260 USA.
RP Mancini, GBJ (reprint author), Vancouver Hosp Res Pavil, Room 489,828 10th Ave, Vancouver, BC V5Z 1M9, Canada.
EM mancini@mail.ubc.ca
OI Sedlis, Steven/0000-0002-8194-8017
FU Merck; National Heart, Lung, and Blood Institute; American Heart
Association; American College of Cardiology Foundation; Lilly;
BMS/Sanofi; Cordis; United Healthcare; Gilead; St Jude Medical
FX Dr Mancini has received grant funding from Merck (>$10 000) and
honoraria from Merck (>$10 000), GlaxoSmithKline (>$10 000),
AstraZeneca, and Pfizer. Dr Spertus has received grant funding of >$10
000 from the National Heart, Lung, and Blood Institute; American Heart
Association; American College of Cardiology Foundation; Lilly;
BMS/Sanofi; Cordis; and EvaHeart and consulting fees <$10 000 from
United Healthcare, Gilead, and St Jude Medical.
NR 16
TC 21
Z9 23
U1 1
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1941-7640
J9 CIRC-CARDIOVASC INTE
JI Circ.-Cardiovasc. Interv.
PD DEC
PY 2011
VL 4
IS 6
BP 545
EP 552
DI 10.1161/CIRCINTERVENTIONS.110.960062
PG 8
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 896EZ
UT WOS:000300549500005
PM 22045968
ER
PT J
AU Azadani, AN
Tseng, EE
AF Azadani, Ali N.
Tseng, Elaine E.
TI Transcatheter Heart Valves for Failing Bioprostheses State-of-the-Art
Review of Valve-in-Valve Implantation
SO CIRCULATION-CARDIOVASCULAR INTERVENTIONS
LA English
DT Article
DE valve-in-valve implantation; transcatheter heart valve; transcatheter
aortic valve implantation
ID SEVERE AORTIC REGURGITATION; EDWARDS-SAPIEN VALVE; HIGH-RISK PATIENTS;
COREVALVE REVALVING SYSTEM; DEGENERATED BIOPROSTHESIS; ENERGY-LOSS;
FOLLOW-UP; REPLACEMENT; STENOSIS; PERFORMANCE
C1 [Tseng, Elaine E.] Univ Calif San Francisco, Div Cardiothorac Surg, Dept Surg, Med Ctr, San Francisco, CA 94143 USA.
[Azadani, Ali N.] San Francisco VA Med Ctr, San Francisco, CA USA.
RP Tseng, EE (reprint author), Univ Calif San Francisco, Div Cardiothorac Surg, Dept Surg, Med Ctr, 500 Parnassus Ave,Suite 405W,Box 0118, San Francisco, CA 94143 USA.
EM elaine.tseng@ucsfmedctr.org
FU American Heart Association; Northern California Institute for Research
and Education
FX This study was funded by an American Heart Association Grant-in-Aid and
Northern California Institute for Research and Education. No relevant
industry relationship is reported.
NR 81
TC 19
Z9 19
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1941-7640
J9 CIRC-CARDIOVASC INTE
JI Circ.-Cardiovasc. Interv.
PD DEC
PY 2011
VL 4
IS 6
BP 621
EP U189
DI 10.1161/CIRCINTERVENTIONS.111.964478
PG 51
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 896EZ
UT WOS:000300549500014
PM 22186106
ER
PT J
AU Tannock, LR
AF Tannock, Lisa R.
TI Ursolic acid effect on atherosclerosis: Apples and apples, or apples and
oranges?
SO ATHEROSCLEROSIS
LA English
DT Editorial Material
DE Ursolic acid; Atherosclerosis; Mouse models
ID RECEPTOR-DEFICIENT MICE; APOLIPOPROTEIN-E
C1 [Tannock, Lisa R.] Univ Kentucky, Div Endocrinol & Mol Med, Lexington, KY 40536 USA.
[Tannock, Lisa R.] US Dept Vet Affairs, Lexington, KY USA.
RP Tannock, LR (reprint author), Univ Kentucky, Div Endocrinol & Mol Med, Wethington Bldg,Room 567,900 S Limestone St, Lexington, KY 40536 USA.
EM Lisa.Tannock@uky.edu
NR 8
TC 5
Z9 5
U1 0
U2 12
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
IRELAND
SN 0021-9150
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD DEC
PY 2011
VL 219
IS 2
BP 397
EP 398
DI 10.1016/j.atherosclerosis.2011.09.029
PG 2
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA 872MN
UT WOS:000298813900007
PM 21993411
ER
PT J
AU Kaz, AM
Wong, CJ
Luo, YX
Virgin, JB
Washington, MK
Willis, JE
Leidner, RS
Chak, A
Grady, WM
AF Kaz, Andrew M.
Wong, Chao-Jen
Luo, Yanxin
Virgin, Jeffrey B.
Washington, M. Kay
Willis, Joseph E.
Leidner, Rom S.
Chak, Amitabh
Grady, William M.
TI DNA methylation profiling in Barrett's esophagus and esophageal
adenocarcinoma reveals unique methylation signatures and molecular
subclasses
SO EPIGENETICS
LA English
DT Article
DE Barrett's esophagus; esophageal adenocarcinoma; DNA methylation;
methylation microarray
ID HIGH-GRADE DYSPLASIA; NEOPLASTIC PROGRESSION; PREDICTS PROGRESSION;
CANCER; PHENOTYPE; RISK; HYPERMETHYLATION; OVEREXPRESSION; METAPLASIA;
BIOMARKERS
AB Barrett's esophagus (BE) is a metaplastic process whereby the normal stratified, squamous esophageal epithelium is replaced by specialized intestinal epithelium. Barrett's is the only accepted precursor lesion for esophageal adenocarcinoma (EAC), a solid tumor that is rapidly increasing in incidence in western countries. BE evolves into EAC through intermediate steps that involve increasing degrees of dysplasia. Current histologic criteria are quite subjective and the clinical behavior of BE is highly variable and difficult to predict using these standards. It is widely believed that molecular alterations present in BE and EAC will provide more precise prognostic and predictive markers for these conditions than the current clinical and histologic features in use. In order to further define molecular alterations that can classify unique groups of BE and EAC, we utilized methylation microarrays to compare the global gene methylation status of a collection of normal squamous, BE, BE+ high-grade dysplasia (HGD) and EAC cases. We found distinct global methylation signatures, as well as differential methylation of specific genes, that discriminated these histological groups. We also noted high and low methylation epigenotypes among the BE and EAC cases. Additional validation of those CpG sites that distinguished BE from BE + HGD and EAC may lead to the discovery of useful biomarkers with potential clinical applications in the diagnosis and prognosis of BE and EAC.
C1 [Kaz, Andrew M.; Luo, Yanxin; Grady, William M.] Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98104 USA.
[Kaz, Andrew M.; Grady, William M.] Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA.
[Virgin, Jeffrey B.] VA Puget Sound Hlth Care Syst, Dept Pathol, Seattle, WA USA.
[Kaz, Andrew M.] VA Puget Sound Hlth Care Syst, Res & Dev Serv, Seattle, WA USA.
[Luo, Yanxin] Sun Yat Sen Univ, Affiliated Hosp 6, Dept Colorectal Surg, Guangzhou 510275, Guangdong, Peoples R China.
[Luo, Yanxin] Sun Yat Sen Univ, Gastrointestinal Inst, Guangzhou 510275, Guangdong, Peoples R China.
[Washington, M. Kay] Vanderbilt Univ, Dept Pathol, Nashville, TN USA.
[Willis, Joseph E.] Case Western Reserve Univ, Sch Med, Dept Pathol, Case Comprehens Canc Ctr, Cleveland, OH 44106 USA.
[Chak, Amitabh] Case Western Reserve Univ, Sch Med, Div Gastroenterol, Case Comprehens Canc Ctr, Cleveland, OH USA.
[Leidner, Rom S.; Chak, Amitabh] Case Western Reserve Univ, Sch Med, Div Oncol, Case Comprehens Canc Ctr, Cleveland, OH USA.
RP Grady, WM (reprint author), Fred Hutchinson Canc Res Ctr, Div Clin Res, 1124 Columbia St, Seattle, WA 98104 USA.
EM akaz@fhcrc.org; wgrady@fhcrc.org
FU NIH/NIDDK [05K08-DK080630, K24DK002800]; NIH/NCI [CA135692]; Midcareer
Award in Patient Orient Research; Burroughs Wellcome Fund; [U54
CA163060-01]; [U01CA152756-01]
FX This research was supported by NIH/NIDDK grant 05K08-DK080630 (A.M.K.),
NIH/NCI CA135692 (A.C.), a Midcareer Award in Patient Orient Research,
NIH/NIDDK K24DK002800 (A.C.), U54 CA163060-01 (W.M.G, A.K., A.C.),
Burroughs Wellcome Fund (W.M.G.) and U01CA152756-01 (W.M.G).
NR 51
TC 22
Z9 24
U1 0
U2 2
PU LANDES BIOSCIENCE
PI AUSTIN
PA 1806 RIO GRANDE ST, AUSTIN, TX 78702 USA
SN 1559-2294
J9 EPIGENETICS-US
JI Epigenetics
PD DEC
PY 2011
VL 6
IS 12
BP 1403
EP 1412
DI 10.4161/epi.6.12.18199
PG 10
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 886CI
UT WOS:000299828200001
PM 22139570
ER
PT J
AU Miller, AM
Boro, MS
Korman, NE
Ben Davoren, J
AF Miller, Allison M.
Boro, Maureen S.
Korman, Nancy E.
Ben Davoren, J.
TI Provider and pharmacist responses to warfarin drug-drug interaction
alerts: a study of healthcare downstream of CPOE alerts
SO JOURNAL OF THE AMERICAN MEDICAL INFORMATICS ASSOCIATION
LA English
DT Article
ID PHYSICIAN ORDER ENTRY; CLINICAL DECISION-SUPPORT; PLASMINOGEN-ACTIVATOR;
MYOCARDIAL-INFARCTION; PHASE-I; MEDICATION; SYSTEM; RATES; THROMBOLYSIS;
PRESCRIBERS
AB Objective To categorize the appropriateness of provider and pharmacist responses to warfarin critical drug-drug interaction (cDDI) alerts, assess responses and actions to the cDDI, and determine the occurrence of warfarin adverse drug events (ADE) after alerts.
Design An 18-month, retrospective study of acute care admissions at a single Veterans Affairs medical center using computerized provider order entry (CPOE).
Measurements Patients included had at least one warfarin cDDI alert. Chart reviews included baseline laboratory values and demographics, provider actions, patient outcomes, and associated factors, including other interacting medications and number of simultaneously processed alerts.
Results 137 admissions were included (133 unique patients). Amiodarone, vitamin E in a multivitamin, sulfamethoxazole, and levothyroxine accounted for 75% of warfarin cDDI. Provider responses were clinically appropriate in 19.7% of admissions and pharmacist responses were appropriate in 9.5% of admissions. There were 50 ADE (36.6% of admissions) with warfarin; 80% were rated as having no or mild clinical effect. An increased number of non-critical alerts at the time of the reference cDDI alert was the only variable associated with an inappropriate provider response (p=0.01).
Limitations This study was limited by being a retrospective review and the possibility of confounding variables, such as other interacting medications.
Conclusion The large number of CPOE alerts may lead to inappropriate responses by providers and pharmacists. The high rate of ADE suggests a need for improved medication management systems for patients on warfarin. This study highlights the possibility of alert fatigue contributing to the high prevalence of inappropriate alert over-ride text responses.
C1 [Miller, Allison M.] Univ Calif San Francisco, Dept Pharmaceut Serv, San Francisco, CA 94143 USA.
[Boro, Maureen S.; Korman, Nancy E.] San Francisco VA Med Ctr, Serv Pharm, San Francisco, CA USA.
[Ben Davoren, J.] San Francisco VA Med Ctr, Dept Med, San Francisco, CA USA.
RP Miller, AM (reprint author), Univ Calif San Francisco, Dept Pharmaceut Serv, 505 Parnassus Ave,Rm M39C,Box 0622, San Francisco, CA 94143 USA.
EM allison.miller@ucsfmedctr.org
NR 31
TC 20
Z9 20
U1 2
U2 12
PU B M J PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 1067-5027
J9 J AM MED INFORM ASSN
JI J. Am. Med. Inf. Assoc.
PD DEC
PY 2011
VL 18
SU 1
BP I45
EP I50
DI 10.1136/amiajnl-2011-000262
PG 6
WC Computer Science, Information Systems; Computer Science,
Interdisciplinary Applications; Health Care Sciences & Services;
Information Science & Library Science; Medical Informatics
SC Computer Science; Health Care Sciences & Services; Information Science &
Library Science; Medical Informatics
GA 886RJ
UT WOS:000299871300009
PM 22037888
ER
PT J
AU Ding, P
Geng, Z
Yan, W
Zhou, XH
AF Ding, Peng
Geng, Zhi
Yan, Wei
Zhou, Xiao-Hua
TI Identifiability and Estimation of Causal Effects by Principal
Stratification With Outcomes Truncated by Death
SO JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION
LA English
DT Article
DE Causal inference; Quality of life; Survivor average causal effect
ID INFERENCE; MODELS
AB In medical studies, there are many situations where the final outcomes are truncated by death, in which patients die before outcomes of interest are measured. In this article we consider identifiability and estimation of causal effects by principal stratification when some outcomes are truncated by death. Previous studies mostly focused on large sample bounds, Bayesian analysis, sensitivity analysis. In this article, we propose a new method for identifying the causal parameter of interest under a nonparametric and semiparametric model. We show that the causal parameter of interest is identifiable under some regularity assumptions and the assumption that there exists a pretreatment covariate whose conditional distributions among two principal strata are not the same, but our approach does not need the assumption of a mixture normal distribution for outcomes as required by Zhang, Rubin, and Mealli (2009). Hence, the proposed method is applicable not only to a continuous outcome but also to a binary outcome. When some of the assumptions are violated, we discuss biases of estimators and propose methods to reduce these biases. We conduct several simulation studies to evaluate the finite-sample performance of the proposed approach. Finally, we apply the proposed approach to a real dataset from a Southwest Oncology Group (SWOG) clinical trial.
C1 [Zhou, Xiao-Hua] Univ Washington, Dept Biostat, Seattle, WA 98105 USA.
[Ding, Peng; Geng, Zhi; Yan, Wei] Peking Univ, Sch Math Sci, Beijing 100871, Peoples R China.
[Ding, Peng; Geng, Zhi; Yan, Wei] Peking Univ, Ctr Stat Sci, Beijing 100871, Peoples R China.
[Zhou, Xiao-Hua] VA Puget Sound Hlth Care Syst, Biostat Unit, HSR&D Ctr Excellence, Seattle, WA USA.
RP Zhou, XH (reprint author), Univ Washington, Dept Biostat, Seattle, WA 98105 USA.
EM pengdingpku@gmail.com; zgeng@math.pku.edu.cn; yanwei1982@pku.edu.cn;
azhou@u.washington.edu
FU NSFC [30728019, 11021463, 10931002]; NIH [R03 TW007197]; Department of
Veterans Affairs [05-196]
FX Peng Ding is Postgraduate Student (E-mail: pengdingpku@gmail.com), Zhi
Geng is Professor (E-mail: zgeng@math.pku.edu.cn), and Wei Yan is Ph.D.
Student (E-mail: yanwei1982@pku.edu.cn), School of Mathematical Sciences
and Center for Statistical Science, Peking University, Beijing 100871,
China. Xiao-Hua Zhou is Professor, Department of Biostatistics,
University of Washington, Seattle, WA 98105, and Director of
Biostatistics Unit, HSR&D Center of Excellence, VA Puget Sound Health
Care System (E-mail: azhou@u.washington.edu). This research was
supported by NSFC grants 30728019, 11021463, 10931002, NIH R03 TW007197,
and Department of Veterans Affairs HSR&D RCS Award 05-196. It does not
necessarily represent the views of VA HSR&D Service. We thank the
editor, the associate editor, and two anonymous referees for their
detailed comments and suggestions, which helped us greatly improve our
article. We also thank the Genitourinary Committee of the South Oncology
Group for providing data and scientific support.
NR 24
TC 11
Z9 11
U1 0
U2 16
PU AMER STATISTICAL ASSOC
PI ALEXANDRIA
PA 732 N WASHINGTON ST, ALEXANDRIA, VA 22314-1943 USA
SN 0162-1459
J9 J AM STAT ASSOC
JI J. Am. Stat. Assoc.
PD DEC
PY 2011
VL 106
IS 496
BP 1578
EP 1591
DI 10.1198/jasa.2011.tm10265
PG 14
WC Statistics & Probability
SC Mathematics
GA 883VL
UT WOS:000299662900028
ER
PT J
AU Rubenstein, LZ
Vivrette, R
Harker, JO
Stevens, JA
Kramer, BJ
AF Rubenstein, Laurence Z.
Vivrette, Rebecca
Harker, Judith O.
Stevens, Judy A.
Kramer, B. Josea
TI Validating an evidence-based, self-rated fall risk questionnaire (FRQ)
for older adults
SO JOURNAL OF SAFETY RESEARCH
LA English
DT Article
DE Falls; Fall prevention; Geriatrics; Risk assessment
ID PREVENTION; PEOPLE; EPIDEMIOLOGY; METAANALYSIS
AB Background: Falls are a common, serious, and often unrecognized problem facing older adults. The objective of this study was to provide an initial clinical and statistical validation for a public health strategy of fall risk self-assessment by older adults using a Fall Risk Questionnaire (FRQ). Methods: Adults age 65+ (n = 40) were recruited at a Los Angeles Veterans Affairs (VA) medical facility and at a local assisted living facility. Participants completed the FRQ self-assessment and results were compared to a "gold standard" of a clinical evaluation of risks using the American/British Geriatrics Society guidelines to assess independent predictors of falls: history of previous falls, fear of falling, gait/balance, muscle weakness, incontinence, sensation and proprioception, depression, vision, and medications. For the comparison, we used an iterative statistical approach, weighing items based on relative risk. Results: There was strong agreement between the FRQ and clinical evaluation (kappa = .875, p < .0001). Individual item kappa values ranged from .305-832. After dropping one FRQ item (vision risk) because of inadequate agreement with the clinical evaluation (kappa = .139, p = .321), the final FRQ had good concurrent validity. Conclusions: The FRQ goes beyond existing screening tools in that it is based on both evidence and clinical acceptability and has been initially validated with clinical examination data. A larger validation with longitudinal follow-up should determine the actual strength of the FRQ in predicting future falls. (C) 2011 National Safety Council and Elsevier Ltd. All rights reserved.
C1 [Rubenstein, Laurence Z.] Univ Oklahoma, Coll Med, Donald W Reynolds Dept Geriatr Med, Oklahoma City, OK 73104 USA.
[Rubenstein, Laurence Z.; Vivrette, Rebecca; Harker, Judith O.] Greater Los Angeles VA Med Ctr 11E, GRECC, Sepulveda, CA 91343 USA.
[Stevens, Judy A.] Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA 30341 USA.
[Rubenstein, Laurence Z.; Kramer, B. Josea] Univ Calif Los Angeles, Sch Med, Sepulveda, CA 91343 USA.
[Rubenstein, Laurence Z.; Kramer, B. Josea] Greater Los Angeles VA Med Ctr, GRECC, Sepulveda, CA 91343 USA.
RP Rubenstein, LZ (reprint author), Univ Oklahoma, Coll Med, Donald W Reynolds Dept Geriatr Med, 921 NE 13th St,VAMC 11 G, Oklahoma City, OK 73104 USA.
EM Laurence-rubenstein@ouhsc.edu
NR 26
TC 7
Z9 7
U1 2
U2 9
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0022-4375
J9 J SAFETY RES
JI J. Saf. Res.
PD DEC
PY 2011
VL 42
IS 6
BP 493
EP 499
DI 10.1016/j.jsr.2011.08.006
PG 7
WC Ergonomics; Public, Environmental & Occupational Health; Social
Sciences, Interdisciplinary; Transportation
SC Engineering; Public, Environmental & Occupational Health; Social
Sciences - Other Topics; Transportation
GA 876WQ
UT WOS:000299138900012
PM 22152267
ER
PT J
AU McKay, JR
AF McKay, James R.
TI Negative Mood, Craving, and Alcohol Relapse: Can Treatment Interrupt the
Process?
SO CURRENT PSYCHIATRY REPORTS
LA English
DT Editorial Material
DE Alcohol dependence; Behavioral treatment; Moderation; Mediation;
Negative mood; Craving; Relapse; Coping with craving;
Cognitive-behavioral therapy; Mechanisms of action
ID SUBSTANCE USE; LAPSES
C1 [McKay, James R.] Univ Penn, Philadelphia, PA 19104 USA.
[McKay, James R.] Philadelphia VA Med Ctr, Philadelphia, PA 19104 USA.
RP McKay, JR (reprint author), Univ Penn, 3900 Chestnut St, Philadelphia, PA 19104 USA.
EM mckay_j@mail.trc.upenn.edu
FU NIAAA NIH HHS [P01 AA016821, P01 AA016821-03]
NR 8
TC 3
Z9 4
U1 0
U2 2
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1523-3812
J9 CURR PSYCHIAT REP
JI Curr. Psychiatry Rep.
PD DEC
PY 2011
VL 13
IS 6
BP 431
EP 433
DI 10.1007/s11920-011-0225-z
PG 3
WC Psychiatry
SC Psychiatry
GA 876FG
UT WOS:000299092300001
PM 21822936
ER
PT J
AU Thase, ME
AF Thase, Michael E.
TI Combined Antidepressant Strategies Are Not More Effective Than Vigorous
Escitalopram Monotherapy: Results of the CO-MED Study
SO CURRENT PSYCHIATRY REPORTS
LA English
DT Editorial Material
DE Major depressive disorder; MDD; Depression; Randomized controlled trial;
RCT; Antidepressants; Combination therapy; Monotherapy; Escitalopram;
Bupropion; Venlafaxine; Mirtazapine; STAR*D; Depression Treatment
Network
ID MAJOR DEPRESSIVE DISORDER; DOUBLE-BLIND
C1 [Thase, Michael E.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA.
[Thase, Michael E.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA.
[Thase, Michael E.] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA.
RP Thase, ME (reprint author), Univ Penn, Perelman Sch Med, 3535 Market St,Suite 670, Philadelphia, PA 19104 USA.
EM thase@mail.med.upenn.edu
NR 9
TC 1
Z9 1
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1523-3812
J9 CURR PSYCHIAT REP
JI Curr. Psychiatry Rep.
PD DEC
PY 2011
VL 13
IS 6
BP 434
EP 436
DI 10.1007/s11920-011-0236-9
PG 3
WC Psychiatry
SC Psychiatry
GA 876FG
UT WOS:000299092300002
PM 21956831
ER
PT J
AU Thase, ME
AF Thase, Michael E.
TI The Small Specific Effects of Antidepressants in Clinical Trials: What
Do They Mean to Psychiatrists?
SO CURRENT PSYCHIATRY REPORTS
LA English
DT Article
DE Antidepressants; Placebo; Meta-analysis; Randomized controlled trials;
RCT; Clinical trials; Psychiatrists
ID SEROTONIN REUPTAKE INHIBITORS; NATIONAL PATTERNS; MAJOR DEPRESSION;
PLACEBO-RESPONSE; REMISSION RATES; METAANALYSIS; EFFICACY;
PSYCHOTHERAPY; PHARMACOTHERAPY; MEDICATION
AB Although antidepressants continue to be a mainstay for clinicians who treat people suffering from depressive disorders, there have recently been articles published in both the scientific literature and the popular press that have raised questions about the utility of this class of medications. This paper briefly examines recent meta-analyses that have reported small drug versus placebo differences in randomized controlled trials and, from the perspective of a prescribing psychiatrist, discusses the clinical significance of these findings. It is concluded that antidepressants do have relatively modest effects (as compared with placebo) in contemporary randomized controlled trials, and that the contribution of placebo-expectancy factors to individual outcomes is often underestimated. Nevertheless, it is also concluded that the modest benefits of antidepressants in grouped datasets obscure large, specific, and very meaningful therapeutic effects for 10% to 20% of those treated with antidepressants.
C1 Univ Penn, Med Ctr, Philadelphia Vet Affairs Med Ctr, Perelman Sch Med,Univ Pittsburgh, Philadelphia, PA 19104 USA.
RP Thase, ME (reprint author), Univ Penn, Med Ctr, Philadelphia Vet Affairs Med Ctr, Perelman Sch Med,Univ Pittsburgh, 3535 Market St,Suite 670, Philadelphia, PA 19104 USA.
EM thase@mail.med.upenn.edu
FU Agency for Healthcare Research and Quality; Eli Lilly and Company;
Forest Pharmaceuticals; GlaxoSmithKline; National Institute of Mental
Health; Otsuka Pharmaceutical Co.; Sepracor; American Psychiatric
Foundation; Guilford Publications; Herald House; W.W. Norton Company
FX Dr. Thase has served as a consultant for Alkermes, AstraZeneca,
Bristol-Myers Squibb, Eli Lilly and Company, Dey Pharma, Forest
Laboratories, Gerson Lehrman Group, GlaxoSmithKline, Guidepoint Global,
H. Lundbeck A/S, MedAvante, Merck & Co. (formerly Schering-Plough and
Organon Pharmaceuticals USA), Neuronetics, Novartis, Otsuka
Pharmaceutical Co., Ortho-McNeil Pharmaceuticals (Johnson & Johnson),
Pamlab, Pfizer (formerly Wyeth-Ayerst International), PGxHealth, Shire
US, Supernus Pharmaceuticals, Takeda Pharmaceuticals North America, and
Transcept Pharmaceuticals; has received grant support from the Agency
for Healthcare Research and Quality, Eli Lilly and Company, Forest
Pharmaceuticals, GlaxoSmithKline, the National Institute of Mental
Health, Otsuka Pharmaceutical Co., and Sepracor; has received honoraria
from AstraZeneca, Bristol-Myers Squibb, Dey Pharma, Eli Lilly and
Company, Merck & Co., Pfizer (formerly Wyeth-Ayerst International); has
received royalties from the American Psychiatric Foundation, Guilford
Publications, Herald House, and W.W. Norton & Company; has received
payment for development of educational presentations (including service
on speakers' bureaus) from Pfizer and Bristol-Myers Squibb; and has held
stock/stock options in MedAvante. His wife has been employed by Embryon
(formerly Advogent).
NR 39
TC 9
Z9 9
U1 1
U2 5
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1523-3812
J9 CURR PSYCHIAT REP
JI Curr. Psychiatry Rep.
PD DEC
PY 2011
VL 13
IS 6
BP 476
EP 482
DI 10.1007/s11920-011-0235-x
PG 7
WC Psychiatry
SC Psychiatry
GA 876FG
UT WOS:000299092300008
PM 21964929
ER
PT J
AU Wang, ZW
Baker, DG
Harrer, J
Hamner, M
Price, M
Amstadter, A
AF Wang, Zhewu
Baker, Dewleen G.
Harrer, Judith
Hamner, Mark
Price, Matthew
Amstadter, Ananda
TI The relationship between combat-related posttraumatic stress disorder
and the 5-HTTLPR/rs25531 polymorphism
SO DEPRESSION AND ANXIETY
LA English
DT Article
DE post traumatic stress disorder; 5-HTTLPR; combat trauma; genetic risk;
5-HTTLPR genotypes; combat veteran
ID ADMINISTERED PTSD SCALE; ENVIRONMENTAL-INFLUENCES; EXPOSED ADULTS;
RISK-FACTORS; SEROTONIN; GENE; SYMPTOMS; INJURY; SUSCEPTIBILITY;
POPULATION
AB Background: Empirical evidence suggests that there is a significant genetic influence in the development of posttraumatic stress disorder (PTSD). The serotonin transporter (5-HTT) gene (SLC6A4) has been identified as a prime candidate for the development of the disorder, as 5-HTT is a working target for selective serotonin reuptake inhibitors (SSRIs), first line treatment agents for PTSD. Several studies have reported associations between 5-HTT-linked promoter region (5-HTTLPR) polymorphism variants and increased rates of PTSD in civilian samples. This study investigated the role of the 5-HTTLPR polymorphism, triallelically classified, in a sample of combat veterans with and without PTSD. Methods: Rates of PTSD were examined across three genotypes in a sample of 388 combat veterans. The short/long polymorphism of 5-HTTLPR and the A-G polymorphism within the 5-HTTLPR (rs25531) were genotyped, and statistical analyses were conducted. Results: There were significant intergroup (PTSD versus non-PTSD) differences in the genotype frequencies of 5-HTTLPR/rs25531 (2[1, n = 388] = 16.23, P = 5.62 x 10-5). The 5- HTTLPR S'/S' (low transcriptionally efficient) genotype was also associated with the PTSD severity score in the 228 participants who had combat severity data (r = .15, P = 0.03). Conclusions: The findings are consistent with previous research among civilian populations that have indicated that the low transcriptionally efficient S'/S' genotype of 5-HTTLPR is a risk factor for the development of PTSD after trauma exposure. Our findings are the first to examine this polymorphism and PTSD in a military sample. Additional large-scale investigations are needed to replicate these findings. Depression and Anxiety, 2011. (C) 2011 Wiley Periodicals, Inc.
C1 [Wang, Zhewu; Hamner, Mark] Ralph H Johnson VA Med Ctr, Charleston, SC 29401 USA.
[Wang, Zhewu; Hamner, Mark; Price, Matthew] Med Univ S Carolina, Dept Psychiat, Charleston, SC 29425 USA.
[Baker, Dewleen G.] VA San Diego, VA Ctr Exellence Stress & Mental Hlth, San Diego, CA USA.
[Baker, Dewleen G.] Univ Calif San Diego, Dept Psychiat, San Diego, CA 92103 USA.
[Harrer, Judith] Cincinnati VA Med Ctr, Cincinnati, OH USA.
[Amstadter, Ananda] Virginia Commonwealth Univ, Virginia Inst Psychiat & Behav Genet, Richmond, VA USA.
RP Wang, ZW (reprint author), Ralph H Johnson VA Med Ctr, 109 Bee St, Charleston, SC 29401 USA.
EM wanzh@musc.edu
RI Schueter, nicos/A-3625-2014
FU Ralph H. Johnson VA Medical Center; Department of Veterans Affairs;
NARSAD
FX The authors disclose the following financial relationships within the
past 3 years: Contract grant sponsors: Ralph H. Johnson VA Medical
Center; The Department of Veterans Affairs; NARSAD.
NR 33
TC 38
Z9 39
U1 2
U2 7
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1091-4269
J9 DEPRESS ANXIETY
JI Depress. Anxiety
PD DEC
PY 2011
VL 28
IS 12
BP 1067
EP 1073
DI 10.1002/da.20872
PG 7
WC Psychology, Clinical; Psychiatry; Psychology
SC Psychology; Psychiatry
GA 855GW
UT WOS:000297552900005
PM 21818827
ER
PT J
AU Kimbrell, T
Pyne, JM
Kunik, ME
Magruder, KM
Petersen, NJ
Yu, HJ
Hudson, TJ
Schulz, PE
Qureshi, SU
AF Kimbrell, Tim
Pyne, Jeffrey M.
Kunik, Mark E.
Magruder, Kathy M.
Petersen, Nancy J.
Yu, Hong-Jen
Hudson, Teresa J.
Schulz, Paul E.
Qureshi, Salah U.
TI The impact of Purple Heart commendation and PTSD on mortality rates in
older veterans
SO DEPRESSION AND ANXIETY
LA English
DT Article
DE posttraumatic stress; combat; resilience; injury; mortality; veteran
ID POSTTRAUMATIC-STRESS-DISORDER; VIETNAM VETERANS; COMBAT; PREVALENCE;
RESILIENCE; EXPOSURE; HEALTH; CARE; MEN; COMORBIDITY
AB Background: To determine whether having received a Purple Heart (PH) or having been diagnosed with posttraumatic stress disorder (PTSD) affected mortality in older veterans. Methods: We compared mortality rates of older veterans with a PH but without PTSD (PH+/PTSD-) to veterans with a PH and PTSD (PH+/PTSD+), veterans without a PH but with PTSD (PH-/PTSD+), and a comparison group without a PH or PTSD (PH-/PTSD-). Administrative data from the Veterans Integrated Service Network 16 were collected between 10/01/97 and 09/30/99 for veterans who were 65 years or older. Proportional hazards regression was used to compare the survival times for the four groups (n = 10,255) from entry into the study until death or study termination (9/30/2008). The Charleson co-morbidity index was used to control for potential co-morbid illness burden differences between the groups. Results: Older veterans with a PH (PH+/PTSD- and PH+/PTSD+) had significantly lower mortality rates than PH-/PTSD- veterans (hazard ratio [HR] = 0.6, 95% confidence interval [CI] 0.5 to 0.6, P<.0001; and HR = 0.5, 95% CI 0.4 to 0.7, P<.0001). The PH-/PTSD+ group had a higher mortality rate than the PH-/PTSD- group (HR = 1.1, 95% CI 1.0 to 1.2, P<.01). Conclusions: Veterans who had PH citations and survived into their seventh decade had half the mortality rate of veterans without PH citations with or without PTSD. Veterans with PTSD but without a PH had a significantly higher mortality rate compared to (PH-/PTSD-). Veterans who suffer combat injury without developing PTSD may provide a useful study population for determining the factors that confer resilience. Depression and Anxiety, 2011. (C) 2011 Wiley Periodicals, Inc.
C1 [Kimbrell, Tim; Pyne, Jeffrey M.; Hudson, Teresa J.] Cent Arkansas Vet Healthcare Syst, Ctr Mental Hlth & Outcomes Res, Little Rock, AR USA.
[Kimbrell, Tim; Pyne, Jeffrey M.; Hudson, Teresa J.] Univ Arkansas Med Sci, Coll Med, Dept Psychiat, Little Rock, AR 72205 USA.
[Kimbrell, Tim; Pyne, Jeffrey M.; Kunik, Mark E.; Petersen, Nancy J.; Yu, Hong-Jen; Hudson, Teresa J.; Qureshi, Salah U.] VA S Cent Mental Illness Res Educ & Clin Ctr, Little Rock, AR USA.
[Kunik, Mark E.; Petersen, Nancy J.; Yu, Hong-Jen; Qureshi, Salah U.] Michael E DeBakey VA Med Ctr, Houston Ctr Qual Care & Utilizat Studies, Hlth Serv Res & Dev Serv, Houston, TX USA.
[Kunik, Mark E.; Qureshi, Salah U.] Baylor Coll Med, Menninger Dept Psychiat & Behav Sci, Houston, TX 77030 USA.
[Magruder, Kathy M.] Med Univ S Carolina, Dept Psychiat & Behav Sci, Ralph H Johnson VA Med Ctr, Charleston, SC 29425 USA.
[Schulz, Paul E.] Michael E DeBakey VA Med Ctr, Houston, TX USA.
[Schulz, Paul E.] Univ Texas Hlth Sci Ctr Houston, Dept Neurol, Houston, TX USA.
RP Kimbrell, T (reprint author), Eugene Towbin VA Med Ctr, 116A NLR,2N112 Bldg 170,2200 Ft Roots Dr, N Little Rock, AR 72114 USA.
EM timothy.kimbrell@va.gov
RI Schueter, nicos/A-3625-2014
FU Houston Center for Quality of Care & Utilization Studies; VA South
Central Mental Illness Research and Clinical Center; Central Arkansas
Veterans Healthcare System Center for Mental Healthcare and Outcomes
Research
FX The authors disclose the following financial relationships within the
past 3 years: Contract grant sponsors: Houston Center for Quality of
Care & Utilization Studies; VA South Central Mental Illness Research and
Clinical Center; Central Arkansas Veterans Healthcare System Center for
Mental Healthcare and Outcomes Research.
NR 29
TC 3
Z9 3
U1 3
U2 8
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1091-4269
J9 DEPRESS ANXIETY
JI Depress. Anxiety
PD DEC
PY 2011
VL 28
IS 12
BP 1086
EP 1090
DI 10.1002/da.20850
PG 5
WC Psychology, Clinical; Psychiatry; Psychology
SC Psychology; Psychiatry
GA 855GW
UT WOS:000297552900008
PM 21751302
ER
PT J
AU Knapp, H
Anaya, HD
Feld, JE
Hoang, T
Goetz, MB
AF Knapp, H.
Anaya, H. D.
Feld, J. E.
Hoang, T.
Goetz, M. B.
TI Launching nurse-initiated HIV rapid testing in Veterans Affairs primary
care: a comprehensive overview of a self-sustaining implementation
SO INTERNATIONAL JOURNAL OF STD & AIDS
LA English
DT Article
DE HIV; AIDS; diagnostic; testing; primary care; rapid test; point-of-care
test; Veterans Affairs
AB Our objectives were to use foundational pilot findings to guide the implementation of an HIV rapid testing (RT) intervention at one Veterans Affairs outpatient clinic and to evaluate the success and sustainability of this intervention over the course of one year. Policy modifications were drafted and adopted to enable nurses to order, administer, interpret and document HIV RTs. Staff enrolled in a two-part training sessions designed to teach pre- and post-test counselling techniques and the mechanics of administering, interpreting and coding test results in the patients' medical records. They were subsequently evaluated on their efforts at: (1) increasing HIV RT, (2) sustaining this effort one year post-launch. Enabling nurses to carry out HIV RT resulted in a significant increase in not only HIV RT, but also HIV testing rates overall at this facility, measured over the first year of this implementation. Our findings indicate that targeted strategies, aimed at increasing HIV RT rates, worked to increase testing rates overall, and also, that our initial testing strategies were independently sustainable, which is in contrast to findings in the literature on implementation science.
C1 [Knapp, H.; Anaya, H. D.; Feld, J. E.; Hoang, T.; Goetz, M. B.] VA Greater Los Angeles Healthcare Syst, Vet Affairs Greater Los Angeles Hlth Serv Res & D, Vet Affairs Qual Enhancement Res Initiat HIV & He, Los Angeles, CA USA.
[Knapp, H.; Anaya, H. D.; Feld, J. E.; Hoang, T.; Goetz, M. B.] VA Greater Los Angeles Healthcare Syst, Vet Affairs Greater Los Angeles Hlth Serv Res & D, Ctr Study Healthcare Provider Behav, Los Angeles, CA USA.
[Anaya, H. D.; Goetz, M. B.] Univ Calif Los Angeles, David Geffen Sch Med, Div Gen Internal Med, Los Angeles, CA 90095 USA.
RP Knapp, H (reprint author), 11301 Wilshire Blvd,111G,Bldg 500,Off 4681, Los Angeles, CA 90073 USA.
EM Herschel.Knapp@va.gov
NR 6
TC 1
Z9 1
U1 0
U2 2
PU ROYAL SOC MEDICINE PRESS LTD
PI LONDON
PA 1 WIMPOLE STREET, LONDON W1G 0AE, ENGLAND
SN 0956-4624
J9 INT J STD AIDS
JI Int. J. STD AIDS
PD DEC
PY 2011
VL 22
IS 12
SI SI
BP 734
EP 737
DI 10.1258/ijsa.2009.009252
PG 4
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA 876ZB
UT WOS:000299145200009
PM 22174056
ER
PT J
AU Vitkin, E
Turzhitsky, V
Qiu, L
Guo, LY
Itzkan, I
Hanlon, EB
Perelman, LT
AF Vitkin, Edward
Turzhitsky, Vladimir
Qiu, Le
Guo, Lianyu
Itzkan, Irving
Hanlon, Eugene B.
Perelman, Lev T.
TI Photon diffusion near the point-of-entry in anisotropically scattering
turbid media
SO NATURE COMMUNICATIONS
LA English
DT Article
ID MONTE-CARLO-SIMULATION; CONFOCAL LIGHT-ABSORPTION; REFLECTANCE
SPECTROSCOPY; STEADY-STATE; RADIATIVE TRANSPORT; OPTICAL-PROPERTIES;
DENSITY WAVES; APPROXIMATION; TISSUE; MICROSCOPY
AB From astronomy to cell biology, the manner in which light propagates in turbid media has been of central importance for many decades. However, light propagation near the point-of-entry in turbid media has never been analytically described, until now. Here we report a straightforward and accurate method that overcomes this longstanding, unsolved problem in radiative transport. Our theory properly treats anisotropic photon scattering events and takes the specific form of the phase function into account. As a result, our method correctly predicts the spatially dependent diffuse reflectance of light near the point-of-entry for any arbitrary phase function. We demonstrate that the theory is in excellent agreement with both experimental results and Monte Carlo simulations for several commonly used phase functions.
C1 [Vitkin, Edward; Turzhitsky, Vladimir; Qiu, Le; Guo, Lianyu; Itzkan, Irving; Hanlon, Eugene B.; Perelman, Lev T.] Harvard Univ, Dept Obstet Gynecol & Reprod Biol, Ctr Adv Biomed Imaging & Photon, Boston, MA 02215 USA.
[Vitkin, Edward; Turzhitsky, Vladimir; Qiu, Le; Guo, Lianyu; Itzkan, Irving; Hanlon, Eugene B.; Perelman, Lev T.] Harvard Univ, Dept Med, Boston, MA 02215 USA.
[Vitkin, Edward; Turzhitsky, Vladimir; Qiu, Le; Guo, Lianyu; Itzkan, Irving; Hanlon, Eugene B.; Perelman, Lev T.] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
[Hanlon, Eugene B.] Med Res Serv, US Dept Vet Affairs, Bedford, MA 01730 USA.
[Hanlon, Eugene B.] US Dept Vet Affairs, Geriatr Res Educ & Clin Ctr, Bedford, MA 01730 USA.
RP Perelman, LT (reprint author), Harvard Univ, Dept Obstet Gynecol & Reprod Biol, Ctr Adv Biomed Imaging & Photon, Boston, MA 02215 USA.
EM ltperel@caregroup.harvard.edu
FU US National Science Foundation [CBET-0922876, CBET-0943180,
CBET-1144025]; US National Institutes of Health [R01 EB003472, R01
EB006462, R33 RR017361]; Department of Veterans Affairs, Office of
Research and Development
FX This work was supported by the US National Science Foundation grants
CBET-0922876, CBET-0943180 and CBET-1144025, US National Institutes of
Health grants R01 EB003472, R01 EB006462 and R33 RR017361 and in part by
the Department of Veterans Affairs, Office of Research and Development.
NR 41
TC 25
Z9 25
U1 2
U2 21
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-1723
J9 NAT COMMUN
JI Nat. Commun.
PD DEC
PY 2011
VL 2
AR 587
DI 10.1038/ncomms1599
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 877EM
UT WOS:000299159900019
PM 22158442
ER
PT J
AU Lyon, BR
Lee, PA
Bennett, JM
DiTullio, GR
Janech, MG
AF Lyon, Barbara R.
Lee, Peter A.
Bennett, Jennifer M.
DiTullio, Giacomo R.
Janech, Michael G.
TI Proteomic Analysis of a Sea-Ice Diatom: Salinity Acclimation Provides
New Insight into the Dimethylsulfoniopropionate Production Pathway
SO PLANT PHYSIOLOGY
LA English
DT Article
ID PHOTOSYNTHETIC ENERGY-CONVERSION; ALDEHYDE DEHYDROGENASE GENE; SALT
STRESS; MARINE-ALGAE; PHAEODACTYLUM-TRICORNUTUM; BINDING PROTEINS;
FRAGILARIOPSIS-CYLINDRUS; BIOSYNTHETIC-PATHWAY; ARABIDOPSIS-THALIANA;
LIPID-PEROXIDATION
AB Dimethylsulfoniopropionate (DMSP) plays important roles in oceanic carbon and sulfur cycling and may significantly impact climate. It is a biomolecule synthesized from the methionine (Met) pathway and proposed to serve various physiological functions to aid in environmental stress adaptation through its compatible solute, cryoprotectant, and antioxidant properties. Yet, the enzymes and mechanisms regulating DMSP production are poorly understood. This study utilized a proteomics approach to investigate protein changes associated with salinity-induced DMSP increases in the model sea-ice diatom Fragilariopsis cylindrus (CCMP 1102). We hypothesized proteins associated with the Met-DMSP biosynthesis pathway would increase in relative abundance when challenged with elevated salinity. To test this hypothesis axenic log-phase cultures initially grown at a salinity of 35 were gradually shifted to a final salinity of 70 over a 24-h period. Intracellular DMSP was measured and two-dimensional gel electrophoresis was used to identify protein changes at 48 h after the shift. Intracellular DMSP increased by approximately 85% in the hypersaline cultures. One-third of the proteins increased under high salinity were associated with amino acid pathways. Three protein isoforms of S-adenosylhomo-cysteine hydrolase, which synthesizes a Met precursor, increased 1.8- to 2.1-fold, two isoforms of S-adenosyl Met synthetase increased 1.9- to 2.5-fold, and S-adenosyl Met methyltransferase increased by 2.8-fold, suggesting active methyl cycle proteins are recruited in the synthesis of DMSP. Proteins from the four enzyme classes of the proposed algal Met transaminase DMSP pathway were among the elevated proteins, supporting our hypothesis and providing candidate genes for future characterization studies.
C1 [Janech, Michael G.] Med Univ S Carolina, Dept Med, Div Nephrol, Charleston, SC 29425 USA.
[Lyon, Barbara R.; Lee, Peter A.; Bennett, Jennifer M.; DiTullio, Giacomo R.] Hollings Marine Lab, Charleston, SC 29412 USA.
[Lyon, Barbara R.] Med Univ S Carolina, Marine Biomed & Environm Sci Ctr, Charleston, SC 29412 USA.
[Lee, Peter A.; Bennett, Jennifer M.; DiTullio, Giacomo R.] Coll Charleston, Grice Marine Lab, Charleston, SC 29412 USA.
[Janech, Michael G.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC 29425 USA.
RP Janech, MG (reprint author), Med Univ S Carolina, Dept Med, Div Nephrol, Charleston, SC 29425 USA.
EM janechmg@musc.edu
OI Janech, Michael/0000-0002-3202-4811
FU National Science Foundation [ANT-0739597, ANT-0739446, OPP0338097]
FX This work was supported by the National Science Foundation (grant nos.
ANT-0739597 to M. G. J., ANT-0739446 to P. A. L. and G. R. D., and
OPP0338097 to G.R.D.).
NR 92
TC 19
Z9 21
U1 3
U2 39
PU AMER SOC PLANT BIOLOGISTS
PI ROCKVILLE
PA 15501 MONONA DRIVE, ROCKVILLE, MD 20855 USA
SN 0032-0889
EI 1532-2548
J9 PLANT PHYSIOL
JI Plant Physiol.
PD DEC
PY 2011
VL 157
IS 4
BP 1926
EP 1941
DI 10.1104/pp.111.185025
PG 16
WC Plant Sciences
SC Plant Sciences
GA 866JC
UT WOS:000298375600026
PM 22034629
ER
PT J
AU Hebert, PL
Taylor, LT
Wang, JJ
Bergman, MA
AF Hebert, Paul L.
Taylor, Leslie T.
Wang, Jason J.
Bergman, Margo A.
TI Methods for Using Data Abstracted from Medical Charts to Impute
Longitudinal Missing Data in a Clinical Trial
SO VALUE IN HEALTH
LA English
DT Article
DE blood pressure; clinical trials; imputation; longitudinal data; missing
data
ID CARE OUTCOME ANALYSES; MULTIPLE IMPUTATION; VALUES; ATTRITION
AB Objective: To describe a method for imputing missing follow-up blood pressure data in a clinical hypertension trial using blood pressures abstracted from medical charts. Methods: We tested a two-step method. In the first, a longitudinal mixed-effects model was estimated on blood pressures abstracted from medical charts. In the second, the patient-specific fitted values from this model at follow-up were used to impute blood pressures missing at follow-up in the trial. Simulations that imposed alternative missing data mechanisms on observed trial data were used to compare this approach to imputation approaches that do not incorporate data from charts. Results: For data that are missing at random, incorporating the fitted values from chart-based longitudinal models leads to estimates of the trial-based blood pressures that are unbiased and have lower mean squared deviation than do blood pressures imputed without the chart-based data. For data that are missing not at random, incorporating fitted values ameliorates but does not eliminate the inherent missing data bias. Conclusions: Incorporating chart data into an imputation algorithm via the use of longitudinal mixed-effects model is an efficient way to impute longitudinal data that are missing from a randomized trial.
C1 [Hebert, Paul L.; Taylor, Leslie T.; Bergman, Margo A.] NW Ctr Outcomes Res Older Adults, VA Puget Sound Hlth Care Syst, Dept Vet Affairs, Seattle, WA USA.
[Wang, Jason J.] Primary Care Informat Project, Dept Hlth & Mental Hyg, New York, NY USA.
[Hebert, Paul L.] Mt Sinai Sch Med, Dept Hlth Policy, New York, NY USA.
RP Hebert, PL (reprint author), 1100 Olive Way,Suite 1400, Seattle, WA 98101 USA.
EM Paul.Hebert2@va.gov
FU National Institutes of Health, National Center for Minority Health and
Health Disparities [1P60MD000270-01]
FX Source of financial support: This work was funded by a grant from the
National Institutes of Health, National Center for Minority Health and
Health Disparities (1P60MD000270-01). The views expressed herein are
those of the authors and do not necessarily represent the views of the
National Institutes of Health and other affiliated institutions.
NR 17
TC 2
Z9 2
U1 0
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1098-3015
J9 VALUE HEALTH
JI Value Health
PD DEC
PY 2011
VL 14
IS 8
BP 1085
EP 1091
DI 10.1016/j.jval.2011.05.049
PG 7
WC Economics; Health Care Sciences & Services; Health Policy & Services
SC Business & Economics; Health Care Sciences & Services
GA 876BM
UT WOS:000299081900015
PM 22152178
ER
PT J
AU Hwang, U
Weber, EJ
Richardson, LD
Sweet, V
Todd, K
Abraham, G
Ankel, F
AF Hwang, Ula
Weber, Ellen J.
Richardson, Lynne D.
Sweet, Vicki
Todd, Knox
Abraham, Gallane
Ankel, Felix
TI A Research Agenda to Assure Equity During Periods of Emergency
Department Crowding
SO ACADEMIC EMERGENCY MEDICINE
LA English
DT Article
ID HEALTH-CARE DISPARITIES; UNITED-STATES; LANGUAGE BARRIERS; CHEST-PAIN;
RACIAL DISPARITIES; ETHNIC DISPARITIES; ELDERLY-PATIENTS; TRAUMA;
MANAGEMENT; ACCESS
AB The effect of emergency department (ED) crowding on equitable care is the least studied of the domains of quality as defined by the Institute of Medicine (IOM). Inequities in access and treatment throughout the health care system are well documented in all fields of medicine. While there is little evidence demonstrating that inequity is worsened by crowding, theory and evidence from social science disciplines, as well as known barriers to care for vulnerable populations, would suggest that crowding will worsen inequities. To design successful interventions, however, it is important to first understand how crowding can result in disparities and base interventions on these mechanisms. A research agenda is proposed to understand mechanisms that may threaten equity during periods of crowding and design and test potential interventions that may ensure the equitable aspect of quality of care.
C1 [Hwang, Ula; Richardson, Lynne D.; Abraham, Gallane] Mt Sinai Sch Med, Dept Emergency Med, New York, NY 10029 USA.
[Hwang, Ula] Mt Sinai Sch Med, Brookdale Dept Geriatr & Palliat Med, New York, NY USA.
[Richardson, Lynne D.] Mt Sinai Sch Med, Dept Hlth Evidence & Policy, New York, NY USA.
[Hwang, Ula] James J Peters VA Med Ctr, Geriatr Res Educ & Clin Ctr, Bronx, NY USA.
[Weber, Ellen J.] Univ Calif San Francisco, Dept Emergency Med, San Francisco, CA 94143 USA.
[Sweet, Vicki] Emergency Serv & PreHosp Care, St Jude Med Ctr, Fullerton, CA USA.
[Todd, Knox] Univ Texas MD Anderson Canc Ctr, Dept Emergency Med, Houston, TX 77030 USA.
[Ankel, Felix] Univ Minnesota, Sch Med, Dept Emergency Med, Minneapolis, MN 55455 USA.
RP Hwang, U (reprint author), Mt Sinai Sch Med, Dept Emergency Med, New York, NY 10029 USA.
EM ula.hwang@mountsinai.org
OI Weber, Ellen/0000-0002-0094-1973
FU Agency for Healthcare Research and Quality (AHRQ) [1R13HS020139-01];
Robert Wood Johnson Foundation
FX Funding for this conference was made possible (in part) by
1R13HS020139-01 from the Agency for Healthcare Research and Quality
(AHRQ). The views expressed in written conference materials or
publications and by speakers and moderators do not necessarily reflect
the official policies of the Department of Health and Human Services,
nor does mention of trade names, commercial practices, or organizations
imply endorsement by the U. S. Government. This issue of Academic
Emergency Medicine is funded by the Robert Wood Johnson Foundation.
NR 53
TC 5
Z9 5
U1 0
U2 6
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1069-6563
J9 ACAD EMERG MED
JI Acad. Emerg. Med.
PD DEC
PY 2011
VL 18
IS 12
SI SI
BP 1318
EP 1323
DI 10.1111/j.1553-2712.2011.01233.x
PG 6
WC Emergency Medicine
SC Emergency Medicine
GA 861IQ
UT WOS:000298013000015
PM 22168197
ER
PT J
AU Silverman, S
Cates, M
Saunders, G
AF Silverman, ShienPei
Cates, Megan
Saunders, Gabrielle
TI Is Measured Hearing Aid Benefit Affected by Seeing Baseline Outcome
Questionnaire Responses?
SO AMERICAN JOURNAL OF AUDIOLOGY
LA English
DT Article
DE outcomes; hearing aids; audiologic rehabilitation
ID TEST-RETEST RELIABILITY; QUALITY-OF-LIFE; HANDICAP INVENTORY;
SATISFACTION; DISEASE; ADULTS; TRIAL
AB Purpose: To determine whether hearing aid outcome measured by the Hearing Handicap Inventory (HHI) for the Elderly/Adults (Newman, Weinstein, Jacobson, & Hug, 1990; Ventry & Weinstein, 1982) is differentially affected by informed vs. blind administration of the postfitting questionnaire.
Method: Participants completed the HHI at their hearing aid evaluation and again at their hearing aid follow-up visit. At follow-up, half received a clean HHI form (blind administration), whereas the remainder responded on their original form (informed administration) and could thus base their follow-up responses on those they gave at the hearing aid evaluation.
Results: The data show that for the population examined here, informed administration of the follow-up HHI did not yield a different outcome to blind administration of the follow-up HHI. This was not influenced by past hearing aid use, age of the participant, or the duration of time between baseline questionnaire completion and follow-up completion.
Conclusion: These data suggest that completion of follow-up questionnaires in either informed or blind format will have little impact on HHI responses, most likely because of the many other factors that combined to influence hearing aid outcome.
C1 [Silverman, ShienPei; Saunders, Gabrielle] Portland VA Med Ctr, Natl Ctr Rehabil Auditory Res, Portland, OR USA.
[Cates, Megan] Univ Arkansas, Univ Arkansas Med Sci, Little Rock, AR 72204 USA.
RP Saunders, G (reprint author), Portland VA Med Ctr, Natl Ctr Rehabil Auditory Res, Portland, OR USA.
EM gabrielle.saunders@va.gov
FU National Institutes of Health [T35 DC008764]; VA Rehabilitation Research
& Development Grant [C4844C]
FX Support was provided by National Institutes of Health Pre-doctoral
Training Grant T35 DC008764 and by VA Rehabilitation Research &
Development Grant C4844C awarded to the VA RR&D National Center for
Rehabilitative Auditory Research. We thank Portland VAMC Audiology
clinic staff for their participation and assistance with data
collection.
NR 36
TC 0
Z9 1
U1 0
U2 3
PU AMER SPEECH-LANGUAGE-HEARING ASSOC
PI ROCKVILLE
PA 10801 ROCKVILLE PIKE, ROCKVILLE, MD 20852-3279 USA
SN 1059-0889
J9 AM J AUDIOL
JI Am. J. Audiol.
PD DEC
PY 2011
VL 20
IS 2
BP 90
EP 99
DI 10.1044/1059-0889(2011/10-0003)
PG 10
WC Audiology & Speech-Language Pathology; Otorhinolaryngology
SC Audiology & Speech-Language Pathology; Otorhinolaryngology
GA 865ZJ
UT WOS:000298349100003
PM 21940983
ER
PT J
AU Peron, EP
Gray, SL
Hanlon, JT
AF Peron, Emily P.
Gray, Shelly L.
Hanlon, Joseph T.
TI Medication Use and Functional Status Decline in Older Adults: A
Narrative Review
SO AMERICAN JOURNAL OF GERIATRIC PHARMACOTHERAPY
LA English
DT Review
DE activities of daily living; aged; drug use
ID RANDOMIZED CONTROLLED-TRIAL; DRUG BURDEN INDEX; FRAIL ELDERLY
POPULATION; LOWER-EXTREMITY FUNCTION; NURSING-HOME RESIDENTS; PHYSICAL
FUNCTION; VITAMIN-D; GROWTH-HORMONE; HIP-FRACTURE; CALCIUM
SUPPLEMENTATION
AB Background: Functional status is the cornerstone of geriatric care and serves as an indicator of general well-being. A decline in function can increase health care use, worsen quality of life, threaten independence, and increase the risk of mortality. One of several risk factors for decline in functional status is medication use.
Objective: Our aim was to critically review published articles that have examined the relationship between medication use and functional status decline in the elderly.
Methods: The MEDLINE and EMBASE databases were searched for English-language articles published from January 1986 to June 2011. Search terms included aged, humans, drug utilization, polypharmacy, inappropriate prescribing, anticholinergics, psychotropics, antihypertensives, drug burden index, functional status, function change or decline, activities of daily living, gait, mobility limitation, and disability. A manual search of the reference lists of the identified articles and the authors' article files, book chapters, and recent reviews was conducted to retrieve additional publications. Only articles that used rigorous observational or interventional designs were included. Cross-sectional studies and case series were excluded from this review.
Results: Nineteen studies met the inclusion criteria. Five studies addressed the impact of suboptimal prescribing on function, 3 of which found an increased risk of worse function in community-dwelling subjects receiving polypharmacy. Three of the 4 studies that assessed benzodiazepine use and functional status decline found a statistically significant association. One cohort study identified no relationship between antidepressant use and functional status, whereas a randomized trial found that amitriptyline, but not desipramine or paroxetine, impaired certain measures of gait. Two studies found that increasing anticholinergic burden was associated with worse functional status. In a study of hospitalized rehabilitation patients, users of hypnotics/anxiolytics (eg, phenobarbital, zolpidem) had lower relative Functional Independence Measure motor gains than nonusers. Use of multiple central nervous system (CNS) drugs (using different definitions) was linked to greater declines in self-reported mobility and Short Physical Performance Battery (SPPB) scores in 2 community-based studies. Another study of nursing home patients did not report a significant decrease in SPPB scores in those taking multiple CNS drugs. Finally, 2 studies found mixed effects between antihypertensive use and functional status in the elderly.
Conclusions: Benzodiazepines and anticholinergics have been consistently associated with impairments in functional status in the elderly. The relationships between suboptimal prescribing, antidepressants, and antihypertensives and functional status decline were mixed. Further research using established measures and methods is needed to better describe the impact of medication use on functional status in older adults. (Am J Geriatr Pharmacother. 2011;9: 378-391) (C) 2011 Elsevier HS Journals, Inc. All rights reserved.
C1 [Peron, Emily P.; Hanlon, Joseph T.] Univ Pittsburgh, Dept Med, Div Geriatr Med, Pittsburgh, PA 15213 USA.
[Gray, Shelly L.] Univ Washington, Sch Pharm, Seattle, WA 98195 USA.
[Hanlon, Joseph T.] Univ Pittsburgh, Dept Biomed Informat, Pittsburgh, PA 15213 USA.
[Hanlon, Joseph T.] Univ Pittsburgh, Dept Pharm & Therapeut, Pittsburgh, PA 15213 USA.
[Hanlon, Joseph T.] Univ Pittsburgh, Dept Epidemiol, Pittsburgh, PA 15213 USA.
[Hanlon, Joseph T.] VA Pittsburgh Hlth Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA USA.
[Hanlon, Joseph T.] VA Pittsburgh Hlth Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA.
RP Peron, EP (reprint author), Univ Pittsburgh, Dept Geriatr Med, Kaufmann Med Bldg,Suite 500,3471 5th Ave, Pittsburgh, PA 15213 USA.
EM emp56@pitt.edu
FU National Institute on Aging [U01 AG00678121, R01 AG027017, P30 AG024827,
T32 AG021885, K07 AG033174, R56 AG027017, R01 AG034056]; National
Institute of Mental Health [R34 MH082682]; National Institute of Nursing
Research [R01 NR010135]; Agency for Healthcare Research and Quality [R01
HS017695, R01 HS018721, K12 HS019461]; VA Health Services [IIR-06-062]
FX This study was primarily supported by National Institute on Aging grants
and contracts (U01 AG00678121, R01 AG027017, P30 AG024827, T32 AG021885,
K07 AG033174, R56 AG027017, R01 AG034056), a National Institute of
Mental Health grant (R34 MH082682), a National Institute of Nursing
Research grant (R01 NR010135), an Agency for Healthcare Research and
Quality grants (R01 HS017695, R01 HS018721, K12 HS019461), and a VA
Health Services Research grant (IIR-06-062).
NR 97
TC 36
Z9 37
U1 3
U2 27
PU EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC
PI BRIDGEWATER
PA 685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA
SN 1543-5946
J9 AM J GERIATR PHARMAC
JI Am. J. Geriatr. Pharmacother.
PD DEC
PY 2011
VL 9
IS 6
BP 378
EP 391
DI 10.1016/j.amjopharm.2011.10.002
PG 14
WC Geriatrics & Gerontology; Pharmacology & Pharmacy
SC Geriatrics & Gerontology; Pharmacology & Pharmacy
GA 869BM
UT WOS:000298570700003
PM 22057096
ER
PT J
AU Linnebur, SA
Fish, DN
Ruscin, JM
Radcliff, TA
Oman, KS
Fink, R
Van Dorsten, B
Liebrecht, D
Fish, R
McNulty, M
Hutt, E
AF Linnebur, Sunny A.
Fish, Douglas N.
Ruscin, J. Mark
Radcliff, Tiffany A.
Oman, Kathy S.
Fink, Regina
Van Dorsten, Brent
Liebrecht, Debra
Fish, Ron
McNulty, Monica
Hutt, Evelyn
TI Impact of a Multidisciplinary Intervention on Antibiotic Use for Nursing
Home-Acquired Pneumonia
SO AMERICAN JOURNAL OF GERIATRIC PHARMACOTHERAPY
LA English
DT Article
DE academic detailing; antibacterial agents; guideline adherence; nursing
homes; physician practice patterns; pneumonia
ID RANDOMIZED CONTROLLED-TRIAL; TERM-CARE FACILITIES; GUIDELINES;
PREVENTION; MANAGEMENT; RESIDENTS; ADHERENCE; COMMUNITY; EDUCATION;
THERAPY
AB Background: Academic detailing in nursing homes (NHs) has been shown to improve drug use patterns and adherence to guidelines.
Objective: The purpose of this study was to evaluate the impact of a multidisciplinary intervention that included academic detailing on adherence to national nursing home acquired pneumonia (NHAP) guidelines related to use of antibiotics.
Methods: This quasi-experimental study evaluated the effects of a 2-year multifaceted and multidisciplinary intervention targeting implementation of national evidence-based guidelines for NHAP. Interventions took place in 8 NHs in Colorado; 8 NHs in Kansas and Missouri served as controls. Interventions included (1) educational sessions for nurses to improve recognition and timely treatment of NHAP symptoms and (2) academic detailing to clinicians by pharmacists regarding diagnostic and prescribing practices. Differences in antibiotic use between groups were compared after 2 intervention years relative to baseline.
Results: A total of 549 episodes of NHAP were evaluated in the intervention group and 574 in the control group. Compared with baseline, 1 facility in the intervention group significantly improved in guideline adherence for optimal antibiotic use (P = 0.007), whereas no facilities in the control group improved. The mean adherence score for optimal antibiotic use in intervention NHs increased from 60% to 66%, whereas the control NHs increased from 32% to 39% (P = 0.3). Mean adherence to guidelines recommending antibiotic use within 4 hours of NHAP diagnosis increased from 57% to 75% in intervention NHs but decreased from 38% to 31% in control NHs (P = 0.0003 for difference). There was no difference between intervention and control NHs for guideline adherence regarding optimal duration of antibiotic use.
Conclusions: The ability of this multifaceted study to repeatedly remind nursing staff of the importance of timely antibiotic administration contrasts with its limited academic detailing interaction with clinicians. This difference within the intervention may explain the differential impact of the intervention on antibiotic guideline adherence. (Am J Geriatr Pharmacother. 2011;9:442-450) (C) 2011 Elsevier HS Journals, Inc. All rights reserved.
C1 [Linnebur, Sunny A.] Univ Colorado, Skaggs Sch Pharm & Pharmaceut Sci, Aurora, CO 80045 USA.
[Ruscin, J. Mark] So Illinois Univ, Sch Pharm, Edwardsville, IL 62026 USA.
[Radcliff, Tiffany A.; Hutt, Evelyn] Denver Vet Affairs Med Ctr, Denver, CO USA.
RP Linnebur, SA (reprint author), Univ Colorado, Skaggs Sch Pharm & Pharmaceut Sci, Anschutz Med Campus,12850 E Montview Blvd,Campus, Aurora, CO 80045 USA.
EM sunny.linnebur@ucdenver.edu
FU Agency for Health Care Research and Quality [RO1 HS13618-01A1]
FX This study was supported by an investigator-initiated research grant
from the Agency for Health Care Research and Quality (RO1 HS13618-01A1).
The authors have indicated that they have no other conflicts of interest
regarding the content of this article.
NR 30
TC 13
Z9 14
U1 2
U2 6
PU EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC
PI BRIDGEWATER
PA 685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA
SN 1543-5946
J9 AM J GERIATR PHARMAC
JI Am. J. Geriatr. Pharmacother.
PD DEC
PY 2011
VL 9
IS 6
BP 442
EP 450
DI 10.1016/j.amjopharm.2011.09.009
PG 9
WC Geriatrics & Gerontology; Pharmacology & Pharmacy
SC Geriatrics & Gerontology; Pharmacology & Pharmacy
GA 869BM
UT WOS:000298570700009
PM 22055208
ER
PT J
AU Chopra, P
Verma, P
Klaustermeyer, WB
AF Chopra, Preet
Verma, Prashant
Klaustermeyer, William B.
TI SUCCESSFUL USE OF PRASUGREL, AN ALTERNATIVE ANTIPLATELET AGENT, IN A
PATIENT WITH CLOPIDOGREL ALLERGY
SO ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY
LA English
DT Letter
C1 [Chopra, Preet; Verma, Prashant; Klaustermeyer, William B.] Univ Calif Los Angeles, VA Greater Los Angeles Healthcare, Dept Allergy Immunol, Los Angeles, CA 90095 USA.
RP Chopra, P (reprint author), Univ Calif Los Angeles, VA Greater Los Angeles Healthcare, Dept Allergy Immunol, Los Angeles, CA 90095 USA.
EM preetichopra14@gmail.com
NR 8
TC 5
Z9 5
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1081-1206
J9 ANN ALLERG ASTHMA IM
JI Ann. Allergy Asthma Immunol.
PD DEC
PY 2011
VL 107
IS 6
BP 541
EP 542
DI 10.1016/j.anai.2011.08.003
PG 2
WC Allergy; Immunology
SC Allergy; Immunology
GA 862EN
UT WOS:000298072700014
PM 22123386
ER
PT J
AU Gabayan, GZ
Derose, SF
Asch, SM
Yiu, S
Lancaster, EM
Poon, KT
Hoffman, JR
Sun, BC
AF Gabayan, Gelareh Z.
Derose, Stephen F.
Asch, Steven M.
Yiu, Sau
Lancaster, Elizabeth M.
Poon, K. Trudy
Hoffman, Jerome R.
Sun, Benjamin C.
TI Patterns and Predictors of Short-Term Death After Emergency Department
Discharge
SO ANNALS OF EMERGENCY MEDICINE
LA English
DT Article
ID STAGE RENAL-DISEASE; AFTER-DISCHARGE; CARDIOVASCULAR-DISEASE;
OLDER-ADULTS; DATA SYSTEM; ALL-CAUSE; MORTALITY; COMORBIDITY; DIAGNOSIS;
SURVIVAL
AB Study objective: The emergency department (ED) is an inherently high-risk setting. Early death after an ED evaluation is a rare and devastating outcome; understanding it can potentially help improve patient care and outcomes. Using administrative data from an integrated health system, we describe characteristics and predictors of patients who experienced 7-day death after ED discharge.
Methods: Administrative data from 12 hospitals were used to identify death after discharge in adults aged 18 year or older within 7 days of ED presentation from January 1, 2007, to December 31, 2008. Patients who were nonmembers of the health system, in hospice care, or treated at out-of-network EDs were excluded. Predictors of 7-day postdischarge death were identified with multivariable logistic regression.
Results: The study cohort contained a total of 475,829 members, with 728,312 discharges from Kaiser Permanente Southern California EDs in 2007 and 2008. Death within 7 days of discharge occurred in 357 cases (0.05%). Increasing age, male sex, and number of preexisting comorbidities were associated with increased risk of death. The top 3 primary discharge diagnoses predictive of 7-day death after discharge included noninfectious lung disease (odds ratio [OR] 7.1; 95% confidence interval [Cl] 2.9 to 17.4), renal disease (OR 5.6; 95% Cl 2.2 to 14.2), and ischemic heart disease (OR 3.8; 95% Cl 1.0 to 13.6).
Conclusion: Our study suggests that 50 in 100,000 patients in the United States die within 7 days of discharge from an ED. To our knowledge, our study is the first to identify potentially "high-risk" discharge diagnoses in patients who experience a short-term death after discharge. [Ann Emerg Med. 2011;58:551-558.]
C1 [Gabayan, Gelareh Z.; Asch, Steven M.; Sun, Benjamin C.] Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA.
[Gabayan, Gelareh Z.; Asch, Steven M.; Sun, Benjamin C.] Greater Los Angeles Vet Affairs Healthcare Syst, Dept Med, Los Angeles, CA USA.
[Gabayan, Gelareh Z.; Lancaster, Elizabeth M.] Ronald Reagan UCLA, Ctr Emergency Med, Los Angeles, CA USA.
[Derose, Stephen F.; Yiu, Sau; Lancaster, Elizabeth M.; Poon, K. Trudy] Kaiser Permanente So Calif, Div Res & Evaluat, Pasadena, CA USA.
[Hoffman, Jerome R.] Univ So Calif, Dept Emergency Med, Los Angeles, CA USA.
RP Gabayan, GZ (reprint author), Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA.
EM gelareh@gabayan.com
FU Kaiser Permanente Southern California; UCLA Oppenheimer Foundation;
Greater Los Angeles Veterans Affairs Department of Health Services
Research and Development; UCLA Older Americans Independence Center,
NIH/NIA [P30-AG028748]; Emergency Medicine Foundation [59668]
FX By Annals policy, all authors are required to disclose any and all
commercial, financial, and other relationships in any way related to the
subject of this article as per ICMJE conflict of interest guidelines
(see www.icmje.org). The authors have stated that no such relationships
exist. This research was supported by Kaiser Permanente Southern
California and the UCLA Oppenheimer Foundation. During the initial phase
of this project Dr. Gabayan received support from the Greater Los
Angeles Veterans Affairs Department of Health Services Research and
Development. Continued support was obtained from the Emergency Medicine
Foundation Career Development Award (59668: G. Gabayan). Dr. Sun
received support from the UCLA Older Americans Independence Center,
NIH/NIA grant P30-AG028748, and the content does not necessarily
represent the official views of the National Institute on Aging or the
National Institutes of Health.
NR 34
TC 18
Z9 18
U1 2
U2 12
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0196-0644
J9 ANN EMERG MED
JI Ann. Emerg. Med.
PD DEC
PY 2011
VL 58
IS 6
BP 551
EP 558
DI 10.1016/j.annemergmed.2011.07.001
PG 8
WC Emergency Medicine
SC Emergency Medicine
GA 864GI
UT WOS:000298224600012
PM 21802775
ER
PT J
AU Asgari, MM
Warton, EM
Neugebauer, R
Chren, MM
AF Asgari, Maryam M.
Warton, E. Margaret
Neugebauer, Romain
Chren, Mary-Margaret
TI Predictors of Patient Satisfaction With Mohs Surgery Analysis of
Preoperative, Intraoperative, and Postoperative Factors in a Prospective
Cohort
SO ARCHIVES OF DERMATOLOGY
LA English
DT Article
ID CAUSAL DIAGRAMS; BREAST-CANCER; SKIN-CANCER; LIFE; CARE; MORBIDITY;
KNOWLEDGE; OUTCOMES
AB Objective: To identify preoperative, intraoperative, and postoperative variables that predict higher short-and long-term patient satisfaction with Mohs surgery.
Design: Prospective cohort study.
Setting: A university-based dermatology practice and the affiliated Veterans Affairs medical center dermatology clinic.
Patients: A total of 339 consecutive patients treated with Mohs surgery in 1999 and 2000.
Main Outcome Measures: Short-term satisfaction at 1 week and long-term satisfaction at 1 year. We used directed acyclic graphs to determine appropriate confounding adjustment for preoperative, intraoperative, and postoperative variables that influence satisfaction with Mohs surgery in logistic regression models.
Results: Better preoperative skin-related quality of life (measured using Skindex) and more intraoperative Mohs stages were the most salient predictors of higher short-and long-term satisfaction; these odds ratios (ORs) were 2.33 (95% CI, 1.01-5.35) and 5.19 (1.66-16.29), respectively, for preoperative skin-related quality of life and 7.06 (2.02-24.67) and 5.30 (1.24-22.64), respectively, for more intraoperative Mohs stages. Patients not bothered by postoperative bleeding were more likely to be satisfied short term (OR, 2.25; 95% CI, 1.25-4.05), as were those who considered themselves involved in decision making about their treatment (3.05; 1.52-6.10). Higher long-term satisfaction with Mohs surgery was observed among patients who were married (2.36; 1.10-5.09).
Conclusions: Higher short-and long-term satisfaction with Mohs surgery is predicted by better preoperative skin-related quality of life and by more intraoperative Mohs stages. The effect of postoperative variables wanes over time, suggesting that factors influencing satisfaction can vary depending on the time frame when satisfaction is measured. Our results may help clinicians identify patients who are at higher risk of dissatisfaction following Mohs surgery.
C1 [Asgari, Maryam M.; Warton, E. Margaret; Neugebauer, Romain] Kaiser Permanente No Calif, Div Res, Oakland, CA 94612 USA.
[Asgari, Maryam M.; Chren, Mary-Margaret] Univ Calif San Francisco, Dept Dermatol, San Francisco, CA 94143 USA.
[Chren, Mary-Margaret] San Francisco VA Med Ctr, Hlth Serv Res Enhancement Award Program, San Francisco, CA USA.
RP Asgari, MM (reprint author), Kaiser Permanente No Calif, Div Res, 2000 Broadway, Oakland, CA 94612 USA.
EM maryam.m.asgari@kp.org
RI Asgari, Maryam/O-4947-2016
FU National Institute of Arthritis and Musculoskeletal and Skin Diseases
[K23 AR 051037, K24 AR052667]; Health Services Research and Development
Service, Department of Veterans Affairs [IIR 04-043-3]
FX This study was supported in part by grants K23 AR 051037 (Dr Asgari) and
K24 AR052667 (Dr Chren) from the National Institute of Arthritis and
Musculoskeletal and Skin Diseases and by grant IIR 04-043-3 (Dr Chren)
from the Health Services Research and Development Service, Department of
Veterans Affairs.
NR 35
TC 6
Z9 6
U1 1
U2 5
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA
SN 0003-987X
J9 ARCH DERMATOL
JI Arch. Dermatol.
PD DEC
PY 2011
VL 147
IS 12
BP 1387
EP 1394
PG 8
WC Dermatology
SC Dermatology
GA 864QV
UT WOS:000298255800005
PM 22184760
ER
PT J
AU Lawson, EH
Gibbons, MM
Ingraham, AM
Shekelle, PG
Ko, CY
AF Lawson, Elise H.
Gibbons, Melinda Maggard
Ingraham, Angela M.
Shekelle, Paul G.
Ko, Clifford Y.
TI Appropriateness Criteria to Assess Variations in Surgical Procedure Use
in the United States
SO ARCHIVES OF SURGERY
LA English
DT Review
ID BYPASS GRAFT-SURGERY; UPPER GASTROINTESTINAL ENDOSCOPY; ACADEMIC
MEDICAL-CENTERS; HEALTH-CARE SERVICES; NEW-YORK-STATE;
CAROTID-ENDARTERECTOMY; CORONARY REVASCULARIZATION; PHYSICIAN RATINGS;
CARDIAC REVASCULARIZATION; PRACTICE GUIDELINES
AB Objectives: To systematically describe appropriateness criteria (AC) developed in the United States for surgical procedures and to summarize how these criteria have been applied to identify overuse and underuse of procedures in US populations.
Data Sources: MEDLINE literature search performed in February 2010 and May 2011.
Study Selection: Studies were included if they addressed the appropriateness of a surgical procedure using the RAND-UCLA Appropriateness Method. Non-US studies were excluded.
Data Extraction: Information was abstracted on study design, surgical procedure, and reported rates of appropriate use, overuse, and underuse. Identified AC were cross-referenced with lists of common procedures from the Nationwide Inpatient Sample and the State Ambulatory Surgery databases.
Data Synthesis: A total of 1601 titles were identified; 39 met the inclusion criteria. Of these, 17 developed AC and 27 applied AC to US populations. Appropriateness criteria have been developed for 16 surgical procedures. Underuse has only been studied for coronary artery bypass graft surgery, and rates range from 24% to 57%. Overuse has been more broadly studied, with rates ranging from 9% to 53% for carotid endarterectomy, 0% to 14% for coronary artery bypass graft, 11% to 24% for upper gastrointestinal tract endoscopy, and 16% to 70% for hysterectomy. Appropriateness criteria exist for 10 of the 25 most common inpatient procedures and 6 of the 15 top ambulatory procedures in the United States. Most studies are more than 5 years old.
Conclusions: Most existing AC are outdated, and AC have never been developed for most common surgical procedures. A broad and coordinated effort to develop and maintain AC would be required to implement this tool to address variation in the use of surgical procedures.
C1 [Lawson, Elise H.] Univ Calif Los Angeles, Med Ctr, Dept Surg, David Geffen Sch Med, Los Angeles, CA 90095 USA.
[Lawson, Elise H.; Ingraham, Angela M.; Ko, Clifford Y.] Amer Coll Surg, Div Res & Optimal Patient Care, Chicago, IL USA.
[Gibbons, Melinda Maggard] Olive View UCLA Univ Calif Los Angeles, Dept Surg, Med Ctr, Sylmar, CA USA.
[Ingraham, Angela M.] Univ Cincinnati, Coll Med, Dept Surg, Cincinnati, OH 45267 USA.
[Shekelle, Paul G.] RAND Hlth, Santa Monica, CA USA.
[Shekelle, Paul G.; Ko, Clifford Y.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
RP Lawson, EH (reprint author), Univ Calif Los Angeles, Med Ctr, Dept Surg, David Geffen Sch Med, CHS 72-215,10833 LeConte Ave, Los Angeles, CA 90095 USA.
EM elawson@mednet.ucla.edu
FU Robert Wood Johnson Foundation through the American College of Surgeons
FX Dr Lawson's time was supported by the Robert Wood Johnson Foundation
Clinical Scholars Program through the American College of Surgeons.
NR 60
TC 22
Z9 22
U1 1
U2 4
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA
SN 0004-0010
J9 ARCH SURG-CHICAGO
JI Arch. Surg.
PD DEC
PY 2011
VL 146
IS 12
BP 1433
EP 1440
PG 8
WC Surgery
SC Surgery
GA 864RF
UT WOS:000298256900025
PM 22184308
ER
PT J
AU Thase, ME
Larsen, KG
Kennedy, SH
AF Thase, Michael E.
Larsen, Klaus G.
Kennedy, Sidney H.
TI Assessing the 'true' effect of active antidepressant therapy v. placebo
in major depressive disorder: use of a mixture model
SO BRITISH JOURNAL OF PSYCHIATRY
LA English
DT Article
ID ESCITALOPRAM; SEVERITY; TRIALS; TRAJECTORIES; METAANALYSIS; EFFICACY
AB Background
There is controversy about the implications of relatively small average drug-placebo differences observed in randomised controlled trials of antidepressant medications.
Aims
To investigate whether efficacy is better understood as a large effect in a subgroup of patients.
Method
The mixture model was used to identify patient subgroups (patients benefiting or not benefiting from treatment) to directly model the skewness of Montgomery-Asberg Depression Rating Scale (MADRS) scores at week 8.
Results
The MADRS scores improved by 15.9 points (95% CI 15.2-16.6) among patients who benefited from treatment. The proportion of patients who benefited from escitalopram and not from placebo treatment was 19.5%, corresponding to a number needed to treat of 5.
Conclusions
This model gave a considerably better fit to the data than the analysis of covariance model in which all patients were assumed to benefit from treatment. The small average antidepressant-placebo difference obscures a much larger effect in a clinically meaningful subgroup of patients.
C1 [Thase, Michael E.] Univ Penn, Sch Med, Philadelphia, PA 19104 USA.
[Thase, Michael E.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA.
[Larsen, Klaus G.] H Lundbeck & Co AS, Copenhagen, Denmark.
[Kennedy, Sidney H.] Univ Toronto, Toronto, ON, Canada.
RP Thase, ME (reprint author), Univ Penn, Sch Med, Suite 689,3535 Market St, Philadelphia, PA 19104 USA.
EM thase@mail.med.upenn.edu
FU Agency for Healthcare Research and Quality; Aldolor; Alkermes;
AstraZeneca; Bristol-Myers Squibb; Cephalon; Cyberonics; Dey
Pharmaceuticals; Eli Lilly; GlaxoSmithKline; Janssen Pharmaceutica;
MedAvante; Merck
FX M.E.T. is an advisor/consultant for H. Lundbeck A/S. During the past 5
years has been advisor/consultant for, and/or received research funding
and/or honoraria for talks from: the Agency for Healthcare Research and
Quality, Aldolor, Alkermes, AstraZeneca, Bristol-Myers Squibb, Cephalon,
Cyberonics, Dey Pharmaceuticals, Eli Lilly, Forest Laboratories
(including PGx), GlaxoSmithKline, Janssen Pharmaceutica, MedAvante,
Merck (including Organon and Schering-Plough), National Institute of
Mental Health, Neuronetics, Novartis, Otsuka, PamLab, Pfizer (including
Wyeth), Rexahn, Sanofi Aventis, Sepracor, Shire US, Takeda and
Transcept. He has equity holdings in MedAvante and has received income
from royalties from American Psychiatric Publishing, Guilford
Publications and Herald House. S.H.K has received grant funding and
consulting honoraria from H. Lundbeck A/S. In the past 5 years he has
also received grant funding or consulting honoraria from AstraZeneca,
Biovail, Boehringer-Ingelheim, Eli Lilly, GlaxoSmithKline,
Janssen-Ortho, Merck-Frosst, Organon, Pfizer, Servier and St Jude
Medical. K.G.L. is an employee of H. Lundbeck A/S.
NR 29
TC 27
Z9 27
U1 1
U2 7
PU ROYAL COLLEGE OF PSYCHIATRISTS
PI LONDON
PA BRITISH JOURNAL OF PSYCHIATRY 17 BELGRAVE SQUARE, LONDON SW1X 8PG,
ENGLAND
SN 0007-1250
EI 1472-1465
J9 BRIT J PSYCHIAT
JI Br. J. Psychiatry
PD DEC
PY 2011
VL 199
IS 6
BP 501
EP 507
DI 10.1192/bjp.bp.111.093336
PG 7
WC Psychiatry
SC Psychiatry
GA 867FO
UT WOS:000298440500014
PM 22130749
ER
PT J
AU Park, LS
Tate, JP
Justice, AC
Lo Re, V
Lim, JK
Brau, N
Brown, ST
Butt, AA
Gibert, C
Goetz, MB
Rimland, D
Rodriguez-Barradas, MC
Dubrow, R
AF Park, Lesley S.
Tate, Janet P.
Justice, Amy C.
Lo Re, Vincent, III
Lim, Joseph K.
Braeu, Norbert
Brown, Sheldon T.
Butt, Adeel A.
Gibert, Cynthia
Goetz, Matthew Bidwell
Rimland, David
Rodriguez-Barradas, Maria C.
Dubrow, Robert
TI FIB-4 Index Is Associated with Hepatocellular Carcinoma Risk in
HIV-Infected Patients
SO CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
LA English
DT Article
ID C VIRUS-INFECTION; DIABETES-MELLITUS; UNITED-STATES; HEPATITIS;
EPIDEMIOLOGY; COINFECTION; MORTALITY; CIRRHOSIS; FIBROSIS; OBESITY
AB Background: Chronic inflammation caused by hepatitis B virus infection, hepatitis Cvirus infection, and/or heavy alcohol use can lead to fibrosis, cirrhosis, and eventually hepatocellular carcinoma (HCC). FIB-4 is an index score calculated from platelet count, alanine transaminase, aspartate transaminase, and age that predicts fibrosis and cirrhosis. We hypothesized that high FIB-4 would be associated with development of HCC in HIV infected persons, who are at high risk due to high prevalence of viral hepatitis and alcohol consumption, and possibly due to HIV infection itself.
Methods: Using proportional hazards models, we tested this hypothesis among 22,980 HIV-infected men from the Veterans Aging Cohort Study. We identified incident HCC cases from the Veterans Affairs Central Cancer Registry.
Results: During follow-up, there were 112 incident HCC diagnoses. The age-and race/ethnic group adjusted HR was 4.2 [95% confidence interval (CI), 2.4-7.4] for intermediate FIB-4 and 13.0 (95% CI, 7.2-23.4) for high FIB-4, compared with low FIB-4. After further adjustment for enrollment year, CD4 count, HIV-1 RNA level, antiretroviral therapy use, hepatitis B and C virus infection, alcohol abuse/dependency, and diabetes, FIB-4 remained a strong, significant, independent risk factor for HCC. The multivariate-adjusted HR was 3.6 (95% CI, 2.1-6.4) for intermediate FIB-4 and 9.6 (95% CI, 5.2-17.4) for high FIB-4.
Conclusions: Calculated from routine, noninvasive laboratory tests, FIB-4 is a strong, independent HCC risk factor in HIV-infected patients. Impact: FIB-4 might prove valuable as an easily measured index to identify those at highest risk for HCC, even prior to development of clinical cirrhosis. Cancer Epidemiol Biomarkers Prev; 20(12); 2512-7. (C) 2011 AACR.
C1 [Park, Lesley S.; Tate, Janet P.; Justice, Amy C.; Lim, Joseph K.; Dubrow, Robert] Yale Univ, Sch Med, West Haven, CT 06516 USA.
[Dubrow, Robert] Yale Univ, Sch Publ Hlth, New Haven, CT USA.
[Tate, Janet P.; Justice, Amy C.] VA Connecticut Healthcare Syst, West Haven, CT USA.
[Lo Re, Vincent, III] Philadelphia VA Med Ctr, Philadelphia, PA USA.
[Lo Re, Vincent, III] Univ Penn, Sch Med, Philadelphia, PA 19104 USA.
[Butt, Adeel A.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
[Butt, Adeel A.] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA.
[Braeu, Norbert; Brown, Sheldon T.] James J Peters Vet Affairs Med Ctr, Bronx, NY USA.
[Brown, Sheldon T.] Mt Sinai Sch Med, New York, NY USA.
[Gibert, Cynthia] Washington DC Vet Affairs Med Ctr, Washington, DC USA.
[Goetz, Matthew Bidwell] VA Greater Angeles Healthcare Syst, Los Angeles, CA USA.
[Goetz, Matthew Bidwell] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
[Rimland, David] Atlanta Vet Affairs Med Ctr, Atlanta, GA USA.
[Rimland, David] Emory Univ, Sch Med, Atlanta, GA USA.
[Rodriguez-Barradas, Maria C.] Michael E DeBakey VA Med Ctr, Houston, TX USA.
[Rodriguez-Barradas, Maria C.] Baylor Coll Med, Houston, TX 77030 USA.
RP Park, LS (reprint author), Yale Univ, Sch Med, 950 Campbell Ave,Bldg 35A, West Haven, CT 06516 USA.
EM lesley.park@yale.edu
RI Lo Re, Vincent/N-7817-2015
OI Goetz, Matthew/0000-0003-4542-992X
FU NIH: National Institute on Alcohol Abuse and Alcoholism [U01-AA13566];
National Institute on Aging [R01-AG029154]; National Heart, Lung, and
Blood Institute [R01-HL095136, R01-HL090342, RCI-HL100347]; National
Institute of Allergy and Infectious Diseases [U01-AI069918]; National
Institute of Mental Health [P30-MH062294]; Veterans Health
Administration Office of Research and Development [VA REA 08-266];
Office of Academic Affiliations
FX This work was supported by NIH: National Institute on Alcohol Abuse and
Alcoholism (U01-AA13566); National Institute on Aging (R01-AG029154);
National Heart, Lung, and Blood Institute (R01-HL095136, R01-HL090342,
RCI-HL100347); National Institute of Allergy and Infectious Diseases
(U01-AI069918); National Institute of Mental Health (P30-MH062294); and
the Veterans Health Administration Office of Research and Development
(VA REA 08-266) and Office of Academic Affiliations (Medical Informatics
Fellowship).
NR 22
TC 21
Z9 21
U1 1
U2 5
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1055-9965
J9 CANCER EPIDEM BIOMAR
JI Cancer Epidemiol. Biomarkers Prev.
PD DEC
PY 2011
VL 20
IS 12
BP 2512
EP 2517
DI 10.1158/1055-9965.EPI-11-0582
PG 6
WC Oncology; Public, Environmental & Occupational Health
SC Oncology; Public, Environmental & Occupational Health
GA 864JA
UT WOS:000298234900006
PM 22028407
ER
PT J
AU Stott-Miller, M
Houck, JR
Lohavanichbutr, P
Mendez, E
Upton, MP
Futran, ND
Schwartz, SM
Chen, C
AF Stott-Miller, Marni
Houck, John R.
Lohavanichbutr, Pawadee
Mendez, Eduardo
Upton, Melissa P.
Futran, Neal D.
Schwartz, Stephen M.
Chen, Chu
TI Tumor and Salivary Matrix Metalloproteinase Levels Are Strong Diagnostic
Markers of Oral Squamous Cell Carcinoma
SO CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
LA English
DT Article
ID SINGLE NUCLEOTIDE POLYMORPHISM; GENE-EXPRESSION; HUMAN-PAPILLOMAVIRUS;
POTENTIAL BIOMARKERS; OROPHARYNGEAL CANCER; CDNA MICROARRAY;
RISK-FACTOR; HEAD; NECK; PROGRESSION
AB Background: The matrix metalloproteinases (MMP) cause degradation of the extracellular matrix and basement membranes, and thus may play a key role in cancer development.
Methods: In our search for biomarkers for oral squamous cell carcinomas (OSCC), we compared primary OSCC, oral dysplasia and control subjects with respect to: (i) expression of MMP1, MMP3, MMP10, and MMP12 in oral epithelial tissue using Affymetrix U133 2.0 Plus GeneChip arrays, followed by quantitative reverse transcription-PCR (qRT-PCR) for MMP1, and (ii) determination of MMP1 and MMP3 concentrations in saliva.
Results: MMP1 expression in primary OSCC (n = 119) was > 200-fold higher (P 7.16 x 10(-40)) compared with expression levels in nonneoplastic oral epithelium from controls (n 35). qRT-PCR results on 30 cases and 22 controls confirmed this substantial differential expression. The exceptional discriminatory power to separate OSCC from controls was validated in two independent testing sets (AUC% 100; 95% CI: 100-100 and AUC% 98.4; 95% CI: 95.6-100). Salivary concentrations of MMP1 and MMP3 in OSCC patients (33 stage I/II, 26 stage III/IV) were 6.2 times (95% CI: 3.32-11.73) and 14.8 times (95% CI: 6.75-32.56) higher, respectively, than in controls, and displayed an increasing trend with higher stage disease.
Conclusion: Tumor and salivary MMPs are robust diagnostic biomarkers of OSCC.
Impact: The capacity of MMP gene expression to identify OSCC provides support for further investigation into MMPs as potential markers for OSCC development. Detection of MMP proteins in saliva in particular may provide a promising means to detect and monitor OSCC noninvasively. Cancer Epidemiol Biomarkers Prev; 20(12); 2628-36. (C) 2011 AACR.
C1 [Stott-Miller, Marni; Houck, John R.; Lohavanichbutr, Pawadee; Mendez, Eduardo; Schwartz, Stephen M.; Chen, Chu] Fred Hutchinson Canc Res Ctr, Program Epidemiol, Seattle, WA 98109 USA.
[Stott-Miller, Marni; Schwartz, Stephen M.; Chen, Chu] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA.
[Mendez, Eduardo; Futran, Neal D.; Chen, Chu] Univ Washington, Dept Otolaryngol Head & Neck Surg, Seattle, WA 98195 USA.
[Upton, Melissa P.] Univ Washington, Dept Pathol, Seattle, WA 98195 USA.
[Mendez, Eduardo] VA Puget Sound Hlth Care Syst, Surg & Perioperat Care Serv, Seattle, WA USA.
RP Chen, C (reprint author), Fred Hutchinson Canc Res Ctr, Program Epidemiol, 1100 Fairview Ave N,M5-C800,POB 19024, Seattle, WA 98109 USA.
EM cchen@fhcrc.org
FU U.S. NIH (from the National Cancer Institute) [R01CA095419]; NIH
[5T32DE007132-28]; Fred Hutchinson Cancer Research Center
FX U.S. NIH (R01CA095419 from the National Cancer Institute), NIH
5T32DE007132-28 (Comprehensive training in inter-disciplinary oral
health research), and institutional funds from the Fred Hutchinson
Cancer Research Center.
NR 49
TC 15
Z9 15
U1 0
U2 8
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1055-9965
J9 CANCER EPIDEM BIOMAR
JI Cancer Epidemiol. Biomarkers Prev.
PD DEC
PY 2011
VL 20
IS 12
BP 2628
EP 2636
DI 10.1158/1055-9965.EPI-11-0503
PG 9
WC Oncology; Public, Environmental & Occupational Health
SC Oncology; Public, Environmental & Occupational Health
GA 864JA
UT WOS:000298234900019
PM 21960692
ER
PT J
AU Jones, JA
Stroud, RE
O'Quinn, EC
Black, LE
Barth, JL
Elefteriades, JA
Bavaria, JE
Gorman, JH
Gorman, RC
Spinale, FG
Ikonomidis, JS
AF Jones, Jeffrey A.
Stroud, Robert E.
O'Quinn, Elizabeth C.
Black, Laurel E.
Barth, Jeremy L.
Elefteriades, John A.
Bavaria, Joseph E.
Gorman, Joseph H., III
Gorman, Robert C.
Spinale, Francis G.
Ikonomidis, John S.
TI Selective MicroRNA Suppression in Human Thoracic Aneurysms Relationship
of miR-29a to Aortic Size and Proteolytic Induction
SO CIRCULATION-CARDIOVASCULAR GENETICS
LA English
DT Article
DE aneurysm; thoracic aorta; microRNA; MMP; remodeling
ID CARDIOVASCULAR-DISEASE ENTERPRISES; IN-SITU LOCALIZATION; MATRIX
METALLOPROTEINASES; ENDOGENOUS INHIBITORS; MAJOR SHAREHOLDERS;
MARFAN-SYNDROME; IV COLLAGENASE; MURINE MODEL; EXPRESSION;
MATRIX-METALLOPROTEINASE-9
AB Background-Increasing evidence points to a direct role for altered microRNA (miRNA or miR) expression levels in cardiovascular remodeling and disease progression. Although alterations in miR expression levels have been directly linked to cardiac hypertrophy, fibrosis, and remodeling, their role in regulating gene expression during thoracic aortic aneurysm (TAA) development has yet to be explored.
Methods and Results-The present study examined miR expression levels in aortic tissue specimens collected from patients with ascending TAAs by quantitative real-time PCR, and observed decreased miR expression (miRs -1, -21, -29a, -133a, and -486) as compared with normal aortic specimens. A significant relationship between miR expression levels (miRs -1, -21, -29a, and -133a) and aortic diameter was identified; as aortic diameter increased, miR expression decreased. Through the use of a bioinformatics approach, members of the matrix metalloproteinase (MMP) family, proteins involved in TAA development, were examined for putative miR binding sites. MMP-2 and MMP-9 were identified as potential targets for miR-29a and miR-133a, respectively, and MMP-2 was subsequently verified as a miR-29a target in vitro. A significant inverse relationship between miR-29a and total MMP-2 was then identified in the clinical TAA specimens.
Conclusions-These findings demonstrate altered miR expression patterns in clinical TAA specimens, suggesting that the loss of specific miR expression may allow for the elaboration of specific MMPs capable of driving aortic remodeling during TAA development. Importantly, these data suggest that these miRs have biological and clinical relevance to the behavior of TAAs and may provide significant targets for therapeutic and diagnostic applications. (Circ Cardiovasc Genet. 2011;4:605-613.)
C1 [Ikonomidis, John S.] Med Univ S Carolina, Div Cardiothorac Surg, S Carolina Heart Valve Ctr, Charleston, SC 29425 USA.
[Jones, Jeffrey A.; Spinale, Francis G.] Ralph H Johnson Vet Affairs Med Ctr, Res Serv, Charleston, SC USA.
[Barth, Jeremy L.] Med Univ S Carolina, Dept Regenerat Med & Cell Biol, Charleston, SC 29425 USA.
[Elefteriades, John A.] Yale Univ, Sch Med, Dept Cardiothorac Surg, New Haven, CT USA.
[Bavaria, Joseph E.; Gorman, Joseph H., III; Gorman, Robert C.] Univ Penn, Gorman Cardiovasc Res Grp, Glenolden Res Lab, Glenolden, PA USA.
RP Ikonomidis, JS (reprint author), Med Univ S Carolina, Div Cardiothorac Surg, S Carolina Heart Valve Ctr, 25 Courtenay Dr,Suite 7030, Charleston, SC 29425 USA.
EM ctsxresearch@musc.edu
FU Department of Veterans Affairs; National Institutes of Health; NIH/NCRR
[RR16434, RR16461]; [NHLBI/R01s HL057952-08]; [HL059165-09];
[NHLBI/R21 HL089170-01A1]; [R01 HL102121-01A1]
FX This work was supported by the Department of Veterans Affairs: Career
Development Award (CDA-2) and a Merit Award to Dr Jones and a Merit
Award to Dr Spinale; National Institutes of Health grants NIH/NCRR
RR16434 and RR16461 to Dr Barth; NHLBI/R01s HL057952-08 and HL059165-09
to Dr Spinale; and NHLBI/R21 HL089170-01A1 and R01 HL102121-01A1 to Dr
Ikonomidis.
NR 35
TC 41
Z9 43
U1 0
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1942-325X
J9 CIRC-CARDIOVASC GENE
JI Circ.-Cardiovasc. Genet.
PD DEC
PY 2011
VL 4
IS 6
BP 605
EP U264
DI 10.1161/CIRCGENETICS.111.960419
PG 15
WC Cardiac & Cardiovascular Systems; Genetics & Heredity
SC Cardiovascular System & Cardiology; Genetics & Heredity
GA 866VR
UT WOS:000298414800006
PM 22010139
ER
PT J
AU Zile, MR
Mehurg, SM
Arroyo, JE
Stroud, RE
DeSantis, SM
Spinale, FG
AF Zile, Michael R.
Mehurg, Shannon M.
Arroyo, Jazmine E.
Stroud, Robert E.
DeSantis, Stacia M.
Spinale, Francis G.
TI Relationship Between the Temporal Profile of Plasma microRNA and Left
Ventricular Remodeling in Patients After Myocardial Infarction
SO CIRCULATION-CARDIOVASCULAR GENETICS
LA English
DT Article
DE myocardial infarction; remodeling; microRNA
ID CIRCULATING MICRORNAS; DISEASE; EXPRESSION; BIOMARKERS; HEART; FIBROSIS;
MARKERS; CANCER; OCCURS; BLOOD
AB Background-microRNAs (miRs) are small noncoding RNAs that recognize and bind to mRNAs and inhibit protein translation or degrade mRNA. Studies in animal models have suggested that miRs play a translational or posttranslational regulatory role in myocardial growth, fibrosis, viability, and remodeling. However, whether specific temporal changes in miRs occur in patients during the left ventricular (LV) remodeling process that follows a myocardial infarction (post-MI) remains unknown. The current pilot study tested the hypotheses that plasma miRs could be reliably measured in post-MI patients and that there is a relationship between temporal changes in specific miRs and post-MI LV structural remodeling.
Methods and Results-LV end-diastolic volume (echocardiography) and plasma miR were measured in age-matched referent controls (CTLs, n = 12) and post-MI patients (n = 12) from day 2 through day 90 post-MI. Selected miRs (miR-1, miR-21, miR-29a, miR-133a, and miR-208) were measured using quantitative reverse transcription-polymerase chain reaction and normalized for endogenous small nuclear RNA U6. After MI, LV end-diastolic volume increased progressively compared with CTL; this was accompanied by time-dependent changes in specific miRs. For example, miR-21 initially decreased 2 days post-MI (0.3 +/- 0.1-fold versus CTL; P<0.05), increased 5 days post-MI (2 +/- 1-fold versus CTL; P<0.05), and returned to CTL values at later post-MI time points. In contrast, miR-29a increased 5 days post-MI (4 +/- 1-fold versus CTL; P<0.05) and then decreased to CTL at later time points. miR-208 increased 5 days post-MI (3 +/- 1-fold versus CTL; P<0.05) and remained elevated up to 90 days post-MI.
Conclusions-A time-dependent change in miRs occurred in post-MI patients, including an early and robust increase in miRs that has affected myocardial growth, fibrosis, and viability. Thus, serially profiling miRs in the plasma of post-MI patients may hold both mechanistic and prognostic significance. (Circ Cardiovasc Genet. 2011;4:614-619.)
C1 [Zile, Michael R.; Mehurg, Shannon M.] Med Univ S Carolina, Dept Med, Div Cardiol, Charleston, SC 29425 USA.
[Arroyo, Jazmine E.; Stroud, Robert E.; Spinale, Francis G.] Med Univ S Carolina, Div Cardiothorac Surg, Dept Surg, Charleston, SC 29425 USA.
[DeSantis, Stacia M.] Med Univ S Carolina, Ralph H Johnson Dept Vet Affairs Med Ctr, Charleston, SC 29425 USA.
[DeSantis, Stacia M.] Med Univ S Carolina, Dept Biostat Bioinformat & Epidemiol, Charleston, SC 29425 USA.
RP Zile, MR (reprint author), Med Univ S Carolina, Dept Med, Div Cardiol, Ashley River Towers,25 Courtenay Dr,Room 7067, Charleston, SC 29425 USA.
EM zilem@musc.edu
FU Doris Duke Foundation and Health Sciences of South Carolina; Research
Service of the Department of Veterans Affairs; National Institutes of
Health [HL057952, HL059165, HL095608]
FX This study was supported by the Doris Duke Foundation and Health
Sciences of South Carolina (Dr Zile); the Research Service of the
Department of Veterans Affairs (Drs Zile and Spinale); grants HL057952,
HL059165, and HL095608 from the National Institutes of Health (Dr
Spinale).
NR 24
TC 61
Z9 66
U1 0
U2 7
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1942-325X
J9 CIRC-CARDIOVASC GENE
JI Circ.-Cardiovasc. Genet.
PD DEC
PY 2011
VL 4
IS 6
BP 614
EP 619
DI 10.1161/CIRCGENETICS.111.959841
PG 6
WC Cardiac & Cardiovascular Systems; Genetics & Heredity
SC Cardiovascular System & Cardiology; Genetics & Heredity
GA 866VR
UT WOS:000298414800007
PM 21956146
ER
PT J
AU O'Leary, TJ
AF O'Leary, Timothy J.
TI "Research Use Only" Reagents: Is There an Imperative for Increased FDA
Oversight?
SO CLINICAL CHEMISTRY
LA English
DT Article
C1 Vet Hlth Adm, Off Res & Dev, US Dept Vet Affairs, Washington, DC 20420 USA.
RP O'Leary, TJ (reprint author), Vet Hlth Adm, Off Res & Dev, US Dept Vet Affairs, 810 Vermont Ave NW, Washington, DC 20420 USA.
EM timothy.oleary@va.gov
NR 3
TC 1
Z9 1
U1 0
U2 2
PU AMER ASSOC CLINICAL CHEMISTRY
PI WASHINGTON
PA 2101 L STREET NW, SUITE 202, WASHINGTON, DC 20037-1526 USA
SN 0009-9147
J9 CLIN CHEM
JI Clin. Chem.
PD DEC
PY 2011
VL 57
IS 12
BP 1681
EP 1683
DI 10.1373/clinchem.2011.174268
PG 3
WC Medical Laboratory Technology
SC Medical Laboratory Technology
GA 862UM
UT WOS:000298119600009
PM 21998341
ER
PT J
AU Mukete, BN
Atlas, SA
AF Mukete, Bertrand N.
Atlas, Steven A.
TI Implications of Changes in Plasma Asymmetric Dimethylarginine During
Treatment of Hypertension
SO CURRENT HYPERTENSION REPORTS
LA English
DT Editorial Material
DE Dimethylarginine; Hypertension; Treatment; Clinical trial; Nebivolol;
Metoprolol; Beta-blockers; Nitric oxide synthase; Arginine;
Antihypertensive agents
ID BETA(3)-ADRENOCEPTOR AGONISTS; NEBIVOLOL; DRUGS
C1 [Mukete, Bertrand N.; Atlas, Steven A.] James J Peters VA Med Ctr, Bronx, NY 10468 USA.
[Mukete, Bertrand N.; Atlas, Steven A.] Mt Sinai Sch Med, New York, NY 10028 USA.
RP Atlas, SA (reprint author), James J Peters VA Med Ctr, 130 W Kingsbridge Rd, Bronx, NY 10468 USA.
EM steven.atlas@va.gov
NR 9
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1522-6417
J9 CURR HYPERTENS REP
JI Curr. Hypertens. Rep.
PD DEC
PY 2011
VL 13
IS 6
BP 406
EP 408
DI 10.1007/s11906-011-0233-8
PG 3
WC Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA 874ZA
UT WOS:000298996300004
PM 22045470
ER
PT J
AU Egede, LE
Gebregziabher, M
Lynch, CP
Gilbert, GE
Echols, C
AF Egede, Leonard E.
Gebregziabher, Mulugeta
Lynch, Cheryl P.
Gilbert, Gregory E.
Echols, Carrae
TI Longitudinal ethnic differences in multiple cardiovascular risk factor
control in a cohort of US adults with diabetes
SO DIABETES RESEARCH AND CLINICAL PRACTICE
LA English
DT Article
DE Diabetes; Cardiovascular disease; Risk factor control; Ethnicity;
Veterans
ID OF-VETERANS-AFFAIRS; HEALTH-CARE-SYSTEM; INTERMEDIATE OUTCOMES; DISEASE
RISK; PREVENTION; POPULATION; PREVALENCE; QUALITY; TRIAD
AB Aim: To examine longitudinal differences in multiple cardiovascular risk factor control (glycemia, blood pressure, and lipids) by race/ethnicity.
Methods: Data were analyzed on a cohort of 11,203 veterans with type 2 diabetes. Primary outcome was odds of none of the risk factors out of control vs. having at least one out of control (HbA1c > 8.0%, BP > 140/90 mmHg, and LDL > 100 mg/dL). Secondary outcome was odds of having none out of control vs. having one, two or three risk factors out of control, respectively. Generalized linear mixed models assessed the relationship between race/ethnicity and multiple risk factor control adjusted for covariates.
Results: Adjusted models for primary outcome showed that NHB had two-fold (95% CI 1.8-2.3) and Hispanics had 48% higher (95% CI 1.3-1.7) odds of multiple risk factors out of control over time compared to NHW. Adjusted models for secondary outcome showed that NHB and Hispanics also had higher odds of having one, two, and three risk factors out of control over time compared to NHW.
Conclusions: Ethnic minority veterans with diabetes are less likely to have multiple cardiovascular risk factor control over time compared to whites. Thus, greater risk reduction efforts are needed to reduce the heavier disease burden among ethnic minorities. (C) 2011 Elsevier Ireland Ltd. All rights reserved.
C1 [Egede, Leonard E.; Gebregziabher, Mulugeta; Lynch, Cheryl P.] Med Univ S Carolina, Ctr Hlth Dispar Res, Charleston, SC 29425 USA.
[Egede, Leonard E.; Lynch, Cheryl P.; Gilbert, Gregory E.; Echols, Carrae] Ralph H Johnson Vet Affairs Med Ctr, Ctr Dis Prevent & Hlth Intervent Diverse Populat, Charleston, SC USA.
[Gebregziabher, Mulugeta] Med Univ S Carolina, Div Biostat & Epidemiol, Charleston, SC 29425 USA.
RP Egede, LE (reprint author), Med Univ S Carolina, Ctr Hlth Dispar Res, 135 Rutledge Ave,Room 280H,POB 250593, Charleston, SC 29425 USA.
EM egedel@musc.edu
RI Gilbert, Gregory/C-7735-2016
OI Gilbert, Gregory/0000-0003-0879-5496; Gebregziabher,
Mulugeta/0000-0002-4826-481X
FU Center for Disease Prevention and Health Interventions for Diverse
Populations [REA 08-261]; Veterans Affairs Health Services Research and
Development (PI - Leonard Egede)
FX This study was supported by Grant # REA 08-261, Center for Disease
Prevention and Health Interventions for Diverse Populations funded by
Veterans Affairs Health Services Research and Development (PI - Leonard
Egede).
NR 31
TC 13
Z9 13
U1 0
U2 4
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
IRELAND
SN 0168-8227
J9 DIABETES RES CLIN PR
JI Diabetes Res. Clin. Pract.
PD DEC
PY 2011
VL 94
IS 3
BP 385
EP 394
DI 10.1016/j.diabres.2011.08.003
PG 10
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 863EA
UT WOS:000298144400019
PM 21903291
ER
PT J
AU Nett, JE
Sanchez, H
Cain, MT
Ross, KM
Andes, DR
AF Nett, Jeniel E.
Sanchez, Hiram
Cain, Michael T.
Ross, Kelly M.
Andes, David R.
TI Interface of Candida albicans Biofilm Matrix-Associated Drug Resistance
and Cell Wall Integrity Regulation
SO EUKARYOTIC CELL
LA English
DT Article
ID ANTIFUNGAL AGENTS; SACCHAROMYCES-CEREVISIAE; FLUCONAZOLE RESISTANCE;
GENE DISRUPTION; BETA-GLUCANS; EFFLUX PUMPS; IN-VIVO; SUSCEPTIBILITY;
INFECTIONS; PATHWAY
AB Candida albicans frequently infects medical devices by growing as a biofilm, i.e., a community of adherent organisms entrenched in an extracellular matrix. During biofilm growth, Candida spp. acquire the ability to resist high concentrations of antifungal drugs. One recently recognized biofilm resistance mechanism involves drug sequestration by matrix beta-1,3 glucan. Using a candidate gene approach, we investigated potential C. albicans beta-1,3-glucan regulators, based on their homology to Saccharomyces cerevisiae, including SMI1 and protein kinase C (PKC) pathway components. We identified a role for the SMI1 in biofilm matrix glucan production and development of the associated drug resistance phenotype. This pathway appears to act through transcription factor Rlmp and glucan synthase Fks1p. The phenotypes of these mutant biofilms mimicked those of the smi1 Delta/smi1 Delta biofilm, and overexpression of FKS1 in the smi1 Delta/smi1 Delta mutant restored the biofilm resistant phenotype. However, control of this pathway is distinct from that of the upstream PKC pathway because the pkc1 Delta/pkc1 Delta, bck1 Delta/bck1 Delta, mkk2 Delta/mkk2 Delta, and mkc1 Delta/mkc1 Delta biofilms retained the resistant phenotype of the parent strain. In addition, resistance to cell-perturbing agents and gene expression data do not support a significant role for the cell wall integrity pathway during the biofilm formation. Here we show that Smi1p functions in conjunction with Rlm1p and Fks1p to produce drug-sequestering biofilm beta-glucan. Our work provides new insight into how the C. albicans biofilm matrix production and drug resistance pathways intersect with the planktonic cell wall integrity pathway. This novel connection helps explain how pathogens in a multicellular biofilm community are protected from anti-infective therapy.
C1 [Nett, Jeniel E.; Sanchez, Hiram; Cain, Michael T.; Ross, Kelly M.; Andes, David R.] Univ Wisconsin, Dept Med, Madison, WI 53705 USA.
[Andes, David R.] Univ Wisconsin, Dept Med Microbiol & Immunol, Madison, WI 53705 USA.
[Nett, Jeniel E.] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA.
RP Andes, DR (reprint author), Univ Wisconsin, Dept Med, 5211 UW Med Fdn Centennial Bldg,1685 Highland Ave, Madison, WI 53705 USA.
EM dra@medicine.wisc.edu
FU National Institutes of Health [RO1 AI073289-01]; Veteran Women's Health
Fellowship
FX This work was supported by the National Institutes of Health (grant RO1
AI073289-01) and the Veteran Women's Health Fellowship.
NR 52
TC 45
Z9 53
U1 1
U2 10
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 1535-9778
J9 EUKARYOT CELL
JI Eukaryot. Cell
PD DEC
PY 2011
VL 10
IS 12
BP 1660
EP 1669
DI 10.1128/EC.05126-11
PG 10
WC Microbiology; Mycology
SC Microbiology; Mycology
GA 863HN
UT WOS:000298153500007
PM 21666076
ER
PT J
AU Pantaleo, MA
Astolfi, A
Nannini, M
Ceccarelli, C
Formica, S
Santini, D
Heinrich, MC
Corless, C
Dei Tos, AP
Paterini, P
Catena, F
Maleddu, A
Saponara, M
Di Battista, M
Biasco, G
AF Pantaleo, Maria A.
Astolfi, Annalisa
Nannini, Margherita
Ceccarelli, Claudio
Formica, Serena
Santini, Donatella
Heinrich, Michael C.
Corless, Christopher
Dei Tos, Angelo Paolo
Paterini, Paola
Catena, Fausto
Maleddu, Alessandra
Saponara, Maristella
Di Battista, Monica
Biasco, Guido
TI Differential expression of neural markers in KIT and PDGFRA wild-type
gastrointestinal stromal tumours
SO HISTOPATHOLOGY
LA English
DT Article
DE gene expression profiling; GIST; ICC; ICC mature; ICC precursor; IGF1R;
KIT; PDGFRA
ID INTERSTITIAL-CELLS; C-KIT; THERAPEUTIC TARGET; MUTATIONS; CAJAL; GISTS;
STOMACH; COMMON; RECEPTOR; SIZE
AB Aims: To compare the genomic signatures of wildtype (WT) and mutated GISTs and the murine interstitial cells of Cajal (ICCs) to find markers of cell differentiation and other functions that may identify cells that give rise to WT tumours.
Methods and results: We analysed the gene expression profiles of a total of 30 tumour samples (four WT GISTs and 26 mutated GISTs), selected the genes most differentially expressed (P < 0.001: 448 probe sets) and validated these results by quantitative polymerase chain reaction (PCR) and immunohistochemistry. In addition, we conducted a meta-analysis merging data from human GISTs with a genomic data set from murine ICCs. The gene expression profiles of WT and mutated GISTs differed profoundly, especially in the expression of those genes restricted primarily to neural tissues. We found that mature ICCs are more similar to mutated GISTs than WT GISTs.
Conclusions: WT GISTs have different genomic profiles from both mutated GISTs and murine mature ICCs. Considering that IGF1R expression is common to both WT GISTs and putative precursor ICCs, this study suggests that WT GISTs may derive either from ICCs at a different step of differentiation or from a different cell of origin.
C1 [Pantaleo, Maria A.; Nannini, Margherita; Maleddu, Alessandra; Saponara, Maristella; Di Battista, Monica; Biasco, Guido] Univ Bologna, S Orsola Malpighi Hosp, Dept Hematol & Oncol Sci LA Seragnoli, I-40138 Bologna, Italy.
[Pantaleo, Maria A.; Astolfi, Annalisa; Formica, Serena; Paterini, Paola; Biasco, Guido] Univ Bologna, Interdept Ctr Canc Res G Prodi, I-40138 Bologna, Italy.
[Ceccarelli, Claudio; Santini, Donatella] Univ Bologna, S Orsola Malpighi Hosp, Dept Radiol & Histopathol Sci, Surg Pathol Unit, I-40138 Bologna, Italy.
[Heinrich, Michael C.; Corless, Christopher] Portland VA Med Ctr, Dept Med, Portland, OR USA.
[Heinrich, Michael C.; Corless, Christopher] Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97201 USA.
[Dei Tos, Angelo Paolo] Gen Hosp Treviso, Dept Oncol, Treviso, Italy.
[Catena, Fausto] Univ Bologna, S Orsola Malpighi Hosp, Emergency Surg & Transplant Dept, I-40138 Bologna, Italy.
RP Pantaleo, MA (reprint author), Univ Bologna, S Orsola Malpighi Hosp, Dept Hematol & Oncol Sci LA Seragnoli, Via Massarenti 9, I-40138 Bologna, Italy.
EM maria.pantaleo@unibo.it
RI Saponara, Maristella/J-9904-2016; nannini, margherita/J-9866-2016
OI Saponara, Maristella/0000-0003-0715-171X; PANTALEO, MARIA
ABBONDANZA/0000-0002-0177-6957; DEI TOS, ANGELO/0000-0002-1228-8940;
Ceccarelli, Claudio/0000-0003-0743-2087; NANNINI,
MARGHERITA/0000-0002-2103-1960; astolfi, annalisa/0000-0002-2732-0747
FU Fondazione Cassa di Risparmio of Bologna (CARISBO), Italy; Fondazione
Giuseppe Alazio; Palermo Italy; Fondazione Vanini-Cavagnino, Bologna,
Italy
FX Research programmes on GIST are supported by Fondazione Cassa di
Risparmio of Bologna (CARISBO), Italy, Fondazione Giuseppe Alazio,
Palermo Italy and Fondazione Vanini-Cavagnino, Bologna, Italy.
NR 30
TC 10
Z9 10
U1 1
U2 4
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0309-0167
J9 HISTOPATHOLOGY
JI Histopathology
PD DEC
PY 2011
VL 59
IS 6
BP 1071
EP 1080
DI 10.1111/j.1365-2559.2011.04071.x
PG 10
WC Cell Biology; Pathology
SC Cell Biology; Pathology
GA 866CT
UT WOS:000298358000005
PM 22175887
ER
PT J
AU Lai, YY
Chen, B
Shi, JB
Palmer, JN
Kennedy, DW
Cohen, NA
AF Lai, Yinyan
Chen, Bei
Shi, Jianbo
Palmer, James N.
Kennedy, David W.
Cohen, Noam A.
TI Inflammation-mediated upregulation of centrosomal protein 110, a
negative modulator of ciliogenesis, in patients with chronic
rhinosinusitis
SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
LA English
DT Article
DE Chronic rhinosinusitis; ciliated epithelial cell; ciliogenesis;
cytokine; inflammation; centrosomal protein 110
ID LIQUID INTERFACE CULTURES; CHRONIC SINUSITIS; NASAL POLYPOSIS;
PSEUDOMONAS-AERUGINOSA; HUMAN-CELLS; EXPRESSION; CILIA; CENTRIOLE;
INTERLEUKIN-5; EPITHELIUM
AB Background: Sinonasal mucosa in patients with chronic rhinosinusitis (CRS) is often devoid of motile cilia. This defect is presumed to result from prolonged inflammation, infection, or both. However, the mechanism underlying this observation is unknown. Recently, centrosomal protein 110 (Cp110) was shown to prevent the terminal step in ciliary maturation (ie, elongation), suggesting that Cp110 might be involved in pathological states in which ciliation is abnormal.
Objectives: First, we sought to investigate the expression of Cp110 in sinonasal mucosa from patients with CRS and control subjects. Second, we sought to determine the extent that inflammatory cytokines modulate Cp110 expression and ciliary maturation in vitro.
Methods: Sinonasal mucosal specimens from patients with and without CRS were analyzed for Cp110 mRNA and protein expression. Furthermore, human and murine nasal respiratory epithelial cultures were used to investigate Cp110 expression under normal growth conditions and in the presence of exogenous proinflammatory cytokines.
Results: Increased Cp110 mRNA and protein expression was found in sinonasal mucosal specimens from patients with CRS compared with that seen in control specimens. During ciliogenesis in vitro, the expression of Cp110 gradually decreased in cultures derived from patients without CRS but remained increased in cultures derived from patients with CRS. Furthermore, cultures grown in the presence of proinflammatory cytokines demonstrated increased levels of Cp110 expression with concomitant inhibition of ciliogenesis.
Conclusion: Increased Cp110 expression in mucosa from patients with CRS might contribute to the poor ciliation observed in patients with CRS. Exogenous cytokine exposure maintains increased levels of Cp110 expression. Regulation of Cp110 expression by inflammation warrants additional investigation because it might offer a novel target in the management of respiratory tract diseases. (J Allergy Clin Immunol 2011;128:1207-15.)
C1 [Lai, Yinyan; Chen, Bei; Palmer, James N.; Kennedy, David W.; Cohen, Noam A.] Univ Penn, Dept Otorhinolaryngol Head & Neck Surg, Philadelphia, PA 19104 USA.
[Lai, Yinyan; Shi, Jianbo] Sun Yat Sen Univ, Otorhinolaryngol Hosp, Affiliated Hosp 1, Guangzhou 510275, Guangdong, Peoples R China.
[Palmer, James N.; Cohen, Noam A.] Philadelphia Vet Affairs Med Ctr, Surg Serv, Div Otolaryngol, Philadelphia, PA USA.
RP Cohen, NA (reprint author), Univ Penn, Dept Otorhinolaryngol Head & Neck Surg, Ravdin Bldg,5th Floor,3400 Spruce St, Philadelphia, PA 19104 USA.
EM cohenn@uphs.upenn.edu
OI Cohen, Noam/0000-0002-9462-3932
FU China Scholarship Council; Flight Attendant Medical Research Institute
[082478]
FX Supported by the China Scholarship Council and the Flight Attendant
Medical Research Institute Clinical Innovator Award (082478; to N.A.C.).
NR 42
TC 31
Z9 33
U1 1
U2 8
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0091-6749
J9 J ALLERGY CLIN IMMUN
JI J. Allergy Clin. Immunol.
PD DEC
PY 2011
VL 128
IS 6
BP 1207
EP U526
DI 10.1016/j.jaci.2011.09.001
PG 10
WC Allergy; Immunology
SC Allergy; Immunology
GA 865WX
UT WOS:000298342700008
PM 21982113
ER
PT J
AU Udelson, JE
Bilsker, M
Hauptman, PJ
Sequeira, R
Thomas, I
O'Brien, T
Zimmer, C
Orlandi, C
Konstam, MA
AF Udelson, James E.
Bilsker, Martin
Hauptman, Paul J.
Sequeira, Rafael
Thomas, Ignatius
O'Brien, Terrence
Zimmer, Christopher
Orlandi, Cesare
Konstam, Marvin A.
TI A Multicenter, Randomized, Double-blind, Placebo-controlled Study of
Tolvaptan Monotherapy Compared to Furosemide and the Combination of
Tolvaptan and Furosemide in Patients With Heart Failure and Systolic
Dysfunction
SO JOURNAL OF CARDIAC FAILURE
LA English
DT Article
DE Heart failure; diuretics; vasopressin
ID LEFT-VENTRICULAR DYSFUNCTION; NEONATAL-RAT CARDIOMYOCYTE; VASOPRESSIN
ANTAGONIST; RENAL-FUNCTION; RECEPTOR ANTAGONIST; PROTEIN-SYNTHESIS;
DIURETIC THERAPY; ACTIVATION; SODIUM; TRIAL
AB Background: Increased vasopressin levels may be present in patient with chronic heart failure (HF) and contribute to pathophysiology through effects on the vasopressin V2 receptor. The presence of background diuretic therapy may confound evaluations of vasopressin receptor antagonists (VRA).
Methods and Results: Eligible patients had FIF (New York Heart Association Class 11411), systolic dysfunction (left ventricular ejection fraction <= 0.40) and signs of congestion (eg, edema, rales). At screening, patients were removed from baseline diuretic therapy and placed on a low-sodium diet (2 g/day). After a 2-day run-in period, 83 patients were randomized to placebo (n = 21), monotherapy with the vasopressin V2 receptor antagonist tolvaptan (TLV) 30 mg (n = 20), monotherapy with furosernide 80 mg (FURO, n = 22) or both TLV 30 mg and FURO 80 mg (n = 20) once daily for 7 days. Patients were on standard background therapy and not fluid-restricted throughout the study. A decrease in body weight of -1.37 +/- 1.61, -0.54 +/- 1.59, and -1.13 +/- 1.49 kg was observed versus baseline for TLV, FURO, and TLV+FURO, respectively, at day 8. At the same point, the placebo group showed a body weight increase of +0.72 +/- 2.42 kg versus baseline (P = .0006 for TLV versus placebo). Increases in urine volume from baseline were greater with TLV alone (2646 +/- 1503 mL/24 hours) than with FURO (894 +/- 853 mL/24 hours, P < .001), or PLC (423 +/- 786 mL/24 hours, P < .001), and similar to TLV+FURO (2585 2119 mL/24 hours). An increase in serum sodium within the normal range was also observed in TLV-treated patients (P < .02 versus placebo; P < .01 versus FURO). No changes in serum potassium, other laboratory values, or blood pressure were observed. TLV therapy was well tolerated.
Conclusions: In patients with HF and signs of volume overload, TLV monotherapy without concomitant loop diuretic therapy reduced body weight when compared to placebo without adverse changes in serum electrolytes, during a sodium restricted diet while on background medications including angiotensin-converting enzyme inhibitors and beta-blockers. (J Cardiac Fail 2011;17:973-981)
C1 [Udelson, James E.; Konstam, Marvin A.] Tufts Med Ctr, Div Cardiol, Boston, MA 02111 USA.
[Udelson, James E.; Konstam, Marvin A.] Tufts Med Ctr, CardioVasc Ctr, Boston, MA 02111 USA.
[Bilsker, Martin; Sequeira, Rafael] Univ Miami, Jackson Mem Hosp, Div Cardiol, Miami, FL 33136 USA.
[Hauptman, Paul J.] St Louis Univ, Sch Med, St Louis, MO USA.
[Thomas, Ignatius] Med Res Inst, Slidell, LA USA.
[O'Brien, Terrence] Ralph H Johnson Vet Adm Med Ctr, Charleston, SC USA.
[Zimmer, Christopher; Orlandi, Cesare] Otsuka Maryland Res Inst, Rockville, MD USA.
RP Udelson, JE (reprint author), Tufts Med Ctr, Div Cardiol, 750 Washington St,Box 70, Boston, MA 02111 USA.
EM JUdelson@tuftsmedicalcenter.org
NR 32
TC 22
Z9 24
U1 1
U2 5
PU CHURCHILL LIVINGSTONE INC MEDICAL PUBLISHERS
PI PHILADELPHIA
PA CURTIS CENTER, INDEPENDENCE SQUARE WEST, PHILADELPHIA, PA 19106-3399 USA
SN 1071-9164
J9 J CARD FAIL
JI J. Card. Fail.
PD DEC
PY 2011
VL 17
IS 12
BP 973
EP 981
DI 10.1016/j.cardfail.2011.08.005
PG 9
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 864AB
UT WOS:000298208300001
PM 22123358
ER
PT J
AU Goedecke, JH
Evans, J
Keswell, D
Stimson, RH
Livingstone, DEW
Hayes, P
Adams, K
Dave, JA
Victor, H
Levitt, NS
Lambert, EV
Walker, BR
Seckl, JR
Olsson, T
Kahn, SE
AF Goedecke, Julia H.
Evans, Juliet
Keswell, Dheshnie
Stimson, Roland H.
Livingstone, Dawn E. W.
Hayes, Philip
Adams, Kevin
Dave, Joel A.
Victor, Hendriena
Levitt, Naomi S.
Lambert, Estelle V.
Walker, Brian R.
Seckl, Jonathan R.
Olsson, Tommy
Kahn, Steven E.
TI Reduced Gluteal Expression of Adipogenic and Lipogenic Genes in Black
South African Women Is Associated with Obesity-Related Insulin
Resistance
SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
LA English
DT Article
ID ADIPOSE-TISSUE; IMPAIRED ADIPOGENESIS; BODY-FAT; DIFFERENTIATION;
SENSITIVITY; PROFILE; PREADIPOCYTES; INFLAMMATION; HEALTH; MUSCLE
AB Context: Black South African women are less insulin sensitive than their White counterparts, despite less central and greater peripheral fat deposition. We hypothesized that this paradox may be explained, in part, by differences in the adipogenic capacity of sc adipose tissue (SAT).
Objective: Our objective was to measure adipogenic and lipogenic gene expression in abdominal and gluteal SAT depots and determine their relationships with insulin sensitivity (S(I)) in South African women.
Participants and Design: Fourteen normal-weight [body mass index (BMI) <25 kg/m(2)] Black, 13 normal-weight White, 14 obese (BMI >30 kg/m(2)) Black, and 13 obese White premenopausal South African women participated in this cross-sectional study.
Main outcomes: S(I) (frequently sampled iv glucose tolerance test) in relation to expression of adipogenic and lipogenic genes in abdominal and gluteal SAT depots.
Results: With increasing BMI, Black women had less visceral fat (P = 0.03) and more abdominal (P = 0.017) and gynoid (P = 0.041) SAT but had lower S(I) (P < 0.01) than White women. The expression of adipogenic and lipogenic genes was proportionately lower with obesity in Black but not White women in the gluteal and deep SAT depots (P < 0.05 for ethnicity x BMI effect). In Black women only, the expression of these genes correlated positively with S(I) (all P < 0.05), independently of age and fat mass.
Conclusions: Obese Black women have reduced SAT expression of adipogenic and lipogenic genes compared with White women, which associates with reduced S(I). These findings suggest that obesity in Black women impairs SAT adipogenesis and storage, potentially leading to insulin resistance and increased risk of type 2 diabetes. (J Clin Endocrinol Metab 96: E2029-E2033, 2011)
C1 [Goedecke, Julia H.; Evans, Juliet; Keswell, Dheshnie; Victor, Hendriena; Lambert, Estelle V.] Univ Cape Town, Med Res Council Res Unit Exercise Sci & Sports Me, ZA-7725 Newlands, South Africa.
[Hayes, Philip; Adams, Kevin] Univ Cape Town, Dept Human Biol, ZA-7725 Newlands, South Africa.
[Dave, Joel A.; Levitt, Naomi S.] Univ Cape Town, Plast Surg Units, Dept Med, ZA-7725 Newlands, South Africa.
[Dave, Joel A.; Levitt, Naomi S.] Univ Cape Town, Endocrine Units, Dept Med, ZA-7725 Newlands, South Africa.
[Goedecke, Julia H.] S African MRC, ZA-7505 Tygerberg, South Africa.
[Stimson, Roland H.; Livingstone, Dawn E. W.; Walker, Brian R.; Seckl, Jonathan R.] Univ Edinburgh, Endocrinol Unit, Univ British Heart Fdn Ctr Cardiovasc Sci, Edinburgh EH16 4TJ, Midlothian, Scotland.
[Olsson, Tommy] Umea Univ, Dept Med, SE-90187 Umea, Sweden.
[Kahn, Steven E.] Univ Washington, Div Metab Endocrinol & Nutr, Dept Med, Seattle, WA 98108 USA.
[Kahn, Steven E.] Univ Washington, Div Metab Endocrinol & Nutr, Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA 98108 USA.
RP Goedecke, JH (reprint author), Univ Cape Town, Med Res Council Res Unit Exercise Sci & Sports Me, 3rd Floor Sports Sci Inst S Africa,POB 115, ZA-7725 Newlands, South Africa.
EM julia.goedecke@uct.ac.za
RI Seckl, Jonathan/C-3555-2013; Goedecke, Julia/J-8628-2013; Goedecke,
Julia/E-1820-2016
OI Goedecke, Julia/0000-0001-6795-4771; Goedecke,
Julia/0000-0001-6795-4771; Olsson, Tommy/0000-0001-7768-1076; Kahn,
Steven/0000-0001-7307-9002
FU South African Medical Research Council; International Atomic Energy
Agency; National Research Foundation of South Africa; Royal Society
SA-UK; University of Cape Town; British Heart Foundation; Wellcome
Trust; U.S. Department of Veterans Affairs
FX This work was supported by the South African Medical Research Council,
International Atomic Energy Agency, National Research Foundation of
South Africa and Royal Society SA-UK Science Networks Program,
University of Cape Town, British Heart Foundation, Wellcome Trust, and
U.S. Department of Veterans Affairs.
NR 20
TC 11
Z9 11
U1 0
U2 2
PU ENDOCRINE SOC
PI CHEVY CHASE
PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA
SN 0021-972X
J9 J CLIN ENDOCR METAB
JI J. Clin. Endocrinol. Metab.
PD DEC
PY 2011
VL 96
IS 12
BP E2029
EP E2033
DI 10.1210/jc.2011-1576
PG 5
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 865FA
UT WOS:000298295200016
PM 21956425
ER
PT J
AU Schafer, AL
Sellmeyer, DE
Schwartz, AV
Rosen, CJ
Vittinghoff, E
Palermo, L
Bilezikian, JP
Shoback, DM
Black, DM
AF Schafer, Anne L.
Sellmeyer, Deborah E.
Schwartz, Ann V.
Rosen, Clifford J.
Vittinghoff, Eric
Palermo, Lisa
Bilezikian, John P.
Shoback, Dolores M.
Black, Dennis M.
TI Change in Undercarboxylated Osteocalcin Is Associated with Changes in
Body Weight, Fat Mass, and Adiponectin: Parathyroid Hormone (1-84) or
Alendronate Therapy in Postmenopausal Women with Osteoporosis (the PaTH
Study)
SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
LA English
DT Article
ID VITAMIN-K STATUS; SERUM OSTEOCALCIN; PLASMA-GLUCOSE; METABOLISM;
PROTEIN; MEN
AB Context: The undercarboxylated form of the osteoblast-secreted protein osteocalcin has favorable effects on fat and glucose metabolism in mice. In human subjects, cross-sectional studies suggest a relevant association.
Objective: We investigated whether changes in undercarboxylated osteocalcin (ucOC) during osteoporosis treatment are associated with changes in metabolic parameters.
Design, Setting, Participants, and Interventions: We measured ucOC in sera from a subset of osteoporotic postmenopausal women who were treated with PTH(1-84) or alendronate (n = 64 and n = 33, respectively) during the Parathyroid Hormone and Alendronate study.
Main Outcome Measures: We measured serum adiponectin, leptin, and insulin and analyzed existing data on body weight, fat mass, and serum glucose concentration. Three-month changes in ucOC levels were evaluated as predictors of 12-month changes in indices of fat and glucose metabolism.
Results: ucOC levels increased with PTH(1-84) and decreased with alendronate administration (P <= 0.01 for both treatment groups). Three-month change in ucOC was inversely associated with 12-month changes in body weight (standardized beta = -0.25, P = 0.04) and fat mass (beta = -0.23, P = 0.06), after adjustment for the treatment group. Three-month change in ucOC was positively associated with a 12-month change in adiponectin (beta = 0.30, P = 0.01), independent of change in fat mass. There were no interactions between treatment and change in ucOC on changes in weight, fat mass, or adiponectin.
Conclusions: PTH(1-84) increases and alendronate decreases ucOC levels. Changes in ucOC induced by PTH(1-84) and alendronate are associated with changes in metabolic indices. These associations are consistent with observations from animal models and support a role for ucOC in the skeletal regulation of energy metabolism in humans. (J Clin Endocrinol Metab 96: E1982-E1989, 2011)
C1 [Schafer, Anne L.; Shoback, Dolores M.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA.
[Schwartz, Ann V.; Vittinghoff, Eric; Palermo, Lisa; Black, Dennis M.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA.
[Schafer, Anne L.; Shoback, Dolores M.] San Francisco VA Med Ctr, Med Serv, Endocrine Res Unit, San Francisco, CA 94121 USA.
[Sellmeyer, Deborah E.] Johns Hopkins Univ, Dept Med, Baltimore, MD 21224 USA.
[Rosen, Clifford J.] Maine Med Ctr, Res Inst, Scarborough, ME 04074 USA.
[Bilezikian, John P.] Columbia Univ, Coll Phys & Surg, New York, NY 10032 USA.
RP Schafer, AL (reprint author), 4150 Clement St,Box 111N, San Francisco, CA 94121 USA.
EM anne.schafer@ucsf.edu
FU National Institute of Arthritis and Musculoskeletal and Skin Diseases
[NIAMS-045, N01-AR-9-2245]; Veterans Affairs; Department of Veterans
Affairs; Amgen; Novartis; Merck; Roche
FX The PaTH study was supported by a contract with the National Institute
of Arthritis and Musculoskeletal and Skin Diseases (NIAMS-045,
N01-AR-9-2245; to D.M.B.). The study drugs were supplied by NPS
Pharmaceuticals, Inc. [PTH(1-84)] and Merck & Co., Inc. (alendronate).
The authors have full control of all primary data. This ancillary study
was supported by the Veterans Affairs Research Enhancement Award
Program. Additional support for A.L.S. came from the Department of
Veterans Affairs, through a Health Issues of Women Veterans Fellowship
and a Career Development Award.; D.E.S. has received research support
from Amgen and Novartis. A.V.S. has received research support from
Merck. L.P. has consulted for NPS Pharmaceuticals, Inc. and Nycomed.
D.M.B. has received research support from Amgen, Merck, Novartis, and
Roche and has consulted for Nycomed.
NR 20
TC 56
Z9 60
U1 0
U2 1
PU ENDOCRINE SOC
PI CHEVY CHASE
PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA
SN 0021-972X
J9 J CLIN ENDOCR METAB
JI J. Clin. Endocrinol. Metab.
PD DEC
PY 2011
VL 96
IS 12
BP E1982
EP E1989
DI 10.1210/jc.2011-0587
PG 8
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 865FA
UT WOS:000298295200009
PM 21994958
ER
PT J
AU Bloch, MJ
Basile, JN
AF Bloch, Michael J.
Basile, Jan N.
TI UK Guidelines Call for Routine 24-Hour Ambulatory Blood Pressure
Monitoring in All Patients to Make the Diagnosis of HypertensionuNot
Ready for Prime Time in the United States
SO JOURNAL OF CLINICAL HYPERTENSION
LA English
DT Editorial Material
C1 [Bloch, Michael J.] St Marys Reg Med Ctr, Risk Reduct Ctr, Reno, NV 89503 USA.
[Bloch, Michael J.] Univ Nevada, Sch Med, Dept Internal Med, Reno, NV 89557 USA.
[Basile, Jan N.] Med Univ S Carolina, Ralph H Johnson VA Med Ctr, Seinsheimer Cardiovasc Hlth Program, Div Gen Internal Med Geriatr, Charleston, SC 29425 USA.
RP Bloch, MJ (reprint author), St Marys Reg Med Ctr, Risk Reduct Ctr, 645 N Arlington St,Suite 460, Reno, NV 89503 USA.
EM mbloch@aol.com
NR 1
TC 6
Z9 6
U1 0
U2 1
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1524-6175
J9 J CLIN HYPERTENS
JI J. Clin. Hypertens.
PD DEC
PY 2011
VL 13
IS 12
BP 871
EP 872
DI 10.1111/j.1751-7176.2011.00551.x
PG 2
WC Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA 859DJ
UT WOS:000297854700003
PM 22142345
ER
PT J
AU Patel, M
Gonzalez, R
Halford, C
Lewinski, MA
Landaw, EM
Churchill, BM
Haake, DA
AF Patel, Mayank
Gonzalez, Rodrigo
Halford, Colin
Lewinski, Michael A.
Landaw, Elliot M.
Churchill, Bernard M.
Haake, David A.
TI Target-Specific Capture Enhances Sensitivity of Electrochemical
Detection of Bacterial Pathogens
SO JOURNAL OF CLINICAL MICROBIOLOGY
LA English
DT Article
ID GENOMIC DNA; URINE; UROPATHOGENS; GUIDELINES; SPECIMENS; DIAGNOSIS;
WOMEN
AB We report the concentration and purification of bacterial 16S rRNA by the use of a biotinylated DNA target-specific capture (TSC) probe. For both cultivated bacterial and urine specimens from urinary tract infection patients, TSC resulted in a 5- to 8-fold improvement in the sensitivity of bacterial detection in a 16S rRNA electrochemical sensor assay.
C1 [Haake, David A.] VA Greater Los Angeles Healthcare Syst, Div Infect Dis, Los Angeles, CA 90073 USA.
[Patel, Mayank; Halford, Colin; Churchill, Bernard M.; Haake, David A.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Urol, Los Angeles, CA 90095 USA.
[Landaw, Elliot M.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Biomath, Los Angeles, CA 90095 USA.
[Lewinski, Michael A.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pathol & Lab Med, Los Angeles, CA 90095 USA.
[Haake, David A.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA.
[Haake, David A.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Microbiol Immunol & Mol Genet, Los Angeles, CA 90095 USA.
RP Haake, DA (reprint author), VA Greater Los Angeles Healthcare Syst, Div Infect Dis, 111F,11301 Wilshire Blvd, Los Angeles, CA 90073 USA.
EM DHAAKE@UCLA.EDU
FU National Institute of Allergy and Infectious Diseases [AI075565]; Wendy
and Ken Ruby Fund for Excellence in Pediatric Urology Research
FX This study was supported by Cooperative Agreement Award AI075565 (to
D.A.H.) from the National Institute of Allergy and Infectious Diseases
and by the Wendy and Ken Ruby Fund for Excellence in Pediatric Urology
Research. B.M.C. is the Judith and Robert Winston Chair in Pediatric
Urology.
NR 15
TC 5
Z9 5
U1 0
U2 5
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0095-1137
J9 J CLIN MICROBIOL
JI J. Clin. Microbiol.
PD DEC
PY 2011
VL 49
IS 12
BP 4293
EP 4296
DI 10.1128/JCM.01261-11
PG 4
WC Microbiology
SC Microbiology
GA 862SC
UT WOS:000298113400043
PM 21940468
ER
PT J
AU Peters, ME
Vaidya, V
Drye, LT
Rosenberg, PB
Martin, BK
Porsteinsson, AP
Frangakis, CE
Mintzer, J
Weintraub, D
Schneider, LS
Rabins, PV
Munro, CA
Meinert, CL
Lyketsos, CG
Dimitri, A
AF Peters, Matthew E.
Vaidya, Vijay
Drye, Lea T.
Rosenberg, Paul B.
Martin, Barbara K.
Porsteinsson, Anton P.
Frangakis, Constantine E.
Mintzer, Jacobo
Weintraub, Daniel
Schneider, Lon S.
Rabins, Peter V.
Munro, Cynthia A.
Meinert, Curtis L.
Lyketsos, Constantine G.
Dimitri, Avramopoulos
CA DIADS-2 Res Grp
TI Sertraline for the Treatment of Depression in Alzheimer Disease: Genetic
Influences
SO JOURNAL OF GERIATRIC PSYCHIATRY AND NEUROLOGY
LA English
DT Article
DE Alzheimer disease; sertraline; depression; randomized trial; dementia;
antidepressant
ID DOUBLE-BLIND; NEUROPSYCHIATRIC SYMPTOMS; CLINICAL-TRIAL; POLYMORPHISM;
DEMENTIA; PREVALENCE; PSYCHOSIS; EFFICACY; CRITERIA
AB Objective. To assess the potential for genetic influences on sertraline treatment efficacy for depression of Alzheimer disease (dAD). Four functional genetic variants were studied: 2 serotonin receptors (HTR2A-T102C and HTR2C-Cys23Ser), the serotonin transporter (5HTT-LPR), and brain-derived neurotrophic factor (BDNF-Val66Met). Treatment response by genotype was measured by (1) the modified Alzheimer's Disease Cooperative Study Clinical Global Impression of Change, (2) the Cornell scale for Depression in Dementia, and (3) remission of depression. Methods. We utilized data from the Depression in Alzheimer's Disease Study 2 (DIADS-2), a 24-week, randomized, multicenter trial showing no significant treatment effect of sertraline on dAD. Proportional odds logistic regression and mixed effects models were used to examine the above mentioned outcome measures. Results. No significant interactions were seen between any of the genetic polymorphisms and the selected outcomes above at 12 or 24 weeks. Discussion. Treatment outcomes in the DIADS-2 trial were not significantly influenced by genetic variation at the loci that were assessed. Future studies should continue to examine the interaction of depression-related genetic variants with antidepressant treatment in Alzheimer disease patients with depression.
C1 [Peters, Matthew E.; Rosenberg, Paul B.; Rabins, Peter V.; Munro, Cynthia A.; Lyketsos, Constantine G.; Dimitri, Avramopoulos] Johns Hopkins Univ, Baltimore, MD 21224 USA.
[Vaidya, Vijay; Drye, Lea T.; Martin, Barbara K.; Frangakis, Constantine E.; Meinert, Curtis L.] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA.
[Porsteinsson, Anton P.] Univ Rochester, Rochester, NY USA.
[Mintzer, Jacobo] Med Univ S Carolina, Charleston, SC 29425 USA.
[Mintzer, Jacobo] Ralph H Johnson VA Med Ctr, Charleston, SC USA.
[Weintraub, Daniel] Univ Penn, Philadelphia, PA 19104 USA.
[Schneider, Lon S.] Univ So Calif, Keck Sch Med, Los Angeles, CA 90033 USA.
RP Lyketsos, CG (reprint author), Johns Hopkins Univ, 5300 Alpha Commons Dr, Baltimore, MD 21224 USA.
EM kostas@jhmi.edu
OI Drye, Lea/0000-0002-2964-1878
FU National Institute of Mental Health [1U01MH066136, 1U01MH068014,
1U01MH066174, 1U01MH066175, 1U01MH066 176, 1U01MH066177]; National
Institutes of Health; Michael J. Fox Foundation for Parkinson's
Research; Baxter; Bristol-Myers Squibb; Elan Pharmaceuticals; Janssen
Alzheimer Initiative; Medivation Inc; Pfizer Inc; Toyama; Eisai Inc; Eli
Lilly; Forest Laboratories; Janssen; GlaxoSmithKline; Merck; Mitsubishi;
Myriad; Neurochem; Ono Pharma; Wyeth; Alzheimer's Disease Cooperative
Study Group [NIA-U01AG10483]; Alzheimer's Disease Neuroimaging
Initiative [NIA-U01AG024904]; ADAPT-FS [NIA-U01AG15477]]; CitAD
[NIMH-R01AG031348]; DIADS-2 [NIMH-U01MH066177]; NIA; Pfizer; Janssen
Alzheimer's Immunotherapy; Genentech; NIMH; Associated Jewish Federation
of Baltimore; Weinberg Foundation; Forest; Eisai; Astra-Zeneca; Lilly;
Ortho-McNeil; BristolMyers; Novartis; National Football League; Elan
FX The authors disclosed receipt of the following financial support for the
research, authorship and/or publication of this article: This work was
supported by National Institute of Mental Health, 1U01MH066136,
1U01MH068014, 1U01MH066174, 1U01MH066175, 1U01MH066 176, 1U01MH066177.
DW has received grants or research funding from National Institutes of
Health and the Michael J. Fox Foundation for Parkinson's Research. APP
received research support from Baxter, Bristol-Myers Squibb, Elan
Pharmaceuticals, Janssen Alzheimer Initiative, Medivation Inc, Pfizer
Inc, Toyama, Eisai Inc, Eli Lilly, Forest Laboratories, Janssen,
GlaxoSmithKline, Merck, Mitsubishi, Myriad, Neurochem, Ono Pharma,
Wyeth, the Alzheimer's Disease Cooperative Study Group (NIA-U01AG10483),
Alzheimer's Disease Neuroimaging Initiative NIA-U01AG024904, ADAPT-FS
(NIA-U01AG15477], CitAD study (NIMH-R01AG031348), and DIADS-2 study
(NIMH-U01MH066177). JM received research support from NIA, Eli Lilly,
Pfizer, Janssen Alzheimer's Immunotherapy, and Genentech. CGL received
grant support (research or CME) from NIMH, NIA, Associated Jewish
Federation of Baltimore, Weinberg Foundation, Forest, GlaxoSmithKline,
Eisai, Pfizer, Astra-Zeneca, Lilly, Ortho-McNeil, BristolMyers,
Novartis, National Football League, and Elan.
NR 34
TC 6
Z9 7
U1 0
U2 2
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0891-9887
EI 1552-5708
J9 J GERIATR PSYCH NEUR
JI J. Geriatr. Psychiatry Neurol.
PD DEC
PY 2011
VL 24
IS 4
BP 222
EP 228
DI 10.1177/0891988711422527
PG 7
WC Geriatrics & Gerontology; Clinical Neurology; Psychiatry
SC Geriatrics & Gerontology; Neurosciences & Neurology; Psychiatry
GA 873BJ
UT WOS:000298855400007
PM 22228829
ER
PT J
AU Forrest, GN
Arnold, RS
Gammie, JS
Gilliam, BL
AF Forrest, Graeme N.
Arnold, Ryan S.
Gammie, James S.
Gilliam, Bruce L.
TI Single center experience of a vancomycin resistant enterococcal
endocarditis cohort
SO JOURNAL OF INFECTION
LA English
DT Article
DE Vancomycin resistant enterococci; Hemodialysis; Organ transplantation;
Endocarditis
ID INFECTIVE ENDOCARDITIS; STAPHYLOCOCCUS-AUREUS; RISK-FACTORS;
ANTIMICROBIAL THERAPY; BACTEREMIA; FAECALIS; SAFETY; SURVEILLANCE;
DAPTOMYCIN; DIAGNOSIS
AB Objectives: Vancomycin resistant enterococcus (VRE) infective endocarditis (IE) is an increasing nosocomial problem. We describe the clinical management and outcomes of a cohort of patients with VRE IE at a tertiary endocarditis referral center.
Methods: Retrospective review of all proven cases of VRE IE, from July 2000 through January 2008 was performed. Demographics, comorbidities and therapeutic details were collected and analyzed to assess for risk factors and clinical outcomes.
Results: Fifty cases of VRE IE were identified: 26 (52%) were Enterococcus faecium and 24 were Enterococcus faecalis. Vancomycin resistant E. faecalis IE was associated with the presence of a central venous line, liver transplantation, and mitral valve infection while VR E. faecium IE was significantly associated with tricuspid valve infection (p = 0.03). The median duration of bacteremia was 14 days for E. faecium and 4 days for E. faecalis, respectively (p = 0.002). Factors associated with mortality on bivariate analysis were hemodialysis via a catheter with VR E. faecium (OR = 11.7. CI 1.1-122, p = 0.02) and liver transplantation with both species. Combination antimicrobial therapy (OR = 0.5 CI = 0.06-3.2, p = 0.1) and valve surgery (OR 1.3 CI 0.8-20, p = 0.02) trended toward improved survival with E. faecalis on bivariate analysis. On multivariate analysis, none of the associations were significant.
Conclusions: Hemodialysis and liver transplantation were factors associated with acquisition of VRE IE. There was a higher mortality and prolonged bacteremia with VR E. faecium IE than VR E. faecalis IE. Although not significant, combination antimicrobial therapy and surgical intervention trended toward improved survival. Published by Elsevier Ltd on behalf of The British Infection Association.
C1 [Forrest, Graeme N.] Portland VA Med Ctr, Div Infect Dis, Portland, OR 97239 USA.
[Arnold, Ryan S.] Univ Maryland, Sch Med, Div Infect Dis, Baltimore, MD 21201 USA.
[Gammie, James S.] Univ Maryland, Sch Med, Div Cardiac Surg, Baltimore, MD 21201 USA.
[Gilliam, Bruce L.] Univ Maryland, Sch Med, Inst Human Virol, Baltimore, MD 21201 USA.
RP Forrest, GN (reprint author), Portland VA Med Ctr, Div Infect Dis, 3710 SW US Vet Hosp Rd,P3-ID, Portland, OR 97239 USA.
EM forrestg@ohsu.edu
FU Cubist Pharmaceuticals, Inc.
FX Graeme Forrest has received research funding from Cubist
Pharmaceuticals, Inc. Bruce Gilliam has been a speaker for Cubist
Pharmaceuticals, Inc.
NR 26
TC 9
Z9 10
U1 0
U2 1
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0163-4453
J9 J INFECTION
JI J. Infect.
PD DEC
PY 2011
VL 63
IS 6
BP 420
EP 428
DI 10.1016/j.jinf.2011.08.014
PG 9
WC Infectious Diseases
SC Infectious Diseases
GA 869GP
UT WOS:000298586100187
PM 21920382
ER
PT J
AU Harder, LH
Chen, S
Baker, DG
Chow, B
McFall, M
Saxon, A
Smith, MW
AF Harder, Laura H.
Chen, Shuo
Baker, Dewleen G.
Chow, Bruce
McFall, Miles
Saxon, Andrew
Smith, Mark W.
TI The Influence of Posttraumatic Stress Disorder Numbing and Hyperarousal
Symptom Clusters in the Prediction of Physical Health Status in Veterans
With Chronic Tobacco Dependence and Posttraumatic Stress Disorder
SO JOURNAL OF NERVOUS AND MENTAL DISEASE
LA English
DT Article
DE Health-related quality of life; PTSD; numbing; hyperarousal; avoidance;
smoking; tobacco; SF-36
ID QUALITY-OF-LIFE; ADMINISTERED PTSD SCALE; WAR VETERANS; PRIMARY-CARE;
NICOTINE DEPENDENCE; VIETNAM VETERANS; FEMALE VETERANS; OLDER-ADULTS;
SMOKING; RISK
AB Smoking and PTSD are predictors of poor physical health status. This study examined the unique contribution of PTSD symptoms in the prediction of the SF-36 physical health status subscales accounting for cigarette smoking, chronic medical conditions, alcohol and drug use disorders, and depression. This study examined baseline interview and self-report data from a national tobacco cessation randomized, controlled trial (Veterans Affairs Cooperative Study 519) that enrolled tobacco-dependent veterans with chronic PTSD (N = 943). A series of blockwise multiple regression analyses indicated that PTSD numbing and hyperarousal symptom clusters explained a significant proportion of the variance across all physical health domains except for the Physical Functioning subscale, which measures impairments in specific physical activities. Our findings further explain the impact of PTSD on health status by exploring the way PTSD symptom clusters predict self-perceptions of health, role limitations, pain, and vitality.
C1 [Harder, Laura H.; Baker, Dewleen G.] VA San Diego Healthcare Syst, San Diego, CA 92161 USA.
[Chen, Shuo; Smith, Mark W.] Vet Affairs Palo Alto Hlth Care Syst, Hlth Econ Resource Ctr, Menlo Pk, CA USA.
[Baker, Dewleen G.] VA San Diego, Vet Affairs Ctr Excellence Stress & Mental Hlth, San Diego, CA USA.
[Baker, Dewleen G.] Univ Calif San Diego, Dept Psychiat, San Diego, CA 92103 USA.
[Chow, Bruce] Vet Affairs Palo Alto Hlth Care Syst, Cooperat Studies Program, Mountain View, CA USA.
[McFall, Miles; Saxon, Andrew] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA.
[McFall, Miles; Saxon, Andrew] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA.
[Smith, Mark W.] Stanford Med Sch, Ctr Primary Care & Outcomes Res, Stanford, CA USA.
RP Harder, LH (reprint author), VA San Diego Healthcare Syst, 3350 La Jolla Village Dr 151, San Diego, CA 92161 USA.
EM Laura.Harder@va.gov
RI Smith, Mark/G-1522-2012; Schueter, nicos/A-3625-2014
OI Smith, Mark/0000-0002-4582-9088;
FU Clinical Science Research and Development Service, US Department of
Veterans Affairs [519, NCT00118534]; Tobacco-Related Disease Research
Program [19DT-0003]; Department of Defense (Navy BUMED) [CDMRP PTO
090738]; DVA [HSRD SDR09-128]; VA Center of Excellence for Stress and
Mental Health; VA Merit [821]; NIAAA [1 P20 AA017839-01]; NIDA [5 U10
DA013714-08]; TRA [05-081]; CPS [636F4574119]
FX This study was supported by the Cooperative Studies Program of the
Clinical Science Research and Development Service, US Department of
Veterans Affairs (DVA; CSP #519, NCT00118534). Ms. Harder is supported
in part by the Tobacco-Related Disease Research Program 19DT-0003. Dr.
Baker receives research support from the Department of Defense (Navy
BUMED and CDMRP PTO 090738) and the DVA (HSR&D SDR09-128) and is
supported in part by the VA Center of Excellence for Stress and Mental
Health. Dr. McFall receives research support from VA Merit #821 and DVA.
Dr. Saxon receives research support from NIAAA (1 P20 AA017839-01) and
NIDA (5 U10 DA013714-08). Dr. Smith is supported in part by TRA 05-081
and CPS #636F4574119.
NR 43
TC 11
Z9 11
U1 3
U2 7
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0022-3018
J9 J NERV MENT DIS
JI J. Nerv. Ment. Dis.
PD DEC
PY 2011
VL 199
IS 12
BP 940
EP 945
DI 10.1097/NMD.0b013e3182392bfb
PG 6
WC Clinical Neurology; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA 863CD
UT WOS:000298139500008
PM 22134452
ER
PT J
AU Bekelman, DB
Nowels, CT
Retrum, JH
Allen, LA
Shakar, S
Hutt, E
Heyborne, T
Main, DS
Kutner, JS
AF Bekelman, David B.
Nowels, Carolyn T.
Retrum, Jessica H.
Allen, Larry A.
Shakar, Simon
Hutt, Evelyn
Heyborne, Theresa
Main, Deborah S.
Kutner, Jean S.
TI Giving Voice to Patients' and Family Caregivers' Needs in Chronic Heart
Failure: Implications for Palliative Care Programs
SO JOURNAL OF PALLIATIVE MEDICINE
LA English
DT Article
ID PHYSICAL IMPAIRMENT; COLLABORATIVE CARE; CHRONIC ILLNESS; DEPRESSION;
CANCER; ASSOCIATION; MANAGEMENT; STATEMENT; AMERICAN; SERVICES
AB Background: The American College of Cardiology Foundation/American Heart Association (ACC/AHA) Guidelines for the Management of Heart Failure recommend palliative care in the context of Stage D HF or at the end of life. Previous studies related to heart failure (HF) palliative care provide useful information about patients' experiences, but they do not provide concrete guidance for what palliative care needs are most important and how a palliative care program should be structured.
Objectives: Describe HF patients' and their family caregivers' major concerns and needs. Explore whether, how, and when palliative care would be useful to them.
Design and participants: Qualitative study using in-depth interviews of 33 adult outpatients with symptomatic HF identified using purposive sampling and 20 of their family caregivers.
Approach: Interviews were transcribed verbatim and analyzed using the constant comparative method.
Key results: Overall, patients and caregivers desired early support adjusting to the limitations and future course of illness, relief of a number of diverse symptoms, and the involvement of family caregivers using a team approach. A diverse group of participants desired these elements of palliative care early in illness, concurrent with their disease-specific care, coordinated by a provider who understood their heart condition and knew them well. Some diverging needs and preferences were found based on health status and age.
Conclusions: HF patients and their family caregivers supported early integration of palliative care services, particularly psychosocial support and symptom control, using a collaborative team approach. Future research should test the feasibility and effectiveness of integrating such a program into routine HF care.
C1 [Bekelman, David B.; Hutt, Evelyn] Dept Vet Affairs Med Ctr, Res Sect, Denver, CO USA.
[Bekelman, David B.; Hutt, Evelyn] Dept Vet Affairs Med Ctr, Genet Sect, Denver, CO USA.
[Bekelman, David B.; Nowels, Carolyn T.; Hutt, Evelyn; Kutner, Jean S.] Univ Colorado, Sch Med, Dept Med, Div Gen Internal Med, Aurora, CO USA.
[Bekelman, David B.; Allen, Larry A.] Colorado Cardiovasc Outcomes Res, Denver, CO USA.
[Retrum, Jessica H.] Univ Colorado, Sch Publ Affairs, Denver, CO 80202 USA.
[Allen, Larry A.; Shakar, Simon] Univ Colorado, Sch Med, Dept Med, Div Cariol, Aurora, CO USA.
[Main, Deborah S.] Univ Colorado, Dept Hlth & Behav Sci, Denver, CO 80202 USA.
RP Bekelman, DB (reprint author), Denver VA Med Ctr, 1055 Clermont St, Denver, CO 80220 USA.
EM david.bekelman@va.gov
FU University of Colorado Denver Hartford/Jahnigen Center for Excellence in
Geriatric Medicine; Mordecai Palliative Care Grants Fund; Department of
Veterans Affairs [HSRD CDA 08-022]
FX This research was funded by the University of Colorado Denver
Hartford/Jahnigen Center for Excellence in Geriatric Medicine and the
Mordecai Palliative Care Grants Fund. Dr. Bekelman is funded by a
Department of Veterans Affairs Career Development Award (HSR&D CDA
08-022). The funding organizations had no role in any part of the study.
We thank Sheldon Gottlieb, MD, for contributing to the title, and Traci
Yamashita, MA, for assistance with survey data. The views in this
article are those of the authors and do not necessarily reflect the
views of the Department of Veterans Affairs.
NR 40
TC 34
Z9 34
U1 0
U2 6
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1096-6218
J9 J PALLIAT MED
JI J. Palliat. Med.
PD DEC
PY 2011
VL 14
IS 12
BP 1317
EP 1324
DI 10.1089/jpm.2011.0179
PG 8
WC Health Care Sciences & Services
SC Health Care Sciences & Services
GA 863EO
UT WOS:000298145800010
PM 22107107
ER
PT J
AU Krimshtein, NS
Luhrs, CA
Puntillo, KA
Cortez, TB
Livote, EE
Penrod, JD
Nelson, JE
AF Krimshtein, Nina S.
Luhrs, Carol A.
Puntillo, Kathleen A.
Cortez, Therese B.
Livote, Elayne E.
Penrod, Joan D.
Nelson, Judith E.
TI Training Nurses for Interdisciplinary Communication with Families in the
Intensive Care Unit: An Intervention
SO JOURNAL OF PALLIATIVE MEDICINE
LA English
DT Article
ID OF-LIFE CARE; PALLIATIVE CARE; CRITICALLY-ILL; MORAL DISTRESS;
FOLLOW-UP; END; SKILLS; PHYSICIANS; EFFICACY; MEETINGS
AB Background: Critical care nurse communication training has largely been limited to didactic materials, interactive training for nurse supervisors, or brief participatory learning programs within the context of comprehensive end-of-life care educational seminars. Preliminary evidence suggests that an interactive approach can also be effective in communication skills training for intensive care unit (ICU) nurses.
Methods: We implemented a 1-day educational intervention in five acute care hospitals within Veterans Integrated Service Network (VISN) 3 (New York-New Jersey region) of the Department of Veterans Affairs and focused solely on communication skills and targeted specifically to nurses providing bedside care for critically ill patients. A "learner centered'' approach to skills training that has several integral components was employed. Among these are: a cognitive, evidence-based foundation upon which to build new skills; a method such as role-play that allows participants to practice newly learned skills; and an affective component, during which trainees can freely discuss their impressions of the exercise or explore difficulties that may have been encountered. Before and after the program we conducted a detailed assessment of participants' self-rated communication skills and of the techniques and materials we used.
Results and conclusions: Post-program responses documented significant improvement in self-evaluated skills for each of the core tasks we assessed. Evidence suggests that communication with patients and families in the ICU can be most effectively approached in an interdisciplinary way. For nurses to fully realize their potential for optimal communication as members of the multidisciplinary team, they must be equipped with the necessary skills. We believe this new program helps to expand the range of approaches for training nurses in essential communication skills.
C1 [Krimshtein, Nina S.; Nelson, Judith E.] Mt Sinai Sch Med, Div Pulm & Crit Care, New York, NY 10029 USA.
[Luhrs, Carol A.; Cortez, Therese B.] New York Harbor Healthcare Syst, Dept Vet Affairs, Brooklyn, NY USA.
[Puntillo, Kathleen A.] Univ Calif San Francisco, Dept Physiol Nursing, San Francisco, CA USA.
[Livote, Elayne E.; Penrod, Joan D.] James J Peters VA Med Ctr, Bronx, NY USA.
RP Nelson, JE (reprint author), Mt Sinai Sch Med, Div Pulm & Crit Care, 1 Gustave Levy Pl, New York, NY 10029 USA.
EM judith.nelson@mountsinai.org
FU Veterans Integrated Service Network (VISN); Center for the Study of
Health Care Across Systems and Sites of Care at the James J. Peters VA
Medical Center, Bronx, New York; National Institute on Aging [AG04234]
FX This project was supported by the Veterans Integrated Service Network
(VISN) 3 Palliative Care Program and by the Center for the Study of
Health Care Across Systems and Sites of Care at the James J. Peters VA
Medical Center, Bronx, New York. Additional organizational support for
the program was provided by nursing leadership within the hospitals
participating in the program. Dr. Nelson is the recipient of a K07
Academic Career Leadership Award (AG04234) from the National Institute
on Aging.
NR 41
TC 32
Z9 32
U1 3
U2 17
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1096-6218
J9 J PALLIAT MED
JI J. Palliat. Med.
PD DEC
PY 2011
VL 14
IS 12
BP 1325
EP 1332
DI 10.1089/jpm.2011.0225
PG 8
WC Health Care Sciences & Services
SC Health Care Sciences & Services
GA 863EO
UT WOS:000298145800011
PM 22132740
ER
PT J
AU Stone, SC
Mohanty, S
Grudzen, CR
Shoenberger, J
Asch, S
Kubricek, K
Lorenz, KA
AF Stone, Susan C.
Mohanty, Sarita
Grudzen, Corita R.
Shoenberger, Jan
Asch, Steve
Kubricek, Katrina
Lorenz, Karl A.
TI Emergency Medicine Physicians' Perspectives of Providing Palliative Care
in an Emergency Department
SO JOURNAL OF PALLIATIVE MEDICINE
LA English
DT Article
ID CONTROLLED-TRIAL; OF-LIFE; CONSULTATION; COST
AB This study describes emergency physicians' perspectives on the challenges and benefits to providing palliative care in an academic, urban, public hospital in Los Angeles. Participants underwent a semi-structured interview on their training and experiences related to palliative care, perceptions of providing palliative care, and their recommendations for education and training in this area. Overall, respondents felt that palliative care is not prioritized appropriately, leading patients to be unaware of their options for end-of-life care. Providing educational materials and courses that have been developed from the ED perspective should be included in ongoing continuing medical education. Having a palliative care team that is responsive to the needs of the ED will further enhance collaboration with the ED. Future research should focus on understanding the range of benefits to having palliative care in the ED.
C1 [Stone, Susan C.] Univ Calif Los Angeles, Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA.
[Lorenz, Karl A.] Univ Calif Los Angeles, W Los Angeles VA, Los Angeles, CA 90048 USA.
[Shoenberger, Jan] Univ So Calif, Keck Sch Med, Los Angeles, CA 90033 USA.
[Grudzen, Corita R.] Mt Sinai Sch Med, New York, NY USA.
[Asch, Steve] Stanford Univ, Sch Med, Palo Alto VA, Stanford, CA 94305 USA.
[Kubricek, Katrina] Childrens Hosp Los Angeles, Los Angeles, CA USA.
RP Stone, SC (reprint author), Univ Calif Los Angeles, Cedars Sinai Med Ctr, 8700 Beverly Blvd, Los Angeles, CA 90048 USA.
EM sstone.90064@yahoo.com
OI Grudzen, Corita/0000-0003-3039-8497
FU Archstone Foundation
FX This study was funded by the Archstone Foundation.
NR 15
TC 20
Z9 20
U1 1
U2 4
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1096-6218
J9 J PALLIAT MED
JI J. Palliat. Med.
PD DEC
PY 2011
VL 14
IS 12
BP 1333
EP 1338
DI 10.1089/jpm.2011.0106
PG 6
WC Health Care Sciences & Services
SC Health Care Sciences & Services
GA 863EO
UT WOS:000298145800012
PM 22136262
ER
PT J
AU Moore, MS
AF Moore, Mary S.
TI Re: A Simple Thank You
SO JOURNAL OF PERIANESTHESIA NURSING
LA English
DT Letter
C1 S Texas Vet Healthcare Syst, San Antonio, TX USA.
RP Moore, MS (reprint author), S Texas Vet Healthcare Syst, San Antonio, TX USA.
NR 2
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1089-9472
J9 J PERIANESTH NURS
JI J. PeriAnesthesia Nurs.
PD DEC
PY 2011
VL 26
IS 6
BP 370
EP 370
DI 10.1016/j.jopan.2011.09.010
PG 1
WC Nursing
SC Nursing
GA 864WM
UT WOS:000298271200002
PM 22099126
ER
PT J
AU Mikuls, TR
LeVan, TD
Sayles, H
Yu, F
Caplan, L
Cannon, GW
Kerr, GS
Reimold, AM
Johnson, DS
Thiele, GM
AF Mikuls, Ted R.
LeVan, Tricia D.
Sayles, Harlan
Yu, Fang
Caplan, Liron
Cannon, Grant W.
Kerr, Gail S.
Reimold, Andreas M.
Johnson, Dannette S.
Thiele, Geoffrey M.
TI Soluble CD14 and CD14 Polymorphisms in Rheumatoid Arthritis
SO JOURNAL OF RHEUMATOLOGY
LA English
DT Article
DE SOLUBLE CD14; RHEUMATOID ARTHRITIS; ACUTE-PHASE RESPONSE; DISEASE
SEVERITY; DISEASE ACTIVITY; POLYMORPHISMS
ID SINGLE-NUCLEOTIDE POLYMORPHISMS; DISEASE-ACTIVITY; LIPOPOLYSACCHARIDE;
ASSOCIATION; PERIODONTITIS; PROTEIN; PLASMA; LPS; VALIDATION; ACTIVATION
AB Objective. Soluble CD14 (sCD14) is involved in innate immune responses and has been implicated to play a pathogenic role in inflammatory diseases including rheumatoid arthritis (RA). No studies have identified the specific factors that influence sCD14 expression in RA. We used cross-sectional data to evaluate the relationship of sCD14 concentrations in RA with measures of disease activity and severity. We hypothesized that sCD14 concentrations would be elevated in subjects with greater RA disease severity and markers of disease activity, compared to subjects with lower disease activity. We also examined whether well-defined polymorphisms in CD14 are associated with sCD14 expression in RA.
Methods. Soluble CD14 concentrations were measured using banked serum from patients with RA (n = 1270) and controls (n = 186). Associations of patient factors including demographics, measures of RA disease activity/severity, and select CD14 single-nucleotide polymorphisms (SNP) with sCD14 concentration were examined in patients with RA using ordinal logistic regression.
Results. Circulating concentrations of sCD14 were higher in patients with RA compared to controls (p < 0.0001). Factors significantly and independently associated with higher sCD14 levels in patients with RA included older age, being white (vs African American), lower body mass index, elevated high sensitivity C-reactive protein, and higher levels of disease activity based on the Disease Activity Score (DAS28). There were no significant associations of CD14 tagging SNP with sCD14 level in either univariate or multivariable analyses.
Conclusion. Circulating levels of sCD14 are increased in RA and are highest in patients with increased levels of RA disease activity. In the context of RA, sCD14 concentrations also appear to be strongly influenced by specific patient factors including older age and race but not by genetic variation in CD14. (First Release Sept 15 2011; J Rheumatol 2011;38:2509-16; doi:10.3899/jrheum.110378)
C1 [Mikuls, Ted R.] Omaha VA Med Ctr, Dept Med, Div Rheumatol & Immunol, Omaha, NE USA.
[LeVan, Tricia D.] Omaha VA Med Ctr, Dept Epidemiol, Omaha, NE USA.
[Sayles, Harlan] Omaha VA Med Ctr, Dept Biostat, Omaha, NE USA.
[Caplan, Liron] Denver VAMC, Denver, CO USA.
[Caplan, Liron] Univ Colorado, Boulder, CO 80309 USA.
[Cannon, Grant W.] Salt Lake City VAMC, Salt Lake City, UT USA.
[Kerr, Gail S.] VAMC, Georgetown, Guyana.
[Kerr, Gail S.] Howard Univ Hosp, Washington, DC 20059 USA.
[Reimold, Andreas M.] Dallas VAMC, Dallas, TX USA.
[Reimold, Andreas M.] Univ Texas SW Med Ctr, Dallas, TX USA.
[Johnson, Dannette S.] Sonny Montgomery VAMC, Montgomery, AL USA.
RP Mikuls, TR (reprint author), Omaha VA Med Ctr, Dept Med, Div Rheumatol & Immunol, Omaha, NE USA.
EM tmikuls@unmc.edu
RI Yu, Fang/B-9874-2013
OI Thiele, Geoffrey/0000-0001-5688-8596
FU VA CSRD; VA HSRD Program
FX Supported by a Merit Grant from VA CSR&D. The Veterans Affairs
Rheumatoid Arthritis registry has received research support from the VA
HSR&D Program.
NR 47
TC 10
Z9 10
U1 0
U2 2
PU J RHEUMATOL PUBL CO
PI TORONTO
PA 365 BLOOR ST E, STE 901, TORONTO, ONTARIO M4W 3L4, CANADA
SN 0315-162X
J9 J RHEUMATOL
JI J. Rheumatol.
PD DEC
PY 2011
VL 38
IS 12
BP 2509
EP 2516
DI 10.3899/jrheum.110378
PG 8
WC Rheumatology
SC Rheumatology
GA 868NU
UT WOS:000298530800004
PM 21921097
ER
PT J
AU Kong, A
Beresford, SAA
Alfano, CM
Foster-Schubert, KE
Neuhouser, ML
Johnson, DB
Duggan, C
Wang, CY
Xiao, LR
Bain, CE
McTiernan, A
AF Kong, Angela
Beresford, Shirley A. A.
Alfano, Catherine M.
Foster-Schubert, Karen E.
Neuhouser, Marian L.
Johnson, Donna B.
Duggan, Catherine
Wang, Ching-Yun
Xiao, Liren
Bain, Carolyn E.
McTiernan, Anne
TI Associations between Snacking and Weight Loss and Nutrient Intake among
Postmenopausal Overweight to Obese Women in a Dietary Weight-Loss
Intervention
SO JOURNAL OF THE AMERICAN DIETETIC ASSOCIATION
LA English
DT Article
ID LOOK-AHEAD ACTION; ENERGY-INTAKE; FOOD-INTAKE; EATING OCCASIONS; US
ADULTS; PATTERNS; HEALTH; FREQUENCY; MEAL; BMI
AB Snacking may play a role in weight control. The associations of timing and frequency of snacking with observed weight change and nutrient intake were assessed in an ancillary study to a 12-month randomized controlled trial in Seattle, WA. Overweight-to-obese postmenopausal women (n=123) enrolled in the two dietary weight-loss arms from 2007 to 2008 with complete data at 12 months were included in these analyses.. Generalized linear models were used to test the associations between snacking and weight loss (percent) and nutrient intake at the 12-month time point. Participants were, on average, 58 years old and mainly non-Hispanic white (84%). Ninety-seven percent reported one or more snacks per day. Weight loss (percent) was significantly lower among mid-morning (10:30 AM to 11:29 Am) snackers (7.0%, 95% confidence interval: 4.3 to 9.7) compared to non mid-morning snackers (11.4%, 95% confidence interval: 10.2 to 12.6; P=0.005). A higher proportion of mid-morning snackers reported more than one snack per day (95.7%), compared to afternoon (82.8%) and evening (80.6%) snackers, although differences were not statistically significant (P>0.05). Women who reported two or more snacks per day vs one or no snacks per day had higher fiber intake (P=0.027). Afternoon snackers had higher fruit and vegetable intake compared to non-afternoon-snackers (P=0.035). These results suggest that snack meals can be a source for additional fruits, vegetables, and fiber-rich foods; however, snacking patterns might also reflect unhealthy eating habits and impede weight-loss progress. Future dietary weight-loss interventions should evaluate the effects of timing, frequency, and quality of snacks on weight loss. J Am Diet Assoc. 2011;111:1898-1903.
C1 [McTiernan, Anne] Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, Prevent Ctr, Seattle, WA 98109 USA.
[Kong, Angela] Univ Illinois, Inst Hlth Res & Policy, Canc Educ & Career Dev Program, Chicago, IL USA.
[Beresford, Shirley A. A.] Univ Washington, Sch Publ Hlth & Community Med, Dept Epidemiol, Seattle, WA 98195 USA.
[Alfano, Catherine M.] NCI, Off Canc Survivorship, Div Canc Control & Populat Sci, NIH, Bethesda, MD 20892 USA.
[Foster-Schubert, Karen E.] Univ Washington, VA Puget Sound Hlth Care, Seattle, WA 98195 USA.
[Duggan, Catherine] Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, Program Epidemiol, Seattle, WA 98109 USA.
[Johnson, Donna B.] Univ Washington, Ctr Publ Hlth Nutr, Seattle, WA 98195 USA.
RP McTiernan, A (reprint author), Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, Prevent Ctr, 1100 Fairview Ave N,M4-B874,POB 19024, Seattle, WA 98109 USA.
EM amctiern@fhcrc.org
RI Duggan, Catherine/F-9414-2015
OI Duggan, Catherine/0000-0001-7369-4021
FU National Cancer Institute (NCI) National Institutes of Health (NIH) [R01
CA105204-01A1, U54-CA116847]; NIH [5KL2RR025015-03]; NCI [R25CA094880,
2R25CA057699-16]
FX This study was funded by National Cancer Institute (NCI) National
Institutes of Health (NIH) grants R01 CA105204-01A1 and U54-CA116847
(Transdisciplinary Research on Energetics and Cancer). K.E.F.-S.
received support from NIH 5KL2RR025015-03 and A.K. was supported by NCI
R25CA094880 at the time of this study and is currently supported by NCI
2R25CA057699-16.
NR 32
TC 6
Z9 6
U1 2
U2 6
PU AMER DIETETIC ASSOC
PI CHICAGO
PA 120 S RIVERSIDE PLZ, STE 2000, CHICAGO, IL 60606-6995 USA
SN 0002-8223
J9 J AM DIET ASSOC
JI J. Am. Diet. Assoc.
PD DEC
PY 2011
VL 111
IS 12
BP 1898
EP 1903
DI 10.1016/j.jada.2011.09.012
PG 6
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA 872RY
UT WOS:000298828200016
PM 22117666
ER
PT J
AU Burgio, KL
Goode, PS
Johnson, TM
Hammontree, L
Ouslander, JG
Markland, AD
Colli, J
Vaughan, CP
Redden, DT
AF Burgio, Kathryn L.
Goode, Patricia S.
Johnson, Theodore M., II
Hammontree, Lee
Ouslander, Joseph G.
Markland, Alayne D.
Colli, Janet
Vaughan, Camille P.
Redden, David T.
TI Behavioral Versus Drug Treatment for Overactive Bladder in Men: The Male
Overactive Bladder Treatment in Veterans (MOTIVE) Trial
SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
LA English
DT Article; Proceedings Paper
CT Annual Meeting of the American-Urological-Association
CY JUN 06, 2010
CL San Francisco, CA
SP Amer Urol Assoc
DE overactive bladder; behavioral treatment; drug therapy; lower urinary
tract symptoms; urinary incontinence
ID URINARY-TRACT SYMPTOMS; BENIGN PROSTATIC HYPERPLASIA; RANDOMIZED
CONTROLLED-TRIAL; SIDED TESTS PROCEDURE; OLDER WOMEN; INCONTINENT WOMEN;
MANAGEMENT; THERAPY; COMBINATION; EFFICACY
AB OBJECTIVES: To compare the effectiveness of behavioral treatment with that of antimuscarinic therapy in men without bladder outlet obstruction who continue to have overactive bladder (OAB) symptoms with alpha-blocker therapy. DESIGN: The Male Overactive Bladder Treatment in Veterans (MOTIVE) Trial was a two-site randomized, controlled, equivalence trial with 4-week alpha-blocker run-in. SETTING: Veterans Affairs Medical Center outpatient clinics. PARTICIPANTS: Volunteer sample of 143 men aged 42 to 88 who continued to have urgency and more than eight voids per day, with or without incontinence, after run-in. INTERVENTIONS: Participants were randomized to 8 weeks of behavioral treatment (pelvic floor muscle exercises, urge suppression techniques, delayed voiding) or drug therapy (individually titrated, extended-release oxybutynin, 5-30 mg/d). MEASUREMENTS: Seven-day bladder diaries and a validated urgency scale were used to calculate changes in 24-hour voiding frequency, nocturia, urgency, and incontinence. Secondary outcomes were global patient ratings and American Urological Association Symptom Index. RESULTS: Mean voids per day decreased from 11.3 to 9.1 (- 18.8%) with behavioral treatment and 11.5 to 9.5 (- 16.9%) with drug therapy. Equivalence analysis indicated that posttreatment means were equivalent (P <.01). After treatment, 85% of participants rated themselves as much better or better; more than 90% were completely or somewhat satisfied, with no betweengroup differences. The behavioral group showed greater reductions in nocturia (mean = -0.70 vs - 0.32 episodes/ night; P =.05). The drug group showed greater reductions in maximum urgency scores (mean = -0.44 vs -0.12; P =.02). Other between-group differences were nonsignificant. CONCLUSION: Behavioral and antimuscarinic therapy are effective when added to alpha-blocker therapy for OAB in men without outlet obstruction. Behavioral treatment is at least as effective as antimuscarinic therapy. J Am Geriatr Soc 59: 2209-2216, 2011.
C1 [Burgio, Kathryn L.; Goode, Patricia S.; Johnson, Theodore M., II; Hammontree, Lee; Markland, Alayne D.; Colli, Janet; Vaughan, Camille P.; Redden, David T.] Birmingham Atlanta Geriatr Res Educ & Clin Ctr, Dept Vet Affairs, Birmingham, AL USA.
[Burgio, Kathryn L.; Goode, Patricia S.; Markland, Alayne D.] Univ Alabama, Dept Med, Birmingham, AL 35294 USA.
[Hammontree, Lee; Colli, Janet] Univ Alabama, Dept Surg, Birmingham, AL 35294 USA.
[Redden, David T.] Univ Alabama, Dept Biostat, Birmingham, AL 35294 USA.
[Johnson, Theodore M., II; Vaughan, Camille P.] Emory Univ, Atlanta, GA 30322 USA.
[Ouslander, Joseph G.] Florida Atlantic Univ, Charles E Schmidt Coll Biomed Sci, Dept Clin Biomed Sci, Miami, FL USA.
RP Burgio, KL (reprint author), Birmingham VA Med Ctr, Geriatr Res Educ & Clin Ctr, 11G,700 S 19th St, Birmingham, AL 35233 USA.
EM kburgio@aging.uab.edu
RI Vaughan, Camille/I-3758-2014
NR 39
TC 35
Z9 35
U1 3
U2 11
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0002-8614
J9 J AM GERIATR SOC
JI J. Am. Geriatr. Soc.
PD DEC
PY 2011
VL 59
IS 12
BP 2209
EP 2216
DI 10.1111/j.1532-5415.2011.03724.x
PG 8
WC Geriatrics & Gerontology; Gerontology
SC Geriatrics & Gerontology
GA 869LU
UT WOS:000298600300003
PM 22092152
ER
PT J
AU Blackwell, T
Yaffe, K
Ancoli-Israel, S
Redline, S
Ensrud, KE
Stefanick, ML
Laffan, A
Stone, KL
AF Blackwell, Terri
Yaffe, Kristine
Ancoli-Israel, Sonia
Redline, Susan
Ensrud, Kristine E.
Stefanick, Marcia L.
Laffan, Alison
Stone, Katie L.
CA Osteoporotic Fractures Men Study
TI Associations Between Sleep Architecture and Sleep-Disordered Breathing
and Cognition in Older Community-Dwelling Men: The Osteoporotic
Fractures in Men Sleep Study
SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
LA English
DT Article
DE sleep architecture; sleep-disordered breathing; cognitive function;
hypoxemia
ID APNEA SYNDROME; ALZHEIMERS-DISEASE; CPAP TREATMENT; HEART HEALTH;
REM-SLEEP; MEMORY; DYSFUNCTION; CONSOLIDATION; PERFORMANCE; IMPROVEMENT
AB OBJECTIVES: To examine the association between sleep architecture, sleep-disordered breathing, and cognition in older men. DESIGN: Population-based cross-sectional study. SETTING: Six clinical sites in the United States. PARTICIPANTS: Two thousand nine hundred nine community- dwelling men aged 67 and older who were not selected on the basis of sleep problems or cognitive impairment. MEASUREMENTS: Predictors were measured using in-home polysomnography: sleep architecture, nocturnal hypoxemia (any sleep time with arterial oxygen saturation < 80%), apnea-hypopnea index (AHI), and arousal index. Cognitive outcomes were measured using the modified Mini-Mental State Examination (3MS), Trail-Making Test Part B (TMT-B), and the Digit Vigilance Test (DVT). RESULTS: Analyses adjusted for age, race, education, body mass index, lifestyle, comorbidities, and medication use showed that participants who spent less percentage of time in rapid eye movement (REM) sleep had lower levels of cognition; participants in the lowest quartile (< 14.8%) took an average of 5.9 seconds longer on the TMT-B and 20.1 seconds longer on the DVT than those in the highest quartile (>= 23.7%). Similarly, greater percentage of time spent in Stage 1 sleep was related to poorer cognitive function. Participants in the highest quartile of Stage 1 sleep (>= 8.6%) had worse cognitive scores on average than those in the lowest quartile (< 4.0%). Those with nocturnal hypoxemia took an average of 22.3 seconds longer to complete the DVT than those without, but no associations were found with 3MS or the TMT-B. CONCLUSION: Spending less percentage of time in REM sleep and greater percentage of time in Stage 1 sleep and having higher levels of nocturnal hypoxemia were associated with poorer cognition in older men. Further studies are needed to clarify the direction of these associations and to explore potential mechanisms. J Am Geriatr Soc 59: 2217-2225, 2011.
C1 [Blackwell, Terri; Laffan, Alison; Stone, Katie L.] Calif Pacific Med Ctr, Res Inst, San Francisco, CA USA.
[Yaffe, Kristine] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA.
[Yaffe, Kristine] Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA.
[Yaffe, Kristine] Univ Calif San Francisco, Dept Epidemiol, San Francisco, CA 94143 USA.
[Yaffe, Kristine] San Francisco VA Med Ctr, San Francisco, CA USA.
[Ancoli-Israel, Sonia] Univ Calif San Diego, Dept Psychiat, La Jolla, CA 92093 USA.
[Redline, Susan] Harvard Univ, Brigham & Womens Hosp, Dept Med, Sch Med, Boston, MA 02115 USA.
[Redline, Susan] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Boston, MA 02215 USA.
[Ensrud, Kristine E.] Vet Affairs Med Ctr, Ctr Chron Dis Outcomes Res, Minneapolis, MN USA.
[Ensrud, Kristine E.] Univ Minnesota, Dept Med, Div Epidemiol & Community Hlth, Minneapolis, MN 55455 USA.
[Stefanick, Marcia L.] Stanford Univ, Dept Med, Sch Med, Stanford Prevent Res Ctr, Stanford, CA 94305 USA.
RP Blackwell, T (reprint author), San Francisco Coordinating Ctr, 185 Berry St,Lobby 5,Suite 5700, San Francisco, CA 94107 USA.
EM tblackwell@sfcc-cpmc.net
FU National Institutes of Health (NIH); National Institute of Arthritis and
Musculoskeletal and Skin Diseases; National Institute on Aging; National
Cancer Institute; National Center for Research Resources; NIH Roadmap
for Medical Research [U01 AR45580, U01 AR45614, U01 AR45632, U01
AR45647, U01 AR45654, U01 AR45583, U01 AG18197, U01-AG027810, UL1
RR024140, AG08415]; National Heart, Lung, and Blood Institute [R01
HL071194, R01 HL070848, R01 HL070847, R01 HL070842, R01 HL070841, R01
HL070837, R01 HL070838, R01 HL070839]; Sepracor; Litebook
FX Conflict of Interest: MrOS is supported by National Institutes of Health
(NIH) funding. The following institutes provide support: the National
Institute of Arthritis and Musculoskeletal and Skin Diseases, the
National Institute on Aging, the National Cancer Institute, the National
Center for Research Resources, and NIH Roadmap for Medical Research
under Grants U01 AR45580, U01 AR45614, U01 AR45632, U01 AR45647, U01
AR45654, U01 AR45583, U01 AG18197, U01-AG027810, UL1 RR024140, and
AG08415.; The National Heart, Lung, and Blood Institute provides funding
for the MrOS Sleep ancillary study "Out-comes of Sleep Disorders in
Older Men" under Grants R01 HL071194, R01 HL070848, R01 HL070847, R01
HL070842, R01 HL070841, R01 HL070837, R01 HL070838, and R01 HL070839.
Dr. Yaffe received funding from K 24 grant AG031155.; Dr. Ancoli-Israel
has consulted for or is on the advisory board of Ferring
Pharmaceuticals, GlaxoSmithKline, Merck, NeuroVigil, Pfizer, Philips
Respironics, Sanofi-Aventis, Sepracor, Scherling-Plough, and Perdue, and
has received research support from Sepracor and Litebook.
NR 50
TC 37
Z9 37
U1 3
U2 5
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0002-8614
J9 J AM GERIATR SOC
JI J. Am. Geriatr. Soc.
PD DEC
PY 2011
VL 59
IS 12
BP 2217
EP 2225
DI 10.1111/j.1532-5415.2011.03731.x
PG 9
WC Geriatrics & Gerontology; Gerontology
SC Geriatrics & Gerontology
GA 869LU
UT WOS:000298600300004
PM 22188071
ER
PT J
AU Gray, SL
Boudreau, RM
Newman, AB
Studenski, SA
Shorr, RI
Bauer, DC
Simonsick, EM
Hanlon, JT
AF Gray, Shelly L.
Boudreau, Robert M.
Newman, Anne B.
Studenski, Stephanie A.
Shorr, Ronald I.
Bauer, Douglas C.
Simonsick, Eleanor M.
Hanlon, Joseph T.
CA Hlth Aging Body Composition Study
TI Angiotensin-Converting Enzyme Inhibitor and Statin Use and Incident
Mobility Limitation in Community-Dwelling Older Adults: The Health,
Aging and Body Composition Study
SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
LA English
DT Article
DE medications; mobility; pharmacoepidemiology
ID PERIPHERAL ARTERIAL-DISEASE; RANDOMIZED CONTROLLED-TRIAL;
LOWER-EXTREMITY FUNCTION; C-REACTIVE PROTEIN; WOMEN AGED 65; PHYSICAL
FUNCTION; WALKING PERFORMANCE; VASCULAR-DISEASE; PRAVASTATIN;
ATORVASTATIN
AB OBJECTIVES: To evaluate whether the use of angiotensin- converting enzyme (ACE) inhibitors and statins is associated with a lower risk of incident mobility limitation in older community dwelling adults. DESIGN: Longitudinal cohort study. SETTING: Health, Aging and Body Composition (Health ABC) study. PARTICIPANTS: Three thousand fifty-five participants who were well functioning at baseline (no mobility limitations). MEASUREMENTS: Summated standardized daily doses (low, medium, high) and duration of ACE inhibitor and statin use were computed. Mobility limitation (two consecutive self-reports of having any difficulty walking onequarter of a mile or climbing 10 steps without resting) was assessed every 6 months after baseline. Multivariable Cox proportional hazards analyses were conducted, adjusting for demographics, health status, and health behaviors. RESULTS: At baseline, 15.2% used ACE inhibitors and 12.9% used statins; use of both was greater than 25% by Year 6. Over 6.5 years of follow-up, 49.8% had developed mobility limitation. In separate multivariable models, neither ACE inhibitor (multivariate hazard ratio (HR) = 0.95, 95% confidence interval (CI) = 0.82-1.09) nor statin use (multivariate HR = 1.02, 95% CI = 0.87-1.17) was associated with lower risk of mobility limitation. Similar findings were seen in analyses examining dose-response and duration-response relationships and a sensitivity analysis restricted to those with hypertension. CONCLUSION: ACE inhibitors and statins widely prescribed to treat hypertension and hypercholesterolemia, respectively, do not lower risk of mobility limitation, an important indicator of quality of life. J Am Geriatr Soc 59: 2226-2232, 2011.
C1 [Gray, Shelly L.] Univ Washington, Sch Pharm, Seattle, WA 98195 USA.
[Boudreau, Robert M.; Newman, Anne B.] Univ Pittsburgh, Dept Epidemiol, Sch Publ Hlth, Pittsburgh, PA 15261 USA.
[Newman, Anne B.; Studenski, Stephanie A.; Hanlon, Joseph T.] Univ Pittsburgh, Sch Med, Dept Med, Div Geriatr, Pittsburgh, PA USA.
[Hanlon, Joseph T.] Univ Pittsburgh, Sch Pharm, Dept Pharm & Therapeut, Pittsburgh, PA 15261 USA.
[Studenski, Stephanie A.; Hanlon, Joseph T.] Vet Affairs Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Geriatr Res Educ, Pittsburgh, PA USA.
[Studenski, Stephanie A.; Hanlon, Joseph T.] Vet Affairs Pittsburgh Healthcare Syst, Ctr Clin, Pittsburgh, PA USA.
[Shorr, Ronald I.] N Florida S Georgia Vet Hlth Syst, Geriatr Res Educ & Clin Ctr, Gainesville, FL USA.
[Bauer, Douglas C.] Univ Calif San Francisco, Div Gen Internal Med, San Francisco, CA 94143 USA.
[Simonsick, Eleanor M.] NIA, Intramural Res Program, Baltimore, MD 21224 USA.
RP Gray, SL (reprint author), Univ Washington, Sch Pharm, Box 357630, Seattle, WA 98195 USA.
EM slgray@u.washington.edu
RI Newman, Anne/C-6408-2013
OI Newman, Anne/0000-0002-0106-1150; Boudreau, Robert/0000-0003-0162-5187
FU National Institutes of Health, National Institute on Aging (NIA)
[N01-AG-6-2101, N01-AG-6-2103, N01-AG-6-2106]; NIA [R01AG027017,
P30AG024827, T32 AG021885, K07AG033174, R56AG027017, R01AG034056];
National Institute of Mental Health [R34 MH082682]; National Institute
of Nursing Research [R01 NR010135]; Agency for Healthcare Research and
Quality [R01 HS017695, R01 HS018721, K12 HS019461]; Veterans Affairs
Health Services Research [IIR-06-062]; Merck; Novartis; GTX; Hazzard
Text McGraw Hill
FX This research was supported in part by the Intramural Research Program
of the National Institutes of Health, National Institute on Aging (NIA)
and Contracts N01-AG-6-2101, N01-AG-6-2103, and N01-AG-6-2106. The
authors were also supported by NIA Grants and Contracts R01AG027017,
P30AG024827, T32 AG021885, K07AG033174, R56AG027017, and R01AG034056;
National Institute of Mental Health Grant R34 MH082682; National
Institute of Nursing Research Grant R01 NR010135; Agency for Healthcare
Research and Quality Grants R01 HS017695, R01 HS018721, and K12
HS019461; and Veterans Affairs Health Services Research Grant
IIR-06-062.; Dr. Studenski received institutional grant support, travel
expenses, and consultancy fees from Merck; consultancy fees from
Novartis and GTX; and royalties from Hazzard Text McGraw Hill.
NR 37
TC 14
Z9 14
U1 1
U2 1
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0002-8614
J9 J AM GERIATR SOC
JI J. Am. Geriatr. Soc.
PD DEC
PY 2011
VL 59
IS 12
BP 2226
EP 2232
DI 10.1111/j.1532-5415.2011.03721.x
PG 7
WC Geriatrics & Gerontology; Gerontology
SC Geriatrics & Gerontology
GA 869LU
UT WOS:000298600300005
PM 22092102
ER
PT J
AU Feil, DG
Rajan, M
Soroka, O
Tseng, CL
Miller, DR
Pogach, LM
AF Feil, Denise G.
Rajan, Mangala
Soroka, Orysya
Tseng, Chin-Lin
Miller, Donald R.
Pogach, Leonard M.
TI Risk of Hypoglycemia in Older Veterans with Dementia and Cognitive
Impairment: Implications for Practice and Policy
SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
LA English
DT Article
DE diabetes mellitus; dementia; cognitive impairment; glycemic control;
hypoglycemia
ID TYPE-2 DIABETES-MELLITUS; BLOOD-GLUCOSE CONTROL; ADVERSE DRUG EVENTS;
GLYCEMIC CONTROL; CARE; PERFORMANCE; INSULIN; HEALTH; COMPLICATIONS;
SULFONYLUREAS
AB OBJECTIVES: To examine the relationship between management of diabetes mellitus and hypoglycemia in older adults with and without dementia and cognitive impairment. DESIGN: Cross-sectional database analysis of veterans aged 65 years and older stratified according to dementia, cognitive impairment, age, antiglycemic medications, and glycosylated hemoglobin (Hba1c) level. SETTING: Research database with linked clinical, laboratory, pharmacy, and International Classification of Diseases, Ninth Revision, Clinical Modification, codes. PARTICIPANTS: Four hundred ninety-seven thousand nine hundred veterans aged 65 and older with diabetes mellitus who obtained services from the Department of Veterans Affairs in fiscal years (FYs) 2002 and 2003. MEASUREMENTS: Hypoglycemia, the outcome variable, was identified from outpatient visits, emergency department and inpatient admission codes in FY2003. Independent variables (FY2002-03) included dementia and cognitive impairment, comorbid conditions, extended care and nursing home stays, demographics, antiglycemic medication, and HbA1c levels. RESULTS: Prevalence of combined dementia and cognitive impairment was 13.1% for individuals aged 65 to 74 and 24.2% for those aged 75 and older. Mean HbA1c levels were 7.0 +/- 1.3% for all participants and 6.9 +/- 1.3% for those with dementia. The proportion of participants taking insulin was higher in those with dementia or cognitive impairment (30%) than in those with neither condition (24%). Of all participants taking insulin, more with dementia (26.5%) and cognitive impairment (19.5%) were hypoglycemic than of those with neither condition (14.4%). For all participants, unadjusted odds ratios (ORs) for hypoglycemia were 2.42 (95% confidence interval (CI) = 2.36-2.48) for dementia and 1.72 (95% CI = 1.65-1.79) for cognitive impairment; adjusted ORs were 1.58 (95% CI = 1.53-1.62) for dementia and 1.13 (95% CI = 1.08-1.18) for cognitive impairment. CONCLUSION: Diabetes mellitus was managed more intensively in older veterans with dementia and cognitive impairment, and dementia and cognitive impairment were independently associated with greater risk of hypoglycemia. J Am Geriatr Soc 59: 2263-2272, 2011.
C1 [Feil, Denise G.] Univ Calif Los Angeles, Div Geriatr Psychiat, W Los Angeles Vet Affairs Healthcare Ctr, Los Angeles, CA USA.
[Feil, Denise G.] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA.
[Rajan, Mangala; Soroka, Orysya; Tseng, Chin-Lin; Pogach, Leonard M.] Ctr Healthcare Knowledge Management, Dept Vet Affairs New Jersey Healthcare Syst, E Orange, NJ USA.
[Miller, Donald R.] Boston Univ, Sch Publ Hlth, Boston, MA USA.
[Miller, Donald R.] Bedford Vet Affairs Med Ctr Hlth Qual Outcomes &, Bedford, MA USA.
[Tseng, Chin-Lin; Pogach, Leonard M.] Univ Med & Dent New Jersey, New Jersey Med Sch, Newark, NJ 07103 USA.
RP Pogach, LM (reprint author), VA New Jersey Healthcare Syst, VA HSR&D Ctr Healthcare Knowledge Management Res, 385 Tremont Ave, E Orange, NJ 07018 USA.
EM leonard.pogach@va.gov
FU VA Health Services Research and Development (HSRD); VA HSRD Diabetes
Quality Enhancement Research Initiative
FX Dr. Feil received grant support from a VA Health Services Research and
Development (HSRD) Career Development Award. Dr. Pogach and Dr. Miller
report funding from the VA HSRD Diabetes Quality Enhancement Research
Initiative.
NR 51
TC 36
Z9 36
U1 4
U2 9
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0002-8614
J9 J AM GERIATR SOC
JI J. Am. Geriatr. Soc.
PD DEC
PY 2011
VL 59
IS 12
BP 2263
EP 2272
DI 10.1111/j.1532-5415.2011.03726.x
PG 10
WC Geriatrics & Gerontology; Gerontology
SC Geriatrics & Gerontology
GA 869LU
UT WOS:000298600300010
PM 22150156
ER
PT J
AU Kelley, AS
Ettner, SL
Wenger, NS
Sarkisian, CA
AF Kelley, Amy S.
Ettner, Susan L.
Wenger, Neil S.
Sarkisian, Catherine A.
TI Determinants of Death in the Hospital Among Older Adults
SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
LA English
DT Article
DE hospital use; end-of-life care; health services
ID OF-LIFE CARE; TERMINALLY-ILL PATIENTS; TREATMENT INTENSITY;
ETHNIC-DIFFERENCES; FAMILY-MEMBERS; END; PLACE; PREFERENCES; CANCER;
QUALITY
AB OBJECTIVES: To investigate patient-level determinants of in-hospital death, adjusting for patient and regional characteristics. DESIGN: Using multivariable regression, the relationship between in-hospital death and participants' social, functional, and health characteristics was investigated, controlling for regional Hospital Care Intensity Index (HCI) from the Dartmouth Atlas of Health Care. SETTING: The Health and Retirement Study, a longitudinal nationally representative cohort of older adults. PARTICIPANTS: People aged 67 and older who died between 2,000 and 2,006 (N = 3,539) were sampled. MEASUREMENTS: In-hospital death. RESULTS: Thirty-nine percent (n = 1,380) of participants died in the hospital (range 34% in Midwest to 45% in Northeast). Nursing home residence, functional dependence, and cancer or dementia diagnosis, among other characteristics, were associated with lower adjusted odds of in-hospital death. Being black or Hispanic, living alone, and having more medical comorbidities were associated with greater adjusted odds, as was higher HCI. Sex, education, net worth, and completion of an advance directive did not correlate with in-hospital death. CONCLUSION: Black race, Hispanic ethnicity, and other functional and social characteristics are correlates of inhospital death, even after controlling for the role of HCI. Further work must be done to determine whether preferences, provider characteristics and practice patterns, or differential access to medical and community services drive this difference. J Am Geriatr Soc 59: 2321-2325, 2011.
C1 [Kelley, Amy S.] Mt Sinai Sch Med, Dept Geriatr & Palliat Med, New York, NY USA.
[Ettner, Susan L.; Wenger, Neil S.] Univ Calif Los Angeles, David Geffen Sch Med, Div Gen Internal Med & Hlth Serv Res, Los Angeles, CA 90095 USA.
[Sarkisian, Catherine A.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Geriatr, Los Angeles, CA 90095 USA.
[Sarkisian, Catherine A.] Vet Affairs Greater Los Angeles Healthcare Syst, Geriatr Res Educ Clin Ctr, Los Angeles, CA USA.
RP Kelley, AS (reprint author), 1 Gustave L Levy Pl,Box 1070, New York, NY 10029 USA.
EM amy.kelley@mssm.edu
FU Univeristy of California at Los Angeles; Veterans Affairs Greater Los
Angeles Healthcare System Geriatric Research Education Clinical Center
FX The authors report no financial or personal conflicts of interest. While
conducting this work, Dr. Kelley was supported by the National Research
Service Award Fellowship Program at the Univeristy of California at Los
Angeles and the Brookdale Leadership in Aging Fellowship. Dr. Sarkisian
is supported by the Veterans Affairs Greater Los Angeles Healthcare
System Geriatric Research Education Clinical Center.
NR 23
TC 9
Z9 9
U1 1
U2 9
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0002-8614
J9 J AM GERIATR SOC
JI J. Am. Geriatr. Soc.
PD DEC
PY 2011
VL 59
IS 12
BP 2321
EP 2325
DI 10.1111/j.1532-5415.2011.03718.x
PG 5
WC Geriatrics & Gerontology; Gerontology
SC Geriatrics & Gerontology
GA 869LU
UT WOS:000298600300017
PM 22092014
ER
PT J
AU Afaq, F
Katiyar, SK
AF Afaq, F.
Katiyar, S. K.
TI Polyphenols: Skin Photoprotection and Inhibition of Photocarcinogenesis
SO MINI-REVIEWS IN MEDICINAL CHEMISTRY
LA English
DT Review
DE Polyphenols; photoprotection; photocarcinogenesis; proliferation; skin
cancer; inflammation; immunosuppression; DNA repair; cellular signaling
pathway; reactive oxygen species; ultraviolet radiation
ID GREEN TEA POLYPHENOLS; SKH-1 HAIRLESS MICE; FACTOR-KAPPA-B; HUMAN
EPIDERMAL-KERATINOCYTES; ACTIVATED PROTEIN-KINASES; INDUCED OXIDATIVE
STRESS; RADIATION-INDUCED IMMUNOSUPPRESSION; INDUCED IMMUNE SUPPRESSION;
UV-INDUCED IMMUNOSUPPRESSION; HUMAN RECONSTITUTED SKIN
AB Polyphenols are a large family of naturally occurring plant products and are widely distributed in plant foods, such as, fruits, vegetables, nuts, flowers, bark and seeds, etc. These polyphenols contribute to the beneficial health effects of dietary products. Clinical and epidemiological studies suggest that exposure of the skin to environmental factors/pollutants, such as solar ultraviolet (UV) radiation induce harmful effects and leads to various skin diseases including the risk of melanoma and non-melanoma skin cancers. The incidence of non-melanoma skin cancer, comprising of squamous cell carcinoma and basal cell carcinoma, is a significant public health concern world-wide. Exposure of the skin to solar UV radiation results in inflammation, oxidative stress, DNA damage, dysregulation of cellular signaling pathways and immunosuppression thereby resulting in skin cancer. The regular intake of natural plant products, especially polyphenols, which are widely present in fruits, vegetables, dry legumes and beverages have gained considerable attention as protective agents against the adverse effects of UV radiation. In this article, we first discussed the impact of polyphenols on human health based on their structure-activity relationship and bioavailability. We then discussed in detail the photoprotective effects of some selected polyphenols on UV-induced skin inflammation, proliferation, immunosuppression, DNA damage and dysregulation of important cellular signaling pathways and their implications in skin cancer management. The selected polyphenols include: green tea polyphenols, pomegranate fruit extract, grape seed proanthocyanidins, resveratrol, silymarin, genistein and delphinidin. The new information on the mechanisms of action of these polyphenols supports their potential use in skin photoprotection and prevention of photocarcinogenesis in humans.
C1 [Afaq, F.; Katiyar, S. K.] Univ Alabama, Dept Dermatol, Birmingham, AL 35294 USA.
[Katiyar, S. K.] Birmingham Vet Affairs Med Ctr, Birmingham, AL 35294 USA.
RP Afaq, F (reprint author), Univ Alabama, Dept Dermatol, 1670 Univ Blvd,Volker Hall 557, Birmingham, AL 35294 USA.
EM fafaq@uab.edu; skatiyar@uab.edu
FU National Institutes of Health [R21 AT002429-02, CA104428, CA140832,
AT002536]; Veterans Administration
FX This work was supported by funds from the National Institutes of Health
[(R21 AT002429-02, F.A.) (CA104428, CA140832, AT002536, S.K.K.)] and
Veterans Administration Merit Review Award (S.K.K.). The content of this
article does not necessarily reflect the views or policies of the
funding agencies.
NR 109
TC 58
Z9 60
U1 3
U2 43
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y26, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
EMIRATES
SN 1389-5575
J9 MINI-REV MED CHEM
JI Mini-Rev. Med. Chem.
PD DEC
PY 2011
VL 11
IS 14
BP 1200
EP 1215
PG 16
WC Chemistry, Medicinal
SC Pharmacology & Pharmacy
GA 869YH
UT WOS:000298635800004
PM 22070679
ER
PT J
AU Cloninger, C
Bernath, A
Bashir, T
Holmes, B
Artinian, N
Ruegg, T
Anderson, L
Masri, J
Lichtenstein, A
Gera, J
AF Cloninger, Cheri
Bernath, Andrew
Bashir, Tariq
Holmes, Brent
Artinian, Nicholas
Ruegg, Teresa
Anderson, Lauren
Masri, Janine
Lichtenstein, Alan
Gera, Joseph
TI Inhibition of SAPK2/p38 Enhances Sensitivity to mTORC1 Inhibition by
Blocking IRES-Mediated Translation Initiation in Glioblastoma
SO MOLECULAR CANCER THERAPEUTICS
LA English
DT Article
ID ACTIVATED PROTEIN-KINASE; P38 MAP KINASE; NUCLEAR RIBONUCLEOPROTEIN A1;
SIGNAL-REGULATING KINASE-1; ENDOTHELIAL GROWTH-FACTOR; MAMMALIAN TARGET;
CYCLIN D1; MULTIPLE-MYELOMA; AKT ACTIVITY; RAPAMYCIN
AB A variety of mechanisms confer hypersensitivity of tumor cells to the macrolide rapamycin, the prototypic mTORC1 inhibitor. Several studies have shown that the status of the AKT kinase plays a critical role in determining hypersensitivity. Cancer cells in which AKT activity is elevated are exquisitely sensitive to mTORC1 inhibitors while cells in which the kinase is quiescent are relatively resistant. Our previous work has shown that a transcript-specific protein synthesis salvage pathway is operative in cells with quiescent AKT levels, maintaining the translation of crucial mRNAs involved in cell-cycle progression in the face of global eIF-4E-mediated translation inhibition. The activation of this salvage pathway is dependent on SAPK2/p38-mediated activation of IRES-dependent initiation of the cyclin D1 and c-MYC mRNAs, resulting in the maintenance of their protein expression levels. Here, we show that both genetic and pharmacologic inhibition of SAPK2/p38 in glioblastoma multiforme cells significantly reduces rapamycin-induced IRES-mediated translation initiation of cyclin D1 and c-MYC, resulting in increased G(1) arrest in vitro and inhibition of tumor growth in xenografts. Moreover, we observed that the AKT-dependent signaling alterations seen in vitro are also displayed in engrafted tumors cells and were able to show that combined inhibitor treatments markedly reduced the mRNA translational state of cyclin D1 and c-MYC transcripts in tumors isolated from mice. These data support the combined use of SAPK2/p38 and mTORC1 inhibitors to achieve a synergistic antitumor therapeutic response, particularly in rapamycin-resistant quiescent AKT-containing cells. Mol Cancer Ther; 10(12); 2244-56. (C)2011 AACR.
C1 [Cloninger, Cheri; Bernath, Andrew; Bashir, Tariq; Holmes, Brent; Artinian, Nicholas; Ruegg, Teresa; Anderson, Lauren; Masri, Janine; Lichtenstein, Alan; Gera, Joseph] Greater Los Angeles Vet Affairs Healthcare Syst, Dept Res & Dev, Los Angeles, CA USA.
[Lichtenstein, Alan; Gera, Joseph] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA.
[Lichtenstein, Alan; Gera, Joseph] Jonsson Comprehens Canc Ctr, Los Angeles, CA 90034 USA.
[Gera, Joseph] Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90024 USA.
RP Gera, J (reprint author), Greater Los Angeles VA Healthcare Syst, Dept Res & Dev, 16111 Plummer St 151, Sepulveda, CA 91343 USA.
EM jgera@mednet.ucla.edu
FU NIH [CA16042, AI28697, R01CA111448, R01CA109312]; Jonsson Comprehensive
Cancer Center; UCLA AIDS Institute; David Geffen School of Medicine at
UCLA; Veterans Administration
FX We thank members of the Lichtenstein and Gera labs for helpful
discussions and Dr. Robert Nishimura for comments on the manuscript. We
also thank Alex Funk and Jonathan Li for technical assistance. Flow
cytometry was performed in the UCLA Jonsson Comprehensive Cancer Center
and Center for AIDS Research, Janis Giorgi Flow Cytometry Core Facility
(supported by NIH grants CA16042 and AI28697 and by the Jonsson
Comprehensive Cancer Center, the UCLA AIDS Institute and the David
Geffen School of Medicine at UCLA). We thank Ardella Sherwood for
excellent administrative assistance.; This work was supported, in whole
or in part, by NIH grants R01CA111448 (A. Lichtenstein), R01CA109312 (J.
Gera), and funds from the Veterans Administration.
NR 41
TC 8
Z9 8
U1 0
U2 1
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1535-7163
J9 MOL CANCER THER
JI Mol. Cancer Ther.
PD DEC
PY 2011
VL 10
IS 12
BP 2244
EP 2256
DI 10.1158/1535-7163.MCT-11-0478
PG 13
WC Oncology
SC Oncology
GA 865XO
UT WOS:000298344400004
PM 21911485
ER
PT J
AU Jin, JF
Samuvel, DJ
Zhang, XM
Li, YC
Lu, ZY
Lopes-Virella, MF
Huang, Y
AF Jin, Junfei
Samuvel, Devadoss J.
Zhang, Xiaoming
Li, Yanchun
Lu, Zhongyang
Lopes-Virella, Maria F.
Huang, Yan
TI Coactivation of TLR4 and TLR2/6 coordinates an additive augmentation on
IL-6 gene transcription via p38MAPK pathway in U937 mononuclear cells
SO MOLECULAR IMMUNOLOGY
LA English
DT Article
DE Toll-like receptor; Interleukin 6; p38 mitogen-activated protein kinase;
Inflammation
ID ACTIVATED PROTEIN-KINASE; TOLL-LIKE RECEPTOR-2; NF-KAPPA-B; P38 MAPK;
ASP299GLY POLYMORPHISM; SIGNALING PATHWAYS; INSULIN-RESISTANCE; MMP-1
EXPRESSION; DENDRITIC CELLS; TNF-ALPHA
AB Studies have demonstrated that TLR4 and TLR2 expression by monocytes and the blood levels of TLR4 and TLR2 ligand in diabetic patients are significantly incased compared to nondiabetic patients, indicating that more monocytes in diabetic patients may have coactivation of TLR4 and TLR2. Although it has been shown that either TLR4 or TLR2 activation leads to increased expression of proinflammatory cytokines, the effect of coactivation of TLR2 and TLR4 in mononuclear cells on proinflammatory cytokine expression and the underlying molecular mechanisms remain largely unknown. In this study, we found that while TLR1, TLR2, TLR4 and TLR6 were expressed by U937 mononuclear cells, TLR4 was expressed at the highest level. Interestingly, results showed that while activation of either TLR4 or TLR2/6 (TLR2dimerized with TLR6), but not TLR2/1 (TLR2dimerized with TLR1), significantly increased IL-6 expression by U937 mononuclear cells, coactivation of TLR4 and TLR2/6, but not TLR4 and TLR2/1, led to a further augmentation on IL-6 expression by increasing IL-6 transcriptional activity, but not mRNA stability. To explore the signaling mechanisms involved in the augmentation, we found that p38MAPK and NF kappa B pathways, but not ERK and JNK pathways, were required for the augmentation of IL-6 expression by coactivation of TLR4 and TLR2/6. Furthermore, we found that coactivation of TLR4 and TLR2/6 increased p38 phosphorylation, but not NFkB activity, as compared to activation of TLR4or TLR2/6 alone. Taken together, this study showed that coactivation of TLR4 and TLR2/6 coordinates an additive augmentation of IL-6 gene transcription via p38MAPK pathway in U937 mononuclear cells. Published by Elsevier Ltd.
C1 [Lopes-Virella, Maria F.; Huang, Yan] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC 29401 USA.
[Jin, Junfei; Samuvel, Devadoss J.; Zhang, Xiaoming; Li, Yanchun; Lu, Zhongyang; Lopes-Virella, Maria F.; Huang, Yan] Med Univ S Carolina, Div Endocrinol Diabet & Med Genet, Dept Med, Charleston, SC 29425 USA.
RP Huang, Y (reprint author), Med Univ S Carolina, Div Endocrinol Diabet & Med Genet, Dept Med, 114 Doughty St, Charleston, SC 29403 USA.
EM huangyan@musc.edu
FU NIH [DE016353]; Department of Veterans Affairs
FX This work was supported by NIH grant DE016353 and a Merit Review Grant
from Department of Veterans Affairs (to Y.H.).
NR 52
TC 16
Z9 16
U1 0
U2 5
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0161-5890
J9 MOL IMMUNOL
JI Mol. Immunol.
PD DEC
PY 2011
VL 49
IS 3
BP 423
EP 432
DI 10.1016/j.molimm.2011.08.026
PG 10
WC Biochemistry & Molecular Biology; Immunology
SC Biochemistry & Molecular Biology; Immunology
GA 872AV
UT WOS:000298779700002
PM 22030478
ER
PT J
AU Pelak, VS
Smyth, SF
Boyer, PJ
Filley, CM
AF Pelak, Victoria S.
Smyth, Shawn F.
Boyer, Philip J.
Filley, Christopher M.
TI Computerized visual field defects in posterior cortical atrophy
SO NEUROLOGY
LA English
DT Article
ID ALZHEIMERS-DISEASE; DEMENTIA; CONSORTIUM; DIAGNOSIS; SERIES
AB Background and objective: Posterior cortical atrophy (PCA) is a progressive neurodegenerative syndrome that presents with cortical visual dysfunction and relatively preserved memory. Although higher cortical visual syndromes are well known in PCA, visual field defects detected by computerized visual field (CVF) perimetry have not been systematically described. The objective of this study was to describe CVF defects measured by threshold perimetry in PCA.
Methods: This was a retrospective case series of patients meeting proposed PCA diagnostic criteria seen in the Neuro-ophthalmology and Neurobehavior Clinics at the University of Colorado during 2002 to 2006. History, examination, neuroimaging, autopsy, and CVF studies were analyzed.
Results: Nine of 11 patients who met the criteria for PCA and had CVF testing were included. Seven of the 9 patients had homonymous hemianopia or quadrantanopia, and 2 had bilateral constriction. All patients progressed to dementia. Criteria were met for probable Alzheimer disease (AD) in 7, definite AD in 1, and definite dementia with Lewy bodies associated with AD pathology in 1. Seven of 9 patients had early and prominent complaints of difficulty driving.
Conclusions: CVF defects were characterized by homonymous visual field defects or bilateral constriction. Eight of 9 patients progressed to probable or definite AD, but the CVF defects were distinctly different from those in typical AD. This observation probably reflects a posterior shift of cortical pathology to the primary and early secondary visual cortices in PCA. CVF testing should be considered in older patients with unexplained visual complaints, particularly when associated with difficulty driving, which may indicate the possibility of PCA and prompt early neurobehavioral evaluation. Neurology (R) 2011; 77:2119-2122
C1 [Pelak, Victoria S.; Smyth, Shawn F.; Filley, Christopher M.] Univ Colorado Denver Sch Med, Dept Neurol, Denver, CO USA.
[Boyer, Philip J.] Univ Colorado Denver Sch Med, Dept Pathol, Denver, CO USA.
[Pelak, Victoria S.] Univ Colorado Denver Sch Med, Dept Ophthalmol, Denver, CO USA.
[Filley, Christopher M.] Univ Colorado Denver Sch Med, Dept Psychiat, Denver, CO USA.
[Pelak, Victoria S.; Filley, Christopher M.] Denver Vet Affairs Med Ctr, Denver, CO USA.
RP Pelak, VS (reprint author), Acad Off 1,Mailstop B185,12631 E 17th Ave,Room 52, Aurora, CO 80045 USA.
EM victoria.pelak@ucdenver.edu
FU UpToDate, Inc.; NIH; Alzheimer's Association; University Press of
Colorado; Behavioral Neurology of White Matter (Oxford University
Press); University of Colorado Alzheimer's Disease and Cognition Center
(ADCC); NIH/NIAMSD
FX Dr. Pelak receives publishing royalties from UpToDate, Inc.; serves as a
consultant for Anthem Blue Cross and Blue Shield; receives research
support from the NIH and the Alzheimer's Association; and has given
expert testimony in medico-legal cases. Dr. Smyth reports no
disclosures. Dr. Boyer serves on the editorial board of the Journal of
Pathology Informatics and has given expert testimony in medico-legal
cases. Dr. Filley receives publishing royalties for Neurobehavioral
Anatomy, 2nd ed.(University Press of Colorado, 2001) and The Behavioral
Neurology of White Matter (Oxford University Press, 2001); receives
research support from University of Colorado Alzheimer's Disease and
Cognition Center (ADCC), Alzheimer's Association, and the NIH/NIAMSD;
and has given expert testimony in medico-legal cases.
NR 18
TC 12
Z9 12
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0028-3878
J9 NEUROLOGY
JI Neurology
PD DEC
PY 2011
VL 77
IS 24
BP 2119
EP 2122
DI 10.1212/WNL.0b013e31823e9f2a
PG 4
WC Clinical Neurology
SC Neurosciences & Neurology
GA 865PT
UT WOS:000298323500015
PM 22131540
ER
PT J
AU McGinnis, KA
Brandt, CA
Skanderson, M
Justice, AC
Shahrir, S
Butt, AA
Brown, ST
Freiberg, MS
Gibert, CL
Goetz, MB
Kim, JW
Pisani, MA
Rimland, D
Rodriguez-Barradas, MC
Sico, JJ
Tindle, HA
Crothers, K
AF McGinnis, Kathleen A.
Brandt, Cynthia A.
Skanderson, Melissa
Justice, Amy C.
Shahrir, Shahida
Butt, Adeel A.
Brown, Sheldon T.
Freiberg, Matthew S.
Gibert, Cynthia L.
Goetz, Matthew Bidwell
Kim, Joon Woo
Pisani, Margaret A.
Rimland, David
Rodriguez-Barradas, Maria C.
Sico, Jason J.
Tindle, Hilary A.
Crothers, Kristina
TI Validating Smoking Data From the Veteran's Affairs Health Factors
Dataset, an Electronic Data Source
SO NICOTINE & TOBACCO RESEARCH
LA English
DT Article
ID HIV-NEGATIVE VETERANS; INFECTION; MORTALITY; COHORT; DISEASE; SYSTEM;
IMPACT
AB We assessed smoking data from the Veterans Health Administration (VHA) electronic medical record (EMR) Health Factors dataset.
To assess the validity of the EMR Health Factors smoking data, we first created an algorithm to convert text entries into a 3-category smoking variable (never, former, and current). We compared this EMR smoking variable to 2 different sources of patient self-reported smoking survey data: (a) 6,816 HIV-infected and -uninfected participants in the 8-site Veterans Aging Cohort Study (VACS-8) and (b) a subset of 13,689 participants from the national VACS Virtual Cohort (VACS-VC), who also completed the 1999 Large Health Study (LHS) survey. Sensitivity, specificity, and kappa statistics were used to evaluate agreement of EMR Health Factors smoking data with self-report smoking data.
For the EMR Health Factors and VACS-8 comparison of current, former, and never smoking categories, the kappa statistic was .66. For EMR Health Factors and VACS-VC/LHS comparison of smoking, the kappa statistic was .61.
Based on kappa statistics, agreement between the EMR Health Factors and survey sources is substantial. Identification of current smokers nationally within the VHA can be used in future studies to track smoking status over time, to evaluate smoking interventions, and to adjust for smoking status in research. Our methodology may provide insights for other organizations seeking to use EMR data for accurate determination of smoking status.
C1 [McGinnis, Kathleen A.; Skanderson, Melissa] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA 15206 USA.
[Brandt, Cynthia A.; Justice, Amy C.; Sico, Jason J.] VA Connecticut Healthcare Syst, West Haven, CT USA.
[Brandt, Cynthia A.] Yale Univ, Sch Med, Dept Emergency Med, New Haven, CT USA.
[Justice, Amy C.; Pisani, Margaret A.] Yale Univ, Dept Med, New Haven, CT 06520 USA.
[Shahrir, Shahida; Crothers, Kristina] Univ Washington, Harborview Med Ctr, Dept Med, Seattle, WA 98104 USA.
[Butt, Adeel A.; Freiberg, Matthew S.; Tindle, Hilary A.] Univ Pittsburgh, Sch Med, Dept Med, Pittsburgh, PA USA.
[Brown, Sheldon T.; Kim, Joon Woo] James J Peterson VAMC, Bronx, NY USA.
[Gibert, Cynthia L.] VA Med Ctr, Washington, DC USA.
[Goetz, Matthew Bidwell] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
[Goetz, Matthew Bidwell] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
[Rimland, David] Emory Univ, Sch Med, Atlanta, GA USA.
[Rimland, David] VA Med Ctr, Atlanta, GA USA.
[Rodriguez-Barradas, Maria C.] Michael E DeBakey VAMC, Infect Dis Sect, Houston, TX USA.
[Rodriguez-Barradas, Maria C.] Baylor Coll Med, Dept Med, Houston, TX 77030 USA.
[Sico, Jason J.] Yale Univ, Sch Med, Dept Neurol, New Haven, CT 06510 USA.
RP McGinnis, KA (reprint author), VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, 7180 Highland Dr 151C-H, Pittsburgh, PA 15206 USA.
EM kathleen.mcginnis3@va.gov
OI Goetz, Matthew/0000-0003-4542-992X
FU VAHS HSRD [RCD 04-125-1]; National Institute on Aging (NIA) [K08
AG00826]; National Institute of Mental Health; National Institute on
Alcohol Abuse and Alcoholism [U01-13566]; NIH/NHLBI [1R01 HL090342]
FX Supported by VAHS HSR&D RCD 04-125-1, NIA K08 AG00826, an interagency
agreement between the National Institute on Aging and the National
Institute of Mental Health, and the National Institute on Alcohol Abuse
and Alcoholism (Grant No. U01-13566; ACJ); NIH/NHLBI 1R01 HL090342 (KC).
NR 23
TC 37
Z9 37
U1 1
U2 5
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1462-2203
J9 NICOTINE TOB RES
JI Nicotine Tob. Res.
PD DEC
PY 2011
VL 13
IS 12
BP 1233
EP 1239
DI 10.1093/ntr/ntr206
PG 7
WC Substance Abuse; Public, Environmental & Occupational Health
SC Substance Abuse; Public, Environmental & Occupational Health
GA 852RY
UT WOS:000297376400009
PM 21911825
ER
PT J
AU Matlock, DD
Nowels, CT
Masoudi, FA
Sauer, WH
Bekelman, DB
Main, DS
Kutner, JS
AF Matlock, Dan D.
Nowels, Carolyn T.
Masoudi, Frederick A.
Sauer, William H.
Bekelman, David B.
Main, Deborah S.
Kutner, Jean S.
TI Patient and Cardiologist Perceptions on Decision Making for Implantable
Cardioverter-Defibrillators: A Qualitative Study
SO PACE-PACING AND CLINICAL ELECTROPHYSIOLOGY
LA English
DT Article
DE Implantable cardioverter-defibrillators; qualitative research; medical
decision making
ID HEART-FAILURE; OF-LIFE; PROPHYLACTIC IMPLANTATION; CARE; DEACTIVATION;
CONSEQUENCES; AMIODARONE; MANAGEMENT; THERAPY; CHOICE
AB Background: Although implantable cardioverter-defibrillators (ICDs) reduce mortality in selected patients, they are also associated with potential risks. Periprocedural decision making requires understanding both benefits and risks.
Methods: This qualitative study aims to understand cardiologists' and patients' perspectives about decision making surrounding ICD implantation using semi-structured, in-depth interviews. We interviewed 11 cardiologists (including four electrophysiologists) and 20 patients (14 with ICDs; six who declined ICDs). The data were analyzed through the theoretical lens of patient-centered care using the constant comparative method.
Results: Cardiologists emphasized the benefits of ICD therapy but varied substantially in the extent to which they emphasized the various risks associated with ICD implantation with patients. Cardiologists indicated that they were influenced by the benefits of therapy as presented in published guidelines. Many patients who chose to receive an ICD indicated that they followed the advice of their physician without questioning the risks and benefits of the device. Some ICD recipients described not learning many of the risks until after device implantation or when they experienced these side effects. Patients who declined ICD implantation were concerned that the ICD was unnecessary or believed that the risks related to sudden death without an ICD did not apply to them. Only one patient considered the trade-off between dying quickly versus living longer with progressive heart failure.
Conclusions: In our sample, cardiologists' desire to adhere to published guidelines appears to inhibit shared decision making. The marked variability in the discussions surrounding ICD decisions highlights a need for an improved process of ICD decision making. (PACE 2011; 34: 1634-1644)
C1 [Matlock, Dan D.] Univ Colorado, Acad Off 1, Dept Med, Div Gen Internal Med,Sch Med, Aurora, CO 80045 USA.
[Matlock, Dan D.; Masoudi, Frederick A.; Bekelman, David B.] Univ Colorado, Colorado Cardiovasc Outcomes Res Grp, Denver, CO 80202 USA.
[Matlock, Dan D.; Masoudi, Frederick A.] Univ Colorado, Kaiser Permanente Colorado, Inst Hlth Res, Denver, CO 80202 USA.
[Bekelman, David B.] Univ Colorado, Denver Vet Affairs Med Ctr, Denver, CO 80202 USA.
[Main, Deborah S.] Univ Colorado, Dept Hlth & Behav Sci, Denver, CO 80202 USA.
RP Matlock, DD (reprint author), Univ Colorado, Acad Off 1, Dept Med, Div Gen Internal Med,Sch Med, 12631 E 17th Ave,Campus Box B-180, Aurora, CO 80045 USA.
EM daniel.matlock@ucdenver.edu
FU Foundation for Informed Medical Decision Making (FIMDM)
FX Financial support for this study was provided by a George Bennett
Postdoctoral Research Grant from the Foundation for Informed Medical
Decision Making (FIMDM) awarded to Dr. Matlock. The views in this
article are those of the authors and do not necessarily reflect the
views of the Department of Veterans Affairs.
NR 38
TC 25
Z9 26
U1 0
U2 3
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0147-8389
J9 PACE
JI PACE-Pacing Clin. Electrophysiol.
PD DEC
PY 2011
VL 34
IS 12
BP 1634
EP 1644
DI 10.1111/j.1540-8159.2011.03237.x
PG 11
WC Cardiac & Cardiovascular Systems; Engineering, Biomedical
SC Cardiovascular System & Cardiology; Engineering
GA 860HZ
UT WOS:000297940700013
PM 21972983
ER
PT J
AU Naik, AD
Teal, CR
Rodriguez, E
Haidet, P
AF Naik, Aanand D.
Teal, Cayla R.
Rodriguez, Elisa
Haidet, Paul
TI Knowing the ABCs: A comparative effectiveness study of two methods of
diabetes education
SO PATIENT EDUCATION AND COUNSELING
LA English
DT Article
DE Diabetes education; Self-management; Patient empowerment; Team-based
learning; Group clinics
ID SELF-MANAGEMENT EDUCATION; GLYCEMIC CONTROL; HYPERTENSION CONTROL;
PATIENT EMPOWERMENT; VULNERABLE PATIENTS; CARE; A1C; KNOWLEDGE;
OUTCOMES; ADULTS
AB Objective: To test an active-learning, empowerment approach to teaching patients about the "diabetes ABCs" (hemoglobin A(1)C, systolic blood pressure, and low density lipoprotein cholesterol).
Methods: 84 (97%) diabetic patients who participated in a randomized effectiveness trial of two clinic-based group educational methods and completed a post-intervention assessment. The empowerment arm participated in a group session that incorporated two educational innovations (a conceptual metaphor to foster understanding, and team-based learning methods to foster active learning). The traditional diabetes education arm received a didactic group session focused on self-management and educational materials about the diabetes ABCs. Participants in both arms received individual review of their current ABC values.
Results: A questionnaire evaluated knowledge, understanding, and recall of the diabetes ABCs was administered three months after enrollment in the study. At three months, participants in the empowerment group demonstrated greater understanding of the diabetes ABCs (P < 0.0001), greater knowledge of their own values (P < 0.0001), and greater knowledge of guideline-derived target goals for the ABCs compared with participants in the traditional arm (P < 0.0001).
Conclusion: An active-learning, empowerment-based approach applied to diabetes education can lead to greater understanding and knowledge retention. Practice implications: An empowerment approach to education can facilitate informed, activated patients and increase performance of self-management behaviors. Published by Elsevier Ireland Ltd.
C1 [Naik, Aanand D.; Rodriguez, Elisa] Michael E DeBakey VA Med Ctr, Houston Hlth Serv Res & Dev Ctr Excellence, Houston, TX USA.
[Naik, Aanand D.; Teal, Cayla R.] Baylor Coll Med, Dept Med, Houston, TX 77030 USA.
[Haidet, Paul] Penn State Univ, Coll Med, Off Med Educ, Hershey, PA USA.
[Haidet, Paul] Penn State Univ, Coll Med, Dept Med, Hershey, PA USA.
[Haidet, Paul] Penn State Univ, Coll Med, Dept Humanities, Hershey, PA USA.
[Naik, Aanand D.; Rodriguez, Elisa; Haidet, Paul] Houston Ctr Res & Educ Therapeut, Houston, TX USA.
[Teal, Cayla R.] Baylor Coll Med, Off Undergrad Med Educ, Houston, TX 77030 USA.
RP Naik, AD (reprint author), Michael E DeBakey VA Med Ctr 152, Houston Hlth Serv Res & Dev Ctr Excellence, 2002 Holcombe Blvd, Houston, TX 77030 USA.
EM anaik@bcm.edu
RI Herring, Anna/L-7859-2014
FU Agency for Healthcare Research and Quality [U18HS016093]; Centers for
Research and Education on Therapeutics (Houston CERT. Suarez-Almazor,
PI); Doris Duke Charitable Foundation; National Institute on Aging
[K23AG027144]
FX This work was supported by a grant from the Agency for Healthcare
Research and Quality (#U18HS016093), Centers for Research and Education
on Therapeutics (Houston CERT. Suarez-Almazor, PI). The authors
acknowledge additional project support from a Clinical Scientist
Development Award from the Doris Duke Charitable Foundation and
resources in the preparation of this manuscript from the Houston Health
Services Research and Development Center of Excellence (HFP90-020) at
the Michael E. DeBakey VA Medical Center. Dr. Naik receives additional
support from the National Institute on Aging (K23AG027144). These
sources had no role in the preparation, review, or approval of the
manuscript. The authors thank Andrea Price, BA, and Donna Rochon, PhD,
for their assistance with patient recruitment, retention and project
support, Teresa Zhang, PhD, and Annette Walder, MS with data analysis.
NR 29
TC 6
Z9 6
U1 0
U2 13
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
IRELAND
SN 0738-3991
J9 PATIENT EDUC COUNS
JI Patient Educ. Couns.
PD DEC
PY 2011
VL 85
IS 3
BP 383
EP 389
DI 10.1016/j.pec.2011.01.010
PG 7
WC Public, Environmental & Occupational Health; Social Sciences,
Interdisciplinary
SC Public, Environmental & Occupational Health; Social Sciences - Other
Topics
GA 864EM
UT WOS:000298219800008
PM 21300516
ER
PT J
AU Naik, AD
Street, RL
Castillo, D
Abraham, NS
AF Naik, Aanand D.
Street, Richard L., Jr.
Castillo, Diana
Abraham, Neena S.
TI Health literacy and decision making styles for complex antithrombotic
therapy among older multimorbid adults
SO PATIENT EDUCATION AND COUNSELING
LA English
DT Article
DE Aging; Drugs; Prevention; Literacy; Doctor-patient relationship
ID PATIENT PARTICIPATION; IDENTIFY PATIENTS; COMMUNICATION; PREFERENCES;
QUESTIONS; ENCOUNTER; OUTCOMES; CANCER; RISK
AB Objectives: To evaluate the effect of functional health literacy (FHL) on preferences for decision-making; and among those initially preferring a passive decision-making role, to explore how preferences change if their physician actively encourages their involvement.
Methods: Consecutive older adults with cardiovascular disease receiving complex antithrombotic therapy completed a comprehensive assessment including measures of FHL and preferences for shared decision making.
Results: Half of all participants had inadequate or marginal FHL. Those with inadequate FHL were more likely (P = 0.01) to prefer passive rather than active decision making styles even after controlling for age, education, and numeracy. However, 40% of patients preferring passive styles had adequate FHL and these patients were significantly more likely to change their preference to more active styles (odds ratio = 7.17, P < .01) if their physician "was more supportive or encouraged participation".
Conclusions: Screening FHL can provide insight into patients' preferences for active participation in decision making. Clinicians' encouragement of participation can increase engagement by patients with adequate FHL.
Practice implications: We propose an algorithm for screening FHL and preferences for participating in decisions about complex medication regimens. Published by Elsevier Ireland Ltd.
C1 [Naik, Aanand D.; Street, Richard L., Jr.; Castillo, Diana; Abraham, Neena S.] Michael E DeBakey VA Med Ctr, Houston HSR&D Ctr Excellence, Houston, TX USA.
[Naik, Aanand D.; Abraham, Neena S.] Baylor Coll Med, Dept Med, Houston, TX 77030 USA.
[Street, Richard L., Jr.] Texas A&M Univ, Dept Commun, College Stn, TX USA.
RP Naik, AD (reprint author), Michael E DeBakey VA Med Ctr 152, 2002 Holcombe Blvd, Houston, TX 77030 USA.
EM anaik@bcm.tmc.edu
FU Houston Veterans Affairs Health Sciences Research and Development Center
of Excellence [HFP90-020]; National Institute on Aging [K23AG027144];
Doris Duke Charitable Foundation; American Gastroenterological
Association Foundation-Sucampo-Association; Department of Veterans
Affairs [VA IIR 08-028]
FX This study was supported by a locally funded pilot grant and use of
facilities at the Houston Veterans Affairs Health Sciences Research and
Development Center of Excellence (HFP90-020). Dr. Naik is also supported
by a National Institute on Aging Career Development Award (K23AG027144)
and a Doris Duke Charitable Foundation Clinical Scientist Development
Award. Dr. Abraham is supported by an American Gastroenterological
Association Foundation-Sucampo-Association of Specialty Professors
Designated Research Award in Geriatric Gastroenterology and by a Merit
Review Award from the Department of Veterans Affairs (VA IIR 08-028). No
funding agencies had a role in the design and conduct of the study,
analysis and interpretation of data, or preparation and approval of the
manuscript. The views expressed herein are those of the authors and do
not necessarily reflect those of the Department of Veterans Affairs or
Baylor College of Medicine.
NR 32
TC 18
Z9 18
U1 3
U2 7
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
IRELAND
SN 0738-3991
J9 PATIENT EDUC COUNS
JI Patient Educ. Couns.
PD DEC
PY 2011
VL 85
IS 3
BP 499
EP 504
DI 10.1016/j.pec.2010.12.015
PG 6
WC Public, Environmental & Occupational Health; Social Sciences,
Interdisciplinary
SC Public, Environmental & Occupational Health; Social Sciences - Other
Topics
GA 864EM
UT WOS:000298219800025
PM 21251788
ER
PT J
AU Arjomandi, M
Galanter, JM
Choudhry, S
Eng, C
Hu, DL
Beckman, K
Chapela, R
Rodriguez-Santana, JR
Rodriguez-Cintron, W
Ford, J
Avila, PC
Burchard, EG
AF Arjomandi, Mehrdad
Galanter, Josh M.
Choudhry, Shweta
Eng, Celeste
Hu, Donglei
Beckman, Kenneth
Chapela, Rocio
Rodriguez-Santana, Jose R.
Rodriguez-Cintron, William
Ford, Jean
Avila, Pedro C.
Burchard, Esteban G.
TI Polymorphism in Osteopontin Gene (SPP1) Is Associated with Asthma and
Related Phenotypes in a Puerto Rican Population
SO PEDIATRIC ALLERGY IMMUNOLOGY AND PULMONOLOGY
LA English
DT Article
ID MURINE MODEL; MICE LACKING; EXPRESSION; DISEASE; RISK; TNF-ALPHA-308;
EPIDEMIOLOGY; EOSINOPHILS; MACROPHAGES; ACTIVATION
AB Recent studies have shown that osteopontin, a cytokine with suggested immunoregulatory functions, may contribute to pathogenesis of asthma. To determine whether single-nucleotide polymorphisms (SNPs) in SPP1, the gene encoding osteopontin, are associated with risk of asthma, we genotyped 6 known SNPs in SPP1 in the well-characterized Genetics of Asthma in Latino Americans population of 294 Mexican and 365 Puerto Rican parent-child asthma trios. The associations between SNPs and asthma or asthma-related phenotypes were examined by transmission disequilibrium tests as implemented in the family-based association test program. Three polymorphisms, 1 in exon 7 (rs1126616C) and 2 in the 3'-untranslated region (rs1126772A and rs9138A) of SPP1, were associated with diagnosis of asthma, severity of asthma, asthma in subjects with elevated immunoglobulin E (IgE) (IgE > 100 IU/mL), and postbronchodilator FEV(1) in Puerto Ricans (P values = 0.00007-0.04). The CC genotype of rs1126616 conferred an odds ratio of 1.7 (95% CI = [1.3, 2.3], P value adjusted for multiple comparisons = 0.001) for asthma compared with the CT and TT genotypes. Furthermore, haplotype analysis identified rs1126616C-rs1126772A-rs9138A to be associated with an increased risk for asthma, severity of asthma, and asthma in subjects with elevated IgE (P = 0.03). There was no association between the SPP1 SNPs and asthma outcomes in Mexicans. Our findings suggest that the SPP1 gene is a risk factor for asthma and asthma-related phenotypes in Puerto Ricans, and are consistent with previous animal and human studies on the role of osteopontin in pathogenesis of asthma.
C1 [Arjomandi, Mehrdad] Univ Calif San Francisco, Div Pulm & Crit Care Med, San Francisco Vet Affairs Med Ctr, San Francisco, CA 94121 USA.
[Arjomandi, Mehrdad] Univ Calif San Francisco, Human Exposure Lab, San Francisco, CA 94121 USA.
[Galanter, Josh M.; Choudhry, Shweta; Eng, Celeste; Hu, Donglei; Burchard, Esteban G.] Univ Calif San Francisco, Dept Med, Lung Biol Ctr, San Francisco, CA 94121 USA.
[Choudhry, Shweta; Eng, Celeste; Hu, Donglei; Burchard, Esteban G.] Univ Calif San Francisco, Dept Epidemiol & Biostat, Inst Human Genet, San Francisco, CA 94121 USA.
[Beckman, Kenneth] Univ Minnesota, Biomed Genom Ctr, Minneapolis, MN USA.
[Chapela, Rocio] Inst Nacl Enfermedades Resp, Mexico City, DF, Mexico.
[Rodriguez-Santana, Jose R.; Rodriguez-Cintron, William] CSP, Ctr Neumol Pediat, San Juan, PR USA.
[Ford, Jean] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA.
[Avila, Pedro C.] Northwestern Univ, Div Allergy Immunol, Chicago, IL 60611 USA.
[Burchard, Esteban G.] Univ Calif San Francisco, Dept Bioengn & Therapeut Sci, San Francisco, CA 94121 USA.
RP Arjomandi, M (reprint author), Univ Calif San Francisco, Div Pulm & Crit Care Med, San Francisco Vet Affairs Med Ctr, Bldg 203,Room 3A-128,Mailstop 111-D,4150 Clement, San Francisco, CA 94121 USA.
EM mehrdad.arjomandi@ucsf.edu
FU NIH/NHLBI [HL083099]; GALA [HL078885, HL088133]; tobacco-related disease
research program (TRDRP) (GALA) [15KT-0008]; Northern California
Institute for Research and Education (Arjomandi); University of
California San Francisco Cardiovascular Research Institute Faculty
(Arjomandi)
FX This study was supported by NIH/NHLBI HL083099 (Arjomandi K23 award),
HL078885, and HL088133 (GALA funding), tobacco-related disease research
program (TRDRP) 15KT-0008 (GALA funding), Northern California Institute
for Research and Education (Arjomandi), and University of California San
Francisco Cardiovascular Research Institute Faculty Development Funds
(Arjomandi).
NR 51
TC 9
Z9 11
U1 0
U2 1
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 2151-321X
J9 PEDIAT ALLER IMM PUL
JI Pediatr. Allergy Immunol. Pulmonol.
PD DEC
PY 2011
VL 24
IS 4
BP 207
EP 214
DI 10.1089/ped.2011.0095
PG 8
WC Allergy; Immunology; Pediatrics; Respiratory System
SC Allergy; Immunology; Pediatrics; Respiratory System
GA 864IT
UT WOS:000298234100005
ER
PT J
AU Baca, CB
Vickrey, BG
Caplan, R
Vassar, SD
Berg, AT
AF Baca, Christine B.
Vickrey, Barbara G.
Caplan, Rochelle
Vassar, Stefanie D.
Berg, Anne T.
TI Psychiatric and Medical Comorbidity and Quality of Life Outcomes in
Childhood-Onset Epilepsy
SO PEDIATRICS
LA English
DT Article
DE epilepsy; psychiatric comorbidity; quality of life; Child Health
Questionnaire; child and adolescent health
ID WELL-CONTROLLED EPILEPSY; NEWLY-DIAGNOSED EPILEPSY; LONG-TERM PROGNOSIS;
PEDIATRIC EPILEPSY; DEPRESSIVE SYMPTOMS; SPECTRUM DISORDER; CHILDREN;
HEALTH; ADOLESCENTS; SEIZURE
AB OBJECTIVE: We compared associations of epilepsy remission status and severity as well as psychiatric and other comorbidities with child and parent-proxy reports of health-related quality of life (HRQoL) in adolescents previously diagnosed with epilepsy.
METHODS: In a prospective, community-based study of newly diagnosed childhood epilepsy, HRQoL of 277 children was assessed 8 to 9 years after diagnosis by using child and parent-proxy versions of the Child Health Questionnaire (CHQ). Multiple linear regression models adjusted for age and gender were used to compare associations of epilepsy remission and "complicated" epilepsy (secondary to an underlying neurologic insult or epileptic encephalopathy) status and psychiatric and other comorbidities with HRQoL.
RESULTS: Mean age of epilepsy onset was 4.4 years (SD: 2.6). At the 9-year reassessment, children were, on average, 13.0 years old (SD: 2.6); 64% were seizure-free for 5 years, 31% were taking antiepileptic drugs, and 19% had a complicated epilepsy. Prevalence of comorbidities at follow-up were 26% psychiatric diagnosis; 39% neurodevelopmental spectrum disorder (NDSD); 24% chronic medical illness; and 15% migraine. In multivariable analysis, having a psychiatric disorder was broadly associated with child (6 of 11 scales) and parent-proxy (7 of 12 scales) HRQoL (P <= .0125). Five-year remission and complicated epilepsy status had few or no associations with HRQoL. Although parent-proxy HRQoL was strongly associated with NDSD (6 of 11 scales), child-reported HRQoL was not (2 of 11 scales).
CONCLUSIONS: Psychiatric comorbidities are strongly associated with long-term HRQoL in childhood-onset epilepsy, which suggests that comprehensive epilepsy care must include screening and treatment for these conditions, even if seizures remit. Pediatrics 2011;128:e1532-e1543
C1 [Baca, Christine B.; Vickrey, Barbara G.; Vassar, Stefanie D.] Univ Calif Los Angeles, Dept Neurol, Los Angeles, CA 90095 USA.
[Baca, Christine B.; Vickrey, Barbara G.; Vassar, Stefanie D.] Univ Calif Los Angeles, Dept Psychiat, Los Angeles, CA 90095 USA.
[Caplan, Rochelle] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
[Berg, Anne T.] NW Childrens Hosp, Chicago, IL USA.
RP Baca, CB (reprint author), Univ Calif Los Angeles, Dept Neurol, Box 951769,C-239 RNRC, Los Angeles, CA 90095 USA.
EM cbower@mednet.ucla.edu
FU National Institutes of Health (NIH); National Institutes of Health,
National Institute of Neurological Disorders and Stroke [R37-NS31146];
Robert Wood Johnson Foundation [59982]
FX Funded by the National Institutes of Health (NIH).; This work was
supported by National Institutes of Health, National Institute of
Neurological Disorders and Stroke grant R37-NS31146 (principal
investigator Dr Berg). Dr Baca was supported by Robert Wood Johnson
Foundation Clinical Scholars Program grant 59982.
NR 77
TC 57
Z9 58
U1 2
U2 13
PU AMER ACAD PEDIATRICS
PI ELK GROVE VILLAGE
PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA
SN 0031-4005
J9 PEDIATRICS
JI Pediatrics
PD DEC
PY 2011
VL 128
IS 6
BP E1532
EP E1543
DI 10.1542/peds.2011-0245
PG 12
WC Pediatrics
SC Pediatrics
GA 862ZA
UT WOS:000298131400021
PM 22123895
ER
PT J
AU Broyles, LM
Rodriguez, KL
Price, PA
Bayliss, NK
Sevick, MA
AF Broyles, Lauren Matukaitis
Rodriguez, Keri L.
Price, Patrice A.
Bayliss, Nichole K.
Sevick, Mary Ann
TI Overcoming Barriers to the Recruitment of Nurses as Participants in
Health Care Research
SO QUALITATIVE HEALTH RESEARCH
LA English
DT Article
DE alcohol / alcoholism; focus groups; health care; health care, acute /
critical; nursing; relationships, research; research participation;
research, access to participants; research, qualitative; sensitive
topics
ID QUALITY-OF-LIFE; NURSING-RESEARCH; FOCUS GROUPS; PERCEPTIONS;
EXPERIENCES; INTERVIEWS; STRATEGIES; PROVIDERS; EMPLOYEES; HEART
AB Adequate participant recruitment is critical for the successful execution of research studies involving human subjects. Participant recruitment can be particularly challenging when the intended study participants are health care providers as opposed to patients. Discussions of the challenges and successful strategies associated with provider recruitment are limited, particularly regarding providers other than physicians and settings outside of primary care. Using a case study format, we present our experiences recruiting inpatient nurses into a study which involved focus group methodology at a United States Veterans Health Administration facility. We describe the initial logistical and ethical issues involved, various challenges we encountered, and five successful action strategies used during a second recruitment wave addressing logistical issues; on-site recruitment; increased scheduling flexibility and peer-to-peer recruitment; attention to the sensitive nature of the research topic; and increased involvement of stakeholders. In conclusion, we advocate for multimodal recruitment strategies that facilitate ongoing investigator-clinician partnerships.
C1 [Broyles, Lauren Matukaitis; Rodriguez, Keri L.; Bayliss, Nichole K.; Sevick, Mary Ann] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA 15206 USA.
[Broyles, Lauren Matukaitis] VA Pittsburgh Healthcare Syst, Mental Illness Res Educ & Clin Ctr, Pittsburgh, PA 15206 USA.
[Rodriguez, Keri L.; Sevick, Mary Ann] VA Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA 15206 USA.
[Price, Patrice A.] VA Pittsburgh Healthcare Syst, Crit Care Serv Line, Pittsburgh, PA 15206 USA.
RP Broyles, LM (reprint author), VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, 7180 Highland Dr,151C-H, Pittsburgh, PA 15206 USA.
EM Lauren.Broyles@va.gov
NR 53
TC 7
Z9 7
U1 0
U2 5
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1049-7323
J9 QUAL HEALTH RES
JI Qual. Health Res.
PD DEC
PY 2011
VL 21
IS 12
BP 1705
EP 1718
DI 10.1177/1049732311417727
PG 14
WC Information Science & Library Science; Social Sciences,
Interdisciplinary; Social Sciences, Biomedical
SC Information Science & Library Science; Social Sciences - Other Topics;
Biomedical Social Sciences
GA 854VJ
UT WOS:000297522600009
PM 21844286
ER
PT J
AU Thompson, GR
Wickes, BL
Herrera, ML
Haman, TC
Lewis, JS
Jorgensen, JH
AF Thompson, G. R., III
Wickes, B. L.
Herrera, M. L.
Haman, T. C.
Lewis, J. S., II
Jorgensen, J. H.
TI Disseminated Burkholderia gladioli infection in a lung transplant
recipient with underlying hypocomplementemic urticarial vasculitis
SO TRANSPLANT INFECTIOUS DISEASE
LA English
DT Article
DE hypocomplementemic urticarial vasculitis; Burkholderia gladioli;
Burkholderia; lung transplantation
ID CHRONIC GRANULOMATOUS-DISEASE; CYSTIC-FIBROSIS; PSEUDOMONAS-AERUGINOSA;
IDENTIFICATION; CEPACIA; ANTIBODIES; PCR
AB Burkholderia gladioli is difficult to definitively identify within the laboratory using phenotypic testing alone. We describe a case of recurrent B. gladioli infection in a lung transplant recipient with underlying hypocomplementemic urticarial vasculitis syndrome, discuss the difficulties encountered with laboratory identification, provide a review of the methodology required for definitive identification, and discuss potential pathophysiologic mechanisms in this patient responsible for the difficulty in treatment.
C1 [Thompson, G. R., III] Univ Calif Davis, Coccidioidomycosis Serol Lab, Dept Med Microbiol & Immunol, Davis, CA 95616 USA.
[Thompson, G. R., III] Univ Calif Davis, Dept Internal Med, Div Infect Dis, Davis, CA 95616 USA.
[Wickes, B. L.; Herrera, M. L.; Jorgensen, J. H.] Univ Texas San Antonio, Dept Microbiol, Hlth Sci Ctr San Antonio, San Antonio, TX USA.
[Haman, T. C.] S Texas Vet Hlth Care Syst, San Antonio, TX USA.
[Lewis, J. S., II] Univ Hlth Syst, Dept Pharm, San Antonio, TX USA.
RP Thompson, GR (reprint author), Univ Calif Davis, Coccidioidomycosis Serol Lab, Dept Med Microbiol & Immunol, 1 Shields Ave,Tupper Hall, Davis, CA 95616 USA.
EM george.thompson@ucdmc.ucdavis.edu
NR 24
TC 1
Z9 1
U1 1
U2 2
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1398-2273
J9 TRANSPL INFECT DIS
JI Transpl. Infect. Dis.
PD DEC
PY 2011
VL 13
IS 6
BP 641
EP 645
DI 10.1111/j.1399-3062.2011.00638.x
PG 5
WC Immunology; Infectious Diseases; Transplantation
SC Immunology; Infectious Diseases; Transplantation
GA 865RL
UT WOS:000298327900013
PM 21504528
ER
PT J
AU Chin, CT
Weintraub, WS
Dai, D
Mehta, RH
Rumsfeld, JS
Anderson, HV
Messenger, JC
Kutcher, MA
Peterson, ED
Brindis, RG
Rao, SV
AF Chin, Chee Tang
Weintraub, William S.
Dai, David
Mehta, Rajendra H.
Rumsfeld, John S.
Anderson, H. Vernon
Messenger, John C.
Kutcher, Michael A.
Peterson, Eric D.
Brindis, Ralph G.
Rao, Sunil V.
TI Trends and predictors of length of stay after primary percutaneous
coronary intervention: A report from the CathPCI Registry
SO AMERICAN HEART JOURNAL
LA English
DT Article
ID ACUTE MYOCARDIAL-INFARCTION; CARDIOVASCULAR DATA REGISTRY; EARLY
DISCHARGE; PRIMARY ANGIOPLASTY; COST-EFFECTIVENESS; MORTALITY; OUTCOMES
AB Background Post hoc analyses of clinical trials suggest that certain patients are eligible for early discharge after ST-segment elevation myocardial infarction. The extent to which ST-segment elevation myocardial infarction patients are discharged early after primary percutaneous coronary intervention (PPCI) in current practice is unknown.
Methods We examined 115,113 patients in the CathPCI Registry to assess temporal trends in length of stay (LOS) after PPCI. Baseline characteristics were compared between patients with LOS <= 2 and >2 days. Predictors of LOS >2 days were determined by logistic regression and adjusted for clustering among centers. Patterns of discharge within 2 days for low-risk patients with no inhospital complications were examined.
Results From January 2005 through March 2009, mean LOS (4.0 +/- 3.0 to 3.6 +/- 2.7 days) (P for trend <.001) and the proportion of patients discharged after 2 days decreased (72.0%-65.9%), while predicted inhospital mortality risk remained unchanged. Patients with LOS >2 days (n = 77,471; 67.3%) were older and more likely to have had an intra-aortic balloon pump, cardiogenic shock, transfusions, and post-PPCI complications. Of 958 hospitals, 437 (45.6%) discharged at least half of their low-risk patients with no inhospital complications within 2 days.
Conclusions While the predicted risk profile has remained stable, there has been a significant decrease in LOS after PPCI. Nevertheless, hospitals vary in discharging low-risk and uncomplicated patients early. Discharge within 2 days was associated with specific patient, procedure, and hospital factors. Further study is needed to determine the safety of early discharge among patients undergoing PPCI. (Am Heart J 2011;162:1052-61.)
C1 [Chin, Chee Tang] Natl Heart Ctr Singapore, Singapore 168752, Singapore.
[Chin, Chee Tang; Dai, David; Mehta, Rajendra H.; Peterson, Eric D.; Rao, Sunil V.] Duke Clin Res Inst, Durham, NC USA.
[Weintraub, William S.] Christiana Care Hlth Syst, Newark, DE USA.
[Rumsfeld, John S.] Denver Vet Affairs Med Ctr, Denver, CO USA.
[Anderson, H. Vernon] Univ Texas Houston, Hlth Sci Ctr, Houston, TX USA.
[Messenger, John C.] Univ Colorado, Denver Sch Med, Aurora, CO USA.
[Kutcher, Michael A.] Wake Forest Univ, Sch Med, Winston Salem, NC 27109 USA.
[Brindis, Ralph G.] No Calif Kaiser Permanente, Oakland, CA USA.
RP Chin, CT (reprint author), Natl Heart Ctr Singapore, 17 3rd Hosp Ave, Singapore 168752, Singapore.
EM chin.chee.tang@nhcs.com.sg
FU Agency for Healthcare Research and Quality (AHRQ) [U18HS016964]
FX This project was supported by grant number U18HS016964 from the Agency
for Healthcare Research and Quality (AHRQ). The content is solely the
responsibility of the authors and does not necessarily represent the
official views of the AHRQ. The funding source had no role in the design
or implementation of the study, or in the decision to seek publication.
NR 16
TC 10
Z9 10
U1 0
U2 4
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-8703
J9 AM HEART J
JI Am. Heart J.
PD DEC
PY 2011
VL 162
IS 6
BP 1052
EP 1061
DI 10.1016/j.ahj.2011.09.008
PG 10
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 861QC
UT WOS:000298033300013
PM 22137079
ER
PT J
AU Donohue, JM
Zhang, YT
Men, AM
Perera, S
Lave, JR
Hanlon, JT
Reynolds, CF
AF Donohue, Julie M.
Zhang, Yuting
Men, Aiju
Perera, Subashan
Lave, Judith R.
Hanlon, Joseph T.
Reynolds, Charles F.
TI Impact of Medicare Part D on Antidepressant Treatment, Medication
Choice, and Adherence Among Older Adults With Depression
SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY
LA English
DT Article
DE Adherence; depression; insurance coverage; medicare
ID PRIMARY-CARE PATIENTS; MAJOR DEPRESSION; HEALTH-SERVICES; DRUG;
SYMPTOMS; COST; NONADHERENCE; BENEFICIARIES; MORTALITY; TRIAL
AB Objectives: Depression in older adults is often undertreated due, in part, to medication costs. We examined the impact of improved prescription drug coverage under Medicare Part D on use of antidepressants, medication choice, and adherence.
Design, Setting and Participants: Observational claims-based study of older adults with depression (ICD-9: 296.2, 296.3, 311, 300.4) continuously enrolled in a Medicare managed care plan between 2004 and 2007. Three groups with limited ($ 150 or $ 350 quarterly caps) or no drug coverage in 2004-2005 obtained Part D benefits in 2006. A comparison group had stable employer-sponsored coverage throughout.
Measurements: Any antidepressant prescription fill, antidepressant choice (tricyclics or monoamine oxidase inhibitors versus newer antidepressants), and adherence (80% of days covered) in the first 6 months of treatment. Results: Part D was associated with increased odds of any antidepressant use among those who previously lacked coverage (odds ratio [OR] 1.61, 95% confidence interval [CI] 1.41-1.85) but odds of use did not change among those with limited prior coverage. Use of older antidepressant agents did not change with Part D. All three groups whose coverage improved with Part D had significantly higher odds of 80% of days covered with an antidepressant (OR = 1.86 [95% CI: 1.44-2.39] for no coverage, 1.74 [95% CI: 1.25% 3.42] for $ 150 cap; and 1.19 [95% CI: 1.06-1.34] for the $ 350 cap groups).
Conclusions: Medicare Part D was associated with improvements in antidepressant use and adherence in depressed older adults who previously had no or limited drug coverage but not with changes in use of older agents. use and adherence in depressed older adults who previously had no or limited drug coverage but not with changes in use of older agents. (Am J Geriatr Psychiatry 2011; 19:989-997)
C1 [Donohue, Julie M.; Zhang, Yuting; Lave, Judith R.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Hlth Policy & Management, Pittsburgh, PA 15261 USA.
[Donohue, Julie M.; Reynolds, Charles F.] Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA 15261 USA.
[Perera, Subashan; Hanlon, Joseph T.] Univ Pittsburgh, Sch Med, Dept Geriatr Med, Pittsburgh, PA 15261 USA.
[Perera, Subashan; Hanlon, Joseph T.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Biostat, Pittsburgh, PA 15261 USA.
[Hanlon, Joseph T.] Univ Pittsburgh, Sch Pharm, Dept Pharm & Therapeut, Pittsburgh, PA 15261 USA.
[Hanlon, Joseph T.] Univ Pittsburgh, Clin & Translat Sci Inst, Ctr Hlth Equ Res, Pittsburgh, PA 15261 USA.
[Hanlon, Joseph T.] Univ Pittsburgh, Ctr Geriatr Res Educ & Clin, Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA 15261 USA.
[Donohue, Julie M.; Reynolds, Charles F.] Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15261 USA.
RP Donohue, JM (reprint author), Univ Pittsburgh, Grad Sch Publ Hlth, Dept Hlth Policy & Management, 130 DeSoto St,Crabtree Hall A613, Pittsburgh, PA 15261 USA.
EM jdonohue@pitt.edu
RI Perera, Subashan/D-7603-2014
OI Donohue, Julie/0000-0003-2418-6017; Zhang, Yuting/0000-0002-6460-6779
FU National Center for Research Resources, National Institutes of Health
(NIH) [KL2 RR-024154-04]; Agency for Healthcare Research and Quality
[R01HS017695]; NIH [R34 MH082682, R01AG027017, P30AG024827, P30MH71944,
T32AG021885, K07AG033174, R01AG034056]; Veterans Administration Health
Services Research and Development Service [IIR-06-062]; UPMC endowment
in geriatric psychiatry; John A. Hartford Foundation
FX This publication was supported by the National Center for Research
Resources, National Institutes of Health (NIH) (KL2 RR-024154-04),
Agency for Healthcare Research and Quality (R01HS017695), NIH grants
(R34 MH082682, R01AG027017, P30AG024827, P30MH71944, T32AG021885,
K07AG033174, R01AG034056), the Veterans Administration Health Services
Research and Development Service (IIR-06-062), the UPMC endowment in
geriatric psychiatry, and John A. Hartford Foundation.
NR 32
TC 16
Z9 16
U1 2
U2 8
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1064-7481
J9 AM J GERIAT PSYCHIAT
JI Am. J. Geriatr. Psychiatr.
PD DEC
PY 2011
VL 19
IS 12
BP 989
EP 997
DI 10.1097/JGP.0b013e3182051a9b
PG 9
WC Geriatrics & Gerontology; Gerontology; Psychiatry
SC Geriatrics & Gerontology; Psychiatry
GA 857ES
UT WOS:000297699600002
PM 22123272
ER
PT J
AU Jack, CR
Vemuri, P
Wiste, HJ
Weigand, SD
Aisen, PS
Trojanowski, JQ
Shaw, LM
Bernstein, MA
Petersen, RC
Weiner, MW
Knopman, DS
AF Jack, Clifford R., Jr.
Vemuri, Prashanthi
Wiste, Heather J.
Weigand, Stephen D.
Aisen, Paul S.
Trojanowski, John Q.
Shaw, Leslie M.
Bernstein, Matthew A.
Petersen, Ronald C.
Weiner, Michael W.
Knopman, David S.
CA Alzheimer's Dis Neuroimaging Initi
TI Evidence for Ordering of Alzheimer Disease Biomarkers
SO ARCHIVES OF NEUROLOGY
LA English
DT Article
ID MILD COGNITIVE IMPAIRMENT; PITTSBURGH COMPOUND-B; CEREBROSPINAL-FLUID
A-BETA(42); NORMAL OLDER-ADULTS; ASSOCIATION WORKGROUPS; DIAGNOSTIC
GUIDELINES; NATIONAL INSTITUTE; CSF BIOMARKERS; A-BETA; AMYLOID
DEPOSITION
AB Objective: To empirically assess the concept that Alzheimer disease (AD) biomarkers significantly depart from normality in a temporally ordered manner.
Design: Validation sample.
Setting: Multisite, referral centers.
Participants: A total of 401 elderly participants in the Alzheimer's Disease Neuroimaging Initiative who were cognitively normal, who had mild cognitive impairment, or who had AD dementia. We compared the proportions of 3 AD biomarker values (the A beta 42 level in cerebrospinal fluid [CSF], the total tau level in CSF, and the hippocampal volume adjusted for intracranial volume [hereafter referred to as the adjusted hippocampal volume]) that were abnormal as cognitive impairment worsened. Cut points demarcating normal vs abnormal for each biomarker were established by maximizing diagnostic accuracy in independent autopsy samples.
Main Outcome Measures: Three AD biomarkers (ie, the CSF A beta 42 level, the CSF total tau level, and the adjusted hippocampal volume).
Results: Within each clinical group of the entire sample (n=401), the CSF A beta 42 level was abnormal more often than was the CSF total tau level or the adjusted hippocampal volume. Among the 298 participants with both baseline and 12-month data, the proportion of participants with an abnormal A beta 42 level did not change from baseline to 12 months in any group. The proportion of participants with an abnormal total tau level increased from baseline to 12 months in cognitively normal participants (P=.05) but not in participants with mild cognitive impairment or AD dementia. For 209 participants with an abnormal CSF A beta 42 level at baseline, the percentage with an abnormal adjusted hippocampal volume but normal CSF total tau level increased from baseline to 12 months in participants with mild cognitive impairment. No change in the percentage of MCI participants with an abnormal total tau level was seen between baseline and 12 months.
Conclusions: A reduction in the CSF A beta 42 level denotes a pathophysiological process that significantly departs from normality (ie, becomes dynamic) early, whereas the CSF total tau level and the adjusted hippocampal volume are biomarkers of downstream pathophysiological processes. The CSF total tau level becomes dynamic before the adjusted hippocampal volume, but the hippocampal volume is more dynamic in the clinically symptomatic mild cognitive impairment and AD dementia phases of the disease than is the CSF total tau level.
Arch Neurol. 2011; 68(12): 1526-1535. Published online August 8, 2011. doi:10.1001/archneurol.2011.183
C1 [Jack, Clifford R., Jr.; Vemuri, Prashanthi; Bernstein, Matthew A.] Mayo Clin & Mayo Fdn Med Educ & Res, Dept Radiol, Rochester, MN 55905 USA.
[Wiste, Heather J.; Weigand, Stephen D.] Mayo Clin & Mayo Fdn Med Educ & Res, Div Biomed Stat & Informat, Rochester, MN 55905 USA.
[Petersen, Ronald C.; Knopman, David S.] Mayo Clin & Mayo Fdn Med Educ & Res, Dept Neurol, Rochester, MN 55905 USA.
[Aisen, Paul S.] Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA.
[Weiner, Michael W.] Univ Calif San Francisco, Ctr Imaging Neurodegenerat Dis, San Francisco Vet Affairs Med Ctr, San Francisco, CA 94143 USA.
[Weiner, Michael W.] Univ Calif San Francisco, Dept Radiol & Biomed Imaging, San Francisco, CA 94143 USA.
[Trojanowski, John Q.; Shaw, Leslie M.] Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA.
[Trojanowski, John Q.; Shaw, Leslie M.] Univ Penn, Sch Med, Inst Aging, Philadelphia, PA 19104 USA.
RP Jack, CR (reprint author), Mayo Clin & Mayo Fdn Med Educ & Res, Dept Radiol, 200 1st St SW, Rochester, MN 55905 USA.
EM jack.clifford@mayo.edu
RI Jack, Clifford/F-2508-2010; Vemuri, Prashanthi/K-7030-2012
OI Jack, Clifford/0000-0001-7916-622X; Bernstein, Matt/0000-0003-3770-0441
FU Pfizer; Baxter International Inc; Merck; Avid; Elan Pharmaceuticals;
Forest Pharmaceuticals; Baxter Healthcare; National Institutes of Health
[AG11378]; ADNI
FX Dr Aisen serves on a scientific advisory board for NeuroPhage; serves as
a consultant to Elan Corporation, Wyeth, Eisai Inc, Bristol-Myers
Squibb, Eli Lilly and Company, NeuroPhage, Merck, Roche, Amgen, Abbott,
Pfizer, Novartis, Bayer, Astellas, Dainippon, Biomarin, Solvay, Otsuka,
Daiichi, AstraZeneca, Janssen, and Medivation Inc; receives research
support from Pfizer and Baxter International Inc; and has received stock
options from Medivation Inc and NeuroPhage. Dr Petersen reports serving
as a consultant for Elan Pharmaceuticals and GE Healthcare and serving
on data monitoring committees for Pfizer and Janssen Alzheimer
Immunotherapy. Dr Weiner reports serving on the advisory boards of
Elan/Wyeth, Novartis, Banner, Lilly, VACO, Biogen Idec, Araclon, and
Pfizer. He serves as a consultant to Elan/Wyeth, Novartis, Forest,
Ipsen, Daiichi Sankyo Inc, AstraZeneca, Araclon, Pfizer, TauRx
Therapeutics, Bayer, Biogen Idec, Exonhit Therapeutics, Servier, and
Synarc. He has received honoraria from the American Academy of
Neurology, Ipsen, NeuroVigil Inc, and the Institut Catala de
Neurociencies Aplicades. He receives research funding from Merck and
Avid. He owns stock in Synarc and Elan. He serves on the editorial
advisory board for Alzheimer's & Dementia and the Journal of Magnetic
Resonance Imaging. Dr Knopman reports that he serves on a Data Safety
Monitoring Board for Lilly Pharmaceuticals and is an investigator for
clinical trials sponsored by Elan Pharmaceuticals, Forest
Pharmaceuticals, and Baxter Healthcare. He is deputy editor of Neurology
and receives compensation for editorial services.; This work was support
by the National Institutes of Health (grant AG11378) and the ADNI.
Online-Only Material: The eTables and eFigures are available at
http://www.archneurol.com.
NR 86
TC 105
Z9 105
U1 3
U2 6
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA
SN 0003-9942
J9 ARCH NEUROL-CHICAGO
JI Arch. Neurol.
PD DEC
PY 2011
VL 68
IS 12
BP 1526
EP 1535
DI 10.1001/archneurol.2011.183
PG 10
WC Clinical Neurology
SC Neurosciences & Neurology
GA 861BJ
UT WOS:000297993500005
PM 21825215
ER
PT J
AU Weintraub, D
Doshi, J
Koka, D
Davatzikos, C
Siderowf, AD
Duda, JE
Wolk, DA
Moberg, PJ
Xie, SX
Clark, CM
AF Weintraub, Daniel
Doshi, Jimit
Koka, Deepthi
Davatzikos, Christos
Siderowf, Andrew D.
Duda, John E.
Wolk, David A.
Moberg, Paul J.
Xie, Sharon X.
Clark, Christopher M.
TI Neurodegeneration Across Stages of Cognitive Decline in Parkinson
Disease
SO ARCHIVES OF NEUROLOGY
LA English
DT Article
ID ALZHEIMERS-DISEASE; LEWY BODIES; PATTERN-CLASSIFICATION; ELASTIC
REGISTRATION; BRAIN ATROPHY; MCI PATIENTS; DEMENTIA; IMPAIRMENT;
HIPPOCAMPAL; MRI
AB Objective: To assess regions and patterns of brain atrophy in patients with Parkinson disease (PD) with normal cognition (PD-NC), mild cognitive impairment (PD-MCI), and dementia-level cognitive deficits (PDD).
Design: Images were quantified using a region-ofinterest approach and voxel-based morphometry analysis. We used a high-dimensional pattern classification approach to delineate brain regions that collectively formed the Spatial Pattern of Abnormalities for Recognition of PDD.
Setting: The Parkinson's Disease and Movement Disorders Center at the University of Pennsylvania.
Subjects: Eighty-four PD patients (61 PD-NC, 12 PD-MCI, and 11 PDD) and 23 healthy control subjects (HCs) underwent magnetic resonance imaging of the brain.
Results: The PD-NC patients did not demonstrate significant brain atrophy compared with HCs. Compared with PD-NC patients, PD-MCI patients had hippocam-pal atrophy (beta=-0.37; P=.001), and PDD patients demonstrated hippocampal (beta=-0.32; P=.004) and additional medial temporal lobe atrophy (beta=-0.36; P=.003). The PD-MCI patients had a different pattern of atrophy compared with PD-NC patients (P=.04) and a similar pattern to that of PDD patients (P=.81), characterized by hippocampal, prefrontal cortex gray and white matter, occipital lobe gray and white matter, and parietal lobe white matter atrophy. In nondemented PD patients, there was a correlation between memory-encoding performance and hippocampal volume.
Conclusions: Hippocampal atrophy is a biomarker of initial cognitive decline in PD, including impaired memory encoding and storage, suggesting heterogeneity in the neural substrate of memory impairment. Use of a pattern classification approach may allow identification of diffuse regions of cortical gray and white matter atrophy early in the course of cognitive decline.
Arch Neurol. 2011; 68(12):1562-1568
C1 [Weintraub, Daniel; Moberg, Paul J.] Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA.
[Weintraub, Daniel; Siderowf, Andrew D.; Duda, John E.; Wolk, David A.; Clark, Christopher M.] Univ Penn, Dept Neurol, Philadelphia, PA 19104 USA.
[Doshi, Jimit; Koka, Deepthi; Davatzikos, Christos] Univ Penn, Dept Radiol, Philadelphia, PA 19104 USA.
[Xie, Sharon X.] Univ Penn, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA.
[Weintraub, Daniel; Duda, John E.; Moberg, Paul J.] Philadelphia Vet Affairs Med Ctr, Parkinsons Dis Res Educ & Clin Ctr, Philadelphia, PA USA.
[Weintraub, Daniel] Philadelphia Vet Affairs Med Ctr, Mental Illness Res Educ & Clin Ctr, Philadelphia, PA USA.
[Clark, Christopher M.] Avid Radiopharmaceut, Philadelphia, PA USA.
RP Weintraub, D (reprint author), Univ Penn, Dept Psychiat, 3615 Chestnut St,Ste 330, Philadelphia, PA 19104 USA.
EM daniel.weintraub@uphs.upenn.edu
FU Department of Health of the Commonwealth of Pennsylvania
[SAP4100027296]; National Institute of Neurological Disorders and Stroke
(Penn Udall Center) [P50 NS053488]; National Institute on Aging
[R01-14971, P30-AG10124]
FX This study was supported by health research grant SAP4100027296 from the
Department of Health of the Commonwealth of Pennsylvania from the
Tobacco Master Settlement Agreement under Act 200177; by P50 NS053488
from the National Institute of Neurological Disorders and Stroke (Penn
Udall Center); and by grants R01-14971 and P30-AG10124 from the National
Institute on Aging.
NR 52
TC 78
Z9 79
U1 2
U2 13
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA
SN 0003-9942
J9 ARCH NEUROL-CHICAGO
JI Arch. Neurol.
PD DEC
PY 2011
VL 68
IS 12
BP 1562
EP 1568
PG 7
WC Clinical Neurology
SC Neurosciences & Neurology
GA 861BJ
UT WOS:000297993500010
PM 22159053
ER
PT J
AU Wang, V
Liu, CF
Bryson, CL
Sharp, ND
Maciejewski, ML
AF Wang, Virginia
Liu, Chuan-Fen
Bryson, Christopher L.
Sharp, Nancy D.
Maciejewski, Matthew L.
TI Does Medication Adherence Following a Copayment Increase Differ by
Disease Burden?
SO HEALTH SERVICES RESEARCH
LA English
DT Article
DE Cost sharing; medication adherence; diabetes; hypertension; veterans
ID ACUTE MYOCARDIAL-INFARCTION; MANAGED CARE; PRESCRIPTION DRUGS; PHARMACY
BENEFITS; STATIN THERAPY; RETROSPECTIVE COHORT; HEALTH-INSURANCE; RISK
ADJUSTMENT; CHRONICALLY ILL; PART-D
AB Objectives. To compare changes in medication adherence between patients with high- or low-comorbidity burden after a copayment increase.
Methods. We conducted a retrospective observational study at four Veterans Affairs (VA) medical centers by comparing veterans with hypertension or diabetes required to pay copayments with propensity score-matched veterans exempt from copayments. Disease cohorts were stratified by Diagnostic Cost Group risk score: low-(<1) and high-comorbidity (>1) burden. Medication adherence from February 2001 to December 2003, constructed from VA pharmacy claims data based on the ReComp algorithm, were assessed using generalized estimating equations.
Results. Veterans with lower comorbidity were more responsive to a U.S.$5 copayment increase than higher comorbidity veterans. In the lower comorbidity groups, veterans with diabetes had a greater reduction in adherence than veterans with hypertension. Adherence trends were similar for copayment-exempt and nonexempt veterans with higher comorbidity.
Conclusion. Medication copayment increases are associated with different impacts for low- and high-risk patients. High-risk patients incur greater out-of-pocket costs from continued adherence, while low- risk patients put themselves at increased risk for adverse health events due to greater nonadherence.
C1 [Wang, Virginia] Duke Univ, Ctr Hlth Serv Res Primary Care, Durham VA Med Ctr, Dept Med,Div Gen Internal Med, Durham, NC 27705 USA.
[Liu, Chuan-Fen; Bryson, Christopher L.; Sharp, Nancy D.] Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA.
[Liu, Chuan-Fen; Bryson, Christopher L.; Sharp, Nancy D.] VA Puget Sound Hlth Care Syst, NW Ctr Outcomes Res Older Adults, Seattle, WA USA.
[Maciejewski, Matthew L.] Duke Univ, Div Gen Internal Med, Dept Med, Durham, NC 27706 USA.
[Maciejewski, Matthew L.] Durham VA Med Ctr, Ctr Hlth Serv Res Primary Care, Durham, NC USA.
RP Wang, V (reprint author), Duke Univ, Ctr Hlth Serv Res Primary Care, Durham VA Med Ctr, Dept Med,Div Gen Internal Med, 508 Fulton St 152, Durham, NC 27705 USA.
EM virginia.wang@duke.edu
FU Office of Research and Development, Health Services Research and
Development Service, Department of Veterans Affairs [IIR 03-200];
Department of Veteran Affairs Office of Academic Affiliations; AHRQ [K12
HS 019479]
FX This research was supported by Office of Research and Development,
Health Services Research and Development Service, Department of Veterans
Affairs, project number IIR 03-200, Department of Veteran Affairs Office
of Academic Affiliations, and AHRQ grant number K12 HS 019479. The views
expressed in this article are those of the authors and do not
necessarily reflect the position or policy of the Department of Veteran
Affairs, AHRQ, University of Washington, or Duke University Health
System.
NR 73
TC 10
Z9 10
U1 5
U2 11
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0017-9124
J9 HEALTH SERV RES
JI Health Serv. Res.
PD DEC
PY 2011
VL 46
IS 6
BP 1963
EP 1985
DI 10.1111/j.1475-6773.2011.01286.x
PN 1
PG 23
WC Health Care Sciences & Services; Health Policy & Services
SC Health Care Sciences & Services
GA 851BT
UT WOS:000297244000015
PM 21689097
ER
PT J
AU Larsen, GK
Evans, J
Lambert, WE
Chen, YY
Raitt, MH
AF Larsen, Gail K.
Evans, John
Lambert, William E.
Chen, Yiyi
Raitt, Merritt H.
TI Shocks burden and increased mortality in implantable
cardioverter-defibrillator patients
SO HEART RHYTHM
LA English
DT Article
DE Implantable cardioverter-defibrillator; Shocks; Antitachycardia pacing;
Ventricular arrhythmia; Death
ID SUDDEN CARDIAC DEATH; HEART-FAILURE; VENTRICULAR-ARRHYTHMIA; MADIT-II;
THERAPY; CARDIOMYOPATHY; PREVENTION; SURVIVAL
AB BACKGROUND Implantable cardioverter-defibrillator (ICD) shocks are associated with an increased risk of death. It is unclear whether ICD shocks are detrimental per se or a marker of higher risk patients.
OBJECTIVE We aimed to assess the association between ICD shocks and time to death after correction for baseline mortality based on the Seattle Heart Failure Model (SHFM).
METHODS The primary analysis compared time-to-death between patients receiving no shocks and patients receiving shocks of any type adjusted for SHFM score at time of implantation and other comorbidities. Subgroup analyses were performed to further describe the relationship between shocks and mortality risk.
RESULTS Over a median follow-up of 41 months (interquartile range 23-64), one or more shock episodes occurred in 59% of 425 patients and 40% of the patients died. Patients receiving shocks of any type had increased risk of death (hazard ratio 1.55; 95% confidence interval 1.07-2.23; P = .02) versus patients receiving no shocks. While patients with 1-5 days with shock (shock days) did not show evidence of increased risk of death (1.30 [0.88-.94]; P = 0.19), those with 6-10 shock days (2.22 [1.21-4.08]; P <.01) and >10 shock days (3.66 [1.86 -7.19]; P <.01) had increasingly higher risk. There was no increased hazard for death (0.73 [0.34 -1.57]; P = .41) in patients treated only with antitachycardia pacing (ATP).
CONCLUSION ICD shocks were associated with increased mortality risk after adjustment for SHFM-predicted mortality, and the burden of shocks played a role in this association. ATP did not increase mortality risk, suggesting that shocks may themselves be detrimental.
C1 [Raitt, Merritt H.] Portland VA Med Ctr, Portland, OR 97239 USA.
[Larsen, Gail K.; Lambert, William E.; Chen, Yiyi; Raitt, Merritt H.] Oregon Hlth & Sci Univ, Sch Med, Dept Publ Hlth & Prevent Med, Portland, OR 97201 USA.
[Evans, John] Stanford Univ, Sch Med, Stanford, CA 94305 USA.
RP Raitt, MH (reprint author), Portland VA Med Ctr, 3710 SW US Vet Rd, Portland, OR 97239 USA.
EM merritt.raitt@va.gov
OI Raitt, Merritt/0000-0001-5638-7732
NR 18
TC 48
Z9 49
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1547-5271
J9 HEART RHYTHM
JI Heart Rhythm
PD DEC
PY 2011
VL 8
IS 12
BP 1881
EP 1886
DI 10.1016/j.hrthm.2011.07.036
PG 6
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 863CE
UT WOS:000298139600011
PM 21816127
ER
PT J
AU El-Shewy, HM
Abdel-Samie, SA
Al Qalam, AM
Lee, MH
Kitatani, K
Anelli, V
Jaffa, AA
Obeid, LM
Luttrell, LM
AF El-Shewy, Hesham M.
Abdel-Samie, Souzan A.
Al Qalam, Abdelmohsen M.
Lee, Mi-Hye
Kitatani, Kazuyuki
Anelli, Viviana
Jaffa, Ayad A.
Obeid, Lina M.
Luttrell, Louis M.
TI Phospholipase C and Protein Kinase C-beta 2 Mediate Insulin-Like Growth
Factor II-Dependent Sphingosine Kinase 1 Activation
SO MOLECULAR ENDOCRINOLOGY
LA English
DT Article
ID HETEROTRIMERIC G-PROTEINS; G-ALPHA-Q; FACTOR-II/MANNOSE-6-PHOSPHATE
RECEPTOR; RECYCLING ENDOSOMES; PLASMA-MEMBRANE; ADULT-RAT; CELLS;
EXPRESSION; TRANSLOCATION; PKC
AB We recently reported that IGF-II binding to the IGF-II/mannose-6-phosphate (M6P) receptor activates the ERK1/2 cascade by triggering sphingosine kinase 1 (SK1)-dependent transactivation of G protein-coupled sphingosine 1-phosphate (S1P) receptors. Here, we investigated the mechanism of IGF-II/M6P receptor-dependent sphingosine kinase 1 (SK1) activation in human embryonic kidney 293 cells. Pretreating cells with protein kinase C (PKC) inhibitor, bisindolylmaleimide-I, abolished IGF-II-stimulated translocation of green fluorescent protein (GFP)-tagged SK1 to the plasma membrane and activation of endogenous SK1, implicating PKC as an upstream regulator of SK1. Using confocal microscopy to examine membrane translocation of GFP-tagged PKC alpha, beta 1, beta 2, delta, and zeta, we found that IGF-II induced rapid, transient, and isoform-specific translocation of GFP-PKC beta 2 to the plasma membrane. Immunoblotting of endogenous PKC phosphorylation confirmed PKC beta 2 activation in response to IGF-II. Similarly, IGF-II stimulation caused persistent membrane translocation of the kinase-deficient GFP-PKC beta 2 (K371R) mutant, which does not dissociate from the membrane after translocation. IGF-II stimulation increased diacylglycerol (DAG) levels, the established activator of classical PKC. Interestingly, the polyunsaturated fraction of DAG was increased, indicating involvement of phosphatidyl inositol/phospholipase C (PLC). Pretreating cells with the PLC inhibitor, U73122, attenuated IGF-II-dependent DAG production and PKC beta 2 phosphorylation, blocked membrane translocation of the kinase-deficient GFP-PKC beta 2 (K371R) mutant, and reduced sphingosine 1-phosphate production, suggesting that PLC/PKC beta 2 are upstream regulators of SK1 in the pathway. Taken together, these data provide evidence that activation of PLC and PKC beta 2 by the IGF-II/M6P receptor are required for the activation of SK1. (Molecular Endocrinology 25:2144-2156, 2011)
C1 [El-Shewy, Hesham M.] Med Univ S Carolina, Div Endocrinol Diabet & Med Genet, Dept Med, Charleston, SC 29425 USA.
[Abdel-Samie, Souzan A.; Kitatani, Kazuyuki; Anelli, Viviana; Luttrell, Louis M.] Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA.
[Obeid, Lina M.; Luttrell, Louis M.] Ralph H Johnson Vet Affairs Med Ctr, Res Serv, Charleston, SC 29401 USA.
RP El-Shewy, HM (reprint author), Med Univ S Carolina, Div Endocrinol Diabet & Med Genet, Dept Med, 114 Doughty St,MSC 776, Charleston, SC 29425 USA.
EM elshewy@musc.edu
FU South Carolina Center for Biomedical Research Excellence in Lipidomics
and Pathology; National Institutes of Health (NIH) [DK55524]; NIH/NCRR
[P20 RR17677, HL087986, HL077192]; Department of Veterans Affairs;
Veteran Affairs Merit Award
FX This work was supported by a grant from South Carolina Center for
Biomedical Research Excellence in Lipidomics and Pathology (to H. M.
E.), National Institutes of Health (NIH) Grants DK55524 (to L.M.L.) and
NIH/NCRR P20 RR17677 (to L.M.O.), HL087986 and HL077192 (to A.A.J.),
Department of Veterans Affairs Research Enhancement Award (L.M.L.), and
Veteran Affairs Merit Award (to L.M.O.).
NR 44
TC 11
Z9 11
U1 0
U2 16
PU ENDOCRINE SOC
PI CHEVY CHASE
PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA
SN 0888-8809
J9 MOL ENDOCRINOL
JI Mol. Endocrinol.
PD DEC
PY 2011
VL 25
IS 12
BP 2144
EP 2156
DI 10.1210/me.2011-0101
PG 13
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 861YB
UT WOS:000298055800015
PM 22016563
ER
PT J
AU Nair, G
Pardue, MT
Kim, M
Duong, TQ
AF Nair, Govind
Pardue, Machelle T.
Kim, Moon
Duong, Timothy Q.
TI Manganese-Enhanced MRI Reveals Multiple Cellular and Vascular Layers in
Normal and Degenerated Retinas
SO JOURNAL OF MAGNETIC RESONANCE IMAGING
LA English
DT Article
DE magnetic resonance imaging; MEMRI; retinal degeneration; high resolution
imaging; MRI microscopy; RCS
ID OPTICAL COHERENCE TOMOGRAPHY; VISUAL PATHWAY; FUNCTIONAL MRI; RAT
RETINA; RCS RAT; BRAIN; RESOLUTION; CLEARANCE; TRANSPORT; CONTRAST
AB Purpose: To use manganese-enhanced magnetic resonance imaging (MEMRI) at 25 x 25 x 800 mu m(3) to image different retinal and vascular layers in the rat retinas.
Materials and Methods: Manganese-chloride was injected intraocularly in normal (n = 5) and Royal College of Surgeons (RCS, an model of photoreceptor degeneration) (n = 5) rats at postnatal day 90. MEMRI at 4.7 T was performed 24 hours later. MRI was repeated following intravenous Gd-DTPA in the same animals to highlight the vasculatures. Layer assignment and thickness were compared to histology.
Results: MEMRI 24 hours after intravitreal manganese-chloride injection revealed seven bands of alternating hyper- and hypointensities, corresponding histologically to the ganglion cell layer, inner plexiform layer, inner nuclear layer, outer plexiform layer, outer nuclear layer, photoreceptor-segment layer, and choroidal vascular layer. Intravenous Gd-DTPA-which does not cross the blood-retinal barrier and the retinal pigment epithelium-further enhanced the two layers bounding the retina, corresponding to the retinal and choroidal vascular layers, but not the avascular outer nuclear layer and the photoreceptor-segment layer. MEMRI of the RCS retinas revealed the loss of the outer plexiform layer, outer nuclear layer, and photoreceptor-segment layer. Histological analysis corroborated the MRI laminar assignments and thicknesses.
Conclusion: Lamina-specific retinal structures neurodegenerative changes to structure in retinal diseases can be detected using MEMRI.
C1 [Duong, Timothy Q.] UTHSCSA, Res Imaging Inst, Dept Ophthalmol, San Antonio, TX 78229 USA.
[Duong, Timothy Q.] UTHSCSA, Res Imaging Inst, Dept Physiol, San Antonio, TX 78229 USA.
[Nair, Govind] Univ Massachusetts, Sch Med, Grad Sch Biomed Sci, Worcester, MA USA.
[Nair, Govind] Worcester Polytech Inst, Worcester, MA 01609 USA.
[Nair, Govind] Emory Univ, Yerkes Imaging Ctr, Neurosci Div, Atlanta, GA 30322 USA.
[Pardue, Machelle T.; Kim, Moon] Atlanta Vet Affairs Med Ctr, Atlanta, GA USA.
[Pardue, Machelle T.] Emory Univ, Dept Ophthalmol, Atlanta, GA 30322 USA.
[Duong, Timothy Q.] S Texas Vet Hlth Care Syst, Dept Vet Affairs, San Antonio, TX USA.
RP Duong, TQ (reprint author), UTHSCSA, Res Imaging Inst, Dept Ophthalmol, 8403 Floyd Curl Dr, San Antonio, TX 78229 USA.
EM duongt@uthscsa.edu
RI Duong, Timothy/B-8525-2008
FU NEI NIH HHS [R01 EY018855, R01 EY014211]
NR 33
TC 12
Z9 12
U1 0
U2 0
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1053-1807
J9 J MAGN RESON IMAGING
JI J. Magn. Reson. Imaging
PD DEC
PY 2011
VL 34
IS 6
BP 1422
EP 1429
DI 10.1002/jmri.22719
PG 8
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA 851VG
UT WOS:000297298800020
PM 21964629
ER
PT J
AU Liang, HY
Ward, WF
Jang, YC
Bhattacharya, A
Bokov, AF
Li, Y
Jernigan, A
Richardson, A
Van Remmen, H
AF Liang, Huiyun
Ward, Walter F.
Jang, Youngmok C.
Bhattacharya, Arunabh
Bokov, Alex F.
Li, Yan
Jernigan, Amanda
Richardson, Arlan
Van Remmen, Holly
TI PGC-1 alpha PROTECTS NEURONS AND ALTERS DISEASE PROGRESSION IN AN
AMYOTROPHIC LATERAL SCLEROSIS MOUSE MODEL
SO MUSCLE & NERVE
LA English
DT Article
DE amyotrophic lateral sclerosis; excitatory amino acid transporter protein
2 (EAAT2); motor neuron; neuromuscular junction; PGC-1 alpha transgenic
mice
ID CU,ZN SUPEROXIDE-DISMUTASE; OXYGEN SPECIES PRODUCTION;
ACETYLCHOLINE-RECEPTOR; MITOCHONDRIAL BIOGENESIS; CALORIC RESTRICTION;
SKELETAL-MUSCLE; TRANSGENIC MICE; TRANSCRIPTIONAL COACTIVATOR;
NEUROMUSCULAR-JUNCTION; RADICAL GENERATION
AB Introduction: Amyotrophic lateral sclerosis (ALS) is a devastating neurodegenerative disease. We sought to determine whether peroxisome proliferator-activated receptor gamma coactivator 1 alpha (PGC-1 alpha) would have a beneficial effect on this disease. Methods: PGC-1 alpha transgenic mice were crossed with SOD1 mutant G93A DL mice. Results: We observed a moderate but non-significant increase in average lifespan in PGC-1 alpha/G93A DL mice, as compared with G93A DL mice (292 +/- 3 days vs. 274 +/- 7 days). Although the onset of ALS was not altered, progression of the disease was significantly slower (similar to 34% increase in duration) in the PGC-1 alpha/G93A DL mice. These mice also exhibited markedly improved performance on the rotarod test, and the improved motor activity was associated with a decreased loss of motor neurons and less degeneration of neuromuscular junctions. Conclusion: A sustained level of excitatory amino acid transporter protein 2 (EAAT2) in astrocytes of the PGC-1 alpha/G93A DL mice may contribute to neuronal protection. Muscle Nerve 44: 947-956, 2011
C1 [Liang, Huiyun; Ward, Walter F.; Jang, Youngmok C.; Bhattacharya, Arunabh; Bokov, Alex F.; Li, Yan; Jernigan, Amanda; Richardson, Arlan; Van Remmen, Holly] Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA.
[Ward, Walter F.] Univ Texas Hlth Sci Ctr San Antonio, Dept Physiol, San Antonio, TX 78229 USA.
[Bokov, Alex F.] Univ Texas Hlth Sci Ctr San Antonio, Dept Biostat & Epidemiol, San Antonio, TX 78229 USA.
[Bhattacharya, Arunabh; Richardson, Arlan; Van Remmen, Holly] Univ Texas San Antonio, Barshop Inst Longev & Aging Studies, San Antonio, TX 78229 USA.
[Richardson, Arlan; Van Remmen, Holly] S Texas Vet Hlth Care Syst, GRECC, San Antonio, TX USA.
RP Van Remmen, H (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA.
EM vanremmen@uthscsa.edu
FU Muscular Dystrophy Association [MDA 69814, 10047]; VA Merit grant
FX The authors thank Dr. Florian Muller for his helpful input for this
study. This work was supported by Muscular Dystrophy Association grants
MDA 69814 (to H.L.) and 10047 (to H.v.R.), and a VA Merit grant (to
H.v.R.).
NR 59
TC 39
Z9 39
U1 0
U2 6
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0148-639X
J9 MUSCLE NERVE
JI Muscle Nerve
PD DEC
PY 2011
VL 44
IS 6
BP 947
EP 956
DI 10.1002/mus.22217
PG 10
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 860HG
UT WOS:000297938800017
PM 22102466
ER
PT J
AU Baddley, JW
Pappas, PG
AF Baddley, John W.
Pappas, Peter G.
TI Pulmonary Fungal Infections PREFACE
SO SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE
LA English
DT Editorial Material
C1 [Baddley, John W.; Pappas, Peter G.] Univ Alabama, Dept Med, Div Infect Dis, Birmingham, AL 35294 USA.
[Baddley, John W.] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA.
RP Baddley, JW (reprint author), Univ Alabama, Dept Med, Div Infect Dis, Tinsley Harrison Tower 229,1530 3rd Ave S, Birmingham, AL 35294 USA.
EM jbaddley@uab.edu
NR 0
TC 1
Z9 1
U1 0
U2 1
PU THIEME MEDICAL PUBL INC
PI NEW YORK
PA 333 SEVENTH AVE, NEW YORK, NY 10001 USA
SN 1069-3424
J9 SEMIN RESP CRIT CARE
JI Semin. Respir. Crit. Care Med.
PD DEC
PY 2011
VL 32
IS 6
BP 661
EP 662
DI 10.1055/s-0031-1295713
PG 2
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA 860OZ
UT WOS:000297958900001
PM 22167393
ER
PT J
AU Thompson, GR
Patterson, TF
AF Thompson, George R., III
Patterson, Thomas F.
TI Pulmonary Aspergillosis: Recent Advances
SO SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE
LA English
DT Review
DE Aspergillosis; chronic cavitary aspergillosis; aspergilloma
ID STEM-CELL TRANSPLANTATION; CRITICALLY-ILL PATIENTS; BETA-GLUCAN
RECEPTOR; INVASIVE MOLD INFECTION; AMPHOTERICIN-B THERAPY; ANTIFUNGAL
THERAPY; NEUTROPENIC PATIENTS; CANCER-PATIENTS; FUMIGATUS; POSACONAZOLE
AB Aspergillosis remains a significant cause of morbidity and mortality. The spectrum of disease is diverse and ranges from noninvasive disease with an excessive immune response, such as in allergic bronchopulmonary aspergillosis (ABPA), to a lack of an immune response as seen in patients with quantitative or qualitative granulocyte deficits and subsequent invasive pulmonary aspergillosis.
Noninvasive diagnostic testing has improved the time to initiation of effective antifungal therapy, and numerous agents in different therapeutic classes are now available as treatment options. Voriconazole remains the preferred agent in the treatment of invasive pulmonary aspergillosis, and recent data have increased interest in the potential of combination therapy against this often lethal infection. The role of host genetics in selecting patients that may benefit from more aggressive antifungal prophylaxis or treatment practices remains unclear but is likely to guide therapeutic choices as newer data become available.
C1 [Thompson, George R., III] Univ Calif Davis, Dept Internal Med, Div Infect Dis, Davis, CA 95616 USA.
[Thompson, George R., III] Univ Calif Davis, Dept Med Microbiol & Immunol, Davis, CA 95616 USA.
[Patterson, Thomas F.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA.
[Patterson, Thomas F.] S Texas Vet Hlth Care Syst, San Antonio, TX USA.
RP Thompson, GR (reprint author), Univ Calif Davis, Dept Internal Med, Div Infect Dis, 1 Shields Ave,Tupper Hall,Rm 3146, Davis, CA 95616 USA.
EM grthompson@ucdavis.edu
NR 74
TC 18
Z9 18
U1 1
U2 5
PU THIEME MEDICAL PUBL INC
PI NEW YORK
PA 333 SEVENTH AVE, NEW YORK, NY 10001 USA
SN 1069-3424
EI 1098-9048
J9 SEMIN RESP CRIT CARE
JI Semin. Respir. Crit. Care Med.
PD DEC
PY 2011
VL 32
IS 6
BP 673
EP 681
DI 10.1055/s-0031-1295715
PG 9
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA 860OZ
UT WOS:000297958900003
PM 22167395
ER
PT J
AU Brizendine, KD
Baddley, JW
Pappas, PG
AF Brizendine, Kyle D.
Baddley, John W.
Pappas, Peter G.
TI Pulmonary Cryptococcosis
SO SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE
LA English
DT Review
DE Cryptococcus; pulmonary; cryptococcosis; cryptococcal; pneumonia
ID HUMAN-IMMUNODEFICIENCY-VIRUS; INVASIVE FUNGAL-INFECTIONS; ACTIVE
ANTIRETROVIRAL THERAPY; BRONCHOALVEOLAR LAVAGE FLUID; ORGAN TRANSPLANT
RECIPIENTS; NECROSIS-FACTOR-ALPHA; NEOFORMANS INFECTION; IMMUNOCOMPETENT
PATIENTS; MAINTENANCE THERAPY; NEGATIVE PATIENTS
AB Cryptococcosis is an invasive fungal infection (IFI), caused predominantly by Cryptococcus neoformans or Cryptococcus gattii, that affects both immunocompromised (IC) and non-IC patients. Although the most serious disease manifestation is meningoencephalitis, cryptococcal pneumonia is underdiagnosed and may disseminate to the central nervous system (CNS) and other sites depending upon host defenses and administration of appropriate antifungal therapy. The clinical presentation of pulmonary cryptococcosis varies along a spectrum from asymptomatic infection to severe pneumonia and respiratory failure, and the radiological presentation can be characterized by an array of findings, including nodules, consolidation, cavitary lesions, and a diffuse interstitial pattern. Diagnosis most often relies upon isolation of Cryptococcus from a pulmonary specimen in the appropriate clinical and radiological context. Treatment recommendations include induction therapy with an amphotericin B preparation and flucytosine for IC patients and those with severe disease and fluconazole for mild-to-moderate, localized disease. Knowledge of the pathophysiology, epidemiology, clinical presentation, and treatment of pulmonary cryptococcosis may lead to greater recognition of this underdiagnosed IFI and improved outcomes.
C1 [Brizendine, Kyle D.; Baddley, John W.; Pappas, Peter G.] Univ Alabama, Dept Med, Div Infect Dis, Birmingham, AL 35294 USA.
[Baddley, John W.] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA.
RP Pappas, PG (reprint author), Univ Alabama, Dept Med, Div Infect Dis, Tinsley Harrison Tower 229,1530 3rd Ave S, Birmingham, AL 35294 USA.
EM pappas@uab.edu
NR 71
TC 19
Z9 22
U1 1
U2 10
PU THIEME MEDICAL PUBL INC
PI NEW YORK
PA 333 SEVENTH AVE, NEW YORK, NY 10001 USA
SN 1069-3424
J9 SEMIN RESP CRIT CARE
JI Semin. Respir. Crit. Care Med.
PD DEC
PY 2011
VL 32
IS 6
BP 727
EP 734
DI 10.1055/s-0031-1295720
PG 8
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA 860OZ
UT WOS:000297958900008
PM 22167400
ER
PT J
AU Howard, G
Cushman, M
Kissela, BM
Kleindorfer, DO
McClure, LA
Safford, MM
Rhodes, JD
Soliman, EZ
Moy, CS
Judd, SE
Howard, VJ
AF Howard, George
Cushman, Mary
Kissela, Brett M.
Kleindorfer, Dawn O.
McClure, Leslie A.
Safford, Monika M.
Rhodes, J. David
Soliman, Elsayed Z.
Moy, Claudia S.
Judd, Suzanne E.
Howard, Virginia J.
CA REGARDS Investigators
TI Traditional Risk Factors as the Underlying Cause of Racial Disparities
in Stroke Lessons From the Half-Full (Empty?) Glass
SO STROKE
LA English
DT Article
DE stroke; risk factors; hypertension; diabetes mellitus; mediation
analysis
ID SOUTHEASTERN UNITED-STATES; CARDIOVASCULAR-DISEASES; BLOOD-PRESSURE;
FOLLOW-UP; HYPERTENSION; AWARENESS; ASSOCIATION; PREVALENCE; MORTALITY;
REASONS
AB Background and Purpose-Black/white disparities in stroke incidence are well documented, but few studies have assessed the contributions to the disparity. Here we assess the contribution of "traditional" risk factors.
Methods-A total of 25 714 black and white men and women, aged >= 45 years and stroke-free at baseline, were followed for an average of 4.4 years to detect stroke. Mediation analysis using proportional hazards analysis assessed the contribution of traditional risk factors to racial disparities.
Results-At age 45 years, incident stroke risk was 2.90 (95% CI: 1.72-4.89) times more likely in blacks than in whites and 1.66 (95% CI: 1.34-2.07) times at age 65 years. Adjustment for risk factors attenuated these excesses by 40% and 45%, respectively, resulting in relative risks of 2.14 (95% CI: 1.25-3.67) and 1.35 (95% CI: 1.08-1.71). Approximately one half of this mediation is attributable to systolic blood pressure. Further adjustment for socioeconomic factors resulted in total mediation of 47% and 53% to relative risks of 2.01 (95% CI: 1.16-3.47) and 1.30 (1.03-1.65), respectively.
Conclusions-Between ages 45 to 65 years, approximately half of the racial disparity in stroke risk is attributable to traditional risk factors (primarily systolic blood pressure) and socioeconomic factors, suggesting a critical need to understand the disparity in the development of these traditional risk factors. Because half of the excess stroke risk in blacks is not attributable to traditional risk factors and socioeconomic factors, differential impact of risk factors, residual confounding, or nontraditional risk factors may also play a role. (Stroke. 2011;42:3369-3375.)
C1 [Howard, George; McClure, Leslie A.; Rhodes, J. David; Judd, Suzanne E.] Univ Alabama, Sch Publ Hlth, Dept Biostat, Birmingham, AL 35294 USA.
[Howard, Virginia J.] Univ Alabama, Sch Publ Hlth, Dept Epidemiol, Birmingham, AL 35294 USA.
[Safford, Monika M.] Univ Alabama, Deep S Ctr Effectiveness, Birmingham Vet Affairs Med Ctr, Birmingham, AL USA.
[Safford, Monika M.] Univ Alabama, Dept Med, Div Prevent Med, Birmingham, AL 35294 USA.
[Cushman, Mary] Univ Vermont, Coll Med, Dept Med, Burlington, VT 05405 USA.
[Kissela, Brett M.; Kleindorfer, Dawn O.] Univ Cincinnati, Dept Neurol, Cincinnati, OH USA.
[Soliman, Elsayed Z.] Wake Forest Univ, Sch Med, Dept Epidemiol & Prevent, Winston Salem, NC 27109 USA.
[Moy, Claudia S.] Natl Inst Neurol Disorders & Stroke, NIH, Bethesda, MD USA.
RP Howard, G (reprint author), Univ Alabama, Sch Publ Hlth, Dept Biostat, 1665 Univ Blvd, Birmingham, AL 35294 USA.
EM ghoward@uab.edu
RI McClure, Leslie/P-2929-2015
OI Kissela, Brett/0000-0002-9773-4013
FU National Institute of Neurological Disorders and Stroke [NS 041588]
FX The research reported in this article was supported by cooperative
agreement NS 041588 from the National Institute of Neurological
Disorders and Stroke.
NR 29
TC 56
Z9 57
U1 0
U2 6
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0039-2499
J9 STROKE
JI Stroke
PD DEC
PY 2011
VL 42
IS 12
BP 3369
EP 3375
DI 10.1161/STROKEAHA.111.625277
PG 7
WC Clinical Neurology; Peripheral Vascular Disease
SC Neurosciences & Neurology; Cardiovascular System & Cardiology
GA 860IH
UT WOS:000297941500017
PM 21960581
ER
PT J
AU Green, SM
Selzer, F
Mulukutla, SR
Tadajweski, EJ
Green, JA
Wilensky, RL
Laskey, WK
Cohen, HA
Rao, SV
Weisbord, SD
Lee, JS
Reis, SE
Kip, KE
Kelsey, SF
Williams, DO
Marroquin, OC
AF Green, Sandy M.
Selzer, Faith
Mulukutla, Suresh R.
Tadajweski, Edward J.
Green, Jamie A.
Wilensky, Robert L.
Laskey, Warren K.
Cohen, Howard A.
Rao, Sunil V.
Weisbord, Steven D.
Lee, Joon S.
Reis, Steven E.
Kip, Kevin E.
Kelsey, Sheryl F.
Williams, David O.
Marroquin, Oscar C.
TI Comparison of Bare-Metal and Drug-Eluting Stents in Patients with
Chronic Kidney Disease (from the NHLBI Dynamic Registry)
SO AMERICAN JOURNAL OF CARDIOLOGY
LA English
DT Article
ID PERCUTANEOUS CORONARY INTERVENTION; GLOMERULAR-FILTRATION-RATE;
RENAL-INSUFFICIENCY; ARTERY-DISEASE; CARDIOVASCULAR OUTCOMES;
MYOCARDIAL-INFARCTION; THROMBOSIS; ANGIOPLASTY; EVENTS; ERA
AB Patients with chronic kidney disease (CKD) have a disproportionate burden of coronary artery disease and commonly undergo revascularization. The role and safety of percutaneous coronary intervention (PCI) using drug-eluting stents (DESs) verses bare-metal stents in patients with CKD not on renal replacement therapy has not been fully evaluated. This study investigated the efficacy and safety of DES in patients with CKD not on renal replacement therapy. Patients were drawn from the National Heart, Lung, and Blood Institute Dynamic Registry and were stratified by renal function based on estimated glomerular filtration rate (GFR). Of the 4,157 participants, 1,108 had CKD ("low GFR" <60 ml/min/1.73 m(2)), whereas 3,049 patients had normal renal function ("normal GFR" >= 60 ml/min/1.73 m(2)). For each stratum of renal function we compared risk of death, myocardial infarction, or repeat revascularization between subjects who received DESs and bare-metal stents at the index procedure. Patients with low GFR had higher 1-year rates of death and myocardial infarction and a decreased rate of repeat revascularization compared to patients with normal GFR. Use of DESs was associated with a decreased need for repeat revascularization in the normal-GFR group (adjusted hazard ratio 0.63, 95% confidence interval 0.50 to 0.79, p <0.001) but not in the low-GFR group (hazard ratio 0.69, 95% confidence interval 0.45 to 1.06, p = 0.09). Risks of death and myocardial infarction were not different between the 2 stents in either patient population. In conclusion, presence of CKD predicted poor outcomes after PCI with high rates of mortality regardless of stent type. The effect of DES in decreasing repeat revascularization appeared to be attenuated in these patients. (C) 2011 Elsevier Inc. All rights reserved. (Am J Cardiol 2011;108:1658-1664)
C1 [Green, Sandy M.; Mulukutla, Suresh R.; Tadajweski, Edward J.; Green, Jamie A.; Weisbord, Steven D.; Lee, Joon S.; Reis, Steven E.; Marroquin, Oscar C.] Univ Pittsburgh, Med Ctr, Inst Heart & Vasc, Pittsburgh, PA 15260 USA.
[Wilensky, Robert L.] Univ Penn Hlth Syst, Philadelphia, PA USA.
[Laskey, Warren K.] Univ New Mexico, Albuquerque, NM USA.
[Cohen, Howard A.] Lenox Hill Heart & Vasc Inst, New York, NY USA.
[Rao, Sunil V.] Duke Univ, Med Ctr, Durham, NC USA.
[Weisbord, Steven D.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
[Kip, Kevin E.] Univ S Florida, Tampa, FL USA.
[Williams, David O.] Brigham & Womens Hosp, Boston, MA 02115 USA.
[Selzer, Faith; Mulukutla, Suresh R.; Kelsey, Sheryl F.; Marroquin, Oscar C.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA USA.
RP Marroquin, OC (reprint author), Univ Pittsburgh, Med Ctr, Inst Heart & Vasc, Pittsburgh, PA 15260 USA.
EM marroquinoc@upmc.edu
RI Reis, Steven/J-3957-2014; Marroquin, Oscar/F-2214-2015
OI Marroquin, Oscar/0000-0002-0909-0319
FU National Heart, Lung, and Blood Institute, Bethesda, Maryland [HL033292]
FX This study was supported in part by Grant HL033292 from the National
Heart, Lung, and Blood Institute, Bethesda, Maryland.
NR 30
TC 12
Z9 12
U1 1
U2 4
PU EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC
PI BRIDGEWATER
PA 685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA
SN 0002-9149
J9 AM J CARDIOL
JI Am. J. Cardiol.
PD DEC 1
PY 2011
VL 108
IS 11
BP 1658
EP 1664
DI 10.1016/j.amjcard.2011.07.029
PG 7
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 859MH
UT WOS:000297880000022
PM 21890077
ER
PT J
AU Au, DH
AF Au, David H.
TI Health Care Reform and Comparative Effectiveness Research in Critical
Care Medicine
SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
LA English
DT Editorial Material
ID COSTS
C1 [Au, David H.] VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, Seattle, WA USA.
[Au, David H.] Univ Washington, Div Pulm & Crit Care Med, Seattle, WA 98195 USA.
RP Au, DH (reprint author), VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, Seattle, WA USA.
NR 15
TC 0
Z9 0
U1 0
U2 2
PU AMER THORACIC SOC
PI NEW YORK
PA 61 BROADWAY, FL 4, NEW YORK, NY 10006 USA
SN 1073-449X
J9 AM J RESP CRIT CARE
JI Am. J. Respir. Crit. Care Med.
PD DEC 1
PY 2011
VL 184
IS 11
BP 1219
EP 1220
DI 10.1164/rccm.201107-1354ED
PG 2
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA 855NU
UT WOS:000297572100003
PM 22162878
ER
PT J
AU Cannon, GW
Mikuls, TR
Hayden, CL
Ying, J
Curtis, JR
Reimold, AM
Caplan, L
Kerr, GS
Richards, JS
Johnson, DS
Sauer, BC
AF Cannon, Grant W.
Mikuls, Ted R.
Hayden, Candace L.
Ying, Jian
Curtis, Jeffrey R.
Reimold, Andreas M.
Caplan, Liron
Kerr, Gail S.
Richards, J. Steuart
Johnson, Dannette S.
Sauer, Brian C.
TI Merging Veterans Affairs rheumatoid arthritis registry and pharmacy data
to assess methotrexate adherence and disease activity in clinical
practice
SO ARTHRITIS CARE & RESEARCH
LA English
DT Article
ID MODIFYING ANTIRHEUMATIC DRUGS; HEALTH-ASSESSMENT QUESTIONNAIRE;
MEDICATION ADHERENCE; PREDICTORS; NONADHERENCE; PATIENT; CARE;
PERSISTENCE; MANAGEMENT; DATABASES
AB Objective The Veterans Affairs (VA) Rheumatoid Arthritis (VARA) registry and the VA Pharmacy Benefits Management database were linked to determine the association of methotrexate (MTX) adherence with rheumatoid arthritis (RA) disease activity.
Methods. For each patient, the medication possession ratio (MPR) was calculated for the first episode of MTX exposure of a duration of > 12 weeks for both new and established MTX users. High MTX adherence was defined as an MPR > 0.80 and low MTX adherence was defined as an MPR < 0.80. For each patient, the mean Disease Activity Score with 28 joints (DAS28) score, erythrocyte sedimentation rate (ESR), and C-reaction protein (CRP) level observed during registry followup were compared in high-versus low-adherence groups.
Results. In 455 RA patients, the prescribed doses of MTX (mean +/- SD 16 +/- 4 mg versus 16 +/- 4 mg; P = 0.6) were similar in high-adherence patients (n = 370) in comparison to low-adherence patients (n = 85). However, the actual observed MTX doses taken by patients were significantly higher in the high-adherence group (mean +/- SD 16 +/- 5 mg versus 11 +/- 3 mg; P < 0.001). DAS28 (mean +/- SD 3.6 +/- 1.2 versus 3.9 +/- 1.5; P < 0.02), ESR (mean +/- SD 24 +/- 18 versus 29 +/- 24 mm/hour; P = 0.05), and CRP level (mean +/- SD 1.2 +/- 1.3 versus 1.6 +/- 1.5 mg/dl; P < 0.03) were lower in the high-adherence group compared to those with low MTX adherence. These variances were not explained by differences in baseline demographic features, concurrent treatments, or whether MTX was initiated before or after VARA enrollment.
Conclusion. High MTX adherence was associated with improved clinical outcomes in RA patients treated with MTX. Adjustment for potential confounders did not alter the estimated effect of adherence. These results demonstrate the advantages of being able to merge clinical observations with pharmacy databases to evaluate antirheumatic drugs in clinical practice.
C1 [Cannon, Grant W.; Hayden, Candace L.; Sauer, Brian C.] George E Wahlen VA Med Ctr, Salt Lake City, UT 84148 USA.
[Cannon, Grant W.; Hayden, Candace L.; Ying, Jian; Sauer, Brian C.] Univ Utah, Salt Lake City, UT USA.
[Mikuls, Ted R.] Omaha VA Med Ctr, Omaha, NE USA.
[Mikuls, Ted R.] Univ Nebraska Med Ctr, Omaha, NE USA.
[Curtis, Jeffrey R.] Univ Alabama Birmingham, Birmingham, AL USA.
[Reimold, Andreas M.] VA Med Ctr, Dallas, TX USA.
[Reimold, Andreas M.] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA.
[Caplan, Liron] Denver VA Med Ctr, Aurora, CO USA.
[Caplan, Liron] Univ Colorado, Aurora, CO USA.
[Kerr, Gail S.] Georgetown Univ, VA Med Ctr, Washington, DC USA.
[Kerr, Gail S.] Howard Univ, Washington, DC 20059 USA.
[Johnson, Dannette S.] Montgomery VA Med Ctr, Jackson, VA USA.
[Johnson, Dannette S.] Univ Mississippi, Jackson, MS 39216 USA.
RP Cannon, GW (reprint author), George E Wahlen VA Med Ctr, 500 Foothill Blvd, Salt Lake City, UT 84148 USA.
EM grant.cannon@va.gov
FU VA Health Services [SHP-08-172]; VA; NIH [K23, AR053351]; Agency for
Healthcare Research and Quality [R01-HS-018517]; VA Career Development
Awards [RCD-06-300-2, CDA-07-221]
FX Supported by a VA Health Services Research & Development grant
(SHP-08-172). Dr. Mikuls's work was supported by a VA Clinical Science
Research & Development Merit award. Dr. Curtis's work was supported by
the NIH (grants K23 and AR053351) and the Agency for Healthcare Research
and Quality (grant R01-HS-018517). Drs. Caplan and Sauer's work was
supported by VA Career Development Awards (RCD-06-300-2 and CDA-07-221).
NR 40
TC 26
Z9 26
U1 0
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 2151-464X
J9 ARTHRIT CARE RES
JI Arthritis Care Res.
PD DEC
PY 2011
VL 63
IS 12
BP 1680
EP 1690
DI 10.1002/acr.20629
PG 11
WC Rheumatology
SC Rheumatology
GA 853WV
UT WOS:000297457300006
PM 21905260
ER
PT J
AU LaBode, V
Sher, L
AF LaBode, Vanessa
Sher, Leo
TI Suicide prevention in older men: do medical professionals know enough?
SO AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY
LA English
DT Letter
C1 [LaBode, Vanessa] James J Peters Vet Adm Med Ctr, New York, NY USA.
Mt Sinai Sch Med, New York, NY USA.
RP LaBode, V (reprint author), James J Peters Vet Adm Med Ctr, New York, NY USA.
NR 5
TC 1
Z9 1
U1 0
U2 3
PU INFORMA HEALTHCARE
PI NEW YORK
PA 52 VANDERBILT AVE, NEW YORK, NY 10017 USA
SN 0004-8674
J9 AUST NZ J PSYCHIAT
JI Aust. N. Z. J. Psych.
PD DEC
PY 2011
VL 45
IS 12
BP 1094
EP 1094
DI 10.3109/00048674.2011.613066
PG 1
WC Psychiatry
SC Psychiatry
GA 854BK
UT WOS:000297469300014
PM 22014105
ER
PT J
AU Sacks, HS
Fain, JN
AF Sacks, Harold S.
Fain, John N.
TI Human epicardial fat: what is new and what is missing?
SO CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY
LA English
DT Article
DE adipokines; coronary atherosclerosis; epicardial fat; genes;
inflammation
ID CORONARY-ARTERY-DISEASE; PERIVASCULAR ADIPOSE-TISSUE; PERICARDIAL FAT;
CARDIOVASCULAR-DISEASE; NONDIABETIC PATIENTS; COMPUTED-TOMOGRAPHY;
SURROUNDING TISSUE; INSULIN-RESISTANCE; METABOLIC SYNDROME; BARIATRIC
SURGERY
AB 1. Putative physiological functions of human epicardial adipose tissue (EAT) include: (i) lipid storage for the energy needs of the myocardium; (ii) thermoregulation, whereby brown fat components of EAT generate heat by non-shivering thermogenesis in response to core cooling; (iii) neuroprotection of the cardiac autonomic ganglia and nerves; and (iv) regulation of vasomotion and luminal size of the coronary arteries. Under pathophysiological circumstances, EAT may play an adverse paracrine role in cardiac arrhythmias and in lipotoxic cardiomyopathy, but of major current interest is its hypothetical role as an immunological organ contributing to inflammation around coronary artery disease (CAD).
C1 [Sacks, Harold S.] VA Greater Los Angeles Healthcare Syst, Endocrinol & Diabet Div 111D, Los Angeles, CA 90073 USA.
[Fain, John N.] Univ Tennessee, Dept Mol Sci, Hlth Sci Ctr, Memphis, TN USA.
RP Sacks, HS (reprint author), VA Greater Los Angeles Healthcare Syst, Endocrinol & Diabet Div, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA.
EM hsacks@hotmail.com
FU van Vleet Chair of Excellence (University of Tennessee); Baptist Heart
Institute and Foundation (Memphis, TN, USA); Cardiometabolic Disease
Research Foundation (Memphis, TN, USA)
FX The authors' work reported herein was supported by the van Vleet Chair
of Excellence (University of Tennessee), The Baptist Heart Institute and
Foundation (Memphis, TN, USA) and The Cardiometabolic Disease Research
Foundation (Memphis, TN, USA). Both authors contributed equally to this
work and the authors have no conflicts of interest to declare.
NR 75
TC 38
Z9 40
U1 1
U2 8
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0305-1870
J9 CLIN EXP PHARMACOL P
JI Clin. Exp. Pharmacol. Physiol.
PD DEC
PY 2011
VL 38
IS 12
BP 879
EP 887
DI 10.1111/j.1440-1681.2011.05601.x
PG 9
WC Pharmacology & Pharmacy; Physiology
SC Pharmacology & Pharmacy; Physiology
GA 853GE
UT WOS:000297413400015
PM 21895738
ER
PT J
AU Leung, FW
AF Leung, Felix W.
TI Water Exchange May Be Superior to Water Immersion for Colonoscopy
SO CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
LA English
DT Editorial Material
ID US VETERANS; SEDATION; IMPACT
C1 [Leung, Felix W.] Vet Affairs Greater Los Angeles Healthcare Syst, Sepulveda Ambulatory Care Ctr, North Hills, CA USA.
[Leung, Felix W.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
RP Leung, FW (reprint author), Vet Affairs Greater Los Angeles Healthcare Syst, Sepulveda Ambulatory Care Ctr, North Hills, CA USA.
NR 15
TC 20
Z9 20
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1542-3565
J9 CLIN GASTROENTEROL H
JI Clin. Gastroenterol. Hepatol.
PD DEC
PY 2011
VL 9
IS 12
BP 1012
EP 1014
DI 10.1016/j.cgh.2011.09.007
PG 3
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 857WJ
UT WOS:000297754100009
PM 21946120
ER
PT J
AU Foster, T
Hon, HM
Kanwal, F
Han, S
Spiegel, B
AF Foster, Temitope
Hon, Huiming
Kanwal, Fasiha
Han, Steven
Spiegel, Brennan
TI Screening High Risk Individuals for Hepatitis B: Physician Knowledge,
Attitudes, and Beliefs
SO DIGESTIVE DISEASES AND SCIENCES
LA English
DT Article
DE Hepatitis B; Vaccines; Screening; Guideline adherence
ID ACUTE VIRAL-HEPATITIS; VIRUS INFECTION; UNITED-STATES; RECOMMENDATIONS;
PREVENTION; IMMUNIZATION; SURVEILLANCE; IMMUNITY; ADULTS
AB Background Although the overall incidence of hepatitis B virus (HBV) has declined since the introduction of universal vaccine guidelines, the incidence remains elevated in high risk groups. Recent guidelines from the Centers for Disease Control (CDC) have underscored the importance of vaccination against HBV in high risk individuals. However, the incidence of HBV in this group remains elevated, suggesting underuse of vaccinations by healthcare providers.
Aim The purpose of this study was to measure practice patterns of HBV vaccination, and identify predictors of vaccination underuse.
Methods We created a survey with four vignettes describing patients at high risk for contracting HBV, followed by questions regarding knowledge, attitudes, and beliefs (KAB) of HBV screening and vaccination. A random sample of 1,000 physicians, including internists, family medicine, OB/GYN, gastroenterologists, and experts in HBV epidemiology were surveyed. Regression analysis on composite guideline adherence scores identified KAB profiles that predict scores.
Results On average, responders endorsed 71% of the CDC HBV vaccination guidelines. There were three predictors of diminished screening proclivity: (1) younger provider age (P = 0.028), (2) lower awareness that adult HBV is contracted primarily through heterosexual sex (P = 0.023), and (3) being a provider other than a gastroenterologist (P = 0.009).
Conclusions Respondents endorsed most-but not all-CDC supported HBV screening practices. Lower adherence was predicted by specific and modifiable KAB profiles, and by younger age. Future efforts to improve adherence should target trainees, emphasize the importance of obtaining sexual histories in high risk patients, and inform that HBV is predominantly a heterosexually transmitted infection.
C1 [Foster, Temitope; Hon, Huiming] Emory Univ, Sch Med, Div Digest Dis, Atlanta, GA 30303 USA.
[Kanwal, Fasiha] St Louis Univ, St Louis, MO 63103 USA.
[Han, Steven; Spiegel, Brennan] Univ Calif Los Angeles, Los Angeles, CA USA.
[Spiegel, Brennan] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
[Spiegel, Brennan] CURE Digest Dis Res Ctr, Los Angeles, CA USA.
[Spiegel, Brennan] UCLA VA Ctr Outcomes Res & Educ CORE, Los Angeles, CA USA.
RP Foster, T (reprint author), Emory Univ, Sch Med, Div Digest Dis, 49 Jesse Hill Jr Dr SE,Rm 437, Atlanta, GA 30303 USA.
EM tyfoste@emory.edu
FU Ruth L. Kirschstein-National Service [T32 DK 07180-34]; Bristol-Meyers
Squibb
FX Dr. Foster was supported by a Ruth L. Kirschstein-National Service
Research Award (T32 DK 07180-34). This study was supported by an
investigator-initiated research grant by Bristol-Meyers Squibb.
NR 20
TC 4
Z9 4
U1 1
U2 3
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0163-2116
J9 DIGEST DIS SCI
JI Dig. Dis. Sci.
PD DEC
PY 2011
VL 56
IS 12
BP 3471
EP 3487
DI 10.1007/s10620-011-1928-z
PG 17
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 857UM
UT WOS:000297747300010
PM 22001940
ER
PT J
AU Yan, W
Ding, P
Geng, Z
Zhou, XH
AF Yan, Wei
Ding, Peng
Geng, Zhi
Zhou, Xiaohua
TI Identifiability of causal effects on a binary outcome within principal
strata
SO FRONTIERS OF MATHEMATICS IN CHINA
LA English
DT Article
DE Causal inference; identifiability; principal effect; multi-component
intervention
ID INFERENCE; STRATIFICATION; STATISTICS
AB Principal strata are defined by the potential values of a post-treatment variable, and a principal effect is a causal effect within a principal stratum. Identifying the principal effect within every principal stratum is quite challenging. In this paper, we propose an approach for identifying principal effects on a binary outcome via a pre-treatment covariate. We prove the identifiability with single post-treatment intervention under the monotonicity assumption. Furthermore, we discuss the local identifiability with multicomponent intervention. Simulations are performed to evaluate our approach. We also apply it to a real data set from the Improving Mood-Promoting Access to Collaborate Treatment program.
C1 [Yan, Wei; Ding, Peng; Geng, Zhi] Peking Univ, Sch Math Sci, Beijing 100871, Peoples R China.
[Zhou, Xiaohua] Peking Univ, Beijing Int Ctr Math Res, Beijing 100871, Peoples R China.
[Zhou, Xiaohua] Univ Washington, Dept Biostat, Seattle, WA 98195 USA.
[Zhou, Xiaohua] VA Puget Sound Hlth Care Syst, HSR&D Ctr Excellence, Biostat Unit, Seattle, WA 98101 USA.
RP Geng, Z (reprint author), Peking Univ, Sch Math Sci, Beijing 100871, Peoples R China.
EM zgeng@math.pku.edu.cn
FU NIH [R03 TW007197]; National Natural Science Foundation of China
[10721403, 10931002]
FX The authors would like to thank the referees for their valuable comments
and suggestions. The authors are grateful to Dr. Unutzer and the IMPACT
study team for making their data available. This work was supported by
NIH R03 TW007197 and the National Natural Science Foundation of China
(Grant Nos. 10721403, 10931002).
NR 10
TC 1
Z9 1
U1 0
U2 6
PU HIGHER EDUCATION PRESS
PI BEIJING
PA SHATANHOU ST 55, BEIJING 100009, PEOPLES R CHINA
SN 1673-3452
J9 FRONT MATH CHINA
JI Front. Math. China
PD DEC
PY 2011
VL 6
IS 6
BP 1249
EP 1263
DI 10.1007/s11464-011-0127-8
PG 15
WC Mathematics
SC Mathematics
GA 856MT
UT WOS:000297647000013
ER
PT J
AU Lemonovich, TL
Haynes, K
Lautenbach, E
Amorosa, VK
AF Lemonovich, T. L.
Haynes, K.
Lautenbach, E.
Amorosa, V. K.
TI Combination therapy with an aminoglycoside for Staphylococcus aureus
endocarditis and/or persistent bacteremia is associated with a decreased
rate of recurrent bacteremia: a cohort study
SO INFECTION
LA English
DT Article
ID ANTIMICROBIAL THERAPY; RISK-FACTORS; PROSPECTIVE MULTICENTER; INFECTIVE
ENDOCARDITIS; BACTERIAL-ENDOCARDITIS; GENTAMICIN; MORTALITY; CARE;
PREDICTORS; DIAGNOSIS
AB Purpose Although limited data exist on the efficacy and potential risk of synergistic aminoglycoside therapy for persistent Staphylococcus aureus bacteremia and endocarditis, aminoglycosides are frequently used in clinical practice.
Methods As our study population, we included subjects fulfilling the modified Duke criteria for S. aureus endocarditis and/or having greater than 72 h of S. aureus bacteremia. Among these subjects, we compared patients who did and did not receive aminoglycoside therapy for their S. aureus bloodstream infection. These groups were compared for the primary outcome of recurrent bacteremia, as well as for the duration of bacteremia, mortality, complication rate, and incident renal failure.
Results Eighty-seven subjects fulfilled the inclusion criteria. Of these, 49 received aminoglycoside therapy, whereas 38 did not. There were no significant differences in the baseline characteristics when comparing groups who did or did not receive aminoglycoside therapy. Four (8.2%) subjects treated with aminoglycoside therapy experienced recurrent bacteremia versus nine (23.7%) who did not receive aminoglycoside therapy [relative risk and 95% confidence interval [RR (95% CI)] = 0.51 (0.22-1.17), p = 0.04]. In multivariable analyses, aminoglycoside use remained significantly associated with a decrease in recurrent bacteremia [adjusted odds ratio (OR) (95% CI) = 0.26 (0.07-0.98), p = 0.046]. No significant differences were seen between groups treated with and without an aminoglycoside in terms of the 6-month all-cause mortality (51.0 vs. 42.1%, p = 0.41), complication rate (71.4 vs. 73.7%, p = 0.82), or incident renal failure (54.5 vs. 46.9%, p = 0.54).
Conclusions The use of combination therapy with an aminoglycoside in persistent S. aureus bacteremia and/or endocarditis may be associated with a lower rate of recurrent bacteremia without significant differences in the incident renal failure.
C1 [Lemonovich, T. L.] Case Western Reserve Univ, Div Infect Dis & HIV Med, Dept Med, Cleveland, OH 44106 USA.
[Haynes, K.; Lautenbach, E.] Univ Penn, Sch Med, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA.
[Lautenbach, E.; Amorosa, V. K.] Univ Penn, Sch Med, Div Infect Dis, Dept Med, Philadelphia, PA 19104 USA.
[Lautenbach, E.] Univ Penn, Sch Med, Ctr Educ, Philadelphia, PA 19104 USA.
[Lautenbach, E.] Univ Penn, Sch Med, Ctr Res Therapeut, Philadelphia, PA 19104 USA.
[Amorosa, V. K.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA.
RP Lemonovich, TL (reprint author), Case Western Reserve Univ, Div Infect Dis & HIV Med, Dept Med, 11100 Euclid Ave, Cleveland, OH 44106 USA.
EM tracy.lemonovich@UHhospitals.org
FU Merck; Ortho-McNeil; AstraZeneca
FX Ebbing Lautenbach has received research funding from Merck,
Ortho-McNeil, and AstraZeneca. All other authors have no conflicts.
NR 32
TC 4
Z9 4
U1 0
U2 1
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 0300-8126
EI 1439-0973
J9 INFECTION
JI Infection
PD DEC
PY 2011
VL 39
IS 6
BP 549
EP 554
DI 10.1007/s15010-011-0189-2
PG 6
WC Infectious Diseases
SC Infectious Diseases
GA 855RX
UT WOS:000297583200009
PM 21898120
ER
PT J
AU Sonnenberg, A
Melton, SD
Genta, RM
Lewis, AD
AF Sonnenberg, Amnon
Melton, Shelby D.
Genta, Robert M.
Lewis, Anne D.
TI Absence of Focally Enhanced Gastritis in Macaques with Idiopathic
Colitis
SO INFLAMMATORY BOWEL DISEASES
LA English
DT Article
DE etiology of inflammatory bowel disease; focally enhanced gastritis;
gastritis; idiopathic chronic colitis of macaques; infectious organisms
in inflammatory bowel disease; rhesus macaques (Macaca mulatta)
ID RHESUS MACAQUES; CROHNS-DISEASE; HELICOBACTER-PYLORI; CHRONIC DIARRHEA;
MACACA-MULATTA; MONKEYS; BIOPSIES; MODEL
AB Background: Focally enhanced gastritis has been described in association with Crohn's disease and ulcerative colitis, but is rare in the general population. The study aim was to test whether idiopathic colitis in macaques was associated with any characteristic changes of the gastric mucosa resembling similar changes in humans.
Methods: The presence or absence of idiopathic colitis was established by gross and microscopic examination of the colons of rhesus macaques (Macaca mulatta), which died at the Oregon National Primate Research Center. Gastric tissue specimens were compared between a case population of 26 macaques with idiopathic colitis and a control population of 21 macaques without colitis. The specimens were histologically assessed by two independent pathologists blinded to the presence or absence of idiopathic colitis. Differences between cases and controls were compared using a two-sided Fisher's exact test.
Results: Of the 26 cases of macaques with colitis, 11 animals (42%) harbored signs of chronic gastritis. Of the 21 control macaques without colitis, nine animals (43%) harbored signs of chronic gastritis, P = 1.0000. Of all animals with gastritis, 1/11 animals with colitis and 2/9 control animals showed rare active gastritis as evidenced by the presence of neutrophils, P = 0.5658. Lymphocytic infiltrates of the gastric mucosa were seen in 4/11 colitis cases and 0/9 controls, P = 0.0942. No gastric specimens with focally enhanced gastritis were found among any of the case or control animals.
Conclusions: Unlike chronic inflammatory bowel disease in humans, idiopathic colitis in macaques is not associated with focally enhanced gastritis or any other type of specific gastritis. (Inflamm Bowel Dis 2011;17:2456-2461)
C1 [Sonnenberg, Amnon] Portland VA Med Ctr, Portland, OR USA.
[Sonnenberg, Amnon; Lewis, Anne D.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
[Melton, Shelby D.; Genta, Robert M.] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA.
[Melton, Shelby D.; Genta, Robert M.] Caris Diagnost, Dallas, TX USA.
[Melton, Shelby D.; Genta, Robert M.] Dallas VA Med Ctr, Dallas, TX USA.
[Lewis, Anne D.] Oregon Natl Primate Res Ctr, Portland, OR USA.
RP Sonnenberg, A (reprint author), Portland VA Med Ctr P3 GI, 3710 SW US Vet Hosp Rd, Portland, OR 97239 USA.
EM sonnenbe@ohsu.edu
FU Takeda Pharmaceuticals; Oregon National Primate Research Center NCRR
[RR000163]
FX The authors have no potential conflicts of interest to declare. Amnon
Sonnenberg has been supported by a grant from Takeda Pharmaceuticals.
Anne D. Lewis has been supported by the Oregon National Primate Research
Center NCRR base grant RR000163.
NR 17
TC 4
Z9 4
U1 0
U2 0
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1078-0998
J9 INFLAMM BOWEL DIS
JI Inflamm. Bowel Dis.
PD DEC
PY 2011
VL 17
IS 12
BP 2456
EP 2461
DI 10.1002/ibd.21696
PG 6
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 857QP
UT WOS:000297734000013
PM 21425215
ER
PT J
AU Hage, FG
Dean, P
Iqbal, F
Heo, J
Iskandrian, AE
AF Hage, Fadi G.
Dean, Phillip
Iqbal, Fahad
Heo, Jaekyeong
Iskandrian, Ami E.
TI A blunted heart rate response to regadenoson is an independent
prognostic indicator in patients undergoing myocardial perfusion imaging
SO JOURNAL OF NUCLEAR CARDIOLOGY
LA English
DT Article
DE Regadenoson; heart rate response; myocardial perfusion imaging; risk
stratification
ID DIABETES-MELLITUS; ADENOSINE; STRESS; RECLASSIFICATION; PREDICTOR;
MORTALITY; AGONIST; TRIAL; AGE
AB Regadenoson myocardial perfusion imaging (MPI) is a useful method for risk assessment. We hypothesized that the heart rate response (HRR) to regadenoson carries incremental prognostic information to that derived from perfusion pattern and left ventricular (LV) ejection fraction (EF).
The study population included 1,156 (60 +/- A 13 years, 46% women, 40% diabetes mellitus, 53% chronic kidney disease) patients. During a follow-up period of 22 +/- A 5 months, 103 patients died (9%). Independent determinants of the HRR included age, gender, race, diabetes mellitus, coronary revascularization, LVEF, use of insulin and aldosterone antagonists. Decreasing HRR was associated with stepwise increase in mortality (log-rank P < .0001). In a Cox proportional model for mortality that adjusted for age, gender, diabetes mellitus, renal disease, and MPI findings, HRR in the lowest quartile was independently associated with fivefold increase in mortality compared to the highest quartile [HR 5.2, 95% CI 2.3-12.0, P < .0001]. Patients with a normal HRR had a relatively low annualized total mortality despite the presence of risk factors. The addition of HRR to traditional MPI findings had a net reclassification improvement of 15%, P = .02.
A blunted HRR to regadenoson is an independent predictor of poor outcome, adds incremental value to MPI, and helps in better risk stratification.
C1 [Hage, Fadi G.; Iqbal, Fahad; Heo, Jaekyeong; Iskandrian, Ami E.] Univ Alabama, Div Cardiovasc Dis, Birmingham, AL 35294 USA.
[Dean, Phillip] Univ Alabama, Dept Med, Birmingham, AL 35294 USA.
[Hage, Fadi G.] Birmingham Vet Affairs Med Ctr, Div Cardiol, Birmingham, AL USA.
RP Hage, FG (reprint author), Univ Alabama, Div Cardiovasc Dis, ZRB 1024,1530 3rd AVE S, Birmingham, AL 35294 USA.
EM fadihage@uab.edu
OI Hage, Fadi/0000-0002-1397-4942
FU Astellas
FX Ami Iskandrian has received research funds from Astellas and served as
consultant for Gilead.
NR 25
TC 24
Z9 24
U1 0
U2 5
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1071-3581
J9 J NUCL CARDIOL
JI J. Nucl. Cardiol.
PD DEC
PY 2011
VL 18
IS 6
BP 1086
EP 1094
DI 10.1007/s12350-011-9429-1
PG 9
WC Cardiac & Cardiovascular Systems; Radiology, Nuclear Medicine & Medical
Imaging
SC Cardiovascular System & Cardiology; Radiology, Nuclear Medicine &
Medical Imaging
GA 856GK
UT WOS:000297626600016
PM 21785922
ER
PT J
AU Goreshi, R
Chock, M
Foering, K
Feng, R
Okawa, J
Rose, M
Fiorentino, D
Werth, V
AF Goreshi, Renato
Chock, Monika
Foering, Kristen
Feng, Rui
Okawa, Joyce
Rose, Matt
Fiorentino, David
Werth, Victoria
TI Quality of life in dermatomyositis
SO JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
LA English
DT Article
DE autoimmune disease; clinical research; connective tissue disease;
cutaneous lupus; dermatomyositis; itch; pruritus; quality of life
ID HEALTH SURVEY SF-36; PSYCHIATRIC-DISORDERS; SKIN-DISEASE; DERMATOLOGICAL
OUTPATIENTS; PSYCHOLOGICAL DISTRESS; VALIDITY; RELIABILITY; MORBIDITY;
PSORIASIS; PRURITUS
AB Background: Quality of life (QoL) for patients with inflammatory skin disease can he significant, but has been evaluated in just one study in dermatomyositis (DM).
Objective: We sought to examine the relationship between the Cutaneous Dermatomyositis Area (CDASI) and Severity Index, a DM-specific cutaneous severity instrument. and various QoL study instruments and to determine the impact of DM on QoL.
Methods: Skin-specific QoL instruments, the Skindex and the Dermatology Life Quality Index, and global medical QoL instruments, the Short Form 36 and the Health Assessment Questionnaire-Disability Index, were used. Pruritus was evaluated by a visual analog scale and a 0-to-10 scale in DM and cutaneous lupus erythematosus (CLE) populations, respectively.
Results: There was a significant correlation between the CDASI and all skin-specific QoL scores (lowest P = .0377). Using the Short Form 36, DM population was found to have significantly worse QoL scores than the general population with the exception of bodily pain (all subscore P values < .01). Furthermore, DM had a significantly lower vitality score, representing energy level, compared with CLE, hypertension, diabetes, and recent myocardial infarction scores (lowest P = .003). There was a significantly lower mental health score, representing overall mood, to all compared diseases except CLE and clinical depression (P values < .01 when significant). We found that DM produces more pruritus than CLE (P < .0001).
Limitations: A larger patient population needs to be studied to further assess QoL in patients with DM.
Conclusion: We conclude that DM has a large impact on QoL, even when compared with other diseases, and that DM skin disease activity correlates with a poorer QoL. (J Am Acad Dermatol 2011;65:1107-16.)
C1 [Goreshi, Renato; Foering, Kristen; Okawa, Joyce; Rose, Matt; Werth, Victoria] Philadelphia Dept Vet Affairs Med Ctr, Philadelphia, PA USA.
[Goreshi, Renato; Foering, Kristen; Okawa, Joyce; Rose, Matt; Werth, Victoria] Univ Penn, Sch Med, Philadelphia, PA 19104 USA.
[Chock, Monika; Fiorentino, David] Stanford Univ, Sch Med, Stanford, CA 94305 USA.
[Feng, Rui] Univ Penn, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA.
RP Werth, V (reprint author), Perelman Ctr Adv Med, Dept Dermatol, Suite 1-330A,3400 Civ Ctr Blvd, Philadelphia, PA 19104 USA.
EM werth@mail.med.upenn.edu
OI Fiorentino, David/0000-0001-7951-3674
FU National Institutes of Health (NIH) [NIH K24-AR 02207, NIH
5-R25-HL084665-04]; Department of Veterans Affairs Veterans Health
Administration, Office of Research and Development, Biomedical
Laboratory Research and Development; Centocor; Abbott Laboratories;
Amgen
FX This material is based on work supported by the National Institutes of
Health (NIH), including NIH K24-AR 02207 (Dr Werth) and training grant
NIH 5-R25-HL084665-04 (Dr Goreshi). This work was also partially
supported by a Merit Review Grant from the Department of Veterans
Affairs Veterans Health Administration, Office of Research and
Development, Biomedical Laboratory Research and Development.; Dr
Fiorentino received honoraria from Amgen, Centocor, Chemocentryx, and
MedImmune; received grants from Centocor, Abbott Laboratories, and
Amgen; and filed a patent (US patent application serial number
12/694,980 for "Profiling for Determination of Response to Treatment for
Inflammatory Disease" filed on January 27, 2010). Drs Goreshi, Chock,
Feng, and Werth, Ms Foering, Ms Okawa, and Mr Rose have no conflicts of
interest to declare.
NR 53
TC 23
Z9 24
U1 0
U2 7
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0190-9622
J9 J AM ACAD DERMATOL
JI J. Am. Acad. Dermatol.
PD DEC
PY 2011
VL 65
IS 6
BP 1107
EP 1116
DI 10.1016/j.jaad.2010.10.016
PG 10
WC Dermatology
SC Dermatology
GA 857KK
UT WOS:000297717200004
PM 21722989
ER
PT J
AU Asgari, MM
Chren, MM
Warton, EM
Friedman, GD
White, E
AF Asgari, Maryam M.
Chren, Mary-Margaret
Warton, E. Margaret
Friedman, Gary D.
White, Emily
TI Supplement use and risk of cutaneous squamous cell carcinoma
SO JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
LA English
DT Article
DE antioxidant; epidemiology; skin cancer; squamous cell carcinoma;
supplement; vitamin
ID NONMELANOMA SKIN-CANCER; ORAL VITAMIN-E; GRAPE SEED; ALPHA-TOCOPHEROL;
CONTROLLED-TRIAL; BETA-CAROTENE; BASAL-CELL; IN-VITRO; POLYPHENOLIC
FRACTION; DIETARY FACTORS
AB Background: Laboratory and epidemiologic studies suggest that certain dietary supplements may alter risk of cutaneous squamous cell carcinoma (SCC).
Objective: We sought to examine the association between supplement use and SCC risk.
Methods: Cases (n = 415) were defined as Kaiser Permanente Northern California members with a pathology-verified SCC in 2004 and control subjects (n = 415) were age-, sex-, and race-matched members with no history of skin cancer. Supplement use and SCC risk factors were ascertained by questionnaire. Associations of SCC with use of multivitamins; vitamins A, C, D, and E; and grape seed extract were estimated as odds ratios and 95% confidence intervals using conditional logistic regression. Models were adjusted for SCC risk factors and other supplement use.
Results: Grape seed extract users had a significantly decreased risk of cutaneous SCC (adjusted odds ratio 0.26, confidence interval 0.08-0.89, P = .031). Multivitamin use was associated with a borderline significant reduction in SCC risk (adjusted odds ratio 0.71, confidence interval 0.51-1.00, P = .049). Use of vitamins A, C, 0, and E was not associated with SCC risk.
Limitations: The data may be prone to recall and selection bias because of the case-control design. No information was obtained on dose or duration of supplement use.
Conclusions: Use of grape seed extract may be associated with a decreased risk of cutaneous SCC. The other supplements included in our study did not reveal clear associations with SCC risk. (J Am Acad Dermatol 2011;65:1145-51.)
C1 [Asgari, Maryam M.; Warton, E. Margaret; Friedman, Gary D.] Kaiser Permanente No Calif, Div Res, Oakland, CA 94612 USA.
[Asgari, Maryam M.; Chren, Mary-Margaret] Univ Calif San Francisco, Dept Dermatol, San Francisco, CA 94143 USA.
[Chren, Mary-Margaret] San Francisco VA Med Ctr, Hlth Serv Res Enhancement Award Program, San Francisco, CA USA.
[Friedman, Gary D.] Stanford Univ, Sch Med, Dept Hlth Res & Policy, Stanford, CA 94305 USA.
[White, Emily] Univ Washington, Med Ctr, Dept Epidemiol, Seattle, WA 98195 USA.
[White, Emily] Fred Hutchinson Canc Res Ctr, Canc Prevent Program, Seattle, WA 98104 USA.
RP Asgari, MM (reprint author), Kaiser Permanente No Calif, Div Res, 2000 Broadway, Oakland, CA 94612 USA.
EM maryam.m.asgari@kp.org
RI Asgari, Maryam/O-4947-2016
FU National Institute of Arthritis and Musculoskeletal and Skin Diseases
[K23 AR 051037, K24 AR 052667]; National Cancer Institute [R01 CA
098838, K05CA154337]
FX Supported by the National Institute of Arthritis and Musculoskeletal and
Skin Diseases (K23 AR 051037 to Dr Asgari, K24 AR 052667 to Dr Chren)
and by the National Cancer Institute (R01 CA 098838 to Dr Friedman,
K05CA154337 to Dr White).
NR 47
TC 6
Z9 6
U1 1
U2 3
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0190-9622
J9 J AM ACAD DERMATOL
JI J. Am. Acad. Dermatol.
PD DEC
PY 2011
VL 65
IS 6
BP 1145
EP 1151
DI 10.1016/j.jaad.2010.09.009
PG 7
WC Dermatology
SC Dermatology
GA 857KK
UT WOS:000297717200008
PM 21664718
ER
PT J
AU Sacks, HS
Fain, JN
Cheema, P
Bahouth, SW
Garrett, E
Wolf, RY
Wolford, D
Samaha, J
AF Sacks, Harold S.
Fain, John N.
Cheema, Paramjeet
Bahouth, Suleiman W.
Garrett, Edward
Wolf, Rodney Y.
Wolford, David
Samaha, Joseph
TI Depot-Specific Overexpression of Proinflammatory, Redox, Endothelial
Cell, and Angiogenic Genes in Epicardial Fat Adjacent to Severe Stable
Coronary Atherosclerosis
SO METABOLIC SYNDROME AND RELATED DISORDERS
LA English
DT Article
ID ADIPOSE-TISSUE; ARTERY-DISEASE; CARDIOVASCULAR-DISEASE;
INSULIN-RESISTANCE; OXIDATIVE STRESS; EXPRESSION; MEDIATORS
AB Background: Pro- and antiinflammatory genes are expressed in epicardial adipose tissue (EAT). Our objectives were to characterize genes in EAT that may contribute specifically to coronary atherogenesis and to measure circulating adipokines matched to their messenger RNAs (mRNAs) in EAT. We hypothesized that severe coronary atherosclerosis (CAD) would preferentially affect gene expression in EAT as compared to substernal fat or subcutaneous thoracic adipose tissue (SAT), as well as circulating levels of adipokines.
Methods: Fat mRNA was quantified using reverse transcription polymerase chain reaction (RT-PCR), and circulating adipokines were measured by enzyme-linked immunosorbent assays (ELISAs) in patients with severe stable CAD and controls without severe CAD undergoing open heart surgery.
Results: A total of 39 of 70 mRNAs in EAT were significantly increased in CAD. Only 4 and 3 of these mRNAs were increased in substernal fat and SAT, respectively. Of the mRNAs increased in EAT, 17 were either inflammatory adipokines or proteins known to be involved in inflammatory processes, 7 were involved in oxidative stress and or oxygen species regulation, whereas 15 were proteins involved in metabolism and regulation of gene transcription or proteins unique to fat cells. The largest increases, over three-fold, were seen in GPX3, gp91 phox, p47phox, heme oxygenase, and interleukin-8 (IL-8). Tpl2 mRNA was uniquely elevated in all three fat depots from CAD patients, and its expression in SAT, but not in EAT or substernal fat, was directly correlated with homeostasis model assessment of insulin resistance (HOMA-IR) values. Compared to controls, there were no associations between circulating levels of IL-8, lipocalin-2, nerve growth factor (NGF), RANTES, CD-163, GPX-3, monocyte chemotactic protein-1 (MCP-1)/CCL2, leptin, soluble vascular endothelial growth factor receptor-1 (sFLT1), fatty acid binding protein-4 (FABP-4), and plasminogen activator inhibitor-1 (PAI-1) and increases in their gene expression in EAT adjacent to CAD.
Conclusions: Expression of proinflammatory, redox, endothelial cell, and angiogenic genes in EAT is depot specific and supports the hypothesis that pathophysiologically EAT contributes locally to CAD. CAD links with these fat depots might involve Tpl2 as a primary response indicator.
C1 [Sacks, Harold S.] Univ Tennessee, Hlth Sci Ctr, Coll Med, Dept Med, Memphis, TN USA.
[Fain, John N.; Cheema, Paramjeet] Univ Tennessee, Hlth Sci Ctr, Coll Med, Dept Mol Sci, Memphis, TN USA.
[Bahouth, Suleiman W.] Univ Tennessee, Hlth Sci Ctr, Coll Med, Dept Pharmacol, Memphis, TN USA.
[Sacks, Harold S.; Garrett, Edward; Wolf, Rodney Y.; Wolford, David; Samaha, Joseph] Baptist Mem Hosp, Baptist Heart Inst, Memphis, TN 38146 USA.
RP Sacks, HS (reprint author), VA Greater Angeles Healthcare Syst, Endocrinol & Diabet Div, 111D,11301 Wilshire Blvd, Los Angeles, CA 90073 USA.
EM hsacks@hotmail.com
FU Van Vleet Chair of Excellence, University of Tennessee; Baptist Heart
Institute and Foundation, Memphis, TN; Cardiometabolic Disease Research
Foundation, Memphis, TN
FX This study was supported by the Van Vleet Chair of Excellence,
University of Tennessee; the Baptist Heart Institute and Foundation,
Memphis, TN; and the Cardiometabolic Disease Research Foundation,
Memphis, TN.
NR 28
TC 17
Z9 17
U1 0
U2 0
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1540-4196
J9 METAB SYNDR RELAT D
JI Metab. Syndr. Relat. Disord.
PD DEC
PY 2011
VL 9
IS 6
BP 433
EP 439
DI 10.1089/met.2011.0024
PG 7
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA 859BL
UT WOS:000297849000004
PM 21679057
ER
PT J
AU Vogel, KS
Perez, M
Momand, JR
Acevedo-Torres, K
Hildreth, K
Garcia, RA
Torres-Ramos, CA
Ayala-Torres, S
Prihoda, TJ
McMahan, CA
Walter, CA
AF Vogel, Kristine S.
Perez, Marissa
Momand, Jamila R.
Acevedo-Torres, Karina
Hildreth, Kim
Garcia, Rebecca A.
Torres-Ramos, Carlos A.
Ayala-Torres, Sylvette
Prihoda, Thomas J.
McMahan, C. Alex
Walter, Christi A.
TI Age-Related Instability in Spermatogenic Cell Nuclear and Mitochondrial
DNA Obtained From Apex1 Heterozygous Mice
SO MOLECULAR REPRODUCTION AND DEVELOPMENT
LA English
DT Article
ID BASE EXCISION-REPAIR; HUMAN APURINIC ENDONUCLEASE; INDUCED
SPECIFIC-LOCUS; POLYMERASE-BETA; OXIDATIVE STRESS; MAMMALIAN-CELLS;
HUMAN SPERM; OLD MICE; SPERMATOZOAL CHROMATIN; SPONTANEOUS MUTATION
AB The prevalence of spontaneous mutations increases with age in the male germline; consequently, older men have an increased risk of siring children with genetic disease due to de novo mutations. The lacI transgenic mouse can be used to study paternal age effects, and in this system, the prevalence of de novo mutations increases in the male germline at old ages. Mutagenesis is linked with DNA repair capacity, and base excision repair (BER), which can ameliorate spontaneous DNA damage, decreases in nuclear extracts of spermatogenic cells from old mice. Mice heterozygous for a null allele of the Apex1 gene, which encodes apurinic/apyrimidinic endonuclease I (APEN), an essential BER enzyme, display an accelerated increase in spontaneous germline mutagenesis early in life. Here, the consequences of lifelong reduction of APEN on genetic instability in the male germline were examined, for the first time, at middle and old ages. Mutant frequency increased earlier in spermatogenic cells from Apex1(+/-) mice (by 6 months of age). Nuclear DNA damage increased with age in the spermatogenic lineage for both wild-type and Apex1(+/-) mice. By old age, mutant frequencies were similar for wild-type and APEN-deficient mice. Mitochondrial genome-repair also depends on APEN, and novel analysis of mitochondrial-DNA(mtDNA) damage revealed an increase in the Apex1(+/-) spermatogenic cells by middle age. Thus, Apex1 heterozygosity results in accelerated damage to mtDNA and spontaneous mutagenesis, consistent with an essential role for APEN in maintaining nuclear and mtDNA integrity in spermatogenic cells throughout life.
C1 [Vogel, Kristine S.; Perez, Marissa; Momand, Jamila R.; Hildreth, Kim; Garcia, Rebecca A.; Walter, Christi A.] Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA.
[Acevedo-Torres, Karina; Torres-Ramos, Carlos A.] Univ Puerto Rico, Dept Physiol, San Juan, PR 00936 USA.
[Ayala-Torres, Sylvette] Univ Puerto Rico, Dept Pharmacol, San Juan, PR 00936 USA.
[Prihoda, Thomas J.; McMahan, C. Alex] Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, San Antonio, TX 78229 USA.
[Walter, Christi A.] Univ Texas Hlth Sci Ctr San Antonio, Barshop Inst Longev & Aging Studies, San Antonio, TX 78229 USA.
[Walter, Christi A.] S Texas Vet Hlth Care Syst, San Antonio, TX USA.
RP Walter, CA (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.
EM walter@uthscsa.edu
FU NIH-NIA [AG0211663, AG024364]; NIH-NCI [CCSG CA054174]; NIH-NINDS
[5U54NS039408]; NIH-NIGMS [NIH-NCRR-G12RR03051, 5SC3GM084759,
5R25GM061838]
FX The authors would like to thank Roderick Haesevoets, DNA Sequencing
Facility, Centre for Biomedical Research at the University of Victoria,
for lacI sequencing and mutation spectrum data. This work was supported
by grants AG0211663 and AG024364 (NIH-NIA) to C.A.W., the CCSG CA054174
(NIH-NCI) to UTHSCSA, and by grants 5U54NS039408 (NIH-NINDS),
NIH-NCRR-G12RR03051, 5SC3GM084759 (NIH-NIGMS), and 5R25GM061838
(NIH-NIGMS) to C.A.T.-R.
NR 68
TC 10
Z9 10
U1 0
U2 2
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1040-452X
J9 MOL REPROD DEV
JI Mol. Reprod. Dev.
PD DEC
PY 2011
VL 78
IS 12
BP 906
EP 919
DI 10.1002/mrd.21374
PG 14
WC Biochemistry & Molecular Biology; Cell Biology; Developmental Biology;
Reproductive Biology
SC Biochemistry & Molecular Biology; Cell Biology; Developmental Biology;
Reproductive Biology
GA 855EU
UT WOS:000297547400004
PM 21919107
ER
PT J
AU Kim, E
Cameron, M
Lovera, J
Schaben, L
Bourdette, D
Whitham, R
AF Kim, E.
Cameron, M.
Lovera, J.
Schaben, L.
Bourdette, D.
Whitham, R.
TI American ginseng does not improve fatigue in multiple sclerosis: a
single center randomized double-blind placebo-controlled crossover pilot
study
SO MULTIPLE SCLEROSIS JOURNAL
LA English
DT Article
DE clinical trial; complementary therapies; fatigue; ginseng; Panax;
multiple sclerosis
ID MODAFINIL; IMPACT; SCALE
AB This study examined the safety and efficacy of an escalating dose (100 mg, 200 mg, 400 mg/day) of American ginseng over 6 weeks in a single-center, randomized, double-blind, placebo-controlled, crossover trial with 56 subjects with multiple sclerosis and fatigue. There were no serious adverse events but fatigue on ginseng, as assessed by the Fatigue Severity Scale, was not significantly different from fatigue on placebo.
C1 [Kim, E.; Cameron, M.; Bourdette, D.; Whitham, R.] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97239 USA.
[Kim, E.; Cameron, M.; Bourdette, D.; Whitham, R.] Portland VA Med Ctr, Neurol Serv, Portland, OR USA.
[Kim, E.; Cameron, M.; Bourdette, D.; Whitham, R.] Portland VA Med Ctr, MS Ctr Excellence W, Portland, OR USA.
[Lovera, J.] Louisiana State Univ, Hlth Sci Ctr, Dept Neurol, New Orleans, LA USA.
[Schaben, L.] Bend Neurol Associates, Bend, OR USA.
RP Cameron, M (reprint author), Oregon Hlth & Sci Univ, Dept Neurol, 3181 SW Sam Jackson Pk Rd,CR120, Portland, OR 97239 USA.
EM cameromi@ohsu.edu
FU Department of Veterans Affairs; Department of Veterans Affairs,
Rehabilitation Research and Development Service; National MS Society
[PP1307, CA 1055-A-3]; PHS [5 M01 RR000334]; Medical Research
Foundation; Nancy Davis Center without Walls; Oregon Clinical and
Translational Research Institute (OCTRI); National Center for Research
Resources (NCRR), a component of the National Institutes of Health (NIH)
[UL1 RR024140]; NIH Roadmap for Medical Research
FX Dr Kim and Dr Schaben were Multiple Sclerosis Fellows supported by the
Department of Veterans Affairs. Dr Cameron was supported by a Career
Development Award from the Department of Veterans Affairs,
Rehabilitation Research and Development Service. Ginseng and placebo
products were donated by Afexa Life Sciences Inc. (Edmonton, Canada).;
This study was supported by National MS Society grants PP1307 (Pilot
Project Award) and CA 1055-A-3 (Collaborative MS Research Center Award);
PHS Grant 5 M01 RR000334; the Medical Research Foundation; and the Nancy
Davis Center without Walls. This publication was made possible with
support from the Oregon Clinical and Translational Research Institute
(OCTRI), grant number UL1 RR024140 from the National Center for Research
Resources (NCRR), a component of the National Institutes of Health
(NIH), and NIH Roadmap for Medical Research.
NR 10
TC 5
Z9 5
U1 0
U2 8
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1352-4585
J9 MULT SCLER J
JI Mult. Scler. J.
PD DEC
PY 2011
VL 17
IS 12
BP 1523
EP 1526
DI 10.1177/1352458511412062
PG 4
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 854UZ
UT WOS:000297521400018
PM 21803872
ER
PT J
AU Corless, CL
Barnett, CM
Heinrich, MC
AF Corless, Christopher L.
Barnett, Christine M.
Heinrich, Michael C.
TI Gastrointestinal stromal tumours: origin and molecular oncology
SO NATURE REVIEWS CANCER
LA English
DT Review
ID FACTOR-RECEPTOR-ALPHA; C-KIT GENE; OF-FUNCTION MUTATIONS;
POSITRON-EMISSION-TOMOGRAPHY; CYCLE REGULATORY PROTEINS; TYROSINE KINASE
INHIBITOR; V600E BRAF MUTATIONS; TERM-FOLLOW-UP; IMATINIB MESYLATE;
INTERSTITIAL-CELLS
AB Gastrointestinal stromal tumours (GISTs) are a paradigm for the development of personalized treatment for cancer patients. The nearly simultaneous discovery of a biomarker that is reflective of their origin and the presence of gain-of-function kinase mutations in these tumours set the stage for more accurate diagnosis and the development of kinase inhibitor therapy. Subsequent studies of genotype and phenotype have led to a molecular classification of GIST and to treatment optimization on the basis of molecular subtype. The study of drug-resistant tumours has advanced our understanding of kinase biology, enabling the development of novel kinase inhibitors. Further improvements in GIST treatment may require targeting GIST stem cell populations and/or additional genomic events.
C1 [Heinrich, Michael C.] Oregon Hlth & Sci Univ, Knight Canc Inst, Div Haematol & Oncol, Portland, OR 97239 USA.
Oregon Hlth & Sci Univ, Dept Pathol, Portland VA Med Ctr, Portland, OR 97239 USA.
RP Heinrich, MC (reprint author), Oregon Hlth & Sci Univ, Knight Canc Inst, Div Haematol & Oncol, Portland, OR 97239 USA.
EM heinrich@ohsu.edu
FU GIST; BP Lester Foundation; LifeRaft Group; Department of Veterans
Affairs
FX The authors wish to acknowledge all of the members of their laboratories
for their continuing efforts on gastrointestinal stromal tumour (GIST)
research. Some of the work referenced in this article was supported by
generous donations from the GIST Cancer Research Fund and the BP Lester
Foundation, and by grant support from the LifeRaft Group. In addition,
M. C. H. received research grant funding from the Department of Veterans
Affairs (Merit Review Award).
NR 194
TC 238
Z9 253
U1 5
U2 33
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1474-175X
J9 NAT REV CANCER
JI Nat. Rev. Cancer
PD DEC
PY 2011
VL 11
IS 12
BP 865
EP 878
DI 10.1038/nrc3143
PG 14
WC Oncology
SC Oncology
GA 859DC
UT WOS:000297853900013
PM 22089421
ER
PT J
AU Tregellas, JR
Wylie, KP
Rojas, DC
Tanabe, J
Martin, J
Kronberg, E
Cordes, D
Cornier, MA
AF Tregellas, Jason R.
Wylie, Korey P.
Rojas, Donald C.
Tanabe, Jody
Martin, Jesse
Kronberg, Eugene
Cordes, Dietmar
Cornier, Marc-Andre
TI Altered Default Network Activity in Obesity
SO OBESITY
LA English
DT Article
ID POSITRON-EMISSION-TOMOGRAPHY; VISUAL FOOD CUES; HUMAN BRAIN; RESTING
STATE; NEURONAL RESPONSE; NEURAL RESPONSES; FUNCTIONAL MRI; LIQUID-MEAL;
REWARD; FMRI
AB The regulation of energy intake is a complex process involving the integration of homeostatic signals and both internal and external sensory inputs. To better understand the neurobiology of this process and how it may be dysfunctional in obesity, this study examined activity of the brain's "default network" in reduced-obese (RO) as compared to lean individuals. The default network is a group of functionally connected brain regions thought to play an important role in internally directed cognitive activity and the interplay between external and internal sensory processing. Functional magnetic resonance imaging was performed in 24 lean and 18 RO individuals in the fasted state after 2 days of eucaloric energy intake and after 2 days of 30% overfeeding in a counterbalanced design. Scanning was performed while subjects passively viewed images of food and nonfood objects. Independent component analysis was used to identify the default network component. In the eucaloric state, greater default network activity was observed in RO compared to lean individuals in the lateral inferior parietal and posterior cingulate cortices. Activity was positively correlated with appetite. Overfeeding resulted in increased default network activity in lean but not RO individuals. These findings suggest that the function of the default network, a major contributor to intrinsic neuronal activity, is altered in obesity and/or obese-prone individuals. Future studies of the network's function and its relationship to other brain networks may improve our understanding of the mechanisms and treatment of obesity.
C1 [Tregellas, Jason R.; Wylie, Korey P.; Rojas, Donald C.; Tanabe, Jody; Martin, Jesse; Kronberg, Eugene; Cordes, Dietmar] Denver VA Med Ctr, Dept Psychiat, Aurora, CO USA.
[Cornier, Marc-Andre] Univ Colorado Denver, Div Endocrinol, Dept Med, Aurora, CO USA.
[Tanabe, Jody; Cordes, Dietmar] Univ Colorado, Dept Radiol, Denver, CO 80202 USA.
RP Tregellas, JR (reprint author), Denver VA Med Ctr, Dept Psychiat, Aurora, CO USA.
EM Jason.tregellas@ucdenver.edu
RI Rojas, Don/F-4296-2012; Tregellas, Jason/J-3637-2015
OI Rojas, Don/0000-0001-6560-9616
FU NIH/NCRR Colorado CTSI [UL1 RR025780]; NIH/NIDDK Clinical Nutrition
Research Unit [DK48520]; NIH/NCRR [RR016185, R01DK072174, R01DK089095]
FX This study was supported by NIH/NCRR Colorado CTSI Grant Number UL1
RR025780, NIH/NIDDK Clinical Nutrition Research Unit Grant Number
DK48520, and NIH/NCRR Grant Numbers RR016185, R01DK072174 and
R01DK089095.
NR 46
TC 29
Z9 29
U1 1
U2 8
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1930-7381
EI 1930-739X
J9 OBESITY
JI Obesity
PD DEC
PY 2011
VL 19
IS 12
BP 2316
EP 2321
DI 10.1038/oby.2011.119
PG 6
WC Endocrinology & Metabolism; Nutrition & Dietetics
SC Endocrinology & Metabolism; Nutrition & Dietetics
GA 853EM
UT WOS:000297409000005
PM 21633398
ER
PT J
AU Martin, JL
Fiorentino, L
Jouldjian, S
Mitchell, M
Josephson, KR
Alessi, CA
AF Martin, Jennifer L.
Fiorentino, Lavinia
Jouldjian, Stella
Mitchell, Michael
Josephson, Karen R.
Alessi, Cathy A.
TI Poor Self-Reported Sleep Quality Predicts Mortality within One Year of
Inpatient Post-Acute Rehabilitation among Older Adults
SO SLEEP
LA English
DT Article
DE Aging; rehabilitation; mortality
ID ILLNESS RATING-SCALE; FOLLOW-UP; DAYTIME SLEEPINESS; POPULATION;
DISTURBANCES; VALIDATION; RECOVERY; DISEASE; PEOPLE; MODEL
AB Study Objective: To evaluate the association between self-reported sleep quality among older adults during inpatient post-acute rehabilitation and one-year survival.
Design: Prospective, observational cohort study.
Setting: Two inpatient post-acute rehabilitation sites (one community and one Veterans Administration).
Participants: Older patients (aged >= 65 years, n = 245) admitted for inpatient post-acute rehabilitation.
Interventions: None.
Measurements and Results: Within one year of post-acute rehabilitation, 57 participants (23%) were deceased. Cox proportional hazards models showed that worse Pittsburgh Sleep Quality Index (PSQI) total scores during the post-acute care stay were associated with increased mortality risk when controlling for amount of rehabilitation therapy received, comorbidities, and cognitive functioning (Hazard ratio [95% CI] = 1.11 [1.02-1.20]). Actigraphically estimated sleep was unrelated to mortality risk.
Conclusions: Poorer self-reported sleep quality, but not objectively estimated sleep parameters, during post-acute rehabilitation was associated with shorter survival among older adults. This suggests self-reported poor sleep may be an important and potentially modifiable risk factor for negative outcomes in these vulnerable older adults. Studies of interventions to improve sleep quality during inpatient rehabilitation should therefore be undertaken, and the long-term health benefits of improved sleep should be explored.
C1 [Martin, Jennifer L.; Alessi, Cathy A.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
[Martin, Jennifer L.; Jouldjian, Stella; Mitchell, Michael; Josephson, Karen R.; Alessi, Cathy A.] VA Greater Los Angeles Healthcare Syst, Geriatr Res Educ & Clin Ctr, Los Angeles, CA USA.
[Fiorentino, Lavinia] Univ Calif San Diego, Dept Psychiat, Div Geriatr Mental Hlth, San Diego, CA 92103 USA.
RP Martin, JL (reprint author), VA GRECC 11E, 16111 Plummer St, North Hills, CA 91007 USA.
EM Jennifer.Martin@va.gov
FU NIA [K23 AG028452]; VA HSRD [IIR-01-053-1, IIR 04-321-2, AIA-03-047];
NIMH [T32 MH 019925-11, T32 MH019934]; VA Greater Los Angeles Healthcare
System Geriatric Research, Education and Clinical Center (GRECC)
FX The authors thank the participating facilities and their staff, and the
members of the research team who made this study possible. In
particular, the authors thank Terry Vandenberg, MA, Sergio Martinez,
Maryanne Devereaux, Christina Kurtz, RN, Rebecca Saia, Crystal Barker,
RN, Jae Lee, MD, David Kim, PA, and Adam Webber, BSc(Hons), MRCP (UK).
This study was supported by NIA K23 AG028452; VA HSR&D (IIR-01-053-1;
IIR 04-321-2; AIA-03-047), NIMH T32 MH 019925-11, NIMH T32 MH019934, and
VA Greater Los Angeles Healthcare System Geriatric Research, Education
and Clinical Center (GRECC).
NR 28
TC 17
Z9 17
U1 2
U2 6
PU AMER ACAD SLEEP MEDICINE
PI WESTCHESTER
PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA
SN 0161-8105
J9 SLEEP
JI Sleep
PD DEC 1
PY 2011
VL 34
IS 12
BP 1715
EP 1721
DI 10.5665/sleep.1444
PG 7
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 857BT
UT WOS:000297689800018
PM 22131610
ER
PT J
AU Barton, C
Morris, R
Rothlind, J
Yaffe, K
AF Barton, Cynthia
Morris, Rebecca
Rothlind, Johannes
Yaffe, Kristine
TI Video-Telemedicine in a Memory Disorders Clinic: Evaluation and
Management of Rural Elders with Cognitive Impairment
SO TELEMEDICINE AND E-HEALTH
LA English
DT Article
DE telemedicine; telehealth; telecommunications
ID DEMENTIA; DIAGNOSIS; TELEHEALTH; CONSULTATION; ASSESSMENTS
AB Objective: Telemedicine is increasingly being used to provide consultation for healthcare in rural areas. Little work has been done with dementia although preliminary research suggests that clinical diagnosis performed via telemedicine consultation is valid. We implemented a program to provide multidisciplinary, state-of-the-art diagnosis of cognitive impairment by video-telemedicine (VTM) integrated into a clinical setting. Methods: Patients at a rural veteran's community clinic were referred by their local provider for evaluation of memory complaints by the multidisciplinary team of the San Francisco Veterans Administration (SFVA) Memory Disorders Clinic (MDC). The evaluation was integrated into the usual clinic structure and included a neurological evaluation and neuropsychological testing by the MDC team via video assisted by a remote clinician at the community clinic. Results: We evaluated 15 new patients referred to our multidisciplinary clinic. In each case, the VTM format permitted the MDC team to arrive at a working diagnosis; 12 patients with dementia, two with mild cognitive impairment, and one cognitively normal. Relevant treatment recommendations were made to the patients and caregivers. The evaluation results were discussed with providers who joined the MDC postclinic conference via VTM. In the majority of cases, recommendations were followed and there was satisfaction with VTM by providers and patients. Conclusions: VTM is emerging as an effective way to provide consultation and care to rural residents who may not have access to specialty services and can be integrated into current clinical settings.
C1 [Barton, Cynthia; Yaffe, Kristine] Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA.
[Barton, Cynthia; Rothlind, Johannes; Yaffe, Kristine] San Francisco Vet Adm Med Ctr, San Francisco, CA USA.
[Morris, Rebecca] Vet Adm Community Based Clin, Eureka, CA USA.
[Rothlind, Johannes; Yaffe, Kristine] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA.
RP Barton, C (reprint author), San Francisco VAMC Memory Disorders Clin, UCSF Memory & Aging Ctr, 4150 Clement St,Box 127, San Francisco, CA 94121 USA.
EM cbarton@memory.ucsf.edu
NR 23
TC 14
Z9 15
U1 2
U2 6
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1530-5627
J9 TELEMED E-HEALTH
JI Telemed. e-Health
PD DEC
PY 2011
VL 17
IS 10
BP 789
EP 793
DI 10.1089/tmj.2011.0083
PG 5
WC Health Care Sciences & Services
SC Health Care Sciences & Services
GA 860BD
UT WOS:000297919800008
PM 22023458
ER
PT J
AU Lee, JS
Primack, BA
Mor, MK
Stone, RA
Obrosky, DS
Yealy, DM
Fine, MJ
AF Lee, Jonathan S.
Primack, Brian A.
Mor, Maria K.
Stone, Roslyn A.
Obrosky, D. Scott
Yealy, Donald M.
Fine, Michael J.
TI Processes of Care and Outcomes for Community-Acquired Pneumonia
SO AMERICAN JOURNAL OF MEDICINE
LA English
DT Article
DE Pneumonia; Processes of care; Quality of care
ID CHI-SQUARED TESTS; QUALITY-OF-CARE; MYOCARDIAL-INFARCTION;
ELDERLY-PATIENTS; RISK PATIENTS; GUIDELINES; MANAGEMENT; THERAPY;
IMPROVEMENT; MORTALITY
AB BACKGROUND: Although processes of care are common proxies for health care quality, their associations with medical outcomes remain uncertain.
METHODS: For 2076 patients hospitalized with pneumonia from 32 emergency departments, we used multilevel logistic regression modeling to assess independent associations between patient outcomes and the performance of 4 individual processes of care (assessment of oxygenation, blood cultures, and rapid initiation [<4 hours] and appropriate selection of antibiotic therapy) and the cumulative number of processes of care performed.
RESULTS: Overall, 141 patients (6.8%) died. Mortality was 0.3% to 1.7% lower for patients who had each of the individual processes of care performed (P >= .13 for each comparison); mortality was 7.5% for patients who had 0 to 2 processes of care, 7.2% for those with 3 processes of care, and 5.8% for those with all 4 processes of care performed (P = .39). Mortality was not significantly associated with either individual or cumulative process measures in multivariable models.
CONCLUSION: Neither the individual processes of care nor the cumulative number performed is associated with short-term mortality for pneumonia. Published by Elsevier Inc. The American Journal of Medicine (2011) 124, 1175.e9-1175.e17
C1 [Lee, Jonathan S.; Primack, Brian A.; Fine, Michael J.] Univ Pittsburgh, Sch Med, Dept Med, Div Gen Internal Med, Pittsburgh, PA USA.
[Primack, Brian A.; Stone, Roslyn A.; Fine, Michael J.] Univ Pittsburgh, Sch Med, Ctr Res Hlth Care, Pittsburgh, PA USA.
[Primack, Brian A.] Univ Pittsburgh, Sch Med, Dept Pediat, Div Adolescent Med, Pittsburgh, PA 15261 USA.
[Yealy, Donald M.] Univ Pittsburgh, Sch Med, Dept Emergency Med, Pittsburgh, PA USA.
[Mor, Maria K.; Stone, Roslyn A.; Obrosky, D. Scott; Fine, Michael J.] VA Pittsburgh Healthcare Syst, VA Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA.
[Mor, Maria K.; Stone, Roslyn A.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Biostat, Pittsburgh, PA 15261 USA.
RP Fine, MJ (reprint author), Vet Adm Pittsburgh Healthcare Syst 151 C H, Ctr Hlth Equ Res & Promot, 7180 Highland Dr,Room 4059E, Pittsburgh, PA 15206 USA.
EM Michael.Fine@va.gov
FU Agency for Healthcare Research and Quality [R01-HS10049]; National
Institute of Allergy and Infectious Diseases [K24-AI001769]; Robert Wood
Johnson Foundation; National Cancer Institute [K07-CA114315]
FX Grant R01-HS10049 from the Agency for Healthcare Research and Quality.
Dr Fine was supported in part from a career development award from the
National Institute of Allergy and Infectious Diseases (Grant Number
K24-AI001769). Dr Primack was supported in part by a Physician Faculty
Scholar Award from the Robert Wood Johnson Foundation and a career
development award from the National Cancer Institute (K07-CA114315).
NR 32
TC 7
Z9 7
U1 0
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9343
J9 AM J MED
JI Am. J. Med.
PD DEC
PY 2011
VL 124
IS 12
AR 1175.e9
DI 10.1016/j.amjmed.2011.05.029
PG 9
WC Medicine, General & Internal
SC General & Internal Medicine
GA 853CZ
UT WOS:000297405100027
PM 22000624
ER
PT J
AU Finlayson, E
Wang, L
Landefeld, CS
Dudley, RA
AF Finlayson, Emily
Wang, Li
Landefeld, C. Seth
Dudley, R. Adams
TI Major Abdominal Surgery in Nursing Home Residents A National Study
SO ANNALS OF SURGERY
LA English
DT Article
ID ACUTE APPENDICITIS; SURGICAL OUTCOMES; OLDER; OCTOGENARIANS; CANCER
AB Objective: To determine surgical risk in nursing home residents undergoing major abdominal surgery.
Background: Recent studies suggest that surgery can be performed safely in the very old. Surgical risk in nursing home residents is poorly understood.
Methods: We used national Medicare claims and the nursing home Minimum Data Set (1999-2006) to identify nursing home residents undergoing surgery (surgery for bleeding duodenal ulcer, cholecystectomy, appendectomy, and colectomy, n = 70,719). We compared operative mortality and use of invasive interventions (mechanical ventilation, intravascular hemodynamic monitoring, feeding tube placement, tracheostomy, and vena cava filters) among nursing home residents to rates among noninstitutionalized Medicare enrollees age 65 and older undergoing the same procedures. (n = 1,060,389). We adjusted for patient characteristics using logistic regression.
Results: Operative mortality among nursing home residents was substantially higher than among noninstitutionalized Medicare enrollees for all procedures (surgery for bleeding duodenal ulcer, 42% versus 26%, adjusted odds ratio (AOR) 1.79; colectomy, 32% versus 13%, AOR 2.06; appendectomy, 12% versus 2%, AOR 3.27; cholecystectomy, 11% versus 3%, AOR 2.65; P < 0.001 for all comparisons). Overall, invasive interventions were more common among nursing home residents than controls (ranging from 18% and 5%, respectively, for cholecystectomy to 55% and 43%, respectively, for surgery for bleeding duodenal ulcer, P < 0.0001 for all comparisons).
Conclusions: Nursing home residents experience substantially higher rates of mortality and invasive interventions after major surgery than other Medicare beneficiaries that are independent of age and measured comorbidities. Our data suggest that the risks of major surgery are substantially higher in nursing home residents and this information should inform decisions of physicians and patients and their families.
C1 [Finlayson, Emily; Dudley, R. Adams] Univ Calif San Francisco, Philip R Lee Inst Hlth Policy Studies, San Francisco, CA 94118 USA.
[Finlayson, Emily] Univ Calif San Francisco, Dept Surg, San Francisco, CA 94118 USA.
[Wang, Li] StatinMed, Ann Arbor, MI USA.
[Landefeld, C. Seth] Univ Calif San Francisco, Div Geriatr, San Francisco, CA 94118 USA.
[Landefeld, C. Seth] San Francisco VA Med Ctr, San Francisco, CA USA.
[Dudley, R. Adams] Univ Calif San Francisco, Dept Med, San Francisco, CA 94118 USA.
RP Finlayson, E (reprint author), Univ Calif San Francisco, Philip R Lee Inst Hlth Policy Studies, 3333 Calif St,Suite 265, San Francisco, CA 94118 USA.
EM emily.finlayson@ucsfmedctr.org
FU National Institute on Aging [5K08AG028965]; Robert Wood Johnson
Foundation
FX Supported by a National Institute on Aging/Paul B. Beeson Clinical
Scientist Development Award in Aging (5K08AG028965). Dr. Dudley's work
was supported by an Investigator Award in Health Policy from the Robert
Wood Johnson Foundation.
NR 15
TC 15
Z9 15
U1 1
U2 6
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0003-4932
J9 ANN SURG
JI Ann. Surg.
PD DEC
PY 2011
VL 254
IS 6
BP 921
EP 926
DI 10.1097/SLA.0b013e3182383a78
PG 6
WC Surgery
SC Surgery
GA 852RM
UT WOS:000297375200013
PM 22020197
ER
PT J
AU Chu, D
Bakaeen, FG
AF Chu, Danny
Bakaeen, Faisal G.
TI Hypoalbuminemia as a Contributor to the Progression of Cardiovascular
Diseases Reply
SO ANNALS OF THORACIC SURGERY
LA English
DT Letter
C1 [Chu, Danny; Bakaeen, Faisal G.] Baylor Coll Med, Div Cardiothorac Surg, Texas Heart Inst, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA.
RP Chu, D (reprint author), Baylor Coll Med, Div Cardiothorac Surg, Texas Heart Inst, Michael E DeBakey Vet Affairs Med Ctr, 2002 Holcombe Blvd,OCL 112, Houston, TX 77030 USA.
EM dchu@bcm.edu
NR 2
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0003-4975
J9 ANN THORAC SURG
JI Ann. Thorac. Surg.
PD DEC
PY 2011
VL 92
IS 6
BP 2305
EP 2306
PG 4
WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery
SC Cardiovascular System & Cardiology; Respiratory System; Surgery
GA 852EL
UT WOS:000297333300080
ER
PT J
AU Bhargava, P
Vaidya, S
Kolokythas, O
Katz, DS
Dighe, M
AF Bhargava, P.
Vaidya, S.
Kolokythas, O.
Katz, D. S.
Dighe, M.
TI Hepatic vascular shunts: embryology and imaging appearances
SO BRITISH JOURNAL OF RADIOLOGY
LA English
DT Review
ID HEREDITARY HEMORRHAGIC TELANGIECTASIA; PORTOSYSTEMIC VENOUS SHUNT;
HEPATOCELLULAR-CARCINOMA; CT; SONOGRAPHY; CIRRHOSIS
AB The purpose of this pictorial review is to understand the embryological basis of the development of congenital hepatic vascular shunts and to review the multimodality imaging appearances of congenital and acquired hepatic vascular shunts. Hepatic vascular shunts are commonly seen in imaging. Familiarity with their characteristic appearances is important in order to accurately characterise these shunts and diagnose the underlying disorders.
C1 [Bhargava, P.] Univ Washington, Vet Affairs Puget Sound Hlth Care Ctr, Sch Med, Dept Radiol, Seattle, WA 98108 USA.
[Bhargava, P.] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA.
[Katz, D. S.] Winthrop Univ Hosp, Dept Radiol, Mineola, NY 11501 USA.
RP Bhargava, P (reprint author), Univ Washington, Vet Affairs Puget Sound Hlth Care Ctr, Sch Med, Dept Radiol, Mail Box 358280,1660 S Columbian Way, Seattle, WA 98108 USA.
EM bhargp@uw.edu
OI Bhargava, Puneet/0000-0002-3849-9666
NR 17
TC 4
Z9 5
U1 0
U2 2
PU BRITISH INST RADIOLOGY
PI LONDON
PA 36 PORTLAND PLACE, LONDON W1N 4AT, ENGLAND
SN 0007-1285
J9 BRIT J RADIOL
JI Br. J. Radiol.
PD DEC
PY 2011
VL 84
IS 1008
BP 1142
EP 1152
DI 10.1259/bjr/82649468
PG 11
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA 851IZ
UT WOS:000297263000018
PM 22101582
ER
PT J
AU Marks, G
Gardner, LI
Craw, J
Giordano, TP
Mugavero, MJ
Keruly, JC
Wilson, TE
Metsch, LR
Drainoni, ML
Malitz, F
AF Marks, Gary
Gardner, Lytt I.
Craw, Jason
Giordano, Thomas P.
Mugavero, Michael J.
Keruly, Jeanne C.
Wilson, Tracey E.
Metsch, Lisa R.
Drainoni, Mari-Lynn
Malitz, Faye
TI The Spectrum of Engagement in HIV Care: Do More Than 19% of HIV-Infected
Persons in the US Have Undetectable Viral Load?
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Letter
C1 [Marks, Gary; Gardner, Lytt I.; Craw, Jason] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA 30333 USA.
[Giordano, Thomas P.] Baylor Coll Med, Thomas St Hlth Ctr, Houston, TX 77030 USA.
[Giordano, Thomas P.] DeBakey VA Med Ctr, Houston, TX USA.
[Mugavero, Michael J.] Univ Alabama Birmingham UAB, UAB Ctr AIDS Res, Birmingham, AL USA.
[Mugavero, Michael J.] UAB 1917 Clin, Birmingham, AL USA.
[Keruly, Jeanne C.] Johns Hopkins Univ, Dept Med, Baltimore, MD USA.
[Wilson, Tracey E.] Suny Downstate Med Ctr, Sch Publ Hlth, Brooklyn, NY 11203 USA.
[Metsch, Lisa R.] Univ Miami, Miller Sch Med, Dev Ctr AIDS Res, Coral Gables, FL 33124 USA.
[Drainoni, Mari-Lynn] Boston Univ, Dept Hlth Policy & Management, Sch Publ Hlth, Sect Infect Dis,Dept Med,Sch Med, Boston, MA 02215 USA.
[Malitz, Faye] Hlth Resources & Serv Adm, HIV AIDS Bur, Rockville, MD USA.
RP Marks, G (reprint author), Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA 30333 USA.
EM gmarks@cdc.gov
NR 4
TC 16
Z9 16
U1 0
U2 11
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1058-4838
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD DEC 1
PY 2011
VL 53
IS 11
BP 1168
EP U154
DI 10.1093/cid/cir678
PG 2
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 851OH
UT WOS:000297279900025
PM 21976466
ER
PT J
AU Mendez, MF
Shapira, JS
AF Mendez, Mario F.
Shapira, Jill S.
TI Loss of emotional insight in behavioral variant frontotemporal dementia
or "frontal anosodiaphoria"
SO CONSCIOUSNESS AND COGNITION
LA English
DT Article
DE Insight; Anosognosia; Anosodiaphoria; Dementia; Frontotemporal dementia;
Alzheimer's disease
ID ALZHEIMERS-DISEASE; SELF-AWARENESS; COGNITIVE IMPAIRMENT;
DIAGNOSTIC-CRITERIA; PREFRONTAL CORTEX; ANOSOGNOSIA; DEFICITS;
UNAWARENESS; DEGENERATION; RECOGNITION
AB Loss of insight is a prominent clinical manifestation of behavioral variant frontotemporal dementia (bvFTD), but its characteristics are poorly understood. Twelve bvFTD patients were compared with 12 Alzheimer's disease (AD) patients on a structured insight interview of cognitive insight (awareness of having a disorder) and emotional insight (concern over having a disorder). Compared to the AD patients, the bvFTD patients were less aware and less concerned about their disorder, and they had less appreciation of its effects on themselves and on others. After corrective feedback ("updating"), the bvFTD patients were just as aware of their disorder as the AD patients but remained unconcerned and unappreciative of its effects. These findings suggest that lack of insight in bvFTD is not due to "anosognosia," or impaired cognitive and executive awareness of disease, but to "frontal anosodiaphoria," or lack of emotional concern over having bvFTD and its impact on themselves and others. Published by Elsevier Inc.
C1 [Mendez, Mario F.] VA Greater Los Angeles Healthcare Ctr, Neurobehav Unit 691 116AF, Los Angeles, CA 90073 USA.
Univ Calif Los Angeles, Dept Neurol, Los Angeles, CA 90024 USA.
Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA.
RP Mendez, MF (reprint author), VA Greater Los Angeles Healthcare Ctr, Neurobehav Unit 691 116AF, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA.
EM mmendez@UCLA.edu
FU NIA NIH HHS [R01 AG034499, R01 AG034499-03, R01AG034499-02]
NR 66
TC 22
Z9 23
U1 1
U2 7
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1053-8100
J9 CONSCIOUS COGN
JI Conscious. Cogn.
PD DEC
PY 2011
VL 20
IS 4
SI SI
BP 1690
EP 1696
DI 10.1016/j.concog.2011.09.005
PG 7
WC Psychology, Experimental
SC Psychology
GA 851NP
UT WOS:000297278100066
PM 21959203
ER
PT J
AU Samuvel, DJ
Jin, JF
Sundararaj, KP
Li, YC
Zhang, XM
Lopes-Virella, MF
Huang, Y
AF Samuvel, Devadoss J.
Jin, Junfei
Sundararaj, Kamala P.
Li, Yanchun
Zhang, Xiaoming
Lopes-Virella, Maria F.
Huang, Yan
TI TLR4 Activation and IL-6-Mediated Cross Talk between Adipocytes and
Mononuclear Cells Synergistically Stimulate MMP-1 Expression
SO ENDOCRINOLOGY
LA English
DT Article
ID ADIPOSE-TISSUE DEVELOPMENT; LOW-GRADE INFLAMMATION; DIET-INDUCED
OBESITY; NF-KAPPA-B; INSULIN-RESISTANCE; MATRIX METALLOPROTEINASES;
TRANSCRIPTION FACTOR; ACID; ANGIOGENESIS; INHIBITION
AB Obesity is associated with increased monocyte infiltration into adipose tissue and hence increased interaction between adipocytes and monocytes. Although it has been shown that matrix metalloproteinases (MMP) play a critical role in adipose tissue development, the effect of adipocyte and monocyte interaction on MMP production remains largely unknown. Furthermore, although it has been shown that Toll-like receptor 4 (TLR4), a receptor mediating innate immune response, plays an important role in the obesity-associated inflammation and insulin resistance, the effect of TLR4 activation in coculture of adipocytes and monocytes on MMP production has not been investigated. In this study, we cocultured adipocytes with U937 mononuclear cells in a Transwell coculture system and activated TLR4 with lipopolysaccharide or palmitic acid. We found that TLR4 activation and the coculture had a synergistic effect on MMP-1 production. In our further investigation on the underlying mechanisms, it was indicated that adipocyte-derived IL-6 and TLR4 activation acted in concert to synergistically stimulate MMP-1 expression by U937 cells. Taken together, this study has uncovered a novel mechanism potentially involved in MMP-1 up-regulation in adipose tissue, which may facilitate adipose tissue development and obesity. (Endocrinology 152: 4662-4671, 2011)
C1 [Lopes-Virella, Maria F.; Huang, Yan] Med Univ S Carolina, Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC 29425 USA.
[Samuvel, Devadoss J.; Jin, Junfei; Sundararaj, Kamala P.; Li, Yanchun; Zhang, Xiaoming; Lopes-Virella, Maria F.; Huang, Yan] Med Univ S Carolina, Div Endocrinol Diabet & Med Genet, Charleston, SC 29425 USA.
[Samuvel, Devadoss J.; Jin, Junfei; Sundararaj, Kamala P.; Li, Yanchun; Zhang, Xiaoming; Lopes-Virella, Maria F.; Huang, Yan] Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA.
RP Huang, Y (reprint author), Med Univ S Carolina, Ralph H Johnson Vet Affairs Med Ctr, 114 Doughty St, Charleston, SC 29403 USA.
EM huangyan@musc.edu
FU Department of Veterans Affairs; National Institutes of Health [DE16353]
FX This work was supported by a Merit Review Grant from Department of
Veterans Affairs and National Institutes of Health Grant DE16353 (to
Y.H.).
NR 36
TC 6
Z9 6
U1 0
U2 4
PU ENDOCRINE SOC
PI CHEVY CHASE
PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA
SN 0013-7227
J9 ENDOCRINOLOGY
JI Endocrinology
PD DEC
PY 2011
VL 152
IS 12
BP 4662
EP 4671
DI 10.1210/en.2011-1026
PG 10
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 852RZ
UT WOS:000297376500022
PM 21952248
ER
PT J
AU Carrithers, LM
Hulseberg, P
Sandor, M
Carrithers, MD
AF Carrithers, Lisette M.
Hulseberg, Paul
Sandor, Matyas
Carrithers, Michael D.
TI The human macrophage sodium channel NaV1.5 regulates mycobacteria
processing through organelle polarization and localized calcium
oscillations
SO FEMS IMMUNOLOGY AND MEDICAL MICROBIOLOGY
LA English
DT Article
DE macrophage; phagocytosis; voltage-gated sodium channel; calcium
signaling
ID INTRACELLULAR CA2+ STORES; HUMAN NEUTROPHILS; PHAGOCYTOSIS; PROTEIN;
CELLS; TUBERCULOSIS; INHIBITION; PHAGOSOME; DYNAMICS; RELEASE
AB Phagocytosis and intracellular processing of mycobacteria by macrophages are complex cellular processes that require spatial and temporal coordination of particle uptake, organelle movement, activation of signaling pathways, and channel-mediated ionic flux. Recent work demonstrated that human macrophage NaV1.5, an intracellular voltage-gated sodium channel expressed on late endosomes, enhances endosomal acidification and phagocytosis. Here, using bacillus Camille-Guerin (BCG) as a model of mycobacterial infection, we examined how this channel regulates phagocytosis and phagosome maturation in human macrophages. Knockdown of NaV1.5 reduced high capacity uptake of labeled BCG. BCG-containing, NaV1.5-expressing cells demonstrated localization of NaV1.5 and Rab-7 positive endosomes and mitochondria to periphagosome regions that was not observed in NaV1.5-deficient cells. Knockdown of the channel reduced the initial calcium response following bacterial challenge and prevented the generation of prolonged and localized calcium oscillations during phagosome maturation. Inhibition of the mitochondrial Na+/Ca2+ exchanger also prevented prolonged calcium oscillations during phagosome maturation. These results suggest that NaV1.5 and mitochondrial-dependent calcium signaling regulate mycobacteria phagocytosis and phagosome maturation in human macrophages through spatial-temporal coordination of calcium signaling within a unique subcellular region.
C1 [Carrithers, Lisette M.; Carrithers, Michael D.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Neurol, Madison, WI 53706 USA.
[Hulseberg, Paul; Sandor, Matyas] Univ Wisconsin, Sch Med & Publ Hlth, Dept Pathol, Madison, WI 53706 USA.
Univ Wisconsin, Sch Med & Publ Hlth, Madison, WI 53706 USA.
[Carrithers, Michael D.] William S Middleton Mem Vet Adm Med Ctr, Neurol Serv, Madison, WI USA.
RP Carrithers, MD (reprint author), Univ Wisconsin, Sch Med & Publ Hlth, Dept Neurol, 1300 Univ Ave,Room 2679, Madison, WI 53706 USA.
EM carrithers@neurology.wisc.edu
FU University of Wisconsin; VA Merit Award (BLRD)
FX This work is supported by the University of Wisconsin and a VA Merit
Award (BLR&D) to M.D.C.
NR 27
TC 23
Z9 23
U1 0
U2 10
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0928-8244
J9 FEMS IMMUNOL MED MIC
JI FEMS Immunol. Med. Microbiol.
PD DEC
PY 2011
VL 63
IS 3
BP 319
EP 327
DI 10.1111/j.1574-695X.2011.00853.x
PG 9
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 850PH
UT WOS:000297207200002
PM 22092558
ER
PT J
AU Wiren, KM
Hashimoto, JG
Zhang, XW
AF Wiren, Kristine M.
Hashimoto, Joel G.
Zhang, Xiao-Wei
TI Stem Cell Activation in Adults Can Reverse Detrimental Changes in Body
Composition to Reduce Fat and Increase Lean Mass in Both Sexes
SO JOURNAL OF CELLULAR BIOCHEMISTRY
LA English
DT Article
DE STEM CELL; AGING; TESTOSTERONE; ANDROGEN RECEPTOR; LEAN MASS; FAT MASS;
NEURAL CREST
ID ANDROGEN REPLACEMENT THERAPY; BONE-MINERAL DENSITY; POSTMENOPAUSAL
WOMEN; TRANSDERMAL TESTOSTERONE; METABOLIC SYNDROME; HYPOGONADAL MEN;
SEXUAL FUNCTION; DOUBLE-BLIND; RECEPTOR; MICE
AB Detrimental changes in body composition are often associated with declining levels of testosterone. Here, we evaluated the notion that multipotent mesenchymal stem cells, that give rise to both fat and muscle tissue, can play a significant role to alter existing body composition in the adult. Transgenic mice with targeted androgen receptor (AR) overexpression in stem cells were employed. Wild-type littermate and AR-transgenic male and female mice were gonadectomized and left untreated for 2 months. After the hypogonadal period, mice were then treated with 5 alpha-dihydrotestosterone (DHT) for 6 weeks. After orchidectomy (ORX), wild-type males have reduced lean mass and increased fat mass compared to shams. DHT treatment was beneficial to partially restore body composition. In wild-type females, ovariectomy (OVX) produced a similar change but there was no improvement with DHT. In targeted AR transgenic mice, DHT treatment increased lean and reduced fat mass to sham levels. In contrast to wild-type females, DHT treatment in female transgenic mice significantly ameliorated the increased fat and decreased lean mass changes that result after OVX. Our results show that DHT administration reduces fat mass and increases lean mass in wildtype males but not females, indicating that wild-type females are not as sensitive to androgen treatment. Because both male and female transgenic mice are more responsive than wild-type, results suggest that body composition remains linked to stem cell fate in the adult and that targeted androgen signaling in stem cells can play a significant role to reverse detrimental changes in body composition in both sexes. J. Cell. Biochem. 112: 3638-3647, 2011. (C) 2011 Wiley Periodicals, Inc.
C1 [Wiren, Kristine M.] Oregon Hlth & Sci Univ, Dept Med, Portland VA Med Ctr, Res Serv P3 R&D39, Portland, OR 97239 USA.
[Wiren, Kristine M.; Hashimoto, Joel G.; Zhang, Xiao-Wei] Vet Affairs Med Ctr, Res Serv, Portland, OR 97239 USA.
[Wiren, Kristine M.] Oregon Hlth & Sci Univ, Dept Behav Neurosci, Portland VA Med Ctr, Res Serv P3 R&D39, Portland, OR 97239 USA.
RP Wiren, KM (reprint author), Oregon Hlth & Sci Univ, Dept Med, Portland VA Med Ctr, Res Serv P3 R&D39, 3710 SW Vet Hosp Rd, Portland, OR 97239 USA.
EM wirenk@ohsu.edu
OI Wiren, Kristine/0000-0002-6159-4450
FU National Institute of Diabetes, Digestive and Kidney Disease [R01
DK067541]; Department of Defense; United States Army [W81XWH-05-1-0086]
FX Grant sponsor: National Institute of Diabetes, Digestive and Kidney
Disease; Grant number: R01 DK067541; Grant sponsor: Department of
Defense; United States Army Research Acquisition Activity Award No.;
Grant number: W81XWH-05-1-0086.
NR 48
TC 2
Z9 2
U1 0
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0730-2312
J9 J CELL BIOCHEM
JI J. Cell. Biochem.
PD DEC
PY 2011
VL 112
IS 12
BP 3638
EP 3647
DI 10.1002/jcb.23288
PG 10
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 851YV
UT WOS:000297309600018
PM 21793043
ER
PT J
AU Gahramanov, S
Muldoon, LL
Li, X
Neuwelt, EA
AF Gahramanov, Seymur
Muldoon, Leslie L.
Li, Xin
Neuwelt, Edward A.
TI Improved Perfusion MR Imaging Assessment of Intracerebral Tumor Blood
Volume and Antiangiogenic Therapy Efficacy in a Rat Model with
Ferumoxytol
SO RADIOLOGY
LA English
DT Article
ID CONTRAST-ENHANCED MR; BRAIN-TUMORS; GLIOBLASTOMA-MULTIFORME; GLIOMA
MODEL; GRADE; PROGRESSION; SURVIVAL; AGENT; MAPS; BEVACIZUMAB
AB Purpose: To evaluate the consistency of tumor blood volume measurements and antiangiogenic therapy efficacy assessments with a low-molecular-weight gadolinium-based contrast agent (GBCA, gadodiamide) versus an iron oxide nanoparticle (ferumoxytol) in the presence or absence of a loading dose of contrast agent before perfusion magnetic resonance (MR) imaging (preload method).
Materials and Methods: The protocol was approved by the institutional animal care and use committee. U87MG tumor cells were implanted intracerebrally in 13 rats. All 13 rats underwent 11.75-T MR imaging with gadodiamide (60 mu L) 13 days after tumor implantation. The next day, nine rats underwent MR imaging with ferumoxytol (60 mu L). Immediately after ferumoxytol imaging, six rats received bevacizumab (45 mg/kg). MR imaging was repeated 48 hours after bevacizumab treatment with gadodiamide and 72 hours after treatment with ferumoxytol. Each study included three consecutive dynamic susceptibility-weighted contrast material-enhanced (DSC) MR acquisitions, which were performed without preload, with single-dose preload, and with double-dose preload. Tumor relative cerebral blood volume (rCBV) was estimated from each DSC MR acquisition. Two-way repeated measures analysis of variance was performed to test for differences between groups with both contrast agents.
Results: DSC MR imaging with gadodiamide and without preload showed low rCBV (<= 1.75) in nine of the 13 tumors; estimated rCBV increased progressively with both single- and double-dose preloads (P < .001). Conversely, rCBVs obtained with ferumoxytol were high (>1.75) and remained constant with all three acquisitions. The magnitude of rCBV decrease after bevacizumab administration was dependent: on the dose of gadodiamide preload, whereas the magnitude of rCBV decrease with ferumoxytol was constant regardless of whether contrast agent preload was used.
Conclusion: With GBCA, tumor rCBV can be underestimated without preload and becomes dose dependent with preload correction. Conversely, ferumoxytol provides consistent assessment of tumor rCBV and antiangiogenic therapy efficacy. (C) RSNA, 2011
C1 [Gahramanov, Seymur; Muldoon, Leslie L.; Neuwelt, Edward A.] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97239 USA.
[Neuwelt, Edward A.] Oregon Hlth & Sci Univ, Dept Neurosurg, Portland, OR 97239 USA.
[Li, Xin] Oregon Hlth & Sci Univ, Adv Imaging Res Ctr, Portland, OR 97239 USA.
[Neuwelt, Edward A.] Portland VA Med Ctr, Portland, OR USA.
RP Neuwelt, EA (reprint author), Oregon Hlth & Sci Univ, Dept Neurol, 3181 SW Sam Jackson Pk Rd,Room L603, Portland, OR 97239 USA.
EM neuwelte@ohsu.edu
FU Veterans Administration; National Institutes of Health [NS053468,
CA137488, NS044687]; AMAG Pharmaceuticals
FX Supported by a Veterans Administration Merit Review grant.; This study
was supported by the National Institutes of Health (grants NS053468,
CA137488, and NS044687).; Disclosures of Potential Conflicts of
Interest: S.G. No potential conflicts of interest to disclose. L.L.M. No
potential conflicts of interest to disclose. X.I.. No potential
conflicts of interest, to disclose. E.A.N. Financial activities related
to the present article: ferumoxytol ultrasmall superparamagnetic iron
oxide nanoparticles were donated by AMAG Pharmaceuticals. Financial
activities not, related to the present article: has a sponsored research
agreement with AMAG Pharmaceuticals. Other relationships: none to
disclose.
NR 38
TC 25
Z9 25
U1 0
U2 10
PU RADIOLOGICAL SOC NORTH AMERICA
PI OAK BROOK
PA 820 JORIE BLVD, OAK BROOK, IL 60523 USA
SN 0033-8419
J9 RADIOLOGY
JI Radiology
PD DEC
PY 2011
VL 261
IS 3
BP 796
EP 804
DI 10.1148/radiol.11103503
PG 9
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA 849PR
UT WOS:000297138100016
PM 21940504
ER
PT J
AU Alley, DE
Lloyd, J
Pagan, JA
Pollack, CE
Shardell, M
Cannuscio, C
AF Alley, Dawn E.
Lloyd, Jennifer
Pagan, Jose A.
Pollack, Craig E.
Shardell, Michelle
Cannuscio, Carolyn
TI Mortgage Delinquency and Changes in Access to Health Resources and
Depressive Symptoms in a Nationally Representative Cohort of Americans
Older Than 50 Years
SO AMERICAN JOURNAL OF PUBLIC HEALTH
LA English
DT Article
ID US ELDERLY PERSONS; SOCIOECONOMIC DISPARITIES; FOOD INSECURITY;
UNITED-STATES; MORTALITY; HOME; PEOPLE; CONSEQUENCES; ASSOCIATION;
COMMUNITY
AB Objectives. We evaluated associations between mortgage delinquency and changes in health and health-relevant resources over 2 years, with data from the Health and Retirement Study, a longitudinal survey representative of US adults older than 50 years.
Methods. In 2008, participants reported whether they had fallen behind on mortgage payments since 2006 (n=2474). We used logistic regression to compare changes in health (incidence of elevated depressive symptoms, major declines in self-rated health) and access to health-relevant resources (food, prescription medications) between participants who fell behind on their mortgage payments and those who did not.
Results. Compared with nondelinquent participants, the mortgage-delinquent group had worse health status and less access to health-relevant resources at baseline. They were also significantly more likely to develop incident depressive symptoms (odds ratio [OR]=8.60; 95% confidence interval [CI]=3.38, 21.85), food insecurity (OR=7.53; 95% CI=3.01, 18.84), and cost-related medication nonadherence (OR=8.66; 95% CI=3.72, 20.16) during follow-up.
Conclusions. Mortgage delinquency was associated with significant elevations in the incidence of mental health impairments and health-relevant material disadvantage. Widespread mortgage default may have important public health implications. (Am J Public Health. 2011;101:2293-2298. doi:10.2105/AJPH.2011.300245)
C1 [Alley, Dawn E.; Lloyd, Jennifer; Shardell, Michelle] Univ Maryland, Sch Med, Dept Epidemiol & Publ Hlth, Baltimore, MD 21201 USA.
[Pagan, Jose A.] Univ N Texas Hlth Sci Ctr, Sch Publ Hlth, Dept Hlth Management & Policy, Ft Worth, TX USA.
[Pollack, Craig E.] Johns Hopkins Sch Med, Dept Med, Baltimore, MD USA.
[Cannuscio, Carolyn] Dept Vet Affairs Med Ctr, Vet Affairs Ctr Hlth Equ Res & Promot, Philadelphia, PA 19104 USA.
RP Alley, DE (reprint author), 660 W Redwood St,221B, Baltimore, MD 21201 USA.
EM dalley@epi.umaryland.edu
RI Cannuscio, Carolyn/A-1123-2007
FU National Institutes of Health [T32AG000262, K12HC043489]; Philadelphia
Veterans Affairs Medical Center; Organized Research Center on Aging at
the University of Maryland, Baltimore
FX This study was supported by the National Institutes of Health (grants
T32AG000262 and K12HC043489). It was conducted with support, resources,
and use of facilities from the Philadelphia Veterans Affairs Medical
Center in conjunction with the Organized Research Center on Aging at the
University of Maryland, Baltimore
NR 38
TC 32
Z9 32
U1 2
U2 11
PU AMER PUBLIC HEALTH ASSOC INC
PI WASHINGTON
PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA
SN 0090-0036
J9 AM J PUBLIC HEALTH
JI Am. J. Public Health
PD DEC
PY 2011
VL 101
IS 12
BP 2293
EP 2298
DI 10.2105/AJPH.2011.300245
PG 6
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 849QT
UT WOS:000297140900022
PM 22021301
ER
PT J
AU Doherty-King, B
Bowers, B
AF Doherty-King, Barbara
Bowers, Barbara
TI How Nurses Decide to Ambulate Hospitalized Older Adults: Development of
a Conceptual Model
SO GERONTOLOGIST
LA English
DT Article
DE Conceptual development; Grounded theory; Hospital; ambulatory care;
Nursing studies; Function (physical; mental)
ID FUNCTIONAL DECLINE; LOW MOBILITY; CARE; OUTCOMES
AB Adults over the age of 65 years account for 60% of all hospital admissions and experience consequential negative outcomes directly related to hospitalization. Negative outcomes include falls, delirium, loss in ability to perform basic activities of daily living, and new walking dependence. New walking dependence, defined as the loss in ability to walk independently, occurs in 16%--59% of hospitalized older patients. Nurses are pivotal in promoting functional walking independence in hospitalized patients. However, little is known about how nurses make decisions about whether, when, and how to ambulate older patients. A qualitative study using grounded dimensional analysis was conducted to further explore how nurses make decisions about ambulating hospitalized older adults. Twenty-five registered nurses participated in in-depth interviews lasting 30--60 min. Open, axial, and selective coding was used during the analysis. A conceptual model, which is grounded in how nurses experience ambulating patients, was developed. Multiple categories and dimensions interact and produce an action by the nurse to either restrict mobilization to the level of the bed or progress the patient to ambulation in the hallway. Factors that seemed to have a greater impact on nurses' decisions on whether, when, and how to ambulate were the risk/opportunity assessment, preventing complications, and the presence of a unit expectation to ambulate patients.
C1 [Doherty-King, Barbara] William S Middleton Mem Vet Adm Med Ctr, GRECC, Geriatr Educ Res & Clin Ctr, Madison, WI 53705 USA.
[Doherty-King, Barbara; Bowers, Barbara] Univ Wisconsin, Sch Nursing, Madison, WI 53706 USA.
RP Doherty-King, B (reprint author), William S Middleton Mem Vet Adm Med Ctr, GRECC, Geriatr Educ Res & Clin Ctr, 2500 Overlook Terrace G11, Madison, WI 53705 USA.
EM Barbara.king4@va.gov
OI King, Barbara/0000-0003-0577-9028; Bowers, Barbara/0000-0002-3226-0718
NR 20
TC 13
Z9 13
U1 0
U2 6
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0016-9013
J9 GERONTOLOGIST
JI Gerontologist
PD DEC
PY 2011
VL 51
IS 6
BP 786
EP 797
DI 10.1093/geront/gnr044
PG 12
WC Gerontology
SC Geriatrics & Gerontology
GA 851BD
UT WOS:000297242400007
PM 22024979
ER
PT J
AU Davis, MM
Bond, LA
Howard, A
Sarkisian, CA
AF Davis, Melinda M.
Bond, Lynne A.
Howard, Alan
Sarkisian, Catherine A.
TI Primary Care Clinician Expectations Regarding Aging
SO GERONTOLOGIST
LA English
DT Article
DE Attitudes toward aging; Successful aging; Expectations regarding aging
ID OLDER-ADULTS; SELF-PERCEPTIONS; HEALTH; DEPRESSION; ATTITUDES; AGEISM
AB Purpose: Expectations regarding aging (ERA) in community-dwelling older adults are associated with personal health behaviors and health resource usage. Clinicians' age expectations likely influence patients' expectations and care delivery patterns; yet, limited research has explored clinicians' age expectations. The Expectations Regarding Aging Survey (ERA-12) was used to assess (a) age expectations in a sample of primary care clinicians practicing in the United States and (b) clinician characteristics associated with ERA-12 scores. Design and Methods: This study was a cross-sectional survey of primary care clinicians affiliated with 5 practice-based research networks, October 2008 to June 2009. A total of 374 of the 1,510 distributed surveys were returned (24.8% response rate); 357 analyzed. Mean respondent age was 48.6 years (SD = 11.6; range 23-87 years); 88.0% physicians, 96.0% family medicine, 94.9% White, and 61.9% male. Results: Female clinicians reported higher ERA-12 scores; clinicians' age expectations decreased with greater years in practice. Among the clinicians, higher ERA-12 scores were associated with higher clinician ratings of the importance of and personal skill in administering preventive counseling and the importance of delivering preventive services. Agreement with individual ERA-12 items varied widely. Implications: Unrealistically high or low ERA could negatively influence the quality of care provided to patients and patients' own age expectations. Research should examine the etiology of clinicians' age expectations and their association with older adult diagnoses and treatment. Medical education must incorporate strategies to promote clinician attitudes that facilitate successful patient aging.
C1 [Davis, Melinda M.] Oregon Hlth & Sci Univ, Dept Family Med, Oregon Rural Practice Based Res Network, Portland, OR 97239 USA.
[Bond, Lynne A.] Univ Vermont, Dept Psychol, Burlington, VT 05405 USA.
[Howard, Alan] Univ Vermont, Acad Comp Serv, Burlington, VT 05405 USA.
[Sarkisian, Catherine A.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
[Sarkisian, Catherine A.] Univ Calif Los Angeles, Dept Med, Div Geriatr, Geriatr Res Educ Clin Ctr, Los Angeles, CA USA.
RP Davis, MM (reprint author), Oregon Hlth & Sci Univ, Dept Family Med, Oregon Rural Practice Based Res Network, 3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA.
EM davismel@ohsu.edu
FU NCRR NIH HHS [1U1 RR02414-01]
NR 39
TC 6
Z9 6
U1 2
U2 11
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0016-9013
J9 GERONTOLOGIST
JI Gerontologist
PD DEC
PY 2011
VL 51
IS 6
BP 856
EP 866
DI 10.1093/geront/gnr017
PG 11
WC Gerontology
SC Geriatrics & Gerontology
GA 851BD
UT WOS:000297242400013
PM 21430129
ER
PT J
AU Deo, R
Katz, R
Shlipak, MG
Sotoodehnia, N
Psaty, BM
Sarnak, MJ
Fried, LF
Chonchol, M
de Boer, IH
Enquobahrie, D
Siscovick, D
Kestenbaum, B
AF Deo, Rajat
Katz, Ronit
Shlipak, Michael G.
Sotoodehnia, Nona
Psaty, Bruce M.
Sarnak, Mark J.
Fried, Linda F.
Chonchol, Michel
de Boer, Ian H.
Enquobahrie, Daniel
Siscovick, David
Kestenbaum, Bryan
TI Vitamin D, Parathyroid Hormone, and Sudden Cardiac Death Results From
the Cardiovascular Health Study
SO HYPERTENSION
LA English
DT Article
DE sudden cardiac death; vitamin D; parathyroid hormone; elderly; risk
factors
ID SMOOTH-MUSCLE-CELLS; D DEFICIENCY; MYOCARDIAL-INFARCTION;
CORONARY-ANGIOGRAPHY; SEASONAL-VARIATION; RISK; HYPERTROPHY; MORTALITY;
POPULATION; 25-HYDROXYVITAMIN-D
AB Recent studies have demonstrated greater risks of cardiovascular events and mortality among persons who have lower 25-hydroxyvitamin D (25-OHD) and higher parathyroid hormone (PTH) levels. We sought to evaluate the association between markers of mineral metabolism and sudden cardiac death (SCD) among the 2312 participants from the Cardiovascular Health Study who were free of clinical cardiovascular disease at baseline. We estimated associations of baseline 25-OHD and PTH concentrations individually and in combination with SCD using Cox proportional hazards models after adjustment for demographics, cardiovascular risk factors, and kidney function. During a median follow-up of 14 years, there were 73 adjudicated SCD events. The annual incidence of SCD was greater among subjects who had lower 25-OHD concentrations, 2 events per 1000 for 25-OHD >= 20 ng/mL and 4 events per 1000 for 25-OHD <20 ng/mL. Similarly, SCD incidence was greater among subjects who had higher PTH concentrations, 2 events per 1000 for PTH <65 pg/mL and 4 events per 1000 for PTH >= 65 pg/mL. Multivariate adjustment attenuated associations of 25-OHD and PTH with SCD. Finally, 267 participants (11.7% of the cohort) had high PTH and low 25-OHD concentrations. This combination was associated with a >2-fold risk of SCD after adjustment (hazard ratio: 2.19 [95% CI: 1.17-4.10]; P=0.017) compared with participants with normal levels of PTH and 25-OHD. The combination of lower 25-OHD and higher PTH concentrations appears to be associated independently with SCD risk among older adults without cardiovascular disease. (Hypertension. 2011;58:1021-1028.)
C1 [Deo, Rajat] Univ Penn, Sect Electrophysiol, Div Cardiovasc Med, Philadelphia, PA 19104 USA.
[Katz, Ronit] Univ Washington, Collaborat Hlth Studies Coordinating Ctr, Seattle, WA 98195 USA.
[Sotoodehnia, Nona] Univ Washington, Div Cardiol, Seattle, WA 98195 USA.
[Psaty, Bruce M.; Enquobahrie, Daniel; Siscovick, David] Univ Washington, Dept Med, Cardiovasc Hlth Res Unit, Seattle, WA USA.
[Psaty, Bruce M.; Enquobahrie, Daniel; Siscovick, David] Univ Washington, Dept Epidemiol, Cardiovasc Hlth Res Unit, Seattle, WA USA.
[Psaty, Bruce M.; Enquobahrie, Daniel; Siscovick, David] Univ Washington, Dept Hlth Serv, Cardiovasc Hlth Res Unit, Seattle, WA USA.
[de Boer, Ian H.; Kestenbaum, Bryan] Univ Washington, Div Nephrol, Seattle, WA 98195 USA.
[de Boer, Ian H.; Kestenbaum, Bryan] Univ Washington, Kidney Res Inst, Seattle, WA 98195 USA.
[Shlipak, Michael G.] Vet Affairs Med Ctr, Gen Internal Med Sect, San Francisco, CA 94121 USA.
[Shlipak, Michael G.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA.
[Shlipak, Michael G.] Univ Calif San Francisco, Dept Epidemiol, San Francisco, CA 94143 USA.
[Shlipak, Michael G.] Univ Calif San Francisco, Dept Biostat, San Francisco, CA 94143 USA.
[Sarnak, Mark J.] Tufts Med Ctr, Div Nephrol, Boston, MA USA.
[Fried, Linda F.] Univ Pittsburgh, Sch Med, Renal Electrolyte Div, Pittsburgh, PA USA.
[Fried, Linda F.] Vet Affairs Pittsburgh Healthcare Syst, Renal Sect, Pittsburgh, PA USA.
[Chonchol, Michel] Univ Colorado Denver & Hlth Sci Ctr, Div Renal Dis & Hypertens, Aurora, CO USA.
RP Deo, R (reprint author), Univ Penn, Sect Electrophysiol, Div Cardiovasc Med, 3400 Spruce St,9 Founders Cardiol, Philadelphia, PA 19104 USA.
EM Rajat.Deo@uphs.upenn.edu
FU National Institute on Aging at the National Institutes of Health
[AG-023629]; National Heart, Lung, and Blood Institute at the National
Institutes of Health [N01-HC-80007, N01-HC-85079, N01-HC-85086,
N01-HC-35129, N01-HC-15103, N01-HC-55222, N01-HC-75150, N01-HC-45133,
U01-HL-080295]; National Institute on Aging [R01 AG-15928, R01 AG-20098,
AG-027058]; National Heart, Lung, and Blood Institute [R01 HL-075366];
University of Pittsburgh Claude D. Pepper Older Americans Independence
Center [P30-AG-024827]; National Institutes of Health [R01 HL084443, R01
HL088456]; [K23DK089118]
FX This work was supported by the National Institute on Aging at the
National Institutes of Health (grant AG-023629). The CHS was supported
by contracts N01-HC-80007, N01-HC-85079 through N01-HC-85086,
N01-HC-35129, N01-HC-15103, N01-HC-55222, N01-HC-75150, N01-HC-45133,
and U01-HL-080295 from the National Heart, Lung, and Blood Institute at
the National Institutes of Health, with additional contribution from the
National Institute of Neurological Disorders and Stroke at the National
Institutes of Health. Additional support was provided through grants R01
AG-15928, R01 AG-20098, and AG-027058 from the National Institute on
Aging; R01 HL-075366 from the National Heart, Lung, and Blood Institute;
and the University of Pittsburgh Claude D. Pepper Older Americans
Independence Center P30-AG-024827. R.D. was supported by K23DK089118.
Additional grant support includes National Institutes of Health grants
R01 HL084443 and R01 HL088456.
NR 38
TC 48
Z9 49
U1 1
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0194-911X
J9 HYPERTENSION
JI Hypertension
PD DEC
PY 2011
VL 58
IS 6
BP 1021
EP 1028
DI 10.1161/HYPERTENSIONAHA.111.179135
PG 8
WC Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA 850TI
UT WOS:000297221900015
PM 22068871
ER
PT J
AU Linville, D
Stice, E
Gau, J
O'Neil, M
AF Linville, Deanna
Stice, Eric
Gau, Jeff
O'Neil, Maya
TI Predictive Effects of Mother and Peer Influences on Increases in
Adolescent Eating Disorder Risk Factors and Symptoms: A 3-Year
Longitudinal Study
SO INTERNATIONAL JOURNAL OF EATING DISORDERS
LA English
DT Article
DE maternal and peer; eating disorders; predictive effects
ID DUAL-PATHWAY MODEL; BODY DISSATISFACTION; BULIMIC PATHOLOGY;
WEIGHT-LOSS; DIAGNOSTIC SCALE; GIRLS; BEHAVIORS; DEPRESSION; IMAGE; BOYS
AB Objective: To investigate the relation of maternal and peer attitudes and behaviors to changes in eating disorder risk factors and symptoms in adolescent females.
Method: We tested whether maternal and peer eating attitudes, behaviors, and deficits in social support at baseline predicted subsequent increases in eating disorder risk factors and symptoms among 483 late adolescent females followed over 3 years.
Results: Data provide partial support for hypotheses, as eating disorder risk factors and symptoms increased over time and maternal thin ideal internalization significantly predicted a future increases in adolescent bulimic symptoms. There were no significant predictors of adolescent thin ideal internalization or body dissatisfaction.
Discussion: Findings only partially support the hypothesis that unhealthy attitudes and behaviors of mothers increase risk for eating disorder symptoms in their late adolescent daughters. These results underscore why eating disorder prevention programs should be based on risk factor research that has used prospective and rigorous designs. (C) 2011 by Wiley Periodicals, Inc.
C1 [Linville, Deanna] Univ Oregon, Dept Counseling Psychol & Human Serv, Eugene, OR 97403 USA.
[Stice, Eric] Univ Texas Austin, Dept Psychol, Austin, TX 78712 USA.
[Gau, Jeff] Oregon Res Inst, Eugene, OR 97403 USA.
[O'Neil, Maya] Portland VA Med Ctr, Hlth Serv Res & Dev Serv, Portland, OR USA.
RP Linville, D (reprint author), Univ Oregon, Dept Counseling Psychol & Human Serv, 5251 Univ Oregon, Eugene, OR 97403 USA.
EM Linville@uoregon.edu
FU National Institutes of Health [MH01708, MH/DK61957]
FX Supported by MH01708, MH/DK61957 from National Institutes of Health.
NR 50
TC 11
Z9 12
U1 1
U2 19
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0276-3478
J9 INT J EAT DISORDER
JI Int. J. Eating Disord.
PD DEC
PY 2011
VL 44
IS 8
BP 745
EP 751
DI 10.1002/eat.20907
PG 7
WC Psychology, Clinical; Nutrition & Dietetics; Psychiatry; Psychology
SC Psychology; Nutrition & Dietetics; Psychiatry
GA 851YS
UT WOS:000297309300013
PM 21344465
ER
PT J
AU Kalkonde, YV
Shelton, R
Villarreal, M
Sigala, J
Mishra, PK
Ahuja, SS
Barea-Rodriguez, E
Moretti, P
Ahuja, SK
AF Kalkonde, Y. V.
Shelton, R.
Villarreal, M.
Sigala, J.
Mishra, P. K.
Ahuja, S. S.
Barea-Rodriguez, E.
Moretti, P.
Ahuja, S. K.
TI THE CC CHEMOKINE RECEPTOR 5 REGULATES OLFACTORY AND SOCIAL RECOGNITION
IN MICE
SO NEUROSCIENCE
LA English
DT Article
DE chemokine; CC-chemokine receptor 5; CC-chemokine ligand 3; behavior;
social recognition; N-methyl D-aspartate receptor 1
ID LONG-TERM-MEMORY; MOUSE MODEL; NERVOUS-SYSTEM; BRAIN; EXPRESSION;
OXYTOCIN; BEHAVIOR; NEURONS; DISEASE; GENE
AB Chemokines are chemotactic cytokines that regulate cell migration and are thought to play an important role in a broad range of inflammatory diseases. The availability of chemokine receptor blockers makes them an important therapeutic target. In vitro, chemokines are shown to modulate neurotransmission. However, it is not very clear if chemokines play a role in behavior and cognition. Here we evaluated the role of CC chemokine receptor 5 (CCR5) in various behavioral tasks in mice using Wt (Ccr5(+/+)) and Ccr5-null (Ccr5(-/-)) mice. Ccr5(-/-) mice showed enhanced social recognition. Administration of CC chemokine ligand 3 (CCL3), one of the CCR5-ligands, impaired social recognition. Since the social recognition task is dependent on the sense of olfaction, we tested olfactory recognition for social and non-social scents in these mice. Ccr5(-/-) mice had enhanced olfactory recognition for both these scents indicating that enhanced performance in social recognition task could be due to enhanced olfactory recognition in these mice. Spatial memory and aversive memory were comparable in Wt and Ccr5(-/-) mice. Collectively, these results suggest that chemokines/chemokine receptors might play an important role in olfactory recognition tasks in mice and to our knowledge represents the first direct demonstration of an in vivo role of CCR5 in modulating social behavior in mice. These studies are important as CCR5 blockers are undergoing clinical trials and can potentially modulate behavior. (C) 2011 IBRO. Published by Elsevier Ltd. All rights reserved.
C1 [Kalkonde, Y. V.; Shelton, R.; Sigala, J.; Ahuja, S. S.; Ahuja, S. K.] S Texas Vet Hlth Care Syst, Vet Adm Res Ctr AIDS & HIV Infect 1, San Antonio, TX USA.
[Kalkonde, Y. V.; Shelton, R.; Sigala, J.; Ahuja, S. S.; Ahuja, S. K.] S Texas Vet Hlth Care Syst, Ctr Personalized Med, San Antonio, TX USA.
[Kalkonde, Y. V.; Shelton, R.; Sigala, J.; Ahuja, S. S.; Ahuja, S. K.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA.
[Villarreal, M.; Mishra, P. K.; Barea-Rodriguez, E.] Univ Texas San Antonio, Dept Biol, San Antonio, TX USA.
[Moretti, P.] Baylor Coll Med, Dept Neurol, Houston, TX 77030 USA.
RP Kalkonde, YV (reprint author), SEARCH, PO Gadchiroli, Gadchiroli 442605, Maharashtra, India.
EM yvkalkonde@gmail.com
FU Veterans Administration Center on AIDS and HIV infection of the South
Texas Veterans Health Care System; MERIT [R37046326]; NIH [AI043279,
MH069270]; Elizabeth Glaser Scientist Award; Burroughs Wellcome Clinical
Scientist Award in Translational Research
FX We thank William Kuziel for providing Ccr5-/- mice on
C57BL6/J background, Timothy Freeman and Carlo Condello for help with
experiments and Ivan Becerra, William Pate and Harjeet Singh for help
with illustrations. This work was supported by the Veterans
Administration Center on AIDS and HIV infection of the South Texas
Veterans Health Care System, and a MERIT (R37046326) and other awards
(AI043279 and MH069270) from the NIH to S.K.A. S.K.A. is a recipient of
the Elizabeth Glaser Scientist Award and the Burroughs Wellcome Clinical
Scientist Award in Translational Research. The funding sources had no
role
NR 46
TC 6
Z9 7
U1 1
U2 2
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0306-4522
J9 NEUROSCIENCE
JI Neuroscience
PD DEC 1
PY 2011
VL 197
BP 153
EP 161
DI 10.1016/j.neuroscience.2011.09.039
PG 9
WC Neurosciences
SC Neurosciences & Neurology
GA 849QR
UT WOS:000297140700016
PM 21963866
ER
PT J
AU Xi, M
Fung, SJ
Sampogna, S
Chase, MH
AF Xi, M.
Fung, S. J.
Sampogna, S.
Chase, M. H.
TI EXCITATORY PROJECTIONS FROM THE AMYGDALA TO NEURONS IN THE NUCLEUS
PONTIS ORALIS IN THE RAT: AN INTRACELLULAR STUDY
SO NEUROSCIENCE
LA English
DT Article
DE amygdala; electrical stimulation; REM sleep; synaptic potentials;
nucleus pontis oralis
ID EYE-MOVEMENT SLEEP; TERM SYNAPTIC PLASTICITY; REM-SLEEP;
ELECTRICAL-STIMULATION; RETICULAR-FORMATION; PONTOGENICULOOCCIPITAL
WAVES; PARADOXICAL SLEEP; BRAIN-STEM; FUNCTIONAL NEUROANATOMY; LUMBAR
MOTONEURONS
AB There is a consensus that active (REM) sleep (AS) is controlled by cholinergic projections from the laterodorsal and pedunculopontine tegmental nuclei (LDT/PPT) to neurons in the nucleus pontis oralis (NPO) that generate AS (i.e. AS-Generator neurons). The present study was designed to provide evidence that other projections to the NPO, such as those from the amygdala, are also capable of inducing AS. Accordingly, the responses of neurons, recorded intracellularly in the NPO, were examined following stimulation of the ipsilateral central nucleus of the amygdala (CNA) in urethane-anesthetized rats. Single pulse stimulation in the CNA produced an early, fast depolarizing potential (EPSP) in neurons within the NPO. The mean latency to the onset of these excitatory postsynaptic potentials (EPSPs) was 3.6 +/- 0.2 ms. A late, small-amplitude inhibitory synaptic potential (IPSP) was present following EPSPs in a portion of the NPO neurons. Following stimulation of the CNA with a train of 8-10 pulses, NPO neurons exhibited a sustained depolarization (5-10 my) of their resting membrane potential. When single subthreshold intracellular depolarizing current pulses were delivered to NPO neurons, CNA-induced EPSPs were sufficient to promote the discharge of these cells. Stimulation of the CNA with a short train of stimuli induced potent temporal facilitation of EPSPs in NPO neurons. Two forms of synaptic plasticity were revealed by the patterns of response of NPO neurons following stimulation of the CNA: paired-pulse facilitation (PPF) and post-tetanic potentiation (PIP). Six of recorded NPO neurons were identified morphologically with neurobiotin. They were medium to large, multipolar cells with diameters >20 mu M, which resemble AS-on cells in the NPO. The present results demonstrate that amygdalar projections are capable of exerting a powerful excitatory postsynaptic drive that activates NPO neurons. Therefore, we suggest that the amygdala is capable of inducing AS via direct projections to AS-Generator neurons in the NPO. (C) 2011 IBRO. Published by Elsevier Ltd. All rights reserved.
C1 [Xi, M.; Fung, S. J.; Sampogna, S.; Chase, M. H.] WebSci Int, Los Angeles, CA 90024 USA.
[Xi, M.; Fung, S. J.; Chase, M. H.] VA Greater Angeles Healthcare Syst, Los Angeles, CA 90073 USA.
[Chase, M. H.] Univ Calif Los Angeles, Sch Med, Los Angeles, CA 90025 USA.
RP Xi, M (reprint author), WebSci Int, 1251 Westwood Blvd, Los Angeles, CA 90024 USA.
EM mxi@websciences.org
FU NIH [NS 60917]
FX This research was supported by NIH grant NS 60917. We are grateful to
Mr. Vincent Lim. Ms. Nichole Stevens and Mr. Daniel Bronson for their
excellent technical assistance.
NR 61
TC 10
Z9 10
U1 0
U2 5
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0306-4522
J9 NEUROSCIENCE
JI Neuroscience
PD DEC 1
PY 2011
VL 197
BP 181
EP 190
DI 10.1016/j.neuroscience.2011.09.029
PG 10
WC Neurosciences
SC Neurosciences & Neurology
GA 849QR
UT WOS:000297140700019
PM 21955600
ER
PT J
AU Sher, L
LaBode, V
AF Sher, Leo
LaBode, Vanessa
TI TEACHING HEALTH CARE PROFESSIONALS ABOUT SUICIDE SAFETY PLANNING
SO PSYCHIATRIA DANUBINA
LA English
DT Article
DE suicide; training; public health
AB The suicide safety plan is a plan of action created by the clinician and patient that essentially charts the course of what the patient should do if he/she begins to experience suicidal urges. It is important for clinicians to learn how to implement a safety plan so that they can offer this service to their patients and teach their colleagues and associates about suicide safety planning. The safety plan is a great tool employed to help patients with suicidal urges, but trainees-clinicians and clinician associates alike - should fully understand that it is not a form of treatment. However, since an effective treatment for suicidality does not exist, practitioners should definitely use suicide safety planning. Although more resources are now being provided to individuals with suicidal behavior, more research needs to be done to develop new, effective methods of treatment and prevention of suicidal behavior.
C1 [Sher, Leo; LaBode, Vanessa] James J Peters Vet Adm Med Ctr, New York, NY USA.
RP Sher, L (reprint author), Mt Sinai Sch Med, Dept Psychiat, Med Ctr, James J Peters Vet Adm, 130 W Kingsbridge Rd, Bronx, NY 10468 USA.
EM Leo.Sher@mssm.edu
NR 12
TC 4
Z9 4
U1 0
U2 2
PU MEDICINSKA NAKLADA
PI ZAGREB
PA VLASKA 69, HR-10000 ZAGREB, CROATIA
SN 0353-5053
J9 PSYCHIAT DANUB
JI Psychiatr. Danub.
PD DEC
PY 2011
VL 23
IS 4
BP 396
EP 397
PG 2
WC Psychiatry
SC Psychiatry
GA 850YZ
UT WOS:000297236800010
PM 22075742
ER
PT J
AU Sawyer, AM
Gooneratne, NS
Marcus, CL
Ofer, D
Richards, KC
Weaver, TE
AF Sawyer, Amy M.
Gooneratne, Nalaka S.
Marcus, Carole L.
Ofer, Dafna
Richards, Kathy C.
Weaver, Terri E.
TI A systematic review of CPAP adherence across age groups: Clinical and
empiric insights for developing CPAP adherence interventions
SO SLEEP MEDICINE REVIEWS
LA English
DT Review
DE Obstructive sleep apnea; Continuous positive airway pressure; Patient
compliance
ID POSITIVE AIRWAY PRESSURE; OBSTRUCTIVE-SLEEP-APNEA; QUALITY-OF-LIFE;
LONG-TERM COMPLIANCE; APNOEA/HYPOPNOEA SYNDROME; NASAL CPAP;
APNEA/HYPOPNEA SYNDROME; HYPOPNEA-SYNDROME; RANDOMIZED-TRIAL; BREATHING
DISORDERS
AB Continuous positive airway pressure (CPAP) is a highly efficacious treatment for obstructive sleep apnea (OSA) but adherence to the treatment limits its overall effectiveness across all age groups of patients. Factors that influence adherence to CPAP include disease and patient characteristics, treatment titration procedures, technological device factors and side effects, and psychological and social factors. These influential factors have guided the development of interventions to promote CPAP adherence. Various intervention strategies have been described and include educational, technological, psychosocial, pharmacological, and multi-dimensional approaches. Though evidence to date has led to innovative strategies that address adherence in CPAP-treated children, adults, and older adults, significant opportunities exist to develop and test interventions that are clinically applicable, specific to sub-groups of patients likely to demonstrate poor adherence, and address the multi-factorial nature of CPAP adherence. The translation of CPAP adherence promotion interventions to clinical practice is imperative to improve health and functional outcomes in all persons with,CPAP-treated OSA. (C) 2011 Elsevier Ltd. All rights reserved.
C1 [Gooneratne, Nalaka S.] Univ Penn, Sch Med, Div Geriatr Med, Philadelphia, PA 19104 USA.
[Sawyer, Amy M.; Richards, Kathy C.] Univ Penn, Sch Nursing, Biobehav Hlth Sci Div, Philadelphia, PA 19104 USA.
[Gooneratne, Nalaka S.; Marcus, Carole L.; Ofer, Dafna] Univ Penn, Sch Med, Ctr Sleep & Circadian Neurobiol, Philadelphia, PA 19104 USA.
[Richards, Kathy C.] Univ Penn, Sch Nursing, Ctr Integrat Sci Aging, Philadelphia, PA 19104 USA.
[Sawyer, Amy M.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA.
[Marcus, Carole L.; Ofer, Dafna] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA.
[Weaver, Terri E.] Univ Illinois, Coll Nursing, Chicago, IL 60612 USA.
RP Sawyer, AM (reprint author), Penn State Univ, Sch Nursing, 201 HHD Bldg E, University Pk, PA 16802 USA.
EM ams24@psu.edu; ngoonera@mail.med.upenn.edu; Dafna.ofer@uphs.upenn.edu;
kathyr@nursing.upenn.edu; teweaver@uic.edu
FU National Institutes of Health, National Institute of Nursing Research
[K99NR011173]
FX This work was supported by a grant from National Institutes of Health,
National Institute of Nursing Research K99NR011173 (Sawyer AM).
NR 94
TC 134
Z9 139
U1 3
U2 17
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 1087-0792
J9 SLEEP MED REV
JI Sleep Med. Rev.
PD DEC
PY 2011
VL 15
IS 6
BP 343
EP 356
DI 10.1016/j.smrv.2011.01.003
PG 14
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 850WT
UT WOS:000297231000002
PM 21652236
ER
PT J
AU Guirand, AS
Dicianno, BE
Mahajan, H
Cooper, RA
AF Guirand, Alcinto S.
Dicianno, Brad E.
Mahajan, Harshal
Cooper, Rory A.
TI Tuning Algorithms for Control Interfaces for Users with Upper-Limb
Impairments
SO AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION
LA English
DT Article
DE Assistive Technology; Isometric Joystick; Rehabilitation; Movement
Disorders; Wheelchairs
ID ELECTRIC-POWERED WHEELCHAIRS; ISOMETRIC JOYSTICKS; POSITION; INDIVIDUALS
AB Guirand AS, Dicianno BE, Mahajan H, Cooper RA: Tuning algorithms for control interfaces for users with upper-limb impairments. Am J Phys Med Rehabil 2011;90:992-998.
Objective: Approximately 40% of Americans with disabilities cannot operate wheeled mobility devices and computers adequately because of diminished upper-limb motor control, sensory limitations, and cognitive impairments. We developed tuning software that can customize control interfaces for individuals with upper-limb impairments. This study compared the differences in each parameter among different diagnostic groups.
Design: The age of the subjects ranged from 18 to 80 yrs. The participants were classified into the following groups: athetoid cerebral palsy, spastic cerebral palsy, multiple sclerosis, upper-limb spasticity, and control. We used a validated tuning software protocol to customize an isometric joystick before a virtual tracing or driving task. Tuning parameters were then compared across groups.
Results: Seventy-five subjects were included. Gain, the parameter responsible for force-to-output ratios, in each directional axis (leftward gain: P = 0.018; rightward gain: P = 0.003; reverse gain: P = 0.007; forward gain: P = 0.014) was significantly different across the diagnostic groups. Post hoc analyses showed that the control group required smaller leftward gain than spastic cerebral palsy, multiple sclerosis and upper-limb spasticity groups and smaller gain in all other directions compared with spastic cerebral palsy.
Conclusions: Gain may be a useful parameter in tuning by clinicians, and efforts aimed at gain customization may aid the development of commercially available tuning software packages.
C1 [Guirand, Alcinto S.] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA.
[Guirand, Alcinto S.; Dicianno, Brad E.; Mahajan, Harshal; Cooper, Rory A.] Highland Drive VA Med Ctr, Human Engn Res Labs, Pittsburgh, PA USA.
[Dicianno, Brad E.; Mahajan, Harshal; Cooper, Rory A.] Univ Pittsburgh, Dept Rehabil Sci & Technol, Pittsburgh, PA USA.
[Dicianno, Brad E.; Mahajan, Harshal; Cooper, Rory A.] Univ Pittsburgh, Med Ctr, Dept Phys Med & Rehabil PM&R, Pittsburgh, PA USA.
[Dicianno, Brad E.; Mahajan, Harshal; Cooper, Rory A.] VA Pittsburgh Healthcare Syst, Ctr Excellence Wheelchairs & Associated Rehabil E, Pittsburgh, PA USA.
RP Dicianno, BE (reprint author), UPMC Dept PM&R, 3471 5th Ave,Suite 202, Pittsburgh, PA 15213 USA.
OI Dicianno, Brad/0000-0003-0738-0192
FU NIH [K12 HD001097-09]; VA Center of Excellence for Wheelchairs and
Associated Rehabilitation Engineering [B3142C]; VA Merit Review
[B3287R]; University of Pittsburgh School of Medicine
FX Funded by the Rehabilitation Medicine Scientist Training Program NIH:
K12 HD001097-09, the VA Center of Excellence for Wheelchairs and
Associated Rehabilitation Engineering (B3142C), VA Merit Review
(B3287R), and the University of Pittsburgh School of Medicine Dean's
Summer Research Stipend.
NR 20
TC 4
Z9 4
U1 3
U2 10
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0894-9115
J9 AM J PHYS MED REHAB
JI Am. J. Phys. Med. Rehabil.
PD DEC
PY 2011
VL 90
IS 12
BP 992
EP 998
DI 10.1097/PHM.0b013e318228ca9f
PG 7
WC Rehabilitation; Sport Sciences
SC Rehabilitation; Sport Sciences
GA 846RX
UT WOS:000296922000004
PM 22019961
ER
PT J
AU Cadena, J
Nair, S
Henao-Martinez, AF
Jorgensen, JH
Patterson, JE
Sreeramoju, PV
AF Cadena, Jose
Nair, Shalini
Henao-Martinez, Andres F.
Jorgensen, James H.
Patterson, Jan E.
Sreeramoju, Pranavi V.
TI Dose of Trimethoprim-Sulfamethoxazole To Treat Skin and Skin Structure
Infections Caused by Methicillin-Resistant Staphylococcus aureus
SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
LA English
DT Article
ID SOFT-TISSUE INFECTIONS; CLINDAMYCIN; THERAPY; CEPHALEXIN; TRIAL
AB We undertook this study to investigate whether treatment with a higher dose of trimethoprim-sulfamethoxazole (TMP/SMX) led to greater clinical resolution in patients with skin and soft tissue infections (SSTIs) caused by methicillin-resistant Staphylococcus aureus (MRSA). A prospective, observational cohort with nested case-control study was performed at a public tertiary health system. Among patients with MRSA SSTIs during the period from May 2008 to September 2008 who received oral monotherapy with TMP/SMX and whose clinical outcome was known, the clinical characteristics and outcomes were compared between patients treated with a high dose of TMP/SMX (320 mg/1,600 mg twice daily) for 7 to 15 days and patients treated with the standard dose of TMP/SMX (160 mg/800 mg twice daily) for 7 to 15 days. In patients with MRSA SSTIs, those treated with the high dose of TMP/SMX (n = 121) had clinical characteristics similar to those of patients treated with the standard dose of TMP/SMX (n = 170). The only exception was a higher proportion of patients with a history of trauma upon admission among the patients treated with the higher dose. The proportion of patients with clinical resolution of infection was not different in the two groups (88/121 [73%] versus 127/170 [75%]; P = 0.79). The lack of significance remained in patients with abscess upon stratified analysis by whether surgical drainage was performed. The study found that patients with MRSA SSTIs treated with the higher dose of TMP/SMX (320/1,600 mg twice daily) for 7 to 15 days had a similar rate of clinical resolution as patients treated with the standard dose of TMP/SMX (160/800 mg twice daily) for 7 to 15 days.
C1 [Sreeramoju, Pranavi V.] Univ Texas SW Med Ctr Dallas, Dept Med Infect Dis, Dallas, TX 75390 USA.
[Cadena, Jose; Patterson, Jan E.] S Texas Vet Healthcare Syst, San Antonio, TX USA.
[Cadena, Jose; Patterson, Jan E.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med Infect Dis, San Antonio, TX 78229 USA.
[Nair, Shalini; Henao-Martinez, Andres F.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA.
[Jorgensen, James H.; Patterson, Jan E.] Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, San Antonio, TX 78229 USA.
RP Sreeramoju, PV (reprint author), Univ Texas SW Med Ctr Dallas, Dept Med Infect Dis, 5323 Harry Hines Blvd,MC 9113, Dallas, TX 75390 USA.
EM pranavi.sreeramoju@utsouthwestern.edu
OI Henao-Martinez, Andres/0000-0001-7363-8652
NR 12
TC 6
Z9 7
U1 0
U2 4
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0066-4804
J9 ANTIMICROB AGENTS CH
JI Antimicrob. Agents Chemother.
PD DEC
PY 2011
VL 55
IS 12
BP 5430
EP 5432
DI 10.1128/AAC.00706-11
PG 3
WC Microbiology; Pharmacology & Pharmacy
SC Microbiology; Pharmacology & Pharmacy
GA 846RJ
UT WOS:000296920600002
PM 21930870
ER
PT J
AU Schneider, L
Giordano, S
Zelickson, BR
Johnson, MS
Benavides, GA
Ouyang, XS
Fineberg, N
Darley-Usmar, VM
Zhang, JH
AF Schneider, Lonnie
Giordano, Samantha
Zelickson, Blake R.
Johnson, Michelle S.
Benavides, Gloria A.
Ouyang, Xiaosen
Fineberg, Naomi
Darley-Usmar, Victor M.
Zhang, Jianhua
TI Differentiation of SH-SY5Y cells to a neuronal phenotype changes
cellular bioenergetics and the response to oxidative stress
SO FREE RADICAL BIOLOGY AND MEDICINE
LA English
DT Article
DE HNE; DMNQ; Oxidative stress; Cellular bioenergetics; SH-SY5Y; Free
radicals
ID LIPID-PEROXIDATION PRODUCTS; SPARE RESPIRATORY CAPACITY;
CYTOCHROME-C-OXIDASE; IN-VITRO MODEL; HUMAN NEUROBLASTOMA;
PARKINSONS-DISEASE; MITOCHONDRIAL RESPIRATION; GLUTAMATE EXCITOTOXICITY;
COMPLEX-I; MEMBRANE
AB Cell differentiation is associated with changes in metabolism and function. Understanding these changes during differentiation is important in the context of stem cell research, cancer, and neurodegenerative diseases. An early event in neurodegenerative diseases is the alteration of mitochondrial function and increased oxidative stress. Studies using both undifferentiated and differentiated SH-SY5Y neuroblastoma cells have shown distinct responses to cellular stressors; however, the mechanisms remain unclear. We hypothesized that because the regulation of glycolysis and oxidative phosphorylation is modulated during cellular differentiation, this would change bioenergetic function and the response to oxidative stress. To test this, we used retinoic acid (RA) to induce differentiation of SH-SY5Y cells and assessed changes in cellular bioenergetics using extracellular flux analysis. After exposure to RA, the SH-SY5Y cells had an increased mitochondrial membrane potential, without changing mitochondria! number. Differentiated cells exhibited greater stimulation of mitochondrial respiration with uncoupling and an increased bioenergetic reserve capacity. The increased reserve capacity in the differentiated cells was suppressed by the inhibitor of glycolysis 2-deoxy-D-glucose. Furthermore, we found that differentiated cells were substantially more resistant to cytotoxicity and mitochondrial dysfunction induced by the reactive lipid species 4-hydroxynonenal or the reactive oxygen species generator 2,3-dimethoxy-1,4-naphthoquinone. We then analyzed the levels of selected mitochondrial proteins and found an increase in complex IV subunits, which we propose contributes to the increase in reserve capacity in the differentiated cells. Furthermore, we found an increase in MnSOD that could, at least in part, account for the increased resistance to oxidative stress. Our findings suggest that profound changes in mitochondrial metabolism and antioxidant defenses occur upon differentiation of neuroblastoma cells to a neuron-like phenotype. (C) 2011 Elsevier Inc. All rights reserved.
C1 [Schneider, Lonnie; Giordano, Samantha; Zelickson, Blake R.; Johnson, Michelle S.; Benavides, Gloria A.; Ouyang, Xiaosen; Darley-Usmar, Victor M.; Zhang, Jianhua] Univ Alabama Birmingham, Dept Pathol, Sch Publ Hlth, Birmingham, AL 35294 USA.
[Schneider, Lonnie; Giordano, Samantha; Zelickson, Blake R.; Johnson, Michelle S.; Benavides, Gloria A.; Darley-Usmar, Victor M.; Zhang, Jianhua] Univ Alabama Birmingham, Sch Publ Hlth, Ctr Free Rad Biol, Birmingham, AL 35294 USA.
[Ouyang, Xiaosen; Zhang, Jianhua] Birmingham VA Med Ctr, Dept Vet Affairs, Birmingham, AL 35233 USA.
[Fineberg, Naomi] Univ Alabama Birmingham, Dept Biostat, Sch Publ Hlth, Birmingham, AL 35294 USA.
RP Zhang, JH (reprint author), Univ Alabama Birmingham, Dept Pathol, Sch Publ Hlth, Birmingham, AL 35294 USA.
EM zhanja@uab.edu
RI zhang, jianhua/D-3404-2009
OI Zhang, Jianhua/0000-0002-2128-9574
FU Michael J. Fox Foundation; NIH [R01-NS064090]; VA merit award;
[ES/HL10167]; [DK75865]
FX We thank members of Dr. Zhang's and Dr. Darley-Usmar's laboratories for
technical help and discussions. We thank Dr. Balu Chacko for help with
confocal imaging. This work was supported by ES/HL10167 and DK75865 (to
V.M.D.U.), the Michael J. Fox Foundation, NIHR01-NS064090, and a VA
merit award (to J.Z.).
NR 57
TC 62
Z9 62
U1 3
U2 19
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0891-5849
J9 FREE RADICAL BIO MED
JI Free Radic. Biol. Med.
PD DEC 1
PY 2011
VL 51
IS 11
BP 2007
EP 2017
DI 10.1016/j.freeradbiomed.2011.08.030
PG 11
WC Biochemistry & Molecular Biology; Endocrinology & Metabolism
SC Biochemistry & Molecular Biology; Endocrinology & Metabolism
GA 848FR
UT WOS:000297036500007
PM 21945098
ER
PT J
AU Estrada, CA
Safford, MM
Salanitro, AH
Houston, TK
Curry, W
Williams, JH
Ovalle, F
Kim, Y
Foster, P
Allison, JJ
AF Estrada, Carlos A.
Safford, Monika M.
Salanitro, Amanda H.
Houston, Thomas K.
Curry, William
Williams, Jessica H.
Ovalle, Fernando
Kim, Yongin
Foster, Pamela
Allison, Jeroan J.
TI A web-based diabetes intervention for physician: a cluster-randomized
effectiveness trial
SO INTERNATIONAL JOURNAL FOR QUALITY IN HEALTH CARE
LA English
DT Article
DE internet; translational research; diabetes mellitus; rural health
services; education; medical; continuing process assessment (Health
Care)
ID CONTINUING MEDICAL-EDUCATION; PRACTICE IMPROVEMENT MODULE; RE-AIM
FRAMEWORK; SELF-ASSESSMENT; CARE; CME; BENEFICIARIES; MANAGEMENT;
QUALITY; IMPACT
AB To determine the effectiveness of a provider-based education and implementation intervention for improving diabetes control.
Cluster-randomized trial with baseline and follow-up cross sections of diabetes patients in each participating physicians practice.
Eleven US Southeastern states, 200608.
Two hundred and five rural primary care physicians.
Multi-component interactive intervention including Web-based continuing medical education, performance feedback and quality improvement tools.
oAcceptable control' [hemoglobin A1c 9, blood pressure (BP) 140/90 mmHg, low-density lipoprotein cholesterol (LDL) 130 mg/dl] and ooptimal control' (A1c 7, BP 130/80 mmHg, LDL 100 mg/dl).
Of 364 physicians attempting to register, 205 were randomized to the intervention (n 102) or control arms (n 103). Baseline and follow-up data were provided by 95 physicians (2127 patients). The proportion of patients with A1c 9 was similar at baseline and follow-up in both the control [adjusted odds ratio (AOR): 0.94; 95 confidence interval (CI): 0.61, 1.47] and intervention arms [AOR: 1.16 (95 CI: 0.80, 1.69)]; BP 140/90 mmHg and LDL 130 mg/dl were also similar at both measurement points (P 0.66, P 0.46; respectively). We observed no significant effect on diabetes control attributable to the intervention for any of the primary outcome measures. Intervention physicians engaged with the Website over a median of 64.7 weeks [interquartile range (IQR): 45.481.8) for a median total of 37 min (IQR: 1666).
A wide-reach, low-intensity, Web-based interactive multi-component intervention did not improve control of glucose, BP or lipids for patients with diabetes of physicians practicing in the rural Southeastern US.
C1 [Estrada, Carlos A.; Curry, William] Birmingham Vet Affairs Med Ctr, Birmingham, AL 35294 USA.
[Estrada, Carlos A.] Vet Affairs Natl Qual Scholars Program, Birmingham, AL USA.
[Estrada, Carlos A.; Safford, Monika M.; Curry, William; Williams, Jessica H.; Ovalle, Fernando; Kim, Yongin] Univ Alabama, Birmingham, AL USA.
[Salanitro, Amanda H.; Houston, Thomas K.] VA Tennessee Valley Healthcare Geriatr Res Educ C, Nashville, TN USA.
[Salanitro, Amanda H.; Houston, Thomas K.] Vanderbilt Univ, Nashville, TN USA.
[Houston, Thomas K.] Bedford Vet Affairs Med Ctr, Bedford, MA USA.
[Foster, Pamela] Univ Alabama, Tuscaloosa, AL USA.
[Allison, Jeroan J.] Univ Massachusetts, Sch Med, Worcester, MA USA.
RP Estrada, CA (reprint author), Birmingham Vet Affairs Med Ctr, Birmingham, AL 35294 USA.
EM cestrada@uab.edu
RI Houston, Thomas/F-2469-2013
OI Allison, Jeroan/0000-0003-4472-2112
FU National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
[5R18DK065001]; Veterans Affairs National Quality Scholars Program
FX Awards by the National Institute of Diabetes and Digestive and Kidney
Diseases (NIDDK) 5R18DK065001 to Dr J.J.A. Drs A. H. S and C. A. E. were
supported by the Veterans Affairs National Quality Scholars Program.
NR 28
TC 7
Z9 7
U1 1
U2 10
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1353-4505
J9 INT J QUAL HEALTH C
JI Int. J. Qual. Health Care
PD DEC
PY 2011
VL 23
IS 6
BP 682
EP 689
DI 10.1093/intqhc/mzr053
PG 8
WC Health Care Sciences & Services; Health Policy & Services
SC Health Care Sciences & Services
GA 848QL
UT WOS:000297067900009
PM 21831967
ER
PT J
AU Dvorak-Ewell, MM
Chen, TH
Liang, N
Garvey, C
Liu, B
Tu, CL
Chang, WH
Bikle, DD
Shoback, DM
AF Dvorak-Ewell, Melita M.
Chen, Tsui-Hua
Liang, Nathan
Garvey, Caitlin
Liu, Betty
Tu, Chialing
Chang, Wenhan
Bikle, Daniel D.
Shoback, Dolores M.
TI Osteoblast Extracellular Ca2+-Sensing Receptor Regulates Bone
Development, Mineralization, and Turnover
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE EXTRACELLULAR Ca2+-SENSING RECEPTOR; OSTEOBLASTS; BONE DEVELOPMENT;
OSTEOBLAST DIFFERENTIATION
ID CALCIUM-SENSING RECEPTOR; ALKALINE-PHOSPHATASE; CANCELLOUS BONE;
SKELETAL PHENOTYPE; MC3T3-E1 CELLS; DEFICIENT MICE; MURINE BONE;
DIFFERENTIATION; CASR; OSTEOPROTEGERIN
AB The extracellular Ca2+-sensing receptor (CaR), a G protein-coupled receptor responsible for maintenance of calcium homeostasis, is implicated in regulation of skeletal metabolism. To discern the role of the osteoblast CaR in regulation of bone development and remodeling, we generated mice in which the CaR is excised in a broad population of osteoblasts expressing the 3.6-kb a(1)(I) collagen promoter. Conditional knockouts had abnormal skeletal histology at birth and developed progressively reduced mineralization secondary to retarded osteoblast differentiation, evident by significantly reduced numbers of osteoblasts and decreased expression of collagen I, osteocalcin, and sclerostin mRNAs. Elevated expression of ankylosis protein, ectonucleotide pyrophosphatase/phospho-diesterase 1, and osteopontin mRNAs in the conditional knockout indicate altered regulation of genes important in mineralization. Knockout of the osteoblast CaR also resulted in increased expression of the receptor activator of NF-kappa B ligand (RANKL), the major stimulator of osteoclast differentiation and function, consistent with elevated osteoclast numbers in vivo. Osteoblasts from the conditional knockouts exhibited delayed differentiation, reduced mineralizing capacity, altered expression of regulators of mineralization, and increased ability to promote osteoclastogenesis in coculture experiments. We conclude that CaR signaling in a broad population of osteoblasts is essential for bone development and remodeling and plays an important role in the regulation of differentiation and expression of regulators of bone resorption and mineralization. (C) 2011 American Society for Bone and Mineral Research.
C1 [Shoback, Dolores M.] Univ Calif San Francisco, San Francisco VA Med Ctr, Endocrine Res Unit, Dept Vet Affairs Med Ctr,Dept Med, San Francisco, CA 94121 USA.
RP Shoback, DM (reprint author), Univ Calif San Francisco, San Francisco VA Med Ctr, Endocrine Res Unit, Dept Vet Affairs Med Ctr,Dept Med, 111N,4150 Clement St, San Francisco, CA 94121 USA.
EM dolores.shoback@ucsf.edu
FU Veterans Affairs Merit Review; Department of Veterans Research
Enhancement; NIH [RO1 AG21353, RO1 AR055888, RO1 DK054793]
FX We gratefully acknowledge Dr Barbara Kream for the gift of the Col
3.6-Cre mice, as well as the technical help of Hashem Elalieh and
Michelle Buttler. This work was supported by a Veterans Affairs Merit
Review (DS), a Department of Veterans Research Enhancement Award Program
in Bone Disease (DS, DB), NIH RO1 AG21353 (WC), NIH RO1 AR055888 (DS),
and NIH RO1 DK054793 (DB).
NR 39
TC 36
Z9 38
U1 0
U2 12
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0884-0431
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD DEC
PY 2011
VL 26
IS 12
BP 2935
EP 2947
DI 10.1002/jbmr.520
PG 13
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 849QB
UT WOS:000297139100016
PM 21956637
ER
PT J
AU McDonald, CC
Deatrick, JA
Kassam-Adams, N
Richmond, TS
AF McDonald, Catherine C.
Deatrick, Janet A.
Kassam-Adams, Nancy
Richmond, Therese S.
TI Community Violence Exposure and Positive Youth Development in Urban
Youth
SO JOURNAL OF COMMUNITY HEALTH
LA English
DT Article
DE Community violence; Family functioning; Positive youth development;
Urban
ID INNER-CITY ADOLESCENTS; MENTAL-HEALTH; POSTTRAUMATIC STRESS; PROTECTIVE
FACTORS; SOCIAL SUPPORT; SYMPTOMS; TRAJECTORIES; BEHAVIORS; 4-H;
STRATEGIES
AB Youth in urban environments are exposed to community violence, yet some do well and continue on a positive developmental trajectory. This study investigated the relationships between lifetime community violence exposure (including total, hearing about, witnessing, and victimization), family functioning, and positive youth development (PYD) among 110 urban youth ages 10-16 years (54% female) using a paper and pen self-report survey. This cross-sectional study was part of an interdisciplinary community-based participatory research effort in West/Southwest Philadelphia. Almost 97% of the sample reported some type of community violence exposure. Controlling for presence of mother in the home and presence of father in the home, separate linear regression models for PYD by each type of community violence exposure indicated that gender and family functioning were significantly associated with PYD. None of the types of community violence exposure were significant in the models. Significant interactions between gender and presence of mother in the home and gender and family functioning helped better explain these relationships for some of the types of community violence exposure. Presence of mother was associated with higher PYD for girls, but not for boys. Boys with poor family functioning had lower PYD than girls with poor family functioning. This study helps to better delineate relationships between CVE and PYD by adding new knowledge to the literature on the role of family functioning. Points of intervention should focus on families, with attention to parental figures in the home and overall family functioning.
C1 [McDonald, Catherine C.; Deatrick, Janet A.] Univ Penn, Sch Nursing, Ctr Hlth Equ Res, Philadelphia, PA 19104 USA.
[McDonald, Catherine C.; Kassam-Adams, Nancy; Richmond, Therese S.] Philadelphia Collaborat Violence Prevent Ctr, Philadelphia, PA 19104 USA.
[Kassam-Adams, Nancy] Childrens Hosp Philadelphia, Ctr Injury Res & Prevent, Philadelphia, PA 19104 USA.
[Richmond, Therese S.] Univ Penn, Sch Nursing, Div Biobehav & Hlth Sci, Philadelphia, PA 19104 USA.
RP McDonald, CC (reprint author), Univ Penn, Sch Nursing, Ctr Hlth Equ Res, 2L,418 Curie Blvd, Philadelphia, PA 19104 USA.
EM mcdonalc@nursing.upenn.edu
RI Kassam-Adams, Nancy/C-4091-2009
FU NCIPC CDC HHS [5 U49 CE001093, U49 CE001093]; NINR NIH HHS [F31
NR011107, F31 NR011107-02, F31NR011107]
NR 48
TC 5
Z9 5
U1 3
U2 15
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0094-5145
J9 J COMMUN HEALTH
JI J. Community Health
PD DEC
PY 2011
VL 36
IS 6
BP 925
EP 932
DI 10.1007/s10900-011-9391-5
PG 8
WC Health Policy & Services; Public, Environmental & Occupational Health
SC Health Care Sciences & Services; Public, Environmental & Occupational
Health
GA 838NV
UT WOS:000296300400005
PM 21461763
ER
PT J
AU Brewster, LP
Hall, DE
Joehl, RJ
AF Brewster, Luke P.
Hall, Dan E.
Joehl, Raymond J.
TI Assessing Residents in Surgical Ethics: We Do It a Lot; We Only Know a
Little
SO JOURNAL OF SURGICAL RESEARCH
LA English
DT Article
DE surgical ethics; resident education; clinical ethics
ID EDUCATION; FUTURE
AB Background. PGY-1 year of surgical residency brings together many persons of disparate experiences and educational backgrounds, including their exposure to ethics. We hypothesized that surgical PGY-1s would have a similar exposure to ethical scenarios but lack the confidence in practice and understanding of ethical principles compared with more senior residents.
Materials and Methods. Surgical residents were invited to resident-initiated surgical ethics workshops utilizing a standardized text. Here a survey and multiple choice tests were administered to participants. The survey determined prior exposure to ethics curricula, the frequency of exposure to various ethics topics, and their comfort with these scenarios. A multiple choice test then quantified the knowledge base of participating residents. The results were collected and compared between surgical PGY-1s and more senior residents.
Results. Eighteen PGY-1s and 12 senior residents completed this curriculum. Resident exposure to ethical concepts was common. Resident confidence in these topics was ranked moderate or higher for both groups. Despite frequent clinical exposure and strong confidence in their skills of addressing these topics, performance on the test was poor, with an average score of 59% for PGY-1s and 47% for more senior residents (P = 0.03).
Conclusions. Despite clinical exposure to and confidence in their management of ethical topics, their knowledge base was poor and worse for more senior residents. Given the overall interest in a formal ethics curriculum and the knowledge deficit demonstrated, educational intervention and professional ethics support should be provided for surgical residents even with the current educational time constraints. (c) 2011 Elsevier Inc. All rights reserved.
C1 [Brewster, Luke P.] Emory Univ Hosp, Dept Surg, Atlanta, GA 30022 USA.
[Hall, Dan E.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA.
[Hall, Dan E.] Univ Pittsburgh, Dept Surg, Pittsburgh, PA USA.
[Joehl, Raymond J.] Edward J Hines Jr VA Hosp, Hines, IL USA.
[Joehl, Raymond J.] Loyola Univ, Med Ctr, Maywood, IL 60153 USA.
RP Brewster, LP (reprint author), Emory Univ Hosp, Dept Surg, 1364 Clifton Rd, Atlanta, GA 30022 USA.
EM lukebrewst@aol.com
RI Hall, Daniel/H-4843-2013
OI Hall, Daniel/0000-0001-6382-0522
NR 7
TC 2
Z9 2
U1 0
U2 0
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0022-4804
J9 J SURG RES
JI J. Surg. Res.
PD DEC
PY 2011
VL 171
IS 2
BP 395
EP 398
DI 10.1016/j.jss.2011.04.008
PG 4
WC Surgery
SC Surgery
GA 847FS
UT WOS:000296957900018
PM 21601880
ER
PT J
AU Hammer, GE
Turer, EE
Taylor, KE
Fang, CJ
Advincula, R
Oshima, S
Barrera, J
Huang, EJ
Hou, B
Malynn, BA
Reizis, B
DeFranco, A
Criswell, LA
Nakamura, MC
Ma, A
AF Hammer, Gianna Elena
Turer, Emre E.
Taylor, Kimberly E.
Fang, Celia J.
Advincula, Rommel
Oshima, Shigeru
Barrera, Julio
Huang, Eric J.
Hou, Baidong
Malynn, Barbara A.
Reizis, Boris
DeFranco, Anthony
Criswell, Lindsey A.
Nakamura, Mary C.
Ma, Averil
TI Expression of A20 by dendritic cells preserves immune homeostasis and
prevents colitis and spondyloarthritis
SO NATURE IMMUNOLOGY
LA English
DT Article
ID TOLL-LIKE RECEPTORS; NF-KAPPA-B; SYSTEMIC-LUPUS-ERYTHEMATOSUS;
PATTERN-RECOGNITION RECEPTORS; GENOME-WIDE ASSOCIATION; INFLAMMATORY
DISEASE; IN-VIVO; ANKYLOSING-SPONDYLITIS; PERIPHERAL TOLERANCE; ADAPTIVE
IMMUNITY
AB Dendritic cells (DCs), which are known to support immune activation during infection, may also regulate immune homeostasis in resting animals. Here we show that mice lacking the ubiquitin-editing molecule A20 specifically in DCs spontaneously showed DC activation and population expansion of activated T cells. Analysis of DC-specific epistasis in compound mice lacking both A20 and the signaling adaptor MyD88 specifically in DCs showed that A20 restricted both MyD88-independent signals, which drive activation of DCs and T cells, and MyD88-dependent signals, which drive population expansion of T cells. In addition, mice lacking A20 specifically in DCs spontaneously developed lymphocyte-dependent colitis, seronegative ankylosing arthritis and enthesitis, conditions stereotypical of human inflammatory bowel disease (IBD). Our findings indicate that DCs need A20 to preserve immune quiescence and suggest that A20-dependent DC functions may underlie IBD and IBD-associated arthritides.
C1 [Hammer, Gianna Elena; Turer, Emre E.; Taylor, Kimberly E.; Fang, Celia J.; Advincula, Rommel; Oshima, Shigeru; Barrera, Julio; Huang, Eric J.; Malynn, Barbara A.; Criswell, Lindsey A.; Nakamura, Mary C.; Ma, Averil] Univ Calif San Francisco, Dept Med, San Francisco, CA 94080 USA.
[Fang, Celia J.] San Francisco VA Med Ctr, San Francisco, CA USA.
[Huang, Eric J.; Nakamura, Mary C.] Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94140 USA.
[Huang, Eric J.; Nakamura, Mary C.] VA Med Ctr, Pathol Serv, San Francisco, CA USA.
[Hou, Baidong; DeFranco, Anthony] Univ Calif San Francisco, Dept Microbiol & Immunol, San Francisco, CA 94143 USA.
[Reizis, Boris] Columbia Univ, Dept Microbiol & Immunol, New York, NY USA.
RP Ma, A (reprint author), Univ Calif San Francisco, Dept Med, San Francisco, CA 94080 USA.
EM averil.ma@ucsf.edu
RI Oshima, Shigeru/C-9865-2015
OI Oshima, Shigeru/0000-0003-1186-9177; Huang, Eric/0000-0002-5381-3801;
Reizis, Boris/0000-0003-1140-7853
FU US National Institutes of Health; Crohn's and Colitis Foundation of
America; Damon Runyon Cancer Research Foundation; Kenneth Rainin
Foundation; UCSF Liver Center; Wellcome Trust [076113, 085475]
FX This work was supported by the US National Institutes of Health (A. M.),
The Crohn's and Colitis Foundation of America (A. M. and S.O.), The
Damon Runyon Cancer Research Foundation (G. E. H.), the Kenneth Rainin
Foundation and the UCSF Liver Center and the Wellcome Trust (076113 and
085475 to the Wellcome Trust Case-Control Consortium). A full list of
investigators who contributed to this work is available from the
Wellcome Trust Case-Control Consortium website.
NR 56
TC 102
Z9 104
U1 0
U2 15
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1529-2908
J9 NAT IMMUNOL
JI Nat. Immunol.
PD DEC
PY 2011
VL 12
IS 12
BP 1184
EP U77
DI 10.1038/ni.2135
PG 11
WC Immunology
SC Immunology
GA 850NT
UT WOS:000297202700013
PM 22019834
ER
PT J
AU Falowski, SM
Sharan, A
Reyes, BAS
Sikkema, C
Szot, P
Van Bockstaele, EJ
AF Falowski, Steven M.
Sharan, Ashwini
Reyes, Beverly A. S.
Sikkema, Carl
Szot, Patricia
Van Bockstaele, Elisabeth J.
TI An Evaluation of Neuroplasticity and Behavior After Deep Brain
Stimulation of the Nucleus Accumbens in an Animal Model of Depression
SO NEUROSURGERY
LA English
DT Article
DE DBS; Deep brain stimulation; Dendritic plasticity; Depression;
Neuroplasticity; Nucleus accumbens
ID MEDIAL PREFRONTAL CORTEX; WISTAR-KYOTO RATS; NEUROPSYCHIATRIC DISORDERS;
STRAIN DIFFERENCES; STRESS; SHELL; THALAMUS; ANTIDEPRESSANT;
EPIDEMIOLOGY; CONVERGENCE
AB BACKGROUND: Recent interest has demonstrated the nucleus accumbens (NAcc) as a potential target for the treatment of depression with deep brain stimulation (DBS).
OBJECTIVE: To demonstrate that DBS of the NAcc is an effective treatment modality for depression and that chemical and structural changes associated with these behavioral changes are markers of neuroplasticity.
METHODS: A deep brain stimulator was placed in the NAcc of male Wistar-Kyoto rats. Groups were divided into sham (no stimulation), intermittent (3 h/d for 2 weeks), or continuous (constant stimulation for 2 weeks). Exploratory and anxietylike behaviors were evaluated with the open-field test before and after stimulation. Tissue samples of the prefrontal cortex (PFC) were processed with Western blot analysis of markers of noradrenergic activity that included the noradrenergic synthesizing enzyme tyrosine hydroxylase. Analysis of tissue levels for catecholamines was achieved with high-performance liquid chromatography. Morphological properties of cortical pyramidal neurons were assessed with Golgi-Cox staining.
RESULTS: Subjects undergoing intermittent and continuous stimulation of the NAcc exhibited an increase in exploratory behavior and reduced anxietylike behaviors. Tyrosine hydroxylase expression levels were decreased in the PFC after intermittent and continuous DBS, and dopamine and norepinephrine levels were decreased after continuous stimulation. Golgi-Cox staining indicated that DBS increased the length of apical and basilar dendrites in pyramidal neurons of the PFC.
CONCLUSION: Deep brain stimulation induces behavioral improvement in and neurochemical and morphological alterations of the PFC that demonstrate changes within the circuitry of the brain different from the target area of stimulation. This observed dendritic plasticity may underlie the therapeutic efficacy of this treatment.
C1 [Falowski, Steven M.; Sharan, Ashwini] Thomas Jefferson Univ, Dept Neurosurg, Philadelphia, PA 19107 USA.
[Reyes, Beverly A. S.; Van Bockstaele, Elisabeth J.] Thomas Jefferson Univ, Dept Neurosci, Farber Inst Neurosci, Philadelphia, PA 19107 USA.
[Sikkema, Carl; Szot, Patricia] VA Puget Sound Hlth Care Syst, MIRECC, Seattle, WA USA.
RP Falowski, SM (reprint author), Thomas Jefferson Univ, Dept Neurosurg, 909 Walnut St, Philadelphia, PA 19107 USA.
EM sfalowski@gmail.com
FU NIDA NIH HHS [R01 DA009082]
NR 50
TC 29
Z9 30
U1 1
U2 8
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0148-396X
J9 NEUROSURGERY
JI Neurosurgery
PD DEC
PY 2011
VL 69
IS 6
BP 1281
EP 1290
DI 10.1227/NEU.0b013e3182237346
PG 10
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA 845AF
UT WOS:000296794500033
PM 21566538
ER
PT J
AU Chao, LDL
Abadjian, L
Hlavin, J
Meyerhoff, DJ
Weiner, MW
AF Chao, Linda L.
Abadjian, Linda
Hlavin, Jennifer
Meyerhoff, Deiter J.
Weiner, Michael W.
TI Effects of low-level sarin and cyclosarin exposure and Gulf War Illness
on Brain Structure and Function: A study at 4 T
SO NEUROTOXICOLOGY
LA English
DT Article
DE Magnetic resonance imaging; Morphometric analysis; Brain; Central
nervous system; Cognitive functioning; Chemical warfare agents; Sarin;
Cyclosarin; Gulf War veterans
ID US ARMY VETERANS; NEUROBEHAVIORAL DEFICITS; PARKINSONS-DISEASE;
RISK-FACTORS; MULTISYMPTOM ILLNESS; ALZHEIMER-DISEASE; MR SPECTROSCOPY;
INJURY; KHAMISIYAH; DEMENTIA
AB Background: More than 100,000 US troops were potentially exposed to chemical warfare agents sarin (GB) and cyclosarin (GF) when an ammunition dump at Khamisiyah, Iraq was destroyed during the 1991 Persian Gulf War (GW). We previously found reduced total gray matter (GM) volume in 40 GW veterans with suspected GB/GF exposure relative to 40 matched, unexposed GW veterans on a 1.5 T MR scanner. In this study, we reexamine the relationship between GB/GF exposure and volumetric measurements of gross neuroanatomical structures in a different cohort of GW veterans on a 4 T MR scanner.
Methods: Neuropsychological and magnetic resonance imaging (MRI) data from a cross sectional study on Gulf War Illness performed between 2005 and 2010 were used in this study. 4T MRI data were analyzed using automated image processing techniques that produced volumetric measurements of gray matter (GM), white matter (WM) and cerebrospinal fluid (CSF).
Results: Binary comparisons of 64 GB/GF exposed veterans and 64 'matched', unexposed veterans revealed reduced GM (p = 0.03) and WM (p = 0.03) volumes in the exposed veterans. Behaviorally, exposed veterans committed more errors of omission (p = 0.02) and tended to have slower responses (p = 0.05) than unexposed veterans on the Continuous Performance Test (CPT), a measure sustained and selective attention. Regression analyses confirmed that GB/GF exposure status predicted GM (beta = -0.11, p = 0.02) and WM (beta = -0.14, p = 0.03) volumes, and number of CPT omission errors (beta = 0.22, p = 0.02) over and above potentially confounding demographic, clinical, and psychosocial variables. There was no dose-response relationship between estimated levels of GB/GF exposure and brain volume. However, we did find an effect of Gulf War Illness/Chronic Mulitsymptom Illness on both GM and WM volume in the GB/GF exposed veterans.
Conclusions: These findings confirm previous reports by our group and others of central nervous system pathology in GW veterans with suspected exposure to low levels of GB/GF two decades after the exposure. (C) 2011 Elsevier Inc. All rights reserved.
C1 [Chao, Linda L.; Abadjian, Linda; Hlavin, Jennifer; Meyerhoff, Deiter J.; Weiner, Michael W.] San Francisco VA Med Ctr, Ctr Imaging Neurodegenerat Dis, San Francisco, CA USA.
[Chao, Linda L.; Weiner, Michael W.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA.
[Chao, Linda L.; Meyerhoff, Deiter J.; Weiner, Michael W.] Univ Calif San Francisco, Dept Radiol & Biomed Imaging, San Francisco, CA 94143 USA.
RP Chao, LDL (reprint author), 4150 Clement St,114M, San Francisco, CA 94121 USA.
EM linda.chao@ucsf.edu
FU NIH/NCRR UCSF-CTSI [UL1 RR024131]; Department of Defense
[DAMD17-01-1-0764]; US Army Medical Research and Materiel Command and a
Department of Veterans Affairs [B3776]; Department of Veteran's Affairs
FX This publication was supported by NIH/NCRR UCSF-CTSI Grant Number UL1
RR024131. Its contents are solely the responsibility of the authors and
do not necessarily represent the official views of the NIH. This study
was also supported by Department of Defense grant DAMD17-01-1-0764
entitled 'Magnetic Resonance and Spectroscopy of the Human Brain in Gulf
War Illness', awarded to the Northern California Institute for Research
and Education from the Department of Defense Gulf War Illnesses Research
Program, US Army Medical Research and Materiel Command and a Department
of Veterans Affairs grant VA GWI No. B3776 entitled 'Effects of Gulf War
Illness on Brain Structure Function and Metabolism: MRI/MRS at 4 T',
awarded to Dr. Michael Weiner. This material is the result of work
supported with resources and the use of facilities at the San Francisco
Veterans Affairs Medical Center. The authors acknowledge Col. Karl
Friedl, US Army Medical Research and Materiel Command, Derek Flenniken
for managing the database, Diana Truran Sacrey and her staff for
scanning the subjects and processing the MRI data, Larry Sippos,
Executive Officer to the Deputy Assistant Secretary of Defense for Force
Health Protection and Readiness for providing information about the
presence or absence of the research participants' units in the modeled
hazard areas and the cumulative estimated GB/GF exposure levels, and the
Gulf War veterans who participated in these studies.; The opinions or
assertions contained herein are the private views of the author(s) and
are not to be construed as official or reflecting the views of the Army,
Department of Defense, or Department of Veterans Affairs. Drs. Chao,
Meyerhoff, and Weiner have received grant support from the Department of
Defense and Dr. Weiner receives grant support from the Department of
Veteran's Affairs.
NR 49
TC 19
Z9 19
U1 2
U2 12
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0161-813X
J9 NEUROTOXICOLOGY
JI Neurotoxicology
PD DEC
PY 2011
VL 32
IS 6
BP 814
EP 822
DI 10.1016/j.neuro.2011.06.006
PG 9
WC Neurosciences; Pharmacology & Pharmacy; Toxicology
SC Neurosciences & Neurology; Pharmacology & Pharmacy; Toxicology
GA 847VK
UT WOS:000297000400016
PM 21741405
ER
PT J
AU Eagan, MJ
Bluth, BE
Zhao, KW
Brinkmann, EJ
Wu, BM
McAllister, DR
AF Eagan, Michael J.
Bluth, Benjamin E.
Zhao, Ke-Wei
Brinkmann, Elyse J.
Wu, Benjamin M.
McAllister, David R.
TI The Effect of Growth and Differentiation Factor-5 on Two-Dimensional
Cultures of Mouse Bone Marrow Stromal Cells
SO JOURNAL OF BIOMATERIALS AND TISSUE ENGINEERING
LA English
DT Article
DE GDF-5; Ligament Engineering; BMSCs; ACL
ID ANTERIOR CRUCIATE LIGAMENT; MESENCHYMAL STEM-CELLS; MEDIAL COLLATERAL
LIGAMENT; TGF-BETA-SUPERFAMILY; ACHILLES-TENDON; IN-VITRO; SILK
SCAFFOLD; RABBIT MODEL; YOUNG-ADULTS; FIBROBLASTS
AB Rupture of the anterior cruciate ligament (ACL) is one of the most common sports-related injuries. However, with its poor healing capacity, surgical reconstruction is currently required to restore its function. Due to serious complications associated with these reconstructions, the use of tissue engineering as an alternative has grown in appeal. Engineering approaches using ligament-derived fibroblasts have been promising but their slow growth rate may limit their practical application. More promising results have been being achieved using stem cells, in combination with appropriate growth factors. As a growth factor, GDF-5 has been shown to play a role in ligament and tendon formation, while bone marrow stem cells have shown promise in their repair. Combining these two parameters, previous work by our group has shown that a combination of GDF-5 and bone marrow stem cells in a 3D environment results in increased expression of several ligament tissue markers. In this study, we continue this work to explore if a dose-response relationship exists between GDF-5 and the stem cell. For this, murine bone marrow stem cells (D1 cells) were exposed to increasing doses of GDF-5 in a standard monolayer culture system and the expression of several ligament genes quantified. In contrast to our previous 3D system, exposing D1 cells to increasing doses of GDF-5 in a 2D culture system did not significantly affect the expression of these markers. Therefore, a more appropriate system for determining the effect of growth factors on stem cells may be a 3D culture system.
C1 [Eagan, Michael J.; McAllister, David R.] Univ Calif Los Angeles, David Geffen Sch Med, Ctr Hlth Sci, Dept Orthopaed Surg, Los Angeles, CA 90095 USA.
[Bluth, Benjamin E.; Brinkmann, Elyse J.] Univ Calif Los Angeles, David Geffen Sch Med, Div Plast Surg, Dept Surg,Ctr Hlth Sci, Los Angeles, CA 90095 USA.
[Zhao, Ke-Wei; McAllister, David R.] VA Greater Los Angeles Healthcare Syst, W Los Angeles Healthcare Ctr, Orthopaed Tissue Engn Lab Los Angeles, Los Angeles, CA 90073 USA.
[Brinkmann, Elyse J.; Wu, Benjamin M.] Univ Calif Los Angeles, Henry Samueli Sch Engn & Appl Sci, Dept Biomed Engn, Los Angeles, CA 90095 USA.
RP McAllister, DR (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Ctr Hlth Sci, Dept Orthopaed Surg, Los Angeles, CA 90095 USA.
FU VA Rehabilitation RRD
FX This study was supported by a VA Rehabilitation RR&D grant.
NR 40
TC 1
Z9 1
U1 0
U2 2
PU AMER SCIENTIFIC PUBLISHERS
PI VALENCIA
PA 26650 THE OLD RD, STE 208, VALENCIA, CA 91381-0751 USA
SN 2157-9083
J9 J BIOMATER TISS ENG
JI J. Biomater. Tissue Eng.
PD DEC
PY 2011
VL 1
IS 2
BP 210
EP 214
DI 10.1166/jbt.2011.1025
PG 5
WC Cell & Tissue Engineering
SC Cell Biology
GA 057NP
UT WOS:000312570600010
ER
PT J
AU Singh, H
Classen, DC
Sittig, DF
AF Singh, Hardeep
Classen, David C.
Sittig, Dean F.
TI Creating an Oversight Infrastructure for Electronic Health
Record-Related Patient Safety Hazards
SO JOURNAL OF PATIENT SAFETY
LA English
DT Article
DE electronic health record; patient safety; surveillance
AB Electronic health records (EHRs) have potential quality and safety benefits. However, reports of EHR-related safety hazards are now emerging. The Office of the National Coordinator for Health Information Technology recently sponsored an Institute of Medicine committee to evaluate how health information technology use affects patient safety. In this article, we propose the creation of a national EHR oversight program to provide dedicated surveillance of EHR-related safety hazards and to promote learning from identified errors, close calls, and adverse events. The program calls for data gathering, investigation/analysis, and regulatory components. The first 2 functions will depend on institution-level EHR safety committees that will investigate all known EHR-related adverse events and near-misses and report them nationally using standardized methods. These committees should also perform routine safety self-assessments to proactively identify new risks. Nationally, we propose the long-term creation of a centralized, nonpartisan board with an appropriate legal and regulatory infrastructure to ensure the safety of EHRs. We discuss the rationale of the proposed oversight program and its potential organizational components and functions. These include mechanisms for robust data collection and analyses of all safety concerns using multiple methods that extend beyond reporting, multidisciplinary investigation of selected high-risk safety events, and enhanced coordination with other national agencies to facilitate broad dissemination of hazards information. Implementation of this proposed infrastructure can facilitate identification of EHR-related adverse events and errors and potentially create a safer and more effective EHR-based health care delivery system.
C1 [Singh, Hardeep] Houston VA Hlth Serv Res & Dev Ctr Excellence, Houston, TX USA.
[Singh, Hardeep] Baylor Coll Med, Houston VA Patient Safety Ctr Inquiry, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA.
[Singh, Hardeep] Baylor Coll Med, Dept Med, Sect Hlth Serv Res, Houston, TX 77030 USA.
[Classen, David C.] Univ Utah, Salt Lake City, UT USA.
[Classen, David C.] CSC, Salt Lake City, UT USA.
[Sittig, Dean F.] Univ Texas Hlth Sci Ctr, Sch Biomed Informat, Univ Texas Mem Hermann Ctr Healthcare Qual & Safe, Houston, TX USA.
RP Sittig, DF (reprint author), Univ Texas Sch Hlth Informat Sci Houston, UT Mem Hermann Ctr Healthcare Qual & Safety, 6410 Fannin St,UTPB 1100-13, Houston, TX 77030 USA.
EM Dean.F.Sittig@uth.tmc.edu
FU National Institutes of Health K23 career development award
[K23CA125585]; VA National Center of Patient Safety, Agency for Health
Care Research and Quality; Office of the National Coordinator for Health
Information Technology (ONC) [10510592]; Houston VA Health Services
Research and Development Service Center of Excellence [HFP90-020];
National Library of Medicine [R01-LM006942]
FX Dr Singh is supported by a National Institutes of Health K23 career
development award (K23CA125585), the VA National Center of Patient
Safety, Agency for Health Care Research and Quality, a SHARP contract
from the Office of the National Coordinator for Health Information
Technology (ONC no. 10510592), and in part by the Houston VA Health
Services Research and Development Service Center of Excellence
(HFP90-020). Dr Sittig is supported in part by a grant from the National
Library of Medicine R01-LM006942 and by a SHARP contract from the Office
of the National Coordinator for Health Information Technology (ONC no.
10510592). Dr Classen is an employee of CSC, a technology services
company. These sources had no role in the preparation, review, or
approval of the article.
NR 72
TC 17
Z9 17
U1 1
U2 9
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1549-8417
J9 J PATIENT SAF
JI J. Patient Saf.
PD DEC
PY 2011
VL 7
IS 4
BP 169
EP 174
DI 10.1097/PTS.0b013e31823d8df0
PG 6
WC Health Care Sciences & Services; Health Policy & Services
SC Health Care Sciences & Services
GA V27KQ
UT WOS:000208612500001
PM 22080284
ER
PT J
AU Lyles, CR
Karter, AJ
Young, BA
Spigner, C
Grembowski, D
Schillinger, D
Adler, N
AF Lyles, Courtney R.
Karter, Andrew J.
Young, Bessie A.
Spigner, Clarence
Grembowski, David
Schillinger, Dean
Adler, Nancy
TI Provider factors and patient-reported healthcare discrimination in the
Diabetes Study of California (DISTANCE)
SO PATIENT EDUCATION AND COUNSELING
LA English
DT Article
DE Race/ethnicity; Discrimination; Provider factors; Diabetes care; Managed
care
AB Objective: We examined provider-level factors and reported discrimination in the healthcare setting.
Methods: With data from the Diabetes Study of Northern California (DISTANCE) - a race-stratified survey of diabetes patients in Kaiser Permanente Northern California - we analyzed patient-reported racial/ethnic discrimination from providers. Primary exposures were characteristics of the primary care provider (PCP, who coordinates care in this system), including specialty/type, and patient-provider relationship variables, including racial concordance.
Results: Subjects (n = 12,151) included 20% black, 20% Latino, 23% Asian, 30% white, and 6% other patients, with 2-8% reporting discrimination by racial/ethnic group. Patients seeing nurse practitioners as their PCP (OR = 0.09; 95% CI: 0.01-0.67) and those rating their provider higher on communication (OR = 0.70; 95% CI: 0.66-0.74) were less likely to report discrimination, while those with more visits (OR = 1.10; 95% CI: 1.03-1.18) were more likely to report discrimination. Racial concordance was not significant once adjusting for patient race/ethnicity.
Conclusions: Among diverse diabetes patients in managed care, provider type and communication were significantly related to patient-reported discrimination.
Practice implications: Given potential negative impacts on patient satisfaction and treatment decisions, future studies should investigate which interpersonal aspects of the provider-patient relationship reduce patient perceptions of unfair treatment. (C) 2011 Elsevier Ireland Ltd. All rights reserved.
C1 [Lyles, Courtney R.; Karter, Andrew J.; Young, Bessie A.; Spigner, Clarence; Grembowski, David] Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA.
[Karter, Andrew J.] Kaiser Permanente No Calif, Div Res, Oakland, CA USA.
[Young, Bessie A.] VA Puget Sound Hlth Care Syst, Seattle, WA USA.
[Schillinger, Dean; Adler, Nancy] UCSF, Dept Med Psychol, San Francisco, CA USA.
[Schillinger, Dean; Adler, Nancy] UCSF, Dept Psychiat, San Francisco, CA USA.
[Schillinger, Dean; Adler, Nancy] UCSF, Dept Pediat, San Francisco, CA USA.
[Schillinger, Dean] UCSF, Dept Med, San Francisco, CA USA.
[Schillinger, Dean] San Francisco Gen Hosp, Ctr Vulnerable Populat, San Francisco, CA 94110 USA.
RP Lyles, CR (reprint author), Univ Washington, Sch Publ Hlth, Dept Hlth Serv, Box 359455, Seattle, WA 98195 USA.
EM crees@u.washington.edu
FU National Research Service Award from the Agency for Healthcare Research
and Quality [HS013853]; National Institute of Diabetes, Digestive and
Kidney Diseases [R01 DK65664]; National Institute of Child Health and
Human Development [R01 HD46113]
FX This project was supported by a National Research Service Award, grant
number HS013853 from the Agency for Healthcare Research and Quality, and
funds were provided by National Institute of Diabetes, Digestive and
Kidney Diseases R01 DK65664 and National Institute of Child Health and
Human Development R01 HD46113. None of the authors had conflicts of
interest, and the funders had no role in the design and conduct of the
study; collection, management, analysis, or interpretation of the data;
or preparation, review, or approval of the manuscript.
NR 64
TC 7
Z9 7
U1 1
U2 2
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
IRELAND
SN 0738-3991
J9 PATIENT EDUC COUNS
JI Patient Educ. Couns.
PD DEC
PY 2011
VL 85
IS 3
BP E216
EP E224
DI 10.1016/j.pec.2011.04.031
PG 9
WC Public, Environmental & Occupational Health; Social Sciences,
Interdisciplinary
SC Public, Environmental & Occupational Health; Social Sciences - Other
Topics
GA V41JR
UT WOS:000209543000007
PM 21605956
ER
PT J
AU Saha, S
Sanders, DS
Korthuis, PT
Cohn, JA
Sharp, VL
Haidet, P
Moore, RD
Beach, MC
AF Saha, Somnath
Sanders, David S.
Korthuis, Philip Todd
Cohn, Jonathan A.
Sharp, Victoria L.
Haidet, Paul
Moore, Richard D.
Beach, Mary Catherine
TI The role of cultural distance between patient and provider in explaining
racial/ethnic disparities in HIV care
SO PATIENT EDUCATION AND COUNSELING
LA English
DT Article
DE Physician-patient relations; Culture; HIV
AB Objective: We sought to evaluate whether cultural distance between patients and providers was associated with quality of care for people living with HIV/AIDS, and whether cultural distance helped explain racial/ethnic disparities in HIV care.
Methods: We surveyed 437 patients and 45 providers at 4 HIV clinics in the U.S. We examined the association of patients' perceived cultural distance from their providers with patient ratings of healthcare quality, trust in provider, receipt of antiretroviral therapy, medication adherence, and viral suppression. We also examined whether racial/ethnic disparities in these aspects of HIV care were mediated by cultural distance.
Results: Greater cultural distance was associated with lower patient ratings of healthcare quality and less trust in providers. Compared to white patients, nonwhites had significantly lower levels of trust, adherence, and viral suppression. Adjusting for patient-provider cultural distance did not significantly affect any of these disparities (p-values for mediation >.10).
Conclusion: Patient-provider cultural distance was negatively associated with perceived quality of care and trust but did not explain racial/ethnic disparities in HIV care.
Practice implications: Bridging cultural differences may improve patient-provider relationships but may have limited impact in reducing racial/ethnic disparities, unless coupled with efforts to address other sources of unequal care. Published by Elsevier Ireland Ltd.
C1 [Saha, Somnath] Portland VA Med Ctr, Gen Internal Med Sect, Portland, OR 97239 USA.
[Saha, Somnath; Korthuis, Philip Todd] Oregon Hlth & Sci Univ, Div Gen Internal Med & Geriatr, Portland, OR 97201 USA.
[Sanders, David S.] Oregon Hlth & Sci Univ, Sch Med, Portland, OR 97201 USA.
[Cohn, Jonathan A.] Wayne State Univ, Dept Med, Detroit, MI 48202 USA.
[Sharp, Victoria L.] St Lukes Roosevelt Hosp, Ctr Comprehens Care, New York, NY USA.
[Haidet, Paul] Penn State Univ, Coll Med, Hershey, PA USA.
[Moore, Richard D.; Beach, Mary Catherine] Johns Hopkins Univ, Dept Med, Baltimore, MD USA.
RP Saha, S (reprint author), Portland VA Med Ctr, Gen Internal Med Sect, 3710 SW US Vet Hosp Rd P3HSRD, Portland, OR 97239 USA.
EM sahas@ohsu.edu
FU Agency for Healthcare Research and Quality [AHRQ 290-01-0012, K08
HS013903-05]; Robert Wood Johnson Foundation Generalist Physician
Faculty Scholar Awards; National Institute on Drug Abuse [K23DA019809];
Department of Veterans Affairs
FX This research was supported by a contract from the Agency for Healthcare
Research and Quality (AHRQ 290-01-0012). Dr. Beach was supported by the
Agency for Healthcare Research and Quality (K08 HS013903-05) and both
Drs. Beach and Saha were supported by Robert Wood Johnson Foundation
Generalist Physician Faculty Scholar Awards. Dr. Korthuis was supported
by the National Institute on Drug Abuse (K23DA019809). Dr. Saha was
supported by the Department of Veterans Affairs.
NR 39
TC 21
Z9 21
U1 2
U2 2
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
IRELAND
SN 0738-3991
J9 PATIENT EDUC COUNS
JI Patient Educ. Couns.
PD DEC
PY 2011
VL 85
IS 3
BP E278
EP E284
DI 10.1016/j.pec.2011.01.012
PG 7
WC Public, Environmental & Occupational Health; Social Sciences,
Interdisciplinary
SC Public, Environmental & Occupational Health; Social Sciences - Other
Topics
GA V41JR
UT WOS:000209543000016
PM 21310581
ER
PT J
AU Vick, CC
Graham, LA
Henderson, WG
Houston, TK
Hawn, MT
AF Vick, Catherine C.
Graham, Laura A.
Henderson, William G.
Houston, Thomas K., II
Hawn, Mary T.
TI Translating preoperative smoking cessation interventions into routine
clinical care of veterans: provider beliefs
SO TRANSLATIONAL BEHAVIORAL MEDICINE
LA English
DT Article
DE Smoking cessation; Counseling; Preoperative; Advise; Assess;
Postoperative surgical complications; Primary care clinic; Anesthesia;
Smoking status
AB Smoking among veterans undergoing surgery is estimated to be 36%. Smoking has been linked to postoperative surgical complications including ischemia and cardiac arrhythmias, pneumonia, deep venous thrombosis, pulmonary embolism, and surgical site infection. Preoperative smoking cessation interventions, in which smokers quit at least 6weeks prior to surgery, have been shown to be effective both in smoking cessation and reduction of postoperative complications; however, little is known about physician beliefs regarding the optimal location and the responsible provider for intervention, or whether surgery should be postponed or delayed based on smoking status. Within the routine coordination from medical to surgical care, how should cessation interventions best be implemented? To better inform the translation of preoperative best practices for smoking cessation into clinical care in VA, a survey regarding preoperative smoking cessation beliefs and practices was administered to primary care physicians, surgeons, and anesthesia providers. Chi-square tests were used to examine differences in proportions by provider type. Most providers agreed that the primary care clinic is the best location for intervention, with preoperative and surgical clinics ranked by few as the optimal location (13% and 11%, respectively); most respondents (82%) reported that they would refuse or delay surgery in some cases based on smoking status. There were no differences in either beliefs on location or delay based on provider type. Primary care providers were most likely to advise (86.7%) and assess (80.0%) while anesthesia providers were least likely (59.1% and 22.7%, respectively). Taking time to counsel and the belief that dedicated resources would improve quit rates were associated with advising patients to quit smoking, while being uncomfortable with counseling, the belief that acute health takes precedence and the belief that there is not always time to counsel were identified as barriers to assessing patients for smoking cessation intervention. Primary care providers were more optimistic (100%) that patients would quit if counseled, more often (73.3%) reported having time to counsel, and were less likely to report that acute health takes precedence. Most providers believe that smoking cessation would reduce postoperative complications, with the ideal location for the intervention being the primary care clinic, and that some surgical cases should be delayed for this intervention.
C1 [Vick, Catherine C.; Graham, Laura A.; Hawn, Mary T.] Birmingham VAMC, Ctr Surg Med Acute Care Res & Transit, Birmingham, AL 35233 USA.
[Henderson, William G.] Univ Colorado, Hlth Outcomes Program, Aurora, CO USA.
[Houston, Thomas K., II] Bedford VAMC, VA eHlth Qual Enhancement Res Initiat, Bedford, MA USA.
[Houston, Thomas K., II] Univ Massachusetts, Sch Med, Div Hlth Informat & Implementat Sci Quantitat Hlt, Worcester, MA USA.
[Hawn, Mary T.] Univ Alabama Birmingham, Sch Med, Dept Surg, Sect Gastrointestinal Surg, Birmingham, AL 35294 USA.
RP Vick, CC (reprint author), Birmingham VAMC, Ctr Surg Med Acute Care Res & Transit, Birmingham, AL 35233 USA.
EM catherine.vick@va.gov
FU United States Department of Veterans' Affairs Health Services Research
and Development grant [IAB 06-038]
FX The authors would like to acknowledge Heather Coley, MPH, for assistance
in development of the survey instrument and data collection. The authors
would like to acknowledge Jasvinder Singh, MD, for critical revision of
the manuscript. This research was funded by the United States Department
of Veterans' Affairs Health Services Research and Development grant IAB
06-038.
NR 25
TC 2
Z9 2
U1 1
U2 2
PU SPRINGER INTERNATIONAL PUBLISHING AG
PI CHAM
PA GEWERBESTRASSE 11, CHAM, CH-6330, SWITZERLAND
SN 1869-6716
EI 1613-9860
J9 TRANSL BEHAV MED
JI Transl. Behav. Med.
PD DEC
PY 2011
VL 1
IS 4
BP 604
EP 608
DI 10.1007/s13142-011-0096-1
PG 5
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA V39LJ
UT WOS:000209412200016
PM 24073083
ER
PT J
AU Tafti, BA
Shaba, W
Li, YX
Yevdayev, E
Berenji, GR
Glass, E
AF Tafti, Bashir Akhavan
Shaba, Wisam
Li, Yuxin
Yevdayev, Ella
Berenji, Gholam Reza
Glass, Edwin
TI Detection of a Sinus of Valsalva Aneurysm by F-18 FDG PET/CT Imaging
SO CLINICAL NUCLEAR MEDICINE
LA English
DT Editorial Material
DE sinus of Valsalva; aneurysm; positron emission tomography/CT
AB An echocardiographic examination performed on a 72-year-old man for assessment of left ventricular hypertrophy revealed a right atrial mass, approximately 4 cm in size, attached to the interatrial septum. Given his history of leiomyosarcoma with vascular invasion, the patient was referred for PET/CT to assess the possibility of metastatic involvement. The results suggested an aneurysmal mass of the aortic noncoronary cusp consistent with a sinus of Valsalva aneurysm. A subsequent CT angiogram and surgery confirmed the diagnosis. To the best of our knowledge, this is the first reported case of a sinus of Valsalva aneurysm detected in PET/CT images.
C1 [Tafti, Bashir Akhavan; Shaba, Wisam; Li, Yuxin; Yevdayev, Ella; Berenji, Gholam Reza; Glass, Edwin] Vet Adm Greater Los Angeles Hlth Care Syst, Nucl Med Sect, Dept Radiol, Los Angeles, CA 90073 USA.
RP Glass, E (reprint author), Vet Adm Greater Los Angeles Hlth Care Syst, Nucl Med Sect, Dept Radiol, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA.
EM edwin.glass@va.gov
NR 11
TC 0
Z9 0
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0363-9762
J9 CLIN NUCL MED
JI Clin. Nucl. Med.
PD DEC
PY 2011
VL 36
IS 12
BP 1144
EP 1145
DI 10.1097/RLU.0b013e3182335f4d
PG 2
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA 845BC
UT WOS:000296796800040
PM 22064097
ER
PT J
AU Guyatt, GH
Oxman, AD
Kunz, R
Woodcock, J
Brozek, J
Helfand, M
Alonso-Coello, P
Glasziou, P
Jaeschke, R
Akl, EA
Norris, S
Vist, G
Dahm, P
Shukla, VK
Higgins, J
Falck-Ytter, Y
Schunemann, HJ
AF Guyatt, Gordon H.
Oxman, Andrew D.
Kunz, Regina
Woodcock, James
Brozek, Jan
Helfand, Mark
Alonso-Coello, Pablo
Glasziou, Paul
Jaeschke, Roman
Akl, Elie A.
Norris, Susan
Vist, Gunn
Dahm, Philipp
Shukla, Vijay K.
Higgins, Julian
Falck-Ytter, Yngve
Schuenemann, Holger J.
CA GRADE Working Grp
TI GRADE guidelines: 7. Rating the quality of evidence-inconsistency
SO JOURNAL OF CLINICAL EPIDEMIOLOGY
LA English
DT Article
DE GRADE; Inconsistency; Heterogeneity; Variability; Sub-group analysis;
Interaction
ID CLINICAL-TRIALS; METAANALYSIS; EPINEPHRINE; VASOPRESSIN
AB This article deals with inconsistency of relative (rather than absolute) treatment effects in binary/dichotomous outcomes. A body of evidence is not rated up in quality if studies yield consistent results, but may be rated down in quality if inconsistent. Criteria for evaluating consistency include similarity of point estimates, extent of overlap of confidence intervals, and statistical criteria including tests of heterogeneity and I(2). To explore heterogeneity, systematic review authors should generate and test a small number of a priori hypotheses related to patients, interventions, outcomes, and methodology. When inconsistency is large and unexplained, rating down quality for inconsistency is appropriate, particularly if some studies suggest substantial benefit, and others no effect or harm (rather than only large vs. small effects).
Apparent subgroup effects may be spurious. Credibility is increased if subgroup effects are based on a small number of a priori hypotheses with a specified direction; subgroup comparisons come from within rather than between studies; tests of interaction generate low P-values; and have a biological rationale. (C) 2011 Elsevier Inc. All rights reserved.
C1 [Guyatt, Gordon H.] McMaster Univ, Dept Clin Epidemiol & Biostat, CLARITY Res Grp, W Hamilton, ON L8N 3Z5, Canada.
[Guyatt, Gordon H.; Jaeschke, Roman; Schuenemann, Holger J.] McMaster Univ, Dept Med, W Hamilton, ON L8N 3Z5, Canada.
[Oxman, Andrew D.; Vist, Gunn] Norwegian Knowledge Ctr Hlth Serv, N-0130 Oslo, Norway.
[Kunz, Regina] Univ Basel Hosp, Basel Inst Clin Epidemiol, CH-4031 Basel, Switzerland.
[Woodcock, James] London Sch Hyg & Trop Med, London WC1, England.
[Helfand, Mark] Oregon Hlth & Sci Univ, Portland VA Med Ctr, Oregon Evidence Based Practice Ctr, Portland, OR 97201 USA.
[Alonso-Coello, Pablo] Univ Autonoma Barcelona, Serv Epidemiol Clin & Salud Publ, Iberoamer Cochrane Ctr, Barcelona 08041, Spain.
[Alonso-Coello, Pablo] Univ Autonoma Barcelona, Hosp St Pau, CIBERESP, Barcelona 08041, Spain.
[Glasziou, Paul] Bond Univ, Fac Hlth Sci, Ctr Res Evidence Based Practice, Gold Coast, Qld 4229, Australia.
[Akl, Elie A.] SUNY Buffalo, Dept Med, Buffalo, NY 14260 USA.
[Norris, Susan] Oregon Hlth & Sci Univ, Dept Med Informat & Clin Epidemiol, Portland, OR 97239 USA.
[Dahm, Philipp] Univ Florida, Coll Med, Dept Urol, Gainesville, FL USA.
[Shukla, Vijay K.] CADTH, Ottawa, ON K1S 5S8, Canada.
[Higgins, Julian] MRC Biostat Unit, Cambridge, England.
[Falck-Ytter, Yngve] Case Western Reserve Univ, Div Gastroenterol, Case Med Ctr & VA, Cleveland, OH 44106 USA.
RP Guyatt, GH (reprint author), McMaster Univ, Dept Clin Epidemiol & Biostat, CLARITY Res Grp, Room 2C12,1200 Main St, W Hamilton, ON L8N 3Z5, Canada.
EM guyatt@mcmaster.ca
RI Higgins, Julian/H-4008-2011; Glasziou, Paul/A-7832-2008
OI Higgins, Julian/0000-0002-8323-2514; Glasziou, Paul/0000-0001-7564-073X
FU Medical Research Council [MC_U105285807]
NR 18
TC 492
Z9 505
U1 4
U2 18
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0895-4356
J9 J CLIN EPIDEMIOL
JI J. Clin. Epidemiol.
PD DEC
PY 2011
VL 64
IS 12
BP 1294
EP 1302
DI 10.1016/j.jclinepi.2011.03.017
PG 9
WC Health Care Sciences & Services; Public, Environmental & Occupational
Health
SC Health Care Sciences & Services; Public, Environmental & Occupational
Health
GA 847TI
UT WOS:000296995000007
PM 21803546
ER
PT J
AU Guyatt, GH
Oxman, AD
Kunz, R
Woodcock, J
Brozek, J
Helfand, M
Alonso-Coello, P
Falck-Ytter, Y
Jaeschke, R
Vist, G
Akl, EA
Post, PN
Norris, S
Meerpohl, J
Shukla, VK
Nasser, M
Schunemann, HJ
AF Guyatt, Gordon H.
Oxman, Andrew D.
Kunz, Regina
Woodcock, James
Brozek, Jan
Helfand, Mark
Alonso-Coello, Pablo
Falck-Ytter, Yngve
Jaeschke, Roman
Vist, Gunn
Akl, Elie A.
Post, Piet N.
Norris, Susan
Meerpohl, Joerg
Shukla, Vijay K.
Nasser, Mona
Schuenemann, Holger J.
CA GRADE Working Group
TI GRADE guidelines: 8. Rating the quality of evidence-indirectness
SO JOURNAL OF CLINICAL EPIDEMIOLOGY
LA English
DT Article
DE GRADE; Quality of evidence; Indirectness; Indirect comparisons;
Applicability; Generalizability
ID RANDOMIZED CONTROLLED-TRIALS; METAANALYSIS; INTERVENTIONS; THERAPY;
CANCER
AB Direct evidence comes from research that directly compares the interventions in which we are interested when applied to the populations in which we are interested and measures outcomes important to patients. Evidence can be indirect in one of four ways. First, patients may differ from those of interest (the term applicability is often used for this form of indirectness). Secondly, the intervention tested may differ from the intervention of interest. Decisions regarding indirectness of patients and interventions depend on an understanding of whether biological or social factors are sufficiently different that one might expect substantial differences in the magnitude of effect.
Thirdly, outcomes may differ from those of primary interest-for instance, surrogate outcomes that are not themselves important, but measured in the presumption that changes in the surrogate reflect changes in an outcome important to patients.
A fourth type of indirectness, conceptually different from the first three, occurs when clinicians must choose between interventions that have not been tested in head-to-head comparisons. Making comparisons between treatments under these circumstances requires specific statistical methods and will be rated down in quality one or two levels depending on the extent of differences between the patient populations, co-interventions, measurements of the outcome, and the methods of the trials of the candidate interventions. (C) 2011 Elsevier Inc. All rights reserved.
C1 [Guyatt, Gordon H.] McMaster Univ, Dept Clin Epidemiol & Biostat, CLARITY Res Grp, W Hamilton, ON L8N 3Z5, Canada.
[Guyatt, Gordon H.; Jaeschke, Roman; Schuenemann, Holger J.] McMaster Univ, Dept Med, W Hamilton, ON L8N 3Z5, Canada.
[Oxman, Andrew D.; Vist, Gunn] Norwegian Knowledge Ctr Hlth Serv, N-0130 Oslo, Norway.
[Kunz, Regina] Univ Basel Hosp, Acad Swiss Insurance Med, CH-4031 Basel, Switzerland.
[Kunz, Regina] Univ Basel Hosp, Basel Inst Clin Epidemiol, CH-4031 Basel, Switzerland.
[Woodcock, James] London Sch Hyg & Trop Med, London WC1, England.
[Helfand, Mark] Oregon Hlth & Sci Univ, Portland VA Med Ctr, Oregon Evidence Based Practice Ctr, Portland, OR 97201 USA.
[Alonso-Coello, Pablo] Univ Autonoma Barcelona, Iberoamer Cochrane Ctr, Serv Epidemiol Clin & Salud Publ, Barcelona 08041, Spain.
[Alonso-Coello, Pablo] Univ Autonoma Barcelona, Hosp St Pau, CIBERESP, Barcelona 08041, Spain.
[Falck-Ytter, Yngve] Case Western Reserve Univ, Case & VA Med Ctr, Div Gastroenterol, Cleveland, OH 44106 USA.
[Falck-Ytter, Yngve] Univ Oxford, Oxford, England.
[Akl, Elie A.] SUNY Buffalo, Dept Med, Buffalo, NY 14260 USA.
[Post, Piet N.] Dutch Inst Healthcare Improvement CBO, Utrecht, Netherlands.
[Norris, Susan] Oregon Hlth & Sci Univ, Dept Med Informat & Clin Epidemiol, Portland, OR 97239 USA.
[Meerpohl, Joerg] Univ Med Ctr Freiburg, Inst Med Biometry & Med Informat, German Cochrane Ctr, D-79104 Freiburg, Germany.
[Meerpohl, Joerg] Univ Med Ctr Freiburg, Dept Pediat & Adolescent Med, Div Pediat Hematol & Oncol, D-79106 Freiburg, Germany.
[Shukla, Vijay K.] CADTH, Ottawa, ON K1S 5S8, Canada.
[Nasser, Mona] Inst Qual & Efficiency Hlth Care IQWiG, Dept Hlth Informat, Cologne, Germany.
RP Guyatt, GH (reprint author), McMaster Univ, Dept Clin Epidemiol & Biostat, CLARITY Res Grp, Room 2C12,1200 Main St, W Hamilton, ON L8N 3Z5, Canada.
EM guyatt@mcmaster.ca
RI Nasser, Mona/J-3601-2013; Meerpohl, Joerg/J-4224-2013
OI Meerpohl, Joerg/0000-0002-1333-5403
NR 21
TC 306
Z9 318
U1 1
U2 9
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0895-4356
J9 J CLIN EPIDEMIOL
JI J. Clin. Epidemiol.
PD DEC
PY 2011
VL 64
IS 12
BP 1303
EP 1310
DI 10.1016/j.jclinepi.2011.04.014
PG 8
WC Health Care Sciences & Services; Public, Environmental & Occupational
Health
SC Health Care Sciences & Services; Public, Environmental & Occupational
Health
GA 847TI
UT WOS:000296995000008
PM 21802903
ER
PT J
AU Hunt, KJ
Gonzalez, ME
Lopez, R
Haffner, SM
Stern, MP
Gonzalez-Villalpando, C
AF Hunt, Kelly J.
Elena Gonzalez, Maria
Lopez, Ruy
Haffner, Steve M.
Stern, Michael P.
Gonzalez-Villalpando, Clicerio
TI Diabetes is More Lethal in Mexicans and Mexican-Americans Compared to
Non-Hispanic Whites
SO ANNALS OF EPIDEMIOLOGY
LA English
DT Article
DE World Health; Epidemiology; Mortality
ID CARDIOVASCULAR RISK-FACTORS; IMPAIRED GLUCOSE-TOLERANCE; SAN-ANTONIO;
MYOCARDIAL-INFARCTION; DISEASE MORTALITY; PLASMA-GLUCOSE; US ADULTS;
ALL-CAUSE; CITY; PREVALENCE
AB PURPOSE: To examine the mortality risk associated with diabetes in the Mexico City Diabetes Study (MCDS) and the San Antonio Heart Study (SAHS).
METHODS: Prospective cohorts conducted 1990-2007 in MCDS and 1979-2000 in SAHS. Mortality risk was examined using Cox proportional hazard models in 1402 non-Hispanic whites (NHW), 1907 U.S.-born Mexican-Americans (MA), 444 Mexican-horn MA, and 2281 Mexico City residents (MCR) between the ages of 35-64.
RESULTS: Age- and sex-adjusted mortality hazard ratios (FIR) comparing U.S.-born MA, Mexican-born MA, and MCR to NHW were 1.09(95% confidence interval [CI]: 0.86, 1.37), 1.23 (95% Cl: 0.86, 1.76), and 0.97 (95% Cl: 0.77, 1.23), respectively, in nondiabetic individuals; in contrast, mortality risk varied in diabetic individuals with respective HRs of 1.77 (95% Cl: 1.20, 2.61), 1.08 (95% Cl: 0.59, 1.97), and 2.27 (95% Cl: 1.53, 3.35) (interaction p = .0003). Excluding Mexican-born MA and nondiabetic individuals, controlling for medication use, insulin use, fasting glucose levels, and duration of diabetes explained a significant proportion of the mortality differential (HRs relative to NHW were 1.31 [95% Cl: 0.87, 1.981 in U.S.-born MA and 1.38(95% CI: 0.89, 2.121 in MCR).
CONCLUSIONS: This study provides evidence that diabetes is more lethal in U.S.-born MA and MCR than in NHW. Ann Epidemiol 201121:899-906. (C) 2011 Elsevier Inc. All rights reserved.
C1 [Hunt, Kelly J.] Med Univ S Carolina, Charleston, SC 29425 USA.
[Hunt, Kelly J.] Ralph H Johnson Dept Vet Affairs Med Ctr, Ctr Dis Prevent & Hlth Intervent Diverse Populat, Charleston, SC USA.
[Elena Gonzalez, Maria; Lopez, Ruy; Gonzalez-Villalpando, Clicerio] Unidad Invest Diabet, Mexico City, DF, Mexico.
[Elena Gonzalez, Maria; Lopez, Ruy; Gonzalez-Villalpando, Clicerio] Riesgo Cardiovasc Inst Nacl Salud Publ, Mexico City, DF, Mexico.
[Elena Gonzalez, Maria; Lopez, Ruy; Gonzalez-Villalpando, Clicerio] Ctr Estudios Diabet, Mexico City, DF, Mexico.
[Haffner, Steve M.] Baylor Coll Med, Houston, TX 77030 USA.
[Stern, Michael P.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA.
RP Hunt, KJ (reprint author), Med Univ S Carolina, 135 Cannon St,Suite 302,POB 250835, Charleston, SC 29425 USA.
EM huntke@musc.edu
FU Consejo Nacional de Ciencia y Tecnologia Apoyo [14502]; National Heart
Lung and Blood Institute [R01-HL24799, R01-HL36820]; National Institute
of Diabetes and Digestive and Kidney Diseases [K01-DK064867]; National
Center on Minority Health and Health Disparities [R01-MD004251]; Office
of Research and Development, Department of Veterans Affairs; Ralph H.
Johnson VAMC; VA HSRD [IIR-06-219]
FX This work was supported by grants from the Consejo Nacional de Ciencia y
Tecnologia Apoyo (14502), the National Heart Lung and Blood Institute
(R01-HL24799 and R01-HL36820), the National Institute of Diabetes and
Digestive and Kidney Diseases (K01-DK064867), the National Center on
Minority Health and Health Disparities (R01-MD004251), the Office of
Research and Development, Department of Veterans Affairs, and the Ralph
H. Johnson VAMC,. Further support was provided through VA HSR&D REAP
Award (grant IIR-06-219). The funding agencies did not participate in
the design and conduct of the study; collection, management, analysis,
and interpretation of the data; and preparation, review, or approval of
the manuscript. The views expressed in this manuscript are those of the
authors and do not necessarily represent the views of the U.S.
Department of Veterans Affairs.
NR 27
TC 9
Z9 10
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1047-2797
J9 ANN EPIDEMIOL
JI Ann. Epidemiol.
PD DEC
PY 2011
VL 21
IS 12
BP 899
EP 906
DI 10.1016/j.annepidem.2011.07.003
PG 8
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 844NX
UT WOS:000296755400005
PM 21840730
ER
PT J
AU Inslicht, SS
Otte, C
McCaslin, SE
Apfel, BA
Henn-Haase, C
Metzler, T
Yehuda, R
Neylan, TC
Marmar, CR
AF Inslicht, Sabra S.
Otte, Christian
McCaslin, Shannon E.
Apfel, Brigitte A.
Henn-Haase, Clare
Metzler, Thomas
Yehuda, Rachel
Neylan, Thomas C.
Marmar, Charles R.
TI Cortisol Awakening Response Prospectively Predicts Peritraumatic and
Acute Stress Reactions in Police Officers
SO BIOLOGICAL PSYCHIATRY
LA English
DT Article
DE Acute stress disorder; cortisol; peritraumatic dissociation; police
stress; posttraumatic stress disorder
ID VEHICLE ACCIDENT VICTIMS; POSTTRAUMATIC-STRESS; SALIVARY CORTISOL; SLEEP
QUALITY; PTSD SYMPTOMS; PSYCHOMETRIC PROPERTIES; TRAUMA VICTIMS; HPA
AXIS; DISORDER; ADULTS
AB Background: The hypothalamic-pituitary-adrenal axis is a major stress response system hypothesized to be involved in the pathogenesis of posttraumatic stress disorder (PTSD). However, few studies have prospectively examined the relationships among pre-exposure hypothalamic-pituitary-adrenal activity, acute stress reactions and PTSD.
Methods: Two hundred ninety-six police recruits were assessed during academy training before critical incident exposure and provided salivary cortisol at first awakening and after 30 minutes. A measure of cortisol awakening response (CAR) was computed as the change in cortisol level from the first to the second collection. At 12, 24, and 36 months following the start of active police service, officers were assessed for peritraumatic distress, peritraumatic dissociation, acute stress disorder (ASD) symptoms, and PTSD symptoms to their self-identified worst duty-related critical incident. Mixed models for repeated measures were used to analyze the effects of CAR on the outcome variables pooled across the three follow-up assessments.
Results: After controlling for time of awakening, first awakening cortisol levels, and cumulative critical incident stress exposure, CAR during academy training was associated with greater peritraumatic dissociation, beta = .14, z = 3.49, p < .0001, and greater ASD symptoms during police service assessed at 12, 24, and 36 months, beta = .09, Z = 2.03, p < .05, but not with peritraumatic distress, beta = .03, z = .81, p = .42, or PTSD symptoms, beta = -.004, z = -.09, p = .93.
Conclusions: These findings suggest that greater cortisol response to awakening is a pre-exposure risk factor for peritraumatic dissociation and ASD symptoms during police service.
C1 [Inslicht, Sabra S.; McCaslin, Shannon E.; Apfel, Brigitte A.; Metzler, Thomas; Neylan, Thomas C.] San Francisco VA Med Ctr, PTSD Res Program, San Francisco, CA USA.
[Inslicht, Sabra S.; McCaslin, Shannon E.; Apfel, Brigitte A.; Neylan, Thomas C.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA.
[Metzler, Thomas] No Calif Inst Res & Educ, San Francisco, CA USA.
[Otte, Christian] Charite, Dept Psychiat & Psychotherapy, Ctr Berlin, D-13353 Berlin, Germany.
[Henn-Haase, Clare; Marmar, Charles R.] NYU, Sch Med, Dept Psychiat, New York, NY USA.
[Yehuda, Rachel] Mt Sinai Sch Med, Traumat Stress Div, Bronx, NY USA.
James J Peters Vet Affairs Med Ctr, Bronx, NY USA.
RP Inslicht, SS (reprint author), Vet Affairs Med Ctr, PTSD Res Program, 4150 Clement St,116P, San Francisco, CA 94121 USA.
EM Sabra.Inslicht@ucsf.edu
FU National Institute of Mental Health [R01 - MH056350-06]; Veterans
Affairs Clinical Science Research and Development [CDA-2-037-07F,
CDA-2-032-06F]
FX This research was supported by National Institute of Mental Health Grant
(R01 - MH056350-06) to CRM. SSI and SEM were supported by Veterans
Affairs Clinical Science Research and Development, Career Development
Awards (CDA-2-037-07F and CDA-2-032-06F, respectively).
NR 67
TC 21
Z9 24
U1 3
U2 23
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0006-3223
J9 BIOL PSYCHIAT
JI Biol. Psychiatry
PD DEC 1
PY 2011
VL 70
IS 11
BP 1055
EP 1062
DI 10.1016/j.biopsych.2011.06.030
PG 8
WC Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA 842FL
UT WOS:000296578800010
PM 21906725
ER
PT J
AU Bendlin, BB
Canu, E
Willette, A
Kastman, EK
McLaren, DG
Kosmatka, KJ
Xu, G
Field, AS
Colman, RJ
Coe, CL
Weindruch, RH
Alexander, AL
Johnson, SC
AF Bendlin, B. B.
Canu, E.
Willette, A.
Kastman, E. K.
McLaren, D. G.
Kosmatka, K. J.
Xu, G.
Field, A. S.
Colman, R. J.
Coe, C. L.
Weindruch, R. H.
Alexander, A. L.
Johnson, S. C.
TI Effects of aging and calorie restriction on white matter in rhesus
macaques
SO NEUROBIOLOGY OF AGING
LA English
DT Article
DE Rhesus macaque; Diffusion tensor imaging; Magnetic resonance imaging;
Aging; Caloric restriction; White matter
ID LATERAL GENICULATE NEURONS; PRIMARY VISUAL-CORTEX; AGE-RELATED DECLINE;
DIETARY RESTRICTION; BRAIN ABNORMALITIES; ALZHEIMERS-DISEASE; MYELIN
BREAKDOWN; OXIDATIVE DAMAGE; HUMAN OBESITY; IN-VIVO
AB Rhesus macaques on a calorie restricted diet (CR) develop less age-related disease, have virtually no indication of diabetes, are protected against sarcopenia, and potentially live longer. Beneficial effects of caloric restriction likely include reductions in age-related inflammation and oxidative damage. Oligodendrocytes are particularly susceptible to inflammation and oxidative stress, therefore, we hypothesized that CR would have a beneficial effect on brain white matter and would attenuate age-related decline in this tissue. CR monkeys and controls underwent diffusion tensor imaging (DTI). A beneficial effect of CR indexed by DTI was observed in superior longitudinal fasciculus, fronto-occipital fasciculus, external capsule, and brainstem. Aging effects were observed in several regions, although CR appeared to attenuate age-related alterations in superior longitudinal fasciculus, frontal white matter, external capsule, right parahippocampal white matter, and dorsal occipital bundle. The results, however, were regionally specific and also suggested that CR is not salutary across all white matter. Further evaluation of this unique cohort of elderly primates to mortality will shed light on the ultimate benefits of an adult-onset, moderate CR diet for deferring brain aging. Published by Elsevier Inc.
C1 [Bendlin, B. B.; Canu, E.; Kastman, E. K.; McLaren, D. G.; Kosmatka, K. J.; Xu, G.; Weindruch, R. H.; Johnson, S. C.] William S Middleton Mem Vet Adm Med Ctr, Geriatr Res Educ & Clin Ctr, Madison, WI 53705 USA.
[Bendlin, B. B.; Canu, E.; Kastman, E. K.; McLaren, D. G.; Kosmatka, K. J.; Xu, G.; Weindruch, R. H.; Johnson, S. C.] Univ Wisconsin, Dept Med, Sch Med & Publ Hlth, Madison, WI USA.
[Willette, A.; Coe, C. L.] Univ Wisconsin, Dept Psychol, Harlow Primate Lab, Madison, WI 53706 USA.
[Willette, A.; Colman, R. J.; Coe, C. L.; Weindruch, R. H.] Wisconsin Natl Primate Res Ctr, Madison, WI USA.
[Field, A. S.] Univ Wisconsin, Dept Radiol, Sch Med & Publ Hlth, Madison, WI 53706 USA.
[Alexander, A. L.] Univ Wisconsin, Dept Psychiat, Sch Med & Publ Hlth, Madison, WI 53706 USA.
[Alexander, A. L.] Univ Wisconsin, Dept Med Phys, Madison, WI 53706 USA.
[Alexander, A. L.] Waisman Lab Brain Imaging & Behav, Madison, WI USA.
RP Johnson, SC (reprint author), William S Middleton Mem Vet Adm Med Ctr, Geriatr Res Educ & Clin Ctr, 2500 Overlook Terrace 11G, Madison, WI 53705 USA.
EM scj@medicine.wisc.edu
RI McLaren, Donald/G-9906-2011; Kastman, Erik/N-6645-2016; Canu,
Elisa/K-1423-2016
OI Kastman, Erik/0000-0001-7221-9042; Canu, Elisa/0000-0001-5804-3378;
Bendlin, Barbara/0000-0002-0580-9875
FU Waisman Center, UW-Madison; NIH [AG11915, RR000167, AG000213]; NCRR
[RR15459-01, RR020141-01]
FX The authors gratefully acknowledge the support of researchers and staff
at the Waisman Center, UW-Madison, where MR imaging took place, and the
technical assistance provided by S. Baum, J. Christensen, JA.
Adriansjach, and C. E. Armstrong. We also acknowledge the assistance
provided by the Animal Care, Veterinary and Pathology Staff of the
Wisconsin National Primate Research Center. The project was supported by
funding from the NIH to the Wisconsin National Primate Research Center
grants AG11915 and RR000167 and NIH grant AG000213. This research was
conducted in part at a facility constructed with support from Research
Facilities Improvement Program grant numbers RR15459-01 and RR020141-01
from NCRR. The project also benefited from resources and facilities at
the Wm. S. Middleton Memorial Veterans Hospital. GRECC Manuscript
2010-11.
NR 67
TC 2
Z9 2
U1 1
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0197-4580
J9 NEUROBIOL AGING
JI Neurobiol. Aging
PD DEC
PY 2011
VL 32
IS 12
AR 2319.e1
DI 10.1016/j.neurobiolaging.2010.04.008
PG 11
WC Geriatrics & Gerontology; Neurosciences
SC Geriatrics & Gerontology; Neurosciences & Neurology
GA 839PJ
UT WOS:000296379900030
PM 20541839
ER
PT J
AU Chu, SH
Roeder, K
Ferrell, RE
Devlin, B
DeMichele-Sweet, MAA
Kamboh, MI
Lopez, OL
Sweet, RA
AF Chu, Su Hee
Roeder, Kathryn
Ferrell, Robert E.
Devlin, Bernie
DeMichele-Sweet, Mary Ann A.
Kamboh, M. Ilyas
Lopez, Oscar L.
Sweet, Robert A.
TI TOMM40 poly-T repeat lengths, age of onset and psychosis risk in
Alzheimer disease
SO NEUROBIOLOGY OF AGING
LA English
DT Article
DE Apolipoprotein E (APOE) epsilon 4; Late-onset Alzheimer disease (LOAD);
Psychosis; TOMM40; Variable length poly-T repeat sequence
ID DEMENTIA; HERITABILITY; ASSOCIATION; APOE
AB Apolipoprotein E (APOE) epsilon 4 alleles increase the risk for late-onset Alzheimer disease (LOAD) and decrease the age of onset. Recently, sequencing the APOE region in a small sample of LOAD subjects identified a variable length poly-T repeat sequence in the nearby gene, TOMM40, which may affect age of onset. We genotyped the TOMM40 poly-T repeat using a novel statistical approach to refine the identification of allele length in 892 LOAD subjects and evaluated its effects on age of onset. Because psychosis in LOAD is a heritable phenotype which has shown conflicting associations with APOE genotype, we also evaluated the association of poly-T repeat length with psychosis. Poly-T repeat lengths had a trimodal distribution which differed between APOE genotype groups. After accounting for APOE epsilon 4 there was no association of poly-T repeat length with age of onset. Neither APOE epsilon 4 nor poly-T repeat length was associated with psychosis. Our findings do not support the association of poly-T repeat length with age of onset in LOAD. The clinical implications of this repeat length polymorphism remain to be elucidated. (C) 2011 Elsevier Inc. All rights reserved.
C1 [Chu, Su Hee; Roeder, Kathryn] Carnegie Mellon Univ, Dept Stat, Pittsburgh, PA 15213 USA.
[Ferrell, Robert E.; Kamboh, M. Ilyas] Univ Pittsburgh, Dept Human Genet, Pittsburgh, PA USA.
[Devlin, Bernie; DeMichele-Sweet, Mary Ann A.; Kamboh, M. Ilyas; Lopez, Oscar L.; Sweet, Robert A.] Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA USA.
[Lopez, Oscar L.; Sweet, Robert A.] Univ Pittsburgh, Dept Neurol, Pittsburgh, PA 15260 USA.
[Sweet, Robert A.] VA Pittsburgh Healthcare Syst, MIRECC, VISN Mental Illness Res Educ & Clin Ctr 4, Pittsburgh, PA USA.
RP Sweet, RA (reprint author), Biomed Sci Tower,Rm W-1645,3811 OHara St, Pittsburgh, PA 15213 USA.
EM sweetra@upmc.edu
OI Kamboh, M. Ilyas/0000-0002-3453-1438
FU National Institute on Aging (NIA) [AG 027224, AG030653, AG 05133]
FX This work was supported by National Institute on Aging (NIA) grants AG
027224, AG030653, and AG 05133.
NR 19
TC 6
Z9 7
U1 2
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0197-4580
J9 NEUROBIOL AGING
JI Neurobiol. Aging
PD DEC
PY 2011
VL 32
IS 12
AR 2328.e1
DI 10.1016/j.neurobiolaging.2011.06.016
PG 9
WC Geriatrics & Gerontology; Neurosciences
SC Geriatrics & Gerontology; Neurosciences & Neurology
GA 839PJ
UT WOS:000296379900053
PM 21820212
ER
PT J
AU Wang, J
Ono, K
Dickstein, DL
Arrieta-Cruz, I
Zhao, W
Qian, XJ
Lamparello, A
Subnani, R
Ferruzzi, M
Pavlides, C
Ho, L
Hof, PR
Teplow, DB
Pasinetti, GM
AF Wang, Jun
Ono, Kenjiro
Dickstein, Dara L.
Arrieta-Cruz, Isabel
Zhao, Wei
Qian, Xianjuan
Lamparello, Ashley
Subnani, Rakesh
Ferruzzi, Mario
Pavlides, Constantine
Ho, Lap
Hof, Patrick R.
Teplow, David B.
Pasinetti, Giulio M.
TI Carvedilol as a potential novel agent for the treatment of Alzheimer's
disease
SO NEUROBIOLOGY OF AGING
LA English
DT Article
DE Oligomeric A beta; Cognitive function; Spatial memory; Basal neuronal
transmission; Dendritic spine; Synaptic plasticity; Bioavailability
ID AMYLOID-BETA-PROTEIN; LONG-TERM POTENTIATION; SCANNING MICROSCOPY
IMAGES; MOUSE MODEL; SYNAPTIC PLASTICITY; DENDRITIC SPINES; IN-VIVO;
COGNITIVE FUNCTION; PREFRONTAL CORTEX; NATURAL OLIGOMERS
AB Oligomeric beta-amyloid (A beta) has recently been linked to synaptic plasticity deficits, which play a major role in progressive cognitive decline in Alzheimer's disease (AD). Here we present evidence that chronic oral administration of carvedilol, a nonselective beta-adrenergic receptor blocker, significantly attenuates brain oligomeric beta-amyloid content and cognitive deterioration in 2 independent AD mouse models. We found that carvedilol treatment significantly improved neuronal transmission, and that this improvement was associated with the maintenance of number of the less stable "learning" thin spines in the brains of AD mice. Our novel observation that carvedilol interferes with the neuropathologic, biochemical, and electrophysiological mechanisms underlying cognitive deterioration in AD supports the potential development of carvedilol as a treatment for AD. (C) 2011 Elsevier Inc. All rights reserved.
C1 [Wang, Jun; Arrieta-Cruz, Isabel; Zhao, Wei; Qian, Xianjuan; Lamparello, Ashley; Subnani, Rakesh; Ho, Lap; Pasinetti, Giulio M.] Mt Sinai Sch Med, Dept Neurol, New York, NY 10029 USA.
[Wang, Jun; Ho, Lap; Pasinetti, Giulio M.] Mt Sinai Sch Med, Dept Psychiat, New York, NY 10029 USA.
[Ono, Kenjiro; Teplow, David B.] Univ Calif Los Angeles, Brain Res Inst, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90024 USA.
[Ono, Kenjiro; Teplow, David B.] Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90024 USA.
[Dickstein, Dara L.; Hof, Patrick R.; Pasinetti, Giulio M.] Mt Sinai Sch Med, Dept Neurosci, New York, NY 10029 USA.
[Ferruzzi, Mario] Purdue Univ, Dept Food Sci, W Lafayette, IN 47907 USA.
[Pavlides, Constantine] Rockefeller Univ, New York, NY 10021 USA.
[Ho, Lap; Pasinetti, Giulio M.] James J Peters Vet Affairs Med Ctr, Geriatr Res Educ & Clin Ctr, Bronx, NY USA.
RP Pasinetti, GM (reprint author), Mt Sinai Sch Med, Dept Neurol, 1425 Madison Ave,Box 1230, New York, NY 10029 USA.
EM giulio.pasinetti@mssm.edu
RI Dickstein, Dara/F-3036-2013
FU NIH [UO1 AG29310]; Altschul Foundation
FX This work is supported by NIH UO1 AG29310 (GMP) and funding provided by
Altschul Foundation.
NR 56
TC 5
Z9 6
U1 1
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0197-4580
J9 NEUROBIOL AGING
JI Neurobiol. Aging
PD DEC
PY 2011
VL 32
IS 12
AR 2321.e1
DI 10.1016/j.neurobiolaging.2010.05.004
PG 12
WC Geriatrics & Gerontology; Neurosciences
SC Geriatrics & Gerontology; Neurosciences & Neurology
GA 839PJ
UT WOS:000296379900036
PM 20579773
ER
PT J
AU Gupta, AO
Singh, N
AF Gupta, Ashish O.
Singh, Nina
TI Immune reconstitution syndrome and fungal infections
SO CURRENT OPINION IN INFECTIOUS DISEASES
LA English
DT Review
DE fungal infections; HIV; immune reconstitution syndrome; mycoses;
transplants
ID ORGAN TRANSPLANT RECIPIENTS; CRYPTOCOCCUS-NEOFORMANS INFECTION;
PENICILLIUM-MARNEFFEI INFECTION; ADJUVANT CORTICOSTEROID-THERAPY; ACTIVE
ANTIRETROVIRAL THERAPY; HIV-POSITIVE PATIENTS; VERSUS-HOST-DISEASE;
REGULATORY T-CELLS; INFLAMMATORY SYNDROME; DISSEMINATED HISTOPLASMOSIS
AB Purpose of review
Fungal infections-related immune reconstitution syndrome (IRS) poses challenging diagnostic and management issues in immunocompromised hosts. This review summarizes the current state of knowledge regarding its pathophysiologic basis, presentation, and treatment strategies.
Recent findings
Existing evidence suggests that IRS is a state of an imbalance between protective immunity and inflammatory pathology versus anti-inflammatory responses that restrain inflammation. IRS has been observed in diverse hosts including HIV-infected patients initiating potent antiretroviral therapy, transplant recipients, pregnant women, and recipients of iatrogenic biologic agents. Among the most common fungal infections associated with IRS is cryptococcosis, although this entity has been documented during the course of invasive aspergillosis, histoplasmosis, and candidiasis. Unique risk factors for IRS have been recognized in specific hosts.
Summary
IRS is a culmination of immunologic sequelae of host-pathogen interaction during evolution of an opportunistic infection, and as such the development of biomarkers that differentiate it from progressive disease would represent an important advance. Optimal management of immunosuppression and immunomodulatory approaches that target precise regulatory pathways for IRS warrant future investigations.
C1 [Singh, Nina] Univ Pittsburgh, VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
[Gupta, Ashish O.] Univ Pittsburgh, Childrens Hosp, Div Hematol & Oncol, Pittsburgh, PA 15260 USA.
RP Singh, N (reprint author), VA Med Ctr, Infect Dis Sect, Univ Dr C, Pittsburgh, PA 15240 USA.
EM nis5@pitt.edu
FU Pfizer
FX N.S. has received investigator-initiated grant support from Pfizer.
NR 71
TC 15
Z9 15
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0951-7375
J9 CURR OPIN INFECT DIS
JI Curr. Opin. Infect. Dis.
PD DEC
PY 2011
VL 24
IS 6
BP 527
EP 533
DI 10.1097/QCO.0b013e32834ab20a
PG 7
WC Infectious Diseases
SC Infectious Diseases
GA 841FB
UT WOS:000296496800003
PM 22025021
ER
PT J
AU Kraft, S
Mackler, E
Schlickman, P
Welch, K
DePestel, DD
AF Kraft, Shawna
Mackler, Emily
Schlickman, Peter
Welch, Kathy
DePestel, Daryl D.
TI Outcomes of therapy: vancomycin-resistant enterococcal bacteremia in
hematology and bone marrow transplant patients
SO SUPPORTIVE CARE IN CANCER
LA English
DT Article
DE Daptomycin; Linezolid; Vancomycin-resistant enterococci; Hematology;
Bone marrow transplant; Bacteremia
ID GRAM-POSITIVE INFECTIONS; BLOOD-STREAM INFECTION; FAECIUM BACTEREMIA;
RISK-FACTORS; DAPTOMYCIN; MORTALITY; NEUTROPENIA; MULTICENTER; IMPACT
AB The purpose of this study was to evaluate the risk factors associated with the treatment failure and 30-day mortality in hematology and bone marrow transplant patients treated with daptomycin or linezolid for vancomycin-resistant enterococci (VRE) bacteremia. The safety and tolerability of therapy was also assessed.
This single-center, retrospective study included adult patients admitted to the hematology or bone marrow transplant service with documented vancomycin-resistant Enterococcus faecium or Enterococcus faecalis bacteremia and received at least 48 h of either linezolid or daptomycin as primary treatment. Clinical and microbiologic outcomes were assessed at day 7, 14, and 30 of hospital stay.
A total of 72 patients were included in the analysis. Forty-three patients received daptomycin as primary treatment and 29 received linezolid as primary treatment. Overall success rate at day 7 was 81.9%, day 14 success rate was 79.2%, and day 30 success rate was 76.4% for all patients. Forty-one patients (57.0%) had high-grade bacteremia defined as greater than one positive blood culture for VRE. The mortality rate was significantly higher if high-grade bacteremia was present (34.1% vs. 7.0%; p = 0.009).
This study suggests that linezolid and daptomycin are both reasonable options for treating VRE bacteremia in hematology and bone marrow transplant patients; however, patients with high-grade VRE bacteremia may be at increased risk for treatment failure.
C1 [Kraft, Shawna; Mackler, Emily; DePestel, Daryl D.] Univ Michigan Hlth Syst, Dept Pharm, Ann Arbor, MI 48109 USA.
[Schlickman, Peter] Denver VA Med Ctr, Dept Pharm, Denver, CO 80220 USA.
[Welch, Kathy] Univ Michigan, Ctr Stat Consultat & Res, Ann Arbor, MI 48109 USA.
RP Kraft, S (reprint author), Univ Michigan Hlth Syst, Dept Pharm, Ann Arbor, MI 48109 USA.
EM svandeko@umich.edu
FU Cubist Pharmaceuticals
FX Dr. DePestel is a consultant for Pfizer and Cubist Pharmaceuticals and
has received funding for other projects from Cubist Pharmaceuticals. All
other authors have nothing to disclose.
NR 19
TC 24
Z9 25
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0941-4355
J9 SUPPORT CARE CANCER
JI Support. Care Cancer
PD DEC
PY 2011
VL 19
IS 12
BP 1969
EP 1974
DI 10.1007/s00520-010-1038-z
PG 6
WC Oncology; Health Care Sciences & Services; Rehabilitation
SC Oncology; Health Care Sciences & Services; Rehabilitation
GA 839KA
UT WOS:000296362900010
PM 21110047
ER
PT J
AU Jardin, BF
LaRowe, SD
Hall, BJ
Malcolm, RJ
AF Jardin, Bianca F.
LaRowe, Steven D.
Hall, Brian J.
Malcolm, Robert J.
TI The Obsessive Compulsive Cocaine Scale: Assessment of factor structure,
reliability, and validity
SO ADDICTIVE BEHAVIORS
LA English
DT Article
DE Obsessive Compulsive Cocaine Scale; Cocaine; Confirmatory factor
analysis; Psychometric properties
ID DRINKING-SCALE; FIT INDEXES; ALCOHOL; BEHAVIOR; OCDS; QUANTIFICATION;
QUESTIONNAIRE; DEPENDENCE; GOODNESS
AB The present study assessed the factor structure, reliability, test retest, convergent validity, and predictive validity of the Obsessive Compulsive Cocaine Scale (OCCS), a newly developed questionnaire adapted from the Obsessive Compulsive Drinking Scale (OCDS). The questionnaire was administered to 189 cocaine-dependent individuals participating in two medication treatment trials for cocaine dependence. Confirmatory factor analysis of this measure revealed that it primarily assesses two factors, obsessions and compulsions. In addition, the data provided strong support for the internal consistency, test-retest reliability, predictive validity, and convergent validity of this two-factor measure. Overall, the data provide support for the psychometric strength of a modified version of the OCDS specifically designed to assess obsessive and compulsive cocaine use among those with cocaine dependence. (C) 2011 Elsevier Ltd. All rights reserved.
C1 [Jardin, Bianca F.; LaRowe, Steven D.; Hall, Brian J.] Charleston Consortium Psychol Internship Training, Charleston, SC 29425 USA.
[LaRowe, Steven D.; Malcolm, Robert J.] Med Univ S Carolina, Dept Psychiat & Behav Sci, Ctr Drug & Alcohol Programs, Charleston, SC 29425 USA.
[LaRowe, Steven D.] Ralph H Johnson VAMC, Charleston, SC 29401 USA.
RP Jardin, BF (reprint author), Charleston Consortium Psychol Internship Training, 67 President St, Charleston, SC 29425 USA.
EM jardin@musc.edu
OI Hall, Brian/0000-0001-9358-2377; LaRowe, Steven/0000-0002-7664-2451
FU NIDA [DA019903, DA016368]
FX Funding for this study was provided by NIDA grants DA019903 and
DA016368. NIDA had no role in the study design, collection, analysis or
interpretation of the data, writing the manuscript, or the decision to
submit the paper for publication.
NR 29
TC 2
Z9 2
U1 1
U2 2
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0306-4603
J9 ADDICT BEHAV
JI Addict. Behav.
PD DEC
PY 2011
VL 36
IS 12
BP 1223
EP 1227
DI 10.1016/j.addbeh.2011.07.028
PG 5
WC Psychology, Clinical; Substance Abuse
SC Psychology; Substance Abuse
GA 836LZ
UT WOS:000296114500016
PM 21862227
ER
PT J
AU Paul, LA
Grubaugh, AL
Frueh, BC
Ellis, C
Egede, LE
AF Paul, Lisa A.
Grubaugh, Anouk L.
Frueh, B. Christopher
Ellis, Charles
Egede, Leonard E.
TI Associations between binge and heavy drinking and health behaviors in a
nationally representative sample
SO ADDICTIVE BEHAVIORS
LA English
DT Article
DE Binge drinking; Heavy drinking; Health behaviors; Preventive care; BUSS
ID ALCOHOL-CONSUMPTION; ADULTS; RISK; POPULATION; PATTERNS; DEFINITIONS;
PREVALENCE; SERVICES; WOMEN; OLDER
AB Background: Binge and heavy drinking are noted in the literature for their relatively high prevalence and adverse health-related effects.
Design and participants: We used data from the 2006 Behavioral Risk Factor Surveillance Survey (BRFSS) to determine the associations between binge and heavy drinking and a wide range of health-related variables, including positive and negative health behaviors, preventive care practices, and quality of life indices in a nationally representative sample of 344,793 adults.
Results: Rates of binge and heavy drinking in the current sample were 15% and 5%, respectively. Binge and heavy drinking were more common among men, younger adults, and individuals with higher incomes and at least some college education. After controlling for relevant demographic variables, binge and heavy drinking were associated with a number of adverse health-related and preventive care behaviors (e.g., smoking, failing to receive a mammogram), as well as less life satisfaction and a greater number of poor mental health days than those who did not engage in these drinking behaviors. Interestingly, binge and heavy drinking were also associated with some positive health-related variables (e.g., recent physical activity, positive perceptions of one's own health).
Conclusions: The current study findings provide additional information regarding the relations between health-related attitudes and behaviors and binge and heavy drinking in the U.S. population. Implications of study findings are discussed. Published by Elsevier Ltd.
C1 [Paul, Lisa A.; Grubaugh, Anouk L.] Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA.
[Grubaugh, Anouk L.; Ellis, Charles; Egede, Leonard E.] Ralph H Johnson VA Med Ctr, Charleston VA REAP, Charleston, SC USA.
[Frueh, B. Christopher] Univ Hawaii, Dept Psychol, Hilo, HI 96720 USA.
[Frueh, B. Christopher] Menninger Clin, Houston, TX USA.
[Ellis, Charles] Med Univ S Carolina, Dept Hlth Sci & Res, Charleston, SC 29425 USA.
[Egede, Leonard E.] Med Univ S Carolina, Dept Med, Ctr Hlth Dispar Res, Charleston, SC 29425 USA.
RP Grubaugh, AL (reprint author), Med Univ S Carolina, Dept Psychiat & Behav Sci, POB 250861, Charleston, SC 29425 USA.
EM grubaugh@musc.edu
FU NIDDK NIH HHS [K24 DK093699]; NIMH NIH HHS [T32 MH018869]
NR 33
TC 18
Z9 19
U1 0
U2 12
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0306-4603
J9 ADDICT BEHAV
JI Addict. Behav.
PD DEC
PY 2011
VL 36
IS 12
BP 1240
EP 1245
DI 10.1016/j.addbeh.2011.07.034
PG 6
WC Psychology, Clinical; Substance Abuse
SC Psychology; Substance Abuse
GA 836LZ
UT WOS:000296114500019
PM 21868171
ER
PT J
AU Estrada, CA
Krishnamoorthy, P
Smith, A
Staton, L
Korf, MJ
Allison, JJ
Houston, TK
AF Estrada, Carlos A.
Krishnamoorthy, Periyakaruppan
Smith, Ann
Staton, Lisa
Korf, Michele J.
Allison, Jeroan J.
Houston, Thomas K.
TI Marketing to Increase Participation in a Web-Based Continuing Medical
Education Cultural Competence Curriculum
SO JOURNAL OF CONTINUING EDUCATION IN THE HEALTH PROFESSIONS
LA English
DT Article
DE marketing; continuing medical education; Internet; Web; online; cultural
competence
ID ONLINE CME
AB Introduction: CME providers may be interested in identifying effective marketing strategies to direct users to specific content. Online advertisements for recruiting participants into activities such as clinical trials, public health programs, and continuing medical education (CME) have been effective in some but not all studies. The purpose of this study was to compare the impact of 2 marketing strategies in the context of an online CME cultural competence curriculum (www.c-comp.org).
Methods: In an interrupted time-series quasi-experimental design, 2 marketing strategies were tested: (1) wide dissemination to relevant organizations over a period of approximately 4 months, and (2) Internet paid search using Google Ads (5 consecutive 8-week periods-control 1, cultural/CME advertisement, control 2, hypertension/content advertisement, control 3). Outcome measures were CME credit requests, Web traffic (visits per day, page views, pages viewed per visit), and cost.
Results: Overall, the site was visited 19,156 times and 78,160 pages were viewed. During the wide dissemination phase, the proportion of visits requesting CME credit decreased between the first (5.3%) and second (3.3%) halves of this phase (p = .04). During the Internet paid search phase, the proportion of visits requesting CME credit was highest during the cultural/CME advertisement period (control 1, 1.4%; cultural/CME ad, 4.3%; control 2, 1.5%; hypertension/content ad, 0.6%; control 3, 0.8%; p < .001). All measures of Web traffic changed during the Internet paid search phase (p < .01); however, changes were independent of the advertisement periods. The incremental cost for the cultural advertisement per CME credit requested was US$0.64.
Discussion: Internet advertisement focusing on cultural competence and CME was associated with about a threefold increase in requests for CME credit at an incremental cost of under US$1; however, Web traffic changes were independent of the advertisement strategy.
C1 [Estrada, Carlos A.] Univ Alabama, Birmingham Vet Affairs Med Ctr, Div Gen Internal Med, VA Natl Qual Scholars Program, Birmingham, AL 35294 USA.
[Estrada, Carlos A.] Univ Alabama, DSCE, REAP Ctr Surg Med Acute Care Res & Transit C SMAR, Birmingham VA Med Ctr, Birmingham, AL 35294 USA.
[Krishnamoorthy, Periyakaruppan] Univ Alabama, Div Continuing Med Educ, Birmingham, AL 35294 USA.
[Smith, Ann] Univ Alabama, Div Prevent Med, UAB Minor Hlth & Hlth Dispar Res Ctr, Birmingham, AL 35294 USA.
[Staton, Lisa] Univ Tennessee, Coll Med Chattanooga, Knoxville, TN 37996 USA.
[Houston, Thomas K.] Univ Massachusetts, Sch Med, CHQOER, Bedford VAMC, Amherst, MA 01003 USA.
[Houston, Thomas K.] Univ Massachusetts, Sch Med, Div Hlth Informat & Implementat Sci, Amherst, MA 01003 USA.
RP Estrada, CA (reprint author), Univ Alabama, Birmingham Vet Affairs Med Ctr, Div Gen Internal Med, VA Natl Qual Scholars Program, 732 Fac Off Tower,510 20th St S, Birmingham, AL 35294 USA.
EM cestrada@uab.edu
RI Houston, Thomas/F-2469-2013
OI Allison, Jeroan/0000-0003-4472-2112
FU National Heart, Lung, and Blood Institute [K07 HL081373-01]
FX This study was funded by a grant from the National Heart, Lung, and
Blood Institute (K07 HL081373-01) to Dr. Estrada; approved by the
institutional review boards of the University of Alabama at Birmingham;
and presented in part at the 2009 and 2010 Southern Society of General
Internal Medicine Annual Meetings, New Orleans, Louisiana. The authors
report no conflict of interest.
NR 23
TC 4
Z9 4
U1 0
U2 4
PU WILEY PERIODICALS, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN STREET, MALDEN, MA 02148-529 USA
SN 0894-1912
J9 J CONTIN EDUC HEALTH
JI J. Contin. Educ. Health Prof.
PD WIN
PY 2011
VL 31
IS 1
BP 21
EP 27
DI 10.1002/chp.20097
PG 7
WC Education, Scientific Disciplines; Health Care Sciences & Services
SC Education & Educational Research; Health Care Sciences & Services
GA 738AL
UT WOS:000288611600004
PM 21425356
ER
PT J
AU Qureshi, SU
Long, ME
Bradshaw, MR
Pyne, JM
Magruder, KM
Kimbrell, T
Hudson, TJ
Jawaid, A
Schulz, PE
Kunik, ME
AF Qureshi, Salah U.
Long, Mary E.
Bradshaw, Major R.
Pyne, Jeffrey M.
Magruder, Kathy M.
Kimbrell, Timothy
Hudson, Teresa J.
Jawaid, Ali
Schulz, Paul E.
Kunik, Mark E.
TI Does PTSD Impair Cognition Beyond the Effect of Trauma?
SO JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES
LA English
DT Article
ID POSTTRAUMATIC-STRESS-DISORDER; SMALLER HIPPOCAMPAL VOLUME;
NEUROPSYCHOLOGICAL FUNCTION; ALZHEIMERS-DISEASE; EXECUTIVE FUNCTION;
WORKING-MEMORY; SURVIVORS; SYMPTOMS; VETERANS; DEFICITS
AB This systematic review analyzed data from studies examining memory and cognitive function in subjects with posttraumatic stress disorder (PTSD), compared with subjects exposed to trauma (but without PTSD).
Based on analysis of 21 articles published in English from 1968 to 2009, the conclusion is that individuals with PTSD, particularly veterans, show signs of cognitive impairment when tested with neuropsychological instruments, more so than individuals exposed to trauma who do not have PTSD. (The Journal of Neuropsychiatry and Clinical Neurosciences 2011; 23:16-28)
C1 [Qureshi, Salah U.; Long, Mary E.; Kunik, Mark E.] Michael E DeBakey Vet Affairs VA Med Ctr, Hlth Serv Res & Dev Serv, Houston Ctr Qual Care & Utilizat Studies, Houston, TX USA.
[Qureshi, Salah U.; Schulz, Paul E.] Baylor Coll Med, Neurosensory Ctr, Houston, TX 77030 USA.
[Qureshi, Salah U.; Schulz, Paul E.] Michael E DeBakey VA Med Ctr, Neurol Care Line, Houston, TX USA.
[Qureshi, Salah U.; Long, Mary E.; Kimbrell, Timothy; Kunik, Mark E.] Baylor Coll Med, VA S Cent Mental Illness Res Educ & Clin Ctr, Houston, TX 77030 USA.
[Bradshaw, Major R.; Jawaid, Ali; Schulz, Paul E.] Baylor Coll Med, Dept Neurol, Houston, TX 77030 USA.
[Pyne, Jeffrey M.; Kimbrell, Timothy; Hudson, Teresa J.] Univ Arkansas Med Sci, Ctr Mental Hlth & Outcomes Res, Cent Arkansas Vet Healthcare Syst, Coll Med, Little Rock, AR 72205 USA.
[Pyne, Jeffrey M.; Kimbrell, Timothy; Hudson, Teresa J.] Univ Arkansas Med Sci, Coll Med, Dept Psychiat, Little Rock, AR 72205 USA.
[Magruder, Kathy M.] Med Univ S Carolina, Dept Psychiat & Behav Sci, Ralph H Johnson VA Med Ctr, Charleston, SC 29425 USA.
[Kunik, Mark E.] Baylor Coll Med, Dept Med, Houston, TX 77030 USA.
[Kunik, Mark E.] Baylor Coll Med, Menninger Dept Psychiat & Behav Sci, Houston, TX 77030 USA.
RP Kunik, ME (reprint author), Michael E DeBakey VAMC 152, Houston Ctr Qual Care & Utilizat Studies, 2002 Holcombe, Houston, TX 77030 USA.
EM mkunik@bcm.tmc.edu
RI Schueter, nicos/A-3625-2014
FU Houston Center for Quality of Care & Utilization Studies, Health
Services Research and Development Service, Office of Research and
Development, Department of Veterans Affairs [HFP90-020]
FX This material is based on work supported in part by the Houston Center
for Quality of Care & Utilization Studies, Health Services Research and
Development Service, Office of Research and Development, Department of
Veterans Affairs (HFP90-020).; The views expressed are those of the
authors and do not necessarily reflect those of the VA or Baylor College
of Medicine.
NR 55
TC 49
Z9 50
U1 3
U2 16
PU AMER PSYCHIATRIC PUBLISHING, INC
PI ARLINGTON
PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA
SN 0895-0172
J9 J NEUROPSYCH CLIN N
JI J. Neuropsychiatr. Clin. Neurosci.
PD WIN
PY 2011
VL 23
IS 1
BP 16
EP 28
DI 10.1176/appi.neuropsych.23.1.16
PG 13
WC Clinical Neurology; Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA 717VY
UT WOS:000287076700028
PM 21304135
ER
PT J
AU Gordon, AJ
Ettaro, L
Rodriguez, KL
Mocik, J
Clark, DB
AF Gordon, Adam J.
Ettaro, Lorraine
Rodriguez, Keri L.
Mocik, John
Clark, Duncan B.
TI Provider, Patient, and Family Perspectives of Adolescent Alcohol Use and
Treatment in Rural Settings
SO JOURNAL OF RURAL HEALTH
LA English
DT Article
DE Access to care; adolescents; alcohol abuse; geography; patient
assessment
ID RANDOMIZED CONTROLLED-TRIAL; HIGH-RISK DRINKING; PRIMARY-CARE; BRIEF
INTERVENTION; COLLEGE-STUDENTS; SUBSTANCE-ABUSE; USE DISORDERS;
SCREENING-TEST; PREVENTION; BEHAVIORS
AB Purpose: We examined rural primary care providers' (PCPs) self-reported practices of screening, brief interventions, and referral to treatment (SBIRT) on adolescent alcohol use and examined PCPs', adolescents', and parents' attitudes regarding SBIRT on adolescent alcohol use in rural clinic settings.
Methods: In 2007, we mailed surveys that inquired about alcohol-related knowledge, attitudes, and treatment practices of adolescent alcohol use to all PCPs in 8 counties in rural Pennsylvania who may have treated adolescents. We then conducted 7 focus groups of PCPs and their staffs (n = 3), adolescents (n = 2), and parents (n = 2) and analyzed the narratives using structured grounded theory, evaluating for consistent or discordant themes.
Results: Twenty-seven PCPs from 7 counties returned the survey. While 92% of PCPs felt that routine screening for alcohol use should begin by age 14, 84% reportedly screened for alcohol use occasionally, and reportedly 32% screened all adolescent patients. The provider focus groups (n = 20 PCPs/staff) related that SBIRT for alcohol use for adolescents was not currently effective. Poor provider training, lack of alcohol screening tools, and lack of referral treatment options were identified barriers. Adolescents (n = 12) worried that physicians would not maintain confidentiality. Parents (n = 12) acknowledged a parental contribution to adolescent alcohol use. All groups indicated computer-based methods to screen for alcohol use among adolescents may facilitate PCP engagement.
Conclusions: Despite awareness that rural adolescent alcohol use is a significant problem, PCPs, adolescents, and parents recognize that SBIRT for adolescent alcohol use in rural PCP settings is ineffective, but it may improve with computer-based screening and intervention techniques.
C1 [Gordon, Adam J.] VA Pittsburgh Healthcare Syst, Mental Illness Res Educ & Clincal Ctr, Pittsburgh, PA USA.
[Gordon, Adam J.; Rodriguez, Keri L.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA.
[Gordon, Adam J.] Ctr Res Healthcare, Pittsburgh, PA USA.
[Gordon, Adam J.; Ettaro, Lorraine; Mocik, John; Clark, Duncan B.] NW Penn Adolescent Alcohol Res Cooperat, Pittsburgh, PA USA.
[Ettaro, Lorraine; Mocik, John] Univ Pittsburgh, Ctr Rural Hlth Practice, Bradford, PA USA.
[Rodriguez, Keri L.] VA Pittsburgh Healthcare Syst, Ctr Geriatr Res Educ & Clin, Pittsburgh, PA USA.
[Clark, Duncan B.] Pittsburgh Adolescent Alcohol Res Ctr, Pittsburgh, PA USA.
[Gordon, Adam J.; Rodriguez, Keri L.; Clark, Duncan B.] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA.
RP Gordon, AJ (reprint author), Mailcode 151-C-H,7180 Highland Dr, Pittsburgh, PA 15206 USA.
EM adam.gordon@va.gov
FU National Institutes of Health (NIH), National Institute of Alcohol Abuse
and Alcoholism (NIAAA) [U01AA016482, K02AA00291]
FX This study was supported by the National Institutes of Health (NIH),
National Institute of Alcohol Abuse and Alcoholism (NIAAA) from grants
U01AA016482 (PI: Clark) and K02AA00291 (PI: Clark). The authors wish to
acknowledge Margaret Krumm, BA, for her assistance in editing this
manuscript. The authors affirm that they have listed everyone who has
contributed significantly to the work of this manuscript. For further
information, contact: Adam J. Gordon, MD, MPH, FACP, FASAM, CHERP;
Mailcode 151-C-H, 7180 Highland Drive, Pittsburgh, PA 15206; e-mail
adam.gordon@va.gov.
NR 45
TC 12
Z9 12
U1 2
U2 12
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0890-765X
J9 J RURAL HEALTH
JI J. Rural Health
PD WIN
PY 2011
VL 27
IS 1
BP 81
EP 90
DI 10.1111/j.1748-0361.2010.00321.x
PG 10
WC Health Care Sciences & Services; Health Policy & Services; Public,
Environmental & Occupational Health
SC Health Care Sciences & Services; Public, Environmental & Occupational
Health
GA 702JZ
UT WOS:000285891700010
PM 21204975
ER
PT J
AU Dohgu, S
Fleegal-DeMotta, MA
Banks, WA
AF Dohgu, Shinya
Fleegal-DeMotta, Melissa A.
Banks, William A.
TI Lipopolysaccharide-enhanced transcellular transport of HIV-1 across the
blood-brain barrier is mediated by luminal microvessel IL-6 and GM-CSF
SO JOURNAL OF NEUROINFLAMMATION
LA English
DT Article
DE Blood-brain barrier; Human immunodeficiency virus type 1;
Lipopolysaccharide; Interleukin-6; Granulocyte-macrophage
colony-stimulating factor; Mitogen-activated protein kinase
ID TUMOR-NECROSIS-FACTOR; IMMUNODEFICIENCY-VIRUS-INFECTION; JUNCTION
PROTEIN EXPRESSION; ENDOTHELIAL-CELLS; IN-VITRO; ADSORPTIVE ENDOCYTOSIS;
SURFACE-PROTEINS; PERMEABILITY; CYTOKINES; ACTIVATION
AB Elevated levels of cytokines/chemokines contribute to increased neuroinvasion of human immunodeficiency virus type 1 (HIV-1). Previous work showed that lipopolysaccharide (LPS), which is present in the plasma of patients with HIV-1, enhanced transcellular transport of HIV-1 across the blood-brain barrier (BBB) through the activation of p38 mitogen-activated protein kinase (MAPK) signaling in brain microvascular endothelial cells (BMECs). Here, we found that LPS (100 mu g/mL, 4 hr) selectively increased interleukin (IL)-6 and granulocyte-macrophage colony-stimulating factor (GM-CSF) release from BMECs. The enhancement of HIV-1 transport induced by luminal LPS was neutralized by treatment with luminal, but not with abluminal, antibodies to IL-6 and GM-CSF without affecting paracellular permeability as measured by transendothelial electrical resistance (TEER). Luminal, but not abluminal, IL-6 or GMCSF also increased HIV-1 transport. U0126 (MAPK kinase (MEK) 1/2 inhibitor) and SB203580 (p38 MAPK inhibitor) decreased the LPS-enhanced release of IL-6 and GM-CSF. These results show that p44/42 and p38 MAPK signaling pathways mediate the LPS-enhanced release of IL-6 and GM-CSF. These cytokines, in turn, act at the luminal surface of the BMEC to enhance the transcellular transport of HIV-1 independently of actions on paracellular permeability.
C1 [Dohgu, Shinya; Fleegal-DeMotta, Melissa A.; Banks, William A.] Geriatr Res Educ & Clin Ctr St Louis, St Louis, MO USA.
[Dohgu, Shinya] Fukuoka Univ, Fac Pharmaceut Sci, Dept Pharmaceut Care & Hlth Sci, Fukuoka 81401, Japan.
[Dohgu, Shinya; Fleegal-DeMotta, Melissa A.; Banks, William A.] St Louis Univ, Sch Med, Dept Internal Med, Div Geriatr Med, St Louis, MO 63103 USA.
[Fleegal-DeMotta, Melissa A.] Clarke Univ, Dept Biol, Dubuque, IA USA.
[Banks, William A.] Vet Affairs Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA USA.
[Banks, William A.] Univ Washington, Dept Internal Med, Div Gerontol & Geriatr Med, Seattle, WA 98195 USA.
RP Banks, WA (reprint author), Geriatr Res Educ & Clin Ctr St Louis, St Louis, MO USA.
EM wabanks1@uw.edu
FU National Cancer Institute, National Institutes of Health [N01-CO-12400];
VA Merit Review; NIH [R01NS050547, R01AG029839]
FX The authors thank Dr. Maria A. Deli (Institute of Biophysics, Biological
Research Centre of the Hungarian Academy of Sciences) for technical
advice on primary BMEC culture and comments on this study. The virus was
a kind gift the National Cancer Institute, National Institutes of
Health. Funded in part with Federal funds from National Cancer
Institute, National Institutes of Health, under Contract No.
N01-CO-12400. The content of this publication does not necessarily
reflect the views or policies of the Department of Health and Human
Services, nor does mention of names, commercial products, or
organization imply endorsement by the U. S. government. Supported by VA
Merit Review (WAB), NIH R01NS050547 (WAB), and NIH R01AG029839 (WAB).
NR 53
TC 26
Z9 26
U1 1
U2 2
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1742-2094
J9 J NEUROINFLAMM
JI J. Neuroinflamm.
PD NOV 30
PY 2011
VL 8
AR 167
DI 10.1186/1742-2094-8-167
PG 12
WC Immunology; Neurosciences
SC Immunology; Neurosciences & Neurology
GA 878SK
UT WOS:000299276600001
PM 22129063
ER
PT J
AU Li, XB
Large, CH
Ricci, R
Taylor, JJ
Nahas, Z
Bohning, DE
Morgan, P
George, MS
AF Li, Xingbao
Large, Charles H.
Ricci, Raffaella
Taylor, Joseph J.
Nahas, Ziad
Bohning, Daryl E.
Morgan, Paul
George, Mark S.
TI Using interleaved transcranial magnetic stimulation/functional magnetic
resonance imaging (fMRI) and dynamic causal modeling to understand the
discrete circuit specific changes of medications: Lamotrigine and
valproic acid changes in motor or prefrontal effective connectivity
SO PSYCHIATRY RESEARCH-NEUROIMAGING
LA English
DT Article
DE Transcranial magnetic stimulation; Neuroimaging; Dynamic causal
modeling; Network; Lamotrigine; Valproic acid
ID ANTIEPILEPTIC DRUGS; BIPOLAR DISORDER; CORTICAL EXCITABILITY; TMS;
CORTEX; MECHANISMS; SYSTEM; MOOD; MRI; DEPRESSION
AB The purpose of this study was to use interleaved transcranial magnetic stimulation/functional magnetic resonance imaging (TMS/fMRI) to investigate the effects of lamotrigine (LTG) and valproic acid (VPA) on effective connectivity within motor and corticolimbic circuits. In this randomized, double-blind, crossover trial, 30 healthy volunteers received either drug or placebo 3.5 h prior to interleaved TMS/fMRI. We utilized dynamic causal modeling (DCM) to assess changes in the endogenous effective connectivity of bidirectional networks in the motor-sensory system and corticolimbic circuit. Results indicate that both LTG and VPA have network-specific effects. When TMS was applied over the motor cortex, both LTG and VPA reduced TMS-specific effective connectivity between primary motor (M1) and pre-motor cortex (PMd), and between M1 and the supplementary area motor (SMA). When TMS was applied over prefrontal cortex, however, LTG alone increased TMS-specific effective connectivity between the left dorsolateral prefrontal cortex (DLPFC) and the anterior cingulate cortex (ACC). In summary, LTG and VPA both inhibited effective connectivity in motor circuits, but LTG alone increased effective connectivity in prefrontal circuits. These results suggest that interleaved TMS/fMRI can assess region- and circuit-specific effects of medications or interventions. Published by Elsevier Ireland Ltd.
C1 [Li, Xingbao] Med Univ S Carolina, Brain Stimulat Lab, MUSC IOP, Dept Psychiat, Charleston, SC 29425 USA.
[Li, Xingbao; Taylor, Joseph J.; Bohning, Daryl E.; Morgan, Paul; George, Mark S.] Med Univ S Carolina, Ctr Adv Imaging Res, Charleston, SC 29425 USA.
[Large, Charles H.] GlaxoSmithKline SpA, Med Res Ctr, Verona, Italy.
[George, Mark S.] Ralph H Johnson VA Med Ctr, Charleston, SC USA.
RP Li, XB (reprint author), Med Univ S Carolina, Brain Stimulat Lab, MUSC IOP, Dept Psychiat, 502 N,67 President St, Charleston, SC 29425 USA.
EM lixi@musc.edu
FU GlaxoSmithKline; Center for Advanced Imaging Research; Brain Stimulation
Laboratory
FX This study was funded primarily by an unrestricted research grant from
GlaxoSmithKline to Dr. George, as well as from Center for Advanced
Imaging Research and Brain Stimulation Laboratory infrastructure and
resources. CHL is a full-time employee of GlaxoSmithKline S.p.A. None of
the other authors has equity or financial conflicts. Drs. Li and George
had full access to all of the data in the study and take responsibility
for the integrity of the data and the accuracy of the data analysis.
Presented in abstract form at the annual meeting of American College of
Neuropsychopharmacology, Hollywood, FL, Dec 14, 2006 and the annual
meeting of the Society of Biological Psychiatry, San Diego, CA, May 21,
2007.
NR 50
TC 15
Z9 15
U1 0
U2 1
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
IRELAND
SN 0925-4927
J9 PSYCHIAT RES-NEUROIM
JI Psychiatry Res. Neuroimaging
PD NOV 30
PY 2011
VL 194
IS 2
BP 141
EP 148
DI 10.1016/j.pscychresns.2011.04.012
PG 8
WC Clinical Neurology; Neuroimaging; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA 843QD
UT WOS:000296686200005
PM 21924874
ER
PT J
AU Levine, DA
Funkhouser, EM
Houston, TK
Gerald, JK
Johnson-Roe, N
Allison, JJ
Richman, J
Kiefe, CI
AF Levine, Deborah A.
Funkhouser, Ellen M.
Houston, Thomas K.
Gerald, Joe K.
Johnson-Roe, Nancy
Allison, Jeroan J.
Richman, Joshua
Kiefe, Catarina I.
TI Improving Care After Myocardial Infarction Using a 2-Year
Internet-Delivered Intervention The Department of Veterans Affairs
Myocardial Infarction-Plus Cluster-Randomized Trial
SO ARCHIVES OF INTERNAL MEDICINE
LA English
DT Article
ID CORONARY-HEART-DISEASE; CONTINUOUS-QUALITY-IMPROVEMENT; RE-AIM
FRAMEWORK; MEDICARE BENEFICIARIES; SECONDARY PREVENTION; MANAGEMENT
PROGRAMS; CARDIAC-DISEASE; AMBULATORY-CARE; RISK-FACTORS; MI-PLUS
AB Background: Cardiovascular risk reduction in ambulatory patients who survive myocardial infarction (MI) is effective but underused. We sought to evaluate a provider-directed, Internet-delivered intervention to improve cardiovascular management for post-MI outpatients.
Methods: The Department of Veterans Affairs (VA) MI-Plus study was a cluster-randomized trial involving 168 community-based primary care clinics and 847 providers in 26 states, the Virgin Islands, and Puerto Rico, from January 1, 2002, through December 31, 2008, with the clinic as the randomization unit. We collected administrative data for 15 847 post-MI patients and medical record data for 10 452 of these. A multicomponent, Internet-delivered intervention included quarterly educational modules, practice guidelines, monthly literature summaries, and automated e-mail reminders delivered to providers for 27 months. Main outcome measures included percentage of patients who achieved each of 7 clinical indicators, a composite score of the 7 clinical indicators, and mean low-density lipoprotein cholesterol and hemoglobin A(1c) levels.
Results: Clinics had a median of 3 providers (interquartile range, 2-6), with a median of 50.0% of providers (33.3%-66.7%) participating in the study. Patients in intervention clinics had greater improvements (from 70.0% to 85.5%) in the percentages prescribed beta-blockers than patients in control clinics (71.9% to 84.0%; adjusted improvement gain for intervention vs control, 2.6%; 95% CI, 0.1%-4.1%). We found nonsignificant differences in improvements favoring patients in intervention clinics for 5 of 6 remaining clinical indicators and levels of low-density lipoprotein cholesterol and hemoglobin A(1c).
Conclusion: A longitudinal, Internet-delivered intervention improved only 1 of 7 clinical indicators of cardiovascular management in ambulatory post-MI patients.
C1 [Levine, Deborah A.] Univ Michigan, Div Gen Med, Dept Med, Ann Arbor, MI 48109 USA.
[Levine, Deborah A.] Univ Michigan, Dept Neurol, Ann Arbor, MI 48109 USA.
[Levine, Deborah A.] Ann Arbor Vet Affairs VA Healthcare Syst, Ann Arbor, MI USA.
[Levine, Deborah A.; Funkhouser, Ellen M.] Univ Alabama Birmingham Sch Med, Dept Med, Birmingham, AL USA.
[Richman, Joshua] Univ Alabama Birmingham Sch Med, Dept Surg, Birmingham, AL USA.
[Johnson-Roe, Nancy; Richman, Joshua] Birmingham VA Med Ctr, VA Res Enhancement Award Program, Birmingham, AL USA.
[Houston, Thomas K.; Allison, Jeroan J.; Kiefe, Catarina I.] Univ Massachusetts, Sch Med, Dept Quantitat Hlth Sci, Worcester, MA USA.
[Allison, Jeroan J.; Kiefe, Catarina I.] Univ Massachusetts, Sch Med, Transit Risks & Act Coronary Events Ctr Outcomes, Worcester, MA USA.
[Houston, Thomas K.] Bedford VA Med Ctr, Ctr Hlth Qual Outcomes & Econ Res, Bedford, MA USA.
[Gerald, Joe K.] Univ Arizona, Mel & Enid Zuckerman Coll Publ Hlth, Div Publ Hlth Policy & Management, Tucson, AZ USA.
RP Levine, DA (reprint author), Univ Michigan, Div Gen Med, Dept Med, 300 N Ingalls St,Room 7C27, Ann Arbor, MI 48109 USA.
EM deblevin@umich.edu
RI Houston, Thomas/F-2469-2013
OI Allison, Jeroan/0000-0003-4472-2112
FU VA Health Services Research and Development office [IHD-04-387];
National Institutes of Health [R01 HL70786-02]
FX This study was supported by grant IHD-04-387 from the VA Health Services
Research and Development office and grant R01 HL70786-02 from the
National Institutes of Health for a parallel study.
NR 51
TC 8
Z9 8
U1 0
U2 4
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA
SN 0003-9926
J9 ARCH INTERN MED
JI Arch. Intern. Med.
PD NOV 28
PY 2011
VL 171
IS 21
BP 1910
EP 1917
PG 8
WC Medicine, General & Internal
SC General & Internal Medicine
GA 853JV
UT WOS:000297423000006
PM 22123798
ER
PT J
AU Alia, I
de la Cal, MA
Esteban, A
Abella, A
Ferrer, R
Molina, FJ
Torres, A
Gordo, F
Elizalde, JJ
de Pablo, R
Huete, A
Anzueto, A
AF Alia, Inmaculada
de la Cal, Miguel A.
Esteban, Andres
Abella, Ana
Ferrer, Ricard
Molina, Francisco J.
Torres, Antoni
Gordo, Federico
Elizalde, Jose J.
de Pablo, Raul
Huete, Alejandro
Anzueto, Antonio
TI Efficacy of Corticosteroid Therapy in Patients With an Acute
Exacerbation of Chronic Obstructive Pulmonary Disease Receiving
Ventilatory Support
SO ARCHIVES OF INTERNAL MEDICINE
LA English
DT Article
ID ACUTE RESPIRATORY-FAILURE; INTENSIVE-CARE-UNIT; COMMUNITY-ACQUIRED
PNEUMONIA; RANDOMIZED CONTROLLED-TRIAL; INVASIVE MECHANICAL VENTILATION;
PLACEBO-CONTROLLED TRIAL; NONINVASIVE VENTILATION; SYSTEMIC
GLUCOCORTICOIDS; DISTRESS-SYNDROME; CLINICAL-COURSE
AB Background: Randomized trials assessing the effect of systemic corticosteroids on chronic obstructive pulmonary disease (COPD) exacerbations excluded patients who were mechanically ventilated or admitted to the intensive care unit (ICU). Critically ill patients constitute a population of persons who are prone to develop complications that are potentially associated with the use of corticosteroids (eg, infections, hyperglycemia, ICU-acquired paresis) that could prolong the duration of mechanical ventilation and even increase mortality.
Methods: A double-blind placebo-controlled trial was conducted to evaluate the efficacy and safety of systemic corticosteroid treatment in patients with an exacerbation of COPD who were receiving ventilatory support (invasive or noninvasive mechanical ventilation). A total of 354 adult patients who were admitted to the ICUs of 8 hospitals in 4 countries from July 2005 through July 2009 were screened, and 83 were randomized to receive intravenous methylprednisolone (0.5 mg/kg every 6 hours for 72 hours, 0.5 mg/kg every 12 hours on days 4 through 6, and 0.5 mg/kg/d on days 7 through 10) or placebo. The main outcome measures were duration of mechanical ventilation, length of ICU stay, and need for intubation in patients treated with noninvasive mechanical ventilation.
Results: There were no significant differences between the groups in demographics, severity of illness, reasons for COPD exacerbation, gas exchange variables, and corticosteroid rescue treatment. Corticosteroid treatment was associated with a significant reduction in the median duration of mechanical ventilation (3 days vs 4 days; P=.04), a trend toward a shorter median length of ICU stay (6 days vs 7 days; P=.09), and significant reduction in the rate of NIV failure (0% vs 37%; P=.04).
Conclusion: Systemic corticosteroid therapy in patients with COPD exacerbations requiring mechanical ventilation is associated with a significant increase in the success of noninvasive mechanical ventilation and a reduction in the duration of mechanical ventilation
C1 [Alia, Inmaculada; de la Cal, Miguel A.; Esteban, Andres; Abella, Ana; Huete, Alejandro] Hosp Univ Getafe, Intens Care Units ICUs, Ctr Invest Biomed Red Enfermedades Resp CIBERes, Getafe, Spain.
[Ferrer, Ricard] Consorci Hosp Parc Tauli, CIBERes, Sabadell, Spain.
[Torres, Antoni] Hosp Clin Barcelona, CIBERes, Barcelona, Spain.
[Molina, Francisco J.] Clin Univ Bolivariana, ICU, Medellin, Colombia.
[Gordo, Federico] Hosp Univ Fdn Alcorcon, ICU, Madrid, Spain.
[Elizalde, Jose J.] Hosp ABC, ICU, Mexico City, DF, Mexico.
[de Pablo, Raul] Hosp Univ Principe Asturias, ICU, Alcala De Henares, Spain.
[Anzueto, Antonio] Univ Texas Hlth Sci Ctr, ICU, San Antonio, TX USA.
[Anzueto, Antonio] S Texas Vet Hlth Care Syst, San Antonio, TX USA.
RP Esteban, A (reprint author), Hosp Getafe, Unidad Cuidados Intens, Carretera Toledo Km 12-5, Getafe 28905, Spain.
EM aesteban@ucigetafe.com
FU Fondo de Investigacion Sanitaria [PI041233]
FX This study was funded in part by grant PI041233 from Fondo de
Investigacion Sanitaria.
NR 44
TC 30
Z9 30
U1 0
U2 3
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA
SN 0003-9926
J9 ARCH INTERN MED
JI Arch. Intern. Med.
PD NOV 28
PY 2011
VL 171
IS 21
BP 1939
EP 1946
PG 8
WC Medicine, General & Internal
SC General & Internal Medicine
GA 853JV
UT WOS:000297423000013
PM 22123804
ER
PT J
AU Tallaj, JA
Pamboukian, SV
George, JF
Brown, RN
Pajaro, OE
Bourge, RC
Cadeiras, M
Smallfield, M
Kirklin, JK
McGiffin, DC
AF Tallaj, Jose A.
Pamboukian, Salpy V.
George, James F.
Brown, Robert N.
Pajaro, Octavio E.
Bourge, Robert C.
Cadeiras, Martin
Smallfield, Melissa
Kirklin, James K.
McGiffin, David C.
TI Total Lymphoid Irradiation in Heart Transplantation: Long-Term Efficacy
and Survival-An 18-Year Experience
SO TRANSPLANTATION
LA English
DT Article
DE Total lymphoid irradiation; Outcomes; Heart transplantation
ID RISK-FACTORS; LUNG TRANSPLANTATION; CARDIAC TRANSPLANTATION; RECURRENT
REJECTION; ALLOGRAFT-REJECTION; HODGKINS-DISEASE; IMMUNOSUPPRESSION;
DEATH
AB Background. Total lymphoid irradiation (TLI) has been used in transplantation for over 20 years and is currently used in a number of major heart transplant centers as a secondary therapy for recalcitrant recurrent rejection or rejection with hemodynamic compromise. The purpose of this study is to evaluate the long-term risks and efficacy of TLI in the treatment of rejection.
Methods. Between 1990 and 1996, 73 adult patients (from 211 adult transplant recipients) received TLI for recurrent rejection (71%), rejection with hemodynamic compromise (25%), and rejection with vasculitis (4%). The treatment consisted of 80 cGy twice per week for 5 weeks. Fifty-five patients received at least 80% of the full dose (>640 cGy). Follow-up ended December 31, 2007, comprising a total 18 year experience.
Results. Patients treated with TLI exhibited a short-term decrease in hazard for rejection in the first 12 months posttransplantation (relative risk, 0.36) but exhibited increased cumulative rejection over the long term. There were no differences in the rates of infection, allograft coronary disease, or malignancy, but seven patients developed myelodysplasia or acute myelogenous leukemia, four of those being the rare but uniformly fatal acute megakaryocytic leukemia type 7.
Conclusions. Patients treated with TLI seemed to experience a reduction in the early hazard for rejection, but long-term outcomes indicate that such patients continued to accumulate more rejection and rejection-death events, likely because these patients were overall at much higher risk for rejection than the other patient groups. We observed minimal long-term complications, except for the unique occurrence of myelodysplasia and acute megakaryocytic leukemia type 7.
C1 [Tallaj, Jose A.; Pamboukian, Salpy V.; Bourge, Robert C.; Cadeiras, Martin; Smallfield, Melissa] Univ Alabama Birmingham, Dept Med, Div Cardiovasc Dis, Birmingham, AL 35294 USA.
[Tallaj, Jose A.] Birmingham VA Med Ctr, Dept Med, Birmingham, AL USA.
[George, James F.; Brown, Robert N.; Pajaro, Octavio E.; Kirklin, James K.; McGiffin, David C.] Univ Alabama Birmingham, Dept Med, Div Cardiothorac Surg, Birmingham, AL 35294 USA.
RP Tallaj, JA (reprint author), Univ Alabama Birmingham, Dept Med, Div Cardiovasc Dis, THT331,1900 Univ Blvd, Birmingham, AL 35294 USA.
EM jtallaj@uab.edu
NR 30
TC 2
Z9 2
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0041-1337
EI 1534-6080
J9 TRANSPLANTATION
JI Transplantation
PD NOV 27
PY 2011
VL 92
IS 10
BP 1159
EP 1164
DI 10.1097/TP.0b013e318231e9d3
PG 6
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA 845BP
UT WOS:000296798100021
PM 22015463
ER
PT J
AU Shen, Q
Huang, SL
Du, F
Duong, TQ
AF Shen, Qiang
Huang, Shiliang
Du, Fang
Duong, Timothy Q.
TI Probing ischemic tissue fate with BOLD fMRI of brief oxygen challenge
SO BRAIN RESEARCH
LA English
DT Article
DE MRI; Perfusion; Diffusion; Oxygen inhalation; Penumbra
ID CEREBRAL-BLOOD-FLOW; FUNCTIONAL MRI; QUANTITATIVE PREDICTION; FOCAL
ISCHEMIA; PERFUSION; HYPEROXIA; DIFFUSION; PENUMBRA; STROKE; RATS
AB It has been recently shown that at-risk tissue exhibits exaggerated T*(2)-weighted MRI signal increases during transient oxygen challenge (OC), suggesting that the tissue is still metabolically active. This study further characterized the effects of transient OC on T*(2)-weighted MRI in permanent focal stroke rats (N=8) using additional quantitative measures. The major findings were: i) the ischemic core cluster showed no significant response, whereas the mismatch cluster showed markedly higher percent changes relative to normal tissue in the acute phase. ii) Many of the mismatch pixels showed exaggerated OC responses which became hyperintense on T(2)-weighted MRI at 24 h. The area with exaggerated OC responses was larger than the mismatch, suggesting that some tissue with reduced diffusion were potentially at risk. iii) Basal T*(2)-weighted intensities on the perfusion-diffusion contourplot were high in normal tissue and low in the core, with a sharp transition in the mismatch. iv) OC-induced changes on the perfusion-diffusion contourplot dropped as perfusion and diffusion values fell below their respective viability thresholds. v) Basal T(1) increased slightly in the ischemic core (P<0.05). OC decreased T(1) in normal (P<0.05) but not in mismatch and core pixels. vi) OC decreased CBF in normal (P<0.05) but not in mismatch and core pixels. T*(2)-weighted MRI of OC has the potential to offer unique clinically relevant data. (C) 2011 Elsevier B.V. All rights reserved.
C1 [Duong, Timothy Q.] Univ Texas Hlth Sci Ctr San Antonio, Res Imaging Inst, Dept Ophthalmol Radiol & Physiol, San Antonio, TX 78229 USA.
S Texas Vet Hlth Care Syst, Res Serv, San Antonio, TX USA.
RP Duong, TQ (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Res Imaging Inst, Dept Ophthalmol Radiol & Physiol, 8403 Floyd Curl Dr, San Antonio, TX 78229 USA.
EM duongt@uthscsa.edu
RI Duong, Timothy/B-8525-2008; Shen, Qiang/B-8784-2008; Huang,
Shiliang/F-3143-2010
OI Shen, Qiang/0000-0002-4287-3403;
FU NIH [R01-NS45879]; American Heart Association [ELA 0940104 N, SDG
0830293 N]; Clinical and Translational Science Awards [UL1RR025767]
FX This work was supported by the NIH (R01-NS45879), the American Heart
Association (EIA 0940104 N and SDG 0830293 N) and Clinical and
Translational Science Awards (parent grant UL1RR025767).
NR 28
TC 17
Z9 18
U1 1
U2 15
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0006-8993
J9 BRAIN RES
JI Brain Res.
PD NOV 24
PY 2011
VL 1425
BP 132
EP 141
DI 10.1016/j.brainres.2011.09.052
PG 10
WC Neurosciences
SC Neurosciences & Neurology
GA 862VN
UT WOS:000298122300014
PM 22032876
ER
PT J
AU Bokov, AF
Garg, N
Ikeno, Y
Thakur, S
Musi, N
DeFronzo, RA
Zhang, N
Erickson, RC
Gelfond, J
Hubbard, GB
Adamo, ML
Richardson, A
AF Bokov, Alex F.
Garg, Neha
Ikeno, Yuji
Thakur, Sachin
Musi, Nicolas
DeFronzo, Ralph A.
Zhang, Ning
Erickson, Rebecca C.
Gelfond, Jon
Hubbard, Gene B.
Adamo, Martin L.
Richardson, Arlan
TI Does Reduced IGF-1R Signaling in Igf1r(+/-) Mice Alter Aging?
SO PLOS ONE
LA English
DT Article
ID GROWTH-FACTOR-I; LIFE-SPAN EXTENSION; FATAL NEOPLASTIC DISEASES; AMES
DWARF MICE; INSULIN-RECEPTOR; CAENORHABDITIS-ELEGANS; CALORIE
RESTRICTION; DELAYED OCCURRENCE; LONGEVITY; GENE
AB Mutations in insulin/IGF-1 signaling pathway have been shown to lead to increased longevity in various invertebrate models. Therefore, the effect of the haplo-insufficiency of the IGF-1 receptor (Igf1r(+/-)) on longevity/aging was evaluated in C57Bl/6 mice using rigorous criteria where lifespan and end-of-life pathology were measured under optimal husbandry conditions using large sample sizes. Igf1r(+/-) mice exhibited reductions in IGF-1 receptor levels and the activation of Akt by IGF-1, with no compensatory increases in serum IGF-1 or tissue IGF-1 mRNA levels, indicating that the Igf1r(+/-) mice show reduced IGF-1 signaling. Aged male, but not female Igf1r(+/-) mice were glucose intolerant, and both genders developed insulin resistance as they aged. Female, but not male Igf1r(+/-) mice survived longer than wild type mice after lethal paraquat and diquat exposure, and female Igf1r(+/-) mice also exhibited less diquat-induced liver damage. However, no significant difference between the lifespans of the male Igf1r(+/-) and wild type mice was observed; and the mean lifespan of the Igf1r(+/-) females was increased only slightly (less than 5%) compared to wild type mice. A comprehensive pathological analysis showed no significant difference in end-of-life pathological lesions between the Igf1r(+/-) and wild type mice. These data show that the Igf1r(+/-) mouse is not a model of increased longevity and delayed aging as predicted by invertebrate models with mutations in the insulin/IGF-1 signaling pathway.
C1 [Bokov, Alex F.; Ikeno, Yuji; Musi, Nicolas; Gelfond, Jon; Hubbard, Gene B.; Adamo, Martin L.; Richardson, Arlan] Univ Texas Hlth Sci Ctr San Antonio, Barshop Inst Longev & Aging Studies, San Antonio, TX 78229 USA.
[Bokov, Alex F.; Richardson, Arlan] Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA.
[Garg, Neha; Thakur, Sachin; Adamo, Martin L.] Univ Texas Hlth Sci Ctr San Antonio, Dept Biochem, San Antonio, TX 78229 USA.
[Gelfond, Jon] Univ Texas Hlth Sci Ctr San Antonio, Dept Epidemiol & Biostat, San Antonio, TX 78229 USA.
[Ikeno, Yuji; Hubbard, Gene B.] Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, San Antonio, TX 78229 USA.
[Musi, Nicolas; DeFronzo, Ralph A.; Zhang, Ning] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA.
[Ikeno, Yuji; Musi, Nicolas; Richardson, Arlan] S Texas Vet Hlth Care Syst, GRECC, San Antonio, TX USA.
[Erickson, Rebecca C.] Univ Texas Austin, Coll Nat Sci, Austin, TX 78712 USA.
RP Bokov, AF (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Barshop Inst Longev & Aging Studies, San Antonio, TX 78229 USA.
EM Richardson@uthscsa.edu
FU National Institutes of Health (NIH) [AGO-21890]; Beeson Career
Development Award [AG-030979, DK-80157, DK-089229, DK-24092 RAD,
R01AG026012, AG-19316, AG-13319, AG-23843, AG-26557]; Nathan Shock
[1P30-AG-13319]; Department of Veteran's Affairs; University of Texas
System
FX This work was supported by National Institutes of Health (NIH)
(http://grants.nih.gov/grants/oer.htm) AGO-21890 to AFB; AG-030979
(Beeson Career Development Award), DK-80157 and DK-089229 to NM;
DK-24092 RAD; R01AG026012 to MLA; AG-19316, AG-13319, AG-23843, and
AG-26557 to AR; Nathan Shock: 1P30-AG-13319 to AR; Department of
Veteran's Affairs: Research Enhancement Award Program, Merit Grant to
AR; and University of Texas System's Graduate Programs Initiative:
Translational Science Training (TST) Across Disciplines to NG. The
funders had no role in study design, data collection and analysis,
decision to publish, or preparation of the manuscript.
NR 51
TC 49
Z9 50
U1 0
U2 10
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD NOV 23
PY 2011
VL 6
IS 11
AR e26891
DI 10.1371/journal.pone.0026891
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 863KL
UT WOS:000298162000007
PM 22132081
ER
PT J
AU Dubin, R
Li, YM
Ix, JH
Shlipak, M
Whooley, M
Peralta, CA
AF Dubin, Ruth
Li, Yongmei
Ix, Joachim H.
Shlipak, Michael
Whooley, Mary
Peralta, Carmen A.
TI Associations of Pentraxin-3 With Cardiovascular Events, Incident Heart
Failure and Mortality Among Persons With Coronary Heart Disease: Data
From the Heart and Soul Study
SO CIRCULATION
LA English
DT Meeting Abstract
DE Biomarkers; Heart failure; Renal function; Epidemiology
C1 [Dubin, Ruth; Peralta, Carmen A.] UC San Francisco, San Francisco, CA USA.
[Li, Yongmei; Shlipak, Michael; Whooley, Mary] San Francisco VA Med Ctr, San Francisco, CA USA.
[Ix, Joachim H.] UC San Diego, La Jolla, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0009-7322
J9 CIRCULATION
JI Circulation
PD NOV 22
PY 2011
VL 124
IS 21
SU S
MA A15991
PG 2
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA 884WE
UT WOS:000299738707258
ER
PT J
AU Dubin, R
Schiller, NB
Teerlink, JR
Alokozai, D
Johansen, K
AF Dubin, Ruth
Schiller, Nelson B.
Teerlink, John R.
Alokozai, Dean
Johansen, Kirsten
TI Dialysis-Related Symptoms are Associated with Deterioration of Cardiac
Function During Dialysis
SO CIRCULATION
LA English
DT Meeting Abstract
DE Kidney; Diastolic function; Ejection fraction
C1 [Dubin, Ruth; Schiller, Nelson B.; Johansen, Kirsten] UC San Francisco, San Francisco, CA USA.
[Teerlink, John R.] San Francisco VA Med Ctr, San Francisco, CA USA.
[Alokozai, Dean] Cardiocore, Echocardiog, San Francisco, CA USA.
RI Teerlink, John/D-2986-2012
NR 0
TC 0
Z9 0
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0009-7322
J9 CIRCULATION
JI Circulation
PD NOV 22
PY 2011
VL 124
IS 21
SU S
MA A11164
PG 2
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA 884WE
UT WOS:000299738703153
ER
PT J
AU Felker, GM
Tang, WHW
Hernandez, AF
Hasselblad, V
Armstrong, PW
Fonarow, GC
Voors, AA
Metra, M
Butler, J
Dickstein, K
Troughton, RW
Anker, SD
Heizer, GM
Massie, BM
McMurray, JJ
Califf, RM
Starling, RC
O'Connor, CM
AF Felker, G. Michael
Tang, W. H. Wilson
Hernandez, Adrian F.
Hasselblad, Vic
Armstrong, Paul W.
Fonarow, Gregg C.
Voors, Adriaan A.
Metra, Marco
Butler, Javed
Dickstein, Kenneth
Troughton, Richard W.
Anker, Stefan D.
Heizer, Gretchen M.
Massie, Barry M.
McMurray, John J.
Califf, Robert M.
Starling, Randall C.
O'Connor, Christopher M.
TI High Sensitivity Troponin I in Acute Decompensated Heart Failure:
Insights from the ASCEND-HF Study
SO CIRCULATION
LA English
DT Meeting Abstract
CT Scientific Sessions of the American-Heart-Association/Resuscitation
Science Symposium
CY NOV 12-16, 2011
CL Orlando, FL
SP Amer Heart Assoc
DE Biomarkers
C1 [Felker, G. Michael; Hernandez, Adrian F.; Hasselblad, Vic; Heizer, Gretchen M.; O'Connor, Christopher M.] Duke Univ, Med Ctr, Duke Clin Rsch Inst, Durham, NC USA.
[Tang, W. H. Wilson; Starling, Randall C.] Cleveland Clin, Cleveland, OH 44106 USA.
[Armstrong, Paul W.] Univ Alberta, Edmonton, AB, Canada.
[Fonarow, Gregg C.] Univ Calif Los Angeles, Los Angeles, CA USA.
[Voors, Adriaan A.] Univ Groningen, Univ Med Ctr Groningen, NL-9713 AV Groningen, Netherlands.
[Metra, Marco] Univ Brescia, Brescia, Italy.
[Butler, Javed] Emory Univ, Atlanta, GA 30322 USA.
[Dickstein, Kenneth] Univ Bergen, Inst Internal Med, Stavanger Univ Hosp, Bergen, Norway.
[Troughton, Richard W.] Univ Otago, Christchurch, New Zealand.
[Anker, Stefan D.] Appl Cachexia Rsch, Dept Cardiol, Berlin, Germany.
[Massie, Barry M.] Univ Calif San Francisco, San Francisco VA Med Ctr, San Francisco, CA 94143 USA.
[McMurray, John J.] Univ Glasgow, Glasgow, Lanark, Scotland.
[Califf, Robert M.] Duke Univ, Med Ctr, Duke Translat Med Inst, Durham, NC USA.
RI Tang, Wai Hong/I-1238-2013
NR 0
TC 0
Z9 0
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0009-7322
J9 CIRCULATION
JI Circulation
PD NOV 22
PY 2011
VL 124
IS 21
SU S
MA A13262
PG 2
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA 884WE
UT WOS:000299738705098
ER
PT J
AU Lam, CS
Anand, IS
Carson, PE
Massie, BM
Rector, TS
Kuskowski, M
McKelvie, RS
Zile, MR
McMurray, JJ
Komajda, M
Kitzman, DW
AF Lam, Carolyn S.
Anand, Inder S.
Carson, Peter E.
Massie, Barry M.
Rector, Thomas S.
Kuskowski, Michael
McKelvie, Robert S.
Zile, Michael R.
McMurray, John J.
Komajda, Michel
Kitzman, Dalane W.
TI Sex Differences in Clinical Characteristics and Outcomes in Elderly
Patients with Heart Failure and Preserved Ejection Fraction: The
I-PRESERVE Trial
SO CIRCULATION
LA English
DT Meeting Abstract
C1 [Lam, Carolyn S.] Natl Univ Hlth Syst, Natl Univ Heart Ctr Singapore, Singapore, Singapore.
[Anand, Inder S.; Rector, Thomas S.; Kuskowski, Michael] Vet Adm Med Ctr, Minneapolis, MN 55417 USA.
[Anand, Inder S.] Univ Minnesota, Minneapolis, MN USA.
[Carson, Peter E.] Georgetown Univ, Washington, DC USA.
[Carson, Peter E.] Washington DC Vet Affairs Med Ctr, Washington, DC USA.
[Massie, Barry M.] Univ Calif San Francisco, Vet Affairs Med Ctr 111C, San Francisco, CA 94143 USA.
[Massie, Barry M.] San Francisco VA Med Ctr, San Francisco, CA USA.
[McKelvie, Robert S.] McMaster Univ, Hamilton, ON, Canada.
[Zile, Michael R.] RHJ Dept Vet Affairs Med Ctr, Dept Med, Div Cardiol, Charleston, SC USA.
[Zile, Michael R.] Med Univ S Carolina, Charleston, SC 29425 USA.
[McMurray, John J.] Univ Glasgow, British Heart Fdn Glasgow Cardiovasc Rsch Ctr, Glasgow, Lanark, Scotland.
[Komajda, Michel] Univ Paris, Pitie Salpetriere Hosp, Dept Cardiol, F-75252 Paris, France.
[Kitzman, Dalane W.] Wake Forest Univ, Dept Internal Med Cardiol & Geriatr, Sch Med, Winston Salem, NC 27109 USA.
NR 0
TC 0
Z9 0
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0009-7322
J9 CIRCULATION
JI Circulation
PD NOV 22
PY 2011
VL 124
IS 21
SU S
MA A10912
PG 2
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA 884WE
UT WOS:000299738703086
ER
PT J
AU Miller, PS
Evangelista, LS
Giger, JN
Martinez-Maza, O
Corvera-Tindel, T
Doering, LV
AF Miller, Pamela S.
Evangelista, Lorraine S.
Giger, Joyce Newman
Martinez-Maza, Otoniel
Corvera-Tindel, Teresita
Doering, Lynn V.
TI Bypassing Troubles: Relation of Exhaustion, Viral Burden, and
Inflammation to Depressive Symptoms After Cardiac Surgery
SO CIRCULATION
LA English
DT Meeting Abstract
DE Cardiac surgery; Coronary artery disease; Inflammation
C1 [Miller, Pamela S.] Univ Calif San Francisco, Sch Nursing, San Francisco, CA 94143 USA.
[Evangelista, Lorraine S.] Univ Calif Irvine, Coll Hlth Sci, Program Nursing Sci, Irvine, CA USA.
[Giger, Joyce Newman; Doering, Lynn V.] Univ Calif Los Angeles, Sch Nursing, Los Angeles, CA 90024 USA.
[Corvera-Tindel, Teresita] Vet Affairs Greater Los Angeles Hlth Care Syst, Nursing Rsch Dept, Los Angeles, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0009-7322
J9 CIRCULATION
JI Circulation
PD NOV 22
PY 2011
VL 124
IS 21
SU S
MA A14769
PG 2
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA 884WE
UT WOS:000299738706205
ER
PT J
AU Miller, PS
Evangelista, LS
Giger, JN
Corvera-Tindel, T
Martinez-Maza, O
Dracup, K
Doering, LV
AF Miller, Pamela S.
Evangelista, Lorraine S.
Giger, Joyce Newman
Corvera-Tindel, Teresita
Martinez-Maza, Otoniel
Dracup, Kathleen
Doering, Lynn V.
TI Who is at Risk for Exhaustion Post-Cardiac Surgery
SO CIRCULATION
LA English
DT Meeting Abstract
DE Coronary heart disease; Cardiac surgery
C1 [Miller, Pamela S.; Dracup, Kathleen] Univ Calif San Francisco, Sch Nursing, San Francisco, CA 94143 USA.
[Evangelista, Lorraine S.] Univ Calif Irvine, Coll Hlth Sci, Program Nursing Sci 2, Irvine, CA USA.
[Giger, Joyce Newman; Doering, Lynn V.] Univ Calif Los Angeles, Sch Nursing, Los Angeles, CA 90024 USA.
[Corvera-Tindel, Teresita] Vet Affairs Greater Los Angeles Hlth Care Syst, Nursing Rsch Dept, Los Angeles, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0009-7322
J9 CIRCULATION
JI Circulation
PD NOV 22
PY 2011
VL 124
IS 21
SU S
MA A14574
PG 2
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA 884WE
UT WOS:000299738706159
ER
PT J
AU Murray, DR
Mummidi, S
Valente, AJ
Dinarello, CA
Delafontaine, P
Chandrasekar, B
AF Murray, David R.
Mummidi, Srinivas
Valente, Anthony J.
Dinarello, Charles A.
Delafontaine, Patrice
Chandrasekar, Bysani
TI IL-18 Binding Protein (IL-18BP) Inhibits beta-AR Induced Cardiomyocyte
Hypertrophy in vitro and Myocardial Hypertrophy in vivo
SO CIRCULATION
LA English
DT Meeting Abstract
DE Hypertrophic cardiomyopathy; Heart failure; Inflammation; Signal
transduction; Cardioprotection
C1 [Murray, David R.] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA.
[Mummidi, Srinivas; Valente, Anthony J.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA.
[Dinarello, Charles A.] Univ Colarado, Aurora, CO USA.
[Delafontaine, Patrice; Chandrasekar, Bysani] Tulane Univ, Sch Med, Inst Heart & Vasc, New Orleans, LA 70112 USA.
RI Mummidi, Srinivas/C-1004-2008
OI Mummidi, Srinivas/0000-0002-4068-6380
NR 0
TC 0
Z9 0
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0009-7322
J9 CIRCULATION
JI Circulation
PD NOV 22
PY 2011
VL 124
IS 21
SU S
MA A8393
PG 2
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA 884WE
UT WOS:000299738701090
ER
PT J
AU Tang, WHW
Felker, GM
Hernandez, AF
Hsu, AP
Gottlieb, SS
Voors, AA
Butler, J
Metra, M
Anker, SD
Troughton, RW
McMurray, JJ
Armstrong, PW
Massie, BM
Califf, RM
O'Connor, CM
Starling, RC
AF Tang, W. H. Wilson
Felker, G. Michael
Hernandez, Adrian F.
Hsu, Amy P.
Gottlieb, Stephen S.
Voors, Adriaan A.
Butler, Javed
Metra, Marco
Anker, Stefan D.
Troughton, Richard W.
McMurray, John J.
Armstrong, Paul W.
Massie, Barry M.
Califf, Robert M.
O'Connor, Christopher M.
Starling, Randall C.
TI Baseline Cystatin C is Associated with Short-Term Adverse Events in
Acute Heart Failure but Does Not Predict Treatment Effects with
Nesiritide Therapy
SO CIRCULATION
LA English
DT Meeting Abstract
CT Scientific Sessions of the American-Heart-Association/Resuscitation
Science Symposium
CY NOV 12-16, 2011
CL Orlando, FL
SP Amer Heart Assoc
DE Renal function
C1 [Tang, W. H. Wilson; Hsu, Amy P.; Starling, Randall C.] Cleveland Clin, Cleveland, OH 44106 USA.
[Felker, G. Michael; Hernandez, Adrian F.; O'Connor, Christopher M.] Duke Univ, Med Ctr, Duke Clin Rsch Inst, Durham, NC USA.
[Gottlieb, Stephen S.] Univ Maryland, Baltimore, MD 21201 USA.
[Voors, Adriaan A.] Univ Groningen, Univ Med Ctr Groningen, NL-9713 AV Groningen, Netherlands.
[Butler, Javed] Emory Univ, Atlanta, GA 30322 USA.
[Metra, Marco] Univ Brescia, Brescia, Italy.
[Anker, Stefan D.] Appl Cachexia Rsch, Dept Cardiol, Berlin, Germany.
[Troughton, Richard W.] Univ Otago, Christchurch, New Zealand.
[McMurray, John J.] Univ Glasgow, Glasgow, Lanark, Scotland.
[Armstrong, Paul W.] Univ Alberta, Edmonton, AB, Canada.
[Massie, Barry M.] Univ Calif San Francisco, San Francisco VA Med Ctr, San Francisco, CA 94143 USA.
[Califf, Robert M.] Duke Univ, Med Ctr, Duke Translat Med Inst, Durham, NC USA.
RI Tang, Wai Hong/I-1238-2013
NR 0
TC 0
Z9 0
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0009-7322
J9 CIRCULATION
JI Circulation
PD NOV 22
PY 2011
VL 124
IS 21
SU S
MA A13339
PG 2
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA 884WE
UT WOS:000299738705119
ER
PT J
AU Tsai, TT
Maddox, TM
Nallamothu, BK
Stanislawski, MA
Adams, JC
Box, TL
Ho, PM
Rao, SV
Casserly, IP
Rumsfeld, JS
Brilakis, ES
AF Tsai, Thomas T.
Maddox, Thomas M.
Nallamothu, Brahmajee K.
Stanislawski, Maggie A.
Adams, Jill C.
Box, Tamara L.
Ho, P. Michael
Rao, Sunil V.
Casserly, Ivan P.
Rumsfeld, John S.
Brilakis, Emmanouil S.
TI Use and Effectiveness of Drug-Eluting versus Bare Metal Stents in
Saphenous Vein Bypass Graft Percutaneous Coronary Interventions:
Insights from the National VA Clinical Assessment, Reporting and
Tracking (CART) Program
SO CIRCULATION
LA English
DT Meeting Abstract
DE Percutaneous coronary intervention; Interventional cardiology; Drug
eluting stents
C1 [Tsai, Thomas T.; Maddox, Thomas M.; Stanislawski, Maggie A.; Adams, Jill C.; Box, Tamara L.; Ho, P. Michael; Casserly, Ivan P.; Rumsfeld, John S.] Denver VAMC, Denver, CO USA.
[Nallamothu, Brahmajee K.] Ann Arbor VAMC, Ann Arbor, MI USA.
[Rao, Sunil V.] Durham VA Med Cntr, Durham, NC USA.
[Brilakis, Emmanouil S.] VA N Texas Hlth Care Syst, Dallas, TX USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0009-7322
J9 CIRCULATION
JI Circulation
PD NOV 22
PY 2011
VL 124
IS 21
SU S
MA A17341
PG 2
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA 884WE
UT WOS:000299738708367
ER
PT J
AU Tsai, TT
Maddox, TM
Bradley, SM
Gylys-Colwell, I
McDermott, K
Helfrich, CD
Fihn, SD
Bryson, CL
Rumsfeld, JS
Ho, PM
AF Tsai, Thomas T.
Maddox, Thomas M.
Bradley, Steven M.
Gylys-Colwell, Ina
McDermott, Kelly
Helfrich, Christian D.
Fihn, Stephan D.
Bryson, Christopher L.
Rumsfeld, John S.
Ho, P. Michael
TI Long-Term Risk of Bleeding and Impact of Non-Therapeutic INRs in
Patients Discharged on Triple Antithrombotic Therapy After
Hospitalization For Acute Coronary Syndrome
SO CIRCULATION
LA English
DT Meeting Abstract
DE Acute coronary syndromes; Anticoagulants; Antiplatelet drugs
C1 [Tsai, Thomas T.; Maddox, Thomas M.; Rumsfeld, John S.; Ho, P. Michael] Denver VAMC, Denver, CO USA.
[Bradley, Steven M.] VA Puget Sound Hlth Care Syst, Internal Med Cardiol, Seattle, WA USA.
[Gylys-Colwell, Ina; McDermott, Kelly; Helfrich, Christian D.; Fihn, Stephan D.; Bryson, Christopher L.] VA Puget Sound Hlth Care Syst, Internal Med, Seattle, WA USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0009-7322
J9 CIRCULATION
JI Circulation
PD NOV 22
PY 2011
VL 124
IS 21
SU S
MA A14336
PG 2
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA 884WE
UT WOS:000299738706085
ER
PT J
AU McCabe, JM
Bhave, PD
McGlothlin, D
Teerlink, JR
AF McCabe, James M.
Bhave, Prashant D.
McGlothlin, Dana
Teerlink, John R.
TI Running From Her Past A Case of Rapidly Progressive Dyspnea on Exertion
SO CIRCULATION
LA English
DT Article
DE microvascular obstruction; pulmonary hypertension; right ventricular
failure; tumor; microangiopathy
ID TUMOR THROMBOTIC MICROANGIOPATHY; PULMONARY-HYPERTENSION; DIAGNOSIS;
CATHETER
C1 [McCabe, James M.; Bhave, Prashant D.; McGlothlin, Dana; Teerlink, John R.] Univ Calif San Francisco, Div Cardiol, San Francisco, CA USA.
[Teerlink, John R.] San Francisco VA Med Ctr, Cardiol Sect, San Francisco, CA USA.
RP McCabe, JM (reprint author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Cardiol, 75 Francis St, Boston, MA 02115 USA.
EM mccabe@aya.yale.edu
RI Teerlink, John/D-2986-2012
NR 13
TC 4
Z9 4
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0009-7322
J9 CIRCULATION
JI Circulation
PD NOV 22
PY 2011
VL 124
IS 21
BP 2355
EP 2361
DI 10.1161/CIRCULATIONAHA.111.045906
PG 7
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA 852BR
UT WOS:000297320900020
PM 22105198
ER
PT J
AU Kuranov, RV
Kazmi, S
McElroy, AB
Kiel, JW
Dunn, AK
Milner, TE
Duong, TQ
AF Kuranov, Roman V.
Kazmi, Shams
McElroy, Austin B.
Kiel, Jeffrey W.
Dunn, Andrew K.
Milner, Thomas E.
Duong, Timothy Q.
TI In vivo depth-resolved oxygen saturation by dual-wavelength photothermal
(DWP) OCT
SO OPTICS EXPRESS
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; RETINAL OXYGENATION; BLOOD-FLOW; TISSUE;
RAT; RESOLUTION; TENSION; BRAIN; PHOSPHORESCENCE; ERYTHROCYTES
AB Microvasculature hemoglobin oxygen saturation (SaO(2)) is important in the progression of various pathologies. Non-invasive depth-resolved measurement of SaO(2) levels in tissue microvasculature has the potential to provide early biomarkers and a better understanding of the pathophysiological processes allowing improved diagnostics and prediction of disease progression. We report proof-of-concept in vivo depth-resolved measurement of SaO(2) levels in selected 30 mu m diameter arterioles in the murine brain using Dual-Wavelength Photothermal (DWP) Optical Coherence Tomography (OCT) with 800 nm and 770 nm photothermal excitation wavelengths. Depth location of back-reflected light from a target arteriole was confirmed using Doppler and speckle contrast OCT images. SaO(2) measured in a murine arteriole with DWP-OCT is linearly correlated (R-2=0.98) with systemic SaO(2) values recorded by a pulse-oximeter. DWP-OCT are steadily lower (10.1%) than systemic SaO(2) values except during pure oxygen breathing. DWP-OCT is insensitive to OCT intensity variations and is a candidate approach for in vivo depth-resolved quantitative imaging of microvascular SaO(2) levels. (C) 2011 Optical Society of America
C1 [Kuranov, Roman V.; Kiel, Jeffrey W.; Duong, Timothy Q.] Univ Texas Hlth Sci Ctr San Antonio, Dept Ophthalmol, San Antonio, TX 78229 USA.
[Kuranov, Roman V.; Kazmi, Shams; McElroy, Austin B.; Dunn, Andrew K.; Milner, Thomas E.] Univ Texas Austin, Dept Biomed Engn, Austin, TX 78712 USA.
[Duong, Timothy Q.] S Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA.
RP Kuranov, RV (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Ophthalmol, San Antonio, TX 78229 USA.
EM rkuranov@yahoo.com
RI Duong, Timothy/B-8525-2008; Dunn, Andrew/I-9527-2014
FU NIH [UL1RR025767, KL2RR025766, R01 EY018855, R01 EY014211]; San Antonio
Area Foundation [130977]; Department of Veterans Affairs
FX This research was partially supported by NIH KL2 training grants (Parent
grants UL1RR025767 and KL2RR025766), San Antonio Area Foundation grant
130977 to RVK, Department of Veterans Affairs (VA MERIT Award) to TQD
and NIH (R01 EY018855 and R01 EY014211) to TQD. Authors would like to
thank Joe Ho of OptoWaves Inc. (San Jose, CA) for the endowment of 800
nm couplers to combine 770 nm and 800 nm photothermal excitation lights.
NR 56
TC 15
Z9 15
U1 0
U2 7
PU OPTICAL SOC AMER
PI WASHINGTON
PA 2010 MASSACHUSETTS AVE NW, WASHINGTON, DC 20036 USA
SN 1094-4087
J9 OPT EXPRESS
JI Opt. Express
PD NOV 21
PY 2011
VL 19
IS 24
BP 23831
EP 23844
DI 10.1364/OE.19.023831
PG 14
WC Optics
SC Optics
GA 865PE
UT WOS:000298322000021
PM 22109408
ER
PT J
AU Thameem, F
Puppala, S
Arar, NH
Blangero, J
Duggirala, R
Abboud, HE
AF Thameem, Farook
Puppala, Sobha
Arar, Nedal H.
Blangero, John
Duggirala, Ravindranath
Abboud, Hanna E.
TI Genetic variants in Transient Receptor Potential cation channel,
subfamily M 1 (TRPM1) and their risk of albuminuria-related traits in
Mexican Americans
SO CLINICA CHIMICA ACTA
LA English
DT Article
DE TRPM1; Type 2 diabetes; Albumin to creatinine ration; Polymorphisms;
Association analysis; Mexican Americans
ID CORONARY-ARTERY-DISEASE; MEASURED GENOTYPE; CANDIDATE GENES; MELASTATIN;
MELANOMA; LINKAGE; SEARCH; CELLS; LOCI
AB Background: Evidence for linkage of albuminuria to GABRB3 marker region on chromosome 15q12 was previously reported in Mexican Americans. The objective of this study is to scan a positional candidate gene. Transient Receptor Potential cation channel, subfamily M 1 (TRPM1), for genetic variants that may contribute to the variation in albumin-to-creatinine ratio (ACR).
Methods: To identify the sequence variants, the exons and 2 kb putative promoter region of TRPM1 were PCR amplified and sequenced in 32 selected individuals. Identified variants were genotyped in the entire data set (N = 670; 39 large families) by TaqMan assays. Association analyses between the sequence variants and ACR, type 2 diabetes (T2DM) and related phenotypes were carried out using a measured genotype approach as implemented in the program SOLAR.
Results: Sequencing analysis identified 18 single nucleotide polymorphisms (SNPs) including 8 SNPs in the coding regions, 7 SNPs in the promoter region and 3 SNPs in introns. Of the 8 SNPs identified in the coding regions, 3 were non synonymous [Met(1)Thr, Ser(32)Asn, Val(1395)Ile] and one SNP caused stop codon (Glu1375/*). Of the SNPs examined, none of them exhibited statistically significant association with ACR after accounting for the effect of age, sex, diabetes, duration of diabetes, systolic blood pressure and anti-hypertensive medications. However, a SNP (rs11070811) located in the putative promoter region showed a modest association with triglycerides levels (P= 0.039).
Conclusion: The present investigation found no evidence for an association between sequence variation at the TRPM1 gene and ACR in Mexican Americans, although it appears to have modest influence on T2DM risk factors. (C) 2011 Elsevier B.V. All rights reserved.
C1 [Thameem, Farook; Arar, Nedal H.; Abboud, Hanna E.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Div Nephrol, San Antonio, TX 78229 USA.
[Puppala, Sobha; Blangero, John; Duggirala, Ravindranath] Texas Biomed Res Inst, Dept Genet, San Antonio, TX 78227 USA.
[Arar, Nedal H.; Abboud, Hanna E.] S Texas Vet Healthcare Syst, San Antonio, TX 78229 USA.
RP Thameem, F (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Div Nephrol, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.
EM thameem@uthscsa.edu
FU American Heart Association; Diabetes Action Research and Education
Foundation; American Society of Nephrology; Satellite Health Care;
George O'Brien Kidney Research Center [P50 DK061597]; VA-Merit Review;
National Institute of Diabetes, Digestive and Kidney Diseases [DK42273,
DK47482, DK53889]; National Center for Research Resources [UL1 RR025767,
KL2 RR025766]
FX We thank members of the SAFDGS for their participation and cooperation.
This study was supported by the American Heart Association, Diabetes
Action Research and Education Foundation, American Society of
Nephrology, Satellite Health Care, George O'Brien Kidney Research Center
(P50 DK061597), VA-Merit Review, and by grants from the National
Institute of Diabetes, Digestive and Kidney Diseases (DK42273, DK47482
and DK53889). This work was also supported by the National Center for
Research Resources contracts UL1 RR025767 and KL2 RR025766 for the
Institute for Integration of Medicine and Science. We also thank the
General Clinical Research Center, and South Texas Healthcare System.
NR 33
TC 0
Z9 0
U1 0
U2 3
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0009-8981
J9 CLIN CHIM ACTA
JI Clin. Chim. Acta
PD NOV 20
PY 2011
VL 412
IS 23-24
BP 2058
EP 2062
DI 10.1016/j.cca.2011.03.024
PG 5
WC Medical Laboratory Technology
SC Medical Laboratory Technology
GA 843QC
UT WOS:000296686100007
PM 21439949
ER
PT J
AU Mahon, JL
Beam, CA
Marcovina, SM
Boulware, DC
Palmer, JP
Winter, WE
Skyler, JS
Krischer, JP
AF Mahon, Jeffrey L.
Beam, Craig A.
Marcovina, Santica M.
Boulware, David C.
Palmer, Jerry P.
Winter, William E.
Skyler, Jay S.
Krischer, Jeffrey P.
CA Type 1 Diabet TrialNet Study Grp
TI Comparison of two insulin assays for first-phase insulin release in type
1 diabetes prediction and prevention studies
SO CLINICA CHIMICA ACTA
LA English
DT Article
DE First-phase insulin release; Insulin radioimmunoassay; Insulin
immunoenzymometric assay; Prediction and prevention of type 1 diabetes
ID INTRAVENOUS GLUCOSE; INTERVENTION TRIAL; STANDARDIZATION; PROGRESSION;
RELATIVES; RISK
AB Background: Detection of below-threshold first-phase insulin release or FPIR (1 + 3 minute insulin concentrations during an intravenous glucose tolerance test [IVGTT]) is important in type 1 diabetes prediction and prevention studies including the TrialNet Oral Insulin Prevention Trial. We assessed whether an insulin immunoenzymometric assay (IEMA) could replace the less practical but current standard of a radioimmunoassay (RIA) for FPIR.
Methods: One hundred thirty-three islet autoantibody positive relatives of persons with type 1 diabetes underwent 161 IVGTTs. Insulin concentrations were measured by both assays in 1056 paired samples. A rule classifying FPIR (below-threshold, above-threshold, uncertain) by the IEMA was derived and validated against FPIR by the RIA.
Results: The insulin IEMA-based rule accurately classified below- and above-threshold FPIRs by the RIA in 110/161(68%) IVGTTs, but was uncertain in 51/161 (32%) tests for which FPIR by RIA is needed. An uncertain FPIR by the IEMA was more likely among below-threshold vs above-threshold FPIRs by the RIA (64%[30/47] vs. 18% [21/114], respectively; p<0.05).
Conclusions: An insulin IEMA for FPIR in subjects at risk for type 1 diabetes accurately determined below- and above-threshold FPIRs in 2/3 of tests relative to the current standard of the insulin RIA. but could not reliably classify the remaining FPIRs. TrialNet is limiting the insulin RIA for FPIR to the latter given the practical advantages of the more specific IEMA. (C) 2011 Elsevier B.V. All rights reserved.
C1 [Mahon, Jeffrey L.] Univ Western Ontario, Dept Epidemiol & Biostat, London, ON, Canada.
[Mahon, Jeffrey L.] Univ Western Ontario, Dept Med, London, ON, Canada.
[Beam, Craig A.; Boulware, David C.; Krischer, Jeffrey P.] Univ S Florida, Dept Pediat, Pediat Epidemiol Ctr, Tampa, FL 33620 USA.
[Marcovina, Santica M.] Univ Washington, NW Lipid Metab & Diabet Res Labs, Seattle, WA 98195 USA.
[Palmer, Jerry P.] VA Puget Sound Hlth Care Syst, Seattle, WA USA.
[Winter, William E.] Univ Florida, Dept Pathol, Gainesville, FL 32611 USA.
[Winter, William E.] Univ Florida, Dept Immunol & Lab Med, Gainesville, FL USA.
[Skyler, Jay S.] Univ Miami, Div Endocrinol, Miami, FL USA.
RP Mahon, JL (reprint author), Robarts Clin Trials, POB 5015,100 Perth Dr, London, ON N6A 5K8, Canada.
EM JLMahon@Ihsc.on.ca
RI Skyler, Jay/F-4211-2016
FU National Institutes of Health through the National Institute of Diabetes
and Digestive and Kidney Diseases, National Institute of Allergy and
Infectious Diseases; Eunice Kennedy Shriver National Institute of Child
Health and Human Development; National Center for Research Resources;
Juvenile Diabetes Research Foundation International; American Diabetes
Diabetes Association
FX TrialNet is funded by the National Institutes of Health through the
National Institute of Diabetes and Digestive and Kidney Diseases,
National Institute of Allergy and Infectious Diseases, the Eunice
Kennedy Shriver National Institute of Child Health and Human
Development, and National Center for Research Resources; the Juvenile
Diabetes Research Foundation International; and the American Diabetes
Diabetes Association.
NR 16
TC 9
Z9 9
U1 0
U2 5
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0009-8981
J9 CLIN CHIM ACTA
JI Clin. Chim. Acta
PD NOV 20
PY 2011
VL 412
IS 23-24
BP 2128
EP 2131
DI 10.1016/j.cca.2011.07.019
PG 4
WC Medical Laboratory Technology
SC Medical Laboratory Technology
GA 843QC
UT WOS:000296686100018
PM 21843518
ER
PT J
AU Liel, MS
Klein, R
Recht, M
Greenberg, DL
Taylor, J
AF Liel, Meghan S.
Klein, Robert
Recht, Michael
Greenberg, Daniel L.
Taylor, Jason
TI Reduced Bone Mineral Density in Factor VIII Deficient Mice and the Role
of Inflammatory Cytokines
SO BLOOD
LA English
DT Meeting Abstract
CT 53rd Annual Meeting and Exposition of the American-Society-of-Hematology
(ASH)
CY DEC 10-13, 2011
CL San Diego, CA
SP Amer Soc Hematol (ASH)
C1 [Klein, Robert] Oregon Hlth & Sci Univ, Bone & Mineral Res Unit, Dept Endocrinol, Portland, OR 97201 USA.
[Recht, Michael; Greenberg, Daniel L.] Oregon Hlth & Sci Univ, Hemophilia Ctr, Portland, OR 97201 USA.
[Taylor, Jason] Oregon Hlth & Sci Univ, Portland VA Med Ctr, Portland, OR 97201 USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD NOV 18
PY 2011
VL 118
IS 21
BP 14
EP 14
PG 1
WC Hematology
SC Hematology
GA 882XL
UT WOS:000299597100022
ER
PT J
AU Lewis, KB
Nguyen, PC
Schuman, JT
Walsh, CE
Josephson, NC
Howard, TE
Matthews, DC
Key, NS
Pratt, KP
AF Lewis, Kenneth B.
Phuong-Cac Nguyen
Schuman, Jason T.
Walsh, Christopher E.
Josephson, Neil C.
Howard, Tom E.
Matthews, Dana C.
Key, Nigel S.
Pratt, Kathleen P.
TI Determination of Anti-Factor VIIII Antibody Titers, Isotypes and
Epitopes by SPR Analysis of Human Plasma
SO BLOOD
LA English
DT Meeting Abstract
CT 53rd Annual Meeting and Exposition of the American-Society-of-Hematology
(ASH)/Symposium on the Basic Science of Hemostasis and Thrombosis
CY DEC 10-13, 2011
CL San Diego, CA
SP Amer Soc Hematol (ASH)
C1 [Lewis, Kenneth B.; Phuong-Cac Nguyen; Josephson, Neil C.; Pratt, Kathleen P.] Puget Sound Blood Ctr, Res Inst, Seattle, WA 98104 USA.
[Schuman, Jason T.] GE Healthcare, Life Sci, Piscataway, NJ USA.
[Walsh, Christopher E.] Mt Sinai Sch Med, New York, NY USA.
[Howard, Tom E.] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
[Matthews, Dana C.] Seattle Childrens Hosp, Seattle, WA USA.
[Key, Nigel S.] Univ N Carolina, Chapel Hill, NC USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD NOV 18
PY 2011
VL 118
IS 21
BP 94
EP 95
PG 2
WC Hematology
SC Hematology
GA 882XL
UT WOS:000299597100203
ER
PT J
AU Lentzsch, S
O'Sullivan, A
Kennedy, R
Abbas, M
Gill, N
Dai, L
Andreas, C
Gardner, D
Pregja, SL
Burt, S
Redner, RL
Volkin, R
Roodman, GD
Mapara, MY
Viverette, JF
Agha, M
Waas, JK
Shuai, YL
Normolle, D
Zonder, JA
AF Lentzsch, Suzanne
O'Sullivan, Amy
Kennedy, Ryan
Abbas, Mohammad
Gill, Navkiranjit
Dai, Lijun
Andreas, Carrie
Gardner, Diane
Pregja, Silvana Lalo
Burt, Steve
Redner, Robert L.
Volkin, Robert
Roodman, G. David
Mapara, Markus Y.
Viverette, J. Franklin
Agha, Mounzer
Waas, John K.
Shuai, Yongli
Normolle, Daniel
Zonder, Jeffrey A.
TI Combination of Bendamustine, Lenalidomide, and Dexamethasone (BLD) in
Patients with Refractory or Relapsed Multiple Myeloma Is Safe and Highly
Effective: Results of Phase I/II Open-Label, Dose Escalation Study
SO BLOOD
LA English
DT Meeting Abstract
CT 53rd Annual Meeting and Exposition of the American-Society-of-Hematology
(ASH)/Symposium on the Basic Science of Hemostasis and Thrombosis
CY DEC 10-13, 2011
CL San Diego, CA
SP Amer Soc Hematol (ASH)
C1 [Lentzsch, Suzanne; O'Sullivan, Amy; Kennedy, Ryan; Abbas, Mohammad; Gill, Navkiranjit; Dai, Lijun; Andreas, Carrie; Gardner, Diane; Redner, Robert L.; Mapara, Markus Y.] Univ Pittsburgh, Sch Med, Dept Med, Div Hematol Oncol, Pittsburgh, PA USA.
[Lentzsch, Suzanne; O'Sullivan, Amy; Kennedy, Ryan; Abbas, Mohammad; Gill, Navkiranjit; Dai, Lijun; Andreas, Carrie; Gardner, Diane; Redner, Robert L.; Mapara, Markus Y.] Pittsburgh Canc Inst, Pittsburgh, PA 15213 USA.
[Pregja, Silvana Lalo; Burt, Steve; Zonder, Jeffrey A.] Barbara Ann Karmanos Canc Inst, MYELOMA PROGRAM, Detroit, MI USA.
[Volkin, Robert; Agha, Mounzer] UPMC Canc Ctr, Pittsburgh, PA USA.
[Roodman, G. David] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
[Viverette, J. Franklin; Waas, John K.] UPMC Canc Ctr, Greensburg, PA USA.
[Shuai, Yongli; Normolle, Daniel] Univ Pittsburgh, Inst Canc, Biostat Facil, Pittsburgh, PA USA.
RI mapara, markus/A-2134-2013
NR 0
TC 1
Z9 1
U1 0
U2 1
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD NOV 18
PY 2011
VL 118
IS 21
BP 142
EP 142
PG 1
WC Hematology
SC Hematology
GA 882XL
UT WOS:000299597100305
ER
PT J
AU Mielcarek, M
Storer, B
Martin, PJ
Negrin, RS
Forman, SJ
Flowers, MED
Inamoto, Y
Chauncey, T
Storb, R
Appelbaum, FR
Bensinger, WI
AF Mielcarek, Marco
Storer, Barry
Martin, Paul J.
Negrin, Robert S.
Forman, Stephen J.
Flowers, Mary E. D.
Inamoto, Yoshihiro
Chauncey, Thomas
Storb, Rainer
Appelbaum, Frederick R.
Bensinger, William I.
TI Transplantation of Peripheral Blood Cells As Compared with Bone Marrow
From HLA-Identical Related Donors Is Associated with Superior Long-Term
Outcomes
SO BLOOD
LA English
DT Meeting Abstract
CT 53rd Annual Meeting and Exposition of the American-Society-of-Hematology
(ASH)/Symposium on the Basic Science of Hemostasis and Thrombosis
CY DEC 10-13, 2011
CL San Diego, CA
SP Amer Soc Hematol (ASH)
C1 [Mielcarek, Marco; Storer, Barry; Martin, Paul J.; Inamoto, Yoshihiro; Appelbaum, Frederick R.] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA.
[Negrin, Robert S.] Stanford Univ, Stanford, CA 94305 USA.
[Forman, Stephen J.] City Hope Natl Med Ctr, Beckman Res Inst, Dept Hematol & Hematopoiet Cell Transplantat, Dept Canc Immunotherapeut & Tumor Immunol, Duarte, CA 91010 USA.
[Flowers, Mary E. D.; Storb, Rainer; Bensinger, William I.] Univ Washington, Seattle, WA 98195 USA.
[Chauncey, Thomas] VA Puget Sound Hlth Care Syst, Seattle, WA USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD NOV 18
PY 2011
VL 118
IS 21
BP 149
EP 149
PG 1
WC Hematology
SC Hematology
GA 882XL
UT WOS:000299597100320
ER
PT J
AU Freytes, CO
Vesole, DH
Zhong, XB
Le-Rademacher, J
Dispenzieri, A
Lonial, S
Milone, G
Hari, P
AF Freytes, Cesar O.
Vesole, David H.
Zhong, Xiaobo
Le-Rademacher, Jennifer
Dispenzieri, Angela
Lonial, Sagar
Milone, Gustavo
Hari, Parameswaran
TI Second Transplants in Relapsed Multiple Myeloma (MM): Autologous (AHCT)
Versus Non-Myeloablative/Reduced Intensity (NST/RIC) Allogeneic
Transplantation (AlloHCT)
SO BLOOD
LA English
DT Meeting Abstract
CT 53rd Annual Meeting and Exposition of the American-Society-of-Hematology
(ASH)/Symposium on the Basic Science of Hemostasis and Thrombosis
CY DEC 10-13, 2011
CL San Diego, CA
SP Amer Soc Hematol (ASH)
C1 [Freytes, Cesar O.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA.
[Freytes, Cesar O.] S Vet Hlth Care Syst, BMT, San Antonio, TX USA.
[Vesole, David H.] Hackensack Univ, John Theurer Canc Ctr, Med Ctr, Hackensack, NJ USA.
[Zhong, Xiaobo] Med Coll Wisconsin, Ctr Int Blood & Marrow Transplant Res, Milwaukee, WI 53226 USA.
[Le-Rademacher, Jennifer; Hari, Parameswaran] Med Coll Wisconsin CIBMTR, Rochester, MN USA.
[Dispenzieri, Angela] Mayo Clin, Rochester, MN USA.
[Lonial, Sagar] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA.
[Milone, Gustavo] FUNDALEU, Buenos Aires, DF, Argentina.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD NOV 18
PY 2011
VL 118
IS 21
BP 375
EP 375
PG 1
WC Hematology
SC Hematology
GA 882XL
UT WOS:000299597101095
ER
PT J
AU Pandey, GS
Garfield, S
Curran, JE
Moses, EK
Kimchi-Sarfaty, C
Yanover, C
Howard, TE
Sauna, ZE
AF Pandey, Gouri Shankar
Garfield, Susan
Curran, Joanne E.
Moses, Eric K.
Kimchi-Sarfaty, Chava
Yanover, Chen
Howard, Tom E.
Sauna, Zuben E.
TI The Entire Primary Sequence of Factor VIII Is Synthesized As Two
Polypeptide Chains in Hemophilia A Patients with the Intron-22-Inversion
SO BLOOD
LA English
DT Meeting Abstract
CT 53rd Annual Meeting and Exposition of the American-Society-of-Hematology
(ASH)/Symposium on the Basic Science of Hemostasis and Thrombosis
CY DEC 10-13, 2011
CL San Diego, CA
SP Amer Soc Hematol (ASH)
C1 [Pandey, Gouri Shankar] US FDA, Lab Hemostasis, DH CBER, Bethesda, MD 20014 USA.
[Garfield, Susan] NCI, NIH, Bethesda, MD 20892 USA.
[Curran, Joanne E.] SW Fdn Biomed Res, Dept Genet, San Antonio, TX USA.
[Kimchi-Sarfaty, Chava; Sauna, Zuben E.] US FDA, Ctr Biol Evaluat & Res, Div Hematol, Bethesda, MD 20892 USA.
[Yanover, Chen] Fred Hutchinson Canc Res Ctr, Program Computat Biol, Seattle, WA 98104 USA.
[Howard, Tom E.] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 3
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD NOV 18
PY 2011
VL 118
IS 21
BP 531
EP 532
PG 2
WC Hematology
SC Hematology
GA 882XL
UT WOS:000299597101445
ER
PT J
AU Dao, KHT
Rotelli, MD
Petersen, CL
Brown, BR
Nelson, WD
Yates, JE
Newell, AH
Olson, SB
Druker, BJ
Bagby, GC
AF Dao, Kim-Hien T.
Rotelli, Michael D.
Petersen, Curtis L.
Brown, Brie R.
Nelson, Whitney D.
Yates, Jane E.
Newell, Amy Hanlon
Olson, Susan B.
Druker, Brian J.
Bagby, Grover C., Jr.
TI FANCL Ubiquitinates Beta-Catenin and Enhances Its Nuclear Function
SO BLOOD
LA English
DT Meeting Abstract
CT 53rd Annual Meeting and Exposition of the American-Society-of-Hematology
(ASH)/Symposium on the Basic Science of Hemostasis and Thrombosis
CY DEC 10-13, 2011
CL San Diego, CA
SP Amer Soc Hematol (ASH)
C1 [Dao, Kim-Hien T.; Rotelli, Michael D.; Petersen, Curtis L.; Brown, Brie R.; Nelson, Whitney D.] Oregon Hlth & Sci Univ, Ctr Hematol Malignancies, Knight Canc Inst Hematol Oncol, Portland, OR 97201 USA.
[Yates, Jane E.] NW VA Canc Res Ctr, Portland, OR USA.
[Druker, Brian J.] Oregon Hlth & Sci Univ, Knight Canc Inst, Howard Hughes Med Inst, Portland, OR 97201 USA.
[Bagby, Grover C., Jr.] Portland VA Med Ctr, Portland, OR USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD NOV 18
PY 2011
VL 118
IS 21
BP 588
EP 589
PG 2
WC Hematology
SC Hematology
GA 882XL
UT WOS:000299597101604
ER
PT J
AU Newell, LF
Othus, M
Walter, RB
Petergdorf, SH
Chauncey, T
Anderson, JE
Godwin, JE
Kopecky, KJ
Appelbaum, FR
Estey, EH
AF Newell, Laura F.
Othus, Megan
Walter, Roland B.
Petergdorf, Stephen H.
Chauncey, Thomas
Anderson, Jeanne E.
Godwin, John E.
Kopecky, Kenneth J.
Appelbaum, Frederick R.
Estey, Elihu H.
TI Prognostic Import of French-American-British (FAB) System As Embedded in
2008 Revision of World Health Organization Classification of AML: Review
of SWOG Data
SO BLOOD
LA English
DT Meeting Abstract
CT 53rd Annual Meeting and Exposition of the American-Society-of-Hematology
(ASH)/Symposium on the Basic Science of Hemostasis and Thrombosis
CY DEC 10-13, 2011
CL San Diego, CA
SP Amer Soc Hematol (ASH)
C1 [Newell, Laura F.; Walter, Roland B.] Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98104 USA.
[Petergdorf, Stephen H.; Chauncey, Thomas; Estey, Elihu H.] Univ Washington, Fred Hutchinson Canc Res Ctr, Seattle, WA 98195 USA.
[Chauncey, Thomas] VA Puget Sound Hlth Care Syst, Seattle, WA USA.
[Anderson, Jeanne E.] Katmai Oncol Grp, Anchorage, AK USA.
[Godwin, John E.] So Illinois Univ, Simmons Canc Inst, Div Hematol Oncol, Springfield, IL USA.
[Kopecky, Kenneth J.] Fred Hutchinson Canc Res Ctr, SWOG Stat Ctr, Seattle, WA 98104 USA.
RI Walter, Roland/C-1064-2008
OI Walter, Roland/0000-0002-9268-3341
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD NOV 18
PY 2011
VL 118
IS 21
BP 628
EP 629
PG 2
WC Hematology
SC Hematology
GA 882XL
UT WOS:000299597102041
ER
PT J
AU Haile, DJ
Utz, K
Toro, JJ
Frye, BL
Neumon, B
Shuko, L
Freytes, CO
AF Haile, David J.
Utz, Kenneth
Toro, Juan J.
Frye, Brenda L.
Neumon, Bonita
Shuko, Lee
Freytes, Cesar O.
TI Nicotine Use During Mobilization Is Associated with More Efficient Stem
Cell Collection
SO BLOOD
LA English
DT Meeting Abstract
CT 53rd Annual Meeting and Exposition of the American-Society-of-Hematology
(ASH)/Symposium on the Basic Science of Hemostasis and Thrombosis
CY DEC 10-13, 2011
CL San Diego, CA
SP Amer Soc Hematol (ASH)
C1 [Utz, Kenneth] Audie L Murphy Mem Vet Adm Med Ctr, S Texas Vet Hlth Care Syst, Dept Pharm, San Antonio, TX 78284 USA.
[Frye, Brenda L.] Audie Murphy Vet Affairs BMT, San Antonio, TX USA.
[Shuko, Lee] S Texas Vet Hlth Care Syst, Res & Dev Serv, San Antonio, TX USA.
[Freytes, Cesar O.] Audie L Murphy Mem Vet Adm Med Ctr, Med Serv BMT 111, San Antonio, TX 78284 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD NOV 18
PY 2011
VL 118
IS 21
BP 843
EP 843
PG 1
WC Hematology
SC Hematology
GA 882XL
UT WOS:000299597102529
ER
PT J
AU Thompson, LA
Guthrie, KA
Budde, LE
Till, BG
Press, OW
Chauncey, T
Pagel, JM
Petersdorf, SH
Bensinger, WI
Holmberg, L
Shustov, AR
Green, DJ
Maloney, DG
Gopal, AK
AF Thompson, Leslie A.
Guthrie, Katherine A.
Budde, Lihua Elizabeth
Till, Brian G.
Press, Oliver W.
Chauncey, Thomas
Pagel, John M.
Petersdorf, Stephen H.
Bensinger, William I.
Holmberg, Leona
Shustov, Andrei R.
Green, Damian J.
Maloney, David G.
Gopal, Ajay K.
TI The Pre-Transplant Mantle Cell Lymphoma International Prognostic Index
Predicts Overall and Progression-Free Survival Following High-Dose
Therapy and Autologus Stem Cell Transplant for Mantle Cell Lymphoma
SO BLOOD
LA English
DT Meeting Abstract
CT 53rd Annual Meeting and Exposition of the American-Society-of-Hematology
(ASH)/Symposium on the Basic Science of Hemostasis and Thrombosis
CY DEC 10-13, 2011
CL San Diego, CA
SP Amer Soc Hematol (ASH)
C1 [Thompson, Leslie A.] Seattle Canc Care Alliance, Gen Oncol & Hematol, Seattle, WA USA.
[Budde, Lihua Elizabeth] Fed Hutchinson Canc Res Ctr, Seattle, WA USA.
[Press, Oliver W.; Pagel, John M.; Bensinger, William I.; Green, Damian J.; Gopal, Ajay K.] Univ Washington, Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98195 USA.
[Chauncey, Thomas] VA Puget Sound Hlth Care Syst, Seattle, WA USA.
[Shustov, Andrei R.] Univ Washington, Med Ctr, Fred Hutchinson Canc Res Ctr, Seattle, WA 98195 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD NOV 18
PY 2011
VL 118
IS 21
BP 886
EP 887
PG 2
WC Hematology
SC Hematology
GA 882XL
UT WOS:000299597102621
ER
PT J
AU Cappelli, E
Svahn, J
Anur, P
Corsolini, F
Farruggia, P
Bagby, GC
Dufour, C
AF Cappelli, Enrico
Svahn, Johanna
Anur, Praveen
Corsolini, Fabio
Farruggia, Piero
Bagby, Grover C., Jr.
Dufour, Carlo
TI Kinase Inhibitors Reduce TNF-Alpha Over-Production in Monocytes From
Fanconi Anemia Group A Patients
SO BLOOD
LA English
DT Meeting Abstract
CT 53rd Annual Meeting and Exposition of the American-Society-of-Hematology
(ASH)/Symposium on the Basic Science of Hemostasis and Thrombosis
CY DEC 10-13, 2011
CL San Diego, CA
SP Amer Soc Hematol (ASH)
C1 [Cappelli, Enrico; Svahn, Johanna; Corsolini, Fabio; Dufour, Carlo] Ist Giannina Gaslini, I-16148 Genoa, Italy.
[Anur, Praveen] Doernbecher Childrens Hosp, Portland, OR USA.
[Anur, Praveen; Bagby, Grover C., Jr.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
[Farruggia, Piero] G Di Cristina Hosp, Palermo, Italy.
[Bagby, Grover C., Jr.] Portland VA Med Ctr, Portland, OR USA.
RI Cappelli, Enrico/K-7954-2016
OI Cappelli, Enrico/0000-0001-5910-9260
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD NOV 18
PY 2011
VL 118
IS 21
BP 1036
EP 1036
PG 1
WC Hematology
SC Hematology
GA 882XL
UT WOS:000299597103275
ER
PT J
AU Kadoch, C
Wong, V
Chen, LJ
Bet-Lachin, A
Roy, R
Hyun, W
Behler, C
Lowell, C
Rubenstein, JL
AF Kadoch, Cicall
Wong, Valerie
Chen, Lingjing
Bet-Lachin, Anna
Roy, Ritu
Hyun, William
Behler, Caroline
Lowell, Clifford
Rubenstein, James L.
TI Dynamic Changes in Macrophage Polarization Correlate with Progression
and Response in CNS Lymphoma: Insights Into the Transcriptome of
Lymphoma-Associated M2 Macrophages
SO BLOOD
LA English
DT Meeting Abstract
CT 53rd Annual Meeting and Exposition of the American-Society-of-Hematology
(ASH)/Symposium on the Basic Science of Hemostasis and Thrombosis
CY DEC 10-13, 2011
CL San Diego, CA
SP Amer Soc Hematol (ASH)
C1 [Roy, Ritu] UCSF, Ctr Comprehens Canc, San Francisco, CA USA.
[Behler, Caroline] San Francisco VA Med Ctr, San Francisco, CA USA.
[Lowell, Clifford] Univ CA, San Francisco, CA USA.
[Rubenstein, James L.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
NR 0
TC 0
Z9 0
U1 1
U2 2
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD NOV 18
PY 2011
VL 118
IS 21
BP 1390
EP 1390
PG 1
WC Hematology
SC Hematology
GA 882XL
UT WOS:000299597104569
ER
PT J
AU Gunasekera, D
Ettinger, RA
Hughes, RJ
Epstein, MS
Barrett, JC
Thompson, AA
Withycombe, J
Pratt, KP
AF Gunasekera, Devi
Ettinger, Ruth A.
Hughes, Richard J.
Epstein, Melinda S.
Barrett, John C.
Thompson, Alexis A.
Withycombe, Janice
Pratt, Kathleen P.
TI Potential Immunogenicity of Amino Acid Sequences Encoded by Ns-SNPs in
Factor VIII
SO BLOOD
LA English
DT Meeting Abstract
CT 53rd Annual Meeting and Exposition of the American-Society-of-Hematology
(ASH)/Symposium on the Basic Science of Hemostasis and Thrombosis
CY DEC 10-13, 2011
CL San Diego, CA
SP Amer Soc Hematol (ASH)
C1 [Gunasekera, Devi; Ettinger, Ruth A.; Pratt, Kathleen P.] Puget Sound Blood Ctr, Res Inst, Seattle, WA 98104 USA.
[Hughes, Richard J.; Epstein, Melinda S.] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
[Barrett, John C.] Virginia Commonwealth Univ, Cent Virginia Ctr Coagulat Disorders, Richmond, VA USA.
[Thompson, Alexis A.] Childrens Mem Hosp, Chicago, IL 60614 USA.
[Withycombe, Janice] Palmetto Hlth Childrens Hosp, Columbia, SC USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD NOV 18
PY 2011
VL 118
IS 21
BP 1430
EP 1431
PG 2
WC Hematology
SC Hematology
GA 882XL
UT WOS:000299597105059
ER
PT J
AU D'Souza, S
Kurihara, N
Shiozawa, Y
Joseph, J
Taichman, R
Galson, D
Roodman, D
AF D'Souza, Sonia
Kurihara, Noriyoshi
Shiozawa, Yusuke
Joseph, Jeena
Taichman, Russell
Galson, Deborah
Roodman, David
TI Annexin II Interactions with the Annexin II Receptor Enhance Multiple
Myeloma Cell Adhesion and Growth in the Bone Marrow Microenvironment
SO BLOOD
LA English
DT Meeting Abstract
CT 53rd Annual Meeting and Exposition of the American-Society-of-Hematology
(ASH)/Symposium on the Basic Science of Hemostasis and Thrombosis
CY DEC 10-13, 2011
CL San Diego, CA
SP Amer Soc Hematol (ASH)
C1 [D'Souza, Sonia; Kurihara, Noriyoshi; Galson, Deborah] Univ Pittsburgh, Bone Biol Ctr, UPMC, Pittsburgh, PA USA.
[D'Souza, Sonia; Kurihara, Noriyoshi; Galson, Deborah] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
[Shiozawa, Yusuke; Joseph, Jeena; Taichman, Russell] Univ Michigan, Ann Arbor, MI 48109 USA.
[Roodman, David] Univ Pittsburgh, Sch Med, Dept Med, Div Hematol Oncol, Pittsburgh, PA USA.
[Roodman, David] Inst Canc Res, Pittsburgh, PA USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD NOV 18
PY 2011
VL 118
IS 21
BP 1685
EP 1685
PG 1
WC Hematology
SC Hematology
GA 882XL
UT WOS:000299597106112
ER
PT J
AU Dai, LJ
O'Sullivan, A
Kennedy, R
Abbas, M
Shuai, YL
Passero, VA
Andreas, C
Gardner, D
Redner, RL
Roodman, GD
Marks, SM
Raptis, A
Hou, JZ
Petro, D
Sun, M
Evans, T
Pietragallo, LV
Waas, JK
Viverette, JF
Osborn, J
Reyes, V
Pinkerton, R
Crandall, T
Fierro, R
Volkin, R
Normolle, D
Mapara, MY
Lentzsch, S
AF Dai, Lijun
O'Sullivan, Amy
Kennedy, Ryan
Abbas, Mohammad
Shuai, Yongli
Passero, Vida Almario
Andreas, Carrie
Gardner, Diane
Redner, Robert L.
Roodman, G. David
Marks, Stanley M.
Raptis, Anastasios
Hou, Jing-Zhou
Petro, Daniel
Sun, Min
Evans, Terry
Pietragallo, Louis V.
Waas, John K.
Viverette, J. Franklin
Osborn, Jennifer
Reyes, Vincent
Pinkerton, Richard
Crandall, Theodore
Fierro, Ronald
Volkin, Robert
Normolle, Daniel
Mapara, Markus Y.
Lentzsch, Suzanne
TI A Randomized Clinical Trial of Lenalidomide and Dexamethasone with and
without Autologous Stem Cell Transplant in Patients with Newly Diagnosed
Multiple Myeloma: Interim Study Results
SO BLOOD
LA English
DT Meeting Abstract
CT 53rd Annual Meeting and Exposition of the American-Society-of-Hematology
(ASH)/Symposium on the Basic Science of Hemostasis and Thrombosis
CY DEC 10-13, 2011
CL San Diego, CA
SP Amer Soc Hematol (ASH)
C1 [Dai, Lijun; O'Sullivan, Amy; Kennedy, Ryan; Abbas, Mohammad; Passero, Vida Almario; Andreas, Carrie; Gardner, Diane; Redner, Robert L.; Mapara, Markus Y.; Lentzsch, Suzanne] Univ Pittsburgh, Sch Med, Dept Med, Div Hematol Oncol, Pittsburgh, PA USA.
[Dai, Lijun; O'Sullivan, Amy; Kennedy, Ryan; Abbas, Mohammad; Passero, Vida Almario; Andreas, Carrie; Gardner, Diane; Redner, Robert L.; Mapara, Markus Y.; Lentzsch, Suzanne] Pittsburgh Canc Inst, Pittsburgh, PA 15213 USA.
[Shuai, Yongli; Normolle, Daniel] Univ Pittsburgh, Inst Canc, Biostat Facil, Pittsburgh, PA USA.
[Roodman, G. David] VA Pittsburgh Healthcare Syst, Med Hem Onc, Pittsburgh, PA USA.
[Marks, Stanley M.; Raptis, Anastasios; Hou, Jing-Zhou; Petro, Daniel; Sun, Min; Pietragallo, Louis V.; Osborn, Jennifer; Reyes, Vincent; Volkin, Robert] UPMC Canc Ctr, Pittsburgh, PA USA.
[Evans, Terry; Waas, John K.; Viverette, J. Franklin] UPMC Canc Ctr, Greensburg, PA USA.
[Pinkerton, Richard] UPMC Canc Ctr, Indiana, PA USA.
[Crandall, Theodore] UPMC Canc Ctr, Wexford, PA USA.
[Fierro, Ronald] UPMC Canc Ctr, Clairton, PA USA.
RI mapara, markus/A-2134-2013; pinkerton, ross/I-4808-2014
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD NOV 18
PY 2011
VL 118
IS 21
BP 1771
EP 1772
PG 2
WC Hematology
SC Hematology
GA 882XL
UT WOS:000299597106309
ER
PT J
AU Lahar, N
Lei, NY
Wang, JF
Jabaji, Z
Tung, SC
Joshi, V
Lewis, M
Stelzner, M
Martin, MG
Dunn, JCY
AF Lahar, Nicholas
Lei, Nan Ye
Wang, Jiafang
Jabaji, Ziyad
Tung, Stephaine C.
Joshi, Vaidehi
Lewis, Michael
Stelzner, Matthias
Martin, Martin G.
Dunn, James C. Y.
TI Intestinal Subepithelial Myofibroblasts Support in vitro and in vivo
Growth of Human Small Intestinal Epithelium
SO PLOS ONE
LA English
DT Article
ID STEM-CELLS; DIFFERENTIATION; RENEWAL; NICHE
AB The intestinal crypt-niche interaction is thought to be essential to the function, maintenance, and proliferation of progenitor stem cells found at the bases of intestinal crypts. These stem cells are constantly renewing the intestinal epithelium by sending differentiated cells from the base of the crypts of Lieberkuhn to the villus tips where they slough off into the intestinal lumen. The intestinal niche consists of various cell types, extracellular matrix, and growth factors and surrounds the intestinal progenitor cells. There have recently been advances in the understanding of the interactions that regulate the behavior of the intestinal epithelium and there is great interest in methods for isolating and expanding viable intestinal epithelium. However, there is no method to maintain primary human small intestinal epithelium in culture over a prolonged period of time. Similarly no method has been published that describes isolation and support of human intestinal epithelium in an in vivo model. We describe a technique to isolate and maintain human small intestinal epithelium in vitro from surgical specimens. We also describe a novel method to maintain human intestinal epithelium subcutaneously in a mouse model for a prolonged period of time. Our methods require various growth factors and the intimate interaction between intestinal sub-epithelial myofibroblasts (ISEMFs) and the intestinal epithelial cells to support the epithelial in vitro and in vivo growth. Absence of these myofibroblasts precluded successful maintenance of epithelial cell formation and proliferation beyond just a few days, even in the presence of supportive growth factors. We believe that the methods described here can be used to explore the molecular basis of human intestinal stem cell support, maintenance, and growth.
C1 [Lahar, Nicholas; Lei, Nan Ye; Jabaji, Ziyad; Tung, Stephaine C.; Stelzner, Matthias; Dunn, James C. Y.] Univ Calif Los Angeles, David Geffen Sch Med, Div Gastroenterol & Nutr, Dept Surg, Los Angeles, CA 90095 USA.
[Lei, Nan Ye; Joshi, Vaidehi; Dunn, James C. Y.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Bioengn, Div Gastroenterol & Nutr, Los Angeles, CA 90095 USA.
[Wang, Jiafang; Tung, Stephaine C.; Martin, Martin G.] Univ Calif Los Angeles, David Geffen Sch Med, Div Gastroenterol & Nutr, Dept Pediat, Los Angeles, CA 90095 USA.
[Lewis, Michael] Univ Calif Los Angeles, Dept Pathol, Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA 90024 USA.
RP Lahar, N (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Div Gastroenterol & Nutr, Dept Surg, Los Angeles, CA 90095 USA.
EM jdunn@mednet.ucla.edu
FU National Institute of Diabetes and Digestive and Kidney Diseases,
Intestinal Stem Cell Consortium [DK085535-01, DK085535-02S2]; California
Institute for Regenerative Medicine (CIRM) [RT2-01985]; [DK083762];
[DK083319]
FX This work was supported by grants from the National Institute of
Diabetes and Digestive and Kidney Diseases U01 Intestinal Stem Cell
Consortium (DK085535-01 and DK085535-02S2), DK083762, DK083319 and the
California Institute for Regenerative Medicine (CIRM) (Grant Number
RT2-01985). The contents of this publication are solely the
responsibility of the authors and do not necessarily represent the
official views of CIRM or any other agency of the State of California.
The funders had no role in study design, data collection and analysis,
decision to publish, or preparation of the manuscript.
NR 18
TC 49
Z9 50
U1 0
U2 9
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD NOV 17
PY 2011
VL 6
IS 11
AR e26898
DI 10.1371/journal.pone.0026898
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 855HZ
UT WOS:000297555800010
PM 22125602
ER
PT J
AU De Franceschi, L
Tomelleri, C
Matte, A
Brunati, AM
Bovee-Geurts, PH
Bertoldi, M
Lasonder, E
Tibaldi, E
Danek, A
Walker, RH
Jung, HH
Bader, B
Siciliano, A
Ferru, E
Mohandas, N
Bosman, GJCGM
AF De Franceschi, Lucia
Tomelleri, Carlo
Matte, Alessandro
Brunati, Anna Maria
Bovee-Geurts, Petra H.
Bertoldi, Mariarita
Lasonder, Edwin
Tibaldi, Elena
Danek, Adrian
Walker, Ruth H.
Jung, Hans H.
Bader, Benedikt
Siciliano, Angela
Ferru, Emanuela
Mohandas, Narla
Bosman, Giel J. C. G. M.
TI Erythrocyte membrane changes of chorea-acanthocytosis are the result of
altered Lyn kinase activity
SO BLOOD
LA English
DT Article
ID RED-CELL MEMBRANE; SRC FAMILY KINASES; PHOSPHORYLATION SITES;
MULTIPROTEIN COMPLEX; MCLEOD-SYNDROME; NEUROACANTHOCYTOSIS;
IDENTIFICATION; PLATELETS; PATHWAYS; VESICLES
AB Acanthocytic RBCs are a peculiar diagnostic feature of chorea-acanthocytosis (ChAc), a rare autosomal recessive neurodegenerative disorder. Although recent years have witnessed some progress in the molecular characterization of ChAc, the mechanism(s) responsible for generation of acanthocytes in ChAc is largely unknown. As the membrane protein composition of ChAc RBCs is similar to that of normal RBCs, we evaluated the tyrosine (Tyr)-phosphorylation profile of RBCs using comparative proteomics. Increased Tyr phosphorylation state of several membrane proteins, including band 3, beta-spectrin, and adducin, was noted in ChAc RBCs. In particular, band 3 was highly phosphorylated on the Tyr-904 residue, a functional target of Lyn, but not on Tyr-8, a functional target of Syk. In ChAc RBCs, band 3 Tyr phosphorylation by Lyn was independent of the canonical Syk-mediated pathway. The ChAc-associated alterations in RBC membrane protein organization appear to be the result of increased Tyr phosphorylation leading to altered linkage of band 3 to the junctional complexes involved in anchoring the membrane to the cytoskeleton as supported by coimmunoprecipitation of beta-adducin with band 3 only in ChAc RBC-membrane treated with the Lyn-inhibitor PP2. We propose this altered association between membrane skeleton and membrane proteins as novel mechanism in the generation of acanthocytes in ChAc. (Blood. 2011;118(20):5652-5663)
C1 [De Franceschi, Lucia; Tomelleri, Carlo; Matte, Alessandro; Siciliano, Angela; Ferru, Emanuela] Univ Verona, Dept Med, I-37134 Verona, Italy.
[Brunati, Anna Maria; Tibaldi, Elena] Univ Padua, Dept Biochem, Padua, Italy.
[Bovee-Geurts, Petra H.; Bosman, Giel J. C. G. M.] Radboud Univ Nijmegen, Med Ctr, Dept Biochem, NL-6525 ED Nijmegen, Netherlands.
[Lasonder, Edwin] Radboud Univ Nijmegen, Med Ctr, Nijmegen Ctr Mol Life Sci, Ctr Mol & Biomol Informat, NL-6525 ED Nijmegen, Netherlands.
[Bertoldi, Mariarita] Univ Verona, Biochem Sect, Dept Life & Reprod Sci, I-37134 Verona, Italy.
[Danek, Adrian; Bader, Benedikt] Univ Munich, Dept Neurol, D-8000 Munich, Germany.
[Walker, Ruth H.] James J Peters Vet Adm Med Ctr, Dept Neurol, Bronx, NY USA.
[Walker, Ruth H.] Mt Sinai Sch Med, New York, NY USA.
[Jung, Hans H.] Univ Zurich Hosp, CH-8091 Zurich, Switzerland.
[Ferru, Emanuela] Univ Turin, Dept Genet Biol & Biochem, Turin, Italy.
[Mohandas, Narla] New York Blood Ctr, New York, NY 10021 USA.
RP De Franceschi, L (reprint author), Univ Verona, Dept Med, Ple L Scuro 10, I-37134 Verona, Italy.
EM lucia.defranceschi@univr.it
RI Bosman, G.J.C.G.M./L-4221-2015; Danek, Adrian/G-7339-2011
OI Danek, Adrian/0000-0001-8857-5383
FU Advocacy for Neuroacanthocytosis Patients; Carl H. and Elizabeth S.
Pforzheimer III, New York; Ginger and Glenn Irvine, London; Telethon
[GPP07007]
FX This work was supported by the Advocacy for Neuroacanthocytosis Patients
(B. B., P. H. B.-G., E. L., G.J.C. G. M. B., and L. D. F.), Carl H. and
Elizabeth S. Pforzheimer III, New York (B. B., P. H. B.-G., E. L.,
G.J.C. G. M. B., and R. H. W.), Ginger and Glenn Irvine, London (P. B.,
E. L., and G.J.C. G. M. B.) and Telethon (grant GPP07007, L. D. F.).
Preliminary data were generated by Dr Christan Pozzobon.
NR 47
TC 24
Z9 24
U1 0
U2 5
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD NOV 17
PY 2011
VL 118
IS 20
BP 5652
EP 5663
DI 10.1182/blood-2011-05-355339
PG 12
WC Hematology
SC Hematology
GA 851JT
UT WOS:000297265400036
PM 21951684
ER
PT J
AU Del Tredici, K
Duda, JE
AF Del Tredici, Kelly
Duda, John E.
TI Peripheral Lewy body pathology in Parkinson's disease and incidental
Lewy body disease: Four cases
SO JOURNAL OF THE NEUROLOGICAL SCIENCES
LA English
DT Article; Proceedings Paper
CT 7th International Congress on Mental Dysfunction and other Non-Motor
Features in Parkinsons Disease and Related Disorders
CY DEC 09-12, 2010
CL Barcelona, SPAIN
DE Alpha-synuclein; Auerbach plexus; Autonomic nervous system; Axonal;
Brainstem; Celiac ganglion; Cognitive dysfunction; Incidental Lewy body
disease; Lewy bodies/Lewy neurites; Non-motor symptoms; Parkinson's
disease; Submandibular gland; Superior cervical ganglion; Sympathetic
trunk; Synucleinopathy; Thyroid gland
ID AUTONOMIC NERVOUS-SYSTEM; HUMAN ALPHA-SYNUCLEIN; NONMOTOR SYMPTOMS;
MOVEMENT-DISORDERS; AXONAL-TRANSPORT; BRAIN PATHOLOGY; BODIES; PLEXUSES;
GANGLIA; DEGENERATION
AB The accumulation of Lewy pathology (LP) within autonomic nervous system tissues has received increased attention recently as a possible induction site for Lewy neurodegeneration and a possible source of biopsy material for biomarkers of early Parkinson's disease (PD). Here, we describe LP accumulation within various tissues involving peripheral autonomic nervous system neurons in three PD cases and one case of incidental Lewy body disease. Findings highlight the value of examining pathology within functional neuroanatomical systems and particularly the importance of Lewy neurites (LNs) in the pathophysiology of PD. Published by Elsevier B.V.
C1 [Del Tredici, Kelly] Univ Ulm, Dept Neurol, Clin Res Ctr, D-89081 Ulm, Germany.
[Duda, John E.] Philadelphia VA Med Ctr, Parkinsons Dis Res Educ & Clin Ctr, Philadelphia, PA 19104 USA.
[Duda, John E.] Univ Penn, Sch Med, Dept Neurol, Philadelphia, PA 19104 USA.
RP Del Tredici, K (reprint author), Univ Ulm, Dept Neurol, Clin Res Ctr, Helmholtzstr 8-1, D-89081 Ulm, Germany.
EM kelly.del-tredici@uni-ulm.de
NR 48
TC 10
Z9 10
U1 0
U2 5
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0022-510X
J9 J NEUROL SCI
JI J. Neurol. Sci.
PD NOV 15
PY 2011
VL 310
IS 1-2
SI SI
BP 100
EP 106
DI 10.1016/j.jns.2011.06.003
PG 7
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 846UA
UT WOS:000296927500025
PM 21689832
ER
PT J
AU Morley, JF
Duda, JE
AF Morley, James F.
Duda, John E.
TI Neuropsychological correlates of olfactory dysfunction in Parkinson's
disease
SO JOURNAL OF THE NEUROLOGICAL SCIENCES
LA English
DT Article; Proceedings Paper
CT 7th International Congress on Mental Dysfunction and Other Non-Motor
Features in Parkinson's Disease and Related Disorders
CY DEC 09-12, 2010
CL Barcelona, SPAIN
DE Parkinson's disease; Olfaction; Non-motor symptoms; Psychiatric
symptoms; Cognitive symptoms
ID ODOR IDENTIFICATION; COGNITIVE IMPAIRMENT; BODY PATHOLOGY; DEFICITS;
RISK; DISCRIMINATION; SYMPTOMS; SIGN
AB Olfactory impairment is a common early non-motor manifestation in Parkinson's disease that has garnered interest as a clinical biomarker for early "pre-motor" diagnosis and prediction of associated clinical phenotypes. Whether olfactory impairment correlates well with motor symptoms is not yet clear, and recent interest has focused on the relationship between hyposmia and other non-motor symptoms. In this paper, we will review emerging evidence for a relationship between hyposmia and neuropsychiatric manifestations, discussing the potential pathophysiology together with challenges and opportunities for future research. Published by Elsevier B.V.
C1 [Duda, John E.] Philadelphia VA Med Ctr, Parkinsons Dis Res Educ & Clin Ctr, Philadelphia, PA 19104 USA.
Univ Penn, Dept Neurol, Sch Med, Philadelphia, PA 19104 USA.
RP Duda, JE (reprint author), Philadelphia VA Med Ctr, Parkinsons Dis Res Educ & Clin Ctr, 3900 Woodland Ave, Philadelphia, PA 19104 USA.
EM John.Duda@va.gov
NR 31
TC 7
Z9 7
U1 1
U2 4
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0022-510X
J9 J NEUROL SCI
JI J. Neurol. Sci.
PD NOV 15
PY 2011
VL 310
IS 1-2
SI SI
BP 228
EP 230
DI 10.1016/j.jns.2011.05.030
PG 3
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 846UA
UT WOS:000296927500050
PM 21658728
ER
PT J
AU Beyth, RJ
Landefeld, CS
AF Beyth, Rebecca J.
Landefeld, C. Seth
TI Learning the Respective Roles of Warfarin and Dabigatran to Prevent
Stroke in Patients With Nonvalvular Atrial Fibrillation
SO ANNALS OF INTERNAL MEDICINE
LA English
DT Editorial Material
ID THERAPY; ANTICOAGULATION
C1 [Landefeld, C. Seth] Univ Calif San Francisco, Div Geriatr, San Francisco, CA 94118 USA.
[Landefeld, C. Seth] San Francisco VA Med Ctr, San Francisco, CA 94118 USA.
[Beyth, Rebecca J.] Univ Florida, Gainesville, FL 32608 USA.
[Beyth, Rebecca J.] N Florida S Georgia Vet Hlth Syst, Gainesville, FL 32608 USA.
RP Landefeld, CS (reprint author), Univ Calif San Francisco, Div Geriatr, Suite 380,3333 Calif St, San Francisco, CA 94118 USA.
NR 12
TC 2
Z9 2
U1 0
U2 2
PU AMER COLL PHYSICIANS
PI PHILADELPHIA
PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA
SN 0003-4819
EI 1539-3704
J9 ANN INTERN MED
JI Ann. Intern. Med.
PD NOV 15
PY 2011
VL 155
IS 10
BP 714
EP +
DI 10.7326/0003-4819-155-10-201111150-00012
PG 3
WC Medicine, General & Internal
SC General & Internal Medicine
GA 849EI
UT WOS:000297108000008
PM 22084336
ER
PT J
AU Furmaga, H
Shah, A
Frazer, A
AF Furmaga, Havan
Shah, Aparna
Frazer, Alan
TI Serotonergic and Noradrenergic Pathways Are Required for the
Anxiolytic-like and Antidepressant-like Behavioral Effects of Repeated
Vagal Nerve Stimulation in Rats
SO BIOLOGICAL PSYCHIATRY
LA English
DT Article
DE 5,7-dihydroxytryptamine; 6-hydroxydopamine; desipramine; forced swim
test; novelty suppressed feeding test; sertraline; vagal nerve
stimulation
ID TREATMENT-RESISTANT DEPRESSION; FORCED SWIMMING TEST; VAGUS NERVE;
ANXIETY DISORDERS; ANIMAL-MODEL; NOREPINEPHRINE TRANSPORTERS;
ANTIINFLAMMATORY CYTOKINES; MEDULLA-OBLONGATA; INDUCED REMISSION; RAPHE
NUCLEUS
AB Background: Vagal nerve stimulation (VNS) is used for treatment-refractory depression, but there are few preclinical studies of its effects when administered repeatedly over time using clinically relevant stimulation parameters in nonanesthetized animals.
Methods: The novelty-suppressed feeding test (NSFT) and forced swim test (FST) were used to evaluate the anxiolytic- and antidepressant-like potential of VNS in rats, respectively. The behavioral effects of VNS were compared with those of desipramine (DMI; 10 mg/kg/day) and sertraline (7.5 mg/kg/day) administered via osmotic minipump. Such experiments were carried out in intact rats as well as those that had selective destruction of either serotonin or noradrenergic neurons in brain caused by the neurotoxins, 5,7-dihyroxytryptamine (5,7-DHT), or 6-hydroxydopamine (6-OHDA).
Results: Repeated administration of VNS, DMI, and sertraline decreased latency to feed in the NSFT. In the FST, repeated VNS, DMI, and sertraline caused decreased immobility; the VNS-induced decrease in immobility resulted from increases in both swimming and climbing behaviors. Effects of VNS and sertraline, but not DMI, in both the NSFT and the FST were abolished in rats treated with 5,7-DHT. Effects of DMI in both behavioral tests, but not those of sertraline, were abolished in 6-OHDA treated rats. VNS effects on immobility and climbing in the FST were not blocked in the 6-OHDA-treated rats. There was no significant difference in locomotor activity caused by any of the treatments or by the lesions.
Conclusions: Serotonergic nerves are required for repeated VNS-induced anxiolytic- and antidepressant-like effects. Noradrenergic nerves can also be activated by VNS to cause its anxiolytic-like effect.
C1 [Furmaga, Havan; Shah, Aparna; Frazer, Alan] Univ Texas Hlth Sci Ctr San Antonio, Dept Pharmacol, San Antonio, TX 78229 USA.
[Frazer, Alan] S Texas Vet Hlth Care Syst, Audie L Murphy Div, San Antonio, TX USA.
RP Frazer, A (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Pharmacol, 7703 Floyd Curl Dr,Mail Code 7764, San Antonio, TX 78229 USA.
EM frazer@uthscsa.edu
FU National Institute of Mental Health [MH082933]; Cyberonics Inc.
FX We acknowledge the technical assistance of Mohona Sadhu and thank Dr.
David Morilak for his insightful suggestions throughout the course of
the experiment. This work was supported by National Institute of Mental
Health Grant No. MH082933 (AF). The electrodes, VNS stimulators, and
dummy stimulators were gifts from Cyberonics Inc.; Dr. Furmaga and Ms.
Shah report no biomedical financial interests or potential conflicts of
interest. Dr. Frazer has served on advisory boards for Lundbeck and for
Takeda in the last three years. Previously, Dr. Frazer had received
financial compensation as a consultant for Cyberonics Inc. and had also
obtained grant support from them for a preclinical study.
NR 75
TC 25
Z9 25
U1 0
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0006-3223
J9 BIOL PSYCHIAT
JI Biol. Psychiatry
PD NOV 15
PY 2011
VL 70
IS 10
BP 937
EP 945
DI 10.1016/j.biopsych.2011.07.020
PG 9
WC Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA 841DX
UT WOS:000296493800007
PM 21907323
ER
PT J
AU Ueno, K
Hirata, H
Majid, S
Tabatabai, ZL
Hinoda, Y
Dahiya, R
AF Ueno, Koji
Hirata, Hiroshi
Majid, Shahana
Tabatabai, Z. Laura
Hinoda, Yuji
Dahiya, Rajvir
TI IGFBP-4 activates the Wnt/beta-catenin signaling pathway and induces
M-CAM expression in human renal cell carcinoma
SO INTERNATIONAL JOURNAL OF CANCER
LA English
DT Article
DE RCC; IGFBP-4; metastasis; beta-catenin; TOPflash
ID FACTOR BINDING-PROTEIN; GROWTH-FACTOR FAMILY; COLORECTAL-CANCER;
IMMUNOGLOBULIN SUPERFAMILY; POOR-PROGNOSIS; CLEAR-CELL; TUMOR;
IDENTIFICATION; PROGRESSION; TARGET
AB The Wnt/beta-catenin signaling pathway is inactivated by Wnt antagonists in most cancers and IGFBP-4 is an antagonist of the Wnt/beta-catenin signaling pathway. However, the function of IGFBP-4 is not currently understood in renal cell carcinoma (RCC). We initially found that the expression of IGFBP-4 was significantly lower in primary RCC and higher in metastatic RCC compared to normal human kidney tissues. To assess the function of IGFBP4, we established IGFBP4 transfectants (primary renal cancer cell line) and performed functional analyses including Tcf reporter assays, cell viability, invasive capability, mortality, and in vivo tumor growth. Interestingly IGFBP-4 transfectants promoted cell growth (in vitro and in vivo), invasion, and motility in primary renal cancer. Tcf transcriptional activity was significantly increased in IGFBP-4 transfectants compared to mock cells and beta-catenin expression was increased. Also the beta-catenin downstream effector, MT1-MMP showed increased expression in IGFBP4 transfectants. Additionally IGFBP4 induced the expression of M-CAM, a marker of tumor progression. In order to assess the role of IGFBP4 in metastatic renal cancer, IGFBP-4 mRNA in a metastatic renal cancer cell lines (ACHN) was knocked-down using a siRNA technique. The cell growth and motility was decreased in si-IGFBP4 transfected ACHN cells compared to cells transfected with control siRNA. Tcf activity in ACHN cells was also decreased with si-IGFBP-4 transfection. This is a first report documenting that IGFBP-4 expression in RCC activates cell growth, metastasis, Wnt/beta-catenin signaling and may be involved in RCC metastasis.
C1 [Ueno, Koji; Hirata, Hiroshi; Majid, Shahana; Dahiya, Rajvir] San Francisco VA Med Ctr, Dept Urol, San Francisco, CA USA.
[Ueno, Koji; Hirata, Hiroshi; Majid, Shahana; Tabatabai, Z. Laura; Dahiya, Rajvir] Univ Calif San Francisco, San Francisco, CA 94121 USA.
[Tabatabai, Z. Laura] San Francisco VA Med Ctr, Dept Pathol, San Francisco, CA USA.
[Hinoda, Yuji] Yamaguchi Univ, Grad Sch Med, Dept Oncol & Lab Med, Yamaguchi, Japan.
RP Dahiya, R (reprint author), Vet Affairs Med Ctr, Urol Res Ctr 112F, 4150 Clement St, San Francisco, CA 94121 USA.
EM rdahiya@urology.ucsf.edu
FU NIH [R01CA130860, R01CA111470, R01CA138642, T32DK007790]; VA Research
Enhancement Award Program (REAP)
FX Grant sponsor: NIH; Grant numbers: R01CA130860, R01CA111470,
R01CA138642, T32DK007790; Grant sponsor: VA Research Enhancement Award
Program (REAP), Merit Review grants
NR 32
TC 21
Z9 22
U1 0
U2 3
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0020-7136
J9 INT J CANCER
JI Int. J. Cancer
PD NOV 15
PY 2011
VL 129
IS 10
BP 2360
EP 2369
DI 10.1002/ijc.25899
PG 10
WC Oncology
SC Oncology
GA 824VT
UT WOS:000295231000007
PM 21207373
ER
PT J
AU Landefeld, CS
AF Landefeld, C. Seth
TI Goals of Care for Hip Fracture Promoting Independence and Reducing
Mortality
SO ARCHIVES OF INTERNAL MEDICINE
LA English
DT Editorial Material
ID OUTCOMES
C1 [Landefeld, C. Seth] Univ Calif San Francisco, Div Geriatr, San Francisco, CA 94118 USA.
[Landefeld, C. Seth] San Francisco VA Med Ctr, Geriatr Palliat & Extended Care Serv, San Francisco, CA USA.
[Landefeld, C. Seth] San Francisco VA Med Ctr, Hlth Serv Res Enhancement Award Program, San Francisco, CA USA.
RP Landefeld, CS (reprint author), Univ Calif San Francisco, Div Geriatr, 3333 Calif St,Ste 380, San Francisco, CA 94118 USA.
EM sethl@medicine.ucsf.edu
NR 10
TC 2
Z9 2
U1 0
U2 2
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA
SN 0003-9926
J9 ARCH INTERN MED
JI Arch. Intern. Med.
PD NOV 14
PY 2011
VL 171
IS 20
BP 1837
EP 1838
PG 3
WC Medicine, General & Internal
SC General & Internal Medicine
GA 848MS
UT WOS:000297056300009
PM 22083570
ER
PT J
AU Jones, CK
Engers, DW
Thompson, AD
Field, JR
Blobaum, AL
Lindsley, SR
Zhou, Y
Gogliotti, RD
Jadhav, S
Zamorano, R
Bogenpohl, J
Smith, Y
Morrison, R
Daniels, JS
Weaver, CD
Conn, PJ
Lindsley, CW
Niswender, CM
Hopkins, CR
AF Jones, Carrie K.
Engers, Darren W.
Thompson, Analisa D.
Field, Julie R.
Blobaum, Anna L.
Lindsley, Stacey R.
Zhou, Ya
Gogliotti, Rocco D.
Jadhav, Satyawan
Zamorano, Rocio
Bogenpohl, Jim
Smith, Yoland
Morrison, Ryan
Daniels, J. Scott
Weaver, C. David
Conn, P. Jeffrey
Lindsley, Craig W.
Niswender, Colleen M.
Hopkins, Corey R.
TI Discovery, Synthesis, and Structure-Activity Relationship Development of
a Series of N-4-(2,5-Dioxopyrrolidin-1-yl)phenylpicolinamides
(VU0400195, ML182): Characterization of a Novel Positive Allosteric
Modulator of the Metabotropic Glutamate Receptor 4 (mGlu(4)) with Oral
Efficacy in an Antiparkinsonian Animal Model
SO JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
ID PARKINSONS-DISEASE; MGLUR4; PHARMACOLOGY; DOPAMINE; LEVODOPA; PAMS
AB There is an increasing amount of literature data showing the positive effects on preclinical antiparkinsonian rodent models with selective positive allosteric modulators of metabotropic glutamate receptor 4 (mGlu(4)). However, most of the data generated utilize compounds that have not been optimized for druglike properties, and as a consequence, they exhibit poor pharmacokinetic properties and thus do not cross the blood-brain barrier. Herein, we report on a series of N-4-(2,5-dioxopyrrolidin-1-yl)phenylpicolinamides with improved PK properties with excellent potency and selectivity as well as improved brain exposure in rodents. Finally, ML182 was shown to be orally active in the haloperidol induced catalepsy model, a well-established antiparkinsonian model.
C1 [Jones, Carrie K.; Engers, Darren W.; Thompson, Analisa D.; Field, Julie R.; Blobaum, Anna L.; Lindsley, Stacey R.; Zhou, Ya; Gogliotti, Rocco D.; Jadhav, Satyawan; Zamorano, Rocio; Morrison, Ryan; Daniels, J. Scott; Weaver, C. David; Conn, P. Jeffrey; Lindsley, Craig W.; Niswender, Colleen M.; Hopkins, Corey R.] Vanderbilt Univ, Med Ctr, Dept Pharmacol, Nashville, TN 37232 USA.
[Jones, Carrie K.; Engers, Darren W.; Thompson, Analisa D.; Blobaum, Anna L.; Lindsley, Stacey R.; Zhou, Ya; Gogliotti, Rocco D.; Jadhav, Satyawan; Zamorano, Rocio; Morrison, Ryan; Daniels, J. Scott; Conn, P. Jeffrey; Lindsley, Craig W.; Niswender, Colleen M.; Hopkins, Corey R.] Vanderbilt Univ, Med Ctr, Vanderbilt Ctr Neurosci Drug Discovery, Nashville, TN 37232 USA.
[Jones, Carrie K.] US Dept Vet Affairs, Tennessee Valley Healthcare Syst, Nashville, TN 37212 USA.
[Lindsley, Craig W.; Hopkins, Corey R.] Vanderbilt Univ, Dept Chem, Nashville, TN 37232 USA.
[Weaver, C. David; Conn, P. Jeffrey; Lindsley, Craig W.] Vanderbilt Univ, Vanderbilt Inst Chem Biol, Nashville, TN 37232 USA.
[Engers, Darren W.; Conn, P. Jeffrey; Lindsley, Craig W.; Hopkins, Corey R.] Vanderbilt Specialized Chem Ctr Accelerated Probe, Nashville, TN 37232 USA.
[Bogenpohl, Jim; Smith, Yoland] Emory Univ, Yerkes Natl Primate Res Ctr, Atlanta, GA 30329 USA.
[Bogenpohl, Jim; Smith, Yoland] Emory Univ, Dept Neurol, Atlanta, GA 30329 USA.
RP Niswender, CM (reprint author), Vanderbilt Univ, Med Ctr, Dept Pharmacol, Nashville, TN 37232 USA.
EM colleen.niswender@vanderbilt.edu; corey.r.hopkins@vanderbilt.edu
RI Conn, Peter/D-7848-2012; Zhou, Ya/F-1220-2013
FU National Institute of Mental Health, National Institute of Neurological
Disorders and Stroke; Micheal J. Fox Foundation; Vanderbilt Department
of Pharmacology; Vanderbilt Institute of Chemical Biology; NIH/MLPCN
[5U54MH08465-02]
FX The authors warmly acknowledge Emily L. Days, Tasha Nalywajko, Cheryl A.
Austin, and Michael Baxter Williams for their critical contributions to
the HTS portion of the projects; Matt Mulder, Chris Denicola, Nathan
Kett, and Sichen Chang for the purification of compounds utilizing the
mass-directed HPLC system; and Katrina Brewer for technical assistance
with the PK assays. The dog cassette in vivo experiment was performed at
Calvert Labs, and the rhesus in vivo experiment was performed at the
Yerkes Primate Center at Emory University, GA. This work was supported
by the National Institute of Mental Health, National Institute of
Neurological Disorders and Stroke, the Micheal J. Fox Foundation, the
Vanderbilt Department of Pharmacology, and the Vanderbilt Institute of
Chemical Biology. In addition, the authors thank the NIH/MLPCN (Grant
5U54MH08465-02) for support of this research. Vanderbilt is a member of
the MLPCN and houses the Vanderbilt Specialized Chemistry Center for
Accelerated Probe Development.
NR 27
TC 35
Z9 36
U1 0
U2 6
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0022-2623
J9 J MED CHEM
JI J. Med. Chem.
PD NOV 10
PY 2011
VL 54
IS 21
BP 7639
EP 7647
DI 10.1021/jm200956q
PG 9
WC Chemistry, Medicinal
SC Pharmacology & Pharmacy
GA 839ZN
UT WOS:000296408100018
PM 21966889
ER
PT J
AU von Korff, M
Katon, WJ
Lin, EHB
Ciechanowski, P
Peterson, D
Ludman, EJ
Young, B
Rutter, CM
AF von Korff, Michael
Katon, Wayne J.
Lin, Elizabeth H. B.
Ciechanowski, Paul
Peterson, Do
Ludman, Evette J.
Young, Bessie
Rutter, Carolyn M.
TI Functional outcomes of multi-condition collaborative care and successful
ageing: results of randomised trial
SO BRITISH MEDICAL JOURNAL
LA English
DT Article
ID QUALITY-OF-LIFE; CORONARY-HEART-DISEASE; MAJOR DEPRESSION; HEALTH-CARE;
DISABILITY; MANAGEMENT; THERAPY; ANTIDEPRESSANT; COMPRESSION; VALIDATION
AB Objective To evaluate the effectiveness of integrated care for chronic physical diseases and depression in reducing disability and improving quality of life.
Design A randomised controlled trial of multi-condition collaborative care for depression and poorly controlled diabetes and/or risk factors for coronary heart disease compared with usual care among middle aged and elderly people
Setting Fourteen primary care clinics in Seattle, Washington.
Participants Patients with diabetes or coronary heart disease, or both, and blood pressure above 140/90 mm Hg, low density lipoprotein concentration >3.37 mmol/L, or glycated haemoglobin 8.5% or higher, and PHQ-9 depression scores of >= 10.
Intervention A 12 month intervention to improve depression, glycaemic control, blood pressure, and lipid control by integrating a "treat to target" programme for diabetes and risk factors for coronary heart disease with collaborative care for depression. The intervention combined self management support, monitoring of disease control, and pharmacotherapy to control depression, hyperglycaemia, hypertension, and hyperlipidaemia.
Main outcome measures Social role disability (Sheehan disability scale), global quality of life rating, and World Health Organization disability assessment schedule (WHODAS-2) scales to measure disabilities in activities of daily living (mobility, self care, household maintenance).
Results Of 214 patients enrolled (106 intervention and 108 usual care), disability and quality of life measures were obtained for 97 intervention patients at six months (92%) and 92 at 12 months (87%), and for 96 usual care patients at six months (89%) and 92 at 12 months (85%). Improvements from baseline on the Sheehan disability scale (-0.9, 95% confidence interval -1.5 to -0.2; P=0.006) and global quality of life rating (0.7, 0.2 to 1.2; P=0.005) were significantly greater at six and 12 months in patients in the intervention group. There was a trend toward greater improvement in disabilities in activities of daily living (-1.5, -3.3 to 0.4; P=0.10).
Conclusions Integrated care that covers chronic physical disease and comorbid depression can reduce social role disability and enhance global quality of life.
C1 [von Korff, Michael; Lin, Elizabeth H. B.; Peterson, Do; Ludman, Evette J.; Rutter, Carolyn M.] Grp Hlth Res Inst, Seattle, WA 98101 USA.
[Katon, Wayne J.; Ciechanowski, Paul] Univ Washington, Dept Psychiat & Behav Sci, Sch Med, Seattle, WA 98195 USA.
[Young, Bessie] Univ Washington, Vet Affairs Puget Sound Hlth Care Syst, Sch Med, Seattle, WA 98195 USA.
[Young, Bessie] Univ Washington, Div Nephrol, Sch Med, Dept Med, Seattle, WA 98195 USA.
[Rutter, Carolyn M.] Univ Washington, Dept Biostat, Sch Publ Hlth, Seattle, WA 98195 USA.
RP von Korff, M (reprint author), Grp Hlth Res Inst, 1730 Minor Ave, Seattle, WA 98101 USA.
EM vonkorff.m@ghc.org
FU Group Health; National Institute of Mental Health Services Division,
Bethesda, MD [MH041739, MH069741]
FX The TEAMcare study would not have been possible without the support and
participation of Group Health patients, primary care physicians,
consultants, and leaders. We also acknowledge efforts and expertise by
Tara Beatty, Malia Oliver, Sue Ruedebusch, Diana Griffith, and Sandy
Randles. We also thank Michelle Wong, R James Dudl, and Kaiser
Permanente Care Management Institute for providing the treat to target
diabetes guidelines that we adapted. The content is solely the
responsibility of the authors and does not necessarily represent the
official views of the organisations that employ them.; This study was
supported by grants MH041739 and MH069741 from the National Institute of
Mental Health Services Division, Bethesda, MD (WJK) and by institutional
support from Group Health Cooperative. The sponsors of this research had
no influence over the conduct of the study, the analyses of study data,
or the content of this paper.
NR 41
TC 26
Z9 26
U1 0
U2 13
PU B M J PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0959-535X
J9 BRIT MED J
JI Br. Med. J.
PD NOV 10
PY 2011
VL 343
AR d6612
DI 10.1136/bmj.d6612
PG 7
WC Medicine, General & Internal
SC General & Internal Medicine
GA 848NT
UT WOS:000297059000003
PM 22074851
ER
PT J
AU Wu, YN
Johnson, SW
AF Wu, Y. -N.
Johnson, S. W.
TI DOPAMINE OXIDATION FACILITATES ROTENONE-DEPENDENT POTENTIATION OF
N-METHYL-D-ASPARTATE CURRENTS IN RAT SUBSTANTIA NIGRA DOPAMINE NEURONS
SO NEUROSCIENCE
LA English
DT Article
DE reactive oxygen species; rotenone; N-methyl-D-aspartate; monoamine
oxidase; pargyline; reserpine
ID PROTEIN-KINASE-C; MITOCHONDRIAL COMPLEX-I; PARKINSONS-DISEASE;
NMDA-RECEPTOR; TYROSINE KINASE; DEPRENYL PROTECTS; RAPID DEVELOPMENT;
TREATED RATS; PC12 CELLS; TOXICITY
AB Rotenone is a mitochondrial poison that causes dopamine cell death and is used as a model of Parkinson's disease in rodents. Recently, we showed that rotenone augments currents evoked by N-methyl-D-aspartate (NMDA) by relieving voltage-dependent Mg(2+) block in rat substantia nigra compacta (SNC) dopamine neurons. Because rotenone is well known to generate reactive oxygen species (ROS), we conducted the present experiments to evaluate the role of ROS in mediating the effect of rotenone on NMDA current augmentation. Using patch pipettes to record whole-cell currents from SNC neurons in slices of rat brain, we found that the ability of rotenone (100 nM) to increase NMDA (3-30 mu M) current was antagonized by the antioxidant agent N-acetylcysteine (1 mM). In contrast, mercaptosuccinate (1 mM), which blocks glutathione peroxidase and raises tissue levels of H(2)O(2), mimicked rotenone by augmenting inward currents evoked by NMDA. Because oxidation of dopamine can also generate ROS, we explored the role of dopamine on this action of rotenone. We prepared dopamine-depleted midbrain slices from rats that had been pretreated with reserpine (5 mg/kg ip) and alpha-methyl-para-tyrosine (AMPT, 250 mg/kg ip). Dopamine depletion blocked the ability of rotenone (100 nM) to increase inward current evoked by NMDA (30 mu M). Rotenone-dependent augmentation of NMDA current was also blocked by the monoamine oxidase inhibitor pargyline (100 mu M) in slices prepared from normal rats. In contrast, the dopamine precursor levodopa potentiated the action of rotenone on NMDA current. These results suggest that ROS and/or dopamine oxidation products mediate the ability of rotenone to potentiate NMDA currents. Because excessive NMDA receptor stimulation can produce excitotoxicity, our results suggest that oxidative metabolism of dopamine might facilitate the neurotoxicity of rotenone. Published by Elsevier Ltd on behalf of IBRO.
C1 [Wu, Y. -N.; Johnson, S. W.] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97239 USA.
[Johnson, S. W.] Portland VA Med Ctr, Portland, OR 97207 USA.
RP Johnson, SW (reprint author), Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97239 USA.
EM johnsost@ohsu.edu
FU Veterans Affairs Merit Review [0383]; Portland Veterans Affairs
Parkinson's Disease Research, Education, and Clinical Center
FX This research was supported by Veterans Affairs Merit Review grant 0383
and by the Portland Veterans Affairs Parkinson's Disease Research,
Education, and Clinical Center.
NR 53
TC 11
Z9 11
U1 0
U2 5
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0306-4522
J9 NEUROSCIENCE
JI Neuroscience
PD NOV 10
PY 2011
VL 195
BP 138
EP 144
DI 10.1016/j.neuroscience.2011.08.041
PG 7
WC Neurosciences
SC Neurosciences & Neurology
GA 833EF
UT WOS:000295863900014
PM 21884756
ER
PT J
AU Hill-Burns, EM
Factor, SA
Zabetian, CP
Thomson, G
Payami, H
AF Hill-Burns, Erin M.
Factor, Stewart A.
Zabetian, Cyrus P.
Thomson, Glenys
Payami, Haydeh
TI Evidence for More than One Parkinson's Disease-Associated Variant within
the HLA Region
SO PLOS ONE
LA English
DT Article
ID POPULATION; METAANALYSIS; HAPLOTYPES; IMPUTATION; GENETICS; SNCA
AB Parkinson's disease (PD) was recently found to be associated with HLA in a genome-wide association study (GWAS). Followup GWAS's replicated the PD-HLA association but their top hits differ. Do the different hits tag the same locus or is there more than one PD-associated variant within HLA? We show that the top GWAS hits are not correlated with each other (0.00 <= r(2)<= 0.15). Using our GWAS (2000 cases, 1986 controls) we conducted step-wise conditional analysis on 107 SNPs with P, 10 23 for PD-association; 103 dropped-out, four remained significant. Each SNP, when conditioned on the other three, yielded P(SNP1) = 5610 24, P(SNP2) = 5610 24, P(SNP3) = 4610 23 and P(SNP4) = 0.025. The four SNPs were not correlated (0.01 <= r(2)<= 0.20). Haplotype analysis (excluding rare SNP2) revealed increasing PD risk with increasing risk alleles from OR = 1.27, P = 5610 23 for one risk allele to OR = 1.65, P = 4610 28 for three. Using additional 843 cases and 856 controls we replicated the independent effects of SNP1 (P(conditioned-on-SNP4) = 0.04) and SNP4 (P(conditioned-on-SNP1) = 0.04); SNP2 and SNP3 could not be replicated. In pooled GWAS and replication, SNP1 had OR(conditioned-on-SNP4) = 1.23, P(conditioned-on-SNP4) = 6610 27; SNP4 had OR(conditioned-on-SNP1) = 1.18, P(conditioned-on-SNP1) = 3610 23; and the haplotype with both risk alleles had OR = 1.48, P = 2x10(-12). Genotypic OR increased with the number of risk alleles an individual possessed up to OR = 1.94, P = 2610 211 for individuals who were homozygous for the risk allele at both SNP1 and SNP4. SNP1 is a variant in HLA-DRA and is associated with HLA-DRA, DRB5 and DQA2 gene expression. SNP4 is correlated (r(2) = 0.95) with variants that are associated with HLA-DQA2 expression, and with the top HLA SNP from the IPDGC GWAS (r(2) = 0.60). Our findings suggest more than one PD-HLA association; either different alleles of the same gene, or separate loci.
C1 [Hill-Burns, Erin M.; Payami, Haydeh] New York State Dept Hlth, Wadsworth Ctr, Albany, NY USA.
[Factor, Stewart A.] Emory Univ, Sch Med, Dept Neurol, Atlanta, GA 30322 USA.
[Zabetian, Cyrus P.] Univ Washington, Dept Neurol, Seattle, WA 98195 USA.
[Zabetian, Cyrus P.] Univ Washington, Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA 98195 USA.
[Thomson, Glenys] Univ Calif Berkeley, Dept Integrat Biol, Berkeley, CA 94720 USA.
RP Hill-Burns, EM (reprint author), New York State Dept Hlth, Wadsworth Ctr, Albany, NY USA.
EM hpayami@wadsworth.org
OI Zabetian, Cyrus/0000-0002-7739-4306
FU National Institute of Neurological Disorders And Stroke (NINDS) [R01
NS36960, R01 NS067469]; Edmond J. Safra Michael J. Fox Foundation Global
Genetic Consortium Initiative; Department of Veterans Affairs
[I01BX000531]; Close to a Cure Foundation: A Fund for Parkinson's
Research of Foundation for the Carolinas; National Institute of Allergy
and Infectious Disease [AI40076]
FX Study was supported by grants from the National Institute of
Neurological Disorders And Stroke (NINDS R01 NS36960 and R01 NS067469 to
HP), the Edmond J. Safra Michael J. Fox Foundation Global Genetic
Consortium Initiative (HP), the Department of Veterans Affairs
('I01BX000531 to CZ), The Close to a Cure Foundation: A Fund for
Parkinson's Research of Foundation for the Carolinas (SF), and the
National Institute of Allergy and Infectious Disease (AI40076, GT).
Funding support for the replication dataset was provided by the National
Institute of Neurological Disorders and Stroke (Foroud/Myers, PI). The
content is solely the responsibility of the authors and does not
necessarily represent the official views of the funding agencies. The
funders had no role in study design, data collection and analysis,
decision to publish, or preparation of the manuscript.
NR 29
TC 20
Z9 20
U1 0
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD NOV 9
PY 2011
VL 6
IS 11
AR e27109
DI 10.1371/journal.pone.0027109
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 852II
UT WOS:000297350800027
PM 22096524
ER
PT J
AU Konno, T
Hata, S
Hamada, Y
Horikoshi-Sakuraba, Y
Nakaya, T
Saito, Y
Yamamoto, T
Yamamoto, T
Maeda, M
Ikeuchi, T
Gandy, S
Akatsu, H
Suzuki, T
AF Konno, Tomoko
Hata, Saori
Hamada, Yukiko
Horikoshi-Sakuraba, Yuko
Nakaya, Tadashi
Saito, Yuhki
Yamamoto, Tohru
Yamamoto, Takayuki
Maeda, Masahiro
Ikeuchi, Takeshi
Gandy, Sam
Akatsu, Hiroyasu
Suzuki, Toshiharu
CA Japanese Alzheimers Dis
TI Coordinated increase of gamma-secretase reaction products in the plasma
of some female Japanese sporadic Alzheimer's disease patients:
quantitative analysis of p3-Alc alpha with a new ELISA system
SO MOLECULAR NEURODEGENERATION
LA English
DT Article
ID TRAUMATIC BRAIN-INJURY; AMYLOID-BETA; APOLIPOPROTEIN-E; ASSOCIATION;
ESTROGEN; PEPTIDE; GENE; NEURODEGENERATION; DEGRADATION; METABOLISM
AB Background: Aggregatable amyloid beta-peptide (A beta) and non-aggregatable p3-Alc alpha are metabolic products of the gamma-secretase cleavage of amyloid beta-protein precursor (APP) and Alcadein alpha (Alc alpha), respectively. Familial AD (FAD)-linked mutations in the presenilin 1 or 2 (PS1 or PS2) component of gamma-secretase can cause alternative intramembranous processing of APP and Alc alpha, leading to a coordinated generation of variants of both A beta and p3-Alc alpha. Variant Alc alpha peptides have been observed in the cerebrospinal fluid (CSF) of patients with mild cognitive impairment and sporadic Alzheimer's disease (AD). Since, like APP, Alc alpha is largely expressed in brain, one might predict that alternative processing of Alca would be reflected in body fluids of some AD patients. These patients with misprocessing of multiple gamma-secretase substrates might define an endophenotype of p3-Alc alpha, in whom AD is due either to dysfunction of gamma-secretase or to a disorder of the clearance of hydrophobic peptides such as those derived from transmembrane domains.
Results: We developed a simple procedure for extraction of p3-Alc alpha from plasma and for analyzing this extract in a sensitive, p3-Alc alpha-specific sandwich enzyme-linked immunosorbent assay (ELISA) system. Plasma p3-Alca levels and A beta 40 levels were examined in sporadic AD subjects from two independent Japanese cohorts. In some of these patients, levels of plasma p3-Alc alpha were significantly higher, and were accompanied by parallel changes in A beta 40 levels. This AD-related difference was more marked in female subjects, but this phenomenon was not observed in subjects with frontotemporal lobar degeneration (FTLD).
Conclusion: Reagents and procedures have been established that enable extraction of p3-Alc alpha from plasma and for quantification of plasma p3-Alc alpha levels by ELISA. Some populations of AD subjects apparently show increased levels of both p3-Alc alpha and A beta 40. Quantification of p3-Alc alpha level may be useful as a readily accessible biomarker for a population of sporadic AD patients in which disease pathogenesis is associated with either dysfunction of gamma-secretase or with a disorder of the clearance of transmembrane domain-derived peptides.
C1 [Konno, Tomoko; Hata, Saori; Nakaya, Tadashi; Saito, Yuhki; Yamamoto, Tohru; Suzuki, Toshiharu] Hokkaido Univ, Grad Sch Pharmaceut Sci, Neurosci Lab, Sapporo, Hokkaido 0600812, Japan.
[Hamada, Yukiko; Horikoshi-Sakuraba, Yuko; Maeda, Masahiro] Immunobiol Labs Co Ltd IBL, Fujioka 3750005, Japan.
[Yamamoto, Takayuki; Akatsu, Hiroyasu] Fukushimura Hosp, Choju Med Inst, Toyohashi, Aichi 4418124, Japan.
[Ikeuchi, Takeshi] Niigata Univ, Brain Res Inst, Dept Mol Neurosci, Niigata 9518585, Japan.
[Gandy, Sam] Alzheimers Dis Res Ctr, Mt Sinai Sch Med, Dept Neurol, New York, NY 10029 USA.
[Gandy, Sam] Alzheimers Dis Res Ctr, Mt Sinai Sch Med, Dept Psychiat, New York, NY 10029 USA.
[Gandy, Sam] James J Peters Vet Adm Med Ctr, Bronx, NY 10468 USA.
RP Suzuki, T (reprint author), Hokkaido Univ, Grad Sch Pharmaceut Sci, Neurosci Lab, Sapporo, Hokkaido 0600812, Japan.
EM tsuzuki@pharm.hokudai.ac.jp
RI Hata, Saori /A-3829-2012; Yamamoto, Tohru/A-3801-2012; Suzuki,
Toshiharu/B-5342-2013
OI Yamamoto, Tohru/0000-0002-1652-0233;
FU Ministry of Education, Culture, Sports, Science and Technology (MEXT);
Ministry of Health, Labor and Welfare (MHLW); New Energy and Industrial
Technology Development Organization (NEDO) in Japan; NIA Alzheimer's
Disease Research Center [P50 05138]
FX This work was supported in part by Grants-in-aid for Scientific Research
from the Ministry of Education, Culture, Sports, Science and Technology
(MEXT), a grant from the Ministry of Health, Labor and Welfare (MHLW),
and a grant from the New Energy and Industrial Technology Development
Organization (NEDO) in Japan. S.G. was supported by the NIA Alzheimer's
Disease Research Center grant P50 05138 to Mary Sano.
NR 32
TC 5
Z9 5
U1 0
U2 2
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1750-1326
J9 MOL NEURODEGENER
JI Mol. Neurodegener.
PD NOV 8
PY 2011
VL 6
AR 76
DI 10.1186/1750-1326-6-76
PG 12
WC Neurosciences
SC Neurosciences & Neurology
GA 864NT
UT WOS:000298247600001
PM 22067061
ER
PT J
AU Singh, T
Sharma, SD
Katiyar, SK
AF Singh, Tripti
Sharma, Som D.
Katiyar, Santosh K.
TI Grape Proanthocyanidins Induce Apoptosis by Loss of Mitochondrial
Membrane Potential of Human Non-Small Cell Lung Cancer Cells In Vitro
and In Vivo
SO PLOS ONE
LA English
DT Article
ID SKH-1 HAIRLESS MICE; DEPENDENT KINASES; ANTICANCER DRUGS;
CARCINOMA-CELLS; CYCLE CONTROL; BCL-2 FAMILY; DEATH; INHIBITORS;
PROTEIN; GROWTH
AB Lung cancer remains the leading cause of cancer-related deaths worldwide, and non-small cell lung cancer (NSCLC) represents approximately 80% of total lung cancer cases. The use of non-toxic dietary phytochemicals can be considered as a chemotherapeutic strategy for the management of the NSCLC. Here, we report that grape seed proanthocyanidins (GSPs) induce apoptosis of NSCLC cells, A549 and H1299, in vitro which is mediated through increased expression of pro-apoptotic protein Bax, decreased expression of anti-apoptotic proteins Bcl2 and Bcl-xl, disruption of mitochondrial membrane potential, and activation of caspases 9, 3 and poly (ADP-ribose) polymerase (PARP). Pre-treatment of A549 and H1299 cells with the caspase-3 inhibitor (z-DEVD-fmk) significantly blocked the GSPs-induced apoptosis of these cells confirmed that GSPs-induced apoptosis is mediated through activation of caspases-3. Treatments of A549 and H1299 cells with GSPs resulted in an increase in G1 arrest. G0/G1 phase of the cell cycle is known to be controlled by cyclin dependent kinases (Cdk), cyclin-dependent kinase inhibitors (Cdki) and cyclins. Our western blot analyses showed that GSPs-induced G1 cell cycle arrest was mediated through the increased expression of Cdki proteins (Cip1/p21 and Kip1/p27), and a simultaneous decrease in the levels of Cdk2, Cdk4, Cdk6 and cyclins. Further, administration of 50, 100 or 200 mg GSPs/kg body weight of mice by oral gavage (5 d/week) markedly inhibited the growth of s.c. A549 and H1299 lung tumor xenografts in athymic nude mice, which was associated with the induction of apoptotic cell death, increased expression of Bax, reduced expression of anti-apoptotic proteins and activation of caspase-3 in tumor xenograft cells. Based on the data obtained in animal study, human equivalent dose of GSPs was calculated, which seems affordable and attainable. Together, these results suggest that GSPs may represent a potential therapeutic agent for the non-small cell lung cancer.
C1 [Singh, Tripti; Sharma, Som D.; Katiyar, Santosh K.] Univ Alabama, Dept Dermatol, Birmingham, AL 35294 USA.
[Katiyar, Santosh K.] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA.
[Katiyar, Santosh K.] Univ Alabama, Nutr Obes Res Ctr, Birmingham, AL USA.
[Katiyar, Santosh K.] Univ Alabama, Ctr Comprehens Canc, Birmingham, AL 35294 USA.
RP Singh, T (reprint author), Univ Alabama, Dept Dermatol, Birmingham, AL 35294 USA.
EM skatiyar@uab.edu
FU Veterans Administration Merit Review Award
FX This work was supported by funds from the Veterans Administration Merit
Review Award (SKK). The funders had no role in study design, data
collection and analysis, decision to publish, or preparation of the
manuscript.
NR 41
TC 34
Z9 37
U1 1
U2 12
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD NOV 8
PY 2011
VL 6
IS 11
AR e27444
DI 10.1371/journal.pone.0027444
PG 13
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 852HZ
UT WOS:000297349700046
PM 22087318
ER
PT J
AU Azadani, A
Chitsaz, S
Tseng, E
Ge, L
AF Azadani, Ali
Chitsaz, Sam
Tseng, Elaine
Ge, Liang
TI Finite Element Analysis of Transcatheter Aortic Valve Implantation:
Impact of Oversizing on Stent and Leaflet Stresses
SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
LA English
DT Meeting Abstract
CT 23rd Annual Transcatheter Cardiovascular Therapeutics (TCT) Symposium
CY NOV 07-11, 2011
CL San Francisco, CA
C1 [Azadani, Ali; Chitsaz, Sam; Tseng, Elaine; Ge, Liang] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Azadani, Ali; Chitsaz, Sam; Tseng, Elaine; Ge, Liang] San Francisco VA Med Ctr, San Francisco, CA USA.
RI Chitsaz, Sam/C-4586-2008
NR 0
TC 0
Z9 0
U1 1
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0735-1097
J9 J AM COLL CARDIOL
JI J. Am. Coll. Cardiol.
PD NOV 8
PY 2011
VL 58
IS 20
SU B
BP B198
EP B198
PG 1
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 846IZ
UT WOS:000296891900736
ER
PT J
AU Chitsaz, S
Jaussaud, N
Meadows, A
Wintermark, M
Cambronero, N
Azadani, AN
Saloner, DA
Chuter, TA
Ge, L
Tseng, EE
AF Chitsaz, Sam
Jaussaud, Nicolas
Meadows, Alison
Wintermark, Max
Cambronero, Neil
Azadani, Ali N.
Saloner, David A.
Chuter, Timothy A.
Ge, Liang
Tseng, Elaine E.
TI Thoracic Endovascular Aortic Repair for Acute Type A Dissection: A
Computational and Anatomic Analysis of Technical Limitations for
Available Devices
SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
LA English
DT Meeting Abstract
CT 23rd Annual Transcatheter Cardiovascular Therapeutics (TCT) Symposium
CY NOV 07-11, 2011
CL San Francisco, CA
C1 [Chitsaz, Sam; Jaussaud, Nicolas; Wintermark, Max; Cambronero, Neil; Azadani, Ali N.; Chuter, Timothy A.; Ge, Liang; Tseng, Elaine E.] Univ Calif San Francisco, Dept Surg, San Francisco, CA USA.
[Chitsaz, Sam; Jaussaud, Nicolas; Azadani, Ali N.; Saloner, David A.; Ge, Liang; Tseng, Elaine E.] San Francisco VA Med Ctr, San Francisco, CA USA.
[Meadows, Alison; Saloner, David A.] Univ Calif San Francisco, Dept Radiol, San Francisco, CA USA.
RI Chitsaz, Sam/C-4586-2008
NR 0
TC 0
Z9 0
U1 1
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0735-1097
J9 J AM COLL CARDIOL
JI J. Am. Coll. Cardiol.
PD NOV 8
PY 2011
VL 58
IS 20
SU B
BP B155
EP B155
PG 1
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 846IZ
UT WOS:000296891900575
ER
PT J
AU Dattilo, PB
Tsai, TT
Casserly, IP
AF Dattilo, Philip B.
Tsai, Thomas T.
Casserly, Ivan P.
TI Endovascular Therapy of Common Femoral Arterial Disease
SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
LA English
DT Meeting Abstract
CT 23rd Annual Transcatheter Cardiovascular Therapeutics (TCT) Symposium
CY NOV 07-11, 2011
CL San Francisco, CA
C1 [Dattilo, Philip B.; Tsai, Thomas T.; Casserly, Ivan P.] Univ Colorado, Sch Med, Aurora, CO USA.
[Tsai, Thomas T.; Casserly, Ivan P.] Denver VA Med Ctr, Denver, CO USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0735-1097
J9 J AM COLL CARDIOL
JI J. Am. Coll. Cardiol.
PD NOV 8
PY 2011
VL 58
IS 20
SU B
BP B157
EP B157
PG 1
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 846IZ
UT WOS:000296891900582
ER
PT J
AU Owens, CD
Gasper, WJ
Kim, JM
Rapp, J
Grenon, M
Seward, K
AF Owens, Christopher D.
Gasper, Warren J.
Kim, Ji Min
Rapp, Joseph
Grenon, Marlene
Seward, Kirk
TI Dexamethasone Infusion to the Adventitia to Enhance Clinical Efficacy
after Femoropopliteal Revascularization: A First in Man Study
SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
LA English
DT Meeting Abstract
CT 23rd Annual Transcatheter Cardiovascular Therapeutics (TCT) Symposium
CY NOV 07-11, 2011
CL San Francisco, CA
C1 [Owens, Christopher D.; Gasper, Warren J.; Kim, Ji Min; Rapp, Joseph; Grenon, Marlene] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Owens, Christopher D.; Gasper, Warren J.; Rapp, Joseph; Grenon, Marlene] San Francisco Vet Adm Med Ctr, San Francisco, CA USA.
[Seward, Kirk] Mercator MedSyst Inc, San Leandro, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0735-1097
J9 J AM COLL CARDIOL
JI J. Am. Coll. Cardiol.
PD NOV 8
PY 2011
VL 58
IS 20
SU B
BP B155
EP B155
PG 1
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 846IZ
UT WOS:000296891900574
ER
PT J
AU Rugge, M
Fassan, M
Pizzi, M
Farinati, F
Sturniolo, GC
Plebani, M
Graham, DY
AF Rugge, Massimo
Fassan, Matteo
Pizzi, Marco
Farinati, Fabio
Sturniolo, Giacomo Carlo
Plebani, Mario
Graham, David Y.
TI Operative link for gastritis assessment vs operative link on intestinal
metaplasia assessment
SO WORLD JOURNAL OF GASTROENTEROLOGY
LA English
DT Article
DE Gastritis; Staging; Atrophic gastritis; Intestinal metaplasia; Operative
link for gastritis assessment; Operative link on intestinal metaplasia
assessment
ID LYMPH-NODE DISSECTION; ASSISTED DISTAL GASTRECTOMY; OPEN SUBTOTAL
GASTRECTOMY; BILLROTH-I GASTRECTOMY; QUALITY-OF-LIFE; CANCER; TRIAL
AB AIM: To compare the reliability of gastritis staging systems in ranking gastritis-associated cancer risk in a large series of consecutive patients.
METHODS: Gastric mucosal atrophy is the precancerous condition in which intestinal-type gastric cancer (GC) most frequently develops. The operative link for gastritis assessment (OLGA) staging system ranks the GC risk according to both the topography and the severity of gastric atrophy (as assessed histologically on the basis of the Sydney protocol for gastric mucosal biopsy). Both cross-sectional and long-term follow-up trials have consistently associated OLGA stages III-IV with a higher risk of GC. A recently-proposed modification of the OLGA staging system (OLGIM) basically incorporates the OLGA frame, but replaces the atrophy score with an assessment of intestinal metaplasia (IM) alone. A series of 4552 consecutive biopsy sets (2007-2009) was retrieved and reassessed according to both the OLGA and the OLGIM staging systems. A set of at least 5 biopsy samples was available for all the cases considered.
RESULTS: In 4460 of 4552 cases (98.0%), both the high-risk stages (III + IV) and the low-risk stages (0 + I + II) were assessed applying the OLGA and OLGIM criteria. Among the 243 OLGA high-risk stages, 14 (5.8%) were down-staged to a low risk using OLGIM. The 67 (1.5%) incidentally-found neoplastic lesions (intraepithelial or invasive) were consistently associated with high-risk stages, as assessed by both OLGA and OLGIM (P < 0.001 for both). Two of 34 intestinal-type GCs coexisting with a high-risk OLGA stage (stage III) were associated with a low-risk OLGIM stage (stage II).
CONCLUSION: Gastritis staging systems (both OLGA and OLGIM) convey prognostically important information on the gastritis-associated cancer risk. Because of its clinical impact, the stage of gastritis should be included as a conclusive message in the gastritis histology report. Since it focuses on IM alone, OLGIM staging is less sensitive than OLGA staging in the identification of patients at high risk of gastric cancer. (C) 2011 Baishideng. All rights reserved.
C1 [Rugge, Massimo] Univ Padua, Surg Pathol & Cytopathol Unit, Dept Med Diagnost Sci & Special Therapies, Ist Oncol Veneto IOV IRCCS, I-35100 Padua, Italy.
[Farinati, Fabio; Sturniolo, Giacomo Carlo] Univ Padua, Dept Gastroenterol & Surg Sci, Gastroenterol Unit, I-35100 Padua, Italy.
[Plebani, Mario] Univ Padua, Dept Diagnost Med Sci & Special Therapies, Clin Chem Unit, I-35100 Padua, Italy.
[Graham, David Y.] Vet Adm Hosp, Baylor Coll Med, Div Digest Dis, Houston, TX 77030 USA.
RP Rugge, M (reprint author), Univ Padua, Surg Pathol & Cytopathol Unit, Dept Med Diagnost Sci & Special Therapies, Ist Oncol Veneto IOV IRCCS, Via Aristide Gabelli 61, I-35100 Padua, Italy.
EM massimo.rugge@unipd.it
RI Fassan, Matteo/F-5152-2012; Rugge, Massimo/K-7525-2016
OI Fassan, Matteo/0000-0001-6515-5482;
FU AIRC from the Veneto Regional Authorities; "Guido Berlucchi" Foundation;
"Morgagni" Association for Oncological Research (Padova; PD)
FX Supported by An AIRC grant from the Veneto Regional Authorities, 2009;
the "Guido Berlucchi" Foundation; and the "Morgagni" Association for
Oncological Research (Padova; PD)
NR 18
TC 26
Z9 27
U1 0
U2 2
PU BAISHIDENG PUBL GRP CO LTD
PI BEIJING
PA RM 903, BLDG D, OCEAN INTERNATIONAL CTR, NO 62 DONGSIHUAN ZHONGLU,
BEIJING, CHAOYANG DISTRICT 100025, PEOPLES R CHINA
SN 1007-9327
J9 WORLD J GASTROENTERO
JI World J. Gastroenterol.
PD NOV 7
PY 2011
VL 17
IS 41
BP 4596
EP 4606
DI 10.3748/wjg.v17.i41.4596
PG 11
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 861ER
UT WOS:000298002500007
PM 22147965
ER
PT J
AU Sorror, ML
Sandmaier, BM
Storer, BE
Franke, GN
Laport, GG
Chauncey, TR
Agura, E
Maziarz, RT
Langston, A
Hari, P
Pulsipher, MA
Bethge, W
Sahebi, F
Bruno, B
Maris, MB
Yeager, A
Petersen, FB
Vindelov, L
McSweeney, PA
Hubel, K
Mielcarek, M
Georges, GE
Niederwieser, D
Blume, KG
Maloney, DG
Storb, R
AF Sorror, Mohamed L.
Sandmaier, Brenda M.
Storer, Barry E.
Franke, Georg N.
Laport, Ginna G.
Chauncey, Thomas R.
Agura, Edward
Maziarz, Richard T.
Langston, Amelia
Hari, Parameswaran
Pulsipher, Michael A.
Bethge, Wolfgang
Sahebi, Firoozeh
Bruno, Benedetto
Maris, Michael B.
Yeager, Andrew
Petersen, Finn Bo
Vindelov, Lars
McSweeney, Peter A.
Huebel, Kai
Mielcarek, Marco
Georges, George E.
Niederwieser, Dietger
Blume, Karl G.
Maloney, David G.
Storb, Rainer
TI Long-term Outcomes Among Older Patients Following Nonmyeloablative
Conditioning and Allogeneic Hematopoietic Cell Transplantation for
Advanced Hematologic Malignancies
SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LA English
DT Article
ID ACUTE MYELOID-LEUKEMIA; VERSUS-HOST-DISEASE; MINIMAL RESIDUAL DISEASE;
MARROW TRANSPLANTATION; MYELODYSPLASTIC SYNDROMES; COMORBIDITY INDEX;
RISK-ASSESSMENT; FLOW-CYTOMETRY; AGE; METHOTREXATE
AB Context A minimally toxic nonmyeloablative regimen was developed for allogeneic hematopoietic cell transplantation (HCT) to treat patients with advanced hematologic malignancies who are older or have comorbid conditions.
Objective To describe outcomes of patients 60 years or older after receiving minimally toxic nonmyeloablative allogeneic HCT.
Design, Setting, and Participants From 1998 to 2008, 372 patients aged 60 to 75 years were enrolled in prospective clinical HCT trials at 18 collaborating institutions using conditioning with low-dose total body irradiation alone or combined with fludarabine, 90 mg/m(2), before related (n=184) or unrelated (n=188) donor transplants. Postgrafting immunosuppression included mycophenolate mofetil and a calcineurin inhibitor.
Main Outcome Measures Overall and progression-free survival were estimated by Kaplan-Meier method. Cumulative incidence estimates were calculated for acute and chronic graft-vs-host disease, toxicities, achievement of full donor chimerism, complete remission, relapse, and nonrelapse mortality. Hazard ratios (HRs) were estimated from Cox regression models.
Results Overall, 5-year cumulative incidences of nonrelapse mortality and relapse were 27% (95% CI, 22%-32%) and 41% (95% CI, 36%-46%), respectively, leading to 5-year overall and progression-free survival of 35% (95% CI, 30%-40%) and 32% (95% CI, 27%-37%), respectively. These outcomes were not statistically significantly different when stratified by age groups. Furthermore, increasing age was not associated with increases in acute or chronic graft-vs-host disease or organ toxicities. In multivariate models, HCT-specific comorbidity index scores of 1 to 2 (HR, 1.58 [95% CI, 1.08-2.31]) and 3 or greater (HR, 1.97 [95% CI, 1.38-2.80]) were associated with worse survival compared with an HCT-specific comorbidity index score of 0 (P=.003 overall). Similarly, standard relapse risk (HR, 1.67 [95% CI, 1.10-2.54]) and high relapse risk (HR, 2.22 [95% CI, 1.43-3.43]) were associated with worse survival compared with low relapse risk (P<.001 overall).
Conclusion Among patients aged 60 to 75 years treated with nonmyeloablative allogeneic HCT, 5-year overall and progression-free survivals were 35% and 32%, respectively. JAMA. 2011; 306(17): 1874-1883
C1 [Sorror, Mohamed L.; Sandmaier, Brenda M.; Chauncey, Thomas R.; Mielcarek, Marco; Georges, George E.; Maloney, David G.; Storb, Rainer] Fred Hutchinson Canc Res Ctr, Div Clin Res, Transplantat Biol Program, Seattle, WA 98109 USA.
[Storer, Barry E.] Fred Hutchinson Canc Res Ctr, Div Clin Res, Clin Stat Program, Seattle, WA 98109 USA.
[Sorror, Mohamed L.; Sandmaier, Brenda M.; Chauncey, Thomas R.; Mielcarek, Marco; Georges, George E.; Maloney, David G.; Storb, Rainer] Univ Washington, Sch Med, Dept Med, Div Med Oncol, Seattle, WA 98195 USA.
[Storer, Barry E.] Univ Washington, Sch Publ Hlth, Dept Biostat, Seattle, WA 98195 USA.
[Chauncey, Thomas R.] VA Puget Sound Hlth Care Syst, Marrow Transplant Unit, Seattle, WA USA.
[Franke, Georg N.; Niederwieser, Dietger] Univ Leipzig, Dept Med, Div Hematol Oncol & Hemostaseol, Leipzig, Germany.
[Laport, Ginna G.; Blume, Karl G.] Stanford Sch Med, Div Blood & Marrow Transplantat, Dept Med, Stanford, CA USA.
[Agura, Edward] Baylor Univ, Hematopoiet Stem Cell Program, Sch Med, Dallas, TX USA.
[Maziarz, Richard T.] Oregon Hlth & Sci Univ, Sch Med, Hematopoiet Stem Cell Transplant Program, Portland, OR 97201 USA.
[Maziarz, Richard T.] Oregon Hlth & Sci Univ, Sch Med, Ctr Hematol Malignancies, Knight Canc Inst, Portland, OR 97201 USA.
[Maziarz, Richard T.] Oregon Hlth & Sci Univ, Sch Med, Div Hematol & Med Oncol, Portland, OR 97201 USA.
[Langston, Amelia] Emory Univ, Sch Med, Div Hematol Oncol, Atlanta, GA USA.
[Langston, Amelia] Emory Univ, Bone Marrow & Stem Cell Transplant Ctr, Winship Canc Inst, Atlanta, GA 30322 USA.
[Hari, Parameswaran] Med Coll Wisconsin, Div Hematol & Oncol, Sch Med, Milwaukee, WI 53226 USA.
[Pulsipher, Michael A.] Univ Utah, Sch Med, Div Hematol Blood & Marrow Transplantat, Salt Lake City, UT USA.
[Pulsipher, Michael A.] Primary Childrens Med Ctr, Pediat Blood & Marrow Transplant Program, Huntsman Canc Inst, Salt Lake City, UT 84103 USA.
[Bethge, Wolfgang] Univ Tubingen, Sch Med, Tubingen, Germany.
[Sahebi, Firoozeh] City Hope Sch Med, Duarte, CA USA.
[Bruno, Benedetto] Univ Turin, Sch Med, Turin, Italy.
[Maris, Michael B.; McSweeney, Peter A.] Colorado Blood Canc Inst, Denver, CO USA.
[Yeager, Andrew] Univ Arizona, Sch Med, Dept Med & Pediat, Tucson, AZ USA.
[Petersen, Finn Bo] Intermt Hlth Care, Intermt Blood & Marrow Transplant Acute Leukemia, Salt Lake City, UT USA.
[Petersen, Finn Bo] Univ Aarhus, Sch Med, Aarhus, Denmark.
[Vindelov, Lars] Rigshosp, Hematopoiet Cell Transplantat Program, Dept Hematol, DK-2100 Copenhagen, Denmark.
[McSweeney, Peter A.] Univ Colorado, Sch Med, Boulder, CO 80309 USA.
[Huebel, Kai] Univ Cologne, Dept Internal Med, Sch Med, Stem Cell Transplant Program, Cologne, Germany.
RP Sorror, ML (reprint author), Fred Hutchinson Canc Res Ctr, Clin Res Div D1 100, 1100 Fairview Ave N, Seattle, WA 98109 USA.
EM msorror@fhcrc.org
OI Hari, Parameswaran/0000-0002-8800-297X
FU Japanese Heath Sciences; Athersys Inc; BMT/CTN; Medac GmbH; Fresenius
GmbH; Pfizer; Miltenyi Biotech GmbH; Millennium Pharmaceuticals; Danish
Cancer Society; Lundbeck Foundation; Research Council of Rigshospitalet;
Region of the Capital of Denmark; National Institutes of Health (NIH)
[P01HL036444, P01CA078902, P01CA018029, P30CA015704, R00HL088021];
Leukemia/Lymphoma Society [7008-08]
FX All authors have completed and submitted the ICMJE Form for Disclosure
of Potential Conflicts of Interest. Dr Sandmaier reported serving on the
board of ArevaMed. Dr Franke reported receiving
travel/accommodations/meeting expenses for the European Group of Blood
and Marrow Transplantation 2009 meeting. Dr Maziarz reported receiving
grants or grants pending (grant money to institution) from Japanese
Heath Sciences, Athersys Inc, and BMT/CTN; serving on the speakers
bureaus of Millennium Pharmaceuticals Inc and Genzyme Inc; receiving
royalties from Springer for publication of a book; and receiving
honoraria for lectures (groups change yearly; usually related to
community oncology educational efforts). Dr Bethge reported serving as a
consultant for Miltenyi Biotech GmbH; receiving grants or grants pending
from Medac GmbH, Fresenius GmbH, Pfizer, and Miltenyi Biotech GmbH;
receiving payment for lectures from Miltenyi Biotech GmbH; and receiving
travel/accommodations/meeting expenses from Medac GmbH. Dr Sahebi
reported receiving travel/accommodations/meeting expenses and a research
fund from Millennium Pharmaceuticals. Dr Vindelov reported receiving
research grants from the Danish Cancer Society, The Lundbeck Foundation,
and the Research Council of Rigshospitalet and receiving a travel and
research grant from the Region of the Capital of Denmark. No other
authors reported disclosures.; Research for this study has been
supported by grants from the National Institutes of Health (NIH)
(P01HL036444, P01CA078902, P01CA018029, P30CA015704, and R00HL088021)
and from the Leukemia/Lymphoma Society (7008-08).
NR 38
TC 101
Z9 101
U1 0
U2 5
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0098-7484
EI 1538-3598
J9 JAMA-J AM MED ASSOC
JI JAMA-J. Am. Med. Assoc.
PD NOV 2
PY 2011
VL 306
IS 17
BP 1874
EP 1883
DI 10.1001/jama.2011.1558
PG 10
WC Medicine, General & Internal
SC General & Internal Medicine
GA 839OD
UT WOS:000296376200021
PM 22045765
ER
PT J
AU Hoang, T
Byers, AL
Barnes, D
Cawthon, PM
Yaffe, K
AF Hoang, T.
Byers, A. L.
Barnes, D.
Cawthon, P. M.
Yaffe, K.
TI ALCOHOL CONSUMPTION OVER THE LIFE COURSE AND COGNITIVE OUTCOMES IN OLDER
WOMEN
SO GERONTOLOGIST
LA English
DT Meeting Abstract
C1 [Hoang, T.; Byers, A. L.; Barnes, D.; Yaffe, K.] San Francisco VA Med Ctr, San Francisco, CA USA.
[Byers, A. L.; Barnes, D.; Yaffe, K.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Cawthon, P. M.] Calif Pacific Med Ctr, Res Inst, San Francisco Coordinating Ctr, San Francisco, CA USA.
[Yaffe, K.] Univ Calif San Francisco, Dept Neurol, Dept Epidemiol & Biostat, San Francisco, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0016-9013
J9 GERONTOLOGIST
JI Gerontologist
PD NOV
PY 2011
VL 51
SU 2
BP 20
EP 20
PG 1
WC Gerontology
SC Geriatrics & Gerontology
GA 936PH
UT WOS:000303602000094
ER
PT J
AU Spira, AP
Covinsky, K
Rebok, G
Punjabi, N
Stone, KL
Hillier, TA
Ensrud, K
Yaffe, K
AF Spira, A. P.
Covinsky, K.
Rebok, G.
Punjabi, N.
Stone, K. L.
Hillier, T. A.
Ensrud, K.
Yaffe, K.
TI OBJECTIVELY MEASURED SLEEP AND FUNCTIONAL DECLINE IN OLDER WOMEN
SO GERONTOLOGIST
LA English
DT Meeting Abstract
C1 [Spira, A. P.; Rebok, G.; Punjabi, N.] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA.
[Covinsky, K.; Yaffe, K.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Covinsky, K.; Yaffe, K.] San Francisco VA Med Ctr, San Francisco, CA USA.
[Punjabi, N.] Johns Hopkins Sch Med, Baltimore, MD USA.
[Stone, K. L.] Calif Pacific Med Ctr, Res Inst, San Francisco, CA USA.
[Hillier, T. A.] Kaiser Permanente, Ctr Hlth Res, Portland, OR USA.
[Ensrud, K.] Minneapolis VAMC, Minneapolis, MN USA.
[Ensrud, K.] Univ Minnesota, Minneapolis, MN USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0016-9013
J9 GERONTOLOGIST
JI Gerontologist
PD NOV
PY 2011
VL 51
SU 2
BP 20
EP 20
PG 1
WC Gerontology
SC Geriatrics & Gerontology
GA 936PH
UT WOS:000303602000093
ER
PT J
AU Sanders, J
Fitzpatrick, A
Boudreau, R
Arnold, A
Aviv, A
Fried, LF
Harris, TB
Newman, AB
AF Sanders, J.
Fitzpatrick, A.
Boudreau, R.
Arnold, A.
Aviv, A.
Fried, L. F.
Harris, T. B.
Newman, A. B.
TI LEUKOCYTE TELOMERE LENGTH IS ASSOCIATED WITH AGE-RELATED CHRONIC DISEASE
BURDEN IN OLDER ADULTS
SO GERONTOLOGIST
LA English
DT Meeting Abstract
C1 [Sanders, J.; Boudreau, R.; Newman, A. B.] Univ Pittsburgh, Pittsburgh, PA USA.
[Fitzpatrick, A.; Arnold, A.] Univ Washington, Seattle, WA 98195 USA.
[Aviv, A.] Univ Med & Dent New Jersey, Newark, NJ 07103 USA.
[Fried, L. F.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
[Harris, T. B.] NIA, Bethesda, MD 20892 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0016-9013
J9 GERONTOLOGIST
JI Gerontologist
PD NOV
PY 2011
VL 51
SU 2
BP 22
EP 23
PG 2
WC Gerontology
SC Geriatrics & Gerontology
GA 936PH
UT WOS:000303602000105
ER
PT J
AU Hilgeman, MM
Snow, A
Mahaney-Price, AF
Kertesz, S
Davis, L
AF Hilgeman, M. M.
Snow, A.
Mahaney-Price, A. F.
Kertesz, S.
Davis, L.
TI EXAMINATION OF THE MONTREAL COGNITIVE ASSESSMENT (MOCA): FINDINGS FROM
THE ALABAMA VETERANS RURAL HEALTH INITIATIVE
SO GERONTOLOGIST
LA English
DT Meeting Abstract
C1 [Hilgeman, M. M.; Snow, A.; Mahaney-Price, A. F.; Davis, L.] Tuscaloosa VA Med Ctr, Tuscaloosa, AL USA.
[Kertesz, S.] Birmingham VA Med Ctr, Birmingham, AL USA.
[Kertesz, S.] Univ Alabama Birmingham, Birmingham, AL USA.
[Davis, L.] Univ Alabama, Sch Med, Tuscaloosa, AL 35401 USA.
NR 0
TC 0
Z9 0
U1 1
U2 4
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0016-9013
J9 GERONTOLOGIST
JI Gerontologist
PD NOV
PY 2011
VL 51
SU 2
BP 31
EP 32
PG 2
WC Gerontology
SC Geriatrics & Gerontology
GA 936PH
UT WOS:000303602000149
ER
PT J
AU Bolkan, C
Bonner, L
Campbell, DG
Lanto, A
Rubenstein, L
Chaney, E
AF Bolkan, C.
Bonner, L.
Campbell, D. G.
Lanto, A.
Rubenstein, L.
Chaney, E.
TI THE COMPLEX RELATIONSHIP BETWEEN SOCIAL SUPPORT AND DEPRESSION: THE
SIGNIFICANCE OF PATIENT SATISFACTION AND MEDICATION ADHERENCE
SO GERONTOLOGIST
LA English
DT Meeting Abstract
C1 [Bolkan, C.] Washington State Univ, Vancouver, WA USA.
[Bonner, L.] VA Puget Sound Hlth Care Syst, Dept Vet Affairs, Hlth Serv Res & Dev Ctr Excellence, Seattle, WA USA.
[Campbell, D. G.] Univ Montana, Missoula, MT 59812 USA.
[Lanto, A.; Rubenstein, L.] VA Greater Angeles Healthcare Syst, Dept Vet Affairs, Hlth Serv Res & Dev Ctr Excellence, Los Angeles, CA USA.
[Rubenstein, L.] Univ Calif Los Angeles, Sch Med, Los Angeles, CA USA.
[Rubenstein, L.] RAND Hlth Program, Santa Monica, CA USA.
[Chaney, E.] Univ Washington, Seattle, WA 98195 USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0016-9013
J9 GERONTOLOGIST
JI Gerontologist
PD NOV
PY 2011
VL 51
SU 2
BP 34
EP 34
PG 1
WC Gerontology
SC Geriatrics & Gerontology
GA 936PH
UT WOS:000303602000159
ER
PT J
AU Kresevic, DM
Burant, CJ
Denton, JE
Ibrahim, S
AF Kresevic, D. M.
Burant, C. J.
Denton, J. E.
Ibrahim, S.
TI OUTPATIENT ANTICOAGULATION EDUCATION AND OUTCOMES
SO GERONTOLOGIST
LA English
DT Meeting Abstract
C1 [Kresevic, D. M.; Burant, C. J.; Denton, J. E.] Louis Stokes Cleveland VA Med Ctr, Cleveland, OH USA.
[Kresevic, D. M.] Univ Hosp, Case Med Ctr, Cleveland, OH USA.
[Kresevic, D. M.; Burant, C. J.] Case Western Reserve Univ, Frances Payne Bolton Sch Nursing, Cleveland, OH 44106 USA.
[Ibrahim, S.] Philadelphia VA Med Ctr, Philadelphia, PA USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0016-9013
J9 GERONTOLOGIST
JI Gerontologist
PD NOV
PY 2011
VL 51
SU 2
BP 74
EP 74
PG 1
WC Gerontology
SC Geriatrics & Gerontology
GA 936PH
UT WOS:000303602000332
ER
PT J
AU Hughes, J
Martin, JL
AF Hughes, J.
Martin, J. L.
TI SLEEP: AN OVERLOOKED COMPONENT OF HEALTH AND QUALITY OF LIFE IN OLDER
ADULTS
SO GERONTOLOGIST
LA English
DT Meeting Abstract
C1 [Hughes, J.; Martin, J. L.] VA Greater Los Angeles Healthcare Syst, Geriatr Res Educ & Clin Ctr, North Hills, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0016-9013
J9 GERONTOLOGIST
JI Gerontologist
PD NOV
PY 2011
VL 51
SU 2
BP 78
EP 78
PG 1
WC Gerontology
SC Geriatrics & Gerontology
GA 936PH
UT WOS:000303602000348
ER
PT J
AU Vitiello, MV
Baker, LD
Borson, S
Friedman, SD
Barsness, S
Merriam, GR
AF Vitiello, M. V.
Baker, L. D.
Borson, S.
Friedman, S. D.
Barsness, S.
Merriam, G. R.
TI TESAMORELIN, A HUMAN GROWTH HORMONE RELEASING HORMONE ANALOGUE, IMPROVES
COGNITIVE FUNCTION IN MCI AND HEALTHY AGING: RESULTS OF A RANDOMIZED
PLACEBO-CONTROLLED TRIAL
SO GERONTOLOGIST
LA English
DT Meeting Abstract
C1 [Vitiello, M. V.; Baker, L. D.; Borson, S.; Barsness, S.; Merriam, G. R.] Univ Washington, Seattle, WA 98195 USA.
[Friedman, S. D.] Childrens Hosp, Seattle, WA USA.
[Merriam, G. R.] VA Puget Sound Hlth Care Syst, Tacoma, WA USA.
[Merriam, G. R.] VA Puget Sound Hlth Care Syst, Seattle, WA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0016-9013
J9 GERONTOLOGIST
JI Gerontologist
PD NOV
PY 2011
VL 51
SU 2
BP 106
EP 106
PG 1
WC Gerontology
SC Geriatrics & Gerontology
GA 936PH
UT WOS:000303602000481
ER
PT J
AU Wittich, AR
Williams, BR
Woodby, LL
Burgio, KL
AF Wittich, A. R.
Williams, B. R.
Woodby, L. L.
Burgio, K. L.
TI "THE WHOLE POWER OF ATTORNEY": UNDERSTANDING ADVANCE DIRECTIVES AMONG
NEXT-OF-KIN IN VA MEDICAL CENTERS
SO GERONTOLOGIST
LA English
DT Meeting Abstract
C1 [Wittich, A. R.; Williams, B. R.; Woodby, L. L.; Burgio, K. L.] Birmingham VAMC, Birmingham, AL USA.
[Williams, B. R.; Woodby, L. L.; Burgio, K. L.] Univ Alabama Birmingham, Birmingham, AL USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0016-9013
J9 GERONTOLOGIST
JI Gerontologist
PD NOV
PY 2011
VL 51
SU 2
BP 136
EP 137
PG 2
WC Gerontology
SC Geriatrics & Gerontology
GA 936PH
UT WOS:000303602000623
ER
PT J
AU Mavandadi, S
Mamikonyan, E
Duda, JE
Weintraub, D
AF Mavandadi, S.
Mamikonyan, E.
Duda, J. E.
Weintraub, D.
TI INTERPERSONAL FUNCTIONING IN PARKINSON'S DISEASE: A DYADIC ANALYSIS OF
VETERANS AND CAREGIVERS
SO GERONTOLOGIST
LA English
DT Meeting Abstract
C1 [Mavandadi, S.; Weintraub, D.] Philadelphia VA Med Ctr, Mental Illness Res Educ & Clin Ctr, Philadelphia, PA USA.
[Mavandadi, S.; Mamikonyan, E.; Weintraub, D.] Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA.
[Duda, J. E.; Weintraub, D.] Philadelphia VA Med Ctr, Parkinsons Dis Res Educ & Clin Ctr, Philadelphia, PA USA.
[Duda, J. E.] Univ Penn, Dept Neurol, Penn Hosp, Parkinsons Dis & Movement Disorders Ctr, Philadelphia, PA 19104 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0016-9013
J9 GERONTOLOGIST
JI Gerontologist
PD NOV
PY 2011
VL 51
SU 2
BP 141
EP 141
PG 1
WC Gerontology
SC Geriatrics & Gerontology
GA 936PH
UT WOS:000303602000643
ER
PT J
AU Mahaney-Price, AF
Hilgeman, MM
Kertesz, S
Davis, L
AF Mahaney-Price, A. F.
Hilgeman, M. M.
Kertesz, S.
Davis, L.
TI RURAL ALABAMA VETERAN ADVANCE DIRECTIVE BEHAVIOR AND DESIRE FOR HELP
COMPLETING AN ADVANCE DIRECTIVE
SO GERONTOLOGIST
LA English
DT Meeting Abstract
C1 [Mahaney-Price, A. F.; Hilgeman, M. M.; Davis, L.] Tuscaloosa VA Med Ctr, Tuscaloosa, AL USA.
[Kertesz, S.] Birmingham VA Med Ctr, Birmingham, AL USA.
[Davis, L.] Univ Alabama, Sch Med, Tuscaloosa, AL 35401 USA.
NR 0
TC 0
Z9 0
U1 1
U2 2
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0016-9013
J9 GERONTOLOGIST
JI Gerontologist
PD NOV
PY 2011
VL 51
SU 2
BP 174
EP 174
PG 1
WC Gerontology
SC Geriatrics & Gerontology
GA 936PH
UT WOS:000303602001103
ER
PT J
AU Wolden-Hanson, T
AF Wolden-Hanson, T.
TI HYPOTHALAMIC CONTROL OF THE ANOREXIA OF AGING
SO GERONTOLOGIST
LA English
DT Meeting Abstract
C1 [Wolden-Hanson, T.] VA Puget Sound Healthcare Syst, Seattle, WA USA.
[Wolden-Hanson, T.] Univ Washington, Seattle, WA 98195 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0016-9013
J9 GERONTOLOGIST
JI Gerontologist
PD NOV
PY 2011
VL 51
SU 2
BP 188
EP 188
PG 1
WC Gerontology
SC Geriatrics & Gerontology
GA 936PH
UT WOS:000303602001162
ER
PT J
AU Kramer, B
Barczi, S
Chernoff, R
Horvath, KJ
Howe, JL
Huh, J
Tumosa, N
Saunders, MJ
AF Kramer, B.
Barczi, S.
Chernoff, R.
Horvath, K. J.
Howe, J. L.
Huh, J.
Tumosa, N.
Saunders, M. J.
TI THE VA GERIATRIC SCHOLARS PROGRAM: ENHANCING SKILLS IN RURAL PRIMARY
CARE SETTINGS
SO GERONTOLOGIST
LA English
DT Meeting Abstract
C1 [Kramer, B.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
[Kramer, B.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
[Horvath, K. J.] Bedford GRECC, Boston, MA USA.
[Barczi, S.] Madison GRECC, Madison, WI USA.
[Huh, J.] Palo Alto GRECC, Palo Alto, CA USA.
[Saunders, M. J.] San Antonio GRECC, San Antonio, TX USA.
[Tumosa, N.] St Louis GRECC, St Louis, MO USA.
[Chernoff, R.] Birmingham GRECC, Birmingham, AL USA.
[Howe, J. L.] Bronx GRECC, New York, NY USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0016-9013
J9 GERONTOLOGIST
JI Gerontologist
PD NOV
PY 2011
VL 51
SU 2
BP 204
EP 204
PG 1
WC Gerontology
SC Geriatrics & Gerontology
GA 936PH
UT WOS:000303602001244
ER
PT J
AU Anderson, R
AF Anderson, R.
TI IMPACT OF CALORIE RESTRICTION (CR) ON CELLULAR ASPECTS OF METABOLIC
DECLINE IN AGING RHESUS SKELETAL MUSCLE
SO GERONTOLOGIST
LA English
DT Meeting Abstract
C1 [Anderson, R.] Univ Wisconsin, Madison, WI USA.
[Anderson, R.] William S Middleton Mem Vet Adm Med Ctr, GRECC, Madison, WI USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0016-9013
J9 GERONTOLOGIST
JI Gerontologist
PD NOV
PY 2011
VL 51
SU 2
BP 242
EP 242
PG 1
WC Gerontology
SC Geriatrics & Gerontology
GA 936PH
UT WOS:000303602001441
ER
PT J
AU Garcia, C
Espinoza, SE
Hazuda, HP
AF Garcia, C.
Espinoza, S. E.
Hazuda, H. P.
TI LEVELS OF HEALTH LITERACY AMONG HISPANIC ELDERLY PATIENTS AND THEIR
CAREGIVERS
SO GERONTOLOGIST
LA English
DT Meeting Abstract
C1 [Garcia, C.; Espinoza, S. E.; Hazuda, H. P.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA.
[Espinoza, S. E.; Hazuda, H. P.] S Texas Vet Healthcare Syst, San Antonio, TX USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0016-9013
J9 GERONTOLOGIST
JI Gerontologist
PD NOV
PY 2011
VL 51
SU 2
BP 283
EP 283
PG 1
WC Gerontology
SC Geriatrics & Gerontology
GA 936PH
UT WOS:000303602001643
ER
PT J
AU Pasinetti, GM
AF Pasinetti, G. M.
TI THE ROLE OF NUTRI-EPIGENETICS AND PERSONALIZED MEDICINE IN DIETARY
LIFESTYLE CHOICES IN ALZHEIMER'S DISEASE
SO GERONTOLOGIST
LA English
DT Meeting Abstract
C1 Mt Sinai Sch Med, New York, NY USA.
James J Peters Vet Affairs Med Ctr, Bronx, NY USA.
NR 0
TC 0
Z9 0
U1 1
U2 4
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0016-9013
J9 GERONTOLOGIST
JI Gerontologist
PD NOV
PY 2011
VL 51
SU 2
BP 296
EP 296
PG 1
WC Gerontology
SC Geriatrics & Gerontology
GA 936PH
UT WOS:000303602001704
ER
PT J
AU Espinoza, SE
Hazuda, HP
AF Espinoza, S. E.
Hazuda, H. P.
TI ETHNIC DIFFERENCE IN PERFORMANCE-BASED MEASURES OF BASIC AND
INSTRUMENTAL ACTIVITIES OF DAILY LIVING
SO GERONTOLOGIST
LA English
DT Meeting Abstract
C1 [Espinoza, S. E.; Hazuda, H. P.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA.
[Espinoza, S. E.; Hazuda, H. P.] S Texas Vet Healthcare Syst, San Antonio, TX USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0016-9013
J9 GERONTOLOGIST
JI Gerontologist
PD NOV
PY 2011
VL 51
SU 2
BP 308
EP 309
PG 2
WC Gerontology
SC Geriatrics & Gerontology
GA 936PH
UT WOS:000303602002041
ER
PT J
AU Jones, LI
Kramer, J
Chernoff, R
Howe, JL
Francisco, F
AF Jones, L. I.
Kramer, J.
Chernoff, R.
Howe, J. L.
Francisco, F.
TI CREATING A LEARNING COMMUNITY AND WEBINAR SERIES FOR CLINICIANS WORKING
WITH OLDER VETERANS IN RURAL SETTINGS
SO GERONTOLOGIST
LA English
DT Meeting Abstract
C1 [Kramer, J.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
[Howe, J. L.; Francisco, F.] Mt Sinai Sch Med, Dept Geriatr & Palliat Med, New York, NY USA.
[Howe, J. L.; Francisco, F.] James J Peters VAMC, VISN GRECC 3, Bronx, NY USA.
[Chernoff, R.] Univ Arkansas Med Sci, Little Rock, AR 72205 USA.
[Chernoff, R.] Cent Arkansas Vet Healthcare Syst Little Rock GRE, Little Rock, AR USA.
[Jones, L. I.; Kramer, J.] VA Greater Los Angeles Healthcare Syst Greater Lo, Los Angeles, CA USA.
NR 0
TC 0
Z9 0
U1 1
U2 2
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0016-9013
J9 GERONTOLOGIST
JI Gerontologist
PD NOV
PY 2011
VL 51
SU 2
BP 374
EP 374
PG 1
WC Gerontology
SC Geriatrics & Gerontology
GA 936PH
UT WOS:000303602002363
ER
PT J
AU Kramer, J
Harker, JO
Mitchell, M
Rubenstein, L
AF Kramer, J.
Harker, J. O.
Mitchell, M.
Rubenstein, L.
TI INSTEP: MAJOR RESEARCH QUESTIONS
SO GERONTOLOGIST
LA English
DT Meeting Abstract
C1 [Kramer, J.] Univ Calif Los Angeles, David Geffen Sch Med, GRECC, VA Greater Los Angeles Healthcare Syst, Sepulveda, CA USA.
[Mitchell, M.] Ctr Study Healthcare Provider Behav, Dept Vet Affairs, Sepulveda, CA USA.
[Rubenstein, L.] Univ Oklahoma, Reynolds Dept Geriatr Med, Oklahoma City, OK USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0016-9013
J9 GERONTOLOGIST
JI Gerontologist
PD NOV
PY 2011
VL 51
SU 2
BP 377
EP 378
PG 2
WC Gerontology
SC Geriatrics & Gerontology
GA 936PH
UT WOS:000303602002379
ER
PT J
AU Semla, T
Damron-Rodriguez, J
Berger, S
Goodwin, C
Beizer, J
AF Semla, T.
Damron-Rodriguez, J.
Berger, S.
Goodwin, C.
Beizer, J.
TI THE RATIONALE AND DEVELOPMENT PROCESS FOR THE PHA MULTIDISCIPLINARY
COMPETENCIES
SO GERONTOLOGIST
LA English
DT Meeting Abstract
C1 [Semla, T.] US Dept Vet Affairs, PBM, Evanston, IL USA.
[Semla, T.] Northwestern Univ, Chicago, IL 60611 USA.
[Damron-Rodriguez, J.] UCLA Sch Publ Affairs, Los Angeles, CA USA.
[Berger, S.] Boston Univ, Coll Hlth & Rehabil Sci, Boston, MA 02215 USA.
[Goodwin, C.] Amer Geriatr Soc, New York, NY USA.
[Beizer, J.] St Johns Coll Pharmcy, New York, NY USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0016-9013
J9 GERONTOLOGIST
JI Gerontologist
PD NOV
PY 2011
VL 51
SU 2
BP 377
EP 377
PG 1
WC Gerontology
SC Geriatrics & Gerontology
GA 936PH
UT WOS:000303602002375
ER
PT J
AU Garrido, MM
Penrod, JD
AF Garrido, M. M.
Penrod, J. D.
TI DEPRESSION AND ANXIETY ASSESSMENT AND TREATMENT IN VETERANS RECEIVING
PALLIATIVE CARE
SO GERONTOLOGIST
LA English
DT Meeting Abstract
C1 [Garrido, M. M.; Penrod, J. D.] James J Peters VA Med Ctr, Bronx, NY USA.
[Garrido, M. M.; Penrod, J. D.] Mt Sinai Sch Med, New York, NY USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0016-9013
J9 GERONTOLOGIST
JI Gerontologist
PD NOV
PY 2011
VL 51
SU 2
BP 388
EP 388
PG 1
WC Gerontology
SC Geriatrics & Gerontology
GA 936PH
UT WOS:000303602002436
ER
PT J
AU Spira, AP
Covinsky, K
Rebok, G
Stone, KL
Redline, S
Punjabi, N
Yaffe, K
AF Spira, A. P.
Covinsky, K.
Rebok, G.
Stone, K. L.
Redline, S.
Punjabi, N.
Yaffe, K.
TI OBJECTIVELY MEASURED SLEEP FRAGMENTATION AND NURSING HOME PLACEMENT IN
OLDER WOMEN
SO GERONTOLOGIST
LA English
DT Meeting Abstract
C1 [Spira, A. P.; Rebok, G.; Punjabi, N.] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA.
[Covinsky, K.; Yaffe, K.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Covinsky, K.; Yaffe, K.] San Francisco VA Med Ctr, San Francisco, CA USA.
[Stone, K. L.] Calif Pacific Med Ctr, Res Inst, San Francisco, CA USA.
[Redline, S.] Harvard Univ, Sch Med, Cambridge, MA 02138 USA.
[Punjabi, N.] Johns Hopkins Sch Med, Baltimore, MD USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0016-9013
J9 GERONTOLOGIST
JI Gerontologist
PD NOV
PY 2011
VL 51
SU 2
BP 398
EP 398
PG 1
WC Gerontology
SC Geriatrics & Gerontology
GA 936PH
UT WOS:000303602002490
ER
PT J
AU Cotter, VT
Streim, JE
O'Donnell, DF
Forciea, M
Evans, LK
AF Cotter, V. T.
Streim, J. E.
O'Donnell, D. F.
Forciea, M.
Evans, L. K.
TI TRAINING INITIATIVES IN BEHAVIORAL TREATMENT PLANNING IN LONG-TERM CARE
SO GERONTOLOGIST
LA English
DT Meeting Abstract
C1 [Cotter, V. T.; Evans, L. K.] Univ Penn, Sch Nursing, Philadelphia, PA 19104 USA.
[Streim, J. E.; Forciea, M.] Univ Penn, Sch Med, Philadelphia, PA 19104 USA.
[Streim, J. E.] Philadelphia VA Med Ctr, Philadelphia, PA USA.
[O'Donnell, D. F.] Coatesville VA Med Ctr, Coatesville, PA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0016-9013
J9 GERONTOLOGIST
JI Gerontologist
PD NOV
PY 2011
VL 51
SU 2
BP 479
EP 479
PG 1
WC Gerontology
SC Geriatrics & Gerontology
GA 936PH
UT WOS:000303602003163
ER
PT J
AU Byers, AL
Vittinghoff, E
Lui, L
Covinsky, K
Cauley, JA
Ensrud, K
Hillier, TA
Yaffe, K
AF Byers, A. L.
Vittinghoff, E.
Lui, L.
Covinsky, K.
Cauley, J. A.
Ensrud, K.
Hillier, T. A.
Yaffe, K.
TI CHARACTERIZATION OF LONG-TERM DEPRESSIVE TRAJECTORIES AMONG ELDERLY
WOMEN
SO GERONTOLOGIST
LA English
DT Meeting Abstract
C1 [Byers, A. L.; Vittinghoff, E.; Covinsky, K.; Yaffe, K.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Byers, A. L.; Covinsky, K.; Yaffe, K.] San Francisco VA Med Ctr, San Francisco, CA USA.
[Lui, L.] Calif Pacific Med Ctr Res Inst, San Francisco, CA USA.
[Cauley, J. A.] Univ Pittsburgh, Pittsburgh, PA USA.
[Ensrud, K.] Univ Minnesota, Minneapolis, MN USA.
[Ensrud, K.] Minneapolis VA Med Ctr, Minneapolis, MN USA.
[Hillier, T. A.] Kaiser Permanente Ctr Hlth Res, Portland, OR USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0016-9013
J9 GERONTOLOGIST
JI Gerontologist
PD NOV
PY 2011
VL 51
SU 2
BP 518
EP 518
PG 1
WC Gerontology
SC Geriatrics & Gerontology
GA 936PH
UT WOS:000303602003331
ER
PT J
AU Hung, WW
Morano, B
Boockvar, K
AF Hung, W. W.
Morano, B.
Boockvar, K.
TI FEASIBILITY OF INTEGRATING THE USE OF REGIONAL HEALTH INFORMATION
ORGANIZATION FOR A VA-BASED CARE TRANSITION INTERVENTION
SO GERONTOLOGIST
LA English
DT Meeting Abstract
C1 [Hung, W. W.; Morano, B.; Boockvar, K.] James J Peters Vet Affairs Med Ctr, Hlth Serv Res & Dev Res Enhancement Award Program, Bronx, NY USA.
[Hung, W. W.; Morano, B.; Boockvar, K.] James J Peters Vet Affairs Med Ctr, Geriatr Res Educ & Clin Ctr, Bronx, NY USA.
[Hung, W. W.; Morano, B.; Boockvar, K.] Mt Sinai Sch Med, Dept Geriatr & Palliat Med, New York, NY USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0016-9013
J9 GERONTOLOGIST
JI Gerontologist
PD NOV
PY 2011
VL 51
SU 2
BP 526
EP 526
PG 1
WC Gerontology
SC Geriatrics & Gerontology
GA 936PH
UT WOS:000303602003374
ER
PT J
AU Vuckovic, NH
Edes, T
Nichols, LO
AF Vuckovic, N. H.
Edes, T.
Nichols, L. O.
TI I COULDN'T MAKE IT WITHOUT THEM: PATIENT AND CAREGIVER PERSPECTIVE OF
HOME BASED PRIMARY CARE
SO GERONTOLOGIST
LA English
DT Meeting Abstract
C1 [Vuckovic, N. H.] Intel Corp, Hlth Res & Innovat, Beaverton, OR USA.
[Edes, T.] US Dept Vet Affairs, Washington, DC USA.
[Nichols, L. O.] Vet Affairs Med Ctr, Memphis, TN USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0016-9013
J9 GERONTOLOGIST
JI Gerontologist
PD NOV
PY 2011
VL 51
SU 2
BP 614
EP 614
PG 1
WC Gerontology
SC Geriatrics & Gerontology
GA 936PH
UT WOS:000303602004207
ER
PT J
AU Stephens, C
Covinsky, K
Blegen, MA
Lee, S
AF Stephens, C.
Covinsky, K.
Blegen, M. A.
Lee, S.
TI FALLS ARE A POWERFUL DETERMINANT OF ER USE BY NURSING HOME RESIDENTS
SO GERONTOLOGIST
LA English
DT Meeting Abstract
C1 [Stephens, C.; Covinsky, K.; Blegen, M. A.; Lee, S.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Stephens, C.; Covinsky, K.; Lee, S.] San Francisco VA Med Ctr, San Francisco, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0016-9013
J9 GERONTOLOGIST
JI Gerontologist
PD NOV
PY 2011
VL 51
SU 2
BP 627
EP 627
PG 1
WC Gerontology
SC Geriatrics & Gerontology
GA 936PH
UT WOS:000303602004268
ER
PT J
AU Jue, JJS
Metlay, JP
AF Jue, J. Jane S.
Metlay, Joshua P.
TI Web-Based Health Resources at US Colleges: Early Patterns and Missed
Opportunities in Preventive Health
SO PREVENTING CHRONIC DISEASE
LA English
DT Article
ID STUDENT POPULATION; CONTROLLED-TRIAL; UNITED-STATES; INTERNET USE;
INFORMATION; ADOLESCENTS; INTERVENTIONS; TECHNOLOGY; PREVALENCE;
BEHAVIOR
AB Introduction
Web-based health resources on college websites have the potential to reach a substantial number of college students. The objective of this study was to characterize how colleges use their websites to educate about and promote health.
Methods
This study was a cross-sectional analysis of websites from a nationally representative sample of 426 US colleges. Reviewers abstracted information about Web-based health resources from college websites, namely health information, Web links to outside health resources, and interactive Web-based health programs.
Results
Nearly 60% of US colleges provided health resources on their websites, 49% provided health information, 48% provided links to outside resources, and 28% provided interactive Web-based health programs. The most common topics of Web-based health resources were mental health and general health.
Conclusion
We found widespread presence of Web-based health resources available from various delivery modes and covering a range of health topics. Although further research in this new modality is warranted, Web-based health resources hold promise for reaching more US college students.
C1 [Jue, J. Jane S.] Philadelphia VA Med Ctr, Dept Vet Affairs, Philadelphia, PA USA.
[Jue, J. Jane S.] Univ Penn, Sch Med, Robert Wood Johnson Fdn Clin Scholars Program, Philadelphia, PA 19104 USA.
RP Jue, JJS (reprint author), ECRI Inst, 5200 Butler Pike, Plymouth Meeting, PA 19462 USA.
EM janejuemd@gmail.com
FU Robert Wood Johnson Foundation at the University of Pennsylvania;
Department of Veterans Affairs; University of Pennsylvania
[K24-AI073957]
FX During the course of this study, Dr Jue was funded by the Robert Wood
Johnson Foundation Clinical Scholars Program at the University of
Pennsylvania in partnership with the Department of Veterans Affairs. Dr
Metlay was funded by a Mid-Career Patient Oriented Investigator Award
(K24-AI073957) at the University of Pennsylvania. Neither funding
entities had a role in the design or conduct of the study; collection,
management, analysis, or interpretation of the data; nor preparation,
review, or approval of the manuscript.
NR 30
TC 1
Z9 1
U1 2
U2 5
PU CENTERS DISEASE CONTROL
PI ATLANTA
PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA
SN 1545-1151
J9 PREV CHRONIC DIS
JI Prev. Chronic Dis.
PD NOV
PY 2011
VL 8
IS 6
AR A138
PG 14
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 896JZ
UT WOS:000300563000021
PM 22005631
ER
PT J
AU Hamburger, M
Baraf, HSB
Adamson, TC
Basile, J
Bass, L
Cole, B
Doghramji, PP
Guadagnoli, GA
Hamburger, F
Harford, R
Lieberman, JA
Mandel, DR
Mandelbrot, DA
McClain, BP
Mizuno, E
Morton, AH
Mount, DB
Pope, RS
Rosenthal, KG
Setoodeh, K
Skosey, JL
Edwards, NL
AF Hamburger, Max
Baraf, Herbert S. B.
Adamson, Thomas C., III
Basile, Jan
Bass, Lewis
Cole, Brent
Doghramji, Paul P.
Guadagnoli, Germano A.
Hamburger, Frances
Harford, Regine
Lieberman, Joseph A., III
Mandel, David R.
Mandelbrot, Didier A.
McClain, Bonny P.
Mizuno, Eric
Morton, Allan H.
Mount, David B.
Pope, Richard S.
Rosenthal, Kenneth G.
Setoodeh, Katy
Skosey, John L.
Edwards, N. Lawrence
TI 2011 Recommendations for the Diagnosis and Management of Gout and
Hyperuricemia
SO PHYSICIAN AND SPORTSMEDICINE
LA English
DT Article
DE gout; hyperuricemia; guideline recommendations; rheumatology
ID SERUM URIC-ACID; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; INDEPENDENT
RISK-FACTOR; POPULATION-BASED COHORT; URATE-LOWERING THERAPY;
TREATMENT-FAILURE GOUT; CHRONIC-RENAL-FAILURE; METABOLIC SYNDROME;
DOUBLE-BLIND; LONG-TERM
AB Gout is a major health problem in the United States; it affects 8.3 million people, which is approximately 4% of the adult population. Gout is most often diagnosed and managed in primary care practices; thus, primary care physicians have a significant opportunity to improve patient outcomes. Following publication of the 2006 European League Against Rheumatism (EULAR) gout guidelines, significant new evidence has accumulated, and new treatments for patients with gout have become available. It is the objective of these 2011 recommendations to update the 2006 EULAR guidelines, paying special attention to the needs of primary care physicians. The revised 2011 recommendations are based on the Grading of Recommendations Assessment, Development, and Evaluation approach as an evidence-based strategy for rating quality of evidence and grading the strength of recommendation formulated for use in clinical practice. A total of 26 key recommendations, 10 for diagnosis and 16 for management, of patients with gout were evaluated, resulting in important updates for patient care. The presence of monosodium urate crystals and/or tophus and response to colchicine have the highest clinical diagnostic value. The key aspect of effective management of an acute gout attack is initiation of treatment within hours of symptom onset. Low-dose colchicine is better tolerated and is as effective as a high dose. When urate-lowering therapy (ULT) is indicated, the xanthine oxidase inhibitors allopurinol and febuxostat are the options of choice. Febuxostat can be prescribed at unchanged doses for patients with mild-to-moderate renal or hepatic impairment. The target of ULT should be a serum uric acid level that is 6 mg/dL. For patients with refractory and tophaceous gout, intravenous pegloticase is a new treatment option. This article is a summary of the 2011 clinical guidelines published in Postgraduate Medicine. This article provides a streamlined, accessible overview intended for quick review by primary care physicians, with the full guidelines being a resource for those seeking additional background information and expanded discussion.
C1 [Hamburger, Max] Rheumatol Associates Long Isl, Melville, NY 11747 USA.
[Hamburger, Max] SUNY Stony Brook, Stony Brook, NY USA.
[Hamburger, Max] Amer Soc Clin Rheumatologists, Melville, NY USA.
[Baraf, Herbert S. B.] George Washington Univ, Wheaton, IL USA.
[Adamson, Thomas C., III] Sharp Rees Stealy Med Grp, Div Rheumatol, San Diego, CA USA.
[Basile, Jan] Med Univ S Carolina, Ralph H Johnson VA Med Ctr, Seinsheimer Cardiovasc Hlth Program, Div Gen Internal Med, Charleston, SC 29425 USA.
[Bass, Lewis] NYCOM, Ridgewood, NY USA.
[Bass, Lewis] Touro Coll Osteopath Med TouroCOM, Ridgewood, NY USA.
[Doghramji, Paul P.] Ursinus Coll, Collegeville, PA USA.
[Guadagnoli, Germano A.] Bridgeport Hosp, Rheumatol Sect, Bridgeport, CT USA.
[Hamburger, Frances] Rheumatol Associates Long Isl, Psychol Serv, Dix Hills, NY USA.
[Lieberman, Joseph A., III] Jefferson Med Coll, Hockessin, DE USA.
[Mandelbrot, Didier A.; Mount, David B.] Harvard Univ, Sch Med, Boston, MA USA.
[McClain, Bonny P.] ASSESSmint Analyt & Outcomes, Greensboro, NC USA.
[Mizuno, Eric] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA.
[Morton, Allan H.] Michigan State Univ, Coll Osteopath Med, E Lansing, MI 48824 USA.
[Mount, David B.] Brigham & Womens Hosp, Div Renal, Boston, MA 02115 USA.
[Pope, Richard S.] Quinnipiac Univ, Dept PA Studies, Hamden, CT USA.
[Skosey, John L.] Univ Chicago, Chicago, IL 60637 USA.
[Edwards, N. Lawrence] Univ Florida, Dept Med, Gainesville, FL USA.
RP Hamburger, M (reprint author), Rheumatol Associates Long Isl, 1895 Walt Whitman Rd, Melville, NY 11747 USA.
EM mcapacious@aol.com
FU Regine Harford; MS; MSTPC; URL Pharma; American Society of Clinical
Rheumatologists; Mary Shah; MLS; medical library archivist and Caroline
Marshall; Danbury Hospital Library; Abbott; Amgen; Bristol-Myers Squibb;
Crescendo Bioscience; Genentech; Janssen Biotech; Takeda
Pharmaceuticals; North America, Inc; NHLBI (SPRINT); AstraZeneca; Biogen
Idec; Celegene; Merck Sharp and Dohme; Novartis; Pfizer; Roche; Stryker;
VQ OrthoCare; Nuon Therapeutics
FX The authors wish to gratefully acknowledge the invaluable editorial
support from Regine Harford, MS, MSTPC, and statistical support from
Bonny McClain, MS, DC of ASSESS-mint Analytics. Funding for the
preparation of the article was received from URL Pharma, and from the
American Society of Clinical Rheumatologists. The authors also wish to
acknowledge the invaluable support from Mary Shah, MLS, medical library
archivist and Caroline Marshall, MLS, health sciences librarian, both
from Danbury Hospital Library.; Max Hamburger, MD is a member of the
speakers' bureau for Abbott, Amgen, Bristol-Myers Squibb, Genentech,
GSK, HGSI, Novartis, and UCB; is a consultant for Bristol-Myers Squibb,
Genentech, and UCB; is in receipt of educational grants in support of
CME activities from Abbott, Amgen, Bristol-Myers Squibb, Crescendo
Bioscience, Genentech, Janssen Biotech, Takeda Pharmaceuticals, North
America, Inc, and URL Pharma. Herbert S. B. Baraf, MD is a member of the
speakers' bureau for Savient Pharmaceuticals and Takeda Pharmaceuticals,
North America, Inc; is a consultant for Ardea Biosciences and Savient
Pharmaceuticals; is an investigator for Ardea Biosciences, Metabolex,
Novartis, Regeneron, Savient Pharmaceuticals., and Takeda
Pharmaceuticals, North America, Inc; and is a member of the advisory
board for Takeda Pharmaceuticals, North America, Inc. Thomas C. Adamson
III, MD, FACP, CPE is a member of the speakers' bureau for
sanofi-aventis, Takeda Pharmaceuticals, North America, Inc, and Warner
Chilcott; and is a consultant for Sanofi-Aventis and Takeda
Pharmaceuticals, North America, Inc. Jan Basile, MD is a member of the
speakers' bureau for Boehringer Ingelheim, Daiichi-Sankyo, Forest
Laboratories, and Takeda Pharmaceuticals, North America, Inc; is a
consultant for Daiichi-Sankyo, Eli Lilly/Boehringer Ingelheim, Forest
Laboratories, and Takeda Pharmaceuticals, North America, Inc; and has
received grant/research support from the NHLBI (SPRINT). Lewis Bass, DO,
FACOFP discloses no conflicts of interest. Brent Cole, MD discloses no
conflicts of interest. Paul P. Doghramji, MD is a member of the
speakers' bureau and advisory board for URL Pharma. Germano A.
Guadagnoli, MD is a member of the speakers' bureau for Amgen/Pfizer,
Forest Laboratories, and Takeda Pharmaceuticals, North America, Inc.
Frances Hamburger, PhD is employed by Miller Professional Group. Regine
Harford, MS, MSTPC discloses no conflicts of interest. Joseph A.
Lieberman III, MD, MPH is a member of the advisory board for Takeda
Pharmaceuticals, North America, Inc and URL Pharma. David R. Mandel, MD
is a member of the speakers' bureau for Abbott, Amgen, Auxilium
Pharmaceuticals, Forest Laboratories, Forest Pharmaceuticals,
GlaxoSmithKline, Lilly, Novartis, Savient Pharmaceuticals, Sunovion
Pharmaceuticals, Takeda Pharmaceuticals, North America, Inc, and UCB; is
a member of the advisory board for Amgen, Auxilium Pharmaceuticals,
Crescendo Bioscience, Pfizer, and Savient Pharmaceuticals; is a
consultant for Amgen, Auxilium Pharmaceuticals; Crescendo Bioscience,
Pfizer, Savient Pharmaceuticals, and UCB; and has received research
support from Abbott, Amgen, AstraZeneca, Biogen Idec, Celegene, Janssen
Biotech, Crescendo Bioscience, Genentech, Merck Sharp and Dohme,
Novartis, Pfizer, Roche, Stryker, and VQ OrthoCare. Didier A.
Mandelbrot, MD discloses no conflicts of interest. Bonny P. McClain, MS,
DC discloses no conflicts of interest. Eric Mizuno, MD is an advisor for
Takeda Pharmaceuticals, North America, Inc. Allan H. Morton, DO is a
member of the speakers' bureau for Abbott, Amgen, Bristol-Myers Squibb,
Genentech, Pfizer, Takeda Pharmaceuticals, North America, Inc, Savient
Pharmaceuticals, UCB, URL Pharma, and Warner Chilcott; and is a
consultant for Amgen, Bristol-Myers Squibb, Novartis, Pfizer, Savient
Pharmaceuticals, UCB, and URL Pharma. David B.; Mount, MD has received
grant support from Nuon Therapeutics; is on the medical advisory board
and educational planning committees for Savient Pharmaceuticals; and
provides internal talks for Takeda Pharmaceuticals, North America, Inc;
nd has pending grants with Takeda Pharmaceuticals, North America, Inc
and URL Pharma. Richard S. Pope, MPAS, PA-C, DFAAPA is a member of the
speakers' bureau for AstraZeneca, Amgen, Takeda Pharmaceuticals, North
America, Inc, UCB, and URL Pharma. Kenneth G. Rosenthal, MD, PC
discloses no conflicts of interest. Katy Setoodeh, MD, FACR is a member
of the speakers' bureau for Amgen and Human Genome Sciences. John L.
Skosey, MD, PhD, FACR, FACP is an advisory board participant for
Cardinal Health; a director of Theratest Laboratories; and a stockholder
in Amgen. N. Lawrence Edwards, MD, FACP, FACR is a consultant for Ardea
Biosciences, Savient Pharmaceuticals, Novartis, and Takeda
Pharmaceuticals, North America, Inc.
NR 137
TC 20
Z9 26
U1 4
U2 20
PU JTE MULTIMEDIA
PI BERWYN
PA 1235 WESTLAKES DR, STE 220, BERWYN, PA 19312 USA
SN 0091-3847
J9 PHYSICIAN SPORTSMED
JI Physician Sportsmed.
PD NOV
PY 2011
VL 39
IS 4
BP 98
EP 123
DI 10.3810/psm.2011.11.1946
PG 26
WC Primary Health Care; Orthopedics; Sport Sciences
SC General & Internal Medicine; Orthopedics; Sport Sciences
GA 893VD
UT WOS:000300384200016
PM 22293773
ER
PT J
AU Brooks-Worrell, B
Tree, T
Mannering, SI
Durinovic-Bello, I
James, E
Gottlieb, P
Wong, S
Zhou, Z
Yang, L
Cilio, CM
Reichow, J
Menart, B
Rutter, R
Schreiner, R
Pham, M
de Marquesini, LP
Lou, O
Scotto, M
Mallone, R
Schloot, NC
AF Brooks-Worrell, B.
Tree, T.
Mannering, S. I.
Durinovic-Bello, I.
James, E.
Gottlieb, P.
Wong, S.
Zhou, Z.
Yang, L.
Cilio, C. M.
Reichow, J.
Menart, B.
Rutter, R.
Schreiner, R.
Pham, M.
de Marquesini, L. Petrich
Lou, O.
Scotto, M.
Mallone, R.
Schloot, N. C.
CA Immunology Diabet Soc
TI Comparison of cryopreservation methods on T-cell responses to islet and
control antigens from type 1 diabetic patients and controls
SO DIABETES-METABOLISM RESEARCH AND REVIEWS
LA English
DT Article; Proceedings Paper
CT 11th International Congress of the Immunology-of-Diabetes-Society (IDS)
CY OCT 31-NOV 03, 2010
CL Incheon, SOUTH KOREA
SP Immunol Diabet Soc (IDS)
DE T cells; proliferation; ELISPOT; tetramer; cryopreservation; CFSE; islet
antigens; type 1 diabetes
ID BLOOD MONONUCLEAR-CELLS; PROINSULIN; IMMUNOLOGY; PHENOTYPE; PROTEINS;
WORKSHOP; SUBSETS; SOCIETY; LYT-2+; L3T4+
AB Background Type 1 diabetes (T1D) is a cell-mediated autoimmune disease characterized by destruction of the pancreatic islet cells. The use of cryopreserved cells is preferable to the use of freshly isolated cells to monitor clinical trials to decrease assay and laboratory variability.
Methods The T-Cell Workshop Committee of the Immunology of Diabetes Society compared two widely accepted T-cell freezing protocols (warm and cold) to freshly isolated peripheral blood mononuclear cells from patients with T1D and controls in terms of recovery, viability, cell subset composition, and performance in functional assays currently in use in T1D-related research. Nine laboratories participated in the study with four different functional assays included.
Results The cold freezing method yielded higher recovery and viability compared with the warm freezing method. Irrespective of freezing protocol, B cells and CD8+ T cells were enriched, monocyte fraction decreased, and islet antigen-reactive responses were lower in frozen versus fresh cells. However, these results need to take in to account that the overall response to islet autoantigens was low in some assays.
Conclusions In the current study, none of the tested T-cell functional assays performed well using frozen samples. More research is required to identify a freezing method and a T-cell functional assay that will produce responses in patients with T1D comparable to responses using fresh peripheral blood mononuclear cells. Copyright (C) 2011 John Wiley & Sons, Ltd.
C1 [Brooks-Worrell, B.] Univ Washington, Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA 98108 USA.
[Tree, T.] Kings Coll London, Sch Med, London WC2R 2LS, England.
[Mannering, S. I.] Univ Melbourne, Dept Med, St Vincents Inst Med Res, Fitzroy, Vic 3065, Australia.
[Durinovic-Bello, I.; James, E.] Benaroya Res Inst, Seattle, WA USA.
[Gottlieb, P.] Univ Colorado, Sch Med, Barbara Davis Ctr Childhood Diabet, Dept Pediat & Med, Denver, CO USA.
[Wong, S.] Cardiff Univ, Ctr Endocrine & Diabet Sci, Dept Med, Sch Med, Cardiff, S Glam, Wales.
[Zhou, Z.; Yang, L.] Cent S Univ, Sch Med, Changsha, Hunan, Peoples R China.
[Cilio, C. M.] Lund Univ, Dept Sci, Cellular Autoimmun Unit, Malmo, Sweden.
[Reichow, J.] Seattle Inst Biomed & Clin Res, Seattle, WA USA.
[Menart, B.; Rutter, R.; Schreiner, R.; Pham, M.; Schloot, N. C.] Univ Dusseldorf, German Diabet Ctr, Inst Clin Diabetol, D-40225 Dusseldorf, Germany.
[de Marquesini, L. Petrich] Univ Bristol, Henry Wellcome Lab Integrat Neurosci & Endocrinol, Bristol, Avon, England.
[Lou, O.] JDRF Int, JDRF Canadian Clin Trial Network, Toronto, ON, Canada.
[Scotto, M.; Mallone, R.] Hop St Vincent de Paul, INSERM, U986, DeAR Lab Avenir, F-75674 Paris, France.
[Schloot, N. C.] Univ Dusseldorf, Clin Metab Dis, D-40225 Dusseldorf, Germany.
RP Brooks-Worrell, B (reprint author), Univ Washington, Vet Affairs Puget Sound Hlth Care Syst, 1660 S Columbian Way, Seattle, WA 98108 USA.
EM bbrooks@u.washington.edu
RI Mallone, Roberto/H-4430-2013
OI James, Eddie/0000-0002-7217-5729
NR 25
TC 9
Z9 9
U1 0
U2 5
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1520-7552
J9 DIABETES-METAB RES
JI Diabetes-Metab. Res. Rev.
PD NOV
PY 2011
VL 27
IS 8
SI SI
BP 737
EP 745
DI 10.1002/dmrr.1245
PG 9
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 889XD
UT WOS:000300108000004
PM 22069253
ER
PT J
AU Finlayson, E
Maselli, J
Steinman, MA
Rothberg, MB
Lindenauer, PK
Auerbach, AD
AF Finlayson, Emily
Maselli, Judith
Steinman, Michael A.
Rothberg, Michael B.
Lindenauer, Peter K.
Auerbach, Andrew D.
TI Inappropriate Medication Use in Older Adults Undergoing Surgery: A
National Study
SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
LA English
DT Article
DE surgery; potentially inappropriate medications (PIMs); older adults
ID POTENTIALLY INAPPROPRIATE; ADMINISTRATIVE DATA; SURGICAL-PATIENTS;
MEPERIDINE USE; HIP FRACTURE; DELIRIUM; OUTCOMES; INDICATORS; CRITERIA;
IMPACT
AB OBJECTIVES: To determine the prevalence and factors associated with use of potentially inappropriate medications (PIMs) in older adults undergoing surgery.
DESIGN: Retrospective cohort study.
SETTING: Three hundred seventy-nine acute care hospitals participating in the nationally representative Perspective database (2006-2008).
PARTICIPANTS: Individuals aged 65 and older under going major inpatient gastrointestinal, gynecological, urological, and orthopedic surgery (N=272,351).
MEASUREMENTS: Medications were classified as PIMs using previously published criteria defining 33 medications deemed potentially inappropriate in people aged 65 and older. Information about participant and provider characteristics and administration of PIMs was obtained from hospital discharge file data. Logistic regression techniques were used to examine factors associated with use of PIMs in the perioperative period.
RESULTS: One-quarter of participants received at least one PIM during their surgical admission. Meperidine was the most frequently prescribed PIM (37,855, 14% of participants). In adjusted analysis, PIM use was less likely as age advanced (adjusted odds ratio (AOR) = 0.98 per year of age, 95% confidence interval (CI) = 0.97-0.98) and in men (AOR = 0.83, 95% CI = 0.81-0.85). PIMs were more likely to be prescribed to participants cared for by orthopedic surgeons than for those cared for by general surgeons (AOR = 1.22, 95% CI = 1.08-1.40). Participants undergoing surgery in the West (AOR = 1.79, 95% CI = 1.02-3.16) and South (AOR = 2.24, 95% CI = 1.38-3.64) were more likely to receive a PIM than those in the Northeast.
CONCLUSION: Receipt of PIMs in older adults undergoing surgery is common and varies widely between providers and geographic regions and according to participant characteristics. Interventions aimed at reducing the use of PIMs in the perioperative period should be considered in quality improvement efforts. J Am Geriatr Soc 59:2139-2144, 2011.
C1 [Finlayson, Emily] Univ Calif San Francisco, Philip R Lee Inst Hlth Policy Studies, San Francisco, CA 94118 USA.
[Finlayson, Emily] Univ Calif San Francisco, Dept Surg, San Francisco, CA 94118 USA.
[Maselli, Judith; Auerbach, Andrew D.] Univ Calif San Francisco, Div Hosp Med, San Francisco, CA 94118 USA.
[Steinman, Michael A.] Univ Calif San Francisco, Div Geriatr, Dept Med, San Francisco, CA 94118 USA.
[Steinman, Michael A.] San Francisco VA Med Ctr, San Francisco, CA USA.
[Rothberg, Michael B.; Lindenauer, Peter K.] Baystate Med Ctr, Ctr Qual Care Res, Springfield, MA USA.
[Rothberg, Michael B.; Lindenauer, Peter K.] Tufts Univ, Sch Med, Dept Med, Boston, MA 02111 USA.
RP Finlayson, E (reprint author), Univ Calif San Francisco, Philip R Lee Inst Hlth Policy Studies, 3333 Calif St, San Francisco, CA 94118 USA.
EM emily.finlayson@ucsfmedctr.org
FU National Heart, Blood, Lund Institute [K24HL098372]; National Institute
on Aging [K08AG028965]; American Federation for Aging Research
[K23AG030999]
FX Work on this study was funded in part by National Heart, Blood, Lund
Institute Award K24HL098372 to Dr. Auerbach. Dr. Finlayson was supported
by National Institute on Aging/Paul B. Beeson Clinical Scientist
Development Award in Aging K08AG028965. Dr. Steinman was supported by
the National Institute on Aging and the American Federation for Aging
Research (K23AG030999).
NR 23
TC 8
Z9 8
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0002-8614
EI 1532-5415
J9 J AM GERIATR SOC
JI J. Am. Geriatr. Soc.
PD NOV
PY 2011
VL 59
IS 11
BP 2139
EP 2144
DI 10.1111/j.1532-5415.2011.03567.x
PG 6
WC Geriatrics & Gerontology; Gerontology
SC Geriatrics & Gerontology
GA 853FG
UT WOS:000297411000020
PM 21883113
ER
PT J
AU Wong, CH
Landefeld, CS
AF Wong, Chek Hooi
Landefeld, C. Seth
TI Academic Geriatrics in Singapore
SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
LA English
DT Article
DE education; research; geriatrics
ID CARE; MEDICINE; POPULATION; EDUCATION
AB Singapore is one of the fastest-aging countries in the world. The proportion of adults aged 65 and older is projected to increase from 8.7% to 20% over the next 20 years. The country has developed various strategies to meet the needs of this increase in older adults. There is an acute shortage of geriatricians and a need to train more healthcare workers to care for older adults. Geriatric medicine is a relatively new specialty, and a small number of geriatricians have been tasked with providing an increasing load of clinical service, education, and research. Hence, there is a need to develop a cohesive structure of support for faculty development and retention, advanced specialty trainee recruitment, leadership in medical education, research, and clinical service to care for the rapidly aging population. In addition, geriatric medicine is primarily a hospital-based specialty in Singapore. There is still opportunity to collaborate and improve the academic and practice integration of geriatric medicine into primary care and intermediate and long-term care where it is most needed. J Am Geriatr Soc 59:2145-2150, 2011.
C1 [Wong, Chek Hooi] Khoo Teck Puat Hosp, Dept Geriatr Med, Singapore 768828, Singapore.
[Landefeld, C. Seth] Univ Calif San Francisco, Div Geriatr, San Francisco, CA 94143 USA.
[Landefeld, C. Seth] San Francisco VA Med Ctr, San Francisco, CA USA.
RP Wong, CH (reprint author), Khoo Teck Puat Hosp, Dept Geriatr Med, 90 Yishun Cent, Singapore 768828, Singapore.
EM chekhooi@yahoo.com
FU U.S., Department of State, Bureau of Educational and Cultural Affairs
FX Chek Hooi Wong and C. Seth Landefeld both state no financial interest,
stock, or derived direct financial benefit. Chek Hooi Wong was funded by
a Fulbright Singapore Researcher Program, U.S., Department of State,
Bureau of Educational and Cultural Affairs.
NR 22
TC 0
Z9 0
U1 0
U2 1
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0002-8614
J9 J AM GERIATR SOC
JI J. Am. Geriatr. Soc.
PD NOV
PY 2011
VL 59
IS 11
BP 2145
EP 2150
DI 10.1111/j.1532-5415.2011.03630.x
PG 6
WC Geriatrics & Gerontology; Gerontology
SC Geriatrics & Gerontology
GA 853FG
UT WOS:000297411000021
PM 22091794
ER
PT J
AU Beeri, MS
Moshier, E
Schmeidler, J
Godbold, J
Uribarri, J
Reddy, S
Sano, M
Grossman, HT
Cai, WJ
Vlassara, H
Silverman, JM
AF Beeri, Michal Schnaider
Moshier, Erin
Schmeidler, James
Godbold, James
Uribarri, Jaime
Reddy, Sarah
Sano, Mary
Grossman, Hillel T.
Cai, Weijing
Vlassara, Helen
Silverman, Jeremy M.
TI Serum concentration of an inflammatory glycotoxin, methylglyoxal, is
associated with increased cognitive decline in elderly individuals
SO MECHANISMS OF AGEING AND DEVELOPMENT
LA English
DT Article
DE Methylglyoxal; Advanced glycation end products; Type 2 diabetes;
Cognitive decline; Alzheimer's disease
ID ADVANCED GLYCATION ENDPRODUCTS; ALZHEIMERS-DISEASE; CARBONYL SCAVENGERS;
CEREBROSPINAL-FLUID; PROTEIN GLYCATION; OXIDATIVE STRESS; OLDEST-OLD;
DEMENTIA; AGE; NEUROPATHOLOGY
AB Background: Advanced glycations end products increase oxidant stress, inflammation, and neurotoxicity. Serum levels are increased in diabetes and aging. We examined the relationship between serum methylglyoxal derivatives (sMG), and cognitive decline, in 267 non-demented elderly.
Methods: Tobit mixed regression models assessed the association of baseline sMG with cognitive decline in the Mini Mental State Exam (MMSE) over time, controlling for sociodemographic factors (age, sex, and years of education), cardiovascular risk factors (diabetes and presence of an ApoE4 allele), and kidney function. sMG was assessed by ELISA.
Results: The fully adjusted model showed an annual decline of 0.26 MMSE points per unit increase in baseline sMG (p = 0.03). Significance was unchanged as additional risk factors were added to the model. The interactions of sMG with diabetes, sex, age, kidney function, and ApoE4 genotype were not significant.
Conclusions: Higher levels of baseline sMG were associated with a faster rate of cognitive decline, after adjusting for several sociodemographic and clinical characteristics. This relationship did not differ by sex, ApoE4 genotype, or diabetes status suggesting its generality. Since subjects were cognitively normal at the beginning of the study, elevated sMG may be indicative of brain cell injury initiated before clinically evident cognitive compromise. (C) 2011 Elsevier Ireland Ltd. All rights reserved.
C1 [Beeri, Michal Schnaider; Schmeidler, James; Reddy, Sarah; Sano, Mary; Grossman, Hillel T.; Silverman, Jeremy M.] Mt Sinai Sch Med, Dept Psychiat, New York, NY 10029 USA.
[Moshier, Erin; Godbold, James] Mt Sinai Sch Med, Dept Biostat, New York, NY 10029 USA.
[Uribarri, Jaime] Mt Sinai Sch Med, Dept Med, New York, NY 10029 USA.
[Cai, Weijing; Vlassara, Helen] Mt Sinai Sch Med, Dept Geriatr, New York, NY 10029 USA.
[Beeri, Michal Schnaider; Sano, Mary] James J Peters Vet Affairs Med Ctr, Bronx, NY USA.
RP Beeri, MS (reprint author), Mt Sinai Sch Med, Dept Psychiat, 1 Gustave Levy Pl,Box 1230, New York, NY 10029 USA.
EM michal.beeri@mssm.edu
FU NIA [K01 AG023515-01, R01 AG034087, P01 AG02219, P50 AG05138,
R37AG023188]; Irma T. Hirschl Award; Berkman Trust
FX Supported by NIA grants K01 AG023515-01 and R01 AG034087 to Dr. Beeri,
Project 4 in P01 AG02219 to Dr. Silverman, P50 AG05138 to Dr. Mary Sano,
and R37AG023188 (MERIT) to Dr. Vlassara, as well as by the Irma T.
Hirschl Award to Dr. Beeri and the Berkman Trust to Dr. Vahram
Haroutunian.
NR 39
TC 32
Z9 32
U1 0
U2 8
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
IRELAND
SN 0047-6374
J9 MECH AGEING DEV
JI Mech. Ageing Dev.
PD NOV-DEC
PY 2011
VL 132
IS 11-12
BP 583
EP 587
DI 10.1016/j.mad.2011.10.007
PG 5
WC Cell Biology; Geriatrics & Gerontology
SC Cell Biology; Geriatrics & Gerontology
GA 888CG
UT WOS:000299980800007
PM 22079406
ER
PT J
AU Chan, K
Lai, MN
Groessl, EJ
Hanchate, A
Hernandez, L
Wong, JB
Clark, JA
Asch, S
Gifford, AL
Ho, S
AF Chan, K.
Lai, M. N.
Groessl, E. J.
Hanchate, A.
Hernandez, L.
Wong, J. B.
Clark, J. A.
Asch, S.
Gifford, A. L.
Ho, S.
TI POTENTIAL COSTS ASSOCIATED WITH NEW DIRECT ACTING ANTIVIRAL (DAAS)
THERAPY FOR UNTREATED CHRONIC HEPATITIS C GENOTYPE 1 INFECTION IN THE
VETERANS HEALTH ADMINISTRATION
SO VALUE IN HEALTH
LA English
DT Meeting Abstract
C1 [Chan, K.; Hanchate, A.; Hernandez, L.; Clark, J. A.] Boston Univ, Boston, MA 02215 USA.
[Lai, M. N.; Ho, S.] Vet Affairs San Diego Healthcare Syst, San Diego, CA USA.
[Groessl, E. J.] Univ Calif San Diego, La Jolla, CA 92093 USA.
[Wong, J. B.] Tufts Univ, Boston, MA 02111 USA.
[Asch, S.] VA Greater Los Angeles Healthcare Syst GLA, Los Angeles, CA USA.
[Gifford, A. L.] Edith Nourse Rogers Mem Vet Adm Hosp, Bedford, MA 01730 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1098-3015
J9 VALUE HEALTH
JI Value Health
PD NOV
PY 2011
VL 14
IS 7
BP A269
EP A270
PG 2
WC Economics; Health Care Sciences & Services; Health Policy & Services
SC Business & Economics; Health Care Sciences & Services
GA 876KT
UT WOS:000299107100193
ER
PT J
AU Tanaka, K
Babic, I
Nathanson, D
Akhavan, D
Guo, DL
Gini, B
Dang, J
Zhu, SJ
Yang, HJ
De Jesus, J
Amzajerdi, AN
Zhang, YN
Dibble, CC
Dan, HC
Rinkenbaugh, A
Yong, WH
Vinters, HV
Gera, JF
Cavenee, WK
Cloughesy, TF
Manning, BD
Baldwin, AS
Mischel, PS
AF Tanaka, Kazuhiro
Babic, Ivan
Nathanson, David
Akhavan, David
Guo, Deliang
Gini, Beatrice
Dang, Julie
Zhu, Shaojun
Yang, Huijun
De Jesus, Jason
Amzajerdi, Ali Nael
Zhang, Yinan
Dibble, Christian C.
Dan, Hancai
Rinkenbaugh, Amanda
Yong, William H.
Vinters, Harry V.
Gera, Joseph F.
Cavenee, Webster K.
Cloughesy, Timothy F.
Manning, Brendan D.
Baldwin, Albert S.
Mischel, Paul S.
TI Oncogenic EGFR Signaling Activates an mTORC2-NF-kappa B Pathway That
Promotes Chemotherapy Resistance
SO CANCER DISCOVERY
LA English
DT Article
ID NF-KAPPA-B; GROWTH-FACTOR RECEPTOR; MTOR COMPLEX 2; MAMMALIAN TARGET;
MOTIF PHOSPHORYLATION; GLIOBLASTOMA PATIENTS; KINASE INHIBITORS;
CANCER-THERAPY; AKT; RICTOR
AB Although it is known that mTOR complex 2 (mTORC2) functions upstream of Akt, the role of this protein kinase complex in cancer is not well understood. Through an integrated analysis of cell lines, in vivo models, and clinical samples, we demonstrate that mTORC2 is frequently activated in glioblastoma (GBM), the most common malignant primary brain tumor of adults. We show that the common activating epidermal growth factor receptor (EGFR) mutation (EGFRvIII) stimulates mTORC2 kinase activity, which is partially suppressed by PTEN. mTORC2 signaling promotes GBM growth and survival and activates NF-kappa B. Importantly, this mTORC2-NF-kappa B pathway renders GBM cells and tumors resistant to chemotherapy in a manner independent of Akt. These results highlight the critical role of mTORC2 in the pathogenesis of GBM, including through the activation of NF-kappa B downstream of mutant EGFR, leading to a previously unrecognized function in cancer chemotherapy resistance. These findings suggest that therapeutic strategies targeting mTORC2, alone or in combination with chemotherapy, will be effective in the treatment of cancer. SIGNIFICANCE: This study demonstrates that EGFRvIII-activated mTORC2 signaling promotes GBM proliferation, survival, and chemotherapy resistance through Akt-independent activation of NF-kappa B. These results highlight the role of mTORC2 as an integrator of two canonical signaling networks that are commonly altered in cancer, EGFR/phosphoinositide-3 kinase (PI3K) and NF-kappa B. These results also validate the importance of mTORC2 as a cancer target and provide new insights into its role in mediating chemotherapy resistance, suggesting new treatment strategies. Cancer Discovery; 1(6); 524-38. (C) 2011 AACR.
C1 [Mischel, Paul S.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pathol & Lab Med, Ctr Hlth Sci, Los Angeles, CA 90095 USA.
[Mischel, Paul S.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA.
[Yong, William H.; Cloughesy, Timothy F.; Mischel, Paul S.] Univ Calif Los Angeles, David Geffen Sch Med, Henry Singleton Brain Tumor Program, Los Angeles, CA 90095 USA.
[Yong, William H.; Cloughesy, Timothy F.; Mischel, Paul S.] Univ Calif Los Angeles, David Geffen Sch Med, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90095 USA.
[Vinters, Harry V.; Cloughesy, Timothy F.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA.
[Gera, Joseph F.] Greater Los Angeles Vet Affairs Healthcare Syst, Dept Res & Dev, Sepulveda, CA USA.
[Guo, Deliang] Ohio State Univ, Sch Med, Dept Radiat Oncol, Arthur G James Comprehens Canc Ctr, Columbus, OH 43210 USA.
[Cavenee, Webster K.] Univ Calif San Diego, Ludwig Inst Canc Res, La Jolla, CA 92093 USA.
[Zhang, Yinan; Dibble, Christian C.; Manning, Brendan D.] Harvard Univ, Sch Publ Hlth, Dept Genet & Complex Dis, Boston, MA 02115 USA.
[Dan, Hancai; Rinkenbaugh, Amanda; Baldwin, Albert S.] Univ N Carolina, Sch Med, Lineberger Comprehens Canc Ctr, Chapel Hill, NC USA.
RP Mischel, PS (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Pathol & Lab Med, Ctr Hlth Sci, 10833 Le Conte Ave,Room 13-321, Los Angeles, CA 90095 USA.
EM pmischel@mednet.ucla.edu
RI Guo, Deliang/I-3735-2014; Zhang, Yinan/N-6432-2014
OI Guo, Deliang/0000-0002-8359-390X; Zhang, Yinan/0000-0002-3471-6598;
Nael, Ali/0000-0002-9671-5531
FU NIH [CA119347, NS73831, P01-CA95616, CA122617, CA75080, CA73756];
Accelerate Brain Cancer Cure; STOP Cancer; Fred Miller Family; John W.
Carson Foundation; Lya and Harrison Latter endowed Chair; Ziering Family
Foundation in memory of Sigi Ziering; Ben and Catherine Ivy Foundation;
Art of the Brain Fund; Henry Singleton Brain Cancer Fund; Samuel Waxman
Cancer Research Foundation; Uehara Memorial Foundation
FX This work was supported by NIH grants CA119347 and NS73831 (P.S.
Mischel), Accelerate Brain Cancer Cure (P.S. Mischel), STOP Cancer (P.S.
Mischel), The Fred Miller Family (P.S. Mischel), The John W. Carson
Foundation (P.S. Mischel), The Lya and Harrison Latter endowed Chair
(P.S. Mischel), Ziering Family Foundation in memory of Sigi Ziering
(T.F. Cloughesy and P.S. Mischel), The Ben and Catherine Ivy Foundation
Fund (W.H. Yong and T.F. Cloughesy), Art of the Brain Fund (W.H. Yong
and T.F. Cloughesy), Henry Singleton Brain Cancer Fund (W.H. Yong and
T.F. Cloughesy), NIH grant P01-CA95616 (W.K. Cavenee), NIH grant
CA122617 (B.D. Manning), NIH grants CA75080 and CA73756 (A.S. Baldwin),
Samuel Waxman Cancer Research Foundation (A.S. Baldwin), and Uehara
Memorial Foundation (K. Tanaka).
NR 54
TC 112
Z9 116
U1 1
U2 11
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 2159-8274
J9 CANCER DISCOV
JI Cancer Discov.
PD NOV
PY 2011
VL 1
IS 6
BP 524
EP 538
DI 10.1158/2159-8290.CD-11-0124
PG 15
WC Oncology
SC Oncology
GA 880MR
UT WOS:000299411700031
PM 22145100
ER
PT J
AU Kofonow, JM
Bhuskute, A
Doghramji, L
Palmer, JN
Cohen, NA
Chiu, AG
AF Kofonow, Jennifer M.
Bhuskute, Aditi
Doghramji, Laurel
Palmer, James N.
Cohen, Noam A.
Chiu, Alexander G.
TI One-way valve bottle contamination rates in the immediate
post-functional endoscopic sinus surgery period
SO AMERICAN JOURNAL OF RHINOLOGY & ALLERGY
LA English
DT Article
ID RHINOSINUSITIS PATIENTS
AB Background: Sinonasal saline irrigation has become an accepted practice in the immediate postoperative management of functional endoscopic sinus surgery (FESS) patients. Recent studies have found that valveless delivery systems of sinonasal irrigation are colonized with bacteria. An alternative delivery system uses a one-way valve to reduce saline backflow and may limit bottle contamination. Our sole objective was to determine whether this system in post-FESS patients eliminates microbial bottle contamination.
Methods: Eight patients undergoing FESS were given one-way valve irrigation bottles to use immediately after surgery. Bottles were collected after 1 week of use and another set of bottles after an additional week. Endoscopic-directed cultures of the middle meatus were performed at the time of surgery. Returned used bottles were swabbed for bacteria and the valve system of the bottle was analyzed under scanning electron microscopy (SEM) for the presence of bacteria.
Results: All sinus swabs collected at the time of surgery grew bacteria with Staphylococcus sp. present in all samples. After the 1st week of use, 5/8 bottles grew bacterial cultures and showed bacterial presence on the valves by SEM. After the 2nd week, 4/5 bottles had positive culture results and also showed bacterial presence on the valves by SEM.
Conclusion: Despite commercial claims that the use of valves and limit of backflow into the bottle will eliminate contamination, our study showed that one-way valve delivery systems become contaminated with bacteria after 1 week of use. We also showed that the bottle valves themselves harbor bacteria after 1 week of use. (Am J Rhinol Allergy 25, 393-396, 2011; doi:10.2500/ajra.2011.25.3664)
C1 [Kofonow, Jennifer M.; Doghramji, Laurel; Palmer, James N.; Cohen, Noam A.] Univ Penn, Dept Otorhinolaryngol, Philadelphia, PA 19104 USA.
[Bhuskute, Aditi; Chiu, Alexander G.] Univ Arizona, Dept Surg, Tucson, AZ USA.
[Cohen, Noam A.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA.
RP Cohen, NA (reprint author), Univ Penn, Dept Otorhinolaryngol, Ravdin Bldg 5th Floor,3400 Spruce St, Philadelphia, PA 19104 USA.
EM Noam.Cohen@uphs.upenn.edu
RI Chiu, Alexander/J-1230-2014
OI Chiu, Alexander/0000-0002-7592-6575; Cohen, Noam/0000-0002-9462-3932
FU NeilMed Pharmaceuticals, Inc.
FX J.N. Palmer, N.A. Cohen and A.G. Chiu have in the past received
royalties from NeilMed Pharmaceuticals, Inc. The remaining authors have
nothing to declare pertaining to this article
NR 11
TC 2
Z9 2
U1 0
U2 5
PU OCEAN SIDE PUBLICATIONS INC
PI PROVIDENCE
PA 95 PITMAN ST, PROVIDENCE, RI 02906 USA
SN 1945-8924
J9 AM J RHINOL ALLERGY
JI Am. J. Rhinol. Allergy
PD NOV-DEC
PY 2011
VL 25
IS 6
BP 393
EP 396
DI 10.2500/ajra.2011.25.3664
PG 4
WC Otorhinolaryngology
SC Otorhinolaryngology
GA 868RT
UT WOS:000298543100019
PM 22185742
ER
PT J
AU Teitelman, AM
Stringer, M
Nguyen, GT
Hanlon, AL
Averbuch, T
Stimpfel, AW
AF Teitelman, Anne M.
Stringer, Marilyn
Nguyen, Giang T.
Hanlon, Alexandra L.
Averbuch, Tali
Stimpfel, Amy Witkoski
TI Social Cognitive and Clinical Factors Associated with HPV Vaccine
Initiation Among Urban, Economically Disadvantaged Women
SO JOGNN-JOURNAL OF OBSTETRIC GYNECOLOGIC AND NEONATAL NURSING
LA English
DT Article
DE HPV vaccine; theory of planned behavior; sexual health; adolescent;
women's health; cervical cancer; prevention
ID HUMAN-PAPILLOMAVIRUS VACCINATION; PLANNED BEHAVIOR; REASONED ACTION;
UNITED-STATES; CERVICAL-CANCER; ACCEPTABILITY; ACCEPTANCE; INFECTION;
DAUGHTERS; KNOWLEDGE
AB Objective: To learn more about human papilloma virus (HPV) knowledge and vaccination among teens and young women age 13 to 26 years from an economically disadvantaged, urban community. Our aim was to identify common beliefs about HPV vaccine initiation and describe the relationship between attitudes, norms, perceived control, and intention to receive HPV vaccine, drawing from the theory of planned behavior (TPB).
Design: Mixed method, descriptive design. Guided by the TPB, HPV vaccine beliefs were assessed through focus groups. Intention to receive the vaccine, demographic and clinical factors, and theoretical predictor variables (attitudes, norms, and control) were assessed through questionnaires.
Setting: After recruitment, focus groups were held at a convenient date and time for our participants in a small university conference room.
Participants: Participants were economically disadvantaged young women, age 13 to 26 (N = 34).
Methods: Specific behavioral, normative, and control beliefs were elicited in focus groups and analyzed using content analysis. Simple and multivariate general linear modeling with adjustment for prognostic demographic and clinical factors was completed to assess the influence of the theoretical predictor variables on the outcome of HPV vaccine initiation.
Results: Influential beliefs toward vaccination were identified. Analysis indicated attitudes, norms, and perceived control toward HPV vaccine initiation were highly significant predictors of intent, as was tobacco use; all p's < .001.
Conclusion: Barriers to HPV vaccine initiation were identified, and strong preliminary evidence supports use of the TPB to guide programs to promote urban, economically disadvantaged young women's intent to begin the HPV vaccine. JOGNN, 40, 691-701; 2011. DOI: 10.1111/j.1552-6909.2011.01297.x
C1 [Teitelman, Anne M.] Univ Penn, Sch Nursing, Ctr Hlth Equ Res, Philadelphia, PA 19194 USA.
[Nguyen, Giang T.] Univ Penn, Sch Med, Dept Family Med & Community Hlth, Philadelphia, PA 19194 USA.
[Averbuch, Tali] Univ Penn, Sch Nursing, Womens Hlth Nurse Practitioner Program, Philadelphia, PA 19194 USA.
[Averbuch, Tali] Univ Penn, Sch Nursing, Nurse Midwifery Program, Philadelphia, PA 19194 USA.
RP Teitelman, AM (reprint author), Univ Penn, Sch Nursing, Ctr Hlth Equ Res, Fagin Hall 2L,Rm 244,418 Curie Blvd, Philadelphia, PA 19194 USA.
EM teitelm@nursing.upenn.edu
OI Nguyen, Giang/0000-0003-2031-9943
FU University of Pennsylvania School of Nursing; American Cancer Society
[CCCDA-05-161-01]
FX Supported by University of Pennsylvania School of Nursing Investing in
the Future Grant. Dr. Nguyen was supported by a Cancer Control Career
Development Award from the American Cancer Society (CCCDA-05-161-01) and
a Pfizer Fellowship in Health Literacy/Clear Health Communication.
NR 49
TC 9
Z9 9
U1 2
U2 10
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0884-2175
J9 JOGNN-J OBST GYN NEO
JI JOGNN
PD NOV-DEC
PY 2011
VL 40
IS 6
BP 691
EP 701
DI 10.1111/j.1552-6909.2011.01297.x
PG 11
WC Nursing; Obstetrics & Gynecology
SC Nursing; Obstetrics & Gynecology
GA 855OY
UT WOS:000297575300005
PM 22092373
ER
PT J
AU Bloch, MJ
Basile, JN
AF Bloch, Michael J.
Basile, Jan N.
TI New British Guidelines Mandate Ambulatory Blood Pressure Monitoring to
Diagnose Hypertension in All Patients: Not Ready for Prime Time in the
United States
SO JOURNAL OF CLINICAL HYPERTENSION
LA English
DT Editorial Material
C1 [Bloch, Michael J.] St Marys Reg Med Ctr, Risk Reduct Ctr, Reno, NV USA.
[Basile, Jan N.] Med Univ S Carolina, Seinsheimer Cardiovasc Hlth Program, Div Gen Internal Med Geriatr, Charleston, SC 29425 USA.
[Bloch, Michael J.] Univ Nevada, Sch Med, Dept Internal Med, Reno, NV 89557 USA.
[Basile, Jan N.] Ralph H Johnson VA Med Ctr, Charleston, SC USA.
RP Bloch, MJ (reprint author), St Marys Reg Med Ctr, Risk Reduct Ctr, 645 N Arlington St,Suite 460, Reno, NV USA.
EM mbloch@aol.com
NR 1
TC 12
Z9 12
U1 0
U2 0
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1524-6175
J9 J CLIN HYPERTENS
JI J. Clin. Hypertens.
PD NOV
PY 2011
VL 13
IS 11
BP 785
EP 786
DI 10.1111/j.1751-7176.2011.00532.x
PG 2
WC Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA 859DG
UT WOS:000297854300001
PM 22051420
ER
PT J
AU Lynch, CP
Strom, JL
Egede, LE
AF Lynch, Cheryl P.
Strom, Joni L.
Egede, Leonard E.
TI Disparities in diabetes self-management and quality of care in rural
versus urban veterans
SO JOURNAL OF DIABETES AND ITS COMPLICATIONS
LA English
DT Article
DE Veterans; Diabetes; Quality of care; Self-management; Rural health
ID GLYCEMIC CONTROL; HEALTH-CARE; ACCESS; TELEMEDICINE; EDUCATION; POLICY
AB Background: There are distinct geographic differences in diabetes-related morbidity and mortality; however, data regarding self-management and clinical outcomes are limited. This study examined diabetes care among veterans residing in rural versus urban areas.
Methods: A national data set was analyzed based on 10,570 veterans with type 2 diabetes. Residence was determined according to US census-based metropolitan statistical area. Primary outcomes were self-management behaviors (lifestyle and self-monitoring) and quality of care indicators (provider visits, laboratory monitoring and preventive measures). Multivariate analyses were done using STATA v10 to assess the independent effect of veteran residence on each outcome measure and to account for the complex survey design.
Results: Among veterans with diabetes, 21.4% were rural residents. Compared to urban veterans, rural veterans had significantly lower education, less annual income and less received diabetes education (P=.002). The final regression model showed that daily foot self-check was the only self-management behavior significantly higher among rural veterans (odds ratio 1.36, 95% confidence interval 1.10-1.70). Provider-based quality of care was not significantly different between groups.
Conclusions: Diabetes self-foot care was significantly better among rural veterans than their urban counterparts, but quality of care was equivalent. This suggests that clinical diabetes care among veterans is uniform; however, greater efforts for patient education and support in diabetes self-management are needed to improve outcomes. Published by Elsevier Inc.
C1 [Egede, Leonard E.] Med Univ S Carolina, Charleston VA REAP, Ctr Hlth Dispar Res, Dept Med, Charleston, SC 29425 USA.
[Lynch, Cheryl P.; Egede, Leonard E.] Ralph H Johnson Vet Affairs Med Ctr, Ctr Dis Prevent & Hlth Intervent Diverse Populat, Charleston, SC USA.
RP Egede, LE (reprint author), Med Univ S Carolina, Charleston VA REAP, Ctr Hlth Dispar Res, Dept Med, Charleston, SC 29425 USA.
EM egedel@musc.edu
FU NIDDK NIH HHS [K24 DK093699]
NR 30
TC 7
Z9 7
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1056-8727
J9 J DIABETES COMPLICAT
JI J. Diabetes Complications
PD NOV-DEC
PY 2011
VL 25
IS 6
BP 387
EP 392
DI 10.1016/j.jdiacomp.2011.08.003
PG 6
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 865UA
UT WOS:000298335200007
PM 21983152
ER
PT J
AU Murrough, JW
Iacoviello, B
Neumeister, A
Charney, DS
Iosifescu, DV
AF Murrough, James W.
Iacoviello, Brian
Neumeister, Alexander
Charney, Dennis S.
Iosifescu, Dan V.
TI Cognitive dysfunction in depression: Neurocircuitry and new therapeutic
strategies
SO NEUROBIOLOGY OF LEARNING AND MEMORY
LA English
DT Review
DE Depression; Cognition; Neuropsychology; Emotion regulation;
Neuroimaging; Therapeutics; Cognitive dysfunction
ID OBSESSIVE-COMPULSIVE DISORDER; WHITE-MATTER HYPERINTENSITIES;
POSITRON-EMISSION-TOMOGRAPHY; SUBGENUAL PREFRONTAL CORTEX; UNIPOLAR
MAJOR DEPRESSION; HAPPY FACIAL EXPRESSIONS; BRAIN GLUCOSE-METABOLISM;
STAR-ASTERISK-D; ANTIDEPRESSANT-TREATMENT; EMOTION REGULATION
AB Major depressive disorder (MDD) is a disabling medical condition associated with significant morbidity, mortality and public health costs. However, neurocircuitry abnormalities underlying depression remain incompletely understood and consequently current treatment options are unfortunately limited in efficacy. Recent research has begun to focus specifically on cognitive aspects of depression and potential neurobiological correlates. Two fundamental types of cognitive dysfunction observed in MOD are cognitive biases, which include distorted information processing or attentional allocation toward negative stimuli, and cognitive deficits, which include impairments in attention, short-term memory and executive functioning. In this article, we present a selective review of current research findings in these domains and examine neuroimaging research that is beginning to characterize the neurocircuitry underlying these biases and deficits. We propose that deficient cognitive functioning, attention biases and the sustained negative affect characteristic of MOD can be understood as arising in part from dysfunctional prefrontal-subcortical circuitry and related disturbances in the cognitive control of emotion. Finally, we highlight potential new pharmacological and non-pharmacological therapeutic strategies for MDD based on an evolving mechanistic understanding of the disorder. (C) 2011 Elsevier Inc. All rights reserved.
C1 [Murrough, James W.; Iacoviello, Brian; Neumeister, Alexander; Iosifescu, Dan V.] Mt Sinai Sch Med, Dept Psychiat, Mood & Anxiety Disorders Program, New York, NY 10029 USA.
[Iacoviello, Brian] James J Peters VA Med Ctr, MIRECC, Bronx, NY USA.
[Neumeister, Alexander] VA Connecticut Healthcare Syst, Mol Imaging Program, West Haven, CT USA.
[Charney, Dennis S.] Mt Sinai Sch Med, Dept Neurosci, New York, NY 10029 USA.
[Charney, Dennis S.] Mt Sinai Sch Med, Dept Syst Pharmacol & Therapeut, New York, NY 10029 USA.
[Charney, Dennis S.] Mt Sinai Sch Med, Off Dean, New York, NY 10029 USA.
RP Murrough, JW (reprint author), Mt Sinai Sch Med, Dept Psychiat, Mood & Anxiety Disorders Program, Box 1230, New York, NY 10029 USA.
EM james.murrough@mssm.edu
RI Murrough, James/J-7129-2013
OI Murrough, James/0000-0001-6286-1242
FU Mount Sinai School of Medicine
FX Dr. Charney has been named as an inventor on a use-patent of ketamine
for the treatment of depression. If ketamine were shown to be effective
in the treatment of depression and received approval from the Food and
Drug Administration for this indication, Dr. Chamey and the Mount Sinai
School of Medicine could benefit financially. All other authors report
no completing interests.
NR 175
TC 103
Z9 106
U1 20
U2 68
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1074-7427
J9 NEUROBIOL LEARN MEM
JI Neurobiol. Learn. Mem.
PD NOV
PY 2011
VL 96
IS 4
SI SI
BP 553
EP 563
DI 10.1016/j.nlm.2011.06.006
PG 11
WC Behavioral Sciences; Neurosciences; Psychology; Psychology,
Multidisciplinary
SC Behavioral Sciences; Neurosciences & Neurology; Psychology
GA 859UD
UT WOS:000297900400006
PM 21704176
ER
PT J
AU Bowman, CC
Johnson, L
Cox, M
Rick, C
Dougherty, M
Alt-White, AC
Wyte, T
Needleman, J
Dobalian, A
AF Bowman, Candice C.
Johnson, Linda
Cox, Malcolm
Rick, Catherine
Dougherty, Mary
Alt-White, Anna C.
Wyte, Tamar
Needleman, Jack
Dobalian, Aram
TI The Department of Veterans Affairs Nursing Academy (VANA): Forging
strategic alliances with schools of nursing to address nursing's
workforce needs
SO NURSING OUTLOOK
LA English
DT Article
DE Partnerships; Clinical instruction; Veterans Affairs
ID INTERORGANIZATIONAL RELATIONSHIPS; EDUCATION
AB In 2007, the Department of Veterans Affairs (VA) established the VA Nursing Academy (VANA), a 5-year, $60-million pilot program funding 15 partnerships between schools of nursing and local VA health care facilities nationwide, to expand nursing faculty, enhance clinical faculty development, increase nursing student enrollment, and promote educational innovations. VA is an ideal setting for educating nursing students owing to a well-educated registered nurse staff, an array of traditional and nontraditional settings, a state-of-the-art computerized electronic health record system, and a unique patient population. Challenges related to the complex nature of VANA partnerships, conceptualized as strategic alliances created between disparate subunits, each embedded in a larger organization, require careful governance to ensure smooth implementation. To ensure the program's aims are met, a 6-year national evaluation has been funded to help identify which strategies best achieve VANA's goals. The speed of economic recovery and the resulting changes in the nursing workforce are important determinants of VANA's future.
C1 [Bowman, Candice C.; Wyte, Tamar; Dobalian, Aram] VA Greater Los Angeles Healthcare Syst, HSR&D Ctr Study Healthcare Provider Behav, Sepulveda, CA 91343 USA.
[Johnson, Linda; Cox, Malcolm; Rick, Catherine; Dougherty, Mary; Alt-White, Anna C.] Vet Affairs Nursing Acad, Off Acad Affiliat, Dept Vet Affairs, Washington, DC USA.
[Needleman, Jack; Dobalian, Aram] Univ Calif Los Angeles, Sch Publ Hlth, Dept Hlth Serv, Los Angeles, CA 90024 USA.
RP Bowman, CC (reprint author), VA Greater Los Angeles Healthcare Syst, HSR&D Ctr Study Healthcare Provider Behav, 16111 Plummer St 152, Sepulveda, CA 91343 USA.
EM candice.bowman@va.gov
RI Needleman, Jack/I-5461-2013
OI Needleman, Jack/0000-0002-2875-0589
FU Department of Veterans Affairs, Veterans Health Administration, Office
of Academic Affiliations; Department of Veterans Affairs, Veterans
Health Administration, Office of Nursing Service
FX This material is based upon work supported by the Department of Veterans
Affairs, Veterans Health Administration, Offices of Academic
Affiliations and Nursing Service.
NR 31
TC 9
Z9 9
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0029-6554
J9 NURS OUTLOOK
JI Nurs. Outlook
PD NOV-DEC
PY 2011
VL 59
IS 6
BP 299
EP 307
DI 10.1016/j.outlook.2011.04.006
PG 9
WC Nursing
SC Nursing
GA 854IS
UT WOS:000297488800003
PM 21684561
ER
PT J
AU Tache, Y
Stengel, A
Vaudry, H
AF Tache, Yvette
Stengel, Andreas
Vaudry, Hubert
TI Special Issue: Ghrelin
SO PEPTIDES
LA English
DT Editorial Material
ID METABOLISM; PEPTIDES; HORMONE
C1 [Tache, Yvette] Univ Calif Los Angeles, David Geffen Sch Med, Digest Dis Res Ctr Anim Care, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA.
[Stengel, Andreas] Obes Ctr Berlin, Div Psychosomat Med, D-10117 Berlin, Germany.
[Vaudry, Hubert] Univ Rouen, Inserm U982, Lab Neuronal & Neuroendocrine Differentiat & Comm, Int Associated Lab Samuel de Champlain,European I, F-76821 Mont St Aignan, France.
RP Tache, Y (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Digest Dis Res Ctr Anim Care, VA Greater Los Angeles Healthcare Syst, 11301 Wilshire Blvd,CURE Bldg 115, Los Angeles, CA 90073 USA.
EM ytache@mednet.ucla.edu; hubert.vaudry@univ-rouen.fr
NR 12
TC 0
Z9 0
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0196-9781
J9 PEPTIDES
JI Peptides
PD NOV
PY 2011
VL 32
IS 11
SI SI
BP 2151
EP 2152
DI 10.1016/j.peptides.2011.10.015
PG 2
WC Biochemistry & Molecular Biology; Endocrinology & Metabolism;
Pharmacology & Pharmacy
SC Biochemistry & Molecular Biology; Endocrinology & Metabolism;
Pharmacology & Pharmacy
GA 863XO
UT WOS:000298201800001
PM 22024141
ER
PT J
AU Stengel, A
Wang, LX
Tache, Y
AF Stengel, Andreas
Wang, Lixin
Tache, Yvette
TI Stress-related alterations of acyl and desacyl ghrelin circulating
levels: Mechanisms and functional implications
SO PEPTIDES
LA English
DT Review
DE Abdominal surgery; Food intake; Ghrelin-O-acyltransferase (GOAT);
Motility; Somatostatin 2 receptor
ID GROWTH-HORMONE SECRETAGOGUE; POSTOPERATIVE GASTRIC ILEUS; GENE-RELATED
PEPTIDE; O-ACYLTRANSFERASE GOAT; FASTED PLASMA GHRELIN; ACUTE LUNG
INJURY; RAT STOMACH; FOOD-INTAKE; MESSENGER-RNA; RECEPTOR EXPRESSION
AB Ghrelin is the only known peripherally produced and centrally acting peptide hormone that stimulates food intake and digestive functions. Ghrelin circulates as acylated and desacylated forms and recently the acylating enzyme, ghrelin-O-acyltransferase (GOAT) and the de-acylating enzyme, thioesterase 1/lysophospholipase 1 have been identified adding new layers of complexity to the regulation of ghrelin. Stress is known to alter gastrointestinal motility and food intake and was recently shown to modify circulating ghrelin and GOAT levels with differential responses related to the type of stressors including a reduction induced by physical stressors (abdominal surgery and immunological/endotoxin injection, exercise) and elevation by metabolic (cold exposure, acute fasting and caloric restriction) and psychological stressors. However, the pathways underlying the alterations of ghrelin under these various stress conditions are still largely to be defined and may relate to stress-associated autonomic changes. There is evidence that alterations of circulating ghrelin may contribute to the neuroendocrine and behavioral responses along with sustaining the energetic requirement needed upon repeated exposure to stressors. A better understanding of these mechanisms will allow targeting components of ghrelin signaling that may improve food intake and gastric motility alterations induced by stress. Published by Elsevier Inc.
C1 [Tache, Yvette] VA Greater Los Angeles Healthcare Syst, CURE Digest Dis Res Ctr, Los Angeles, CA 90073 USA.
[Stengel, Andreas; Wang, Lixin; Tache, Yvette] Univ Calif Los Angeles, David Geffen Sch Med, CURE Digest Dis Res Ctr, Los Angeles, CA 90095 USA.
[Stengel, Andreas; Wang, Lixin; Tache, Yvette] Univ Calif Los Angeles, David Geffen Sch Med, Ctr Neurobiol Stress & Womens Hlth, Div Digest Dis, Los Angeles, CA 90095 USA.
[Stengel, Andreas] Univ Med, Charite, Dept Med, Div Psychosomat Med & Psychotherapy, Berlin, Germany.
RP Tache, Y (reprint author), VA Greater Los Angeles Healthcare Syst, CURE Digest Dis Res Ctr, Bldg 115,Room 117,11301 Wilshire Blvd, Los Angeles, CA 90073 USA.
EM andreas.stengel@charite.de; ytache@mednet.ucla.edu
FU VA; NIH [DK-33061, DK-57238]
FX Y.T. is recipient of VA Research Career Scientist Award and NIH
R01grants DK-33061, DK-57238 and VA Merit Award. We thank Ms. Eugenia Hu
for careful reading of the manuscript.
NR 141
TC 28
Z9 29
U1 1
U2 10
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0196-9781
EI 1873-5169
J9 PEPTIDES
JI Peptides
PD NOV
PY 2011
VL 32
IS 11
SI SI
BP 2208
EP 2217
DI 10.1016/j.peptides.2011.07.002
PG 10
WC Biochemistry & Molecular Biology; Endocrinology & Metabolism;
Pharmacology & Pharmacy
SC Biochemistry & Molecular Biology; Endocrinology & Metabolism;
Pharmacology & Pharmacy
GA 863XO
UT WOS:000298201800007
PM 21782868
ER
PT J
AU Vu, JP
Wang, HS
Germano, PM
Pisegna, JR
AF Vu, John P.
Wang, Hank S.
Germano, Patrizia M.
Pisegna, Joseph R.
TI Ghrelin in neuroendocrine tumors
SO PEPTIDES
LA English
DT Review
DE Ghrelin; Metastatic neuroendocrine tumors; Endogenous; Orexigenic;
Cancer cachexia
ID GROWTH-HORMONE SECRETAGOGUE; DES-ACYL GHRELIN; AGOUTI-RELATED PROTEIN;
CARCINOID-TUMORS; MESSENGER-RNA; GASTROINTESTINAL-TRACT; ENDOCRINE
TUMORS; CHROMOGRANIN-A; SOMATOSTATIN ANALOGS; HELICOBACTER-PYLORI
AB Ghrelin is a 28 amino acid peptide, primarily produced by the oxyntic mucosa X/A like neuroendocrine cells in the stomach. It is also found in the small intestine, hypothalamus, pituitary gland, pancreas, heart, adipose tissue, and immune system. In gastrointestinal neuroendocrine tumors (NETs) ghrelin release has been well documented. Ghrelin is a brain-gut circuit peptide with an important role in the physiological regulation of appetite, response to hunger and starvation, metabolic and endocrine functions as energy expenditure, gastric motility and acid secretion, insulin secretion and glucose homeostasis, as well as in the potential connection to the central nervous system. Recently, there has been a significant interest in the biological effects of ghrelin in NETs. In this article, we present a comprehensive review of ghrelin's expression and a brief summary of ghrelin's physiological role in NETs patients with carcinoids, type A chronic atrophic gastritis (CAG), with or without MEN-1, and with and without liver metastases. We hope, with the research reviewed here, to offer compelling evidence of the potential significance of ghrelin in NETs, as well as to provide a useful guide to the future work in this area. Published by Elsevier Inc.
C1 [Vu, John P.; Wang, Hank S.; Germano, Patrizia M.; Pisegna, Joseph R.] Vet Adm GIAHS, Dept Gastroenterol & Hepatol, Los Angeles, CA 90073 USA.
[Vu, John P.; Wang, Hank S.; Germano, Patrizia M.; Pisegna, Joseph R.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA.
RP Pisegna, JR (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Div Gastroenterol & Hepatol, VA Greater Los Angeles Healthcare Syst, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA.
EM jpisegna@ucla.edu
NR 73
TC 7
Z9 7
U1 1
U2 8
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0196-9781
J9 PEPTIDES
JI Peptides
PD NOV
PY 2011
VL 32
IS 11
SI SI
BP 2340
EP 2347
DI 10.1016/j.peptides.2011.10.006
PG 8
WC Biochemistry & Molecular Biology; Endocrinology & Metabolism;
Pharmacology & Pharmacy
SC Biochemistry & Molecular Biology; Endocrinology & Metabolism;
Pharmacology & Pharmacy
GA 863XO
UT WOS:000298201800025
PM 22041110
ER
PT J
AU Maestas, KL
Benge, JF
Pastorek, NJ
LeMaire, A
Darrow, R
AF Maestas, Kacey Little
Benge, Jared F.
Pastorek, Nicholas J.
LeMaire, Ashley
Darrow, Rachel
TI Factor Structure of Posttraumatic Stress Disorder Symptoms in OEF/OIF
Veterans Presenting to a Polytrauma Clinic
SO REHABILITATION PSYCHOLOGY
LA English
DT Article
DE factor analysis; posttraumatic stress; veterans; mild traumatic brain
injury
ID TRAUMATIC BRAIN-INJURY; CONFIRMATORY FACTOR-ANALYSIS; PERSISTENT
POSTCONCUSSIVE SYMPTOMS; MEASUREMENT INVARIANCE; WAR VETERANS; CHRONIC
PAIN; CHECKLIST; COMBAT; IRAQ; AFGHANISTAN
AB Objective: A significant number of Operation Iraqi Freedom/Operation Enduring Freedom (OEF/OIF) veterans are returning from deployment and presenting to Veterans Health Administration (VHA) polytrauma clinics with elevated rates of posttraumatic stress disorder (PTSD) and mild traumatic brain injury (mTBI). Inherent to the accurate assessment and treatment of this diagnostically complex group of veterans is the assumption that the construct of PTSD is the same in this population as in other trauma groups. To our knowledge, no previous study has examined the structure of PTSD in this relevant and fast-growing population of treatment-seeking OEF/OIF veterans. Evidence suggests that the latent structure of PTSD symptoms is best represented by a four-factor model, rather than the three-factor model found in the current DSM-IV-TR. Thus, we examined the three and four-factor models using the PTSD Check List-Civilian (PCL-C) in a sample of treatment-seeking OEF/OIF veterans seen through a VHA polytrauma clinic. Method: A chart review was conducted for OEF/OIF veterans (N = 361) seen through a VHA outpatient polytrauma clinic from September 2007 through August 2008. Participants completed the PCL-C as part of a comprehensive polytrauma evaluation. Results: Confirmatory factor analyses showed that the DSM-IV-TR three-factor model did not fit the data well. A direct comparison showed that the four-factor model provided a superior fit relative to the three-factor model. Conclusion: Results extend the generalizability of the four-factor model to OEF/OIF veterans presenting to Veterans Health Administration (VHA) polytrauma clinics.
C1 [Maestas, Kacey Little] Michael E DeBakey VA Med Ctr, Houston, TX 77030 USA.
[Maestas, Kacey Little; Pastorek, Nicholas J.] Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX 77030 USA.
[Benge, Jared F.; Pastorek, Nicholas J.] Jack C Montgomery VA Med Ctr, Rehabil Care Line, Muskogee, OK USA.
[LeMaire, Ashley] Mem Hosp Gulfport, Dept Neurosci & Rehabil, Gulfport, MS USA.
[Darrow, Rachel] Ralph H Johnson VA Med Ctr, Mental Hlth Care Line, Charleston, SC USA.
RP Pastorek, NJ (reprint author), Michael E DeBakey VA Med Ctr, 2002 Holcombe Blvd,RCL 117, Houston, TX 77030 USA.
EM nicholas.pastorek@va.gov
RI Schueter, nicos/A-3625-2014
NR 51
TC 7
Z9 7
U1 2
U2 6
PU EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC
PI WASHINGTON
PA 750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA
SN 0090-5550
J9 REHABIL PSYCHOL
JI Rehabil. Psychol.
PD NOV
PY 2011
VL 56
IS 4
BP 366
EP 373
DI 10.1037/a0025447
PG 8
WC Psychology, Clinical; Rehabilitation
SC Psychology; Rehabilitation
GA 862AQ
UT WOS:000298062600010
PM 21928917
ER
PT J
AU Scalapino, KJ
Thomas, CR
AF Scalapino, Kenneth J.
Thomas, Charles R., Jr.
TI Preface Paraneoplastic and Cancer Treatment-Related Rheumatic Disorders
SO RHEUMATIC DISEASE CLINICS OF NORTH AMERICA
LA English
DT Editorial Material
C1 [Scalapino, Kenneth J.] Portland VA Med Ctr, Rheumatol Sect, Portland, OR 97239 USA.
[Thomas, Charles R., Jr.] Oregon Hlth & Sci Univ, Knight Canc Inst, Dept Radiat Med, Portland, OR 97239 USA.
RP Scalapino, KJ (reprint author), Portland VA Med Ctr, Rheumatol Sect, 3710 SW US Verterans Hosp Rd, Portland, OR 97239 USA.
EM Kenneth.Scalapino@va.gov; thomasch@ohsu.edu
NR 0
TC 0
Z9 0
U1 0
U2 0
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0889-857X
J9 RHEUM DIS CLIN N AM
JI Rheum. Dis. Clin. North Am.
PD NOV
PY 2011
VL 37
IS 4
BP IX
EP X
DI 10.1016/j.rdc.2011.09.005
PG 2
WC Rheumatology
SC Rheumatology
GA 865KU
UT WOS:000298310600001
PM 22075202
ER
PT J
AU Ashouri, JF
Daikh, DI
AF Ashouri, Judith F.
Daikh, David I.
TI Rheumatic Manifestations of Cancer
SO RHEUMATIC DISEASE CLINICS OF NORTH AMERICA
LA English
DT Article
DE Malignancy; Paraneoplastic manifestation; Rheumatic disease; Fasciitis;
POEMS; Inflammatory myopathy
ID SERONEGATIVE SYMMETRICAL SYNOVITIS; ENDOTHELIAL GROWTH-FACTOR;
POPULATION-BASED COHORT; HENOCH-SCHONLEIN PURPURA; GIANT-CELL ARTERITIS;
PRIMARY HYPERTROPHIC OSTEOARTHROPATHY; ASPARTATE RECEPTOR ENCEPHALITIS;
FASCIITIS-PANNICULITIS SYNDROME; DERMATOMYOSITIS SINE MYOSITIS; PITTING
EDEMA SYNDROME
AB The wide range of rheumatic and musculoskeletal conditions that can appear in association with cancer emphasizes that rheumatic disease is a major component of the spectrum of paraneoplastic manifestations. Although the pathogenetic mechanisms by which neoplasia causes these manifestations are only partially understood in select cases, many are because of immune-mediated effects stimulated by tumor antigens of endocrine factors produced by tumors. The broad overlap in signs and symptoms of occult malignancy and systemic rheumatic disease emphasizes the importance of considering and investigating the possibility of occult malignancy in the evaluation of patients with these symptoms.
C1 [Ashouri, Judith F.; Daikh, David I.] Univ Calif San Francisco, Dept Med, Div Rheumatol, San Francisco, CA 94143 USA.
[Ashouri, Judith F.; Daikh, David I.] San Francisco VA Med Ctr, Dept Med, San Francisco, CA USA.
RP Daikh, DI (reprint author), Univ Calif San Francisco, Dept Med, Div Rheumatol, 400 Parnassus, San Francisco, CA 94143 USA.
EM david.daikh@ucsf.edu
NR 156
TC 2
Z9 2
U1 1
U2 3
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0889-857X
J9 RHEUM DIS CLIN N AM
JI Rheum. Dis. Clin. North Am.
PD NOV
PY 2011
VL 37
IS 4
BP 489
EP +
DI 10.1016/j.rdc.2011.09.001
PG 18
WC Rheumatology
SC Rheumatology
GA 865KU
UT WOS:000298310600002
PM 22075194
ER
PT J
AU Lipton, S
Schwab, P
AF Lipton, Sarah
Schwab, Pascale
TI Neoplasm Mimics of Rheumatologic Presentations: Sialadenitis, Ocular
Masquerade Syndromes, Retroperitoneal Fibrosis, and Regional Pain
Syndromes
SO RHEUMATIC DISEASE CLINICS OF NORTH AMERICA
LA English
DT Article
DE Cancer; Sialadenitis; IgG4-related syndrome; Ocular masquerade syndrome;
Retroperitoneal fibrosis; Complex regional pain syndrome; Amyloidosis
ID REFLEX SYMPATHETIC DYSTROPHY; DIFFUSE INFILTRATING RETINOBLASTOMA;
IGG4-RELATED SCLEROSING DISEASE; PRIMARY INTRAOCULAR LYMPHOMA; PRIMARY
SYSTEMIC AMYLOIDOSIS; SALIVARY-GLAND TUMORS; SJOGRENS-SYNDROME;
CLINICAL-FEATURES; MIKULICZS-DISEASE; LONG-TERM
AB This article reviews a group of miscellaneous malignant conditions that may mimic rheumatologic diseases. Primary salivary gland cancer as well as lymphoproliferative conditions such as lymphoma and IgG4 related syndromes should be considered when evaluating a patient with sialadenosis. Primary intraocular lymphoma and melanoma in adults as well as leukemia and retinoblastoma in children may present as idiopathic ocular inflammation and require a high index of suspicion. Retroperitoneal fibrosis may mimic lymphoma or a solid malignancy and poses diagnostic challenges. Regional pain syndromes, such as complex regional pain and carpal tunnel syndromes, may be a manifestation of cancer and amyloidosis respectively. Awareness of these rare mimics may serve in guiding diagnostic investigations.
C1 [Lipton, Sarah; Schwab, Pascale] Oregon Hlth & Sci Univ, Portland Vet Affairs Med Ctr, Div Arthrit & Rheumat Dis, Portland, OR 97239 USA.
RP Schwab, P (reprint author), Oregon Hlth & Sci Univ, Portland Vet Affairs Med Ctr, Div Arthrit & Rheumat Dis, 3181 SW Sam Jackson Pk Rd,OP09, Portland, OR 97239 USA.
EM schwabp@ohsu.edu
NR 100
TC 2
Z9 2
U1 0
U2 1
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0889-857X
EI 1558-3163
J9 RHEUM DIS CLIN N AM
JI Rheum. Dis. Clin. North Am.
PD NOV
PY 2011
VL 37
IS 4
BP 623
EP +
DI 10.1016/j.rdc.2011.09.004
PG 17
WC Rheumatology
SC Rheumatology
GA 865KU
UT WOS:000298310600009
PM 22075201
ER
PT J
AU Choi, AI
Karter, AJ
Liu, JY
Young, BA
Go, AS
Schillinger, D
AF Choi, Andy I.
Karter, Andrew J.
Liu, Jennifer Y.
Young, Bessie A.
Go, Alan S.
Schillinger, Dean
TI Ethnic Differences in the Development of Albuminuria: The DISTANCE Study
SO AMERICAN JOURNAL OF MANAGED CARE
LA English
DT Article
ID CHRONIC KIDNEY-DISEASE; GLOMERULAR-FILTRATION-RATE;
CARDIOVASCULAR-DISEASE; GLYCEMIC CONTROL; POPULATION; ATHEROSCLEROSIS;
DISPARITIES; HEALTH; PREVALENCE; MORTALITY
AB Objectives: To determine whether ethnic differences in the incidence of albuminuria are present in patients with diabetes, and to identify social, behavioral, and provider factors that explain ethnic differences.
Study Design: Survey follow-up design with a race-stratified baseline survey (2005-2006) in diabetic patients from a nonprofit, fully integrated healthcare system in Northern California. We followed the 10,596 respondents (30% whites, 20% blacks, 23% Hispanics, 14% Asians, and 13% Filipinos) without evidence of prevalent albuminuria at baseline.
Methods: Incident albuminuria was defined by positive dipstick urinalysis (>= 1) or urine albumin to creatinine level (>= 30 mg/g), and confirmed with repeat testing at least 3 months later.
Results: The 27,292 person-years of observation yielded 981 incident albuminuria events. Age-standardized rates of albuminuria (per 1000 person-years) ranged from 13.6 (95% confidence interval [CI] 10.5-17.0) in whites to 27.8 (Cl 18.2-38.3) in blacks. In fully adjusted Cox models, the hazard ratio for blacks (1.22, 95% Cl 1.09-1.38), Asians (1.35, 95% Cl 1.13-1.61), and Filipinos (1.93, 95% Cl 1.61-2.32), but not Hispanics, was significantly greater than it was for whites. In some cases, point estimates changed markedly from the base model when fully adjusted for potential confounders. Moreover, adjustment for an array of potentially mediating factors explained only a small proportion of the observed ethnic disparities.
Conclusions: Despite uniform medical care coverage, Filipinos, blacks, and Asians with diabetes developed albuminuria at higher rates than white and Hispanic adults. (Am J Manag Care. 2071;17(11):737-745)
C1 [Karter, Andrew J.; Liu, Jennifer Y.] Kaiser Permanente, Div Res, Oakland, CA 94612 USA.
[Choi, Andy I.; Schillinger, Dean] Univ Calif San Francisco, Dept Med, San Francisco, CA USA.
[Choi, Andy I.] San Francisco VA Med Ctr, San Francisco, CA USA.
[Karter, Andrew J.; Go, Alan S.] Univ Washington, Dept Hlth Serv Res, Seattle, WA 98195 USA.
VA Puget Sound Healthcare Syst, Seattle Epidemiol Res & Informat Ctr, Seattle, WA USA.
[Young, Bessie A.] Univ Washington, Dept Med, Seattle, WA USA.
[Schillinger, Dean] Univ Calif San Francisco, San Francisco Gen Hosp, Ctr Vulnerable Populat, San Francisco, CA USA.
RP Karter, AJ (reprint author), Kaiser Permanente, Div Res, 2000 Broadway, Oakland, CA 94612 USA.
EM andy.j.karter@kp.org
FU National Institute of Diabetes, Digestive and Kidney Diseases
[R01DK081796, RC1 DK086178, R01 DK080726, R01DK65664]; National
Institutes of Health [P60 DK20595]
FX This work was supported by the National Institute of Diabetes, Digestive
and Kidney Diseases (grants R01DK081796, RC1 DK086178, R01 DK080726, and
R01DK65664). The Diabetes Research and Training Center was also
supported by the National Institutes of Health (grant P60 DK20595).
NR 28
TC 2
Z9 2
U1 0
U2 1
PU MANAGED CARE & HEALTHCARE COMMUNICATIONS LLC
PI PLAINSBORO
PA 666 PLAINSBORO RD, STE 300, PLAINSBORO, NJ 08536 USA
SN 1088-0224
J9 AM J MANAG CARE
JI Am. J. Manag. Care
PD NOV
PY 2011
VL 17
IS 11
BP 737
EP 745
PG 9
WC Health Care Sciences & Services; Health Policy & Services; Medicine,
General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA 854XO
UT WOS:000297528300002
PM 22084893
ER
PT J
AU Kim, H
Helmer, DA
Zhao, ZL
Boockvar, K
AF Kim, Hongsoo
Helmer, Drew A.
Zhao, Zhonglin
Boockvar, Kenneth
TI Potentially Preventable Hospitalizations Among Older Adults With
Diabetes
SO AMERICAN JOURNAL OF MANAGED CARE
LA English
DT Article
ID MULTIPLE CHRONIC CONDITIONS; CARE-SENSITIVE CONDITIONS; AVOIDABLE
HOSPITALIZATIONS; DISPARITIES; MELLITUS; QUALITY; READMISSIONS;
POPULATION; PREVALENCE; INSURANCE
AB Objectives: To examine prevalence of and factors associated with different types of potentially preventable hospitalizations (PPHs) among older adults with diabetes.
Study Design: Population-based secondary analysis.
Methods: We analyzed the California State Inpatient Databases, 2005 to 2006. PPHs for 3 acute and 5 chronic ambulatory care-sensitive conditions relevant for older adults were defined by applying the Prevention Quality Indicator algorithm developed by the Agency for Health Research and Quality. Prevalence and costs of PPHs for acute conditions (acute PPHs) and chronic conditions (chronic PPHs) were examined. Associations of sociodemographic and health-related factors as well as hospitalization history with both types of PPH were estimated.
Results: One-fifth of 555,538 hospitalizations of adults 65 years and older with diabetes were PPHs. Of these, 43.7% were acute PPHs and 56.3% were chronic PPHs. The total hospital cost associated with these PPHs was more than $1.1 billion. Having Medi-Cal as the primary payer and hospitalization through the emergency department were positively associated with both types of PPH. Acute PPH rates were lower, but chronic PPH rates were higher, among blacks, patients with multiple chronic conditions, and those with previous admission(s) in the same year.
Conclusions: PPHs for common medical conditions are costly and prevalent among older patients with diabetes, suggesting a need for more comprehensive primary care, beyond glycemic control. The groups at risk for acute and chronic PPHs may differ, which suggests that more targeted and tailored approaches are necessary to reduce the rates of each type of PPH. (Am J Manag Care. 2011;17(11):e419-e426)
C1 [Kim, Hongsoo] Seoul Natl Univ, Grad Sch Publ Hlth, Seoul 151742, South Korea.
[Kim, Hongsoo] Seoul Natl Univ, Inst Hlth & Environm, Seoul 151742, South Korea.
[Helmer, Drew A.] Michael E DeBakey VA Med Ctr, Houston, TX USA.
[Helmer, Drew A.] Baylor Coll Med, Houston, TX 77030 USA.
[Zhao, Zhonglin] NYU, Coll Dent, New York, NY USA.
[Boockvar, Kenneth] James J Peters VA Med Ctr, Bronx, NY USA.
[Boockvar, Kenneth] Mt Sinai Sch Med, New York, NY USA.
[Boockvar, Kenneth] Jewish Home Lifecare, New York, NY USA.
RP Kim, H (reprint author), Seoul Natl Univ, Grad Sch Publ Hlth, Seoul 151742, South Korea.
EM hk65@snu.ac.kr
FU Greenwall Foundation
FX Dr Boockvar was supported by the Greenwall Foundation. The authors thank
the anonymous reviewers for their insightful comments.
NR 25
TC 10
Z9 10
U1 0
U2 9
PU MANAGED CARE & HEALTHCARE COMMUNICATIONS LLC
PI PLAINSBORO
PA 666 PLAINSBORO RD, STE 300, PLAINSBORO, NJ 08536 USA
SN 1088-0224
J9 AM J MANAG CARE
JI Am. J. Manag. Care
PD NOV
PY 2011
VL 17
IS 11
BP E419
EP E426
PG 8
WC Health Care Sciences & Services; Health Policy & Services; Medicine,
General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA 854XO
UT WOS:000297528300006
PM 22200058
ER
PT J
AU Carpenter, DJ
Fong, R
Kraus, JE
Davies, JT
Moore, C
Thase, ME
AF Carpenter, David J.
Fong, Regan
Kraus, John E.
Davies, John T.
Moore, Christine
Thase, Michael E.
TI Meta-Analysis of Efficacy and Treatment-Emergent Suicidality in Adults
by Psychiatric Indication and Age Subgroup Following Initiation of
Paroxetine Therapy: A Complete Set of Randomized Placebo-Controlled
Trials
SO JOURNAL OF CLINICAL PSYCHIATRY
LA English
DT Review
ID SEROTONIN REUPTAKE INHIBITORS; NEW-YORK-CITY; ANTIDEPRESSANT TREATMENT;
CLINICAL-TRIALS; MAJOR DEPRESSION; RISK; RATES; ADOLESCENTS;
ASSOCIATION; PREVENTION
AB Objective: This meta-analysis of placebo-controlled paroxetine trials examines suicidality incidence in adults, focusing on disorder and age as potential risk factors. The findings are put in context with an efficacy meta-analysis of the same trial datasets.
Data Sources: GlaxoSmithKline paroxetine clinical trial database(s).
Study Selection: All double-blind, randomized, placebo-controlled, parallel-group studies of paroxetine therapy in adults enrolling at least 30 patients total were included in the analysis. The dataset comprised 14,911 patients from 61 trials.
Data Extraction: Possible cases of suicidality were identified and blindly categorized by an expert panel, using methodology previously used by the US Food and Drug Administration. Incidences of suicidal behavior (preparatory act, suicide attempt, or completed suicide) and any suicidality (suicidal behavior or ideation) were compared between paroxetine and placebo. Efficacy assessments were based on standard depression rating scales (eg, Hamilton Depression Rating Scale or Montgomery-Asberg Depression Rating Scale) and Clinical Global Impressions Improvement scale (CGI-I) scores.
Results: In the primary dataset, ie, all disorders combined, there were no significant differences between paroxetine and placebo for overall suicidality (suicidal behavior or ideation: n/n = 83/8,958 [0.93%] vs n/n = 65/5,953 [1.09%], respectively; OR = 0.9 [95% CI, 0.7-1.3]; P = .649) or for suicidal behavior specifically (n/n = 50/8,958 [0.56%] vs n/n = 40/5,953 [0.67%], respectively; OR = 1.2 [95% CI, 0.8-1.9]; P = .483). However, in patients with major depressive disorder (MDD), a greater incidence of suicidal behavior occurred in paroxetine-treated patients than in placebo-treated patients (n/n = 11/3,455 [0.32%] vs n/n = 1/1,978 [0.05%], respectively; OR = 6.7 [95% CI, 1.1-149.4]; P = .058). Across all indications, a higher incidence of suicidal behavior occurred in paroxetine-treated versus placebo-treated adults aged 18 to 24 years (n/n = 17/776 [2.19%] vs n/n = 5/542 [0.92%], respectively; OR = 2.4 [95% CI, 0.9-7.3]). In older age groups, no increase in suicidality was observed. Efficacy was demonstrated in all disorders evaluated, including MDD.
Conclusions: Across all disorders, overall suicidality incidence was similar between paroxetine and placebo. However, a higher frequency of suicidal behavior occurred with paroxetine in MDD, which was largely explained by the higher incidence in young adults. These data support the efficacy of paroxetine therapy; however, they also highlight the need for careful monitoring of suicidality during antidepressant therapy, particularly in younger adults.
C1 [Fong, Regan] GlaxoSmithKline Inc, Discovery Med, King Of Prussia, PA 19406 USA.
[Kraus, John E.] GlaxoSmithKline Inc, Res Triangle Pk, NC USA.
[Davies, John T.] GlaxoSmithKline Inc, Harlow, Essex, England.
[Moore, Christine] I3 Res, Cary, NC USA.
[Thase, Michael E.] Univ Penn, Sch Med, Dept Psychiat, Philadelphia, PA 19104 USA.
[Thase, Michael E.] Philadelphia Vet Affairs Med Ctr, Dept Psychiat, Philadelphia, PA USA.
[Thase, Michael E.] Univ Pittsburgh, Med Ctr, Dept Psychiat, Pittsburgh, PA 15260 USA.
RP Fong, R (reprint author), GlaxoSmithKline Inc, Discovery Med, 2301 Renaissance Blvd, King Of Prussia, PA 19406 USA.
EM Regan.2.fong@GSK.com
FU GlaxoSmithKline; Eli Lilly; National Institute of Mental Health;
Sepracor; American Psychiatric Publishing; Guilford Publications; Herald
House; W. W. Norton Company
FX Drs Carpenter, Fong, and Kraus and Mr Davies are employees of and
shareholders in GlaxoSmithKline. Dr Moore is an employee of i3 Research;
funding for her contribution to this article was provided by
GlaxoSmithKline. Dr Thase has been an advisor or consultant to
AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Forest, GlaxoSmithKline,
MedAvante, Neuronetics, Novartis, Otsuka, Ortho-McNeil, Pfizer,
Schering-Plough, Shire, Supernus, Takeda, and Transcept; has received
grant support from Eli Lilly, GlaxoSmithKline, National Institute of
Mental Health, and Sepracor; has served on speakers bureaus for
AstraZeneca, Bristol-Myers Squibb, Eli Lilly, and Pfizer; has equity
holdings in MedAvante; and has received royalties from American
Psychiatric Publishing, Guilford Publications, Herald House, and W. W.
Norton & Company. Dr Thase's spouse is an employee of Advogent.
NR 75
TC 21
Z9 21
U1 4
U2 10
PU PHYSICIANS POSTGRADUATE PRESS
PI MEMPHIS
PA P O BOX 240008, MEMPHIS, TN 38124 USA
SN 0160-6689
J9 J CLIN PSYCHIAT
JI J. Clin. Psychiatry
PD NOV
PY 2011
VL 72
IS 11
BP 1503
EP 1514
DI 10.4088/JCP.08m04927blu
PG 12
WC Psychology, Clinical; Psychiatry
SC Psychology; Psychiatry
GA 855ME
UT WOS:000297567700009
PM 21367354
ER
PT J
AU Carpenter, DJ
Fong, R
Kraus, JE
Davies, JT
Moore, C
Thase, ME
AF Carpenter, David J.
Fong, Regan
Kraus, John E.
Davies, John T.
Moore, Christine
Thase, Michael E.
TI Odd Odds Reply
SO JOURNAL OF CLINICAL PSYCHIATRY
LA English
DT Letter
C1 [Carpenter, David J.; Fong, Regan] GlaxoSmithKline Inc, King Of Prussia, PA USA.
[Moore, Christine] I3 Res, Cary, NC USA.
[Thase, Michael E.] Univ Penn, Sch Med, Dept Psychiat, Philadelphia, PA 19104 USA.
[Thase, Michael E.] Philadelphia Vet Affairs Med Ctr, Dept Psychiat, Philadelphia, PA USA.
[Thase, Michael E.] Univ Pittsburgh, Med Ctr, Dept Psychiat, Pittsburgh, PA 15260 USA.
RP Carpenter, DJ (reprint author), GlaxoSmithKline Inc, King Of Prussia, PA USA.
EM Regan.2.Fong@gsk.com
NR 1
TC 0
Z9 0
U1 0
U2 0
PU PHYSICIANS POSTGRADUATE PRESS
PI MEMPHIS
PA P O BOX 240008, MEMPHIS, TN 38124 USA
SN 0160-6689
J9 J CLIN PSYCHIAT
JI J. Clin. Psychiatry
PD NOV
PY 2011
VL 72
IS 11
BP 1559
EP 1559
DI 10.4088/JCP.11lr07373a
PG 1
WC Psychology, Clinical; Psychiatry
SC Psychology; Psychiatry
GA 855ME
UT WOS:000297567700020
ER
PT J
AU Odierna, DH
Afable-Munsuz, A
Ikediobi, O
Beattie, M
Knight, S
Ko, M
Wilson, A
Ponce, NA
AF Odierna, Donna H.
Afable-Munsuz, Aimee
Ikediobi, Ogechi
Beattie, Mary
Knight, Sara
Ko, Michelle
Wilson, Adrienne
Ponce, Ninez A.
TI Early developments in gene-expression profiling of breast tumors:
potential for increasing black-white patient disparities in breast
cancer outcomes?
SO PERSONALIZED MEDICINE
LA English
DT Article
DE African-American women; breast cancer mortality; gene-expression
profiling; personalized medicine; racial disparities; social
determinants of health
ID POLYMERASE-CHAIN-REACTION; CORE BIOPSY-TISSUE; SOCIOECONOMIC-STATUS;
AFRICAN-AMERICAN; PROGNOSTIC ROLE; UNITED-STATES; ONCOTYPE DX; SURVIVAL;
WOMEN; STAGE
AB New prognostic tests, such as gene-expression profiling (GEP) of breast tumors, are expected to prolong survival and improve the quality of life for many breast cancer patients. In this article, we argue that GEP has not been adequately validated in minority populations, and that both biological and social factors might affect the broad utility of these tests in diverse populations. We suggest that the widespread use of this technology could potentially lead to suboptimal treatment for black women, resulting in a further increase in black-white patient disparities in treatment response, morbidity and mortality rates. We argue for the need to build a large and diverse evidence base for GEP and other emerging technologies in personalized medicine.
C1 [Odierna, Donna H.; Afable-Munsuz, Aimee] SUNY Downstate Sch Publ Hlth, Dept Community Hlth Sci, Brooklyn, NY 11203 USA.
[Odierna, Donna H.] Univ Calif San Francisco, Dept Clin Pharm, San Francisco Branch, UC Cochrane Ctr, San Francisco, CA 94118 USA.
[Beattie, Mary; Wilson, Adrienne] Univ Calif San Francisco, Div Gen Internal Med, UCSF Canc Risk Program, San Francisco, CA 94143 USA.
[Knight, Sara] Univ Calif San Francisco, Hlth Serv Res & Dev Serv, San Francisco Vet Affairs Med Ctr, Dept Psychiat, San Francisco, CA 94143 USA.
[Knight, Sara] Univ Calif San Francisco, Hlth Serv Res & Dev Serv, San Francisco Vet Affairs Med Ctr, Dept Urol, San Francisco, CA 94143 USA.
[Ko, Michelle; Ponce, Ninez A.] UCLA Sch Publ Hlth, Dept Hlth Serv, Los Angeles, CA 90095 USA.
RP Odierna, DH (reprint author), Univ Calif San Francisco, Dept Clin Pharm, San Francisco Branch, UC Cochrane Ctr, 3333 Calif St,Box 0613, San Francisco, CA 94118 USA.
EM Donna.Odierna@ucsf.edu
OI Odierna, Donna H/0000-0003-4156-1456; Ponce, Ninez/0000-0001-5151-6718
FU UCSF Center for Translational and Policy Research on Personalized
Medicine (TRANSPERS), National Cancer Institute (NCI) [P01
CA130818-02A1, P01 CA 130818]; UCSF Clinical and Translational Science
Institute, NIH/NCRR UCSF-CTSI [UL-1 RR024131]; Health Services Research
and Development, Interdisciplinary Program [IIR 09-135]; UCSF [NCI 2P50
058207]; Avon Foundation; CSF Center for Clinical and Translational
Research; Flight Attendant Medical Research Foundation
FX The study was supported by the UCSF Center for Translational and Policy
Research on Personalized Medicine (TRANSPERS P01 CA130818-02A1) National
Cancer Institute (NCI) P01 CA 130818 (principal investigator: K
Phillips). The study was also supported by the UCSF Clinical and
Translational Science Institute, NIH/NCRR UCSF-CTSI Grant Number UL-1
RR024131. Health Services Research and Development, Interdisciplinary
Program to Improve Health Care for Veterans with Complex Comorbid
Conditions and Health Services Research and Development Investigator
Initiated Award (IIR 09-135). Mary Beattie is also funded by the UCSF
Breast Specialized Program of Research Excellence (SPORE NCI 2P50
058207) and the Avon Foundation. Adrienne Wilson is funded by the Avon
Foundation. Donna H Odierna is funded by the UCSF Center for Clinical
and Translational Research and the Flight Attendant Medical Research
Foundation. Sara Knight is employed by the Health Services Research and
Development Service San Francisco Veterans Affairs Medical Center. This
paper is the responsibility of the authors and the perspectives
expressed within do not necessarily reflect the views of the Department
of Veterans Affairs. The authors have no other relevant affiliations or
financial involvement with any organization or entity with a financial
interest in or financial conflict with the subject matter or materials
discussed in the manuscript apart from those disclosed.
NR 84
TC 2
Z9 2
U1 0
U2 1
PU FUTURE MEDICINE LTD
PI LONDON
PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3
1QB, ENGLAND
SN 1741-0541
J9 PERS MED
JI Pers. Med.
PD NOV
PY 2011
VL 8
IS 6
BP 669
EP 679
DI 10.2217/PME.11.67
PG 11
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 853ZI
UT WOS:000297463800016
PM 22190978
ER
PT J
AU Healy, JM
Patel, T
Lee, S
Sanchez-Reilly, S
AF Healy, Jennifer M.
Patel, Taral
Lee, Shuko
Sanchez-Reilly, Sandra
TI Do Symptoms Matter When Considering Patients for Phase I Clinical
Trials? A Pilot Study of Older Adults With Advanced Cancer
SO AMERICAN JOURNAL OF HOSPICE & PALLIATIVE MEDICINE
LA English
DT Article
DE phase I; palliative care; symptoms; quality of life; older adults
ID COOPERATIVE-ONCOLOGY-GROUP; PROGNOSTIC-FACTORS; BREAST-CANCER;
CHEMOTHERAPY; TOXICITY; SURVIVAL; BENEFITS; CRITERIA; AGE
AB Older adults (OA) with advanced cancer (AC) undergoing phase 1 clinical trials (PICT) have poor prognosis. There are no studies which describe symptoms experienced by OA. Methods: Retrospective chart review of PICT participants > 60 years. OA were compared by age (> 65 vs 60-65) and by number of symptoms (> 3 vs <= 3). Results: N = 56. Mean age = 67.09; 48.21% female. Median life-expectancy = 5 months (interquartile range = 2-9 months); 80.36% had pain; of those 64% without pain scale. Most did not have interdisciplinary professionals or hospice referrals. Older adults with > 3 symptoms had more admissions (37.5% vs 14.29%; P = .0335), complications (46.43% vs 16.07%; P = .0026), and greater decline in functional status (24 participants > 3 symptoms vs 8; P = .0173). There were no significant differences comparing OA by age. Conclusions: Older adults enrolled in PICT with more symptoms may sacrifice QOL for experimental treatment.
C1 [Healy, Jennifer M.; Sanchez-Reilly, Sandra] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Div Geriatr Gerontol & Palliat Care, San Antonio, TX 78229 USA.
[Patel, Taral; Lee, Shuko; Sanchez-Reilly, Sandra] S Texas Vet Hlth Care Syst, San Antonio, TX USA.
RP Healy, JM (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Div Geriatr Gerontol & Palliat Care, 7703 Floyd Curl Dr,MC 7875, San Antonio, TX 78229 USA.
EM Healyj@uthscsa.edu
NR 18
TC 0
Z9 0
U1 0
U2 1
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1049-9091
J9 AM J HOSP PALLIAT ME
JI Am. J. Hosp. Palliat. Med.
PD NOV
PY 2011
VL 28
IS 7
BP 463
EP 466
DI 10.1177/1049909111400723
PG 4
WC Health Care Sciences & Services
SC Health Care Sciences & Services
GA 854IA
UT WOS:000297487000002
PM 21398266
ER
PT J
AU Tranah, GJ
Blackwell, T
Stone, KL
Ancoli-Israel, S
Paudel, ML
Ensrud, KE
Cauley, JA
Redline, S
Hillier, TA
Cummings, SR
Yaffe, K
AF Tranah, Gregory J.
Blackwell, Terri
Stone, Katie L.
Ancoli-Israel, Sonia
Paudel, Misti L.
Ensrud, Kristine E.
Cauley, Jane A.
Redline, Susan
Hillier, Teresa A.
Cummings, Steven R.
Yaffe, Kristine
CA SOF Res Grp
TI Circadian activity rhythms and risk of incident dementia and mild
cognitive impairment in older women
SO ANNALS OF NEUROLOGY
LA English
DT Article
ID NURSING-HOME PATIENTS; SLEEP-WAKE PATTERNS; AGE-RELATED-CHANGES;
CONSTANT DIM LIGHT; ALZHEIMERS-DISEASE; SUPRACHIASMATIC NUCLEUS;
OSTEOPOROTIC FRACTURES; LOCUS-COERULEUS; WRIST ACTIVITY; OREXIN
AB Objective: Previous cross-sectional studies have observed alterations in activity rhythms in dementia patients but the direction of causation is unclear. We determined whether circadian activity rhythms measured in community-dwelling older women are prospectively associated with incident dementia or mild cognitive impairment (MCI).
C1 [Tranah, Gregory J.] UCSF, San Francisco Coordinating Ctr, Calif Pacific Med Ctr Res Inst, San Francisco, CA 94107 USA.
[Ancoli-Israel, Sonia] Univ Calif San Diego, Dept Psychiat, San Diego, CA 92103 USA.
[Paudel, Misti L.; Ensrud, Kristine E.] Univ Minnesota, Div Epidemiol & Community Hlth, Minneapolis, MN 55455 USA.
[Ensrud, Kristine E.] Minneapolis VA Med Ctr, Ctr Chron Dis Outcomes Res, Minneapolis, MN USA.
[Ensrud, Kristine E.] Univ Minnesota, Dept Med, Minneapolis, MN 55455 USA.
[Cauley, Jane A.] Univ Pittsburgh, Dept Epidemiol, Pittsburgh, PA 15261 USA.
[Redline, Susan] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA.
[Redline, Susan] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Boston, MA 02215 USA.
[Hillier, Teresa A.] Kaiser Permanente Ctr Hlth Res NW Hawaii, Portland, OR USA.
[Yaffe, Kristine] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94107 USA.
[Yaffe, Kristine] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94107 USA.
[Yaffe, Kristine] Univ Calif San Francisco, Dept Epidemiol, San Francisco, CA 94107 USA.
San Francisco VA Med Ctr, San Francisco, CA USA.
RP Tranah, GJ (reprint author), UCSF, San Francisco Coordinating Ctr, Calif Pacific Med Ctr Res Inst, 185 Berry St,Lobby 4,Suite 5700, San Francisco, CA 94107 USA.
EM gtranah@sfcc-cpmc.net
OI Cauley, Jane A/0000-0003-0752-4408
FU National Institutes of Health [AG05407/NIA, AR35582/NIAMS, AG05394/NIA,
AR35583/NIAMS, AG005 407/NIA, AG027576-22/NIA, AG00539422A1,
AG08415/NIA, AG030474/NIA, AG027574-22A1/NIA, AG026 720/NIA]; National
Institute of Aging [K24 AG031155/NIA]; Novartis Pharmaceuticals; NIA;
NIH; Alzheimer Association; DOD; AHAF; California Pacific Medical
Center; Roche Molecular Systems; Sepracor and Litbebook, Inc.; NIAMSD
FX The Study of Osteoporotic Fractures (SOF) and SOF-WISE is supported by
the National Institutes of Health funding (AG05407/NIA/S.R.C.,
AR35582/NIAMS/J.A.C., AG05394/NIA/K.E.E., AR35583/NIAMS/S.A-I., AG005
407/NIA/S.R.C., AG027576-22/NIA/J.A.C., AG00539422A1/NIA/K.E.E.,
AG08415/NIA/S.A-I., AG030474/NIA/G.J.T., AG027574-22A1/NIA/J.A.C., and
AG026 720/NIA/K.L.S.). Dr Kristine Yaffe is supported in part by the
National Institute of Aging grant K24 AG031155/NIA/K.Y. and an
Independent Investigator Award from the Alzheimer's Association.; J.A.C.
receives research funding and consulting fees from Novartis
Pharmaceuticals. K.Y. has received a grant from the NIA; has been a
board member at Pfizer, Medivation, NIMH, and Beeson Scientific
Advisory; has grants/grants pending from the NIH, Alzheimer Association,
DOD, and AHAF; has received travel/accommodations/meeting expenses from
the Alzheimer Association, NIH, Beeson, Japan Geriatrics Society, Wake
Forest University, and State of California DHS. K.E.E. has received a
grant from the NIA; is a federal employee of the Veterans Affairs
Medical Center in Minneapolis, MN; and has received research support
from California Pacific Medical Center, which receives funding from
Roche Molecular Systems. S.R.C., K.L.S., T.B., and G.J.T. are employees
of the California Pacific Medical Center and receive research support
from Roche Molecular Systems. T.B., J.A.C., G.J.T., and K.L.S. have
received a grant from the NIH. S.A.-I. has received a grant from the
NIH; has received grants from Sepracor and Litbebook, Inc.; has served
as an advisor or consultant to Ferring Pharmaceuticals, Inc.,
GlaxoSmithKline, Merck, NeuroVigil, Inc., Neurocrine Biosciences,
Pfizer, Philips Respironics, sanofi-aventis, Sepracor, Inc.,
Schering-Plough, and Purdue Pharma LP. T.H. has received grants from the
NIH (from the NIAMSD and the NIA). S.R. has been under subcontract from
the NIH via California Pacific and is also a recipient of an endowed
professorship at Harvard Medical School, donated by Dr. Peter C.
Farrell, the CEO of RosMed, Inc.
NR 94
TC 100
Z9 101
U1 6
U2 22
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0364-5134
J9 ANN NEUROL
JI Ann. Neurol.
PD NOV
PY 2011
VL 70
IS 5
BP 722
EP 732
DI 10.1002/ana.22468
PG 11
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 857TB
UT WOS:000297741600009
PM 22162057
ER
PT J
AU Mintzer, J
O'Neill, C
AF Mintzer, Jacobo
O'Neill, Courtney
TI Depression in Alzheimer's disease: consequence or contributing factor?
SO EXPERT REVIEW OF NEUROTHERAPEUTICS
LA English
DT Editorial Material
DE Alzheimer's disease; cognitive impairment; dementia; depression
ID SERTRALINE; CRITERIA
C1 [Mintzer, Jacobo] Ralph H Johnson VA Med Ctr, Charleston, SC USA.
[O'Neill, Courtney] Med Univ S Carolina, Dept Neurosci, Charleston, SC 29425 USA.
RP Mintzer, J (reprint author), Ralph H Johnson VA Med Ctr, Charleston, SC USA.
EM mintzerj@musc.edu
FU NIMH NIH HHS [U01MH066136]
NR 10
TC 1
Z9 1
U1 0
U2 2
PU EXPERT REVIEWS
PI LONDON
PA UNITEC HOUSE, 3RD FL, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON N3 1QB,
ENGLAND
SN 1473-7175
EI 1744-8360
J9 EXPERT REV NEUROTHER
JI Expert Rev. Neurother.
PD NOV
PY 2011
VL 11
IS 11
BP 1501
EP 1503
DI 10.1586/ERN.11.145
PG 3
WC Clinical Neurology; Pharmacology & Pharmacy
SC Neurosciences & Neurology; Pharmacology & Pharmacy
GA 856HP
UT WOS:000297629900001
PM 22014127
ER
PT J
AU Gladd, DK
Saunders, GH
AF Gladd, Dana K.
Saunders, Gabrielle H.
TI Ambient noise levels in the chemotherapy clinic
SO NOISE & HEALTH
LA English
DT Article
DE Chemotherapy; cisplatin; noise disturbance; noise
ID OFFICE NOISE; STRESS; OTOTOXICITY; CISPLATIN; EXPOSURE
AB Many of the drugs used for chemotherapy treatments are known to be ototoxic, and can result in permanent hearing threshold shifts. The degree of ototoxic damage can be influenced by many factors including dosage, duration of exposure, genetics, and coadministration with other ototoxic agents. Cisplatin is known for its ototoxic effects on hearing thresholds, particularly in the high frequencies. Recent studies have indicated a synergistic relationship between Cisplatin administration and moderate to high noise level exposure starting between 70-85 dB SPL. This study measured the noise levels in the Portland Veterans Affairs Medical Centers outpatient chemotherapy clinic. Average (LAeq) and peak (LCpeak) noise measures were recorded every minute from 7 am until 6 pm on the two busiest clinic days. Patients, visitors, and staff members filled out anonymous surveys regarding their reactions to noise levels. Cumulative noise levels were not at levels known to interact with Cisplatin for a significant period of time. Noise measurement analysis indicated that levels were at or above 70 dB SPL for less than ten minutes during the 11-hour recording window. The patient and visitor surveys indicated that both groups were unbothered by noise in the clinic. However, most staff members were bothered by or concerned about noise levels, and many felt that it caused stress and difficulty communicating on the phone.
C1 [Gladd, Dana K.; Saunders, Gabrielle H.] Portland VA Med Ctr, Natl Ctr Rehabil Auditory Res, Portland, OR USA.
RP Gladd, DK (reprint author), 3710 SW US Vet Hosp Rd NCRAR, Portland, OR 97239 USA.
EM dana.koltenuk@gmail.com
FU NIH [T35 DC008764]; VA RR and D Grant [C4844C]
FX Support for this work was provided by NIH Predoctoral Training Grant T35
DC008764 and VA RR and D Grant # C4844C. We thank Patricia Pulliam,
A.N.P., and other staff and patients of the Portland VA Medical Center
Chemotherapy outpatient clinic for their participation, Roger Ellingson
for his assistance with the equipment and Sarah Weidman for her
assistance with data collection.
NR 19
TC 4
Z9 4
U1 0
U2 2
PU MEDKNOW PUBLICATIONS
PI MUMBAI
PA B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075,
INDIA
SN 1463-1741
J9 NOISE HEALTH
JI Noise Health
PD NOV-DEC
PY 2011
VL 13
IS 55
BP 444
EP 451
DI 10.4103/1463-1741.90322
PG 8
WC Audiology & Speech-Language Pathology; Public, Environmental &
Occupational Health
SC Audiology & Speech-Language Pathology; Public, Environmental &
Occupational Health
GA 855WE
UT WOS:000297596000010
PM 22122961
ER
PT J
AU New, AS
AF New, Antonia S.
TI Partial Success?
SO PERSONALITY AND MENTAL HEALTH
LA English
DT Editorial Material
ID PERSONALITY-DISORDER; DSM-IV
C1 [New, Antonia S.] Mt Sinai Sch Med, New York, NY USA.
[New, Antonia S.] James J Peters VAMC, Mental Illness Res Educ & Clin Care Ctr, Bronx, NY USA.
RP New, AS (reprint author), Mt Sinai Sch Med, New York, NY USA.
EM antonia.new@mssm.edu
NR 4
TC 1
Z9 1
U1 0
U2 0
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1932-8621
J9 PERSONAL MENT HEALTH
JI Personal. Ment. Health
PD NOV
PY 2011
VL 5
IS 4
SI SI
BP 301
EP 303
DI 10.1002/pmh.188
PG 3
WC Psychiatry; Psychology, Social
SC Psychiatry; Psychology
GA 854OS
UT WOS:000297504700010
ER
PT J
AU Zhang, F
Wang, SP
Gan, L
Vosler, PS
Gao, YQ
Zigmond, MJ
Chen, J
AF Zhang, Feng
Wang, Suping
Gan, Li
Vosler, Peter S.
Gao, Yanqin
Zigmond, Michael J.
Chen, Jun
TI Protective effects and mechanisms of sirtuins in the nervous system
SO PROGRESS IN NEUROBIOLOGY
LA English
DT Review
DE SIRT1; Deacetylation; Cell death; Cerebral ischemia; Neurodegenerative
disease; Neuroprotection
ID NF-KAPPA-B; GLOBAL CEREBRAL-ISCHEMIA; OXYGEN-GLUCOSE DEPRIVATION;
ACTIVATED RECEPTOR-ALPHA; NITRIC-OXIDE SYNTHASE; BASE-EXCISION-REPAIR;
FATTY-ACID OXIDATION; SIR2 HISTONE/PROTEIN DEACETYLASES;
AMYOTROPHIC-LATERAL-SCLEROSIS; STRESS-RESPONSIVE DEACETYLASE
AB Silent information regulator two proteins (sirtuins or SIRTs) are a group of histone deacetylases whose activities are dependent on and regulated by nicotinamide adenine dinucleotide (NAD(+)). They suppress genome-wide transcription, yet upregulate a select set of proteins related to energy metabolism and pro-survival mechanisms, and therefore play a key role in the longevity effects elicited by calorie restriction. Recently, a neuroprotective effect of sirtuins has been reported for both acute and chronic neurological diseases. The focus of this review is to summarize the latest progress regarding the protective effects of sirtuins, with a focus on SIRT1. We first introduce the distribution of sirtuins in the brain and how their expression and activity are regulated. We then highlight their protective effects against common neurological disorders, such as cerebral ischemia, axonal injury, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, and multiple sclerosis. Finally, we analyze the mechanisms underlying sirtuin-mediated neuroprotection, centering on their non-histone substrates such as DNA repair enzymes, protein kinases, transcription factors, and coactivators. Collectively, the information compiled here will serve as a comprehensive reference for the actions of sirtuins in the nervous system to date, and will hopefully help to design further experimental research and expand sirtuins as therapeutic targets in the future. Published by Elsevier Ltd.
C1 [Zhang, Feng; Wang, Suping; Vosler, Peter S.; Gao, Yanqin; Zigmond, Michael J.; Chen, Jun] Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15213 USA.
[Zhang, Feng; Wang, Suping; Gao, Yanqin; Zigmond, Michael J.; Chen, Jun] Fudan Univ, State Key Lab Med Neurobiol, Shanghai 200032, Peoples R China.
[Zhang, Feng; Wang, Suping; Gao, Yanqin; Zigmond, Michael J.; Chen, Jun] Fudan Univ, Inst Brain Sci, Shanghai 200032, Peoples R China.
[Gan, Li] Univ Calif San Francisco, Gladstone Inst Neurol Dis, Dept Neurol, San Francisco, CA 94158 USA.
[Zhang, Feng; Wang, Suping; Vosler, Peter S.; Gao, Yanqin; Zigmond, Michael J.; Chen, Jun] Univ Pittsburgh, Sch Med, Ctr Cerebrovasc Dis Res, Pittsburgh, PA 15213 USA.
[Chen, Jun] Vet Affairs Pittsburgh Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA 15261 USA.
RP Chen, J (reprint author), Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15213 USA.
EM zhanfx2@upmc.edu; chenj2@upmc.edu
RI Gao, Yanqin/I-6790-2016
OI Gao, Yanqin/0000-0002-4915-9819
FU Chinese Ministry of Science Technology; National Institutes of Health
[NS36736, NS43802, NS45048, NS62157]; American Heart Association
[10SDG2560122]
FX This work was supported by Special Research Funds from Chinese Ministry
of Science & Technology to State Key laboratories (Y. G., M. Z., and
J.C.), grants from the National Institutes of Health (NS36736, NS43802,
NS45048 and NS62157 to J.C.), and the American Heart Association
(10SDG2560122 to F.Z.). We thank Pat Strickler for secretarial support
and Carol Culver for editorial assistance.
NR 327
TC 69
Z9 74
U1 3
U2 33
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0301-0082
J9 PROG NEUROBIOL
JI Prog. Neurobiol.
PD NOV
PY 2011
VL 95
IS 3
BP 373
EP 395
DI 10.1016/j.pneurobio.2011.09.001
PG 23
WC Neurosciences
SC Neurosciences & Neurology
GA 856CJ
UT WOS:000297614000005
PM 21930182
ER
PT J
AU Schutzer, WE
Xue, H
Reed, J
Oyama, T
Beard, DR
Anderson, S
Mader, SL
AF Schutzer, William E.
Xue, Hong
Reed, John
Oyama, Terry
Beard, Douglas R.
Anderson, Sharon
Mader, Scott L.
TI Age-related beta-adrenergic receptor-mediated vasorelaxation is changed
by altering G protein receptor kinase 2 expression
SO VASCULAR PHARMACOLOGY
LA English
DT Article
DE Adenovirus; Adrenergic-beta; Aging; Fischer 344; Vasorelaxation; G
protein receptor kinase (GRK)
ID VASCULAR SMOOTH-MUSCLE; RAT AORTA; BETA(2)-ADRENERGIC RECEPTOR;
BLOOD-PRESSURE; PLASMA-MEMBRANE; GENE-TRANSFER; DESENSITIZATION;
MECHANISMS; RELAXATION; PHOSPHORYLATION
AB Beta-adrenergic receptor- (beta-AR) mediated vasorelaxation declines with age. This change is likely related to receptor desensitization, rather than down regulation. One kinase responsible for desensitization is G protein receptor kinase 2 (GRK2). We have shown that GRK expression and activity increases with age in Fischer 344 rat aorta. In this study we validated that carotid arteries have similar age-related changes in the beta-AR signaling axis as aorta. This finding allowed use of in vivo infection and delivery of two adenovirus vectors to carotid arteries of 2-month-old (2 M) and 12-month-old (12 M) male Fischer 344 rats. Adeno-GRK2 was used to overexpress GRK2, and adeno-beta-ARK-ct was used to inhibit GRK2 function. Following a five-day infection, vessels were collected and ex vivo tissue bath was used to evaluate vasoreactivity. We used KCl contracted segments, and determined that overexpression of GRK2 significantly impaired isoproterenol (ISO)-mediated vasorelaxation in both age groups. Maximum relaxation (MA)() to ISO in vessels from 2 M decreased from 44% to 21%. MAX to ISO in vessels from 12 M decreased from 12% to 6%. Sensitivity (ED50) in vessels from 2 M and 12 M was also impaired 57%, and 30% respectively. We also determined that expression of adeno-beta-ARK-ct significantly improved ISO-mediated vasorelaxation in both age groups. MAX in vessels from 2 M increased from 44% to 58%. MAX in vessels from 12 M increased from 15% to 69%. ED50 in vessels from 2 M and 12 M was also improved 46%, and 50% respectively. These findings further implicate age-related increases in GRK2 expression as an important regulator of the age-related decline in beta-AR-mediated vasorelaxation. Published by Elsevier Inc.
C1 [Schutzer, William E.; Xue, Hong; Reed, John; Oyama, Terry; Beard, Douglas R.; Anderson, Sharon; Mader, Scott L.] Portland VA Med Ctr, Res Serv, Portland, OR 97239 USA.
[Schutzer, William E.; Anderson, Sharon; Mader, Scott L.] Oregon Hlth & Sci Univ, Sch Med, Portland, OR 97239 USA.
RP Mader, SL (reprint author), Portland VA Med Ctr, Res Serv, RD26,3710 SW US Vet Hosp Rd, Portland, OR 97239 USA.
EM scott.mader@va.gov
FU Research Service, Department of Veterans Affairs
FX This work was supported by the Research Service, Department of Veterans
Affairs. We thank Mohammed Gaballa, PhD, Banner Sun Health Research
Institute, Sun City, AZ for his guidance with the adenovirus delivery
surgical procedures.
NR 53
TC 5
Z9 5
U1 1
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1537-1891
EI 1879-3649
J9 VASC PHARMACOL
JI Vasc. Pharmacol.
PD NOV-DEC
PY 2011
VL 55
IS 5-6
BP 178
EP 188
DI 10.1016/j.vph.2011.09.001
PG 11
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 858EF
UT WOS:000297778000010
PM 21951806
ER
PT J
AU Weston, A
Barton, C
Lesselyong, J
Yaffe, K
AF Weston, Andrea
Barton, Cynthia
Lesselyong, Julia
Yaffe, Kristine
TI Functional deficits among patients with mild cognitive impairment
SO ALZHEIMERS & DEMENTIA
LA English
DT Article
DE Mild cognitive impairment; Dementia; Functional impairment; Instrumental
activities of daily living; Activities of daily living
ID DEMENTIA
AB Background: Diagnostic criteria for mild cognitive impairment (MCI) include no significant functional decline, but recent studies have suggested that subtle deficits often exist. It is not known whether these differ by MCI type. We investigated the level and type of functional impairment among patients with MCI.
Methods: We studied 498 patients, evaluated at the Alzheimer's Disease Research Centers of California between 2006 and 2009, who had multidisciplinary evaluations by experts, including neurologic examination and neuropsychological testing. Patients were diagnosed with MCI and subtype was determined using cognitive domain scores. In a cross-sectional descriptive study, we examined whether functional impairment differed by MCI subtype, using the Blessed Roth Dementia Rating Scale (range: 0-17, higher scores indicating more impairment).
Results: Among the participants, the mean age was 75.4 years, 50.7% were women, and 81.7% were white. Patients with amnestic- (n = 392, 78.7%) and nonamnestic-type (n = 106, 21.3%) MCI had similar total Blessed Roth Dementia Rating Scale (1.6 and 1.5, respectively; P = .84) and MiniMental State Examination (26.5 and 26.7, respectively; P = .60) scores. Patients with amnestic MCI were more likely to have difficulty in remembering lists and recalling recent events (P < .05 for both) and less likely to have difficulty in eating and with continence (P = .01 for both), as compared with those with nonamnestic MCI.
Conclusions: Despite the MCI diagnostic criteria suggesting no functional impairment, our results indicate that patients with MCI experience mild functional deficits that vary according to the type of MCI. (C) 2011 The Alzheimer's Association. All rights reserved.
C1 [Weston, Andrea; Yaffe, Kristine] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA.
[Weston, Andrea; Barton, Cynthia; Lesselyong, Julia; Yaffe, Kristine] San Francisco VA Med Ctr, San Francisco, CA USA.
[Barton, Cynthia; Yaffe, Kristine] Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA.
[Lesselyong, Julia] No Calif Inst Res & Educ, San Francisco, CA USA.
[Yaffe, Kristine] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA.
RP Weston, A (reprint author), Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA.
EM andrea.weston@ucsf.edu
FU National Institute of Aging [K24AG031155]; Mental Illness Research,
Educational, and Clinical Cente; Sierra Pacific Veterans Integrated
Service Network (VISN) Veteran's Administration
FX Dr. Yaffe is supported in part by a Grant from the National Institute of
Aging (K24AG031155) and by a Mental Illness Research, Educational, and
Clinical Center Grant from the Sierra Pacific Veterans Integrated
Service Network (VISN) Veteran's Administration.
NR 15
TC 4
Z9 5
U1 0
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1552-5260
J9 ALZHEIMERS DEMENT
JI Alzheimers. Dement.
PD NOV
PY 2011
VL 7
IS 6
BP 611
EP 614
DI 10.1016/j.jalz.2010.12.011
PG 4
WC Clinical Neurology
SC Neurosciences & Neurology
GA 852WD
UT WOS:000297387300008
PM 22055977
ER
PT J
AU Chou, SW
Marousek, G
Auerochs, S
Stamminger, T
Milbradt, J
Marschall, M
AF Chou, Sunwen
Marousek, Gail
Auerochs, Sabrina
Stamminger, Thomas
Milbradt, Jens
Marschall, Manfred
TI The unique antiviral activity of artesunate is broadly effective against
human cytomegaloviruses including therapy-resistant mutants
SO ANTIVIRAL RESEARCH
LA English
DT Article
DE Human cytomegalovirus; Antiviral activity of artesunate;
Artesunate-related drugs; Therapy-resistant virus mutants; Synergistic
effect
ID STEM-CELL TRANSPLANTATION; DRUG-RESISTANCE; MARIBAVIR; RECOMBINANT;
REPLICATION; INFECTIONS; RECIPIENTS; MUTATIONS; POTENT
AB Current therapy options to treat infections with human cytomegalovirus face severe limitations leading to a continued search for novel drug candidates. Here, we describe novel characteristics of the strong antiviral potency of the drug artesunate. In vitro virus replication systems were applied to analyze a number of laboratory and clinically relevant strains of human cytomegalovirus. An inhibitory block at a very early stage of infection was demonstrated. Time-of-addition experiments indicated that the antiviral efficacy could be optimized when artesunate was applied as fractional doses consecutively added post-infection. Artesunate showed a clearly higher anti-cytomegaloviral activity than its parental drug artemisinin (approximately 10-fold) or other artesunate-related compounds. Mean IC(50) values of artesunate for a variety of standard therapy-resistant virus mutants were within a 2-fold range compared to wild-type virus. Furthermore, a synergistic effect was identified when artesunate was combined with the mechanistically distinct antiviral compound maribavir. These findings point to unique antiviral properties of artesunate which may offer an advantage over standard antiviral therapy particularly in cases of drug resistance. (C) 2011 Published by Elsevier B.V.
C1 [Auerochs, Sabrina; Stamminger, Thomas; Milbradt, Jens; Marschall, Manfred] Univ Erlangen Nurnberg, Inst Clin & Mol Virol, D-91054 Erlangen, Germany.
[Chou, Sunwen] Oregon Hlth & Sci Univ, Div Infect Dis, Portland, OR 97201 USA.
[Chou, Sunwen; Marousek, Gail] US Dept Vet Affairs, Med Ctr, Portland, OR USA.
RP Marschall, M (reprint author), Univ Erlangen Nurnberg, Inst Clin & Mol Virol, Schlossgarten 4, D-91054 Erlangen, Germany.
EM manfred.marschall@viro.med.uni-erlangen.de
FU Department of Veterans Affairs (USA); Deutsche Forschungsgemeinschaft
[MA 1289/7-1, SFB 796 C3/B3]; HHV-6 Foundation (Santa Barbara, CA, USA
[M.M. 2009]; Bayerische Forschungsstiftung [4SC-2010]
FX We like to thank Herwig Jansen (Dafra Pharma, Turhout, Belgium) and
Duong Ngoc Ha (Saokim Pharma, Hanoi, Vietnam) for kindly providing ART,
ART-related drugs and product information. We appreciate the
cooperations with Thomas Efferth (Inst. Pharmacy and Biochem., Univ.
Mainz, Germany) and Dana Wolf (Clin. Virol. Unit, Dept. Clin. Microbiol.
Inf. Diseases, Hadassah Univ. Jerusalem, Israel) in the molecular and
clinical evaluation of ART, respectively. This work was supported by the
Department of Veterans Affairs (USA), Deutsche Forschungsgemeinschaft
(Grant MA 1289/7-1 and SFB 796 C3/B3), HHV-6 Foundation (Santa Barbara,
CA, USA, Grant M.M. 2009) and Bayerische Forschungsstiftung (Grant
4SC-2010).
NR 26
TC 20
Z9 21
U1 0
U2 4
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0166-3542
J9 ANTIVIR RES
JI Antiviral Res.
PD NOV
PY 2011
VL 92
IS 2
BP 364
EP 368
DI 10.1016/j.antiviral.2011.07.018
PG 5
WC Pharmacology & Pharmacy; Virology
SC Pharmacology & Pharmacy; Virology
GA 853LG
UT WOS:000297427200027
PM 21843554
ER
PT J
AU Soleimani, M
Khazalpour, M
Cheng, GM
Zhang, ZH
Acevedo-Bolton, G
Saloner, DA
Mishra, R
Wallace, AW
Guccione, JM
Ge, L
Ratcliffe, MB
AF Soleimani, Mehrdad
Khazalpour, Michael
Cheng, Guangming
Zhang, Zhihong
Acevedo-Bolton, Gabriel
Saloner, David A.
Mishra, Rakesh
Wallace, Arthur W.
Guccione, Julius M.
Ge, Liang
Ratcliffe, Mark B.
TI Moderate Mitral Regurgitation Accelerates Left Ventricular Remodeling
After Posterolateral Myocardial Infarction
SO ANNALS OF THORACIC SURGERY
LA English
DT Article
ID MAGNETIC-RESONANCE; 3-DIMENSIONAL ECHOCARDIOGRAPHY; REPAIR;
REVASCULARIZATION; QUANTIFICATION; METAANALYSIS; SEVERITY; MYOCYTES;
VOLUMES; STRESS
AB Background. Chronic ischemic mitral regurgitation (MR) is associated with poor outcome. However, the effect of chronic ischemic MR on left ventricular (LV) remodeling after posterolateral myocardial infarction (MI) remains controversial. We tested the hypothesis that moderate MR accelerates LV remodeling after posterolateral MI.
Methods. Posterolateral MI was created in 10 sheep. Cardiac magnetic resonance imaging was performed 2 weeks before and 2, 8, and 16 weeks after MI. Left ventricular and right ventricular volumes were measured, and regurgitant volume was calculated as the difference between LV and right ventricle stroke volumes.
Results. Multivariate mixed effects regression showed that LV volumes at end diastole and end systole and LV sphericity were strongly correlated with both regurgitant volume (p < 0.0001, p = 0.0086, and p = 0.0007, respectively) and percent infarct area (p = 0.0156, p = 0.0307, and p < 0.0001, respectively). Conversely, whereas LV hypertrophy (LV wall volume) increased from 2 weeks to 16 weeks after MI, there was no effect of either regurgitant volume or percent infarct.
Conclusions. Moderate MR accelerates LV remodeling after posterolateral MI. Further studies are needed to determine whether mitral valve repair is able to slow or reverse MI remodeling after posterolateral MI. (Ann Thorac Surg 2011;92:1614-20) (C) 2011 by The Society of Thoracic Surgeons
C1 Univ Calif San Francisco, Dept Surg, San Francisco, CA USA.
Univ Calif San Francisco, Dept Anesthesia, San Francisco, CA 94143 USA.
Univ Calif San Francisco, Dept Bioengn, San Francisco, CA 94143 USA.
Univ Calif San Francisco, Dept Med, San Francisco, CA USA.
Univ Calif San Francisco, Dept Radiol, San Francisco, CA USA.
Vet Affairs Med Ctr, San Francisco, CA 94121 USA.
RP Ratcliffe, MB (reprint author), San Francisco VA Med Ctr, Div Surg Serv 112, 4150 Clement St, San Francisco, CA 94121 USA.
EM mark.ratcliffe@va.gov
FU National Institutes of Health [R01-HL-084431, R01-HL-077921]
FX This study was supported by National Institutes of Health grants
R01-HL-084431 (Dr Ratcliffe) and R01-HL-077921 (Dr Guccione).
NR 33
TC 11
Z9 11
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0003-4975
J9 ANN THORAC SURG
JI Ann. Thorac. Surg.
PD NOV
PY 2011
VL 92
IS 5
BP 1614
EP 1620
DI 10.1016/j.athoracsur.2011.05.117
PG 7
WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery
SC Cardiovascular System & Cardiology; Respiratory System; Surgery
GA 846TF
UT WOS:000296925400020
PM 21945222
ER
PT J
AU Chang, AY
Piette, EW
Foering, KP
Tenhave, TR
Okawa, J
Werth, VP
AF Chang, Aileen Y.
Piette, Evan W.
Foering, Kristen P.
Tenhave, Thomas R.
Okawa, Joyce
Werth, Victoria P.
TI Response to Antimalarial Agents in Cutaneous Lupus Erythematosus
SO ARCHIVES OF DERMATOLOGY
LA English
DT Article
ID SEVERITY INDEX; DISEASE AREA; QUINACRINE; RESISTANT; HYDROXYCHLOROQUINE;
CHLOROQUINE; DERMATOLOGY; CLASSIFICATION; ASSOCIATION; THERAPY
AB Objective: To demonstrate response to antimalarial agents in patients with cutaneous lupus erythematosus (CLE) using activity scores from the Cutaneous Lupus Erythematosus Disease Area and Severity Index, a validated outcome measure.
Design: Prospective, longitudinal cohort study.
Setting: University cutaneous autoimmune disease clinic.
Participants: A total of 128 patients with CLE who presented from January 2007 to July 2010 and had at least 2 visits with activity scores.
Intervention: Administration of antimalarial agents.
Main Outcome Measures: Response was defined by a 4-point or 20% decrease in activity score. Response to initiation was determined by the difference between the scores before treatment and at the first visit at least 2 months after treatment. Response to continuation was determined by the difference between the scores at the first visit and the most recent visit while undergoing treatment.
Results: Of 11 patients who initiated treatment with hydroxychloroquine, 55% were responders (n = 6), showing a decrease in median (interquartile range [IQR]) activity score from 8.0 (3.5-13.0) to 3.0 (1.8-7.3) (P = .03). Of 15 patients for whom hydroxychloroquine failed, 67% were responders to initiation of hydroxychloroquine-quinacrine therapy (n = 10), showing a decrease in median (IQR) activity score from 6.0 (4.8-8.3) to 3.0 (0.75-5.0) (P = .004). Nine of 21 patients who continued hydroxychloroquine treatment (43%), and 9 of 21 patients who continued hydroxychloroquine-quinacrine (43%) were responders, showing a decrease in median (IQR) activity score from 6.0 (1.5-9.5) to 1.0 (0.0-4.5) (P = .01) and 8.5 (4.25-17.5) to 5.0 (0.5-11.5) (P = .01), respectively.
Conclusions: The use of quinacrine with hydroxychloroquine is associated with response in patients for whom hydroxychloroquine monotherapy fails. Further reduction in disease activity can be associated with continuation of treatment with antimalarial agents.
C1 [Chang, Aileen Y.; Piette, Evan W.; Foering, Kristen P.; Okawa, Joyce; Werth, Victoria P.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA.
[Chang, Aileen Y.; Piette, Evan W.; Foering, Kristen P.; Okawa, Joyce; Werth, Victoria P.] Univ Penn, Dept Dermatol, Philadelphia, PA 19104 USA.
[Foering, Kristen P.] Univ Penn, Inst Translat Med & Therapeut, Philadelphia, PA 19104 USA.
[Tenhave, Thomas R.] Univ Penn, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA.
RP Werth, VP (reprint author), Perelman Ctr Adv Med, Dept Dermatol, 3400 Civ Ctr Blvd,Ste 1-330A, Philadelphia, PA 19104 USA.
EM werth@mail.med.upenn.edu
FU National Institutes of Health [NIH K24-AR 18 02207]; Doris Duke
Charitable Foundation
FX This work was supported by National Institutes of Health grant NIH
K24-AR 18 02207 (Dr Werth) and a grant from the Doris Duke Charitable
Foundation to the Perelman School of Medicine at the University of
Pennsylvania to fund Clinical Research Fellow Ms Chang.
NR 30
TC 30
Z9 32
U1 0
U2 0
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA
SN 0003-987X
J9 ARCH DERMATOL
JI Arch. Dermatol.
PD NOV
PY 2011
VL 147
IS 11
BP 1261
EP 1267
DI 10.1001/archdermatol.2011.191
PG 7
WC Dermatology
SC Dermatology
GA 850UW
UT WOS:000297226000003
PM 21768444
ER
PT J
AU Wan, J
Abuabara, K
Kurd, SK
Musiek, A
Steinemann, JM
Vittorio, CC
Gelfand, JM
AF Wan, Joy
Abuabara, Katrina
Kurd, Shanu K.
Musiek, Amy
Steinemann, Jane M.
Vittorio, Carmela C.
Gelfand, Joel M.
TI Reliability and Validity of a Photographic Method for Measuring Facial
Hair Density in Men
SO ARCHIVES OF DERMATOLOGY
LA English
DT Letter
C1 [Wan, Joy; Abuabara, Katrina; Kurd, Shanu K.; Musiek, Amy; Steinemann, Jane M.; Vittorio, Carmela C.; Gelfand, Joel M.] Univ Penn, Dept Dermatol, Perelman Sch Med, Philadelphia, PA 19104 USA.
[Abuabara, Katrina; Kurd, Shanu K.] Univ Penn, Dept Internal Med, Perelman Sch Med, Philadelphia, PA 19104 USA.
[Gelfand, Joel M.] Univ Penn, Ctr Clin Epidemiol & Biostat, Perelman Sch Med, Philadelphia, PA 19104 USA.
[Musiek, Amy] Philadelphia VA Med Ctr, Philadelphia, PA USA.
RP Gelfand, JM (reprint author), 1471 Penn Tower,1 Convent Ave, Philadelphia, PA 19104 USA.
EM Joel.Gelfand@uphs.upenn.edu
FU NIAMS NIH HHS [T32-AR07465, T32 AR007465]
NR 5
TC 1
Z9 1
U1 0
U2 0
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA
SN 0003-987X
J9 ARCH DERMATOL
JI Arch. Dermatol.
PD NOV
PY 2011
VL 147
IS 11
BP 1328
EP 1329
PG 2
WC Dermatology
SC Dermatology
GA 850UW
UT WOS:000297226000020
PM 22106126
ER
PT J
AU Rosenbaum, JT
Davey, MP
AF Rosenbaum, James T.
Davey, Michael P.
TI Time for a Gut Check: Evidence for the Hypothesis That HLA-B27
Predisposes to Ankylosing Spondylitis by Altering the Microbiome
SO ARTHRITIS AND RHEUMATISM
LA English
DT Editorial Material
ID ACUTE ANTERIOR UVEITIS; HUMAN MONOCYTIC CELLS; IMMUNE-RESPONSE;
TRANSGENIC RATS; T-CELLS; DISEASE; KLEBSIELLA; BACTERIA; ARTHRITIS;
PEPTIDES
C1 [Rosenbaum, James T.] Oregon Hlth & Sci Univ, Portland, OR 97239 USA.
[Davey, Michael P.] Portland VA Med Ctr, Portland, OR USA.
RP Rosenbaum, JT (reprint author), Oregon Hlth & Sci Univ, 3181 SW Sam Jackson Pk Rd,L467Ad, Portland, OR 97239 USA.
EM rosenbaj@ohsu.edu
FU NEI NIH HHS [R01 EY019604, R01 EY019604-01, R01-EY-019604]
NR 44
TC 25
Z9 27
U1 1
U2 17
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0004-3591
J9 ARTHRITIS RHEUM-US
JI Arthritis Rheum.
PD NOV
PY 2011
VL 63
IS 11
BP 3195
EP 3198
DI 10.1002/art.30558
PG 4
WC Rheumatology
SC Rheumatology
GA 850TC
UT WOS:000297221100002
PM 21792826
ER
PT J
AU Shahouri, SH
Michaud, K
Mikuls, TR
Caplan, L
Shaver, TS
Anderson, JD
Weidensaul, DN
Busch, RE
Wang, S
Wolfe, F
AF Shahouri, Shadi H.
Michaud, Kaleb
Mikuls, Ted R.
Caplan, Liron
Shaver, Timothy S.
Anderson, James D.
Weidensaul, David N.
Busch, Ruth E.
Wang, Shirley
Wolfe, Frederick
TI Remission of Rheumatoid Arthritis in Clinical Practice Application of
the American College of Rheumatology/European League Against Rheumatism
2011 Remission Criteria
SO ARTHRITIS AND RHEUMATISM
LA English
DT Article
ID HEALTH-ASSESSMENT QUESTIONNAIRE; MULTILEVEL LOGISTIC-REGRESSION;
DISEASE-ACTIVITY SCORE; TRIALS; DEFINITION; AGREEMENT; INDEX; CARE
AB Objective. To describe use of the American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) rheumatoid arthritis (RA) remission criteria in clinical practice.
Methods. Remission was examined using data on 1,341 patients with RA (91% men) from the US Department of Veterans Affairs RA (VARA) registry (total of 9,700 visits) and 1,153 patients with RA (25.8% men) in a community rheumatology practice (Arthritis and Rheumatology Clinics of Kansas [ARCK]) (total of 6,362 visits). Cross-sectional and cumulative probabilities were studied, and agreement between the various remission criteria was assessed. Aspects of reliability of the criteria were determined using Boolean-based definitions, as well as the Clinical Disease Activity Index (CDAI) and Simplified Disease Activity Index (SDAI) scoring methods proposed by the ACR/EULAR joint committee.
Results. When the 3-variable ACR/EULAR definition of remission recommended for use in community practice (swollen and tender joint counts <= 1, and visual analog scale score for patient's global assessment of disease activity <= 1) was applied, cross-sectional remission was 7.5% (95% confidence interval [95% CI] 6.4, 8.7%) for ARCK and 8.9% (95% CI 7.9, 9.9%) for VARA, and cumulative remission (remission at any observation) was 18.0% (for ARCK) and 24.4% (for VARA), over a mean followup of similar to 2.2 years. Addition of the erythrocyte sedimentation rate or C-reactive protein level to the criteria set reduced remission to 5.0-6.2%, and use of the CDAI/SDAI increased the proportions to 6.9-10.1%. Moreover, 1.8-4.6% of the patients met remission criteria at >= 2 visits. Agreement between criteria definitions was good, as assessed by kappa statistics and Jaccard coefficients. Among patients in remission, the probability of a remission lasting 2 years was 6.0-14.1%. Among all patients, the probability of a remission lasting 2 years was <3%. Remission status and examination results for each patient varied substantially among physicians, as determined by multilevel analyses.
Conclusion. Cross-sectional remission occurred in 5.0-10.1% of the patients in these cohorts, with cumulative remission being 2-3 times greater; however, long-term remission was rare. Problems with reliability and agreement limit the usefulness of these criteria in the individual patient. However, the criteria can be an effective method for measuring clinical status and treatment effect in groups of patients in the community.
C1 [Michaud, Kaleb; Wolfe, Frederick] Natl Data Bank Rheumat Dis, Wichita, KS 67214 USA.
[Shahouri, Shadi H.; Shaver, Timothy S.; Anderson, James D.; Weidensaul, David N.; Busch, Ruth E.; Wang, Shirley] Arthrit Clin Kansas, Wichita, KS USA.
[Shahouri, Shadi H.; Shaver, Timothy S.; Anderson, James D.; Weidensaul, David N.; Busch, Ruth E.; Wang, Shirley] Rheumatol Clin Kansas, Wichita, KS USA.
[Shahouri, Shadi H.; Shaver, Timothy S.; Anderson, James D.; Weidensaul, David N.; Wang, Shirley; Wolfe, Frederick] Univ Kansas, Sch Med, Wichita, KS 67214 USA.
[Michaud, Kaleb] Univ Nebraska Med Ctr, Omaha, NE USA.
[Mikuls, Ted R.] Omaha VA Med Ctr, Omaha, NE USA.
[Mikuls, Ted R.] Univ Nebraska, Omaha, NE 68182 USA.
[Caplan, Liron] Denver VA Med Ctr, Denver, CO USA.
[Caplan, Liron] Univ Colorado, Denver, CO 80202 USA.
[Busch, Ruth E.] Wichita State Univ, Wichita, KS USA.
RP Wolfe, F (reprint author), Natl Data Bank Rheumat Dis, 1035 N Emporia,Suite 288, Wichita, KS 67214 USA.
EM fwolfe@arthritis-research.org
FU VA Health Services Research & Development Service; Arthritis Foundation;
NIH [1RC1AR058601-01]; VA Merit grant; VA Career Development Award [CDA
07-221]
FX The US VA Rheumatoid Arthritis registry is supported by the VA Health
Services Research & Development Service. Dr. Michaud's work was
supported in part by an Arthritis Foundation New Investigator Award and
a grant from the NIH (American Recovery & Reinvestment Act grant
1RC1AR058601-01). Dr. Mikuls' work was supported by a VA Merit grant.
Dr. Caplan's work was supported by a VA Career Development Award (CDA
07-221).
NR 29
TC 43
Z9 44
U1 0
U2 4
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0004-3591
J9 ARTHRITIS RHEUM-US
JI Arthritis Rheum.
PD NOV
PY 2011
VL 63
IS 11
BP 3204
EP 3215
DI 10.1002/art.30524
PG 12
WC Rheumatology
SC Rheumatology
GA 850TC
UT WOS:000297221100004
PM 21739423
ER
PT J
AU Bartels, CM
Everett, C
McBride, P
Smith, M
Kind, AJH
Mell, M
AF Bartels, Christie M.
Everett, Christine
McBride, Patrick
Smith, Maureen
Kind, Amy J. H.
Mell, Matthew
TI Is the "lipid paradox" in rheumatoid arthritis really a paradox? Comment
on the article by Bartels et al Reply
SO ARTHRITIS AND RHEUMATISM
LA English
DT Letter
ID MORTALITY
C1 [Bartels, Christie M.; Everett, Christine; McBride, Patrick; Smith, Maureen; Kind, Amy J. H.] Univ Wisconsin, Sch Med & Publ Hlth, Madison, WI 53706 USA.
[Kind, Amy J. H.] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA.
[Mell, Matthew] Stanford Univ, Palo Alto, CA 94304 USA.
RP Bartels, CM (reprint author), Univ Wisconsin, Sch Med & Publ Hlth, Madison, WI 53706 USA.
NR 6
TC 1
Z9 1
U1 0
U2 2
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0004-3591
J9 ARTHRITIS RHEUM-US
JI Arthritis Rheum.
PD NOV
PY 2011
VL 63
IS 11
BP 3645
EP 3646
DI 10.1002/art.30587
PG 2
WC Rheumatology
SC Rheumatology
GA 850TC
UT WOS:000297221100061
ER
PT J
AU Anderson, JK
Zimmerman, L
Caplan, L
Michaud, K
AF Anderson, Jaclyn K.
Zimmerman, Lani
Caplan, Liron
Michaud, Kaleb
TI Measures of Rheumatoid Arthritis Disease Activity Patient (PtGA) and
Provider (PrGA) Global Assessment of Disease Activity, Disease Activity
Score (DAS) and Disease Activity Score With 28-Joint Counts (DAS28),
Simplified Disease Activity Index (SDAI), Clinical Disease Activity
Index (CDAI), Patient Activity Score (PAS) and Patient Activity Score-II
(PASII), Routine Assessment of Patient Index Data (RAPID), Rheumatoid
Arthritis Disease Activity Index (RADAI) and Rheumatoid Arthritis
Disease Activity Index-5 (RADAI-5), Chronic Arthritis Systemic Index
(CASI), Patient-Based Disease Activity Score With ESR (PDAS1) and
Patient-Based Disease Activity Score Without ESR (PDAS2), and Mean
Overall Index for Rheumatoid Arthritis (MOI-RA)
SO ARTHRITIS CARE & RESEARCH
LA English
DT Article
ID HEALTH-ASSESSMENT QUESTIONNAIRE; COLLEGE-OF-RHEUMATOLOGY; VISUAL ANALOG
SCALES; RANDOMIZED CONTROLLED-TRIALS; ACUTE-PHASE REACTANTS; FORMAL
JOINT COUNTS; CORE SET MEASURES; RESPONSE CRITERIA; FUNCTIONAL-CAPACITY;
IMPROVEMENT CRITERIA
C1 [Anderson, Jaclyn K.; Zimmerman, Lani; Michaud, Kaleb] Univ Nebraska Med Ctr, Omaha, NE USA.
[Anderson, Jaclyn K.] Abbott Labs, Abbott Pk, IL USA.
[Caplan, Liron] Denver Vet Affairs Med Ctr, Denver, CO USA.
[Caplan, Liron] Univ Colorado, Sch Med, Aurora, CO USA.
[Michaud, Kaleb] Natl Data Bank Rheumat Dis, Wichita, KS USA.
RP Anderson, JK (reprint author), 200 Abbott Pk Rd,Dept R4NE,Bldg AP34-1, Abbott Pk, IL 60064 USA.
EM Jaclyn.Anderson@abbott.com
OI Anderson, Jaclyn/0000-0002-0893-3900
FU American College of Rheumatology
FX Supported in part by the American College of Rheumatology.
NR 121
TC 44
Z9 47
U1 0
U2 10
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 2151-464X
J9 ARTHRIT CARE RES
JI Arthritis Care Res.
PD NOV
PY 2011
VL 63
SU 11
BP S14
EP S36
DI 10.1002/acr.20621
PG 23
WC Rheumatology
SC Rheumatology
GA 850SR
UT WOS:000297219500003
PM 22588741
ER
PT J
AU Rider, LG
Werth, VP
Huber, AM
Alexanderson, H
Rao, AP
Ruperto, N
Herbelin, L
Barohn, R
Isenberg, D
Miller, FW
AF Rider, Lisa G.
Werth, Victoria P.
Huber, Adam M.
Alexanderson, Helene
Rao, Anand Prahalad
Ruperto, Nicolino
Herbelin, Laura
Barohn, Richard
Isenberg, David
Miller, Frederick W.
TI Measures of Adult and Juvenile Dermatomyositis, Polymyositis, and
Inclusion Body Myositis Physician and Patient/Parent Global Activity,
Manual Muscle Testing (MMT), Health Assessment Questionnaire
(HAQ)/Childhood Health Assessment Questionnaire (C-HAQ), Childhood
Myositis Assessment Scale (CMAS), Myositis Disease Activity Assessment
Tool (MDAAT), Disease Activity Score (DAS), Short Form 36 (SF-36), Child
Health Questionnaire (CHQ), Physician Global Damage, Myositis Damage
Index (MDI), Quantitative Muscle Testing (QMT), Myositis Functional
Index-2 (FI-2), Myositis Activities Profile (MAP), Inclusion Body
Myositis Functional Rating Scale (IBMFRS), Cutaneous Dermatomyositis
Disease Area and Severity Index (CDASI), Cutaneous Assessment Tool
(CAT), Dermatomyositis Skin Severity Index (DSSI), Skindex, and
Dermatology Life Quality Index (DLQI)
SO ARTHRITIS CARE & RESEARCH
LA English
DT Article
ID IDIOPATHIC INFLAMMATORY MYOPATHIES; SYSTEMIC-LUPUS-ERYTHEMATOSUS;
MUSCULAR-DYSTROPHY FSHD; RANDOMIZED PILOT TRIAL; HOME EXERCISE PROGRAM;
OF-LIFE; PEDIATRIC RHEUMATOLOGY; NATURAL-HISTORY; PROGNOSTIC-FACTORS;
INTERNATIONAL CONSENSUS
C1 [Rider, Lisa G.] NIEHS, Environm Autoimmun Grp, Program Clin Res, NIH, Bethesda, MD 20892 USA.
[Werth, Victoria P.] Philadelphia VA Med Ctr, Philadelphia, PA USA.
[Werth, Victoria P.] Univ Penn, Philadelphia, PA 19104 USA.
[Huber, Adam M.] Dalhousie Univ, Halifax, NS, Canada.
[Huber, Adam M.] IWK Hlth Ctr, Halifax, NS, Canada.
[Alexanderson, Helene] Karolinska Inst, Stockholm, Sweden.
[Alexanderson, Helene] Karolinska Univ Hosp, Stockholm, Sweden.
[Rao, Anand Prahalad; Ruperto, Nicolino] IRCCS G Gaslini, Paediat Rheumatol Int Trials Org, Genoa, Italy.
[Herbelin, Laura; Barohn, Richard] Univ Kansas, Med Ctr, Kansas City, KS 66103 USA.
[Isenberg, David] UCL, London, England.
RP Rider, LG (reprint author), NIEHS, Environm Autoimmun Grp, Program Clin Res, NIH, CRC 4-2352,MSC 1301,10 Ctr Dr, Bethesda, MD 20892 USA.
EM rider1@mail.nih.gov
OI Rider, Lisa/0000-0002-6912-2458
FU NIH National Institute of Environmental Health Sciences
FX Supported in part by the Intramural Research Program of the NIH National
Institute of Environmental Health Sciences.
NR 112
TC 51
Z9 54
U1 3
U2 12
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 2151-464X
EI 2151-4658
J9 ARTHRIT CARE RES
JI Arthritis Care Res.
PD NOV
PY 2011
VL 63
SU 11
BP S118
EP S157
DI 10.1002/acr.20532
PG 40
WC Rheumatology
SC Rheumatology
GA 850SR
UT WOS:000297219500011
PM 22588740
ER
PT J
AU Melloni, C
Roe, MT
Chen, AY
Wang, TY
Wiviott, SD
Ho, PM
Peterson, ED
Alexander, KP
AF Melloni, Chiara
Roe, Matthew T.
Chen, Anita Y.
Wang, Tracy Y.
Wiviott, Stephen D.
Ho, P. Michael
Peterson, Eric D.
Alexander, Karen P.
TI Use of Early Clopidogrel by Reperfusion Strategy Among Patients
Presenting With ST-Segment Elevation Myocardial Infarction
SO CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES
LA English
DT Article
DE clopidogrel; guideline adherence; fibrinolysis; reperfusion
ID PERCUTANEOUS CORONARY INTERVENTION; PLACEBO-CONTROLLED TRIAL;
FIBRINOLYTIC THERAPY; ASPIRIN; PRETREATMENT; OUTCOMES; RISK
AB Background-The 2007 update of the ACC/AHA guidelines for STEMI patients recommended addition of clopidogrel to aspirin regardless of reperfusion strategy, with a bolus dose in patients <75 years of age.
Methods and Results-We evaluated use and dose of early clopidogrel among 52,140 STEMI patients enrolled in 368 hospitals participating in NCDR's ACTION Registry (R)-Get with the Guidelines (GWTG (TM)) from January 2007-September 2009. Patients were stratified by reperfusion strategy: primary percutaneous coronary intervention (PCI, n = 37,108), fibrinolysis (n = 5805), or no-reperfusion (n = 9227), and by age (<75 or >= 75 years). Adjusted odds for in-hospital outcomes are reported by clopidogrel use across reperfusion strategies. Clopidogrel was administered early to 97% of primary PCI, 18% of fibrinolytic, and 6% of non-reperfused patients. Among patients receiving clopidogrel, a loading dose (>= 300 mg) was often used in primary PCI (91%) but less frequently among fibrinolysis-treated (83%) and non-reperfused patients (74%). A positive time trend from Q1 2007-Q3 2009 in overall clopidogrel use was observed only in fibrinolytic patients (15-20%) Use of clopidogrel was associated with a significant increase in major bleeding only among older patients in the no-reperfusion group (21.9% vs. 13.2%; OR 2.19; 95% CI 1.47-3.27). A significantly lower risk of in-hospital death was associated with clopidogrel use across all reperfusion strategies (OR [95% CI], primary PCI: 0.15 [0.13-0.19]; fibrinolysis: 0.26 [0.12-0.57]; no reperfusion: 0.42 [0.27-0.65]).
Conclusion-Early clopidogrel use has not yet extended to the routine care of STEMI patients treated with fibrinolysis or those not receiving reperfusion as recommended in the guideline update. (Circ Cardiovasc Qual Outcomes. 2011;4:603-609.)
C1 [Melloni, Chiara; Roe, Matthew T.; Chen, Anita Y.; Wang, Tracy Y.; Peterson, Eric D.; Alexander, Karen P.] Duke Univ, Med Ctr, Duke Clin Res Inst, Durham, NC 27705 USA.
[Melloni, Chiara; Roe, Matthew T.; Chen, Anita Y.; Wang, Tracy Y.; Peterson, Eric D.; Alexander, Karen P.] Duke Univ, Med Ctr, Div Cardiol, Durham, NC 27705 USA.
[Wiviott, Stephen D.] Brigham & Womens Hosp, Boston, MA 02115 USA.
[Ho, P. Michael] Denver VA Med Ctr, Cardiol Sect, Denver, CO USA.
Univ Colorado Denver, Denver, CO USA.
RP Melloni, C (reprint author), Duke Univ, Med Ctr, Duke Clin Res Inst, 2400 Pratt St, Durham, NC 27705 USA.
EM mello004@mc.duke.edu
FU Bristol-Myers Squibb (BMS)/Sanofi Pharmaceuticals Partnership;
Schering-Plough Corporation; BMS/Sanofi-Aventis; BMS/Sanofi Partnership;
Merck/Schering-Plough; AstraZeneca; BMS; Ortho; McNeil; Pfizer;
Sanofi-Aventis; Daiichi Sankyo; Eli Lilly; Schering-Plough; VA Research
& Development Career Development Award [05-026-2]
FX The Bristol-Myers Squibb (BMS)/Sanofi Pharmaceuticals Partnership and
Schering-Plough Corporation are founding sponsors of the ACTION
Registry-GWTG. Dr Roe receives research grants from BMS/Sanofi-Aventis
and Merck/Schering-Plough, is on the speaker's bureau for
BMS/Sanofi-Aventis and Merck/Schering-Plough, and consults for
Merck/Schering-Plough; Dr Wang receives research grants from BMS/Sanofi
Partnership and Merck/Schering-Plough; Dr Wiviott receives honoraria for
educational presentations from BMS, Daiichi Sankyo, Eli Lilly,
Schering-Plough, Merck, and The Medicine's Company, receives consulting
fees from AstraZeneca, BMS, Ortho McNeil, Pfizer, and Sanofi-Aventis,
and research grants from Daiichi Sankyo, Eli Lilly, and Schering-Plough;
Dr Ho receives research support from a VA Research & Development Career
Development Award (05-026-2) and is also a consultant for Wellpoint,
Inc; and Dr Peterson receives research grants from BMS.
NR 17
TC 2
Z9 3
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1941-7713
J9 CIRC-CARDIOVASC QUAL
JI Circ.-Cardiovasc. Qual. Outcomes
PD NOV
PY 2011
VL 4
IS 6
BP 603
EP 609
DI 10.1161/CIRCOUTCOMES.111.961045
PG 7
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 850BC
UT WOS:000297168400006
PM 21988922
ER
PT J
AU McDonald, WM
Durkalski, V
Ball, ER
Holtzheimer, PE
Pavlicova, M
Lisanby, SH
Avery, D
Anderson, BS
Nahas, Z
Zarkowski, P
Sackeim, HA
George, MS
AF McDonald, William M.
Durkalski, Valerie
Ball, Edward R., III
Holtzheimer, Paul E., III
Pavlicova, Martina
Lisanby, Sarah H.
Avery, David
Anderson, Berry S.
Nahas, Ziad
Zarkowski, Paul
Sackeim, Harold A.
George, Mark S.
TI IMPROVING THE ANTIDEPRESSANT EFFICACY OF TRANSCRANIAL MAGNETIC
STIMULATION: MAXIMIZING THE NUMBER OF STIMULATIONS AND TREATMENT
LOCATION IN TREATMENT-RESISTANT DEPRESSION
SO DEPRESSION AND ANXIETY
LA English
DT Article
DE transcranial magnetic stimulation; rTMS; high frequency rTMS; low
frequency rTMS; treatment-resistant depression
ID ASTERISK-D REPORT; MAJOR DEPRESSION; CONTROLLED-TRIAL; DISORDER;
OUTPATIENTS; THERAPY
AB Objective: To assess the efficacy of increasing the number of fast left repetitive transcranial magnetic stimulations (rTMS) (10 Hz @ 120% of motor threshold (MT) over the left dorsolateral prefrontal cortex (DLPFC)) needed to achieve remission in treatment-resistant depression (TRD). And, to determine if patients who do not remit to fast left will remit using slow right rTMS (1 Hz @ 120% MTover the right DLPFC). Method: Patients were part of a multicenter sham-controlled trial investigating the efficacy of fast left rTMS. Patients who failed to meet minimal response criteria in the sham-controlled study could enroll in this open fast left rTMS study for an additional 3-6 weeks. Patients who failed to remit to fast left could switch to slow right rTMS for up to 4 additional weeks. The final outcome measure was remission, defined as a HAM-D score of < 3 or 2 consecutive HAM-D scores less than 10. Results: Forty-three of 141 (30.5%) patients who enrolled in the open phase study eventually met criteria for remission. Patients who remitted during fast left treatment received a mean of 26 active treatments (90,000 pulses). Twenty-six percent of patients who failed fast left remitted during slow right treatment. Conclusion: The total number of rTMS stimulations needed to achieve remission in TRD may be higher than is used in most studies. TRD patients who do not respond to fast left rTMS may remit to slow right rTMS or additional rTMS stimulations. Depression and Anxiety 28: 973-980, 2011. (C) 2011 Wiley Periodicals, Inc.
C1 [McDonald, William M.] Emory Univ, Sch Med, Dept Psychiat & Behav Sci, Atlanta, GA 30329 USA.
[Durkalski, Valerie; Ball, Edward R., III] Med Univ S Carolina, Div Biostat & Epidemiol, Charleston, SC 29425 USA.
[Pavlicova, Martina] Columbia Univ Coll Phys & Surg, Dept Biostat, New York, NY 10032 USA.
[Lisanby, Sarah H.] Duke Univ, Dept Psychiat, Durham, NC 27706 USA.
[Avery, David; Zarkowski, Paul] Univ Washington, Dept Psychiat, Seattle, WA 98195 USA.
[Anderson, Berry S.; Nahas, Ziad; George, Mark S.] Med Univ S Carolina, Dept Psychiat, Charleston, SC 29425 USA.
[Sackeim, Harold A.] Columbia Univ Coll Phys & Surg, Dept Psychiat, New York, NY 10032 USA.
[George, Mark S.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA.
RP McDonald, WM (reprint author), Emory Univ, Sch Med, Dept Psychiat & Behav Sci, 1841 Clifton Rd NE, Atlanta, GA 30329 USA.
EM wmcdona@emory.edu
RI Holtzheimer, Paul/B-6212-2015
OI Holtzheimer, Paul/0000-0002-3552-3296
FU National Institute of Mental Health (NIMH) [5R01MH069929, 5R01MH069887,
5R01MH069896, 5R01MH069895, 5R01MH069886]; St. Jude Medical
Neuromodulation; AvaCat Consulting; Tetragenex; Neuronetics; Advanced
Neuromodulatory Systems; Brainsway; Cyberonics; Takeda; MECTA
Corporation; Medtronic; PureTech Ventures; NeoStim and NeoSync;
Brainsonix; Cephos
FX This study was supported by the National Institute of Mental Health
(NIMH) as the Optimization of TMS for the Treatment of Depression Study
(OPT-TMS) involving grants 5R01MH069929 (Dr. Avery), 5R01MH069887 (Dr.
George), 5R01MH069896 (Dr. George), 5R01MH069895 (Dr. Lisanby), and
5R01MH069886 (Dr. McDonald).; The authors disclose the following
financial relationships within the past 3 years: Following a competitive
bid and request involving all TMS manufacturers at the time of trial
initiation, Neuronetics Inc. was selected and loaned the TMS devices,
head holders, and coils for the trial and allowed use of the safety
Investigational Device Exemption for their device. Neuronetics did not
provide any financial support for the study which was funded by the
NIMH. Potential conflicts are reported over the past 3 years. Dr.
McDonald is presently an unpaid consultant to NeoStim. Dr. Holtzheimer
reports consulting fees from St. Jude Medical Neuromodulation, AvaCat
Consulting, and Tetragenex, and is an unpaid consultant to NeoStim. Drs.
McDonald and Holtzheimer are faculty at Emory University which holds a
patent on TMS technology. Neither received royalties or is involved in
the development or promotion of this patent. Dr. Lisanby reports
research grants, speaking fees, or advisory board work with Neuronetics,
Advanced Neuromodulatory Systems, Brainsway, and Cyberonics. Dr. Lisanby
has a patent application with Columbia University on neuromodulation
technology for which she receives no royalties or compensation. Dr.
Avery has received research support from Neuronetics and Takeda, has
been a consultant for Neuronetics and has been on the speaker's bureau
for Eli Lilly, Takeda and Forest Pharmaceuticals. Dr. Nahas reports past
and current research grants, speaking fees or consulting work with
Cyberonics, Neuronetics, MECTA Corporation, and Medtronic. Dr. Nahas has
acted as an unpaid consultant for Neuropace. Dr. Sackeim received
consultant fees from MECTA Corporation and Cyberonics. Dr. George
received consultant fees from PureTech Ventures and reports research
grants, speaking fees, or advisory work with Brainsway, Mecta
Corporation, Neuronetics, Cephos, NeoStim and NeoSync, Brainsonix,
Cyberonics, and Cephos. Dr. George is faculty at MUSC which has two
patent applications in Dr. George's name combining MRI and TMS.
NR 16
TC 34
Z9 36
U1 0
U2 12
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1091-4269
J9 DEPRESS ANXIETY
JI Depress. Anxiety
PD NOV
PY 2011
VL 28
IS 11
BP 973
EP 980
DI 10.1002/da.20885
PG 8
WC Psychology, Clinical; Psychiatry; Psychology
SC Psychology; Psychiatry
GA 850TH
UT WOS:000297221800005
PM 21898711
ER
PT J
AU Gros, DF
Antony, MM
McCabe, RE
Lydiard, RB
AF Gros, Daniel F.
Antony, Martin M.
McCabe, Randi E.
Lydiard, R. Bruce
TI A PRELIMINARY INVESTIGATION OF THE EFFECTS OF COGNITIVE BEHAVIORAL
THERAPY FOR PANIC DISORDER ON GASTROINTESTINAL DISTRESS IN PATIENTS WITH
COMORBID PANIC DISORDER AND IRRITABLE BOWEL SYNDROME
SO DEPRESSION AND ANXIETY
LA English
DT Article
DE cognitive behavioral therapy; comorbidity; panic disorder; irritable
bowel syndrome
ID RANDOMIZED CONTROLLED-TRIAL; ANXIETY STRESS SCALES; DEPRESSION;
SYMPTOMS; DYSREGULATION; FIBROMYALGIA; CYTOKINES; AXIS; INFLAMMATION;
RELIABILITY
AB Background: High comorbidity between panic disorder with/without agoraphobia (PD/A) and irritable bowel syndrome (IBS) has been identified in the literature. These findings have resulted in the recent development of neurobiological models to explain their overlapping symptoms and related origins. This study was a preliminary investigation of the influence of cognitive behavioral therapy (CBT) for PD/A on PD/A patients with and without comorbid IBS. Methods: All patients completed a thorough intake assessment, brief waitlist period, and a 12-week CBT group for PD/A. Results: The results demonstrated significant reductions in the symptoms of anxiety, depression, and overall impairment in both patient groups (ts > 2.3; Ps <.05). In addition, PD/A patients with comorbid IBS also experienced reductions in the disability and distress associated with their gastrointestinal symptoms of IBS (ts > 1.9; Ps <.07). Conclusions: Although additional research still is needed, these preliminary findings suggest that CBT for PD/A can be used to simultaneously treat comorbid symptoms of PD/A and IBS. Implications for the neurobiological models for these comorbid conditions were discussed. Depression and Anxiety 28: 1027-1033, 2011. (C) 2011 Wiley Periodicals, Inc.
C1 [Gros, Daniel F.; Lydiard, R. Bruce] Ralph H Johnson VAMC, Mental Hlth Serv, Charleston, SC USA.
[Gros, Daniel F.; Lydiard, R. Bruce] Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA.
[Antony, Martin M.] Ryerson Univ, Dept Psychol, Toronto, ON, Canada.
[Antony, Martin M.; McCabe, Randi E.] St Josephs Healthcare, Anxiety Treatment & Res Ctr, Hamilton, ON, Canada.
[McCabe, Randi E.] McMaster Univ, Dept Psychiat & Behav Neurosci, Hamilton, ON, Canada.
RP Gros, DF (reprint author), Ralph H Johnson VAMC, Mental Hlth Serv 116, 109 Bee St, Charleston, SC 29401 USA.
EM grosd@musc.edu
RI Antony, Martin/K-1991-2012
OI Antony, Martin/0000-0002-3508-377X
FU Ralph H. Johnson VAMC
FX This material is the result of work supported with resources and the use
of facilities at the Ralph H. Johnson VAMC. The views expressed in this
article are those of the authors and do not necessarily reflect the
position or policy of the Department of Veterans Affairs or the United
States government.
NR 45
TC 2
Z9 2
U1 3
U2 6
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1091-4269
J9 DEPRESS ANXIETY
JI Depress. Anxiety
PD NOV
PY 2011
VL 28
IS 11
BP 1027
EP 1033
DI 10.1002/da.20863
PG 7
WC Psychology, Clinical; Psychiatry; Psychology
SC Psychology; Psychiatry
GA 850TH
UT WOS:000297221800011
PM 21770001
ER
PT J
AU Shin, JM
Inatomi, N
Munson, K
Strugatsky, D
Tokhtaeva, E
Vagin, O
Sachs, G
AF Shin, Jai Moo
Inatomi, Nobuhiro
Munson, Keith
Strugatsky, David
Tokhtaeva, Elmira
Vagin, Olga
Sachs, George
TI Characterization of a Novel Potassium-Competitive Acid Blocker of the
Gastric H,K-ATPase,
1-[5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylm
ethanamine Monofumarate (TAK-438)
SO JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
LA English
DT Article
ID GASTROESOPHAGEAL-REFLUX DISEASE; PROTON PUMP INHIBITOR; BINDING-SITES;
ESOMEPRAZOLE; H+,K+-ATPASE; ATPASE; LANSOPRAZOLE; SECRETION; MEMBRANES;
VESICLES
AB Inhibition of the gastric H, K-ATPase by the potassium-competitive acid blocker (P-CAB) 1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine (TAK-438), is strictly K(+)-competitive with a K(i) of 10 nM at pH 7. In contrast to previous P-CABs, this structure has a point positive charge (pK(a) 9.06) allowing for greater accumulation in parietal cells compared with previous P-CABs [e.g., (8-benzyloxy-2-methyl-imidazo(1,2-a)pyridin-3-yl)acetonitrile (SCH28080), pK(a) 5.6]. The dissociation rate of the compound from the isolated ATPase is slower than other P-CABs, with the t(1/2) being 7.5 h in 20 mM KCl at pH 7. The stoichiometry of binding of TAK-438 to the H,K-ATPase is 2.2 nmol/mg in the presence of Mg-ATP, vanadate, or MgP(i). However, TAK-438 also binds enzyme at 1.3 nmol/mg in the absence of Mg(2+). Modeling of the H, K-ATPase to the homologous Na,K-ATPase predicts a close approach and hydrogen bonding between the positively charged N-methylamino group and the negatively charged Glu795 in the K(+)-binding site in contrast to the planar diffuse positive charge of previous P-CABs. This probably accounts for the slow dissociation and high affinity. The model also predicts hydrogen bonding between the hydroxyl of Tyr799 and the oxygens of the sulfonyl group of TAK-438. A Tyr799Phe mutation resulted in a 3-fold increase of the dissociation rate, showing that this hydrogen bonding also contributes to the slow dissociation rate. Hence, this K(+)-competitive inhibitor of the gastric H,K-ATPase should provide longer-lasting inhibition of gastric acid secretion compared with previous drugs of this class.
C1 [Shin, Jai Moo] VA Greater Los Angeles Healthcare Syst, Membrane Biol Lab, Los Angeles, CA 90073 USA.
[Shin, Jai Moo; Munson, Keith; Strugatsky, David; Tokhtaeva, Elmira; Vagin, Olga; Sachs, George] Univ Calif Los Angeles, David Geffen Sch Med, Dept Physiol & Med, Los Angeles, CA 90024 USA.
[Inatomi, Nobuhiro] Takeda Pharmaceut Co Ltd, Div Pharmaceut Res, Osaka, Japan.
RP Shin, JM (reprint author), VA Greater Los Angeles Healthcare Syst, Membrane Biol Lab, 11301 Wilshire Blvd,Bldg 113,Rm 324, Los Angeles, CA 90073 USA.
EM jaishin@ucla.edu
FU Takeda Pharmaceutical Company Limited; National Institutes of Health
National Institute of Diabetes and Digestive and Kidney Diseases
[DK053642, DK058333, DK077149]; U.S. VA Merit Grant Award
[I01BX001006-01]
FX This work was supported by Takeda Pharmaceutical Company Limited; the
National Institutes of Health National Institute of Diabetes and
Digestive and Kidney Diseases [Grants DK053642, DK058333, DK077149]; and
a U.S. VA Merit Grant Award [I01BX001006-01].
NR 30
TC 40
Z9 42
U1 0
U2 10
PU AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3995 USA
SN 0022-3565
J9 J PHARMACOL EXP THER
JI J. Pharmacol. Exp. Ther.
PD NOV
PY 2011
VL 339
IS 2
BP 412
EP 420
DI 10.1124/jpet.111.185314
PG 9
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 840TS
UT WOS:000296464800011
PM 21828261
ER
PT J
AU Wang, JH
Inoue, T
Higashiyama, M
Guth, PH
Engel, E
Kaunitz, JD
Akiba, Y
AF Wang, Joon-Ho
Inoue, Takuya
Higashiyama, Masaaki
Guth, Paul H.
Engel, Eli
Kaunitz, Jonathan D.
Akiba, Yasutada
TI Umami Receptor Activation Increases Duodenal Bicarbonate Secretion via
Glucagon-Like Peptide-2 Release in Rats
SO JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
LA English
DT Article
ID VASOACTIVE INTESTINAL POLYPEPTIDE; PIG SMALL-INTESTINE; ENTEROENDOCRINE
CELLS; TASTE RECEPTORS; GLP-2 RECEPTOR; GUT; ACID; STIMULATION;
MECHANISMS; TRANSPORT
AB Luminal nutrient chemosensing during meal ingestion is mediated by intestinal endocrine cells, which regulate secretion and motility via the release of gut hormones. We have reported that luminal coperfusion of L-Glu and IMP, common condiments providing the umami or proteinaceous taste, synergistically increases duodenal bicarbonate secretion (DBS) possibly via taste receptor heterodimers, taste receptor type 1, member 1 (T1R1)/R3. We hypothesized that glucose-dependent insulinotropic peptide (GIP) or glucagon-like peptide (GLP) is released by duodenal perfusion with L-Glu/IMP. We measured DBS with pH and CO(2) electrodes through a perfused rat duodenal loop in vivo. GIP, exendin (Ex)-4 (GLP-1 receptor agonist), or GLP-2 was intravenously infused (0.01-1 nmol/kg/h). L-Glu (10 mM) and IMP (0.1 mM) were luminally perfused with or without bolus intravenous injection (3 or 30 nmol/kg) of the receptor antagonists Pro(3)GIP, Ex-3(9-39), or GLP-2(3-33). GIP or GLP-2 infusion dose-dependently increased DBS, whereas Ex-4 infusion gradually decreased DBS. Luminal perfusion of L-Glu/IMP increased DBS, with no effect of Pro(3)GIP or Ex-3(9-39), whereas GLP-2(3-33) inhibited L-Glu/IMP-induced DBS. Vasoactive intestinal peptide (VIP)(6-28) intravenously or N(G)-nitro-L-arginine methyl ester coperfusion inhibited the effect of L-Glu/IMP. Perfusion of L-Glu/IMP increased portal venous concentrations of GLP-2, followed by a delayed increase of GLP-1, with no effect on GIP release. GLP-1/2 and T1R1/R3 were expressed in duodenal endocrine-like cells. These results suggest that luminal L-Glu/IMP-induced DBS is mediated via GLP-2 release and receptor activation followed by VIP and nitric oxide release. Because GLP-1 is insulinotropic and GLP-2 is intestinotrophic, umami receptor activation may have additional benefits in glucose metabolism and duodenal mucosal protection and regeneration.
C1 [Wang, Joon-Ho; Inoue, Takuya; Higashiyama, Masaaki; Kaunitz, Jonathan D.; Akiba, Yasutada] Univ Calif Los Angeles, Sch Med, Dept Med, Los Angeles, CA 90024 USA.
[Engel, Eli] Univ Calif Los Angeles, Dept Biomath, Los Angeles, CA USA.
Greater Los Angeles Vet Affairs Healthcare Syst, Los Angeles, CA USA.
[Kaunitz, Jonathan D.; Akiba, Yasutada] Brentwood Biomed Res Inst, Los Angeles, CA USA.
RP Akiba, Y (reprint author), W Los Angeles VA Med Ctr, 11301 Wilshire Blvd,Bldg 114,Suite 217, Los Angeles, CA 90073 USA.
EM yakiba@mednet.ucla.edu
FU Ajinomoto, Inc. (Tokyo, Japan); Department of Veterans Affairs Merit
Review Award; National Institutes of Health National Institute of
Diabetes and Digestive and Kidney Diseases [R01-DK54221, P30-DK0413]
FX This work was supported by a research grant from Ajinomoto, Inc. (Tokyo,
Japan) (to Y.A.); a Department of Veterans Affairs Merit Review Award
(to J.D.K.); the National Institutes of Health National Institute of
Diabetes and Digestive and Kidney Diseases [Grant R01-DK54221] (to
J.D.K.); and the Animal Core of the National Institutes of Health
National Institute of Diabetes and Digestive and Kidney Diseases [Grant
P30-DK0413] (to J. E. Rozengurt).
NR 42
TC 38
Z9 39
U1 1
U2 5
PU AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3995 USA
SN 0022-3565
J9 J PHARMACOL EXP THER
JI J. Pharmacol. Exp. Ther.
PD NOV
PY 2011
VL 339
IS 2
BP 464
EP 473
DI 10.1124/jpet.111.184788
PG 10
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 840TS
UT WOS:000296464800016
PM 21846840
ER
PT J
AU Deyo, RA
Smith, DHM
Johnson, ES
Donovan, M
Tillotson, CJ
Yang, XH
Petrik, AF
Dobscha, SK
AF Deyo, Richard A.
Smith, David H. M.
Johnson, Eric S.
Donovan, Marilee
Tillotson, Carrie J.
Yang, Xiuhai
Petrik, Amanda F.
Dobscha, Steven K.
TI Opioids for Back Pain Patients: Primary Care Prescribing Patterns and
Use of Services
SO JOURNAL OF THE AMERICAN BOARD OF FAMILY MEDICINE
LA English
DT Article
DE Analgesics; Back Pain; Pain Control; Quality of Health Care
ID CHRONIC NONCANCER PAIN; UNITED-STATES; MENTAL-HEALTH; TRENDS;
PRESCRIPTIONS; ASSOCIATION; INDIVIDUALS; DISORDERS; WORKERS; ABUSE
AB Background: Opioid prescribing for noncancer pain has increased dramatically. We examined whether the prevalence of unhealthy lifestyles, psychologic distress, health care utilization, and co-prescribing of sedative-hypnotics increased with increasing duration of prescription opioid use.
Methods: We analyzed electronic data for 6 months before and after an index visit for back pain in a managed care plan. Use of opioids was characterized as "none," "acute" (<= 90 days), " episodic," or "long term." Associations with lifestyle factors, psychologic distress, and utilization were adjusted for demographics and comorbidity.
Results: There were 26,014 eligible patients. Of these, 61% received a course of opioids, and 19% were long-term users. Psychologic distress, unhealthy lifestyles, and utilization were associated incrementally with duration of opioid prescription, not just with chronic use. Among long-term opioid users, 59% received only short-acting drugs; 39% received both long-and short-acting drugs; and 44% received a sedative-hypnotic. Of those with any opioid use, 36% had an emergency visit.
Conclusions: Prescription of opioids was common among patients with back pain. The prevalence of psychologic distress, unhealthy lifestyles, and health care utilization increased incrementally with duration of use. Coprescribing sedative-hypnotics was common. These data may help in predicting long-term opioid use and improving the safety of opioid prescribing. (J Am Board Fam Med 2011;24:717-727.)
C1 [Deyo, Richard A.] Oregon Hlth & Sci Univ, Dept Family Med, Portland, OR 97239 USA.
[Deyo, Richard A.] Oregon Hlth & Sci Univ, Dept Med, Portland, OR USA.
[Dobscha, Steven K.] Oregon Hlth & Sci Univ, Dept Psychiat, Portland, OR USA.
[Deyo, Richard A.; Tillotson, Carrie J.] Oregon Hlth & Sci Univ, Oregon Clin & Translat Res Inst, Portland, OR USA.
[Deyo, Richard A.] Oregon Hlth & Sci Univ, Ctr Res Occupat & Environm Toxicol, Portland, OR USA.
[Deyo, Richard A.; Smith, David H. M.; Johnson, Eric S.; Donovan, Marilee; Yang, Xiuhai; Petrik, Amanda F.] Kaiser Permanente Ctr Hlth Res, Portland, OR USA.
[Dobscha, Steven K.] Portland VA Med Ctr, Ctr Study Comorbid Mental & Phys Disorders, Portland, OR USA.
RP Deyo, RA (reprint author), Oregon Hlth & Sci Univ, Dept Family Med, Mail Code FM,3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA.
EM deyor@ohsu.edu
FU Oregon Clinical and Translational Research Institute [UL1 RR024140];
National Center for Research Resources, National Institutes of Health;
National Institutes of Health Roadmap for Medical Research
FX This study was made possible with support from the Oregon Clinical and
Translational Research Institute grant no. UL1 RR024140; from the
National Center for Research Resources, a component of the National
Institutes of Health; and the National Institutes of Health Roadmap for
Medical Research.
NR 31
TC 48
Z9 49
U1 1
U2 6
PU AMER BOARD FAMILY MEDICINE
PI LEXINGTON
PA 2228 YOUNG DR, LEXINGTON, KY 40505 USA
SN 1557-2625
J9 J AM BOARD FAM MED
JI J. Am. Board Fam. Med.
PD NOV-DEC
PY 2011
VL 24
IS 6
BP 717
EP 727
DI 10.3122/jabfm.2011.06.100232
PG 11
WC Primary Health Care; Medicine, General & Internal
SC General & Internal Medicine
GA 849UI
UT WOS:000297150400016
PM 22086815
ER
PT J
AU Nace, DA
Perera, S
Handler, SM
Muder, R
Hoffman, EL
AF Nace, David A.
Perera, Subashan
Handler, Steven M.
Muder, Robert
Hoffman, Erika L.
TI Increasing Influenza and Pneumococcal Immunization Rates in a Nursing
Home Network
SO JOURNAL OF THE AMERICAN MEDICAL DIRECTORS ASSOCIATION
LA English
DT Article
DE Nursing homes; immunizations; influenza; health care workers;
pneumococcal vaccine
ID LONG-TERM-CARE; RANDOMIZED CONTROLLED-TRIAL; QUALITY IMPROVEMENT;
UNITED-STATES; VACCINATION RATES; WORKERS; STAFF; HOSPITALIZATIONS;
PERFORMANCE; MORTALITY
AB Introduction and Rationale: Influenza and pneumonia remain serious health concerns for long-term care (LTC) residents. Vaccination of LTC residents and health care workers are reasonable preventive strategies, although most facilities fall short of Healthy People 2010 goals. Improving immunization rates across multiple LTC facilities remains an elusive challenge. This quality improvement study sought to improve immunization rates across 6 LTC facilities and identify persistent barriers to better performance.
Methods: In 2002, 6 facilities associated with the University of Pittsburgh Institute on Aging established a quality improvement network addressing immunization rates. The facilities were provided with a written educational toolkit and shared information through an e-mail distribution list. To help determine optimal program structure in future years, 3 of the facilities participated in a single half-day collaborative training session. Change in immunization rates from baseline to year 2 were compared between those participating in the collaborative training and those not participating. Barriers to improved performance were sought from all groups through focus group analysis.
Results: Facilities participating in the single collaborative training program improved immunization rates modestly, whereas facilities not participating in the collaborative training saw decreases in immunization rates. Staff turnover was cited as a significant barrier to improved performance.
Discussion: It may be possible to improve immunization rates in LTC facilities, at least modestly, using a collaborative training process. Staff turnover may be an important barrier to improved LTC immunization rates. (J Am Med Dir Assoc 2011; 12: 678-684)
C1 [Nace, David A.; Perera, Subashan; Handler, Steven M.] Univ Pittsburgh, Dept Med, Div Geriatr Med, Sch Med, Pittsburgh, PA 15213 USA.
[Perera, Subashan] Univ Pittsburgh, Dept Biostat, Grad Sch Publ Hlth, Pittsburgh, PA 15213 USA.
[Handler, Steven M.; Muder, Robert; Hoffman, Erika L.] Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
RP Nace, DA (reprint author), Univ Pittsburgh, Dept Med, Div Geriatr Med, Sch Med, 3471 5th Ave,Suite 500, Pittsburgh, PA 15213 USA.
EM naceda@upmc.edu
RI Nace, David/D-2638-2014; Perera, Subashan/D-7603-2014
OI Handler, Steven/0000-0002-3940-3224
FU American Medical Directors Association Foundation/Pfizer
FX This project was funded by the 2002 American Medical Directors
Association Foundation/Pfizer Quality Improvement Awards.
NR 41
TC 3
Z9 3
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1525-8610
J9 J AM MED DIR ASSOC
JI J. Am. Med. Dir. Assoc.
PD NOV
PY 2011
VL 12
IS 9
BP 678
EP 684
DI 10.1016/j.jamda.2010.05.002
PG 7
WC Geriatrics & Gerontology
SC Geriatrics & Gerontology
GA 850ZT
UT WOS:000297238800012
PM 21450182
ER
PT J
AU Short, EB
Borckardt, JJ
Anderson, BS
Frohman, H
Beam, W
Reeves, ST
George, MS
AF Short, E. Baron
Borckardt, Jeffrey J.
Anderson, Berry S.
Frohman, Heather
Beam, William
Reeves, Scott T.
George, Mark S.
TI Ten sessions of adjunctive left prefrontal rTMS significantly reduces
fibromyalgia pain: A randomized, controlled pilot study
SO PAIN
LA English
DT Article
DE Depression; Fibromyalgia; Pain; Tender points; Transcranial magnetic
stimulation
ID TRANSCRANIAL MAGNETIC STIMULATION; MAJOR DEPRESSIVE DISORDER;
PLACEBO-CONTROLLED TRIAL; CHRONIC WIDESPREAD PAIN; DOUBLE-BLIND;
CLINICAL-TRIAL; MULTICENTER; EFFICACY; CORTEX; MILNACIPRAN
AB Transcranial magnetic stimulation (TMS) of the prefrontal cortex can cause changes in acute pain perception. Several weeks of daily left prefrontal TMS has been shown to treat depression. We recruited 20 patients with fibromyalgia, defined by American College of Rheumatology criteria, and randomized them to receive 4000 pulses at 10 Hz TMS (n = 10), or sham TMS (n = 10) treatment for 10 sessions over 2 weeks along with their standard medications, which were fixed and stable for at least 4 weeks before starting sessions. Subjects recorded daily pain, mood, and activity. Blinded raters assessed pain, mood, functional status, and tender points weekly with the Brief Pain Inventory, Hamilton Depression Rating Scale, and Fibromyalgia Impact Questionnaire. No statistically significant differences between groups were observed. Patients who received active TMS had a mean 29% (statistically significant) reduction in pain symptoms in comparison to their baseline pain. Sham TMS participants had a 4% nonsignificant change in daily pain from their baseline pain. At 2 weeks after treatment, there was a significant improvement in depression symptoms in the active group compared to baseline. Pain reduction preceded antidepressant effects. TMS was well tolerated, with few side effects. Further studies that address study limitations are needed to determine whether daily prefrontal TMS may be an effective, durable, and clinically useful treatment for fibromyalgia symptoms. (C) 2011 International Association for the Study of Pain. Published by Elsevier B.V. All rights reserved.
C1 [Short, E. Baron; Borckardt, Jeffrey J.; Frohman, Heather; Beam, William; George, Mark S.] Med Univ S Carolina, Dept Psychiat & Behav Sci, Brain Stimulat Lab, Charleston, SC 29425 USA.
[Borckardt, Jeffrey J.; Reeves, Scott T.] Med Univ S Carolina, Dept Anesthesia & Perioperat Med, Charleston, SC 29425 USA.
[Anderson, Berry S.] Med Univ S Carolina, Coll Nursing, Charleston, SC 29425 USA.
[George, Mark S.] Ralph H Johnson VA Med Ctr, Charleston, SC 29401 USA.
RP Short, EB (reprint author), Med Univ S Carolina, Dept Psychiat & Behav Sci, Brain Stimulat Lab, 67 President St,POB 250861, Charleston, SC 29425 USA.
EM shorteb@musc.edu
OI Frohman, Heather/0000-0001-5199-7654
FU Office of the Provost and Vice President for Research [P60 AR049459]
FX Funding for this pilot project, under Multidisciplinary Clinical
Research Center Grant P60 AR049459, was generously provided by the
Office of the Provost and Vice President for Research.
ClinicalTrials.gov identifier NCT00523302.
NR 51
TC 35
Z9 38
U1 0
U2 5
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0304-3959
J9 PAIN
JI Pain
PD NOV
PY 2011
VL 152
IS 11
BP 2477
EP 2484
DI 10.1016/j.pain.2011.05.033
PG 8
WC Anesthesiology; Clinical Neurology; Neurosciences
SC Anesthesiology; Neurosciences & Neurology
GA 842AB
UT WOS:000296556200009
PM 21764215
ER
PT J
AU Liao, YH
Tang, JS
Deng, QJ
Deng, YW
Luo, T
Wang, XY
Chen, HX
Liu, TQ
Chen, XG
Brody, AL
Hao, W
AF Liao, Yanhui
Tang, Jinsong
Deng, Qijian
Deng, Yongwen
Luo, Tao
Wang, Xuyi
Chen, Hongxian
Liu, Tieqiao
Chen, Xiaogang
Brody, Arthur L.
Hao, Wei
TI Bilateral Fronto-Parietal Integrity in Young Chronic Cigarette Smokers:
A Diffusion Tensor Imaging Study
SO PLOS ONE
LA English
DT Article
ID WHITE-MATTER ABNORMALITIES; SPINAL-CORD NEURONS; ANISOTROPIC WATER
DIFFUSION; MAGNETIC-RESONANCE; MICROSTRUCTURAL INTEGRITY;
HUNTINGTONS-DISEASE; TOBACCO CONTROL; NICOTINE; BRAIN; SMOKING
AB Background: Cigarette smoking continues to be the leading cause of preventable morbidity and mortality in China and other countries. Previous studies have demonstrated gray matter loss in chronic smokers. However, only a few studies assessed the changes of white matter integrity in this group. Based on those previous reports of alterations in white matter integrity in smokers, the aim of this study was to examine the alteration of white matter integrity in a large, well-matched sample of chronic smokers and non-smokers.
Methodology/Principal Findings: Using in vivo diffusion tensor imaging (DTI) to measure the differences of whole-brain white matter integrity between 44 chronic smoking subjects (mean age, 28.0 +/- 5.6 years) and 44 healthy age- and sex-matched comparison non-smoking volunteers (mean age, 26.3 +/- 5.8 years). DTI was performed on a 3-Tesla Siemens scanner (Allegra; Siemens Medical System). The data revealed that smokers had higher fractional anisotropy (FA) than healthy non-smokers in almost symmetrically bilateral fronto-parietal tracts consisting of a major white matter pathway, the superior longitudinal fasciculus (SLF).
Conclusion/Significance: We found the almost symmetrically bilateral fronto-parietal whiter matter changes in a relatively large sample of chronic smokers. These findings support the hypothesis that chronic cigarette smoking involves alterations of bilateral fronto-parietal connectivity.
C1 [Liao, Yanhui; Tang, Jinsong; Deng, Qijian; Luo, Tao; Wang, Xuyi; Chen, Hongxian; Liu, Tieqiao; Chen, Xiaogang; Hao, Wei] Cent S Univ, Xiangya Hosp 2, Mental Hlth Inst, Changsha, Hunan, Peoples R China.
[Deng, Yongwen] Peoples Hosp Hunan Prov, Dept Neurosurg, Changsha, Hunan, Peoples R China.
[Brody, Arthur L.] Univ Calif Los Angeles, Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA.
[Brody, Arthur L.] Greater Los Angeles VA Healthcare Syst, Dept Psychiat, Los Angeles, CA USA.
[Brody, Arthur L.] Greater Los Angeles VA Healthcare Syst, Dept Res, Los Angeles, CA USA.
RP Liao, YH (reprint author), Cent S Univ, Xiangya Hosp 2, Mental Hlth Inst, Changsha, Hunan, Peoples R China.
EM abrody@ucla.edu; weihaochangsha@gmail.com
RI Liao, Yanhui/L-1590-2016
OI Liao, Yanhui/0000-0003-4735-3252
FU Central Colleges basic scientific research operating expenses; National
Key Technology R&D Program in the 11th Five-Year Plan of China
[2011QNZT170, 2007BAI07B01]; Natural Science Foundation of China
[81100996, 30971050, 30900486, 81130020]; National Key Basic Research
and Development Program(NKBRDP) (973) [2009CB522000]; Hunan Provincial
Natural Science Foundation of China [10JJ5038]; Tobacco-Related Disease
Research Program [19XT-0135]; National Institute on Drug Abuse [R01
DA20872]; China Scholarship Council; University of Cambridge;
Behavioural and Clinical Neuroscience Institute; Veterans Affairs Type I
Merit Review Award; Richard Metzner Chair in Clinical Neuropharmacology
FX This work was supported by grants from the Central Colleges basic
scientific research operating expenses. 2011QNZT170, National Key
Technology R&D Program in the 11th Five-Year Plan of China
(2007BAI07B01), Natural Science Foundation of China (81100996, 30971050,
30900486, 81130020), National Key Basic Research and Development
Program(NKBRDP) (973, 2009CB522000) and from Hunan Provincial Natural
Science Foundation of China (10JJ5038). Tobacco-Related Disease Research
Program (19XT-0135), the National Institute on Drug Abuse (R01 DA20872),
a Veterans Affairs Type I Merit Review Award, and an endowment from the
Richard Metzner Chair in Clinical Neuropharmacology. Yanhui Liao is
supported by a fellowship from the China Scholarship Council to study at
University of Cambridge, Behavioural and Clinical Neuroscience
Institute. The funders had no role in study design, data collection and
analysis, decision to publish, or preparation of the manuscript.
NR 61
TC 20
Z9 21
U1 1
U2 7
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD NOV 1
PY 2011
VL 6
IS 11
AR e26460
DI 10.1371/journal.pone.0026460
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 849UN
UT WOS:000297150900014
PM 22069452
ER
PT J
AU Kuna, ST
AF Kuna, Samuel T.
TI Back to the Future or Forward to the Past?
SO SLEEP
LA English
DT Editorial Material
ID OBSTRUCTIVE SLEEP-APNEA; NERVE-STIMULATION; HYPOGLOSSAL NERVE; UPPER
AIRWAY
C1 [Kuna, Samuel T.] Philadelphia VA Med Ctr, Pulm Crit Care & Sleep Sect, Philadelphia, PA 19104 USA.
[Kuna, Samuel T.] Univ Penn, Philadelphia, PA 19104 USA.
RP Kuna, ST (reprint author), Philadelphia VA Med Ctr, Pulm Crit Care & Sleep Sect, 111P,3900 Woodland Av, Philadelphia, PA 19104 USA.
EM skuna@mail.med.upenn.edu
NR 14
TC 1
Z9 1
U1 0
U2 1
PU AMER ACAD SLEEP MEDICINE
PI WESTCHESTER
PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA
SN 0161-8105
J9 SLEEP
JI Sleep
PD NOV 1
PY 2011
VL 34
IS 11
BP 1455
EP 1456
DI 10.5665/sleep.1370
PG 2
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 844DF
UT WOS:000296727200003
PM 22043113
ER
PT J
AU Robinson, TN
Wu, DS
Stiegmann, GV
Moss, M
AF Robinson, Thomas N.
Wu, Daniel S.
Stiegmann, Gregory V.
Moss, Marc
TI Frailty predicts increased hospital and six-month healthcare cost
following colorectal surgery in older adults
SO AMERICAN JOURNAL OF SURGERY
LA English
DT Article; Proceedings Paper
CT 35th Annual Meeting of the Association of VA Surgeons
CY APR 10-12, 2011
CL Irvine, CA
SP Assoc VA Surg
DE Geriatric; Surgery; Financial; Frailty; Healthcare resources
AB BACKGROUND: The purpose of this study was to determine the relationship of frailty and 6-month postoperative costs.
METHODS: Subjects aged >= 65 years undergoing elective colorectal operations were enrolled in a prospective observational study. Frailty was assessed by a validated measure of function, cognition, nutrition, comorbidity burden, and geriatric syndromes. Frailty was quantified by summing the number of positive characteristics in each subject.
RESULTS: Sixty subjects (mean age, 75 +/- 8 years) were studied. Inpatient mortality was 2% (n = 1). Overall, 40% of subjects (n = 24) were considered nonfrail, 22% (n = 13) were prefrail, and 38% (n = 22) were frail. With advancing frailty, hospital costs increased (P < .001) and costs from discharge to 6-months increased (P < .001). Higher degrees of frailty were related to increased rates of discharge institutionalization (P < .001) and 30-day readmission (P = .044).
CONCLUSIONS: A simple, brief preoperative frailty assessment accurately forecasts increased surgical hospital costs and postdischarge to 6-month healthcare costs after colorectal operations in older adults. Published by Elsevier Inc.
C1 [Robinson, Thomas N.; Wu, Daniel S.; Stiegmann, Gregory V.] Denver Vet Affairs Med Ctr, Dept Surg, Denver, CO USA.
[Robinson, Thomas N.; Wu, Daniel S.; Stiegmann, Gregory V.] Univ Colorado Denver, Hlth Sci Ctr, Dept Surg, Aurora, CO USA.
[Moss, Marc] Univ Colorado Denver, Hlth Sci Ctr, Dept Med, Aurora, CO USA.
RP Robinson, TN (reprint author), Denver Vet Affairs Med Ctr, Dept Surg, Denver, CO USA.
EM thomas.robinson@ucdenver.edu
FU NHLBI NIH HHS [K24 HL089223, K24 HL089223-04, K24 HL089223-05,
K24-HL-089223]; NIA NIH HHS [K23 AG034632-02, K23 AG034632, K23
AG034632-01A1, K23AG034632]
NR 11
TC 73
Z9 74
U1 1
U2 7
PU EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC
PI BRIDGEWATER
PA 685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA
SN 0002-9610
J9 AM J SURG
JI Am. J. Surg.
PD NOV
PY 2011
VL 202
IS 5
BP 511
EP 514
DI 10.1016/j.amjsurg.2011.06.017
PG 4
WC Surgery
SC Surgery
GA 848CJ
UT WOS:000297025700005
PM 21890098
ER
PT J
AU Khot, S
Billings, M
Owens, D
Longstreth, WT
AF Khot, Sandeep
Billings, Martha
Owens, Darrell
Longstreth, W. T., Jr.
TI Coping With Death and Dying on a Neurology Inpatient Service Death
Rounds as an Educational Initiative for Residents
SO ARCHIVES OF NEUROLOGY
LA English
DT Article
ID CARE; PATIENT
AB Background: Residents in neurology may feel unprepared to care for dying patients. We developed Death Rounds to provide emotional support and end-of-life care teaching for residents caring for dying patients on the inpatient neurology service. Death Rounds are monthly 1-hour clinical case discussions where residents identify issues through shared experiences.
Objective: To survey neurology residents' perceptions of Death Rounds with respect to end-of-life care teaching and emotional support.
Design, Setting, and Participants: We conducted an electronic survey of all (n = 26) neurology residents and recent residency graduates at the University of Washington 2 years after instituting monthly Death Rounds.
Main Outcome Measure: The survey consisted of 10 questions examining residents' perceptions of the extent to which Death Rounds provided emotional support and end-of-life care teaching. We dichotomized responses to statements about Death Rounds as agree or disagree.
Results: All 26 residents responded to the survey and attended at least 1 Death Rounds session. More than half of residents attended more than 3 sessions. Residents agreed that Death Rounds helped them cope with dying patients (17 residents [65%]), delivered closure for the team (16 residents [61%]), and provided emotional support, more for the team (18 residents [69%]) than the individual (10 residents [38%]). Most residents felt that Death Rounds provided useful teaching about end-of-life care (18 residents [69%]), and they were satisfied overall with Death Rounds (16 residents [61%]).
Conclusions: Death Rounds afford an opportunity for physicians-in-training to process as a group their feelings, intense emotions, and insecurities while learning from the dying process. In our inpatient neurology service, most residents found it a rewarding and valuable experience.
C1 [Khot, Sandeep; Longstreth, W. T., Jr.] Univ Washington, Dept Neurol, Seattle, WA 98104 USA.
[Billings, Martha] Vet Affairs Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, Div Pulm & Crit Care Med, Seattle, WA USA.
[Owens, Darrell] Univ Washington, Harborview Med Ctr, Palliat Care Serv, Seattle, WA 98104 USA.
RP Khot, S (reprint author), Univ Washington, Dept Neurol, 325 9th Ave,Box 359775, Seattle, WA 98104 USA.
EM skhot@uw.edu
NR 8
TC 10
Z9 10
U1 0
U2 4
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA
SN 0003-9942
J9 ARCH NEUROL-CHICAGO
JI Arch. Neurol.
PD NOV
PY 2011
VL 68
IS 11
BP 1395
EP 1397
PG 3
WC Clinical Neurology
SC Neurosciences & Neurology
GA 847ZI
UT WOS:000297014900004
PM 22084123
ER
PT J
AU Wecht, JM
Radulovic, M
Rosado-Rivera, D
Zhang, RL
LaFountaine, MF
Bauman, WA
AF Wecht, Jill M.
Radulovic, Miroslav
Rosado-Rivera, Dwindally
Zhang, Run-Lin
LaFountaine, Michael F.
Bauman, William A.
TI Orthostatic Effects of Midodrine Versus L-NAME on Cerebral Blood Flow
and the Renin-Angiotensin-Aldosterone System in Tetraplegia
SO ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION
LA English
DT Article
DE Blood pressure; Hypotension; orthostatic; Rehabilitation; Spinal cord
injuries
ID NITRIC-OXIDE SYNTHASE; SPINAL-CORD-INJURY; SIMULATED MICROGRAVITY;
TRANSCRANIAL DOPPLER; MYOCARDIAL-INFARCTION; HYPOTENSION; INHIBITION;
PRESSURE; RISK; HYDROCHLORIDE
AB Objective: To compare responses to head-up tilt (HUT) in individuals with chronic tetraplegia after midodrine hydrochloride (10mg) versus nitro-L-arginine methyl ester (L-NAME, 1mg/kg) administration.
Design: Prospective comparative drug trial.
Setting: Veterans Affairs medical center.
Participants: Participants (N=7) were studied during 3 laboratory visits: no drug, midodrine (administered orally 30min before HUT), and L-NAME (infused over a 60-min period).
Interventions: Anti-hypotensive agents, midodrine, and L-NAME.
Main Outcome Measures: Mean arterial pressure (MAP), cerebral blood flow (CBF), and markers of the renin-angiotensin-aldosterone system (RAAS, plasma renin and serum aldosterone) were measured in the supine position at baseline (BL) and during a 45 degrees HUT maneuver. Data were compared between BL and the average of 3 assessments collected during HUT. Results: Orthostatic MAP and CBF were increased with the midodrine and L-NAME groups compared with the no drug trial and the relationship between the change in MAP and CBF was significant (r=0.770; P<0.001). Both L-NAME and midodrine appeared to suppress the post-HUT RAAS response compared with no drug.
Conclusions: Increasing orthostatic blood pressure with L-NAME or midodrine appears to increase CBF and suppress the RAAS during HUT in persons with tetraplegia, although more data are needed to confirm these preliminary findings.
C1 [Wecht, Jill M.; Radulovic, Miroslav; Rosado-Rivera, Dwindally; Zhang, Run-Lin; LaFountaine, Michael F.; Bauman, William A.] James J Peters VA Med Ctr, Ctr Excellence, Bronx, NY 10468 USA.
[Wecht, Jill M.; Radulovic, Miroslav; Bauman, William A.] James J Peters VA Med Ctr, Med Serv, Bronx, NY 10468 USA.
[Wecht, Jill M.; Radulovic, Miroslav; LaFountaine, Michael F.; Bauman, William A.] Mt Sinai Sch Med, Dept Med, New York, NY USA.
[Wecht, Jill M.; Radulovic, Miroslav; Bauman, William A.] Mt Sinai Sch Med, Dept Rehabil Med, New York, NY USA.
RP Wecht, JM (reprint author), James J Peters VA Med Ctr, Ctr Excellence Med Consequences Spinal Cord Injur, Room 1E-02,130 W Kingsbridge Rd, Bronx, NY 10468 USA.
EM jm.wecht@va.gov
FU Veterans Affairs Rehabilitation Research and Development Service
[A6161W, B3203R, B4162C]
FX Supported by the Veterans Affairs Rehabilitation Research and
Development Service (grant nos. A6161W, B3203R, and B4162C).
NR 46
TC 7
Z9 7
U1 0
U2 3
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0003-9993
J9 ARCH PHYS MED REHAB
JI Arch. Phys. Med. Rehabil.
PD NOV
PY 2011
VL 92
IS 11
BP 1789
EP 1795
DI 10.1016/j.apmr.2011.03.022
PG 7
WC Rehabilitation; Sport Sciences
SC Rehabilitation; Sport Sciences
GA 846WT
UT WOS:000296934600008
PM 21762873
ER
PT J
AU Kullgren, JT
Werner, RM
AF Kullgren, Jeffrey T.
Werner, Rachel M.
TI Counterpoint: Will Pubic Reporting of Health-care Quality Measures
Inform and Educate Patients? No
SO CHEST
LA English
DT Editorial Material
ID OF-CARE; CONSUMERS; NETWORK
C1 [Kullgren, Jeffrey T.] Robert Wood Johnson Fdn Clin Scholars, Philadelphia, PA 19104 USA.
[Kullgren, Jeffrey T.; Werner, Rachel M.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA.
[Kullgren, Jeffrey T.; Werner, Rachel M.] Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA.
[Werner, Rachel M.] Univ Penn, Div Gen Internal Med, Perelman Sch Med, Philadelphia, PA 19104 USA.
RP Kullgren, JT (reprint author), Robert Wood Johnson Fdn Clin Scholars, 1303B Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA.
EM kullgren@mail.med.upenn.edu
NR 20
TC 4
Z9 4
U1 2
U2 10
PU AMER COLL CHEST PHYSICIANS
PI NORTHBROOK
PA 3300 DUNDEE ROAD, NORTHBROOK, IL 60062-2348 USA
SN 0012-3692
J9 CHEST
JI Chest
PD NOV
PY 2011
VL 140
IS 5
BP 1117
EP 1120
DI 10.1378/chest.11-2094
PG 4
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA 846UK
UT WOS:000296928500006
PM 22045876
ER
PT J
AU Kullgren, JT
Werner, RM
AF Kullgren, Jeffrey T.
Werner, Rachel M.
TI Counterpoint: Will Pubic Reporting of Health-care Quality Measures
Inform and Educate Patients? No Reply
SO CHEST
LA English
DT Editorial Material
ID HOSPITALS
C1 [Kullgren, Jeffrey T.] Robert Wood Johnson Fdn Clin Scholars, Philadelphia, PA 19104 USA.
[Kullgren, Jeffrey T.; Werner, Rachel M.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA.
[Kullgren, Jeffrey T.; Werner, Rachel M.] Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA.
[Werner, Rachel M.] Univ Penn, Perelman Sch Med, Div Gen Internal Med, Philadelphia, PA 19104 USA.
RP Kullgren, JT (reprint author), Robert Wood Johnson Fdn Clin Scholars, 1303B Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA.
EM kullgren@mail.med.upenn.med
NR 7
TC 0
Z9 0
U1 1
U2 2
PU AMER COLL CHEST PHYSICIANS
PI NORTHBROOK
PA 3300 DUNDEE ROAD, NORTHBROOK, IL 60062-2348 USA
SN 0012-3692
J9 CHEST
JI Chest
PD NOV
PY 2011
VL 140
IS 5
BP 1121
EP 1122
DI 10.1378/chest.11-2095
PG 2
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA 846UK
UT WOS:000296928500008
ER
PT J
AU O'Connor, CM
Fiuzat, M
Lombardi, C
Fujita, K
Jia, G
Davison, BA
Cleland, J
Bloomfield, D
Dittrich, HC
DeLucca, P
Givertz, MM
Mansoor, G
Ponikowski, P
Teerlink, JR
Voors, AA
Massie, BM
Cotter, G
Metra, M
AF O'Connor, Christopher M.
Fiuzat, Mona
Lombardi, Carlo
Fujita, Kenji
Jia, Gang
Davison, Beth A.
Cleland, John
Bloomfield, Daniel
Dittrich, Howard C.
DeLucca, Paul
Givertz, Michael M.
Mansoor, George
Ponikowski, Piotr
Teerlink, John R.
Voors, Adriaan A.
Massie, Barry M.
Cotter, Gad
Metra, Marco
TI Impact of Serial Troponin Release on Outcomes in Patients With Acute
Heart Failure Analysis From the PROTECT Pilot Study
SO CIRCULATION-HEART FAILURE
LA English
DT Article
DE cardiac troponin; acute heart failure; rolofylline
ID IN-HOSPITAL MORTALITY; LONG-TERM PROGNOSIS; CARDIAC TROPONIN; AMBULATORY
PATIENTS; ADENOSINE A(1); OPTIMIZE-HF; TASK-FORCE; ASSOCIATION;
DYSFUNCTION; GUIDELINES
AB Background-Cardiac troponin T (cTnT) elevation is common and is a predictor of outcomes in patients with acute heart failure (AHF). The degree and progression of cTnT release during hospitalization of patients with AHF is unclear. We evaluated the incidence of cTnT release during AHF hospitalization and the relationship of cTnT release with outcomes.
Methods and Results-The Placebo-controlled Randomized study of the selective A(1) adenosine receptor antagonist rolofylline for patients hospitalized with acute heart failure and volume Overload to assess Treatment Effect on Congestion and renal funcTion (PROTECT) pilot study was a multicenter, double-blind study of patients with AHF. Measurements of cTnT were collected at randomization and days 2, 3, 4, and 7. Patients were classified on the basis of their serum cTnT levels at baseline: positive (>0.03 ng/mL), detectable (>0.01 ng/mL), and negative (>= 0.01 ng/mL). A detectable cTnT level developed during the study (after baseline) was classified as cTnT conversion: 288 patients were included; 172 (60%) patients had detectable cTnT levels and 97 (34%) had positive values (>0.03 ng/mL) at baseline. Of the 116 patients with negative troponin at baseline, 24 (21%) had elevated cTnT levels by day 7. On multivariable analysis, positive cTnT at baseline was an independent predictor of the composite end point of cardiovascular/renal rehospitalization or death at 60 days (hazard ratio, 1.84; 95% confidence interval, 1.04-3.26; P=0.036). Kaplan-Meier curves showed similar worse outcomes in patients with troponin conversion and positive troponin at baseline.
Conclusions-There was a high prevalence of baseline cTnT elevation in this cohort; 21% of those negative at baseline converted to detectable levels by day 7. Positive troponin at baseline, and conversion to positive levels, were associated with worse outcomes at 60 days. Clinical Trial Registration-URL: http://www.clinicaltrials.gov. Unique identifiers: NCT00328692 and NCT00354458. (Circ Heart Fail. 2011;4:724-732.)
C1 [O'Connor, Christopher M.; Fiuzat, Mona] Duke Univ, Med Ctr, Duke Clin Res Inst, Durham, NC USA.
[Lombardi, Carlo; Metra, Marco] Univ Brescia, Dept Expt & Appl Med, Brescia, Italy.
[Fujita, Kenji; Jia, Gang; Bloomfield, Daniel; Dittrich, Howard C.; DeLucca, Paul; Mansoor, George] Merck Res Labs, Rahway, NJ USA.
[Davison, Beth A.; Cotter, Gad] Momentum Res, Durham, NC USA.
[Cleland, John] Univ Hull, Kingston Upon Hull HU6 7RX, N Humberside, England.
[Givertz, Michael M.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA.
[Ponikowski, Piotr] Med Univ, Clin Mil Hosp, Wroclaw, Poland.
[Teerlink, John R.; Massie, Barry M.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Teerlink, John R.; Massie, Barry M.] San Francisco VA Med Ctr, San Francisco, CA USA.
[Voors, Adriaan A.] Univ Groningen, Univ Med Ctr Groningen, Groningen, Netherlands.
RP O'Connor, CM (reprint author), DUMC Box 3356, Durham, NC 27705 USA.
EM oconn002@mc.duke.edu
RI Teerlink, John/D-2986-2012; lombardi, carlo /O-2130-2013; Ponikowski,
Piotr/O-6454-2015
OI lombardi, carlo /0000-0002-7120-5877; Ponikowski,
Piotr/0000-0002-3391-7064; Davison, Beth/0000-0003-2374-6449; Cleland,
John/0000-0002-1471-7016; Metra, Marco/0000-0001-6691-8568
FU Merck
FX Drs O'Connor, Voors, Ponikowski, Dittrich, Metra, Teerlink, Massie,
Givertz, Cleland, Weatherley, and Cotter received research funding from
Merck. Drs Jia, Fujita, Mansoor, Bloomfield, and DeLucca are employees
of Merck.
NR 32
TC 40
Z9 41
U1 0
U2 7
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1941-3289
J9 CIRC-HEART FAIL
JI Circ.-Heart Fail.
PD NOV
PY 2011
VL 4
IS 6
BP 724
EP 732
DI 10.1161/CIRCHEARTFAILURE.111.961581
PG 9
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 850AF
UT WOS:000297166100012
PM 21900185
ER
PT J
AU Bhattacharya, A
Jernigan, AL
Sabia, M
Zhang, YQ
Li, Y
Qi, WB
Van Remmen, H
AF Bhattacharya, Arunabh
Jernigan, Amanda L.
Sabia, Marian
Zhang, Yiqiang
Li, Yan
Qi, Wenbo
Van Remmen, Holly
TI Disruption of the 12/15-Lipoxygenase Gene (Alox15) Protects Against
Denervation-Induced Muscle Atrophy
SO FREE RADICAL BIOLOGY AND MEDICINE
LA English
DT Meeting Abstract
CT 18th Annual Meeting of the Society-for-Free-Radical-Biology-and-Medicine
(SFRBM)
CY NOV 16-20, 2011
CL Atlanta, GA
SP Soc Free Rad Biol & Med (SFRBM)
C1 [Bhattacharya, Arunabh; Jernigan, Amanda L.; Sabia, Marian; Zhang, Yiqiang; Li, Yan; Qi, Wenbo; Van Remmen, Holly] Univ Texas Hlth Sci Ctr San Antonio, Barshop Inst, San Antonio, TX 78229 USA.
[Van Remmen, Holly] S Texas Vet Hlth Care Syst, San Antonio, TX USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0891-5849
J9 FREE RADICAL BIO MED
JI Free Radic. Biol. Med.
PD NOV 1
PY 2011
VL 51
SU 1
BP S76
EP S76
DI 10.1016/j.freeradbiomed.2011.10.420
PG 1
WC Biochemistry & Molecular Biology; Endocrinology & Metabolism
SC Biochemistry & Molecular Biology; Endocrinology & Metabolism
GA 848FS
UT WOS:000297036600186
ER
PT J
AU Kachadourian, R
Day, BJ
Pugazhenti, S
Franklin, CC
Mahaffey, G
Gauthier, C
Valdameri, G
Di Pietro, A
Boumendjel, A
AF Kachadourian, Remy
Day, Brian J.
Pugazhenti, Subbiah
Franklin, Christopher C.
Mahaffey, Gregory
Gauthier, Charlotte
Valdameri, Glaucio
Di Pietro, Attilio
Boumendjel, Ahcene
TI A New Synthetic Chalcone Derivative is a Potent Inducer of Glutathione
Synthesis
SO FREE RADICAL BIOLOGY AND MEDICINE
LA English
DT Meeting Abstract
CT 18th Annual Meeting of the Society-for-Free-Radical-Biology-and-Medicine
(SFRBM)
CY NOV 16-20, 2011
CL Atlanta, GA
SP Soc Free Rad Biol & Med (SFRBM)
C1 [Kachadourian, Remy; Day, Brian J.; Pugazhenti, Subbiah; Franklin, Christopher C.] Univ Colorado Denver, Denver, CO USA.
[Pugazhenti, Subbiah; Mahaffey, Gregory] Denver VA Med Ctr, Denver, CO USA.
[Gauthier, Charlotte; Valdameri, Glaucio; Di Pietro, Attilio] CNRS, Inst Biol & Chim Prot, Lyon, France.
[Boumendjel, Ahcene] Univ Grenoble 1, Grenoble, France.
RI Valdameri, Glaucio/G-8354-2017
OI Valdameri, Glaucio/0000-0003-1882-1512
NR 2
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0891-5849
J9 FREE RADICAL BIO MED
JI Free Radic. Biol. Med.
PD NOV 1
PY 2011
VL 51
SU 1
BP S88
EP S89
DI 10.1016/j.freeradbiomed.2011.10.407
PG 2
WC Biochemistry & Molecular Biology; Endocrinology & Metabolism
SC Biochemistry & Molecular Biology; Endocrinology & Metabolism
GA 848FS
UT WOS:000297036600221
ER
PT J
AU Shi, Y
Liu, YH
Li, Y
Hamilton, RT
Jernigan, AL
Jang, YC
Van Remmen, H
AF Shi, Yun
Liu, Yuhong
Li, Yan
Hamilton, Ryan T.
Jernigan, Amanda L.
Jang, Youngmok C.
Van Remmen, Holly
TI Age-related Changes in Neurotrophic Factors Expression in Skeletal
Muscle Undergoing Atrophy
SO FREE RADICAL BIOLOGY AND MEDICINE
LA English
DT Meeting Abstract
CT 18th Annual Meeting of the Society-for-Free-Radical-Biology-and-Medicine
(SFRBM)
CY NOV 16-20, 2011
CL Atlanta, GA
SP Soc Free Rad Biol & Med (SFRBM)
C1 [Shi, Yun; Liu, Yuhong; Li, Yan; Hamilton, Ryan T.; Jernigan, Amanda L.; Van Remmen, Holly] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX USA.
[Jang, Youngmok C.] Harvard Univ, Cambridge, MA 02138 USA.
[Van Remmen, Holly] S Texas Vet Hlth Care Syst, San Antonio, TX USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0891-5849
J9 FREE RADICAL BIO MED
JI Free Radic. Biol. Med.
PD NOV 1
PY 2011
VL 51
SU 1
BP S79
EP S80
DI 10.1016/j.freeradbiomed.2011.10.431
PG 2
WC Biochemistry & Molecular Biology; Endocrinology & Metabolism
SC Biochemistry & Molecular Biology; Endocrinology & Metabolism
GA 848FS
UT WOS:000297036600197
ER
PT J
AU Xiang, M
Shi, XL
Li, YH
Xu, J
Yin, LH
Xiao, GZ
Scott, MJ
Billiar, TR
Wilson, MA
Fan, J
AF Xiang, Meng
Shi, Xiaolian
Li, Yuehua
Xu, Jia
Yin, Lianhua
Xiao, Guozhi
Scott, Melanie J.
Billiar, Timothy R.
Wilson, Mark A.
Fan, Jie
TI Hemorrhagic Shock Activation of NLRP3 Inflammasome in Lung Endothelial
Cells
SO JOURNAL OF IMMUNOLOGY
LA English
DT Article
ID MOBILITY GROUP BOX-1; INTERLEUKIN-1 RECEPTOR ANTAGONIST;
RESPIRATORY-DISTRESS-SYNDROME; NEUTROPHIL NADPH OXIDASE; MULTIPLE ORGAN
FAILURE; SEVERE BLUNT TRAUMA; TLR2 UP-REGULATION; NAD(P)H OXIDASE;
ISCHEMIA/REPERFUSION INJURY; ALVEOLAR MACROPHAGES
AB Hemorrhagic shock (HS) due to major trauma and surgery predisposes the host to the development of systemic inflammatory response syndrome (SIRS), including acute lung injury (ALI), through activating and exaggerating the innate immune response. IL-1 beta is a crucial proinflammatory cytokine that contributes to the development of SIRS and ALI. Lung endothelial cells (EC) are one important source of IL-1 beta, and the production of active IL-1 beta is controlled by the inflammasome. In this study, we addressed the mechanism underlying HS activation of the inflammasome in lung EC. We show that high mobility group box 1 acting through TLR4, and a synergistic collaboration with TLR2 and receptor for advanced glycation end products signaling, mediates HS-induced activation of EC NAD(P) H oxidase. In turn, reactive oxygen species derived from NAD(P) H oxidase promote the association of thioredoxin-interacting protein with the nucleotide-binding oligomerization domain-like receptor protein NLRP3 and subsequently induce inflammasome activation and IL-1 beta secretion from the EC. We also show that neutrophil-derived reactive oxygen species play a role in enhancing EC NAD(P) H oxidase activation and therefore an amplified inflammasome activation in response to HS. The present study explores a novel mechanism underlying HS activation of EC inflammasome and thus presents a potential therapeutic target for SIRS and ALI induced after HS. The Journal of Immunology, 2011, 187: 4809-4817.
C1 [Fan, Jie] Vet Affairs Pittsburgh Healthcare Syst, Dept Surg, Res & Dev, Pittsburgh, PA 15240 USA.
[Xiang, Meng; Shi, Xiaolian; Li, Yuehua; Xu, Jia; Scott, Melanie J.; Billiar, Timothy R.; Wilson, Mark A.; Fan, Jie] Univ Pittsburgh, Sch Med, Dept Surg, Pittsburgh, PA 15213 USA.
[Xiang, Meng; Yin, Lianhua] Fudan Univ, Shanghai Med Coll, Dept Physiol & Pathophysiol, Shanghai 200032, Peoples R China.
[Shi, Xiaolian] Xi An Jiao Tong Univ, Coll Med, Dept Pharmacol, Xian 710061, Peoples R China.
[Xu, Jia] So Med Univ, Dept Pathophysiol, Guangzhou 510515, Guangdong, Peoples R China.
[Xiao, Guozhi] Univ Pittsburgh, Sch Med, Dept Med, Pittsburgh, PA 15213 USA.
RP Fan, J (reprint author), Vet Affairs Pittsburgh Healthcare Syst, Dept Surg, Res & Dev, Bldg 1,Room 2W109 151L-U,Univ Dr C, Pittsburgh, PA 15240 USA.
EM jif7@pitt.edu
FU National Institutes of Health [R01-HL-079669]; National Institutes of
Health Center [P50-GM-53789]; Veterans Administration
FX This work was supported by National Institutes of Health Grant
R01-HL-079669 (to J.F. and M.A.W.), National Institutes of Health Center
Grant P50-GM-53789 (to T.R.B. and J.F.), and a Veterans Administration
Merit Award (to J.F.).
NR 61
TC 53
Z9 60
U1 0
U2 6
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD NOV 1
PY 2011
VL 187
IS 9
BP 4809
EP 4817
DI 10.4049/jimmunol.1102093
PG 9
WC Immunology
SC Immunology
GA 841ET
UT WOS:000296496000046
PM 21940680
ER
PT J
AU Penrod, JD
Luhrs, CA
Livote, EE
Cortez, TB
Kwak, J
AF Penrod, Joan D.
Luhrs, Carol A.
Livote, Elayne E.
Cortez, Therese B.
Kwak, Jennifer
TI Implementation and Evaluation of a Network-Based Pilot Program to
Improve Palliative Care in the Intensive Care Unit
SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT
LA English
DT Article
DE Palliative care; critical care; intensive care unit; ICU; quality
improvement
AB Background. Intensive care unit (ICU) care could be improved by implementation of time-triggered evidence-based interventions including identification of a patient/family medical decision maker, the patient's advance directive status, and cardiopulmonary resuscitation preferences by Day 1; offer of social work and spiritual support by Day 3; and a family meeting establishing goals of care by Day 5. We implemented a program to improve care for ICU patients in five Department of Veterans Affairs' ICUs.
Measures. We measured the percent of ICU patients with lengths of stay of five or more days that received the care processes by the appropriate day.
Intervention. Critical care and palliative care providers trained ICU nurse teams to improve care through auditing, performance feedback, improvement tools, education, and monthly team meetings.
Outcomes. Pre- and postintervention care were compared. Offering social work and spiritual support, identification of the medical decision maker, and documentation of family meetings significantly improved.
Conclusions/Lessons Learned. ICU nurse teams can be engaged to improve care under the aegis of a collaborative quality improvement project. J Pain Symptom Manage 2011;42:668-671. Published by Elsevier Inc. on behalf of U.S. Cancer Pain Relief Committee.
C1 [Penrod, Joan D.; Livote, Elayne E.; Kwak, Jennifer] James J Peters VA Med Ctr, Bronx, NY 10468 USA.
[Luhrs, Carol A.; Cortez, Therese B.] VA New York Harbor Healthcare Syst, Brooklyn, NY USA.
RP Penrod, JD (reprint author), James J Peters VA Med Ctr, 130 W Kingsbridge Rd, Bronx, NY 10468 USA.
EM joan.penrod@mssm.edu
FU Department of Veterans Affairs; Health Services Research; Development
Service
FX This work was supported in part by the Department of Veterans Affairs,
Health Services Research and Development Service. The authors declare no
conflicts of interest.
NR 5
TC 13
Z9 14
U1 0
U2 7
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0885-3924
J9 J PAIN SYMPTOM MANAG
JI J. Pain Symptom Manage.
PD NOV
PY 2011
VL 42
IS 5
BP 668
EP 671
DI 10.1016/j.jpainsymman.2011.06.012
PG 4
WC Health Care Sciences & Services; Medicine, General & Internal; Clinical
Neurology
SC Health Care Sciences & Services; General & Internal Medicine;
Neurosciences & Neurology
GA 847YL
UT WOS:000297011800005
PM 22045370
ER
PT J
AU Villarreal, D
Restrepo, MI
Healy, J
Howard, B
Tidwell, J
Ross, J
Hartronft, S
Jawad, M
Sanchez-Reilly, S
Reed, K
Espinoza, SE
AF Villarreal, Deborah
Restrepo, Marcos I.
Healy, Jennifer
Howard, Bonita
Tidwell, Janet
Ross, Jeanette
Hartronft, Scotte
Jawad, Marriyam
Sanchez-Reilly, Sandra
Reed, Kristin
Espinoza, Sara E.
TI A Model for Increasing Palliative Care in the Intensive Care Unit:
Enhancing Interprofessional Consultation Rates and Communication
SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT
LA English
DT Article
DE Palliative care; critical care; end of life; quality improvement;
interprofessional
ID OUTCOMES; STATES
AB Background. Only a minority of patients who die in the medical intensive care unit (MICU) receive palliative care services. At the South Texas Veterans Health Care System Audie L. Murphy Hospital, only 5% of patients who died in the MICU from May to August 2010 received a palliative care consultation.
Measures. We measured the percentage of MICU patients for which there was a palliative care consultation during the intervention period.
Intervention. Starting October 1, 2010 and ending April 30, 2011, the palliative care and MICU teams participated in daily "pre-rounds'' to identify patients at risk for poor outcomes, who may benefit from a palliative care consultation.
Outcomes. Palliative care consultation increased significantly from 5% to 59% for patients who died in the MICU during the intervention period. Additionally, palliative care consultation increased from 5% to 21% for all patients admitted to the MICU during the intervention period.
Conclusions/Lessons Learned. Daily pre-rounds between the palliative care and MICU teams increased palliative care services for MICU patients at risk for poor outcomes, who may benefit from a palliative care consultation. J Pain Symptom Manage 2011;42:676-679. Published by Elsevier Inc. on behalf of U.S. Cancer Pain Relief Committee.
C1 [Villarreal, Deborah] Audie L Murphy Mem Vet Adm Med Ctr, S Texas Vet Hlth Care Syst, Div Geriatr Gerontol & Palliat Med, San Antonio, TX 78229 USA.
[Villarreal, Deborah; Healy, Jennifer; Ross, Jeanette; Jawad, Marriyam; Sanchez-Reilly, Sandra; Espinoza, Sara E.] Univ Texas Hlth Sci Ctr San Antonio, Div Geriatr Gerontol & Palliat Med, San Antonio, TX 78229 USA.
[Restrepo, Marcos I.] Univ Texas Hlth Sci Ctr San Antonio, Div Pulm & Crit Care, San Antonio, TX 78229 USA.
[Jawad, Marriyam] Univ Texas Hlth Sci Ctr San Antonio, Sch Med, San Antonio, TX 78229 USA.
RP Villarreal, D (reprint author), Audie L Murphy Mem Vet Adm Med Ctr, S Texas Vet Hlth Care Syst, Div Geriatr Gerontol & Palliat Med, 7400 Merton Minter, San Antonio, TX 78229 USA.
EM villarreald4@uthscsa.edu
RI Restrepo, Marcos/H-4442-2014
FU U.S. Department of Health and Human Services, Health Resources and
Services Administration, Bureau of Health Professions
FX Dr. Villareal is receiving career development support from the U.S.
Department of Health and Human Services, Health Resources and Services
Administration, Bureau of Health Professions, Geriatric Academic Career
Award.
NR 9
TC 10
Z9 10
U1 1
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0885-3924
J9 J PAIN SYMPTOM MANAG
JI J. Pain Symptom Manage.
PD NOV
PY 2011
VL 42
IS 5
BP 676
EP 679
DI 10.1016/j.jpainsymman.2011.07.004
PG 4
WC Health Care Sciences & Services; Medicine, General & Internal; Clinical
Neurology
SC Health Care Sciences & Services; General & Internal Medicine;
Neurosciences & Neurology
GA 847YL
UT WOS:000297011800007
PM 22045372
ER
PT J
AU Vig, EK
Sudore, RL
Berg, KM
Fromme, EK
Arnold, RM
AF Vig, Elizabeth K.
Sudore, Rebecca L.
Berg, Karina M.
Fromme, Erik K.
Arnold, Robert M.
TI Responding to Surrogate Requests That Seem Inconsistent With a Patient's
Living Will
SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT
LA English
DT Article
DE Surrogates; decision making; advance directives; substituted judgment
ID LIFE DECISION-MAKING; SUSTAINING TREATMENT; PREFERENCES; CHOICES;
INTERESTS; JUDGMENTS; STABILITY; DISAGREE; OTHERS; FAMILY
AB Clinicians may feel conflicted when a patient's legal decision maker is making decisions that seem inconsistent with a patient's living will. We provide evidence-based information to help clinicians consider whether a surrogate's inconsistent decisions are ethically appropriate. Surrogates are not flawless translators of their loved one's preferences; they are influenced by their own hopes and the current clinical context. Patients may be aware of this, are often concerned about burdening their loved ones, and often grant their surrogates leeway in interpreting their wishes. When appropriate, clinicians should respect surrogates' interpretations of patient values and take steps to decrease surrogate stress during the decision-making process. Finally, if clinicians are cognizant of their own values and preferences, they may recognize how these may affect their responses to certain clinical cases. J Pain Symptom Manage 2011;42:777-782. (C) 2011 U.S. Cancer Pain Relief Committee. Published by Elsevier Inc. All rights reserved.
C1 [Vig, Elizabeth K.] VA Puget Sound Hlth Care Syst, Seattle, WA USA.
[Vig, Elizabeth K.] Univ Washington, Seattle, WA 98195 USA.
[Sudore, Rebecca L.] San Francisco VA Med Ctr, San Francisco, CA USA.
[Sudore, Rebecca L.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Berg, Karina M.] Yale Univ, Sch Med, New Haven, CT USA.
[Fromme, Erik K.] Oregon Hlth & Sci Univ, Dept Med, Div Hematol & Med Oncol, Portland, OR 97201 USA.
[Arnold, Robert M.] Univ Pittsburgh, Sch Med, Div Gen Internal Med, Sect Palliat Care & Med Eth,Ctr Bioeth & Hlth Law, Pittsburgh, PA USA.
RP Vig, EK (reprint author), 1660 Columbian Way,S 182 Eth, Seattle, WA 98108 USA.
EM vigster@u.washington.edu
FU Pfizer Fellowship in Clear Communication
FX Dr. Sudore is supported in part by a Pfizer Fellowship in Clear
Communication. The other authors have no sponsorship related to this
manuscript. The authors have no financial conflicts of interest to
disclose.
NR 22
TC 4
Z9 4
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0885-3924
EI 1873-6513
J9 J PAIN SYMPTOM MANAG
JI J. Pain Symptom Manage.
PD NOV
PY 2011
VL 42
IS 5
BP 777
EP 782
DI 10.1016/j.jpainsymman.2011.08.003
PG 6
WC Health Care Sciences & Services; Medicine, General & Internal; Clinical
Neurology
SC Health Care Sciences & Services; General & Internal Medicine;
Neurosciences & Neurology
GA 847YL
UT WOS:000297011800017
PM 22045374
ER
PT J
AU Pierre, JF
Heneghan, AF
Tsao, FHC
Sano, Y
Jonker, MA
Omata, J
Lan, JG
Kudsk, KA
AF Pierre, Joseph F.
Heneghan, Aaron F.
Tsao, Francis H. C.
Sano, Yoshifumi
Jonker, Mark A.
Omata, Jiro
Lan, Jinggang
Kudsk, Kenneth A.
TI Route and Type of Nutrition and Surgical Stress Influence Secretory
Phospholipase A2 Secretion of the Murine Small Intestine
SO JOURNAL OF PARENTERAL AND ENTERAL NUTRITION
LA English
DT Article; Proceedings Paper
CT Meeting of the
American-Society-for-Parenteral-and-Enteral-Nutrition/Clinical Nutrition
Week
CY FEB 07, 2010
CL Las Vegas, NV
SP Amer Soc Parenteral & Enteral Nutr
DE secretory phospholipase A2; parenteral nutrition; surgical stress; small
intestine; defensins; enteral feeding; innate immunity
ID TOTAL PARENTERAL-NUTRITION; BACTERICIDAL PROPERTIES; INFLAMMATORY
MEDIATORS; STAPHYLOCOCCUS-AUREUS; ENTERAL NUTRITION; LYMPHOID-TISSUE;
CELL-WALL; GROUP-II; A(2); EXPRESSION
AB Background: The function of secretory phospholipase A2 (sPLA2) is site dependent. In tissue, sPLA2 regulates eicosanoid production; in circulation, sPLA2 primes neutrophils; and in the intestinal lumen, sPLA2 provides innate bactericidal immunity as a defensin-related protein. Since parenteral nutrition (PN) primes leukocytes while suppressing intraluminal mucosal immunity, the authors hypothesized that (1) PN would diminish luminal sPLA2 activity but increase activity in intestinal tissue and serum and (2) stress would accentuate these changes. Methods: Mice received chow, a complex enteral diet (CED), intragastric PN (IG-PN), or PN in experiment 1 and chow, chow+stress, PN, or PN+stress in experiment 2. Results: In experiment 1, luminal sPLA2 activity was greatest in chow and decreased in CED, IG-PN, and PN, with PN lower than CED and IG-PN. Compared to that after chow, serum sPLA2 activity dropped after CED, IG-PN, and PN. Serum sPLA2 was higher in portal than systemic serum. In experiment 2, PN lowered luminal sPLA2 activity vs chow. Stress lowered luminal sPLA2 activity in chow, without change in PN. Following stress, luminal immunoglobulin A increased in chow but not PN. Serum sPLA2 activity increased in PN. Conclusions: PN attenuates sPLA2 activity in intestinal fluid, consistent with suppressed innate mucosal defense. Stress suppresses luminal fluid sPLA2 activity in chow but not the immunoglobulin A response; PN impairs both. Stress significantly elevates serum sPLA2 in PN-fed mice, consistent with known increased neutrophil priming with PN. PN reduces innate bactericidal immunity of the gut but upregulates serum proinflammatory products poststress. (JPEN J Parenter Enteral Nutr. 2011;35:748-756)
C1 [Pierre, Joseph F.; Heneghan, Aaron F.; Sano, Yoshifumi; Jonker, Mark A.; Omata, Jiro; Lan, Jinggang; Kudsk, Kenneth A.] Univ Wisconsin, Dept Surg, Sch Med & Publ Hlth, Madison, WI USA.
[Pierre, Joseph F.] Univ Wisconsin, Dept Nutr Sci, Madison, WI 53706 USA.
[Heneghan, Aaron F.; Lan, Jinggang; Kudsk, Kenneth A.] William S Middleton Mem Vet Adm Med Ctr, Vet Adm Surg Serv, Madison, WI USA.
[Tsao, Francis H. C.] Univ Wisconsin, Dept Med, Div Allergy Pulm & Crit Care Med, Sch Med & Publ Hlth, Madison, WI USA.
RP Kudsk, KA (reprint author), 600 Highland Ave,H4-736 CSC, Madison, WI 53792 USA.
EM kudsk@sur-gery.wisc.edu
FU NIGMS NIH HHS [R01 GM053439, R01 GM53439]
NR 32
TC 13
Z9 13
U1 0
U2 3
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0148-6071
J9 JPEN-PARENTER ENTER
JI J. Parenter. Enter. Nutr.
PD NOV
PY 2011
VL 35
IS 6
BP 748
EP 756
DI 10.1177/0148607111414025
PG 9
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA 839UL
UT WOS:000296394800011
PM 22042050
ER
PT J
AU Edwardsen, EA
Dichter, ME
Walsh, P
Cerulli, C
AF Edwardsen, Elizabeth A.
Dichter, Melissa E.
Walsh, Patrick
Cerulli, Catherine
TI Instructional Curriculum Improves Medical Staff Knowledge and Efficacy
for Patients Experiencing Intimate Partner Violence
SO MILITARY MEDICINE
LA English
DT Article
ID DOMESTIC VIOLENCE; MENTAL-HEALTH; PRIMARY-CARE; WOMEN; PHYSICIANS;
VICTIMS
AB Objectives: This study assesses Veterans Affairs mental health providers' understanding of intimate partner violence (IPV) and the perception of patient benefit of routine inquiry and service referral. The impact of an instructional curriculum was also examined following an interactive training. Methods: An evidence-based curriculum was offered to Veterans Affairs mental health providers. The curriculum utilized didactic methods, case scenarios, and resources regarding referrals and statutes regarding crimes related to violence and abuse. The participants completed pre- and post-training surveys to assess their perceptions about IPV and to evaluate the training. Results: Seventy-three individuals completed the training. Fifty-four of the participants were female, and thirty-three were over the age of 45 years. Fifty-one individuals completed both surveys. There were no differences between participants' views of the seriousness of IPV in the community or their practices before or after the training. However, participants scored significantly higher on the knowledge and efficacy measures after the training (p < 0.001). Conclusion: Following an educational intervention, providers demonstrate more knowledge and efficacy regarding routine inquiry and referral for IPV. Barriers to universal implementation still warrant attention.
C1 [Edwardsen, Elizabeth A.] Univ Rochester, Sch Med & Dent, Dept Emergency Med, Rochester, NY 14642 USA.
[Dichter, Melissa E.] Philadelphia VA Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA 19104 USA.
[Walsh, Patrick] Univ Rochester, Sch Med & Dent, Ctr Excellence, Dept Psychiat, Rochester, NY 14642 USA.
[Cerulli, Catherine] Univ Rochester, Sch Med & Dent, Dept Psychiat, Lab Interpersonal Violence & Victimizat, Rochester, NY 14642 USA.
RP Edwardsen, EA (reprint author), Univ Rochester, Sch Med & Dent, Dept Emergency Med, 601 Elmwood Ave, Rochester, NY 14642 USA.
FU NIMH [K01MH75965-01]; Center of Excellence for Suicide Prevention,
Department of VA
FX Funding for this work is provided by NIMH K01MH75965-01 (C. Cerulli).
Additional funding is provided by the Center of Excellence for Suicide
Prevention, Department of VA.
NR 25
TC 3
Z9 4
U1 1
U2 6
PU ASSOC MILITARY SURG US
PI BETHESDA
PA 9320 OLD GEORGETOWN RD, BETHESDA, MD 20814 USA
SN 0026-4075
J9 MIL MED
JI Milit. Med.
PD NOV
PY 2011
VL 176
IS 11
BP 1260
EP 1264
PG 5
WC Medicine, General & Internal
SC General & Internal Medicine
GA 845NR
UT WOS:000296830300009
PM 22165653
ER
PT J
AU Schinka, JA
Casey, RJ
Kasprow, W
Rosenheck, RA
AF Schinka, John A.
Casey, Roger J.
Kasprow, Wesley
Rosenheck, Robert A.
TI Requiring Sobriety at Program Entry: Impact on Outcomes in Supported
Transitional Housing for Homeless Veterans
SO PSYCHIATRIC SERVICES
LA English
DT Article
ID 1ST
AB Objective: An important distinction in models of housing for the homeless is whether programs that require abstinence prior to program admission produce better outcomes than unrestricted programs. Data from a large transitional housing program were used to compare client characteristics of and outcomes from programs requiring abstinence at admission and programs not requiring abstinence. Methods: The U.S. Department of Veterans Affairs (VA) Northeast Program Evaluation Center provided records of individuals who were admitted into, and discharged from, the VA Grant and Per Diem program in 2003-2005. Records contained information from intake interviews, program discharge information, and descriptions of provider characteristics. Analyses were based on 3,188 veteran records, 1,250 from programs requiring sobriety at admission and 1,938 from programs without a sobriety requirement. Group differences were examined with t tests and chi square analyses; predictors of program outcome were determined with logistic regression. Results: Individuals using drugs or alcohol at program admission had more problematic histories, as indicated by several general health and mental health variables, and shorter program stays. There were significant differences between groups in the frequency of program completion, recidivism for homelessness, and employment on program discharge, but effect sizes for these analyses were uniformly small and of questionable importance. Regression analyses did not find meaningful support for the importance of sobriety on program entry on any of the outcome measures. Conclusions: The results add evidence to the small body of literature supporting the position that sobriety on program entry is not a critical variable in determining outcomes for individuals in transitional housing programs. (Psychiatric Services 62:1325-1330, 2011)
C1 [Schinka, John A.; Casey, Roger J.] Natl Ctr Homelessness Vet, Tampa, FL 33612 USA.
[Kasprow, Wesley] US Dept Vet Affairs, NE Program Evaluat Ctr, West Haven, CT USA.
[Rosenheck, Robert A.] Yale Univ, Dept Psychiat, West Haven, CT USA.
RP Schinka, JA (reprint author), Natl Ctr Homelessness Vet, MHBS 116B,13000 BB Downs Blvd, Tampa, FL 33612 USA.
EM jschinka@health.usf.edu
RI McCarthy, Jodie/B-5760-2012
FU VA National Center on Homelessness Among Veterans
FX This research was supported by the VA National Center on Homelessness
Among Veterans.
NR 11
TC 5
Z9 5
U1 0
U2 5
PU AMER PSYCHIATRIC PUBLISHING, INC
PI ARLINGTON
PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA
SN 1075-2730
J9 PSYCHIAT SERV
JI Psychiatr. Serv.
PD NOV
PY 2011
VL 62
IS 11
BP 1325
EP 1330
PG 6
WC Health Policy & Services; Public, Environmental & Occupational Health;
Psychiatry
SC Health Care Sciences & Services; Public, Environmental & Occupational
Health; Psychiatry
GA 843LT
UT WOS:000296674000012
PM 22211212
ER
PT J
AU Kim, HM
Pfeiffer, P
Ganoczy, D
Valenstein, M
AF Kim, Hyungjin Myra
Pfeiffer, Paul
Ganoczy, Dara
Valenstein, Marcia
TI Intensity of Outpatient Monitoring After Discharge and Psychiatric
Rehospitalization of Veterans With Depression
SO PSYCHIATRIC SERVICES
LA English
DT Article
ID SUBSTANCE USE DISORDERS; HOSPITALIZATION; PREDICTORS; SUICIDE; RISK;
CARE
AB Objective: This study assessed whether increased frequency of clinical monitoring during the high-risk period of 12 weeks after discharge from a psychiatric hospitalization reduced subsequent rehospitalization in a national cohort of Veterans Health Administration patients receiving depression treatment between 1999 and 2004. Methods: A case-control design was used. Patients who had at least two inpatient psychiatric hospitalizations were identified (case group, N=17,852) and then individually matched with up to two patients who also had been discharged from psychiatric inpatient settings but were not rehospitalized for the number of days between the case-group patient's discharge and subsequent rehospitalization (N=35,511). Results: Covariate-adjusted relative risk (RR) did not show an association between increased monitoring and subsequent psychiatric hospitalization, but there was a significant negative interaction between monitoring and a comorbid substance use disorder diagnosis (p<.001). Increased monitoring was positively associated with rehospitalization of patients without a substance use disorder, whereas increased monitoring was not associated with increased risk of rehospitalization of those with a comorbid substance use disorder. The RR of rehospitalization associated with a weekly monitoring visit (12 visits per 84 days) versus no monitoring visit was 1.14 for patients without a substance use disorder, whereas the RR was reduced to .94 for patients with a substance use disorder. Conclusions: Increased outpatient monitoring during the high-risk period after discharge appears to have a modest protective effect on rehospitalization among depressed patients with a comorbid substance use disorder. (Psychiatric Services 62:1346-1352, 2011)
C1 [Kim, Hyungjin Myra] Univ Michigan, Ctr Stat Consultat & Res, Ann Arbor, MI 48109 USA.
[Kim, Hyungjin Myra; Pfeiffer, Paul; Ganoczy, Dara; Valenstein, Marcia] US Dept Vet Affairs, Serious Mental Illness Treatment Resource & Evalu, Ann Arbor Ctr Excellence, Ann Arbor, MI USA.
[Pfeiffer, Paul; Valenstein, Marcia] Univ Michigan, Dept Psychianj, Ann Arbor, MI 48109 USA.
RP Kim, HM (reprint author), Univ Michigan, Ctr Stat Consultat & Res, 3550 Rackham,915 E Washington St, Ann Arbor, MI 48109 USA.
EM myrakim@umich.edu
FU U.S. Department of Veterans Affairs, Health Services Research and
Development Service [IIR 04-211-1, MRP 03-320]; National Institute of
Mental Health [R01-MH078698-01]
FX The funding sources for this work were grants IIR 04-211-1 and MRP
03-320 from the U.S. Department of Veterans Affairs, Health Services
Research and Development Service, and grant R01-MH078698-01 from the
National Institute of Mental Health. Resources were also contributed by
the Serious Mental Illness Treatment Resource and Evaluation Center, Ann
Arbor.
NR 19
TC 11
Z9 11
U1 2
U2 4
PU AMER PSYCHIATRIC PUBLISHING, INC
PI ARLINGTON
PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA
SN 1075-2730
EI 1557-9700
J9 PSYCHIAT SERV
JI Psychiatr. Serv.
PD NOV
PY 2011
VL 62
IS 11
BP 1346
EP 1352
PG 7
WC Health Policy & Services; Public, Environmental & Occupational Health;
Psychiatry
SC Health Care Sciences & Services; Public, Environmental & Occupational
Health; Psychiatry
GA 843LT
UT WOS:000296674000015
PM 22211215
ER
PT J
AU Mendez, MF
Ramirez-Bermudez, J
AF Mendez, Mario F.
Ramirez-Bermudez, Jesus
TI Cotard Syndrome in Semantic Dementia
SO PSYCHOSOMATICS
LA English
DT Article
ID DELUSIONS; BRAIN
C1 [Mendez, Mario F.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA.
[Mendez, Mario F.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat, Los Angeles, CA 90095 USA.
[Ramirez-Bermudez, Jesus] Natl Inst Neurol & Neurosurg Mexico, Dept Neuropsychiat, Mexico City, DF, Mexico.
RP Mendez, MF (reprint author), VA Greater Angeles, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA.
EM mmendez@UCLA.edu
FU [R01AG034499-03]
FX This work was funded and supported by #R01AG034499-03
NR 17
TC 8
Z9 8
U1 1
U2 4
PU AMER PSYCHIATRIC PUBLISHING, INC
PI ARLINGTON
PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA
SN 0033-3182
J9 PSYCHOSOMATICS
JI Psychosomatics
PD NOV-DEC
PY 2011
VL 52
IS 6
BP 571
EP 574
PG 4
WC Psychiatry; Psychology
SC Psychiatry; Psychology
GA 849PJ
UT WOS:000297137300012
PM 22054629
ER
PT J
AU Horan, WP
Kring, AM
Gur, RE
Reise, SP
Blanchard, JJ
AF Horan, William P.
Kring, Ann M.
Gur, Raquel E.
Reise, Steven P.
Blanchard, Jack J.
TI Development and psychometric validation of the Clinical Assessment
Interview for Negative Symptoms (CAINS)
SO SCHIZOPHRENIA RESEARCH
LA English
DT Article
DE Schizophrenia; Rating scale; Expression; Experience; Negative symptoms;
Clinical trials
ID PSYCHIATRIC RATING-SCALE; SCHIZOPHRENIA; DEFICITS
AB Progress in the development of new pharmacological and psychosocial treatments for the negative symptoms of schizophrenia is impeded by limitations of available assessment instruments. The multi-site Collaboration to Advance Negative Symptom Assessment in Schizophrenia (CANSAS) was established to develop and validate a new clinical rating scale using a transparent, iterative, and data-driven process. The Clinical Assessment Interview for Negative Symptoms (CAINS) was designed to address limitations of existing measures and assess consensus-based sub-domains, including asociality, avolition, anhedonia, affective blunting, and alogia. The structure and psychometric properties of the CAINS were evaluated in a sample of 281 schizophrenia and schizoaffective outpatients at four sites. Converging structural analyses indicated that the scale was comprised of two moderately correlated factors one reflecting experiential impairments (diminished motivation and enjoyment of social, vocational, and recreational activities) and one reflecting expressive impairments (diminished non-verbal and verbal communication). Item-level analyses revealed generally good distributional properties, inter-rater agreement, discriminating anchor points, and preliminary convergent and discriminant validity. Results indicate that the CAINS is a promising new measure for quantifying negative symptoms in clinical neuroscience and treatment studies, Results guided item modification or deletion, and the reliability and validity of the revised, shorter version of the CAINS is in the final phase of development within the CANSAS project. Published by Elsevier B.V.
C1 [Horan, William P.] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90095 USA.
[Kring, Ann M.] Univ Calif Berkeley, Berkeley, CA 94720 USA.
[Gur, Raquel E.] Univ Penn, Philadelphia, PA 19104 USA.
[Blanchard, Jack J.] Univ Maryland, College Pk, MD 20742 USA.
RP Horan, WP (reprint author), Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, VA Greater Los Angeles Healthcare Syst, 300 UCLA Med Plaza,Suite 2255, Los Angeles, CA 90095 USA.
EM horan@ucla.edu
FU National Institute of Mental Health [K02-MH079231, R01-MH082839,
RO1-MH082890, R01-MH082782, R01-MH82783]
FX This work was supported by the National Institute of Mental Health
(K02-MH079231 and R01-MH082839 to JJB: RO1-MH082890 to AMK: R01-MH082782
to WPH; and R01-MH82783 to REG). Funding sources had no role in study
design or in the collection, analysis and interpretation of data; or in
the writing of this report.
NR 32
TC 83
Z9 83
U1 4
U2 14
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0920-9964
J9 SCHIZOPHR RES
JI Schizophr. Res.
PD NOV
PY 2011
VL 132
IS 2-3
BP 140
EP 145
DI 10.1016/j.schres.2011.06.030
PG 6
WC Psychiatry
SC Psychiatry
GA 848ZB
UT WOS:000297092500008
PM 21798716
ER
PT J
AU Meszaros, ZS
Dimmock, JA
Ploutz-Snyder, R
Chauhan, SVS
Abdul-Malak, Y
Middleton, FA
Batki, SL
AF Meszaros, Zsuzsa Szombathyne
Dimmock, Jacqueline A.
Ploutz-Snyder, Robert
Chauhan, Sumerendra Vir Singh
Abdul-Malak, Ynesse
Middleton, Frank A.
Batki, Steven L.
TI Accuracy of self-reported medical problems in patients with alcohol
dependence and co-occurring schizophrenia or schizoaffective disorder
SO SCHIZOPHRENIA RESEARCH
LA English
DT Article
DE Alcohol; Schizophrenia; Schizoaffective disorder; Medical illness;
Self-report
ID MENTAL-DISORDERS; UNITED-STATES; COMORBIDITY; CARE; MORBIDITY;
MORTALITY; ILLNESS; PEOPLE; HEALTH; SCALE
AB Background: Schizophrenia and alcohol dependence (AD) are both major risk factors for a variety of medical problems, yet little is known about the medical status of patients in whom both conditions coexist.
Objective: The objectives of this study are to assess accuracy of self-reported medical problems and to compare the accuracy reports in patients with schizophrenia or schizoaffective disorder and co-occurring AD compared to patients with AD only and to controls. Our hypothesis was that medical problems are under-reported in patients with co-occurring disorders, possibly due to the combination of alcohol use and symptoms of schizophrenia.
Methods: Self-reported medical diagnoses were recorded and compared to medical records obtained from all area hospitals in 42 patients with schizophrenia and AD, 44 patients with schizoaffective disorder and AD, 41 patients with AD only, and 15 control subjects. Patients underwent medical history, physical examination, and review of medical records. Results: Patients with schizophrenia or schizoaffective disorder and co-occurring AD underreported their medical problems significantly more than patients with AD only and controls. Accuracy of self report was significantly lower in patients with schizophrenia-spectrum disorders plus co-occurring alcohol dependence than in AD alone or in controls. The most commonly underreported diagnoses included coronary artery disease, chronic renal failure, seizure disorder, hyperlipidemia, asthma and hypertension.
Discussion: In order to detect potentially unreported medical conditions in patients with co-occurring schizophrenia/schizoaffective disorder and alcohol dependence, the use of targeted screening questionnaires is recommended in addition to physical examination and thorough review of medical records. (C) 2011 Elsevier B.V. All rights reserved.
C1 [Meszaros, Zsuzsa Szombathyne; Dimmock, Jacqueline A.; Chauhan, Sumerendra Vir Singh; Abdul-Malak, Ynesse; Batki, Steven L.] SUNY Upstate Med Univ, Dept Psychiat, Syracuse, NY 13210 USA.
[Ploutz-Snyder, Robert] NASA, Univ Space Res Assoc, Houston, TX USA.
[Middleton, Frank A.] SUNY Upstate Med Univ, Dept Neurosci Physiol, Syracuse, NY 13210 USA.
[Batki, Steven L.] UCSF, Dept Psychiat, San Francisco, CA USA.
[Batki, Steven L.] San Francisco VA Med Ctr, San Francisco, CA USA.
RP Meszaros, ZS (reprint author), SUNY Upstate Med Univ, Dept Psychiat, 750 E Adams St, Syracuse, NY 13210 USA.
EM meszaroz@upstate.edu
FU NIH-NIAAA [RO1 AA01365501, RO1 AA01615103]
FX This research was supported by NIH-NIAAA grant RO1 AA01365501,
"Naltrexone Treatment of Alcohol Abuse in Schizophrenia" (PI: Batki) and
by NIH-NIAAA grant RO1 AA01615103 "Peripheral Pathophysiogenomic Markers
of Ethanol-induced Brain Damage" (PI: Middleton). The NIH had no further
role in study design; in the collection, analysis and interpretation of
data; in the writing of the report; and in the decision to submit this
paper for publication.
NR 32
TC 3
Z9 3
U1 1
U2 3
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0920-9964
EI 1573-2509
J9 SCHIZOPHR RES
JI Schizophr. Res.
PD NOV
PY 2011
VL 132
IS 2-3
BP 190
EP 193
DI 10.1016/j.schres.2011.07.033
PG 4
WC Psychiatry
SC Psychiatry
GA 848ZB
UT WOS:000297092500016
PM 21852074
ER
PT J
AU Paramsothy, P
Knopp, RH
Kahn, SE
Retzlaff, BM
Fish, B
Ma, LN
Ostlund, RE
AF Paramsothy, Pathmaja
Knopp, Robert H.
Kahn, Steven E.
Retzlaff, Barbara M.
Fish, Brian
Ma, Lina
Ostlund, Richard E., Jr.
TI Plasma sterol evidence for decreased absorption and increased synthesis
of cholesterol in insulin resistance and obesity
SO AMERICAN JOURNAL OF CLINICAL NUTRITION
LA English
DT Article
ID CARDIOVASCULAR-DISEASE; METABOLIC SYNDROME; DIETARY-CHOLESTEROL;
MASS-SPECTROMETRY; SENSITIVITY; RISK; FAT; QUANTIFICATION; DYSLIPIDEMIA;
LIPOPROTEINS
AB Background: The rise in LDL with egg feeding in lean insulin-sensitive (LIS) participants is 2- and 3-fold greater than in lean insulin-resistant (LIR) and obese insulin-resistant (OIR) participants, respectively.
Objective: We determined whether differences in cholesterol absorption, synthesis, or both could be responsible for these differences by measuring plasma sterols as indexes of cholesterol absorption and endogenous synthesis.
Design: Plasma sterols were measured by gas chromatography-mass spectrometry in a random subset of 34 LIS, 37 LIR, and 37 OIR participants defined by the insulin sensitivity index (SI) and by BMI criteria selected from a parent group of 197 participants. Cholestanol and plant sterols provide a measure of cholesterol absorption, and lathosterol provides a measure of cholesterol synthesis.
Results: The mean (+/-SD) ratio of plasma total absorption biomarker sterols to cholesterol was 4.48 +/- 1.74 in LIS, 3.25 +/- 1.06 in LIR, and 2.82 +/- 1.08 in OIR participants. After adjustment for age and sex, the relations of the absorption sterol-cholesterol ratios were as follows: LIS. OIR (P < 0.001), LIS. LIR (P < 0.001), and LIR. OIR (P = 0.11). Lathosterol-cholesterol ratios were 0.71 +/- 0.32 in the LIS participants, 0.95 +/- 0.47 in the LIR participants, and 1.29 +/- 0.55 in the OIR participants. After adjustment for age and sex, the relations of lathosterol-cholesterol ratios were as follows: LIS, OIR (P < 0.001), LIS, LIR (P = 0.03), and LIR, OIR (P = 0.002). Total sterol concentrations were positively associated with SI and negatively associated with obesity, whereas lathosterol correlations were the opposite.
Conclusions: Cholesterol absorption was highest in the LIS participants, whereas cholesterol synthesis was highest in the LIR and OIR participants. Therapeutic diets for hyperlipidemia should emphasize low-cholesterol diets in LIS persons and weight loss to improve SI and to decrease cholesterol overproduction in LIR and OIR persons. Am J Clin Nutr 2011;94:1182-8.
C1 [Paramsothy, Pathmaja] Univ Washington, Div Cardiol, Seattle, WA 98195 USA.
[Paramsothy, Pathmaja; Knopp, Robert H.; Retzlaff, Barbara M.; Fish, Brian] Univ Washington, NW Lipid Res Clin, Seattle, WA 98195 USA.
[Knopp, Robert H.; Kahn, Steven E.] Univ Washington, Div Metab Endocrinol & Nutr, Seattle, WA 98195 USA.
[Kahn, Steven E.] VA Puget Sound Hlth Care Syst, Dept Med, Seattle, WA USA.
[Ma, Lina; Ostlund, Richard E., Jr.] Washington Univ, Sch Med, Div Endocrinol Metab & Lipid Res, St Louis, MO USA.
RP Paramsothy, P (reprint author), 325 9th Ave,PSB 5064,UW Mailstop 359720, Seattle, WA 98104 USA.
EM nmbob@uw.edu
OI Kahn, Steven/0000-0001-7307-9002
FU Egg Nutrition Center; NIH [1KL2RR025015-01, RO1 50420, DK20579,
RR00954]; Clinical Nutrition Research Unit at the University of
Washington [DK 35816]; Diabetes and Endocrinology Research Center at the
University of Washington [DK 17047]; General Clinical Research Center
[RR 00037]; Department of Veterans Affairs
FX Supported by a grant in aid from the Egg Nutrition Center (administered
through the US Department of Agriculture), NIH 1KL2RR025015-01 (to PP);
the Clinical Nutrition Research Unit at the University of Washington (DK
35816), the Diabetes and Endocrinology Research Center at the University
of Washington (DK 17047), the General Clinical Research Center (RR
00037), the Department of Veterans Affairs (to SEK), and NIH grants RO1
50420, DK20579 and RR00954 (to REO).
NR 38
TC 17
Z9 18
U1 0
U2 4
PU AMER SOC NUTRITION-ASN
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0002-9165
J9 AM J CLIN NUTR
JI Am. J. Clin. Nutr.
PD NOV
PY 2011
VL 94
IS 5
BP 1182
EP 1188
DI 10.3945/ajcn.110.006668
PG 7
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA 837VV
UT WOS:000296236100005
PM 21940599
ER
PT J
AU Lund, BC
Steinman, MA
Chrischilles, EA
Kaboli, PJ
AF Lund, Brian C.
Steinman, Michael A.
Chrischilles, Elizabeth A.
Kaboli, Peter J.
TI Beers Criteria as a Proxy for Inappropriate Prescribing of Other
Medications Among Older Adults
SO ANNALS OF PHARMACOTHERAPY
LA English
DT Article
DE Beers criteria; health care; inappropriate drug use; older adult;
quality indicators
ID ADVERSE DRUG-REACTIONS; EXPLICIT CRITERIA; QUALITY; EVENTS; OUTPATIENTS;
OUTCOMES; PEOPLE
AB BACKGROUND: The Beers criteria are a compilation of medications deemed potentially inappropriate for older adults, widely used as a prescribing quality indicator.
OBJECTIVE: To determine whether Beers criteria serve as a proxy measure for other forms of inappropriate prescribing, as measured by comprehensive implicit review.
METHODS: Data for patients 65 years and older were obtained from the Veterans Affairs Enhanced Pharmacy Outpatient Clinic (EPOC) and the Iowa Medicaid Pharmaceutical Case Management (PCM) studies. Comprehensive measurement of prescribing quality was conducted using expert clinician review of medical records according to the Medication Appropriateness Index (MAI). MAI scores attributable to non-Beers medications were contrasted between patients who did and did not receive a Beers criteria medication.
RESULTS: Beers criteria medications accounted for 12.9% (EPOC) and 14.0% (PCM) of total MAI scores. Importantly, non-Beers MAI scores were significantly higher in patients receiving a Beers criteria medication in both studies (EPOC: 15.1 vs 12.4, p = 0.02; PCM: 11.1 vs 8.7, p = 0.04), after adjusting for important confounding factors.
CONCLUSIONS: Beers criteria utility extended beyond direct measurement of a limited set of inappropriate prescribing practices by serving as a clinically meaningful proxy for other inappropriate practices. Using prescribing quality indicators to guide interventions should thus identify patients for comprehensive medication review, rather than identifying specific medication targets for discontinuation. Future research should explore both the quality measurement and the intervention targeting applications of the Beers criteria, particularly when integrated with other indicators.
C1 [Lund, Brian C.] Vet Affairs Iowa City Hlth Care Syst, Ctr Comprehens Access & Delivery Res & Evaluat, Iowa City, IA USA.
[Steinman, Michael A.] San Francisco VA Med Ctr, Div Geriatr, San Francisco, CA USA.
[Steinman, Michael A.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Chrischilles, Elizabeth A.] Univ Iowa, Coll Publ Hlth, Dept Epidemiol, Iowa City, IA USA.
[Kaboli, Peter J.] Univ Iowa, Dept Internal Med, Div Gen Internal Med, Carver Coll Med, Iowa City, IA 52242 USA.
RP Lund, BC (reprint author), Vet Affairs Iowa City Hlth Care Syst, Ctr Comprehens Access & Delivery Res & Evaluat, Iowa City, IA USA.
EM Brian.Lund@va.gov
FU Health Services Research and Development Service, Department of Veterans
Affairs [SAF98-152]; Research Career Development award [RCD 01-013-1];
Center for Research in the Implementation of Innovative Strategies in
Practice at the Iowa City Veterans Affairs Medical Center [HFP 04-149];
State of Iowa General Assembly; Iowa Pharmacy Foundation, McKesson HBOC;
Institute for the Advancement of Community Pharmacy; Agency for
Healthcare Research and Quality (AHRQ) Centers for Education and
Research on Therapeutics [5 U18 HS016094]; National Institute on Aging;
American Federation for Aging Research [K23-AG030999]
FX The Enhanced Pharmacy Outpatient Clinic trial was supported by the
Health Services Research and Development Service, Department of Veterans
Affairs, through an investigator-initiated research award (SAF98-152);
Research Career Development award to Dr. Kaboli (RCD 01-013-1); and the
Center for Research in the Implementation of Innovative Strategies in
Practice (HFP 04-149) at the Iowa City Veterans Affairs Medical Center.
The Iowa Medicaid Pharmaceutical Case Management program evaluation was
funded by the State of Iowa General Assembly, the Iowa Pharmacy
Foundation, McKesson HBOC, and the Institute for the Advancement of
Community Pharmacy. This study was supported in part by an Agency for
Healthcare Research and Quality (AHRQ) Centers for Education and
Research on Therapeutics cooperative agreement #5 U18 HS016094. Dr.
Steinman was supported by an award from the National Institute on Aging
and the American Federation for Aging Research (K23-AG030999).
NR 26
TC 19
Z9 23
U1 1
U2 4
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1060-0280
EI 1542-6270
J9 ANN PHARMACOTHER
JI Ann. Pharmacother.
PD NOV
PY 2011
VL 45
IS 11
BP 1363
EP 1370
DI 10.1345/aph.1Q361
PG 8
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 845LK
UT WOS:000296824000005
PM 21972251
ER
PT J
AU Hanratty, R
Chonchol, M
Havranek, EP
Powers, JD
Dickinson, LM
Ho, PM
Magid, DJ
Steiner, JF
AF Hanratty, Rebecca
Chonchol, Michel
Havranek, Edward P.
Powers, J. David
Dickinson, L. Miriam
Ho, P. Michael
Magid, David J.
Steiner, John F.
TI Relationship between Blood Pressure and Incident Chronic Kidney Disease
in Hypertensive Patients
SO CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
LA English
DT Article
ID HEMODIALYSIS-PATIENTS; DIABETES-MELLITUS; RENAL-DISEASE; UNITED-STATES;
PROGRESSION; POPULATION; PREVALENCE; DECLINE; TRIAL; TIME
AB Background and objectives Hypertension is an important cause of chronic kidney disease (CKD). Identifying risk factors for progression to CKD in patients with normal kidney function and hypertension may help target therapies to slow or prevent decline of kidney function. Our objective was to identify risk factors for development of incident CKD and decline in estimated GFR (eGFR) in hypertensive patients.
Design, setting, participants, & measurements Cox proportional hazards models were used to assess the relationship between incident CKD (defined as eGFR <60 ml/min per 1.73 m(2)) and potential risk factors for CKD from a registry of hypertensive patients.
Results Of 43,305 patients meeting the inclusion criteria, 12.1% (5236 patients) developed incident CKD. Diabetes was the strongest predictor of incident CKD (hazard ratio, 1.96; 95% confidence interval, 1.84 to 2.09) and was associated with the greatest rate of decline in eGFR (-2.2 ml/min per 1.73 m(2) per year). Time-varying systolic BP was associated with incident CKD with risk increasing above 120 mmHg; each 10-mmHg increase in baseline and time-varying systolic BP was associated with a 6% increase in the risk of developing CKD (hazard ratio, 1.06; 95% confidence interval, 1.04 to 1.08 for both). Time-weighted systolic BP was associated with a more rapid decline in eGFR of an additional 0.2 ml/min per 1.73 m(2) per year decline for every 10-mmHg increase in systolic BP.
Conclusions We found that time-varying systolic BP was associated with incident CKD, with an increase in risk above a systolic BP of 120 mmHg among individuals with hypertension. Clin J Am Soc Nephrol 6: 2605-2611, 2011. doi: 10.2215/CJN.02240311
C1 [Hanratty, Rebecca] Denver Hlth, Med Ctr, Denver, CO 80204 USA.
[Chonchol, Michel] Univ Colorado, Div Renal Dis & Hypertens, Denver, CO 80202 USA.
[Powers, J. David; Ho, P. Michael; Magid, David J.; Steiner, John F.] Kaiser Permanente Colorado, Inst Hlth Res, Denver, CO USA.
[Dickinson, L. Miriam] Univ Colorado, Colorado Hlth Outcomes Program, Denver, CO USA.
[Ho, P. Michael] Denver Vet Affairs Med Ctr, Denver, CO USA.
RP Hanratty, R (reprint author), Denver Hlth, Med Ctr, 777 Bannock St,MC 3600, Denver, CO 80204 USA.
EM Rebecca.hanratty@dhha.org
FU National Heart Lung and Blood Institute [U19 HL91179-01]; Veterans
Affairs Health Services Research; Development Career Development Award
[05-026]
FX This study was conducted within the Cardiovascular Research Network, a
consortium of research organizations affiliated with the HMO Research
Network and sponsored by the National Heart Lung and Blood Institute
(U19 HL91179-01). The results presented in this paper have not been
published previously in whole or part, except in abstract form at the
43rd Annual American Society of Nephrology Conference.; Dr.
Ho is supported by a Veterans Affairs Health Services Research and
Development Career Development Award 05-026 and serves as a consultant
for Wellpoint, Inc.
NR 24
TC 14
Z9 16
U1 0
U2 3
PU AMER SOC NEPHROLOGY
PI WASHINGTON
PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA
SN 1555-9041
J9 CLIN J AM SOC NEPHRO
JI Clin. J. Am. Soc. Nephrol.
PD NOV
PY 2011
VL 6
IS 11
BP 2605
EP 2611
DI 10.2215/CJN.02240311
PG 7
WC Urology & Nephrology
SC Urology & Nephrology
GA 845KJ
UT WOS:000296821300010
PM 21921154
ER
PT J
AU Lee, CG
Boyko, EJ
Barrett-Connor, E
Miljkovic, I
Hoffman, AR
Everson-Rose, SA
Lewis, CE
Cawthon, PM
Strotmeyer, ES
Orwoll, ES
AF Lee, Christine G.
Boyko, Edward J.
Barrett-Connor, Elizabeth
Miljkovic, Iva
Hoffman, Andrew R.
Everson-Rose, Susan A.
Lewis, Cora E.
Cawthon, Peggy Mannen
Strotmeyer, Elsa S.
Orwoll, Eric S.
CA Osteoporotic Fractures Men MrOS
TI Insulin Sensitizers May Attenuate Lean Mass Loss in Older Men With
Diabetes
SO DIABETES CARE
LA English
DT Article
ID MUSCLE IN-VIVO; SKELETAL-MUSCLE; OSTEOPOROTIC FRACTURES; 1ST-DEGREE
RELATIVES; METFORMIN INCREASES; BODY-COMPOSITION; EXERCISE; PROTEIN;
PHOSPHORYLATION; TROGLITAZONE
AB OBJECTIVE-To examine longitudinal changes in total and appendicular lean body mass in older men with impaired fasting glucose (IFG) or diabetes and to determine whether these changes differ by diabetes treatment.
RESEARCH DESIGN AND METHODS-A total of 3,752 ambulatory men aged 65 years at baseline participated in a multicenter longitudinal cohort study. Baseline glycemic status was categorized as normoglycemia, IFG, undiagnosed/untreated diabetes, or treated diabetes. Insulin sensitizer medication use (metformin and/or thiazolidinediones) was assessed by prescription medication inventory. The change in total lean and appendicular lean mass was derived from dual X-ray absorptiometry scans taken at baseline and 3.5 +/- 0.7 years later.
RESULTS-This male cohort included 1,853 individuals with normoglycemia, 1,403 with IFG, 234 with untreated diabetes, 151 with diabetes treated with insulin sensitizers, and 111 with diabetes treated without insulin sensitizers. Men with untreated diabetes, diabetes treated without insulin sensitizers, or IFG had greater percentage loss in total or appendicular lean mass (P <= 0.05 in comparison to normoglycemic men). There remained a significantly greater percentage loss in appendicular lean mass for these groups even after adjustment for medical comorbidities or lifestyle factors. In contrast, the percentage loss in total or appendicular lean mass in men with diabetes treated with insulin sensitizers was significantly less than that in normoglycemic men in minimally and fully adjusted models.
CONCLUSIONS-Skeletal muscle loss was accelerated in men with IFG and diabetes, except when the latter was treated with insulin sensitizers. These findings suggest that insulin sensitizers may attenuate muscle loss
C1 [Lee, Christine G.; Orwoll, Eric S.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
[Boyko, Edward J.] VA Puget Sound Hlth Care Syst, Seattle, WA USA.
[Barrett-Connor, Elizabeth] Univ Calif San Diego, La Jolla, CA 92093 USA.
[Miljkovic, Iva; Strotmeyer, Elsa S.] Univ Pittsburgh, Pittsburgh, PA USA.
[Hoffman, Andrew R.] Stanford Univ, Sch Med, Palo Alto, CA 94304 USA.
[Everson-Rose, Susan A.] Univ Minnesota, Minneapolis, MN USA.
[Lewis, Cora E.] Univ Alabama, Birmingham, AL USA.
[Cawthon, Peggy Mannen] Calif Pacific Med Ctr, Res Inst, San Francisco, CA USA.
RP Lee, CG (reprint author), Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
EM leechr@ohsu.edu
RI Strotmeyer, Elsa/F-3015-2014
OI Orwoll, Eric/0000-0002-8520-7355; Miljkovic, Iva/0000-0002-3155-9777;
Strotmeyer, Elsa/0000-0002-4093-6036; Boyko, Edward/0000-0002-3695-192X
FU National Institutes of Health; National Institute of Arthritis and
Musculoskeletal and Skin Diseases (NIAMS); National Institute on Aging
(NIA); National Center for Research Resources (NCRR); National
Institutes of Health Roadmap for Medical Research [U01-AR45580,
U01-AR45614, U01-AR45632, U01-AR45647, U01-AR45654, U01-AR45583,
U01-AG18197, U01-AG027810, UL1-RR024140]; Building Interdisciplinary
Careers in Women's Health Program [K12-HD043488-09]; American Diabetes
Association [1-04-JF-46]; National Institute of Diabetes and Digestive
and Kidney Diseases [K01-DK083029]
FX The MrOS study was supported by funding from the National Institutes of
Health. The following institutes provided support: the National
Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS),
the National Institute on Aging (NIA), the National Center for Research
Resources (NCRR), and the National Institutes of Health Roadmap for
Medical Research under the following grant numbers: U01-AR45580,
U01-AR45614, U01-AR45632, U01-AR45647, U01-AR45654, U01-AR45583,
U01-AG18197, U01-AG027810, and UL1-RR024140. C.G.L. received additional
support from the Building Interdisciplinary Careers in Women's Health
Program (grant number K12-HD043488-09). Additional support was provided
by the American Diabetes Association (grant number 1-04-JF-46) to E.S.S.
I.M. was supported by the Mentored Research Scientist Development Award
from the National Institute of Diabetes and Digestive and Kidney
Diseases (K01-DK083029). VA Puget Sound Health Care System provided
support for participation of E.J.B. in this research.
NR 22
TC 34
Z9 35
U1 1
U2 2
PU AMER DIABETES ASSOC
PI ALEXANDRIA
PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA
SN 0149-5992
J9 DIABETES CARE
JI Diabetes Care
PD NOV
PY 2011
VL 34
IS 11
BP 2381
EP 2386
DI 10.2337/dc11-1032
PG 6
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 847EQ
UT WOS:000296955100010
PM 21926282
ER
PT J
AU Zorick, T
Sugar, CA
Hellemann, G
Shoptaw, S
London, ED
AF Zorick, Todd
Sugar, Catherine A.
Hellemann, Gerhard
Shoptaw, Steve
London, Edythe D.
TI Poor response to sertraline in methamphetamine dependence is associated
with sustained craving for methamphetamine
SO DRUG AND ALCOHOL DEPENDENCE
LA English
DT Article
DE Antidepressants; Sertraline; Methamphetamine; Addiction; Craving;
Classification and regression trees
ID PLACEBO-CONTROLLED TRIAL; DRUG-USERS; DEPRESSION; WITHDRAWAL; SEVERITY;
PHARMACOTHERAPY; FLUOXETINE; MANAGEMENT; INVENTORY; OUTCOMES
AB Background: Depression is common among individuals with methamphetamine (MA) use disorders. As agents that enhance serotonergic function are frequently used to treat depression, one might predict that they would be useful medications for MA dependence. However, clinical trials of serotonergic agents for MA addiction have been unsuccessful.
Objective: To identify factors that distinguish MA-dependent research participants who increased MA self-administration while receiving treatment with the selective serotonin reuptake inhibitor (SSRI) sertraline from other groups of participants.
Method: Using a dataset from a 12-week randomized, placebo-controlled trial of sertraline (100 mg daily) for MA addiction, we identified participants who had completed at least 8 weeks of the trial (n = 61 sertraline, n = 68 placebo). We compared the proportions of MA-positive urine tests for weeks 8-12 of the trial for these subjects to their pre-randomization baseline, and identified those subjects who increased MA use during treatment. Using classification trees, we then assessed all data collected during the study to identify factors associated with increasing MA use during treatment with sertraline, compared to placebo.
Results: More subjects in the sertraline condition increased MA use during treatment (n = 13) than in the placebo condition (n = 5: p = 0.03). Classification trees identified multiple factors from both pre-treatment and in-treatment data that were associated with increased MA use during treatment. Only elevated in-treatment craving for MA specifically characterized subjects in the sertraline group who increased their MA use.
Conclusions: Some MA-abusing individuals treated with SSRIs have sustained craving with an increased propensity to relapse during treatment despite psychosocial treatment interventions. Published by Elsevier Ireland Ltd.
C1 [Zorick, Todd] Greater Los Angeles Vet Adm Healthcare Syst, Dept Psychiat, Los Angeles, CA 90073 USA.
[Zorick, Todd; Sugar, Catherine A.; Hellemann, Gerhard; London, Edythe D.] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA.
[Sugar, Catherine A.] Univ Calif Los Angeles, Dept Biostat, Los Angeles, CA 90095 USA.
[Shoptaw, Steve] Univ Calif Los Angeles, Dept Family Med, Los Angeles, CA 90095 USA.
[London, Edythe D.] Univ Calif Los Angeles, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA.
[London, Edythe D.] Univ Calif Los Angeles, Brain Res Inst, Los Angeles, CA 90095 USA.
RP Zorick, T (reprint author), 11301 Wilshire Blvd,MC 116A, Los Angeles, CA 90073 USA.
EM todd.zorick@va.gov
FU NIH [R01 DA010923, P50 DA018185, P20 DA022539]
FX NIH Grants R01 DA010923 (SS), P50 DA018185 (SS, EDL), P20 DA022539
(EDL), endowments from the Katherine K. and Thomas P. Pike Chair in
Addiction Studies (EDL), and the Marjorie M. Greene Trust.
NR 34
TC 7
Z9 7
U1 0
U2 7
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
IRELAND
SN 0376-8716
J9 DRUG ALCOHOL DEPEN
JI Drug Alcohol Depend.
PD NOV 1
PY 2011
VL 118
IS 2-3
BP 500
EP 503
DI 10.1016/j.drugalcdep.2011.04.015
PG 4
WC Substance Abuse; Psychiatry
SC Substance Abuse; Psychiatry
GA 837EL
UT WOS:000296173800060
PM 21592681
ER
EF